<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2017-04-05T16:29:31Z</responseDate><request verb="ListRecords" resumptionToken="oai%3Apubmedcentral.nih.gov%3A5360862!2017-04-04!2017-04-05!pmc!">https://www.ncbi.nlm.nih.gov/oai/oai.cgi</request><ListRecords><record><header><identifier>oai:pubmedcentral.nih.gov:5360862</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Inequal Appl</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Inequal Appl</journal-id>
      <journal-title-group>
        <journal-title>Journal of Inequalities and Applications</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1025-5834</issn>
      <issn pub-type="epub">1029-242X</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5360862</article-id>
      <article-id pub-id-type="pmcid">PMC5360862</article-id>
      <article-id pub-id-type="pmc-uid">5360862</article-id>
      <article-id pub-id-type="publisher-id">1333</article-id>
      <article-id pub-id-type="doi">10.1186/s13660-017-1333-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Sequence spaces <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M2"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq1.gif"/></alternatives></inline-formula> and <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M4"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq2.gif"/></alternatives></inline-formula> with application in clustering</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Khan</surname>
            <given-names>Mohd Shoaib</given-names>
          </name>
          <address>
            <email>shoaibkhanamu@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alamri</surname>
            <given-names>Badriah AS</given-names>
          </name>
          <address>
            <email>baalamri@kau.edu.sa</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Mursaleen</surname>
            <given-names>M</given-names>
          </name>
          <address>
            <email>mursaleenm@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lohani</surname>
            <given-names>QM Danish</given-names>
          </name>
          <address>
            <email>danishlohani@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1776 3258</institution-id><institution-id institution-id-type="GRID">grid.452738.f</institution-id><institution>Department of Mathematics, </institution><institution>South Asian University, </institution></institution-wrap>New Delhi, India </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0619 1117</institution-id><institution-id institution-id-type="GRID">grid.412125.1</institution-id><institution>Operator Theory and Applications Research Group, Department of Mathematics, Faculty of Science, </institution><institution>King Abdulaziz University, </institution></institution-wrap>P.O. Box 80203, Jeddah, 21589 Saudi Arabia </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0765</institution-id><institution-id institution-id-type="GRID">grid.411340.3</institution-id><institution>Department of Mathematics, </institution><institution>Aligarh Muslim University, </institution></institution-wrap>Aligarh, 202002 India </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>21</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>2017</volume>
      <issue>1</issue>
      <elocation-id>63</elocation-id>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>11</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>2</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Distance measures play a central role in evolving the clustering technique. Due to the rich mathematical background and natural implementation of <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{p}$\end{document}</tex-math><mml:math id="M6"><mml:msub><mml:mi>l</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq3.gif"/></alternatives></inline-formula> distance measures, researchers were motivated to use them in almost every clustering process. Beside <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{p}$\end{document}</tex-math><mml:math id="M8"><mml:msub><mml:mi>l</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq4.gif"/></alternatives></inline-formula> distance measures, there exist several distance measures. Sargent introduced a special type of distance measures <inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$m(\phi)$\end{document}</tex-math><mml:math id="M10"><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq5.gif"/></alternatives></inline-formula> and <inline-formula id="IEq6"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n(\phi)$\end{document}</tex-math><mml:math id="M12"><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq6.gif"/></alternatives></inline-formula> which is closely related to <inline-formula id="IEq7"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{p}$\end{document}</tex-math><mml:math id="M14"><mml:msub><mml:mi>l</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq7.gif"/></alternatives></inline-formula>. In this paper, we generalized the Sargent sequence spaces through introduction of <inline-formula id="IEq8"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M16"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq8.gif"/></alternatives></inline-formula> and <inline-formula id="IEq9"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M18"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq9.gif"/></alternatives></inline-formula> sequence spaces. Moreover, it is shown that both spaces are <italic>BK</italic>-spaces, and one is a dual of another. Further, we have clustered the two-moon dataset by using an induced <inline-formula id="IEq10"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M20"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq10.gif"/></alternatives></inline-formula>-distance measure (induced by the Sargent sequence space <inline-formula id="IEq11"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M22"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq11.gif"/></alternatives></inline-formula>) in the k-means clustering algorithm. The clustering result established the efficacy of replacing the Euclidean distance measure by the <inline-formula id="IEq12"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M24"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq12.gif"/></alternatives></inline-formula>-distance measure in the k-means algorithm.</p>
      </abstract>
      <kwd-group xml:lang="--">
        <title>MSC</title>
        <kwd>40H05</kwd>
        <kwd>46A45</kwd>
      </kwd-group>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>clustering</kwd>
        <kwd>double sequence</kwd>
        <kwd>k-means clustering</kwd>
        <kwd>two-moon dataset</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© The Author(s) 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Clustering is a well-known procedure to deal with an unsupervised learning problem appearing in pattern recognition. Clustering is a process of organizing data into groups called clusters so that objects in the same cluster are similar to one another, but are dissimilar to objects in other clusters [<xref ref-type="bibr" rid="CR1">1</xref>]. The main contribution in the field of clustering analysis was the pioneering work of MacQueen [<xref ref-type="bibr" rid="CR1">1</xref>] and Bezdek [<xref ref-type="bibr" rid="CR2">2</xref>]. They had introduced highly significant clustering algorithms such as k-means [<xref ref-type="bibr" rid="CR1">1</xref>] and fuzzy c-means [<xref ref-type="bibr" rid="CR2">2</xref>]. Among all clustering algorithms, k-means is the simplest unsupervised clustering algorithm that makes use of a minimum distance from the center, and it has many applications in scientific and industrial research [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR6">6</xref>] (for more information about the k-means clustering algorithm, see Section <xref rid="Sec8" ref-type="sec">5</xref>). K-means algorithm is distance dependent, so its outputs vary with changing distance measures. Among all distance measures, a clustering process was usually carried out through the Euclidean distance measure [<xref ref-type="bibr" rid="CR7">7</xref>], but many times it failed to offer good results. In this paper, we define <inline-formula id="IEq13"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M26"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq13.gif"/></alternatives></inline-formula>- and <inline-formula id="IEq14"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M28"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq14.gif"/></alternatives></inline-formula>-distance measure. Further, <inline-formula id="IEq15"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi )$\end{document}</tex-math><mml:math id="M30"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq15.gif"/></alternatives></inline-formula>-distance is used to cluster two-moon dataset. The output result is compared with the result of Euclidean distance measure to show the efficacy of <inline-formula id="IEq16"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M32"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq16.gif"/></alternatives></inline-formula>-distance over the Euclidean distance measure. <inline-formula id="IEq17"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi )$\end{document}</tex-math><mml:math id="M34"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq17.gif"/></alternatives></inline-formula> and <inline-formula id="IEq18"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M36"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq18.gif"/></alternatives></inline-formula>-distance measures are the generalization of <inline-formula id="IEq19"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$m(\phi)$\end{document}</tex-math><mml:math id="M38"><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq19.gif"/></alternatives></inline-formula>- and <inline-formula id="IEq20"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n(\phi)$\end{document}</tex-math><mml:math id="M40"><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq20.gif"/></alternatives></inline-formula>-distance measures introduced by Sargent [<xref ref-type="bibr" rid="CR8">8</xref>] and further studied by Mursaleen [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] (to know more about <inline-formula id="IEq21"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$m(\phi )$\end{document}</tex-math><mml:math id="M42"><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq21.gif"/></alternatives></inline-formula> and <inline-formula id="IEq22"><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n(\phi)$\end{document}</tex-math><mml:math id="M44"><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq22.gif"/></alternatives></inline-formula>, refer to [<xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR10">10</xref>]). The <inline-formula id="IEq23"><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M46"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq23.gif"/></alternatives></inline-formula> and <inline-formula id="IEq24"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M48"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq24.gif"/></alternatives></inline-formula> spaces are closely related to <inline-formula id="IEq25"><alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{p}$\end{document}</tex-math><mml:math id="M50"><mml:msub><mml:mi>l</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq25.gif"/></alternatives></inline-formula> distance measures. <inline-formula id="IEq26"><alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{p}$\end{document}</tex-math><mml:math id="M52"><mml:msub><mml:mi>l</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq26.gif"/></alternatives></inline-formula> measures and its variance are mostly used to solve the problems evolving in the fields of Market prediction [<xref ref-type="bibr" rid="CR11">11</xref>], Machine Learning [<xref ref-type="bibr" rid="CR12">12</xref>], Pattern Recognition [<xref ref-type="bibr" rid="CR13">13</xref>], Clustering [<xref ref-type="bibr" rid="CR20">20</xref>] etc.</p>
      <p>Throughout the paper, by <italic>ω</italic> we denote the set of all real or complex sequences. Moreover, by <inline-formula id="IEq27"><alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{\infty}$\end{document}</tex-math><mml:math id="M54"><mml:msub><mml:mi>l</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq27.gif"/></alternatives></inline-formula>, <italic>c</italic> and <inline-formula id="IEq28"><alternatives><tex-math id="M55">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$c_{0}$\end{document}</tex-math><mml:math id="M56"><mml:msub><mml:mi>c</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq28.gif"/></alternatives></inline-formula> we denote the Banach spaces of bounded, convergent and null sequences, respectively; and let <inline-formula id="IEq29"><alternatives><tex-math id="M57">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{p}$\end{document}</tex-math><mml:math id="M58"><mml:msub><mml:mi>l</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq29.gif"/></alternatives></inline-formula> be the Banach space of absolutely <italic>p</italic>-summable sequences with <italic>p</italic>-norm <inline-formula id="IEq30"><alternatives><tex-math id="M59">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}${\Vert \cdot \Vert } _{p}$\end{document}</tex-math><mml:math id="M60"><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mo>⋅</mml:mo><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq30.gif"/></alternatives></inline-formula>. For the following notions, we refer to [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. A double sequence <inline-formula id="IEq31"><alternatives><tex-math id="M61">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = (x_{jk})$\end{document}</tex-math><mml:math id="M62"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq31.gif"/></alternatives></inline-formula> of real or complex numbers is said to be bounded if <inline-formula id="IEq32"><alternatives><tex-math id="M63">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Vert x \Vert _{\infty} &lt; \infty$\end{document}</tex-math><mml:math id="M64"><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mi mathvariant="normal">∞</mml:mi></mml:msub><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq32.gif"/></alternatives></inline-formula>, the space of all bounded double sequences is denoted by <inline-formula id="IEq33"><alternatives><tex-math id="M65">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mathcal{L}_{\infty}$\end{document}</tex-math><mml:math id="M66"><mml:msub><mml:mi mathvariant="script">L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq33.gif"/></alternatives></inline-formula>. A double sequence <inline-formula id="IEq34"><alternatives><tex-math id="M67">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = (x_{jk})$\end{document}</tex-math><mml:math id="M68"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq34.gif"/></alternatives></inline-formula> is said to converge to the limit <italic>L</italic> in Pringsheim’s sense (shortly, convergent to <italic>L</italic>) if for every <inline-formula id="IEq35"><alternatives><tex-math id="M69">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\varepsilon&gt; 0$\end{document}</tex-math><mml:math id="M70"><mml:mi>ε</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq35.gif"/></alternatives></inline-formula>, there exists an integer <italic>N</italic> such that <inline-formula id="IEq36"><alternatives><tex-math id="M71">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\vert x_{jk} - L\vert &lt; \varepsilon$\end{document}</tex-math><mml:math id="M72"><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>L</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mo>&lt;</mml:mo><mml:mi>ε</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq36.gif"/></alternatives></inline-formula> whenever <inline-formula id="IEq37"><alternatives><tex-math id="M73">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$j,k &gt; N$\end{document}</tex-math><mml:math id="M74"><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>N</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq37.gif"/></alternatives></inline-formula>. In this case <italic>L</italic> is called the <italic>p</italic>-limit of <italic>x</italic>. If in addition <inline-formula id="IEq38"><alternatives><tex-math id="M75">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in\mathcal{L}_{\infty}$\end{document}</tex-math><mml:math id="M76"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi mathvariant="script">L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq38.gif"/></alternatives></inline-formula>, then <italic>x</italic> is said to be boundedly convergent to <italic>L</italic> in Pringsheim’s sense (shortly, <italic>bp</italic>-convergent to <italic>L</italic>). A double sequence <inline-formula id="IEq39"><alternatives><tex-math id="M77">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = (x_{jk})$\end{document}</tex-math><mml:math id="M78"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq39.gif"/></alternatives></inline-formula> is said to converge regularly to <italic>L</italic> (shortly, <italic>r</italic>-convergent to <italic>L</italic>) if <italic>x</italic> is <italic>p</italic>-convergent and the limits <inline-formula id="IEq40"><alternatives><tex-math id="M79">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x_{j}: = \lim_{k}x_{jk}$\end{document}</tex-math><mml:math id="M80"><mml:msub><mml:mi>x</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>:</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mo movablelimits="false">lim</mml:mo><mml:mi>k</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq40.gif"/></alternatives></inline-formula> (<inline-formula id="IEq41"><alternatives><tex-math id="M81">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$j \in\mathbb {N} $\end{document}</tex-math><mml:math id="M82"><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq41.gif"/></alternatives></inline-formula>) and <inline-formula id="IEq42"><alternatives><tex-math id="M83">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x^{k}: = \lim_{j}x_{jk}$\end{document}</tex-math><mml:math id="M84"><mml:msup><mml:mi>x</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mo>:</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mo movablelimits="false">lim</mml:mo><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq42.gif"/></alternatives></inline-formula> (<inline-formula id="IEq43"><alternatives><tex-math id="M85">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$k \in\mathbb{N} $\end{document}</tex-math><mml:math id="M86"><mml:mi>k</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq43.gif"/></alternatives></inline-formula>) exist. Note that in this case the limits <inline-formula id="IEq44"><alternatives><tex-math id="M87">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\lim_{j}\lim_{k}x_{jk}$\end{document}</tex-math><mml:math id="M88"><mml:msub><mml:mo movablelimits="false">lim</mml:mo><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mo movablelimits="false">lim</mml:mo><mml:mi>k</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq44.gif"/></alternatives></inline-formula> and <inline-formula id="IEq45"><alternatives><tex-math id="M89">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\lim_{k}\lim_{j}x_{jk}$\end{document}</tex-math><mml:math id="M90"><mml:msub><mml:mo movablelimits="false">lim</mml:mo><mml:mi>k</mml:mi></mml:msub><mml:msub><mml:mo movablelimits="false">lim</mml:mo><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq45.gif"/></alternatives></inline-formula> exist and are equal to the <italic>p</italic>-limit of <italic>x</italic>. In general, for any notion of convergence <italic>ν</italic>, the space of all <italic>ν</italic>-convergent double sequences will be denoted by <inline-formula id="IEq46"><alternatives><tex-math id="M91">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mathcal{C}_{\nu}$\end{document}</tex-math><mml:math id="M92"><mml:msub><mml:mi mathvariant="script">C</mml:mi><mml:mi>ν</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq46.gif"/></alternatives></inline-formula> and the limit of a <italic>ν</italic>-convergent double sequence <italic>x</italic> by <inline-formula id="IEq47"><alternatives><tex-math id="M93">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\nu\textrm{-} \lim_{j,k}x_{jk}$\end{document}</tex-math><mml:math id="M94"><mml:mi>ν</mml:mi><mml:mtext>-</mml:mtext><mml:msub><mml:mo movablelimits="false">lim</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq47.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq48"><alternatives><tex-math id="M95">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\nu\in\{ p,\mathit{bp},r\}$\end{document}</tex-math><mml:math id="M96"><mml:mi>ν</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">bp</mml:mi><mml:mo>,</mml:mo><mml:mi>r</mml:mi><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq48.gif"/></alternatives></inline-formula>.</p>
      <p>Let Ω denote a vector space of all double sequences with the vector space operations defined coordinate-wise. Vector subspaces of Ω are called double sequence spaces. Let us consider a double sequence <inline-formula id="IEq49"><alternatives><tex-math id="M97">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = \{ x_{mn}\}$\end{document}</tex-math><mml:math id="M98"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq49.gif"/></alternatives></inline-formula> and define the sequence <inline-formula id="IEq50"><alternatives><tex-math id="M99">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$s = \{ s_{mn}\}$\end{document}</tex-math><mml:math id="M100"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq50.gif"/></alternatives></inline-formula> via <italic>x</italic> by
<disp-formula id="Equa"><alternatives><tex-math id="M101">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$s_{mn}: = \sum_{i,j}^{m,n} x_{ij}\quad (m,n \in\mathbb{N} ). $$\end{document}</tex-math><mml:math id="M102"><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mo>=</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mspace width="1em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>
</p>
      <p>Then the pair <inline-formula id="IEq51"><alternatives><tex-math id="M103">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$(x,s)$\end{document}</tex-math><mml:math id="M104"><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq51.gif"/></alternatives></inline-formula> and the sequence <inline-formula id="IEq52"><alternatives><tex-math id="M105">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$s = \{ s_{mn}\}$\end{document}</tex-math><mml:math id="M106"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq52.gif"/></alternatives></inline-formula> are called a double series and a sequence of partial sums of the double series, respectively. Let <italic>λ</italic> be the space of double sequences converging with respect to some linear convergence rule <inline-formula id="IEq53"><alternatives><tex-math id="M107">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mu\textrm{-} \lim:\lambda\to \mathbb{R}$\end{document}</tex-math><mml:math id="M108"><mml:mi>μ</mml:mi><mml:mtext>-</mml:mtext><mml:mo movablelimits="false">lim</mml:mo><mml:mo>:</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi mathvariant="double-struck">R</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq53.gif"/></alternatives></inline-formula>. The sum of a double series <inline-formula id="IEq54"><alternatives><tex-math id="M109">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum_{i,j = 1}^{\infty,\infty} x_{ij}$\end{document}</tex-math><mml:math id="M110"><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq54.gif"/></alternatives></inline-formula> with respect to this rule is defined by <inline-formula id="IEq55"><alternatives><tex-math id="M111">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mu\textrm{-} \sum_{i,j = 1}^{\infty,\infty} x_{ij}: = \mu\textrm{-} \lim s_{mn}$\end{document}</tex-math><mml:math id="M112"><mml:mi>μ</mml:mi><mml:mtext>-</mml:mtext><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mo>=</mml:mo><mml:mi>μ</mml:mi><mml:mtext>-</mml:mtext><mml:mo movablelimits="false">lim</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq55.gif"/></alternatives></inline-formula>. Başar and Şever introduced the space <inline-formula id="IEq56"><alternatives><tex-math id="M113">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{p}$\end{document}</tex-math><mml:math id="M114"><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq56.gif"/></alternatives></inline-formula> in [<xref ref-type="bibr" rid="CR16">16</xref>]
<disp-formula id="Equb"><alternatives><tex-math id="M115">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$L_{p}: = \biggl\{ \{ x_{mn}\} \in\Omega:\sum _{m,n} \vert x_{mn}\vert ^{p} &lt; \infty \biggr\} \quad (1 \le p &lt; \infty) $$\end{document}</tex-math><mml:math id="M116"><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>:</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">{</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo>:</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mo stretchy="false">|</mml:mo><mml:mi>p</mml:mi></mml:msup><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">}</mml:mo></mml:mrow><mml:mspace width="1em"/><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equb.gif" position="anchor"/></alternatives></disp-formula> corresponding to the space <inline-formula id="IEq57"><alternatives><tex-math id="M117">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{p}$\end{document}</tex-math><mml:math id="M118"><mml:msub><mml:mi>l</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq57.gif"/></alternatives></inline-formula> for <inline-formula id="IEq58"><alternatives><tex-math id="M119">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$p \ge1$\end{document}</tex-math><mml:math id="M120"><mml:mi>p</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq58.gif"/></alternatives></inline-formula> and examined some of its properties. Altay and Başar [<xref ref-type="bibr" rid="CR17">17</xref>] have generalized the spaces of double sequences <inline-formula id="IEq59"><alternatives><tex-math id="M121">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{\infty}$\end{document}</tex-math><mml:math id="M122"><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq59.gif"/></alternatives></inline-formula>, <inline-formula id="IEq60"><alternatives><tex-math id="M123">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$C_{p}$\end{document}</tex-math><mml:math id="M124"><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq60.gif"/></alternatives></inline-formula> and <inline-formula id="IEq61"><alternatives><tex-math id="M125">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$C_{\mathit{bp}}$\end{document}</tex-math><mml:math id="M126"><mml:msub><mml:mi>C</mml:mi><mml:mi mathvariant="italic">bp</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq61.gif"/></alternatives></inline-formula> to
<disp-formula id="Equc"><alternatives><tex-math id="M127">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document} $$\begin{aligned}&amp; L_{\infty} (t) = \Bigl\{ \{ x_{mn}\} \in\Omega:\sup _{m,n \in\mathbb{N}} \vert x_{mn}\vert ^{t_{mn}} &lt; \infty \Bigr\} , \\&amp; C_{p}(t) = \Bigl\{ \{ x_{mn}\} \in\Omega:p \textrm{-} \lim _{m,n \to \infty} \vert x_{mn} - \ell \vert ^{t_{mn}} = 0 \Bigr\} , \end{aligned}$$ \end{document}</tex-math><mml:math id="M128"><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="3.8ex" minsize="3.8ex" stretchy="true">{</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo>:</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:msup><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo maxsize="3.8ex" minsize="3.8ex" stretchy="true">}</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="3.8ex" minsize="3.8ex" stretchy="true">{</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo>:</mml:mo><mml:mi>p</mml:mi><mml:mtext>-</mml:mtext><mml:munder><mml:mo movablelimits="false">lim</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>ℓ</mml:mi><mml:msup><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:msup><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo maxsize="3.8ex" minsize="3.8ex" stretchy="true">}</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="13660_2017_1333_Article_Equc.gif" position="anchor"/></alternatives></disp-formula> and
<disp-formula id="Equd"><alternatives><tex-math id="M129">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$C_{\mathit{bp}}(t) = C_{p}(t) \cap L_{\infty} (t), $$\end{document}</tex-math><mml:math id="M130"><mml:msub><mml:mi>C</mml:mi><mml:mi mathvariant="italic">bp</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∩</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equd.gif" position="anchor"/></alternatives></disp-formula> respectively, where <inline-formula id="IEq62"><alternatives><tex-math id="M131">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$t = \{ t_{mn}\}$\end{document}</tex-math><mml:math id="M132"><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq62.gif"/></alternatives></inline-formula> is the sequence of strictly positive reals <inline-formula id="IEq63"><alternatives><tex-math id="M133">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$t_{mn}$\end{document}</tex-math><mml:math id="M134"><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq63.gif"/></alternatives></inline-formula>. In the case <inline-formula id="IEq64"><alternatives><tex-math id="M135">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$t_{mn} = 1$\end{document}</tex-math><mml:math id="M136"><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq64.gif"/></alternatives></inline-formula>, for all <inline-formula id="IEq65"><alternatives><tex-math id="M137">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$m,n \in\mathbb{N}$\end{document}</tex-math><mml:math id="M138"><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq65.gif"/></alternatives></inline-formula>, <inline-formula id="IEq66"><alternatives><tex-math id="M139">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{\infty} (t)$\end{document}</tex-math><mml:math id="M140"><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq66.gif"/></alternatives></inline-formula>, <inline-formula id="IEq67"><alternatives><tex-math id="M141">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$C_{p}(t)$\end{document}</tex-math><mml:math id="M142"><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq67.gif"/></alternatives></inline-formula> and <inline-formula id="IEq68"><alternatives><tex-math id="M143">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$C_{\mathit{bp}}(t)$\end{document}</tex-math><mml:math id="M144"><mml:msub><mml:mi>C</mml:mi><mml:mi mathvariant="italic">bp</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq68.gif"/></alternatives></inline-formula> reduce to the sets <inline-formula id="IEq69"><alternatives><tex-math id="M145">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{\infty}$\end{document}</tex-math><mml:math id="M146"><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq69.gif"/></alternatives></inline-formula>, <inline-formula id="IEq70"><alternatives><tex-math id="M147">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$C_{p}$\end{document}</tex-math><mml:math id="M148"><mml:msub><mml:mi>C</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq70.gif"/></alternatives></inline-formula> and <inline-formula id="IEq71"><alternatives><tex-math id="M149">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$C_{\mathit{bp}}$\end{document}</tex-math><mml:math id="M150"><mml:msub><mml:mi>C</mml:mi><mml:mi mathvariant="italic">bp</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq71.gif"/></alternatives></inline-formula>, respectively. Further, let <italic>C</italic> be the space whose elements are finite sets of distinct positive integers. Given any element <italic>σ</italic> of <italic>C</italic>, we denote by <inline-formula id="IEq72"><alternatives><tex-math id="M151">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$c(\sigma)$\end{document}</tex-math><mml:math id="M152"><mml:mi>c</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq72.gif"/></alternatives></inline-formula> the sequence <inline-formula id="IEq73"><alternatives><tex-math id="M153">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ c_{n}(\sigma)\}$\end{document}</tex-math><mml:math id="M154"><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq73.gif"/></alternatives></inline-formula> which is such that <inline-formula id="IEq74"><alternatives><tex-math id="M155">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$c_{n}(\sigma) = 1$\end{document}</tex-math><mml:math id="M156"><mml:msub><mml:mi>c</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq74.gif"/></alternatives></inline-formula> if <inline-formula id="IEq75"><alternatives><tex-math id="M157">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n \in \sigma$\end{document}</tex-math><mml:math id="M158"><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>σ</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq75.gif"/></alternatives></inline-formula>, <inline-formula id="IEq76"><alternatives><tex-math id="M159">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$c_{n}(\sigma) = 0$\end{document}</tex-math><mml:math id="M160"><mml:msub><mml:mi>c</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq76.gif"/></alternatives></inline-formula> otherwise. Further, let
<disp-formula id="Eque"><alternatives><tex-math id="M161">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$C_{s} = \Biggl\{ \sigma\in C:\sum_{n = 1}^{\infty} c_{n}(\sigma) \le s \Biggr\} $$\end{document}</tex-math><mml:math id="M162"><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">{</mml:mo><mml:mi>σ</mml:mi><mml:mo>∈</mml:mo><mml:mi>C</mml:mi><mml:mo>:</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi mathvariant="normal">∞</mml:mi></mml:munderover><mml:msub><mml:mi>c</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>σ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≤</mml:mo><mml:mi>s</mml:mi><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">}</mml:mo></mml:mrow></mml:math><graphic xlink:href="13660_2017_1333_Article_Eque.gif" position="anchor"/></alternatives></disp-formula> be the set of those <italic>σ</italic> whose support has cardinality at most <italic>s</italic>, and
<disp-formula id="Equf"><alternatives><tex-math id="M163">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Phi= \biggl\{ \phi= \{ \phi_{n}\} \in\omega: \phi_{1} &gt; 0,\Delta\phi_{n} \ge0\mbox{ and }\Delta \biggl( \frac{\phi_{n}}{n} \biggr) \le0\ (n = 1,2, \ldots) \biggr\} , $$\end{document}</tex-math><mml:math id="M164"><mml:mi mathvariant="normal">Φ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">{</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi>ω</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>ϕ</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>≥</mml:mo><mml:mn>0</mml:mn><mml:mtext> and </mml:mtext><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mi>n</mml:mi></mml:mfrac><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>≤</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.25em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">}</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equf.gif" position="anchor"/></alternatives></disp-formula> where <inline-formula id="IEq77"><alternatives><tex-math id="M165">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta\phi_{n} = \phi_{n} - \phi_{n - 1}$\end{document}</tex-math><mml:math id="M166"><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>ϕ</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq77.gif"/></alternatives></inline-formula> and <inline-formula id="IEq78"><alternatives><tex-math id="M167">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi _{0} = 0$\end{document}</tex-math><mml:math id="M168"><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq78.gif"/></alternatives></inline-formula>.</p>
      <p>For <inline-formula id="IEq79"><alternatives><tex-math id="M169">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi\in\Phi$\end{document}</tex-math><mml:math id="M170"><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq79.gif"/></alternatives></inline-formula>, the following sequence spaces were introduced and studied in [<xref ref-type="bibr" rid="CR8">8</xref>] by Sargent and further studied by Mursaleen in [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]:
<disp-formula id="Equg"><alternatives><tex-math id="M171">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$m(\phi) = \biggl\{ x = \{ x_{n}\} \in\omega:\sup _{s \ge 1} \sup_{\sigma\in C_{s}} \biggl( \frac{1}{\phi_{s}} \sum_{n \in\sigma} \vert x_{n}\vert \biggr) &lt; \infty \biggr\} , $$\end{document}</tex-math><mml:math id="M172"><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">{</mml:mo><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi>ω</mml:mi><mml:mo>:</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>σ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mfrac><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>σ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">}</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equg.gif" position="anchor"/></alternatives></disp-formula> and
<disp-formula id="Equh"><alternatives><tex-math id="M173">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$n(\phi) = \Biggl\{ x = \{ x_{n}\} \in\omega:\sup _{u \in S(x)} \Biggl( \sum_{m,n = 1,1}^{\infty,\infty} \vert u_{n}\vert \Delta\phi_{n} \Biggr) &lt; \infty \Biggr\} . $$\end{document}</tex-math><mml:math id="M174"><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">{</mml:mo><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi>ω</mml:mi><mml:mo>:</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:munder><mml:mrow><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">(</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>ϕ</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">}</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equh.gif" position="anchor"/></alternatives></disp-formula>
</p>
      <sec id="FPar1">
        <title>Remark 1.1</title>
        <p>
<list list-type="simple"><list-item><label>(i)</label><p>The spaces <inline-formula id="IEq80"><alternatives><tex-math id="M175">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$m(\phi)$\end{document}</tex-math><mml:math id="M176"><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq80.gif"/></alternatives></inline-formula> and <inline-formula id="IEq81"><alternatives><tex-math id="M177">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n(\phi)$\end{document}</tex-math><mml:math id="M178"><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq81.gif"/></alternatives></inline-formula> are <italic>BK</italic>-spaces with their usual norms.</p></list-item><list-item><label>(ii)</label><p>If <inline-formula id="IEq82"><alternatives><tex-math id="M179">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi_{n} = 1$\end{document}</tex-math><mml:math id="M180"><mml:msub><mml:mi>ϕ</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq82.gif"/></alternatives></inline-formula> (<inline-formula id="IEq83"><alternatives><tex-math id="M181">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n = 1,2,3,\ldots$\end{document}</tex-math><mml:math id="M182"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq83.gif"/></alternatives></inline-formula>), then <inline-formula id="IEq84"><alternatives><tex-math id="M183">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$m(\phi) = l_{1}$\end{document}</tex-math><mml:math id="M184"><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq84.gif"/></alternatives></inline-formula> [<inline-formula id="IEq85"><alternatives><tex-math id="M185">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n(\phi) = l_{\infty} $\end{document}</tex-math><mml:math id="M186"><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq85.gif"/></alternatives></inline-formula>], and if <inline-formula id="IEq86"><alternatives><tex-math id="M187">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi_{n} = n$\end{document}</tex-math><mml:math id="M188"><mml:msub><mml:mi>ϕ</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>n</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq86.gif"/></alternatives></inline-formula> (<inline-formula id="IEq87"><alternatives><tex-math id="M189">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n = 1,2,3,\ldots$\end{document}</tex-math><mml:math id="M190"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq87.gif"/></alternatives></inline-formula>), then <inline-formula id="IEq88"><alternatives><tex-math id="M191">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$m(\phi) = l_{\infty}$\end{document}</tex-math><mml:math id="M192"><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq88.gif"/></alternatives></inline-formula> [<inline-formula id="IEq89"><alternatives><tex-math id="M193">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n(\phi) = l_{1} $\end{document}</tex-math><mml:math id="M194"><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq89.gif"/></alternatives></inline-formula>].</p></list-item><list-item><label>(iii)</label><p>
<inline-formula id="IEq90"><alternatives><tex-math id="M195">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{1} \subseteq m(\phi) \subseteq l_{\infty} $\end{document}</tex-math><mml:math id="M196"><mml:msub><mml:mi>l</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⊆</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊆</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq90.gif"/></alternatives></inline-formula> [<inline-formula id="IEq91"><alternatives><tex-math id="M197">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{1} \subseteq n(\phi) \subseteq l_{\infty} $\end{document}</tex-math><mml:math id="M198"><mml:msub><mml:mi>l</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⊆</mml:mo><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊆</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq91.gif"/></alternatives></inline-formula>] for all <inline-formula id="IEq92"><alternatives><tex-math id="M199">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi\in\Phi$\end{document}</tex-math><mml:math id="M200"><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq92.gif"/></alternatives></inline-formula>.</p></list-item><list-item><label>(iv)</label><p>For any <inline-formula id="IEq93"><alternatives><tex-math id="M201">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi\in\Phi$\end{document}</tex-math><mml:math id="M202"><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq93.gif"/></alternatives></inline-formula>, <inline-formula id="IEq94"><alternatives><tex-math id="M203">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$m(\phi)\neq l_{p}$\end{document}</tex-math><mml:math id="M204"><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≠</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq94.gif"/></alternatives></inline-formula> [<inline-formula id="IEq95"><alternatives><tex-math id="M205">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n(\phi)\neq l_{q} $\end{document}</tex-math><mml:math id="M206"><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≠</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq95.gif"/></alternatives></inline-formula>], <inline-formula id="IEq96"><alternatives><tex-math id="M207">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$1 &lt; p &lt; \infty$\end{document}</tex-math><mml:math id="M208"><mml:mn>1</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq96.gif"/></alternatives></inline-formula>.</p></list-item></list>
</p>
        <p>In this paper, we define Sargent’s spaces for double sequences <inline-formula id="IEq97"><alternatives><tex-math id="M209">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = \{ x_{mn}\}$\end{document}</tex-math><mml:math id="M210"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq97.gif"/></alternatives></inline-formula>. For this we first suppose <italic>U</italic> to be the set whose elements are finite sets of distinct elements of <inline-formula id="IEq98"><alternatives><tex-math id="M211">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mathbb{N} \times\mathbb{N}$\end{document}</tex-math><mml:math id="M212"><mml:mi mathvariant="double-struck">N</mml:mi><mml:mo>×</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq98.gif"/></alternatives></inline-formula> obtained by <inline-formula id="IEq99"><alternatives><tex-math id="M213">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sigma\times\varsigma$\end{document}</tex-math><mml:math id="M214"><mml:mi>σ</mml:mi><mml:mo>×</mml:mo><mml:mi>ς</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq99.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq100"><alternatives><tex-math id="M215">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sigma\in C_{s}$\end{document}</tex-math><mml:math id="M216"><mml:mi>σ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq100.gif"/></alternatives></inline-formula> and <inline-formula id="IEq101"><alternatives><tex-math id="M217">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\varsigma\in C_{t}$\end{document}</tex-math><mml:math id="M218"><mml:mi>ς</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq101.gif"/></alternatives></inline-formula> for each <inline-formula id="IEq102"><alternatives><tex-math id="M219">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$s,t \ge1$\end{document}</tex-math><mml:math id="M220"><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq102.gif"/></alternatives></inline-formula>. Therefore, any element <italic>ζ</italic> of <italic>U</italic> means <inline-formula id="IEq103"><alternatives><tex-math id="M221">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$(m,n)$\end{document}</tex-math><mml:math id="M222"><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq103.gif"/></alternatives></inline-formula>; <inline-formula id="IEq104"><alternatives><tex-math id="M223">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$m \in\sigma$\end{document}</tex-math><mml:math id="M224"><mml:mi>m</mml:mi><mml:mo>∈</mml:mo><mml:mi>σ</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq104.gif"/></alternatives></inline-formula> and <inline-formula id="IEq105"><alternatives><tex-math id="M225">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n \in\varsigma$\end{document}</tex-math><mml:math id="M226"><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ς</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq105.gif"/></alternatives></inline-formula> having cardinality at most <italic>st</italic>, where <italic>s</italic> is the cardinality with respect to <italic>m</italic> and <italic>t</italic> is the cardinality with respect to <italic>n</italic>. Given any element <italic>ζ</italic> of <italic>U</italic>, we denote by <inline-formula id="IEq106"><alternatives><tex-math id="M227">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$c(\zeta)$\end{document}</tex-math><mml:math id="M228"><mml:mi>c</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ζ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq106.gif"/></alternatives></inline-formula> the sequence <inline-formula id="IEq107"><alternatives><tex-math id="M229">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ c_{mn}(\zeta)\}$\end{document}</tex-math><mml:math id="M230"><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>ζ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq107.gif"/></alternatives></inline-formula> such that
<disp-formula id="Equi"><alternatives><tex-math id="M231">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{mn}(\zeta) = \textstyle\begin{cases} 1; &amp; \mbox{if } (m,n) \in\zeta,\\ 0; &amp; \mbox{otherwise}. \end{cases} $$\end{document}</tex-math><mml:math id="M232"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>ζ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mn>1</mml:mn><mml:mo>;</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mtext>if </mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mn>0</mml:mn><mml:mo>;</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mtext>otherwise</mml:mtext><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="13660_2017_1333_Article_Equi.gif" position="anchor"/></alternatives></disp-formula> Further, we write
<disp-formula id="Equj"><alternatives><tex-math id="M233">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$U_{st} = \Biggl\{ \zeta\in U:\sum_{m,n = 1}^{\infty,\infty} c_{mn}(\zeta) \le st \Biggr\} $$\end{document}</tex-math><mml:math id="M234"><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">{</mml:mo><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:mi>U</mml:mi><mml:mo>:</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>ζ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≤</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">}</mml:mo></mml:mrow></mml:math><graphic xlink:href="13660_2017_1333_Article_Equj.gif" position="anchor"/></alternatives></disp-formula> for the set of those <italic>ζ</italic> whose support has cardinality at most <italic>st</italic>; and
<disp-formula id="Equk"><alternatives><tex-math id="M235">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Theta= \biggl\{ \phi= \{ \phi_{mn}\} \in\Omega: \phi_{11} &gt; 0,\Delta_{11}\phi_{mn} \ge0\mbox{ and } \Delta_{11} \biggl( \frac{\phi_{mn}}{mn} \biggr) \le0\ (m,n = 1,2, \ldots) \biggr\} , $$\end{document}</tex-math><mml:math id="M236"><mml:mi mathvariant="normal">Θ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">{</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mn>0</mml:mn><mml:mtext> and </mml:mtext><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:mfrac><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>≤</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.25em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">}</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equk.gif" position="anchor"/></alternatives></disp-formula> where <inline-formula id="IEq108"><alternatives><tex-math id="M237">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta_{11}\phi_{mn} = \phi_{mn} - \phi_{m - 1,n} - \phi_{m,n - 1} + \phi_{m - 1,n - 1}$\end{document}</tex-math><mml:math id="M238"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq108.gif"/></alternatives></inline-formula> and <inline-formula id="IEq109"><alternatives><tex-math id="M239">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi_{00}$\end{document}</tex-math><mml:math id="M240"><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>00</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq109.gif"/></alternatives></inline-formula>, <inline-formula id="IEq110"><alternatives><tex-math id="M241">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi_{0m}$\end{document}</tex-math><mml:math id="M242"><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq110.gif"/></alternatives></inline-formula>, <inline-formula id="IEq111"><alternatives><tex-math id="M243">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi_{n0} = 0$\end{document}</tex-math><mml:math id="M244"><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq111.gif"/></alternatives></inline-formula>, <inline-formula id="IEq112"><alternatives><tex-math id="M245">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\forall m,n \in\mathbb{I}^{ +}$\end{document}</tex-math><mml:math id="M246"><mml:mi mathvariant="normal">∀</mml:mi><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mi mathvariant="double-struck">I</mml:mi><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq112.gif"/></alternatives></inline-formula>. Throughout the paper, we write <inline-formula id="IEq113"><alternatives><tex-math id="M247">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum_{m,n \in\zeta}$\end{document}</tex-math><mml:math id="M248"><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq113.gif"/></alternatives></inline-formula> for <inline-formula id="IEq114"><alternatives><tex-math id="M249">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum_{m \in \sigma} \sum_{n \in\varsigma}$\end{document}</tex-math><mml:math id="M250"><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>∈</mml:mo><mml:mi>σ</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ς</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq114.gif"/></alternatives></inline-formula>, and <inline-formula id="IEq115"><alternatives><tex-math id="M251">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$S(x)$\end{document}</tex-math><mml:math id="M252"><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq115.gif"/></alternatives></inline-formula> is used to denote the set of all double sequences that are rearrangements of <inline-formula id="IEq116"><alternatives><tex-math id="M253">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = \{ x_{mn}\} \in \Omega$\end{document}</tex-math><mml:math id="M254"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Ω</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq116.gif"/></alternatives></inline-formula>. For <inline-formula id="IEq117"><alternatives><tex-math id="M255">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi\in\Theta$\end{document}</tex-math><mml:math id="M256"><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Θ</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq117.gif"/></alternatives></inline-formula>, we define the following sequence spaces:
<disp-formula id="Equl"><alternatives><tex-math id="M257">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$M(\phi) = \biggl\{ x = \{ x_{mn}\} \in\Omega: \Vert x \Vert _{M(\phi )} = \sup_{s,t \ge1}\sup_{\zeta\in U_{st}} \biggl( \frac{1}{\phi_{st}}\sum_{m,n \in\zeta} \vert x_{mn} \vert \biggr) &lt; \infty \biggr\} $$\end{document}</tex-math><mml:math id="M258"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">{</mml:mo><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">}</mml:mo></mml:mrow></mml:math><graphic xlink:href="13660_2017_1333_Article_Equl.gif" position="anchor"/></alternatives></disp-formula> and
<disp-formula id="Equm"><alternatives><tex-math id="M259">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N(\phi) = \Biggl\{ x = \{ x_{mn}\} \in\Omega: \Vert x \Vert _{N(\phi)} = \sup_{u \in S(x)} \Biggl(\sum _{m,n = 1}^{\infty,\infty} \vert u_{mn}\vert \Delta_{11}\phi_{mn} \Biggr) &lt; \infty \Biggr\} . $$\end{document}</tex-math><mml:math id="M260"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">{</mml:mo><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:munder><mml:mrow><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">(</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">}</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equm.gif" position="anchor"/></alternatives></disp-formula>
</p>
        <p>Then the distances between <inline-formula id="IEq118"><alternatives><tex-math id="M261">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = \{ x_{mn}\}$\end{document}</tex-math><mml:math id="M262"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq118.gif"/></alternatives></inline-formula> and <inline-formula id="IEq119"><alternatives><tex-math id="M263">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$y = \{ y_{mn}\}$\end{document}</tex-math><mml:math id="M264"><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq119.gif"/></alternatives></inline-formula> induced by <inline-formula id="IEq120"><alternatives><tex-math id="M265">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M266"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq120.gif"/></alternatives></inline-formula> and <inline-formula id="IEq121"><alternatives><tex-math id="M267">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M268"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq121.gif"/></alternatives></inline-formula> can be expressed as
<disp-formula id="Equn"><alternatives><tex-math id="M269">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{M(\phi)} = \sup_{s,t \ge1}\sup_{\zeta \in U_{st}} \biggl( \frac{1}{\phi_{st}}\sum_{m,n \in\zeta} \vert x_{mn} - y_{mn}\vert \biggr) $$\end{document}</tex-math><mml:math id="M270"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow></mml:math><graphic xlink:href="13660_2017_1333_Article_Equn.gif" position="anchor"/></alternatives></disp-formula> and
<disp-formula id="Equo"><alternatives><tex-math id="M271">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{N(\phi)} = \sup_{u,v \in S(x)} \Biggl( \sum _{m,n = 1}^{\infty,\infty} \vert u_{mn} - v_{mn} \vert \Delta_{11}\phi_{mn} \Biggr). $$\end{document}</tex-math><mml:math id="M272"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi><mml:mo>∈</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:munder><mml:mrow><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">(</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equo.gif" position="anchor"/></alternatives></disp-formula>
</p>
      </sec>
      <sec id="FPar2">
        <title>Remark 1.2</title>
        <p>If <inline-formula id="IEq122"><alternatives><tex-math id="M273">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi_{st} = 1$\end{document}</tex-math><mml:math id="M274"><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq122.gif"/></alternatives></inline-formula> (<inline-formula id="IEq123"><alternatives><tex-math id="M275">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$s,t = 1,2,3,\ldots$\end{document}</tex-math><mml:math id="M276"><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq123.gif"/></alternatives></inline-formula>), then <inline-formula id="IEq124"><alternatives><tex-math id="M277">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) = L_{1}$\end{document}</tex-math><mml:math id="M278"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq124.gif"/></alternatives></inline-formula> [<inline-formula id="IEq125"><alternatives><tex-math id="M279">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi) = L_{\infty} $\end{document}</tex-math><mml:math id="M280"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq125.gif"/></alternatives></inline-formula>], and if <inline-formula id="IEq126"><alternatives><tex-math id="M281">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi_{st} = st$\end{document}</tex-math><mml:math id="M282"><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq126.gif"/></alternatives></inline-formula> (<inline-formula id="IEq127"><alternatives><tex-math id="M283">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$s,t = 1,2,3,\ldots$\end{document}</tex-math><mml:math id="M284"><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq127.gif"/></alternatives></inline-formula>), then <inline-formula id="IEq128"><alternatives><tex-math id="M285">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) = L_{\infty}$\end{document}</tex-math><mml:math id="M286"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq128.gif"/></alternatives></inline-formula> [<inline-formula id="IEq129"><alternatives><tex-math id="M287">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi) = L_{1}$\end{document}</tex-math><mml:math id="M288"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq129.gif"/></alternatives></inline-formula>].</p>
        <p>We now state the following known results of [<xref ref-type="bibr" rid="CR18">18</xref>] for single sequences (series) which can also be proved easily for double sequences (series).</p>
      </sec>
      <sec id="FPar3">
        <title>Lemma 1.1</title>
        <p>
<italic>If the series</italic>
<inline-formula id="IEq130"><alternatives><tex-math id="M289">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum u_{n}x_{n}$\end{document}</tex-math><mml:math id="M290"><mml:mo movablelimits="false">∑</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq130.gif"/></alternatives></inline-formula>
<italic>is convergent for every</italic>
<italic>x</italic>
<italic>of a</italic>
<italic>BK</italic>-<italic>space</italic>
<italic>E</italic>, <italic>then the functional</italic>
<inline-formula id="IEq131"><alternatives><tex-math id="M291">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum_{n = 1}^{\infty} u_{n}x_{n}$\end{document}</tex-math><mml:math id="M292"><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi mathvariant="normal">∞</mml:mi></mml:msubsup><mml:msub><mml:mi>u</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq131.gif"/></alternatives></inline-formula>
<italic>is linear and continuous in E</italic>.</p>
      </sec>
      <sec id="FPar4">
        <title>Lemma 1.2</title>
        <p>
<italic>If</italic>
<italic>E</italic>
<italic>and</italic>
<italic>F</italic>
<italic>are</italic>
<italic>BK</italic>-<italic>spaces</italic>, <italic>and if</italic>
<inline-formula id="IEq132"><alternatives><tex-math id="M293">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$E \subseteq F$\end{document}</tex-math><mml:math id="M294"><mml:mi>E</mml:mi><mml:mo>⊆</mml:mo><mml:mi>F</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq132.gif"/></alternatives></inline-formula>, <italic>then there is a real number</italic>
<italic>K</italic>
<italic>such that</italic>, <italic>for all</italic>
<italic>x</italic>
<italic>of</italic>
<italic>E</italic>,
<disp-formula id="Equp"><alternatives><tex-math id="M295">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Vert x \Vert _{F} \le K\Vert x \Vert _{E}. $$\end{document}</tex-math><mml:math id="M296"><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mi>F</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mi>E</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equp.gif" position="anchor"/></alternatives></disp-formula>
</p>
      </sec>
    </sec>
    <sec id="Sec2">
      <title>Properties of the spaces <inline-formula id="IEq133"><alternatives><tex-math id="M297">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M298"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq133.gif"/></alternatives></inline-formula> and <inline-formula id="IEq134"><alternatives><tex-math id="M299">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M300"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq134.gif"/></alternatives></inline-formula></title>
      <sec id="FPar5">
        <title>Theorem 2.1</title>
        <p>
<italic>The space</italic>
<inline-formula id="IEq135"><alternatives><tex-math id="M301">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M302"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq135.gif"/></alternatives></inline-formula>
<italic>is a</italic>
<italic>BK</italic>-<italic>space with the norm</italic>.
<disp-formula id="Equ1"><label>2.1</label><alternatives><tex-math id="M303">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \Vert x \Vert _{M(\phi)} = \sup_{s,t \ge 1}\sup _{\zeta\in U_{st}} \frac{1}{\phi_{st}} \biggl( \sum _{m,n \in\zeta} \vert x_{mn}\vert \biggr). $$\end{document}</tex-math><mml:math id="M304"><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>
</p>
      </sec>
      <sec id="FPar6">
        <title>Proof</title>
        <p>It is a routine verification to show that <inline-formula id="IEq136"><alternatives><tex-math id="M305">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M306"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq136.gif"/></alternatives></inline-formula> is a normed space with the given norm (<xref rid="Equ1" ref-type="">2.1</xref>), and so we omit it. Now, we proceed to showing that <inline-formula id="IEq137"><alternatives><tex-math id="M307">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M308"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq137.gif"/></alternatives></inline-formula> is complete. Let <inline-formula id="IEq138"><alternatives><tex-math id="M309">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ x^{l}\}$\end{document}</tex-math><mml:math id="M310"><mml:mo stretchy="false">{</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mi>l</mml:mi></mml:msup><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq138.gif"/></alternatives></inline-formula> be a Cauchy sequence in <inline-formula id="IEq139"><alternatives><tex-math id="M311">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M312"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq139.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq140"><alternatives><tex-math id="M313">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x^{l} = \{ x_{mn}^{l}\}_{m,n = 1,1}^{\infty,\infty}$\end{document}</tex-math><mml:math id="M314"><mml:msup><mml:mi>x</mml:mi><mml:mi>l</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq140.gif"/></alternatives></inline-formula> for every fixed <inline-formula id="IEq141"><alternatives><tex-math id="M315">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l \in\mathbb{N}$\end{document}</tex-math><mml:math id="M316"><mml:mi>l</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq141.gif"/></alternatives></inline-formula>. Then, for a given <inline-formula id="IEq142"><alternatives><tex-math id="M317">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\varepsilon&gt; 0$\end{document}</tex-math><mml:math id="M318"><mml:mi>ε</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq142.gif"/></alternatives></inline-formula>, there exists a positive integer <inline-formula id="IEq143"><alternatives><tex-math id="M319">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n_{0}(\varepsilon) &gt; 0$\end{document}</tex-math><mml:math id="M320"><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>ε</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq143.gif"/></alternatives></inline-formula> such that
<disp-formula id="Equq"><alternatives><tex-math id="M321">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\bigl\Vert x^{l} - x^{r} \bigr\Vert _{M(\phi)} = \sup_{s,t \ge 1}\sup_{\zeta\in U_{st}}\frac{1}{\phi_{st}} \biggl( \sum_{m,n \in\zeta} \bigl\vert x_{mn}^{l} - x_{mn}^{r} \bigr\vert \biggr) &lt; \varepsilon $$\end{document}</tex-math><mml:math id="M322"><mml:msub><mml:mrow><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">∥</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mi>l</mml:mi></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mi>r</mml:mi></mml:msup><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>r</mml:mi></mml:msubsup><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>&lt;</mml:mo><mml:mi>ε</mml:mi></mml:math><graphic xlink:href="13660_2017_1333_Article_Equq.gif" position="anchor"/></alternatives></disp-formula> for all <inline-formula id="IEq144"><alternatives><tex-math id="M323">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l,r &gt; n_{0}(\varepsilon)$\end{document}</tex-math><mml:math id="M324"><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>r</mml:mi><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>ε</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq144.gif"/></alternatives></inline-formula>, which yields, for each fixed <inline-formula id="IEq145"><alternatives><tex-math id="M325">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$s,t \ge 1$\end{document}</tex-math><mml:math id="M326"><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq145.gif"/></alternatives></inline-formula> and <inline-formula id="IEq146"><alternatives><tex-math id="M327">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\zeta\in U_{st}$\end{document}</tex-math><mml:math id="M328"><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq146.gif"/></alternatives></inline-formula>,
<disp-formula id="Equ2"><label>2.2</label><alternatives><tex-math id="M329">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \sum_{m,n \in\zeta} \bigl\vert x_{mn}^{l} - x_{mn}^{r} \bigr\vert \le\varepsilon \phi_{11}\quad \mbox{for all }l,r &gt; n_{0}(\varepsilon). $$\end{document}</tex-math><mml:math id="M330"><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>r</mml:mi></mml:msubsup><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:mo>≤</mml:mo><mml:mi>ε</mml:mi><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mspace width="1em"/><mml:mtext>for all </mml:mtext><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>r</mml:mi><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>ε</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula> Therefore
<disp-formula id="Equ3"><label>2.3</label><alternatives><tex-math id="M331">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \biggl\vert \sum_{m,n \in\zeta} \bigl\vert x_{mn}^{l} \bigr\vert - \sum_{m,n \in\zeta} \bigl\vert x_{mn}^{r} \bigr\vert \biggr\vert &lt; \varepsilon\phi_{11} \quad \mbox{for all }l,r &gt; n_{ 0} ( \varepsilon). $$\end{document}</tex-math><mml:math id="M332"><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">|</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:mo>−</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>r</mml:mi></mml:msubsup><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">|</mml:mo><mml:mo>&lt;</mml:mo><mml:mi>ε</mml:mi><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mspace width="1em"/><mml:mtext>for all </mml:mtext><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>r</mml:mi><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>ε</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula> This means that <inline-formula id="IEq147"><alternatives><tex-math id="M333">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ \sum_{m,n \in\zeta} \vert x_{mn}^{l}\vert \} _{l \in\mathbb{N}}$\end{document}</tex-math><mml:math id="M334"><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq147.gif"/></alternatives></inline-formula> is a Cauchy sequence in <inline-formula id="IEq148"><alternatives><tex-math id="M335">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mathbb{R}$\end{document}</tex-math><mml:math id="M336"><mml:mi mathvariant="double-struck">R</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq148.gif"/></alternatives></inline-formula> for every fixed <inline-formula id="IEq149"><alternatives><tex-math id="M337">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$s,t \ge1$\end{document}</tex-math><mml:math id="M338"><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq149.gif"/></alternatives></inline-formula> and <inline-formula id="IEq150"><alternatives><tex-math id="M339">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\zeta \in U_{st}$\end{document}</tex-math><mml:math id="M340"><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq150.gif"/></alternatives></inline-formula>. Since <inline-formula id="IEq151"><alternatives><tex-math id="M341">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mathbb{R}$\end{document}</tex-math><mml:math id="M342"><mml:mi mathvariant="double-struck">R</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq151.gif"/></alternatives></inline-formula> is complete, it converges, say
<disp-formula id="Equr"><alternatives><tex-math id="M343">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sum_{m,n \in\zeta} \bigl\vert x_{mn}^{l} \bigr\vert \to\sum_{m,n \in\zeta} \vert x_{mn} \vert \quad \mbox{as }l \to\infty. $$\end{document}</tex-math><mml:math id="M344"><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:mo stretchy="false">→</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mspace width="1em"/><mml:mtext>as </mml:mtext><mml:mi>l</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equr.gif" position="anchor"/></alternatives></disp-formula> Since absolute convergence implies convergence in <inline-formula id="IEq152"><alternatives><tex-math id="M345">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mathbb{R}$\end{document}</tex-math><mml:math id="M346"><mml:mi mathvariant="double-struck">R</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq152.gif"/></alternatives></inline-formula>, hence
<disp-formula id="Equ4"><label>2.4</label><alternatives><tex-math id="M347">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \sum_{m,n \in\zeta} x_{mn}^{l} \to\sum _{m,n \in\zeta} x_{mn} \quad \mbox{as } l \to\infty. $$\end{document}</tex-math><mml:math id="M348"><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo stretchy="false">→</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mspace width="1em"/><mml:mtext>as </mml:mtext><mml:mi>l</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula> Hence we have
<disp-formula id="Equ5"><label>2.5</label><alternatives><tex-math id="M349">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \lim_{l \to\infty} \biggl\Vert \sum_{m,n \in\zeta} x_{mn}^{l} - \sum_{m,n \in\zeta} x_{mn} \biggr\Vert _{M(\phi)} = 0. $$\end{document}</tex-math><mml:math id="M350"><mml:munder><mml:mo movablelimits="false">lim</mml:mo><mml:mrow><mml:mi>l</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">∥</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equ5.gif" position="anchor"/></alternatives></disp-formula> Let <inline-formula id="IEq153"><alternatives><tex-math id="M351">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$y^{l} = \sum_{m,n \in\zeta} \vert x_{mn}^{l}\vert $\end{document}</tex-math><mml:math id="M352"><mml:msup><mml:mi>y</mml:mi><mml:mi>l</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo stretchy="false">|</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq153.gif"/></alternatives></inline-formula>. Then <inline-formula id="IEq154"><alternatives><tex-math id="M353">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ y^{l}\} \in l_{\infty}$\end{document}</tex-math><mml:math id="M354"><mml:mo stretchy="false">{</mml:mo><mml:msup><mml:mi>y</mml:mi><mml:mi>l</mml:mi></mml:msup><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq154.gif"/></alternatives></inline-formula>. Therefore
<disp-formula id="Equs"><alternatives><tex-math id="M355">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sup_{l \in\mathbb{N}} \sum_{m,n \in\zeta} \bigl\vert x_{mn}^{l} \bigr\vert \le k. $$\end{document}</tex-math><mml:math id="M356"><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>l</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi></mml:mrow></mml:munder><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">|</mml:mo><mml:mo>≤</mml:mo><mml:mi>k</mml:mi><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equs.gif" position="anchor"/></alternatives></disp-formula> Since <inline-formula id="IEq155"><alternatives><tex-math id="M357">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum_{m,n \in\zeta} \vert x_{mn}\vert \le\sum_{m,n \in \zeta} \vert x_{mn} - x_{mn}^{l}\vert + \sum_{m,n \in\zeta} \vert x_{mn}^{l}\vert \le\varepsilon \phi_{11} + k$\end{document}</tex-math><mml:math id="M358"><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo stretchy="false">|</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mi>l</mml:mi></mml:msubsup><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:mi>ε</mml:mi><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>k</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq155.gif"/></alternatives></inline-formula>, it follows that <inline-formula id="IEq156"><alternatives><tex-math id="M359">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = \{ x_{mn}\} \in M(\phi)$\end{document}</tex-math><mml:math id="M360"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq156.gif"/></alternatives></inline-formula>. Since <inline-formula id="IEq157"><alternatives><tex-math id="M361">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ x^{l}\}_{l \in\mathbb{N}}$\end{document}</tex-math><mml:math id="M362"><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mi>l</mml:mi></mml:msup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq157.gif"/></alternatives></inline-formula> was an arbitrary Cauchy sequence, the space <inline-formula id="IEq158"><alternatives><tex-math id="M363">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M364"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq158.gif"/></alternatives></inline-formula> is complete. Now we prove that <inline-formula id="IEq159"><alternatives><tex-math id="M365">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M366"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq159.gif"/></alternatives></inline-formula> has continuous coordinate projections <inline-formula id="IEq160"><alternatives><tex-math id="M367">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$p_{mn}$\end{document}</tex-math><mml:math id="M368"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq160.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq161"><alternatives><tex-math id="M369">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$p_{mn}:\Omega\to K$\end{document}</tex-math><mml:math id="M370"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi>K</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq161.gif"/></alternatives></inline-formula> and <inline-formula id="IEq162"><alternatives><tex-math id="M371">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$p_{mn}(x) = x_{mn}$\end{document}</tex-math><mml:math id="M372"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq162.gif"/></alternatives></inline-formula>. The coordinate projections <inline-formula id="IEq163"><alternatives><tex-math id="M373">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$p_{mn}$\end{document}</tex-math><mml:math id="M374"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq163.gif"/></alternatives></inline-formula> are continuous since <inline-formula id="IEq164"><alternatives><tex-math id="M375">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\vert x_{mn}\vert \le\sup_{s,t \ge1}\sup_{\zeta\in U_{st}}\phi_{st}\Vert x \Vert _{M(\phi)}$\end{document}</tex-math><mml:math id="M376"><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:msub><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq164.gif"/></alternatives></inline-formula> for each <inline-formula id="IEq165"><alternatives><tex-math id="M377">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$m,n \in \mathbb{N}$\end{document}</tex-math><mml:math id="M378"><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">N</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq165.gif"/></alternatives></inline-formula>. □</p>
      </sec>
      <sec id="FPar7">
        <title>Remark 2.1</title>
        <p>The space <inline-formula id="IEq166"><alternatives><tex-math id="M379">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M380"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq166.gif"/></alternatives></inline-formula> is a <italic>BK</italic>-space with the norm
<disp-formula id="Equt"><alternatives><tex-math id="M381">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Vert x \Vert _{N(\phi)} = \sup_{u \in S(x)} \Biggl( \sum _{m,n = 1}^{\infty,\infty} \vert u_{mn}\vert \Delta_{11}\phi_{mn} \Biggr). $$\end{document}</tex-math><mml:math id="M382"><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:munder><mml:mrow><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">(</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equt.gif" position="anchor"/></alternatives></disp-formula>
</p>
      </sec>
      <sec id="FPar8">
        <title>Lemma 2.1</title>
        <p>
<list list-type="simple"><list-item><label>(i)</label><p>
<italic>If</italic>
<inline-formula id="IEq167"><alternatives><tex-math id="M383">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M384"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq167.gif"/></alternatives></inline-formula> [<inline-formula id="IEq168"><alternatives><tex-math id="M385">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in N(\phi) $\end{document}</tex-math><mml:math id="M386"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq168.gif"/></alternatives></inline-formula>] <italic>and</italic>
<inline-formula id="IEq169"><alternatives><tex-math id="M387">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in S(x)$\end{document}</tex-math><mml:math id="M388"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq169.gif"/></alternatives></inline-formula>, <italic>then</italic>
<inline-formula id="IEq170"><alternatives><tex-math id="M389">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in M(\phi)$\end{document}</tex-math><mml:math id="M390"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq170.gif"/></alternatives></inline-formula> [<inline-formula id="IEq171"><alternatives><tex-math id="M391">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in N(\phi) $\end{document}</tex-math><mml:math id="M392"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq171.gif"/></alternatives></inline-formula>] <italic>and</italic>
<inline-formula id="IEq172"><alternatives><tex-math id="M393">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Vert u\Vert = \Vert x\Vert $\end{document}</tex-math><mml:math id="M394"><mml:mo stretchy="false">∥</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">∥</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq172.gif"/></alternatives></inline-formula>.</p></list-item><list-item><label>(ii)</label><p>
<italic>If</italic>
<inline-formula id="IEq173"><alternatives><tex-math id="M395">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M396"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq173.gif"/></alternatives></inline-formula> [<inline-formula id="IEq174"><alternatives><tex-math id="M397">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in N(\phi)$\end{document}</tex-math><mml:math id="M398"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq174.gif"/></alternatives></inline-formula>] <italic>and</italic>
<inline-formula id="IEq175"><alternatives><tex-math id="M399">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\vert u_{mn}\vert \le \vert x_{mn}\vert $\end{document}</tex-math><mml:math id="M400"><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq175.gif"/></alternatives></inline-formula>
<italic>for every positive integer</italic>
<italic>m</italic>, <italic>n</italic>, <italic>then</italic>
<inline-formula id="IEq176"><alternatives><tex-math id="M401">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in M(\phi)$\end{document}</tex-math><mml:math id="M402"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq176.gif"/></alternatives></inline-formula> [<inline-formula id="IEq177"><alternatives><tex-math id="M403">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in N(\phi)$\end{document}</tex-math><mml:math id="M404"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq177.gif"/></alternatives></inline-formula>] <italic>and</italic>
<inline-formula id="IEq178"><alternatives><tex-math id="M405">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Vert u\Vert \le \Vert x\Vert $\end{document}</tex-math><mml:math id="M406"><mml:mo stretchy="false">∥</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">∥</mml:mo><mml:mo>≤</mml:mo><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq178.gif"/></alternatives></inline-formula>.</p></list-item></list>
</p>
      </sec>
      <sec id="FPar9">
        <title>Proof</title>
        <p>(i) Let <inline-formula id="IEq179"><alternatives><tex-math id="M407">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M408"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq179.gif"/></alternatives></inline-formula>, then <inline-formula id="IEq180"><alternatives><tex-math id="M409">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sup_{s,t \ge1} \sup_{\zeta\in U_{st}}\frac{1}{\phi_{st}}\sum_{m,n \in\zeta} \vert x_{mn}\vert &lt; \infty$\end{document}</tex-math><mml:math id="M410"><mml:msub><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq180.gif"/></alternatives></inline-formula>. So, we have
<disp-formula id="Equu"><alternatives><tex-math id="M411">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{1}{\phi_{st}}\sum_{m,n \in\zeta} \vert x_{mn} \vert &lt; \infty \quad \mbox{for each }\zeta\in U_{st}\mbox{ and }s,t \ge1. $$\end{document}</tex-math><mml:math id="M412"><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mspace width="1em"/><mml:mtext>for each </mml:mtext><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mtext> and </mml:mtext><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equu.gif" position="anchor"/></alternatives></disp-formula> Since the sum of a finite number of terms remains the same for all the rearrangements,
<disp-formula id="Equv"><alternatives><tex-math id="M413">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{1}{\phi_{st}}\sum_{m,n \in\zeta} \vert u_{mn} \vert = \frac{1}{\phi_{st}}\sum_{m,n \in\zeta} \vert x_{mn}\vert \quad \mbox{for each }u \in S(x)\mbox{ and }\zeta\in U_{st}, s,t \ge1. $$\end{document}</tex-math><mml:math id="M414"><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mspace width="1em"/><mml:mtext>for each </mml:mtext><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mtext> and </mml:mtext><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equv.gif" position="anchor"/></alternatives></disp-formula> Hence
<disp-formula id="Equw"><alternatives><tex-math id="M415">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sup_{s,t \ge1}\sup_{\zeta\in U_{st}}\frac{1}{\phi_{st}}\sum _{m,n \in\zeta} \vert u_{mn}\vert = \sup _{s,t \ge1} \sup_{\zeta\in U_{st}}\frac{1}{\phi_{st}}\sum _{m,n \in\zeta} \vert x_{mn}\vert &lt; \infty, $$\end{document}</tex-math><mml:math id="M416"><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equw.gif" position="anchor"/></alternatives></disp-formula> thus <inline-formula id="IEq181"><alternatives><tex-math id="M417">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in M(\phi)$\end{document}</tex-math><mml:math id="M418"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq181.gif"/></alternatives></inline-formula> and <inline-formula id="IEq182"><alternatives><tex-math id="M419">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Vert u\Vert = \Vert x\Vert $\end{document}</tex-math><mml:math id="M420"><mml:mo stretchy="false">∥</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">∥</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq182.gif"/></alternatives></inline-formula>.</p>
        <p>(ii) By using the definition, easy to prove. □</p>
      </sec>
      <sec id="FPar10">
        <title>Theorem 2.2</title>
        <p>
<italic>For arbitrary</italic>
<inline-formula id="IEq183"><alternatives><tex-math id="M421">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi\in\Theta$\end{document}</tex-math><mml:math id="M422"><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Θ</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq183.gif"/></alternatives></inline-formula>, <italic>we have</italic>
<inline-formula id="IEq184"><alternatives><tex-math id="M423">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta_{11}\phi\in M(\phi)$\end{document}</tex-math><mml:math id="M424"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq184.gif"/></alternatives></inline-formula>
<italic>and</italic>
<inline-formula id="IEq185"><alternatives><tex-math id="M425">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Vert \Delta_{11}\phi \Vert _{M(\phi)} \le2$\end{document}</tex-math><mml:math id="M426"><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mn>2</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq185.gif"/></alternatives></inline-formula>.</p>
      </sec>
      <sec id="FPar11">
        <title>Proof</title>
        <p>Let <italic>s</italic> and <italic>t</italic> be arbitrary positive integers, let <inline-formula id="IEq186"><alternatives><tex-math id="M427">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sigma,\varsigma\in U_{st}$\end{document}</tex-math><mml:math id="M428"><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>ς</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq186.gif"/></alternatives></inline-formula>, and let <inline-formula id="IEq187"><alternatives><tex-math id="M429">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\tau_{1}$\end{document}</tex-math><mml:math id="M430"><mml:msub><mml:mi>τ</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq187.gif"/></alternatives></inline-formula>, <inline-formula id="IEq188"><alternatives><tex-math id="M431">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\tau_{2}$\end{document}</tex-math><mml:math id="M432"><mml:msub><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq188.gif"/></alternatives></inline-formula> constitute the element of <italic>σ</italic> and <italic>ς</italic> exceed by <italic>s</italic> and <italic>t</italic> respectively, also from the definition we have <inline-formula id="IEq189"><alternatives><tex-math id="M433">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta_{11}\phi\ge0$\end{document}</tex-math><mml:math id="M434"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mi>ϕ</mml:mi><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq189.gif"/></alternatives></inline-formula> and <inline-formula id="IEq190"><alternatives><tex-math id="M435">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta_{11} ( \frac{\phi_{mn}}{mn} ) \le0$\end{document}</tex-math><mml:math id="M436"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:mfrac><mml:mo stretchy="false">)</mml:mo><mml:mo>≤</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq190.gif"/></alternatives></inline-formula>. Then
<disp-formula id="Equx"><alternatives><tex-math id="M437">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document} $$\begin{aligned} \sum_{n \in\sigma,m \in\varsigma} \vert \Delta_{11} \phi_{mn} \vert \le&amp; \sum_{n = 1,m = 1}^{s,t} \Delta_{11}\phi_{mn} + \sum_{n \in \tau_{1},m \in\tau_{2}} \Delta_{11}\phi_{mn} \\ \leq&amp; \phi_{st} + \sum_{n \in\tau_{1},m \in\tau_{2}} \biggl( \frac{\phi_{m - 1,n - 1}}{(m - 1)(n - 1)} \biggr) \\ \leq &amp; \phi_{st} + \left . \textstyle\begin{array}{c@{\quad}c@{\quad}c@{\quad}c@{\quad}c} \frac{\phi_{st}}{st} &amp; + \frac{\phi_{s,t + 1}}{s(t + 1)} &amp; + \frac{\phi_{s,t + 2}}{s(t + 2)} &amp; +. &amp;. \\ \frac{\phi_{s + 1,t}}{(s + 1)t} &amp; + \frac{\phi_{s + 1,t + 1}}{(s + 1)(t + 1)} &amp; + \frac{\phi_{s + 1,t + 2}}{(s + 1)(t + 2)} &amp; +. &amp;. \\ + &amp; + &amp; + &amp;. &amp; \\ . &amp;. &amp;. &amp;. &amp; \end{array}\displaystyle \right \} \quad \max(st) \textrm{-terms} \\ \leq&amp; \phi_{st} + st\frac{\phi_{st}}{st} = 2\phi_{st}. \end{aligned}$$ \end{document}</tex-math><mml:math id="M438"><mml:mtable columnalign="right center left" columnspacing="0.2em 0.2em"><mml:mtr><mml:mtd><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>∈</mml:mo><mml:mi>ς</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo></mml:mtd><mml:mtd><mml:mo>≤</mml:mo></mml:mtd><mml:mtd><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>τ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:munder><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>≤</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>τ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>≤</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mtable columnalign="center center center center center" columnspacing="1em 1em 1em 1em"><mml:mtr><mml:mtd><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>+</mml:mo><mml:mo>.</mml:mo></mml:mtd><mml:mtd><mml:mo>.</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>+</mml:mo><mml:mo>.</mml:mo></mml:mtd><mml:mtd><mml:mo>.</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>+</mml:mo></mml:mtd><mml:mtd><mml:mo>+</mml:mo></mml:mtd><mml:mtd><mml:mo>+</mml:mo></mml:mtd><mml:mtd><mml:mo>.</mml:mo></mml:mtd><mml:mtd/></mml:mtr><mml:mtr><mml:mtd><mml:mo>.</mml:mo></mml:mtd><mml:mtd><mml:mo>.</mml:mo></mml:mtd><mml:mtd><mml:mo>.</mml:mo></mml:mtd><mml:mtd><mml:mo>.</mml:mo></mml:mtd><mml:mtd/></mml:mtr></mml:mtable><mml:mo>}</mml:mo></mml:mrow><mml:mspace width="1em"/><mml:mo movablelimits="false">max</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mtext>-terms</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>≤</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="13660_2017_1333_Article_Equx.gif" position="anchor"/></alternatives></disp-formula> □</p>
      </sec>
      <sec id="FPar12">
        <title>Lemma 2.2</title>
        <p>
<italic>If</italic>
<inline-formula id="IEq191"><alternatives><tex-math id="M439">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M440"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq191.gif"/></alternatives></inline-formula>
<italic>and</italic>
<inline-formula id="IEq192"><alternatives><tex-math id="M441">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ c_{11},c_{12}, \ldots,c_{1n},c_{21},c_{22}, \ldots,c_{2n}, \ldots,c_{m1},c_{m2}, \ldots,c_{mn}\}$\end{document}</tex-math><mml:math id="M442"><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>21</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>22</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq192.gif"/></alternatives></inline-formula>
<italic>is a rearrangement of</italic>
<inline-formula id="IEq193"><alternatives><tex-math id="M443">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ b_{11},b_{12}, \ldots,b_{1n},b_{21},b_{22}, \ldots,b_{2n}, \ldots,b_{m1},b_{m2}, \ldots,b_{mn}\}$\end{document}</tex-math><mml:math id="M444"><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mn>21</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mn>22</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq193.gif"/></alternatives></inline-formula>
<italic>such that</italic>
<inline-formula id="IEq194"><alternatives><tex-math id="M445">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\vert c_{11}\vert \ge \vert c_{12}\vert \ge \cdots\ge \vert c_{1n}\vert $\end{document}</tex-math><mml:math id="M446"><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo>⋯</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq194.gif"/></alternatives></inline-formula>, <inline-formula id="IEq195"><alternatives><tex-math id="M447">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\vert c_{21}\vert \ge \vert c_{22}\vert \ge\cdots\ge \vert c_{2n}\vert ,\dots, \vert c_{m1}\vert \ge \vert c_{m2}\vert \ge\cdots\ge \vert c_{mn}\vert $\end{document}</tex-math><mml:math id="M448"><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>21</mml:mn></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>22</mml:mn></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo>⋯</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo>⋯</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq195.gif"/></alternatives></inline-formula>
<italic>and</italic>
<inline-formula id="IEq196"><alternatives><tex-math id="M449">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\vert c_{11}\vert \ge \vert c_{21}\vert \ge\cdots\ge \vert c_{m1}\vert $\end{document}</tex-math><mml:math id="M450"><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>21</mml:mn></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo>⋯</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq196.gif"/></alternatives></inline-formula>, <inline-formula id="IEq197"><alternatives><tex-math id="M451">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\vert c_{12}\vert \ge \vert c_{22}\vert \ge\cdots \ge \vert c_{m2}\vert ,\vert c_{n1}\vert \ge \vert c_{n2}\vert \ge\cdots\ge \vert c_{nm}\vert $\end{document}</tex-math><mml:math id="M452"><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>22</mml:mn></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo>⋯</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≥</mml:mo><mml:mo>⋯</mml:mo><mml:mo>≥</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq197.gif"/></alternatives></inline-formula>, <italic>then</italic>
<disp-formula id="Equy"><alternatives><tex-math id="M453">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sum_{i,j = 1,1}^{m,n} \vert b_{ij}x_{ij} \vert \le \Vert x\Vert _{M(\phi )}\sum_{i,j = 1,1}^{m,n} \vert c_{ij}\vert \Delta_{11}\phi_{ij}. $$\end{document}</tex-math><mml:math id="M454"><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equy.gif" position="anchor"/></alternatives></disp-formula>
</p>
      </sec>
      <sec id="FPar13">
        <title>Proof</title>
        <p>In view of Lemma <xref ref-type="sec" rid="FPar8">2.1</xref>(i), it is sufficient to consider the case when <inline-formula id="IEq198"><alternatives><tex-math id="M455">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$b_{ij} = c_{ij}$\end{document}</tex-math><mml:math id="M456"><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq198.gif"/></alternatives></inline-formula> (<inline-formula id="IEq199"><alternatives><tex-math id="M457">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$i = 1,2, \ldots,m$\end{document}</tex-math><mml:math id="M458"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>m</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq199.gif"/></alternatives></inline-formula>; <inline-formula id="IEq200"><alternatives><tex-math id="M459">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$j = 1,2, \ldots,n$\end{document}</tex-math><mml:math id="M460"><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq200.gif"/></alternatives></inline-formula>). Then writing <inline-formula id="IEq201"><alternatives><tex-math id="M461">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$X_{mn} = \sum_{i,j = 1}^{m,n} \vert x_{ij}\vert $\end{document}</tex-math><mml:math id="M462"><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq201.gif"/></alternatives></inline-formula>, we get
<disp-formula id="Equz"><alternatives><tex-math id="M463">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document} $$\begin{aligned} \sum_{i,j = 1,1}^{m,n} \vert b_{ij}x_{ij} \vert =&amp; \sum_{i = 1}^{m - 1} \sum _{j = 1}^{n - 1} \bigl( \vert c_{ij}\vert - \vert c_{i,j + 1}\vert - \vert c_{i + 1,j}\vert +\vert c_{i + 1,j + 1}\vert \bigr)X_{ij} +\vert c_{mn}\vert X_{mn} \\ \le&amp; \Vert x\Vert _{M(\phi)}\sum_{i = 1}^{m - 1} \sum_{j = 1}^{n - 1} \bigl( \vert c_{ij}\vert - \vert c_{i,j + 1}\vert - \vert c_{i + 1,j}\vert + \vert c_{i + 1,j + 1}\vert \bigr) \phi_{ij} + \Vert x\Vert _{M(\phi)}\vert c_{mn} \vert X_{mn} \\ =&amp; \Vert x\Vert _{M(\phi)}\sum_{i,j = 1,1}^{m,n} \vert c_{ij}\vert \Delta_{11}\phi_{ij}. \end{aligned}$$ \end{document}</tex-math><mml:math id="M464"><mml:mtable columnalign="right center left" columnspacing="0.2em 0.2em"><mml:mtr><mml:mtd><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">(</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>−</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>−</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">)</mml:mo></mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>≤</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">(</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>−</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>−</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo maxsize="2.4ex" minsize="2.4ex" stretchy="true">)</mml:mo></mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="13660_2017_1333_Article_Equz.gif" position="anchor"/></alternatives></disp-formula> Hence we have <inline-formula id="IEq202"><alternatives><tex-math id="M465">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum_{i,j = 1,1}^{m,n} \vert b_{ij}x_{ij}\vert \le \Vert x\Vert _{M(\phi)}\sum_{i,j = 1,1}^{m,n} \vert c_{ij}\vert \Delta_{11}\phi_{ij}$\end{document}</tex-math><mml:math id="M466"><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq202.gif"/></alternatives></inline-formula>. □</p>
      </sec>
      <sec id="FPar14">
        <title>Theorem 2.3</title>
        <p>
<italic>In order that</italic>
<inline-formula id="IEq203"><alternatives><tex-math id="M467">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum u_{ij}x_{ij}$\end{document}</tex-math><mml:math id="M468"><mml:mo movablelimits="false">∑</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq203.gif"/></alternatives></inline-formula>
<italic>be convergent</italic> [<italic>absolutely convergent</italic>] <italic>whenever</italic>
<inline-formula id="IEq204"><alternatives><tex-math id="M469">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M470"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq204.gif"/></alternatives></inline-formula>, <italic>it is necessary and sufficient that</italic>
<inline-formula id="IEq205"><alternatives><tex-math id="M471">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in N(\phi)$\end{document}</tex-math><mml:math id="M472"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq205.gif"/></alternatives></inline-formula>. <italic>Further</italic>, <italic>if</italic>
<inline-formula id="IEq206"><alternatives><tex-math id="M473">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M474"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq206.gif"/></alternatives></inline-formula>
<italic>and</italic>
<inline-formula id="IEq207"><alternatives><tex-math id="M475">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in N(\phi)$\end{document}</tex-math><mml:math id="M476"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq207.gif"/></alternatives></inline-formula>, <italic>then</italic>
<disp-formula id="Equ6"><label>2.6</label><alternatives><tex-math id="M477">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \sum_{i,j = 1,1}^{\infty,\infty} \vert u_{ij}x_{ij} \vert \le \Vert u\Vert _{N(\phi)} \Vert x\Vert _{M(\phi)}. $$\end{document}</tex-math><mml:math id="M478"><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equ6.gif" position="anchor"/></alternatives></disp-formula>
</p>
      </sec>
      <sec id="FPar15">
        <title>Proof</title>
        <p>
<italic>Necessity</italic>. We now suppose that <inline-formula id="IEq208"><alternatives><tex-math id="M479">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum u_{ij}x_{ij}$\end{document}</tex-math><mml:math id="M480"><mml:mo movablelimits="false">∑</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq208.gif"/></alternatives></inline-formula> is convergent whenever <inline-formula id="IEq209"><alternatives><tex-math id="M481">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M482"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq209.gif"/></alternatives></inline-formula>, then from Lemma <xref ref-type="sec" rid="FPar3">1.1</xref> we have
<disp-formula id="Equaa"><alternatives><tex-math id="M483">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Biggl\vert \sum_{i,j = 1,1}^{\infty,\infty} u_{ij}x_{ij} \Biggr\vert \le K \Vert x\Vert _{M(\phi)} $$\end{document}</tex-math><mml:math id="M484"><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">|</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo maxsize="6.6ex" minsize="6.6ex" stretchy="true">|</mml:mo><mml:mo>≤</mml:mo><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:math><graphic xlink:href="13660_2017_1333_Article_Equaa.gif" position="anchor"/></alternatives></disp-formula> for some real number <italic>K</italic> and all <italic>x</italic> of <inline-formula id="IEq210"><alternatives><tex-math id="M485">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M486"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq210.gif"/></alternatives></inline-formula>. In view of Lemma <xref ref-type="sec" rid="FPar8">2.1</xref>(ii), we may replace <inline-formula id="IEq211"><alternatives><tex-math id="M487">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x_{ij}$\end{document}</tex-math><mml:math id="M488"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq211.gif"/></alternatives></inline-formula> by <inline-formula id="IEq212"><alternatives><tex-math id="M489">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x_{ij} \operatorname{sgn} \{ u_{ij}\}$\end{document}</tex-math><mml:math id="M490"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>sgn</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq212.gif"/></alternatives></inline-formula>, obtaining
<disp-formula id="Equ7"><label>2.7</label><alternatives><tex-math id="M491">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \sum_{i,j = 1,1}^{\infty,\infty} \vert u_{ij}x_{ij} \vert \le K \Vert x\Vert _{M(\phi)}. $$\end{document}</tex-math><mml:math id="M492"><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equ7.gif" position="anchor"/></alternatives></disp-formula> Let <inline-formula id="IEq213"><alternatives><tex-math id="M493">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$v \in S(u)$\end{document}</tex-math><mml:math id="M494"><mml:mi>v</mml:mi><mml:mo>∈</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq213.gif"/></alternatives></inline-formula>. Then taking <italic>x</italic> to be a suitable rearrangement of <inline-formula id="IEq214"><alternatives><tex-math id="M495">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta_{11}\phi$\end{document}</tex-math><mml:math id="M496"><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mi>ϕ</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq214.gif"/></alternatives></inline-formula>, it follows from Eq. (<xref rid="Equ7" ref-type="">2.7</xref>) and Theorem <xref ref-type="sec" rid="FPar10">2.2</xref> and Lemma <xref ref-type="sec" rid="FPar8">2.1</xref>(i) that
<disp-formula id="Equab"><alternatives><tex-math id="M497">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sum_{i,j = 1,1}^{\infty,\infty} \vert v_{ij} \vert \Delta_{11}\phi_{ij} \le4K, $$\end{document}</tex-math><mml:math id="M498"><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mn>4</mml:mn><mml:mi>K</mml:mi><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equab.gif" position="anchor"/></alternatives></disp-formula> and thus <inline-formula id="IEq215"><alternatives><tex-math id="M499">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in N(\phi)$\end{document}</tex-math><mml:math id="M500"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq215.gif"/></alternatives></inline-formula>.</p>
        <p>
<italic>Sufficiency</italic>. If <inline-formula id="IEq216"><alternatives><tex-math id="M501">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M502"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq216.gif"/></alternatives></inline-formula> and <inline-formula id="IEq217"><alternatives><tex-math id="M503">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in N(\phi)$\end{document}</tex-math><mml:math id="M504"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq217.gif"/></alternatives></inline-formula>, it follows from Lemma <xref ref-type="sec" rid="FPar12">2.2</xref> that for every positive integer <italic>m</italic> and <italic>n</italic>,
<disp-formula id="Equac"><alternatives><tex-math id="M505">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sum_{i,j = 1,1}^{\infty,\infty} \vert u_{ij}x_{ij} \vert \le \Vert u\Vert _{N(\phi)} \Vert x\Vert _{M(\phi)}. $$\end{document}</tex-math><mml:math id="M506"><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equac.gif" position="anchor"/></alternatives></disp-formula> □</p>
      </sec>
      <sec id="FPar16">
        <title>Theorem 2.4</title>
        <p>
<italic>In order that</italic>
<inline-formula id="IEq218"><alternatives><tex-math id="M507">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum u_{mn}x_{mn}$\end{document}</tex-math><mml:math id="M508"><mml:mo movablelimits="false">∑</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq218.gif"/></alternatives></inline-formula>
<italic>be convergent</italic> [<italic>absolutely convergent</italic>] <italic>whenever</italic>
<inline-formula id="IEq219"><alternatives><tex-math id="M509">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in N(\phi)$\end{document}</tex-math><mml:math id="M510"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq219.gif"/></alternatives></inline-formula>, <italic>it is necessary and sufficient that</italic>
<inline-formula id="IEq220"><alternatives><tex-math id="M511">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in M(\phi)$\end{document}</tex-math><mml:math id="M512"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq220.gif"/></alternatives></inline-formula>.</p>
      </sec>
      <sec id="FPar17">
        <title>Proof</title>
        <p>Since sufficiency is included in Theorem <xref ref-type="sec" rid="FPar14">2.3</xref>, we only consider necessity. We therefore suppose that <inline-formula id="IEq221"><alternatives><tex-math id="M513">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sum u_{mn}x_{mn}$\end{document}</tex-math><mml:math id="M514"><mml:mo movablelimits="false">∑</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq221.gif"/></alternatives></inline-formula> is convergent whenever <inline-formula id="IEq222"><alternatives><tex-math id="M515">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in N(\phi)$\end{document}</tex-math><mml:math id="M516"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq222.gif"/></alternatives></inline-formula>. By arguments similar to those used in Theorem <xref ref-type="sec" rid="FPar14">2.3</xref>, we may therefore have that
<disp-formula id="Equ8"><label>2.8</label><alternatives><tex-math id="M517">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \sum_{m,n = 1,1}^{\infty,\infty} \vert u_{mn}x_{mn} \vert \le K \Vert x\Vert _{N(\phi)} $$\end{document}</tex-math><mml:math id="M518"><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:mi>K</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:math><graphic xlink:href="13660_2017_1333_Article_Equ8.gif" position="anchor"/></alternatives></disp-formula> for some real number <italic>K</italic> and all <italic>x</italic> of <inline-formula id="IEq223"><alternatives><tex-math id="M519">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M520"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq223.gif"/></alternatives></inline-formula>. Let <inline-formula id="IEq224"><alternatives><tex-math id="M521">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = c(\zeta)$\end{document}</tex-math><mml:math id="M522"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ζ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq224.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq225"><alternatives><tex-math id="M523">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\zeta\in U_{st}$\end{document}</tex-math><mml:math id="M524"><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq225.gif"/></alternatives></inline-formula>. Then <inline-formula id="IEq226"><alternatives><tex-math id="M525">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in N(\phi)$\end{document}</tex-math><mml:math id="M526"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq226.gif"/></alternatives></inline-formula>, and
<disp-formula id="Equad"><alternatives><tex-math id="M527">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Vert x\Vert _{N(\phi)} = \sup_{\xi\in U_{st}}\sum _{m,n \in\xi} \Delta_{11}\phi_{mn} \le4 \phi_{st}, $$\end{document}</tex-math><mml:math id="M528"><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>ξ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ξ</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mn>4</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equad.gif" position="anchor"/></alternatives></disp-formula> from Theorem <xref ref-type="sec" rid="FPar10">2.2</xref> and Eq. (<xref rid="Equ8" ref-type="">2.8</xref>) we have
<disp-formula id="Equae"><alternatives><tex-math id="M529">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sum_{m,n \in\zeta} \vert u_{mn}\vert \le4K \phi_{st}\quad (\zeta\in U_{st}; s,t = 1,2,3, \ldots), $$\end{document}</tex-math><mml:math id="M530"><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:mn>4</mml:mn><mml:mi>K</mml:mi><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mspace width="1em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>;</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equae.gif" position="anchor"/></alternatives></disp-formula> and thus <inline-formula id="IEq227"><alternatives><tex-math id="M531">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in M(\phi)$\end{document}</tex-math><mml:math id="M532"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq227.gif"/></alternatives></inline-formula>. □</p>
      </sec>
    </sec>
    <sec id="Sec3">
      <title>Inclusion relations for <inline-formula id="IEq228"><alternatives><tex-math id="M533">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M534"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq228.gif"/></alternatives></inline-formula> and <inline-formula id="IEq229"><alternatives><tex-math id="M535">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M536"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq229.gif"/></alternatives></inline-formula></title>
      <sec id="FPar18">
        <title>Lemma 3.1</title>
        <p>
<italic>In order that</italic>
<inline-formula id="IEq230"><alternatives><tex-math id="M537">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) \subseteq M(\psi)$\end{document}</tex-math><mml:math id="M538"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊆</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq230.gif"/></alternatives></inline-formula> [<inline-formula id="IEq231"><alternatives><tex-math id="M539">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi) \supseteq N(\psi)$\end{document}</tex-math><mml:math id="M540"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊇</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq231.gif"/></alternatives></inline-formula>], <italic>it is necessary and sufficient that</italic>
<disp-formula id="Equaf"><alternatives><tex-math id="M541">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sup_{s,t \ge1} \biggl( \frac{\phi_{st}}{\psi_{st}} \biggr) &lt; \infty. $$\end{document}</tex-math><mml:math id="M542"><mml:munder><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:mfrac><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equaf.gif" position="anchor"/></alternatives></disp-formula>
</p>
      </sec>
      <sec id="FPar19">
        <title>Proof</title>
        <p>Since each of the spaces <inline-formula id="IEq232"><alternatives><tex-math id="M543">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M544"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq232.gif"/></alternatives></inline-formula> and <inline-formula id="IEq233"><alternatives><tex-math id="M545">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi )$\end{document}</tex-math><mml:math id="M546"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq233.gif"/></alternatives></inline-formula> is the dual of the other, by Theorems <xref ref-type="sec" rid="FPar14">2.3</xref> and <xref ref-type="sec" rid="FPar16">2.4</xref>, the second version is equivalent to the first. Moreover, sufficiency follows from the definition of an <inline-formula id="IEq234"><alternatives><tex-math id="M547">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M548"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq234.gif"/></alternatives></inline-formula> space. We therefore suppose that <inline-formula id="IEq235"><alternatives><tex-math id="M549">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) \subseteq M(\psi)$\end{document}</tex-math><mml:math id="M550"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊆</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq235.gif"/></alternatives></inline-formula>. Since <inline-formula id="IEq236"><alternatives><tex-math id="M551">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta\phi\in M(\phi)$\end{document}</tex-math><mml:math id="M552"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq236.gif"/></alternatives></inline-formula>, it follows that <inline-formula id="IEq237"><alternatives><tex-math id="M553">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta \psi\in M(\psi)$\end{document}</tex-math><mml:math id="M554"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ψ</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq237.gif"/></alternatives></inline-formula>, and hence we find that, for every positive integer <inline-formula id="IEq238"><alternatives><tex-math id="M555">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$s,t \ge1$\end{document}</tex-math><mml:math id="M556"><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq238.gif"/></alternatives></inline-formula>,
<disp-formula id="Equag"><alternatives><tex-math id="M557">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\phi_{st} = \sum_{i,j = 1,1}^{s,t} \Delta_{11}\phi_{ij} \le\psi_{st} \Vert \Delta \phi \Vert _{M(\psi)},\quad \mbox{where }\Delta= \Delta_{11}. $$\end{document}</tex-math><mml:math id="M558"><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mtext>where </mml:mtext><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equag.gif" position="anchor"/></alternatives></disp-formula> □</p>
      </sec>
      <sec id="FPar20">
        <title>Theorem 3.1</title>
        <p>
<list list-type="simple"><list-item><label>(i)</label><p>
<inline-formula id="IEq239"><alternatives><tex-math id="M559">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{1} \subseteq M(\phi) \subseteq L_{\infty}$\end{document}</tex-math><mml:math id="M560"><mml:msub><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⊆</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊆</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq239.gif"/></alternatives></inline-formula> [<inline-formula id="IEq240"><alternatives><tex-math id="M561">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{1} \subseteq N(\phi) \subseteq L_{\infty} $\end{document}</tex-math><mml:math id="M562"><mml:msub><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⊆</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊆</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq240.gif"/></alternatives></inline-formula>] <italic>for all</italic>
<italic>ϕ</italic>
<italic>of</italic> Θ.</p></list-item><list-item><label>(ii)</label><p>
<inline-formula id="IEq241"><alternatives><tex-math id="M563">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) = L_{1}$\end{document}</tex-math><mml:math id="M564"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq241.gif"/></alternatives></inline-formula> [<inline-formula id="IEq242"><alternatives><tex-math id="M565">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi) = L_{\infty} $\end{document}</tex-math><mml:math id="M566"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq242.gif"/></alternatives></inline-formula>] <italic>if and only if</italic>
<inline-formula id="IEq243"><alternatives><tex-math id="M567">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mathit{bp}\textit{-}\lim_{s,t}\phi_{st} &lt; \infty$\end{document}</tex-math><mml:math id="M568"><mml:mi mathvariant="italic">bp</mml:mi><mml:mtext mathvariant="italic">-</mml:mtext><mml:msub><mml:mo movablelimits="false">lim</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq243.gif"/></alternatives></inline-formula>.</p></list-item><list-item><label>(iii)</label><p>
<inline-formula id="IEq244"><alternatives><tex-math id="M569">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) = L_{\infty}$\end{document}</tex-math><mml:math id="M570"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq244.gif"/></alternatives></inline-formula> [<inline-formula id="IEq245"><alternatives><tex-math id="M571">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi) = L_{1}$\end{document}</tex-math><mml:math id="M572"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq245.gif"/></alternatives></inline-formula>] <italic>if and only if</italic>
<inline-formula id="IEq246"><alternatives><tex-math id="M573">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mathit{bp}\textit{-}\lim_{s,t}(\phi_{st}/st) &gt; 0$\end{document}</tex-math><mml:math id="M574"><mml:mi mathvariant="italic">bp</mml:mi><mml:mtext mathvariant="italic">-</mml:mtext><mml:msub><mml:mo movablelimits="false">lim</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq246.gif"/></alternatives></inline-formula>.</p></list-item></list>
</p>
      </sec>
      <sec id="FPar21">
        <title>Proof</title>
        <p>We prove here the first version, while the second version follows by Theorems <xref ref-type="sec" rid="FPar14">2.3</xref> and <xref ref-type="sec" rid="FPar16">2.4</xref>. Since <inline-formula id="IEq247"><alternatives><tex-math id="M575">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi_{11} \le\phi_{mn} \le mn\phi_{mn}$\end{document}</tex-math><mml:math id="M576"><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo>≤</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>m</mml:mi><mml:mi>n</mml:mi><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq247.gif"/></alternatives></inline-formula> for all <italic>ϕ</italic> of Θ, we have by Lemma <xref ref-type="sec" rid="FPar18">3.1</xref> that (i) is satisfied. Further, from Lemma <xref ref-type="sec" rid="FPar18">3.1</xref>, it follows that <inline-formula id="IEq248"><alternatives><tex-math id="M577">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) \subseteq L_{1}$\end{document}</tex-math><mml:math id="M578"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊆</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq248.gif"/></alternatives></inline-formula> if and only if <inline-formula id="IEq249"><alternatives><tex-math id="M579">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sup_{s,t \ge 1}\phi_{st} &lt; \infty$\end{document}</tex-math><mml:math id="M580"><mml:msub><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq249.gif"/></alternatives></inline-formula>, while <inline-formula id="IEq250"><alternatives><tex-math id="M581">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{\infty} \subseteq M(\phi)$\end{document}</tex-math><mml:math id="M582"><mml:msub><mml:mi>L</mml:mi><mml:mi mathvariant="normal">∞</mml:mi></mml:msub><mml:mo>⊆</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq250.gif"/></alternatives></inline-formula> if and only if <inline-formula id="IEq251"><alternatives><tex-math id="M583">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sup_{s,t \ge1}(\phi_{st}/st) &lt; \infty$\end{document}</tex-math><mml:math id="M584"><mml:msub><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq251.gif"/></alternatives></inline-formula>; since the sequences <inline-formula id="IEq252"><alternatives><tex-math id="M585">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ \phi_{st}\}$\end{document}</tex-math><mml:math id="M586"><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq252.gif"/></alternatives></inline-formula> and <inline-formula id="IEq253"><alternatives><tex-math id="M587">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ st/\phi_{st}\}$\end{document}</tex-math><mml:math id="M588"><mml:mo stretchy="false">{</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq253.gif"/></alternatives></inline-formula> are monotonic, (ii) and (iii) are also satisfied. □</p>
      </sec>
      <sec id="FPar22">
        <title>Theorem 3.2</title>
        <p>
<italic>Suppose that</italic>
<inline-formula id="IEq254"><alternatives><tex-math id="M589">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$1 &lt; p &lt; \infty$\end{document}</tex-math><mml:math id="M590"><mml:mn>1</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq254.gif"/></alternatives></inline-formula>
<italic>and</italic>
<inline-formula id="IEq255"><alternatives><tex-math id="M591">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\frac{1}{p} + \frac{1}{q} = 1$\end{document}</tex-math><mml:math id="M592"><mml:mfrac><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>q</mml:mi></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq255.gif"/></alternatives></inline-formula>. <italic>Then</italic>
<list list-type="simple"><list-item><label>(i)</label><p>
<italic>Given any</italic>
<italic>ϕ</italic>
<italic>of</italic> Θ, <inline-formula id="IEq256"><alternatives><tex-math id="M593">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)\neq L_{p}$\end{document}</tex-math><mml:math id="M594"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≠</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq256.gif"/></alternatives></inline-formula> [<inline-formula id="IEq257"><alternatives><tex-math id="M595">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi )\neq L_{q}$\end{document}</tex-math><mml:math id="M596"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≠</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq257.gif"/></alternatives></inline-formula>].</p></list-item><list-item><label>(ii)</label><p>
<italic>In order that</italic>
<inline-formula id="IEq258"><alternatives><tex-math id="M597">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{p} \subset M(\phi)$\end{document}</tex-math><mml:math id="M598"><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⊂</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq258.gif"/></alternatives></inline-formula> [<inline-formula id="IEq259"><alternatives><tex-math id="M599">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi) \subset L_{q}$\end{document}</tex-math><mml:math id="M600"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊂</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq259.gif"/></alternatives></inline-formula>], <italic>it is necessary and sufficient that</italic>
<inline-formula id="IEq260"><alternatives><tex-math id="M601">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\sup_{s,t \ge1} ( \frac{(st)^{1/q}}{\phi_{st}} ) &lt; \infty$\end{document}</tex-math><mml:math id="M602"><mml:msub><mml:mo movablelimits="false">sup</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mi>q</mml:mi></mml:mrow></mml:msup><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo stretchy="false">)</mml:mo><mml:mo>&lt;</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq260.gif"/></alternatives></inline-formula>.</p></list-item><list-item><label>(iii)</label><p>
<italic>In order that</italic>
<inline-formula id="IEq261"><alternatives><tex-math id="M603">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) \subset L_{p}$\end{document}</tex-math><mml:math id="M604"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊂</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq261.gif"/></alternatives></inline-formula> [<inline-formula id="IEq262"><alternatives><tex-math id="M605">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi) \supset L_{q}$\end{document}</tex-math><mml:math id="M606"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊃</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq262.gif"/></alternatives></inline-formula>], <italic>it is necessary and sufficient that</italic>
<inline-formula id="IEq263"><alternatives><tex-math id="M607">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta\phi\in L_{p}$\end{document}</tex-math><mml:math id="M608"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq263.gif"/></alternatives></inline-formula>.</p></list-item><list-item><label>(iv)</label><p>
<inline-formula id="IEq264"><alternatives><tex-math id="M609">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\bigcup_{\Delta\phi\in L_{p}} M(\phi) = L_{p}$\end{document}</tex-math><mml:math id="M610"><mml:msub><mml:mo movablelimits="false">⋃</mml:mo><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq264.gif"/></alternatives></inline-formula> [<inline-formula id="IEq265"><alternatives><tex-math id="M611">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\bigcap_{\Delta\phi\in L_{p}} N(\phi) = L_{q} $\end{document}</tex-math><mml:math id="M612"><mml:msub><mml:mo movablelimits="false">⋂</mml:mo><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq265.gif"/></alternatives></inline-formula>].</p></list-item></list>
</p>
      </sec>
      <sec id="FPar23">
        <title>Proof</title>
        <p>(i) Let us suppose that <inline-formula id="IEq266"><alternatives><tex-math id="M613">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) = L_{p}$\end{document}</tex-math><mml:math id="M614"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq266.gif"/></alternatives></inline-formula>.</p>
        <p>Then, by Lemma <xref ref-type="sec" rid="FPar4">1.2</xref>, there exist real numbers <inline-formula id="IEq267"><alternatives><tex-math id="M615">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$r_{1}$\end{document}</tex-math><mml:math id="M616"><mml:msub><mml:mi>r</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq267.gif"/></alternatives></inline-formula> and <inline-formula id="IEq268"><alternatives><tex-math id="M617">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$r_{2}$\end{document}</tex-math><mml:math id="M618"><mml:msub><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq268.gif"/></alternatives></inline-formula> (<inline-formula id="IEq269"><alternatives><tex-math id="M619">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$r_{1} &gt; 0$\end{document}</tex-math><mml:math id="M620"><mml:msub><mml:mi>r</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq269.gif"/></alternatives></inline-formula>, <inline-formula id="IEq270"><alternatives><tex-math id="M621">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$r_{2} &gt; 0$\end{document}</tex-math><mml:math id="M622"><mml:msub><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq270.gif"/></alternatives></inline-formula>) such that, for all <italic>x</italic> of <inline-formula id="IEq271"><alternatives><tex-math id="M623">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M624"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq271.gif"/></alternatives></inline-formula>,
<disp-formula id="Equah"><alternatives><tex-math id="M625">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$r_{1} \Vert x\Vert _{L_{p}} \le \Vert x\Vert _{M(\phi)} \le r_{2} \Vert x\Vert _{L_{p}}. $$\end{document}</tex-math><mml:math id="M626"><mml:msub><mml:mi>r</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:msub><mml:mo>≤</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:msub><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equah.gif" position="anchor"/></alternatives></disp-formula> Taking <inline-formula id="IEq272"><alternatives><tex-math id="M627">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = c(\zeta)$\end{document}</tex-math><mml:math id="M628"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ζ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq272.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq273"><alternatives><tex-math id="M629">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\zeta\in U_{st}$\end{document}</tex-math><mml:math id="M630"><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq273.gif"/></alternatives></inline-formula>, we have that
<disp-formula id="Equai"><alternatives><tex-math id="M631">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$r_{1}(st)^{\frac{1}{p}} \le\frac{st}{\phi_{st}} \le r_{2}(st)^{\frac{1}{p}}\quad (s,t = 1,2,3, \ldots), $$\end{document}</tex-math><mml:math id="M632"><mml:msub><mml:mi>r</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:mfrac></mml:msup><mml:mo>≤</mml:mo><mml:mfrac><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>≤</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:mfrac></mml:msup><mml:mspace width="1em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equai.gif" position="anchor"/></alternatives></disp-formula> and hence that
<disp-formula id="Equaj"><alternatives><tex-math id="M633">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$r_{1} \le\frac{(st)^{\frac{1}{q}}}{\phi_{st}} \le r_{2} \quad (s,t = 1,2,3, \ldots). $$\end{document}</tex-math><mml:math id="M634"><mml:msub><mml:mi>r</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>≤</mml:mo><mml:mfrac><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>q</mml:mi></mml:mfrac></mml:msup><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>≤</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mspace width="1em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equaj.gif" position="anchor"/></alternatives></disp-formula> In view of Lemma <xref ref-type="sec" rid="FPar18">3.1</xref>, this implies that <inline-formula id="IEq274"><alternatives><tex-math id="M635">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) = M(\psi)$\end{document}</tex-math><mml:math id="M636"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq274.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq275"><alternatives><tex-math id="M637">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\psi= \{ (mn)^{\frac{1}{q}}\}$\end{document}</tex-math><mml:math id="M638"><mml:mi>ψ</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>q</mml:mi></mml:mfrac></mml:msup><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq275.gif"/></alternatives></inline-formula>. Since <inline-formula id="IEq276"><alternatives><tex-math id="M639">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta\psi\in M(\psi)$\end{document}</tex-math><mml:math id="M640"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ψ</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq276.gif"/></alternatives></inline-formula> by Theorem <xref ref-type="sec" rid="FPar10">2.2</xref>, but <inline-formula id="IEq277"><alternatives><tex-math id="M641">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta\psi\notin L_{q}$\end{document}</tex-math><mml:math id="M642"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ψ</mml:mi><mml:mo>∉</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq277.gif"/></alternatives></inline-formula>, this leads to a contradiction. Hence (i) follows.</p>
        <p>(ii) If <inline-formula id="IEq278"><alternatives><tex-math id="M643">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{q} \subset M(\phi)$\end{document}</tex-math><mml:math id="M644"><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub><mml:mo>⊂</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq278.gif"/></alternatives></inline-formula>, arguments similar to those used in the proof of (i) show that
<disp-formula id="Equ9"><label>3.1</label><alternatives><tex-math id="M645">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ (st)^{1/q} \le K\phi_{st} \quad (s,t = 1,2,3, \ldots). $$\end{document}</tex-math><mml:math id="M646"><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mi>q</mml:mi></mml:mrow></mml:msup><mml:mo>≤</mml:mo><mml:mi>K</mml:mi><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mspace width="1em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equ9.gif" position="anchor"/></alternatives></disp-formula> For sufficiency, we suppose that (<xref rid="Equ9" ref-type="">3.1</xref>) is satisfied. Then, whenever <inline-formula id="IEq279"><alternatives><tex-math id="M647">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in L_{p}$\end{document}</tex-math><mml:math id="M648"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq279.gif"/></alternatives></inline-formula> and <inline-formula id="IEq280"><alternatives><tex-math id="M649">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\zeta\in U_{st}$\end{document}</tex-math><mml:math id="M650"><mml:mi>ζ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq280.gif"/></alternatives></inline-formula>,
<disp-formula id="Equak"><alternatives><tex-math id="M651">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sum_{m,n \in\zeta} \vert x_{mn}\vert \le \biggl( \sum_{m,n \in\zeta} \vert x_{mn}\vert ^{p} \biggr)^{\frac{1}{p}} \biggl( \sum_{m,n \in\zeta} 1 \biggr)^{\frac{1}{q}} \le \Vert x\Vert _{L_{q}}(st)^{\frac{1}{q}} &lt; K\phi_{st}\Vert x\Vert _{L_{q}}, $$\end{document}</tex-math><mml:math id="M652"><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>≤</mml:mo><mml:msup><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mo stretchy="false">|</mml:mo><mml:mi>p</mml:mi></mml:msup><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:mfrac></mml:msup><mml:msup><mml:mrow><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">(</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>∈</mml:mo><mml:mi>ζ</mml:mi></mml:mrow></mml:munder><mml:mn>1</mml:mn><mml:mo maxsize="5.2ex" minsize="5.2ex" stretchy="true">)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>q</mml:mi></mml:mfrac></mml:msup><mml:mo>≤</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:msub><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>q</mml:mi></mml:mfrac></mml:msup><mml:mo>&lt;</mml:mo><mml:mi>K</mml:mi><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo stretchy="false">∥</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">∥</mml:mo></mml:mrow><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:msub><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equak.gif" position="anchor"/></alternatives></disp-formula> and hence <inline-formula id="IEq281"><alternatives><tex-math id="M653">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M654"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq281.gif"/></alternatives></inline-formula>. In view of (i), it follows that <inline-formula id="IEq282"><alternatives><tex-math id="M655">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{q} \subset M(\phi)$\end{document}</tex-math><mml:math id="M656"><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub><mml:mo>⊂</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq282.gif"/></alternatives></inline-formula>.</p>
        <p>(iii) By Theorem <xref ref-type="sec" rid="FPar10">2.2</xref>, we have <inline-formula id="IEq283"><alternatives><tex-math id="M657">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta\phi\in M(\phi)$\end{document}</tex-math><mml:math id="M658"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq283.gif"/></alternatives></inline-formula>. For sufficiency, we suppose that <inline-formula id="IEq284"><alternatives><tex-math id="M659">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta\phi\in L_{p}$\end{document}</tex-math><mml:math id="M660"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq284.gif"/></alternatives></inline-formula> and that <inline-formula id="IEq285"><alternatives><tex-math id="M661">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M662"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq285.gif"/></alternatives></inline-formula>. Then <inline-formula id="IEq286"><alternatives><tex-math id="M663">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ u_{mn}\Delta_{11}\phi_{mn}\} \in L_{1}$\end{document}</tex-math><mml:math id="M664"><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq286.gif"/></alternatives></inline-formula> whenever <inline-formula id="IEq287"><alternatives><tex-math id="M665">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in L_{q}$\end{document}</tex-math><mml:math id="M666"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq287.gif"/></alternatives></inline-formula>, and it therefore follows from Lemma <xref ref-type="sec" rid="FPar12">2.2</xref> that <inline-formula id="IEq288"><alternatives><tex-math id="M667">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ u_{mn}x_{mn}\} \in L_{1}$\end{document}</tex-math><mml:math id="M668"><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq288.gif"/></alternatives></inline-formula> whenever <inline-formula id="IEq289"><alternatives><tex-math id="M669">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$u \in L_{q}$\end{document}</tex-math><mml:math id="M670"><mml:mi>u</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq289.gif"/></alternatives></inline-formula>. Since <inline-formula id="IEq290"><alternatives><tex-math id="M671">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{p}$\end{document}</tex-math><mml:math id="M672"><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq290.gif"/></alternatives></inline-formula> is the dual of <inline-formula id="IEq291"><alternatives><tex-math id="M673">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{q}$\end{document}</tex-math><mml:math id="M674"><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq291.gif"/></alternatives></inline-formula> and since <inline-formula id="IEq292"><alternatives><tex-math id="M675">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)\neq L_{p}$\end{document}</tex-math><mml:math id="M676"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≠</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq292.gif"/></alternatives></inline-formula>, it follows that <inline-formula id="IEq293"><alternatives><tex-math id="M677">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi) \subset L_{q}$\end{document}</tex-math><mml:math id="M678"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⊂</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq293.gif"/></alternatives></inline-formula>.</p>
        <p>(iv) By using (iii) we have <inline-formula id="IEq294"><alternatives><tex-math id="M679">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\bigcup_{\Delta\phi\in L_{p}} M_{\phi} \subseteq L_{p}$\end{document}</tex-math><mml:math id="M680"><mml:msub><mml:mo movablelimits="false">⋃</mml:mo><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mi>M</mml:mi><mml:mi>ϕ</mml:mi></mml:msub><mml:mo>⊆</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq294.gif"/></alternatives></inline-formula>. Now, for obtaining the complementary relation <inline-formula id="IEq295"><alternatives><tex-math id="M681">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$L_{p} \subseteq\bigcup_{\Delta\phi\in L_{p}} M_{\phi}$\end{document}</tex-math><mml:math id="M682"><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>⊆</mml:mo><mml:msub><mml:mo movablelimits="false">⋃</mml:mo><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mi>M</mml:mi><mml:mi>ϕ</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq295.gif"/></alternatives></inline-formula>, let us suppose that <inline-formula id="IEq296"><alternatives><tex-math id="M683">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in L_{p}$\end{document}</tex-math><mml:math id="M684"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq296.gif"/></alternatives></inline-formula>. Then <inline-formula id="IEq297"><alternatives><tex-math id="M685">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\lim_{m,n \to\infty} x_{mn} = 0$\end{document}</tex-math><mml:math id="M686"><mml:msub><mml:mo movablelimits="false">lim</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo stretchy="false">→</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq297.gif"/></alternatives></inline-formula>, and hence there is an element <italic>u</italic> of <inline-formula id="IEq298"><alternatives><tex-math id="M687">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$S(x)$\end{document}</tex-math><mml:math id="M688"><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq298.gif"/></alternatives></inline-formula> such that <inline-formula id="IEq299"><alternatives><tex-math id="M689">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\{ \vert u_{mn}\vert \}$\end{document}</tex-math><mml:math id="M690"><mml:mo stretchy="false">{</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq299.gif"/></alternatives></inline-formula> is a non-increasing sequence. If we take <inline-formula id="IEq300"><alternatives><tex-math id="M691">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\psi= \{ \sum_{i,j = 1,1}^{m,n} \vert u_{ij}\vert \}$\end{document}</tex-math><mml:math id="M692"><mml:mi>ψ</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq300.gif"/></alternatives></inline-formula>, then it is easy to verify that <inline-formula id="IEq301"><alternatives><tex-math id="M693">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\psi\in \Theta$\end{document}</tex-math><mml:math id="M694"><mml:mi>ψ</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Θ</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq301.gif"/></alternatives></inline-formula> and that <inline-formula id="IEq302"><alternatives><tex-math id="M695">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x \in M(\phi)$\end{document}</tex-math><mml:math id="M696"><mml:mi>x</mml:mi><mml:mo>∈</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq302.gif"/></alternatives></inline-formula>. Since <inline-formula id="IEq303"><alternatives><tex-math id="M697">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\Delta\psi\in L_{p}$\end{document}</tex-math><mml:math id="M698"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ψ</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq303.gif"/></alternatives></inline-formula>, the complementary relation is satisfied. □</p>
      </sec>
    </sec>
    <sec id="Sec4">
      <title>Application of <inline-formula id="IEq304"><alternatives><tex-math id="M699">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M700"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq304.gif"/></alternatives></inline-formula> and <inline-formula id="IEq305"><alternatives><tex-math id="M701">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M702"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq305.gif"/></alternatives></inline-formula> in clustering</title>
      <p>In this section, we implement a k-means clustering algorithm by using <inline-formula id="IEq306"><alternatives><tex-math id="M703">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M704"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq306.gif"/></alternatives></inline-formula>-distance measure. Further, we apply the k-means algorithm into clustering to cluster two-moon data. The clustering result obtained by the <inline-formula id="IEq307"><alternatives><tex-math id="M705">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M706"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq307.gif"/></alternatives></inline-formula>-distance measure is compared with the results derived by the existing Euclidean distance measures (<inline-formula id="IEq308"><alternatives><tex-math id="M707">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{2}$\end{document}</tex-math><mml:math id="M708"><mml:msub><mml:mi>l</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq308.gif"/></alternatives></inline-formula>).</p>
      <sec id="Sec5">
        <title>Algorithm to compute <inline-formula id="IEq309"><alternatives><tex-math id="M709">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M710"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq309.gif"/></alternatives></inline-formula> distance</title>
        <p>Let <inline-formula id="IEq310"><alternatives><tex-math id="M711">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$x = [x_{1},x_{2},x_{3}, \ldots,x_{n}]_{1 \times n}$\end{document}</tex-math><mml:math id="M712"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>×</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq310.gif"/></alternatives></inline-formula> and <inline-formula id="IEq311"><alternatives><tex-math id="M713">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$y = [y_{1},y_{2},y_{3}, \ldots,y_{n}]_{1 \times n}$\end{document}</tex-math><mml:math id="M714"><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>×</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq311.gif"/></alternatives></inline-formula> be two matrices of size <inline-formula id="IEq312"><alternatives><tex-math id="M715">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$1 \times n$\end{document}</tex-math><mml:math id="M716"><mml:mn>1</mml:mn><mml:mo>×</mml:mo><mml:mi>n</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq312.gif"/></alternatives></inline-formula>, and let <inline-formula id="IEq313"><alternatives><tex-math id="M717">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\phi_{m,n} = \phi_{1,n} = n$\end{document}</tex-math><mml:math id="M718"><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>n</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq313.gif"/></alternatives></inline-formula>. <list list-type="order"><list-item><p>Calculate <inline-formula id="IEq314"><alternatives><tex-math id="M719">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$a_{i} = \frac{1}{\phi_{1,i}}\vert x_{i} - y_{i}\vert $\end{document}</tex-math><mml:math id="M720"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">|</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq314.gif"/></alternatives></inline-formula>, <inline-formula id="IEq315"><alternatives><tex-math id="M721">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$i = 1,2,3, \ldots,n$\end{document}</tex-math><mml:math id="M722"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq315.gif"/></alternatives></inline-formula>.</p></list-item><list-item><p>The <inline-formula id="IEq316"><alternatives><tex-math id="M723">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M724"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq316.gif"/></alternatives></inline-formula>-distance between <italic>x</italic> and <italic>y</italic> is <italic>d</italic>, where
<disp-formula id="Equal"><alternatives><tex-math id="M725">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d = \max\{ a_{1},a_{1} + a_{2}, \ldots,a_{1} + a_{2} + \cdots+ a_{n}\}. $$\end{document}</tex-math><mml:math id="M726"><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mo movablelimits="false">max</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mo>⋯</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="13660_2017_1333_Article_Equal.gif" position="anchor"/></alternatives></disp-formula>
</p></list-item></list>
</p>
      </sec>
      <sec id="Sec6">
        <title>K-means clustering algorithm for <inline-formula id="IEq317"><alternatives><tex-math id="M727">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M728"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq317.gif"/></alternatives></inline-formula>-distance measure</title>
        <p>Let <inline-formula id="IEq318"><alternatives><tex-math id="M729">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$X = [x_{1},x_{2},x_{3},\ldots,x_{n}]$\end{document}</tex-math><mml:math id="M730"><mml:mi>X</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq318.gif"/></alternatives></inline-formula> be the data set. <list list-type="order"><list-item><p>Randomly/judiciously select <italic>k</italic> cluster centers (in this paper we choose first <italic>k</italic> data points as the cluster center <inline-formula id="IEq319"><alternatives><tex-math id="M731">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$y = [x_{1},x_{2},\ldots,x_{k}]$\end{document}</tex-math><mml:math id="M732"><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq319.gif"/></alternatives></inline-formula>).</p></list-item><list-item><p>By using <inline-formula id="IEq320"><alternatives><tex-math id="M733">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M734"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq320.gif"/></alternatives></inline-formula> or <inline-formula id="IEq321"><alternatives><tex-math id="M735">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M736"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq321.gif"/></alternatives></inline-formula> distance measure (since both are dual of each other, in application point of view, we only consider <inline-formula id="IEq322"><alternatives><tex-math id="M737">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M738"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq322.gif"/></alternatives></inline-formula>), compute the distance between each data points and cluster centers.</p></list-item><list-item><p>Put data points into the cluster whose <inline-formula id="IEq323"><alternatives><tex-math id="M739">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M740"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq323.gif"/></alternatives></inline-formula>-distance with its center is minimum.</p></list-item><list-item><p>Define cluster centers for the new clusters evolved due to steps 1-3, the new cluster centers are computed as follows: <inline-formula id="IEq324"><alternatives><tex-math id="M741">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$c_{i} = \frac{1}{k_{i}}\sum_{j = 1}^{k_{i}} x_{i}$\end{document}</tex-math><mml:math id="M742"><mml:msub><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>k</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msubsup><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq324.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq325"><alternatives><tex-math id="M743">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$k_{i}$\end{document}</tex-math><mml:math id="M744"><mml:msub><mml:mi>k</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq325.gif"/></alternatives></inline-formula> denotes the number of points in the <italic>i</italic>th cluster.</p></list-item><list-item><p>Repeat the above process until the difference between two consecutive cluster centers reaches less than a small number <italic>ε</italic>.</p></list-item></list>
</p>
      </sec>
      <sec id="Sec7">
        <title>Two-moon dataset clustering by using <inline-formula id="IEq326"><alternatives><tex-math id="M745">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M746"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq326.gif"/></alternatives></inline-formula>-distance measure in k-means algorithm</title>
        <p>Two-moon dataset is a well-known nonconvex data set. It is an artificially designed two dimensional dataset consisting of 373 data points [<xref ref-type="bibr" rid="CR19">19</xref>]. Two-moon dataset is visualized as moon-shaped clusters (see Figure <xref rid="Fig1" ref-type="fig">1</xref>). <fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Original shape of two-moon dataset.</bold>
</p></caption><graphic xlink:href="13660_2017_1333_Fig1_HTML" id="d29e14188"/></fig>
</p>
        <p>By using <inline-formula id="IEq327"><alternatives><tex-math id="M747">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M748"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq327.gif"/></alternatives></inline-formula>-distance measure in the k-means clustering algorithm, the obtained result is represented in Figure <xref rid="Fig2" ref-type="fig">2</xref>. In Figure <xref rid="Fig3" ref-type="fig">3</xref>, we represent the result obtained by using the Euclidean distance measure in the k-means algorithm (we measure the accuracy of the cluster by using the formula, accuracy = (number of data points in the right cluster/total number of data points)). The experimental result shows that cluster accuracy of <inline-formula id="IEq328"><alternatives><tex-math id="M749">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M750"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq328.gif"/></alternatives></inline-formula>-distance measure is 84.72% while <inline-formula id="IEq329"><alternatives><tex-math id="M751">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$l_{2}$\end{document}</tex-math><mml:math id="M752"><mml:msub><mml:mi>l</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq329.gif"/></alternatives></inline-formula>-distance measure’s clustering accuracy is 78.55%. Thus, <inline-formula id="IEq330"><alternatives><tex-math id="M753">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M754"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq330.gif"/></alternatives></inline-formula>-distance measure substantially improves the clustering accuracy. <fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Clustering induced by</bold>
<inline-formula id="IEq331"><alternatives><tex-math id="M755">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\pmb{M(\phi)}$\end{document}</tex-math><mml:math id="M756"><mml:mi mathvariant="bold-italic">M</mml:mi><mml:mo mathvariant="bold" stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo mathvariant="bold" stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq331.gif"/></alternatives></inline-formula>
<bold>-distance measure.</bold>
</p></caption><graphic xlink:href="13660_2017_1333_Fig2_HTML" id="d29e14290"/></fig>
<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Clustering induced by Euclidean distance</bold>
<inline-formula id="IEq332"><alternatives><tex-math id="M757">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\pmb{l_{2}}$\end{document}</tex-math><mml:math id="M758"><mml:msub><mml:mi mathvariant="bold-italic">l</mml:mi><mml:mn mathvariant="bold">2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq332.gif"/></alternatives></inline-formula>
<bold>.</bold>
</p></caption><graphic xlink:href="13660_2017_1333_Fig3_HTML" id="d29e14319"/></fig>
</p>
      </sec>
    </sec>
    <sec id="Sec8">
      <title>Conclusions</title>
      <p>In this paper, we defined Banach spaces <inline-formula id="IEq333"><alternatives><tex-math id="M759">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M760"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq333.gif"/></alternatives></inline-formula> and <inline-formula id="IEq334"><alternatives><tex-math id="M761">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(\phi)$\end{document}</tex-math><mml:math id="M762"><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq334.gif"/></alternatives></inline-formula> with discussion of their mathematical properties. Further, we proved some of their inclusion relation. Furthermore, we applied the distance measure induced by the Banach space <inline-formula id="IEq335"><alternatives><tex-math id="M763">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M764"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq335.gif"/></alternatives></inline-formula> into clustering to cluster the two-moon data by using the k-means clustering algorithm; the result of the experiment shows that the <inline-formula id="IEq336"><alternatives><tex-math id="M765">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$M(\phi)$\end{document}</tex-math><mml:math id="M766"><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq336.gif"/></alternatives></inline-formula>-distance measure extensively improves the clustering accuracy.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors’ contributions</bold>
        </p>
        <p>All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>The second and third authors gratefully acknowledge the financial support from King Abdulaziz University, Jeddah, Saudi Arabia.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>MacQueen</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Some methods for classification and analysis of multivariate observations</article-title>
          <source>Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability</source>
          <year>1967</year>
          <fpage>281</fpage>
          <lpage>297</lpage>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bezdek</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>A review of probabilistic, fuzzy, and neural models for pattern recognition</article-title>
          <source>J. Intell. Fuzzy Syst.</source>
          <year>1993</year>
          <volume>1</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="doi">10.1109/TFUZZ.1993.6027269</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jain</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Data clustering: 50 years beyond k-means</article-title>
          <source>Pattern Recognit. Lett.</source>
          <year>2010</year>
          <volume>31</volume>
          <issue>8</issue>
          <fpage>651</fpage>
          <lpage>666</lpage>
          <pub-id pub-id-type="doi">10.1016/j.patrec.2009.09.011</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>M-Y</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>K-Y</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H-M</given-names>
            </name>
          </person-group>
          <article-title>K-means particle swarm optimization with embedded chaotic search for solving multidimensional problems</article-title>
          <source>Appl. Math. Comput.</source>
          <year>2012</year>
          <volume>219</volume>
          <issue>6</issue>
          <fpage>3091</fpage>
          <lpage>3099</lpage>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Duan</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>An improved k-means clustering algorithm for fish image segmentation</article-title>
          <source>Math. Comput. Model.</source>
          <year>2013</year>
          <volume>58</volume>
          <issue>3</issue>
          <fpage>790</fpage>
          <lpage>798</lpage>
          <pub-id pub-id-type="doi">10.1016/j.mcm.2012.12.025</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cap</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Prez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lozano</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>An efficient approximation to the k-means clustering for massive data</article-title>
          <source>Knowl.-Based Syst.</source>
          <year>2016</year>
          <volume>117</volume>
          <fpage>56</fpage>
          <lpage>69</lpage>
          <pub-id pub-id-type="doi">10.1016/j.knosys.2016.06.031</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Güngör</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Ünler</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>K-harmonic means data clustering with simulated annealing heuristic</article-title>
          <source>Appl. Math. Comput.</source>
          <year>2007</year>
          <volume>184</volume>
          <issue>2</issue>
          <fpage>199</fpage>
          <lpage>209</lpage>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sargent</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Some sequence spaces related to the <inline-formula id="IEq337"><alternatives><tex-math id="M767">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\ell_{p}$\end{document}</tex-math><mml:math id="M768"><mml:msub><mml:mi>ℓ</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq337.gif"/></alternatives></inline-formula> spaces</article-title>
          <source>J. Lond. Math. Soc.</source>
          <year>1960</year>
          <volume>1</volume>
          <issue>2</issue>
          <fpage>161</fpage>
          <lpage>171</lpage>
          <pub-id pub-id-type="doi">10.1112/jlms/s1-35.2.161</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mursaleen</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Some geometric properties of a sequence space related to <inline-formula id="IEq339"><alternatives><tex-math id="M769">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\ell_{p}$\end{document}</tex-math><mml:math id="M770"><mml:msub><mml:mi>ℓ</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq339.gif"/></alternatives></inline-formula></article-title>
          <source>Bull. Aust. Math. Soc.</source>
          <year>2003</year>
          <volume>67</volume>
          <issue>2</issue>
          <fpage>343</fpage>
          <lpage>347</lpage>
          <pub-id pub-id-type="doi">10.1017/S0004972700033803</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mursaleen</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Application of measure of noncompactness to infinite system of differential equations</article-title>
          <source>Can. Math. Bull.</source>
          <year>2013</year>
          <volume>56</volume>
          <fpage>388</fpage>
          <lpage>394</lpage>
          <pub-id pub-id-type="doi">10.4153/CMB-2011-170-7</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>On the marriage of <inline-formula id="IEq341"><alternatives><tex-math id="M771">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\ell_{p}$\end{document}</tex-math><mml:math id="M772"><mml:msub><mml:mi>ℓ</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq341.gif"/></alternatives></inline-formula>-norms and edit distance</article-title>
          <source>Proceedings of the Thirtieth International Conference on Very Large Data Bases</source>
          <year>2004</year>
          <fpage>792</fpage>
          <lpage>803</lpage>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Cristianini</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Shawe-Taylor</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <source>An Introduction to Support Vector Machines and Other Kernel-Based Learning Methods</source>
          <year>2000</year>
          <publisher-loc>Cambridge</publisher-loc>
          <publisher-name>Cambridge University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Clustering algorithm for intuitionistic fuzzy sets</article-title>
          <source>Inf. Sci.</source>
          <year>2008</year>
          <volume>178</volume>
          <issue>19</issue>
          <fpage>3775</fpage>
          <lpage>3790</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ins.2008.06.008</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pringsheim</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Zur theorie der zweifach unendlichen zahlenfolgen</article-title>
          <source>Math. Ann.</source>
          <year>1900</year>
          <volume>53</volume>
          <issue>3</issue>
          <fpage>289</fpage>
          <lpage>321</lpage>
          <pub-id pub-id-type="doi">10.1007/BF01448977</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Mursaleen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mohiuddine</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <source>Convergence Methods for Double Sequences and Applications</source>
          <year>2014</year>
          <publisher-loc>Berlin</publisher-loc>
          <publisher-name>Springer</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Başar</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Şever</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>The space <inline-formula id="IEq343"><alternatives><tex-math id="M773">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$\mathcal{L}_{q}$\end{document}</tex-math><mml:math id="M774"><mml:msub><mml:mi mathvariant="script">L</mml:mi><mml:mi>q</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13660_2017_1333_Article_IEq343.gif"/></alternatives></inline-formula> of double sequences</article-title>
          <source>Math. J. Okayama Univ.</source>
          <year>2009</year>
          <volume>51</volume>
          <fpage>149</fpage>
          <lpage>157</lpage>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Altay</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Başar</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Some new spaces of double sequences</article-title>
          <source>J. Math. Anal. Appl.</source>
          <year>2005</year>
          <volume>309</volume>
          <issue>1</issue>
          <fpage>70</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jmaa.2004.12.020</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Wilansky</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>Summability Through Functional Analysis</source>
          <year>1984</year>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Jain</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Law</surname>
              <given-names>MHC</given-names>
            </name>
          </person-group>
          <article-title>Data clustering: a users dilemma</article-title>
          <source>Proceedings of the First International Conference on Pattern Recognition and Machine Intelligence</source>
          <year>2005</year>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Lohani</surname>
              <given-names>QMD</given-names>
            </name>
          </person-group>
          <article-title>A similarity measure for atanassov intuitionistic fuzzy sets and its application to clustering</article-title>
          <source>Computational Intelligence (IWCI), International Workshop on</source>
          <year>2016</year>
          <publisher-loc>Dhaka, Bangladesh</publisher-loc>
          <publisher-name>IEEE</publisher-name>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5360863</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Parasitol Res</journal-id>
      <journal-id journal-id-type="iso-abbrev">Parasitol. Res</journal-id>
      <journal-title-group>
        <journal-title>Parasitology Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0932-0113</issn>
      <issn pub-type="epub">1432-1955</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5360863</article-id>
      <article-id pub-id-type="pmcid">PMC5360863</article-id>
      <article-id pub-id-type="pmc-uid">5360863</article-id>
      <article-id pub-id-type="pmid">28283799</article-id>
      <article-id pub-id-type="publisher-id">5413</article-id>
      <article-id pub-id-type="doi">10.1007/s00436-017-5413-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Paper</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Encystment of parasitic freshwater pearl mussel (<italic>Margaritifera margaritifera</italic>) larvae coincides with increased metabolic rate and haematocrit in juvenile brown trout (<italic>Salmo trutta</italic>)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Filipsson</surname>
            <given-names>Karl</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brijs</surname>
            <given-names>Jeroen</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Näslund</surname>
            <given-names>Joacim</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wengström</surname>
            <given-names>Niklas</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Adamsson</surname>
            <given-names>Marie</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Závorka</surname>
            <given-names>Libor</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Österling</surname>
            <given-names>E. Martin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Höjesjö</surname>
            <given-names>Johan</given-names>
          </name>
          <address>
            <phone>+46 31 786 36 36</phone>
            <email>johan.hojesjo@bioenv.gu.se</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9919 9582</institution-id><institution-id institution-id-type="GRID">grid.8761.8</institution-id><institution>Department of Biological and Environmental Sciences, </institution><institution>University of Gothenburg, </institution></institution-wrap>SE 413 90 Gothenburg, Sweden </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0721 1351</institution-id><institution-id institution-id-type="GRID">grid.20258.3d</institution-id><institution>Department for Environmental and Life Sciences, </institution><institution>Karlstad University, </institution></institution-wrap>SE 651 88 Karlstad, Sweden </aff>
        <aff id="Aff3"><label>3</label>Swedish Anglers Association, Sjölyckan 6, SE 416 55 Gothenburg, Sweden </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2353 1689</institution-id><institution-id institution-id-type="GRID">grid.11417.32</institution-id><institution>Laboratoire Évolution &amp; Diversité Biologique (EDB UMR 5174), CNRS, </institution><institution>Université de Toulouse, </institution></institution-wrap>Toulouse, France </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>10</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>116</volume>
      <issue>4</issue>
      <fpage>1353</fpage>
      <lpage>1360</lpage>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>12</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>2</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Gill parasites on fish are likely to negatively influence their host by inhibiting respiration, oxygen transport capacity and overall fitness. The glochidia larvae of the endangered freshwater pearl mussel (FPM, <italic>Margaritifera margaritifera</italic> (Linnaeus, 1758)) are obligate parasites on the gills of juvenile salmonid fish. We investigated the effects of FPM glochidia encystment on the metabolism and haematology of brown trout (<italic>Salmo trutta</italic> Linnaeus, 1758). Specifically, we measured whole-animal oxygen uptake rates at rest and following an exhaustive exercise protocol using intermittent flow-through respirometry, as well as haematocrit, in infested and uninfested trout. Glochidia encystment significantly affected whole-animal metabolic rate, as infested trout exhibited higher standard and maximum metabolic rates. Furthermore, glochidia-infested trout also had elevated levels of haematocrit. The combination of an increased metabolism and haematocrit in infested fish indicates that glochidia encystment has a physiological effect on the trout, perhaps as a compensatory response to the potential respiratory stress caused by the glochidia. When relating glochidia load to metabolism and haematocrit, fish with low numbers of encysted glochidia were the ones with particularly elevated metabolism and haematocrit. Standard metabolic rate decreased with substantial glochidia loads towards levels similar to those of uninfested fish. This suggests that initial effects visible at low levels of encystment may be countered by additional physiological effects at high loads, e.g. potential changes in energy utilization, and also that high numbers of glochidia may restrict oxygen uptake by the gills.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Glochidia</kwd>
        <kwd>Haematocrit</kwd>
        <kwd>Host</kwd>
        <kwd>
          <italic>Margaritifera</italic>
        </kwd>
        <kwd>Metabolic rate</kwd>
        <kwd>Parasite</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003745</institution-id>
              <institution>Stiftelserna Wilhelm och Martina Lundgrens</institution>
            </institution-wrap>
          </funding-source>
        </award-group>
        <award-group>
          <funding-source>
            <institution>Herbert and Karin Jacobssons foundation</institution>
          </funding-source>
        </award-group>
        <award-group>
          <funding-source>
            <institution>Swedish Anglers Association</institution>
          </funding-source>
        </award-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003788</institution-id>
              <institution>Helge Ax:son Johnsons Stiftelse</institution>
            </institution-wrap>
          </funding-source>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer-Verlag Berlin Heidelberg 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Parasites can negatively affect their hosts through direct manipulation, inducing immunological responses, and increasing energetic demands, which in many cases influence the behaviour and fitness of the host (Lehmann <xref ref-type="bibr" rid="CR20">1993</xref>; Moore <xref ref-type="bibr" rid="CR23">2002</xref>). A variety of aquatic parasites, such as the larvae (glochidia) of many species of unionoid mussels, attaches and encysts on the gills of fish (Crane et al. <xref ref-type="bibr" rid="CR5">2011</xref>; Denic et al. <xref ref-type="bibr" rid="CR6">2015</xref>; Meyers et al. <xref ref-type="bibr" rid="CR22">1980</xref>; Young and Williams <xref ref-type="bibr" rid="CR38">1984</xref>). Such encystment can affect both the physiology and behaviour of the host. In response to glochidia encystment, fish hosts have been shown to hyperventilate (Crane et al. <xref ref-type="bibr" rid="CR5">2011</xref>), undergo haematological alterations (Meyers et al. <xref ref-type="bibr" rid="CR22">1980</xref>) and exhibit immunological reactions (Alvarez-Pellitero <xref ref-type="bibr" rid="CR1">2008</xref>). The effects of these alterations include impaired gas exchange (Kaiser <xref ref-type="bibr" rid="CR17">2005</xref>), increased risk-taking (Godin and Sproul <xref ref-type="bibr" rid="CR11">1988</xref>), reduced foraging (Österling et al. <xref ref-type="bibr" rid="CR28">2014</xref>) and competitive ability (Filipsson et al. <xref ref-type="bibr" rid="CR8">2016</xref>), reduced swimming performance and, in cases of high infestation rates ( ~350 glochidia per gram fish weight or more), even mortality (Taeubert and Geist <xref ref-type="bibr" rid="CR33">2013</xref>). For example, glochidia encystment on largemouth bass (<italic>Micropterus salmoides</italic> (Lacepède, 1802)) resulted in higher ventilation rates, reduced oxygen consumption and decreased tolerance of low-oxygen conditions for the host fish, suggesting that gill parasites can pose a respiratory burden for their hosts (Kaiser <xref ref-type="bibr" rid="CR17">2005</xref>). In another example, three-spined sticklebacks (<italic>Gasterosteus aculeatus</italic> Linnaeus, 1758) increase their foraging time when infected by parasites even though this poses a greater risk for predation, which suggests that the higher energy demand imposed by the parasites leads to increased risk-taking in order to obtain enough food to sustain fitness (Godin and Sproul <xref ref-type="bibr" rid="CR11">1988</xref>).</p>
      <p>The freshwater pearl mussel (FPM, <italic>Margaritifera margaritifera</italic> (Linnaeus, 1758)) is an extremely long-lived unionoid bivalve with a Holarctic distribution (Geist <xref ref-type="bibr" rid="CR9">2010</xref>; Graf and Cummings <xref ref-type="bibr" rid="CR12">2007</xref>; Lopes-Lima et al. <xref ref-type="bibr" rid="CR21">2016</xref>). It is endangered throughout its range, yet geographically widely distributed in European streams (Lopes-Lima et al. <xref ref-type="bibr" rid="CR21">2016</xref>). In Europe, glochidia of the FPM are obligate parasites on the gills of juvenile brown trout (<italic>Salmo trutta</italic> Linnaeus, 1758) and Atlantic salmon (<italic>Salmo salar</italic> Linnaeus, 1758) (Young and Williams <xref ref-type="bibr" rid="CR38">1984</xref>). Where the two species occur in sympatry, both may function as hosts for FPM (Karlsson et al. <xref ref-type="bibr" rid="CR18">2014</xref>). In some streams, however, only one of the species is the host for certain FPM populations, even though both brown trout and Atlantic salmon are present (Geist et al. <xref ref-type="bibr" rid="CR10">2006</xref>; Ieshko et al. <xref ref-type="bibr" rid="CR15">2016</xref>; Karlsson et al. <xref ref-type="bibr" rid="CR18">2014</xref>). Large conservation efforts have been made to protect FPM and much research is conducted to understand the causes for its decline and its interactions with the salmonid host species (Geist <xref ref-type="bibr" rid="CR9">2010</xref>; Karlsson et al. <xref ref-type="bibr" rid="CR18">2014</xref>; Lopes-Lima et al. <xref ref-type="bibr" rid="CR21">2016</xref>; Österling and Söderberg <xref ref-type="bibr" rid="CR27">2015</xref>). The glochidia are released by gravid females during summer and reach their host passively via the water current. After inhalation by a host fish, glochidia attach and encyst on epithelial cells located on the gill lamellae where they absorb nutrients from the gill tissue (Denic et al. <xref ref-type="bibr" rid="CR6">2015</xref>; Nezlin et al. <xref ref-type="bibr" rid="CR26">1994</xref>). Glochidia are encysted for approximately 10 months, during which they grow approximately 6–10 times in size whilst metamorphosing to juvenile mussels (Bauer and Vogel <xref ref-type="bibr" rid="CR2">1987</xref>; Denic et al. <xref ref-type="bibr" rid="CR6">2015</xref>).</p>
      <p>Infestation of FPM glochidia in juvenile salmonids has traditionally been assumed to be more or less benign to host fish (Moorkens <xref ref-type="bibr" rid="CR24">1999</xref>). However, recent studies reveal that FPM glochidia encystment can increase the recovery time required following a stressful event (Thomas et al. <xref ref-type="bibr" rid="CR34">2014</xref>), induce an immune response (Thomas et al. <xref ref-type="bibr" rid="CR34">2014</xref>), decrease foraging success (Österling et al. <xref ref-type="bibr" rid="CR28">2014</xref>), negatively impact competitive ability (Filipsson et al. <xref ref-type="bibr" rid="CR8">2016</xref>) and reduce the capacity for swimming (Taeubert and Geist <xref ref-type="bibr" rid="CR33">2013</xref>). Previous studies suggest that parasite infestation can have significant implications for the host. For example, trematode infestation was reported to lower the standard metabolic rate of Arctic charr (<italic>Salvelinus alpinus</italic> Linnaeus, 1758), which was suggested to be due to potential perturbations in energy utilization (Seppänen et al. <xref ref-type="bibr" rid="CR31">2009</xref>). Similarly, brown trout infested with high numbers of glochidia took longer to return to their basal rate of ventilation following a stressful event than uninfested fish, which suggests that the glochidia constitute a respiratory burden (Thomas et al. <xref ref-type="bibr" rid="CR34">2014</xref>). Unfortunately, whole-animal oxygen uptake was not quantified in Thomas et al. (<xref ref-type="bibr" rid="CR34">2014</xref>) and therefore it is currently unknown whether or not FPM glochidia affect the metabolism (i.e. standard and maximum metabolic rates) of host fish.</p>
      <p>Haematocrit (Hct, % erythrocytes in total blood volume) can be used as an indicator for oxygen transport capacity in an organism as high levels of erythrocytes allow an increased amount of oxygen to be transported in the blood. Typically, vertebrates that are adapted or acclimatized to increased aerobic demands or oxygen-poor environments usually exhibit elevated Hct values (Sherwood et al. <xref ref-type="bibr" rid="CR32">2005</xref>). However, low Hct values are not necessarily consistent with low oxygen transport capacity as it can be compensated via increases in cardiac output (Wang et al. <xref ref-type="bibr" rid="CR36">2014</xref>). Several fish species, including salmonids, have reduced Hct values when infested with blood- and tissue-consuming parasites (Grimnes and Jakobsen <xref ref-type="bibr" rid="CR13">1996</xref>; Jones and Grutter <xref ref-type="bibr" rid="CR16">2005</xref>; Nair and Nair <xref ref-type="bibr" rid="CR25">1983</xref>; Paperna et al. <xref ref-type="bibr" rid="CR29">1984</xref>), explained as an effect of parasites either causing osmotic failure (as a result of exposed lesions) or by blood ingestion (Grimnes and Jakobsen <xref ref-type="bibr" rid="CR13">1996</xref>; Jones and Grutter <xref ref-type="bibr" rid="CR16">2005</xref>; Nair and Nair <xref ref-type="bibr" rid="CR25">1983</xref>). Reduced Hct can affect oxygen transport capacity through anaemia, which may negatively affect foraging success, swimming capacity, activity and overall survival (Jones and Grutter <xref ref-type="bibr" rid="CR16">2005</xref>; Pearson and Stevens <xref ref-type="bibr" rid="CR30">1991</xref>). However, if parasites affect oxygen uptake or metabolism, Hct could also increase as a compensatory effect to enhance oxygen transport capacity by splenic release of stored blood cells, plasma loss or increased size of erythrocytes (Pearson and Stevens <xref ref-type="bibr" rid="CR30">1991</xref>). Only a few attempts have been made to investigate whether FPM glochidia affect haematological parameters in salmonids. Hct was observed to increase in glochidia-infested chinook (<italic>Oncorhynchus tshawytscha</italic> Walbaum, 1792) and coho (<italic>Oncorhynchus kisutch</italic> Walbaum, 1792) salmon (Meyers et al. <xref ref-type="bibr" rid="CR22">1980</xref>). However, this trend is not universal, as Thomas et al. (<xref ref-type="bibr" rid="CR34">2014</xref>) found no effect of parasitic glochidia on the Hct of infested brown trout. Even, a month after infestation, the spleen of infested trout were enlarged (Thomas et al. <xref ref-type="bibr" rid="CR34">2014</xref>), which indicates that glochidia may indeed affect the haematology in this host fish species as this organ is involved in immunological activity, haematopoiesis and haemolysis, and can also function as an erythrocyte reservoir (Fänge and Nilsson <xref ref-type="bibr" rid="CR7">1985</xref>; Pearson and Stevens <xref ref-type="bibr" rid="CR30">1991</xref>).</p>
      <p>The overall aim of this paper is to investigate the potential effects of natural levels of FPM glochidia encystment on the metabolism and haematology of wild juvenile brown trout. Specifically, we measured whole-animal oxygen uptake rates at rest and following an exhaustive exercise protocol (as a proxy for standard and maximal metabolic rates), as well as Hct, in infested and uninfested individuals captured from the wild. We hypothesised that glochidia-infested trout would exhibit increased standard metabolic rate (SMR), maximum metabolic rate (MMR) and Hct when compared to uninfested fish, in order to compensate for respiratory stress caused by encysted glochidia.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Experimental animals and holding conditions</title>
        <p>Juvenile 1+ brown trout of mixed sexes were collected in April 2015 from the stream Lindåsabäcken in the Häggån catchment, Sweden (57°40.203′ N 13°3.771′ E), using standardized electrofishing (LR-20B, Smith-Root, USA) (Bohlin et al. <xref ref-type="bibr" rid="CR3">1989</xref>). The trout were lightly anaesthetized in the field (MS-222, 5 mL L<sup>−1</sup>, Pharmac Ltd., UK) and visually assessed in order to determine whether they were infested with parasitic glochidia. A total of 62 brown trout were caught (35 infested and 27 uninfested). Fork lengths (range, mean ± SE) were 76–146, 116 ± 3 mm for infested trout and 75–152, 114 ± 4 mm for uninfested trout. Wet weights were 4.0–32.2, 16.5 ± 1.2 g for infested trout and 4.7–36.9, 15.7 ± 1.3 g for uninfested trout. Trout were subsequently transported in a well-aerated tank to the University of Gothenburg, Gothenburg, Sweden. Fish were housed in a 120 L aquarium (0.64 m × 0.48 m × 0.4 m). The aquarium was supplied with freshwater from a flow-through filtration system. Photoperiod followed natural day–light cycles and the water temperature was kept constant at 11.0 ± 0.1 °C.</p>
      </sec>
      <sec id="Sec4">
        <title>Respirometry and exhaustive exercise protocol</title>
        <p>Fish were fasted for 9 days to allow gut evacuation prior to use in respirometry experiments. Individual fish were then selected randomly and lightly anaesthetized in water containing 0.5 mL L<sup>−1</sup> 2-phenoxyethanol (Aldrich Chemistry, Germany). Upon loss of equilibrium, individuals were weighed and placed into cylindrical, intermittent flow-through respirometers (volumes of 0.584 or 1.112 L depending on fish size), which were submerged in a reservoir bath containing flow-through, aerated freshwater (11.0 ± 0.1 °C). The fish were left undisturbed in the respirometers for ~21 h while oxygen consumption was measured using best practices in intermittent flow-through respirometry (see Clark et al. <xref ref-type="bibr" rid="CR4">2013</xref>). Briefly, water was continuously circulated through each respirometer using an in-line submersible pump within a recirculation loop, and the partial pressure of oxygen in the water in the respirometers was measured continuously at 0.5 Hz using a FireSting O<sub>2</sub> system (PyroScience, Aachen, Germany) calibrated in accordance with the supplier’s manual. Automated flush pumps refreshed the water in the respirometers for 5 min in every 20-min period, ensuring that oxygen levels in the respirometers always remained above 90% air saturation. Whole-animal oxygen uptake was calculated from the decline in partial pressure of oxygen in the water of the respirometers during each 15-min period between flush cycles. SMR was calculated for each fish as the mean of the lowest 10% of ln-transformed whole-animal oxygen uptake measurements during the ~21-h period where the fish were left undisturbed after respirometer entry (excluding outliers, which were considered to be &gt;2 SD below the mean of the lowest 10% of values).</p>
        <p>Following the ~21-h undisturbed period, fish were individually removed from their respirometers and subjected to an exhaustive exercise protocol (Clark et al. <xref ref-type="bibr" rid="CR4">2013</xref>) consisting of a 3-min period of manual chasing around a circular tank (diameter 0.6 m, water depth 0.2 m) containing aerated freshwater at 11.0 ± 0.1 °C. All individuals were visibly exhausted by the end of the 3-min exercise period as highlighted by a lack of response to an experimenter tapping the caudal fin. Immediately following the exercise protocol, fish were returned to their individual respirometers (within 10 s), whereupon respirometers were sealed for 5 min and the MMR was taken as the steepest 3-min slope during this time.</p>
      </sec>
      <sec id="Sec5">
        <title>Glochidia load determination</title>
        <p>Glochidia load was estimated for each fish directly after they had been in the respirometers. Trout were anaesthetized (0.5 mL L<sup>−1</sup> 2-phenoxyethanol) and glochidia load was examined by gently lifting the operculum and gill arches using pincers. The number of encysted glochidia was counted as precisely as possible for each fish. However, the number of glochidia on heavily infested fish could not be estimated to an exact number using this method. Thus, trout with more than 100 glochidia encysted on their gills were set to have 100 glochidia when analysing the data.</p>
      </sec>
      <sec id="Sec6">
        <title>Hct measurements</title>
        <p>Following glochidia determination, blood samples were obtained for the determination of Hct. By using heparinized 23 G × 31-in. Sterican® single-use hypodermic needles (B. Braun Medical, Emmenbrücke, Switzerland) attached to 1-mL syringes, it was possible to withdraw ~0.1 mL of blood from an individual via puncture of the venous vasculature directly caudal of the anal fin. However, due to the small size of some individuals, it was not possible to withdraw adequate blood samples from all fish, thus a smaller sample size for the determination of Hct was obtained (34 infested and 24 uninfested fish). Hct was determined as the fractional red cell volume upon centrifugation of a subsample of blood in 80-μL microcapillary tubes at 10,000 rpm for 5 min.</p>
      </sec>
      <sec id="Sec7">
        <title>Statistical analyses</title>
        <p>Fork length, body mass and condition factor of infested and uninfested fish were compared using independent sample <italic>t</italic> tests. Homoscedasticity and normal distribution of residuals were assessed and found to be appropriate assumptions, by inspection of spread and symmetry of boxplots and Q–Q plots. Relationships between size (fork length) and number of glochidia on the gills were investigated using Spearman rank correlations.</p>
        <p>Differences between glochidia-infested and uninfested individuals were analysed using linear models (LMs) including presence/absence of glochidia as a fixed two-level factor and ln (wet mass) as a covariate. Size effects were corrected for in the statistical model, using ln-transformed wet mass as a covariate. Given that metabolic rate is a power function of body mass, we assumed a linear relationship between ln-transformed metabolic rate and ln-transformed wet mass. This was also found to be an appropriate assumption based on inspection of scatterplots. Assumptions regarding residual normality and homoscedasticity of residuals were judged to be adequately fulfilled by visual inspection of residuals (boxplots and Q–Q plots). Differences between infested and uninfested fish were assessed based on the estimated marginal means (EMM) at the mean value of the covariate.</p>
        <p>For infested fish, we descriptively investigated whether glochidia load affected SMR, MMR or Hct, using local regression (LOESS), with glochidia load used as independent variable and Spearman rank correlations. The SMR, MMR and Hct values for each individual were size-standardized as residuals from the LMs used to investigate general effects of infestation (see previous paragraph and Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Linear relationships between mass (ln-transformed) and <bold>a</bold> standard metabolic rate (SMR) (ln-transformed), <bold>b</bold> maximum metabolic rate (MMR) (ln-transformed) and <bold>c</bold> haematocrit (Hct), for naturally infested and uninfested brown trout. Parameter estimates (<italic>B</italic>) and their standard error (SE) for the linear regression analysis and their statistical significance (presented as <italic>t</italic> statistics along with their <italic>p</italic> value) are presented in the <italic>boxes</italic> to the right of the graphs, and <italic>asterisks</italic> denote redundant parameter estimate</p></caption><graphic xlink:href="436_2017_5413_Fig1_HTML" id="MO1"/></fig>
</p>
      </sec>
    </sec>
    <sec id="Sec8">
      <title>Results</title>
      <sec id="Sec9">
        <title>Fish size and condition</title>
        <p>There were no significant differences between infested fish and uninfested fish in fork length, body mass or condition factor (all <italic>p</italic> &gt; 0.45). There was no statistically significant rank correlation between size (fork length) and glochidia load (Spearman’s <italic>ρ</italic> = −0.19, <italic>p</italic> = 0.14).</p>
      </sec>
      <sec id="Sec10">
        <title>Effects of glochidia encystment on SMR, MMR and Hct</title>
        <p>When controlling SMR for the positive effect of body mass (<italic>F</italic>
<sub>1,59</sub> = 351, <italic>p</italic> &lt; 0.001; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>), trout infested with glochidia had a higher SMR than uninfested fish (<italic>F</italic>
<sub>1,59</sub> = 7.26, <italic>p</italic> = 0.009; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). On the arithmetic scale, the infested individuals had on average 26% higher SMR (back-transformed EMM infested = 0.486 mg O<sub>2</sub>·h<sup>−1</sup>, 95% CI: 0.435–0.543 mg O<sub>2</sub>·h<sup>−1</sup>; uninfested = 0.387 mg O<sub>2</sub>·h<sup>−1</sup>, 95% CI: 0.341–0.440 mg O<sub>2</sub>·h<sup>−1</sup>) at the mean of the covariate [ln(mass) = 2.64 (14.0 g)]. Similarly, after controlling for a positive body mass effect (<italic>F</italic>
<sub>1,59</sub> = 603, <italic>p</italic> &lt; 0.001; Fig. <xref rid="Fig1" ref-type="fig">1b</xref>), the MMR was higher in infested trout compared to that in uninfested fish (<italic>F</italic>
<sub>1,59</sub> = 4.27, <italic>p</italic> = 0.043; Fig. <xref rid="Fig1" ref-type="fig">1b</xref>) with the infested individuals having on average 11% higher MMR (back-transformed EMM infested: 8.01 mg O<sub>2</sub>·h<sup>−1</sup>, 95% CI: 7.50–8.57 mg O<sub>2</sub>·h<sup>−1</sup>; uninfested: 7.22 mg O<sub>2</sub>·h<sup>−1</sup>, 95% CI: 6.69–7.79 mg O<sub>2</sub>·h<sup>−1</sup>) at the mean of the covariate [ln(mass) = 2.64 (14.0 g)]. Hct was also positively related to body size (<italic>F</italic>
<sub>1,55</sub> = 18.4, <italic>p</italic> &lt; 0.001; Fig. <xref rid="Fig1" ref-type="fig">1c</xref>) and infested fish had higher Hct than uninfested fish (<italic>F</italic>
<sub>1,55</sub> = 4.50, <italic>p</italic> = 0.038; Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). Infested fish had on average Hct that was 2.53% higher than uninfested fish (95% CI of the difference 0.14–4.91 percentage points). Parameter estimates (<italic>B</italic>) for all three linear models are presented in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.</p>
      </sec>
      <sec id="Sec11">
        <title>Effects of glochidia load on SMR, MMR and Hct</title>
        <p>We found that size-standardized SMR tended to decrease with increasing glochidia load, which made individuals with high glochidia loads resemble the average uninfested fish in their mean SMR values (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). Rank correlation between SMR and glochidia load was significantly negative (Spearman’s <italic>ρ</italic> = −0.40, <italic>p</italic> = 0.017). No tendencies for effects of glochidia load were found for MMR (<italic>ρ</italic> = −0.04, <italic>p</italic> = 0.81; Fig. <xref rid="Fig2" ref-type="fig">2b</xref>) or Hct (<italic>ρ</italic> = −0.08, <italic>p</italic> = 0.66; Fig. <xref rid="Fig2" ref-type="fig">2c</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Effects of glochidia load on <bold>a</bold> standard metabolic rate (SMR), <bold>b</bold> maximum metabolic rate (MMR) and <bold>c</bold> haematocrit (Hct). Boxplots on the left-hand side of each figure show the distribution of values for uninfested fish, the <italic>whiskers</italic> span between maximum and minimum values, the <italic>box</italic> delimits the upper and lower quartile, and the <italic>horizontal bar</italic> within the box shows the median. In the right-hand scatterplots, showing data in relation to glochidia load, the <italic>lines</italic> show the local regression (LOESS), with 95% confidence limits in <italic>grey</italic>. All data was standardized for size by using residuals from the respective linear model presented in Fig. <xref rid="Fig1" ref-type="fig">1</xref>
</p></caption><graphic xlink:href="436_2017_5413_Fig2_HTML" id="MO2"/></fig>
</p>
      </sec>
    </sec>
    <sec id="Sec12">
      <title>Discussion</title>
      <p>Glochidia-infested trout exhibited significantly higher SMR and MMR and elevated levels of Hct, which demonstrates the potential of encysted glochidia to affect whole-animal metabolic rate and oxygen transport capacity. Furthermore, glochidia-infested trout also had elevated levels of Hct. The combination of increased metabolism and increased Hct values in infested fish indicates that there is a physiological effect on the trout caused by the glochidia, perhaps as a compensatory response to the potential respiratory stress caused by glochidia encystment.</p>
      <p>Similarly, our finding that glochidia-infested trout had higher Hct is similar to that of a previous study, whereby Hct of chinook salmon increased following infestation by western pearl shell (<italic>Margaritifera falcata</italic> Gould, 1850) glochidia (Meyers et al. <xref ref-type="bibr" rid="CR22">1980</xref>). The increased Hct of infested chinook salmon was related to a combination of increased number of circulating erythrocytes and cell swelling (i.e. increased mean corpuscular volume and reduced mean corpuscular haemoglobin concentration) (Meyers et al. <xref ref-type="bibr" rid="CR22">1980</xref>). This may also be the case for the infested brown trout in the present study, however, future measures of cell number and size are necessary to substantiate these claims.</p>
      <p>When relating glochidia load to metabolism and Hct, the fish with lower numbers of glochidia per gram body mass were the ones with particularly elevated metabolism (SMR) and Hct. Interestingly, SMR then decreased with substantial glochidia loads towards levels similar to those of uninfested fish. This is not necessarily suggesting that trout with high glochidia loads are unaffected. Rather, we hypothesise that the initial effects visible at low levels of encystment may be countered by additional physiological effects at high loads (e.g. potential perturbations in energy utilization as suggested by Seppänen et al. <xref ref-type="bibr" rid="CR31">2009</xref>). Previous studies have shown that low glochidia loads (&lt;100 glochidia per gram body mass) are not lethal and do not necessarily affect the host salmonid performance, at least when kept under aquaculture conditions (Taeubert and Geist <xref ref-type="bibr" rid="CR33">2013</xref>; Treasurer et al. <xref ref-type="bibr" rid="CR35">2006</xref>). However, very high glochidia loads have been shown to cause mortality in brown trout (up to 60% mortality within 48 h post-infestation with loads of ~900 glochidia per gram body mass) (Taeubert and Geist <xref ref-type="bibr" rid="CR33">2013</xref>). Furthermore, swimming performance decreases with increasing glochidia load, which could be an effect of increased oxygen demand for a given activity or reduced capacity to take up oxygen due to damage on gills in heavily infested fish (Taeubert and Geist <xref ref-type="bibr" rid="CR33">2013</xref>).</p>
      <p>After infestation, glochidia are fully enveloped in the gill tissue, typically the filament (Karna and Millemann <xref ref-type="bibr" rid="CR19">1978</xref>), as a consequence of shape change and migration of gill epithelial cells, without signs of hyperplasia (Nezlin et al. <xref ref-type="bibr" rid="CR26">1994</xref>). After a few days following encystment, the ultrastructure of cysts and normal gill tissue is very similar (Nezlin et al. <xref ref-type="bibr" rid="CR26">1994</xref>). However, filaments with encysted glochidia are on average thicker and longer than normal filaments (Thomas et al. <xref ref-type="bibr" rid="CR34">2014</xref>). The lamellae of the filaments often fuse with the wall of the cyst, and while blood still flows through these lamellae, they may not function to the same extent for respiration (Karna and Millemann <xref ref-type="bibr" rid="CR19">1978</xref>). Glochidia can also pinch arterioles, restricting blood flow to certain filaments, and large cysts increase the physiological dead space in the water flow across the gills (Karna and Millemann <xref ref-type="bibr" rid="CR19">1978</xref>). Our results, where basal oxygen consumption first increases at low glochidia loads and then decreases again with increasing load, indicates that higher numbers of glochidia may restrict oxygen uptake by the gills and a mechanism for this effect may be restriction of blood flow or respiratory functional surface.</p>
      <p>Indeed, previous data show that brown trout infested with high numbers of glochidia take longer to reach basal ventilation rates after a stressor, suggesting that high glochidia loads indeed constitute a respiratory burden (Thomas et al. <xref ref-type="bibr" rid="CR34">2014</xref>). If gill parasites reduce oxygen uptake from the gills, an adaptive response to parasite attachment could be to increase the capacity of the blood to carry oxygen, e.g. through increasing the number of erythrocytes or haemoglobin (Meyers et al. <xref ref-type="bibr" rid="CR22">1980</xref>). Although there are indications that this may be occurring in the present study (i.e. significantly higher Hct in infested brown trout), a more extensive haematological evaluation of infested and uninfested fish is necessary to validate this hypothesis.</p>
      <p>A word of caution is warranted as whole-animal oxygen uptake and Hct may reflect pre-existing differences in the trout phenotypes with infested fish having a generally higher metabolism and activity, which in turn may have caused an increased exposure to glochidia in the wild (Wengström et al. <xref ref-type="bibr" rid="CR37">2016</xref>). Therefore, the effect of glochidia on oxygen uptake capacity should be further investigated in future studies, using artificially infested fish with natural levels of glochidia encystment. However, our findings still reflect the physiological status of infested and uninfested fish within the stream ecosystem, and when used in combination with results from the previous studies outlined above (Meyers et al. <xref ref-type="bibr" rid="CR22">1980</xref>; Thomas et al. <xref ref-type="bibr" rid="CR34">2014</xref>), it seems likely that the effects seen in our study are indeed caused by glochidia encystment.</p>
      <p>The natural glochidia loads in this study are notably lower than the loads where adverse effects are noted in previous studies. Juvenile brown trout examined in the present study were captured approximately 7–9 months after initial glochidia infestation, compared to e.g. 48-h post-infestation as the fish studied by Taeubert and Geist (<xref ref-type="bibr" rid="CR33">2013</xref>). It is likely that heavily infested fish have been outcompeted or suffered high mortality rates during a longer time period (Filipsson et al. <xref ref-type="bibr" rid="CR8">2016</xref>; Taeubert and Geist <xref ref-type="bibr" rid="CR33">2013</xref>), explaining the relatively low number of encysted glochidia found on the fish in this study. Additionally, many glochidia are sloughed off the gills during the initial period of encystment, as the trout’s immune system responds to glochidia infection (Hastie and Young <xref ref-type="bibr" rid="CR14">2003</xref>). Hence, this may also lead to a decrease in encysted glochidia in host fish populations over time.</p>
      <p>When artificially infesting trout with glochidia in mussel conservation programmes, the recommended load on the host fish is between 5 and 100 glochidia per gram body mass (Taeubert and Geist <xref ref-type="bibr" rid="CR33">2013</xref>). The fish in our study are well within this recommended span, and we therefore note, with support from other studies on behaviour (Filipsson et al. <xref ref-type="bibr" rid="CR8">2016</xref>; Österling et al. <xref ref-type="bibr" rid="CR28">2014</xref>; Wengström et al. <xref ref-type="bibr" rid="CR37">2016</xref>), that the higher loads within this span may also be affecting the host fish negatively, to the potential detriment of the mussel glochidia. Based on our findings, we reiterate the conclusion that artificial glochidia infestation of fish within pearl mussel propagation programmes should be done with care and aim for relatively low glochidia encystment rates. This could avoid detrimental effects on host fish, which may translate into unsuccessful deployment of juvenile mussels into the stream where the infested fish are released (Taeubert and Geist <xref ref-type="bibr" rid="CR33">2013</xref>; Thomas et al. <xref ref-type="bibr" rid="CR34">2014</xref>).</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank Fredrik Wahlqvist for assistance in the field and Anna-Maria Kellermann for assistance when conducting respirometry experiments. Funding was provided from the Swedish Anglers Association [N.W], the Wilhelm and Martina Lundgrens foundation [J.B], Herbert and Karin Jacobssons foundation [J.B] and the Helge Axelsson Johnsson foundation [J.B].</p>
      <sec id="FPar1">
        <title>Author contributions</title>
        <p>All authors conceived and designed the experiments. N.W. and K.F. conducted field and laboratory work. J.B. and K.F. performed the metabolism experiments. J.B., M.A. and K.F. performed the haematocrit experiments. J.N., K.F. and J.B. analysed the data. K.F., J.N. and J.B. wrote the initial version of the manuscript; all other authors provided editorial advice.</p>
      </sec>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <sec id="FPar2">
        <title>Conflict of interest</title>
        <p>The authors declare that they have no conflict of interest.</p>
      </sec>
      <sec id="FPar3">
        <title>Ethical approval</title>
        <p>All applicable international, national and institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. Fish were collected with permission from land owners and the County Board Administration in Västra Götaland. Animal care and experimental procedures were approved by the Animal Ethical Board of Sweden (ethical permit 16-2014).</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alvarez-Pellitero</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Fish immunity and parasite infections: from innate immunity to immunoprophylactic prospects</article-title>
          <source>Vet Immunol Immunopathol</source>
          <year>2008</year>
          <volume>126</volume>
          <fpage>171</fpage>
          <lpage>198</lpage>
          <pub-id pub-id-type="doi">10.1016/j.vetimm.2008.07.013</pub-id>
          <?supplied-pmid 18783835?>
          <pub-id pub-id-type="pmid">18783835</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <mixed-citation publication-type="other">Bauer G, Vogel C (1987) The parasitic stage of the freshwater pearl mussel (<italic>Margaritifera margaritifera</italic> L.). I. Host response to glochidiosis. Arch Hydrobiol 76:393–402</mixed-citation>
      </ref>
      <ref id="CR3">
        <mixed-citation publication-type="other">Bohlin T, Hamrin S, Heggberget TG, Rasmussen G, Saltveit SJ (1989) Electrofishing - Theory and practice with special emphasis on salmonids. Hydrobiologia 173:9–43</mixed-citation>
      </ref>
      <ref id="CR4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clark</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Sandblom</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jutfelt</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Aerobic scope measurements of fishes in an era of climate change: respirometry, relevance and recommendations</article-title>
          <source>J Exp Biol</source>
          <year>2013</year>
          <volume>216</volume>
          <fpage>2771</fpage>
          <lpage>2782</lpage>
          <pub-id pub-id-type="doi">10.1242/jeb.084251</pub-id>
          <?supplied-pmid 23842625?>
          <pub-id pub-id-type="pmid">23842625</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crane</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Fritts</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Mathis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lisek</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Barnhart</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Do gill parasites influence the foraging and antipredator behavior of rainbow darters, <italic>Etheostoma caeruleum</italic>?</article-title>
          <source>Anim Behav</source>
          <year>2011</year>
          <volume>82</volume>
          <fpage>817</fpage>
          <lpage>823</lpage>
          <pub-id pub-id-type="doi">10.1016/j.anbehav.2011.07.015</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Denic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Taeubert</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Geist</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Trophic relationships between the larvae of two freshwater mussels and their fish hosts</article-title>
          <source>Invertebr Biol</source>
          <year>2015</year>
          <volume>134</volume>
          <fpage>129</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="doi">10.1111/ivb.12080</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fänge</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The fish spleen: structure and function</article-title>
          <source>Experientia</source>
          <year>1985</year>
          <volume>41</volume>
          <fpage>152</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="doi">10.1007/BF02002607</pub-id>
          <?supplied-pmid 3972063?>
          <pub-id pub-id-type="pmid">3972063</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Filipsson</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Petersson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Höjesjö</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Piccolo</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Näslund</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wengström</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Österling</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Heavy loads of parasitic freshwater pearl mussel (<italic>Margaritifera margaritifera</italic> L.) larvae impair foraging, activity and dominance performance in juvenile brown trout (<italic>Salmo trutta</italic> L.)</article-title>
          <source>Ecol Freshw Fish</source>
          <year>2016</year>
        </element-citation>
      </ref>
      <ref id="CR9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Geist</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Strategies for the conservation of endangered freshwater pearl mussels (<italic>Margaritifera margaritifera</italic> L.): a synthesis of conservation genetics and ecology</article-title>
          <source>Hydrobiologia</source>
          <year>2010</year>
          <volume>644</volume>
          <fpage>69</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="doi">10.1007/s10750-010-0190-2</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Geist</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Porkka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kuehn</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The status of host fish populations and fish species richness in European freshwater pearl mussel (<italic>Margaritifera margaritifera</italic>) streams</article-title>
          <source>Aquatic Conserv: Mar Freshw Ecosyst</source>
          <year>2006</year>
          <volume>16</volume>
          <fpage>251</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="doi">10.1002/aqc.721</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Godin</surname>
              <given-names>J-GJ</given-names>
            </name>
            <name>
              <surname>Sproul</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
          <article-title>Risk taking in parasitized sticklebacks under threat of predation: effects of energetic need and food availability</article-title>
          <source>Can J Zoolog</source>
          <year>1988</year>
          <volume>66</volume>
          <fpage>2360</fpage>
          <lpage>2367</lpage>
          <pub-id pub-id-type="doi">10.1139/z88-350</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Graf</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Cummings</surname>
              <given-names>KS</given-names>
            </name>
          </person-group>
          <article-title>Review of the systematics and global diversity of freshwater mussel species (Bivalvia: Unionoida)</article-title>
          <source>J Molluscan Stud</source>
          <year>2007</year>
          <volume>73</volume>
          <fpage>291</fpage>
          <lpage>314</lpage>
          <pub-id pub-id-type="doi">10.1093/mollus/eym029</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grimnes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jakobsen</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>The physiological effects of salmon lice infection on post-smolt of Atlantic salmon</article-title>
          <source>J Fish Biol</source>
          <year>1996</year>
          <volume>48</volume>
          <fpage>1179</fpage>
          <lpage>1194</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1095-8649.1996.tb01813.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <mixed-citation publication-type="other">Hastie LC, Young MR (2003) Conservation of the freshwater pearl mussel—1. Captive breeding techniques (IN127). Conserving Natura 2000 Rivers Conservation Techniques Series No. 2. English Nature, Peterborough</mixed-citation>
      </ref>
      <ref id="CR15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ieshko</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Geist</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Murzina</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Veselov</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Lebedeva</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Ziuganov</surname>
              <given-names>VV</given-names>
            </name>
          </person-group>
          <article-title>The characteristics of the infection of juvenile Atlantic salmon with glochidia of the freshwater pearl mussel in rivers of Northwest Russia</article-title>
          <source>Knowl Manag Aquat Ecosyst</source>
          <year>2016</year>
          <volume>417</volume>
          <fpage>6</fpage>
          <pub-id pub-id-type="doi">10.1051/kmae/2015039</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Grutter</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Parasitic isopods (<italic>Gnathia</italic> sp.) reduce haematocrit in captive blackeye thicklip (Labridae) on the Great Barrier Reef</article-title>
          <source>J Fish Biol</source>
          <year>2005</year>
          <volume>66</volume>
          <fpage>860</fpage>
          <lpage>864</lpage>
          <pub-id pub-id-type="doi">10.1111/j.0022-1112.2005.00640.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <mixed-citation publication-type="other">Kaiser BE (2005) The effects of glochidiosis on fish respiration. Unpublished MSc thesis, Missouri State University, Springfield, MO</mixed-citation>
      </ref>
      <ref id="CR18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karlsson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Hindar</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Host-dependent genetic variation in freshwater pearl mussel (<italic>Margaritifera margaritifera</italic> L.)</article-title>
          <source>Hydrobiologia</source>
          <year>2014</year>
          <volume>735</volume>
          <fpage>179</fpage>
          <lpage>190</lpage>
          <pub-id pub-id-type="doi">10.1007/s10750-013-1679-2</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karna</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Millemann</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Glochidiosis of salmonid fishes. III. Comparative susceptibility to natural infection with <italic>Margaritifera margaritifera</italic> (Pelecypoda: Magaritanidae) and associated histopathology</article-title>
          <source>J Parasitol</source>
          <year>1978</year>
          <volume>64</volume>
          <fpage>528</fpage>
          <lpage>537</lpage>
          <pub-id pub-id-type="doi">10.2307/3279799</pub-id>
          <?supplied-pmid 660385?>
          <pub-id pub-id-type="pmid">660385</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lehmann</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Ectoparasites: direct impact on host fitness</article-title>
          <source>Parasitol Today</source>
          <year>1993</year>
          <volume>9</volume>
          <fpage>8</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1016/0169-4758(93)90153-7</pub-id>
          <?supplied-pmid 15463655?>
          <pub-id pub-id-type="pmid">15463655</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopes-Lima</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Conservation status of freshwater mussels in Europe: state of the art and future challenges</article-title>
          <source>Biol Rev</source>
          <year>2016</year>
          <?supplied-pmid 26727244?>
          <pub-id pub-id-type="pmid">26727244</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyers</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Millemann</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Fustish</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Glochidiosis of salmonid fishes. IV. Humoral and tissue responses of coho and chinook salmon to experimental infection with <italic>Margaritifera margaritifera</italic> (L.) (Pelecypoda: Margaritanidae)*</article-title>
          <source>J Parasitol</source>
          <year>1980</year>
          <volume>66</volume>
          <fpage>274</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="doi">10.2307/3280818</pub-id>
          <?supplied-pmid 7391868?>
          <pub-id pub-id-type="pmid">7391868</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <source>Parasites and the behavior of animals</source>
          <year>2002</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR24">
        <mixed-citation publication-type="other">Moorkens EA (1999) Conservation management of the freshwater pearl mussel <italic>Margaritifera margaritifera</italic>. Part 1: biology of the species and its present situation in Ireland. Irish Wildlife Manuals, No 8 Dublin: Dúchas, The Heritage Service</mixed-citation>
      </ref>
      <ref id="CR25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nair</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Nair</surname>
              <given-names>NB</given-names>
            </name>
          </person-group>
          <article-title>Effect of infestation with the isopod, <italic>Alitropus typus</italic> M. Edwards (Crustacea: Flabellifera: Aegidae) on the haematological parameters of the host fish <italic>Channa striatus</italic> (Bloch)</article-title>
          <source>Aquaculture</source>
          <year>1983</year>
          <volume>30</volume>
          <fpage>11</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="doi">10.1016/0044-8486(83)90147-3</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nezlin</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Cunjak</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Zotin</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Ziuganov</surname>
              <given-names>VV</given-names>
            </name>
          </person-group>
          <article-title>Glochidium morphology of the freshwater pearl mussel (<italic>Margaritifera margaritifera</italic>) and glochidiosis of Atlantic salmon (<italic>Salmo salar</italic>): a study by scanning electron microscopy</article-title>
          <source>Can J Zoolog</source>
          <year>1994</year>
          <volume>72</volume>
          <fpage>15</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1139/z94-003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Österling</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Söderberg</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Sea-trout habitat fragmentation affects threatened freshwater pearl mussel</article-title>
          <source>Biol Conserv</source>
          <year>2015</year>
          <volume>186</volume>
          <fpage>197</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biocon.2015.03.016</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Österling</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Ferm</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Piccolo</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Parasitic freshwater pearl mussel larvae (<italic>Margaritifera margaritifera</italic> L.) reduce the drift-feeding rate of juvenile brown trout (<italic>Salmo trutta</italic> L.)</article-title>
          <source>Environ Biol Fish</source>
          <year>2014</year>
          <volume>97</volume>
          <fpage>543</fpage>
          <lpage>549</lpage>
          <pub-id pub-id-type="doi">10.1007/s10641-014-0251-x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paperna</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Diamant</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Overstreet</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Monogenean infestations and mortality in wild and cultured Red Sea fishes</article-title>
          <source>Helgolander Meeresunters</source>
          <year>1984</year>
          <volume>37</volume>
          <fpage>445</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="doi">10.1007/BF01989323</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pearson</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>ED</given-names>
            </name>
          </person-group>
          <article-title>Splenectomy impairs swim performance in trout</article-title>
          <source>Can J Zoolog</source>
          <year>1991</year>
          <volume>69</volume>
          <fpage>2089</fpage>
          <lpage>2092</lpage>
          <pub-id pub-id-type="doi">10.1139/z91-291</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seppänen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kuukka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Voutilainen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Huuskonen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Peuhkuri</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Metabolic depression and spleen and liver enlargement in juvenile Arctic charr <italic>Salvelinus alpinus</italic> exposed to chronic parasite infection</article-title>
          <source>J Fish Biol</source>
          <year>2009</year>
          <volume>74</volume>
          <fpage>553</fpage>
          <lpage>561</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1095-8649.2008.02144.x</pub-id>
          <?supplied-pmid 20735578?>
          <pub-id pub-id-type="pmid">20735578</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Sherwood</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Klandorf</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yancey</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <source>Animal physiology: from genes to organisms</source>
          <year>2005</year>
          <publisher-loc>Belmont, CA</publisher-loc>
          <publisher-name>Brooks/Cole</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR33">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taeubert</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Geist</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Critical swimming speed of brown trout (<italic>Salmo trutta</italic>) infested with freshwater pearl mussel (<italic>Margaritifera margaritifera</italic>) glochidia and implications for artificial breeding of an endangered mussel species</article-title>
          <source>Parasitol Res</source>
          <year>2013</year>
          <volume>112</volume>
          <fpage>1607</fpage>
          <lpage>1613</lpage>
          <pub-id pub-id-type="doi">10.1007/s00436-013-3314-6</pub-id>
          <?supplied-pmid 23377147?>
          <pub-id pub-id-type="pmid">23377147</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Garcia de Leaniz</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Does the parasitic freshwater pearl mussel <italic>M. margaritifera</italic> harm its host?</article-title>
          <source>Hydrobiologia</source>
          <year>2014</year>
          <volume>735</volume>
          <fpage>191</fpage>
          <lpage>201</lpage>
          <pub-id pub-id-type="doi">10.1007/s10750-013-1515-8</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Treasurer</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Hastie</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Treasurer</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Effects of (<italic>Margaritifera margaritifera</italic>) glochidial infection on performance of tank-reared Atlantic salmon (<italic>Salmo salar</italic>)</article-title>
          <source>Aquaculture</source>
          <year>2006</year>
          <volume>256</volume>
          <fpage>74</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="doi">10.1016/j.aquaculture.2006.02.031</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lefevre</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Iversen</surname>
              <given-names>NK</given-names>
            </name>
            <name>
              <surname>Findorf</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Buchanan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>McKenzie</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Anaemia only causes a small reduction in the upper critical temperature of sea bass: is oxygen delivery the limiting factor for tolerance of acute warming in fishes?</article-title>
          <source>J Exp Biol</source>
          <year>2014</year>
          <volume>217</volume>
          <fpage>4275</fpage>
          <lpage>4278</lpage>
          <pub-id pub-id-type="doi">10.1242/jeb.104166</pub-id>
          <?supplied-pmid 25394629?>
          <pub-id pub-id-type="pmid">25394629</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wengström</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wahlqvist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Näslund</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aldvén</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Závorka</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Österling</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Höjesjö</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Do individual activity patterns of brown trout (<italic>Salmo trutta</italic>) alter the exposure to parasitic freshwater pearl mussel (<italic>Margaritifera margaritifera</italic>) larvae?</article-title>
          <source>Ethol</source>
          <year>2016</year>
          <volume>122</volume>
          <fpage>769</fpage>
          <lpage>778</lpage>
          <pub-id pub-id-type="doi">10.1111/eth.12524</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Young</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The reproductive biology of the freshwater pearl mussel <italic>Margaritifera margaritifera</italic> (Linn.) in Scotland 1. Field studies</article-title>
          <source>Arch Hydrobiol</source>
          <year>1984</year>
          <volume>99</volume>
          <fpage>405</fpage>
          <lpage>422</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362066</identifier><datestamp>2017-04-04</datestamp><setSpec>wtpa</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">8610614</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">3801</journal-id>
      <journal-id journal-id-type="nlm-ta">Health Policy Plan</journal-id>
      <journal-id journal-id-type="iso-abbrev">Health Policy Plan</journal-id>
      <journal-title-group>
        <journal-title>Health policy and planning</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0268-1080</issn>
      <issn pub-type="epub">1460-2237</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362066</article-id>
      <article-id pub-id-type="pmcid">PMC5362066</article-id>
      <article-id pub-id-type="pmc-uid">5362066</article-id>
      <article-id pub-id-type="pmid">27679522</article-id>
      <article-id pub-id-type="doi">10.1093/heapol/czw132</article-id>
      <article-id pub-id-type="manuscript">ems70793</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Setting healthcare priorities: a description and evaluation of the budgeting and planning process in county hospitals in Kenya</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Barasa</surname>
            <given-names>Edwine W.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cleary</surname>
            <given-names>Susan</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Molyneux</surname>
            <given-names>Sassy</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>English</surname>
            <given-names>Mike</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>KEMRI Centre for Geographic Medicine Research – Coast, and Wellcome Trust Research Programme, Nairobi, Kenya</aff>
      <aff id="A2"><label>2</label>Health Economics Unit, University of Cape Town, Cape Town South Africa</aff>
      <aff id="A3"><label>3</label>Centre for Tropical Medicine, University of Oxford, Oxford, UK</aff>
      <aff id="A4"><label>4</label>Nuffield Department of Medicine, University of Oxford, Oxford, UK</aff>
      <author-notes>
        <corresp id="CR1"><bold>Corresponding author:</bold> Edwine W. Barasa, KEMRI Centre for Geographic Medicine Research – Coast, and Wellcome Trust Research Programme, P.O Box 43,640-00200, Nairobi, Kenya. <email>edwinebarasa@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>15</day>
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>01</day>
        <month>4</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>04</day>
        <month>4</month>
        <year>2017</year>
      </pub-date>
      <volume>32</volume>
      <issue>3</issue>
      <fpage>329</fpage>
      <lpage>337</lpage>
      <!--elocation-id from pubmed: 10.1093/heapol/czw132-->
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p id="P1">This paper describes and evaluates the budgeting and planning processes in public hospitals in Kenya. We used a qualitative case study approach to examine these processes in two hospitals in Kenya. We collected data by in-depth interviews of national level policy makers, hospital managers, and frontline practitioners in the case study hospitals (<italic>n</italic> = 72), a review of documents, and non-participant observations within the hospitals over a 7 month period. We applied an evaluative framework that considers both consequentialist and proceduralist conditions as important to the quality of priority-setting processes. The budgeting and planning process in the case study hospitals was characterized by lack of alignment, inadequate role clarity and the use of informal priority-setting criteria. With regard to consequentialist conditions, the hospitals incorporated economic criteria by considering the affordability of alternatives, but rarely considered the equity of allocative decisions. In the first hospital, stakeholders were aware of - and somewhat satisfied with - the budgeting and planning process, while in the second hospital they were not. Decision making in both hospitals did not result in reallocation of resources. With regard to proceduralist conditions, the budgeting and planning process in the first hospital was more inclusive and transparent, with the stakeholders more empowered compared to the second hospital. In both hospitals, decisions were not based on evidence, implementation of decisions was poor and the community was not included. There were no mechanisms for appeals or to ensure that the proceduralist conditions were met in both hospitals. Public hospitals in Kenya could improve their budgeting and planning processes by harmonizing these processes, improving role clarity, using explicit priority-setting criteria, and by incorporating both consequentialist (efficiency, equity, stakeholder satisfaction and understanding, shifted priorities, implementation of decisions), and proceduralist (stakeholder engagement and empowerment, transparency, use of evidence, revisions, enforcement, and incorporating community values) conditions.</p>
      </abstract>
      <kwd-group>
        <kwd>priority-setting</kwd>
        <kwd>budgeting and planning</kwd>
        <kwd>deliberative democracy</kwd>
        <kwd>hospitals</kwd>
        <kwd>Kenya</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="S1">
      <title>Introduction</title>
      <p id="P2">Hospitals consume a significant proportion (50–60%) of recurrent national health budgets and are avenues for the delivery of key interventions (<xref rid="R7" ref-type="bibr">English <italic>et al.</italic> 2006</xref>). Understanding how these hospitals set their priorities and the factors that influence their allocation of resources is therefore imperative (<xref rid="R20" ref-type="bibr">Martin <italic>et al.</italic> 2003</xref>). However, priority-setting research has mainly focused on macro (national) and micro (patient) level processes and rarely on the meso (regional and/or organizational) level, particularly hospitals (<xref rid="R20" ref-type="bibr">Martin <italic>et al.</italic> 2003</xref>). Further, of the few studies examining the hospital level priority-setting, the majority have been carried out in high income countries (<xref rid="R4" ref-type="bibr">Barasa <italic>et al.</italic> 2015b</xref>). There is therefore a dearth of literature on hospital level priority-setting practices in LMICs. This is consistent with a general lack of evidence on priority setting frameworks and their usefulness in LMICs (<xref rid="R28" ref-type="bibr">Wiseman <italic>et al.</italic> 2016</xref>).</p>
      <p id="P3">This paper focuses on priority-setting practices in public hospitals in Kenya. In 2013, after a national election that ushered in a new government, the country transitioned into a devolved system of government with a central government and 47 semi-autonomous units called counties (<xref rid="R13" ref-type="bibr">Government of Kenya 2010</xref>). Under this new governance structure, the public healthcare delivery system is organized into four tiers, namely the community level, primary care level, county referral hospitals and national referral hospitals (<xref rid="R22" ref-type="bibr">Ministry of Health 2011</xref>). County referral hospitals, which are the focus of this study, are first level referral hospitals in the county health systems.</p>
      <p id="P4">Little is known about how the Kenyan health sector sets its priorities. At the macro level, it has been reported that priority setting is ad hoc, rather than systematic, without explicit priority setting criteria (<xref rid="R24" ref-type="bibr">Ndavi <italic>et al.</italic> 2009</xref>). The sector is guided by a long term (15 years) national health policy which outlines health sector objectives, and a short term (5 years) national health sector strategic plan which articulates sector strategies aimed at achieving the policies laid out in the national health policy. The health sector strategy outlines a package of health services that are to be provided by the public sector, known as the Kenya essential package of health (KEPH) (<xref rid="R23" ref-type="bibr">Ministry of Health 2005</xref>). Hospitals were therefore expected to provide KEPH services, but had the authority to prioritize across these services. On paper, the Ministry of Health employed a combination of top-down and bottom up planning to operationalize the sector strategy (<xref rid="R24" ref-type="bibr">Ndavi <italic>et al.</italic> 2009</xref>). There are no official guidelines in place on how the priority setting should be conducted at the county hospital level. There is also no evidence/literature on how the priority setting process is actually carried out within hospitals in Kenya. We used a case study approach to examine priority-setting practices in two of these hospitals. Specifically, this paper presents a description and evaluation of the budgeting and planning process in the case study hospitals. The budgeting and planning process was selected because it is, in theory, the major expression of identified and selected hospital priority activities and services, with allocation of available resources against those activities.</p>
    </sec>
    <sec sec-type="methods" id="S2">
      <title>Methods</title>
      <p id="P5">This study employed a qualitative case study design. A case study has been defined by <xref rid="R29" ref-type="bibr">Yin (2003)</xref> as an empirical inquiry that investigates a contemporary phenomenon within its real life context. A case study approach is considered suitable to inquiries into phenomena that are highly contextual and where the boundaries between what is being studied and the context are blurred (<xref rid="R29" ref-type="bibr">Yin 2003</xref>). It has been observed by several authors that priority setting practices in hospitals are highly context dependent (<xref rid="R15" ref-type="bibr">Kapiriri and Martin 2010</xref>; <xref rid="R20" ref-type="bibr">Martin and Singer 2003</xref>; <xref rid="R9" ref-type="bibr">Gibson <italic>et al.</italic> 2004</xref>). The case study approach is useful in building an understanding of the contextual influences on the phenomena of interest (<xref rid="R29" ref-type="bibr">Yin 2003</xref>; <xref rid="R18" ref-type="bibr">de Lange and Flyvbjerg 2011</xref>). The case study approach is also considered appropriate for the study of complex social phenomena (<xref rid="R29" ref-type="bibr">Yin 2003</xref>; <xref rid="R18" ref-type="bibr">de Lange and Flyvbjerg 2011</xref>). Priority setting is considered a complex social process that confronts decision makers with significant theoretical, political, and practical obstacles (<xref rid="R14" ref-type="bibr">Hauck <italic>et al.</italic> 2004</xref>; <xref rid="R26" ref-type="bibr">Shayo <italic>et al.</italic> 2013</xref>; <xref rid="R17" ref-type="bibr">Klein 1998</xref>). As observed by <xref rid="R8" ref-type="bibr">Flyvbjerg (2001)</xref>, social processes are complex and unlikely to yield universal truths or accurate predictions. An appropriate analysis should therefore aim to develop concrete, context dependent knowledge (<xref rid="R8" ref-type="bibr">Flyvbjerg 2001</xref>). These context specific insights could then be tested and examined in other contexts in an iterative process of knowledge building.</p>
      <p id="P6">Two county hospitals were purposely selected as cases for the study. The two hospital cases were selected purposefully guided by the following criteria: (1) First level referral hospitals that were designated as county hospitals; (2) hospitals with a high local resource level and those with a low local resource level. This was based on an assumption that priority-setting practices might be influenced by the level of funding. In the financial year preceding data collection, one of the case study hospitals had an annual budget of USD 528 862, while the other had an annual budget of USD 384 472. These budgets remained fairly stable over the past 5 years. In line with case study methodology, the selection of hospital cases aimed to ensure depth in information, as opposed to aiming for representativeness of all county hospitals in Kenya. To maintain confidentiality and minimize the potential identification and possible victimization of study participants, the hospitals selected for the study will only be identified as Hospital A and B. Data were collected through a combination of in-depth interviews with hospital managers and frontline workers, a review of relevant documents including hospital plans, budgets, minutes of meetings, and non-participant observations for a total period of 7 months in both hospitals. The selection of participants for interviews was purposive with the aim of selecting those who had an in-depth knowledge and experience of the budgeting and planning process. This included senior managers, middle level hospital managers, frontline practitioners and key informants within the planning departments of the central Ministry of Health. In total, 72 participants were interviewed; 35 from Hospital A, 32 from Hospital B and 5 from the central Ministry of Health (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
      <p id="P7">This study was broadly guided by the approach proposed by <xref rid="R20" ref-type="bibr">Martin and Singer (2003)</xref> on improving priority-setting in healthcare organizations. This approach proposes that efforts to improve priority-setting in healthcare organizations should entail (<xref rid="R20" ref-type="bibr">Martin and Singer 2003</xref>): (1) critical description of priority-setting processes using case study methods; (2) evaluation of priority-setting using an ethical framework and (3) action research to improve priority-setting based on the findings in the first two steps. While this paper focuses on step one and two, it is part of a wider action learning study to improve governance and accountability in the county health systems in which the case study hospitals are located.</p>
      <p id="P8">To evaluate the budgeting and planning process in the case hospitals we applied a published evaluative framework that was developed from a review of literature on priority-setting evaluation (<xref rid="R3" ref-type="bibr">Barasa <italic>et al.</italic> 2015a</xref>). Our evaluative framework is based on the argument that both consequentialist and proceduralist conditions are important for successful priority-setting (<xref rid="R3" ref-type="bibr">Barasa <italic>et al.</italic> 2015a</xref>). The framework brings together these two perspectives by drawing on ethical and deliberative democratic frameworks such as the well-known ‘accountability for reasonableness’ framework (AFR) (<xref rid="R6" ref-type="bibr">Daniels 2008</xref>), as well as consequentialist conditions of priority-setting (<xref rid="R3" ref-type="bibr">Barasa <italic>et al.</italic> 2015a</xref>). This integrated evaluative framework makes the following proposals (<xref ref-type="fig" rid="F1">Figure 1</xref>) : First, given that priority-setting is necessitated by the scarcity of resources, priority-setting processes should incorporate efficiency considerations by seeking to maximize outcomes within the constraint of available resources. Second, the goal of maximizing desired outcomes should be traded-off against equity. To achieve equity, the distribution of resources should be determined by need rather than other factors such as ability to pay, favouritism or political consideration. Third, other intermediate outcomes of priority-setting processes are also important. These include: (1) Stakeholder satisfaction; (2) Stakeholder understanding; (3) Shifted (reallocation of) resources and (4) Implementation. Fourth, the following proceduralist conditions should be incorporated in priority-setting practices: (1) stakeholder involvement; (2) empowerment; (3) transparency; (4) revisions; (5) use of evidence; (6) enforcement and (7) incorporation of community values.</p>
      <sec id="S3">
        <title>Data analysis</title>
        <p id="P9">Transcribed data were imported into NVIVO 10 for coding and analyzed using a modified framework approach (<xref rid="R25" ref-type="bibr">Pope <italic>et al.</italic> 2000</xref>). This approach was adopted because it is suited to providing findings and interpretations that are relevant to policy and pragmatic recommendations. The approach included an initial open coding step to support the emergence of important themes, which might not have been captured in the evaluative framework described above.</p>
      </sec>
      <sec id="S4">
        <title>Ethical considerations</title>
        <p id="P10">The authors received ethical approval from their organization.</p>
      </sec>
      <sec id="S5">
        <title>Findings</title>
        <sec id="S6">
          <title>Description of the budgeting and planning processes</title>
          <sec id="S7">
            <title>Hospital decision-making structure</title>
            <p id="P11">The case study hospitals did not have an official organogram. However, observations and discussions with hospital managers and staff identified the existence of a management structure which was highly hierarchical (<xref ref-type="fig" rid="F2">Figure 2</xref>). At the lowest level were frontline healthcare workers (such as pharmacists, medical doctors, and nurses) and non-health staff (such as accountants and maintenance personnel), all of whom were answerable to the heads of their respective departments. These heads of departments were middle level managers for clinical departments (e.g. paediatrics, obstetrics and gynaecology), wards (e.g. adult male, adult female and paediatrics), non-clinical departments (e.g. pharmacy and laboratory) and support departments (e.g. accounts and maintenance) who were themselves answerable to the three senior hospital managers namely the medical superintendent, the hospital administrator and the hospital nursing officer in-charge. The medical superintendent was the chief executive of the hospital and was responsible for the overall running of the hospital. The hospital nursing officer in-charge was in charge of the nursing department and hence all nursing wards in charges. The hospital administrative officer was in charge of all the hospital non-clinical departments. The case study hospitals had 3 management and decision-making committees. First, there was a hospital management team (HMT), comprised of all hospital departmental managers (middle level managers) and senior managers. Second, there was an executive expenditure committee (EEC), comprised of only the senior managers, and third, there was the hospital management committee (HMC) which was an oversight committee that drew its membership from the local resident community. The hospital was represented in the HMC by the medical superintendent, who was also its secretary, and the hospital administrative officer.</p>
          </sec>
          <sec id="S8">
            <title>Budgeting and planning process</title>
            <p id="P12">The budgeting and planning process was comprised of two distinct activities; quarterly budgeting and the annual work planning (AWP) process. The development of the hospital budget and the AWP were designed to be linked and aligned. At the beginning of each government fiscal year (July 1), hospitals were required to develop and submit AWPs to the central Ministry of Health (MOH) for approval. Hospitals were then required to develop quarterly budgets that outlined the allocation of available resources to the priorities indicated in the AWPs. Hospital AWPs were developed by the HMT and submitted to the regional office for onward transmission to the central Ministry of Health (MOH) for approval. While the range of services provided by hospitals was guided by KEPH, hospital managers had autonomy to allocate available resources across service areas (i.e. prioritize across these services). The budgeting process should begin at the hospital department level, where departmental managers develop a list of departmental needs and present these to the HMT. The HMT then deliberates on the departmental needs and develop budgets that allocate available cash budgets across hospital departments. These budgets should then be deliberated upon and finalized by the EEC and subsequently presented to the HMC for review and approval. Budgets approved by the HMC should then be submitted to the regional level and from there submitted to the MOH for approval.</p>
          </sec>
          <sec id="S9">
            <title>Non-alignment of the budgeting and planning process</title>
            <p id="P13">While the budgeting and planning process was expected to be linked and aligned, in practice, this was not the finding in both case study hospitals. The AWP was developed almost one quarter in the planning year, while the budgets were developed on time at the beginning of every quarter. This meant that the first budget of the year was often developed without the existence and hence any reference to the AWP. Subsequent budgets were also developed without reference to the AWP. The result was that activities budgeted for in the quarterly budgets were dissimilar to activities planned and budgeted for in the AWP. As a result of this non-alignment, hospital managers placed little importance to the AWP process. Very few managers knew what was contained in the AWP, very few participated in the process, and hardly any cared about implementing the AWP.</p>
            <disp-quote id="Q1">
              <p id="P14">People just fill the [AWP] template very fast but they don’t even know what they are putting in the plans. If you ask people ‘okay you did the AWP some three months ago do you remember what you did?’ Most of the people don’t have an idea. They’ll tell you ‘we did it and it has already been sent to the province. We finished that business. Middle level manager, Hospital A</p>
            </disp-quote>
          </sec>
          <sec id="S10">
            <title>Decision-making criteria</title>
            <p id="P15">Formal and informal criteria were used to allocate budgets. Formal criteria are objective criteria that were used explicitly by hospital decision makers to determine how the hospital budget was allocated across departments and/or services. Informal criteria refer to subjective considerations, which were often implicitly employed, that influenced budget allocation decisions in hospitals. To get an idea of the prominence of criteria used in the case study hospitals, we developed a word cloud by identifying decision-making criteria mentioned in interview transcripts and the number of times they were mentioned (<xref ref-type="fig" rid="F3">Figure 3</xref>). The criteria identified will be discussed next.</p>
            <sec id="S11">
              <title>Formal criteria</title>
              <p id="P16">In both case study hospitals, the dominant criterion used to allocate budgets to hospital departments and services was the revenue generating potential of the departments. Departments or services that generated more revenue from user fee collections were prioritized over departments that generated less revenue and subsequently received a larger share of the hospital budget. The reason given for using the revenue generating potential of departments is that the hospitals experienced a severe scarcity of resources and relied on user fee collection to finance their daily operations (<xref rid="R5" ref-type="bibr">Barasa <italic>et al.</italic> 2016</xref>). To make sure that the hospital continued to run, resources had to be allocated in a manner that assured further generation of revenues: <disp-quote id="Q2"><p id="P17">The hospital generates very little money which means priorities have to change…So first we want to make money, we allocate where we can make money…Middle level manager, Hospital B</p></disp-quote>
</p>
              <p id="P18">Historical budgeting also featured prominently among the criteria used by managers to allocate budgets across departments in both hospitals. Departments often received the same budgetary allocation or increments to previous year’s budgets. The lack of technical competence in budgeting and planning, and lack of priority-setting guidelines, together with resource scarcity also contributed to the use of historical budgeting (Barasa <italic>et al.</italic> in press). Managers also considered the extent of necessity of a service in making budgetary allocation decisions. Services were considered essential if the hospital could not run without them. The perceived medical need in the hospital’s catchment area was also a determinant of hospital allocations. The need was however based on the volume of patients seeking different services at the hospital rather than any formally assessed need in the community. Other formal criteria used included international and national priorities such as the Millennium Development Goals, the feasibility of implementing the service, and affordability of proposed services.</p>
            </sec>
            <sec id="S12">
              <title>Informal criteria</title>
              <p id="P19">In contrast to the formal criteria identified above, managers in Hospital A felt that allocative decisions were influenced by informal criteria such as the lobbying and bargaining ability of departmental managers.</p>
              <disp-quote id="Q3">
                <p id="P20">You see you can have a head of department who is not very vocal and does not articulate your needs as well as they should…some departments…they seem to always get more than others…it all depends on how eloquent and convincing the head of department presents his proposals. Middle level manager, Hospital A</p>
              </disp-quote>
              <p id="P21">Resource allocation was also dependent on interpersonal relationships and mutual benefit between the middle-level managers and the senior managers.</p>
              <disp-quote id="Q4">
                <p id="P22">Allocations depend on your relationship with the hospital administrators…we mean in life sometimes things work because of relationships right? You are a friend of mine and we get along well so we will allocate something to you. Middle level manager, Hospital A</p>
              </disp-quote>
              <p id="P23">Middle level managers at Hospital A also felt that allocations favoured the senior managers who were part of the EEC. The use of these informal criteria was made possible in Hospital A because there was little deliberative space in the budgeting process. Given that actual allocation decisions were made by a small group of senior managers (EEC), this provided an opportunity for the EEC managers to leverage on their unique position to favour their departments and the departments of those with whom they enjoyed good relationships.</p>
              <p id="P24">The situation was different in Hospital B where the middle level managers, through the HMT, were empowered to make allocation decisions. While managers in this hospital also felt that the bargaining and lobbying ability of managers had an influence, the general feeling was that favouritism did not influence decisions. The result was that while in Hospital A managers generally felt that the allocation decisions were unfair, in Hospital B the feeling was that allocations were relatively fair.</p>
              <disp-quote id="Q5">
                <p id="P25">We don’t get all that we need but we can say that the budgeting is fair. The medical superintendent ensures there is equity. At least each department gets something small. Middle level manager, Hospital B</p>
              </disp-quote>
            </sec>
          </sec>
        </sec>
        <sec id="S13">
          <title>Evaluating priority-setting</title>
          <p id="P26">In this section, we use the framework that we previously developed (<xref rid="R3" ref-type="bibr">Barasa <italic>et al.</italic> 2015a</xref>) to evaluate the budgeting and planning process in the case study hospitals. We first present our findings on the use of consequentialist principles followed by the adherence to proceduralist conditions.</p>
          <sec id="S14">
            <title>The use of consequentialist principles</title>
            <sec id="S15">
              <title>Efficiency and equity</title>
              <p id="P27">Hospital managers were unfamiliar with mechanisms such as cost-effectiveness analysis (CEA) and program budgeting and marginal analysis (PBMA). When the basics and rationales of these methods were explained to them, they responded that although the methods were potentially useful in decision-making, they lacked the technical skills and data required. However, in both hospitals, budgeting and planning decisions considered the affordability of competing alternatives. This could be argued to be an attempt to incorporate efficiency, given the capacity and data constraints that the hospitals faced. By taking into account the costs and affordability of competing priorities, managers were recognizing budget limitations and the need to make decisions such that the hospital could get the most out of available resources.</p>
              <p id="P28">In both case study hospitals, the dominance of revenue maximization as a priority-setting criterion meant that departments (and hence patient groups such as children under 5 years) that did not generate user fee revenues were systematically underfunded compared to departments that generated user fee revenues. This practice meant that budget allocations were inequitable. Further, the reported favouritism in resource allocation given to departments headed by senior managers and those whose managers enjoyed good relationships with senior management could also be considered as sources of inequity.</p>
            </sec>
            <sec id="S16">
              <title>Stakeholder satisfaction</title>
              <p id="P29">The level of satisfaction with the budgeting and planning process varied between hospitals. In Hospital A, stakeholders (senior and middle level managers, and frontline practitioners) were not satisfied with the budgeting and planning process because the process was generally not inclusive, leaving most stake-holders disgruntled. Further, the scarcity of resources meant that hospital managers were not satisfied with the resources that were allocated to them. The use of revenue generation criterion also left the managers whose departments generated little revenue disgruntled. In Hospital B, the stakeholders reported having some level of satisfaction with the budgeting and planning process. While they were unhappy with the limited availability of resources, they seemed to understand the scarcity situation. It appeared that this general satisfaction with the process was due to the fact that they were included in the budgeting and planning process. However, managers of departments with low revenue generating potential, like in Hospital A, were unhappy with the process.</p>
            </sec>
            <sec id="S17">
              <title>Stakeholder understanding (awareness)</title>
              <p id="P30">The level of understanding varied across stakeholders and was related to their level of engagement. For example, while in Hospital A the middle level managers had a low level of understanding of the budgeting process given that they were excluded from it, in Hospital B, the middle level managers reported adequate understanding of the process because they were involved in it.</p>
            </sec>
            <sec id="S18">
              <title>Shifted priorities (reallocation of resources)</title>
              <p id="P31">In both case study hospitals, budgeting and planning processes did not result in shifted resources. This was because budgeting and planning in these hospitals was significantly guided by historical allocations. The budgeting and planning process was therefore not responsive to the changing dynamics of resource needs.</p>
            </sec>
            <sec id="S19">
              <title>Implementation of decisions</title>
              <p id="P32">The implementation of budgeting and planning decisions was fairly similar between the case study hospitals. The planning processes in both hospitals were considered to be mainly an activity on paper that was hardly implemented in practice. A number of reasons, which we have reported elsewhere, led to the lack of implementation of decisions including the lack of resources, reduced motivation due to reduced autonomy of hospital managers over planning decisions, a culture where hospital staff lacked a sense of duty and commitment to their roles and responsibilities, and the lack of strong internal accountability mechanisms (Barasa <italic>et al.</italic> in press).</p>
            </sec>
          </sec>
          <sec id="S20">
            <title>Compliance with proceduralist conditions</title>
            <sec id="S21">
              <title>Stakeholder engagement</title>
              <p id="P33">The degree of stakeholder engagement varied across the case study hospitals, with the budgeting and planning process being more inclusive in Hospital B, compared to Hospital A. While hospital budgets were discussed by the HMT in Hospital A, final budgeting decisions were made by the EEC. Given that the EEC was a smaller committee that comprised of senior managers only, middle level managers felt excluded from the budgeting process. In Hospital B however, as mentioned above, final budgeting decisions were made by the HMT which was a larger committee that comprised of both senior and middle level managers. The HMT meetings also allowed for greater deliberation and discussion.</p>
              <disp-quote id="Q6">
                <p id="P34">We present budgets and people are asked to say why they need the money. At least we get to understand why a department’s budget is like this or like that. People also see why for example they are going to get less than what they asked for….because we also discuss what [resources] is available and how much departments can get. Middle level manager, Hospital B</p>
              </disp-quote>
              <p id="P35">In both hospitals, however, frontline clinicians rarely participated in budgeting and planning processes. While it was reported that they were not invited in Hospital A, frontline clinicians did not participate in Hospital B despite being invited. As we have discussed elsewhere, it appeared that the main reason for non-participation of clinicians was professional identity (Barasa <italic>et al.</italic> in press). Clinicians in both hospitals did not seem to think that managerial responsibilities such as budgeting and planning were part of their roles as professionals. They identified themselves more with their clinical roles and considered time spent doing managerial duties as ‘wasted time’ (Barasa, <italic>et al.</italic> in press). The shortage of clinical staff also contributed to the non-participation of clinicians in budgeting and planning meetings (Barasa <italic>et al.</italic> in press). As will be discussed below, community members were involved only very peripherally in the budgeting and planning processes in both case study hospitals.</p>
            </sec>
            <sec id="S22">
              <title>Stakeholder empowerment</title>
              <p id="P36">The level of empowerment of different stakeholders varied between the case study hospitals. In Hospital A, middle level managers appeared to have a low level of empowerment to participate in budgeting and planning activities compared to Hospital B.</p>
              <disp-quote id="Q7">
                <p id="P37">Decision making is not democratic. I think it’s dictatorial because at the end of the day whatever decisions are made at HMT meetings, we’re still going to hear of another meeting that was held with another committee and basically whatever we had come up with will not even be considered. Middle level manager, Hospital A</p>
              </disp-quote>
              <p id="P38">Further, actors who were not engaged in the priority-setting process (clinicians and the community) were clearly not empowered to contribute to decision making either.</p>
            </sec>
            <sec id="S23">
              <title>Transparency</title>
              <p id="P39">The extent to which the budgeting and planning process was transparent varied between the case study hospitals. Generally, Hospital B exhibited more transparency. In Hospital A, there was no mechanism in place for disseminating budgeting and planning decisions, and once the final budgets and AWPs had been prepared, they were not shared with the hospital managers. Only selected senior managers had access to these documents, and for both processes, the reasons for decisions were not communicated to the managers. Front line practitioners also reported that they were in the dark as far as budgeting and planning decisions in the hospital were concerned. In Hospital B, a more inclusive budgeting and planning process meant that managers were generally more aware of the budgeting and planning decisions and the rationales behind them. They therefore reported that the process was transparent. Nevertheless, as with Hospital A, they reported that final budgets and work plans were not made available to them unless they individually sought them out.</p>
            </sec>
            <sec id="S24">
              <title>Use of quality information</title>
              <p id="P40">In both case study hospitals, decisions were rarely made based on information/evidence. Information was gathered using formal channels such as the hospital management information system but ignored. Decision makers often used their gut feeling and hearsay as the basis for decision-making. When information was used, the use was more symbolic rather than functional. Decisions were first made and then information was sought to justify the decisions. One of the reasons given for the low use of information was that the quality of information available was questionable. Managers reported that data captured in clinic registers often had gaps and did not capture all events. They also complained that the data captured in clinic registers were inaccurate.</p>
            </sec>
            <sec id="S25">
              <title>Revisions</title>
              <p id="P41">In both case hospitals the budgeting and planning process did not have a provision for a formal appeals and revision process. Once the quarterly budget or the AWPs had been prepared and approved, they could not be changed or altered over the course of the planning period. This meant that the decision-making process was inflexible and could not be improved with emerging information. It also meant that there was no formal avenue for parties to contest planning and budgeting decisions.</p>
            </sec>
            <sec id="S26">
              <title>Community values</title>
              <p id="P42">In both case hospitals, community views were obtained through two mechanisms namely the suggestion box and community representatives in the HMC. Both mechanisms were however felt to be ineffective as mechanisms for channelling community views. In both case study hospitals, the suggestion box was hardly ever opened by the hospital administration. The incorporation of community representatives in the HMC was also shown to be an ineffective mechanism for obtaining community values in both hospitals. This mechanism was shown to have two main shortcomings. First, the method of appointing community representatives into the committee was not thought to be transparent and inclusive. Senior hospital managers were perceived to influence the selection process to appoint preferred individuals, who were then thought to simply ‘rubber stamp’ hospital decisions. The community representatives in this committee were therefore not empowered to ask questions and contribute to decision-making.</p>
            </sec>
          </sec>
        </sec>
      </sec>
    </sec>
    <sec sec-type="discussion" id="S27">
      <title>Discussion</title>
      <p id="P43">This study is the first in Kenya - and one of very few in LMIC settings - that examines priority-setting processes in hospitals. One of the key findings was the lack of alignment of the budgeting process and the annual work planning process. Non-alignment between budgets and sector priorities has been identified as a reason for Kenya failing to achieve health sector targets (Tsofa <italic>et al.</italic> 2015). This non-alignment appears to be a downstream manifestation of the observed lack of coordination and harmonization of the budgeting and planning processes for the health sector with the central MOH (Tsofa <italic>et al.</italic> 2015). It is imperative that planning and budgeting processes are integrated and harmonized by, for example, ensuring that the same set of actors and administrative units within the county departments of health drive the process, and by harmonizing the timelines for the two processes such that budgeting is carried out only after (and therefore draws from) the planning process.</p>
      <p id="P44">A second observation was the lack of clarity about the roles and composition of the different decision -making organs in the case hospitals. The importance of clarifying roles of decision-making bodies has been highlighted in priority-setting literature (<xref rid="R9" ref-type="bibr">Gibson <italic>et al.</italic> 2004</xref>). Role clarity in the county hospitals could be improved by developing official hospital organograms with clear terms of reference for each position in the structure and specification of the composition of management committees.</p>
      <p id="P45">A third observation concerns the appropriateness of the criteria used to set priorities. It has been pointed out in literature that the criteria used to set healthcare priorities should be clearly defined and understood by stakeholders and decision-makers (<xref rid="R9" ref-type="bibr">Gibson <italic>et al.</italic> 2004</xref>). The dominant criteria used to set priorities in both case study hospitals are the revenue generating potential of the department. These criteria are seen to promote the inequitable allocation of budgets which resulted in frustration and reduced motivation among hospital staff (Barasa <italic>et al.</italic> in press). The use of informal criteria to set priorities also stands out as an area of concern. While this observation was more prominent in Hospital A, it was minimized in Hospital B largely because of the leadership style of the hospital superintendent (Barasa <italic>et al.</italic> in press). The use of informal criteria to set hospital priorities is consistent with findings in a number of settings. For example, in a case study of priority-setting practice in a public hospital in Uganda, it was reported that departments whose leaders knew how to ‘lobby’, ‘make noise’, ‘quickly use up their resources’, or ‘make their case’ were usually prioritized (<xref rid="R16" ref-type="bibr">Kapiriri and Martin 2006</xref>). In these settings, it was reported that the absence of data led to the use of informal or arbitrary considerations in decision making (<xref rid="R11" ref-type="bibr">Gordon <italic>et al.</italic> 2009</xref>). While this is also true of the case study hospitals, it also emerged that multiple additional factors had led to the use of informal criteria including the absence of explicit guidelines to guide budgeting and planning. The use of informal criteria is seen to result in perceptions of unfairness. The case study hospitals could minimize these unwanted consequences by adopting and implementing systematic and explicit priority-setting criteria that hospital actors agree on. Strengthening hospital information systems to provide reliable information for decision-making could also reduce the use of informal decision-making criteria.</p>
      <p id="P46">A number of key issues emerge from the evaluation of the budgeting and planning process in the case hospitals. The use of economic methods such as CEA and PBMA was hampered by a lack of both technical capacity and reliable data. This is consistent with the literature on priority-setting in other settings (<xref rid="R4" ref-type="bibr">Barasa <italic>et al.</italic> 2015b</xref>; <xref rid="R14" ref-type="bibr">Hauck <italic>et al.</italic> 2004</xref>). Managers in the case study hospitals none-the-less appreciated the rationale of incorporating economic considerations in priority-setting processes and attempted to do this by using the affordability criteria. This was perhaps a more pragmatic approach in this and similar settings: priority-setting processes in settings with resource, capacity and data challenges could incorporate efficiency considerations by assessing the affordability and budget impact of competing priorities alongside their effectiveness. Further, while equity was a concept that hospital actors related to, there was no systematic attempt to incorporate it. It is imperative that there is an explicit requirement that allocation of resources in hospitals be based on need, give priority to the worse off and is transparent about where such considerations are traded off with efficiency.</p>
      <p id="P47">With regard to intermediate outcomes of the budgeting and planning processes, stakeholders in Hospital B were more satisfied and better understood the budgeting and planning processes compared to Hospital A because the process in the latter was more inclusive and deliberative, eliciting perceptions of transparency and fairness. The fact that stakeholders were included in Hospital B made them appreciate the reality of resource scarcity which in turn resulted in their being more understanding of the situation. This highlights the relationship between procedural conditions and intermediate outcomes and the importance of both. In both hospitals, however, the budgeting and planning processes often did not lead to shift resources due to the fact that hospitals relied on historical allocations. The use of historical budgeting means that the hospital budgeting and planning process was not responsive to the dynamic healthcare priorities of the communities that they serve. It also served to entrench historical inequities in the allocation of resources within the hospitals. To improve priority-setting, hospitals should adapt criteria that are responsive to hospital needs and health system goals (such as burden of disease, effectiveness and cost-effectiveness, equity) rather than historical budgeting. The implementation of planning decisions in both case study hospitals was also seen to be unsatisfactory. This was attributed to, among others, non-alignment of budgets and plans and lack of internal accountability mechanisms to follow up and ensure that plans and budgets are implemented. It is imperative that hospitals strengthen their internal accountability mechanisms by, among others, introducing and enforcing a system of tracking and monitoring the implementation of budgets and holding hospital managers accountable by a system of rewards and sanctions.</p>
      <p id="P48">With regard to procedural conditions, the case hospitals could improve their budgeting and planning processes by ensuring that the relevant range of stakeholders are included in the process. Notable exclusions in both hospitals were frontline clinicians and the public. This is consistent with the literature on hospital level priority-setting (<xref rid="R4" ref-type="bibr">Barasa <italic>et al.</italic> 2015b</xref>). This exclusion calls into question the legitimacy of the priority-setting processes and resulted in perceptions of unfairness (Barasa <italic>et al.</italic> in press). One way of improving the inclusivity of the process in Kenyan county hospitals is to ensure that actual budgeting decisions are made in a more inclusive decision-making organ, such as the HMT, rather than the more exclusive EEC. Closely related to this, the range of actors excluded from budgeting and planning processes also appear to be less empowered to contribute to decision-making. This exclusion is a function of unclear or sometimes lacking guidelines and systems and also of micropractices of power among hospital actors (Barasa <italic>et al.</italic> in press.). It is imperative that hospitals specify systematic priority-setting processes that clearly outline the procedure, roles of actors, and composition of decision-making organs. Such a system should ensure that the relevant range of actors are included, the decision-making process is deliberative and mechanisms to empower actors are put in place (Barasa <italic>et al.</italic> in press). As has been discussed elsewhere, hospital leadership also plays an important role in ensuring the effectiveness of deliberative processes by actively ensuring that processes are inclusive and managing the power dynamics among actors with varying levels of influence (Barasa <italic>et al.</italic> in press). Transparency is also seen to be a sticky issue in both hospitals with perceptions of lack of transparency being worse in Hospital A. To improve transparency, case study hospitals will need to improve communication and provide information about hospital budgeting decisions, and their rationales to all relevant actors. This information should be made easily accessible to these actors, and also actively pushed to them. In both case study hospitals, budgeting and planning processes did not use evidence to make decisions but rather relied on personal experience and hunches. Improving the quality of information, information systems, and requiring that budgeting and planning decisions be backed by evidence would improve this in the short term. In the long term, however, there is a need to focus on changing the decision-making culture of hospital managers to place more importance on evidence based decision making. Related to this, and consistent with findings in most settings, there is no formal process for revisions. For hospital priority-setting processes to be responsive to the changing dynamics of information and needs, it is imperative that there is a mechanism that allows for budgets and plans to be amended in light of new information.</p>
      <p id="P49">In both case study hospitals, there is no systematic and effective mechanism to elicit and incorporate community values in the budgeting and planning process. If we accept the idea that hospitals are a social institution, then the lack of a mechanism to incorporate community values begs the question of the legitimacy and responsiveness of the hospital budgeting and planning processes (Barasa <italic>et al.</italic> in press). County hospitals in Kenya should incorporate participatory community engagement mechanisms such as the incorporation of community members in hospital planning committees, the use of citizen juries (<xref rid="R19" ref-type="bibr">Lenaghan 1999</xref>) or planning cells (Abelson <italic>et al.</italic> 2001). The selection of community representatives in these mechanisms must however be seen to be transparent and fair. The proposal for implementing and/or strengthening community engagement in decision making is not a new thing in Kenya. The new Kenyan constitution requires that decision making at both the national and county levels involve and engage the public for their inputs (<xref rid="R13" ref-type="bibr">Government of Kenya 2010</xref>). Further, the Kenyan public finance law prescribes a mechanism that requires that the public budgeting processes at the national and county levels organize public forums to share and debate proposals before finalization of budgets (<xref rid="R12" ref-type="bibr">Government of Kenya 2012</xref>). Extending this practice to health sector priority-setting therefore has a precedent from public finance practice in Kenya.</p>
    </sec>
    <sec sec-type="conclusions" id="S28">
      <title>Conclusion</title>
      <p id="P50">In this paper, we have presented a description and evaluation of the budgeting and planning process in county hospitals in Kenya. It is clear that to improve priority-setting practices, decision makers in charge of these hospitals will need to focus their attention not only on the content and outcomes of priority setting but also - equally important - on the process. Fulfilling the consequentialist and proceduralist conditions of our evaluative framework, especially is resource constrained settings, may be challenging, and will require making difficult trade-offs. We recognize these constraints and recommend that when making these decisions, in addition to considering the required resources, decision makers should also consider the merits of implementing a process that incorporates these conditions such as; improvement of the legitimacy of the decisions, strengthening the responsiveness of priority-setting decisions to local needs, minimizing the range of disagreements, and improving the quality of priority-setting decisions. Decision makers may therefore need to consider feasible ways of implementation while considering context. For example, hospitals could start by incorporating some of the conditions, and then progressively add the other elements over time. Also, innovative ways could be used to improve feasibility and affordability. For example, a cost-effective strategy to incorporate community engagement would perhaps be to integrate hospital community engagement initiatives with those already funded by the counties rather than having individual hospital initiatives.</p>
      <p id="P51">One of the limitations of the study is that we did not interview community representatives, who are a key stakeholder in priority-setting processes. While interviewing community representatives were beyond the scope of the study, it would have enriched our findings especially with regard to their role and experiences of hospital priority-setting processes. Another limitation is the inability to generalize findings of a case study. This not-withstanding, this study, in line with the intentions and characteristics of case study methodology, provides in-depth insights that can be considered and tested in comparable settings (<xref rid="R10" ref-type="bibr">Gilson <italic>et al.</italic> 2011</xref>).</p>
    </sec>
  </body>
  <back>
    <ack id="S29">
      <title>Acknowledgement</title>
      <p>The authors are grateful to the staff of case hospitals their participation in this study.</p>
      <p>
        <bold>Funding</bold>
      </p>
      <p>Funds from a Wellcome Trust Strategic Award (#084538) and a Wellcome Trust core grant awarded to the KEMRI-Wellcome Trust Research Programme (#092654) made this work possible. Mike English is supported by a Wellcome Trust Senior Fellowship awarded to ME (#097170) while Sassy Molyneux is supported by a Wellcome Trust Career Development Fellowship to SM (WT 085418). Edwine. W. Barasa, Sassy Molyneux, and Susan Cleary are also members of the Consortium for Resilient and Responsive Health Systems (RESYST). This document is an output from a project funded by the UK Aid from the UK Department for International Development (DFID) for the benefit of developing countries. However, the views expressed and information contained in it are not necessarily those of or endorsed by DFID, which can accept no responsibility for such views or information or for any reliance placed on them. The funders had no role in the design, conduct, analyses or writing of this study or in the decision to submit for publication. This work is published with the permission of the Director of KEMRI.</p>
    </ack>
    <fn-group>
      <fn id="FN1">
        <p id="P52">
          <bold>Ethical considerations</bold>
        </p>
        <p id="P53">Ethics approval was obtained in advance from the University Of Cape Town Faculty Of Health Sciences, the Human Research Ethics Committee in South Africa and the KEMRI ethics review board. All interviewees gave written informed consent, and verbal consent was sought for non-participant observations from hospital administrators and individual staff. Individual and case study hospital information has been anonymized to protect confidentiality.</p>
      </fn>
      <fn fn-type="COI-statement" id="FN2">
        <p id="P54"><italic>Conflict of interest statement</italic>. None declared.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="R1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abelson</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Deliberations about deliberation: issues in the design and evaluation of public consultation processes</article-title>
          <source>Social Science &amp; Medicine</source>
          <year>2003</year>
          <volume>57</volume>
          <fpage>239</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="pmid">12765705</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barasa</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>Molyneux</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>English</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hospitals as complex adaptive systems: a case study of priority setting at the hospital level in Kenya</article-title>
          <source>Social Science &amp; Medicine</source>
          <year>2015</year>
          <volume>30</volume>
          <fpage>386</fpage>
          <lpage>96</lpage>
        </element-citation>
      </ref>
      <ref id="R3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barasa</surname>
              <given-names>EW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Setting healthcare priorities at the macro and meso levels: a framework for evaluation</article-title>
          <source>International Journal of Health Policy and Management</source>
          <year>2015a</year>
          <volume>4</volume>
          <fpage>719</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="pmid">26673332</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barasa</surname>
              <given-names>EW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Setting healthcare priorities in hospitals: a review of empirical studies</article-title>
          <source>Health Policy and Planning</source>
          <year>2015b</year>
          <volume>30</volume>
          <fpage>386</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="pmid">24604831</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Barasa</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Molyneux</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>English</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cleary</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Improving priority setting practices in Kenyaaã s hospitals: Recommendations for county decision-makers and hospital managers (RESYST Policy briefs)</source>
          <year>2016</year>
          <publisher-loc>Nairobi</publisher-loc>
        </element-citation>
      </ref>
      <ref id="R6">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Daniels</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <source>Just Health: Meeting Health Needs Fairly</source>
          <year>2008</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Cambridge University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="R7">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>English</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <chapter-title>The district hospital</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Jamison</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Disease Control Priorities in Developing Countries</source>
          <year>2006</year>
          <publisher-loc>Washington DC</publisher-loc>
          <publisher-name>World Bank</publisher-name>
        </element-citation>
      </ref>
      <ref id="R8">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Flyvbjerg</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <source>Making Social Science Matter: Why Social Inquiry Fails and How It Can Succed Again</source>
          <year>2001</year>
          <publisher-loc>Cambridge UK</publisher-loc>
          <publisher-name>Cambridge University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="R9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gibson</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Setting priorities in health care organizations: criteria, processes, and parameters of success</article-title>
          <source>BMC Health Services Research</source>
          <year>2004</year>
          <volume>4</volume>
          <fpage>25</fpage>
          <pub-id pub-id-type="pmid">15355544</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilson</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Building the field of health policy and systems research: social science matters</article-title>
          <source>PLoS Medicine</source>
          <year>2011</year>
          <volume>8</volume>
          <fpage>e1001079</fpage>
          <pub-id pub-id-type="pmid">21886488</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gordon</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Priority setting in an acute care hospital in Argentina: A qualitative case study</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>184</fpage>
          <lpage>92</lpage>
        </element-citation>
      </ref>
      <ref id="R12">
        <element-citation publication-type="book">
          <collab>Government of Kenya</collab>
          <source>Public Finance Management Act</source>
          <year>2012</year>
          <publisher-loc>Nairobi</publisher-loc>
        </element-citation>
      </ref>
      <ref id="R13">
        <element-citation publication-type="book">
          <collab>Government of Kenya</collab>
          <source>The Constitution of Kenya</source>
          <year>2010</year>
          <publisher-loc>Nairobi, Kenya</publisher-loc>
        </element-citation>
      </ref>
      <ref id="R14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hauck</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Goddard</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The economics of priority setting for health care: a literature review</article-title>
          <source>World Bank HNP Discussion Papers</source>
          <year>2004</year>
          <comment>(September)</comment>
        </element-citation>
      </ref>
      <ref id="R15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kapiriri</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Successful priority setting in low and middle income countries: a framework for evaluation</article-title>
          <source>Health Care Analysis</source>
          <year>2010</year>
          <volume>18</volume>
          <fpage>129</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="pmid">19288200</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kapiriri</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>DK</given-names>
            </name>
          </person-group>
          <article-title>Priority setting in developing countries health care institutions: the case of a Ugandan hospital</article-title>
          <source>BMC Health Services Research</source>
          <year>2006</year>
          <volume>9</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="R17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klein</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Puzzling out priorities. Why we must acknowledge that rationing is a political process</article-title>
          <source>British Medical Journal</source>
          <year>1998</year>
          <volume>317</volume>
          <fpage>959</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">9765158</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>de Lange</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Flyvbjerg</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <chapter-title>Case Study</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Norman</surname>
              <given-names>YSL</given-names>
            </name>
            <name>
              <surname>Denzin</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <source>The Sage Handbook for Qualitative Research</source>
          <year>2011</year>
          <publisher-loc>Thousand Oaks</publisher-loc>
          <fpage>301</fpage>
          <lpage>16</lpage>
        </element-citation>
      </ref>
      <ref id="R19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lenaghan</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Involving the public in rationing decisions. The experience of citizens juries</article-title>
          <source>Health Policy</source>
          <year>1999</year>
          <volume>49</volume>
          <fpage>45</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">10827290</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>A strategy to improve priority setting in health care institutions</article-title>
          <source>Health Care Analysis</source>
          <year>2003</year>
          <volume>11</volume>
          <fpage>59</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">14510309</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>DK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Priority-setting and hospital strategic planning: a qualitative case study</article-title>
          <source>Journal of Health Services Research &amp; Policy</source>
          <year>2003</year>
          <volume>8</volume>
          <fpage>197</fpage>
          <lpage>201</lpage>
          <pub-id pub-id-type="pmid">14596753</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <element-citation publication-type="book">
          <collab>Ministry of Health</collab>
          <source>Comprehensive National Health Policy Framework 2011-2030</source>
          <year>2011</year>
          <publisher-loc>Nairobi</publisher-loc>
        </element-citation>
      </ref>
      <ref id="R23">
        <element-citation publication-type="book">
          <collab>Ministry of Health</collab>
          <source>The Second National Heath Sector Strategic Plan of Kenya (NHSSP II 2005-2010): Reversing the Trends</source>
          <year>2005</year>
          <publisher-loc>Nairobi</publisher-loc>
          <publisher-name>Ministry of Health Kenya</publisher-name>
        </element-citation>
      </ref>
      <ref id="R24">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Ndavi</surname>
              <given-names>PM</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Decentralizing Kenya’s Health Management System: An Evaluation</source>
          <year>2009</year>
          <publisher-loc>Calverton, MD</publisher-loc>
        </element-citation>
      </ref>
      <ref id="R25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pope</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Qualitative research in health care: Analysing qualitative data rapid responses email alerting service analysing qualitative data</article-title>
          <source>British Medical Journal</source>
          <year>2000</year>
          <volume>320</volume>
          <comment>(August 2005)</comment>
        </element-citation>
      </ref>
      <ref id="R26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shayo</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Mboera</surname>
              <given-names>LEG</given-names>
            </name>
            <name>
              <surname>Blystad</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Stakeholders’ participation in planning and priority setting in the context of a decentralised health care system: the case of prevention of mother to child transmission of HIV programme in Tanzania</article-title>
          <source>BMC Health Services Research</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>273</fpage>
          <pub-id pub-id-type="pmid">23849730</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsofa</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Molyneux</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Goodman</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Health sector operational planning and budgeting processes in Kenya - “never the twain shall meet.”</article-title>
          <source>International Journal of Health Planning and Management</source>
          <year>2016</year>
          <volume>31</volume>
          <fpage>260</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="pmid">25783862</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wiseman</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Using economic evidence to set healthcare priorities in low-income and lower-middle-income countries: a systematic review of methodological frameworks</article-title>
          <source>Health Economics</source>
          <year>2016</year>
          <volume>25</volume>
          <issue>Suppl. 1</issue>
          <fpage>140</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">26804361</pub-id>
        </element-citation>
      </ref>
      <ref id="R29">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Yin</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <source>Case Study Research: Design and Methods</source>
          <year>2003</year>
          <publisher-loc>New Delhi</publisher-loc>
          <publisher-name>Sage Publications</publisher-name>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <boxed-text id="BX1" position="float" orientation="portrait">
      <caption>
        <title>Key messages</title>
      </caption>
      <list list-type="bullet" id="L1">
        <list-item>
          <p>Alignment of budgeting and planning practices, clarity of composition and roles of decision-making structures, and the use of explicit and formal decision-making criteria could improve hospital level priority setting</p>
        </list-item>
        <list-item>
          <p>Hospital priority-setting practices could be improved by incorporating both efficiency and equity in decision making, and yielding the following intermediate outcomes; stakeholder satisfaction and understanding, shifted priorities, implementa tion of decisions</p>
        </list-item>
        <list-item>
          <p>Incorporating the following deliberative democratic principles; stakeholder engagement and empowerment, transparency, use of evidence, revisions, enforcement, and incorporating community values, could also improve hospital level priority-setting practices</p>
        </list-item>
      </list>
    </boxed-text>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Framework for evaluation for priority setting</p>
      </caption>
      <graphic xlink:href="emss-70793-f001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Hospital Organogram</p>
      </caption>
      <graphic xlink:href="emss-70793-f002"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Word cloud of priority-setting criteria in the case study hospitals</p>
      </caption>
      <graphic xlink:href="emss-70793-f003"/>
    </fig>
    <table-wrap id="T1" position="float" orientation="portrait">
      <label>Table 1</label>
      <caption>
        <p>Number of participants selected in each hospital under each category</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="2" valign="top" colspan="1">National-level key informants</th>
            <th align="center" colspan="3" rowspan="1">5<hr/></th>
          </tr>
          <tr>
            <th align="center" rowspan="1" colspan="1">Hospital A</th>
            <th align="center" rowspan="1" colspan="1"/>
            <th align="center" rowspan="1" colspan="1">Hospital B</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1">Senior managers</td>
            <td align="center" rowspan="1" colspan="1">  6</td>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">  6</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Mid-level managers</td>
            <td align="center" rowspan="1" colspan="1">22</td>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">19</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Front-line practitioners</td>
            <td align="center" rowspan="1" colspan="1">  7</td>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">  8</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Hospital sub-total</td>
            <td align="center" rowspan="1" colspan="1">35</td>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">32</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">
              <bold>Study total</bold>
            </td>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">
              <bold>72</bold>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362647</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Esophagus</journal-id>
      <journal-id journal-id-type="iso-abbrev">Esophagus</journal-id>
      <journal-title-group>
        <journal-title>Esophagus</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1612-9059</issn>
      <issn pub-type="epub">1612-9067</issn>
      <publisher>
        <publisher-name>Springer Japan</publisher-name>
        <publisher-loc>Tokyo</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362647</article-id>
      <article-id pub-id-type="pmcid">PMC5362647</article-id>
      <article-id pub-id-type="pmc-uid">5362647</article-id>
      <article-id pub-id-type="publisher-id">567</article-id>
      <article-id pub-id-type="doi">10.1007/s10388-016-0567-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Re-evaluation of the role of thoracoscopic esophagectomy as a Japanese-style radical surgery</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2376-202X</contrib-id>
          <name>
            <surname>Udagawa</surname>
            <given-names>Harushi</given-names>
          </name>
          <address>
            <phone>81-3-3588-1111</phone>
            <email>udagawah@toranomon.gr.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ueno</surname>
            <given-names>Masaki</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Haruta</surname>
            <given-names>Shusuke</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tanaka</surname>
            <given-names>Tsuyoshi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mizuno</surname>
            <given-names>Aya</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ohkura</surname>
            <given-names>Yu</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.474863.a</institution-id><institution>Department of Gastroenterological Surgery, </institution><institution>Toranomon Hospital, Okinaka Memorial Institute for Medical Research, </institution></institution-wrap>2-2-2, Toranomon, Minato-ku, Tokyo 105-8470 Japan </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1764 6940</institution-id><institution-id institution-id-type="GRID">grid.410813.f</institution-id><institution>Department of Gastroenterological Surgery, </institution><institution>Toranomon Hospital, </institution></institution-wrap>Minato-ku, Tokyo, Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>3</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>3</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>14</volume>
      <issue>2</issue>
      <fpage>165</fpage>
      <lpage>170</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>3</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>12</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Purpose</title>
          <p>To investigate the value of thoracoscopic surgery in radical esophagectomy with three-field lymphadenectomy.</p>
        </sec>
        <sec>
          <title>Materials and method</title>
          <p>The subjects were 329 consecutive patients who, without preoperative chemoradiotherapy, underwent R0 radical esophagectomy with three-field lymphadenectomy for thoracic squamous cell esophageal cancers during 1998–2013. Open thoracotomy was applied in 212 (O), and thoracoscopic surgery in 117 (V). Survivals according to TNM Stages and Efficacy index (EI) were analyzed.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Hospital death rates of O/V were 1.9/0%. The survivals of V according to TNM Stages had significantly better prognosis in TNM6th cStage III and showed not worse prognosis in general. In the analysis using Cox proportional hazards model, “V or O” was a significant prognostic factor indicating better prognosis of V. More bilateral paratracheal lymph nodes along the recurrent laryngeal nerves tended to be classified as mediastinal instead of cervical in V. Efficacy index of mediastinal paratracheal nodes was higher in V than in O, while cervical lymphadenectomy maintained high EI.</p>
        </sec>
        <sec>
          <title>Discussion and conclusion</title>
          <p>Though our series have limitations of retrospective study and substantial bias, the feasibility and safety of thoracoscopic esophagectomy with three-field lymphadenectomy was shown. Higher paratracheal lymph nodes along the recurrent laryngeal nerves could be dissected from the mediastinal side in V group. Thoracoscopic esophagectomy, which is regarded as minimally invasive surgery in other countries, is being accepted in Japan mainly in the expectation of more thorough and meticulous lymphadenectomy. At the same time, the dissection range is continuously re-evaluated for safer surgery maintaining radicality.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Esophageal cancer</kwd>
        <kwd>Thoracoscopic esophagectomy</kwd>
        <kwd>Video-assisted esophagectomy</kwd>
        <kwd>Three-field lymphadenectomy</kwd>
        <kwd>Minimally invasive surgery</kwd>
        <kwd>Squamous cell carcinoma</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© The Japan Esophageal Society and Springer Japan 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p> In basic Japanese concept of multimodal treatment of esophageal cancer, radical surgery plays the main role in loco-regional control, and wide range of thorough lymphadenectomy is believed to be mandatory. The three-field lymphadenectomy is accepted as the standard procedure for this purpose [<xref ref-type="bibr" rid="CR1">1</xref>]. On the other hand, thoracoscopic esophagectomy is rapidly prevailing in Japan. About 30% of esophagectomy in Japan is performed as thoracoscopic surgery [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Thoracoscopic esophagectomy is generally regarded and accepted as a minimally invasive surgery in western countries [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. However, most of thoracoscopic surgeons in Japan try to perform thoracoscopic esophagectomy as radical as their own open surgery and think that thoracoscopic esophagectomy is even advantageous in accomplishing meticulous radical surgery [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. The purpose of this study was to clarify whether such high radicality was maintained and whether the value of three-field lymphadenectomy had been changed with the introduction of thoracoscopic surgery.</p>
    </sec>
    <sec id="Sec2">
      <title>Materials and method</title>
      <p>A total of 419 consecutive patients who underwent curative radical esophagectomy with three-field lymphadenectomy for thoracic squamous cell esophageal cancers during 1998–2013 were first extracted for this study. Ninety patients who underwent neoadjuvant chemoradiotherapy (NACRT) were excluded because NACRT, which was applied to patients with bulky T3 or suspicious T4 tumors including metastatic lymph nodes, seemed to be the largest bias between the groups of patients with open surgery (NACRT: 85) and thoracoscopic surgery (NACRT: 5). Consequently, subjects of the study were 329 patients, 201 in open thoracotomy group (O group), and 117 in video-assisted (=thoracoscopic) surgery group (V group). The open esophagectomy with three-field lymphadenectomy was performed as had been described by Akiyama [<xref ref-type="bibr" rid="CR8">8</xref>]. The video-assisted esophagectomy was done with essentially similar technique to what had been described by Osugi [<xref ref-type="bibr" rid="CR9">9</xref>]. The video-assisted esophagectomy was started in September of 2006. Survivals according to TNM Stages and Efficacy index [<xref ref-type="bibr" rid="CR10">10</xref>] (EI: metastatic rate % × 5-y survival% × 1/100) were analyzed. The characteristics of the 329 subjects are listed in Table <xref rid="Tab1" ref-type="table">1</xref>. The sixth edition of TNM classification [<xref ref-type="bibr" rid="CR11">11</xref>] was applied in clinical TNM evaluation because number of clinically positive lymph nodes in preoperative staging was not available in patients before 2009. Pathological TNM staging was done according to the seventh edition of TNM [<xref ref-type="bibr" rid="CR12">12</xref>]. The analysis on individual lymph node stations was done according to the latest classification by Japan Esophageal Society [<xref ref-type="bibr" rid="CR13">13</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the subjects</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Subjects</td><td align="left" colspan="2">329 patients</td><td align="left" rowspan="2"/></tr><tr><td align="left">Interval</td><td align="left" colspan="2">1998–2013</td></tr><tr><td align="left">Diagnosis</td><td align="left" colspan="2">Thoracic esophageal squamous cell carcinoma</td><td align="left"/></tr><tr><td align="left">Neoadjuvant Tx.</td><td align="left" colspan="2">None or chemotherapy (CRT excluded)</td><td align="left"/></tr><tr><td align="left">Operation</td><td align="left" colspan="2">Three-field lymphadenectomy, R0 resection</td><td align="left"/></tr><tr><td align="left">Group</td><td align="left">O (open)</td><td align="left">V (video-assisted)</td><td align="left">
<italic>P</italic> value</td></tr><tr><td align="left">Number</td><td align="left">212</td><td align="left">117</td><td align="left"/></tr><tr><td align="left">Age</td><td align="left">62.3 ± 8.5</td><td align="left">62.4 ± 8.3</td><td align="left">.937**</td></tr><tr><td align="left" colspan="4">Sex</td></tr><tr><td align="left"> Male/female</td><td align="left">190/22</td><td align="left">103/14</td><td align="left">.713</td></tr><tr><td align="left" colspan="4">Location</td></tr><tr><td align="left"> U/M/L</td><td align="left">29/127/56</td><td align="left">23/66/28</td><td align="left">.360*</td></tr><tr><td align="left" colspan="4">Preoperative treatment</td></tr><tr><td align="left"> None/Chemo</td><td align="left">166/46</td><td align="left">49/68</td><td align="left">&lt;.001</td></tr><tr><td align="left" colspan="4">cT (TNM6th)</td></tr><tr><td align="left"> 1a/1b/2/3/4</td><td align="left">3/68/42/95/4</td><td align="left">5/38/39/34/1</td><td align="left">.009*</td></tr><tr><td align="left" colspan="4">cN (TNM6th)</td></tr><tr><td align="left"> 0/1</td><td align="left">62/150</td><td align="left">43/74</td><td align="left">.175</td></tr><tr><td align="left" colspan="4">cM (TNM6th)</td></tr><tr><td align="left"> 0/1a/1b</td><td align="left">175/8/29</td><td align="left">107/2/8</td><td align="left">.087*</td></tr><tr><td align="left" colspan="4">cSt (TNM6th)</td></tr><tr><td align="left"> I/IIA/IIB/III/IVA/IVB</td><td align="left">39/23/42/71/8/29</td><td align="left">27/16/40/24/2/8</td><td align="left">.006*</td></tr><tr><td align="left" colspan="4">pT (TNM7th)</td></tr><tr><td align="left"> 0/1a/1b/2/3/4a/4b</td><td align="left">1/15/71/20/100/5/0</td><td align="left">0/15/46/25/31/0/0</td><td align="left">.001*</td></tr><tr><td align="left" colspan="4">pN (TNM7th)</td></tr><tr><td align="left"> 0/1/2/3</td><td align="left">79/62/43/28</td><td align="left">41/46/24/6</td><td align="left">.066*</td></tr><tr><td align="left" colspan="4">pM (TNM7th)</td></tr><tr><td align="left"> 0/1</td><td align="left">173/39</td><td align="left">102/15</td><td align="left">.216</td></tr><tr><td align="left" colspan="4">pSt (TNM7th)</td></tr><tr><td align="left"> IA/IB/IIA/IIB/IIIA/IIIB/IIIC/IV</td><td align="left">41/10/26/30/31/22/13/39</td><td align="left">19/9/10/30/25/7/2/15</td><td align="left">.023*</td></tr><tr><td align="left">Hospital death</td><td align="left">4 (1.9%)</td><td align="left">0</td><td align="left">.301</td></tr></tbody></table><table-wrap-foot><p>In pT(TNM7th) column, ypT0 is listed as T0</p><p>In pSt(TNM7th) column, ypT0N0M0 is included in IA, and ypT0N1M0 is included in IB</p><p>Statistical significance * Pearson’s Chi-square test, ** <italic>t</italic> test, <italic>others</italic> Fisher’s exact test</p></table-wrap-foot></table-wrap>
</p>
      <p>Pearson’s Chi-square test, Fisher’s exact test, and <italic>t</italic> test were used for distributional and numerical comparison. The survival curves were estimated according to the Kaplan–Meier method, and overall survival distributions were compared by use of the log-rank test. Cox proportional hazards model, forward stepwise method by likelihood ratio with the condition of .05 for addition and .1 for deletion, was applied to investigate prognostic factors. IBM SPSS Statistics 23<sup>®</sup> was used for data analysis.</p>
    </sec>
    <sec id="Sec3">
      <title>Results</title>
      <p>Hospital death rates of O/V were 1.9/0% (Table <xref rid="Tab1" ref-type="table">1</xref>). Survivals according to cTNM6th Stages at first presentation of the patients were not statistically different between the two groups except among cSt III patients where V group showed better survival (Table <xref rid="Tab2" ref-type="table">2</xref>, upper). The backgrounds of the 2 groups in this stage are not the same. Preoperative treatment was significantly different (None/Chemo of O was 55/16, while that of V was 5/19.), though preoperative treatment was not a significant prognostic factor in univariate analysis (Table <xref rid="Tab3" ref-type="table">3</xref>). There was no significantly different distribution in other factors (data not shown). V group tended to show better survival in almost every pTNM7th stage though without statistical significance (Table <xref rid="Tab2" ref-type="table">2</xref>, middle). Table <xref rid="Tab2" ref-type="table">2</xref> shows that V group had better survival than O group in TNM7th pN0 patients, the similar tendency in pN1, but did not in pN2 and pN3.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Five-year survival of O group and V group according to TNM factors</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left">O (%)</th><th align="left">V (%)</th><th align="left" rowspan="2">
<italic>P</italic> (Log rank)</th></tr><tr><th align="left">5y.s. (S.E.)</th><th align="left">5y.s. (S.E.)</th></tr></thead><tbody><tr><td align="left" colspan="4">TNM6th cStage</td></tr><tr><td align="left"> I</td><td align="left">86.9 (5.5)</td><td align="left">89.3 (7.5)</td><td align="left">.594</td></tr><tr><td align="left"> IIA</td><td align="left">65.2 (9.9)</td><td align="left">78.7 (11.0)</td><td align="left">.409</td></tr><tr><td align="left"> IIB</td><td align="left">78.6 (6.3)</td><td align="left">83.5 (6.9)</td><td align="left">.370</td></tr><tr><td align="left"> III</td><td align="left">50.9 (6.0)</td><td align="left">73.0 (10.5)</td><td align="left">.026</td></tr><tr><td align="left"> IVA</td><td align="left">25.0 (15.3)</td><td align="left">– (–)</td><td align="left">.685</td></tr><tr><td align="left"> IVB</td><td align="left">64.4 (9.0)</td><td align="left">70.0 (18.2)</td><td align="left">.836</td></tr><tr><td align="left" colspan="4">TNM7th pStage</td></tr><tr><td align="left"> IA</td><td align="left">92.9 (4.1)</td><td align="left">100 (–)</td><td align="left">.239</td></tr><tr><td align="left"> IB</td><td align="left">80.0 (12.6)</td><td align="left">100 (–)</td><td align="left">.194</td></tr><tr><td align="left"> IIA</td><td align="left">72.7 (8.8)</td><td align="left">100 (–)</td><td align="left">.081</td></tr><tr><td align="left"> IIB</td><td align="left">73.3 (8.1)</td><td align="left">86.1 (7.7)</td><td align="left">.266</td></tr><tr><td align="left"> IIIA</td><td align="left">67.0 (8.6)</td><td align="left">61.8 (10.8)</td><td align="left">.701</td></tr><tr><td align="left"> IIIB</td><td align="left">57.1 (10.8)</td><td align="left">75.0 (21.7)</td><td align="left">.290</td></tr><tr><td align="left"> IIIC</td><td align="left">27.7 (13.5)</td><td align="left">0 (–)</td><td align="left">.300</td></tr><tr><td align="left"> IV</td><td align="left">35.9 (7.7)</td><td align="left">70.0 (12.8)</td><td align="left">.125</td></tr><tr><td align="left" colspan="4">TNM7th pN</td></tr><tr><td align="left"> 0</td><td align="left">84.8 (4.1)</td><td align="left">100 (–)</td><td align="left">.011</td></tr><tr><td align="left"> 1</td><td align="left">64.0 (6.1)</td><td align="left">74.2 (8.0)</td><td align="left">.083</td></tr><tr><td align="left"> 2</td><td align="left">59.5 (7.6)</td><td align="left">73.5 (9.4)</td><td align="left">.179</td></tr><tr><td align="left"> 3</td><td align="left">23.2 (8.2)</td><td align="left">25.0 (20.4)</td><td align="left">.796</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Results of univariate Cox regression model</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Covariate</th><th align="left">B</th><th align="left">SE</th><th align="left">
<italic>P</italic>
</th><th align="left">HR</th></tr></thead><tbody><tr><td align="left">V/O</td><td char="." align="char">
<bold>−.837</bold>
</td><td char="." align="char">
<bold>.261</bold>
</td><td align="left">
<bold>.001</bold>
</td><td align="left">
<bold>.433</bold>
</td></tr><tr><td align="left">Period (L/F)</td><td char="." align="char">−.336</td><td char="." align="char">.213</td><td align="left">.116</td><td align="left">.715</td></tr><tr><td align="left" colspan="5">PreTx.</td></tr><tr><td align="left"> CT/NO</td><td char="." align="char">.001</td><td char="." align="char">.208</td><td align="left">.995</td><td align="left">1.001</td></tr><tr><td align="left">Location</td><td align="left"/><td align="left"/><td align="left">.339</td><td align="left"/></tr><tr><td align="left">U/M</td><td char="." align="char">.161</td><td char="." align="char">.268</td><td align="left">.548</td><td align="left">1.175</td></tr><tr><td align="left">L/M</td><td char="." align="char">.307</td><td char="." align="char">.210</td><td align="left">.145</td><td align="left">1.359</td></tr><tr><td align="left">
<bold>Age (+1)</bold>
</td><td char="." align="char">
<bold>.032</bold>
</td><td char="." align="char">
<bold>.012</bold>
</td><td align="left">
<bold>.008</bold>
</td><td align="left">
<bold>1.032</bold>
</td></tr><tr><td align="left">Sex(M/F)</td><td char="." align="char">.424</td><td char="." align="char">.347</td><td align="left">.222</td><td align="left">1.528</td></tr><tr><td align="left">
<bold>cT (TNM6th)</bold>
</td><td align="left"/><td align="left"/><td align="left">
<bold>.000</bold>
</td><td align="left"/></tr><tr><td align="left">
<bold>T1a/T2</bold>
</td><td char="." align="char">
<bold>−1.141</bold>
</td><td char="." align="char">
<bold>1.020</bold>
</td><td align="left">
<bold>.263</bold>
</td><td align="left">
<bold>.320</bold>
</td></tr><tr><td align="left">
<bold>T1b/T2</bold>
</td><td char="." align="char">
<bold>−.480</bold>
</td><td char="." align="char">
<bold>.279</bold>
</td><td align="left">
<bold>.085</bold>
</td><td align="left">
<bold>.619</bold>
</td></tr><tr><td align="left">
<bold>T3/T2</bold>
</td><td char="." align="char">
<bold>.456</bold>
</td><td char="." align="char">
<bold>.235</bold>
</td><td align="left">
<bold>.052</bold>
</td><td align="left">
<bold>1.577</bold>
</td></tr><tr><td align="left">
<bold>T4/T2</bold>
</td><td char="." align="char">
<bold>1.487</bold>
</td><td char="." align="char">
<bold>.614</bold>
</td><td align="left">
<bold>.015</bold>
</td><td align="left">
<bold>4.424</bold>
</td></tr><tr><td align="left">
<bold>cN (TNM6th)</bold>
</td><td char="." align="char"/><td char="." align="char"/><td align="left"/><td align="left"/></tr><tr><td align="left">
<bold>N1/N0</bold>
</td><td char="." align="char">
<bold>.749</bold>
</td><td char="." align="char">
<bold>.226</bold>
</td><td align="left">
<bold>.001</bold>
</td><td align="left">
<bold>2.114</bold>
</td></tr><tr><td align="left">
<bold>cM (TNM6th)</bold>
</td><td char="." align="char"/><td char="." align="char"/><td align="left">
<bold>.004</bold>
</td><td align="left"/></tr><tr><td align="left">
<bold>M1a/M0</bold>
</td><td char="." align="char">
<bold>1.207</bold>
</td><td char="." align="char">
<bold>.393</bold>
</td><td align="left">
<bold>.002</bold>
</td><td align="left">
<bold>3.343</bold>
</td></tr><tr><td align="left">
<bold>M1b/M0</bold>
</td><td char="." align="char">
<bold>.417</bold>
</td><td char="." align="char">
<bold>.265</bold>
</td><td align="left">
<bold>.116</bold>
</td><td align="left">
<bold>1.517</bold>
</td></tr><tr><td align="left">
<bold>pT (TNM7th)</bold>
<sup><bold>*1</bold></sup>
</td><td align="left"/><td align="left"/><td align="left">
<bold>.000</bold>
</td><td align="left"/></tr><tr><td align="left">
<bold>T1a/T2</bold>
</td><td char="." align="char">
<bold>−.500</bold>
</td><td char="." align="char">
<bold>.548</bold>
</td><td align="left">
<bold>.362</bold>
</td><td align="left">
<bold>.607</bold>
</td></tr><tr><td align="left">
<bold>T1b/T2</bold>
</td><td char="." align="char">
<bold>−.119</bold>
</td><td char="." align="char">
<bold>.367</bold>
</td><td align="left">
<bold>.745</bold>
</td><td align="left">
<bold>.887</bold>
</td></tr><tr><td align="left">
<bold>T3/T2</bold>
</td><td char="." align="char">
<bold>.841</bold>
</td><td char="." align="char">
<bold>.340</bold>
</td><td align="left">
<bold>.013</bold>
</td><td align="left">
<bold>2.320</bold>
</td></tr><tr><td align="left">
<bold>T4a/T2</bold>
</td><td char="." align="char">
<bold>1.970</bold>
</td><td char="." align="char">
<bold>.550</bold>
</td><td align="left">
<bold>.000</bold>
</td><td align="left">
<bold>7.171</bold>
</td></tr><tr><td align="left">
<bold>pN (TNM7th)</bold>
</td><td char="." align="char"/><td char="." align="char"/><td align="left">
<bold>.000</bold>
</td><td align="left"/></tr><tr><td align="left">
<bold>N1/N0</bold>
</td><td char="." align="char">
<bold>.918</bold>
</td><td char="." align="char">
<bold>.274</bold>
</td><td align="left">
<bold>.001</bold>
</td><td align="left">
<bold>2.504</bold>
</td></tr><tr><td align="left">
<bold>N2/N0</bold>
</td><td char="." align="char">
<bold>1.188</bold>
</td><td char="." align="char">
<bold>.289</bold>
</td><td align="left">
<bold>.000</bold>
</td><td align="left">
<bold>3.279</bold>
</td></tr><tr><td align="left">
<bold>N3/N0</bold>
</td><td char="." align="char">
<bold>2.199</bold>
</td><td char="." align="char">
<bold>.301</bold>
</td><td align="left">
<bold>.000</bold>
</td><td align="left">
<bold>9.019</bold>
</td></tr><tr><td align="left">
<bold>pM (TNM7th)</bold>
</td><td char="." align="char"/><td char="." align="char"/><td align="left"/><td align="left"/></tr><tr><td align="left">
<bold>M1/M0</bold>
</td><td char="." align="char">
<bold>1.021</bold>
</td><td char="." align="char">
<bold>.210</bold>
</td><td align="left">
<bold>.000</bold>
</td><td align="left">
<bold>2.777</bold>
</td></tr></tbody></table><table-wrap-foot><p>
<italic>B</italic> regression coefficient, <italic>SE</italic> standard error, <italic>HR</italic> hazard ratio = Exp(B)</p><p>
<italic>Period F</italic> operated before we introduced video-assisted esophagectomy</p><p>
<italic>Period L</italic> operated after we introduced video-assisted esophagectomy</p><p>The bold values indicate that the factors are statistically significant in univariate analyses and will be included in the next multivariate analyses</p><p>* 1 One pT0 patient in O group after chemotherapy is excluded to maintain appropriate statistical analysis</p></table-wrap-foot></table-wrap>
</p>
      <p>Twelve clinicopathological factors were examined as univariates for Cox proportional hazard model and found to be statistically significant except preoperative treatment, period of operation, tumor location, and sex (Table <xref rid="Tab3" ref-type="table">3</xref>). Therefore, we decided that 8 factors with statistical significances should be included in the multivariate analysis. Because cTNM6th factors and pTNM7th factors should have strong correlation, Cox proportional hazards model was applied to the data set of 5 patient characteristics including cTNM6th factors but excluding pTNM7th factors. This pointed out that V/O status, cT, cM, and age were significant prognostic factors (Table <xref rid="Tab4" ref-type="table">4</xref>, upper). When the same analysis was done to the data set of 5 patient characteristics including pTNM7th information but excluding cTNM6th pointed out that V/O status, pT, pN, and age were significant prognostic factors (Table <xref rid="Tab4" ref-type="table">4</xref>, lower).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Covariates in the equation of the Cox regression model</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Covariate</th><th align="left">B</th><th align="left">SE</th><th align="left">P</th><th align="left">HR</th></tr></thead><tbody><tr><td align="left" colspan="5">Study with cTNM6th factors</td></tr><tr><td align="left"> V/O</td><td align="left">−.788</td><td align="left">.265</td><td align="left">.003</td><td align="left">.455</td></tr><tr><td align="left"> cT6th</td><td align="left"/><td align="left"/><td align="left">.000</td><td align="left"/></tr><tr><td align="left"> T1a/T2</td><td align="left">−.904</td><td align="left">1.021</td><td align="left">.376</td><td align="left">.405</td></tr><tr><td align="left"> T1b/T2</td><td align="left">−.577</td><td align="left">.281</td><td align="left">.041</td><td align="left">.562</td></tr><tr><td align="left"> T3/T2</td><td align="left">.334</td><td align="left">.239</td><td align="left">.164</td><td align="left">1.396</td></tr><tr><td align="left"> T4/T2</td><td align="left">1.445</td><td align="left">.618</td><td align="left">.019</td><td align="left">4.240</td></tr><tr><td align="left"> cM6th</td><td align="left"/><td align="left"/><td align="left">.46</td><td align="left"/></tr><tr><td align="left"> M1a/M0</td><td align="left">.986</td><td align="left">.400</td><td align="left">.013</td><td align="left">2.690</td></tr><tr><td align="left"> M1b/M0</td><td align="left">.050</td><td align="left">.273</td><td align="left">.859</td><td align="left">1.052</td></tr><tr><td align="left"> Age (+1)</td><td align="left">.036</td><td align="left">.012</td><td align="left">.003</td><td align="left">1.036</td></tr><tr><td align="left" colspan="5">Study with pTNM7th factors<sup>*1</sup>
</td></tr><tr><td align="left"> V/O</td><td align="left">−.629</td><td align="left">.269</td><td align="left">.019</td><td align="left">.533</td></tr><tr><td align="left"> pT7th</td><td align="left"/><td align="left"/><td align="left">.011</td><td align="left"/></tr><tr><td align="left"> T1a/T2</td><td align="left">−.066</td><td align="left">.562</td><td align="left">.907</td><td align="left">.936</td></tr><tr><td align="left"> T1b/T2</td><td align="left">−.162</td><td align="left">.370</td><td align="left">.662</td><td align="left">.850</td></tr><tr><td align="left"> T3/T2</td><td align="left">.578</td><td align="left">.345</td><td align="left">.094</td><td align="left">1.782</td></tr><tr><td align="left"> T4a/T2</td><td align="left">.939</td><td align="left">.579</td><td align="left">.105</td><td align="left">2.557</td></tr><tr><td align="left"> pN7th</td><td align="left"/><td align="left"/><td align="left">.000</td><td align="left"/></tr><tr><td align="left"> N1/N0</td><td align="left">.920</td><td align="left">.281</td><td align="left">.001</td><td align="left">2.510</td></tr><tr><td align="left"> N2/N0</td><td align="left">1.062</td><td align="left">.303</td><td align="left">.000</td><td align="left">2.891</td></tr><tr><td align="left"> N3/N0</td><td align="left">2.143</td><td align="left">.334</td><td align="left">.000</td><td align="left">8.526</td></tr><tr><td align="left"> Age (+1)</td><td align="left">.052</td><td align="left">.012</td><td align="left">.000</td><td align="left">1.053</td></tr></tbody></table><table-wrap-foot><p>
<italic>B</italic> regression coefficient, <italic>SE</italic> standard error, <italic>HR</italic> hazard ratio = Exp(B)</p><p>* 1: One pT0 patient in O group after chemotherapy is excluded to maintain appropriate statistical analysis</p></table-wrap-foot></table-wrap>
</p>
      <p>Number of dissected mediastinal nodes was significantly less in V group (O/V: 42.4/36.0) (Table <xref rid="Tab5" ref-type="table">5</xref>, upper). Evident decrease in number of dissected lymph nodes in the station 106pre, which had the least EI value of .30, was observed (Table <xref rid="Tab5" ref-type="table">5</xref>, lower). The number of bilateral mediastinal paratracheal nodes dissected was a little more in V group, though not statistically significant, and the number of bilateral cervical paratracheal nodes was significantly less in V (Table <xref rid="Tab5" ref-type="table">5</xref>, lower). The percentage of paratracheal recurrent nerve chain nodes dissected from the mediastinal side in both groups is shown in Table <xref rid="Tab6" ref-type="table">6</xref>. The percentage was higher on both sides in V group.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Average numbers of dissected lymph nodes in O group and V group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Field</th><th align="left">O</th><th align="left">V</th><th align="left">
<italic>P</italic> (<italic>t</italic> test)</th></tr></thead><tbody><tr><td align="left"> Cervical</td><td align="left">45.2 ± 16.2</td><td align="left">42.9 ± 14.9</td><td char="." align="char">.189</td></tr><tr><td align="left"> Mediastinal</td><td align="left">42.4 ± 13.4</td><td align="left">36.0 ± 12.3</td><td char="." align="char">&lt;.001.</td></tr><tr><td align="left"> Abdominal</td><td align="left">29.1 ± 11.6</td><td align="left">29.2 ± 11.6</td><td char="." align="char">.973</td></tr><tr><td align="left"> 3 fields</td><td align="left">116.6 ± 28.8</td><td align="left">108.0 ± 28.4</td><td char="." align="char">.010</td></tr><tr><td align="left">Station</td><td align="left">O</td><td align="left">V</td><td char="." align="char">P</td></tr><tr><td align="left"> 106pre</td><td align="left">6.1 ± 5.1</td><td align="left">2.4 ± 2.8</td><td char="." align="char">&lt;.001.</td></tr><tr><td align="left"> 101(R + L)</td><td align="left">6.3 ± 4.0</td><td align="left">5.3 ± 4.1</td><td char="." align="char">.033</td></tr><tr><td align="left"> 106rec(R + L)</td><td align="left">9.9 ± 4.9</td><td align="left">10.9 ± 5.6</td><td char="." align="char">.098</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab6"><label>Table 6</label><caption><p>Percentage of paratracheal lymph nodes dissected from the mediastinal side in O group and V group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Side</th><th align="left">O (%)</th><th align="left">V (%)</th><th align="left">
<italic>P</italic> (<italic>t</italic> test)</th></tr></thead><tbody><tr><td align="left">Right</td><td align="left">58.5 ± 26.5</td><td align="left">66.4 ± 25.1</td><td align="left">.009</td></tr><tr><td align="left">Left</td><td align="left">63.8 ± 23.8</td><td align="left">69.9 ± 23.1</td><td align="left">.024</td></tr><tr><td align="left">Bilateral</td><td align="left">61.2 ± 19.8</td><td align="left">67.8 ± 17.4</td><td align="left">.003</td></tr></tbody></table><table-wrap-foot><p>Percentage of paratracheal lymph nodes dissected from the mediastinal side = number of 106rec nodes/(number of 106rec nodes + number of 101 nodes)</p></table-wrap-foot></table-wrap>
</p>
      <p>EI value of mediastinal paratracheal node station (106rec) was higher in V than in O. This was more evident on the left side (Table <xref rid="Tab7" ref-type="table">7</xref>). The EI’s in both O and V groups for cervical, mediastinal, and abdominal lymphadenectomy were all very high, and no decrease in EI of cervical lymphadenectomy from O group to V group was observed (Table <xref rid="Tab8" ref-type="table">8</xref>).<table-wrap id="Tab7"><label>Table 7</label><caption><p>EI’s of paratracheal (recurrent nerve chain) lymph node stations in O group and V group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Station</th><th align="left">O or V</th><th align="left" colspan="2">Met. r (%)</th><th align="left">5-y s (%)</th><th align="left">Efficacy index</th></tr></thead><tbody><tr><td align="left" rowspan="2">101R</td><td align="left">O</td><td align="left">10.4</td><td align="left" rowspan="2">
<italic>P</italic> = .031*</td><td align="left">45.0</td><td char="." align="char">4.7</td></tr><tr><td align="left">V</td><td align="left">3.4</td><td align="left">66.7</td><td char="." align="char">2.3</td></tr><tr><td align="left" rowspan="2">106recR</td><td align="left">O</td><td align="left" colspan="2">22.2</td><td align="left">51.1</td><td char="." align="char">11.3</td></tr><tr><td align="left">V</td><td align="left" colspan="2">22.2</td><td align="left">62.2</td><td char="." align="char">13.8</td></tr><tr><td align="left" rowspan="2">101L</td><td align="left">O</td><td align="left" colspan="2">6.6</td><td align="left">50.0</td><td char="." align="char">3.3</td></tr><tr><td align="left">V</td><td align="left" colspan="2">5.1</td><td align="left">83.3</td><td char="." align="char">4.2</td></tr><tr><td align="left" rowspan="2">106recL</td><td align="left">O</td><td align="left">10.4</td><td align="left" rowspan="2">
<italic>P</italic> = .005*</td><td align="left">52.5</td><td char="." align="char">5.5</td></tr><tr><td align="left">V</td><td align="left">22.2</td><td align="left">71.5</td><td char="." align="char">15.8</td></tr></tbody></table><table-wrap-foot><p>* Fisher’s exact test</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab8"><label>Table 8</label><caption><p>EI’s of the three fields in O group and V group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Field</th><th align="left">O or V</th><th align="left" colspan="2">Met. r (%)</th><th align="left">5-y s (%)</th><th align="left">Efficacy index</th></tr></thead><tbody><tr><td align="left" rowspan="2">Cervical</td><td align="left">O</td><td align="left" colspan="2">17.1</td><td align="left">67.3</td><td align="left">11.5</td></tr><tr><td align="left">V</td><td align="left" colspan="2">25.5</td><td align="left">46.2</td><td align="left">11.8</td></tr><tr><td align="left" rowspan="2">Mediastinal</td><td align="left">O</td><td align="left" colspan="2">47.6</td><td align="left">51.5</td><td align="left">24.5</td></tr><tr><td align="left">V</td><td align="left" colspan="2">52.1</td><td align="left">67.5</td><td align="left">35.2</td></tr><tr><td align="left" rowspan="2">Abdominal</td><td align="left">O</td><td align="left">38.2</td><td align="left" rowspan="2">
<italic>P</italic> = .021*</td><td align="left">46.6</td><td align="left">17.8</td></tr><tr><td align="left">V</td><td align="left">25.6</td><td align="left">67.4</td><td align="left">17.3</td></tr></tbody></table><table-wrap-foot><p>* Fisher’s exact test</p></table-wrap-foot></table-wrap>
</p>
    </sec>
    <sec id="Sec4">
      <title>Discussion</title>
      <p>Thoracoscopic esophagectomy, which is regarded as minimally invasive surgery in other countries, is being accepted in Japan very rapidly. According to the NCD report, about 30% of all esophagectomies performed in Japan in 2011 were done as video-assisted surgery. However, most Japanese surgeons performing video-assisted esophagectomy have the impression that the largest advantage of video-assisted esophagectomy is not its less invasiveness but the expectation of more thorough and meticulous lymphadenectomy. In our series, most of the analyses on prognosis showed tendency of improvement with video-assisted surgery. Taking the large bias of this study design into account, we feel at least we can conclude that the introduction of video-assisted surgery has not worsened the prognosis of our radical esophagectomy.</p>
      <p>Bilateral paratracheal lymph nodes, which are also known as recurrent nerve chain nodes, are most important nodes to be dissected in radical esophagectomy for thoracic esophageal cancer. They are uninterruptedly located from the mediastinum to the cervical area. Our data showed that more paratracheal lymph nodes tend to be dissected from mediastinal side and fewer nodes were dissected from the cervical side in thoracoscopic esophagectomy. Consequently, EI’s of mediastinal paratracheal lymph node stations are higher in V group than in O group. The large increase in EI of the station 106recL from O to V might show not only the fact that more 106recL nodes including nodes in more cervical location can be dissected but also that more complete lymph node dissection of this station can be achieved in thoracoscopic surgery.</p>
      <p>Although more nodes in cervical paratracheal station (101) can be dissected from the mediastinal side as 106rec in thoracoscopic esophagectomy, high EI value of cervical lymph node dissection is still maintained because of better 5-year survival of cervical node-positive patients in V group. It might mean that the combination of video-assisted mediastinal dissection + cervical lymphadenectomy be superior to the combination of conventional open mediastinal dissection + cervical lymphadenectomy in terms of completeness. At least we can say that three-field lymphadenectomy remains as the standard operative procedure even in the era of video-assisted surgery and multimodal treatment.</p>
      <p>Because this study is a retrospective study, it should contain biases. The largest limitations are that V group was operated later than 2005 and that the distribution of clinical and pathological factors of the patients in both groups was different. The latter can be adjusted to some extent by stratifying patients according to these clinical and pathological factors. However, the former bias cannot be adjusted. We are looking forward to the coming results of JCOG1409, the phase III study among thoracoscopic esophagectomy and open esophagectomy.</p>
      <p>Neoadjuvant chemoradiotherapy followed by surgery for resectable advanced thoracic esophageal cancer is widely accepted in all over the world. On the other hand, preoperative chemotherapy followed by surgery is regarded as standard in Japan. This strategy has yielded very good prognostic result as shown here. In this study, patients with NACRT were excluded because it was strongly associated with advanced T-stage, poorer prognosis, and open surgery. There is no direct evidence to compare NACRT and neoadjuvant chemotherapy particularly when the surgery includes Japanese-style extended lymphadenectomy. Japan Esophageal Oncology Group is executing a three-armed randomized controlled trial, JCOG1109 [<xref ref-type="bibr" rid="CR14">14</xref>], to give answer to this question.</p>
    </sec>
    <sec id="Sec5">
      <title>Conclusion</title>
      <p> Japanese-style three-field lymphadenectomy pursuing best loco-regional control by surgery is feasibly and safely performed as thoracoscopic surgery. Thoracoscopic esophagectomy, which is regarded as minimally invasive surgery in other countries, has ability to realize more thorough and radical lymphadenectomy. This phenomenon was observed in the area along the recurrent laryngeal nerves. This increased radicality seems to improve long-term survival of the patients operated thoracoscopically. However, clear evidence of superiority of thoracoscopic surgery to conventional open surgery cannot be obtained until a phase III trial on this issue such as JCOG 1409 becomes available.</p>
    </sec>
  </body>
  <back>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <sec id="FPar1">
        <title>Ethical Statement</title>
        <p>We authors of this manuscript, “Re-evaluation of the role of thoracoscopic esophagectomy as a Japanese-style radical surgery” declare that our work conforms to the guidelines set forth in the Helsinki Declaration of 1975, as revised in 2000 and 2008, concerning Human and Animal Rights and that we followed out policy concerning Informed Consent as shown on Springer.com. (<ext-link ext-link-type="uri" xlink:href="http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/before-you-start">http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/before-you-start</ext-link>).</p>
      </sec>
      <sec id="FPar2">
        <title>Conflict of interest</title>
        <p>There are no financial or other relations that could lead to a conflict of interest.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Udagawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Akiyama</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Surgical treatment of esophageal cancer: Tokyo experience of the three-field technique</article-title>
          <source>Dis Esophagus</source>
          <year>2001</year>
          <volume>14</volume>
          <fpage>110</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1442-2050.2001.00166.x</pub-id>
          <?supplied-pmid 11553219?>
          <pub-id pub-id-type="pmid">11553219</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takeuchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Miyata</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gotoh</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database</article-title>
          <source>Ann Surg</source>
          <year>2014</year>
          <volume>260</volume>
          <fpage>259</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="doi">10.1097/SLA.0000000000000644</pub-id>
          <?supplied-pmid 24743609?>
          <pub-id pub-id-type="pmid">24743609</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tachimori</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ozawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Numasaki</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comprehensive registry of esophageal cancer in Japan, 2009</article-title>
          <source>Esophagus</source>
          <year>2016</year>
          <volume>13</volume>
          <fpage>110</fpage>
          <lpage>137</lpage>
          <pub-id pub-id-type="doi">10.1007/s10388-016-0531-y</pub-id>
          <?supplied-pmid 27110229?>
          <pub-id pub-id-type="pmid">27110229</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perry</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fernando</surname>
              <given-names>HC</given-names>
            </name>
          </person-group>
          <article-title>Three-field minimally invasive esophagectomy: current results and technique</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <year>2012</year>
          <volume>144</volume>
          <fpage>S63</fpage>
          <lpage>S66</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jtcvs.2012.06.002</pub-id>
          <?supplied-pmid 22743173?>
          <pub-id pub-id-type="pmid">22743173</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Biere</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>van Berge Henegouwen</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Maas</surname>
              <given-names>KW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial</article-title>
          <source>Lancet</source>
          <year>2012</year>
          <volume>379</volume>
          <fpage>1887</fpage>
          <lpage>1892</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60516-9</pub-id>
          <?supplied-pmid 22552194?>
          <pub-id pub-id-type="pmid">22552194</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Udagawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ueno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kinoshita</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Rationale for video-assisted radical esophagectomy</article-title>
          <source>Gen Thorac Cardiovasc Surg.</source>
          <year>2009</year>
          <volume>57</volume>
          <fpage>127</fpage>
          <lpage>131</lpage>
          <pub-id pub-id-type="doi">10.1007/s11748-008-0362-4</pub-id>
          <?supplied-pmid 19280307?>
          <pub-id pub-id-type="pmid">19280307</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ninomiya</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Osugi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fujimura</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thoracoscopic esophagectomy with extended lymph node dissection in the left lateral position: technical feasibility and oncologic outcomes</article-title>
          <source>Dis Esophagus</source>
          <year>2014</year>
          <volume>27</volume>
          <fpage>159</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="doi">10.1111/dote.12071</pub-id>
          <?supplied-pmid 23551804?>
          <pub-id pub-id-type="pmid">23551804</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Akiyama</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <source>Squamous cell carcinoma of the thoracic esophagus. Surgery for Cancer of the Esophagus</source>
          <year>1990</year>
          <publisher-loc>Baltimore</publisher-loc>
          <publisher-name>Williams &amp; Wilkins</publisher-name>
          <fpage>19</fpage>
          <lpage>42</lpage>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Osugi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takemura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thoracoscopic esophagectomy for intrathoracic esophageal cancer</article-title>
          <source>Ann Thorac Cardiovasc Surg</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>221</fpage>
          <lpage>227</lpage>
          <?supplied-pmid 16148867?>
          <pub-id pub-id-type="pmid">16148867</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sasako</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McCulloch</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kinoshita</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>New method to evaluate the therapeutic value of lymph node dissection for gastric cancer</article-title>
          <source>Br J Surg</source>
          <year>1995</year>
          <volume>82</volume>
          <fpage>346</fpage>
          <lpage>351</lpage>
          <pub-id pub-id-type="doi">10.1002/bjs.1800820321</pub-id>
          <?supplied-pmid 7796005?>
          <pub-id pub-id-type="pmid">7796005</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>International Union Against Cancer</collab>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Sobin</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Wittekind</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Oesophagus</article-title>
          <source>TNM classification of malignant tumours</source>
          <year>2002</year>
          <edition>6</edition>
          <publisher-loc>Hoboken</publisher-loc>
          <publisher-name>Wiley-Lis</publisher-name>
          <fpage>60</fpage>
          <lpage>64</lpage>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>International Union Against Cancer</collab>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Sobin</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Gospodarowicz</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Wittekind</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Oesophagus including oesophagogastric junction</article-title>
          <source>TNM classification of malignant tomours</source>
          <year>2009</year>
          <edition>7</edition>
          <publisher-loc>Hoboken</publisher-loc>
          <publisher-name>Wiley-Blackwell</publisher-name>
          <fpage>66</fpage>
          <lpage>72</lpage>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Japan Esophageal Society</collab>
          </person-group>
          <article-title>Japanese classification of esophageal cancer, tenth edition: part I</article-title>
          <source>Esophagus</source>
          <year>2009</year>
          <volume>6</volume>
          <fpage>1</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="doi">10.1007/s10388-009-0169-0</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakamura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Igaki</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study)</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>2013</year>
          <volume>43</volume>
          <fpage>752</fpage>
          <lpage>755</lpage>
          <pub-id pub-id-type="doi">10.1093/jjco/hyt061</pub-id>
          <?supplied-pmid 23625063?>
          <pub-id pub-id-type="pmid">23625063</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362648</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Drug Saf</journal-id>
      <journal-id journal-id-type="iso-abbrev">Drug Saf</journal-id>
      <journal-title-group>
        <journal-title>Drug Safety</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0114-5916</issn>
      <issn pub-type="epub">1179-1942</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362648</article-id>
      <article-id pub-id-type="pmcid">PMC5362648</article-id>
      <article-id pub-id-type="pmc-uid">5362648</article-id>
      <article-id pub-id-type="pmid">28044249</article-id>
      <article-id pub-id-type="publisher-id">491</article-id>
      <article-id pub-id-type="doi">10.1007/s40264-016-0491-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Pierce</surname>
            <given-names>Carrie E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bouri</surname>
            <given-names>Khaled</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pamer</surname>
            <given-names>Carol</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Proestel</surname>
            <given-names>Scott</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodriguez</surname>
            <given-names>Harold W.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Van Le</surname>
            <given-names>Hoa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Freifeld</surname>
            <given-names>Clark C.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brownstein</surname>
            <given-names>John S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Walderhaug</surname>
            <given-names>Mark</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Edwards</surname>
            <given-names>I. Ralph</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4098-605X</contrib-id>
          <name>
            <surname>Dasgupta</surname>
            <given-names>Nabarun</given-names>
          </name>
          <address>
            <phone>+1-919-260-3808</phone>
            <email>nabarun@epidemico.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Epidemico, Inc., Boston, MA USA </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2243 3366</institution-id><institution-id institution-id-type="GRID">grid.417587.8</institution-id><institution/><institution>US Food and Drug Administration, </institution></institution-wrap>Silver Spring, MD USA </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2173 3359</institution-id><institution-id institution-id-type="GRID">grid.261112.7</institution-id><institution/><institution>Northeastern University College of Computer and Information Science, </institution></institution-wrap>Boston, MA USA </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2153 0703</institution-id><institution-id institution-id-type="GRID">grid.420224.2</institution-id><institution>Uppsala Monitoring Centre, </institution><institution>WHO Collaborating Centre for International Drug Monitoring, </institution></institution-wrap>Uppsala, Sweden </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>2</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>2</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>40</volume>
      <issue>4</issue>
      <fpage>317</fpage>
      <lpage>331</lpage>
      <permissions>
        <copyright-statement>© The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Introduction</title>
          <p>The rapid expansion of the Internet and computing power in recent years has opened up the possibility of using social media for pharmacovigilance. While this general concept has been proposed by many, central questions remain as to whether social media can provide earlier warnings for rare and serious events than traditional signal detection from spontaneous report data.</p>
        </sec>
        <sec>
          <title>Objective</title>
          <p>Our objective was to examine whether specific product–adverse event pairs were reported via social media before being reported to the US FDA Adverse Event Reporting System (FAERS).</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>A retrospective analysis of public Facebook and Twitter data was conducted for 10 recent FDA postmarketing safety signals at the drug–event pair level with six negative controls. Social media data corresponding to two years prior to signal detection of each product–event pair were compiled. Automated classifiers were used to identify each ‘post with resemblance to an adverse event’ (Proto-AE), among English language posts. A custom dictionary was used to translate Internet vernacular into Medical Dictionary for Regulatory Activities (MedDRA<sup>®</sup>) Preferred Terms. Drug safety physicians conducted a manual review to determine causality using World Health Organization-Uppsala Monitoring Centre (WHO-UMC) assessment criteria. Cases were also compared with those reported in FAERS.</p>
        </sec>
        <sec>
          <title>Findings</title>
          <p>A total of 935,246 posts were harvested from Facebook and Twitter, from March 2009 through October 2014. The automated classifier identified 98,252 Proto-AEs. Of these, 13 posts were selected for causality assessment of product–event pairs. Clinical assessment revealed that posts had sufficient information to warrant further investigation for two possible product–event associations: dronedarone–vasculitis and Banana Boat Sunscreen--skin burns. No product–event associations were found among the negative controls. In one of the positive cases, the first report occurred in social media prior to signal detection from FAERS, whereas the other case occurred first in FAERS.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>An efficient semi-automated approach to social media monitoring may provide earlier insights into certain adverse events. More work is needed to elaborate additional uses for social media data in pharmacovigilance and to determine how they can be applied by regulatory agencies.</p>
        </sec>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1007/s40264-016-0491-0) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000038</institution-id>
              <institution>U.S. Food and Drug Administration</institution>
            </institution-wrap>
          </funding-source>
          <award-id>HHSF223201210217C</award-id>
          <principal-award-recipient>
            <name>
              <surname>Dasgupta</surname>
              <given-names>Nabarun</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer International Publishing Switzerland 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="FPar1">
      <title>Key Points</title>
      <p>
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Previous work has established that social media can be a viable source for pharmacovigilance signals by drawing information directly from patients that may not have been otherwise reported to regulatory agencies or industry.</td></tr><tr><td align="left">Of 10 recent postmarketing safety signals from the US FDA, public Facebook and Twitter posts showed mentions of one product–event pair before cases were reported to the traditional spontaneous report system.</td></tr><tr><td align="left">Social media can be an adjunct to traditional safety reporting systems to possibly uncover postmarketing safety signals more rapidly, although considerations of noise and volume need to be further characterized.</td></tr></tbody></table></table-wrap>
</p>
    </sec>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Clinical trials are imperative for evaluating the safety and efficacy of new medical products; however, because of patient selection criteria, small sample sizes, and short durations, they provide limited information on rare harms. As a result, traditional clinical drug trials are not designed to detect rare adverse drug events. This is exemplified by the fact that over one-half of approved drugs have serious adverse events (AEs) identified that are not detected before approval [<xref ref-type="bibr" rid="CR1">1</xref>]. In addition, existing postmarket AE reporting systems are significantly underutilized by clinicians and patients. It has been estimated that as much as 96% of adverse drug events go unreported to regulators [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>The normative and burgeoning online representation of human knowledge and the corresponding growth of computing power to analyze unstructured information offer novel opportunities to access the variety of patient-generated experience, which has been referred to as “digital disease detection” when applied to health [<xref ref-type="bibr" rid="CR3">3</xref>]. Adoption of social media tools and smartphones has surged. The USA alone has 160 million Facebook users [<xref ref-type="bibr" rid="CR4">4</xref>] and 140 million Twitter users [<xref ref-type="bibr" rid="CR5">5</xref>]. In the health domain specifically, 59% of US adults had looked online for health information in the past year, and 35% had gone online specifically to determine a medical condition [<xref ref-type="bibr" rid="CR6">6</xref>]. A high volume of discussions about medical products is occurring online, with patients using social media to publicly share concerns and reactions to medications. There is increasing interest in exploring the use of social media data for pharmacovigilance, but questions remain regarding how to validate and best leverage this data source.</p>
      <p>The general benefits and limitations of using social media for pharmacovigilance have been reviewed extensively [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR15">15</xref>]. One area of research has focused on creating online electronic tools that may expedite case reporting by incorporating user-friendly formats, generally referred to as ‘crowdsourcing’ [<xref ref-type="bibr" rid="CR16">16</xref>]. Data mining or ‘social listening’ case studies have established a base of applied examples of how generally unstructured online electronic sources can be used to derive drug safety information from news and social media, commonly including Twitter, Facebook, Google+, patient forums, news reports, blogs, and others. Notable among these are studies evaluating online discussions of benfluorex [<xref ref-type="bibr" rid="CR17">17</xref>], antibiotics [<xref ref-type="bibr" rid="CR18">18</xref>], human papilloma virus (HPV) vaccine and infertility [<xref ref-type="bibr" rid="CR19">19</xref>], oral antineoplastic drugs [<xref ref-type="bibr" rid="CR20">20</xref>], duloxetine [<xref ref-type="bibr" rid="CR21">21</xref>], anti-Parkinsonian agents [<xref ref-type="bibr" rid="CR22">22</xref>], and opioid analgesics [<xref ref-type="bibr" rid="CR23">23</xref>]; a study by Coloma et al. [<xref ref-type="bibr" rid="CR19">19</xref>] used assertion analysis to demonstrate a positive association between rosiglitazone and cardiovascular events in posts acquired from Twitter. Data mining of web search logs has also been considered for pharmacovigilance and drug safety surveillance [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p>
      <p>Data mining approaches to social media for pharmacovigilance have been published by other academic groups and evaluated in the conduct of the research presented here [<xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR37">37</xref>]. However, an outstanding fundamental question is whether analysis of social media could lead to earlier detection of rare and serious AEs. This is the objective of traditional spontaneous reporting and represents a high-value use case by which to evaluate social media, especially for regulatory purposes.</p>
      <p>It was hypothesized that warnings of safety signals for US FDA-regulated medications would have been generated earlier by monitoring social media in the period prior to the discovery of the safety signals via the current pharmacovigilance surveillance system, the FDA Adverse Event Reporting System (FAERS). The objective of this study was to examine whether cases of specific product–event pairs were reported in social media before they were reported to FAERS.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Study Overview</title>
        <p>The main study outcome was to determine whether social media posts for selected product–event pairs occurred prior to the date of the first FAERS case report and the date when the FDA first considered the reports in FAERS a potential safety signal. The date of the potential safety signal was the time at which the FDA first determined through routine pharmacovigilance that evidence of a concern was sufficient and that a formal safety review would be required. Retrospective social media data were acquired and processed to remove spam and duplicates and to identify AEs. Causality assessment was conducted by an independent third party.</p>
        <p>The study process was as follows:<list list-type="order"><list-item><p>Product–event pairs were identified for retrospective analysis.</p></list-item><list-item><p>Search terms were selected to identify products, including brand and generic names, and common misspellings.</p></list-item><list-item><p>Medical Dictionary for Regulatory Activities (MedDRA<sup>®</sup>) Preferred Terms (PTs) indicative of the symptomology of the MedWatch alerts were identified.</p></list-item><list-item><p>Queries were submitted to a third-party vendor to gather historical data.</p></list-item><list-item><p>A vernacular-to-regulatory dictionary was applied to convert the verbatim post text to MedDRA<sup>®</sup> PTs.</p></list-item><list-item><p>Machine learning algorithms were run on the data to automatically identify ‘posts with resemblance to adverse events’ (Proto-AEs), delete spam posts, consolidate duplicates, and remove personally identifiable information.</p></list-item><list-item><p>Symptomatic descriptors for each product–event association were used to identify posts for manual review.</p></list-item><list-item><p>An experienced drug safety physician manually curated auto-tagged Proto-AEs.</p></list-item><list-item><p>An independent third-party medical reviewer conducted causality assessments on the resulting posts.</p></list-item><list-item><p>Social media data were reviewed for concordance with the dates provided by the FDA regarding when the safety signals were first identified using the agency’s standard signal detection processes.</p></list-item></list>
</p>
      </sec>
      <sec id="Sec4">
        <title>Data Sources and Study Period</title>
        <p>The data source was English language public social media posts from Facebook and Twitter collected between March 2009 and October 2014 regardless of geographic location. Follow-up duration was the same for all product–event pairs, starting two calendar years before the first day of the month in which the FDA safety signal was first identified.</p>
        <p>Social media data from public Facebook and Twitter posts were obtained from an authorized third-party data vendor, since an estimated 90% of all Twitter accounts [<xref ref-type="bibr" rid="CR5">5</xref>] and 25% of all Facebook accounts [<xref ref-type="bibr" rid="CR4">4</xref>] are publicly accessible. The commercially available service provided the verbatim text of the body of the original post along with metadata such as timestamp, a link to the original content, and, if available, the poster’s gender and geographical information. Posts that were truncated but still described AEs and contained links to original content (e.g., a Tweet that linked to a longer post on the discussion board MedsChats.com) were followed to retrieve the full text.</p>
        <p>The FDA provided the month and year that the selected safety signals were first identified through the use of routine monitoring of FAERS in combination with other routine data sources for pharmacovigilance. Public data from FAERS were used to extract information on individual cases received by the FDA. Public FAERS data do not contain case narratives, so further information could not be used to determine exact date of onset or a detailed causality assessment. See the Electronic Supplementary Material (ESM) 1 for a list of data elements that were available in the public FAERS dataset and used in this analysis.</p>
      </sec>
      <sec id="Sec5">
        <title>Drug–Event Selection</title>
        <p>A total of 15 safety signals, identified between January 2011 and October 2014, retrieved from the FDA website were initially considered for use in the study [<xref ref-type="bibr" rid="CR38">38</xref>]. The time period was selected based on the availability of historical social media data from a third-party data vendor (Datasift). The final list selected for analysis resulted in 10 product–event pairs (Table <xref rid="Tab1" ref-type="table">1</xref>). The final 10 products were nine prescription medications and one over-the-counter consumer product. See the ESM 2 for a complete list of product–event pairs considered for analysis.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Product–event pairs selected for analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Drug</th><th align="left">Adverse event</th><th align="left">Month identified</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Lisdexamfetamine</td><td align="left">Raynaud’s phenomenon</td><td align="left">Mar 2011</td></tr><tr><td align="left">2</td><td align="left">Olmesartan</td><td align="left">Sprue-like enteropathy</td><td align="left">Sep 2011</td></tr><tr><td align="left">3</td><td align="left">Methylphenidate</td><td align="left">Priapism</td><td align="left">Sep 2011</td></tr><tr><td align="left">4</td><td align="left">Topical econazole</td><td align="left">Increased international normalized ratio (INR)</td><td align="left">Feb 2012</td></tr><tr><td align="left">5</td><td align="left">Pradaxa</td><td align="left">Angioedema</td><td align="left">Apr 2012</td></tr><tr><td align="left">6</td><td align="left">Dronedarone</td><td align="left">Vasculitis</td><td align="left">Apr 2012</td></tr><tr><td align="left">7</td><td align="left">Hydroxyzine</td><td align="left">Serious injection site reactions</td><td align="left">Jul 2012</td></tr><tr><td align="left">8</td><td align="left">Ziprasidone</td><td align="left">Drug reaction with eosinophilia and systemic symptoms (DRESS)</td><td align="left">Jun 2014</td></tr><tr><td align="left">9</td><td align="left">Tecfidera</td><td align="left">Progressive multifocal leukoencephalopathy (PML)</td><td align="left">Oct 2014</td></tr><tr><td align="left">10</td><td align="left">Banana Boat Sunscreen Spray</td><td align="left">Flammablility resulting in serious skin burns</td><td align="left">Jun 2012</td></tr></tbody></table></table-wrap>
</p>
        <p>The following rules reduced the list of 15 initial safety signals to 10:<list list-type="bullet"><list-item><p>Of the 15 safety signals, three were attributed to dronedarone, with another two attributed to Tecfidera. Three of these earlier reported product–event pairs with identical products were removed after it was determined that including multiple events would complicate the selection of negative controls by restricting the number of feasible negative controls. The process for selecting negative controls is described in Sect. <xref rid="Sec7" ref-type="sec">2.5</xref>.</p></list-item><list-item><p>Acetaminophen–skin reactions was eliminated because the amount of curation required to review the high volume of posts for ‘acetaminophen’ and ‘paracetamol’ was too onerous to be feasible in this study.</p></list-item></list>
</p>
        <p>Of note, the safety signal for hydroxyzine was specific to an injectable formulation, but all mentions of hydroxyzine were analyzed to reduce the possibility of missing reports by using injectable-specific search terms.</p>
      </sec>
      <sec id="Sec6">
        <title>Selection of Search Terms</title>
        <p>The brand names and misspellings in Table <xref rid="Tab2" ref-type="table">2</xref> were identified for each of the products of interest from a list of hypothesized spelling variants, using the public Twitter search. This is because drugs posted in social media can take on a variety of forms; aside from being referred to by various brand names and active ingredients, medical products can be misspelled or referred to in more general terms (synecdoche). Any search term that resulted in more than 10 posts was included. To maximize signal-to-noise ratio, an additional search criterion was added to include any posts mentioning ‘vivance’ (a common misspelling of Vyvanse) but to exclude ‘la vivance’, a common French word, because the concept is semantically unrelated to drug safety.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Search strings for selected products</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Product</th><th align="left">Search terms</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Lisdexamfetamine</td><td align="left">Lisdexamfetamine, lisdexamphetamine, vyvanse, vyvance, vivance, vayvanse</td></tr><tr><td align="left">2</td><td align="left">Olmesartan</td><td align="left">Olmesartan, benicar</td></tr><tr><td align="left">3</td><td align="left">Methylphenidate</td><td align="left">Methylphenidate, methylphenadate, ritalin, ritilin, concerta, daytrana, quillivant</td></tr><tr><td align="left">4</td><td align="left">Topical econazole</td><td align="left">Econazole, spectazole</td></tr><tr><td align="left">5</td><td align="left">Pradaxa</td><td align="left">Pradaxa, predaxa, dabigatran</td></tr><tr><td align="left">6</td><td align="left">Dronedarone</td><td align="left">Dronedarone, multaq</td></tr><tr><td align="left">7</td><td align="left">Hydroxyzine</td><td align="left">Hydroxyzine, hydroxizine, vistaril, atarax</td></tr><tr><td align="left">8</td><td align="left">Tecfidera</td><td align="left">Dimethyl fumarate, tecfidera, tecfedera</td></tr><tr><td align="left">9</td><td align="left">Ziprasidone</td><td align="left">Ziprasidone, geodon</td></tr><tr><td align="left">10</td><td align="left">Banana Boat Sunscreen Spray</td><td align="left">Banana boat sunscreen, banana boat sunblock, banana boat spray, banana boat aerosol</td></tr></tbody></table></table-wrap>
</p>
        <p>For the purpose of identifying cases in FAERS, which contains curated data with corrected misspellings, products were searched for using properly spelled brand and generic names.</p>
      </sec>
      <sec id="Sec7">
        <title>Selection of Controls</title>
        <p>The selection of negative controls was modeled after the approach taken by Harpaz et al. [<xref ref-type="bibr" rid="CR39">39</xref>] while establishing a time-indexed reference standard for adverse drug reactions. This approach defines negative controls by randomly pairing each product that appeared in the set of positive controls with one event that appeared in the set of positive controls. This process is repeated until each product is paired with at least one negative control event.</p>
        <p>In addition, we avoided assigning negative controls where the signs and symptoms indicative of the negative control medical concept may be associated with a product’s indication and therefore may trigger a false positive.</p>
        <p>FDA safety reviewers then checked product labeling to ensure that the events were not AEs listed in the product labeling for the randomly assigned negative control product. The most recent product label in October 2014 that was available from the National Library of Medicine DailyMed site was used [<xref ref-type="bibr" rid="CR40">40</xref>]. Of the resulting matches, four were excluded because the AE was listed as an AE in the label for that drug. The six resulting product–event pairs were selected as negative controls: dabigatran etexilate (Pradaxa) and Raynaud’s phenomenon, dimethyl fumarate (Tecfidera) and priapism, hydroxyzine (Atarax) and increased international normalized ratio (INR), ziprasidone (Geodon) and vasculitis, lisdexamfetamine (Vyvanse) and drug reaction with eosinophilia and systemic symptoms (DRESS), olmesartan (Benicar) and progressive multifocal leukoencephalopathy (PML).</p>
      </sec>
      <sec id="Sec8">
        <title>Definitions</title>
        <p>We utilized a previously created colloquial symptom dictionary in the social media listening platform to map colloquial phrases in social media posts to MedDRA<sup>®</sup>, the international medical terminology developed under the auspices of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) [<xref ref-type="bibr" rid="CR41">41</xref>]. The MedDRA<sup>®</sup> taxonomy comprises a five-level hierarchy of terms and codes describing, to varying degrees of specificity, a wide range of medical conditions, diagnoses, treatments, investigations, and signs and symptoms. The hierarchical levels are defined by degree of specificity, starting at the most general ‘System Organ Class’ (SOC) that describes organ- or site-specific disorders. The fourth level of specificity, ‘Preferred Term’ (PT) was chosen for this analysis. A PT represents a distinct clinical concept and is routinely used in pharmacovigilance, including in FAERS data. As described elsewhere [<xref ref-type="bibr" rid="CR29">29</xref>], the colloquial symptom dictionary was developed over four years through a manual curation process. When curators encountered vernacular terms in social media describing medical conditions, the phrases were added to the dictionary. The dictionary encompasses euphemisms (e.g., “I look like a lobster” codes to Erythema), combined words in the form of hashtags (denoted in social media using the # symbol), variations between American and British English, misspellings, abbreviations, homonym confusion, affixes (e.g., plural <italic>-</italic>s, past tense -ed), homographs, heteronyms, metonyms or synecdoche, and other facets of semantics. At the start of this study, the colloquial symptom dictionary contained 8857 vernacular terms mapped to 1956 of the most common PTs. Phrases are mapped to the MedDRA<sup>®</sup> (version 18) PT level since PTs represent distinct clinical concepts and are routinely used in pharmacovigilance, including coding AEs in FAERS data. Each colloquial phrase identified in social media describing a symptom was mapped to a MedDRA<sup>®</sup> PT as described elsewhere [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. For our study, all PTs identified in this analysis for the 10 AEs of interest were available in the colloquial symptom dictionary, including all corresponding AE synonyms.</p>
        <p>Another research group found low recall when using a lexicon-based approach [<xref ref-type="bibr" rid="CR26">26</xref>]. The lexicon studied was optimized for searching biomedical literature. As such, we would not expect that specific lexicon to perform well in social media posts in Twitter and Facebook. However, the lexicon used in our analysis was specifically generated based on empirical observation of patient conversations in social media. Therefore, the results observed by Nikfarjam et al. [<xref ref-type="bibr" rid="CR26">26</xref>] cannot be generalized to this study.</p>
      </sec>
      <sec id="Sec9">
        <title>Case Detection</title>
        <p>The unit of analysis was a single post in Facebook or Twitter that mentioned both a product name and an AE. Those AEs mentioned with a specific product are referred to as Proto-AEs, a term used to differentiate AEs described in social media posts from AE reports that have been vetted to meet the minimum regulatory requirement for reporting AEs, such as those in FAERS. Proto-AEs are conceptually modeled on the regulatory reporting definition, as we consider a network username to be similar to a patient identifier for a MedWatch report.</p>
        <p>We identified standardized symptom lists and definitions that were used to consistently evaluate the Proto-AEs identified in social media posts. This was because patients were more likely to report signs and symptoms of an AE than a medical diagnosis.</p>
        <p>To screen social media posts for cases for causality assessment, symptoms related to the 10 AEs of interest needed to be identified (see ESM 3) to build an event profile for automated Proto-AE detection.</p>
        <p>The process used was as follows:<list list-type="bullet"><list-item><p>If available, Standardized MedDRA<sup>®</sup> Queries (SMQs) were identified, yielding definitions for two AEs: angioedema and vasculitis.</p></list-item><list-item><p>All terms related to medical devices, injection, infusion, implant, stents, vaccinations, and syringes or needles were removed from the angioedema list because only solid oral formulations were under review among drug products.</p></list-item><list-item><p>Injection site-related PTs were selected from the Extravasation events MedDRA<sup>®</sup> SMQ.</p></list-item><list-item><p>To give preference to regulatory precedent on definitions, the FDA website was searched (using search engine-indexed site-specific syntax) to identify additional definitions, resulting in the identification of symptom lists for renal impairment and sprue-like enteropathy.</p></list-item><list-item><p>If other definitions were still not available, clinical reference books (e.g., <italic>Merck Manual</italic>) and trusted medical websites (e.g., Mayo Clinic and National Institutes of Health [NIH]) were consulted and converted into MedDRA<sup>®</sup> PTs.</p></list-item></list>
</p>
        <p>The number of unique PTs for each condition varied considerably; angioedema had by far the highest number of symptoms.</p>
      </sec>
      <sec id="Sec10">
        <title>Indicator Score Calculation</title>
        <p>A machine learning algorithm was employed to distinguish posts containing relevant drug safety information from non-informative posts. This was achieved using a statistical approach for automated document classification that categorized each post as either a Proto-AE or a non-Proto-AE, based on a manually coded training set using Certified MedDRA<sup>®</sup> Coders, as previously described [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. This training set consisted of data collected from Facebook and Twitter between October 2012 and December 2014 using application programming interfaces made publicly available by Facebook and Twitter. There was no overlap between the training set data and the study data. This involved feature extraction, a process by which each post was broken up into a set of discrete elements that were then tallied to determine the number of times each element (or feature) occurred in posts that had been manually coded as Proto-AEs and in posts that had been coded as non-Proto-AEs. To improve computational efficiency, the text was parsed using a single tree structure, based on the dictionary-matching algorithm originally developed for HealthMap, adapted to identify mentions of products and symptoms [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Loading the product and symptom taxonomies into a single tree structure enabled the post to be processed a single time to identify tokens that may have represented both products and symptoms. Next, all punctuation was removed, and the post was divided into tokens comprising one- to three-word phrases. Finally, each token was processed and matched against the vernacular dictionary. Positive matches were established when a ‘leaf’ was reached in the tree and a phrase for either a product or a symptom was identified based on the taxonomy.</p>
        <p>After the feature extraction algorithm was run on the input, the classifier, developed through statistical machine learning computation, was applied to each post. The model for the classifier was taken from Robinson’s approach to eliminating spam in email [<xref ref-type="bibr" rid="CR43">43</xref>]. Using a Bayesian probabilistic model and drawing on a training dataset containing more than 360,000 manually classified posts, the software assigned each post an indicator score on a scale of 0 to 1. For each feature extracted from a post, we calculated a probability score representing the likelihood that the post was a Proto-AE based on the manually classified corpus. We then combined probabilities across features using the inverse chi-squared function and calculated an overall indicator score, as detailed below. A score close to 0 meant there was a low probability that the post was related to an AE discussion (usually spam), whereas a score close to 1 indicated a high probability that the post was related to an AE discussion. In general terms, each new token was compared with the priors, and two probabilities were calculated based on the number of times the token appeared in positive and negative posts in the manually classified priors. Finally, we empirically determined that if a post contained no identifiable symptom, it was less likely to contain a true AE report. To account for this, and as a performance improvement measure, we therefore deducted a penalty of 0.2 from the indicator score if the post did not contain any identifiable symptoms.</p>
        <p>The process for computing the probabilities, combining them, and producing an indicator score was as follows. For each token ‘<italic>w</italic>’:<list list-type="bullet"><list-item><p>b(<italic>w</italic>) = (number of positives containing <italic>w</italic>)/(total number of positives)</p></list-item></list>
</p>
        <p>g(<italic>w</italic>) = (number of negatives containing <italic>w</italic>)/(total number of negatives)<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p(w) = \frac{b(w)}{b(w) + g(w)}$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>w</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>b</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>w</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>w</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>g</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>w</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="40264_2016_491_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>
</p>
        <p>
<italic>p</italic>(<italic>w</italic>) is the ‘raw’ probability that the document is a positive (AE) given that it contains word ‘<italic>w</italic>’.</p>
        <p>To adjust for rare tokens, i.e., phrases that did not occur frequently or at all in the training set, the following statistical adjustment was undertaken:<disp-formula id="Equb"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f(w) = \frac{(s * x) + (n * p(w))}{s + n}$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>w</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mrow/><mml:mo>∗</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>n</mml:mi><mml:mrow/><mml:mo>∗</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>w</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="40264_2016_491_Article_Equb.gif" position="anchor"/></alternatives></disp-formula>
</p>
        <p>
<italic>f</italic>(<italic>w</italic>) is a scaled or ‘weighted’ transformation of <italic>p</italic>(<italic>w</italic>). The weighting is based on priors as well as the frequency of <italic>w</italic> in the training set.</p>
        <p>
<italic>s</italic>: ‘strength’ assigned to background (training) information</p>
        <p>
<italic>x</italic>: assumed probability of spam for unknown token</p>
        <p>
<italic>n:</italic> number of examples containing <italic>w</italic>
</p>
        <p>Strength (<italic>s</italic>) and probability of positive (<italic>x</italic>) are priors. 1.0 and 0.5 are considered neutral values for <italic>s</italic> and <italic>x</italic>, respectively; in our implementation, we used 1.4 for the value of <italic>s</italic> and 0.6 for the value of <italic>x</italic>. These values were determined by experimentation, namely, checking performance metrics for a range of values and selecting the values yielding the best performance. No formal optimization methodology was applied for this process.</p>
        <p>Probabilities were derived using Fisher’s method of combining probabilities, where <italic>C</italic>
<sup>−1</sup> is shorthand for the inverse chi-squared function:<disp-formula id="Equc"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$H = C^{ - 1} \left( { - 2\ln \prod\limits_{w} {f(w),2n} } \right)$$\end{document}</tex-math><mml:math id="M6" display="block"><mml:mrow><mml:mi>H</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo>ln</mml:mo><mml:munder><mml:mo>∏</mml:mo><mml:mi>w</mml:mi></mml:munder><mml:mrow><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>w</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mi>n</mml:mi></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="40264_2016_491_Article_Equc.gif" position="anchor"/></alternatives></disp-formula>
</p>
        <p>Complementary probabilities were combined in this manner:<disp-formula id="Equd"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$S = C^{ - 1} \left( { - 2\ln \prod\limits_{w} {1 - f(w),2n} } \right)$$\end{document}</tex-math><mml:math id="M8" display="block"><mml:mrow><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo>ln</mml:mo><mml:munder><mml:mo>∏</mml:mo><mml:mi>w</mml:mi></mml:munder><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>w</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mi>n</mml:mi></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="40264_2016_491_Article_Equd.gif" position="anchor"/></alternatives></disp-formula>
</p>
        <p>The indicator score was then calculated by averaging the combined probabilities with the inverse probabilities.<disp-formula id="Eque"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$I = \frac{1 + H - S}{2}$$\end{document}</tex-math><mml:math id="M10" display="block"><mml:mrow><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>H</mml:mi><mml:mo>-</mml:mo><mml:mi>S</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="40264_2016_491_Article_Eque.gif" position="anchor"/></alternatives></disp-formula>
</p>
        <p>We average the positive score (<italic>H</italic>) and the negative score (<italic>S</italic>) to produce a bimodal distribution of indicator (<italic>I</italic>) values. That is, with the resulting distribution of <italic>I</italic> in our dataset, we see large numbers of posts scoring either very low (high likelihood of spam) or very high (high likelihood of AE) and a smaller number scattered across the middle. The middle of the distribution represents content that the algorithm determined to be ambiguous. Since there is not enough human analyst time to check and reclassify all posts, we can then focus our analyst efforts on posts falling in the middle of the distribution. Second, the nature of the distribution makes the performance less sensitive to the exact indicator threshold value, since we place the threshold near the middle of the distribution.</p>
        <p>Posts with indicator scores of 0 were generally spam, e.g., advertisements, coupons, or other posts containing text clearly generated by bots. Posts with indicator scores &gt;0 were called ‘mentions.’</p>
        <p>An analysis of classifier performance suggested that optimal thresholds for removing irrelevant posts without excessively sacrificing true positives were indicator scores of 0.6 to 0.7 [<xref ref-type="bibr" rid="CR42">42</xref>]. In the previous analysis, posts with indicator scores of ≥0.65 had a positive predictive value of approximately 0.5 (i.e., 5 of every 10 posts would be relevant for drug safety), while keeping 92% of true AE posts.</p>
      </sec>
      <sec id="Sec11">
        <title>Human Curation</title>
        <p>Given the nuanced nature of social media language, previous experience has consistently suggested that review by a human curator is necessary on some posts that have been automatically identified as AEs by the classifier. This process helps to remove false positives, continuously improve the classifier, and expand the symptom and product taxonomies. This approach, called ‘active learning,’ introduces a feedback loop between the human curators and the automated classifier [<xref ref-type="bibr" rid="CR29">29</xref>]. The high volume of data in this study meant it was not practical to manually review every auto-tagged post; therefore, we established a threshold to identify potentially ambiguous posts that may require curation based on previous analysis of social media data using the machine classifier [<xref ref-type="bibr" rid="CR42">42</xref>]. Posts with indicator scores of at least 0.65 were reviewed by a team of human curators that included Certified MedDRA<sup>®</sup> Coders and medical professionals with a focus on removing false positives, called ‘primary curation.’ All curators received standardized training on curation methods for social media data, according to the MedDRA<sup>®</sup> coding standards and ICH-endorsed guidelines. Standard MedDRA<sup>®</sup> practices were used, including objective coding without any attempt to interpret or infer beyond the stated text. Curators receive annual refreshers, as well as training on each new release of MedDRA<sup>®</sup>. Primary curation is an ongoing process that is conducted for drugs in the general system; however, to prepare the data for causality assessment in this analysis, an additional round of curation was needed.</p>
        <p>Accordingly, ‘secondary curation’ was then conducted to identify relevant posts of interest for the hypothesis in this paper. An experienced drug safety physician (HVL) reviewed posts that had undergone primary curation for a given drug that had any symptom (e.g., from the SMQ list) associated with the product–event pair from positive associations and negative controls. Posts that appeared to describe the product–event pairs of interest were extracted for causality assessment. For SMQs, the presence of any symptom was not sufficient to trigger a positive match; the symptoms listed for SMQs in ESM 3 are often non-specific. As such, it was left to the discretion of the physician reviewer to determine whether the constellation of symptoms described was sufficient for a plausible positive match.</p>
      </sec>
      <sec id="Sec12">
        <title>Causality Review</title>
        <p>World Health Organization-Uppsala Monitoring Centre (WHO-UMC) criteria for causality assessment [<xref ref-type="bibr" rid="CR44">44</xref>] were assigned to each post identified during secondary curation. To accomplish this, the text of the post, along with date and data source, was sent to WHO-UMC for independent review by an experienced senior medical officer (IRE). Posts were classified as being ‘certain,’ ‘likely,’ ‘possible,’ ‘unlikely,’ or ‘unclassified.’ The differentiating factor between certain/likely and possible was the presence of time-to-event information; more granular and plausible time information elevated a case to certain as opposed to likely. It was assumed that most social media posts would likely fall in the possible category since time-to-event information is not routinely reported by patients.</p>
      </sec>
      <sec id="Sec13">
        <title>Ethics Statement</title>
        <p>All social media data used in this analysis came from public sources. Prior to causality assessment, posts were stripped of personally identifiable information (PII), such as screen names, user names, first and last names, and addresses. A hybrid automated–manual process was used to remove first and last names. Using a ‘PII dictionary’ containing a few hundred thousand names from a global database of values [<xref ref-type="bibr" rid="CR42">42</xref>], the software removed from the posts any names that were contained in the dictionary. In addition, text-based pattern matching was used to remove structured information (e.g., phone numbers, email addresses) that could lead to individual identification, other than for the needs of manual review. ‘Verbatim’ post text presented in this manuscript has been paraphrased and/or altered in non-meaningful ways to protect patient identity and prevent unmasking using Internet search engines. AE data from FAERS were also publicly available in an anonymized format. Since all primary data sources used in the analysis were publicly available, no institutional review board approval was sought.</p>
      </sec>
    </sec>
    <sec id="Sec14" sec-type="results">
      <title>Results</title>
      <sec id="Sec15">
        <title>Data Processing Results</title>
        <p>Figure <xref rid="Fig1" ref-type="fig">1</xref> represents the schematic flow of posts and steps taken in data cleaning as well as the number and percent of posts resulting from each process. We started with an initial dataset of 935,246 posts containing text of selected products. These were posted on public Facebook and Twitter accounts from March 2009 to October 2014. Spam posts were identified and eliminated based on indicator scores (less than zero) implying that the posts did not contain text that met our requirements (i.e., posts with the name of a product and only an emoticon, or in non-English languages). This spam-elimination step resulted in the removal of about 25% (<italic>n</italic> = 230,963) of the remaining posts, leaving a corpus of 704,283 non-spam posts mentioning the products of interest. Next, verbatim duplicates (8.3%, <italic>n</italic> = 58,188) were consolidated. A total of 98,252 Proto-AEs were then identified based on indicator scores of ≥0.65, representing about 15% of the remaining posts. After primary and secondary manual curation, which occurred over the course of three months, 13 posts were identified as possibly relevant and were then submitted for causality assessment. This process resulted in six posts of interest that described certain, probable, and possible cases.<fig id="Fig1"><label>Fig. 1</label><caption><p>Data processing results. Public social media data were obtained for Facebook and Twitter, with 935,246 posts identified where each of the 10 products under review were mentioned. An automated classifier was used to remove spam, followed by exclusion of verbatim duplicate posts. Posts with an indicator score of ≥0.65 were considered a ‘post with resemblance to an adverse event’ and manually curated to remove false positives. The resulting 13 posts that mentioned product–event associations from alerts or negative controls were assessed for causality by an independent third party. Six posts contained certain, probable, and possible cases. <italic>AE</italic> adverse event, <italic>Proto-AE</italic> post with resemblance to an adverse event</p></caption><graphic xlink:href="40264_2016_491_Fig1_HTML" id="MO6"/></fig>
</p>
      </sec>
      <sec id="Sec16">
        <title>Comparison of Twitter and Facebook Data</title>
        <p>Volume of mentions varied considerably by product, with controlled substances (e.g., lisdexamfetamine, methylphenidate) showing much higher volume due in considerable part to Internet pharmacy advertisements (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Mentions for the products of interest varied over time, with rapid increases after new product launches (e.g., lisdexamfetamine and Tecfidera). Surges in post counts generally tended to express excitement about the new products among patient communities, but also included sales and stock price forecasts for finance audiences. Most posts came from Twitter, compared with Facebook (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Twitter generally yielded a higher volume of mentions overall due to the prevalence of pharmacy advertisements, references to financial reporting, and links to medication-related news articles or literature. The percent of posts from Facebook varied from 1.4% (lisdexamfetamine [Vyvanse]) to 27.3% (dimethyl fumarate [Tecfidera]). The higher proportion of posts from Facebook for dimethyl fumarate originated from patients posting within open patient groups rather than individuals posting on their personal pages. While Twitter typically generates more posts mentioning medical products, Facebook data typically consists of higher-quality posts with more detailed information. Facebook’s post format and its numerous open patient groups provide a platform for patients to share their experiences without the character limits imposed by Twitter.<fig id="Fig2"><label>Fig. 2</label><caption><p>Volume of mentions of selected products in public Twitter and Facebook social media data. Mentions for the products of interest varied over time, with rapid increases after new product launches,<italic> black bars</italic> by year, and higher volumes for controlled substances</p></caption><graphic xlink:href="40264_2016_491_Fig2_HTML" id="MO7"/></fig>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Comparison of public Twitter and Facebook data for purposes of medical product safety surveillance. Social media data from public Facebook and Twitter posts were analyzed. A greater volume of posts originated from Twitter than from Facebook</p></caption><graphic xlink:href="40264_2016_491_Fig3_HTML" id="MO8"/></fig>
</p>
      </sec>
      <sec id="Sec17">
        <title>Results of Causality Assessment</title>
        <p>In total, 13 posts were submitted to WHO-UMC for causality assessment. The assessor was provided with the complete post of the text and told which product–event pair was under examination for each. The posts covered 5 of the 10 product–event pairs identified in Table <xref rid="Tab1" ref-type="table">1</xref>: ziprasidone–DRESS, methylphenidate–priapism, dimethyl fumarate–PML, dronedarone–vasculitis, and Banana Boat Sunscreen Spray–skin burns. The manual curator assigned the following scores to each of the 13 product–event pair posts: ziprasidone–DRESS: three unlikely posts; dronedarone–vasculitis: three possible posts, one probable post; methylphenidate–priapism: three unlikely posts; dimethyl fumarate–PML: one unlikely post; Banana Boat Sunscreen Spray–skin burns: two certain posts. Of the posts given the classification of unlikely, the greatest limitation was that the vernacular language used was not specific enough to constitute a causal relationship with the paired condition. For example, one Twitter post stated, “I’m severely allergic to geodon—had to go to the hospital just 8 hours after I took my dose.” The phrase “severely allergic” did not adequately describe DRESS. Similarly, another post read, “my doc wants me to try a new anti-psychotic. im fuckin terrified, i dont wanna, i almost lost my life a few times from it, im the only person i know who’s allergic to abilify and geodon.” In this instance “almost lost my life” did not specifically suggest DRESS. In a third example, “So, they took me off Geodon because I had an extreme attack last week and was trying to go into cardiac arrest, that was fun [truncated].”, again “extreme attack” and “trying to go into cardiac arrest” did not provide enough detail to determine a causal relationship to DRESS. All three of these posts would be considered serious AEs and potentially useful information, but they did not meet the strict intent of this analysis. These posts were all reported in social media before the FDA signal threshold for ziprasidone–DRESS had been reached from spontaneous reports.</p>
        <p>For dimethyl fumarate–PML, a single Facebook post was identified from secondary curation that was eventually adjudicated by WHO-UMC to be unlikely: “I tried taking Tecfidera and it made me SO sick I thought I was gonna die. Now I’m thinking of switching to Tysabri, but I tested positive for JC virus. My index value was 1.5 and the doctor told me that risk for PML was low at that range. Just wondering if anyone else is JCV positive and doing well on Tysabri?” In this instance, the link to PML could not be definitively established because no specific adverse drug reaction was being described. However, it is also worth noting that JC virus seropositivity is considered the differentiating risk factor for PML with this medication [<xref ref-type="bibr" rid="CR45">45</xref>]. In strictly medical terms, the combination of a positive JC virus test and “SO sick I thought I was gonna die” may not be sufficient to describe PML, but nonetheless implies a potentially severe and particularly inauspicious event experienced by the patient. This post was reported in Facebook before the FDA signal threshold for dimethyl fumarate–PML had been reached.</p>
        <p>For dronedarone, four specific posts mentioned symptoms that were consistent with vasculitis, all observed in Twitter, but two of these originated in a patient discussion board. One example stated, “Been on 400 mg of Multaq, 2× daily, for almost 6 weeks. Four days ago, noticed I had a rash on the palms of both my hands with dots that kind of look like small blood blisters.” This case was considered probable by the WHO-UMC causality reviewer because of the realistic time-to-onset mentioned in the post. The symptomology in the specific location of the extremities is a known characteristic of vasculitis, with the description of “like small blood blisters” further confirming the suspicion.</p>
        <p>Finally, hypersexuality has long been associated with synthetic pharmaceutical stimulants, from amphetamine to methylphenidate and others [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Identifying priapism cases specifically within a background of normative hypersexual references led to difficulty in drawing a causal link. For example, “@user says …”is one of the side effects of ritalin a hard cock?” LMFAO.” Since no pathology is described in this post, the WHO-UMC reviewer made the determination that it had unlikely causal connection. The other two posts reviewed for this product–event pair also had similar limitations.</p>
      </sec>
      <sec id="Sec18">
        <title>Review of Social Media Posts</title>
        <p>The 13 posts identified as a result of secondary curation appeared to be discussing symptoms associated with the pre-specified product–event pairs. No posts were found to contain symptoms for the negative controls after curation. The 13 posts were associated with 2 of the 10 FDA-identified safety signals, specifically dronedarone-associated vasculitis and skin burns resulting from Banana Boat Sunscreen Spray (Table <xref rid="Tab3" ref-type="table">3</xref>). There did not appear to be specific symptomology discussed in social media for the other eight safety signals identified by routine surveillance methods.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Social media post text and causality assessment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Original post (with additional information from referenced links)</th><th align="left">Original classification</th><th align="left">Source</th><th align="left">WHO review</th><th align="left">WHO comments</th></tr></thead><tbody><tr><td align="left" colspan="5">Dronedarone: vasculitis</td></tr><tr><td align="left"> “Started multaq 4 days ago, already have strange side effects: severe abdominal pain, shortness of breath with almost no activity. My <italic>heart beats are even more irregular</italic> than before and now I have <italic>on and off heart racing</italic> that I didn’t have before. I will call my Cardi tomorrow to get off the meds”</td><td align="left">Likely/probable</td><td align="left">Twitter</td><td align="left">Possible</td><td align="left">Time relationships and absence of other possible cause not specified</td></tr><tr><td align="left"> “Been on 400 mg of Multaq, 2× daily, for almost 6 weeks. Four days ago, noticed I had a <italic>rash on the palms of both my hands</italic> with dots that kind of look like small blood blisters. Came to this site to see if others have the same issue”</td><td align="left">Probable</td><td align="left">Twitter</td><td align="left">Probably</td><td align="left">Known ADR and time-to-onset realistic</td></tr><tr><td align="left"> @user besides gaining weight while on multaq, I’ve had <italic>rashes on my hands</italic>
</td><td align="left">Probable</td><td align="left">Twitter</td><td align="left">Possible</td><td align="left">Possible, but no time info</td></tr><tr><td align="left"> “Haven’t had severe side effects from Multaq … sometimes I get an <italic>itchy rash along the</italic> <italic>side</italic> <italic>of</italic> <italic>my torso.</italic> Eventually it goes away so I think it might be seasonal. I’m mostly concerned with losing a lot of hair. My hair dresser said I was shedding a lot and I notice it when I wash and brush my hair. Could be due to hormones but going to get checked out. Just thought I would ask if this was also a side effect. ##Multaq contains the active ingredient Dronedarone, it is used to treat conditions that cause irregular heartbeat. While <italic>hair loss</italic> is not listed as a regular side effect, there are actually many reports from women using the medication that they have experienced it, generally starting between 1 to 6 months, after they have started taking it. Are there any other que…”</td><td align="left">Probable</td><td align="left">Twitter</td><td align="left">Possible</td><td align="left">Which ADR are we talking about?</td></tr><tr><td align="left" colspan="5">Banana Boat Sunscreen Spray: flammability leading to serious skin burns</td></tr><tr><td align="left"> “Banana Boat Aerosol Sunscreen is extremely flammable. A doctor sprayed it on then caught fire while using a BBQ grill”</td><td align="left">Likely</td><td align="left">Facebook</td><td align="left">Certain</td><td align="left">Certain phenomenologically</td></tr><tr><td align="left"> WOW … A man’s body caught fire after he applied a Banana Boat SUNSCREEN!!! [link]</td><td align="left">Likely</td><td align="left">Twitter</td><td align="left">Certain</td><td align="left">Certain phenomenologically</td></tr></tbody></table><table-wrap-foot><p>Verbatim post text has been paraphrased and/or altered in non-meaningful ways to protect patient identity and prevent unmasking using Internet search engines</p><p>
<italic>ADR</italic> adverse drug reaction, <italic>WHO</italic> World Health Organization</p></table-wrap-foot></table-wrap>
</p>
        <p>For Banana Boat Sunscreen Spray, the first mention was on Facebook on 1 June 2012, followed a few hours into the next day on Twitter. Over the next week, 19 Facebook posts and 144 Twitter posts discussed this topic, fueled initially by a local television morning news story on 3 June.</p>
      </sec>
      <sec id="Sec19">
        <title>Timing of Social Media Posts Compared with FAERS Reporting</title>
        <p>For dronedarone–vasculitis, the social media case was identified from Twitter on 5 December 2010. No cases were identified in Facebook. The first FAERS primary suspect drug case was received on 7 July 2010, with signal detection reported by the FDA on 15 April 2012. Four social media reports were evaluated as possible (<italic>n</italic> = 3), probable (<italic>n</italic> = 1), or certain (<italic>n</italic> = 2), compared with 10 unique Individual Case Safety Reports (ICSRs) leading to signal detection by the FDA.</p>
        <p>For Banana Boat Sunscreen–skin burns, the first social media case was identified from Twitter on 2 June 2012, whereas the first Facebook case was identified on 1 June 2012. The first FAERS case was received on 19 June 2012, with signal detection reported later that month by the FDA. Two social media reports were evaluated as possible or probable, compared with one unique ICSR leading to signal detection by the FDA. The FAERS data suggest that (presumably separate) events occurred on 28 May 2012 and 12 June 2012. It is possible that the case reported in social media was the one that occurred on 28 May, but this cannot be verified. Therefore, only a single post count was attributed.</p>
      </sec>
    </sec>
    <sec id="Sec20" sec-type="discussion">
      <title>Discussion</title>
      <p>This analysis applied strict criteria for evaluating the usefulness of social media data in detecting serious AEs. Despite the very specific nature of this analysis, of the 10 safety signals studied, one was mentioned in social media data prior to meeting FDA signal detection thresholds, whereas another appeared in FAERS prior to social media. The events selected for this analysis were very specific diagnoses, whereas patients are more likely to discuss their medical conditions in common terms and symptoms. Therefore, it was necessary to cast a wide net using a large collection of terms consisting of any symptom that could possibly be associated with the selected medical event. This resulted in a very large number of collected posts that ultimately were deemed irrelevant to the product–events of interest, such as posts that referred to other non-medical products or individuals (e.g., musicians) that happened to have the same name as the chosen medical products. The combined lexical and machine learning approach used in this analysis had a performance of 0.88 sensitivity (recall) and 0.68 positive predictive value (precision) [<xref ref-type="bibr" rid="CR29">29</xref>]. This approach was selected on the basis of performance after comparison with other machine learning techniques [<xref ref-type="bibr" rid="CR48">48</xref>]. A recent analysis using Twitter and one patient forum with a training set of 6000 posts (limited to 81 drugs) returned recall of 0.68–0.78 and precision in the range of 0.76–0.86 with a semantic approach; by comparison, in that analysis, a lexical approach had 0.61–0.72 recall and 0.56–0.58 precision [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p>The WHO-UMC causation scale is a high standard when applied to social media. The drug and the AE must be well described and specific in addition to having plausible time relationships. Possible confounders will reduce the likely causality. When one considers the usefulness of trawling the Internet, WHO-UMC reviewers think of signals that describe ‘something serious happening,’ and the ‘something’ is characterized cohesively enough to suggest the effect is shared by a few unique individuals (generally more than three). Seriousness should therefore be a signal in its own right so that “extreme attack” and “trying to go into cardiac arrest” would be as important a signal as something with a suggestive causal link to a specified disease entity; WHO-UMC reviewers feel that they would always be interested in such reports when identifying and evaluating signals. Perhaps these are the most important contributions from social media—that an early serious concern is expressed about a drug harm before it is medicalized.</p>
      <p>Why social media monitoring did not yield early safety concerns for the other eight product–event pairs bears consideration. One possible explanation is that the events used in this analysis were relatively severe and/or serious, and our assumption is that patients would have sought medical treatment for many of these outcomes. Therefore, there is a likelihood that a patient’s provider might find the event to be significant enough to report, whereas a patient might consider a more severe diagnosis to be private information, thereby increasing the chances of it being detected through formal reporting channels and not mentioned on social media. Similarly, many of the events involved in this analysis may have required formal medical diagnosis for detection or may require medical expertise to describe it to the extent that it might trigger a signal.</p>
      <p>A previous study by the authors investigated concordance at the MedDRA<sup>®</sup> SOC level between social media reports and FAERS data [<xref ref-type="bibr" rid="CR29">29</xref>]. General disorders (usually less serious) were most commonly reported in social media, with patients describing symptoms in more general terms, e.g. “stomach problems” (“Abdominal symptom”), implying that whereas some patients are keen to describe their side effects publicly, many do not describe symptoms using the medical terminology needed to explicitly confirm a certain condition or diagnosis.</p>
      <p>This research contributes to the literature by providing a scientific approach to identifying potential posts containing AE information using an automated process, followed by structured manual review by drug safety physicians, including a process for assessing causality using an international standard.</p>
      <p>As we mentioned above, the nature of the severe events selected for this analysis required us to rely on a large selection of terms for common signs and symptoms that would provide us with a large enough corpus from which to work. This methodology might have been improved upon—and search results could have been much narrower—perhaps by developing an algorithm for each separate event of interest or product that assigned weights to each sign and symptom according to the likelihood that it would indicate the event of interest.</p>
      <p>One unresolved key question is how to operationalize social media surveillance for regulated medical products. Given the curation burden and the large volume of social media data, prospective monitoring of all regulated products may have limitations. Social media could be used to stimulate a safety assessment that the FDA was not already considering. Some pharmaceutical companies have progressed to monitoring a portfolio of products [<xref ref-type="bibr" rid="CR42">42</xref>], but government agency monitoring of the pharmacopeia will require additional effort. Whereas other researchers have developed more directly automated screening methods to identify potential posts of interest (e.g., AEs), a critical component of our study was to elucidate a process by which machine-identified posts could be evaluated for causation within the existing global frameworks used by regulators and industry. This process is a bridge between the computer science tools and existing pharmacovigilance methods. A future can be envisioned of greater machine dependence, but adjudication of causality is likely to remain a fundamentally human function.</p>
      <p>Beyond this, the results of this analysis elicit points for discussion. First, further research is needed to develop best practices and methods for determining what constitutes a ‘safety signal’ in social media. It can be hypothesized that higher signal thresholds than those used in traditional pharmacovigilance may be appropriate for signal detection in social media data, as these data are not specifically intended to be used for reporting adverse drug reactions. A line of interdisciplinary research has been initiated to explore alternative methods for quantitative signal detection using social media data [<xref ref-type="bibr" rid="CR7">7</xref>] in addition to an approach using proportional reporting ratios [<xref ref-type="bibr" rid="CR42">42</xref>]. Second, social listening for postmarketing safety surveillance is a new field, and best practices are still being established. There is some uncertainty on the appropriate use of these data from a regulatory and patient privacy point of view.</p>
      <p>There are several technical limitations to this study that bear mentioning. First, there is inherent variability across data sources that can change rapidly over time. This may include the types of people posting on a particular website and limitations caused by website characteristics (e.g., character limitation). In 2015, Facebook enacted a policy to no longer make post-level verbatim text available for data-mining purposes, citing privacy concerns. This effectively makes the world’s largest social network unavailable for future drug safety surveillance, without special dispensation. Other social networking sites may also make their user-generated data not public, meaning it will be inaccessible using the methods described herein. Second, Internet vernacular may not accurately reflect a medical condition. To alleviate this limitation, the vernacular-to-MedDRA<sup>®</sup> dictionary used for this study was able to pick up on many such peculiarities of language, but some may have been missed. Other researchers have proposed solutions to developing an exhaustive consumer health vocabulary, which will be incorporated in future analyses [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Third, there is the possibility that people may post the same information in multiple social media platforms. As a result, some duplication may exist. However, this was not apparent to curators while manually reviewing posts for this analysis. Potential for duplication will need to be considered in the development of quantitative signal detection methodologies, alongside the perennial problem that stems from the lack of an obvious denominator for rate calculation in spontaneously reported AE data. Finally, the manual curation steps described here were considered necessary to provide a medical understanding of the social media posts. A practical limitation to including the human curation step is in the volume of reports that can be processed. For example, acetaminophen/paracetamol products were not included in this analysis because the volume was too high for manual curation. Specific investigations may need to consider approaches that rely more on automation.</p>
    </sec>
    <sec id="Sec21" sec-type="conclusion">
      <title>Conclusion</title>
      <p>Although we do not foresee that social media monitoring will replace current spontaneous report systems, we present one example of how social media listening, even for rare and serious events, can be modeled as an early warning system for emerging drug safety concerns. In 1999, Cobert and Silvey [<xref ref-type="bibr" rid="CR51">51</xref>] commented “we live in electronically exciting times” in reference to the then-impending explosion of Internet-based options for pharmacovigilance. A decade and a half later, we feel that their vision for the future of drug safety is being borne out and will continue to expand in coming years.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec22">
        <p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40264_2016_491_MOESM1_ESM.pdf"><caption><p>Supplementary material 1 (PDF 77 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="40264_2016_491_MOESM2_ESM.pdf"><caption><p>Supplementary material 2 (PDF 117 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="40264_2016_491_MOESM3_ESM.pdf"><caption><p>Supplementary material 3 (PDF 148 kb)</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors thank the many curators who have contributed to training the classifier, including Chi Bahk, Wenjie Bao, Anne Czernek, Michael Gilbert, Melissa Jordan, Christopher Menone, and Carly Winokur. External independent review of cases was conducted by IRE; he was invited to be an author afterwards in recognition for his contributions. The authors also thank Robert Ball, Henry (Skip) Francis, and other FDA employees for their support of this project. The MedDRA<sup>®</sup> trademark is owned by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on behalf of ICH.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with Ethical Standards</title>
      <sec id="FPar2">
        <title>Funding</title>
        <p>All research presented here was conducted by the authors listed. Additional general development funds for the social listening platform were provided to Epidemico through a public–private partnership but were not used to directly support the specific content of this research. This collaborative effort is provided via the WEB-RADR project (<ext-link ext-link-type="uri" xlink:href="http://www.web-radr.eu">http://www.web-radr.eu</ext-link>), which is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under Grant Agreement No. 115632, resources of which are composed of financial contributions from the EU’s Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contribution (<ext-link ext-link-type="uri" xlink:href="http://www.imi.europa.eu">http://www.imi.europa.eu</ext-link>). In addition, general support for the development of the social media listening platform was provided by GlaxoSmithKline (GSK), independent of the research presented herein. GSK, WEB-RADR, and IMI JU had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
      </sec>
      <sec id="FPar3">
        <title>Conflict of interest</title>
        <p>Carrie Pierce, Hoa Van Le, Harold Rodriguez, John Brownstein, Clark Freifeld, and Nabarun Dasgupta are employees of or contractors to Epidemico, a technology company intending to commercialize the software platform used in this research. Epidemico is a wholly owned subsidiary of Booz Allen Hamilton. I. Ralph Edwards has no conflicts of interest that are directly relevant to the content of this manuscript. Khaled Bouri, Carol Pamer, Scott Proestel, and Mark Walderhaug are employees of the United States Food and Drug Administration. Development of the social listening platform, research conducted, and manuscript development was funded by the US FDA (<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">http://www.fda.gov</ext-link>) under contract with Epidemico, Inc (HHSF223201210217C).</p>
      </sec>
      <sec id="FPar4">
        <title>US Government employee statement</title>
        <p>The following authors are employees of the US Government: Khaled Bouri, Carol Pamer, Scott Proestel, and Mark Walderhaug. The opinions expressed in this manuscript are those of the authors and not intended to represent the opinions of the United States Food and Drug Administration.</p>
      </sec>
      <sec id="FPar5">
        <title>Ethics statement</title>
        <p>All human subject data used in this analysis were publicly available and used in a de-identified format whenever possible.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deyo</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Gaps, tensions, and conflicts in the FDA approval process: implications for clinical practice</article-title>
          <source>J Am Board Fam Med.</source>
          <year>2004</year>
          <volume>17</volume>
          <issue>2</issue>
          <fpage>142</fpage>
          <lpage>149</lpage>
          <pub-id pub-id-type="doi">10.3122/jabfm.17.2.142</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Bennet</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>HM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines</article-title>
          <source>Br J Clin Pharmacol.</source>
          <year>1996</year>
          <volume>42</volume>
          <fpage>423</fpage>
          <lpage>429</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2125.1996.tb00004.x</pub-id>
          <?supplied-pmid 8904613?>
          <pub-id pub-id-type="pmid">8904613</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="other">Brownstein JS, Freifeld CC, Madoff LC. Digital disease detection—harnessing the Web for public health surveillance. N Engl J Med. 2009;360(21):2153–7. doi:10.1056/NEJMp0900702.</mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="other">Brown D. 52 Cool facts about social media--2012 edition dannybrown.me. 2012. <ext-link ext-link-type="uri" xlink:href="http://dannybrown.me/2012/06/06/52-cool-facts-social-media-2012">http://dannybrown.me/2012/06/06/52-cool-facts-social-media-2012</ext-link>. Accessed 6 Oct 2015.</mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="other">Beevolve. An exhaustive study of Twitter users across the world--social media analytics. Beevolve. 2012. <ext-link ext-link-type="uri" xlink:href="http://temp.beevolve.com/twitter-statistics/-cl">http://temp.beevolve.com/twitter-statistics/-cl</ext-link>. Accessed 6 Oct 2015.</mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="other">Fox S, Duggan M. Health Online 2013. Pew Internet: Pew Research Center, 2013. <ext-link ext-link-type="uri" xlink:href="http://www.pewinternet.org/2013/01/15/health-online-2013">http://www.pewinternet.org/2013/01/15/health-online-2013</ext-link>. Accessed 15 Oct 2015.</mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghosh</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media</article-title>
          <source>Expert Opin Drug Saf</source>
          <year>2015</year>
          <volume>14</volume>
          <issue>12</issue>
          <fpage>1845</fpage>
          <lpage>1853</lpage>
          <pub-id pub-id-type="doi">10.1517/14740338.2015.1096342</pub-id>
          <?supplied-pmid 26436834?>
          <pub-id pub-id-type="pmid">26436834</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Golder</surname>
              <given-names>Su</given-names>
            </name>
            <name>
              <surname>Norman</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Loke</surname>
              <given-names>YK</given-names>
            </name>
          </person-group>
          <article-title>Systematic review on the prevalence, frequency and comparative value of adverse events data in social media</article-title>
          <source>Br J Clin Pharmacol</source>
          <year>2015</year>
          <volume>80</volume>
          <issue>4</issue>
          <fpage>878</fpage>
          <lpage>888</lpage>
          <pub-id pub-id-type="doi">10.1111/bcp.12746</pub-id>
          <?supplied-pmid 26271492?>
          <pub-id pub-id-type="pmid">26271492</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lardon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Abdellaoui</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bellet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Asfari</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Souvignet</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Texier</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Jaulent</surname>
              <given-names>M-C</given-names>
            </name>
            <name>
              <surname>Beyens</surname>
              <given-names>M-N</given-names>
            </name>
            <name>
              <surname>Burgun</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bousquet</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Adverse drug reaction identification and extraction in social media: a scoping review</article-title>
          <source>J Med Internet Res</source>
          <year>2015</year>
          <volume>17</volume>
          <fpage>e171</fpage>
          <pub-id pub-id-type="doi">10.2196/jmir.4304</pub-id>
          <?supplied-pmid 26163365?>
          <pub-id pub-id-type="pmid">26163365</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sloane</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Osanlou</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bollegala</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Maskell</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pirmohamed</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Social media and pharmacovigilance: a review of the opportunities and challenges</article-title>
          <source>Br J Clin Pharmacol.</source>
          <year>2015</year>
          <volume>80</volume>
          <issue>4</issue>
          <fpage>910</fpage>
          <lpage>920</lpage>
          <pub-id pub-id-type="doi">10.1111/bcp.12717</pub-id>
          <?supplied-pmid 26147850?>
          <pub-id pub-id-type="pmid">26147850</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ginn</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nikfarjam</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>O’Connor</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jayaraman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Upadhaya</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Utilizing social media data for pharmacovigilance: a review</article-title>
          <source>J Biomed Inform.</source>
          <year>2015</year>
          <volume>54</volume>
          <fpage>202</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbi.2015.02.004</pub-id>
          <?supplied-pmid 25720841?>
          <pub-id pub-id-type="pmid">25720841</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Norén</surname>
              <given-names>G. Niklas</given-names>
            </name>
          </person-group>
          <article-title>Pharmacovigilance for a revolving world: prospects of patient-generated data on the internet</article-title>
          <source>Drug Saf.</source>
          <year>2014</year>
          <volume>37</volume>
          <fpage>761</fpage>
          <lpage>764</lpage>
          <pub-id pub-id-type="doi">10.1007/s40264-014-0205-4</pub-id>
          <?supplied-pmid 25096955?>
          <pub-id pub-id-type="pmid">25096955</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>White</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Harpaz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>DuMouchel</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Horvitz</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Toward enhanced pharmacovigilance using patient-generated data on the internet</article-title>
          <source>Clin Pharmacol Ther.</source>
          <year>2014</year>
          <volume>96</volume>
          <issue>2</issue>
          <fpage>239</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="doi">10.1038/clpt.2014.77</pub-id>
          <?supplied-pmid 24713590?>
          <pub-id pub-id-type="pmid">24713590</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masoni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Guelfi</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Conti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gensini</surname>
              <given-names>GF</given-names>
            </name>
          </person-group>
          <article-title>Pharmacovigilance and use of online health information</article-title>
          <source>Trends Pharmacol Sci.</source>
          <year>2013</year>
          <volume>34</volume>
          <issue>7</issue>
          <fpage>357</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tips.2013.05.001</pub-id>
          <?supplied-pmid 23759353?>
          <pub-id pub-id-type="pmid">23759353</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edwards</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Lindquist</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Social media and networks in pharmacovigilance: boon or bane?</article-title>
          <source>Drug Saf.</source>
          <year>2011</year>
          <volume>34</volume>
          <issue>4</issue>
          <fpage>267</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="doi">10.2165/11590720-000000000-00000</pub-id>
          <?supplied-pmid 21417499?>
          <pub-id pub-id-type="pmid">21417499</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kubota</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Okazaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dobashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hashguchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Doil</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patients views and experiences in online reporting adverse drug reactions: findings of a national pilot study in Japan</article-title>
          <source>Patient Prefer Adher.</source>
          <year>2015</year>
          <volume>9</volume>
          <fpage>173</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="doi">10.2147/PPA.S75761</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abou Taam</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rossard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cantaloube</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bouscaren</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Roche</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pochard</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Analysis of patients’ narratives posted on social media websites on benfluorex’s (Mediator(R)) withdrawal in France</article-title>
          <source>J Clin Pharm Ther.</source>
          <year>2014</year>
          <volume>39</volume>
          <issue>1</issue>
          <fpage>53</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="doi">10.1111/jcpt.12103</pub-id>
          <?supplied-pmid 24304185?>
          <pub-id pub-id-type="pmid">24304185</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dyar</surname>
              <given-names>OJ</given-names>
            </name>
            <name>
              <surname>Castro-Sanchez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>AH</given-names>
            </name>
          </person-group>
          <article-title>What makes people talk about antibiotics on social media? A retrospective analysis of Twitter use</article-title>
          <source>J Antimicrob Chemother.</source>
          <year>2014</year>
          <volume>69</volume>
          <issue>9</issue>
          <fpage>2568</fpage>
          <lpage>2572</lpage>
          <pub-id pub-id-type="doi">10.1093/jac/dku165</pub-id>
          <?supplied-pmid 24862092?>
          <pub-id pub-id-type="pmid">24862092</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coloma</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sturkenboom</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>van Mulligen</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Kors</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Evaluating social media networks in medicines safety surveillance: two case studies</article-title>
          <source>Drug Saf.</source>
          <year>2015</year>
          <volume>38</volume>
          <issue>10</issue>
          <fpage>921</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="doi">10.1007/s40264-015-0333-5</pub-id>
          <?supplied-pmid 26242616?>
          <pub-id pub-id-type="pmid">26242616</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pages</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bondon-Guitton</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Montastruc</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Bagheri</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Undesirable effects related to oral antineoplastic drugs: comparison between patients’ internet narratives and a national pharmacovigilance database</article-title>
          <source>Drug Saf.</source>
          <year>2014</year>
          <volume>37</volume>
          <issue>8</issue>
          <fpage>629</fpage>
          <lpage>637</lpage>
          <pub-id pub-id-type="doi">10.1007/s40264-014-0203-6</pub-id>
          <?supplied-pmid 25027671?>
          <pub-id pub-id-type="pmid">25027671</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harmark</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>van Puijenbroek</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>van Grootheest</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Intensive monitoring of duloxetine: results of a web-based intensive monitoring study</article-title>
          <source>Eur J Clin Pharmacol.</source>
          <year>2013</year>
          <volume>69</volume>
          <issue>2</issue>
          <fpage>209</fpage>
          <lpage>215</lpage>
          <pub-id pub-id-type="doi">10.1007/s00228-012-1313-7</pub-id>
          <?supplied-pmid 22688722?>
          <pub-id pub-id-type="pmid">22688722</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schroder</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zollner</surname>
              <given-names>YF</given-names>
            </name>
            <name>
              <surname>Schaefer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Drug related problems with Antiparkinsonian agents: consumer Internet reports versus published data</article-title>
          <source>Pharmacoepidemiol Drug Saf.</source>
          <year>2007</year>
          <volume>16</volume>
          <issue>10</issue>
          <fpage>1161</fpage>
          <lpage>1166</lpage>
          <pub-id pub-id-type="doi">10.1002/pds.1415</pub-id>
          <?supplied-pmid 17486665?>
          <pub-id pub-id-type="pmid">17486665</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shutler</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Portelli</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Blachford</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Perrone</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Drug use in the Twittersphere: a qualitative contextual analysis of tweets about prescription drugs</article-title>
          <source>J Addict Dis.</source>
          <year>2015</year>
          <volume>34</volume>
          <issue>4</issue>
          <fpage>303</fpage>
          <lpage>310</lpage>
          <pub-id pub-id-type="doi">10.1080/10550887.2015.1074505</pub-id>
          <?supplied-pmid 26364675?>
          <pub-id pub-id-type="pmid">26364675</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simmering</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Polgreen</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Polgreen</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Web search query volume as a measure of pharmaceutical utilization and changes in prescribing patterns</article-title>
          <source>Res Soc Adm Policy.</source>
          <year>2014</year>
          <volume>10</volume>
          <issue>6</issue>
          <fpage>896</fpage>
          <lpage>903</lpage>
          <pub-id pub-id-type="doi">10.1016/j.sapharm.2014.01.003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>White</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pant</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Harpaz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shukla</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early identification of adverse drug reactions from search log data</article-title>
          <source>J Biomed Inform.</source>
          <year>2016</year>
          <volume>59</volume>
          <fpage>42</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbi.2015.11.005</pub-id>
          <?supplied-pmid 26610385?>
          <pub-id pub-id-type="pmid">26610385</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nikfarjam</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sarker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>O’Connor</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ginn</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features</article-title>
          <source>J Am Med Inform Assoc.</source>
          <year>2015</year>
          <volume>22</volume>
          <issue>3</issue>
          <fpage>671</fpage>
          <lpage>681</lpage>
          <?supplied-pmid 25755127?>
          <pub-id pub-id-type="pmid">25755127</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Portable automatic text classification for adverse drug reaction detection via multi-corpus training</article-title>
          <source>J Biomed Inform.</source>
          <year>2015</year>
          <volume>53</volume>
          <fpage>196</fpage>
          <lpage>207</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbi.2014.11.002</pub-id>
          <?supplied-pmid 25451103?>
          <pub-id pub-id-type="pmid">25451103</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarntivijai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Abernethy</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Use of internet search logs to evaluate potential drug adverse events</article-title>
          <source>Clin Pharmacol Ther.</source>
          <year>2014</year>
          <volume>96</volume>
          <issue>2</issue>
          <fpage>149</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.1038/clpt.2014.115</pub-id>
          <?supplied-pmid 25056395?>
          <pub-id pub-id-type="pmid">25056395</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freifeld</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Brownstein</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Menone</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Bao</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Filice</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kass-Hout</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Digital drug safety surveillance: monitoring pharmaceutical products in twitter</article-title>
          <source>Drug Saf.</source>
          <year>2014</year>
          <volume>37</volume>
          <issue>5</issue>
          <fpage>343</fpage>
          <lpage>350</lpage>
          <pub-id pub-id-type="doi">10.1007/s40264-014-0155-x</pub-id>
          <?supplied-pmid 24777653?>
          <pub-id pub-id-type="pmid">24777653</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O’Connor</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pimpalkhute</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nikfarjam</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ginn</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Pharmacovigilance on Twitter? Mining tweets for adverse drug reactions</article-title>
          <source>AMIA Annu Symp Proc.</source>
          <year>2014</year>
          <volume>2014</volume>
          <fpage>924</fpage>
          <lpage>933</lpage>
          <?supplied-pmid 25954400?>
          <pub-id pub-id-type="pmid">25954400</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Stanhope</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Exploiting online discussions to discover unrecognized drug side effects</article-title>
          <source>Methods Inf Med.</source>
          <year>2013</year>
          <volume>52</volume>
          <issue>2</issue>
          <fpage>152</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="doi">10.3414/ME12-02-0004</pub-id>
          <?supplied-pmid 23450374?>
          <pub-id pub-id-type="pmid">23450374</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Azadeh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sarker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>O’Connor</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ginn</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features</article-title>
          <source>J Am Med Inform Assoc.</source>
          <year>2015</year>
          <volume>22</volume>
          <fpage>671</fpage>
          <lpage>681</lpage>
          <pub-id pub-id-type="pmid">25755127</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kiang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shang</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Filtering big data from social media—building an early warning system for adverse drug reactions</article-title>
          <source>J Biomed Inform.</source>
          <year>2015</year>
          <volume>54</volume>
          <fpage>230</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbi.2015.01.011</pub-id>
          <?supplied-pmid 25688695?>
          <pub-id pub-id-type="pmid">25688695</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kunac</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Tatley</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Seddon</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>A new web-based Medication Error Reporting Programme (MERP) to supplement pharmacovigilance in New Zealand—findings from a pilot study in primary care</article-title>
          <source>NZ Med J.</source>
          <year>2014</year>
          <volume>127</volume>
          <issue>1401</issue>
          <fpage>69</fpage>
          <lpage>81</lpage>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karimi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Metke-Jimenez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kemp</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Cadec: a corpus of adverse drug event annotations</article-title>
          <source>J Biomed Inform.</source>
          <year>2015</year>
          <volume>55</volume>
          <fpage>73</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbi.2015.03.010</pub-id>
          <?supplied-pmid 25817970?>
          <pub-id pub-id-type="pmid">25817970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ungar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hennessy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identifying potential adverse effects using the web: a new approach to medical hypothesis generation</article-title>
          <source>J Biomed Inform.</source>
          <year>2011</year>
          <volume>44</volume>
          <issue>6</issue>
          <fpage>989</fpage>
          <lpage>996</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbi.2011.07.005</pub-id>
          <?supplied-pmid 21820083?>
          <pub-id pub-id-type="pmid">21820083</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Benton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ungar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Leonard</surname>
              <given-names>CE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Online discussion of drug side effects and discontinuation among breast cancer survivors</article-title>
          <source>Pharmacoepidemiol Drug Saf.</source>
          <year>2013</year>
          <volume>22</volume>
          <issue>3</issue>
          <fpage>256</fpage>
          <lpage>262</lpage>
          <pub-id pub-id-type="doi">10.1002/pds.3365</pub-id>
          <?supplied-pmid 23322591?>
          <pub-id pub-id-type="pmid">23322591</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <mixed-citation publication-type="other">US Food and Drug Administration. Medical product safety information. Silver Spring: US FDA; 2016.</mixed-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harpaz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Odgers</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gaskin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>DuMouchel</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Winnenburg</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bodenreider</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A time-indexed references tandard of adverse drug reactions</article-title>
          <source>Nature.</source>
          <year>2014</year>
          <volume>43</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <mixed-citation publication-type="other">National Library of Medicine. DailyMed: National Institutes of Health; 2016. <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov">https://dailymed.nlm.nih.gov</ext-link>. Accessed 14 Oct 2014. </mixed-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <mixed-citation publication-type="other">MedDRA The Medical Dictionary for Regulatory Activities. MedDRA. 2015. <ext-link ext-link-type="uri" xlink:href="http://www.meddra.org">http://www.meddra.org</ext-link>. Accessed 17 Dec 2015.</mixed-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Powell</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Reblin</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Burstein</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Blowers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Menius</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Painter</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pierce</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Brownstein</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Freifeld</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Dasgupta</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Social media listening for routine post-marketing safety surveillance</article-title>
          <source>Drug Saf.</source>
          <year>2016</year>
          <volume>39</volume>
          <issue>5</issue>
          <fpage>443</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1007/s40264-015-0385-6</pub-id>
          <?supplied-pmid 26798054?>
          <pub-id pub-id-type="pmid">26798054</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>A statistical approach to the spam problem</article-title>
          <source>Linux J.</source>
          <year>2003</year>
          <volume>107</volume>
          <fpage>3</fpage>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <mixed-citation publication-type="other">World Health Organization. The use of the WHO-UMC system for standardised case causality assessment 2011. <ext-link ext-link-type="uri" xlink:href="http://www.who-umc.org/Graphics/24734.pdf">http://www.who-umc.org/Graphics/24734.pdf</ext-link>. Accessed 16 Dec 2016.</mixed-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calabrese</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Molloy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Sorting out the risks in progressive multifocal leukoencephalopathy</article-title>
          <source>Nat Rev Rheumatol.</source>
          <year>2015</year>
          <volume>11</volume>
          <issue>2</issue>
          <fpage>119</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="doi">10.1038/nrrheum.2014.167</pub-id>
          <?supplied-pmid 25314016?>
          <pub-id pub-id-type="pmid">25314016</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>HB</given-names>
            </name>
          </person-group>
          <article-title>The effects of sensual drugs on behavior: clues to the function of the brain</article-title>
          <source>Adv Psychobiol.</source>
          <year>1974</year>
          <volume>2</volume>
          <fpage>297</fpage>
          <lpage>312</lpage>
          <?supplied-pmid 4476178?>
          <pub-id pub-id-type="pmid">4476178</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greaves</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Sexual disturbances among chronic amphetamine users</article-title>
          <source>J Nerv Ment Dis.</source>
          <year>1972</year>
          <volume>155</volume>
          <issue>5</issue>
          <fpage>363</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="doi">10.1097/00005053-197211000-00009</pub-id>
          <?supplied-pmid 5082173?>
          <pub-id pub-id-type="pmid">5082173</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <mixed-citation publication-type="other">Freifeld, CC (2014). Digital pharmacovigilance: The MedWatcher system for monitoring adverse events through automated processing of Internet social media and crowdsourcing (Doctoral dissertation). Retrieved from ProQuest Dissertations and Theses database (UMI No. 3581025).</mixed-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doing-Harris</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Zeng-Treitler</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>Computer-assisted update of a consumer health vocabulary through mining of social network data</article-title>
          <source>J Med Internet Res.</source>
          <year>2011</year>
          <volume>13</volume>
          <issue>2</issue>
          <fpage>e37</fpage>
          <pub-id pub-id-type="doi">10.2196/jmir.1636</pub-id>
          <?supplied-pmid 21586386?>
          <pub-id pub-id-type="pmid">21586386</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeng</surname>
              <given-names>QT</given-names>
            </name>
            <name>
              <surname>Tse</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Divita</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Keselman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Crowell</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Browne</surname>
              <given-names>AC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Term identification methods for consumer health vocabulary development</article-title>
          <source>J Med Internet Res.</source>
          <year>2007</year>
          <volume>9</volume>
          <issue>1</issue>
          <fpage>e4</fpage>
          <pub-id pub-id-type="doi">10.2196/jmir.9.1.e4</pub-id>
          <?supplied-pmid 17478413?>
          <pub-id pub-id-type="pmid">17478413</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cobert</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Silvey</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The Internet and drug safety: what are the implications for pharmacovigilance?</article-title>
          <source>Drug Saf.</source>
          <year>1999</year>
          <volume>20</volume>
          <issue>2</issue>
          <fpage>95</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="doi">10.2165/00002018-199920020-00001</pub-id>
          <?supplied-pmid 10082068?>
          <pub-id pub-id-type="pmid">10082068</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362649</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Drug Saf</journal-id>
      <journal-id journal-id-type="iso-abbrev">Drug Saf</journal-id>
      <journal-title-group>
        <journal-title>Drug Safety</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0114-5916</issn>
      <issn pub-type="epub">1179-1942</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362649</article-id>
      <article-id pub-id-type="pmcid">PMC5362649</article-id>
      <article-id pub-id-type="pmc-uid">5362649</article-id>
      <article-id pub-id-type="pmid">28130774</article-id>
      <article-id pub-id-type="publisher-id">505</article-id>
      <article-id pub-id-type="doi">10.1007/s40264-017-0505-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Tetteh</surname>
            <given-names>Raymond A.</given-names>
          </name>
          <address>
            <phone>+233 244 279 857</phone>
            <email>r_niiatetteh@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yankey</surname>
            <given-names>Barbara A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nartey</surname>
            <given-names>Edmund T.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lartey</surname>
            <given-names>Margaret</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leufkens</surname>
            <given-names>Hubert G. M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dodoo</surname>
            <given-names>Alexander N. O.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000120346234</institution-id><institution-id institution-id-type="GRID">grid.5477.1</institution-id><institution>Utrecht Institute for Pharmaceutical Sciences, </institution><institution>Utrecht University, </institution></institution-wrap>Utrecht, The Netherlands </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0546 3805</institution-id><institution-id institution-id-type="GRID">grid.415489.5</institution-id><institution>Pharmacy Department, </institution><institution>Korle-Bu Teaching Hospital, </institution></institution-wrap>Korle-Bu, Mamprobi, MP 2362 Accra, Ghana </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7400</institution-id><institution-id institution-id-type="GRID">grid.256304.6</institution-id><institution>School of Public Heath, </institution><institution>Georgia State University, </institution></institution-wrap>Atlanta, GA USA </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 1485</institution-id><institution-id institution-id-type="GRID">grid.8652.9</institution-id><institution>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, </institution><institution>School of Medicine and Dentistry, University of Ghana, </institution></institution-wrap>Legon, Accra, Ghana </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 1485</institution-id><institution-id institution-id-type="GRID">grid.8652.9</institution-id><institution>Department of Epidemiology and Disease Control, </institution><institution>School of Public Health, University of Ghana, </institution></institution-wrap>Legon, Accra, Ghana </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 1485</institution-id><institution-id institution-id-type="GRID">grid.8652.9</institution-id><institution>Department of Medicine, </institution><institution>School of Medicine and Dentistry, University of Ghana, </institution></institution-wrap>Legon, Accra, Ghana </aff>
        <aff id="Aff7"><label>7</label>Medicines Evaluation Board, Utrecht, The Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>28</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>40</volume>
      <issue>4</issue>
      <fpage>273</fpage>
      <lpage>283</lpage>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry “<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>” and scholar.google, using combination search terms ‘pre-exposure prophylaxis’, ‘safety concerns in the use of pre-exposure prophylaxis’, ‘truvada use as PrEP’, ‘guidelines for PrEP use’, ‘HIV pre-exposure prophylaxis’ and ‘tenofovir’ to identify clinical trials and literature on PrEP. We present findings associated with safety issues on the use of PrEP based on a review of 11 clinical trials on PrEP with results on safety and efficacy as at April 2016. We also reviewed findings from routine real-life practice reports. The pharmacological intervention for PrEP was tenofovir disoproxil fumarate/emtricitabine in a combined form as Truvada<sup>®</sup> or tenofovir as a single entity. Both products are efficacious for PrEP and seem to have a good safety profile. Regular monitoring is recommended to prevent long-term toxic effects. The main adverse effects observed with PrEP are gastrointestinal related; basically mild to moderate nausea, vomiting and diarrhea. Other adverse drug effects worth monitoring are liver enzymes, renal function and bone mineral density. PrEP as an intervention to reduce HIV transmission appears to have a safe benefit-risk profile in clinical trials. It is recommended for widespread use but adherence monitoring and real-world safety surveillance are critical in the post-marketing phase to ensure that the benefits observed in clinical trials are maintained in real-world use.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer International Publishing Switzerland 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="FPar1">
      <title>Key Points</title>
      <p>
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Safety concerns about pre-exposure prophylaxis pose challenges in use that should not be overlooked.</td></tr><tr><td align="left">Behavioural counselling and assurance of safety and efficacy are important components of pre-exposure prophylaxis.</td></tr><tr><td align="left">Real-world safety surveillance is critical in the post-marketing phase to ensure that the benefits observed in clinical trials are maintained.</td></tr></tbody></table></table-wrap>
</p>
    </sec>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>At the end of 2015, the World Health Organization established that 36.7 million people were living with human immunodeficiency virus (HIV) with about 2.1 million becoming newly infected in the year [<xref ref-type="bibr" rid="CR1">1</xref>]. With this high prevalence of HIV/acquired immune deficiency syndrome in the world, the World Health Organization related the urgency and importance of novel, effective and safe interventions in the prevention of HIV infection. This became necessary in that preventive behavioural messages on abstinence, faithfulness and condom use presented useful but limited impact as primary prevention on the spread of HIV. This challenge is observed especially among people at high risk because these protective measures were not applied consistently [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>Human immunodeficiency virus continues to be a major public health problem and it has claimed more than 35 million lives so far. In 2015 alone, 1.1 million died from HIV-related causes worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. The various management options for HIV including treatment, post-exposure prophylaxis and prevention of mother-to-child transmission have been integral in lowering HIV incidence, but reaching out to individuals at substantial risk owing to lifestyle practices required newer specific preventive approaches. Pre-exposure prophylaxis (PrEP) is a powerful tool in curbing the transmission of HIV infection [<xref ref-type="bibr" rid="CR3">3</xref>], and it involves taking an antiretroviral (ARV) pill daily in addition to other preventive behavioural measures to prevent HIV infection. This is a protective mechanism used for individuals not diagnosed with HIV but who may be at substantial risk of becoming infected because of their lifestyle or as a partner in a sero-discordant relationship.</p>
      <p>Results from clinical trials demonstrate the efficacy of PrEP, either used alone or in combination with other behavioural preventive methods, where it has been shown that PrEP can reduce the incidence of HIV by up to 86% [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] or even more with strict adherence. Based on results and evidence from PrEP trials, the US Food and Drug Administration (FDA) on 16 July, 2012 approved Truvada<sup>®</sup> [tenofovir (TDF) 300 mg/emtricitabine (FTC) 200 mg] (Gilead Sciences Inc., Foster City, CA, USA) as an effective medication for the prevention of HIV that could be sexually acquired [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] and in all other types of possible HIV infection including injectable drug use. This was followed with guidelines for the provision of PrEP in clinical settings issued by the US Centers for Disease Control (CDC) and recently the World Health Organization also issued similar guidelines recommending PrEP as a prevention option for individuals at substantial risk for acquiring HIV [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p>
      <p>In the 2014 CDC guidelines, TDF alone based on positive results of substantial efficacy and safety in clinical trials with injectable drug use and heterosexual active adults was recommended as an alternative regimen for these populations, but not for men who have sex with men (MSM) because no efficacy studies were concluded as yet in the group. Again, the use of other antiretroviral medications for PrEP, either in place of or in addition to TDF/FTC or TDF alone is not recommended and finally the use of oral PrEP for sex activity-timed or noncontinuous daily use is also not recommended [<xref ref-type="bibr" rid="CR8">8</xref>]. The CDC also recommend in addition to regular follow-up testing for changes in HIV-negative status and adverse drug monitoring including renal function before the initiation of PrEP and regularly while on preventive therapy. Routine bone mineral density (BMD) monitoring was not recommended by the CDC [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>There are several challenges in the implementation and use of PrEP. These concerns include high costs, safety screening, toxicity arising from continuous use, adverse drug reactions, poor adherence, possible abuse and the fear of decreased condom use as an additional protective method [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Poor adherence during PrEP is especially an important factor that may reduce effectiveness and lead to an increase in HIV infection rate with a possible development of HIV-resistant strains and subsequent transfer among the population. Factors that can affect adherence include adverse drug reactions (at regular doses) or toxicity (adverse drug reactions at probable high, intolerant doses or long-term use).</p>
      <p>The ARV drugs presently recommended for oral PrEP are TDF or a combination of TDF/FTC. These medications have proven to be potent [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref>], have a favourable resistance profile and are claimed to have limited adverse effects, thus rendering them efficacious and safe for PrEP [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR17">17</xref>]. Some studies have also assessed the efficacy of a 1% vaginal gel formulation of TDF and found it to be effective in reducing HIV transmission by 39% [<xref ref-type="bibr" rid="CR18">18</xref>]. Essential factors to be considered before using PrEP include a confirmed HIV-negative status with a normal renal function, a negative hepatitis B status, and absence of reduced BMD or a history of bone fractures, bone loss and osteoporosis [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Recipients of PrEP also need to be tested on a minimum of a quarterly basis during follow-up to ensure they remain HIV negative, do not present with decreased estimated creatinine clearance levels or reductions in BMD [<xref ref-type="bibr" rid="CR21">21</xref>]. The aim of this review is to describe and discuss safety concerns on the use of PrEP in the literature. Results from this review will contribute to the growing knowledge on the safety profile or use of PrEP.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Methods</title>
      <p>We performed a search of the literature on PrEP in PubMed (search date: 10 May, 2016), scholar.google (search date: 11 May, 2016), global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database (search date: 12 May, 2016) and the clinical trials, “<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>” (search date: 13 May, 2016), using combination search terms ‘pre-exposure prophylaxis’, ‘safety concerns in the use of pre-exposure prophylaxis’, ‘truvada use as PrEP’, ‘guidelines for PrEP use’, ‘HIV pre-exposure prophylaxis’ and ‘tenofovir’ to identify literature on PrEP safety trials and issues. The coverage dates were from January 2001 to April 2016. We limited the search to articles in English, which were completed with results available and based on the safety or efficacy of TDF, FTC and TDF/FTC. We profiled our findings on safety concerns of PrEP. Information on clinical trials was extracted from PubMed, Aids Vaccine Advocacy Coalition and clinicaltrials.gov based on completed studies (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Chart of search strategy for clinical trials on pre-exposure prophylaxis based on tenofovir (TDF), emtricitabine (FTC) and a TDF/FTC combination. <italic>AVAC</italic> Aids Vaccine Advocacy Coalition</p></caption><graphic xlink:href="40264_2017_505_Fig1_HTML" id="MO1"/></fig>
</p>
      <p>In the clinical trials database, studies that were enrolling or incomplete at the time of this review were excluded. Seventy-two cases were retrieved. We modified the search for closed and completed studies and reduced the number to 42. Further modification with emphasis on the drugs of interest reduced the trials to 23. We then isolated nine studies that were complete with results and enough data for our review (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p>
      <p>In PubMed, we obtained 938 articles after the initial search. We then limited the search to only clinical trials and obtained 79. We then modified to include only trials involving TDF/FTC and TDF and got 35 articles. From here, we isolated 29 articles that were completed and had results. We then focused on efficacy and safety, and retrieved nine articles.</p>
      <p>For AVAC, the initial search on PrEP and then clinical trials and product development yielded 38 articles; we then selected completed studies and obtained 14 articles. We then modified to focus on efficacy and safety and isolated eight articles. We then isolated 11 studies that appeared in all three search engines that satisfied our review requirements and used these for our review and discussion (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p>
    </sec>
    <sec id="Sec3" sec-type="results">
      <title>Results</title>
      <sec id="Sec4">
        <title>Clinical Trials Supporting the Use of PrEP</title>
        <p>Numerous trials involving both humans and animals have tested oral and vaginal routes of administration of PrEP and have been found efficacious in preventing HIV. The basis for PrEP stems from results of clinical and epidemiological research [<xref ref-type="bibr" rid="CR22">22</xref>–<xref ref-type="bibr" rid="CR25">25</xref>]. We reviewed 11 clinical trials on PrEP among different risk groups conducted from 2005 to 2015. These trials had results at the time of our study and allowed for review. Results from literature on PrEP studies are not necessarily universal. The efficacy ranges from lack of protection to protection levels of as high as 96%, attesting to the complex nature of PrEP implementation [<xref ref-type="bibr" rid="CR26">26</xref>]. Aside from the effectiveness of PrEP in most of the studies cited, the Vaginal and Oral Interventions to Control the Epidemic (VOICE) [<xref ref-type="bibr" rid="CR27">27</xref>] and Preexposure Prophylaxis Trial for HIV Prevention among African Women (FEM-PrEP) [<xref ref-type="bibr" rid="CR28">28</xref>] studies were terminated ahead of time because the analysis failed to demonstrate efficacy attributed to poor adherence. Results for the VOICE study differ with findings in three other placebo-controlled vaginal PrEP trials [Partners PrEP [<xref ref-type="bibr" rid="CR14">14</xref>], TDF2 [<xref ref-type="bibr" rid="CR17">17</xref>], Iniciativa Profilaxis Pre-Exposicion (iPrEx) and [<xref ref-type="bibr" rid="CR16">16</xref>] one placebo-controlled vaginal gel trial [Centre for AIDS program of Research in South Africa (CAPRISA 004)] [<xref ref-type="bibr" rid="CR18">18</xref>]. Partners PrEP [<xref ref-type="bibr" rid="CR14">14</xref>] studied Truvada<sup>®</sup> and TDF alone in HIV-discordant committed African couples, TDF2 [<xref ref-type="bibr" rid="CR17">17</xref>] studied heterosexual African women and men, iPrEx [<xref ref-type="bibr" rid="CR16">16</xref>] studied gay and bisexual men on four continents and CAPRISA 004 [<xref ref-type="bibr" rid="CR18">18</xref>] studied South African women. Poor adherence as in FEM-PrEP was the main reason for failure in all three VOICE arms. Among 334 women who became infected with HIV, 22 entered the trial with acute HIV infection. With their exclusion, HIV incidence was 5.7 per 100 person-years, meaning about 6 in every 100 women got infected in every 12 months. HIV incidence rates per 100 person-years were 6.3 and 4.2 for oral TDF vs. placebo, 4.7 and 4.6 for Truvada<sup>®</sup> vs. placebo, and 5.9 and 6.8 for TDF gel vs. placebo; therefore, none of the three strategies worked as hazard ratios (HRs) was for oral TDF: HR 1.49 [95% confidence interval (CI) 0.97–2.29], oral Truvada<sup>®</sup>: HR 1.04 (95% CI 0.73–1.49) and TDF gel: HR 0.85 (95% CI 0.6–1.2). In all cases, women reported 90–91% adherence with return data suggesting the same, but TDF concentrations in plasma told another story: 30% or fewer women in all three treatment arms had detectable concentrations in plasma: 30% in oral TDF, 29% in oral Truvada<sup>®</sup> and 25% using TDF gel. In all three again, 50% or more women never had detectable blood in any sample. Three factors predicted detectable TDF in plasma: first, being married (adjusted odds ratio = 2.24 [95% CI, 1.12–4.49]), the second being older than 25 years (adjusted odds ratio = 1.62 [95% CI, 1.12–2.34]), and the third being multiparous (adjusted odds ratio = 1.84 [95% CI, 1.26–2.69]).</p>
        <p>The FEM-PrEP [<xref ref-type="bibr" rid="CR28">28</xref>] study of 2120 participants reported 56 new HIV infections 14 months after initiation of the study with the infections equally distributed between Truvada<sup>®</sup> and placebo groups (28 in each arm), clearly indicating the lack of protection in the use of Truvada<sup>®</sup>. Overall adherence (based on participants self-report) was 95% with no clear difference in adherence between the two arms.</p>
        <p>These two results revealed that “products that are long acting and require minimum daily adherence may be more suitable for the population under study” contrary to positive results posted by the other findings, which suggest that young, sexually active, single people can be motivated to take oral Truvada<sup>®</sup> or TDF gel regularly enough to protect themselves from HIV. However, the CAPRISA 004 trial [<xref ref-type="bibr" rid="CR18">18</xref>] differed from the FEM-PrEP [<xref ref-type="bibr" rid="CR28">28</xref>] and VOICE [<xref ref-type="bibr" rid="CR27">27</xref>] studies by determining a 65% protection against HIV at a TDF concentration of &gt;100 ng/mL and up to 76% with a TDF concentration of &gt;1000 ng/mL. Results from Pre-exposure Prophylaxis to Prevent the Acquisition of HIV-1 Infection (PROUD) [<xref ref-type="bibr" rid="CR29">29</xref>] in the UK and Intervention Preventive de l’Exposition aux Risques avec Risques avec et pour les Gays (Ipergay) [<xref ref-type="bibr" rid="CR5">5</xref>] in France both showed that PrEP reduced infections among gay men by 86%. None of the participants on PrEP involved in these studies acquired HIV. PrEP was also found to be effective for heterosexual men and women: a study in East Africa (Partners) [<xref ref-type="bibr" rid="CR14">14</xref>] reduced possible HIV infection within couples in which one partner was positive by 75%. The iPrEx study also found that the HIV infection rate in HIV-negative gay men who were given a daily pill containing Truvada<sup>®</sup> was reduced by 44%, compared with men given placebo. Those who confirmed adherence at 90% had a reduction rate of up to 73%. The TDF2 trial in Botswana gave a reduction rate of 63% against placebo and 77.9% after secondary analysis; therefore, confirming the obvious benefit in the use of PrEP. The Bangkok Tenofovir Study [<xref ref-type="bibr" rid="CR30">30</xref>] focused on men and women who inject drugs and found that the risk of acquiring HIV reduced by 49% and up to 79% in those who adhered consistently to their medication. The study also found that participants taking TDF were more likely to experience nausea and or/vomiting than those in the placebo group. No indication of elevated creatinine or renal impairment in the TDF group was reported.</p>
        <p>The PrEP study in USA with 373 participants with 186 taking TDF and 187 taking placebo was successful with [<xref ref-type="bibr" rid="CR31">31</xref>] only four on placebo and three among the delayed-arm participants seroconverting. Estimated adherence by pill load was 92% and by medication event monitoring system was 77%. Oral TDF was well tolerated with no significant renal concerns, while adverse drug events reported did not differ significantly between TDF and placebo arms.</p>
        <p>Sensitivity analysis on oral PrEP demonstrated that both TDF/FTC and TDF are efficacious in the prevention of HIV infection for a variety of high-risk populations irrespective of country [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Both daily and intermittent dosing of PrEP have proven effective and safe [<xref ref-type="bibr" rid="CR15">15</xref>]. Pharmacokinetic modelling of the pre-exposure prophylaxis initiative (iPrEx) data revealed that a PrEP dose regimen of 7 days in the week dosing could achieve as high as 99% efficacy in the prevention of HIV infection among MSM. Additionally, an intermittent dosing of 4 days in the week could result in 96% efficacy [<xref ref-type="bibr" rid="CR15">15</xref>]. In a laboratory analysis, detectable blood concentrations of medications used for PrEP were consistently associated with a protective effect against HIV acquisition [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
      </sec>
      <sec id="Sec5">
        <title>Safety Concerns</title>
        <p>Adverse reactions to medications used for any intervention are undoubtedly a primary safety concern irrespective of the duration of use. A qualitative study of gay and bisexual sero-discordant male couples assessed the concerns for adoption of PrEP and revealed that the main concerns and probable barriers to adoption of PrEP were short- and long-term side effects or adverse effects due to intermittent dosing or early termination of drug use aside from cost and accessibility of the drugs [<xref ref-type="bibr" rid="CR34">34</xref>]. In this review, we acknowledge that the trials discussed are short term and do not give the opportunity to assess the long-term, real-world safety profile of the products used for PrEP. Pre-exposure prophylaxis is premised on ARV medications that have been used by people living with HIV and AIDS for quite some time now, since the inception of ARVs. We would expect based on current evidence that the long-term safety profile will be within acceptable limits with favourable benefit-risk profiles, considering the impact of PrEP on HIV prevention. Nonetheless, established adverse drug events such as renal impairment, reduction in BMD, and gastrointestinal (GI) disturbances captured in scientific literature concerning the use of TDF should be considered and monitoring is recommended in PrEP use. An earlier study by the same authors on the association between the occurrence of adverse drug events and the modification of first-line highly active antiretroviral therapy in Ghanaian patients established that adverse drug events play a major role in treatment modification and could be used as a predictor for possible therapy modification [<xref ref-type="bibr" rid="CR35">35</xref>].</p>
        <p>Other concerns on the use and implementation of PrEP include resistance to PrEP medications, feasibility, acceptability and very importantly adherence to PrEP regimens. Because of the importance of PrEP in reducing the spread of HIV, it is critical that these concerns are addressed and fears alleviated to allow for the promising potential of PrEP. The US Public Health Service recommended guidelines for the use of PrEP in 2014 [<xref ref-type="bibr" rid="CR21">21</xref>] and the CDC has interim guidelines for clinicians on the use of PrEP [<xref ref-type="bibr" rid="CR36">36</xref>]. Essential factors to be considered before using PrEP include a confirmed HIV-negative status with a normal renal function and a negative hepatitis B status [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Recipients of PrEP should be at high risk for HIV infection, receive behavioural and adherence counselling, and need to be tested on a minimum of a quarterly basis during follow-up to ensure they remain HIV negative [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p>
      </sec>
      <sec id="Sec6">
        <title>Adverse Effects</title>
        <p>The TDF/FTC (Truvada<sup>®</sup>) combination or TDF alone used for PrEP generally shows a tolerable profile. In most studies, the experienced side effects did not differ significantly from rates among participants taking placebo. The side effects or adverse events are basically of GIT origin and more prevalent at the start of use, but subside within a month of use. The GIT disturbances are generally upset abdominal pain, nausea, vomiting or diarrhoea. Other reported adverses events not of GIT origin are dizziness, headache, fatigue, weight loss, shortness of breath, cough, anxiety, fever or joint and muscle pain. In most studies, these side effects or adverse events did not differ significantly from rates among participants taking placebo.</p>
        <p>Risk factors in long-term use include age, duration of treatment with TDF, elevated baseline creatinine levels, and treatment with a protease inhibitor boosted with ritonavir combinations and among persons with African descent as against Caucasians [<xref ref-type="bibr" rid="CR37">37</xref>]. Side effects considered potentially serious in the daily use of Truvada<sup>®</sup> or TDF for PrEP are liver function problems, kidney damage, hypophosphatamia, proteinaemia or glucosuria, pancreatitis, bone thinning and lactic acidosis. Flu-like symptoms, hypertriglyceridemia, increased creatinine phosphokinase, unusual dreams and hyperpigmentation are associated with the use of FTC. The Partners PrEP safety trial [<xref ref-type="bibr" rid="CR14">14</xref>], the iPrEx [<xref ref-type="bibr" rid="CR16">16</xref>] and the Bangkok Tenofovir studies [<xref ref-type="bibr" rid="CR30">30</xref>] all recorded increased serum creatinine levels but analyses indicated that they were statistically insignificant compared with placebo. However, changes in estimated glomerular filtration rate were associated with a small but statistically significant decline in the estimated glomerular filtration rate, which was non-progressive and resolved with TDF discontinuation. The use of TDF alone is also associated with liver and pancreatic problems as well as depression [<xref ref-type="bibr" rid="CR38">38</xref>]. The iPrEx study found a modest effect on BMD reduction in men who participated in the study. The study compared changes in BMD between placebo group and study participants with blood concentrations of tenofovir diphosphate associated with 90% efficacy and use of two to three tablets per week. There was a decline of 1% in the hip and 1.8% in the spine by the end of the study in those with optimal TDF diphosphate concentrations but this reduced to normal levels after 1.5 years of stopping PrEP [<xref ref-type="bibr" rid="CR16">16</xref>]. The loss of BMD could lead to potential bone fractures and is a problem for TDF-based PrEP. This could be because of phosphate wasting. TDF/FTC was well tolerated with some nausea but little difference was observed between participants and those taking placebo (9 vs. 5%). No differences in severe (grade 3) or life-threatening (grade 4) adverse laboratory events were observed between the active and placebo groups [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
        <p>In the CAPRISA 004 study [<xref ref-type="bibr" rid="CR18">18</xref>], hepatic flare (defined as an event with an abrupt rise of alanine aminotransferase levels to more than five times the upper limit of normal) during chronic hepatitis B virus infection and considered to be the result of a human leukocyte antigen-1 restricted, cytotoxic T lymphocyte-mediated immune response against hepatitis B virus [<xref ref-type="bibr" rid="CR39">39</xref>] was observed for two hepatitis B carriers but this did not result in drug discontinuation. In the Partners-PrEP study [<xref ref-type="bibr" rid="CR14">14</xref>], there were no significant differences across the study arms with respect to serious adverse effects including the total of 1% deaths per arm.</p>
        <p>The US MSM safety trial [<xref ref-type="bibr" rid="CR31">31</xref>] presented no marked difference in the overall frequency of adverse events between TDF and placebo groups, but in a subset of men at a San Francisco site (<italic>n</italic> = 184), the use of TDF was associated with a small but statistically significant decrease in BMD at the femoral neck (1.1%) and total hip (0.8% decrease) but no bone fractures were detected. Rates of nausea and vomiting were higher among the TDF than among placebo recipients in the first 2 months in the Bangkok Tenofovir Study [<xref ref-type="bibr" rid="CR30">30</xref>] but not thereafter. The rates of adverse drug events, deaths or elevated creatinine were not different between the TDF and the placebo groups [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
        <p>Concerning the trials with questionable efficacy, the FEM-PrEP trial [<xref ref-type="bibr" rid="CR28">28</xref>] presented adverse drug events of nausea and vomiting, which were transient, and a mild elevation of liver enzymes was much more common with the TDF/FTC group than that of placebo group. No change in renal function was reported in either group. In the VOICE study [<xref ref-type="bibr" rid="CR27">27</xref>], a confirmed increase in creatinine levels was observed in the oral TDF/FTC group than in the oral placebo group. There were no significant differences between the active products and placebo groups for other safety outcomes [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
      </sec>
      <sec id="Sec7">
        <title>Resistance</title>
        <p>Generally, resistance to PrEP is rarely observed in seroconverters who are infected with HIV after randomisation. Participants who show resistance are more likely to be the result of circulating resistance and not necessarily, PrEP induced. In the PROUD trial, no one acquired resistance to TDF [<xref ref-type="bibr" rid="CR29">29</xref>]. Resistant virus reported in studies include one with TDF-resistant virus (K65R mutation) in a participant randomised to TDF and one with FTC-resistant virus (M184V mutation) in a participant randomised to FTC/TDF from the Partners-PrEP trial [<xref ref-type="bibr" rid="CR14">14</xref>]. They were found to be infected at randomisation. A rare TDF resistance mutation (K65N) was however reported in the TDF arm of the Partners-PrEP study after randomisation [<xref ref-type="bibr" rid="CR14">14</xref>]. In the TDF2 study, K65R, M184V and A62V resistance mutations occurred in one participant in the TDF/FTC group. The participant was later found to have had HIV infection at enrolment. The iPrEx study presented two of two men in the active group and one of eight in the placebo group with FTC-resistant virus. TDF/FTC resistant virus was detected in five women (one in the placebo group and four in the TDF/FTC group) in the FEM-PrEP study [<xref ref-type="bibr" rid="CR28">28</xref>]. Two women from the TDF/FTC group who were determined after enrolment to have had acute HIV infection at baseline had the virus with the M1841/V mutation associated with FTC resistance. One other woman also had the M1841/V mutation but acquired the HIV infection after enrolment. The development of a resistant mutation seems to be more common with FTC than TDF. Additional care must be deployed to ensure that PrEP use is not approved during the acute infection stage to prevent the development of resistance strains. An abstract authored by Knox et al. presented at the CROI 2016 conference in Boston, MA, USA titled “HIV-1 infection with multiclass resistance despite PrEP” provided evidence of breakthrough HIV infection irrespective of long-term adherence to FTC/TDF (monitored via clinical and pharmacokinetic data) and described a resistant strain irrespective of long-term adherence [<xref ref-type="bibr" rid="CR40">40</xref>]. It is described as the first such report and more efforts would be deployed to closely monitor the use of PrEP following this report.</p>
        <p>The other area of concern is sexual and reproductive health because women of childbearing age are prone to HIV infection and the use of PrEP in discordant relationships could be useful. The Partners PrEP and the FEM-PrEP studies showed that TDF based PrEP does not affect the effectiveness of hormonal contraception and neither does hormonal contraception affect PrEP efficacy [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. There were not significant differences in pregnancy related and infant adverse reaction including premature births, congenital anomalies and growth throughout the early years of life for infants born to women who received PrEP as against placebo in the Partners PrEP study. Therefore, PrEP is relatively safe to be used by women of child-bearing age [<xref ref-type="bibr" rid="CR14">14</xref>] though, like all medicines, its benefits should be weighed against any risks that it may pose in specific individuals.</p>
      </sec>
      <sec id="Sec8">
        <title>Feasibility and Acceptability</title>
        <p>Some research on behavioural tendencies has helped to determine adherence to PrEP, but few studies have assessed the acceptability and use of PrEP. Factors associated with intentions to use PrEP in a sample of men who have sex with men (MSM) in USA included the efficacy, costs and potential side effects of PrEP [<xref ref-type="bibr" rid="CR41">41</xref>]. Preliminary findings from the PrEP Safety trial showed that MSM attending the STD clinic in San Francisco had a high interest in taking PrEP. This trial also demonstrated feasibility of including PrEP in busy clinical settings, indicating that PrEP can be accessed at clinics providing HIV care management [<xref ref-type="bibr" rid="CR42">42</xref>]. Project PrEP, a study on the acceptability and feasibility of PrEP among young men who have sex with men, reported of high feasibility and acceptability of PrEP [<xref ref-type="bibr" rid="CR43">43</xref>]. The PROUD study also affirmed the feasibility of incorporating PrEP in routine activities of clinical settings [<xref ref-type="bibr" rid="CR29">29</xref>]. Acceptability of PrEP as demonstrated in a study among MSM and female sex workers in Nairobi and Mtwapa, Kenya, was also rated as high [<xref ref-type="bibr" rid="CR44">44</xref>]. Suggestions proposed in this study included how best to improve the pill characteristics to make it easy to take, how to reduce stigma and discrimination from other family members, certain barriers and facilitators to adhering to PrEP regimens such as lifestyles, dosing regimen and side effects were identified. Enhanced counselling and commitment to using the products also improved their ability to adhere to the regimens despite the challenges.</p>
        <p>Participants in all the listed studies were receptive to monthly HIV testing and counselling, risk reduction counselling, physical examinations and group-based intervention sessions. Participants were more likely to accept a daily pill compared with multiple daily pills administration, especially if they knew their partner was not infected [<xref ref-type="bibr" rid="CR43">43</xref>]. The Ipergay trial demonstrated that high-risk MSM who do not use condoms consistently, accepted on demand PrEP as a practical alternative to daily PrEP if its effective [<xref ref-type="bibr" rid="CR5">5</xref>]. A substudy of The Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking [<xref ref-type="bibr" rid="CR45">45</xref>] study involving 37 men in Harlem revealed scepticism and distrust by male partners and sometimes resulted in unwillingness of partners to engage in sex after learning about their PrEP use, thus pointing out how stigma and social barriers may impede adherence and therefore acceptability.</p>
      </sec>
      <sec id="Sec9">
        <title>Adherence</title>
        <p>Six clinical trials yielded PrEP efficacy estimates of 0–75% mostly because of differences in adherence among the studies [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Self-reported adherence to PrEP is unreliable as the initial clinical trials quickly established that blood drug concentrations sharply differ from perceived adherence claims. Effective counselling and other support measures are required in all persons who desire to use PrEP for HIV prevention.</p>
        <p>The iPrEx study [<xref ref-type="bibr" rid="CR16">16</xref>] clearly illustrated how adherence produced different outcomes in HIV-negative gay men who were given a daily pill of TDF and FDC and achieved a reduction rate of 44% as against men given a placebo. It was realised that subjects who by self-report and pill count took the drugs more than 90% of the time reduced the infection rate by 73% [<xref ref-type="bibr" rid="CR16">16</xref>]. Meanwhile, another interesting finding of the trial indicated that while 93% of trial subjects reported complete compliance, only 51% actually complied effectively when drug concentrations in blood were determined [<xref ref-type="bibr" rid="CR16">16</xref>]. The investigators concluded through calculations that a reduction in the risk of HIV infection could have been as much as 92% compared with placebo if the study subjects had complied totally [<xref ref-type="bibr" rid="CR16">16</xref>]. This confirms the importance of adherence as a major tool to be deployed in PrEP. The FEM-PrEP trial [<xref ref-type="bibr" rid="CR28">28</xref>], which was halted for futility, reported adherence by self-report and pill count as high, but plasma drug concentrations showed that only 15–26% of samples from HIV seroconverters had detectable concentrations of serum TDF and only 26–38% of non-seroconverting controls. This low level of adherence was recorded as 37% (Table <xref rid="Tab1" ref-type="table">1</xref>) by the researchers and this may have resulted in the inability to assess the protective effect of Truvada<sup>®</sup> in FEM-PrEP trial. This again points to the importance of ensuring adherence in PrEP management.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Abstract on clinical trials on pre-exposure prophylactic agents (tenofovir and emtricitabine)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Year</th><th align="left">Study design</th><th align="left">Study population</th><th align="left">Sample size</th><th align="left">Agent used</th><th align="left">Objective</th><th align="left">Outcome/results</th></tr></thead><tbody><tr><td align="left" rowspan="3">iPrEx trial [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td char="." align="char" rowspan="3">2010</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">MSM</td><td char="." align="char" rowspan="3">2499</td><td align="left" rowspan="3">TDF/FTC</td><td align="left">Effectiveness</td><td align="left">44%</td></tr><tr><td align="left">Safety</td><td align="left">Nausea; ↑serum creatinine</td></tr><tr><td align="left">Adherence</td><td align="left">51%</td></tr><tr><td align="left" rowspan="3">TDF2 [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td char="." align="char" rowspan="3">2012</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">Heterosexual adults</td><td char="." align="char" rowspan="3">1219</td><td align="left" rowspan="3">TDF/FTC</td><td align="left">Effectiveness</td><td align="left">62%</td></tr><tr><td align="left">Safety</td><td align="left">Dizziness; nausea; vomiting; ↓bone mineral density</td></tr><tr><td align="left">Adherence</td><td align="left">84%</td></tr><tr><td align="left" rowspan="3">Partners PrEP [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td char="." align="char" rowspan="3">2012</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">Heterosexual couples</td><td char="." align="char" rowspan="3">1013</td><td align="left" rowspan="3">TDF vs. TDF/FTC</td><td align="left">Effectiveness</td><td align="left">67% (TDF); 75% (TDF/FTC)</td></tr><tr><td align="left">Safety</td><td align="left">GIT; fatigue; neutropaenia; ↑serum creatinine; ↓phosphorous</td></tr><tr><td align="left">Adherence</td><td align="left">82%</td></tr><tr><td align="left" rowspan="3">VOICE [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td char="." align="char" rowspan="3">2015</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">Women of reproductive age</td><td char="." align="char" rowspan="3">3019</td><td align="left" rowspan="3">TDF vs. TDF/FTC</td><td align="left">Effectiveness</td><td align="left">−49% (TDF); −4% (TDF/FTC)</td></tr><tr><td align="left">Safety</td><td align="left">↑Serum creatinine</td></tr><tr><td align="left">Adherence</td><td align="left">28–29%</td></tr><tr><td align="left" rowspan="3">FEM-PrEP [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td char="." align="char" rowspan="3">2012</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">High-risk women</td><td char="." align="char" rowspan="3">2120</td><td align="left" rowspan="3">TDF/FTC</td><td align="left">Effectiveness</td><td align="left">6%</td></tr><tr><td align="left">Safety</td><td align="left">Nausea; vomiting; ↑ALT; hepatic and renal abnormalities</td></tr><tr><td align="left">Adherence</td><td align="left">37%</td></tr><tr><td align="left" rowspan="3">PROUD [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td char="." align="char" rowspan="3">2016</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">MSM</td><td char="." align="char" rowspan="3">545</td><td align="left" rowspan="3">TDF/FTC</td><td align="left">Effectiveness</td><td align="left">86%</td></tr><tr><td align="left">Safety</td><td align="left">Nausea; diarrhoea; abdominal pains; fatigue; headache; flu-like illness; sleep disturbance; ↑creatinine clearance</td></tr><tr><td align="left">Adherence</td><td align="left">86%</td></tr><tr><td align="left" rowspan="3">Ipergay [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td char="." align="char" rowspan="3">2015</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">MSM</td><td char="." align="char" rowspan="3">400</td><td align="left" rowspan="3">TDF/FTC</td><td align="left">Effectiveness</td><td align="left">86%</td></tr><tr><td align="left">Safety</td><td align="left">Abdominal pains; nausea; vomiting; diarrhoea</td></tr><tr><td align="left">Adherence</td><td align="left">43% optimal use; 25% suboptimal use by ACASI</td></tr><tr><td align="left" rowspan="3">ADAPT [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td char="." align="char" rowspan="3">2015</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">MSM; TGW</td><td char="." align="char" rowspan="3">179</td><td align="left" rowspan="3">TDF/FTC</td><td align="left">Effectiveness</td><td align="left">NR</td></tr><tr><td align="left">Safety</td><td align="left">Nausea; unintentional weight loss; ↑serum creatinine</td></tr><tr><td align="left">Adherence</td><td align="left">Daily, 79%; time driven, 63%; event driven, 53%</td></tr><tr><td align="left" rowspan="3">The Bangkok Tenofovir study [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td char="." align="char" rowspan="3">2013</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">Drug injectors</td><td char="." align="char" rowspan="3">2413</td><td align="left" rowspan="3">TDF</td><td align="left">Effectiveness</td><td align="left">48.9%</td></tr><tr><td align="left">Safety</td><td align="left">Nausea; vomiting</td></tr><tr><td align="left">Adherence</td><td align="left">83.8%</td></tr><tr><td align="left" rowspan="3">CAPRISA 004 trial [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td char="." align="char" rowspan="3">2013</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">Women of reproductive age</td><td char="." align="char" rowspan="3">889</td><td align="left" rowspan="3">TDF</td><td align="left">Effectiveness</td><td align="left">39%</td></tr><tr><td align="left">Safety</td><td align="left">↑Serum creatinine; anaemia; diarrhoea</td></tr><tr><td align="left">Adherence</td><td align="left">NR</td></tr><tr><td align="left" rowspan="3">PrEP safety trial [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td char="." align="char" rowspan="3">2013</td><td align="left" rowspan="3">Placebo-controlled RCT</td><td align="left" rowspan="3">MSM</td><td char="." align="char" rowspan="3">400</td><td align="left" rowspan="3">TDF</td><td align="left">Effectiveness</td><td align="left">NR</td></tr><tr><td align="left">Safety</td><td align="left">Back pain; ↓in bone mass density; Hypophosphatemia</td></tr><tr><td align="left">Adherence</td><td align="left">92% (pill count); 77% (MEMS)</td></tr></tbody></table><table-wrap-foot><p>
<italic>ACASI</italic> Audio Computer-Assisted Self-Interview Software, <italic>ADAPT</italic> Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking, <italic>ALT</italic> alanine transaminase, <italic>CAPRISA</italic> Centre for AIDS program of Research in South Africa, <italic>FEM PrEP</italic> Preexposure Prophylaxis Trial for HIV Prevention among African Women, <italic>FTC</italic> emtricitabine, <italic>Ipergay</italic> Intervention Preventive de l’Exposition aux Risques avec Risques avec et pour les Gays, <italic>iPrEX</italic> Iniciativa Profilaxis Pre-Exposicion, <italic>MEMS</italic> medication event monitoring system, <italic>MSM</italic> men who have sex with men, <italic>NR</italic> not reported, <italic>PrEP</italic> pre-exposure prophylaxis, <italic>PROUD</italic> Pre-exposure Prophylaxis to Prevent the Acquisition of HIV-1 Infection, <italic>RCT</italic> randomised controlled trial, <italic>TDF</italic> tenofovir, <italic>TGW</italic> trans-gender women, <italic>VOICE</italic> Vaginal and Oral Interventions to Control the Epidemic, ↑ increased, ↓ decreased</p></table-wrap-foot></table-wrap>
</p>
        <p>Liu et al. [<xref ref-type="bibr" rid="CR42">42</xref>], examined self-reported medication-taking experiences, facilitators and barriers of medication adherence among a geographically diverse online sample of HIV-uninfected MSM in US. Their multivariable analyses showed that age and sex were likely associated with adherence. In this study, 1480 men having sex with other men were surveyed, 806 (54%) of participants indicated regular taking of medicines, 80% of this number reported taking medicines for treatment whilst 55% said they take medicines for preventive purposes. The study also realised that men aged older than 25 years were more likely to report excellent adherence together with those who did not report any adherence barriers. Willingness to use PrEP was also associated with high likelihood of reporting perfect 30-day adherence. They listed factors that improved medication adherence as establishing a routine, keeping medication visible and using a pill-box. Forgetfulness, changes in usual routine, and being busy or away from home were listed as barriers to adherence [<xref ref-type="bibr" rid="CR42">42</xref>]. Counselling strategies to build pill-taking routines can help improve adherence to PrEP. Daily dosing are much more associated with a high level of adherence than post-coital use of PrEP, which is generally low [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
        <p>Following the approval of the use of PrEP in USA and Europe, reports on adherence have been claimed to be higher in recent trials and open label extensions as compared with the initial clinical trials. Explanations provided include available evidence of PrEP efficacy and individual motivations and reasons for taking PrEP [<xref ref-type="bibr" rid="CR46">46</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec10" sec-type="discussion">
      <title>Discussion</title>
      <p>The advent of PrEP is a promising turning point in the prevention of HIV among at-risk groups. TDF-based PrEP is recommended to prevent HIV infection in tandem with other preventive measures. From the trials reviewed, it is evident that PrEP is highly effective against HIV infection when taken as required. Most importantly, PrEP seems to be characterised by low adverse effects. Our current review shows a favourable pattern of adverse events for PrEP among eligible populations. Side effects can lead to a lack of compliance, resulting in low levels of adherence (frequency of medicine intake) to pill use. Some reported symptoms associated with the start of PrEP gradually resolve. Generally, even for some side effects listed as serious, such as kidney dysfunction, observed increases in the serum creatinine level return to normal after the discontinuation of PrEP. Tubular renal toxicity from PrEP is rare and active screening is not recommended. The same applies to the reduction of BMD after cessation in the use of TDF and therefore current evidence does not support constant X-ray monitoring at baseline before initiating PrEP and while taking TDF/FTC.</p>
      <p>Liver toxicity mentioned earlier in the findings was reported by the D.A.D. study, which looked at the use of antiretroviral therapy and the risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. It concluded among that alongside other antiretroviral agents, TDF is associated with an increased risk of end-stage liver disease among HIV-positive patients on long-term therapy. It also indicated that the unexpected viral hepatitis independent TDF association should be investigated further [<xref ref-type="bibr" rid="CR47">47</xref>]. The use of TDF-based PrEP is yet to present any case report involving serious hepatic complications. However, the regular monitoring of liver enzymes in PrEP uses would be helpful in preventing possible toxicities.</p>
      <p>The correspondent decrease in sexual risk behaviour among participants in the course of PrEP is very encouraging. This is attributed to behavioural intervention including sexual health counselling and the provision of condoms across the studies where applicable. Undoubtedly, behavioural interventions should be an integral part of PrEP.</p>
      <p>Because PrEP is meant for HIV-negative individuals, an important aspect of PrEP is the identification of people who are seroconverting [<xref ref-type="bibr" rid="CR14">14</xref>]. Preliminary testing methods, for example polymerase chain reaction that can diagnose people who are recently infected with HIV, are thus important but expensive. This will enable provision of treatment options instead of preventive interventions.</p>
      <p>Exclusion criteria that run across trials were the low level of creatinine clearance below 50 mL/min, some cases of hepatitis and evidence of bone fractures. People who do not qualify for PrEP but are at risk for HIV should be encouraged to adhere to good evidence-based sexual behavioural prevention practices including regular condom use. The reduction in rates of sex without condoms from 27 to 9% after 24 months of the Partners-PrEP trial [<xref ref-type="bibr" rid="CR14">14</xref>] is encouraging and shows that counselling and education on good sexual practices is complementary on HIV prevention. Several other studies [<xref ref-type="bibr" rid="CR48">48</xref>–<xref ref-type="bibr" rid="CR51">51</xref>], including studies conducted in West African women with TDF, also demonstrate a reduction in high-risk sexual behaviour with counselling during PrEP [<xref ref-type="bibr" rid="CR52">52</xref>]. TDF/FTC is the only medication with a label indication as PrEP against HIV infection, but new PrEP drugs and formulations are being considered for future trials (Maraviroc, intravaginal rings containing dapivirine and TDF) and long-acting injectables (rilpivirine, carbotegravir). These newer agents also present a good safety profile when used for the treatment of HIV infection, but use for PrEP purposes in HIV-uninfected persons is unknown as efficacy and clinical safety is yet to be established [<xref ref-type="bibr" rid="CR37">37</xref>]. A new formulation, tenofovir alafenamide that provides 90% lower plasma levels of TDF concentrations compared with standard TDF, has recently being approved by the FDA. It is claimed to have favourable renal and bone safety profile better than original TDF, unfortunately as at the time of this review efficacy and safety in PrEP has not been established in HIV-negative populations [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
    </sec>
    <sec id="Sec11" sec-type="conclusion">
      <title>Conclusion</title>
      <p>The medications currently studied for PrEP (TDF and FTC) are efficacious and seem to have a good safety profile within the average short period of 3 years studied. Emphasis on the use of additional prevention methods should be made alongside. The main adverse effects observed with PrEP are GI related and graded below 2 for severity. These are basically mild to moderate nausea, vomiting and diarrhea. Major concerns are renal, hepatic and bone toxicity, but these are transient and non-progressive and quickly resolved after discontinuation of TDF. Overall, the benefit-risk profiles of the products used for PrEP appear favourable.</p>
      <p>PrEP as an intervention to reduce HIV transmission appears to have a safe benefit-risk profile in clinical trials. It is recommended for widespread use but adherence monitoring and real-world safety surveillance are critical in the post-marketing phase to ensure that the benefits observed in clinical trials are maintained in real-world use. Behavioural counselling and assurance of safety and efficacy are important components of PrEP. Other factors of PrEP implementation that have been suggested include improving access, averting stigma, cost effectiveness, and education on PrEP to improve knowledge and assure people of the efficacy profile of products used for PrEP. Further studies must ultimately look at how safe and beneficial PrEP could be for pregnant women and women seeking to get pregnant.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Authors’ contributions</title>
      <p>The authors, RAT, ANOD, BAY and ETN worked on the conception, study design and the final article composition. RAT, ETN, BAY, ML, HGML and ANOD contributed to the methods, results and its continuous critical review. BAY, RAT, ETN, ML, ANOD and HGML worked on the data analysis, discussions and critical revisions. All the authors read and approved the final manuscript.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with Ethical Standards</title>
      <sec id="FPar2">
        <title>Funding</title>
        <p>No sources of funding were used to assist in the preparation of this review.</p>
      </sec>
      <sec id="FPar3">
        <title>Conflict of interest</title>
        <p>Raymond A. Tetteh, Barbara A. Yankey, Edmund T. Nartey, Margaret Lartey, Hubert G.M. Leufkens, and Alexander N.O. Dodoo have no conflicts of interest that are directly relevant to the content of this review.</p>
      </sec>
      <sec id="FPar4">
        <title>Ethics approval</title>
        <p>Ethical approval for the study was not obtained as it was a review of published work.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">UNAIDS. 2015 facts sheet. Geneva: WHO; 2016. <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/sites/default/files/media_asset/20150901_FactSheet_2015_en.pdf">http://www.unaids.org/sites/default/files/media_asset/20150901_FactSheet_2015_en.pdf</ext-link>. Accessed 3 June 2016.</mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinhardt</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Carey</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Bickham</surname>
              <given-names>NL</given-names>
            </name>
          </person-group>
          <article-title>Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985–1997</article-title>
          <source>Am J Public Health</source>
          <year>1999</year>
          <volume>89</volume>
          <issue>9</issue>
          <fpage>1397</fpage>
          <lpage>1405</lpage>
          <pub-id pub-id-type="doi">10.2105/AJPH.89.9.1397</pub-id>
          <?supplied-pmid 10474559?>
          <pub-id pub-id-type="pmid">10474559</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Castilla</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Del Romero</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hernando</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV</article-title>
          <source>J Acquir Immune Defic Syndr</source>
          <year>2005</year>
          <volume>40</volume>
          <issue>1</issue>
          <fpage>96</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="doi">10.1097/01.qai.0000157389.78374.45</pub-id>
          <?supplied-pmid 16123689?>
          <pub-id pub-id-type="pmid">16123689</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirby</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Thornber-Dunwell</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Uptake of PrEP for HIV slow among MSM</article-title>
          <source>Lancet</source>
          <year>2014</year>
          <volume>383</volume>
          <issue>9915</issue>
          <fpage>399</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60137-9</pub-id>
          <?supplied-pmid 24494225?>
          <pub-id pub-id-type="pmid">24494225</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Molina</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Capitant</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Spire</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>On-demand preexposure prophylaxis in men at high risk for HIV-1 infection</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>373</volume>
          <issue>23</issue>
          <fpage>2237</fpage>
          <lpage>2246</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1506273</pub-id>
          <?supplied-pmid 26624850?>
          <pub-id pub-id-type="pmid">26624850</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holmes</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>FDA paves the way for pre-exposure HIV prophylaxis</article-title>
          <source>Lancet</source>
          <year>2012</year>
          <volume>380</volume>
          <issue>9839</issue>
          <fpage>325</fpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(12)61235-5</pub-id>
          <?supplied-pmid 22852138?>
          <pub-id pub-id-type="pmid">22852138</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="other">US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. Silver Spring, Maryland: US Food and Drug Administration. 2012.</mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="other">Centres for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States. Atlanta, Georgia: Centres for Disease Control and Prevention. 2014.</mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="other">World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015. ISBN: 9789241509565. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/">http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/</ext-link>. Accessed 6 June 2016.</mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Underhill</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Operario</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Skeer</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice</article-title>
          <source>J Acquir Immune Defic Syndr</source>
          <year>2010</year>
          <volume>55</volume>
          <issue>1</issue>
          <fpage>8</fpage>
          <pub-id pub-id-type="doi">10.1097/QAI.0b013e3181e8efe4</pub-id>
          <?supplied-pmid 21423876?>
          <pub-id pub-id-type="pmid">21423876</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arnold</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Hazelton</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection</article-title>
          <source>PLoS One</source>
          <year>2012</year>
          <volume>7</volume>
          <issue>7</issue>
          <fpage>e40603</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0040603</pub-id>
          <?supplied-pmid 22792384?>
          <pub-id pub-id-type="pmid">22792384</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Louissaint</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Y-J</given-names>
            </name>
            <name>
              <surname>Skipper</surname>
              <given-names>PL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue</article-title>
          <source>AIDS Res Hum Retrovir</source>
          <year>2013</year>
          <volume>29</volume>
          <issue>11</issue>
          <fpage>1443</fpage>
          <lpage>1450</lpage>
          <pub-id pub-id-type="doi">10.1089/aid.2013.0044</pub-id>
          <?supplied-pmid 23600365?>
          <pub-id pub-id-type="pmid">23600365</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Kiser</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Gardner</surname>
              <given-names>EM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection</article-title>
          <source>J Antimicrob Chemother</source>
          <year>2011</year>
          <volume>66</volume>
          <issue>2</issue>
          <fpage>240</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="doi">10.1093/jac/dkq447</pub-id>
          <?supplied-pmid 21118913?>
          <pub-id pub-id-type="pmid">21118913</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baeten</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Donnell</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ndase</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antiretroviral prophylaxis for HIV prevention in heterosexual men and women</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>367</volume>
          <issue>5</issue>
          <fpage>399</fpage>
          <lpage>410</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1108524</pub-id>
          <?supplied-pmid 22784037?>
          <pub-id pub-id-type="pmid">22784037</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kibengo</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Ruzagira</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Katende</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <issue>9</issue>
          <fpage>e74314</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0074314</pub-id>
          <?supplied-pmid 24086333?>
          <pub-id pub-id-type="pmid">24086333</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grant</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Lama</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>PL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Preexposure chemoprophylaxis for HIV prevention in men who have sex with men</article-title>
          <source>N Engl J Med</source>
          <year>2010</year>
          <volume>363</volume>
          <issue>27</issue>
          <fpage>2587</fpage>
          <lpage>2599</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1011205</pub-id>
          <?supplied-pmid 21091279?>
          <pub-id pub-id-type="pmid">21091279</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thigpen</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Kebaabetswe</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Paxton</surname>
              <given-names>LA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>367</volume>
          <issue>5</issue>
          <fpage>423</fpage>
          <lpage>434</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1110711</pub-id>
          <?supplied-pmid 22784038?>
          <pub-id pub-id-type="pmid">22784038</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sokal</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Karim</surname>
              <given-names>QA</given-names>
            </name>
            <name>
              <surname>Sibeko</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 trial</article-title>
          <source>Antivir Ther.</source>
          <year>2013</year>
          <volume>18</volume>
          <issue>3</issue>
          <fpage>301</fpage>
          <lpage>310</lpage>
          <pub-id pub-id-type="doi">10.3851/IMP2311</pub-id>
          <?supplied-pmid 22914267?>
          <pub-id pub-id-type="pmid">22914267</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Thigpen</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Nesheim</surname>
              <given-names>SR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults</article-title>
          <source>MMWR Morb Mortal Wkly Rep</source>
          <year>2012</year>
          <volume>61</volume>
          <issue>31</issue>
          <fpage>586</fpage>
          <lpage>589</lpage>
          <pub-id pub-id-type="pmid">22874836</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Grant</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Weidle</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men</article-title>
          <source>MMWR Morb Mortal Wkly Rep</source>
          <year>2011</year>
          <volume>60</volume>
          <issue>3</issue>
          <fpage>65</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">21270743</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="other">CDC. Control CfD, prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States–2014: a clinical practice guideline. Atlanta (GA): CDC; 2014.</mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Celum</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection</article-title>
          <source>J Infect Dis</source>
          <year>2005</year>
          <volume>191</volume>
          <issue>Suppl. 1</issue>
          <fpage>S107</fpage>
          <lpage>S114</lpage>
          <pub-id pub-id-type="doi">10.1086/425272</pub-id>
          <?supplied-pmid 15627220?>
          <pub-id pub-id-type="pmid">15627220</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Derdelinckx</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Wainberg</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection</article-title>
          <source>PLoS Med.</source>
          <year>2006</year>
          <volume>3</volume>
          <issue>11</issue>
          <fpage>e454</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pmed.0030454</pub-id>
          <?supplied-pmid 17090213?>
          <pub-id pub-id-type="pmid">17090213</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Grant</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Buchbinder</surname>
              <given-names>SP</given-names>
            </name>
          </person-group>
          <article-title>Preexposure prophylaxis for HIV: unproven promise and potential pitfalls</article-title>
          <source>JAMA</source>
          <year>2006</year>
          <volume>296</volume>
          <issue>7</issue>
          <fpage>863</fpage>
          <lpage>865</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.296.7.863</pub-id>
          <?supplied-pmid 16905792?>
          <pub-id pub-id-type="pmid">16905792</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardo</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Culver</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Ciesielski</surname>
              <given-names>CA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case-control study of HIV seroconversion in health care workers after percutaneous exposure</article-title>
          <source>N Engl J Med</source>
          <year>1997</year>
          <volume>337</volume>
          <issue>21</issue>
          <fpage>1485</fpage>
          <lpage>1490</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199711203372101</pub-id>
          <?supplied-pmid 9366579?>
          <pub-id pub-id-type="pmid">9366579</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cohen</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Baden</surname>
              <given-names>LR</given-names>
            </name>
          </person-group>
          <article-title>Preexposure prophylaxis for HIV: where do we go from here?</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>367</volume>
          <issue>5</issue>
          <fpage>459</fpage>
          <lpage>461</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMe1207438</pub-id>
          <?supplied-pmid 22784041?>
          <pub-id pub-id-type="pmid">22784041</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marrazzo</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ramjee</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Richardson</surname>
              <given-names>BA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tenofovir-based preexposure prophylaxis for HIV infection among African women</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>372</volume>
          <issue>6</issue>
          <fpage>509</fpage>
          <lpage>518</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1402269</pub-id>
          <?supplied-pmid 25651245?>
          <pub-id pub-id-type="pmid">25651245</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Damme</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Corneli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Preexposure prophylaxis for HIV infection among African women</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>367</volume>
          <issue>5</issue>
          <fpage>411</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1202614</pub-id>
          <?supplied-pmid 22784040?>
          <pub-id pub-id-type="pmid">22784040</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCormack</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dunn</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial</article-title>
          <source>Lancet</source>
          <year>2016</year>
          <volume>387</volume>
          <issue>10013</issue>
          <fpage>53</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(15)00056-2</pub-id>
          <?supplied-pmid 26364263?>
          <pub-id pub-id-type="pmid">26364263</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choopanya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suntharasamai</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial</article-title>
          <source>Lancet</source>
          <year>2013</year>
          <volume>381</volume>
          <issue>9883</issue>
          <fpage>2083</fpage>
          <lpage>2090</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(13)61127-7</pub-id>
          <?supplied-pmid 23769234?>
          <pub-id pub-id-type="pmid">23769234</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grohskopf</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Chillag</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Gvetadze</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States</article-title>
          <source>J Acquir Immune Defic Syndr</source>
          <year>2013</year>
          <volume>64</volume>
          <issue>1</issue>
          <fpage>79</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="doi">10.1097/QAI.0b013e31828ece33</pub-id>
          <?supplied-pmid 23466649?>
          <pub-id pub-id-type="pmid">23466649</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paltiel</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Freedberg</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>CA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness</article-title>
          <source>Clin Infect Dis</source>
          <year>2009</year>
          <volume>48</volume>
          <issue>6</issue>
          <fpage>806</fpage>
          <lpage>815</lpage>
          <pub-id pub-id-type="doi">10.1086/597095</pub-id>
          <?supplied-pmid 19193111?>
          <pub-id pub-id-type="pmid">19193111</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van der Straten</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Van Damme</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Haberer</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Bangsberg</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention</article-title>
          <source>AIDS.</source>
          <year>2012</year>
          <volume>26</volume>
          <issue>7</issue>
          <fpage>F13</fpage>
          <lpage>F19</lpage>
          <pub-id pub-id-type="doi">10.1097/QAD.0b013e3283522272</pub-id>
          <?supplied-pmid 22333749?>
          <pub-id pub-id-type="pmid">22333749</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brooks</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Lieber</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships</article-title>
          <source>AIDS Care.</source>
          <year>2011</year>
          <volume>23</volume>
          <issue>9</issue>
          <fpage>1136</fpage>
          <lpage>1145</lpage>
          <pub-id pub-id-type="doi">10.1080/09540121.2011.554528</pub-id>
          <?supplied-pmid 21476147?>
          <pub-id pub-id-type="pmid">21476147</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tetteh</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Nartey</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Lartey</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association between the occurrence of adverse drug events and modification of first-line highly active antiretroviral therapy in Ghanaian HIV patients</article-title>
          <source>Drug Saf</source>
          <year>2016</year>
          <volume>39</volume>
          <issue>11</issue>
          <fpage>1139</fpage>
          <lpage>1149</lpage>
          <pub-id pub-id-type="doi">10.1007/s40264-016-0460-7</pub-id>
          <?supplied-pmid 27638659?>
          <pub-id pub-id-type="pmid">27638659</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Thigpen</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Nesheim</surname>
              <given-names>SR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults</article-title>
          <source>Morb Mortal Wkly Rep</source>
          <year>2012</year>
          <volume>61</volume>
          <issue>31</issue>
          <fpage>586</fpage>
          <lpage>589</lpage>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mugwanya</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Baeten</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention</article-title>
          <source>Exp Opin Drug Saf.</source>
          <year>2016</year>
          <volume>15</volume>
          <issue>2</issue>
          <fpage>265</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="doi">10.1517/14740338.2016.1128412</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <mixed-citation publication-type="other">Grant RM, van Griensven F. The ADAPT Study: A Phase II, Randomised, Open-Label, Pharmacokinetic and Behavioural Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP). United States: DAIDS. 2011.</mixed-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Liaw</surname>
              <given-names>YF</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management</article-title>
          <source>J Hepatol</source>
          <year>2014</year>
          <volume>61</volume>
          <issue>6</issue>
          <fpage>1407</fpage>
          <lpage>1417</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jhep.2014.08.033</pub-id>
          <?supplied-pmid 25178562?>
          <pub-id pub-id-type="pmid">25178562</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <mixed-citation publication-type="other">Knox D, Tan D, Harrigan R, Anderson P, editors. HIV-1 infection with multiclass resistance despite pre-exposure prophylaxis (PrEP). CROI Conference: Boston (MA); 22–25 Feb 2016.</mixed-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mimiaga</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Case</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>CV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education</article-title>
          <source>J Acquir Immune Defic Syndr</source>
          <year>2009</year>
          <volume>50</volume>
          <issue>1</issue>
          <fpage>77</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1097/QAI.0b013e31818d5a27</pub-id>
          <?supplied-pmid 19295337?>
          <pub-id pub-id-type="pmid">19295337</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Follansbee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cohan</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco</article-title>
          <source>PLoS Med.</source>
          <year>2014</year>
          <volume>11</volume>
          <issue>3</issue>
          <fpage>e1001613</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pmed.1001613</pub-id>
          <?supplied-pmid 24595035?>
          <pub-id pub-id-type="pmid">24595035</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <mixed-citation publication-type="other">Hosek S, Siberry G, Bell M, et al. Project PrEPare (ATN082): the acceptability and feasibility of an HIV pre-exposure prophylaxis (PrEP) trial with young men who have sex with men (YMSM). J Acquir Immune Defic Syndr. 2013;62(4). doi:10.1097/QAI.0b013e3182801081.</mixed-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van der Elst</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Mbogua</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Operario</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya</article-title>
          <source>AIDS Behav</source>
          <year>2013</year>
          <volume>17</volume>
          <issue>6</issue>
          <fpage>2162</fpage>
          <lpage>2172</lpage>
          <pub-id pub-id-type="doi">10.1007/s10461-012-0317-8</pub-id>
          <?supplied-pmid 23080358?>
          <pub-id pub-id-type="pmid">23080358</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <mixed-citation publication-type="other">Bekker J, Hughes J, Amico R, et al. HPTN 067/ADAPT Cape Town: a comparison of daily and nondaily PrEP dosing in African women. CROI 2015. Seattle (WA): The HIV Prevention Trials Network; 2015.</mixed-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haberrer</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice</article-title>
          <source>Curr Opin HIV AIDS.</source>
          <year>2016</year>
          <volume>11</volume>
          <issue>1</issue>
          <fpage>10</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1097/COH.0000000000000220</pub-id>
          <pub-id pub-id-type="pmid">26633638</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ryom</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lundgren</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>De Wit</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons</article-title>
          <source>AIDS.</source>
          <year>2016</year>
          <volume>30</volume>
          <issue>11</issue>
          <fpage>1731</fpage>
          <lpage>1743</lpage>
          <pub-id pub-id-type="doi">10.1097/QAD.0000000000001018</pub-id>
          <?supplied-pmid 26752282?>
          <pub-id pub-id-type="pmid">26752282</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marcus</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Glidden</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>KH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <issue>12</issue>
          <fpage>e81997</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0081997</pub-id>
          <?supplied-pmid 24367497?>
          <pub-id pub-id-type="pmid">24367497</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guest</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Shattuck</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Changes in sexual risk behavior among participants in a PrEP HIV prevention trial</article-title>
          <source>Sex Transm Dis</source>
          <year>2008</year>
          <volume>35</volume>
          <issue>12</issue>
          <fpage>1002</fpage>
          <lpage>1008</lpage>
          <?supplied-pmid 19051397?>
          <pub-id pub-id-type="pmid">19051397</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brooks</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Landovitz</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>RL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study</article-title>
          <source>AIDS Patient Care STDS.</source>
          <year>2012</year>
          <volume>26</volume>
          <issue>2</issue>
          <fpage>87</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="doi">10.1089/apc.2011.0283</pub-id>
          <?supplied-pmid 22149764?>
          <pub-id pub-id-type="pmid">22149764</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mimiaga</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Case</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>CV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education</article-title>
          <source>J Acquir Immun Defic Syndr.</source>
          <year>2009</year>
          <volume>50</volume>
          <issue>1</issue>
          <fpage>77</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1097/QAI.0b013e31818d5a27</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peterson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Roddy</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial</article-title>
          <source>PLoS Clin Trials.</source>
          <year>2007</year>
          <volume>2</volume>
          <issue>5</issue>
          <fpage>e27</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pctr.0020027</pub-id>
          <?supplied-pmid 17525796?>
          <pub-id pub-id-type="pmid">17525796</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362650</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Scientometrics</journal-id>
      <journal-id journal-id-type="iso-abbrev">Scientometrics</journal-id>
      <journal-title-group>
        <journal-title>Scientometrics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0138-9130</issn>
      <publisher>
        <publisher-name>Springer Netherlands</publisher-name>
        <publisher-loc>Dordrecht</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362650</article-id>
      <article-id pub-id-type="pmcid">PMC5362650</article-id>
      <article-id pub-id-type="pmc-uid">5362650</article-id>
      <article-id pub-id-type="publisher-id">2257</article-id>
      <article-id pub-id-type="doi">10.1007/s11192-017-2257-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A first look at multiple institutional affiliations: a study of authors in Germany, Japan and the UK</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Hottenrott</surname>
            <given-names>Hanna</given-names>
          </name>
          <address>
            <email>hanna.hottenrott@tum.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lawson</surname>
            <given-names>Cornelia</given-names>
          </name>
          <address>
            <email>c.lawson@bath.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000123222966</institution-id><institution-id institution-id-type="GRID">grid.6936.a</institution-id><institution>TUM School of Management, </institution><institution>Technische Universität München, </institution></institution-wrap>Arcisstraße 21, 80333 Munich, Germany </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0492 4665</institution-id><institution-id institution-id-type="GRID">grid.13414.33</institution-id><institution/><institution>Centre for European Economic Research (ZEW), </institution></institution-wrap>Mannheim, Germany </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0668 7884</institution-id><institution-id institution-id-type="GRID">grid.5596.f</institution-id><institution>Department of Managerial Economics, Strategy and Innovation, </institution><institution>K.U. Leuven, </institution></institution-wrap>Leuven, Belgium </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2162 1699</institution-id><institution-id institution-id-type="GRID">grid.7340.0</institution-id><institution>School of Management, </institution><institution>University of Bath, </institution></institution-wrap>Quarry Rd, Bath, BA2 7AY UK </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1756 2683</institution-id><institution-id institution-id-type="GRID">grid.454290.e</institution-id><institution>BRICK, </institution><institution>Collegio Carlo Alberto, </institution></institution-wrap>Moncalieri (TO), Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>28</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>111</volume>
      <issue>1</issue>
      <fpage>285</fpage>
      <lpage>295</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>8</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>This study sheds light on the unexplored phenomenon of multiple institutional affiliations using scientific publications. Institutional affiliations are important in the organisation and governance of science. Multiple affiliations may alter the traditional framework of academic employment and careers and may require a reappraisal of institutional assessment based on research outcomes of affiliated staff. Results for authors in three major science and technology nations (Germany, Japan and the UK) and in three fields (biology, chemistry, and engineering) show that multiple affiliations have at least doubled over the past few years. The analysis proposes three major types of multiple affiliations that depend on the structure of the research sector and its international openness. Highly internationalised and higher education-centred affiliations are most common for researchers in the UK whereas Germany and Japan have stronger cross-sector affiliation patterns. International multiple affiliations are, however, still more common in Germany compared to Japan which is characterised by a domestic, cross-sector affiliation distribution. Moreover, multiple affiliation authors are more often found on high impact papers, particularly in the case of authors from Japan and Germany in the fields of biology and chemistry.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>SCI</kwd>
        <kwd>Multiple affiliations</kwd>
        <kwd>Dual appointment</kwd>
        <kwd>International collaboration</kwd>
        <kwd>Science-industry collaboration</kwd>
        <kwd>High-impact research</kwd>
      </kwd-group>
      <kwd-group xml:lang="--">
        <title>JEL Classification</title>
        <kwd>I23</kwd>
        <kwd>J45</kwd>
        <kwd>O30</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id>
              <institution>Deutsche Forschungsgemeinschaft</institution>
            </institution-wrap>
          </funding-source>
          <award-id>HO5390/1-1</award-id>
          <principal-award-recipient>
            <name>
              <surname>Hottenrott</surname>
              <given-names>Hanna</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id>
              <institution>Japan Society for the Promotion of Science</institution>
            </institution-wrap>
          </funding-source>
          <award-id>PE15033</award-id>
          <principal-award-recipient>
            <name>
              <surname>Lawson</surname>
              <given-names>Cornelia</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003484</institution-id>
              <institution>Heinrich-Heine-Universität Düsseldorf</institution>
            </institution-wrap>
          </funding-source>
          <award-id>SFF-F2014/626-15</award-id>
          <principal-award-recipient>
            <name>
              <surname>Hottenrott</surname>
              <given-names>Hanna</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000837</institution-id>
              <institution>University of Nottingham</institution>
            </institution-wrap>
          </funding-source>
          <award-id>ICF</award-id>
          <principal-award-recipient>
            <name>
              <surname>Lawson</surname>
              <given-names>Cornelia</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Akadémiai Kiadó, Budapest, Hungary 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Recent literature has emphasised the importance of intra- as well as inter-institutional collaborations for academic research, which has been documented by the increase in team sizes and cross-institutional collaborations on co-authored papers (Adams et al. <xref ref-type="bibr" rid="CR1">2005</xref>; Wuchty et al. <xref ref-type="bibr" rid="CR18">2007</xref>; Jones et al. <xref ref-type="bibr" rid="CR8">2008</xref>). In this academic environment that promotes collaboration and mobility (Fernandez-Zubieta et al. <xref ref-type="bibr" rid="CR6">2016</xref>), multiple affiliations are increasingly recognised as facilitating knowledge exchange (ESF <xref ref-type="bibr" rid="CR5">2013</xref>) and have been said to become more widespread (Enders and Musselin <xref ref-type="bibr" rid="CR4">2008</xref>). Nonetheless, to date there has been little systematic assessment of the extent and patterns of these multiple affiliations, primarily due to the lack of sufficient bibliometric data which would allow for determining such links (Katz and Martin <xref ref-type="bibr" rid="CR11">1997</xref>).</p>
      <p>There are several factors that may contribute to multiple affiliations. Individual scientists may seek affiliations to gain access to additional research resources or networks, as affiliation to an institution is closely linked to resource access, research infrastructure and career opportunities (Long <xref ref-type="bibr" rid="CR14">1978</xref>; Long and McGuinnis <xref ref-type="bibr" rid="CR15">1981</xref>; Fox <xref ref-type="bibr" rid="CR7">1983</xref>; Stephan <xref ref-type="bibr" rid="CR17">2012</xref>), but may also be motivated by personal financial benefits (Stephan <xref ref-type="bibr" rid="CR17">2012</xref>). While co-authorship can be an effective way of expanding a research group’s competencies, co-affiliation may constitute a way of forming stronger ties between researchers and institutions (ESF <xref ref-type="bibr" rid="CR5">2013</xref>). Lander (<xref ref-type="bibr" rid="CR12">2015</xref>) for instance, found some evidence that in the case of infection and immunity researchers in Canada multiple affiliations facilitate co-authorship. Co-affiliation may also reduce the (administrative) burden of using an institution’s research infrastructure compared to collaboration through co-authorship alone. Furthermore, researchers may seek additional affiliations to increase the visibility and geographic reach of their work, especially if they are placed in more peripheral regions or institutions.</p>
      <p>On the institutional side, performance assessments have led universities across the globe to become more proactive in attracting the most prolific researchers in a bid to enhance their position in national and international rankings (Stephan <xref ref-type="bibr" rid="CR17">2012</xref>). Offering the option of additional affiliations to the most able researchers in a field may provide institutions with access to ‘frontline’ researchers (ESF <xref ref-type="bibr" rid="CR5">2013</xref>). For example, universities in China and Saudi Arabia created special part-time positions to attract leading foreign scholars to enhance their prestige and ranking, which saw an increase in papers from both countries, but with science that did not always originate there (Xin and Normile <xref ref-type="bibr" rid="CR19">2006</xref>; Bhattacharjee <xref ref-type="bibr" rid="CR2">2011</xref>). Affiliations are also offered by past employers in an effort to maintain links with alumni employees and may therefore constitute a direct consequence of increased mobility. Public, non-profit and private sector research centres moreover offer affiliations in order to foster mobility and facilitate research collaborations and knowledge exchange with the academic sector (ESF <xref ref-type="bibr" rid="CR5">2013</xref>).</p>
      <p>The drivers (such as resource access, personal finances or institutional competition) and implications (such as collaboration or research advancement) of multiple affiliations likely differ by the type of affiliation under consideration, as well as by the institutional contexts in which these affiliations form. Thus, for any assessment of their potential implications, one first requires a better understanding of the forms that multiple affiliations take and how they differ between disciplines and countries with distinct science governance structures.</p>
      <p>Addressing the current lack of evidence regarding multiple affiliations, this study proposes an analysis of institutional affiliations based on scientific publications that makes use of a new author-institution tag available in Web of Science (WoS) since 2008. The new tag allows us to unambiguously link authors to their institutions and to determine whether an author has multiple affiliations.<xref ref-type="fn" rid="Fn1">1</xref> We then analyse the types of multiple affiliations in terms of cross-sector and cross-country affiliations. Further, incorporating citation data we investigate the link between multiple affiliations and publication impact. Looking at authors in Germany, Japan and the UK (thus straddling three major science and technology nations) and in three fields (biology, chemistry, and engineering), our results demonstrate that multiple affiliations have increased over the past few years. Yet, the types of multiple affiliations depend on the structure of the research sector and its international openness.</p>
      <p>While this analysis can only provide a first look at the extent and structure of multiple affiliations, we anticipate the findings will encourage more research into their contractual and organisational nature. We also hope to spur discussion regarding academic employment and affiliations that no longer require the day-to-day commitment of academics, with implications for institutional assessment (currently based on research outcomes of affiliated staff) and the funding of academic research, both nationally and internationally.</p>
    </sec>
    <sec id="Sec2">
      <title>Data and methods</title>
      <p>The data used in this study are author-institution pairs retrieved from Web of Science. First we select a set of journals based on the 2013 journal citation report (JCR, Thomson Reuters) in three fields: bioscience, chemistry, and engineering. Journals listed in the JCR are sorted by <italic>eigenfactor</italic> score, a rating of journal importance based on the number of incoming, journal-impact-weighted citations, that enables us to consider journals across all quality spectra. The bottom 50% of the <italic>eigenfactor</italic> distribution is discarded as they represent primarily national journals of little importance within the field. The remaining journals are split into four quartiles of the <italic>eigenfactor</italic> distribution for each scientific field and five journals are randomly drawn from each quartile, thus obtaining three samples of 20 journals by field, stratified by <italic>eigenfactor</italic> score. For each journal we check on a subsample of articles whether addresses are correctly listed and we drop and replace journals with any address inconsistencies. Documents published in each of the selected journals and with an address in one of the three selected countries (Germany, Japan and the UK) are downloaded from WoS for the years 2008–2014. The retrieval relies on author addresses as listed in WoS. Overall, we consider records of 13,827 bioscience articles, 12,155 chemistry articles and 5274 engineering articles.</p>
      <p>Each author on the selected publications is attributed one or more institution based on the [C1] author address field in WoS. The [C1] field provides address information separately for each author and lists more than one address per author where this occurs. We split each publication record by author and address to build a table with author-institution lines. These author-institution records are checked for any address inconsistencies, i.e. whether address information is missing for one or more authors. Publications that do not report addresses for all their authors are excluded. The number of excluded publications is 1351, or 3.8% of all publications.</p>
      <p>Only authors with at least one address in Germany, Japan or the UK are retained. In total we identify 36,035 authors with an address in Germany, 57,604 with an address in Japan, and 31,648 with an address in the UK. It is important to note that this study does not attempt to disambiguate author names and the same author can appear in the data multiple times. As the goal is to provide an application of the [C1] field for measuring multiple affiliations and to gain first insights and identify general trends, no author disambiguation was performed. However, results are robust to the deletion of all repeated names within one subject area and year, or to the deletion of all duplicate names in general.</p>
      <p>All addresses appearing in the data are coded by institution type and country. In doing so, each institution is assigned a unique code to ensure that multiple addresses are truly different and to exclude multiple affiliations ‘within’ the same institution. The coding was undertaken semi-manually, meaning that a search algorithm first identified address entries containing word elements such as “UNIV” and marked these as universities. All entries were then checked manually and organisation names searched online to assign institution types.<xref ref-type="fn" rid="Fn2">2</xref> We not only coded institutions in the three countries of interest but also institutions in other countries if an author had a secondary affiliation there. In total we identified 4064 different institutions. These institutions were coded as belonging to the higher education sector (HEI),<xref ref-type="fn" rid="Fn3">3</xref> public or semi-governmental research institutes (PRO), non-profit research institutes (NGO), private sector institutions, government, or other institutions (such as industry associations).<xref ref-type="fn" rid="Fn4">4</xref> Each institution was moreover assigned a country code. The maximum number of affiliations at truly different institutions observed for one author is seven, while the maximum number of different institution types is three.</p>
      <p>In addition, the number of citations received up to 31st March 2016 is collected for all articles in the sample to measure the impact of multiple affiliations. This means that we have different citation windows depending on the year of publication. As the citation count is highly field and year sensitive, we follow Lee et al. (<xref ref-type="bibr" rid="CR13">2015</xref>) and consider papers that are in the top 1% of citations in their field in each year (as of March 2016) as papers with high scientific impact. This alternative measure corrects for any year or subject bias of the pure citation count. Only 3163 authors in our sample appear on articles that are in the top 1%, we therefore also consider the top 10% as an alternative measure (21,139 authors). This method of determining impact may be preferable to pure citation counts as it is less sensitive to year and field differences.</p>
    </sec>
    <sec id="Sec3" sec-type="results">
      <title>Results</title>
      <sec id="Sec4">
        <title>Trends in multiple affiliations</title>
        <p>Table <xref rid="Tab1" ref-type="table">1</xref> shows the total number of authors reported on the selected publications by country and field, as well as the number and proportion of authors that report more than one institutional address. Of the more than 118,000 authors in the sample, 7.2% have more than one institution attached, with some differences across countries and subject areas.<xref ref-type="fn" rid="Fn5">5</xref> The proportion of authors with multiple institutional addresses is highest with more than 9% of authors in biology and chemistry in the case of Germany, and biology in the case of the UK. This already suggests some country and subject-specific differences regarding the extent of multiple affiliations.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Number of authors by field, and number of authors with addresses in multiple institutions (based on author-publication pairs for the years 2008–2014)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Country</th><th align="left">Subject</th><th align="left">No. of authors</th><th align="left">No. of authors with multiple affiliation</th><th align="left">Proportion (%)</th></tr></thead><tbody><tr><td align="left" rowspan="3">Japan</td><td align="left">Biology</td><td char="." align="char">34,294</td><td char="." align="char">1993</td><td char="." align="char">5.81</td></tr><tr><td align="left">Chemistry</td><td char="." align="char">18,242</td><td char="." align="char">1297</td><td char="." align="char">7.11</td></tr><tr><td align="left">Engineering</td><td char="." align="char">4273</td><td char="." align="char">350</td><td char="." align="char">8.19</td></tr><tr><td align="left" rowspan="3">Germany</td><td align="left">Biology</td><td char="." align="char">12,180</td><td char="." align="char">1183</td><td char="." align="char">9.71</td></tr><tr><td align="left">Chemistry</td><td char="." align="char">16,034</td><td char="." align="char">1480</td><td char="." align="char">9.23</td></tr><tr><td align="left">Engineering</td><td char="." align="char">5971</td><td char="." align="char">417</td><td char="." align="char">6.98</td></tr><tr><td align="left" rowspan="3">UK</td><td align="left">Biology</td><td char="." align="char">10,317</td><td char="." align="char">1050</td><td char="." align="char">10.18</td></tr><tr><td align="left">Chemistry</td><td char="." align="char">11,069</td><td char="." align="char">630</td><td char="." align="char">5.69</td></tr><tr><td align="left">Engineering</td><td char="." align="char">6355</td><td char="." align="char">355</td><td char="." align="char">5.59</td></tr><tr><td align="left">Total</td><td align="left"/><td char="." align="char">118,532</td><td char="." align="char">8553</td><td char="." align="char">7.22</td></tr></tbody></table></table-wrap>
</p>
        <p>Author-institution pairings are available from 2008 onwards which means that we can also observe whether there is a trend towards more institutional affiliations since then. Figure <xref rid="Fig1" ref-type="fig">1</xref> shows how the share of authors with more than one affiliation address evolved over the 2008–2014 period. We see an upward trend in multiple affiliations in all scientific fields and countries from about 5% in 2008 to 10% in 2014. For Japanese authors in bioscience, however, this increase only happened after 2012 and multiple affiliations are still lower than for bioscience authors in Germany and the UK.<fig id="Fig1"><label>Fig. 1</label><caption><p>Share of authors with multiple affiliations, 2008–2014, by country and field. <italic>Note</italic> Colour scheme from Bischof (<xref ref-type="bibr" rid="CR3">2016</xref>)</p></caption><graphic xlink:href="11192_2017_2257_Fig1_HTML" id="MO1"/></fig>
</p>
        <p>These results of a significant and growing proportion of authors with multiple affiliations also corroborate the increasing importance of studying multiple affiliations in the context of scientific research.</p>
      </sec>
      <sec id="Sec5">
        <title>Main affiliations in the three countries</title>
        <p>The research structure differs between the three countries and subject areas, and these differences are reflected in the types of institutions that publish academic research. Table <xref rid="Tab2" ref-type="table">2</xref> reports the different forms of institutional affiliations within the three countries for all 118,532 authors. For this purpose all multiple affiliations outside the focus country are excluded and only affiliations within each of the three countries considered. We observe, that most authors have their address within a HEI. This share is highest for authors in the UK, where 86% of authors have at least one address within a HEI.<xref ref-type="fn" rid="Fn6">6</xref> The share of authors with an address in a HEI is lowest in Germany (69%) and especially in engineering, where only 55% of authors are affiliated with a HEI. Outside the higher education sector authors are primarily affiliated to PROs. In Germany, PROs account for 22% of all author addresses, which has its root in a large non-academic public research sector in Germany. In Japan, PROs account for 12% and in the UK for just 3% of all authors. NGOs are an important affiliation only amongst bioscience authors in the UK, through institutions such as the Wellcome Trust. Here, they account for almost 8% of authors. Private sector authors are found mostly in engineering in Germany and Japan with more than 16% of authors, and in bioscience in Japan with 15%. In the UK they account for just 6% of authors. Government appears as a frequent affiliation amongst engineering and chemistry authors in Germany and the UK with 3–7% of authors.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Author affiliations ‘within’ the three countries (in % of all authors)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Country</th><th align="left">Discipline</th><th align="left">HEI</th><th align="left">PRO</th><th align="left">NGO</th><th align="left">Private</th><th align="left">Government</th><th align="left">Other</th></tr></thead><tbody><tr><td align="left" rowspan="3">Japan</td><td align="left">Bioscience</td><td align="left">75.62</td><td char="." align="char">11.10</td><td align="left">0.78</td><td char="." align="char">14.95</td><td align="left">0.84</td><td align="left">0.13</td></tr><tr><td align="left">Chemistry</td><td align="left">82.43</td><td char="." align="char">13.01</td><td align="left">1.13</td><td char="." align="char">6.34</td><td align="left">0.89</td><td align="left">0.13</td></tr><tr><td align="left">Engineering</td><td align="left">73.06</td><td char="." align="char">13.37</td><td align="left">0.82</td><td char="." align="char">16.57</td><td align="left">0.54</td><td align="left">0.21</td></tr><tr><td align="left" rowspan="3">Germany</td><td align="left">Bioscience</td><td align="left">72.50</td><td char="." align="char">24.80</td><td align="left">0.27</td><td char="." align="char">4.98</td><td align="left">1.35</td><td align="left">0.21</td></tr><tr><td align="left">Chemistry</td><td align="left">71.30</td><td char="." align="char">19.08</td><td align="left">0.81</td><td char="." align="char">8.15</td><td align="left">4.52</td><td align="left">0.04</td></tr><tr><td align="left">Engineering</td><td align="left">55.38</td><td char="." align="char">23.87</td><td align="left">1.09</td><td char="." align="char">16.65</td><td align="left">6.88</td><td align="left">0.02</td></tr><tr><td align="left" rowspan="3">UK</td><td align="left">Bioscience</td><td align="left">81.73</td><td char="." align="char">5.68</td><td align="left">7.57</td><td char="." align="char">4.37</td><td align="left">2.01</td><td align="left">0.10</td></tr><tr><td align="left">Chemistry</td><td align="left">87.51</td><td char="." align="char">1.97</td><td align="left">0.45</td><td char="." align="char">7.06</td><td align="left">3.84</td><td align="left">0.17</td></tr><tr><td align="left">Engineering</td><td align="left">90.07</td><td char="." align="char">2.03</td><td align="left">0.02</td><td char="." align="char">5.90</td><td align="left">2.91</td><td align="left">0.03</td></tr></tbody></table><table-wrap-foot><p>Row sums are larger than 100% as authors can belong to more than one institution type. Only addresses within the three countries are considered. Both, single and multiple affiliation authors are considered</p></table-wrap-foot></table-wrap>
</p>
        <p>The address breakdown by country and sector reflects the research activities of the various sectors in the three countries as well as the research structure. Higher publication participation amongst private sector authors in Japan and Germany compared to the UK suggests that more commonality between sectors and opportunities for joint research may exist there, which may also be conducive to multiple affiliations.</p>
      </sec>
      <sec id="Sec6">
        <title>Cross-sector and international affiliations</title>
        <p>Multiple affiliations can occur across all sectors. Figure <xref rid="Fig2" ref-type="fig">2</xref> reports the share of authors with two or more HEI affiliations, and HEI and selected cross-sector affiliations over all multiple affiliations by countries and fields, including affiliations with institutions abroad. Only the most common combinations are reported. Amongst UK authors, more than 60% with multiple affiliations have a cross-HEI affiliation, i.e. belong to two or more HEI, regardless of academic field. For authors with at least one address in Germany or Japan, this share is much lower at fewer than 40% of multiple afilliation authors. Instead, cross-sector affiliations, especially with PROs, are more often observed. This is reflective of the stronger public research sectors in the two countries, which also seems to extend into joint appointments. For UK authors, cross-affiliations with the non-governmental charity research sector (NGO) are of importance in the biosciences. The share of authors with joint HEI and private sector affiliations is highest in engineering (12%) and for authors in Japan (10%), that is, in those areas, where private sector publications are more often found. Multiple affiliations with other sectors, such as national and local government agencies are less often found. Also cross-affiliations that do not include at least one university are rarely observed. Only 5% of authors with multiple affiliations do not concern HEI authors.<fig id="Fig2"><label>Fig. 2</label><caption><p>Cross-sector affiliations as share of authors with multiple affiliations, by country and field. <italic>Note</italic> Bar sums can be larger than 100% as authors can belong to more than two institution types. Colour scheme from Bischof (<xref ref-type="bibr" rid="CR3">2016</xref>)</p></caption><graphic xlink:href="11192_2017_2257_Fig2_HTML" id="MO2"/></fig>
</p>
        <p>Additional affiliations can not only be in a different sector but also with an institution abroad. We propose to plot affiliations along their international and cross-sector dimensions, to quantify the difference in cross-affiliations between countries and fields. We do this by plotting the share of multiple affiliation authors with a cross-sector affiliation on the <italic>x</italic>-axis and the share of multiple affiliation authors with an international affiliation on the <italic>y</italic>-axis for each country and field combination.</p>
        <p>Figure <xref rid="Fig3" ref-type="fig">3</xref> shows that cross-sector affiliations are more common amongst authors with at least one address in Japan or Germany, as already seen in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. For authors with an address in Japan the domestic nature of multiple affiliations is particularly strong, while authors in Germany show slightly higher levels of internationalisation with 40–50% of multiple affiliations involving an institution abroad. Authors with at least one address in the UK, on the other hand, are characterised by little cross-sector but high international cross-affiliations. This means that authors in the UK primarily cross-affiliate with HEIs abroad. The graphical representation in Fig. <xref rid="Fig3" ref-type="fig">3</xref> thus shows that in this three-country – three-field analysis we can observe three classes of multiple affiliations: (A) a highly internationalised, HEI-centred affiliation distribution as represented by authors in the UK, (B) a balanced affiliation distribution as seen in Germany, and (C) a domestic, cross-sector affiliation distribution as seen in Japan.<fig id="Fig3"><label>Fig. 3</label><caption><p>Cross-sector and international cross-affiliations as share of authors with multiple affiliations, by country and field</p></caption><graphic xlink:href="11192_2017_2257_Fig3_HTML" id="MO3"/></fig>
</p>
      </sec>
      <sec id="Sec7">
        <title>Impact and multiple affiliations</title>
        <p>Previous literature has linked collaboration to higher research quality and impact in terms of citations (Katz and Hicks <xref ref-type="bibr" rid="CR10">1997</xref>; Wuchty et al. <xref ref-type="bibr" rid="CR18">2007</xref>). Using publication level information regarding citations received up to 31st March 2016, we can investigate whether multiple affiliations too are associated with higher impact publications. One may expect a correlation between author numbers and multiple affiliations, and co-author numbers thus to act as confounding factor, however, there is no significant correlation between the two (6.51 vs. 6.50 authors, <italic>p</italic> &gt; 0.1), with the exception of chemistry in Japan and Germany.</p>
        <p>Table <xref rid="Tab3" ref-type="table">3</xref> reports the differences in the number of citations and the share of top-impact papers between those with and without multiple affiliations. It shows that, in the case of Japan, authors with multiple affiliations have higher citation numbers and are more often found on top impact publications in bioscience and chemistry. In the case of Germany, only bioscience publications with multiple affiliation authors have statistically significantly more citations or top impact articles than those with single affiliation status. Finally, UK authors with multiple affiliations do not receive more citations or have more top 1% articles. They do, however, still publish more articles in the top 10% in bioscience and engineering, but not chemistry. These correlations suggest that for UK authors their primarily international affiliations are less associated with higher article impact. Bioscience and chemistry authors in Japan, on the other hand, show higher publication impact that may be due to their links with PROs, but may also represent funding relationships.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Citation impact of authors with single versus multiple affiliations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Discipline</th><th align="left" rowspan="2">Country</th><th align="left" colspan="3">Citation numbers</th><th align="left" colspan="3">Top 1%-cited (in %)</th><th align="left" colspan="3">Top 10%-cited (in %)</th></tr><tr><th align="left">Single-affil</th><th align="left">Multi-affil</th><th align="left">
<italic>t</italic> test</th><th align="left">Single-affil</th><th align="left">Multi-affil</th><th align="left">
<italic>χ</italic>
<sup>2</sup> test</th><th align="left">Single-affil</th><th align="left">Multi-affil</th><th align="left">
<italic>χ</italic>
<sup>2</sup> test</th></tr></thead><tbody><tr><td align="left" rowspan="3">Japan</td><td align="left">Bioscience</td><td char="." align="char">9.5</td><td char="." align="char">18.3</td><td align="left">***</td><td char="." align="char">0.8</td><td char="." align="char">4.3</td><td align="left">***</td><td char="." align="char">4.8</td><td char="." align="char">14.6</td><td align="left">***</td></tr><tr><td align="left">Chemistry</td><td char="." align="char">12.1</td><td char="." align="char">18.4</td><td align="left">***</td><td char="." align="char">0.7</td><td char="." align="char">1.2</td><td align="left">**</td><td char="." align="char">11.7</td><td char="." align="char">24.6</td><td align="left">***</td></tr><tr><td align="left">Engineering</td><td char="." align="char">6.0</td><td char="." align="char">6.7</td><td align="left"/><td char="." align="char">0.5</td><td char="." align="char">2.0</td><td align="left">***</td><td char="." align="char">9.7</td><td char="." align="char">11.4</td><td align="left"/></tr><tr><td align="left" rowspan="3">Germany</td><td align="left">Bioscience</td><td char="." align="char">26.0</td><td char="." align="char">34.8</td><td align="left">***</td><td char="." align="char">5.9</td><td char="." align="char">11.9</td><td align="left">***</td><td char="." align="char">25.5</td><td char="." align="char">38.5</td><td align="left">***</td></tr><tr><td align="left">Chemistry</td><td char="." align="char">19.5</td><td char="." align="char">21.6</td><td align="left"/><td char="." align="char">2.3</td><td char="." align="char">2.8</td><td align="left"/><td char="." align="char">23.1</td><td char="." align="char">31.9</td><td align="left">***</td></tr><tr><td align="left">Engineering</td><td char="." align="char">6.9</td><td char="." align="char">6.7</td><td align="left"/><td char="." align="char">0.3</td><td char="." align="char">0.0</td><td align="left"/><td char="." align="char">12.1</td><td char="." align="char">13.4</td><td align="left"/></tr><tr><td align="left" rowspan="3">UK</td><td align="left">Bioscience</td><td char="." align="char">35.5</td><td char="." align="char">33.0</td><td align="left"/><td char="." align="char">10.0</td><td char="." align="char">9.9</td><td align="left"/><td char="." align="char">35.5</td><td char="." align="char">40.7</td><td align="left">***</td></tr><tr><td align="left">Chemistry</td><td char="." align="char">20.9</td><td char="." align="char">17.5</td><td align="left">**</td><td char="." align="char">2.2</td><td char="." align="char">1.1</td><td align="left">*</td><td char="." align="char">25.6</td><td char="." align="char">27.0</td><td align="left"/></tr><tr><td align="left">Engineering</td><td char="." align="char">8.0</td><td char="." align="char">8.3</td><td align="left"/><td char="." align="char">1.2</td><td char="." align="char">2.0</td><td align="left"/><td char="." align="char">14.2</td><td char="." align="char">19.7</td><td align="left">***</td></tr></tbody></table><table-wrap-foot><p>*** (**, *) indicate significance levels of 1% (5%, 10%) using a <italic>t</italic>-test or a <italic>χ</italic>
<sup>2</sup> test. Significance levels remain in ANOVAs that control for author counts</p></table-wrap-foot></table-wrap>
</p>
      </sec>
    </sec>
    <sec id="Sec8" sec-type="conclusion">
      <title>Conclusion</title>
      <p>This paper studied multiple affiliations of authors in research publications. Results for three scientific fields (biology, chemistry and engineering) and three countries (Germany, Japan and the UK) showed that multiple affiliations are widespread and have increased in all fields and countries during the period 2008–2014.</p>
      <p>We found that multiple affiliations reflect the dynamics of the research sector in specific countries and proposed a classification of the cross-sector and international dimension of author affiliations. To summarise, we find three types of multiple affiliations that can be classified as (A) a highly internationalised, HEI centred affiliation distribution as represented by researchers in the UK, (B) a balanced affiliation distribution as seen in Germany, and (C) a domestic, cross-sector affiliation distribution as seen in Japan. These results suggest that cross-sector affiliations are highest in countries and fields with a large non-university research sector, while cross-country affiliations are highest in countries with an international research base. An analysis of other countries may find additional types. However, the occurrence of low cross-sector affiliations paired with low internationalisation, that is, where academic authors are primarily affiliated with other domestic universities, may be limited by academic employment contracts which generally still limit such arrangements.</p>
      <p>These observed differences have consequences for the types of networking that can be achieved through multiple affiliations in different countries. For example, international affiliations may help to preserve links to ‘frontline’ research institutions, while cross-sector affiliations may be more conducive to knowledge transfer and mobility between sectors (ESF <xref ref-type="bibr" rid="CR5">2013</xref>). Our results did, however, show that most multiple affiliations of academics are with other universities or with PROs, including in the cases of Japan and Germany. The role of multiple affiliations as a facilitator for knowledge transfer between distinct sectors (ESF <xref ref-type="bibr" rid="CR5">2013</xref>) may therefore be rather limited.</p>
      <p>We also find some evidence that multiple affiliation authors are more often found on high impact papers. This complements existing findings of a positive correlation between collaboration and citations (Katz and Hicks <xref ref-type="bibr" rid="CR10">1997</xref>; Wuchty et al. <xref ref-type="bibr" rid="CR18">2007</xref>). Regardless of author team size, citation numbers are higher for authors with multiple affiliations in the biosciences and chemistry in Japan and Germany. In the UK, however, we only find smaller correlations. Resource access considerations may thus be the driver for multiple affiliations in Germany and Japan, while in the UK this may not be the case as they may simply have less to gain from additional affiliation due to their already higher citation numbers.</p>
      <p>Nevertheless, several limitations apply. For example, this analysis does not determine whether the association between citations and affiliations found in Japan and Germany is driven by the affiliation itself, through access to human or other resources, or whether perhaps more able academics are more likely to engage in additional affiliations. To investigate these causal relationships, more information on individual authors is required. Moreover, it is not clear how well publication data can capture multiple affiliations. While institutions may encourage researchers to list them, this may be dependent on the rewards offered. Authors may also take strategic decisions regarding the affiliations they list, depending on the journal or the type of research undertaken. A longitudinal study of authors is therefore encouraged to uncover authors’ choices regarding institution address selection. It is further not clear from publication data what the nature of multiple affiliations is, i.e. whether they are due to second appointments, visiting periods, research funding, or other types of arrangements. We also cannot be certain about an author’s home institution when multiple addresses are listed. This may affect the interpretation of some of the findings as foreign university researchers could be affiliating with PROs, private sector institutions or others in one of the three countries in this analysis. Publications may also not represent the preferred dissemination method for academic authors that are also affiliated with the private or government sector. These may rely on alternative dissemination channels such as reports and thus not be captured through publications in top field journals.</p>
      <p>Regardless, our results document multiple affiliations as another factor in the international and inter-institutional collaboration of academic research as well as its correlation with high impact research. These insights thus contribute to the discussion about increases in team sizes and cross-institutional collaborations on co-authored papers (Adams et al. <xref ref-type="bibr" rid="CR1">2005</xref>; Wuchty et al. <xref ref-type="bibr" rid="CR18">2007</xref>; Jones et al. <xref ref-type="bibr" rid="CR8">2008</xref>).</p>
      <p>The findings also have direct implications for research policy. On the one hand there are multiple affiliations that work as a reallocation mechanism between institutions, which may benefit resource use efficiency, knowledge exchange and collaboration, and should therefore be encouraged. On the other hand there are assessment- or income-driven affiliations, which could give rise to institutions that act purely as a PO-Box for researchers with little or no actual research undertaken there. Such affiliations can distort institutional performance measures and rankings and have ethical implications, due to a lack of research contribution from the additional institution (Safaei et al. <xref ref-type="bibr" rid="CR16">2016</xref>). Multiple affiliations may also reflect (or may be a symptom of) a decline of institutional support for academics, especially regarding resource constraints in university-based research or the casualisation of the academic profession, which require academics to seek resources and work roles outside their main institution. We therefore encourage more research into multiple affiliations in other country and field contexts, and are confident that our analysis will encourage a discourse regarding their scientific and institutional impact.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="Fn1">
        <label>1</label>
        <p>This tag has previously been used by Lander (<xref ref-type="bibr" rid="CR12">2015</xref>) to determine multiple affiliations amongst infection and immunity researchers in Vancouver, Canada.</p>
      </fn>
      <fn id="Fn2">
        <label>2</label>
        <p>Coding of institution types in Japan additionally made use of WoS address dictionaries provided by the National Institute of Science and Technology Policy (NISTEP) (<ext-link ext-link-type="uri" xlink:href="http://www.nistep.go.jp">http://www.nistep.go.jp</ext-link>).</p>
      </fn>
      <fn id="Fn3">
        <label>3</label>
        <p>In the case of Japan this denotes national, regional (public) and private universities; in Germany it includes universities, technical universities and universities of applied sciences (UAS).</p>
      </fn>
      <fn id="Fn4">
        <label>4</label>
        <p>Hospitals were assigned to one of the institution types depending on their organisational structure. The majority were university teaching hospitals and thus assigned to HEI.</p>
      </fn>
      <fn id="Fn5">
        <label>5</label>
        <p>The shares are higher at 12% if we consider multiple affiliations within the same institution. However, such intra-institutional multiple affiliations are not the focus of this analysis.</p>
      </fn>
      <fn id="Fn6">
        <label>6</label>
        <p>This share is higher than previous research by Katz and Hicks (<xref ref-type="bibr" rid="CR9">1996</xref>) suggested. The difference may be due to changes in the UK public research sector organisation, where many previously independent research council laboratories and hospitals have experienced a closer integration with universities.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We are grateful for comments from Reiner Grundmann, Heike Jons, Francesco Lissoni, Sotaro Shibayama and Paula Stephan provided during the preparation of this research. Thanks are also due to participants of the LEI-BRICK Workshop (Torino), the BMBF workshop (Kassel), the BEWIP Seminar (TU München), APIC (Fukuoka) and a NISTEP Seminar. The authors acknowledge financial support through a Grant by the DFG (HO5390/1-1), a JSPS postdoctoral fellowship grant (PE15033), a University of Düsseldorf Strategic Research Fund (SFF-F2014/626-15) and a University of Nottingham International Collaboration Fund.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Clemmons</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Stephan</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
          <article-title>Scientific teams and institutional collaborations: Evidence from U.S. universities, 1981–1999</article-title>
          <source>Research Policy</source>
          <year>2005</year>
          <volume>34</volume>
          <fpage>259</fpage>
          <lpage>285</lpage>
          <pub-id pub-id-type="doi">10.1016/j.respol.2005.01.014</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhattacharjee</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Saudi universities offer cash in exchange for academic prestige</article-title>
          <source>Science</source>
          <year>2011</year>
          <volume>334</volume>
          <fpage>1244</fpage>
          <lpage>1355</lpage>
        </element-citation>
      </ref>
      <ref id="CR3">
        <mixed-citation publication-type="other">Bischof, D. (2016). BLINDSCHEMES: Stata module to provide graph schemes sensitive to color vision deficiency. <italic>Statistical Software Components S458251</italic>. Chestnut Hill, MA: Boston College.</mixed-citation>
      </ref>
      <ref id="CR4">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Enders</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Musselin</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <collab>OECD</collab>
          </person-group>
          <article-title>Back to the future? the academic professions in the 21st century</article-title>
          <source>Higher education to 2030, vol 1 demography</source>
          <year>2008</year>
          <publisher-loc>Paris</publisher-loc>
          <publisher-name>OECD</publisher-name>
          <fpage>125</fpage>
          <lpage>150</lpage>
        </element-citation>
      </ref>
      <ref id="CR5">
        <mixed-citation publication-type="other">ESF (2013). New concepts of researcher mobility—a comprehensive approach including combined/part-time positions. <italic>Science Policy Briefing 49</italic>. Strasbourg: European Science Foundation.</mixed-citation>
      </ref>
      <ref id="CR6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez-Zubieta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Geuna</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lawson</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Productivity pay-offs from academic mobility: Should I stay or should I go?</article-title>
          <source>Industrial and Corporate Change</source>
          <year>2016</year>
          <volume>25</volume>
          <fpage>91</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="doi">10.1093/icc/dtv034</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fox</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Publication productivity among scientists: A critical review</article-title>
          <source>Social Studies of Science</source>
          <year>1983</year>
          <volume>13</volume>
          <fpage>283</fpage>
          <lpage>305</lpage>
          <pub-id pub-id-type="doi">10.1177/030631283013002005</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wuchty</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Uzzi</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Multi-university research teams: Shifting impact, geography, and stratification in science</article-title>
          <source>Science</source>
          <year>2008</year>
          <volume>322</volume>
          <fpage>1259</fpage>
          <lpage>1262</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1158357</pub-id>
          <pub-id pub-id-type="pmid">18845711</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hicks</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Where is science going?</article-title>
          <source>Science, Technology and Human Values</source>
          <year>1996</year>
          <volume>21</volume>
          <fpage>379</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="doi">10.1177/016224399602100401</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hicks</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>How much is collaboration worth? a calibrated bibliometric model</article-title>
          <source>Scientometrics</source>
          <year>1997</year>
          <volume>40</volume>
          <fpage>541</fpage>
          <lpage>554</lpage>
          <pub-id pub-id-type="doi">10.1007/BF02459299</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>BR</given-names>
            </name>
          </person-group>
          <article-title>What is research collaboration?</article-title>
          <source>Research Policy</source>
          <year>1997</year>
          <volume>26</volume>
          <fpage>1</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="doi">10.1016/S0048-7333(96)00917-1</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lander</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Proximity at a distance: The role of institutional and geographical proximities in Vancouver’s infection and immunity research collaborations</article-title>
          <source>Industry and Innovation</source>
          <year>2015</year>
          <volume>22</volume>
          <fpage>575</fpage>
          <lpage>596</lpage>
          <pub-id pub-id-type="doi">10.1080/13662716.2015.1104242</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>Y-N</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Creativity in scientific teams: Unpacking novelty and impact</article-title>
          <source>Research Policy</source>
          <year>2015</year>
          <volume>44</volume>
          <fpage>684</fpage>
          <lpage>697</lpage>
          <pub-id pub-id-type="doi">10.1016/j.respol.2014.10.007</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Long</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Productivity and academic position in the scientific career</article-title>
          <source>American Sociological Review</source>
          <year>1978</year>
          <volume>43</volume>
          <fpage>889</fpage>
          <lpage>908</lpage>
          <pub-id pub-id-type="doi">10.2307/2094628</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Long</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>McGuinnis</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Organizational context and scientific productivity</article-title>
          <source>American Sociological Review</source>
          <year>1981</year>
          <volume>46</volume>
          <fpage>422</fpage>
          <lpage>442</lpage>
          <pub-id pub-id-type="doi">10.2307/2095262</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Safaei</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Goodarzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mahian</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Dahari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wongwises</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A survey of using multiple affiliations by scholars in scientific articles</article-title>
          <source>Scientometrics</source>
          <year>2016</year>
          <volume>107</volume>
          <fpage>317</fpage>
          <lpage>318</lpage>
          <pub-id pub-id-type="doi">10.1007/s11192-016-1875-8</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Stephan</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
          <source>How economics shapes science</source>
          <year>2012</year>
          <publisher-loc>Cambridge, MA</publisher-loc>
          <publisher-name>Harvard University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wuchty</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Uzzi</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The increasing dominance of teams in the production of knowledge</article-title>
          <source>Science</source>
          <year>2007</year>
          <volume>316</volume>
          <fpage>1036</fpage>
          <lpage>1039</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1136099</pub-id>
          <pub-id pub-id-type="pmid">17431139</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Normile</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Frustrations mount over China’s high-priced hunt for trophy professors</article-title>
          <source>Science</source>
          <year>2006</year>
          <volume>313</volume>
          <fpage>1721</fpage>
          <lpage>1723</lpage>
          <pub-id pub-id-type="doi">10.1126/science.313.5794.1721</pub-id>
          <pub-id pub-id-type="pmid">16990526</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362651</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Drug Saf</journal-id>
      <journal-id journal-id-type="iso-abbrev">Drug Saf</journal-id>
      <journal-title-group>
        <journal-title>Drug Safety</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0114-5916</issn>
      <issn pub-type="epub">1179-1942</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362651</article-id>
      <article-id pub-id-type="pmcid">PMC5362651</article-id>
      <article-id pub-id-type="pmc-uid">5362651</article-id>
      <article-id pub-id-type="pmid">28025733</article-id>
      <article-id pub-id-type="publisher-id">493</article-id>
      <article-id pub-id-type="doi">10.1007/s40264-016-0493-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6228-6548</contrib-id>
          <name>
            <surname>Ferrajolo</surname>
            <given-names>Carmen</given-names>
          </name>
          <address>
            <phone>+39 081 5665805</phone>
            <email>carmen.ferrajolo@unina2.it</email>
            <email>c.ferrajolo@erasmusmc.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Verhamme</surname>
            <given-names>Katia M. C.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Trifirò</surname>
            <given-names>Gianluca</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>‘t Jong</surname>
            <given-names>Geert W.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Picelli</surname>
            <given-names>Gino</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Giaquinto</surname>
            <given-names>Carlo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mazzaglia</surname>
            <given-names>Giampiero</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stricker</surname>
            <given-names>Bruno H.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rossi</surname>
            <given-names>Francesco</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Capuano</surname>
            <given-names>Annalisa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sturkenboom</surname>
            <given-names>Miriam C. J. M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Experimental Medicine, Pharmacology Section, Campania Regional Centre of Pharmacovigilance and Pharmacoepidemiology, University of Campania, Via Santa Maria di Costantinopoli, 16, 80138 Naples, Italy </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">000000040459992X</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution>Department of Medical Informatics, </institution><institution>Erasmus University Medical Centre, </institution></institution-wrap>Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2178 8421</institution-id><institution-id institution-id-type="GRID">grid.10438.3e</institution-id><institution>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, </institution><institution>University of Messina, </institution></institution-wrap>Messina, Italy </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9609</institution-id><institution-id institution-id-type="GRID">grid.21613.37</institution-id><institution>Department of Paediatrics and Child Health, </institution><institution>University of Manitoba, </institution></institution-wrap>Winnipeg, MB Canada </aff>
        <aff id="Aff5"><label>5</label>Pedianet-Società Servizi Telematici SRL, Padua, Italy </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 3470</institution-id><institution-id institution-id-type="GRID">grid.5608.b</institution-id><institution>Department of Paediatrics, </institution><institution>University of Padua, </institution></institution-wrap>Padua, Italy </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9962 2301</institution-id><institution-id institution-id-type="GRID">grid.419599.9</institution-id><institution>Health Search–IMS HEALTH LPD (Longitudinal Patient Database), </institution><institution>Italian College of General Practitioners, </institution></institution-wrap>Florence, Italy </aff>
        <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">000000040459992X</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution>Department of Epidemiology and Biostatistics, </institution><institution>Erasmus University Medical Centre, </institution></institution-wrap>Rotterdam, The Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>26</day>
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>40</volume>
      <issue>4</issue>
      <fpage>305</fpage>
      <lpage>315</lpage>
      <permissions>
        <copyright-statement>© The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Introduction</title>
          <p>Antibiotics are the most commonly prescribed drug class in children. Real-world data mining on the paediatric population showed potential associations between antibiotic use and acute liver injury.</p>
        </sec>
        <sec>
          <title>Objective</title>
          <p>We assessed risk estimates of liver injury associated with antibiotic use in children and adolescent outpatients.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>A large, multi-database, population-based, case-control study was performed in people &lt;18 years of age from two European countries (Italy and The Netherlands) during the period 2000–2008. All potential cases of liver injury were automatically extracted from three databases and then manually validated based on Council for International Organizations of Medical Sciences (CIOMS) criteria and by exclusion of all competing causes for liver injury. Up to 100 control participants were sampled for each case and were matched on index date of the event, age, sex and database. Based on prescription data, antibiotic exposure was categorized as current, recent or past use by calculating the time period between the end of prescription and the index date. Multivariate conditional logistic regression analyses were applied to calculate odds ratios (ORs) as a measure of the association (with 95% confidence interval [CI]).</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>We identified 938 cases of liver injury and matched to 93,665 controls. Current use of overall antibiotics is associated with a threefold increased risk of liver injury compared with past use (adjusted OR [OR<sub>adj</sub>] 3.22, 95% CI 2.57–4.03). With regard to individual antibiotics, the risk is significantly increased for current use of each antibiotic (<italic>p</italic> &lt; 0.005), except for azithromycin. Risk estimates vary from the lowest OR<sub>adj</sub> of 1.86 (95% CI 1.08–3.21) for amoxicillin to the highest OR<sub>adj</sub> of 24.16 (95% CI 11.78–49.54) for cotrimoxazole (i.e. sulphamethoxazole/trimethoprim) and 26.70 (95% CI 12.09–58.96) for ceftriaxone. Sensitivity analyses confirm the associations for ceftriaxone, cotrimoxazole, and clarithromycin.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Antibiotic-induced liver injury in children is heterogeneous across the use of individual antibiotics. When prescribing ceftriaxone, cotrimoxazole and clarithromycin in children, paediatricians should definitely be aware of their potential risk of liver injury, even if for short periods.</p>
        </sec>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1007/s40264-016-0493-y) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer International Publishing Switzerland 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="FPar1">
      <title>Key Points</title>
      <p>
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Compared with past use, current use of antibiotics in children was associated with an increase in the risk for liver injury.</td></tr><tr><td align="left">Substantial differences in risk estimates have been found among individual antibiotics.</td></tr><tr><td align="left">Paediatricians should be aware of the potential increase of liver enzymes in children taking ceftriaxone, sulphamethoxazole/trimethoprim combination or clarithromycin, even for short periods.</td></tr></tbody></table></table-wrap>
</p>
    </sec>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Antibiotics are the most common drug class causing liver injury in the general population [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR4">4</xref>]. Antibiotic-induced hepatotoxic reactions are usually idiosyncratic, unpredictable and present a poorly understood pathogenesis [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. The diagnosis of liver injury is challenging due to heterogeneous clinical manifestations, ranging from transient, mild, asymptomatic liver function abnormalities to rare, potentially fatal, acute liver failure [<xref ref-type="bibr" rid="CR5">5</xref>]. Moreover, especially for antibiotics, causality assessment is difficult because the indication for antibiotic treatment acts as confounder. In fact, it is known that bacterial infection may lead to changes in hepatic enzymes, representing an underlying cause of liver injury per se [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
      <p>The diagnosis of antibiotic-induced liver injury is even more of a challenge in the paediatric setting because of the age-dependent maturation of the cytochrome P450 enzymes involved in the antibiotic (and overall medicines) metabolism [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>Although several case reports in paediatrics suggest that antibiotic-induced liver injury in children would be likely, at least as in the general population [<xref ref-type="bibr" rid="CR7">7</xref>], only a few studies addressed this issue specifically in paediatrics [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. Moreover, spontaneous adverse drug reaction (ADR) reporting systems showed that antibiotics are most frequently implicated in hepatic ADRs in children and adolescents [<xref ref-type="bibr" rid="CR1">1</xref>]. However, since these data lack denominator [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref>], findings from spontaneous reports may also be explained by the widespread use of these drugs in the paediatric population [<xref ref-type="bibr" rid="CR15">15</xref>]. Moreover, a previous population-based study investigating the power of real-world data mining on electronic healthcare databases to assess hepatic drug safety in paediatric outpatients showed that antibiotics had the highest risk of acute liver injury compared with non-use of any drug (age- and sex-adjusted relative risks: 25.9, 95% confidence interval [CI] 13.4–50.0, for clarithromycin; 18.6, 95% CI 11.3–30.6, for amoxicillin/clavulanic acid; and 7.5, 95% CI 3.4–16.8, for amoxicillin) [<xref ref-type="bibr" rid="CR2">2</xref>]. However, confounding by indication and protopathic bias could not be fully excluded.</p>
      <p>Given that antibiotics are more commonly prescribed in children than in adults, and since no studies have so far examined antibiotic-induced liver injury specifically in the paediatric population, we conducted a large, multi-database, population-based, case-control study to investigate the risk estimates of liver injury associated with individual antibiotics in children and adolescent outpatients.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Source Population</title>
        <p>We selected all children and adolescents younger than 18 years of age from three longitudinal electronic primary care databases in two European countries: (i) Pedianet, a family paediatrician (FP) registry; (ii) Health Search–IMS Longitudinal Patient Database (HSD), a general practice (GP) registry from Italy; and (iii) the Integrated Primary Care Information (IPCI), a GP database from The Netherlands.</p>
        <p>All three databases contain anonymous data on patient demographics, reasons for clinic visits, medical diagnoses by GP/FP and specialist, hospitalizations, drug prescriptions, and laboratory and other diagnostic findings. In The Netherlands, the paediatric population receives medical care from GPs, while, in Italy, medical care is provided by FPs (up to 14 years of age) and GPs (over 14 years of age). These databases are representative of the Italian and Dutch paediatric populations and have been proven to be valid data sources for pharmacoepidemiological studies [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR19">19</xref>]. The study period ran from 1 January 2000 to 31 December 2008.</p>
      </sec>
      <sec id="Sec4">
        <title>Case and Control Selection</title>
        <p>From this population, we excluded all children with clear competing causes of liver injury, including viral infections, hepatic neoplasm, autoimmune hepatitis, neonatal jaundice, genetic hepatopathy, biliary tract diseases and abdominal trauma. Details on case definition, identification and validation have been previously described [<xref ref-type="bibr" rid="CR2">2</xref>]. In brief, by applying a similar stepwise approach across all three databases, all potential cases were extracted using (i) International Classification of Primary Care (ICPC) codes (as used in the IPCI database) or International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes (as used in the Pedianet and HSD databases) for hepatic reactions/signs (i.e. hepatitis, liver failure, hepatic steatosis, hepatic cirrhosis, hepatic necrosis, hepatomegaly, or jaundice); (ii) specific keywords for free-text search; and (iii) laboratory age-specific values of liver function tests (i.e. alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [AP] and total bilirubin). For each potential case, the complete electronic medical record history (including results of laboratory data, ultrasound and other diagnostic tests, as well as hospital discharge summaries and specialists’ letters) was then manually validated by four medically trained investigators, blinded to the drug exposure. Based on Council for International Organizations of Medical Sciences (CIOMS) criteria and in accordance with previously published evidence [<xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR24">24</xref>], cases of liver injury were defined as (i) any age-specific increase of more than two times the upper limit of normal (ULN) range for liver function tests, i.e. ALT, AST, AP or total bilirubin, or their combinations; or (ii) diagnosis of liver injury confirmed by either a specialist, GP or FP, or via ultrasound evidence [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Specific search terms, such as jaundice and hepatomegaly, which are suggestive of liver injury but are not sufficient by themselves to confirm a diagnosis of livery injury, were considered only in association with other more specific symptoms/signs (e.g. abnormal liver enzyme values, steatosis). Children with elevation of biochemical liver tests (i.e. ALT, AST, or AP) less than two times the ULN, or with isolated increases of γ-glutamyltransferase, were excluded as cases [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. In case of uncertainty, cases were reviewed by expert medical doctors with the aim of reaching consensus on whether the case was indeed indicative of liver injury [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
        <p>The index date of the event was defined as the earliest date of the hepatic symptoms/signs (i.e. fatigue, weakness, anorexia, nausea, jaundice, dark urine, light stools, itching and bloating) or, in the absence of these, the date of abnormal liver tests immediately preceding the diagnosis.</p>
        <p>Within the same underlying study population, we selected up to 100 control participants for each case at the same index date, through <italic>incidence density sampling</italic>, according to which the likelihood of being selected as a control is proportional to the person-time [<xref ref-type="bibr" rid="CR26">26</xref>]. Controls were matched to the corresponding case on index date, year of birth, sex, and database.</p>
      </sec>
      <sec id="Sec5">
        <title>Exposure Definition</title>
        <p>Antibiotic exposure (Anatomical Therapeutic Chemical [ATC] code J01*) was evaluated based on prescription data from these healthcare databases. To estimate the association between antibiotic use and liver injury, we created exposure categories based on timing and duration of use. Exposure was categorized as <italic>current</italic> if the index date fell during antibiotic exposure or within 15 days after the end of the prescription (i.e. carryover period), <italic>recent</italic> if the last prescription ended within 16–90 days before the index date, or <italic>past</italic> if it ended more than 90 days before. <italic>No use</italic> was defined as the absence of a prescription before the index date.</p>
      </sec>
      <sec id="Sec6">
        <title>Patient Comorbidities</title>
        <p>Several comorbidities were addressed as potential risk factors for liver injury. Patient medical histories were screened for diagnoses of diabetes mellitus, hypoglycemia, obesity, hyperlipidemia, nutrition-related disorders, hyper- or hypothyroidism, hypertension, or alcohol intake or smoking within 1 year before the index date, while congenital diseases were identified any time before the index date. We also considered concomitant use (i.e. within 3 months of the index date) of other potential hepatotoxic medications, including antimycotics, drugs for the treatment of tuberculosis, drugs for acid-related disorders, anticonvulsants, drugs for respiratory disorders, paracetamol and its combinations, nervous system drugs (such as psycholeptics and psychoanaleptics), non-steroidal anti-inflammatory drugs (NSAIDs), or immunosuppressants.</p>
      </sec>
      <sec id="Sec7">
        <title>Main Analyses</title>
        <p>We compared characteristics of cases and controls using conditional logistic regression. Covariates associated with liver injury in the univariate analysis at a <italic>p-</italic>value &lt;0.10, and those that changed the point estimate of the association between antibiotics and liver injury by more than 10%, were included in the final adjusted model [<xref ref-type="bibr" rid="CR27">27</xref>–<xref ref-type="bibr" rid="CR29">29</xref>].</p>
        <p>To minimize the effect of confounding by indication, past use of any antibiotic served as the reference category, instead of non-use of antibiotics [<xref ref-type="bibr" rid="CR30">30</xref>]. Children who have never been treated with antibiotics during the study period may be healthier than those receiving antibiotics, and ultimately this may result in an overestimation of the risk of liver injury for all antibiotic users. Several multivariate models have been run as primary analyses to estimate the odds ratios (ORs), together with 95% CIs, as a measure of the association between liver injury and current use of antibiotics grouped as follows: (i) antibiotics overall; (ii) antibiotics by class; (iii) individual antibiotics.</p>
      </sec>
      <sec id="Sec8">
        <title>Sensitivity and Subgroup Analyses</title>
        <p>To rule out possible effects of outcome misclassification, we repeated all the analyses in a dataset restricted to patients for which liver injury was strictly defined as more than twice higher than the ULN of laboratory parameters and confirmed by specialists.</p>
        <p>To better address confounding by indication due to current infections, a sensitivity analysis was conducted using current use of amoxicillin as a reference group. Amoxicillin was chosen since it is the most commonly prescribed antibiotic in children [<xref ref-type="bibr" rid="CR31">31</xref>] and is considered to be ‘non-hepatotoxic’ when used as a single ingredient compared with its combination with clavulanic acid [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p>
        <p>To investigate exposure misclassification, we changed the risk window from 15 days to 0 days (i.e. no carryover period at all). In order to explore the impact of age as an effect modifier, we stratified the analysis by age category.</p>
        <p>All analyses were conducted using SPSS version 20 (IBM Corporation, Armonk, NY, USA). We used a <italic>p</italic> value of &lt;0.05 as the threshold of statistical significance, except for the selection of the covariates to be included in the final multivariate models (<italic>p</italic> &lt; 0.10). Wald’s test was used to compare characteristics among cases and controls.</p>
      </sec>
    </sec>
    <sec id="Sec9" sec-type="results">
      <title>Results</title>
      <sec id="Sec10">
        <title>Main Analysis</title>
        <p>In the database source population of 429,772 children and adolescents (&lt;18 years of age) in Italy (<italic>n</italic> = 145,706 from Pedianet and <italic>n</italic> <italic>=</italic> 190,772 from HSD) and The Netherlands (<italic>n</italic> = 93,294 from IPCI), we identified 938 cases of liver injury after exclusion of all clear competing causes. These cases were matched to 93,665 controls. Case characteristics are described in the electronic supplementary table.</p>
        <p>The majority of cases were males (58.2%) with a mean age of 11.3 years (standard deviation 5.1). Cases had a greater burden of comorbidities such as diabetes, hyperlipidaemia, obesity, thyroid disorders or congenital disease than controls. Children with liver injury were more likely to be currently exposed to acid-suppressant drugs, anticonvulsants, NSAIDs, psycholeptic agents, paracetamol, and anti-asthmatics than children without liver injury (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of cases of liver injury and matched controls from the paediatric population identified</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Cases [<italic>N</italic> <italic>=</italic> 938] (%)</th><th align="left">Controls [<italic>N</italic> <italic>=</italic> 93,665] (%)</th><th align="left">OR (95% CI)</th><th align="left">
<italic>p</italic> value<sup>a</sup>
</th></tr></thead><tbody><tr><td align="left">Gender</td><td align="left"/><td align="left"/><td align="left">Matching factor</td><td align="left"/></tr><tr><td align="left"> Male</td><td align="left">546 (58.2)</td><td align="left">54,559 (58.2)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Mean age, years (±SD)</td><td align="left">11.3 (5.1)</td><td align="left">11.4 (5.2)</td><td align="left">Matching factor</td><td align="left"/></tr><tr><td align="left" colspan="5">Age category, years</td></tr><tr><td align="left"> &lt;2</td><td align="left">88 (9.4)</td><td align="left">8811 (9.4)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> 2–5</td><td align="left">101 (10.8)</td><td align="left">9704 (10.4)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> 6–11</td><td align="left">260 (27.8)</td><td align="left">26,060 (27.7)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> 12–18</td><td align="left">489 (52.1)</td><td align="left">49,090 (52.4)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Database</td><td align="left"/><td align="left"/><td align="left" rowspan="3">Matching factor</td><td char="." align="char" rowspan="3"/></tr><tr><td align="left"> HSD (Italy)</td><td align="left">478 (51.0)</td><td align="left">47,480 (51.0)</td></tr><tr><td align="left"> Pedianet (Italy)</td><td align="left">382 (40.7)</td><td align="left">38,159 (40.7)</td></tr><tr><td align="left"> IPCI (Netherlands)</td><td align="left">78 (8.3)</td><td align="left">7706 (8.2)</td><td align="left">Matching factor</td><td char="." align="char"/></tr><tr><td align="left" colspan="5">Comorbidities<sup>b</sup>
</td></tr><tr><td align="left"> Diabetes mellitus</td><td align="left">16 (1.7)</td><td align="left">264 (0.3)</td><td align="left">6.2 (3.7–10.3)</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left"> Hypoglycaemia</td><td align="left">–</td><td align="left">27</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left"> Obesity</td><td align="left">57 (6.1)</td><td align="left">1767 (1.9)</td><td align="left">3.5 (2.6–4.5)</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left"> Hyperlipidaemia</td><td align="left">7 (0.7)</td><td align="left">177 (0.2)</td><td align="left">4.0 (1.9–8.5)</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left"> Thyroid imbalance</td><td align="left">9 (1.0)</td><td align="left">395 (0.4)</td><td align="left">2.3 (1.2–4.5)</td><td char="." align="char">0.014</td></tr><tr><td align="left"> Nutrition-related disorders<sup>c</sup>
</td><td align="left">10 (1.1)</td><td align="left">762 (0.8)</td><td align="left">1.3 (0.7–2.5)</td><td char="." align="char">0.390</td></tr><tr><td align="left"> Hypertension</td><td align="left">1 (0.1)</td><td align="left">89 (0.1)</td><td align="left">NA</td><td char="." align="char"/></tr><tr><td align="left"> Congenital diseases<sup>d</sup>
</td><td align="left">18 (1.9)</td><td align="left">871 (0.9)</td><td align="left">2.1 (1.3–3.4)</td><td char="." align="char">0.002</td></tr><tr><td align="left"> Alcohol consumption<sup>e</sup>
</td><td align="left">–</td><td align="left">22 (0.0)</td><td align="left">NA</td><td char="." align="char"/></tr><tr><td align="left"> Smoking<sup>e</sup>
</td><td align="left">1 (0.1)</td><td align="left">238 (0.3)</td><td align="left">NA</td><td char="." align="char"/></tr><tr><td align="left" colspan="5">Other hepatotoxic medications<sup>f</sup> [ATC code II level]</td></tr><tr><td align="left"> Drugs for acid-related disorders [A02]</td><td align="left">8 (0.9)</td><td align="left">141 (0.2)</td><td align="left">5.8 (2.8–11.9)</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left"> Antimycotics for systemic use [J02]</td><td align="left">1 (0.01)</td><td align="left">41 (0.1)</td><td align="left">NA</td><td char="." align="char">0.375</td></tr><tr><td align="left"> Antimycobacterials [J04]</td><td align="left">2 (0.2)</td><td align="left">9 (0.1)</td><td align="left">NA</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left"> Sex hormones [G03]</td><td align="left">10 (1.1)</td><td align="left">678 (0.7)</td><td align="left">1.8 (0.8–3.8)</td><td char="." align="char">0.133</td></tr><tr><td align="left"> Immunosuppressants [L04]</td><td align="left">–</td><td align="left">113</td><td align="left">NA</td><td char="." align="char"/></tr><tr><td align="left"> NSAIDs [M01]</td><td align="left">10 (1.1)</td><td align="left">320 (0.3)</td><td align="left">3.4 (1.8–6.3)</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left"> Paracetamol and its combinations [N02BE]</td><td align="left">4 (0.4)</td><td align="left">128 (0.1)</td><td align="left">3.2 (1.2–8.7)</td><td char="." align="char">0.022</td></tr><tr><td align="left"> Anticonvulsants [N03]</td><td align="left">12 (1.3)</td><td align="left">323 (0.3)</td><td align="left">3.7 (2.1–6.7)</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left"> Psycholeptics [N05]</td><td align="left">3(0.3)</td><td align="left">93 (0.1)</td><td align="left">3.3 (1.0–10.4)</td><td char="." align="char">0.043</td></tr><tr><td align="left"> Psychoanaleptics [N06]</td><td align="left">3 (0.3)</td><td align="left">107 (0.1)</td><td align="left">2.9 (0.9–9.1)</td><td char="." align="char">0.075</td></tr><tr><td align="left"> Anti-asthmatic agents [R03]</td><td align="left">37 (3.9)</td><td align="left">1859 (2.0)</td><td align="left">2.4 (1.7–3.3)</td><td char="." align="char">&lt;0.001</td></tr></tbody></table><table-wrap-foot><p>Estimates were only provided in the event of at least three exposed cases</p><p>
<italic>OR</italic> odds ratio, <italic>CI</italic> confidence interval, <italic>SD</italic> standard deviation, <italic>NA</italic> not available, <italic>HSD</italic> Health Search/CSD database, <italic>IPCI</italic> Integrated Primary Care Information, <italic>NSAIDs</italic> non-steroidal anti-inflammatory drugs, <italic>ATC</italic> Anatomical Chemical Therapeutic</p><p>
<sup>a</sup>Wald’s test</p><p>
<sup>b</sup>All the covariates for comorbidity were assessed within 365 days before the index date, except for congenital defects (cardiovascular, haematologic, pregnancy, childbirth and puerperium complications) that have been evaluated from birth</p><p>
<sup>c</sup>Nutrition-related disorders include feeding problems of children</p><p>
<sup>d</sup>Congenital diseases include ‘congenital cardiac defects’, ‘congenital defects’, ‘complications of pregnancy, childbirth, and the puerperium’, ‘haemolytic congenital defects’ and ‘congenital anomalies’</p><p>
<sup>e</sup>Data available only from the HSD</p><p>
<sup>f</sup>Use of other potentially hepatotoxic medications was assessed at the index date</p></table-wrap-foot></table-wrap>
</p>
        <p>Compared with past use, current use of antibiotics overall (adjusted OR [OR<sub>adj</sub>] 3.22, 95% CI 2.57–4.03) was significantly (<italic>p</italic> &lt; 0.001) associated with an increased risk of liver injury. This association, although less strong, was also observed for recent use of any antibiotic (OR<sub>adj</sub> 1.53, 95% CI 1.24–1.89; <italic>p</italic> = 0.043). With regard to different antibiotic classes, we found some heterogeneity, with the lowest risk estimates being those for penicillins (OR<sub>adj</sub> 2.83, 95% CI 2.06–3.90) and the highest for fluoroquinolones (OR<sub>adj</sub> 13.87, 95% CI 4.81–39.95) [Table <xref rid="Tab2" ref-type="table">2</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Associations between the use of antibiotic<sup>a</sup> therapeutic classes and risk of liver injury in the paediatric population identified</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4">Liver injury (broad definition)</th><th align="left" colspan="3">Liver injury (strict definition)</th></tr><tr><th align="left">Cases [<italic>N</italic> <italic>=</italic> 938] (%)</th><th align="left">Controls [<italic>N</italic> <italic>=</italic> 93,665] (%)</th><th align="left">OR<sub>matched</sub> (95% CI)</th><th align="left">OR<sub>adjusted</sub>
<sup>b</sup> (95% CI)</th><th align="left">Cases [<italic>N</italic> <italic>=</italic> 485] (%)</th><th align="left">Controls [<italic>N</italic> <italic>=</italic> 48,500] (%)</th><th align="left">OR<sub>adjusted</sub>
<sup>b</sup> (95% CI)</th></tr></thead><tbody><tr><td align="left">Past use of any antibiotic</td><td align="left">417 (44.5)</td><td char="(" align="char">40,740 (43.5)</td><td align="left">Ref</td><td align="left">Ref</td><td align="left">211 (43.5)</td><td char="(" align="char">21,200 (43.7)</td><td align="left">Ref</td></tr><tr><td align="left">Recent use of any antibiotic</td><td align="left">138 (14.7)</td><td char="(" align="char">8044 (8.6)</td><td align="left">1.73 (1.42–2.12)</td><td align="left">1.53 (1.24–1.89)</td><td align="left">69 (14.2)</td><td char="(" align="char">4198 (8.7)</td><td align="left">0.68 (0.55–0.85)</td></tr><tr><td align="left">Current antibiotic use (ATC code)</td><td align="left">117 (12.5)</td><td char="(" align="char">3398 (3.6)</td><td align="left">3.49 (2.82–4.32)</td><td align="left">3.22 (2.57–4.03)</td><td align="left">59 (12.2)</td><td char="(" align="char">1749 (3.6)</td><td align="left">3.52 (2.60–4.76)</td></tr><tr><td align="left"> Tetracyclines (J01A)</td><td align="left">3 (0.3)</td><td char="(" align="char">68 (0.1)</td><td align="left">4.07 (1.27–13.05)</td><td align="left">4.05 (1.25–13.18)</td><td align="left">–</td><td char="(" align="char">36 (0.1)</td><td align="left">NA</td></tr><tr><td align="left"> Amphenicols (J01B)</td><td align="left">–</td><td char="(" align="char">12 (0.4)</td><td align="left">NA</td><td align="left">NA</td><td align="left">–</td><td char="(" align="char">8 (0)</td><td align="left">NA</td></tr><tr><td align="left"> Penicillins (J01C)</td><td align="left">46 (4.9)</td><td char="(" align="char">1600 (1.7)</td><td align="left">2.91 (2.13–3.98)</td><td align="left">2.83 (2.06–3.90)</td><td align="left">17 (3.5)</td><td char="(" align="char">822 (1.7)</td><td align="left">2.16 (1.30–3.57)</td></tr><tr><td align="left"> Cephalosporins (J01D)</td><td align="left">26 (2.8)</td><td char="(" align="char">719 (0.8)</td><td align="left">3.77 (2.50–5.69)</td><td align="left">3.48 (2.29–5.31)</td><td align="left">15 (3.1)</td><td char="(" align="char">369 (0.8)</td><td align="left">4.47 (2.53–7.53)</td></tr><tr><td align="left"> Sulfonamides (J01E)</td><td align="left">5 (0.5)</td><td char="(" align="char">55 (0.1)</td><td align="left">8.81 (3.51–22.15)</td><td align="left">12.39 (5.49–27.98)</td><td align="left">2 (0.4)</td><td char="(" align="char">32 (0.1)</td><td align="left">NA</td></tr><tr><td align="left"> Macrolides (J01F)</td><td align="left">21 (2.2)</td><td char="(" align="char">695 (0.7)</td><td align="left">3.01 (1.93–4.71)</td><td align="left">2.89 (1.84–4.54)</td><td align="left">12 (2.5)</td><td char="(" align="char">351 (0.7)</td><td align="left">3.53 (1.95–6.40)</td></tr><tr><td align="left"> Aminoglycosides (J01G)</td><td align="left">–</td><td char="(" align="char">5 (0.1)</td><td align="left">NA</td><td align="left">NA</td><td align="left">–</td><td char="(" align="char">5 (0)</td><td align="left">NA</td></tr><tr><td align="left"> Fluoroquinolones<sup>c</sup> (J01M)</td><td align="left">3 (0.3)</td><td char="(" align="char">29 (0)</td><td align="left">10.07(3.04–33.33)</td><td align="left">13.87 (4.81–39.95)</td><td align="left">3 (0.6)</td><td char="(" align="char">16 (0)</td><td align="left">19.03 (5.41–66.88)</td></tr><tr><td align="left"> Other antibiotics</td><td align="left">–</td><td char="(" align="char">44 (1.3)</td><td align="left">NA</td><td align="left">NA</td><td align="left">–</td><td char="(" align="char">22 (0)</td><td align="left">NA</td></tr><tr><td align="left"> More than one antibiotic</td><td align="left">13 (1.4)</td><td char="(" align="char">171 (0.2)</td><td align="left">7.69 (4.32–13.69)</td><td align="left">9.41 (5.54–15.97)</td><td align="left">10 (2.1)</td><td char="(" align="char">88 (0.2)</td><td align="left">12.20 (6.19–24.04)</td></tr><tr><td align="left">No antibiotic use</td><td align="left">266 (28.4)</td><td char="(" align="char">41,483 (44.3)</td><td align="left">0.61 (0.52–0. 72)</td><td align="left">0.76 (0.64–0.89)</td><td align="left">146 (30.1)</td><td char="(" align="char">21,353 (44.0)</td><td align="left">0.68 (0.55–0.85)</td></tr></tbody></table><table-wrap-foot><p>
<italic>OR</italic>
<sub><italic>matched</italic></sub> matched odds ratio, <italic>OR</italic>
<sub><italic>adjusted</italic></sub> adjusted odds ratio, <italic>ATC</italic> Anatomical Chemical Therapeutic, <italic>NA</italic> not available, <italic>OR</italic> odds ratio, <italic>CI</italic> confidence interval, <italic>Ref</italic> reference <italic>TBC</italic> tubercolosis</p><p>
<sup>a</sup>All classes of antibiotics, as retrieved from prescription data, are reported in the table; however, risk estimates were only estimated for antibiotic classes having more than three exposed cases</p><p>
<sup>b</sup>OR adjusted for potential confounders only if, in the univariate analysis, they changed the point estimate of the association between antibiotics and liver injury by more than 10% (such as concomitant use of anti-asthmatics and drugs for the treatment of TBC), or between antibiotics and definite liver injury (any covariate)</p><p>
<sup>c</sup>No further analyses fit within the group because of the low number of cases</p></table-wrap-foot></table-wrap>
</p>
        <p>Table <xref rid="Tab3" ref-type="table">3</xref> shows the risk estimates of liver injury for each individual antibiotic compared with past use of any antibiotic. Except for azithromycin, the risk was significantly increased for current use of each antibiotic (<italic>p</italic> &lt; 0.005), varying from the lowest OR<sub>adj</sub> of 1.86 (95% CI 1.08–3.21) for amoxicillin to the highest OR<sub>adj</sub> of 24.16 (95% CI 11.78–49.54) for cotrimoxazole (i.e. sulphamethoxazole/trimethoprim) and 26.70 (95% CI 12.09–58.96) for ceftriaxone.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Associations<sup>a</sup> between individual antibiotics<sup>b</sup> and the risk of liver injury in the paediatric population identified</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4">Liver injury (broad definition)</th><th align="left" colspan="3">Liver injury (strict definition)</th></tr><tr><th align="left">Cases [<italic>N</italic> <italic>=</italic> 938] (%)</th><th align="left">Controls [<italic>N</italic> <italic>=</italic> 93,665] (%)</th><th align="left">OR<sub>matched</sub> (95% CI)</th><th align="left">OR<sub>adjusted</sub>
<sup>c</sup> (95 CI%)</th><th align="left">Cases [<italic>N</italic> <italic>=</italic> 485] (%)</th><th align="left">Controls [<italic>N</italic> <italic>=</italic> 48,500] (%)</th><th align="left">OR<sub>adjusted</sub>
<sup>c</sup> (95% CI)</th></tr></thead><tbody><tr><td align="left">Past use of any antibiotic</td><td char="(" align="char">417 (44.5)</td><td char="(" align="char">40740 (43.5)</td><td align="left">Ref</td><td align="left">Ref</td><td char="(" align="char">211 (43.5)</td><td char="(" align="char">21,200 (43.7)</td><td align="left">Ref</td></tr><tr><td align="left" colspan="8">Penicillins</td></tr><tr><td align="left"> Amoxicillin</td><td char="(" align="char">19 (2.0)</td><td char="(" align="char">842 (0.9)</td><td align="left">2.31 (1.45–3.70)</td><td align="left">1.86 (1.08–3.21)</td><td char="(" align="char">6 (1.2)</td><td char="(" align="char">424 (0.9)</td><td align="left">1.51 (0.66–3.45)</td></tr><tr><td align="left"> Amoxicillin/clavulanic acid</td><td char="(" align="char">22 (2.3)</td><td char="(" align="char">697 (0.7)</td><td align="left">3.20 (2.07–4.9)</td><td align="left">2.77 (1.70–4.51)</td><td char="(" align="char">10 (2.1)</td><td char="(" align="char">365 (0.8)</td><td align="left">2.83 (1.49–5.40)</td></tr><tr><td align="left" colspan="8">Cephalosporins</td></tr><tr><td align="left"> Cefuroxime</td><td char="(" align="char">1 (0.1)</td><td char="(" align="char">40 (0.0)</td><td align="left">NA</td><td align="left">NA</td><td char="(" align="char">1 (0.2)</td><td char="(" align="char">23 (0.0)</td><td align="left">NA</td></tr><tr><td align="left"> Cefaclor</td><td char="(" align="char">8 (0.9)</td><td char="(" align="char">199 (0.2)</td><td align="left">4.38 (2.12–9.03)</td><td align="left">4.33 (2.03–9.24)</td><td char="(" align="char">2 (0.4)</td><td char="(" align="char">93 (0.2)</td><td align="left">NA</td></tr><tr><td align="left"> Ceftriaxone</td><td char="(" align="char">3 (0.3)</td><td char="(" align="char">37 (0.0)</td><td align="left">8.42 (2.58–27.42)</td><td align="left">26.70 (12.09–58.96)</td><td char="(" align="char">3 (0.6)</td><td char="(" align="char">22 (0.0)</td><td align="left">14.68 (4.36–49.45)</td></tr><tr><td align="left"> Cefixime</td><td char="(" align="char">8 (0.9)</td><td char="(" align="char">192 (0.2)</td><td align="left">4.33 (2.11–8.89)</td><td align="left">4.39 (2.07–9.31)</td><td char="(" align="char">5 (1)</td><td char="(" align="char">88 (0.2)</td><td align="left">6.10 (2.43–15.28)</td></tr><tr><td align="left"> Cefpodoxime</td><td char="(" align="char">2 (0.2)</td><td char="(" align="char">65 (0.1)</td><td align="left">NA</td><td align="left">NA</td><td char="(" align="char">1 (0.2)</td><td char="(" align="char">44 (0.1)</td><td align="left">NA</td></tr><tr><td align="left"> Ceftibuten</td><td char="(" align="char">3 (0.3)</td><td char="(" align="char">82 (0.1)</td><td align="left">3.84 (1.20–12.26)</td><td align="left">3.64 (1.05–12.59)</td><td char="(" align="char">2 (0.4)</td><td char="(" align="char">40 (0.1)</td><td align="left">NA</td></tr><tr><td align="left" colspan="8">Sulfonamides</td></tr><tr><td align="left"> Cotrimoxazole</td><td char="(" align="char">4 (0.4)</td><td char="(" align="char">49 (0.1)</td><td align="left">8.13 (2.92–22.63)</td><td align="left">24.16 (11.78–49.54)</td><td char="(" align="char">2 (0.4)</td><td char="(" align="char">30 (0.1)</td><td align="left">NA</td></tr><tr><td align="left" colspan="8">Macrolides</td></tr><tr><td align="left"> Clarithromycin</td><td char="(" align="char">12 (1.3)</td><td char="(" align="char">293 (0.3)</td><td align="left">4.09 (2.27–7.37)</td><td align="left">4.27 (2.34–7.79)</td><td char="(" align="char">8 (1.6)</td><td char="(" align="char">147 (0.3)</td><td align="left">5.6 (2.7–11.6)</td></tr><tr><td align="left"> Azithromycin</td><td char="(" align="char">4 (0.4)</td><td char="(" align="char">262 (0.3)</td><td align="left">1.53 (0.56–4.14)</td><td align="left">1.25 (0.40–3.90)</td><td char="(" align="char">3 (0.6)</td><td char="(" align="char">128 (0.3)</td><td align="left">2.4 (0.8–7.7)</td></tr><tr><td align="left"> Rokitamycin<sup>d</sup>
</td><td char="(" align="char">3 (0.3)</td><td char="(" align="char">35 (0.0)</td><td align="left">8.69 (2.66–28.36)</td><td align="left">31.84 (14.69–69.0)</td><td char="(" align="char">1 (0.2)</td><td char="(" align="char">21 (0)</td><td align="left">NA</td></tr></tbody></table><table-wrap-foot><p>
<italic>OR</italic>
<sub><italic>matched</italic></sub> matched odds ratio, <italic>OR</italic>
<sub><italic>adjusted</italic></sub> adjusted odds ratio, <italic>NA</italic> not available, <italic>OR</italic> odds ratio, <italic>CI</italic> confidence interval, <italic>Ref</italic> reference <italic>TBC</italic> tubercolosis</p><p>
<sup>a</sup>These results have been confirmed by logistic regression, with penalized likelihood, in order to rule out potential underestimation of the rare events</p><p>
<sup>b</sup>Risk estimates are reported for all antibiotics with at least three exposed cases</p><p>
<sup>c</sup>OR adjusted for potential confounders only if, in the univariate analysis, they changed the point estimate of the association between antibiotics and liver injury by more than 10% (such as concomitant use of anti-asthmatics and drugs for the treatment of TBC), or between antibiotics and definite liver injury (no covariate)</p><p>
<sup>d</sup>Withdrawn from the Italian market in 2013</p></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec id="Sec11">
        <title>Sensitivity and Subgroup Analyses</title>
        <p>When considering current use of amoxicillin as the reference group, we found a statistically significant increase in the risk of liver injury for ceftriaxone (OR<sub>adj</sub> 14.35, 95% CI 5.58–36.87), cotrimoxazole (OR<sub>adj</sub> 12.98, 95% CI 5.34–31.53) and clarithromycin (OR<sub>adj</sub> 2.29, 95% CI 1.04–5.07). The association was still observed for all other antibiotics, such as amoxicillin/clavulanic acid, cefaclor, cefixime, ceftibuten, however results were not statistically significant due to limited statistical power (Table <xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Association between individual antibiotics<sup>a</sup> and the risk of liver injury in paediatric outpatients using current use of amoxicillin as the comparator</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4">Liver injury (broad definition)</th><th align="left" colspan="3">Liver injury (strict definition)</th></tr><tr><th align="left">Cases [<italic>N</italic> <italic>=</italic> 938] (%)</th><th align="left">Controls [<italic>N</italic> <italic>=</italic> 93,665] (%)</th><th align="left">OR<sub>matched</sub> (95% CI)</th><th align="left">OR<sub>adjusted</sub>
<sup>b</sup> (95% CI)</th><th align="left">Cases [<italic>N</italic> <italic>=</italic> 485] (%)</th><th align="left">Controls [<italic>N</italic> <italic>=</italic> 48,500] (%)</th><th align="left">OR<sub>adjusted</sub>
<sup>b</sup> (95% CI)</th></tr></thead><tbody><tr><td align="left">Amoxicillin</td><td char="(" align="char">19 (2.0)</td><td char="(" align="char">842 (0.9)</td><td align="left">Ref</td><td align="left">Ref</td><td char="(" align="char">6 (1.2)</td><td char="(" align="char">424 (0.9)</td><td align="left">Ref</td></tr><tr><td align="left">Amoxicillin/clavulanic acid</td><td char="(" align="char">22 (2.3)</td><td char="(" align="char">697 (0.7)</td><td align="left">1.38 (0.74–2.58)</td><td align="left">1.49 (0.73–3.03)</td><td char="(" align="char">10 (2.1)</td><td char="(" align="char">365 (0.8)</td><td align="left">1.87 (0.67–5.20)</td></tr><tr><td align="left">Cefaclor</td><td char="(" align="char">8 (0.9)</td><td char="(" align="char">199 (0.2)</td><td align="left">1.89 (0.81–4.40)</td><td align="left">2.33 (0.93–5.81)</td><td char="(" align="char">2 (0.4)</td><td char="(" align="char">93 (0.2)</td><td align="left">NA</td></tr><tr><td align="left">Ceftriaxone</td><td char="(" align="char">3 (0.3)</td><td char="(" align="char">37 (0.0)</td><td align="left">3.64 (1.03–12.81)</td><td align="left">14.35 (5.58–36.87)</td><td char="(" align="char">3 (0.6)</td><td char="(" align="char">22 (0.0)</td><td align="left">9.70 (2.28–41.24)</td></tr><tr><td align="left">Cefixime</td><td char="(" align="char">8 (0.9)</td><td char="(" align="char">192 (0.2)</td><td align="left">1.87 (0.81–4.35)</td><td align="left">2.36 (0.95–5.87)</td><td char="(" align="char">5 (1)</td><td char="(" align="char">88 (0.2)</td><td align="left">4.03 (1.20–13.50)</td></tr><tr><td align="left">Ceftibuten</td><td char="(" align="char">3 (0.3)</td><td char="(" align="char">82 (0.1)</td><td align="left">1.66 (0.48–5.74)</td><td align="left">1.95 (0.51–7.50)</td><td char="(" align="char">2 (0.4)</td><td char="(" align="char">40 (0.1)</td><td align="left">NA</td></tr><tr><td align="left">Cotrimoxazole</td><td char="(" align="char">4 (0.4)</td><td char="(" align="char">49 (0.1)</td><td align="left">3.51 (1.15–10.72)</td><td align="left">12.98 (5.34–31.53)</td><td char="(" align="char">2 (0.4)</td><td char="(" align="char">30 (0.1)</td><td align="left">NA</td></tr><tr><td align="left">Clarithromycin</td><td char="(" align="char">12 (1.3)</td><td char="(" align="char">293 (0.3)</td><td align="left">1.77 (0.85–3.70)</td><td align="left">2.29 (1.04–5.07)</td><td char="(" align="char">8 (1.6)</td><td char="(" align="char">147 (0.3)</td><td align="left">3.71 (1.26–10.90)</td></tr><tr><td align="left">Rokitamycin<sup>c</sup>
</td><td char="(" align="char">3 (0.3)</td><td char="(" align="char">35 (0.0)</td><td align="left">3.75 (1.06–13.28)</td><td align="left">17.10 (6.75–43.37)</td><td char="(" align="char">1 (0.2)</td><td char="(" align="char">21 (0)</td><td align="left">NA</td></tr></tbody></table><table-wrap-foot><p>
<italic>OR</italic>
<sub><italic>matched</italic></sub> matched odds ratio, <italic>OR</italic>
<sub><italic>adjusted</italic></sub> adjusted odds ratio, <italic>NA</italic> not available, <italic>OR</italic> odds ratio, <italic>CI</italic> confidence interval, <italic>Ref</italic> reference <italic>TBC</italic> tubercolosis</p><p>
<sup>a</sup>Risk estimates are reported for all antibiotics significantly associated with any liver injury in the main analysis, provided that at least three cases were exposed</p><p>
<sup>b</sup>OR adjusted for potential confounders only if, in the univariate analysis, they changed the point estimate of the association between antibiotics and liver injury by more than 10% (such as concomitant use of anti-asthmatics and drugs for the treatment of TBC), or between antibiotics and definite liver injury (any covariate)</p><p>
<sup>c</sup>Withdrawn from the Italian market in 2013</p></table-wrap-foot></table-wrap>
</p>
        <p>To estimate the effect of potential misclassification of exposure, we removed the carryover period in a sensitivity analysis, which yielded an increase in the risk of liver injury by approximately 20% for current use of amoxicillin/clavulanic acid (OR<sub>adj</sub> 3.34, 95% CI 1.74–6.43), 50% for current use of amoxicillin (OR<sub>adj</sub> 2.82, 95% CI 1.51–5.28), 10-fold for current use of clarithromycin (OR<sub>adj</sub> 46.41, 95% CI 30.86–69.77) and 25-fold for ceftibuten (OR<sub>adj</sub> 93.22, 95% CI 43.59–199.36) [Table <xref rid="Tab5" ref-type="table">5</xref>].<table-wrap id="Tab5"><label>Table 5</label><caption><p>Effect of exclusion of the carryover period on the association between individual antibiotics<sup>a</sup> and the risk of liver injury in the paediatric population identified</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4">Liver injury (broad definition)</th><th align="left" colspan="3">Liver injury (strict definition)</th></tr><tr><th align="left">Cases [<italic>N</italic> <italic>=</italic> 938] (%)</th><th align="left">Controls [<italic>N</italic> <italic>=</italic> 93,665] (%)</th><th align="left">OR<sub>matched</sub> (95% CI)</th><th align="left">OR<sub>adjusted</sub>
<sup>b</sup> (95% CI)</th><th align="left">Cases [<italic>N</italic> <italic>=</italic> 485] (%)</th><th align="left">Controls [<italic>N</italic> <italic>=</italic> 48,500] (%)</th><th align="left">OR<sub>adjusted</sub>
<sup>b</sup> (CI 95%)</th></tr></thead><tbody><tr><td align="left">Past use of any antibiotic</td><td char="(" align="char">417 (44.5)</td><td char="(" align="char">40,740 (43.5)</td><td align="left">Ref</td><td align="left">Ref</td><td char="(" align="char">211 (43.5)</td><td char="(" align="char">21,200 (43.7)</td><td align="left">Ref</td></tr><tr><td align="left">Amoxicillin</td><td char="(" align="char">13 (1.4)</td><td char="(" align="char">413 (0.4)</td><td align="left">3.20 (1.95–5.24)</td><td align="left">2.82 (1.51–5.28)</td><td char="(" align="char">6 (1.2)</td><td char="(" align="char">206 (0.4)</td><td align="left">2.89 (1.26–6.65)</td></tr><tr><td align="left">Amoxicillin/clavulanic acid</td><td char="(" align="char">11 (1.2)</td><td char="(" align="char">311 (0.3)</td><td align="left">3.18 (1.82–5.58)</td><td align="left">3.34 (1.74–6.43)</td><td char="(" align="char">8 (1.6)</td><td char="(" align="char">161 (0.3)</td><td align="left">4.83 (2.34–10.00)</td></tr><tr><td align="left">Ceftibuten</td><td char="(" align="char">3 (0.3)</td><td char="(" align="char">27 (0)</td><td align="left">7.06 (2.18–22.88)</td><td align="left">93.22 (43.59–199.36)</td><td char="(" align="char">2 (0.4)</td><td char="(" align="char">7 (0)</td><td align="left">NA</td></tr><tr><td align="left">Clarithromycin</td><td char="(" align="char">11 (1.2)</td><td char="(" align="char">114 (0.1)</td><td align="left">7.63 (4.21–13.84)</td><td align="left">46.41 (30.86–69.77)</td><td char="(" align="char">8 (1.6)</td><td char="(" align="char">57 (0.1)</td><td align="left">13.05 (6.12–27.83)</td></tr><tr><td align="left">Rokitamycin<sup>c</sup>
</td><td char="(" align="char">3 (0.3)</td><td char="(" align="char">9 (0.0)</td><td align="left">23.44 (6.58–83.53)</td><td align="left">NA</td><td char="(" align="char">1 (0.2)</td><td char="(" align="char">6 (0)</td><td align="left">NA</td></tr></tbody></table><table-wrap-foot><p>
<italic>OR</italic>
<sub><italic>matched</italic></sub> matched odds ratio, <italic>OR</italic>
<sub><italic>adjusted</italic></sub> adjusted odds ratio, <italic>NA</italic> not available, <italic>OR</italic> odds ratio, <italic>CI</italic> confidence interval, <italic>Ref</italic> reference</p><p>
<sup>a</sup>Risk estimates were only reported for antibiotics significantly associated with an increased risk of any liver injury in the main analysis provided that there were at least three exposed cases</p><p>
<sup>b</sup>OR adjusted for potential confounders only if, in the univariate analysis, they changed the point estimate of the association between antibiotics and liver injury/definite liver injury by more than 10% (such as concomitant use of anti-asthmatics)</p><p>
<sup>c</sup>Withdrawn from the Italian market in 2013</p></table-wrap-foot></table-wrap>
</p>
        <p>When restricted to only cases of abnormal liver parameters confirmed by a specialist, the associations between current use of antibiotics and liver injury did not change substantially (Tables <xref rid="Tab2" ref-type="table">2</xref>, <xref rid="Tab3" ref-type="table">3</xref>). In terms of individual antibiotics, the increased risk was confirmed for amoxicillin/clavulanic acid and ceftriaxone, and became stronger for cefixime and clarithromycin. This analysis was limited by statistical power given the few cases exposed to cefaclor, ceftibuten, and cotrimoxazole. The analyses were not stratified by age category because of the very low number of exposed cases among each age subgroup.</p>
      </sec>
    </sec>
    <sec id="Sec12" sec-type="discussion">
      <title>Discussion</title>
      <p>In this population-based, multi-database, case-control study, we found that current use of antibiotics in children and adolescents was associated with a threefold increased risk of liver injury when compared with past use. Risk estimates differed among antibiotic classes and varied even more among individual antibiotics belonging to the same subclass. Although these associations may be partly explained by confounding due to current infections, the use of cotrimoxazole, ceftriaxone, and clarithromycin still remained associated with a higher risk of liver injury when the potential effect of confounding by indication has been ruled out.</p>
      <p>To the best of our knowledge, no other paediatric population-based studies have addressed the association between liver injury and individual antibiotic use specifically providing risk estimates. Thus, our results can only be compared with adult data, descriptive studies from drug/induced liver injury registries [<xref ref-type="bibr" rid="CR11">11</xref>] and results from signal detection analyses [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p>
      <p>Fluoroquinolones, sulfonamides, tetracyclines, cephalosporins, macrolides and penicillins have been associated with liver injury [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR36">36</xref>]. Of course, variations on risk estimates across antibiotic classes depend on different pharmacodynamics and pharmacokinetics which play a crucial role in their manifestations of liver injury [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p>
      <p>Our results confirmed the high risk of ceftriaxone-induced hepatitis or elevated liver enzymes, as already described in a few case reports in children/adolescents [<xref ref-type="bibr" rid="CR37">37</xref>–<xref ref-type="bibr" rid="CR39">39</xref>]. Moreover, the high risk is also supported by our previous finding from signal detection analysis on ADR spontaneous reporting systems in children [<xref ref-type="bibr" rid="CR1">1</xref>]. Clinical manifestation of the ceftriaxone-induced hepatitis may represent a direct toxic effect, an idiosyncratic reaction, or a cholestatic injury associated with its calcium precipitation, which is known to typically occur after 9–11 days of treatment [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Cotrimoxazole-induced liver injury is well-described in adults and has also been detected as an hepatotoxic signal in children from ADR spontaneous reporting system analysis [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR40">40</xref>–<xref ref-type="bibr" rid="CR43">43</xref>]. As in adults, the typical presentation is sudden occurrence of fever and rash, followed by jaundice within a few days or weeks of starting the medication, and the typical pattern of serum enzyme elevations is mixed or cholestatic and often asymptomatic. The mechanism underlying sulphonamide liver injury is probably immunoallergic [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
      <p>In contrast to previous evidence [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], our results showed different hepatotoxic profiles amongst macrolides. A higher risk was observed for rokitamycin (withdrawn from the Italian market in 2013) and clarithromycin, while the association was not significant for azithromycin. The effect of reducing carryover time on the risk estimate for clarithromycin is consistent with the proposed mechanism suggesting the short-term onset of liver injury [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p>
      <p>Consistent with existing evidence, amoxicillin with clavulanic acid is associated with a higher risk of liver injury than amoxicillin alone, supporting the potential role of clavulanic acid in the toxic pathway [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Nevertheless, we cannot definitely exclude an increased risk, however small, of liver injury associated with amoxicillin use.</p>
      <sec id="Sec13">
        <title>Strengths</title>
        <p>First, given the large study population identified from three longitudinal, nationally representative GP and FP databases, the results can be largely generalized to the paediatric population in these countries. Second, these electronic registries are maintained for daily routine healthcare purposes and the exposure is prospectively collected, thus limiting the possibility of recall bias. Third, we were able to adjust the analyses for many potential confounders because of the availability of clinically relevant information in the study databases. In addition, we confirmed, in the paediatric setting, some risk factors for liver injury only known in adults, such as underlying diabetes, obesity, hyperlipidaemia, thyroid imbalance or congenital diseases. Fourth, confounding by indication is a main concern when studying the association between antibiotics and liver injury. Accordingly, the sensitivity analysis in which current exposure to amoxicillin was used as the reference category allowed to control for this potential confounding because amoxicillin is the most frequently used antibiotic in children [<xref ref-type="bibr" rid="CR31">31</xref>] and is usually considered less hepatotoxic than other antibiotics [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Thus, the risk estimate during amoxicillin exposure can be regarded as a proxy of the background risk of liver injury [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
      </sec>
      <sec id="Sec14">
        <title>Limitations</title>
        <p>This study has some potential limitations because of its observational nature. Due to the limited number of exposed cases, we could not explore the effect of heterogeneity by country. Residual confounding due to unmeasured severity of infection cannot be excluded. Moreover, although we carefully excluded viral infections as underlying disease, they still may represent the non-documented indication for antibiotic prescription [<xref ref-type="bibr" rid="CR47">47</xref>–<xref ref-type="bibr" rid="CR49">49</xref>].</p>
        <p>With regard to liver injury case selection, we adopted a very sensitive search strategy, as in previous database studies investigating the same association and thereafter manually validating all automatically detected potential cases. Nevertheless, it is likely that outcome misclassification (if any) is randomly distributed among those exposed and unexposed to antibiotics, thus again eventually leading to risk dilution.</p>
        <p>As we used outpatient prescription and no dispensing data, we might have misclassified the exposure. However, if present, such a bias would likely be non-differential between cases and controls, thus underestimating the actual risk.</p>
        <p>We could not exclude the potential effect of diagnostic bias on the risk estimates because children exposed to specific well-known hepatotoxic antibiotics might receive liver function tests more likely than children exposed to other drugs. Moreover, the analyses were not stratified by dosage; however, since antibiotics are usually responsible for idiosyncratic liver injury reactions, i.e. ‘not dose-related’ by definition [<xref ref-type="bibr" rid="CR50">50</xref>], it is unlikely that the risk of liver injury is influenced by the dose of antibiotic.</p>
        <p>The system of medical record databases did not allow to collect, and then to explore, the over-the-counter medications, such as paracetamol, well-known to be hepatotoxic in children. Thus, although we were able to identify paracetamol as a potential risk factor for liver injury in children, despite the low number of cases and controls exposed, we failed to test it as an effect modifier.</p>
        <p>Lastly, the limited number of cases exposed to individual antibiotics resulted in wide CIs, particularly for cephalosporin antibiotics. As a result, their risk estimates need to be interpreted with caution.</p>
      </sec>
    </sec>
    <sec id="Sec15" sec-type="conclusion">
      <title>Conclusion</title>
      <p>The use of antibiotics in paediatric outpatients is associated with an increased risk of liver injury, with substantial differences in risk among individual antibiotics. In particular, after several analyses, the potential risk of liver injury in children was found to be associated with current exposure to ceftriaxone, cotrimoxazole and clarithromycin. Paediatricians should be aware of this risk when using these antibiotics, even if for short periods. From a methodological point of view, this study demonstrates that combining data from different databases is crucial in paediatric postmarketing surveillance to provide the large sample size required for the adequate assessment of drug safety profiles in routine clinical care. However, a larger and more heterogeneous sample size is needed to investigate safety in terms of less commonly used antibiotics, or even other medications.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec16">
        <p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40264_2016_493_MOESM1_ESM.pdf"><caption><p>Supplementary material 1 (PDF 54 kb)</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors would like to thank Dr. Florentia Kaguelidou for reviewing the manuscript, and to Dr. Janet Sultana for editing.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with Ethical Standards</title>
      <sec id="FPar2">
        <title>Funding</title>
        <p>No sources of funding were used to assist in the preparation of this study.</p>
      </sec>
      <sec id="FPar3">
        <title>Conflict of interest</title>
        <p>Katia M.C. Verhamme works for a department who, in the past, received unconditional grants from Pfizer, Boehringer Ingelheim, Novartis, GlaxoSmithKline, Servier and Yamanouchi, none of which are related to the subject of this manuscript. Miriam J.C.M. Sturkenboom leads a research group that is conducting research for pharmaceutical companies through non-conditional grants, none of which is related to this research. Carmen Ferrajolo, Gianluca Trifirò, Geert W ‘t Jong, Gino Picelli, Carlo Giaquinto, Giampiero Mazzaglia, Bruno H. Stricker, Francesco Rossi and Annalisa Capuano have no conflicts of interest to disclose.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrajolo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Capuano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Verhamme</surname>
              <given-names>KM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in vigibase</article-title>
          <source>Br J Clin Pharmacol</source>
          <year>2010</year>
          <volume>70</volume>
          <issue>5</issue>
          <fpage>721</fpage>
          <lpage>728</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2125.2010.03754.x</pub-id>
          <?supplied-pmid 21039766?>
          <pub-id pub-id-type="pmid">21039766</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrajolo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Verhamme</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Trifiro</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Idiopathic acute liver injury in paediatric outpatients: incidence and signal detection in two european countries</article-title>
          <source>Drug Saf</source>
          <year>2013</year>
          <volume>36</volume>
          <issue>10</issue>
          <fpage>1007</fpage>
          <lpage>1016</lpage>
          <pub-id pub-id-type="doi">10.1007/s40264-013-0045-7</pub-id>
          <?supplied-pmid 23591830?>
          <pub-id pub-id-type="pmid">23591830</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meier</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cavallaro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Roos</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Incidence of drug-induced liver injury in medical inpatients</article-title>
          <source>Eur J Clin Pharmacol</source>
          <year>2005</year>
          <volume>61</volume>
          <issue>2</issue>
          <fpage>135</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="doi">10.1007/s00228-004-0888-z</pub-id>
          <?supplied-pmid 15726344?>
          <pub-id pub-id-type="pmid">15726344</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robles</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Toscano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cotta</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment</article-title>
          <source>Curr Drug Saf.</source>
          <year>2010</year>
          <volume>5</volume>
          <issue>3</issue>
          <fpage>212</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="doi">10.2174/157488610791698307</pub-id>
          <?supplied-pmid 20210729?>
          <pub-id pub-id-type="pmid">20210729</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leitner</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Graninger</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Thalhammer</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Hepatotoxicity of antibacterials: pathomechanisms and clinical</article-title>
          <source>Infection</source>
          <year>2010</year>
          <volume>38</volume>
          <issue>1</issue>
          <fpage>3</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1007/s15010-009-9179-z</pub-id>
          <?supplied-pmid 20107858?>
          <pub-id pub-id-type="pmid">20107858</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andrade</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Tulkens</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Hepatic safety of antibiotics used in primary care</article-title>
          <source>J Antimicrob Chemother</source>
          <year>2011</year>
          <volume>66</volume>
          <issue>7</issue>
          <fpage>1431</fpage>
          <lpage>1446</lpage>
          <pub-id pub-id-type="doi">10.1093/jac/dkr159</pub-id>
          <?supplied-pmid 21586591?>
          <pub-id pub-id-type="pmid">21586591</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Serranti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Montagnani</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Indolfi</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antibiotic induced liver injury: what about children?</article-title>
          <source>J Chemother</source>
          <year>2013</year>
          <volume>25</volume>
          <issue>5</issue>
          <fpage>255</fpage>
          <lpage>272</lpage>
          <pub-id pub-id-type="doi">10.1179/1973947813Y.0000000090</pub-id>
          <?supplied-pmid 24070133?>
          <pub-id pub-id-type="pmid">24070133</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pineiro-Carrero</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Pineiro</surname>
              <given-names>EO</given-names>
            </name>
          </person-group>
          <article-title>Liver</article-title>
          <source>Pediatrics.</source>
          <year>2004</year>
          <volume>113</volume>
          <issue>4 Suppl</issue>
          <fpage>1097</fpage>
          <lpage>1106</lpage>
          <?supplied-pmid 15060205?>
          <pub-id pub-id-type="pmid">15060205</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Devarbhavi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Karanth</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Prasanna</surname>
              <given-names>KS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Drug-induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents</article-title>
          <source>Hepatology</source>
          <year>2011</year>
          <volume>54</volume>
          <issue>4</issue>
          <fpage>1344</fpage>
          <lpage>1350</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.24527</pub-id>
          <?supplied-pmid 21735470?>
          <pub-id pub-id-type="pmid">21735470</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrajolo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Coloma</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Verhamme</surname>
              <given-names>KM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network</article-title>
          <source>Drug Saf</source>
          <year>2014</year>
          <volume>37</volume>
          <issue>2</issue>
          <fpage>99</fpage>
          <lpage>108</lpage>
          <pub-id pub-id-type="doi">10.1007/s40264-013-0132-9</pub-id>
          <?supplied-pmid 24446276?>
          <pub-id pub-id-type="pmid">24446276</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Molleston</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Fontana</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Lopez</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Characteristics of idiosyncratic drug-induced liver injury in children: results from the dilin prospective study</article-title>
          <source>J Pediatr Gastroenterol Nutr</source>
          <year>2011</year>
          <volume>53</volume>
          <issue>2</issue>
          <fpage>182</fpage>
          <lpage>189</lpage>
          <pub-id pub-id-type="doi">10.1097/MPG.0b013e31821d6cfd</pub-id>
          <?supplied-pmid 21788760?>
          <pub-id pub-id-type="pmid">21788760</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazzitello</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Esposito</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>De Francesco</surname>
              <given-names>AE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pharmacovigilance in italy: an overview</article-title>
          <source>J Pharmacol Pharmacother.</source>
          <year>2013</year>
          <volume>4</volume>
          <issue>Suppl 1</issue>
          <fpage>S20</fpage>
          <lpage>S28</lpage>
          <?supplied-pmid 24347976?>
          <pub-id pub-id-type="pmid">24347976</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Bie</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ferrajolo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Straus</surname>
              <given-names>SM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pediatric drug safety surveillance in FDA-AERS: a description of adverse events from grip project</article-title>
          <source>PLoS One</source>
          <year>2015</year>
          <volume>10</volume>
          <issue>6</issue>
          <fpage>e0130399</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0130399</pub-id>
          <?supplied-pmid 26090678?>
          <pub-id pub-id-type="pmid">26090678</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrajolo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Capuano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Trifiro</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pediatric drug safety surveillance in italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001–2012</article-title>
          <source>Expert Opin Drug Saf.</source>
          <year>2014</year>
          <volume>13</volume>
          <issue>Suppl 1</issue>
          <fpage>S9</fpage>
          <lpage>S20</lpage>
          <pub-id pub-id-type="doi">10.1517/14740338.2014.939581</pub-id>
          <?supplied-pmid 25171155?>
          <pub-id pub-id-type="pmid">25171155</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sturkenboom</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Verhamme</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Nicolosi</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Drug use in children: cohort study in three european countries</article-title>
          <source>BMJ</source>
          <year>2008</year>
          <volume>337</volume>
          <fpage>a2245</fpage>
          <pub-id pub-id-type="doi">10.1136/bmj.a2245</pub-id>
          <?supplied-pmid 19029175?>
          <pub-id pub-id-type="pmid">19029175</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valkhoff</surname>
              <given-names>VE</given-names>
            </name>
            <name>
              <surname>van Soest</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Mazzaglia</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: a population-based study</article-title>
          <source>Arthritis Rheum</source>
          <year>2012</year>
          <volume>64</volume>
          <issue>8</issue>
          <fpage>2792</fpage>
          <lpage>2802</lpage>
          <pub-id pub-id-type="doi">10.1002/art.34433</pub-id>
          <?supplied-pmid 22508379?>
          <pub-id pub-id-type="pmid">22508379</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sen</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Verhamme</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Neubert</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Assessment of pediatric asthma drug use in three european countries: a TEDDY study</article-title>
          <source>Eur J Pediatr</source>
          <year>2011</year>
          <volume>170</volume>
          <issue>1</issue>
          <fpage>81</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1007/s00431-010-1275-7</pub-id>
          <?supplied-pmid 20811908?>
          <pub-id pub-id-type="pmid">20811908</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masclee</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Valkhoff</surname>
              <given-names>VE</given-names>
            </name>
            <name>
              <surname>van Soest</surname>
              <given-names>EM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cyclo-oxygenase-2 inhibitors or nonselective nsaids plus gastroprotective agents: what to prescribe in daily clinical practice?</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2013</year>
          <volume>38</volume>
          <issue>2</issue>
          <fpage>178</fpage>
          <lpage>189</lpage>
          <pub-id pub-id-type="doi">10.1111/apt.12348</pub-id>
          <?supplied-pmid 23710837?>
          <pub-id pub-id-type="pmid">23710837</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="other">Valkhoff VE, Schade R, t Jong GW, et al. Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues? BMC Pediatr. 2013;13:192.</mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <mixed-citation publication-type="other">Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. Int J Clin Pharmacol Ther Toxicol. 1990;28(8):317–322.</mixed-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benichou</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Criteria of drug-induced liver disorders. Report of an international consensus meeting</article-title>
          <source>J Hepatol</source>
          <year>1990</year>
          <volume>11</volume>
          <issue>2</issue>
          <fpage>272</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="doi">10.1016/0168-8278(90)90124-A</pub-id>
          <?supplied-pmid 2254635?>
          <pub-id pub-id-type="pmid">2254635</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brauer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Garcia Rodriguez</surname>
              <given-names>LA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in europe</article-title>
          <source>Pharmacoepidemiol Drug Saf</source>
          <year>2016</year>
          <volume>25</volume>
          <issue>Suppl 1</issue>
          <fpage>29</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1002/pds.3861</pub-id>
          <?supplied-pmid 27038354?>
          <pub-id pub-id-type="pmid">27038354</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruigomez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brauer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>LA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ascertainment of acute liver injury in two european primary care databases</article-title>
          <source>Eur J Clin Pharmacol</source>
          <year>2014</year>
          <volume>70</volume>
          <issue>10</issue>
          <fpage>1227</fpage>
          <lpage>1235</lpage>
          <pub-id pub-id-type="doi">10.1007/s00228-014-1721-y</pub-id>
          <?supplied-pmid 25066450?>
          <pub-id pub-id-type="pmid">25066450</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Traversa</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bianchi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Da Cas</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs</article-title>
          <source>BMJ</source>
          <year>2003</year>
          <volume>327</volume>
          <issue>7405</issue>
          <fpage>18</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1136/bmj.327.7405.18</pub-id>
          <?supplied-pmid 12842950?>
          <pub-id pub-id-type="pmid">12842950</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Abajo</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Montero</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Madurga</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute and clinically relevant drug-induced liver injury: a population based case-control study</article-title>
          <source>Br J Clin Pharmacol</source>
          <year>2004</year>
          <volume>58</volume>
          <issue>1</issue>
          <fpage>71</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2125.2004.02133.x</pub-id>
          <?supplied-pmid 15206996?>
          <pub-id pub-id-type="pmid">15206996</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walker</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Observation and inference: an introduction to the methods of epidemiology</article-title>
          <source>J Epidemiol Community Health</source>
          <year>1992</year>
          <volume>46</volume>
          <issue>2</issue>
          <fpage>174</fpage>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greenland</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Modeling and variable selection in epidemiologic analysis</article-title>
          <source>Am J Public Health</source>
          <year>1989</year>
          <volume>79</volume>
          <issue>3</issue>
          <fpage>340</fpage>
          <lpage>349</lpage>
          <pub-id pub-id-type="doi">10.2105/AJPH.79.3.340</pub-id>
          <?supplied-pmid 2916724?>
          <pub-id pub-id-type="pmid">2916724</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bertuola</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Morando</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Menniti-Ippolito</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy</article-title>
          <source>Drug Saf</source>
          <year>2010</year>
          <volume>33</volume>
          <issue>1</issue>
          <fpage>65</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.2165/11530350-000000000-00000</pub-id>
          <?supplied-pmid 20000868?>
          <pub-id pub-id-type="pmid">20000868</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bianciotto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chiappini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Raffaldi</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Drug use and upper gastrointestinal complications in children: a case-control study</article-title>
          <source>Arch Dis Child</source>
          <year>2013</year>
          <volume>98</volume>
          <issue>3</issue>
          <fpage>218</fpage>
          <lpage>221</lpage>
          <pub-id pub-id-type="doi">10.1136/archdischild-2012-302100</pub-id>
          <?supplied-pmid 23264432?>
          <pub-id pub-id-type="pmid">23264432</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="other">Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med. 2010;152(7):418–425, W139–440.</mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piovani</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Clavenna</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bonati</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Review of italian primary care paediatricians identifies 38 commonly prescribed drugs for children</article-title>
          <source>Acta Paediatr</source>
          <year>2014</year>
          <volume>103</volume>
          <issue>12</issue>
          <fpage>e532</fpage>
          <lpage>e537</lpage>
          <pub-id pub-id-type="doi">10.1111/apa.12783</pub-id>
          <?supplied-pmid 25164591?>
          <pub-id pub-id-type="pmid">25164591</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia Rodriguez</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Stricker</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Zimmerman</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
          <article-title>Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid</article-title>
          <source>Arch Intern Med</source>
          <year>1996</year>
          <volume>156</volume>
          <issue>12</issue>
          <fpage>1327</fpage>
          <lpage>1332</lpage>
          <pub-id pub-id-type="doi">10.1001/archinte.156.12.1327</pub-id>
          <?supplied-pmid 8651842?>
          <pub-id pub-id-type="pmid">8651842</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ammann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Neftel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hardmeier</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cephalosporin-induced cholestatic jaundice</article-title>
          <source>Lancet</source>
          <year>1982</year>
          <volume>2</volume>
          <issue>8293</issue>
          <fpage>336</fpage>
          <lpage>337</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(82)90311-7</pub-id>
          <?supplied-pmid 6124751?>
          <pub-id pub-id-type="pmid">6124751</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Desmond</surname>
              <given-names>PV</given-names>
            </name>
          </person-group>
          <article-title>Hepatotoxicity of antimicrobial agents</article-title>
          <source>Semin Liver Dis</source>
          <year>2002</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>157</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2002-30103</pub-id>
          <?supplied-pmid 12016547?>
          <pub-id pub-id-type="pmid">12016547</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paterson</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mamdani</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Manno</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study</article-title>
          <source>CMAJ</source>
          <year>2012</year>
          <volume>184</volume>
          <issue>14</issue>
          <fpage>1565</fpage>
          <lpage>1570</lpage>
          <pub-id pub-id-type="doi">10.1503/cmaj.111823</pub-id>
          <?supplied-pmid 22891208?>
          <pub-id pub-id-type="pmid">22891208</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <mixed-citation publication-type="other">Polson JE. Hepatotoxicity due to antibiotics. Clin Liver Dis. 2007;11(3):549–561, vi.</mixed-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bell</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Stockwell</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Luban</surname>
              <given-names>NL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin sc disease</article-title>
          <source>Pediatr Crit Care Med.</source>
          <year>2005</year>
          <volume>6</volume>
          <issue>3</issue>
          <fpage>363</fpage>
          <lpage>366</lpage>
          <pub-id pub-id-type="doi">10.1097/01.PCC.0000161285.12396.FF</pub-id>
          <?supplied-pmid 15857541?>
          <pub-id pub-id-type="pmid">15857541</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Longo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hastier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Buckley</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone</article-title>
          <source>Am J Gastroenterol</source>
          <year>1998</year>
          <volume>93</volume>
          <issue>5</issue>
          <fpage>836</fpage>
          <lpage>837</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1572-0241.1998.239_a.x</pub-id>
          <?supplied-pmid 9625142?>
          <pub-id pub-id-type="pmid">9625142</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peker</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cagan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dogan</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Ceftriaxone-induced toxic hepatitis</article-title>
          <source>World J Gastroenterol</source>
          <year>2009</year>
          <volume>15</volume>
          <issue>21</issue>
          <fpage>2669</fpage>
          <lpage>2671</lpage>
          <pub-id pub-id-type="doi">10.3748/wjg.15.2669</pub-id>
          <?supplied-pmid 19496200?>
          <pub-id pub-id-type="pmid">19496200</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dujovne</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Zimmerman</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
          <article-title>Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole</article-title>
          <source>N Engl J Med</source>
          <year>1967</year>
          <volume>277</volume>
          <issue>15</issue>
          <fpage>785</fpage>
          <lpage>788</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM196710122771503</pub-id>
          <?supplied-pmid 6046676?>
          <pub-id pub-id-type="pmid">6046676</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mainra</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Card</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>Trimethoprim-sulfamethoxazole-associated hepatotoxicity: part of a hypersensitivity syndrome</article-title>
          <source>Can J Clin Pharmacol.</source>
          <year>2003</year>
          <volume>10</volume>
          <issue>4</issue>
          <fpage>175</fpage>
          <lpage>178</lpage>
          <?supplied-pmid 14712321?>
          <pub-id pub-id-type="pmid">14712321</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abusin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Sulfamethoxazole/trimethoprim induced liver failure: a case report</article-title>
          <source>Cases J.</source>
          <year>2008</year>
          <volume>1</volume>
          <issue>1</issue>
          <fpage>44</fpage>
          <pub-id pub-id-type="doi">10.1186/1757-1626-1-44</pub-id>
          <?supplied-pmid 18637204?>
          <pub-id pub-id-type="pmid">18637204</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bell</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Townsend</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a pediatric patient</article-title>
          <source>Pharmacotherapy.</source>
          <year>2010</year>
          <volume>30</volume>
          <issue>5</issue>
          <fpage>539</fpage>
          <pub-id pub-id-type="doi">10.1592/phco.30.5.539</pub-id>
          <?supplied-pmid 20412003?>
          <pub-id pub-id-type="pmid">20412003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Christopher</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hyatt</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Horkan</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clarithromycin use preceding fulminant hepatic failure</article-title>
          <source>Am J Gastroenterol</source>
          <year>2002</year>
          <volume>97</volume>
          <issue>2</issue>
          <fpage>489</fpage>
          <lpage>490</lpage>
          <?supplied-pmid 11866297?>
          <pub-id pub-id-type="pmid">11866297</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Principi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Esposito</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients</article-title>
          <source>Drug Saf</source>
          <year>1999</year>
          <volume>20</volume>
          <issue>1</issue>
          <fpage>25</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="doi">10.2165/00002018-199920010-00004</pub-id>
          <?supplied-pmid 9935275?>
          <pub-id pub-id-type="pmid">9935275</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaheen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Grimm</surname>
              <given-names>IS</given-names>
            </name>
          </person-group>
          <article-title>Fulminant hepatic failure associated with clarithromycin</article-title>
          <source>Am J Gastroenterol</source>
          <year>1996</year>
          <volume>91</volume>
          <issue>2</issue>
          <fpage>394</fpage>
          <lpage>395</lpage>
          <?supplied-pmid 8607519?>
          <pub-id pub-id-type="pmid">8607519</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mitsuyasu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Groopman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Volberding</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with aids and kaposi’s sarcoma</article-title>
          <source>N Engl J Med</source>
          <year>1983</year>
          <volume>308</volume>
          <issue>25</issue>
          <fpage>1535</fpage>
          <lpage>1536</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM198306233082512</pub-id>
          <?supplied-pmid 6222258?>
          <pub-id pub-id-type="pmid">6222258</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pullen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Murdoch</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis</article-title>
          <source>Lancet</source>
          <year>1967</year>
          <volume>2</volume>
          <issue>7527</issue>
          <fpage>1176</fpage>
          <lpage>1178</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(67)91893-4</pub-id>
          <?supplied-pmid 4168380?>
          <pub-id pub-id-type="pmid">4168380</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uetrecht</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Naisbitt</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Idiosyncratic adverse drug reactions: current concepts</article-title>
          <source>Pharmacol Rev</source>
          <year>2013</year>
          <volume>65</volume>
          <issue>2</issue>
          <fpage>779</fpage>
          <lpage>808</lpage>
          <pub-id pub-id-type="doi">10.1124/pr.113.007450</pub-id>
          <?supplied-pmid 23476052?>
          <pub-id pub-id-type="pmid">23476052</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Russmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kullak-Ublick</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Grattagliano</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Current concepts of mechanisms in drug-induced hepatotoxicity</article-title>
          <source>Curr Med Chem</source>
          <year>2009</year>
          <volume>16</volume>
          <issue>23</issue>
          <fpage>3041</fpage>
          <lpage>3053</lpage>
          <pub-id pub-id-type="doi">10.2174/092986709788803097</pub-id>
          <?supplied-pmid 19689281?>
          <pub-id pub-id-type="pmid">19689281</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362652</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Curr Trop Med Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Curr Trop Med Rep</journal-id>
      <journal-title-group>
        <journal-title>Current Tropical Medicine Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2196-3045</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362652</article-id>
      <article-id pub-id-type="pmcid">PMC5362652</article-id>
      <article-id pub-id-type="pmc-uid">5362652</article-id>
      <article-id pub-id-type="publisher-id">101</article-id>
      <article-id pub-id-type="doi">10.1007/s40475-017-0101-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Tropical Medicine in the Mediterranean Region (F Bruschi, Section Editor)</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Surveillance of Arthropod-Borne Viruses and Their Vectors in the Mediterranean and Black Sea Regions Within the MediLabSecure Network</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
          <name>
            <surname>Failloux</surname>
            <given-names>Anna-Bella</given-names>
          </name>
          <address>
            <email>anna-bella.failloux@pasteur.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Bouattour</surname>
            <given-names>Ali</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Faraj</surname>
            <given-names>Chafika</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Gunay</surname>
            <given-names>Filiz</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Haddad</surname>
            <given-names>Nabil</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Harrat</surname>
            <given-names>Zoubir</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Jancheska</surname>
            <given-names>Elizabeta</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Kanani</surname>
            <given-names>Khalil</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Kenawy</surname>
            <given-names>Mohamed Amin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Kota</surname>
            <given-names>Majlinda</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Pajovic</surname>
            <given-names>Igor</given-names>
          </name>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Paronyan</surname>
            <given-names>Lusine</given-names>
          </name>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Petric</surname>
            <given-names>Dusan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff13">13</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Sarih</surname>
            <given-names>Mhammed</given-names>
          </name>
          <xref ref-type="aff" rid="Aff14">14</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Sawalha</surname>
            <given-names>Samir</given-names>
          </name>
          <xref ref-type="aff" rid="Aff15">15</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Shaibi</surname>
            <given-names>Taher</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Sherifi</surname>
            <given-names>Kurtesh</given-names>
          </name>
          <xref ref-type="aff" rid="Aff17">17</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Sulesco</surname>
            <given-names>Tatiana</given-names>
          </name>
          <xref ref-type="aff" rid="Aff18">18</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Velo</surname>
            <given-names>Enkelejda</given-names>
          </name>
          <xref ref-type="aff" rid="Aff19">19</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Gaayeb</surname>
            <given-names>Lobna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff20">20</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Victoir</surname>
            <given-names>Kathleen</given-names>
          </name>
          <xref ref-type="aff" rid="Aff20">20</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Robert</surname>
            <given-names>Vincent</given-names>
          </name>
          <xref ref-type="aff" rid="Aff21">21</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2353 6535</institution-id><institution-id institution-id-type="GRID">grid.428999.7</institution-id><institution>Department of Virology, Arboviruses and Insect Vectors, </institution><institution>Institut Pasteur, </institution></institution-wrap>Paris, France </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2298 7385</institution-id><institution-id institution-id-type="GRID">grid.418517.e</institution-id><institution>Laboratory of Medical Entomology, </institution><institution>Institut Pasteur of Tunis, </institution></institution-wrap>Tunis, Tunisia </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.418480.1</institution-id><institution>Laboratory of Medical Entomology, </institution><institution>Institut National d’Hygiène, </institution></institution-wrap>Rabat, Morocco </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2342 7339</institution-id><institution-id institution-id-type="GRID">grid.14442.37</institution-id><institution/><institution>Hacettepe University, HU-ESRL-VERG, </institution></institution-wrap>Ankara, Turkey </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2324 3572</institution-id><institution-id institution-id-type="GRID">grid.411324.1</institution-id><institution>Faculty of Public Health, Laboratory of Immunology, </institution><institution>Lebanese University, </institution></institution-wrap>Beirut, Lebanon </aff>
        <aff id="Aff6"><label>6</label>Eco-Epidemiologie Parasitaire et Génétique des Populations, Institut Pasteur of Algeria, Alger, Algeria </aff>
        <aff id="Aff7"><label>7</label>Laboratory for Virology and Molecular Diagnostics, Institute of Public Health, Skopje, Macedonia </aff>
        <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.415773.3</institution-id><institution>Parasitic and Zoonotic Diseases Department, </institution><institution>Ministry of Health, </institution></institution-wrap>Amman, Jordan </aff>
        <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0621 1570</institution-id><institution-id institution-id-type="GRID">grid.7269.a</institution-id><institution>Department of Entomology, Faculty of Science, </institution><institution>Ain Shams University, </institution></institution-wrap>Cairo, Egypt </aff>
        <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 4688 1528</institution-id><institution-id institution-id-type="GRID">grid.414773.2</institution-id><institution>Department of Control of Infectious Diseases, Laboratory of Virology, </institution><institution>Institute of Public Health, </institution></institution-wrap>Tirana, Albania </aff>
        <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2182 0188</institution-id><institution-id institution-id-type="GRID">grid.12316.37</institution-id><institution>Biotechnical Faculty, Laboratory for Applied Zoology, </institution><institution>University of Montenegro, </institution></institution-wrap>Podgorica, Montenegro </aff>
        <aff id="Aff12"><label>12</label>Vector Borne and Parasitic Diseases Epidemiology Department, National Center for Diseases Control and Prevention, Yerevan, Armenia </aff>
        <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2149 743X</institution-id><institution-id institution-id-type="GRID">grid.10822.39</institution-id><institution>Faculty of Agriculture, Laboratory of Medical and Veterinary Entomology, </institution><institution>University of Novi Sad, </institution></institution-wrap>Novi Sad, Serbia </aff>
        <aff id="Aff14"><label>14</label>Laboratory of Vectorial Diseases, Institut Pasteur of Morocco, Casablanca, Morocco </aff>
        <aff id="Aff15"><label>15</label>Laboratory of Public Health, Ministry of Health, Ramallah, Palestine </aff>
        <aff id="Aff16"><label>16</label>Laboratory of Parasitology and Vector-Borne Diseases, National Center for Disease Control, Tripoli, Libya </aff>
        <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.449627.a</institution-id><institution>Faculty of Agriculture and Veterinary Science, Institute of Veterinary Medicine, </institution><institution>University of Prishtina, </institution></institution-wrap>Prishtina, Kosovo </aff>
        <aff id="Aff18"><label>18</label>Laboratory of Systematics and Molecular Phylogeny, Institute of zoology, Chisinau, Republic of Moldova </aff>
        <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 4688 1528</institution-id><institution-id institution-id-type="GRID">grid.414773.2</institution-id><institution>Department of Control of Infectious Diseases, Vector Control Unit, Laboratory of Medical Entomology, </institution><institution>Institute of Public Health, </institution></institution-wrap>Tirana, Albania </aff>
        <aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2353 6535</institution-id><institution-id institution-id-type="GRID">grid.428999.7</institution-id><institution>Department of International Affairs, </institution><institution>Institut Pasteur, </institution></institution-wrap>Paris, France </aff>
        <aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2097 0141</institution-id><institution-id institution-id-type="GRID">grid.121334.6</institution-id><institution>French National Research Institute for Sustainable Development, MIVEGEC Unit, </institution><institution>IRD224-CNRS 5290-Montpellier University, </institution></institution-wrap>Montpellier, France </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>17</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>4</volume>
      <issue>1</issue>
      <fpage>27</fpage>
      <lpage>39</lpage>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Purpose of Review</title>
          <p>Arboviruses, viruses transmitted by arthropods such as mosquitoes, ticks, sandflies, and fleas are a significant threat to public health because of their epidemic and zoonotic potential. The geographical distribution of mosquito-borne diseases such as West Nile (WN), Rift Valley fever (RVF), Dengue, Chikungunya, and Zika has expanded over the last decades. Countries of the Mediterranean and Black Sea regions are not spared. Outbreaks of WN are repeatedly reported in the Mediterranean basin. Human cases of RVF were reported at the southern borders of the Maghreb region. For this reason, establishing the basis for the research to understand the potential for the future emergence of these and other arboviruses and their expansion into new geographic areas became a public health priority. In this context, the European network “MediLabSecure” gathering laboratories in 19 non-EU countries from the Mediterranean and Black Sea regions seeks to improve the surveillance (of animals, humans, and vectors) by reinforcing capacity building and harmonizing national surveillance systems to address this important human and veterinary health issue. The aim of this review is to give an exhaustive overview of arboviruses and their vectors in the region.</p>
        </sec>
        <sec>
          <title>Recent Findings</title>
          <p>The data presented underline the importance of surveillance in the implementation of more adapted control strategies to combat vector-borne diseases. Partner laboratories within the MediLabSecure network present a wide range of infrastructures and have benefited from different training programs.</p>
        </sec>
        <sec>
          <title>Summary</title>
          <p>Although reporting of arboviral presence is not carried out in a systematic manner, the expansion of the area where arboviruses are present cannot be disputed. This reinforces the need for increasing surveillance capacity building in this region to prevent future emergences.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Arboviruses</kwd>
        <kwd>Vectors</kwd>
        <kwd>Emergence</kwd>
        <kwd>Surveillance</kwd>
        <kwd>Mediterranean and Black Sea regions</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer International Publishing AG 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>The global distribution and disease burden associated to arboviruses have increased over recent years. Unexpectedly, Chikungunya hit northeastern Italy in 2007 and struck France in 2010 and 2014 [<xref ref-type="bibr" rid="CR1">1</xref>]. Dengue entered the European scene in 2010 followed by more human cases in subsequent years [<xref ref-type="bibr" rid="CR2">2</xref>]. A more recent threat is the Zika virus (ZIKV) which is still unreported in the European territory, including the Mediterranean region, despite the increasing number of imported cases [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>••].</p>
      <p>In countries of the Mediterranean and Black Sea regions, the epidemiology (presence, risk, transmission, etc.) of arboviruses remains poorly characterized. MediLabSecure is a European project (2014–2018) that has established a laboratory network including partners from 19 countries of the Mediterranean and Black Sea regions. These countries are in the Balkans, around the Black Sea, in South Caucasus, Middle East and North Africa. As they share common public health issues and threats, the overall objective of MediLabSecure is to increase through capacity building and harmonization of surveillance systems the health security in the whole Mediterranean region. Emerging mosquito-borne viruses that are pathogens for humans and/or animals are at the heart of this project: West Nile (WN), Dengue (DEN), Chikungunya (CHIK), and Rift Valley Fever (RVF). Within this One Health network, a subset of laboratories are dedicated to medical and veterinary entomology, while others are focused on human virology, animal virology, and public health. The entomologists target mosquitoes identified as present threats or with potential risk of emergence in the concerned region: <italic>Aedes</italic> mosquitoes (<italic>Aedes aegypti</italic> (=<italic>Stegomyia aegypti</italic>) and <italic>Aedes albopictus</italic> (=<italic>Stegomyia albopicta</italic>)) responsible for transmission of Dengue virus (DENV) and Chikungunya virus (CHIKV) to humans and <italic>Culex</italic> mosquitoes (e.g., <italic>Culex pipiens</italic>) implicated in the transmission of West Nile virus (WNV). Other arboviruses transmitted by sandflies or ticks (e.g., Crimean-Congo hemorrhagic fever (CCHF) virus transmitted by <italic>Hyalomma</italic> tick bites) are also considered in the MediLabSecure program activities.</p>
    </sec>
    <sec id="Sec2">
      <title>The Past of Mosquito-Borne Diseases in Europe</title>
      <p>Dengue (DEN) was not uncommon in the Mediterranean area in the past. The disease was reported in Athens in 1928 which was the theater of the last major epidemic on the European continent with 1 million cases and 1000 deaths [<xref ref-type="bibr" rid="CR5">5</xref>]. It seemed that clinical severity was due to the sequential circulation of viruses DENV-1 and DENV-2. <italic>Aedes aegypti</italic>, the vector of dengue in Greece, disappeared from the Eastern Mediterranean after 1935 [<xref ref-type="bibr" rid="CR6">6</xref>]. Since then, no local transmission of Dengue has been recorded in Europe until 2010 when autochthonous cases of Dengue were reported in Croatia and France [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>Yellow Fever (YF) is mainly transmitted to humans by <italic>Ae. aegypti</italic>. While originating from Africa, YF was first reported in the Caribbean after the introduction of its vector via the slave trade from West Africa. Yellow Fever and <italic>Ae. aegypti</italic> were introduced around 1700 in harbors of Western Europe. Outbreaks occurred on the Iberian Peninsula (Gibraltar, Sevilla, Cadiz, Malaga, Lisbon, Porto, Barcelona), France (Marseille, Brest, Saint-Nazaire, Rochefort, Bordeaux), and Italy (Livorno) during the nineteenth and beginning of the twentieth centuries [<xref ref-type="bibr" rid="CR7">7</xref>]. More than 5000 people died in Barcelona between 1821 and 1824, and more than 6000 in Lisbon in 1857 [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>West Nile (WN) has been discovered in Africa in 1937 and circulated on the continent mainly associated with mild symptoms. Since the 1990s, new viral strains were responsible for increased incidence of human diseases in Europe. While lineage 1 was repeatedly isolated in Europe and North Africa, lineage 2, historically endemic in sub-Saharan Africa and Madagascar, has been recently associated with human cases in Hungary with subsequent spread into Austria, Italy, Russia, Greece, Serbia, and Croatia [<xref ref-type="bibr" rid="CR9">9</xref>]. Currently, WNV is present in Africa, the Middle East, Europe, Asia, America and has become the most widely distributed of the encephalitic flaviviruses. Contrary to related flaviviruses such as DENV and YFV, WNV can be transmitted by wide range of vector species and has been detected in more than 59 different mosquito species [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
    </sec>
    <sec id="Sec3">
      <title>The Vectors of Arboviruses in Europe</title>
      <p>
<bold><italic>Aedes aegypti</italic></bold>: This mosquito was common in southern Europe and the Middle East at the beginning of twentieth century [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. It was present in southern Europe and Western Asia at the beginning of twentieth century, in Syria, Lebanon, Turkey, Greece, former Yugoslavia, Italy, Corsica (France), and Spain [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The species was the vector of a YF outbreak in Livorno in Italy in 1804. Following the development of sanitation and management of urban water collections and anti-malaria vector control with DDT, the vector disappeared from continental Europe after the 1950s. The last record of <italic>Ae. aegypti</italic> in Europe was in Desenzano del Garda (Brescia province, northern Italy) in 1971 [<xref ref-type="bibr" rid="CR12">12</xref>] . An <italic>Ae. Aegypti</italic>-vectored outbreak was reported in Madeira in 2012 [<xref ref-type="bibr" rid="CR13">13</xref>]. After decades of absence, <italic>Ae. aegypti</italic> is back to the Eurasian continent, more specifically around the Black Sea in southern Russia, Apkhazeti, and Georgia in 2004 [<xref ref-type="bibr" rid="CR14">14</xref>], and north-eastern Turkey [<xref ref-type="bibr" rid="CR15">15</xref>••]. Major outbreaks associated with <italic>Ae. aegypti</italic> may occur in South Europe as this mosquito was responsible for large epidemics of Dengue in Greece in 1927–1928 [<xref ref-type="bibr" rid="CR5">5</xref>]. Additionally, this species is a vector of CHIKV and ZIKV.</p>
      <p>
<bold><italic>Aedes albopictus</italic></bold>: From its native home-range in the forests of South-East Asia, <italic>Ae. albopictus</italic> [<xref ref-type="bibr" rid="CR16">16</xref>] has succeeded in colonizing most continents in the past 30–40 years [<xref ref-type="bibr" rid="CR17">17</xref>]. The species was recorded for the first time in Europe in Albania in 1979 [<xref ref-type="bibr" rid="CR18">18</xref>], then in Italy in 1990 [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>], and is now present in 20 European countries [<xref ref-type="bibr" rid="CR21">21</xref>]. Today, it is established in most countries of the Mediterranean Sea, including Lebanon, Syria, and Israel. This mosquito is susceptible to 26 arboviruses including CHIKV, DENV, and YFV when provided by experimental infections [<xref ref-type="bibr" rid="CR22">22</xref>]. Unexpectedly, <italic>Ae. albopictus</italic> was responsible for CHIKV and DENV cases in Europe. Chikungunya virus emerged in Europe: in Italy in 2007 [<xref ref-type="bibr" rid="CR23">23</xref>] and in France in 2010 [<xref ref-type="bibr" rid="CR24">24</xref>] and 2014 [<xref ref-type="bibr" rid="CR25">25</xref>]. Dengue virus was detected in patients in Croatia in 2010 [<xref ref-type="bibr" rid="CR26">26</xref>] and in France in 2010 [<xref ref-type="bibr" rid="CR27">27</xref>], 2013 [<xref ref-type="bibr" rid="CR28">28</xref>], 2015 [<xref ref-type="bibr" rid="CR29">29</xref>].</p>
      <p>
<bold><italic>Culex pipiens</italic></bold>: <italic>Cx. pipiens</italic> complex should be considered as a polytypic species differentiated into several forms. The species <italic>Cx. pipiens</italic> is commonly found in the Palearctic and Oriental regions and described under two morphologically identical biotypes, named <italic>pipiens</italic> (Linnaeus 1758) and <italic>molestus</italic> (Forskål 1775), which show distinct feeding behavior. Biotype <italic>pipiens</italic> prefers birds as blood hosts whereas the biotype <italic>molestus</italic> prefers mammals [<xref ref-type="bibr" rid="CR30">30</xref>]. Hybrids between the two biotypes have an intermediate host preference, which makes them ideal vectors to bridge arboviruses such as WN and Usutu from birds to mammals [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The epidemiological cycle of WN disease involves migratory birds acting as reservoir and ornithophilic <italic>Culex</italic> mosquitoes mainly as vectors amplifying viral traffic between bird populations [<xref ref-type="bibr" rid="CR33">33</xref>]. Migratory birds ensure the introduction of the virus from Africa into temperate areas, North Africa and Europe [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Humans and horses present clinical symptoms, sometimes severe, but are generally considered dead-end hosts, as the level of viremia they develop is not high enough to infect mosquitoes.</p>
      <p>Ticks: In Europe, ticks are the most important vectors of human and animal pathogens. They transmit several viruses such as tick-borne encephalitis virus (TBEV) and Crimean-Congo hemorrhagic fever virus (CCHFV) that are reemerging in many parts of the world. Tick-borne viruses (TBV) are traditionally maintained in a natural cycle between vector ticks and wild animal hosts, humans being accidental hosts. New TBVs are continually being discovered [<xref ref-type="bibr" rid="CR36">36</xref>] presumably resulting from the proliferation of ticks in many regions of the world and incursion of humans into tick-infested habitats. <italic>Ixodes ricinus</italic> is the most widespread and abundant European tick presenting a high potential as vector of different pathogens: <italic>Borrelia</italic> bacteria responsible for Lyme disease, <italic>Anaplasma</italic> spp., <italic>Rickettsia</italic>, <italic>Babesia,</italic> and <italic>Theileria. Hyalomma</italic> ticks are aggressive species, which search for humans actively. <italic>Hyalomma marginatum</italic> and <italic>Hyalomma anatolicum</italic> are the main vectors of CCHF [<xref ref-type="bibr" rid="CR37">37</xref>]. Other species of <italic>Rhipicephalus</italic>, <italic>Boophilus</italic>, <italic>Haemaphysalis</italic>, <italic>Amblyomma</italic>, <italic>Dermacentor</italic>, and <italic>Hyalomma</italic> genera play a role in maintaining enzootic circulation of CCHFV among tick vectors and wild/domestic mammals [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
    </sec>
    <sec id="Sec4">
      <title>The Situation of Arboviruses in Countries Around the Mediterranean and Black Sea Regions (See Fig. <xref rid="Fig1" ref-type="fig">1</xref> and Table <xref rid="Tab1" ref-type="table">1</xref>) (in Alphabetical Order)</title>
      <p>
<fig id="Fig1"><label>Fig. 1</label><caption><p>Map showing the arboviruses detected in countries that are partners of the MediLabsecure network</p></caption><graphic xlink:href="40475_2017_101_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Potential mosquito vectors of arboviruses in 16 non-EU countries from the Mediterranean and Black Sea regions participating to the MediLabsecure network</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Genus</th><th>Sub-genus</th><th>Species</th><th>Albania</th><th>Algeria</th><th>Armenia</th><th>Bosnia and Herzegovine</th><th>Egypt</th><th>Georgia</th><th>Jordan</th><th>Lebanon</th><th>Libya</th><th>Rep. of Macedonia</th><th>Moldova</th><th>Morocco</th><th>Montenegro</th><th>Palestine</th><th>Serbia</th><th>Tunisia</th><th>Turkey</th><th>Ukraine</th><th>Total</th></tr></thead><tbody><tr><td>
<italic>Aedes</italic>
</td><td>
<italic>Stegomyia</italic>
</td><td>
<italic>aegypti</italic>
</td><td/><td/><td/><td/><td>1</td><td>1</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>1</td><td/><td>3</td></tr><tr><td>
<italic>Aedes</italic>
</td><td>
<italic>Stegomyia</italic>
</td><td>
<italic>albopictus</italic>
</td><td>1</td><td>1</td><td>1</td><td>1</td><td/><td>1</td><td>1</td><td>1</td><td/><td/><td/><td>1</td><td>1</td><td>1</td><td>1</td><td/><td>1</td><td/><td>12</td></tr><tr><td>
<italic>Aedes</italic>
</td><td>
<italic>Ochlerotatus</italic>
</td><td>
<italic>caspius</italic>
</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>18</td></tr><tr><td>
<italic>Aedes</italic>
</td><td>
<italic>Aedimorphus</italic>
</td><td>
<italic>vexans</italic>
</td><td>1</td><td>1</td><td>1</td><td>1</td><td/><td>1</td><td/><td/><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td/><td>1</td><td>1</td><td>1</td><td>1</td><td>14</td></tr><tr><td>
<italic>Culex</italic>
</td><td>
<italic>Barraudius</italic>
</td><td>
<italic>modestus</italic>
</td><td>1</td><td>1</td><td/><td/><td/><td>1</td><td/><td/><td/><td>1</td><td>1</td><td>1</td><td>1</td><td/><td>1</td><td/><td>1</td><td>1</td><td>10</td></tr><tr><td>
<italic>Culex</italic>
</td><td>
<italic>Culex</italic>
</td><td>
<italic>perexiguus</italic>
</td><td>1</td><td>1</td><td/><td/><td>1</td><td/><td>1</td><td>1</td><td>1</td><td>1</td><td/><td>1</td><td/><td>1</td><td>1</td><td>1</td><td>1</td><td/><td>12</td></tr><tr><td>
<italic>Culex</italic>
</td><td>
<italic>Culex</italic>
</td><td>
<italic>pipiens</italic>
</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>18</td></tr></tbody></table></table-wrap>
</p>
      <sec id="Sec5">
        <title>Albania</title>
        <p>Former studies on the phlebotomine fauna of Albania showed that eight species are present: <italic>Phlebotomus neglectus</italic>, <italic>Phlebotomus papatasi</italic>, <italic>Phlebotomus perfiliewi</italic>, <italic>Phlebotomus tobbi</italic>, <italic>Phlebotomus similis</italic>, <italic>Phlebotomus simici</italic>, <italic>Sergentomyia dentata</italic> and <italic>Sergentomyia minuta</italic>, with <italic>P. neglectus</italic> being the most abundant and widespread species in Albania [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. A new phlebovirus, provisionally named Adria virus has been detected in 2/12 pools of sandflies trapped close to the Adriatic Sea (Kruje and Lezhe). This new virus is genetically close to Arbia virus (similarity 77.1% at nucleotide level), which belongs to the Salehabad serocomplex. Its distribution and probable pathogenicity to humans are still unknown [<xref ref-type="bibr" rid="CR40">40</xref>]. A new virus has been detected by a next-generation sequencing approach in sandflies of Kruje region in 2014; it has been named Balkan virus belonging to the group of Sandfly fever Naples virus [<xref ref-type="bibr" rid="CR41">41</xref>]. The Balkan virus is closely related to the Tehran virus with 16 and 3% of divergence at nucleotide and amino acid levels, respectively.</p>
        <p>Crimean-Congo hemorrhagic fever virus (CCHFV) is endemic in Albania with intermittent outbreaks. The first CCHF case was described in 1986 in the northern part of the country (Kukes) near the border with Kosovo. Reemergence in the southern part of the country occurred in 2011 (Korce area, bordering Greece). Ticks collected during the 2003–2005 period from cattle were tested for presence of CCHFV RNA, while serum samples collected from goats, cattle, hares, and birds were tested for the presence of specific IgG antibodies to CCHFV. One of the 31 pools of ticks, consisting of four female <italic>Hyalomma</italic> spp. ticks, was found to carry CCHFV RNA with 99.2–100% homology to sequences detected in patients from the same region. Antibodies were not detected in cattle, hares, and birds, but two goats (among 10) presented high titers of IgG antibodies. The shepherd of the flock was a member of a family affected by CCHF 10 days before the collection of goats’sera, and he presented a mild form of the disease [<xref ref-type="bibr" rid="CR42">42</xref>]. The overall CCHFV antibody seroprevalence rate for ruminants in Albania was 23% [<xref ref-type="bibr" rid="CR43">43</xref>].</p>
        <p>In 1958, WN antibodies were detected in two human blood samples [<xref ref-type="bibr" rid="CR44">44</xref>]. In 2011, confirmed cases of WNV infections have been reported in humans. They were located in the coastal and in the central parts of Albania [<xref ref-type="bibr" rid="CR45">45</xref>].</p>
      </sec>
      <sec id="Sec6">
        <title>Algeria</title>
        <p>West Nile virus (WNV) has been first isolated in Algeria in 1968 from a pool of <italic>Culex</italic> mosquitoes in the district of Djanet, a Saharan oasis in the southeastern part of the country [<xref ref-type="bibr" rid="CR46">46</xref>]. In the 1970s (1973, 1975, and 1976), several serological surveys revealed WNV circulation in human populations in the Sahara and steppe areas [<xref ref-type="bibr" rid="CR47">47</xref>]. In 1994, more than 50 human cases and 8 fatalities were documented during an outbreak of WNV encephalitis in Tinerkouk oasis in the south-west of Algeria [<xref ref-type="bibr" rid="CR48">48</xref>]. In 2012, a retrospective serosurvey in Algiers and surrounding areas highlighted specific anti-WNV IgG in 11 out of 164 human samples tested [<xref ref-type="bibr" rid="CR49">49</xref>]. During the same year, a fatal neuro-invasive case was reported for the first time in northern Algeria, in the province of Jijel [<xref ref-type="bibr" rid="CR50">50</xref>]. In 2013, two more cases were notified, in the province of Guelma and in the Sahara desert, in the province of Timimoune [<xref ref-type="bibr" rid="CR51">51</xref>]. Recently, the WNV lineage 1 was detected in a pool of <italic>Culex perexiguus</italic> collected from the Oasis of Aougrout, province of Timimoune (unpublished data).</p>
        <p>Among sandfly-borne phleboviruses reported in Algeria, the Sandfly Fever Sicilian virus (SFSV) has been detected both in humans and sandflies in Tizi Ouzou district, northern part of the country [<xref ref-type="bibr" rid="CR52">52</xref>]. Between 2015 and 2016, serological evidence of Toscana virus (TOSV) circulation was reported both in humans and dogs [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. During the same period, TOSV was isolated from sandflies collected in Tizi Ouzou [<xref ref-type="bibr" rid="CR53">53</xref>]. Furthermore, several cases of meningitis and meningo-encephalitis due to TOSV were detected these last 2 years (unpublished data).</p>
        <p>Regarding Rift Valley fever (RVF), Algeria as well as all North Africa region is at high risk with respect to the epidemiological situation in neighboring countries in the Sahara, with recurrent outbreaks in Mauritania (2010, 2012 and 2015) and recently in Niger (2016). So far, there has been no human case reported in Algeria, despite evidence from serological data that the virus circulated in the southern part of the country [<xref ref-type="bibr" rid="CR55">55</xref>].</p>
        <p>Between 2015 and 2016, only few imported cases of dengue were reported (unpublished data); however, the risk of autochthonous cases remains significant since <italic>Ae. albopictus</italic>, the vector of DENV, CHIKV, and ZIKV, has been recently established in two high densely populated cities in Algeria, Oran [<xref ref-type="bibr" rid="CR56">56</xref>] and Algiers (unpublished data). Earlier this year 2016, the Crimean-Congo Hemorrhagic fever virus (CCHFV) has been isolated from <italic>Hyalomma aegyptium</italic> ticks in the South of Algeria [<xref ref-type="bibr" rid="CR57">57</xref>].</p>
      </sec>
      <sec id="Sec7">
        <title>Armenia</title>
        <p>Armenia is located in the South Caucasus and is mainly composed of highlands and mountains. Until now, five genera of Culicidae have been described in Armenia. The genus <italic>Anopheles</italic> is represented by six species <italic>An. maculipennis</italic>, <italic>An. sacharovi</italic>, <italic>An. claviger</italic>, <italic>An. hyrcanus</italic>, <italic>An. superpictus</italic>, <italic>An. plumbeus</italic> [<xref ref-type="bibr" rid="CR58">58</xref>]. The most common Culicine species are: <italic>Cx. pipiens</italic>, <italic>Cx. hortensis</italic>, <italic>Cx. theileri</italic>, and <italic>Ae. caspius</italic>. In 2006, an extensive entomological survey has allowed to collect 64,567 mosquitoes and 45,180 <italic>Ixodidae</italic> ticks and identify 125 distinct strains of arboviruses in four climatic regions: the dry steppe (up to 800 m above sea level), desert and semi-desert (800–1100 m above sea level), mountain steppe, mountain forest (2000–2500 m) and Alpine (above 2500 m). From the 64,567 mosquitoes, 47,674 were <italic>Anopheles</italic> (73.8%), 11,252 <italic>Culex</italic> (17.4%) and 5641 <italic>Aedes</italic> (8.7%). From 45,180 ticks are found 31,371 <italic>Dermacentor</italic> (70%), 4425 <italic>Rhipicephalus</italic> (10%), 3630 <italic>Hyalomma</italic> (8%), 2913 <italic>Boophilus</italic> (6%), 1747 <italic>Haemaphisalis</italic> (4%), and 1094 <italic>Ixodes</italic> (2%). From mosquitoes, four viruses have been isolated: Batai (<italic>Orthobunyavirus</italic>, Bunyaviridae) in <italic>Culex</italic> mosquitoes, Sindbis (<italic>Alphavirus</italic>, Togaviridae) in <italic>Culex</italic>, Tahyna (<italic>Orthobunyavirus</italic>, Bunyaviridae) in <italic>Aedes</italic> mosquitoes, and WNV in <italic>Cx. pipiens</italic>. From ticks, at least five viruses have been detected: TBEV (<italic>Flavivirus</italic>, Flaviviridae) in <italic>Ixodes</italic>, Dhori (<italic>Thogotovirus</italic>, Orthomyxoviridae) in Ixodidae, Bhanja (Phlebovirus, Bunyaviridae) in <italic>Haemaphysalis</italic>, Tamdy (<italic>Nairovirus</italic>, Bunyaviridae) in Ixodidae, and CCFHV (<italic>Nairovirus</italic>, Bunyaviridae) in <italic>Hyalomma</italic> [<xref ref-type="bibr" rid="CR59">59</xref>].</p>
      </sec>
      <sec id="Sec8">
        <title>Lebanon</title>
        <p>Lebanon is located on the eastern side of the Mediterranean Sea that is considered endemic for several arboviral diseases such as West Nile that has been reported from neighboring countries: Israel [<xref ref-type="bibr" rid="CR60">60</xref>] and Turkey [<xref ref-type="bibr" rid="CR61">61</xref>]. A number of epidemics of Dengue fever had occurred in Lebanon in the past, of which one was reported from Beirut region and affected more than 100,000 individuals in 1945–1946. A serological survey conducted in 1962 to 1963 using the hemagglutination-inhibition test showed a seroprevalence for WNV and DENV of 62.5 and 61.9%, respectively. During the malaria control program and as a result of mosquito control efforts, <italic>Ae. aegypti</italic>, the widespread dengue vector, was eliminated from the country. With the beginning of the civil war in 1975, all vector control programs ceased and never resumed since then. Consequently, mosquito populations became a public health burden and a source of nuisance. Entomological studies conducted in 2002 showed a widespread of <italic>Cx. pipiens</italic> in the country in addition to the presence of other arbovirus vectors such as <italic>Cx. perexiguus</italic>, a species involved in the transmission of WNV in Israel [<xref ref-type="bibr" rid="CR62">62</xref>]. Moreover, <italic>Ae. albopictus</italic> was introduced to Lebanon and recorded for the first time in 2002 [<xref ref-type="bibr" rid="CR63">63</xref>]. This mosquito is now established in the country and is widespread in the coastal areas around big cities and in middle altitude humid regions. Local strains of the Asian tiger mosquito showed to be competent mainly for transmission of CHIKV but also DENV [<xref ref-type="bibr" rid="CR64">64</xref>]. In 2007, an outbreak of Sandfly fever virus occurred in Nahr El Bared, near Tripoli, North Lebanon. More than 700 cases were declared among Lebanese soldiers during military operations. A Sandfly fever virus strain close to the Sicilian strain was identified as the causative agent (Lebanese Ministry of Health sources, unpublished data). Tick-borne viruses have never been documented in Lebanon. Some of these viruses such as CCHFV occur in some neighboring countries: Turkey and Iran [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Presently, Lebanon is considered at risk for the occurrence of several arboviral diseases such as WNV. Not only is Lebanon situated in an endemic area, but it also constitutes a major stopover for migrating birds, WNV principal reservoir. <italic>Aedes</italic>-borne viruses, such as CHIKV, DENV, and ZIKV, should also be regarded as potential threats. Their introduction to the country is highly likely if we consider the important flux of Lebanese expatriates coming from endemic areas in Latin America, Africa, and South-East Asia.</p>
      </sec>
      <sec id="Sec9">
        <title>Libya</title>
        <p>Libya has become a place of passage for migrants who cross the country to Europe. They mainly come from Sub-Saharan Africa, where several arboviral diseases are endemic. As well, the illegal animal trade can be a risk for the introduction of zoonotic viruses such as RVFV. Libya is then subjected to regular serological surveys for arbovirus antibodies [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. In the most recent survey, 950 human blood samples collected in the country were examined to determine the seroprevalence (baseline exposure) to zoonotic viruses and bacteria causing acute febrile illness [<xref ref-type="bibr" rid="CR68">68</xref>]. Antibodies against WNV (13.1%), SFNV (0.5%), SFSV (0.7%), Sindbis virus (SINV, 0.5%), and RVFV (0.4%) have been detected. For WNV, the prevalence among the Tripoli population is 2.8% (unpublished data) and 25% of the population in the Yfran area for TOSV (unpublished data).</p>
      </sec>
      <sec id="Sec10">
        <title>The Former Yugoslav Republic of Macedonia</title>
        <p>In the Republic of Macedonia, CCHF and WN are mandatory notifiable diseases. In 1970, the first outbreak of CCHF occurred in the Ciflik village, Tetovo, with 13 confirmed cases, of which there were two deaths. Until 2002, 11 new cases of CCHF were notified. During the period 2002–2010, only one new case was registered. From a total of 128 ticks collected from cattle, sheep, and goat, the ratio between <italic>Hyalomma</italic> and <italic>Rhipicephalus</italic> ticks was 1:3. Between 2009 and 2011, a seroepidemiological study for CCHFV on 158 serum samples collected from cattle, the prevalence of antibodies rated up to 80% in the cattle population from the Northeastern region of Macedonia [<xref ref-type="bibr" rid="CR69">69</xref>].</p>
        <p>Serological investigation on human for WNV IgM and IgG was performed since 2010 by ELISA. Until 2016, 214 human cases with symptoms of neurologic illness were tested: 53 were positive with WNV IgM antibodies.</p>
      </sec>
      <sec id="Sec11">
        <title>Moldova</title>
        <p>WNV is the main arbovirus isolated in Moldova. It has been detected in ticks in central and southern regions of Moldova between 1974 and 1978: <italic>Ixodes ricinus</italic> (1974, 1975) and <italic>Dermacentor marginatus</italic> (1974, 1976 and 1978) from Nisporeni, Hincesti, and Vulcanesti regions. CCHFV has been isolated from <italic>I. ricinus</italic>, <italic>D. marginatus</italic>, and <italic>Haemaphysalis punctata</italic> between 1973 and 1974 from Slobozia, Nisporeni, Hincesti, and Ceadir-Lunga regions [<xref ref-type="bibr" rid="CR70">70</xref>]. TBEV was isolated from <italic>D. marginatus</italic> in 1975 in Nisporeni region and from mosquitoes in Moldova [<xref ref-type="bibr" rid="CR71">71</xref>]. Batai virus has been detected in <italic>An. maculipennis</italic> s.l. in 1977 in Zberoaia village (western Moldova) [<xref ref-type="bibr" rid="CR72">72</xref>]. Tahyna virus and WNV were isolated from mosquitoes in Moldova [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Recent epidemiological studies in Romania in the Danube Delta, close to the border to Moldova reported the presence of WNV lineage 2 in mosquitoes and Ixodidae ticks collected from migratory birds [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. Migratory birds are well-known reservoir hosts for a number of arboviruses and play an important role in distributing pathogens within and between countries [<xref ref-type="bibr" rid="CR76">76</xref>]. The Danube Delta is one of the most important migratory sites in Europe and the risk of arbovirus dissemination through the birds to Moldova is extremely high.</p>
      </sec>
      <sec id="Sec12">
        <title>Montenegro</title>
        <p>Using different trapping methods of adults and immature stages, 174 sampling sites have been examined during 127 sampling nights in 20 of 22 municipalities in Montenegro. A total of 22 mosquito species were identified: 3 <italic>Anopheles</italic> potential vectors of malaria (<italic>An. saccharovi</italic>, <italic>An. maculipennis</italic>, <italic>An. plumbeus</italic>), 12 <italic>Aedes</italic> with <italic>Aedes vexans</italic> and <italic>Ae. caspius</italic>, potential vector of RVFV, <italic>Ae. albopictus</italic> (vector of CHIKV and DENV), 3 <italic>Culex</italic> with <italic>Cx. modestus</italic> and <italic>Cx. pipiens</italic>, potential vector of WNV and RVFV, 2 <italic>Cs</italic>. (<italic>Culiseta annulata</italic>, <italic>Cs. longiareolata</italic>), and 2 <italic>Coquillettidia</italic> (<italic>Cq. richiardii</italic> and <italic>Cq. buxtoni</italic>) (study done by the LOVCEN project in cooperation with the MediLabSecure and VectorNet projects). Montenegro is a country susceptible to be hit by a mosquito-borne viral disease as its neighboring country Croatia which experienced in 2010 an autochthonous transmission of DENV [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      </sec>
      <sec id="Sec13">
        <title>Morocco</title>
        <p>The most prevalent arbovirus in Morocco is WNV, mainly affecting horses with epizootics detected in 1996 [<xref ref-type="bibr" rid="CR77">77</xref>], 2003 [<xref ref-type="bibr" rid="CR78">78</xref>], and 2010 [<xref ref-type="bibr" rid="CR79">79</xref>]. The viral isolates from 1996 to 2003 belonged to WNV lineage 1, clade 1a. In 1996, WNV infection was first detected in a patient [<xref ref-type="bibr" rid="CR77">77</xref>]. In 2008, a serosurvey of wild birds confirmed the circulation of WNV in native birds [<xref ref-type="bibr" rid="CR80">80</xref>]. Serological surveillance confirmed that WNV is widely present [<xref ref-type="bibr" rid="CR81">81</xref>]. <italic>Culex pipiens</italic> is highly suspected in the transmission of WNV in Morocco [<xref ref-type="bibr" rid="CR82">82</xref>]. Moreover, RVF is another arbovirus also transmitted by <italic>Cx. pipiens</italic>, which circulates at a common border with Mauritania where the first West African outbreak of RVF occurred in 1987 [<xref ref-type="bibr" rid="CR83">83</xref>]. Following this epidemic, Mauritania has experienced several other episodes: in 1993, 1998, 2003, 2010, and 2012 [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. In 2010, following unusual heavy rains, an epidemic affecting mainly camels presenting severe clinical signs and high mortalities was reported in northern Mauritania. It has been suggested that the oasis can play a role as a site of emergence of RVF in the Maghreb where eco-climatic and entomological conditions are suitable for vector development. The border with Mauritania consists of hundreds of kilometers which are a real strainer to unauthorized migrants, nomads and domestic animals. Serological surveys of humans and animals should be reinforced in addition to viral isolations in mosquitoes. Apart from its role as vector, <italic>Cx. pipiens</italic> is mainly considered a nuisance in most urban areas. It is for this reason that it has been targeted for years in mosquito control programs. The most widely used insecticides are pyrethroids, organophosphorus and carbamates. Although the level of resistance to insecticides of this mosquito is the object of a regular surveillance by the Ministry of Health since 2003, published data remain fragmentary. Overall, <italic>Cx. pipiens</italic> populations showed significant resistance to insecticides used [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>] compromising the strategy of mosquito control. Other arboviruses such as DENV, CHIKV and ZIKV were not yet detected in Morocco. However, the vector <italic>Ae. albopictus</italic> has been detected recently in the town of Rabat [<xref ref-type="bibr" rid="CR88">88</xref>].</p>
        <p>Regarding sandfly-borne viruses, TOSV is known to be present in Morocco [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. It was isolated from <italic>P. sergenti</italic> and <italic>P. longicupis</italic> collected in north and center of Morocco between 2008 and 2011 [<xref ref-type="bibr" rid="CR91">91</xref>]. Moreover, CCHFV has been isolated from <italic>Hyalomma marginatum</italic> ticks in South Morocco in 2011 [<xref ref-type="bibr" rid="CR92">92</xref>].</p>
      </sec>
      <sec id="Sec14">
        <title>Palestine</title>
        <p>Only sporadic cases of WN have been detected in Palestine. Since 2000, six human cases were reported in the West Bank of Palestine with four cases occurring in the northern districts (2 cases in 2000 in Nablus and Jenin districts, and 2 cases in 2008–2010 in Qalqilia district) and two cases in Jericho city in 2011–2014. All patients were males between 35 and 65 years old. One patient from Jericho died from the WNV infection. <italic>Cx. pipiens</italic> was suspected as the main vector; it is present in the West Bank, especially in Tubas, Qalqiliah, Jericho, and Bethlehem districts and active all year long with the highest densities in summer. Other arboviral diseases are occasionally detected: CCHF, SINV fever, and Sandfly fever. In Palestine, arboviral diseases must be notified to the Preventive Medicine Division in the district of the patient’s residence. Then a special investigation is set off with reports to the Central Preventive Medicine Department. Control measures are immediately implemented by the vector control unit of the Health Promotion Department. In addition to <italic>Cx. pipiens</italic>, three other mosquito species were reported: <italic>Ae. albopictus</italic>, <italic>An. claviger</italic>, and <italic>Cs. longiareolata. Aedes albopictus</italic> widely found in the West Bank (Tubas, Qalqiliah, Jericho and Bethlehem districts), is active from March to November with the highest densities reported in August. Monthly investigations at district level for breeding sites are implemented by the vector control unit. In 2015, about 7500 sites were inspected for mosquito breeding and 61% were positive for immature stages. Eighty-five percent of positive sites were treated using environmental measures and 9% treated with pesticides (pyrethroids or <italic>Bacillus thuringiensis</italic>).</p>
      </sec>
      <sec id="Sec15">
        <title>Serbia</title>
        <p>Serbia experienced the second largest outbreak of WN in Europe, with 200 confirmed human cases in 2013 (<ext-link ext-link-type="uri" xlink:href="http://ecdc.europa.eu/en/healthtopics/west_nile_fever/West-Nile-fever-maps/Pages/historical-data.aspx%23sthash.S97C32Ep.dpuf">http://ecdc.europa.eu/en/healthtopics/west_nile_fever/West-Nile-fever-maps/Pages/historical-data.aspx#sthash.S97C32Ep.dpuf</ext-link>). The largest numbers of human cases, as well as outbreaks of various magnitudes, have been reported repeatedly in the Vojvodina province of northern Serbia since 2012 (9 in 2012, 85 in 2013, 27 in 2014, and 10 in 2015) (<ext-link ext-link-type="uri" xlink:href="http://www.batut.org.rs/index.php">http://www.batut.org.rs/index.php</ext-link>). The first serological investigation for WNV was conducted in 1972, and antibodies against WNV were found in 2.6–4.7% of human sera [<xref ref-type="bibr" rid="CR93">93</xref>]. Between 2001 and 2005, the seroprevalence for WNV was 6.7% in 45 patients who had been hospitalized for encephalitis or meningoencephalitis. Information on asymptomatic cases was also provided: 3.7% among 406 samples taken from healthy people. In 2001–2009, the seroprevalence was estimated to be 4% (18 of 451). A total of 337 individuals tested in 2009 were exposed to at least one mosquito exposure-related risk factor. Within this group, 5% were seropositive for WNV. Most of the people with IgG positive against WNV did not have screen protections on windows and doors of their houses, while only 0.9% of those using window screens were seropositive for WNV [<xref ref-type="bibr" rid="CR94">94</xref>]. During the same period, 56,757 mosquito specimens sampled on migratory and domestic bird reservoirs, were all negative for WNV RNA. A serological analysis by ELISA based on WNV recombinant envelope E (rE) protein and PRNT showed, for the first time in Serbia, that 12% of 349 horses from the northern part of country sampled in 2009–2010 presented specific neutralizing WNV antibodies [<xref ref-type="bibr" rid="CR95">95</xref>]. Due to the absence of routine diagnosis and the limited resources of hospitals in Serbia, human cases of meningoencephalitis of unknown origin were not tested until 2012. In addition, regular surveillances of sentinel chicken, horses or mosquitoes are not performed. Consequently, the approach used to search for the virus in Serbia had been focused on detection of IgG-positive humans and virus in field-collected mosquitoes. In 2010, WNV linage 2 was detected in <italic>Cx. pipiens</italic> [<xref ref-type="bibr" rid="CR94">94</xref>]. In August 2012, an outbreak of WN in humans was reported for the first time in Serbia (<ext-link ext-link-type="uri" xlink:href="http://www.episouthnetwork.org/content/episouth-weekly-epi-bulletin-e-web">http://www.episouthnetwork.org/content/episouth-weekly-epi-bulletin-e-web</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://ecdc.europa.eu/en/healthtopics/west_nile_fever/West-Nile-fever-maps/Pages/index.aspx">http://ecdc.europa.eu/en/healthtopics/west_nile_fever/West-Nile-fever-maps/Pages/index.aspx</ext-link>.). During the same year, viral RNA was detected for the first time in nine wild birds. All these isolates belonged to the WNV lineage 2 and were closely related to strains responsible for recent outbreaks in Greece, Italy and Hungary [<xref ref-type="bibr" rid="CR96">96</xref>]. From 2005 to 2013, WNV surveillance activities in Vojvodina province, northern Serbia, were performed as part of ongoing research projects. In 2014, a specific and integrated surveillance system targeting mosquitoes [<xref ref-type="bibr" rid="CR97">97</xref>], wild and sentinel birds as well as horses, was set up by the National Veterinary Directorate in Vojvodina. The main goals of this nationwide WNV surveillance have been to provide warnings of WNV circulation and evidence-based tools for controlling the spread of WNV infections in humans.</p>
      </sec>
      <sec id="Sec16">
        <title>Tunisia</title>
        <p>Since the first half of last century, rapid urbanization and changes in agriculture practices have created environmental conditions favorable to the proliferation of <italic>Cx. perexiguus</italic> and <italic>Cx. pipiens</italic>. The latter became the dominant species in urban and rural areas. Consequently, WN became the most important arboviral disease for public health. In Tunisia, the first outbreak of meningoencephalitis due to WNV was observed in autumn 1997 in two coastal districts (Sousse and Sfax) causing more than 173 cases with 8 deaths [<xref ref-type="bibr" rid="CR98">98</xref>]. The WNV belonged to the lineage 1a (Tunisian strain PaH001) which is closely related to the group of American/Israeli viruses collected between 1998 and 2000 [<xref ref-type="bibr" rid="CR99">99</xref>]. The second WN outbreak was reported in 2003 in all East coastal districts. Twenty patients with neurological signs including three fatal cases were reported in the district of Sousse [<xref ref-type="bibr" rid="CR100">100</xref>]. In 2007, a total of 1854 sera collected from healthy patients from three different districts (north, center and south) were investigated by ELISA to detect specific IgG against WNV. Specific IgG were detected in 12.5% of studied population. The seroprevalence varied largely between the three districts: high endemicity in the center (27.7% in Kairouan district), moderate in the southern region (7.5% in the Sfax district), and low in the north (0.7% in the Bizerte district) [<xref ref-type="bibr" rid="CR101">101</xref>]. The third important outbreak of WN was observed in 2012; 86 cases with neurological signs were confirmed by serological tests, 12 patients died [<xref ref-type="bibr" rid="CR102">102</xref>]. Equids are also affected: the serological investigation tested by competitive enzyme-linked immunoassay of 284 horses conducted in 2012 in the southern west region of the country showed that 120 (42.3%) had WNV-specific neutralizing antibodies. The prevalence was significantly higher in areas close to the oasis compared with that of the surrounding arid areas [<xref ref-type="bibr" rid="CR103">103</xref>].</p>
        <p>Sandfly fever viruses belonging to the <italic>Phlebovirus</italic> genus of the <italic>Bunyaviridae</italic> family were occasionally reported. They include two main serocomplexes: Naples (Sandfly fever Naples virus, SFNV) and Sicilian (Sandfly fever Sicilian virus, SFSV), which are associated with human diseases. Besides, Toscana virus (TOSV) is a variant of Sandfly fever Naples virus. It is endemic in Mediterranean countries especially in Tunisia. In a recent study, Fezaa et al. [<xref ref-type="bibr" rid="CR104">104</xref>] showed that out of 263 patients with neurological disorder tested using ELISA, 12.2% (<italic>n</italic> = 32/263) were IgM positive for TOSV. Of these 32 patients, 78% (<italic>n</italic> = 25/32) were IgG positive. In addition, 12.8% (<italic>n</italic> = 18/140) of the cerebrospinal fluid (CSF) samples tested by RT-PCR were positive for TOSV. One CSF sample tested by RT-PCR revealed the presence of SFSV [<xref ref-type="bibr" rid="CR104">104</xref>]. By RT-PCR, TOSV was detected in <italic>Phlebotomus perniciosus</italic> and <italic>Phlebotomus perfiliewi</italic> collected in north Tunisia. In addition, the Punique virus was identified in <italic>P. perniciosus</italic> [<xref ref-type="bibr" rid="CR104">104</xref>]. Among 494 healthy individuals from various regions of Tunisia tested by ELISA for anti-TOSV IgGs, 47 people (9.5%) were positive. Seroprevalence varied with bioclimatic regions and gender [<xref ref-type="bibr" rid="CR104">104</xref>].</p>
        <p>Usutu Virus (USUV), which is a “new” emerging <italic>Flavivirus</italic> antigenically close to WNV and also transmitted by <italic>Culex</italic> mosquitoes, has never been reported in humans in Tunisia. In a recent study, antibody titers against USUV were reported in 10 equines (among 284) [<xref ref-type="bibr" rid="CR103">103</xref>]. In a serological investigation, Nabli et al. [<xref ref-type="bibr" rid="CR105">105</xref>] recorded that 0.2% of human serum samples (<italic>n</italic> = 1406) from different regions of Tunisia were positive to the Sindbis virus [<xref ref-type="bibr" rid="CR105">105</xref>].</p>
      </sec>
      <sec id="Sec17">
        <title>Turkey</title>
        <p>Arbovirus screening in vertebrate hosts and vectors conducted in the last 15 years have revealed the activity of arboviruses transmitted by mosquitoes, sandflies, ticks and <italic>Culicoides</italic> [<xref ref-type="bibr" rid="CR106">106</xref>–<xref ref-type="bibr" rid="CR108">108</xref>]. Among mosquito-borne viruses, WNV is known to be present in Turkey since the 1970s [<xref ref-type="bibr" rid="CR109">109</xref>]. After the detection of serological evidence of WNV in various animals (ass-mule, cattle, dog, horse and sheep) in eight provinces [<xref ref-type="bibr" rid="CR110">110</xref>], human cases were detected [<xref ref-type="bibr" rid="CR61">61</xref>]. The WNV Lineage 1 clade 1a was confirmed in both humans and horses [<xref ref-type="bibr" rid="CR111">111</xref>]. Further studies corroborated the circulation of the virus in the East (ducks and horses) as well as South East (horses and sheep), South (horses) and West parts of the country (dogs and sheep) [<xref ref-type="bibr" rid="CR112">112</xref>]. The virus was also detected in primary and secondary vectors <italic>Cx. pipiens</italic> s.s. and <italic>Ae. caspius</italic> samples in North West [<xref ref-type="bibr" rid="CR113">113</xref>], in <italic>Cx. quinquefasciatus</italic> and <italic>Cx. perexiguus</italic> in the South [<xref ref-type="bibr" rid="CR112">112</xref>]. These results also confirmed the presence of the most important vector of the virus worldwide, <italic>Cx. quinquefasciatus</italic> with DNA barcoding for the first time in the country [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]. Established populations of the invasive <italic>Ae. aegypti</italic> and <italic>Ae. albopictus</italic> were recorded in the northeast of the country in 2015 [<xref ref-type="bibr" rid="CR15">15</xref>••]. Due to the fact that these species are involved in the transmission of CHIKV, DENV, YFV, and ZIKV, they will become a public health concern. Data from blood donors in recent years have shown evidence for DENV exposure in Central Anatolia, thus its reemergence is probable [<xref ref-type="bibr" rid="CR115">115</xref>]. Imported cases of CHIK also represent a threat [<xref ref-type="bibr" rid="CR116">116</xref>].</p>
        <p>On the other hand, some major and novel <italic>Phlebovirus</italic> serotypes are endemic in Turkey. Sandfly fever Sicilian virus (SFSV), Naples virus (SFNV), and Toscana virus (TOSV) are known to be present in the country [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. In addition, Sandfly fever Turkish virus (SFTV), a variant of SFSV was discovered and <italic>Phlebotomus major</italic> s.l. is detected as the best vector candidate so far [<xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. Last year, Adana virus, a novel <italic>Phlebovirus</italic> belonging to the Salehabad virus complex was identified, with high seroprevalences in dogs, goats, sheeps but a low seroprevalence in humans [<xref ref-type="bibr" rid="CR53">53</xref>]. A recent study revealed that dogs are candidate reservoirs of TOSV in Turkey and co-infection of this virus with <italic>Leishmania infantum</italic> is detected [<xref ref-type="bibr" rid="CR120">120</xref>]. To put that into perspective, co-infection of TOSV and WNV was also documented in a human case for the first time, causing enhanced pathogenicity with severe clinical outcomes [<xref ref-type="bibr" rid="CR121">121</xref>].</p>
        <p>Caused by biting midges, bluetongue virus (BTV) is one of the most important diseases of domestic livestock. It was recorded in 15 provinces of Turkey, on Western [<xref ref-type="bibr" rid="CR108">108</xref>], North Western [<xref ref-type="bibr" rid="CR122">122</xref>], Eastern [<xref ref-type="bibr" rid="CR123">123</xref>], South Eastern [<xref ref-type="bibr" rid="CR124">124</xref>], and Central Anatolia [<xref ref-type="bibr" rid="CR125">125</xref>] throughout the years, sharing lineages 2, 4, 6, 9, 10, 13, and 16 with its neighboring countries [<xref ref-type="bibr" rid="CR108">108</xref>].</p>
        <p>Tick-borne encephalitis (TBE) and Crimean-Congo hemorrhagic fever (CCHF) had a significant impact in Turkey. Since 2002, there have been more than 9700 patients infected with CCHFV with around 5% overall mortality rate [<xref ref-type="bibr" rid="CR107">107</xref>]. Ticks collected from migratory birds were found infected with CCHFV genotype 4, whereas CCHFV Europe I clade is known to be present in Central Anatolia [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR127">127</xref>]. In the same region, a recent study has shown that clade I is also affecting the Anatolian wild sheep <italic>Ovis gmelinii anatolica</italic> [<xref ref-type="bibr" rid="CR128">128</xref>]. The virus was also detected in the north-western part of the country, outside the endemic region for several tick species [<xref ref-type="bibr" rid="CR129">129</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec18" sec-type="conclusion">
      <title>Conclusions</title>
      <p>Arboviruses, mosquito-borne viruses in particular, including DENV, CHIKV, and WNV, are becoming a global health issue, spreading beyond their natural range of distribution, mainly in sub-Saharan Africa. DENV and CHIKV have benefitted from increasing human mobility and the larger geographical distribution of the vectors <italic>Ae. aegypti</italic> and <italic>Ae. albopictus</italic> which expand their area of activity to new regions and continents including high-income countries. The introduction of these viruses in naive countries relies on long distance spread taking advantage of human travels. By contrast, the spread of WNV depends primarily on bird migration and local viral dynamics relying on activities of mosquito populations. Given this global threat, the surveillance system (animal, human and vectors) must be strengthened to prevent outbreaks and/or to ensure the early detection of a potential epidemic. These are the objectives of the MedilLabSecure project: strengthen the preparedness for arboviral diseases in countries of the Mediterranean and Black Sea regions that should be considered a unique episystem for emergence of vector-borne diseases in Europe.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>Anna-Bella Failloux, Ali Bouattour, Chafika Faraj, Filiz Gunay, Nabil Haddad, Zoubir Harrat, Elizabeta Jancheska, Khalil Kanani, Mohamed Amin Kenawy, Majlinda Kota, Igor Pajovic, Lusine Paronyan, Dusan Petric, Mhammed Sarih, Samir Sawalha, Taher Shaibi, Kurtesh Sherifi, Tatiana Sulesco, Enkelejda Velo, Lobna Gaayeb, Kathleen Victoir and Vincent Robert have contributed equally.</p>
      </fn>
      <fn>
        <p>This article is part of the Topical Collection on <italic>Tropical Medicine in the Mediterranean Region</italic>
</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We are grateful to Béatrice de Cougny (Institut Pasteur) for preparing the figure. Our thanks also go to Tamaš Petrović from Scientific Veterinary Institute “Novi Sad,” Serbia, and Ivana Hrnjaković Cvetković from the Institute of Public Health of Vojvodina Province/Faculty of Medicine, University of Novi Sad, Serbia for providing data on viruses in animal and human populations, and to Adbdallah Samy from Ain Shams University, Egypt, for the data on vector biology. The MediLabSecure project is supported by the European Commission (DEVCO: IFS/21010/23/_194) <ext-link ext-link-type="uri" xlink:href="http://www.medilabsecure.com">http://www.medilabsecure.com</ext-link>.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with Ethical Standards</title>
      <sec id="FPar1">
        <title>Conflict of Interest</title>
        <p>All authors declare that they have no conflict of interest.</p>
      </sec>
      <sec id="FPar2">
        <title>Human and Animal Rights and Informed Consent</title>
        <p>This article does not contain any studies with human or animal subjects performed by any of the authors.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref-list id="BSec1">
        <title>Papers of particular interest, published recently, have been highlighted as: •• Of major importance</title>
        <ref id="CR1">
          <label>1.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Amraoui</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Failloux</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Chikungunya: an unexpected emergence in Europe</article-title>
            <source>Curr Opin Virol</source>
            <year>2016</year>
            <volume>21</volume>
            <fpage>146</fpage>
            <lpage>50</lpage>
            <?supplied-pmid 27771517?>
            <pub-id pub-id-type="pmid">27771517</pub-id>
          </element-citation>
        </ref>
        <ref id="CR2">
          <label>2.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Rezza</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Dengue and chikungunya: long-distance spread and outbreaks in naive areas</article-title>
            <source>Pathog Glob Health</source>
            <year>2014</year>
            <volume>108</volume>
            <issue>8</issue>
            <fpage>349</fpage>
            <lpage>55</lpage>
            <?supplied-pmid 25491436?>
            <pub-id pub-id-type="pmid">25491436</pub-id>
          </element-citation>
        </ref>
        <ref id="CR3">
          <label>3.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Septfons</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leparc-Goffart</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Couturier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Franke</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Deniau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Balestier</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Travel-associated and autochthonous Zika virus infection in mainland France, 1 January to 15 July 2016</article-title>
            <source>Eur Surveill</source>
            <year>2016</year>
            <volume>21</volume>
            <issue>32</issue>
            <fpage>30315</fpage>
          </element-citation>
        </ref>
        <ref id="CR4">
          <label>4.</label>
          <mixed-citation publication-type="other">•• Escadafal C, Gaayeb L, Riccardo F, Perez-Ramirez E, Picard M, Dente MG, et al. Risk of Zika virus transmission in the Euro-Mediterranean area and the added value of building preparedness to arboviral threats from a one health perspective. BMC Public Health. 2016;16(1):1219. <bold>The MediLabSecure network, created in 2014, comprising 55 laboratories in 19 countries in the Mediterranean and the Black Sea regions, aims to improve capacity-building for arbovirus diagnostics through trainings on techniques common to several arboviruses, including Zika.</bold>.</mixed-citation>
        </ref>
        <ref id="CR5">
          <label>5.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Rosen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Dengue in Greece in 1927 and 1928 and the pathogenesis of dengue hemorrhagic fever: new data and a different conclusion</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>1986</year>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>642</fpage>
            <lpage>53</lpage>
            <?supplied-pmid 3518510?>
            <pub-id pub-id-type="pmid">3518510</pub-id>
          </element-citation>
        </ref>
        <ref id="CR6">
          <label>6.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Curtin</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Status of Aedes aegypti in the Eastern Mediterranean</article-title>
            <source>J Med Entomol</source>
            <year>1967</year>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <lpage>50</lpage>
            <?supplied-pmid 6074036?>
            <pub-id pub-id-type="pmid">6074036</pub-id>
          </element-citation>
        </ref>
        <ref id="CR7">
          <label>7.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bres</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>A century of progress in combating yellow fever</article-title>
            <source>Bull World Health Organ</source>
            <year>1986</year>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>775</fpage>
            <lpage>86</lpage>
            <?supplied-pmid 3549030?>
            <pub-id pub-id-type="pmid">3549030</pub-id>
          </element-citation>
        </ref>
        <ref id="CR8">
          <label>8.</label>
          <mixed-citation publication-type="other">Fontenille D, Failloux AB, Romi R. Should we expect chikungunya and dengue in Southern Europe? Emerging pests and vector-borne diseases in Europe. 2007;169–84.</mixed-citation>
        </ref>
        <ref id="CR9">
          <label>9.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Erdelyi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ursu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ferenczi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Szeredi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ratz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Skare</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clinical and pathologic features of lineage 2 West Nile virus infections in birds of prey in Hungary</article-title>
            <source>Vector Borne Zoonotic Dis</source>
            <year>2007</year>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <lpage>8</lpage>
            <?supplied-pmid 17627436?>
            <pub-id pub-id-type="pmid">17627436</pub-id>
          </element-citation>
        </ref>
        <ref id="CR10">
          <label>10.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ciota</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Vector-virus interactions and transmission dynamics of West Nile virus</article-title>
            <source>Viruses</source>
            <year>2013</year>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>3021</fpage>
            <lpage>47</lpage>
            <?supplied-pmid 24351794?>
            <pub-id pub-id-type="pmid">24351794</pub-id>
          </element-citation>
        </ref>
        <ref id="CR11">
          <label>11.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Aitken</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trapido</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The status of anophelism and malaria in Sardinia during 1951 and 1952</article-title>
            <source>Am J Hyg</source>
            <year>1954</year>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <lpage>51</lpage>
            <?supplied-pmid 13180500?>
            <pub-id pub-id-type="pmid">13180500</pub-id>
          </element-citation>
        </ref>
        <ref id="CR12">
          <label>12.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Callot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delecolle</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Entomological notes. VI. Septentrional localization of Aedes Aegypti</article-title>
            <source>Ann Parasitol Hum Comp</source>
            <year>1972</year>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>665</fpage>
            <?supplied-pmid 4650815?>
            <pub-id pub-id-type="pmid">4650815</pub-id>
          </element-citation>
        </ref>
        <ref id="CR13">
          <label>13.</label>
          <mixed-citation publication-type="other">Wilder-Smith A, Quam M, Sessions O, Rocklov J, Liu-Helmersson J, Franco L, Khan K. The 2012 dengue outbreak in Madeira: exploring the origins. Euro Surveill. 2014. doi:10.2807/1560-7917.ES2014.19.8.20718.</mixed-citation>
        </ref>
        <ref id="CR14">
          <label>14.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yunicheva</surname>
                <given-names>YU</given-names>
              </name>
              <name>
                <surname>Ryabova</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Markovich</surname>
                <given-names>NY</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>First data on the presence of breeding populations of the Aedes aegypti L. mosquito in Greater Sochi and various cities of Abkhazia</article-title>
            <source>Med Parazitol</source>
            <year>2008</year>
            <volume>3</volume>
            <fpage>40</fpage>
            <lpage>3</lpage>
          </element-citation>
        </ref>
        <ref id="CR15">
          <label>15.</label>
          <mixed-citation publication-type="other">•• Akiner MM, Demirci B, Babuadze G, Robert V, Schaffner F. Spread of the invasive mosquitoes <italic>Aedes aegypti and Aedes albopictus</italic> in the Black Sea region increases risk of Chikungunya, Dengue, and Zika outbreaks in Europe. PLoS Negl Trop Dis. 2016;10(4):e0004664. <bold>The mosquitoes</bold><bold><italic>Aedes aegypti</italic></bold><bold>and</bold><bold><italic>Aedes albopictus</italic></bold><bold>are spreading in Europe with concerns about resurgences of the pathogens that they transmit. International collaboration, in particular around the Black Sea, is crucial in order to support local capacities and boost Europe’s preparedness</bold>.</mixed-citation>
        </ref>
        <ref id="CR16">
          <label>16.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Smith</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>The history of dengue in tropical Asia and its probable relationship to the mosquito Aedes aegypti</article-title>
            <source>J Trop Med Hyg</source>
            <year>1956</year>
            <volume>59</volume>
            <issue>10</issue>
            <fpage>243</fpage>
            <lpage>51</lpage>
            <?supplied-pmid 13368255?>
            <pub-id pub-id-type="pmid">13368255</pub-id>
          </element-citation>
        </ref>
        <ref id="CR17">
          <label>17.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bonizzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gasperi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>The invasive mosquito species Aedes albopictus: current knowledge and future perspectives</article-title>
            <source>Trends Parasitol</source>
            <year>2013</year>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>460</fpage>
            <lpage>8</lpage>
            <?supplied-pmid 23916878?>
            <pub-id pub-id-type="pmid">23916878</pub-id>
          </element-citation>
        </ref>
        <ref id="CR18">
          <label>18.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Adhami</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Introduction and establishment of Aedes (Stegomyia) albopictus skuse (Diptera: Culicidae) in Albania</article-title>
            <source>J Am Mosq Control Assoc</source>
            <year>1998</year>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>340</fpage>
            <lpage>3</lpage>
            <?supplied-pmid 9813831?>
            <pub-id pub-id-type="pmid">9813831</pub-id>
          </element-citation>
        </ref>
        <ref id="CR19">
          <label>19.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Sabatini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raineri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Trovato</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Coluzzi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Aedes albopictus in Italy and possible diffusion of the species into the Mediterranean area</article-title>
            <source>Parassitologia</source>
            <year>1990</year>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>301</fpage>
            <lpage>4</lpage>
            <?supplied-pmid 2132441?>
            <pub-id pub-id-type="pmid">2132441</pub-id>
          </element-citation>
        </ref>
        <ref id="CR20">
          <label>20.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Dalla Pozza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Majori</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>First record of Aedes albopictus establishment in Italy</article-title>
            <source>J Am Mosq Control Assoc</source>
            <year>1992</year>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>318</fpage>
            <lpage>20</lpage>
            <?supplied-pmid 1402871?>
            <pub-id pub-id-type="pmid">1402871</pub-id>
          </element-citation>
        </ref>
        <ref id="CR21">
          <label>21.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Medlock</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hansford</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Schaffner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Versteirt</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hendrickx</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zeller</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A review of the invasive mosquitoes in Europe: ecology, public health risks, and control options</article-title>
            <source>Vector Borne Zoonotic Dis</source>
            <year>2012</year>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>435</fpage>
            <lpage>47</lpage>
            <?supplied-pmid 22448724?>
            <pub-id pub-id-type="pmid">22448724</pub-id>
          </element-citation>
        </ref>
        <ref id="CR22">
          <label>22.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Paupy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delatte</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bagny</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Corbel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fontenille</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Aedes albopictus, an arbovirus vector: from the darkness to the light</article-title>
            <source>Microbes Infect Inst Pasteur</source>
            <year>2009</year>
            <volume>11</volume>
            <issue>14–15</issue>
            <fpage>1177</fpage>
            <lpage>85</lpage>
          </element-citation>
        </ref>
        <ref id="CR23">
          <label>23.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Rezza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nicoletti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Angelini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Romi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Finarelli</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Panning</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Infection with chikungunya virus in Italy: an outbreak in a temperate region</article-title>
            <source>Lancet</source>
            <year>2007</year>
            <volume>370</volume>
            <issue>9602</issue>
            <fpage>1840</fpage>
            <lpage>6</lpage>
            <?supplied-pmid 18061059?>
            <pub-id pub-id-type="pmid">18061059</pub-id>
          </element-citation>
        </ref>
        <ref id="CR24">
          <label>24.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Grandadam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Plumet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thiberge</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Souares</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Failloux</surname>
                <given-names>AB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Chikungunya virus, southeastern France</article-title>
            <source>Emerg Infect Dis</source>
            <year>2011</year>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>910</fpage>
            <lpage>3</lpage>
            <?supplied-pmid 21529410?>
            <pub-id pub-id-type="pmid">21529410</pub-id>
          </element-citation>
        </ref>
        <ref id="CR25">
          <label>25.</label>
          <mixed-citation publication-type="other">Delisle E, Rousseau C, Broche B, Leparc-Goffart I, L’Ambert G, Cochet A, Prat C, Foulongne V, Ferré JB, Catelinois O, Flusin O, Tchernonog E, Moussion IE, Wiegandt A, Septfons A, Mendy A, Moyano MB, Laporte L, Maurel J, Jourdain F, Reynes J, Paty MC, Golliot F. Chikungunya outbreak in Montpellier, France, September to October 2014. Euro Surveill. 2015. doi:10.2807/1560-7917.ES2015.20.17.21108.</mixed-citation>
        </ref>
        <ref id="CR26">
          <label>26.</label>
          <mixed-citation publication-type="other">Schmidt-Chanasit J, Haditsch M, Schöneberg I, Günther S, Stark K, Frank C. Dengue virus infection in a traveller returning from Croatia to Germany. Euro Surveill. 2010. <ext-link ext-link-type="uri" xlink:href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19677">http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19677</ext-link>.</mixed-citation>
        </ref>
        <ref id="CR27">
          <label>27.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>La Ruche</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Souares</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Armengaud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peloux-Petiot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Delaunay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Despres</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>First two autochthonous dengue virus infections in metropolitan France, September 2010</article-title>
            <source>Eur Surveill</source>
            <year>2010</year>
            <volume>15</volume>
            <issue>39</issue>
            <fpage>19676</fpage>
          </element-citation>
        </ref>
        <ref id="CR28">
          <label>28.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Marchand</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Prat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jeannin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lafont</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Flusin</surname>
                <given-names>O</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Autochthonous case of dengue in France, October 2013</article-title>
            <source>Eur Surveill</source>
            <year>2013</year>
            <volume>18</volume>
            <issue>50</issue>
            <fpage>20661</fpage>
          </element-citation>
        </ref>
        <ref id="CR29">
          <label>29.</label>
          <mixed-citation publication-type="other">Succo T, Leparc-Goffart I, Ferré J, Roiz D, Broche B, Maquart M, Noel H, Catelinois O, Entezam F, Caire D, Jourdain F, Esteve-Moussion I, Cochet A, Paupy C, Rousseau C, Paty M, Golliot F. Autochthonous dengue outbreak in Nîmes, South of France, July to September 2015. Euro Surveill. 2016. doi:10.2807/1560-7917.ES.2016.21.21.30240.</mixed-citation>
        </ref>
        <ref id="CR30">
          <label>30.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Byrne</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Culex pipiens in London Underground tunnels: differentiation between surface and subterranean populations</article-title>
            <source>Heredity</source>
            <year>1999</year>
            <volume>82</volume>
            <issue>Pt 1</issue>
            <fpage>7</fpage>
            <lpage>15</lpage>
            <?supplied-pmid 10200079?>
            <pub-id pub-id-type="pmid">10200079</pub-id>
          </element-citation>
        </ref>
        <ref id="CR31">
          <label>31.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Fritz</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Severson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Dworkin</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Divergent host preferences of above- and below-ground Culex pipiens mosquitoes and their hybrid offspring</article-title>
            <source>Med Vet Entomol</source>
            <year>2015</year>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <lpage>23</lpage>
            <?supplied-pmid 25600086?>
            <pub-id pub-id-type="pmid">25600086</pub-id>
          </element-citation>
        </ref>
        <ref id="CR32">
          <label>32.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Fros</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Geertsema</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vogels</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Roosjen</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Failloux</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Vlak</surname>
                <given-names>JM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>West Nile virus: high transmission rate in North-Western European mosquitoes indicates its epidemic potential and warrants increased surveillance</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2015</year>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>e0003956</fpage>
            <?supplied-pmid 26225555?>
            <pub-id pub-id-type="pmid">26225555</pub-id>
          </element-citation>
        </ref>
        <ref id="CR33">
          <label>33.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Hubalek</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Halouzka</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>West Nile fever—a reemerging mosquito-borne viral disease in Europe</article-title>
            <source>Emerg Infect Dis</source>
            <year>1999</year>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>643</fpage>
            <lpage>50</lpage>
            <?supplied-pmid 10511520?>
            <pub-id pub-id-type="pmid">10511520</pub-id>
          </element-citation>
        </ref>
        <ref id="CR34">
          <label>34.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Traore-Lamizana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeller</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Mondo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hervy</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Digoutte</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Isolations of West Nile and Bagaza viruses from mosquitoes (Diptera: Culicidae) in central Senegal (Ferlo)</article-title>
            <source>J Med Entomol</source>
            <year>1994</year>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>934</fpage>
            <lpage>8</lpage>
            <?supplied-pmid 7815413?>
            <pub-id pub-id-type="pmid">7815413</pub-id>
          </element-citation>
        </ref>
        <ref id="CR35">
          <label>35.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Zeller</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Schuffenecker</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas</article-title>
            <source>Eur J Clin Microbiol Infect Dis</source>
            <year>2004</year>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>147</fpage>
            <lpage>56</lpage>
            <?supplied-pmid 14986160?>
            <pub-id pub-id-type="pmid">14986160</pub-id>
          </element-citation>
        </ref>
        <ref id="CR36">
          <label>36.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Brackney</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Transmission and evolution of tick-borne viruses</article-title>
            <source>Curr Opin Virol</source>
            <year>2016</year>
            <volume>21</volume>
            <fpage>67</fpage>
            <lpage>74</lpage>
            <?supplied-pmid 27569396?>
            <pub-id pub-id-type="pmid">27569396</pub-id>
          </element-citation>
        </ref>
        <ref id="CR37">
          <label>37.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Hoogstraal</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa</article-title>
            <source>J Med Entomol</source>
            <year>1979</year>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>307</fpage>
            <lpage>417</lpage>
            <?supplied-pmid 113533?>
            <pub-id pub-id-type="pmid">113533</pub-id>
          </element-citation>
        </ref>
        <ref id="CR38">
          <label>38.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Velo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuli-Lito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gradoni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maroli</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Recrudescence of visceral leishmaniasis in Albania: retrospective analysis of cases during 1997 to 2001 and results of an entomological survey carried out during 2001 in some districts</article-title>
            <source>Trans R Soc Trop Med Hyg</source>
            <year>2003</year>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>288</fpage>
            <lpage>90</lpage>
            <?supplied-pmid 15228243?>
            <pub-id pub-id-type="pmid">15228243</pub-id>
          </element-citation>
        </ref>
        <ref id="CR39">
          <label>39.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Adhami</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murati</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Phlebotomine sand flies (diptera: Psychodidae) of domestic places in Albania</article-title>
            <source>Rev Mjeksore</source>
            <year>2000</year>
            <volume>1</volume>
            <fpage>60</fpage>
            <lpage>75</lpage>
          </element-citation>
        </ref>
        <ref id="CR40">
          <label>40.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Papa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Velo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bino</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A novel phlebovirus in Albanian sandflies</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2011</year>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>585</fpage>
            <lpage>7</lpage>
            <?supplied-pmid 21414085?>
            <pub-id pub-id-type="pmid">21414085</pub-id>
          </element-citation>
        </ref>
        <ref id="CR41">
          <label>41.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ayhan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Velo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Lamballerie</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kota</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kadriaj</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ozbel</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Detection of Leishmania infantum and a Novel Phlebovirus (Balkan Virus) from Sand Flies in Albania</article-title>
            <source>Vector Borne Zoonotic Dis</source>
            <year>2016</year>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>802</fpage>
            <lpage>6</lpage>
            <?supplied-pmid 27788062?>
            <pub-id pub-id-type="pmid">27788062</pub-id>
          </element-citation>
        </ref>
        <ref id="CR42">
          <label>42.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Papa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Velo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Papadimitriou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cahani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kota</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bino</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ecology of the Crimean-Congo hemorrhagic fever endemic area in Albania</article-title>
            <source>Vector Borne Zoonotic Dis</source>
            <year>2009</year>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>713</fpage>
            <lpage>6</lpage>
            <?supplied-pmid 19402760?>
            <pub-id pub-id-type="pmid">19402760</pub-id>
          </element-citation>
        </ref>
        <ref id="CR43">
          <label>43.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Schuster</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mrenoshki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Staubach</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruning</surname>
                <given-names>F</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Sheep and goats as indicator animals for the circulation of CCHFV in the environment</article-title>
            <source>Exp Appl Acarol</source>
            <year>2016</year>
            <volume>68</volume>
            <issue>3</issue>
            <fpage>337</fpage>
            <lpage>46</lpage>
            <?supplied-pmid 26704262?>
            <pub-id pub-id-type="pmid">26704262</pub-id>
          </element-citation>
        </ref>
        <ref id="CR44">
          <label>44.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bardos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Adamcova</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dedei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gjini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rosicky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Simkova</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neutralizing antibodies against some neurotropic viruses determined in human sera in Albania</article-title>
            <source>J Hyg Epidemiol Microbiol Immunol</source>
            <year>1959</year>
            <volume>3</volume>
            <fpage>277</fpage>
            <lpage>82</lpage>
            <?supplied-pmid 13796704?>
            <pub-id pub-id-type="pmid">13796704</pub-id>
          </element-citation>
        </ref>
        <ref id="CR45">
          <label>45.</label>
          <mixed-citation publication-type="other">EpiSouth Weekly Epi Bulletin, No 178, 10th August 2011 – 16th August 2011.</mixed-citation>
        </ref>
        <ref id="CR46">
          <label>46.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Pilo-Moron</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Le Corroller</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Isolation of a West-Nile virus in the extreme south of the Algerian Sahara (Djanet)</article-title>
            <source>Arch Inst Pasteur Alger</source>
            <year>1970</year>
            <volume>48</volume>
            <fpage>181</fpage>
            <lpage>4</lpage>
            <?supplied-pmid 4148584?>
            <pub-id pub-id-type="pmid">4148584</pub-id>
          </element-citation>
        </ref>
        <ref id="CR47">
          <label>47.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bouguermouh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bouslama</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bitam</surname>
                <given-names>I</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Ces arbovirus qui menacent l’Algérie</article-title>
            <source>La revue medicopharmaceutique</source>
            <year>2008</year>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>46</fpage>
            <lpage>52</lpage>
          </element-citation>
        </ref>
        <ref id="CR48">
          <label>48.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Le Guenno</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bougermouh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Azzam</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bouakaz</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>West Nile: a deadly virus?</article-title>
            <source>Lancet</source>
            <year>1996</year>
            <volume>348</volume>
            <issue>9037</issue>
            <fpage>1315</fpage>
            <?supplied-pmid 8909403?>
            <pub-id pub-id-type="pmid">8909403</pub-id>
          </element-citation>
        </ref>
        <ref id="CR49">
          <label>49.</label>
          <mixed-citation publication-type="other">Hachid A, Beloufa MA, Bahoura N, Fall G, Dia M, Sall AA, Seghier M. First serological evidence of human circulation of West Nile virus in central-north Algeria.. Communication at 23th European society in clinical microbiology and infectious diseases (ECCMID) Berlin, Germany. 2013.</mixed-citation>
        </ref>
        <ref id="CR50">
          <label>50.</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <collab>INVS</collab>
            </person-group>
            <source>Bulletin hebdomadaire international du 10 au 16 Octobre 2012</source>
            <year>2012</year>
            <publisher-loc>France</publisher-loc>
            <publisher-name>Institut de Veille Sanitaire</publisher-name>
            <fpage>369</fpage>
          </element-citation>
        </ref>
        <ref id="CR51">
          <label>51.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ayhan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Velo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Lamballerie</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kota</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kadriaj</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ozbel</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Detection of Leishmania infantum and a Novel Phlebovirus (Balkan Virus) from Sand Flies in Albania</article-title>
            <source>Vector Borne Zoonotic Dis</source>
            <year>2016</year>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>802</fpage>
            <lpage>6</lpage>
            <?supplied-pmid 27788062?>
            <pub-id pub-id-type="pmid">27788062</pub-id>
          </element-citation>
        </ref>
        <ref id="CR52">
          <label>52.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Izri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Temmam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moureau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hamrioui</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de Lamballerie</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Charrel</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Sandfly fever Sicilian virus, Algeria</article-title>
            <source>Emerg Infect Dis</source>
            <year>2008</year>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>795</fpage>
            <lpage>7</lpage>
            <?supplied-pmid 18439364?>
            <pub-id pub-id-type="pmid">18439364</pub-id>
          </element-citation>
        </ref>
        <ref id="CR53">
          <label>53.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Alkan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alwassouf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Piorkowski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bichaud</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tezcan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dincer</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Isolation, genetic characterization, and seroprevalence of Adana virus, a novel phlebovirus belonging to the Salehabad virus complex, in Turkey</article-title>
            <source>J Virol</source>
            <year>2015</year>
            <volume>89</volume>
            <issue>8</issue>
            <fpage>4080</fpage>
            <lpage>91</lpage>
            <?supplied-pmid 25653443?>
            <pub-id pub-id-type="pmid">25653443</pub-id>
          </element-citation>
        </ref>
        <ref id="CR54">
          <label>54.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Tahir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alwassouf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loudahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davoust</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Charrel</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Seroprevalence of Toscana virus in dogs from Kabylia (Algeria)</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2016</year>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>e16</fpage>
            <lpage>7</lpage>
            <?supplied-pmid 26551844?>
            <pub-id pub-id-type="pmid">26551844</pub-id>
          </element-citation>
        </ref>
        <ref id="CR55">
          <label>55.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Arsevska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lancelot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>El Mamy</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Cetre-Sossah</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Situation épidémiologique de la fièvre de la Vallée du Rift en Afrique de l’Ouest et du Nord</article-title>
            <source>Bull Epidémiol</source>
            <year>2016</year>
            <volume>74</volume>
            <fpage>25</fpage>
            <lpage>9</lpage>
          </element-citation>
        </ref>
        <ref id="CR56">
          <label>56.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Benallal</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Allal-Ikhlef</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benhamouda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schaffner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Harrat</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>First report of Aedes (Stegomyia) albopictus (Diptera: Culicidae) in Oran, West of Algeria</article-title>
            <source>Acta Trop</source>
            <year>2016</year>
            <volume>164</volume>
            <fpage>411</fpage>
            <lpage>3</lpage>
            <?supplied-pmid 27697483?>
            <pub-id pub-id-type="pmid">27697483</pub-id>
          </element-citation>
        </ref>
        <ref id="CR57">
          <label>57.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Kautman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tiar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Papa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siroky</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>AP92-like Crimean-Congo hemorrhagic fever virus in Hyalomma aegyptium ticks, Algeria</article-title>
            <source>Emerg Infect Dis</source>
            <year>2016</year>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>354</fpage>
            <lpage>6</lpage>
            <?supplied-pmid 26812469?>
            <pub-id pub-id-type="pmid">26812469</pub-id>
          </element-citation>
        </ref>
        <ref id="CR58">
          <label>58.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Avetisyan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Manukyan</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Modern epidemiological geography of malaria of Armenia</article-title>
            <source>Med Sci Armenia</source>
            <year>2010</year>
            <volume>2</volume>
            <fpage>101</fpage>
            <lpage>7</lpage>
          </element-citation>
        </ref>
        <ref id="CR59">
          <label>59.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Manukian</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Oganesian</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Shakhnazarian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Aleskanian</surname>
                <given-names>IT</given-names>
              </name>
            </person-group>
            <article-title>The species composition of mosquitoes and ticks in Armenia</article-title>
            <source>Med Parazitol (Mosk)</source>
            <year>2006</year>
            <volume>1</volume>
            <fpage>31</fpage>
            <lpage>3</lpage>
          </element-citation>
        </ref>
        <ref id="CR60">
          <label>60.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Anis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grotto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mendelson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Orshan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gandacu</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>West Nile fever in Israel: the reemergence of an endemic disease</article-title>
            <source>J Infect</source>
            <year>2014</year>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <lpage>5</lpage>
            <?supplied-pmid 24183889?>
            <pub-id pub-id-type="pmid">24183889</pub-id>
          </element-citation>
        </ref>
        <ref id="CR61">
          <label>61.</label>
          <mixed-citation publication-type="other">Kalaycioglu H, Korukluoglu G, Ozkul A, Oncul O, Tosun S, Karabay O, Gozalan A, Uyar Y, Caglayık DY, Atasoylu G, Altas AB, Yolbakan S, Ozden TN, Bayrakdar F, Sezak N, Pelıtlı TS, Kurtcebe ZO, Aydın E, Ertek M. Emergence of West Nile virus infections in humans in Turkey, 2010 to 2011. Euro Surveill. 2012. <ext-link ext-link-type="uri" xlink:href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20182">http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20182</ext-link></mixed-citation>
        </ref>
        <ref id="CR62">
          <label>62.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Orshan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schnur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valinsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mosquito vectors of West Nile fever in Israel</article-title>
            <source>J Med Entomol</source>
            <year>2008</year>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>939</fpage>
            <lpage>47</lpage>
            <?supplied-pmid 18826039?>
            <pub-id pub-id-type="pmid">18826039</pub-id>
          </element-citation>
        </ref>
        <ref id="CR63">
          <label>63.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Haddad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harbach</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Chamat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bouharoun-Tayoun</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Presence of Aedes albopictus in Lebanon and Syria</article-title>
            <source>J Am Mosq Control Assoc</source>
            <year>2007</year>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>226</fpage>
            <lpage>8</lpage>
            <?supplied-pmid 17847859?>
            <pub-id pub-id-type="pmid">17847859</pub-id>
          </element-citation>
        </ref>
        <ref id="CR64">
          <label>64.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Haddad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mousson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vazeille</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chamat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tayeh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Osta</surname>
                <given-names>MA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Aedes albopictus in Lebanon, a potential risk of arboviruses outbreak</article-title>
            <source>BMC Infect Dis</source>
            <year>2012</year>
            <volume>12</volume>
            <fpage>300</fpage>
            <?supplied-pmid 23151056?>
            <pub-id pub-id-type="pmid">23151056</pub-id>
          </element-citation>
        </ref>
        <ref id="CR65">
          <label>65.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Mertens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sas</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vatansever</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hubalek</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Guven</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Crimean-Congo hemorrhagic fever virus in Bulgaria and Turkey</article-title>
            <source>Vector Borne Zoonotic Dis</source>
            <year>2016</year>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>619</fpage>
            <lpage>23</lpage>
            <?supplied-pmid 27467142?>
            <pub-id pub-id-type="pmid">27467142</pub-id>
          </element-citation>
        </ref>
        <ref id="CR66">
          <label>66.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Sharififard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alavi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Salmanzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Safdari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kamali</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological survey of Crimean-Congo hemorrhagic fever (CCHF), a fatal infectious disease in Khuzestan province, Southwest Iran, during 1999–2015</article-title>
            <source>Jundishapur J Microbiol</source>
            <year>2016</year>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>e30883</fpage>
            <?supplied-pmid 27540454?>
            <pub-id pub-id-type="pmid">27540454</pub-id>
          </element-citation>
        </ref>
        <ref id="CR67">
          <label>67.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Darwish</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>A serological survey on group A and B arbovirus antibodies in Libya</article-title>
            <source>J Egypt Public Health Assoc</source>
            <year>1974</year>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <lpage>6</lpage>
            <?supplied-pmid 4850294?>
            <pub-id pub-id-type="pmid">4850294</pub-id>
          </element-citation>
        </ref>
        <ref id="CR68">
          <label>68.</label>
          <mixed-citation publication-type="other">Elahmer OR, Abdelfadeel M, Safwat S, Smeo MN, Abudher A, Sammoud MA, et al. A retrospective study to define viral and bacterial etiologies causing acute febrile illness in Libya. The conference of endemic and emerging infectious diseases of priority in the Middle East and North Africa ‐ research opportunities and biosafety in a changing environment June 18–21, 2012; Istanbul, Turkey. 2012.</mixed-citation>
        </ref>
        <ref id="CR69">
          <label>69.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Mertens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vatansever</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mrenoshki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krstevski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stefanovska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Djadjovski</surname>
                <given-names>I</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Circulation of Crimean-Congo hemorrhagic fever virus in the former Yugoslav Republic of Macedonia revealed by screening of cattle sera using a novel enzyme-linked immunosorbent assay</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2015</year>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>e0003519</fpage>
            <?supplied-pmid 25742017?>
            <pub-id pub-id-type="pmid">25742017</pub-id>
          </element-citation>
        </ref>
        <ref id="CR70">
          <label>70.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Chumakov</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Bashkirtsev</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Golger</surname>
                <given-names>EI</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Isolation and identification of Crimean hemorrhagic fever and West Nile fever viruses from ticks collected in Moldavia (in Russian)</article-title>
            <source>Medicinskaya Virusol</source>
            <year>1974</year>
            <volume>22</volume>
            <fpage>45</fpage>
            <lpage>9</lpage>
          </element-citation>
        </ref>
        <ref id="CR71">
          <label>71.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Scoferta</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Stepanova</surname>
                <given-names>OA</given-names>
              </name>
            </person-group>
            <article-title>Arboviral infections and lymphocytic choriomeningitis in Moldova</article-title>
            <source>Virusologia</source>
            <year>1992</year>
            <volume>27</volume>
            <fpage>97</fpage>
            <lpage>101</lpage>
          </element-citation>
        </ref>
        <ref id="CR72">
          <label>72.</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Chumakov</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Spasski</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tihon</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Uspenskaia</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Konovalov</surname>
                <given-names>YN</given-names>
              </name>
            </person-group>
            <person-group person-group-type="editor">
              <name>
                <surname>Markevich</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>The mixed foci of arbovirus infections in Moldavia</article-title>
            <source>Proceedings of the 2nd Vsesoiuznii Siezd Parazitotsenologov. 1983 October 11–14</source>
            <year>1983</year>
            <publisher-loc>Kiev, Ukraine</publisher-loc>
            <publisher-name>Naukova dumka</publisher-name>
            <fpage>368</fpage>
            <lpage>9</lpage>
          </element-citation>
        </ref>
        <ref id="CR73">
          <label>73.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Scoferta</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Ciobanu</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Spinu</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Belous</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mikhailenko</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Isolation of West Nile fever virus in Moldova Republic</article-title>
            <source>J Prev Med</source>
            <year>1996</year>
            <volume>4</volume>
            <fpage>111</fpage>
          </element-citation>
        </ref>
        <ref id="CR74">
          <label>74.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Kolodziejek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marinov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Alexe</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nowotny</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The complete sequence of a West Nile virus lineage 2 strain detected in a Hyalomma marginatum marginatum tick collected from a song thrush (Turdus philomelos) in eastern Romania in 2013 revealed closest genetic relationship to strain Volgograd 2007</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>e109905</fpage>
            <?supplied-pmid 25279973?>
            <pub-id pub-id-type="pmid">25279973</pub-id>
          </element-citation>
        </ref>
        <ref id="CR75">
          <label>75.</label>
          <mixed-citation publication-type="other">Dinu S, Cotar AI, Pănculescu-Gătej IR, Fălcuţă E, Prioteasa FL, Sîrbu A, Oprişan G, Bădescu D, Reiter P, Ceianu CS. West Nile virus circulation in south-eastern Romania, 2011 to 2013. Euro Surveill. 2015. doi:10.2807/1560-7917.ES2015.20.20.21130</mixed-citation>
        </ref>
        <ref id="CR76">
          <label>76.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Marcutan</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Kalmar</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ionica</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>D’Amico</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mihalca</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Vasile</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Spotted fever group rickettsiae in ticks of migratory birds in Romania</article-title>
            <source>Parasit Vectors</source>
            <year>2016</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>294</fpage>
            <?supplied-pmid 27207258?>
            <pub-id pub-id-type="pmid">27207258</pub-id>
          </element-citation>
        </ref>
        <ref id="CR77">
          <label>77.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>El Harrak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Gounon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Le Gounon</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Isolation of West Nile virus in Morocco [in French]</article-title>
            <source>Virologie</source>
            <year>1997</year>
            <volume>1</volume>
            <fpage>248</fpage>
            <lpage>9</lpage>
          </element-citation>
        </ref>
        <ref id="CR78">
          <label>78.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Schuffenecker</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Peyrefitte</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>el Harrak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeller</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>West Nile virus in Morocco, 2003</article-title>
            <source>Emerg Infect Dis</source>
            <year>2005</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>306</fpage>
            <lpage>9</lpage>
            <?supplied-pmid 15752452?>
            <pub-id pub-id-type="pmid">15752452</pub-id>
          </element-citation>
        </ref>
        <ref id="CR79">
          <label>79.</label>
          <mixed-citation publication-type="other">World Animal Health Information Database. Event summary: West Nile fever, Morocco. 2010.</mixed-citation>
        </ref>
        <ref id="CR80">
          <label>80.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Figuerola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baouab</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Soriguer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fassi-Fihri</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Llorente</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jimenez-Clavero</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>West Nile virus antibodies in wild birds, Morocco, 2008</article-title>
            <source>Emerg Infect Dis</source>
            <year>2009</year>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>1651</fpage>
            <lpage>3</lpage>
            <?supplied-pmid 19861065?>
            <pub-id pub-id-type="pmid">19861065</pub-id>
          </element-citation>
        </ref>
        <ref id="CR81">
          <label>81.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>El-Harrak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martin-Folgar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Llorente</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fernandez-Pacheco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Figuerola</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Rift Valley and West Nile virus antibodies in camels, North Africa</article-title>
            <source>Emerg Infect Dis</source>
            <year>2011</year>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>2372</fpage>
            <lpage>4</lpage>
            <?supplied-pmid 22172452?>
            <pub-id pub-id-type="pmid">22172452</pub-id>
          </element-citation>
        </ref>
        <ref id="CR82">
          <label>82.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Faraj</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elkohli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lyagoubi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The gonotrophic cycle of Culex pipiens (Diptera: Culicidae), West Nile virus potential vector, in Morocco: evaluation of its duration in laboratory</article-title>
            <source>Bull Soc Pathol Exot</source>
            <year>2006</year>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <lpage>21</lpage>
            <?supplied-pmid 16821445?>
            <pub-id pub-id-type="pmid">16821445</pub-id>
          </element-citation>
        </ref>
        <ref id="CR83">
          <label>83.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Jouan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Guenno</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Digoutte</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Philippe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Riou</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>An RVF epidemic in southern Mauritania</article-title>
            <source>Ann Inst Pasteur Virol</source>
            <year>1988</year>
            <volume>139</volume>
            <issue>3</issue>
            <fpage>307</fpage>
            <lpage>8</lpage>
            <?supplied-pmid 3207509?>
            <pub-id pub-id-type="pmid">3207509</pub-id>
          </element-citation>
        </ref>
        <ref id="CR84">
          <label>84.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Nabeth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Abdalahi</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Diallo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ndiaye</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ba</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Rift Valley fever outbreak, Mauritania, 1998: seroepidemiologic, virologic, entomologic, and zoologic investigations</article-title>
            <source>Emerg Infect Dis</source>
            <year>2001</year>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>1052</fpage>
            <lpage>4</lpage>
            <?supplied-pmid 11747742?>
            <pub-id pub-id-type="pmid">11747742</pub-id>
          </element-citation>
        </ref>
        <ref id="CR85">
          <label>85.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Sow</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faye</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ba</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ba</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Diallo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Faye</surname>
                <given-names>O</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Rift Valley fever outbreak, southern Mauritania, 2012</article-title>
            <source>Emerg Infect Dis</source>
            <year>2014</year>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>296</fpage>
            <lpage>9</lpage>
            <?supplied-pmid 24447334?>
            <pub-id pub-id-type="pmid">24447334</pub-id>
          </element-citation>
        </ref>
        <ref id="CR86">
          <label>86.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>El Ouali Lalami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El-Akhal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>El Amri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maniar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faraj</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>State resistance of the mosquito Culex pipiens towards temephos central Morocco</article-title>
            <source>Bull Soc Pathol Exot</source>
            <year>2014</year>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>194</fpage>
            <lpage>8</lpage>
            <?supplied-pmid 24827876?>
            <pub-id pub-id-type="pmid">24827876</pub-id>
          </element-citation>
        </ref>
        <ref id="CR87">
          <label>87.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>El Joubari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faraj</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Louah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Himmi</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Sensibilité des moustiques Anopheles labranchiae, Culex pipiens, Ochlerotatus detritus et Ochlerotatus caspius de la région de Smir (Nord-Ouest du Maroc) aux organophosphorés utilisés en santé publique</article-title>
            <source>Environ Risque Sante</source>
            <year>2015</year>
            <volume>14</volume>
            <fpage>72</fpage>
            <lpage>9</lpage>
          </element-citation>
        </ref>
        <ref id="CR88">
          <label>88.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bennouna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Balenghien</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>El Rhaffouli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schaffner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garros</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gardès</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>First record of Stegomyia albopicta (=Aedes albopictus) in Morocco: a major threat to public health in North Africa?</article-title>
            <source>Med Vet Entomol</source>
            <year>2017</year>
            <volume>31</volume>
            <fpage>102</fpage>
            <lpage>6</lpage>
            <?supplied-pmid 27775162?>
            <pub-id pub-id-type="pmid">27775162</pub-id>
          </element-citation>
        </ref>
        <ref id="CR89">
          <label>89.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Es-Sette</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nourlil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hamdi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mellouki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lemrani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>First detection of Toscana virus RNA from sand flies in the genus Phlebotomus (Diptera: Phlebotomidae) naturally infected in Morocco</article-title>
            <source>J Med Entomol</source>
            <year>2012</year>
            <volume>49</volume>
            <fpage>1507</fpage>
            <lpage>9</lpage>
            <?supplied-pmid 23270183?>
            <pub-id pub-id-type="pmid">23270183</pub-id>
          </element-citation>
        </ref>
        <ref id="CR90">
          <label>90.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Es-Sette</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ajaoud</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bichaud</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hamdi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mellouki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Charrel</surname>
                <given-names>RN</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Phlebotomus sergenti a common vector of Leishmania tropica and Toscana virus in Morocco</article-title>
            <source>J Vector Borne Dis</source>
            <year>2014</year>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>86</fpage>
            <lpage>90</lpage>
            <?supplied-pmid 24947214?>
            <pub-id pub-id-type="pmid">24947214</pub-id>
          </element-citation>
        </ref>
        <ref id="CR91">
          <label>91.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Es-sette</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ajaoud</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anga</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mellouki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lemrani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Toscana virus isolated from sandflies, Morocco</article-title>
            <source>Parasit Vectors</source>
            <year>2015</year>
            <volume>8</volume>
            <fpage>205</fpage>
            <?supplied-pmid 25886511?>
            <pub-id pub-id-type="pmid">25886511</pub-id>
          </element-citation>
        </ref>
        <ref id="CR92">
          <label>92.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Palomar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Portillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santibanez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mazuelas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arizaga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crespo</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Crimean-Congo hemorrhagic fever virus in ticks from migratory birds, Morocco</article-title>
            <source>Emerg Infect Dis</source>
            <year>2013</year>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>260</fpage>
            <lpage>3</lpage>
            <?supplied-pmid 23347801?>
            <pub-id pub-id-type="pmid">23347801</pub-id>
          </element-citation>
        </ref>
        <ref id="CR93">
          <label>93.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bordjoski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gligić</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boskovic</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Arbovirusne infekcije u SR Srbiji</article-title>
            <source>Vojnosanit Pregl</source>
            <year>1972</year>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>173</fpage>
            <lpage>5</lpage>
            <pub-id pub-id-type="pmid">5031508</pub-id>
          </element-citation>
        </ref>
        <ref id="CR94">
          <label>94.</label>
          <mixed-citation publication-type="other">Petrić D, Petrović T, Hrnjaković Cvjetković I, Zgomba M, Milošević V, Lazić G, et al. West Nile virus “circulation” in Vojvodina, Serbia: Mosquito, bird, horse and human surveillance. Molecular and Cellular Probes 31, February 2017, p. 28–36, ISSN 0890–8508.</mixed-citation>
        </ref>
        <ref id="CR95">
          <label>95.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lupulovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martin-Acebes</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lazic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alonso-Padilla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blazquez</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Escribano-Romero</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>First serological evidence of West Nile virus activity in horses in Serbia</article-title>
            <source>Vector Borne Zoonotic Dis</source>
            <year>2011</year>
            <volume>11</volume>
            <issue>9</issue>
            <fpage>1303</fpage>
            <lpage>5</lpage>
            <?supplied-pmid 21438694?>
            <pub-id pub-id-type="pmid">21438694</pub-id>
          </element-citation>
        </ref>
        <ref id="CR96">
          <label>96.</label>
          <mixed-citation publication-type="other">Petrović T, Blázquez AB, Lupulović D, Lazić G, Escribano-Romero E, Fabijan D, Kapetanov M, Lazić S, Saiz JC. Monitoring West Nile virus (WNV) infection in wild birds in Serbia during 2012: first isolation and characterisation of WNV strains from Serbia. Euro Surveill. 2013. <ext-link ext-link-type="uri" xlink:href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20622">http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20622</ext-link>.</mixed-citation>
        </ref>
        <ref id="CR97">
          <label>97.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Petric</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hrnjakovic Cvjetkovic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Radovanov</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cvjetkovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jerant Patic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Milosevic</surname>
                <given-names>V</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>West Nile virus surveillance in humans and mosquitoes and detection of cell fusing agent virus in Vojvodina Province (Serbia)</article-title>
            <source>HealthMED</source>
            <year>2012</year>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>462</fpage>
            <lpage>8</lpage>
          </element-citation>
        </ref>
        <ref id="CR98">
          <label>98.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Triki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Le Guenno</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bahri</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hili</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sidhom</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>West Nile viral meningo-encephalitis in Tunisia</article-title>
            <source>Med Trop (Mars)</source>
            <year>2001</year>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>487</fpage>
            <lpage>90</lpage>
            <pub-id pub-id-type="pmid">11980397</pub-id>
          </element-citation>
        </ref>
        <ref id="CR99">
          <label>99.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Charrel</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Brault</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gallian</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lemasson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Murgue</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Murri</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Evolutionary relationship between Old World West Nile virus strains. Evidence for viral gene flow between Africa, the Middle East, and Europe</article-title>
            <source>Virology</source>
            <year>2003</year>
            <volume>315</volume>
            <issue>2</issue>
            <fpage>381</fpage>
            <lpage>8</lpage>
            <?supplied-pmid 14585341?>
            <pub-id pub-id-type="pmid">14585341</pub-id>
          </element-citation>
        </ref>
        <ref id="CR100">
          <label>100.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Hachfi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bougmiza</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bellazreg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bahri</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kaabia</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bahri</surname>
                <given-names>F</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Second epidemic of West Nile virus meningoencephalitis in Tunisia</article-title>
            <source>Med Mal Infect</source>
            <year>2010</year>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>456</fpage>
            <lpage>61</lpage>
            <?supplied-pmid 20079988?>
            <pub-id pub-id-type="pmid">20079988</pub-id>
          </element-citation>
        </ref>
        <ref id="CR101">
          <label>101.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bahri</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dhifallah</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ben Alaya-Bouafif</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fekih</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gargouri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Triki</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Sero-epidemiological study of West Nile virus circulation in human in Tunisia</article-title>
            <source>Bull Soc Pathol Exot</source>
            <year>2011</year>
            <volume>104</volume>
            <issue>4</issue>
            <fpage>272</fpage>
            <lpage>6</lpage>
            <?supplied-pmid 21161623?>
            <pub-id pub-id-type="pmid">21161623</pub-id>
          </element-citation>
        </ref>
        <ref id="CR102">
          <label>102.</label>
          <mixed-citation publication-type="other">Bougatef S, Ben Alaya Bouafif N, Achour N. Bilan de la surveillance des infections à virus de West Nile en Tunisie (Année 2012).Surveillance de l’infection à VWN en Tunisie. 2013.</mixed-citation>
        </ref>
        <ref id="CR103">
          <label>103.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ben Hassine</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>De Massis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Calistri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Savini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>BelHaj Mohamed</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ranen</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>First detection of co-circulation of West Nile and Usutu viruses in equids in the south-west of Tunisia</article-title>
            <source>Transbound Emerg Dis</source>
            <year>2014</year>
            <volume>61</volume>
            <issue>5</issue>
            <fpage>385</fpage>
            <lpage>9</lpage>
            <?supplied-pmid 25065813?>
            <pub-id pub-id-type="pmid">25065813</pub-id>
          </element-citation>
        </ref>
        <ref id="CR104">
          <label>104.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Fezaa</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>M’Ghirbi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Savellini</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Ammari</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hogga</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Triki</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Serological and molecular detection of Toscana and other Phleboviruses in patients and sandflies in Tunisia</article-title>
            <source>BMC Infect Dis</source>
            <year>2014</year>
            <volume>14</volume>
            <fpage>598</fpage>
            <?supplied-pmid 25398483?>
            <pub-id pub-id-type="pmid">25398483</pub-id>
          </element-citation>
        </ref>
        <ref id="CR105">
          <label>105.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Nabli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chippaux-Hyppolite</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chippaux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tamalet</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Serological study of arboviruses in Tunisia</article-title>
            <source>Bull World Health Organ</source>
            <year>1970</year>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>297</fpage>
            <lpage>303</lpage>
            <?supplied-pmid 5310141?>
            <pub-id pub-id-type="pmid">5310141</pub-id>
          </element-citation>
        </ref>
        <ref id="CR106">
          <label>106.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ergunay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Whitehouse</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ozkul</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Current status of human arboviral diseases in Turkey</article-title>
            <source>Vector Borne Zoonotic Dis</source>
            <year>2011</year>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>731</fpage>
            <lpage>41</lpage>
            <?supplied-pmid 21133776?>
            <pub-id pub-id-type="pmid">21133776</pub-id>
          </element-citation>
        </ref>
        <ref id="CR107">
          <label>107.</label>
          <mixed-citation publication-type="other">Leblebicioglu H, Sunbul M, Guner R, Bodur H, Bulut C, Duygu F, et al. Healthcare-associated Crimean-Congo haemorrhagic fever in Turkey, 2002–2014: a multicentre retrospective cross-sectional study. Clin Microbiol Infect. 2016;22(4):387 e1-4.</mixed-citation>
        </ref>
        <ref id="CR108">
          <label>108.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Mellor</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Wittmann</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Bluetongue virus in the Mediterranean Basin 1998–2001</article-title>
            <source>Vet J</source>
            <year>2002</year>
            <volume>164</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <lpage>37</lpage>
            <?supplied-pmid 12359482?>
            <pub-id pub-id-type="pmid">12359482</pub-id>
          </element-citation>
        </ref>
        <ref id="CR109">
          <label>109.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Meco</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>West Nile arbovirus antibodies with hemagglutination inhibition (HI) in residents of Southeast Anatolia</article-title>
            <source>Mikrobiol Bul</source>
            <year>1977</year>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <lpage>17</lpage>
          </element-citation>
        </ref>
        <ref id="CR110">
          <label>110.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ozkul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yildirim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pinar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Akcali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Colak</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Serological evidence of West Nile Virus (WNV) in mammalian species in Turkey</article-title>
            <source>Epidemiol Infect</source>
            <year>2006</year>
            <volume>134</volume>
            <issue>4</issue>
            <fpage>826</fpage>
            <lpage>9</lpage>
            <?supplied-pmid 16316496?>
            <pub-id pub-id-type="pmid">16316496</pub-id>
          </element-citation>
        </ref>
        <ref id="CR111">
          <label>111.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ozkul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ergunay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koysuren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alkan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Arsava</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Tezcan</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Concurrent occurrence of human and equine West Nile virus infections in Central Anatolia, Turkey: the first evidence for circulation of lineage 1 viruses</article-title>
            <source>Int J Infect Dis</source>
            <year>2013</year>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>e546</fpage>
            <lpage>51</lpage>
            <?supplied-pmid 23517780?>
            <pub-id pub-id-type="pmid">23517780</pub-id>
          </element-citation>
        </ref>
        <ref id="CR112">
          <label>112.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ergunay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gunay</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Erisoz Kasap</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Oter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gargari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karaoglu</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Serological, molecular and entomological surveillance demonstrates widespread circulation of West Nile virus in Turkey</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2014</year>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>e3028</fpage>
            <?supplied-pmid 25058465?>
            <pub-id pub-id-type="pmid">25058465</pub-id>
          </element-citation>
        </ref>
        <ref id="CR113">
          <label>113.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ergunay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gunay</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kasap</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Orsten</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akkutay</surname>
                <given-names>AZ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Arboviral surveillance of field-collected mosquitoes reveals circulation of West Nile virus lineage 1 strains in Eastern Thrace, Turkey</article-title>
            <source>Vector Borne Zoonotic Dis</source>
            <year>2013</year>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>744</fpage>
            <lpage>52</lpage>
            <?supplied-pmid 23919608?>
            <pub-id pub-id-type="pmid">23919608</pub-id>
          </element-citation>
        </ref>
        <ref id="CR114">
          <label>114.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Gunay</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alten</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Simsek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aldemir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Linton</surname>
                <given-names>YM</given-names>
              </name>
            </person-group>
            <article-title>Barcoding Turkish Culex mosquitoes to facilitate arbovirus vector incrimination studies reveals hidden diversity and new potential vectors</article-title>
            <source>Acta Trop</source>
            <year>2015</year>
            <volume>143</volume>
            <fpage>112</fpage>
            <lpage>20</lpage>
            <?supplied-pmid 25446171?>
            <pub-id pub-id-type="pmid">25446171</pub-id>
          </element-citation>
        </ref>
        <ref id="CR115">
          <label>115.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ergunay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saygan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Aydogan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Menemenlioglu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Ozkul</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>West Nile virus seroprevalence in blood donors from Central Anatolia, Turkey</article-title>
            <source>Vector Borne Zoonotic Dis</source>
            <year>2010</year>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>771</fpage>
            <lpage>5</lpage>
            <?supplied-pmid 20021274?>
            <pub-id pub-id-type="pmid">20021274</pub-id>
          </element-citation>
        </ref>
        <ref id="CR116">
          <label>116.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yagci Caglayik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Uyar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Korukluoglu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ertek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Unal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>An imported Chikungunya fever case from New Delhi, India to Ankara, Turkey: the first imported case of Turkey and review of the literature</article-title>
            <source>Mikrobiol Bul</source>
            <year>2012</year>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>122</fpage>
            <lpage>8</lpage>
          </element-citation>
        </ref>
        <ref id="CR117">
          <label>117.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ocal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orsten</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Inkaya</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Yetim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Acar</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Alp</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Ongoing activity of Toscana virus genotype A and West Nile virus lineage 1 strains in Turkey: a clinical and field survey</article-title>
            <source>Zoonoses Public Health</source>
            <year>2014</year>
            <volume>61</volume>
            <issue>7</issue>
            <fpage>480</fpage>
            <lpage>91</lpage>
            <?supplied-pmid 25285941?>
            <pub-id pub-id-type="pmid">25285941</pub-id>
          </element-citation>
        </ref>
        <ref id="CR118">
          <label>118.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Carhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uyar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ozkaya</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ertek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dobler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dilcher</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Characterization of a sandfly fever Sicilian virus isolated during a sandfly fever epidemic in Turkey</article-title>
            <source>J Clin Virol</source>
            <year>2010</year>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>264</fpage>
            <lpage>9</lpage>
            <?supplied-pmid 20579934?>
            <pub-id pub-id-type="pmid">20579934</pub-id>
          </element-citation>
        </ref>
        <ref id="CR119">
          <label>119.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ergunay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sayiner</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Litzba</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lederer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Charrel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kreher</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Multicentre evaluation of central nervous system infections due to Flavi and Phleboviruses in Turkey</article-title>
            <source>J Infect</source>
            <year>2012</year>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>343</fpage>
            <lpage>9</lpage>
            <?supplied-pmid 22705706?>
            <pub-id pub-id-type="pmid">22705706</pub-id>
          </element-citation>
        </ref>
        <ref id="CR120">
          <label>120.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Dincer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gargari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ozkul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ergunay</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Potential animal reservoirs of Toscana virus and coinfections with Leishmania infantum in Turkey</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2015</year>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>690</fpage>
            <lpage>7</lpage>
            <?supplied-pmid 25711610?>
            <pub-id pub-id-type="pmid">25711610</pub-id>
          </element-citation>
        </ref>
        <ref id="CR121">
          <label>121.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Erdem</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ergunay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akata</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Inan</surname>
                <given-names>AS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Emergence and co-infections of West Nile virus and Toscana virus in Eastern Thrace, Turkey</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2014</year>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>319</fpage>
            <lpage>25</lpage>
            <?supplied-pmid 23910388?>
            <pub-id pub-id-type="pmid">23910388</pub-id>
          </element-citation>
        </ref>
        <ref id="CR122">
          <label>122.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Karaoğlu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Özgünlük</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Demir</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Özkul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burgu</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Seroprevalence of culicoides-borne disease in cattle in European Turkey</article-title>
            <source>Ank Üniv Vet Fak Derg</source>
            <year>2007</year>
            <volume>54</volume>
            <fpage>121</fpage>
            <lpage>5</lpage>
          </element-citation>
        </ref>
        <ref id="CR123">
          <label>123.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yilmaz</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Yildirim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Coskun</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Serological investigation of Bluetongue virus and Rift valley fever virus infections in sheep in Kars province of Turkey</article-title>
            <source>EBSCOhost</source>
            <year>2016</year>
            <volume>26</volume>
            <fpage>119</fpage>
            <lpage>22</lpage>
          </element-citation>
        </ref>
        <ref id="CR124">
          <label>124.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Gur</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A serologic investigation of blue tongue virus (BTV) in cattle, sheep and gazella subgutturosa subgutturosa in southeastern Turkey</article-title>
            <source>Trop Anim Health Prod</source>
            <year>2008</year>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>217</fpage>
            <lpage>21</lpage>
            <?supplied-pmid 18484124?>
            <pub-id pub-id-type="pmid">18484124</pub-id>
          </element-citation>
        </ref>
        <ref id="CR125">
          <label>125.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Azkur</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Gazyagci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aslan</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Serological and epidemiological investigation of bluetongue, Maedi-Visna and Caprien arthritis-encephalitis viruses in small ruminant in Kirikkale district in Turkey</article-title>
            <source>Kafkas Univ Vet Fak Derg</source>
            <year>2011</year>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>803</fpage>
            <lpage>8</lpage>
          </element-citation>
        </ref>
        <ref id="CR126">
          <label>126.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bursali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tekin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keskin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ekici</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dundar</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Species diversity of ixodid ticks feeding on humans in Amasya, Turkey: seasonal abundance and presence of Crimean-Congo hemorrhagic fever virus</article-title>
            <source>J Med Entomol</source>
            <year>2011</year>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <lpage>93</lpage>
            <?supplied-pmid 21337953?>
            <pub-id pub-id-type="pmid">21337953</pub-id>
          </element-citation>
        </ref>
        <ref id="CR127">
          <label>127.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Leblebicioglu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eroglu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Erciyas-Yavuz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hokelek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Acici</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Role of migratory birds in spreading Crimean-Congo hemorrhagic fever, Turkey</article-title>
            <source>Emerg Infect Dis</source>
            <year>2014</year>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>1331</fpage>
            <lpage>4</lpage>
            <?supplied-pmid 25062428?>
            <pub-id pub-id-type="pmid">25062428</pub-id>
          </element-citation>
        </ref>
        <ref id="CR128">
          <label>128.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Orkun</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Emir</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Karaer</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Ticks threatening lineage of Anatolian wild sheep (Ovis gmelinii anatolica) and determination of their tick-borne pathogens</article-title>
            <source>Vet Parasitol</source>
            <year>2016</year>
            <volume>228</volume>
            <fpage>77</fpage>
            <lpage>84</lpage>
            <?supplied-pmid 27692336?>
            <pub-id pub-id-type="pmid">27692336</pub-id>
          </element-citation>
        </ref>
        <ref id="CR129">
          <label>129.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yesilbag</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dincer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alpay</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Girisgin</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Tuncer</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Tick survey and detection of Crimean-Congo hemorrhagic fever virus in tick species from a non-endemic area, South Marmara region, Turkey</article-title>
            <source>Exp Appl Acarol</source>
            <year>2013</year>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>253</fpage>
            <lpage>61</lpage>
            <?supplied-pmid 23229492?>
            <pub-id pub-id-type="pmid">23229492</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362654</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Drug Saf</journal-id>
      <journal-id journal-id-type="iso-abbrev">Drug Saf</journal-id>
      <journal-title-group>
        <journal-title>Drug Safety</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0114-5916</issn>
      <issn pub-type="epub">1179-1942</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362654</article-id>
      <article-id pub-id-type="pmcid">PMC5362654</article-id>
      <article-id pub-id-type="pmc-uid">5362654</article-id>
      <article-id pub-id-type="pmid">28074423</article-id>
      <article-id pub-id-type="publisher-id">501</article-id>
      <article-id pub-id-type="doi">10.1007/s40264-016-0501-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Brandenburg</surname>
            <given-names>Nancy A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bwire</surname>
            <given-names>Robert</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Freeman</surname>
            <given-names>John</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Houn</surname>
            <given-names>Florence</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6732-7284</contrib-id>
          <name>
            <surname>Sheehan</surname>
            <given-names>Paul</given-names>
          </name>
          <address>
            <phone>+01 (908) 679-1909</phone>
            <email>psheehan@celgene.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zeldis</surname>
            <given-names>Jerome B.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0461 1802</institution-id><institution-id institution-id-type="GRID">grid.418722.a</institution-id><institution/><institution>Celgene Corporation, </institution></institution-wrap>556 Morris Ave, Summit, NJ 07901 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>10</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>40</volume>
      <issue>4</issue>
      <fpage>333</fpage>
      <lpage>341</lpage>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Introduction</title>
          <p>The effectiveness of patient education activities conducted within the lenalidomide and thalidomide risk evaluation and mitigation strategies (REMS) programs was evaluated by measuring understanding of serious risk and safe-use messages.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Results from mandatory knowledge, attitude, and behavior surveys and voluntary patient surveys completed between June 2012 and June 2013 were analyzed, and responses to questions relating to compliance with birth control measures and understanding of safe-use messages are presented by patient risk category.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>In total, 73,645 patients were enrolled into the REMS programs for lenalidomide and thalidomide and completed mandatory surveys prior to medication dispense. Of these, 2790 (3.8%) completed an additional voluntary survey. Among voluntary survey participants, for all patient pregnancy risk categories, reported compliance with birth control requirements was above 90% when starting therapy and at follow-up. At the beginning of therapy, complete compliance was 96.3%; 3 months later it was 96.4%. Patient understanding of safe-use messages was very high in all pregnancy risk groups, notably for messages repeated at each physician visit. Overall, 98.2% of patients knew that lenalidomide and thalidomide could cause birth defects, which is part of the repeated educational messaging. In contrast, 87.1% recalled that unused product should be returned to their healthcare professional, which is not included in repeated messaging.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>The lenalidomide and thalidomide REMS programs enhance patient understanding of safe-use messages, resulting in high levels of compliance with the birth control precautions essential to prevent fetal exposure to these known and potential human teratogens. Overall compliance was maintained after 3 months of follow-up and throughout therapy.</p>
        </sec>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1007/s40264-016-0501-2) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006436</institution-id>
              <institution>Celgene</institution>
            </institution-wrap>
          </funding-source>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer International Publishing Switzerland 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="FPar1">
      <title>Key Points</title>
      <p>
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Regular risk evaluation and mitigation strategies (REMS) patient survey data indicate high levels of understanding/retention of REMS safe-use messages.</td></tr><tr><td align="left">High compliance rates with REMS program contraception requirements were also reflected.</td></tr></tbody></table></table-wrap>
</p>
    </sec>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>The exposure of thousands of unborn fetuses to thalidomide in the 1950s and 1960s resulted in major changes to the US pharmacovigilance and risk management legislation and regulations [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Thalidomide was first marketed in Europe as a non-barbiturate sedative in the late 1950s, and preclinical and clinical studies had led to the conclusion that it was non-toxic in humans [<xref ref-type="bibr" rid="CR3">3</xref>]. Thalidomide was found to be antiemetic and was used extensively to treat and prevent ‘morning sickness’ associated with pregnancy. In 1961, two physicians independently associated thalidomide use in pregnancy with congenital malformations including phocomelia, amelia, syndactyly, and underdeveloped long bones [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Fetal thalidomide exposure has also been associated with a range of internal defects, resulting in an early mortality rate of around 40% [<xref ref-type="bibr" rid="CR6">6</xref>]. Once the link between thalidomide and birth defects was established, the drug was withdrawn worldwide and US pharmaceutical regulatory processes were strengthened [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
      <p>Interest in thalidomide revived when it was shown to be effective in treating erythema nodosum leprosum (ENL), an inflammatory reaction that complicates lepromatous leprosy [<xref ref-type="bibr" rid="CR8">8</xref>]. Subsequently, thalidomide was found to inhibit the expression of tumor necrosis factor (TNF), also known as ‘cachectin’, a cytokine associated with wasting [<xref ref-type="bibr" rid="CR9">9</xref>]. The HIV/AIDS community began to use thalidomide to treat HIV-associated wasting, creating a need to allow access to thalidomide for those who might benefit, while preventing access by those who could be at risk from the drug’s teratogenic effects.</p>
      <p>In 1998, thalidomide was approved by the US FDA for acute treatment of the cutaneous manifestations of moderate to severe ENL. Prior to its approval, thalidomide was found to be anti-angiogenic [<xref ref-type="bibr" rid="CR10">10</xref>], leading to research into its use to treat angiomas and malignancies. Subsequent clinical studies determined thalidomide’s activity in multiple myeloma (MM) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. In 2006, thalidomide (THALOMID<sup>®</sup>; Celgene Corporation, Summit, NJ, USA) in combination with dexamethasone was approved by the FDA to treat newly diagnosed MM.</p>
      <p>While Celgene was developing thalidomide, it created chemical congeners called IMiD<sup>®</sup> products that shared many of the immune modulatory and other properties of thalidomide. Celgene discovered that each IMiD product had slightly different properties from each other and from thalidomide. The first IMiD product to be commercialized was lenalidomide (REVLIMID<sup>®</sup>, Celgene Corporation), which was approved by the FDA in 2005 for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality and in 2006 in combination with dexamethasone for MM in patients who have received at least one prior therapy.</p>
      <p>The approvals of lenalidomide and thalidomide were achieved in a different regulatory environment from that of the 1950s and 1960s and, in tandem with approval of these drugs, systems were implemented to prevent fetal exposure [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Since the 2007 FDA Amendments Act, the FDA has required sponsors of new drug applications (NDAs), biologics license applications (BLAs), generic and biosimilar applications to submit a risk evaluation and mitigation strategies (REMS) program if there is concern that the risks of the product cannot be addressed by routine product labelling. A REMS program is intended to ensure that, through the implementation of additional risk-mitigation measures, the benefits of the drug outweigh the risks. All REMS programs include a timetable for submission of assessments, and the FDA may require that a product-specific REMS program includes a communication plan, medication guide, patient package insert, ‘elements to assure safe use’ (ETASU), and an implementation system.</p>
      <p>Lenalidomide and thalidomide have REMS programs with ETASUs that have two goals: (1) to prevent the risk of embryo-fetal exposure and (2) to inform prescribers, patients, and pharmacists of the serious risks and safe-use conditions of the product. To achieve these goals, some key safe-use messages in the REMS programs are repeated at each physician visit. The repeated messages vary according to patient risk categories but include warnings on birth defects, sexual intercourse, birth control, drug sharing, and donations to blood and sperm banks.</p>
      <p>One of the ETASU measures introduced to achieve these goals is to ensure the product is dispensed to patients enrolled in the REMS only after they have received, and confirm they understand, comprehensive safe-use education messages and agree to participate in frequent mandatory knowledge, attitude, and behavior (KAB) surveys. Additional voluntary patient surveys were conducted up to 2013 to examine patient understanding and compliance with safe-use measures.</p>
      <p>While the FDA has been able to mandate REMS programs since 2007, published data available on the effectiveness of these programs are limited. In an evaluation of REMS medication guides, 30.3% of medication guide assessments led to ‘acceptable knowledge’ (≥80% correct responses), with higher correct response rates reported for REMS programs including ETASUs [<xref ref-type="bibr" rid="CR15">15</xref>]. Previous analysis of voluntary survey data from the lenalidomide RevAssist<sup>®</sup> risk management program (from 2006) reported over 95% comprehension of safe-use messaging for male patients and females of childbearing potential [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
      <p>This study was conducted to evaluate the effectiveness of patient education activities in the lenalidomide and thalidomide REMS programs by analyzing the results of the mandatory KAB surveys and additional voluntary patient surveys to assess comprehension of safe-use messages and patient-reported compliance with birth control measures.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <p>The surveys described here were conducted in support of a regulatory commitment of the REMS programs to serve as a practical indicator of safe-use conditions rather than for research purposes. Mandatory surveys from June 2012 to June 2013 were interrogated alongside data from the voluntary surveys from June 2012 to February 2013 to establish receipt of patient brochures, patient understanding of safe-use messages, and reported compliance with birth control requirements. Demographic data were collected for both survey populations.</p>
      <sec id="Sec3">
        <title>Lenalidomide and Thalidomide Risk Evaluation and Mitigation Strategies (REMS) Program</title>
        <p>The main elements of the Celgene REMS programs are presented in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. Every prescriber intending to prescribe lenalidomide or thalidomide must first become certified into the respective REMS program. A certified prescriber may then enroll patients into the REMS program in a similar manner. The prescriber provides the patient with educational material highlighting the serious risks and safe-use conditions of the product and describes the frequent interactions with the REMS program during therapy. All patient materials were written to be comprehensible by a patient at 8th grade literacy levels. The prescriber and patient choose a unique identifier that is used in future REMS interactions, and information about the patient risk category, age, and indication is recorded in the Celgene REMS database. Throughout therapy, both the prescriber and the patient are required to provide the REMS program with information that confirms continued patient understanding of the safe-use measures before each subsequent prescription can be filled.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart highlighting the main components of the Celgene risk evaluation and mitigation strategies (REMS) programs. <italic>PPAF</italic> patient–physician agreement form</p></caption><graphic xlink:href="40264_2016_501_Fig1_HTML" id="MO1"/></fig>
</p>
        <p>The safe-use messages provided to patients prior to enrollment into the REMS program are as follows: (1) these products can cause birth defects, (2) contraceptive measures must be taken while receiving therapy, (3) these drugs cannot be shared, (4) patients must not donate blood to a blood bank, (5) any unused product must be returned to a healthcare professional. This information is described in patient brochures and in the patient–physician agreement form (PPAF) that is signed by patients and returned to Celgene. The PPAF also includes patient demographics and <italic>International Classification of Diseases</italic> (ICD) diagnosis codes, which are provided by the prescriber. The serious risk messages are also conveyed in the prescriber brochure to ensure prescribers are sufficiently informed to educate their patients about the risks before initiating therapy. Safe-use messages appropriate to the patients’ risk categories are repeated at each physician visit.</p>
        <p>Other patient resources include a patient resource kit, which contains a REMS patient guide and an emergency contraception brochure. These materials are provided to the patient at the time of enrollment by the prescriber in support of the PPAF discussion. They are also available publicly on the REMS websites (<ext-link ext-link-type="uri" xlink:href="http://www.revlimidrems.com">http://www.revlimidrems.com</ext-link> for lenalidomide; <ext-link ext-link-type="uri" xlink:href="http://www.thalomidrems.com">http://www.thalomidrems.com</ext-link> for thalidomide). Additionally, each patient is counseled by a REMS-certified counselor with a REMS Education and Counseling Checklist for Pharmacies before each dispense.</p>
        <p>Importantly, lenalidomide and thalidomide are dispensed to patients enrolled in the REMS only after they have received, and confirmed they understand, comprehensive safe-use messages. All patients must agree to participate in frequent KAB surveys initially, as well as during treatment, with the frequency depending on patient risk category. These surveys may be taken online, via an interactive voice-response system, or by calling the Celgene Customer Care Center. Mandatory surveys occur monthly for boys, men, girls who have not undergone menarche, and females of reproductive potential, and every 6 months for women not of reproductive potential. The number and nature of questions varies between risk categories. Mandatory surveys for adult males and females of reproductive potential include questions on the use of birth control methods and drug sharing. The survey for females of reproductive potential also includes questions that confirm their risk category, obtains confirmation of acceptable contraception behaviors as outlined by REMS, and affirms the patient understands the potential for the product to cause birth defects.</p>
        <p>Mandatory surveys are also completed by prescribers when a prescription is written. Prescriber surveys include questions on contraception counselling, pregnancy testing, and drug prescribing. All mandatory surveys for patients and prescribers are reviewed using a computer algorithm that ‘flags’ discrepant responses that indicate a potential cause for concern. Responses were identified as discrepant if (1) they diverged from the desired answers or (2) there was discrepancy between patient and prescriber responses. If a flag occurs to halt the REMS authorization process, an outbound call from Celgene is placed to the prescriber to provide the appropriate patient information to remedy the flag and verify safe-use conditions. All flags must be resolved prior to drug dispense.</p>
      </sec>
      <sec id="Sec4">
        <title>Voluntary Patient Survey</title>
        <p>Patients in the REMS program indicated on the PPAF whether they would be willing to participate in additional voluntary surveys (an initial survey for patients ≤14 days from initial dispense and a follow-up for patients &gt;90 days from enrollment) that further examined their understanding and compliance with safe-use measures in relation to the REMS program. The patients who volunteered were categorized into one of four risk categories (children, females of childbearing potential, females not of childbearing potential, and adult males). Of these patients, one child (if available) and at least 77 other patients were randomly selected each week for the voluntary patient population. All eligible females of childbearing potential were included in the initial survey, whereas one-third of eligible females of childbearing potential were included in the follow-up survey (with no minimum or maximum number for patients in this category in either survey). The remaining patients were randomly selected from the females not of childbearing potential (40%, minimum of four patients) and adult males (60%, minimum of six patients).</p>
        <p>The survey queried patients whether they were provided with the REMS program education materials and engaged in sufficient conversations with their healthcare providers to understand the contents. Patients were then classified into pregnancy risk groups similar to those in the mandatory KAB survey. Short- and long-term understanding and retention of educational materials was evaluated by sampling patients within 14 days of the first lenalidomide or thalidomide prescription (short-term retention) and after they had received therapy for at least 3 months (long-term retention).</p>
        <p>The voluntary surveys also assessed patient compliance with birth control requirements. Acceptable forms of birth control for patients receiving lenalidomide and thalidomide include true abstinence or one highly effective and one additional effective method of contraception. Highly effective contraception methods include an intrauterine device, hormonal birth control pills or devices, tubal ligation, or partner’s vasectomy. Additional effective methods include male condom, diaphragm, or cervical cap. The THALOMID (thalidomide) voluntary patient survey for female patients of childbearing potential is provided in the Electronic Supplementary Material.</p>
        <p>Information provided during enrollment into the mandatory REMS program and the optional voluntary patient survey, together with the results from the mandatory surveys, was analyzed to determine the effectiveness of patient education activities.</p>
      </sec>
    </sec>
    <sec id="Sec5">
      <title>Results</title>
      <sec id="Sec6">
        <title>Patients in the REMS Programs</title>
        <p>Between June 2012 and June 2013, a total of 73,645 patients enrolled into the REMS programs, including 56,709 patients receiving lenalidomide and 16,936 patients receiving thalidomide. The vast majority of patients (82.9%) enrolled in the REMS were treated for MM, with lower numbers of patients treated for myelodysplastic syndrome (6.4%), ENL (0.1%), and other conditions (10.5%).</p>
        <p>The distribution of patients by risk category is summarized in Fig. <xref rid="Fig2" ref-type="fig">2</xref>a. Consistent with published epidemiological data for MM [<xref ref-type="bibr" rid="CR16">16</xref>], there were more males (40,774 [55.4%]) than females (32,871 [44.6%]). Of the female patients, 2216 (6.7%) were of reproductive potential, and the majority (93.1%) were adult females not of reproductive potential, indicating the older population expected for patients with the diseases associated with the use of these drugs. Children represented &lt;1% of the enrolled patients.<fig id="Fig2"><label>Fig. 2</label><caption><p>Characteristics of the patient populations. <bold>a</bold> Distribution of patients enrolled in the lenalidomide and thalidomide Risk Evaluation and Mitigation Strategies (REMS) programs between June 2012 and June 2013 by risk category (<italic>N</italic> = 73,645). <bold>b</bold> Distribution of patients in the voluntary survey population by risk category (<italic>N</italic> = 2790). <bold>C</bold> Proportion of patients in the voluntary survey population who received and read the patient education brochure by risk category</p></caption><graphic xlink:href="40264_2016_501_Fig2_HTML" id="MO2"/></fig>
</p>
        <p>Of the 73,645 patients enrolled in the REMS programs, 10,391 (14.1%) agreed to participate in the additional voluntary survey. Of these, 3981 patients were randomly selected for inclusion in the voluntary survey sample, of whom 2790 (70.1%) responded. The distribution of responding patients is presented by risk category in Fig. <xref rid="Fig2" ref-type="fig">2</xref>b. The proportion of patients in each risk category was generally consistent with those recorded for the whole population enrolled in the REMS programs (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a), with more females of reproductive potential, as expected from the sampling strategy used (see Methods). The voluntary survey confirmed that 89.4% of patients received the initial education materials from their healthcare professional and 85.9% read them before starting treatment with lenalidomide or thalidomide (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c).</p>
        <p>During the study period, 264,417 mandatory patient surveys were performed and 14,848 (5.6%) were flagged as a potential cause for concern (Table <xref rid="Tab1" ref-type="table">1</xref>). Females of reproductive potential had the highest number of flagged surveys (6062 [45.0%]), all of which were resolved before the patient received her prescription. Follow-up determined that 696 (11.5%) were due to the patient not understanding or not complying with risk/safe-use messages. These reports were investigated and resolved prior to drug dispense, as described in the Methods section. A further 4025 (66.4%) of the surveys for females of reproductive potential were flagged because, since their initial enrollment into the REMS program, the patient had either had their uterus removed, or their menstrual periods had stopped for more than 24 months. These patients were re-classified as females not of reproductive potential.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Distribution of risk evaluation and mitigation strategies (REMS) patient survey flags by pregnancy risk category (June 2012–June 2013)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Risk category</th><th align="left">Surveys completed (<italic>N</italic>)</th><th align="left">Number (%) of surveys flagged</th></tr></thead><tbody><tr><td align="left">Females of reproductive potential (adult and child)</td><td char="." align="char">13,481</td><td char="(" align="char">6062 (45.0)</td></tr><tr><td align="left">Females not of reproductive potential (adult and child)</td><td char="." align="char">33,364</td><td char="(" align="char">5289 (15.9)</td></tr><tr><td align="left">Males (adult and child)</td><td char="." align="char">217,572</td><td char="(" align="char">3497 (1.6)</td></tr><tr><td align="left">Total</td><td char="." align="char">264,417</td><td char="(" align="char">14,848 (5.6)</td></tr></tbody></table></table-wrap>
</p>
        <p>The voluntary surveys for the same period indicated that 97.9% of the women of reproductive potential and adult females not of reproductive potential (<italic>n</italic> = 1126) surveyed understood that women should not get pregnant while taking the product, and 94.0% complied with birth control requirements at initial survey (91.2% at follow-up), demonstrating the effectiveness of these interventions in ensuring patient understanding of, and compliance with, safe-use messages.</p>
      </sec>
      <sec id="Sec7">
        <title>Compliance with Birth Control Requirements</title>
        <p>Patient-reported compliance with pregnancy-prevention measures was determined in the voluntary survey. Compliance with the required two forms of birth control was assessed when starting therapy and 3 months later (Table <xref rid="Tab2" ref-type="table">2</xref>). Reported birth control compliance was high: 96.3% of patients used the required birth control when starting therapy, and 96.4% reconfirmed this later.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Patient birth control compliance by risk category (voluntary survey), June 2012–February 2013</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Risk category</th><th align="left">Initial surveys</th><th align="left">Initial birth control compliance (%)</th><th align="left">Follow-up surveys</th><th align="left">Follow-up birth control compliance (%)</th></tr></thead><tbody><tr><td align="left">Females of reproductive potential</td><td char="." align="char">233</td><td char="(" align="char">219 (94.0)</td><td char="." align="char">147</td><td char="(" align="char">134 (91.2)</td></tr><tr><td align="left">Males (adult and child)</td><td char="." align="char">1532</td><td char="(" align="char">1480 (96.6)</td><td char="." align="char">1443</td><td char="(" align="char">1399 (97.0)</td></tr><tr><td align="left">Total</td><td char="." align="char">1765</td><td char="(" align="char">1699 (96.3)</td><td char="." align="char">1590</td><td char="(" align="char">1533 (96.4)</td></tr></tbody></table></table-wrap>
</p>
      </sec>
      <sec id="Sec8">
        <title>Understanding of Safe<italic>-</italic>Use Messages</title>
        <p>The impact of repeated educational messages on patient understanding and compliance with safe-use messages was assessed by reviewing surveys conducted in the voluntary survey population several months after starting therapy (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Patient understanding of messages by risk category (voluntary survey), June 2012–February 2013</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Message</th><th align="left">Females of reproductive potential</th><th align="left">Adult females not of reproductive potential</th><th align="left">Males aged ≥18 years</th><th align="left">Males aged 12–17 years</th><th align="left">Children aged &lt;12 years</th><th align="left">Total (%)</th></tr></thead><tbody><tr><td align="left">Total surveyed</td><td align="left">147</td><td align="left">979</td><td align="left">1441</td><td align="left">2</td><td align="left">7</td><td align="left">2576</td></tr><tr><td align="left">Product can cause birth defects</td><td align="left">146</td><td align="left">958</td><td align="left">1417</td><td align="left">2</td><td align="left">7</td><td align="left">2530 (98.2)</td></tr><tr><td align="left">Sharing product with others can be dangerous</td><td align="left">146</td><td align="left">969</td><td align="left">1417</td><td align="left">2</td><td align="left">7</td><td align="left">2541 (98.6)</td></tr><tr><td align="left">Women should not get pregnant while taking product</td><td align="left">144</td><td align="left">958</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">1102 (97.9)</td></tr><tr><td align="left">Men should use condoms while on product if they are sexually active with a woman who is able to become pregnant</td><td align="left">–</td><td align="left">–</td><td align="left">1418</td><td align="left">2</td><td align="left">–</td><td align="left">1420 (98.4)</td></tr><tr><td align="left">Unused product needs to be returned</td><td align="left">129</td><td align="left">866</td><td align="left">1239</td><td align="left">2</td><td align="left">7</td><td align="left">2243 (87.1)</td></tr></tbody></table></table-wrap>
</p>
        <p>Overall understanding of safe-use messages was very high: around 98% of patients demonstrated an understanding of most of these messages. Importantly, 98.2% of patients knew that lenalidomide and thalidomide can cause birth defects, which is part of the repeated educational messaging, whereas 87.1% recalled that unused product should be returned to their healthcare professional, which is not included in repeated messaging (Table <xref rid="Tab3" ref-type="table">3</xref>).</p>
      </sec>
    </sec>
    <sec id="Sec9">
      <title>Discussion</title>
      <p>Effectiveness of the REMS programs for lenalidomide and thalidomide in driving patient understanding and retention of safe-use messages was assessed using data from mandatory KAB assessments and voluntary patient surveys. Patients surveyed had high levels of compliance with birth control requirements, both initially and at follow-up, as well as very high levels of understanding of safe-use messages. This study determined that mandated REMS programs are effective tools for educating patients in the safe use of lenalidomide and thalidomide and re-enforcing compliance with safe-use measures by repeated messaging. Previous studies have determined that levels of fetal exposure to both lenalidomide and thalidomide are very low in patients enrolled in US risk management programs for these drugs [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. A third Celgene IMiD product, pomalidomide (Pomalyst<sup>®</sup>, approved in the USA for advanced MM in 2013) is distributed through an REMS identical to that for lenalidomide. It is anticipated that the REMS program will be similarly effective for this product.</p>
      <p>Patient understanding of safe-use messages in the Celgene REMS programs reported in this study (approximately 98% for key messages related to pregnancy, teratogenicity, and sharing the product) is consistent with the high levels of understanding reported in a previous analysis of voluntary surveys conducted as part of the original lenalidomide risk management program (RevAssist<sup>®</sup>) [<xref ref-type="bibr" rid="CR14">14</xref>]. However, published data on the effectiveness of messaging in other REMS programs are limited. A recent study investigating patient understanding of key risks based on medication guide assessments for 66 drugs between September 2008 and June 2012 found that primary drug risk knowledge questions were answered correctly by 63.8% of respondents on average [<xref ref-type="bibr" rid="CR15">15</xref>]. Higher rates were recorded for REMS that also included ETASU or a communication plan and ETASU (89.8 and 82.7%, respectively). The continued high understanding of safe-use messages for patients in the Celgene REMS programs is consistent with the higher rate of patient understanding in REMS programs with ETASUs and indicates the relative effectiveness of the Celgene programs.</p>
      <p>The high reported adherence to birth control measures for the Celgene REMS programs is particularly important given the teratogenic potential of the drugs involved. Thalidomide is a proven human teratogen, and lenalidomide caused thalidomide-like malformations in newborn monkeys in pre-clinical studies. Therefore, both must be considered products with teratogenic potential [<xref ref-type="bibr" rid="CR17">17</xref>]. A limitation of the current study is that the surveys do not report on patient behavior, which may not necessarily reflect survey responses. In a study of oral contraception use in over 6 million US women of childbearing age, only 59.8% of those receiving both category X medications and oral contraceptives were considered to be adherent to oral contraception [<xref ref-type="bibr" rid="CR18">18</xref>]. Consequently, an estimated 5.8% of pregnancies in the USA occur in women receiving medications of known teratogenic risk (categories D or X) [<xref ref-type="bibr" rid="CR19">19</xref>]. In this context, the high reported adherence to birth control requirements in this study (consistently over 90%) indicates the effectiveness of repeated messaging enabling understanding of birth control requirements in the REMS programs for lenalidomide and thalidomide. Crucially, Celgene risk management measures have been executed over 18 years, with no reported births with teratogenicity due to Celgene products.</p>
      <p>In this study, understanding was particularly high for safe-use messages that were part of repeated messaging. For each of these safety messages, around 98% of patients demonstrated understanding, considerably higher than for a message not included in repeated messaging (Table <xref rid="Tab3" ref-type="table">3</xref>). This demonstrates the crucial role of repeated messaging in the REMS programs, particularly for messages related to teratogenicity and the need for adequate birth control measures. The high rate of understanding of these messages is reflected in a high rate of reported adherence to birth control measures. Repeated messaging has previously been shown to be effective in influencing prescriber behavior in a study of the provision of calcium and vitamin D supplements to UK patients receiving anti-epileptic drugs [<xref ref-type="bibr" rid="CR20">20</xref>]. In the Celgene REMS programs, the use of mandatory monthly (for patients of reproductive potential) or 6-monthly (for other patients) KAB surveys allows patients’ continued understanding of safe-use messages to be regularly and continually assessed prior to dispensing. Approximately 5% of the 264,417 surveys completed during this study were flagged, providing the opportunity to investigate and resolve concerns before lenalidomide or thalidomide was dispensed.</p>
      <p>It should be noted that the surveys described here were conducted in support of a regulatory commitment of the REMS programs to serve as a practical indicator of safe-use conditions rather than for research purposes. Consequently, the goals and objectives of these surveys differ from those of surveys conducted as purely research exercises. One limitation of this study is the limited duration of follow-up. Messaging within REMS programs needs to be developed to prevent patient ‘fatigue’ with repeated messaging [<xref ref-type="bibr" rid="CR21">21</xref>], which could potentially diminish patients’ attention to serious risk and safe-use messaging. There was no evidence in this study that the repeated messaging in the lenalidomide and thalidomide REMS programs led to a reduction in patients’ attention to safety messages; however, there was no follow-up beyond 3 months. Additional studies are required to assess whether repeated messaging leads to diminution of patient attention.</p>
      <p>In addition, although analysis of the patient surveys allowed us to assess patient understanding of REMS messaging, it did not provide any data on the impact of the REMS programs on prescribers. We believe that the results presented in this report, the record of birth control compliance with other category X drugs, and the overarching REMS programs rationale should be considered when evaluating the burden incurred by healthcare providers in relation to REMS programs. In a survey of 364 healthcare providers in Southern California, USA, most respondents (63%) considered that REMS improved patient safety, whereas 62% considered that REMS was very or somewhat meaningful in improving patient safety. Among oncology prescribers (<italic>N</italic> = 28), 68% considered that REMS improved patient safety, whereas 75% responded that REMS was meaningful [<xref ref-type="bibr" rid="CR22">22</xref>]. Despite this, the additional administrative burden incurred by REMS programs is a recognized concern among oncology practitioners [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. To mitigate this, online enrollment systems have been developed to minimize the administrative burden on healthcare providers enrolling patients in the REMS programs for lenalidomide and thalidomide [<xref ref-type="bibr" rid="CR24">24</xref>]. Further studies are required to assess the burden of REMS programs and to evaluate potential improvements to the REMS process.</p>
      <p>The necessary extra administrative burden incurred by these REMS programs must be considered in the context of the risk of fetal exposure and the effectiveness of the programs in preventing this exposure. Data presented here and elsewhere [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] clearly demonstrate that these programs drive the high levels of patient understanding and compliance necessary to prevent fetal exposure.</p>
    </sec>
    <sec id="Sec10">
      <title>Conclusion</title>
      <p>Lenalidomide and thalidomide are both important treatments for an increasing variety of malignant conditions. For these and other teratogenic compounds to be used safely, it is crucial that both the pharmaceutical industry and regulatory authorities work to minimize the risk of fetal exposure. The data from this study support the conclusion that the lenalidomide and thalidomide REMS programs in the USA enhance patient understanding of safe-use messages, leading to high levels of compliance with the birth control precautions essential to prevent fetal exposure to these known and potential human teratogens. The 3-month follow-up with the voluntary survey means there are no data on longer-term patient understanding of the REMS. However, the mandatory surveys show that overall compliance was maintained after 3 months of follow-up and throughout therapy.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec11">
        <p>Below is the link to the electronic supplementary material. 
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40264_2016_501_MOESM1_ESM.pdf"><caption><p>Supplementary material 1 (PDF 1043 kb)</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>Medical writing and editorial support for the preparation of the manuscript was provided by Graham Buttrick, PhD, of Insight Medical Writing (Oxford, UK) and funded by Celgene Corporation.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with Ethical Standards</title>
      <sec id="FPar2">
        <title>Funding</title>
        <p>This study was sponsored by Celgene Corporation.</p>
      </sec>
      <sec id="FPar3">
        <title>Conflicts of interest</title>
        <p>Robert Bwire, John Freeman, Florence Houn, and Paul Sheehan are employees of Celgene Corporation. Nancy Brandenburg and Jerome Zeldis are former Celgene employees.</p>
      </sec>
      <sec id="FPar4">
        <title>Patient consent</title>
        <p>All patients included in the study gave consent for their data to be used on the PPAF. Ethical approval was not required for this study.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rehman</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Arfons</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Lazarus</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development</article-title>
          <source>Ther Adv Hematol.</source>
          <year>2011</year>
          <volume>2</volume>
          <fpage>291</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="doi">10.1177/2040620711413165</pub-id>
          <?supplied-pmid 23556097?>
          <pub-id pub-id-type="pmid">23556097</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Waller</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <source>An introduction to pharmacovigilance</source>
          <year>2010</year>
          <publisher-loc>Chichester</publisher-loc>
          <publisher-name>Wiley-Blackwell</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Somers</surname>
              <given-names>GF</given-names>
            </name>
          </person-group>
          <article-title>Pharmacological properties of thalidomide (α-phthalimido glutarimide), a new sedative</article-title>
          <source>Br J Pharmacol Chemother.</source>
          <year>1960</year>
          <volume>15</volume>
          <fpage>111</fpage>
          <lpage>116</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1476-5381.1960.tb01217.x</pub-id>
          <?supplied-pmid 13832739?>
          <pub-id pub-id-type="pmid">13832739</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lenz</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Kindliche missbildungen nach medikament-einnahme während der gravidität?</article-title>
          <source>Dtsch Med Wochenschr</source>
          <year>1961</year>
          <volume>86</volume>
          <fpage>2555</fpage>
          <lpage>2556</lpage>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McBride</surname>
              <given-names>WG</given-names>
            </name>
          </person-group>
          <article-title>Thalidomide and congenital abnormalities</article-title>
          <source>Lancet</source>
          <year>1961</year>
          <volume>2</volume>
          <fpage>1358</fpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(61)90927-8</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smithells</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Newman</surname>
              <given-names>CG</given-names>
            </name>
          </person-group>
          <article-title>Recognition of thalidomide defects</article-title>
          <source>J Med Genet</source>
          <year>1992</year>
          <volume>29</volume>
          <fpage>716</fpage>
          <lpage>723</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.29.10.716</pub-id>
          <?supplied-pmid 1433232?>
          <pub-id pub-id-type="pmid">1433232</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greene</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Podolsky</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Reform, regulation, and pharmaceuticals—the Kefauver-Harris Amendments at 50</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>367</volume>
          <fpage>1481</fpage>
          <lpage>1483</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMp1210007</pub-id>
          <?supplied-pmid 23075174?>
          <pub-id pub-id-type="pmid">23075174</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iyer</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Languillon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ramanujam</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients</article-title>
          <source>Bull World Health Organ</source>
          <year>1971</year>
          <volume>45</volume>
          <fpage>719</fpage>
          <lpage>732</lpage>
          <?supplied-pmid 4947831?>
          <pub-id pub-id-type="pmid">4947831</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sampaio</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Sarno</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>Galilly</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes</article-title>
          <source>J Exp Med</source>
          <year>1991</year>
          <volume>173</volume>
          <fpage>699</fpage>
          <lpage>703</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.173.3.699</pub-id>
          <?supplied-pmid 1997652?>
          <pub-id pub-id-type="pmid">1997652</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D’Amato</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Loughnan</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Flynn</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thalidomide is an inhibitor of angiogenesis</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1994</year>
          <volume>91</volume>
          <fpage>4082</fpage>
          <lpage>4085</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.91.9.4082</pub-id>
          <?supplied-pmid 7513432?>
          <pub-id pub-id-type="pmid">7513432</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singhal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Desikan</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antitumor activity of thalidomide in refractory multiple myeloma</article-title>
          <source>N Engl J Med</source>
          <year>1999</year>
          <volume>341</volume>
          <fpage>1565</fpage>
          <lpage>1571</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199911183412102</pub-id>
          <?supplied-pmid 10564685?>
          <pub-id pub-id-type="pmid">10564685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rajkumar</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Blood</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vesole</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>431</fpage>
          <lpage>436</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2005.03.0221</pub-id>
          <?supplied-pmid 16365178?>
          <pub-id pub-id-type="pmid">16365178</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uhl</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rogan</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme</article-title>
          <source>Drug Saf</source>
          <year>2006</year>
          <volume>29</volume>
          <fpage>321</fpage>
          <lpage>329</lpage>
          <pub-id pub-id-type="doi">10.2165/00002018-200629040-00003</pub-id>
          <?supplied-pmid 16569081?>
          <pub-id pub-id-type="pmid">16569081</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Castaneda</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Zeldis</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide</article-title>
          <source>Drug Saf</source>
          <year>2008</year>
          <volume>31</volume>
          <fpage>743</fpage>
          <lpage>752</lpage>
          <pub-id pub-id-type="doi">10.2165/00002018-200831090-00003</pub-id>
          <?supplied-pmid 18707189?>
          <pub-id pub-id-type="pmid">18707189</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Knox</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hampp</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Willy</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patient understanding of drug risks: an evaluation of medication guide assessments</article-title>
          <source>Pharmacoepidemiol Drug Saf</source>
          <year>2015</year>
          <volume>24</volume>
          <fpage>518</fpage>
          <lpage>525</lpage>
          <pub-id pub-id-type="doi">10.1002/pds.3762</pub-id>
          <?supplied-pmid 25808393?>
          <pub-id pub-id-type="pmid">25808393</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975–2011, National Cancer Institute. Bethesda, MD. <ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/csr/1975_2011/">http://seer.cancer.gov/csr/1975_2011/</ext-link>. Based on November 2013 SEER data submission, posted to the SEER website, April 2014. Accessed 6 Nov 2014.</mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="other">Celgene Corporation. REVLIMID [lenalidomide] full prescribing information 2015. <ext-link ext-link-type="uri" xlink:href="http://www.revlimid.com/wp-content/uploads/2013/11/PI.pdf">http://www.revlimid.com/wp-content/uploads/2013/11/PI.pdf</ext-link>. Accessed 19 Feb 2015.</mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steinkellner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Denison</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>Adherence to oral contraception in women on Category X medications</article-title>
          <source>Am J Med</source>
          <year>2010</year>
          <volume>123</volume>
          <fpage>929</fpage>
          <lpage>934</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjmed.2010.05.009</pub-id>
          <?supplied-pmid 20920695?>
          <pub-id pub-id-type="pmid">20920695</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andrade</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Raebel</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Morse</surname>
              <given-names>AN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Use of prescription medications with a potential for fetal harm among pregnant women</article-title>
          <source>Pharmacoepidemiol Drug Saf</source>
          <year>2006</year>
          <volume>15</volume>
          <fpage>546</fpage>
          <lpage>554</lpage>
          <pub-id pub-id-type="doi">10.1002/pds.1235</pub-id>
          <?supplied-pmid 16586470?>
          <pub-id pub-id-type="pmid">16586470</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minshall</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mahon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Neligan</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Bone protection and anti-epileptic drugs: the effect of audit and computer messaging on supplementation prescribing practices</article-title>
          <source>Seizure.</source>
          <year>2013</year>
          <volume>22</volume>
          <fpage>757</fpage>
          <lpage>759</lpage>
          <pub-id pub-id-type="doi">10.1016/j.seizure.2013.06.002</pub-id>
          <?supplied-pmid 23810527?>
          <pub-id pub-id-type="pmid">23810527</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>American Pharmacists Association</collab>
          </person-group>
          <article-title>APhA 2011 REMS white paper: summary of the REMS stakeholder meeting on improving program design and implementation</article-title>
          <source>J Am Pharm Assoc.</source>
          <year>2011</year>
          <volume>51</volume>
          <fpage>340</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="doi">10.1331/JAPhA.2011.11519</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rashid</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cheetham</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Aranda</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A descriptive evaluation of prescriber perceptions and experience with Risk Evaluation and Mitigation Strategy (REMS) programs in an integrated health care system</article-title>
          <source>Ther Innov Regul Sci.</source>
          <year>2015</year>
          <volume>49</volume>
          <fpage>503</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="doi">10.1177/2168479014567318</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frame</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>WH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Assessment of risk evaluation and mitigation strategies in oncology: summary of the oncology risk evaluation and mitigation strategies workshop</article-title>
          <source>J Oncol Pract.</source>
          <year>2013</year>
          <volume>9</volume>
          <fpage>e24</fpage>
          <lpage>e39</lpage>
          <pub-id pub-id-type="doi">10.1200/JOP.2012.000620</pub-id>
          <?supplied-pmid 23814522?>
          <pub-id pub-id-type="pmid">23814522</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="other">Celgene: REMS program portal. <ext-link ext-link-type="uri" xlink:href="https://www.celgeneriskmanagement.com">https://www.celgeneriskmanagement.com</ext-link>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362655</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sleep Biol Rhythms</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sleep Biol Rhythms</journal-id>
      <journal-title-group>
        <journal-title>Sleep and Biological Rhythms</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1446-9235</issn>
      <issn pub-type="epub">1479-8425</issn>
      <publisher>
        <publisher-name>Springer Japan</publisher-name>
        <publisher-loc>Tokyo</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362655</article-id>
      <article-id pub-id-type="pmcid">PMC5362655</article-id>
      <article-id pub-id-type="pmc-uid">5362655</article-id>
      <article-id pub-id-type="publisher-id">94</article-id>
      <article-id pub-id-type="doi">10.1007/s41105-017-0094-x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Activation of the ventral tegmental area increased wakefulness in mice</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>Huan-Xin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Dian-Ru</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ye</surname>
            <given-names>Chen-Bo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>Zhen-Zhen</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Chen-Yao</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>Zhi-Li</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Yang</surname>
            <given-names>Su-Rong</given-names>
          </name>
          <address>
            <phone>86-21-54237228</phone>
            <email>sryang@shmu.edu.cn</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution>Department of Pharmacology, School of Basic Medical Sciences, </institution><institution>Fudan University, </institution></institution-wrap>138 Yixueyuan Road, Box 229, Shanghai, 200032 China </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution>Institutes of Brain Science, </institution><institution>Fudan University, </institution></institution-wrap>Shanghai, 200032 China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>24</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>15</volume>
      <issue>2</issue>
      <fpage>107</fpage>
      <lpage>115</lpage>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>7</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>2</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>The ventral tegmental area (VTA) is crucial for brain functions, such as voluntary movement and cognition; however, the role of VTA in sleep-wake regulation when directly activated or inhibited remains unknown. In this study, we investigated the effects of activation or inhibition of VTA neurons on sleep-wake behavior using the pharmacogenetic “designer receptors exclusively activated by designer drugs (DREADD)” approach. Immunohistochemistry staining was performed to confirm the microinjection sites, and combined with electrophysiological experiments, to determine whether the VTA neurons were activated or inhibited. The hM3Dq-expressing VTA neurons were excited confirmed by clozapine-N-oxide (CNO)-driven c-Fos expression and firing in patch-clamp recordings; whereas the hM4Di-expressing VTA neurons inhibited by reduction of firing. Compared with controls, the activation of VTA neurons at 9:00 (inactive period) produced a 120.1% increase in the total wakefulness amount for 5 h, whereas NREM and REM sleep were decreased by 62.5 and 92.2%, respectively. Similarly, when VTA neurons were excited at 21:00 (active period), the total wakefulness amount increased 81.5%, while NREM and REM sleep decreased 64.6 and 93.8%, respectively, for 8 h. No difference of the amount and EEG power density of the NREM sleep was observed following the arousal effects of CNO. The inhibition of VTA neurons during active or inactive periods gave rise to no change in the time spent in the wakefulness, REM, and NREM sleep compared with control. The results indicated that VTA neurons activated pharmacogentically played important roles in promoting wakefulness.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Clozapine-<italic>N</italic>-oxide</kwd>
        <kwd>Pharmacogenetics</kwd>
        <kwd>Sleep-wake</kwd>
        <kwd>Ventral tegmental area</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>National Natural Science Foundation of China (CN)</institution>
          </funding-source>
          <award-id>81420108015</award-id>
          <principal-award-recipient>
            <name>
              <surname>Huang</surname>
              <given-names>Zhi-Li</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <award-group>
          <funding-source>
            <institution>Shanghai Leading Academic Discipline Project</institution>
          </funding-source>
          <award-id>B119</award-id>
          <principal-award-recipient>
            <name>
              <surname>Yang</surname>
              <given-names>Su-Rong</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id>
              <institution>National Natural Science Foundation of China</institution>
            </institution-wrap>
          </funding-source>
          <award-id>81571296</award-id>
          <principal-award-recipient>
            <name>
              <surname>Yang</surname>
              <given-names>Su-Rong</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Japanese Society of Sleep Research 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>The ventral tegmental area (VTA) contains dopamine (DA) containing neurons and is traversed by many blood vessels and nerve fibers. Close to its poorly defined borders are found DA and 5-HT containing neurons [<xref ref-type="bibr" rid="CR1">1</xref>]. The VTA comprises several subdivisions and neurons synthesizing neurotransmitters, such as DA, GABA, or glutamate [<xref ref-type="bibr" rid="CR2">2</xref>]. The DA neurons arises in the VTA and projects to: (1) the septal area, olfactory tubercle, nucleus accumbens, amygdaloid complex, and piriform cortex (mesolimbic projection) and (2) the medial prefrontal, cingulate, and entorhinal areas (mesocortical projection) [<xref ref-type="bibr" rid="CR1">1</xref>]. The VTA is crucial for brain functions, such as voluntary movement and goal-directed behavior, as well as cognition, emotion, reward, working memory, and decision making [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p>Accordingly, DA midbrain system dysfunction is associated with neurologic and psychiatric diseases, such as schizophrenia, addiction, attention deficit hyperactivity disorder, and Parkinson’s disease [<xref ref-type="bibr" rid="CR7">7</xref>]. Several lines of evidence suggest that DA signals are closely associated with regulation of sleep-wake activity [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. In humans, malfunction of the brain DA system is associated with neuropsychopathy, with disruption of sleep as one symptom [<xref ref-type="bibr" rid="CR10">10</xref>]. Systemic administration of a selective D<sub>1</sub> receptor agonist induced an increase of wakefulness (W) and a reduction of slow wave sleep (SWS) and REM sleep. On the other hand, low doses of D<sub>2</sub> receptor agonist reduced W and increased SWS and REM, whereas large doses induced the opposite effect [<xref ref-type="bibr" rid="CR11">11</xref>]. Psycho-stimulants promote wakefulness by inhibiting the DA reuptake transporter (DAT) and thereby enhancing the extracellular DA levels in mice [<xref ref-type="bibr" rid="CR12">12</xref>]. The results are often controversial by drug effects on targets outside the VTA area or by potential disruption of neural circuits during development after gene knockout. The effects of activation or inhibition of VTA neurons on sleep/wake behavior remains to be directly tested.</p>
      <p>The VTA is a heterogeneous area where dopaminergic and non-dopaminergic neurons are intermixed [<xref ref-type="bibr" rid="CR2">2</xref>]. The pharmacogenetic technique “designer receptors exclusively activated by a designer drug” DREADD [<xref ref-type="bibr" rid="CR13">13</xref>] utilizes extrinsic muscarinic receptors (hM3Dq for excitation and hM4Di for inhibition) that have lost their affinity for endogenous acetylcholine but can still be activated by a synthetic inert ligand (clozapine-<italic>N</italic>-oxide [CNO]). Activation of Gq-coupled hM3Dq by CNO has previously been shown to activate neurons through a phospholipase C-dependent mechanism [<xref ref-type="bibr" rid="CR14">14</xref>]. CNO can also stimulate the Gi/o-coupled hM4Di receptor, thereby activating the inwardly rectifying potassium 3 channel, resulting in membrane hyperpolarization and neuronal silencing [<xref ref-type="bibr" rid="CR13">13</xref>]. In this way, the activity of VTA neurons can be manipulated temporarily and reversibly. Our study established a direct link between the activity of midbrain VTA neurons and arousal promotion. The results will contribute for understanding the roles of the VTA area in regulation of sleep and wake states, which will provide a therapeutic basis for sleep disorders involved in VTA neurons.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Animals</title>
        <p>Pathogen-free adult male S129 mice (25–30 g) were obtained from the Laboratory Animal Center of Chinese Academy of Sciences (Shanghai, China). The animals were housed in individual cages at a constant temperature (24 ± 1 °C) with a relative humidity (60 ± 2%) on an automatically controlled 12:12 light/dark cycle (lights on at 7:00). The mice had free access to food and water. The experimental protocols were approved by the Committee on the Ethics of Animal Experiments of the University of Fudan, Shanghai Medical College (Shanghai, China). Every effort was made to minimize the number of animals used and any pain and discomfort experienced by the animals.</p>
      </sec>
      <sec id="Sec4">
        <title>Surgery</title>
        <sec id="Sec5">
          <title>Virus injection</title>
          <p>Male mice were anesthetized with chloral hydrate (5% in saline [360 mg/kg]), then placed in a stereotaxic frame, so that the head was fixed. A burr hole was made, and a fine glass pipette (1 mm glass stock, tapering slowly to a 10–20 μm tip) containing adeno-associated viral (AAV) was bilaterally lowered to the VTA (coordinates relative to bregma: anterioposterior = − 3.4 mm, mediolateral = ± 0.3 mm, dorsoventral = −4.0 mm) [<xref ref-type="bibr" rid="CR15">15</xref>]. Then, the AAV vectors (0.05 µl per side) were injected with nitrogen gas pulses. After ten additional min, the pipette was slowly withdrawn. In our study, we employed an evolved G-protein-coupled muscarinic receptor (hM3Dq or hM4Di) that is selectively activated or inhibited by the exogenous ligand CNO. The animals recovered for 2 weeks before electrodes were implanted for electroencephalogram (EEG) and electromyogram (EMG) recordings.</p>
        </sec>
        <sec id="Sec6">
          <title>Sleep recording and vigilance state analysis</title>
          <p>To monitor EEG signals, two stainless steel screws were positioned 1 mm anterior to the bregma, both of which were 1.5 mm laterals to the midline [<xref ref-type="bibr" rid="CR15">15</xref>]. Two Teflon-coated, stainless steel wires were placed into the trapezius muscles bilaterally for EMG recording. All electrodes were attached to a micro-connector and fixed to the skull with dental cement. After surgery, each mouse was allowed recover for 1 week before polygraphic recording. The recordings were started at 7:00 (onset of light period) or 19:00 (onset of dark period). We recorded EEG and EMG for two consecutive days. On day 1, the mice were treated with vehicle (intrape ritoneal [i.p.] saline) at 9:00 or 21:00, and the recordings served as the baseline data. On the next day, CNO (1 mg/kg) was injected at the same time on day 1. The same mice were used four times for different injection time and drug (9:00 saline/CNO; 21:00 saline/CNO). The interval for each experiment was 2 days.</p>
          <p>The EEG and EMG signals were amplified and filtered (EEG, 0.5–30 Hz; EMG, 20–200 Hz), then digitized at a sampling rate of 128 Hz and recorded by VitalRecorder (Kissei Comtec, Nagano, Japan) [<xref ref-type="bibr" rid="CR16">16</xref>]. Vigilant states were automatically classified off-line under 10-s epochs into three stages, i.e., wakefulness, rapid eye movement (REM), and non-rapid eye movement (NREM) sleep, using SLEEPSIGN (Kissei Comtec) according to standard criteria [<xref ref-type="bibr" rid="CR17">17</xref>]. Wakefulness is defined by a low-amplitude and high-frequency EEG with a high activity of EMG. REM sleep is characterized by a low-amplitude, high-frequency EEG associated with the absence of EMG activity; the presence of EEG theta-activity (6–9 Hz) in the recording can be used to confirm this state. NREM sleep is commonly defined by a high-amplified EEG associated with a low-voltage EMG. The presence of high EEG delta activity (0.65–4 Hz) is also employed to characterize this state. As a final step, defined sleep-wake stages were examined visually and corrected if necessary [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
        </sec>
      </sec>
      <sec id="Sec500">
        <title>Drugs and administration</title>
        <p>CNO (LKT Labs C4759, USA) was dissolved in saline to a concentration of 1 mg/10 ml before treatment. CNO was administered by i.p.to each mouse (0.1 ml/10 g body weight).</p>
      </sec>
      <sec id="Sec7">
        <title>Immunohistochemistry</title>
        <p>One group of mice was injected with saline and the other with CNO at a dose of 1 mg/kg. Two hours later, the animals were deeply anesthetized with 5% chloral hydrate (360 mg/kg) and were immediately perfused transcardially with 60 ml of saline, followed by 50 ml of ice-cold 4% paraformaldehyde (PFA). The brains were removed and post-fixed for 24 h at 4 °C in 4% PFA, then equilibrated in phosphate buffer containing 30% sucrose at 4 °C. Coronal Sect. (30 μm) were cut serially on a cryostat. For double immunohistochemistry analysis, sections were thrice washed with phosphate-buffered saline (PBS) and incubated with 0.3% hydrogen peroxide in 0.1 M PBS for 30 min. After washing in PBS, the sections were incubated with a primary rabbit anti-c-Fos (1:10000, Millipore 2239640, USA) antibody diluted in PBS containing 0.3% Triton X-100 (PBST) for 48 h. On the second day, the sections were rinsed and incubated in biotinylated anti-rabbit secondary antiserum (1:1000, Jackson ImmunoResearch BA-100, West Grove, PA, USA) for 2 h. After thrice washing in PBS, all sections were then treated with avidin-biotin-peroxidase complex (1:1:1000, Vectastain ABC Elite kit; Vector Laboratories PK-6100, San Francisio, CA, USA) for 90 min. The peroxidase reactions were visualized with 0.05% 3, 3- diamino-benzidine (DAB; Sigma SK-4100, St. Louis, MO, USA) in 0.1 M PB and 0.01% hydrogen peroxide. After three washes in PBS, the sections were incubated in another primary rabbit anti-DsRed (1:10000, Takara 632496, USA) antibody diluted in PBST overnight. The procedure was similar as c-Fos staining previously described above with the exception of the last step; the color reagents of DAB did not include nickel. All sections were mounted onto gelatin-coated slides, dehydrated in graded ethanol, placed into xylene, and cover-slipped.</p>
        <p>The sections were examined under bright-field illumination with a microscope (Leica Microsystems, Wetzlar, Germany). Using light microscopy, neurons positive for c-Fos were identified by dense black nuclear staining; the mCherry were identified by brown cytomembrane staining. Locations in the brain were confirmed by staining and reference to the primary literature and a mouse brain atlas.</p>
      </sec>
      <sec id="Sec8">
        <title>Electrophysiologic experiments</title>
        <sec id="Sec9">
          <title>Preparation for brain slices</title>
          <p>Electrophysiologic experiments were performed on slices retrieved from the mice injected with virus 3 weeks earlier. Briefly, the mice were sacrificed by decapitation, and the VTA and SNc were identified according to stereotaxic coordinates [<xref ref-type="bibr" rid="CR15">15</xref>]. Coronal midbrain slices (300 μm thick) containing VTA and SNc were cut using a vitratome (Leica VT 1000 S, USA) in ice-cold glycerol-based artificial cerebrospinal fluid containing: glycerol (260 mM), KCL (5 mM), KH<sub>2</sub>PO<sub>4</sub> (1.25 mM), MgSO<sub>4</sub> (1.3 mM), CaCL<sub>2</sub> (0.5 mM), NaHCO<sub>3</sub>(20 mM) and glucose (10 mM), and saturated with 95% O<sub>2</sub>–5% CO<sub>2</sub>. Slices were allowed to recover for at least 1 h in a holding chamber at a water bath (32 °C) before recording.</p>
        </sec>
        <sec id="Sec10">
          <title>Patch-clamp recordings in the whole-cell configuration</title>
          <p>This recording configuration was used to study the effects of CNO application on a single VTA/SNc cell. The path electrodes were pulled from borosilicate glass capillaries (1.5 mm outside diameter, 0.86 inside diameter, Sutter Instrument, Novato, CA) on a Brown-Flaming micropipette (Model P-97, Sutter Instrument, Novato, CA, USA). The path electrode had a resistance of 4–6 MΩ when filled with pipette solution containing potassium gluconate (120 mM), KCl (20 mM), MgCl2 (1 mM), CaCl2 (0.16 mM), HEPES (10 mM), EGTA (0.5 mM), MgATP (2 mM), and NaGTP (0.5 mM); with the pH was adjusted to 7.4 with KOH. A single coronal slice was transferred to the recording chamber, where the slice was held down with a platinum ring. Artificial cerebrospinal fluid (ACSF) gassed with 95% O<sub>2</sub>–5% CO<sub>2</sub> flowed through the bath (2 ml/min). VTA/SNc neurons were identified under visual guidance using upright microscope (BX-51, Olympus, Japan) with a 40× water immersion objective lens. The cells were recorded using mCherry fluorescent signals. The image was detected with a CCD camera (U-TV1X-2, Olympus, Japan) and displayed on a monitor. The mCherry-positive neurons were clamped to record spontaneous action potentials and/or membrane potentials. The series resistance (3–5 MΩ) and input resistance (300–400 MΩ) were monitored throughout the cell recording, and data were discarded when either of the two resistances changed by &gt;20% [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
        </sec>
      </sec>
      <sec id="Sec11">
        <title>Statistical analysis</title>
        <p>All data were presented as the mean ± standard error. Histograms of the amounts of sleep and wakefulness after vehicle or CNO injection were compared using a Student’s two-tailed paired <italic>t</italic> test. The hourly amounts of each stage for sleep–wake profiles in mice treated with vehicle or CNO were compared using repeated-measures analysis of variance followed by Fisher’s probable least-squares difference (PLSD) test, <italic>p</italic> &lt; 0.05 was considered statically significant.</p>
      </sec>
    </sec>
    <sec id="Sec12" sec-type="results">
      <title>Results</title>
      <sec id="Sec13">
        <title>Injection sites confirmed by mCherry expression of AAV</title>
        <p>To control the VTA neurons in behaving animals, we bilaterally injected the AAV containing excitatory (hSyn-hM3Dq-mCherry-AAV<sub>10</sub>) or inhibitory (hSyn-hM4Di-mCherry-AAV<sub>10</sub>) modified muscarinic G-protein-coupled receptors which can be activated by CNO into the VTA (Fig. <xref rid="Fig1" ref-type="fig">1</xref>AB). AAV vectors without hM3Dq or hM4Di receptors (hSyn-mCherry-AAV<sub>10</sub>) were used as control (Fig. <xref rid="Fig1" ref-type="fig">1</xref>Cc). Robust cell-surface expression of the hM3Dq (Fig. <xref rid="Fig1" ref-type="fig">1</xref>Dd) or hM4Dq receptors (Fig. <xref rid="Fig1" ref-type="fig">1</xref>Ee) was observed in the VTA.</p>
        <p>
<fig id="Fig1"><label>Fig. 1</label><caption><p>Expression of the mCherry, hM3Dq-mCherry, or hM4Di-mCherry in VTA. <italic>A</italic> Schematic representation of AAV vector microinjected. ITR, inverted terminal repeat; hSyn, human synapsin promoter; WPRE, woodchuck hepatitis virus post-transcriptional regulatory element. <italic>B</italic> Red colored sites in coronal section show the injection target in mice. <italic>C, D, E</italic> Coronal brain sections at the level of VTA prepared from mice expressing mCherry, hM3Dq-mCherry, or hM4Di-mCherry following hSyn-mCherry-AAV<sub>10</sub> (<italic>C</italic>), hSyn-hM3Dq-AAV<sub>10</sub> (<italic>D</italic>), and hSyn-hM4Di -AAV<sub>10</sub> (<italic>E</italic>) microinjection. “<italic>c, d, e</italic>” higher magnification of the square region indicated in “<italic>A, B, C</italic>”. <italic>Scale bars</italic> = 100 μm (<italic>C, D, E</italic>); 50 μm (<italic>c, d, e</italic>)</p></caption><graphic xlink:href="41105_2017_94_Fig1_HTML" id="d29e524"/></fig>
</p>
      </sec>
      <sec id="Sec14">
        <title>Modulation of the activities of VTA neurons by CNO</title>
        <p>CNO was given by i.p. with minimal perturbation. The effects of excitatory hM3Dq and inhibitory hM4Di were examined during both the light and dark periods. After EEG/EMG recording, following treatment of CNO or saline in mice expressing mCherry, hM3Dq, or hM4Di, the animals were sacrificed and fixed 2 h later for staining. The VTA slices of these mice were examined by double staining with anti-mCherry and anti-Fos antibodies to assess the activity of these VTA neurons.</p>
        <p>In wild-type mice with control AAV (hSyn-mCherry-AAV<sub>10</sub>) microinjection, in which VTA neurons did not express hM3Dq or hM4Di, the double-labeled neurons (mCherry-positive neurons with c-Fos-positive nuclei) were not seen (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a). There was an apparent increase in the number of double-labeled neurons in the mice microinjected with hSyn-hM3Dq-AAV<sub>10</sub> (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). Because the neuron activity was inhibited by hM4Di, the mice microinjected with hSyn-hM4Di-AAV<sub>10</sub> showed no expression of the double-labeled neurons (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c). Then, we carried out target recordings from hM3Dq/mCherry or hM4Di/mCherry neurons in brain slices to determine the effects of CNO on VTA neurons.</p>
        <p>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Activation or inhibition of VTA neurons by DREADD demonstrated by double staining of c-Fos and mCherry expression. <bold>a, c</bold> Only small numbers of c-Fos- immunoreactive nuclei were observed in mCherry-positive neurons after saline or CNO administration in mice microinjected with hSyn-mCherry-AAV<sub>10</sub> (<bold>a</bold>) and hSyn-hM4Di-mCherry-AAV<sub>10</sub> (<bold>c</bold>). <bold>b</bold> Double expression of c-Fos and mCherry (<italic>red arrows</italic>) induced by CNO was higher than that by saline in mice microinjected with hSyn-hM3Dq-mCherry- AAV<sub>10</sub>. Inset, high power view. <italic>Scale bars</italic> = 100 μm; <italic>inset scales bars</italic> = 50 μm. <bold>d, e</bold> Whole-cell current clamp recording showed that bath application of CNO (<italic>horizontal bar</italic>) produced vigorous firing of action potentials from hM3Dq/mCherry neurons (<italic>n</italic> = 6) (<bold>d</bold>) but inhibited firing from hM4Di/mCherry neurons (<italic>n</italic> = 6) (<bold>e</bold>) in the VTA. <italic>VTA</italic> ventral tegmental area, <italic>ml</italic> medial lemniscus, <italic>IPn</italic> interpeduncular nucleus</p></caption><graphic xlink:href="41105_2017_94_Fig2_HTML" id="d29e622"/></fig>
</p>
        <p>Whole-cell current–clamp recordings demonstrated that CNO (5 μmol/l) elicited vigorous firing of action potentials (Fig. <xref rid="Fig2" ref-type="fig">2</xref>d) in hM3Di/mCherry-positive neurons, but inhibited firing of VTA hM4Di/mCherry neurons (Fig. <xref rid="Fig2" ref-type="fig">2</xref>e).</p>
      </sec>
      <sec id="Sec15">
        <title>Modulation of activities of VTA neurons altered behavioral states in mice</title>
        <p>After confirming the effectiveness of the pharmacogenetic approach, we tested whether or not the selective activation or inhibition of VTA neurons affects sleep-wake states. When CNO was given at 9:00 or 21:00, the amount of wakefulness, REM, and NREM sleep in mice microinjected hSyn-mCherry-AAV<sub>10</sub> or hSyn-hM4Di-AAV<sub>10</sub> did not change compared with the control group (Figs. <xref rid="Fig3" ref-type="fig">3</xref>a, c, <xref rid="Fig4" ref-type="fig">4</xref>a, c).</p>
        <p>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Effects of modulation of VTA neurons’ activity by DREADD during light period on vigilant states of mice. <bold>a</bold>–<bold>c</bold> Hourly amount of wakefulness, REM, and NREM sleep after CNO administration in the mice microinjected with hSyn-mCherry-AAV<sub>10</sub> (<italic>n</italic> = 6) (<bold>a</bold>), hSyn-hM3Dq-AAV<sub>10</sub> (<italic>n</italic> = 6) (<bold>b</bold>), and hSyn- hM4Di -AAV<sub>10</sub> (<italic>n</italic> = 5) (<bold>c</bold>) into the VTA. <italic>Each circle</italic> represents the hourly mean ± SEM of each stage. The <italic>horizontal open</italic> and <italic>filled bars</italic> on the X-axes indicate the 12 h light and 12 h dark period, respectively. <bold>d</bold>–<bold>g</bold> In mice microinjected with hSyn-hM3Dq-AAV<sub>10</sub>, examples of polygraphic recording and corresponding hypnogram after treatment with saline (<bold>d</bold>) and CNO (<bold>e</bold>); time spent in each stage in 5 h (9:00–14:00) following saline or CNO injection (<bold>f</bold>); amount and EEG power density of NREM sleep in 5 h (14:00–19:00) following CNO-induced arousal (<bold>g</bold>). *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, assessed by two-tailed paired Student’s <italic>t</italic> test</p></caption><graphic xlink:href="41105_2017_94_Fig3_HTML" id="d29e735"/></fig>
</p>
        <p>
<fig id="Fig4"><label>Fig. 4</label><caption><p>Effects of modulation of VTA neurons by DREADD’ activity during dark period on vigilant states of mice. <bold>a</bold>–<bold>c</bold> Hourly amount of wakefulness, REM, and NREM sleep after CNO administration in the mice microinjected with hSyn-mCherry-AAV<sub>10</sub> (<italic>n</italic> = 6) (<bold>a</bold>), hSyn-hM3Dq- AAV<sub>10</sub> (<italic>n</italic> = 6) (<bold>b</bold>), and hSyn- hM4Di-AAV<sub>10</sub> (<italic>n</italic> = 5) (<bold>c</bold>) into the VTA. <italic>Each circle</italic> represents the hourly mean ± SEM of each stage. The <italic>horizontal open</italic> and <italic>filled bars</italic> on the x-axes indicate the 12 h light and 12 h dark periods, respectively. <bold>d</bold>–<bold>g</bold> In mice microinjected with hSyn-hM3Dq-AAV<sub>10</sub>, examples of polygraphic recording and corresponding hypnogram after treatment with saline (<bold>d</bold>) and CNO (<bold>e</bold>); time spent in each stage in 8 h (21:00–5:00) following saline and CNO injection (<bold>f</bold>); amount and EEG power density of NREM sleep in 2 h (5:00–7:00) following CNO-induced arousal (<bold>g</bold>). *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, assessed by two-tailed paired Student’s <italic>t</italic> test</p></caption><graphic xlink:href="41105_2017_94_Fig4_HTML" id="d29e823"/></fig>
</p>
        <p>However, the mice microinjected with hSyn-hM3Dq- AAV<sub>10</sub> showed a remarkable increase in wakefulness accompanied by reduction in REM and NREM sleep after CNO administration (Fig. <xref rid="Fig3" ref-type="fig">3</xref>b, d, e). The sum of wakefulness in 5 h following CNO injection on light period increased 144.9% (174.2 ± 3.1 versus 71.1 ± 8.9 min, <italic>p</italic> &lt; 0.01); meanwhile, the sum of REM sleep decreased 100% (0 versus 13.9 ± 1.5 min, <italic>p</italic> &lt; 0.01), and NREM sleep decreased 94.0% (5.8 ± 3.1 versus 94.8 ± 7.9 min, <italic>p</italic> &lt; 0.01) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>f). When CNO was administered at 21:00 (active period), a similar phenomenon was noted in the mice microinjected with hSyn-hM3Dq- AAV<sub>10</sub> as the wakefulness increased, while REM and NREM sleep decreased (Fig. <xref rid="Fig4" ref-type="fig">4</xref>b, d, e). The sum of wakefulness in 8 h following CNO injection increased 81.5% (396.3 ± 16.8 versus 218.4 ± 12.4 min, <italic>p</italic> &lt; 0.01), meanwhile, the sum of REM sleep decreased 93.8% (1.9 ± 0.9 versus 30.8 ± 2.4 min, p &lt; 0.01) and NREM sleep decreased 64.6% (81.8 ± 16.3 versus 230.9 ± 10.4 min, <italic>p</italic> &lt; 0.01) (Fig. <xref rid="Fig4" ref-type="fig">4</xref>f).</p>
        <p>Next, we analyze the EEG power density of NREM sleep after the VTA neurons’ activities were modified. In the mice microinjected with AAV-hM4Di or AAV- control, EEG power density of NREM sleep did not change (data were not shown). As for the hM3Dq positive mice, although the activation of the VTA neurons by CNO injection at 9:00 (Fig. <xref rid="Fig3" ref-type="fig">3</xref>g) or 21:00 (Fig. <xref rid="Fig4" ref-type="fig">4</xref>g) increased remarkable wakefulness, but no difference of the amount and EEG power density of the NREM sleep was observed during the time period following the arousal effects of CNO.</p>
      </sec>
    </sec>
    <sec id="Sec16" sec-type="discussion">
      <title>Discussion</title>
      <p>The first occurrence of the VTA in the literature is due to Tsai in 1925 [<xref ref-type="bibr" rid="CR20">20</xref>]. In its description of the opossum brain, he identified with Nissl and Golgi staining a region lateral to the interpeduncular nucleus as the trigonum interpeduncular. Recently, the VTA DA neurons were thought to be homogeneous in their properties and behavioral functions, such that they express characteristic phasic excitatory responses to rewards and cue that predict rewards while being inhibited by omission of rewards [<xref ref-type="bibr" rid="CR21">21</xref>]. A prior study wherein the catecholamine-containing neurons in mesencephalon were given electrolytic lesion in cats and the animals had an obvious decrease in behavioral waking indicated the catecholamine-containing neurons played a role in sleep/wake regulation [<xref ref-type="bibr" rid="CR22">22</xref>]. However, this method produced irreversible death of neurons and may also lead to some compensatory reactions of other brain areas. Despite higher dopamine levels usually associated with arousal [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], the previous studies did not establish a direct link between the activity of VTA neurons and wakefulness.</p>
      <p>In the present study, we applied DREADD to pharmacogenetically manipulate the activity of VTA neurons. DREADD utilizes G-protein-coupled receptor signaling, which can affect neuronal activity in a relatively chronic and consistent manner and allow investigation of the behavioral effects of activation or inhibition of VTA neurons. Besides, the AAV has proven to be very effective for studying neuronal function and behavior, it is long-lived, highly neurotropic, non-pathogenic and, importantly, it can drive transgene expression at significantly high levels necessary to alter neuronal function and produce a behavioral phenotype [<xref ref-type="bibr" rid="CR24">24</xref>]. In this study, we confirmed its effect by in vitro electrophysiological experiments, in which the spontaneous firing rates of the hM3Dq-positive neurons were increased obviously, while the hM4Di-positive neurons were inhibited by CNO administration. In this way, we can selectively manipulate the neurons in the VTA acutely and reversibly.</p>
      <p>Considering that the firing activity of DA neurons peaked between 07:00 and 11:00 and between 19:00 and 23:00 [<xref ref-type="bibr" rid="CR1">1</xref>], we examined the effects of the pharmacogenetic activation of the VTA neurons either at 9:00 or at 21:00 on sleep-wake behaviors in mice. We found no matter the level of sleep pressure was high or low [<xref ref-type="bibr" rid="CR25">25</xref>], and the activation of VTA produced remarkable increase in wakefulness, which lasted longer when CNO was given during the active period in mice. The findings demonstrate for the first time that injection of CNO in mice expressing hM3Dq in the VTA is able to significantly increase arousal. Our results were consistent with previous reports that DAT knockout mice exhibited an increase in wakefulness [<xref ref-type="bibr" rid="CR23">23</xref>], selectively activating midbrain dopaminergic neurons using DREADD induced hyperactivity in DAT-Cre mice [<xref ref-type="bibr" rid="CR6">6</xref>], and optogenetic stimulation of VTA dopaminergic neurons initiated and maintained wakefulness in TH-Cre mice [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p>Although the VTA is generally known as the source of dopaminergic projection neurons, the VTA contains multiple cell types: dopaminergic (about 60%); GABAergic (about 35%); and glutamatergic neurons (about 5%) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Therefore, we think that all types of VTA neurons were simultaneously activated by this nonspecific pharmacogenetic DREADD system. VTA DA neurons project heavily to several limbic structures, including the nucleus accumbens, amygdala, and prefrontal cortex. In the rat, both GABAergic and glutamatergic neurons form local synapses in the VTA [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>] and project in parallel with the DA neurons to limbic regions [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. As a result, the increased wakefulness induced by activation of VTA may be caused not only by activated dopamine neurons but also by glutamatergic neurons. It may increase the dopamine and glutamate levels in targeted area which may also contribute to the wakefulness.</p>
      <p>It is recognized that sleep is under the control of circadian and homeostatic processes, and animals will attempt to regain or compensate for sleep that was previously depleted [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Previous studies showed that sleep deprivation often accompanied with the increase of EEG power density of NREM [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Our results showed that the activation of VTA no matter during the day or night is responsible for wakefulness. However, the NREM sleep amount or delta power in mice expressing hM3Dq receptors treated with CNO following the induced extended wakefulness did not increase. The possible reasons may be involved the different methods of sleep deprivation, in which gentle handling or water platform techniques were employed in the previous studies, whereas the arousal was induced by VTA activation using DREADD approach. The present phenomena was in agreement with Qiu’s study, in which they did not find EEG or behavioral sleep rebound even after 4 days of induced wakefulness by chemogenetic stimulation of the pontine parabrachial nucleus [<xref ref-type="bibr" rid="CR36">36</xref>].</p>
      <p>To investigate whether the VTA has some roles in physiological sleep regulation, the sleep analysis in mice with hSyn-hM4Di-AAV<sub>10</sub> was carried out. The inhibition of VTA neurons was confirmed with patch-clamp recording, in which CNO bath application decreased the firing of the mCherry-hM4Di positive neurons. We found there were no differences in the mice microinjected with hSyn-hM4Di-AAV<sub>10</sub> between CNO and saline group in sleep-wake behavior. The reason may be a comprehensive effect by inhibition of different type neurons in VTA. When the VTA nucleus was inhibited, on one hand, the dopaminergic neurons were inhibited; on the other hand, the inhibition of the GABAergic neurons could produce disinhibition of local dopaminergic neurons. However, we cannot exclude some roles of single cell type neurons in VTA in sleep-wake regulation under physiological conditions. In fact, a recent study has shown the VTA dopaminergic neurons are necessary for wakefulness since the inhibition of these neurons suppressed wakefulness in TH-Cre mice [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p>In this study, we investigated the role of the VTA in sleep/wake regulation; however, viruses indiscriminately transduce most cell types within the introduced region. Next, we will manipulate neuronal subtypes independently to understand the genetic basis of the sleep-wake phenomena for therapeutic purposes.</p>
    </sec>
  </body>
  <back>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <sec id="FPar1">
        <title>Conflict of interest</title>
        <p>This was not an industry supported study. None of the authors has any financial interest or conflicts of interest related to this work.</p>
      </sec>
      <sec id="FPar2">
        <title>Source of funding</title>
        <p>This study was supported by the National Natural Science Foundation of China (81420108015 and 81571296) and Shanghai Leading Academic Discipline Project (B119).</p>
      </sec>
      <sec id="FPar3">
        <title>Ethical committee permission</title>
        <p>Experimental protocols were approved by the Shanghai Medical Experimental Animal Administrative Committee.</p>
      </sec>
      <sec id="FPar4">
        <title>Animals</title>
        <p>Male S129 mice were obtained from the Laboratory Center, Chinese Academy of Sciences (Shanghai, China).</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oades</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Halliday</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
          <article-title>Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity</article-title>
          <source>Brain Res</source>
          <year>1987</year>
          <volume>434</volume>
          <issue>2</issue>
          <fpage>117</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="doi">10.1016/0165-0173(87)90011-7</pub-id>
          <?supplied-pmid 3107759?>
          <pub-id pub-id-type="pmid">3107759</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nair-Roberts</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Chatelain-Badie</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Benson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>White-Cooper</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bolam</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Ungless</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat</article-title>
          <source>Neuroscience</source>
          <year>2008</year>
          <volume>152</volume>
          <issue>4</issue>
          <fpage>1024</fpage>
          <lpage>1031</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.01.046</pub-id>
          <?supplied-pmid 18355970?>
          <pub-id pub-id-type="pmid">18355970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grace</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Floresco</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Goto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lodge</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Regulation of firing of dopaminergic neurons and control of goal-directed behaviors</article-title>
          <source>Trends Neurosci</source>
          <year>2007</year>
          <volume>30</volume>
          <issue>5</issue>
          <fpage>220</fpage>
          <lpage>227</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tins.2007.03.003</pub-id>
          <?supplied-pmid 17400299?>
          <pub-id pub-id-type="pmid">17400299</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D’Ardenne</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Eshel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Luka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lenartowicz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nystrom</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Role of prefrontal cortex and the midbrain dopamine system in working memory updating</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2012</year>
          <volume>109</volume>
          <issue>49</issue>
          <fpage>19900</fpage>
          <lpage>19909</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1116727109</pub-id>
          <?supplied-pmid 23086162?>
          <pub-id pub-id-type="pmid">23086162</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chowdhury</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Guitart-Masip</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lambert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dayan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Huys</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Duzel</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dopamine restores reward prediction errors in old age</article-title>
          <source>Nat Neurosci</source>
          <year>2013</year>
          <volume>16</volume>
          <issue>5</issue>
          <fpage>648</fpage>
          <lpage>653</lpage>
          <pub-id pub-id-type="doi">10.1038/nn.3364</pub-id>
          <?supplied-pmid 23525044?>
          <pub-id pub-id-type="pmid">23525044</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Pharmacogenetic activation of midbrain dopaminergic neurons induces hyperactivity</article-title>
          <source>Neurosci Bull</source>
          <year>2013</year>
          <volume>29</volume>
          <issue>5</issue>
          <fpage>517</fpage>
          <lpage>524</lpage>
          <pub-id pub-id-type="doi">10.1007/s12264-013-1327-x</pub-id>
          <?supplied-pmid 23516143?>
          <pub-id pub-id-type="pmid">23516143</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brisch</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Saniotis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bielau</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bernstein</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front</article-title>
          <source>Psychiatry</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>47</fpage>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qu</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>YQ</given-names>
            </name>
            <name>
              <surname>Urade</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>ZL</given-names>
            </name>
          </person-group>
          <article-title>Essential role of dopamine D2 receptor in the maintenance of wakefulness, but not in homeostatic regulation of sleep, in mice</article-title>
          <source>J Neurosci</source>
          <year>2010</year>
          <volume>30</volume>
          <issue>12</issue>
          <fpage>4382</fpage>
          <lpage>4389</lpage>
          <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4936-09.2010</pub-id>
          <?supplied-pmid 20335474?>
          <pub-id pub-id-type="pmid">20335474</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qiu</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Qu</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Urade</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>ZL</given-names>
            </name>
          </person-group>
          <article-title>D(1)/D(2) receptor-targeting <sc>L</sc>-stepholidine, an active ingredient of the Chinese herb Stephonia, induces non-rapid eye movement sleep in mice</article-title>
          <source>Pharmacol Biochem Behav</source>
          <year>2009</year>
          <volume>94</volume>
          <issue>1</issue>
          <fpage>16</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pbb.2009.06.018</pub-id>
          <?supplied-pmid 19604496?>
          <pub-id pub-id-type="pmid">19604496</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Telarovic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mijatovic</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Telarovic</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Effects of various factors on sleep disorders and quality of life in Parkinson’s disease</article-title>
          <source>Acta Neurol Belg</source>
          <year>2015</year>
          <volume>115</volume>
          <issue>4</issue>
          <fpage>615</fpage>
          <lpage>621</lpage>
          <pub-id pub-id-type="doi">10.1007/s13760-015-0478-0</pub-id>
          <?supplied-pmid 25944510?>
          <pub-id pub-id-type="pmid">25944510</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Monti</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Monti</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>The involvement of dopamine in the modulation of sleep and waking</article-title>
          <source>Sleep Med Rev</source>
          <year>2007</year>
          <volume>11</volume>
          <issue>2</issue>
          <fpage>113</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="doi">10.1016/j.smrv.2006.08.003</pub-id>
          <?supplied-pmid 17275369?>
          <pub-id pub-id-type="pmid">17275369</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schenk</surname>
              <given-names>JO</given-names>
            </name>
          </person-group>
          <article-title>The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate</article-title>
          <source>Prog Drug Res</source>
          <year>2002</year>
          <volume>59</volume>
          <fpage>111</fpage>
          <lpage>131</lpage>
          <?supplied-pmid 12458965?>
          <pub-id pub-id-type="pmid">12458965</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armbruster</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Pausch</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Herlitze</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
          <article-title>Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2007</year>
          <volume>104</volume>
          <issue>12</issue>
          <fpage>5163</fpage>
          <lpage>5168</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0700293104</pub-id>
          <?supplied-pmid 17360345?>
          <pub-id pub-id-type="pmid">17360345</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alexander</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Rogan</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Abbas</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Armbruster</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Pei</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors</article-title>
          <source>Neuron</source>
          <year>2009</year>
          <volume>63</volume>
          <issue>1</issue>
          <fpage>27</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuron.2009.06.014</pub-id>
          <?supplied-pmid 19607790?>
          <pub-id pub-id-type="pmid">19607790</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="other">Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates, 2nd edn (2001).</mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oishi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>ZL</given-names>
            </name>
            <name>
              <surname>Fredholm</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Urade</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hayaishi</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Adenosine in the tuberomammillary nucleus inhibits the histaminergic system via A1 receptors and promotes non-rapid eye movement sleep</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2008</year>
          <volume>105</volume>
          <issue>50</issue>
          <fpage>19992</fpage>
          <lpage>19997</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0810926105</pub-id>
          <?supplied-pmid 19066225?>
          <pub-id pub-id-type="pmid">19066225</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>ZL</given-names>
            </name>
            <name>
              <surname>Qu</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Eguchi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Schwarzschild</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Fredholm</surname>
              <given-names>BB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine</article-title>
          <source>Nat Neurosci</source>
          <year>2005</year>
          <volume>8</volume>
          <issue>7</issue>
          <fpage>858</fpage>
          <lpage>859</lpage>
          <pub-id pub-id-type="doi">10.1038/nn1491</pub-id>
          <?supplied-pmid 15965471?>
          <pub-id pub-id-type="pmid">15965471</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>TX</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Basal forebrain cholinergic neurons primarily contribute to inhibition of electroencephalogram delta activity, rather than inducing behavioral wakefulness in mice</article-title>
          <source>Neuropsychopharmacology</source>
          <year>2016</year>
          <volume>41</volume>
          <issue>8</issue>
          <fpage>2133</fpage>
          <lpage>2146</lpage>
          <pub-id pub-id-type="doi">10.1038/npp.2016.13</pub-id>
          <?supplied-pmid 26797244?>
          <pub-id pub-id-type="pmid">26797244</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anaclet</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Arrigoni</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bass</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Saper</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The GABAergic parafacial zone is a medullary slow wave sleep-promoting center</article-title>
          <source>Nat Neurosci</source>
          <year>2014</year>
          <volume>17</volume>
          <issue>9</issue>
          <fpage>1217</fpage>
          <lpage>1224</lpage>
          <pub-id pub-id-type="doi">10.1038/nn.3789</pub-id>
          <?supplied-pmid 25129078?>
          <pub-id pub-id-type="pmid">25129078</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>The optic tracts and centers of the opossum, <italic>Didelphis virginiana</italic></article-title>
          <source>J Comp Neurol</source>
          <year>1925</year>
          <volume>39</volume>
          <issue>2</issue>
          <fpage>173</fpage>
          <lpage>216</lpage>
          <pub-id pub-id-type="doi">10.1002/cne.900390202</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schultz</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Predictive reward signal of dopamine neurons</article-title>
          <source>J Neurophysiol</source>
          <year>1998</year>
          <volume>80</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>27</lpage>
          <?supplied-pmid 9658025?>
          <pub-id pub-id-type="pmid">9658025</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Bobillier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jouvet</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat</article-title>
          <source>Brain Res</source>
          <year>1973</year>
          <volume>58</volume>
          <issue>1</issue>
          <fpage>157</fpage>
          <lpage>177</lpage>
          <pub-id pub-id-type="doi">10.1016/0006-8993(73)90830-5</pub-id>
          <?supplied-pmid 4581335?>
          <pub-id pub-id-type="pmid">4581335</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wisor</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Nishino</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sora</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Uhl</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Mignot</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Edgar</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Dopaminergic role in stimulant-induced wakefulness</article-title>
          <source>J Neurosci</source>
          <year>2001</year>
          <volume>21</volume>
          <issue>5</issue>
          <fpage>1787</fpage>
          <lpage>1794</lpage>
          <?supplied-pmid 11222668?>
          <pub-id pub-id-type="pmid">11222668</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCown</surname>
              <given-names>TJ</given-names>
            </name>
          </person-group>
          <article-title>Adeno-associated virus (AAV) vectors in the CNS</article-title>
          <source>Curr Gene Ther</source>
          <year>2011</year>
          <volume>11</volume>
          <issue>3</issue>
          <fpage>181</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="doi">10.2174/156652311795684759</pub-id>
          <?supplied-pmid 21453285?>
          <pub-id pub-id-type="pmid">21453285</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vyazovskiy</surname>
              <given-names>VV</given-names>
            </name>
            <name>
              <surname>Cirelli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pfister-Genskow</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Faraguna</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Tononi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep</article-title>
          <source>Nat Neurosci</source>
          <year>2008</year>
          <volume>11</volume>
          <issue>2</issue>
          <fpage>200</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="doi">10.1038/nn2035</pub-id>
          <?supplied-pmid 18204445?>
          <pub-id pub-id-type="pmid">18204445</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eban-Rothschild</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rothschild</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giardino</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>de Lecea</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>VTA dopaminergic neurons regulate ethologically relevant sleep-wake behaviors</article-title>
          <source>Nat Neurosci</source>
          <year>2016</year>
          <volume>19</volume>
          <issue>10</issue>
          <fpage>1356</fpage>
          <lpage>1366</lpage>
          <pub-id pub-id-type="doi">10.1038/nn.4377</pub-id>
          <?supplied-pmid 27595385?>
          <pub-id pub-id-type="pmid">27595385</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Badurek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dileone</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Nashmi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Minichiello</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Picciotto</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>GABAergic and glutamatergic efferents of the mouse ventral tegmental area</article-title>
          <source>J Comp Neurol</source>
          <year>2014</year>
          <volume>522</volume>
          <issue>14</issue>
          <fpage>3308</fpage>
          <lpage>3334</lpage>
          <pub-id pub-id-type="doi">10.1002/cne.23603</pub-id>
          <?supplied-pmid 24715505?>
          <pub-id pub-id-type="pmid">24715505</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Omelchenko</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sesack</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Ultrastructural analysis of local collaterals of rat ventral tegmental area neurons: GABA phenotype and synapses onto dopamine and GABA cells</article-title>
          <source>Synapse</source>
          <year>2009</year>
          <volume>63</volume>
          <issue>10</issue>
          <fpage>895</fpage>
          <lpage>906</lpage>
          <pub-id pub-id-type="doi">10.1002/syn.20668</pub-id>
          <?supplied-pmid 19582784?>
          <pub-id pub-id-type="pmid">19582784</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dobi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Margolis</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Harvey</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Morales</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Glutamatergic and nonglutamatergic neurons of the ventral tegmental area establish local synaptic contacts with dopaminergic and nondopaminergic neurons</article-title>
          <source>J Neurosci</source>
          <year>2010</year>
          <volume>30</volume>
          <issue>1</issue>
          <fpage>218</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3884-09.2010</pub-id>
          <?supplied-pmid 20053904?>
          <pub-id pub-id-type="pmid">20053904</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carr</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Sesack</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex</article-title>
          <source>Synapse</source>
          <year>2000</year>
          <volume>38</volume>
          <issue>2</issue>
          <fpage>114</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="doi">10.1002/1098-2396(200011)38:2&lt;114::AID-SYN2&gt;3.0.CO;2-R</pub-id>
          <?supplied-pmid 11018785?>
          <pub-id pub-id-type="pmid">11018785</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamaguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Morales</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Mesocorticolimbic glutamatergic pathway</article-title>
          <source>J Neurosci</source>
          <year>2011</year>
          <volume>31</volume>
          <issue>23</issue>
          <fpage>8476</fpage>
          <lpage>8490</lpage>
          <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1598-11.2011</pub-id>
          <?supplied-pmid 21653852?>
          <pub-id pub-id-type="pmid">21653852</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Laposky</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Bergmann</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Turek</surname>
              <given-names>FW</given-names>
            </name>
          </person-group>
          <article-title>Repeated sleep restriction in rats leads to homeostatic and allostatic responses during recovery sleep</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2007</year>
          <volume>104</volume>
          <issue>25</issue>
          <fpage>10697</fpage>
          <lpage>10702</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0610351104</pub-id>
          <?supplied-pmid 17548824?>
          <pub-id pub-id-type="pmid">17548824</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deboer</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Behavioral and electrophysiological correlates of sleep and sleep homeostasis</article-title>
          <source>Curr Top Behav Neurosci</source>
          <year>2015</year>
          <volume>25</volume>
          <fpage>1</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1007/7854_2013_248</pub-id>
          <?supplied-pmid 24142866?>
          <pub-id pub-id-type="pmid">24142866</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qiu</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Qu</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Urade</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>ZL</given-names>
            </name>
          </person-group>
          <article-title>The role of nucleus accumbens core/shell in sleep-wake regulation and their involvement in modafinil-induced arousal</article-title>
          <source>PLoS One</source>
          <year>2012</year>
          <volume>7</volume>
          <issue>9</issue>
          <fpage>e45471</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0045471</pub-id>
          <?supplied-pmid 23029032?>
          <pub-id pub-id-type="pmid">23029032</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>ZL</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Qu</surname>
              <given-names>WM</given-names>
            </name>
          </person-group>
          <article-title>Repeated sleep restriction in adolescent rats altered sleep patterns and impaired spatial learning/memory ability</article-title>
          <source>Sleep</source>
          <year>2012</year>
          <volume>35</volume>
          <issue>6</issue>
          <fpage>849</fpage>
          <lpage>859</lpage>
          <pub-id pub-id-type="doi">10.5665/sleep.1888</pub-id>
          <?supplied-pmid 22654204?>
          <pub-id pub-id-type="pmid">22654204</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qiu</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Fuller</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Stimulation of the pontine parabrachial nucleus promotes wakefulness via extra-thalamic forebrain circuit nodes</article-title>
          <source>Curr Biol</source>
          <year>2016</year>
          <volume>26</volume>
          <issue>17</issue>
          <fpage>2301</fpage>
          <lpage>2312</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cub.2016.07.054</pub-id>
          <?supplied-pmid 27546576?>
          <pub-id pub-id-type="pmid">27546576</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362656</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Patient</journal-id>
      <journal-id journal-id-type="iso-abbrev">Patient</journal-id>
      <journal-title-group>
        <journal-title>The Patient</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1178-1653</issn>
      <issn pub-type="epub">1178-1661</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362656</article-id>
      <article-id pub-id-type="pmcid">PMC5362656</article-id>
      <article-id pub-id-type="pmc-uid">5362656</article-id>
      <article-id pub-id-type="pmid">27704486</article-id>
      <article-id pub-id-type="publisher-id">198</article-id>
      <article-id pub-id-type="doi">10.1007/s40271-016-0198-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Practical Application</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Successful Stepwise Development of Patient Research Partnership: 14 Years’ Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8428-6354</contrib-id>
          <name>
            <surname>de Wit</surname>
            <given-names>Maarten</given-names>
          </name>
          <address>
            <phone>+31 20 4448219</phone>
            <phone>+31 418 515904</phone>
            <email>mp.dewit@vumc.nl</email>
            <email>martinusdewit@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kirwan</surname>
            <given-names>John R.</given-names>
          </name>
          <address>
            <email>john.kirwan@bristol.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tugwell</surname>
            <given-names>Peter</given-names>
          </name>
          <address>
            <email>Tugwell.BB@uOttawa.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Beaton</surname>
            <given-names>Dorcas</given-names>
          </name>
          <address>
            <email>beatond@smh.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Boers</surname>
            <given-names>Maarten</given-names>
          </name>
          <address>
            <email>m.boers@vumc.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brooks</surname>
            <given-names>Peter</given-names>
          </name>
          <address>
            <email>brooksp@unimelb.edu.au</email>
          </address>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Collins</surname>
            <given-names>Sarah</given-names>
          </name>
          <address>
            <email>sarah.collins_counsellor@btopenworld.com</email>
          </address>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Conaghan</surname>
            <given-names>Philip G.</given-names>
          </name>
          <address>
            <email>P.Conaghan@leeds.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>D’Agostino</surname>
            <given-names>Maria-Antonietta</given-names>
          </name>
          <address>
            <email>maria-antonietta.dagostino@aphp.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hofstetter</surname>
            <given-names>Cathie</given-names>
          </name>
          <address>
            <email>mcfence@on.aibn.com</email>
          </address>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hughes</surname>
            <given-names>Rod</given-names>
          </name>
          <address>
            <email>Rod.Hughes@asph.nhs.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leong</surname>
            <given-names>Amye</given-names>
          </name>
          <address>
            <email>amye@healthymotivation.com</email>
          </address>
          <xref ref-type="aff" rid="Aff13">13</xref>
          <xref ref-type="aff" rid="Aff14">14</xref>
          <xref ref-type="aff" rid="Aff15">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lyddiatt</surname>
            <given-names>Ann</given-names>
          </name>
          <address>
            <email>alyddiatt@primus.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>March</surname>
            <given-names>Lyn</given-names>
          </name>
          <address>
            <email>lyn.march@sydney.edu.au</email>
          </address>
          <xref ref-type="aff" rid="Aff16">16</xref>
          <xref ref-type="aff" rid="Aff17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>May</surname>
            <given-names>James</given-names>
          </name>
          <address>
            <email>jmay@seanet.com</email>
          </address>
          <xref ref-type="aff" rid="Aff18">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Montie</surname>
            <given-names>Pamela</given-names>
          </name>
          <address>
            <email>plmontie@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff11">11</xref>
          <xref ref-type="aff" rid="Aff19">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Richards</surname>
            <given-names>Pamela</given-names>
          </name>
          <address>
            <email>pamrichards@mac.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff20">20</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Simon</surname>
            <given-names>Lee S.</given-names>
          </name>
          <address>
            <email>lssconsult@aol.com</email>
          </address>
          <xref ref-type="aff" rid="Aff21">21</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>Jasvinder A.</given-names>
          </name>
          <address>
            <email>jasvinder.md@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff22">22</xref>
          <xref ref-type="aff" rid="Aff23">23</xref>
          <xref ref-type="aff" rid="Aff24">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Strand</surname>
            <given-names>Vibeke</given-names>
          </name>
          <address>
            <email>vibekestrand@me.com</email>
          </address>
          <xref ref-type="aff" rid="Aff25">25</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Voshaar</surname>
            <given-names>Marieke</given-names>
          </name>
          <address>
            <email>Marieke@voshaar.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff26">26</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bingham</surname>
            <given-names>Clifton O.</given-names>
            <suffix>III</suffix>
          </name>
          <address>
            <email>cbingha2@jhmi.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff27">27</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gossec</surname>
            <given-names>Laure</given-names>
          </name>
          <address>
            <email>laure.gossec@aphp.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff28">28</xref>
          <xref ref-type="aff" rid="Aff29">29</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>OMERACT Patient Research Partner, Amsterdam, The Netherlands </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution>Department of Medical Humanities, </institution><institution>VU University Medical Centre/EMGO+ instituut, </institution></institution-wrap>Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7603</institution-id><institution-id institution-id-type="GRID">grid.5337.2</institution-id><institution>Academic Rheumatology Unit, Bristol Royal Infirmary, </institution><institution>University of Bristol, </institution></institution-wrap>Bristol, BS2 8HW UK </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2182 2255</institution-id><institution-id institution-id-type="GRID">grid.28046.38</institution-id><institution>Department of Medicine, </institution><institution>University of Ottawa, </institution></institution-wrap>Ottawa, ON Canada </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution>Musculoskeletal Health and Outcomes Research, </institution><institution>Li Ka Shing Knowledge Institute, St Michael’s Hospital, University of Toronto, </institution></institution-wrap>Toronto, ON Canada </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution>Department of Epidemiology and Biostatistics, </institution><institution>Amsterdam Rheumatology and Immunology Center, VU University Medical Center, </institution></institution-wrap>Amsterdam, The Netherlands </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2179 088X</institution-id><institution-id institution-id-type="GRID">grid.1008.9</institution-id><institution>Centre for Health Policy School of Population and Global Health, </institution><institution>University of Melbourne, </institution></institution-wrap>Melbourne, VIC Australia </aff>
        <aff id="Aff8"><label>8</label>OMERACT Patient Research Partner, London, UK </aff>
        <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8403</institution-id><institution-id institution-id-type="GRID">grid.9909.9</institution-id><institution>NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, </institution><institution>University of Leeds, </institution></institution-wrap>Leeds, UK </aff>
        <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9982 5352</institution-id><institution-id institution-id-type="GRID">grid.413756.2</institution-id><institution>Department of Rheumatology, </institution><institution>Hôpital Ambroise Paré, APHP, Université Versailles Saint Quentin en Yvelines, </institution></institution-wrap>Boulogne-Billancourt, France </aff>
        <aff id="Aff11"><label>11</label>OMERACT Patient Research Partner, Vancouver, BC Canada </aff>
        <aff id="Aff12"><label>12</label>Ashford St Peter’s Foundation trust Hospital, Chertsey, Surrey, UK </aff>
        <aff id="Aff13"><label>13</label>OMERACT Patient Research Partner, Santa Barbara, CA USA </aff>
        <aff id="Aff14"><label>14</label>Healthy Motivations, Santa Barbara, CA 93108 USA </aff>
        <aff id="Aff15"><label>15</label>Bone and Joint Decade, The Global Alliance for Musculoskeletal Health, Truro, Cornwall UK </aff>
        <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution>Institute of Bone and Joint Research, </institution><institution>Sydney Medical School and School of Public Health, University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff>
        <aff id="Aff17"><label>17</label>Department of Rheumatology, Royal North Shore, St. Leonards, NSW Australia </aff>
        <aff id="Aff18"><label>18</label>OMERACT Patient Research Partner, Seattle, WA USA </aff>
        <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0462 6801</institution-id><institution-id institution-id-type="GRID">grid.418127.9</institution-id><institution/><institution>Arthritis Patient Advisory Board, Arthritis Research Centre Canada, </institution></institution-wrap>Richmond, BC Canada </aff>
        <aff id="Aff20"><label>20</label>OMERACT Patient Research Partner, Bristol, UK </aff>
        <aff id="Aff21"><label>21</label>SDG LLC, Cambridge, MA 02139 USA </aff>
        <aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0419 1326</institution-id><institution-id institution-id-type="GRID">grid.280808.a</institution-id><institution/><institution>Medicine Service, VA Medical Center, </institution></institution-wrap>Birmingham, AL USA </aff>
        <aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ISNI">0000000106344187</institution-id><institution-id institution-id-type="GRID">grid.265892.2</institution-id><institution>Division of Epidemiology at School of Public Health, Department of Medicine at School of Medicine, </institution><institution>University of Alabama, </institution></institution-wrap>Birmingham, AL 35294-0022 USA </aff>
        <aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution>Department of Orthopedic Surgery, </institution><institution>Mayo Clinic College of Medicine, </institution></institution-wrap>Rochester, MN 55905 USA </aff>
        <aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution>Division Immunology/Rheumatology, </institution><institution>Stanford University School of Medicine, </institution></institution-wrap>Palo Alto, CA USA </aff>
        <aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0399 8953</institution-id><institution-id institution-id-type="GRID">grid.6214.1</institution-id><institution>Department of Psychology, Health and Technology, </institution><institution>University of Twente, </institution></institution-wrap>Enschede, The Netherlands </aff>
        <aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution>Division of Rheumatology, </institution><institution>Johns Hopkins University, </institution></institution-wrap>Baltimore, MD USA </aff>
        <aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1955 3500</institution-id><institution-id institution-id-type="GRID">grid.5805.8</institution-id><institution>Institut Pierre Louis d’Epidémiologie et de Santé Publique, </institution><institution>Sorbonne Universités, UPMC Univ Paris 06, GRC-08, </institution></institution-wrap>Paris, France </aff>
        <aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution>Rheumatology Department, </institution><institution>Pitie-Salpétrière Hospital, AP-HP, </institution></institution-wrap>Paris, France </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>5</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>5</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>10</volume>
      <issue>2</issue>
      <fpage>141</fpage>
      <lpage>152</lpage>
      <permissions>
        <copyright-statement>© The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>There is increasing interest in making patient participation an integral component of medical research. However, practical guidance on optimizing this engagement in healthcare is scarce. Since 2002, patient involvement has been one of the key features of the Outcome Measures in Rheumatology (OMERACT) international consensus effort. Based on a review of cumulative data from qualitative studies and internal surveys among OMERACT participants, we explored the potential benefits and challenges of involving patient research partners in conferences and working group activities. We supplemented our review with personal experiences and reflections regarding patient participation in the OMERACT process. We found that between 2002 and 2016, 67 patients have attended OMERACT conferences, of whom 28 had sustained involvement; many other patients contributed to OMERACT working groups. Their participation provided face validity to the OMERACT process and expanded the research agenda. Essential facilitators have been the financial commitment to guarantee sustainable involvement of patients at these conferences, procedures for recruitment, selection and support, and dedicated time allocated in the program for patient issues. Current challenges include the representativeness of the patient panel, risk of pseudo-professionalization, and disparity in patients’ and researchers’ perception of involvement. In conclusion, OMERACT has embedded long-term patient involvement in the consensus-building process on the measurement of core health outcomes. This integrative process continues to evolve iteratively. We believe that the practical points raised here can improve participatory research implementation.</p>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006093</institution-id>
              <institution>Patient-Centered Outcomes Research Institute</institution>
            </institution-wrap>
          </funding-source>
          <award-id>1IP2-PI000737-01</award-id>
          <award-id>SC14-1402-10818</award-id>
          <principal-award-recipient>
            <name>
              <surname>Bingham</surname>
              <given-names>Clifton O.</given-names>
              <suffix>III</suffix>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer International Publishing Switzerland 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="FPar1">
      <title>Key Points for Decision Makers</title>
      <p>
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Outcome Measures in Rheumatology (OMERACT) has shown that long-term involvement of patients in research is beneficial for identifying and validating outcomes that matter to patients.</td></tr><tr><td align="left">Building and sustaining successful partnerships with patients requires restructuring of the research process and investing time and budgets into training and support of patient research partners (PRPs).</td></tr><tr><td align="left">The integration of qualitative and quantitative data, complemented by participation of PRPs, enhances the face validity of outcome research.</td></tr><tr><td align="left">Ensuring representativeness of the patient perspective for diagnosis, disease severity and cultural, social-economic, and geographical diversity is still challenging.</td></tr></tbody></table></table-wrap>
</p>
    </sec>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>There is a growing trend in healthcare research to focus more on outcomes that matter to patients, and more widely on patient-centered research [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. To this end, the involvement of patients not just as subjects of research but as partners in the design, assessment, and implementation of health research is recommended, and is sometimes mandatory for grant approval [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR5">5</xref>]. In the USA, the Patient-Centered Outcomes Research Institute (PCORI) was established in 2010 to promote research that focuses on those aspects of health that are most meaningful and important to patients. PCORI involves patients at critical stages of the research process to ensure that the questions being asked are relevant and the results are meaningful to people living with a given health condition [<xref ref-type="bibr" rid="CR6">6</xref>]. In Canada, a unique study explored perspectives of people with osteoarthritis with full involvement of patients in all research phases [<xref ref-type="bibr" rid="CR7">7</xref>]. In the context of the Innovative Medicine Initiative, the European Union, in collaboration with the pharmaceutical industry, has initiated the European Patients’ Academy on Therapeutic Innovation (EUPATI) to promote the education and active involvement of patients in health research [<xref ref-type="bibr" rid="CR8">8</xref>]. Internationally, the Cochrane Collaboration involves patients in the development of systematic reviews [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. The UK has the longest tradition of public and patient involvement through a National Institute of Health Research program called Involve [<xref ref-type="bibr" rid="CR11">11</xref>]. Within the specialty of rheumatology, the European League Against Rheumatism (EULAR) [<xref ref-type="bibr" rid="CR12">12</xref>], Outcome Measures in Rheumatology (OMERACT), an international consensus effort, and its member working parties [<xref ref-type="bibr" rid="CR13">13</xref>], the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) [<xref ref-type="bibr" rid="CR14">14</xref>], and the Assessment of SpondyloArthritis international Society (ASAS) [<xref ref-type="bibr" rid="CR15">15</xref>] have gained experience and published regarding active involvement of patients in their main activities. In the past years, EULAR and the American College of Rheumatology (ACR) have included patient representatives in their guideline development and other initiatives. In several European countries, arthritis patient organizations have established networks of trained research partners [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p>
      <p>Although patient engagement in research is promoted, it is often limited to evaluating research proposals for funding or participating in advocacy groups. However, patients can contribute to research in different roles, not only as respondents or study participants but also as advocates, advisors, reviewers, or research partners (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). When referring to higher levels of engagement, involving close collaboration in the research process itself, we use the term ‘patient research partner’ (PRP). A PRP is someone living with the relevant disease or condition who participates as an active team member on an equal basis with professional researchers, adding the benefit of his/her experiential knowledge to research projects [<xref ref-type="bibr" rid="CR13">13</xref>]. There is limited guidance on how high-level patient involvement in research can be achieved, and few case studies to illustrate its success [<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR20">20</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>The empirical research circle: potential patient contributions and potential patient roles in research. Phases of the empirical research circle are in <italic>blue</italic>, examples of potential patient contributions are in <italic>orange</italic>, and five potential patient roles in research are in <italic>black</italic>. The role of patient research partner and patient advisor are applicable throughout the research circle. The role of patient reviewer is particularly relevant in the phase of assessing grant applications, often used by research funding bodies. The roles of patient respondent or patient participant mostly relate to the phase of data collection. The role of patient advocate is generally beneficial in the phases of fundraising, establishing supportive legislation for medical research, and dissemination</p></caption><graphic xlink:href="40271_2016_198_Fig1_HTML" id="MO1"/></fig>
</p>
      <p>OMERACT, an independent international organization of health professionals, epidemiologists, outcomes researchers, pharmaceutical representatives, and patients [<xref ref-type="bibr" rid="CR21">21</xref>], has engaged PRPs consistently and increasingly over a period of 14 years [<xref ref-type="bibr" rid="CR22">22</xref>]. The involvement of patients has been rewarding for both the researchers and the patient representatives. By collaborating with PRPs, relevant outcomes for patients such as fatigue, well-being, and sleep-disturbances have been identified, and PRPs have reported increased knowledge, self-confidence, and empowerment [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. OMERACT has incrementally learned how to support, promote, and gain from this process. Here we review how PRP involvement in OMERACT was developed, supported, and promoted, how challenges were addressed, and the benefits that have accrued.</p>
    </sec>
    <sec id="Sec2">
      <title>Outcome Measures in Rheumatology (OMERACT) and the Involvement of Patients</title>
      <p>The first OMERACT conference (1992) was convened at a time of actively questioning traditional but arbitrary approaches to assessing the benefits of treatment in rheumatic diseases. The conference aimed to consolidate methodologically oriented approaches that had begun separately in the USA through activities within the ACR and in Europe through the World Health Organization and International League of Associations of Rheumatology (WHO/ILAR). One of the objectives of the first OMERACT conference was to develop consensus on the minimum number of outcome measures to be included in all rheumatoid arthritis (RA) randomized controlled trials. The conference brought together 92 rheumatologists, methodologists, regulatory officials, and pharmaceutical industry researchers from around the world. Agreement was achieved on the outcome domains that are known as the RA core set [<xref ref-type="bibr" rid="CR25">25</xref>].</p>
      <p>Subsequent meetings of OMERACT followed every 2 years, developing and validating specific outcome measures and developing core sets for other rheumatic diseases as proposed by Working Groups within OMERACT. The basis of OMERACT is evidence-based discussions with consensus through nominal group techniques.</p>
      <p>In 2000, during discussions about “minimum clinically important” differences in outcome measures [<xref ref-type="bibr" rid="CR26">26</xref>], there was uncertainty whether the perspective of physicians and researchers was similar to that of patients. Concluding that a representative consensus should include all three, the final plenary voting session at the conference recognized that the patients’ perspective was needed [<xref ref-type="bibr" rid="CR27">27</xref>], and a decision was made to invite patients to the next meeting.</p>
      <p>The 11 PRPs who attended OMERACT 6 (2002) had a limited degree of participation in the meeting. They were asked to review the RA core set from the patient perspective and to identify domains that mattered to patients. It became clear that the views of researchers and patients were not identical [<xref ref-type="bibr" rid="CR28">28</xref>]. Symptoms of importance to patients such as fatigue, overall well-being, and sleep disturbances were not included in the existing RA core set. Also, the design of clinical trials at that time would not provide patients with the information they felt was needed to judge the success of new treatments. After this meeting, the leadership of OMERACT and a sufficiently large proportion of those actively involved in OMERACT-related research were convinced that PRPs should continue to be involved. Since then, between 17 and 21 patients have participated in each of the OMERACT conferences (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of patients attending Outcome Measures in Rheumatology (OMERACT) conferences</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">2002: Gold Coast, QLD, Australia</th><th align="left">2004: Asilomar, CA, USA</th><th align="left">2006: St. Julian’s Bay, Malta</th><th align="left">2008: Kanaskis, AB, Canada</th><th align="left">2010: Borneo, Malaysia</th><th align="left">2012: Pinehurst, NC, USA</th><th align="left">2014: Budapest, Hungary</th><th align="left">2016: Whistler, BC, Canada</th></tr></thead><tbody><tr><td align="left" colspan="9">Sex</td></tr><tr><td align="left"> Female</td><td char="." align="char">9</td><td char="." align="char">13</td><td char="." align="char">12</td><td char="." align="char">11</td><td char="." align="char">10</td><td char="." align="char">15</td><td char="." align="char">18</td><td char="." align="char">18</td></tr><tr><td align="left"> Male</td><td char="." align="char">2</td><td char="." align="char">5</td><td char="." align="char">8</td><td char="." align="char">6</td><td char="." align="char">11</td><td char="." align="char">5</td><td char="." align="char">3</td><td char="." align="char">4</td></tr><tr><td align="left" colspan="9">Previous attendance</td></tr><tr><td align="left"> Yes</td><td char="." align="char">0</td><td char="." align="char">6</td><td char="." align="char">15</td><td char="." align="char">8</td><td char="." align="char">14</td><td char="." align="char">10</td><td char="." align="char">16</td><td char="." align="char">14</td></tr><tr><td align="left"> No</td><td char="." align="char">11</td><td char="." align="char">12</td><td char="." align="char">5</td><td char="." align="char">9</td><td char="." align="char">7</td><td char="." align="char">10</td><td char="." align="char">5</td><td char="." align="char">8</td></tr><tr><td align="left" colspan="9">Condition</td></tr><tr><td align="left"> Rheumatoid arthritis</td><td char="." align="char">11</td><td char="." align="char">17</td><td char="." align="char">15</td><td char="." align="char">7</td><td char="." align="char">12</td><td char="." align="char">10</td><td char="." align="char">10</td><td char="." align="char">9</td></tr><tr><td align="left"> Osteoarthritis</td><td align="left"/><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1</td><td align="left"/><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">1</td></tr><tr><td align="left"> Psoriatic arthritis</td><td align="left"/><td align="left"/><td char="." align="char">4</td><td char="." align="char">2</td><td char="." align="char">2</td><td char="." align="char">2</td><td char="." align="char">2</td><td char="." align="char">4</td></tr><tr><td align="left"> Fibromyalgia</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">3</td><td char="." align="char">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Gout</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">3</td><td char="." align="char">2</td><td char="." align="char">2</td><td align="left"/><td align="left"/></tr><tr><td align="left"> Vasculitis</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">2</td><td char="." align="char">2</td><td char="." align="char">2</td></tr><tr><td align="left"> Ankylosing spondylitis</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">2</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Myositis</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1</td></tr><tr><td align="left"> Polymyalgia rheumatica</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">2</td></tr><tr><td align="left"> Connective tissue diseases</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1</td></tr><tr><td align="left"> Behçet’s syndrome</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td><td char="." align="char">1</td></tr><tr><td align="left"> Chronic pain</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td><td align="left"/></tr><tr><td align="left"> Juvenile idiopathic arthritis</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td></tr><tr><td align="left" colspan="9">Country</td></tr><tr><td align="left"> USA</td><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">6</td><td char="." align="char">4</td><td char="." align="char">7</td><td char="." align="char">6</td><td char="." align="char">7</td></tr><tr><td align="left"> UK</td><td char="." align="char">3</td><td char="." align="char">4</td><td char="." align="char">3</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">4</td><td char="." align="char">5</td><td char="." align="char">4</td></tr><tr><td align="left"> Australia</td><td char="." align="char">3</td><td char="." align="char">2</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">3</td><td align="left"/><td align="left"/><td char="." align="char">1</td></tr><tr><td align="left"> Norway</td><td char="." align="char">2</td><td char="." align="char">2</td><td char="." align="char">2</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td><td align="left"/></tr><tr><td align="left"> Sweden</td><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="." align="char">1</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Denmark</td><td align="left"/><td char="." align="char">1</td><td char="." align="char">1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Canada</td><td align="left"/><td char="." align="char">3</td><td char="." align="char">4</td><td char="." align="char">5</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">4</td><td char="." align="char">5</td></tr><tr><td align="left"> The Netherlands</td><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">2</td><td char="." align="char">1</td><td char="." align="char">4</td><td char="." align="char">3</td><td char="." align="char">4</td><td char="." align="char">4</td></tr><tr><td align="left"> Germany</td><td align="left"/><td align="left"/><td char="." align="char">1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> New Zealand</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td><td align="left"/><td char="." align="char">1</td><td align="left"/><td align="left"/></tr><tr><td align="left"> France</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td><td char="." align="char">1</td><td align="left"/><td align="left"/></tr><tr><td align="left"> Malaysia</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">3</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Turkey</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td><td align="left"/></tr><tr><td align="left"> Italy</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1</td></tr><tr><td align="left">Proportion of all attending the conference (%)</td><td char="." align="char">7.9</td><td char="." align="char">7.0</td><td char="." align="char">7.4</td><td char="." align="char">9.0</td><td char="." align="char">18.1</td><td char="." align="char">10.2</td><td char="." align="char">9.5</td><td char="." align="char">10.0</td></tr></tbody></table></table-wrap>
</p>
      <p>Each meeting included patients with the rheumatologic condition featured in the program because experiential knowledge of the condition itself was felt to be critical. Thirty of the 67 PRPs (45 %) have participated in at least two OMERACT conferences, ten of whom have participated in at least four OMERACT conferences. In recent years many more PRPs have been members of OMERACT Working Groups, which carry forward the research agenda between the biannual meetings.</p>
      <p>The extent to which PRPs are integrated into the OMERACT meeting program has steadily expanded (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). As a consequence, the timetable commitment for PRPs during the meeting has increased from 7.5 h in 2002 to 47 h in 2016. In parallel, OMERACT has developed systems for the selection and support of PRPs, with the funding and organization of their attendance being a practical challenge. However, developing and implementing rules and guidelines recognizing that PRPs are an essential element of all OMERACT activities has been the greatest intellectual challenge [<xref ref-type="bibr" rid="CR13">13</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Outcome measures in rheumatology (OMERACT) conference timetabled hours designated for full participation of patient research partners in the program and for patient research partners support sessions</p></caption><graphic xlink:href="40271_2016_198_Fig2_HTML" id="MO2"/></fig>
</p>
    </sec>
    <sec id="Sec3">
      <title>Recognizing Patient Research Partners (PRPs) as an Essential Element of all OMERACT Activities</title>
      <sec id="Sec4">
        <title>Endorsement by the Leadership and Full Participation in the OMERACT Process</title>
        <p>The continuous support of the OMERACT leadership has been crucial, as has the continued increase of experience and patient involvement (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR29">29</xref>]. Initiatives taken by patients, such as producing the OMERACT Glossary (which is now part of every conference information pack) have gradually convinced the majority of OMERACT participants that PRPs make a positive contribution. Results from a recent survey of repeat OMERACT attendees concluded that working with PRPs was one of the aspects that made them return to these meetings [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
        <p>OMERACT values the perspectives of all stakeholders and stimulates open discussions through an interactive meeting design. All participants should be treated as equals and have the same opportunities to contribute to the process. An introductory patient session familiarizes PRPs with the conditions under discussion at the meeting, OMERACT terminology, and procedures. Session moderators provide patients with a pre-session subject overview and provide an environment that encourages all stakeholders, but particularly patients, to speak up and contribute actively in all aspects of the meeting. When voting on consensus decisions, PRPs have full voting rights. The roles played by PRPs at and between OMERACT meetings have steadily expanded to include leading, mentoring, reporting small group discussions, chairing plenary sessions, writing reports, helping to design and facilitate research between meetings, securing funding, and writing and editing papers.</p>
      </sec>
      <sec id="Sec5">
        <title>Support of PRPs and the Sustainability of Participation</title>
        <p>OMERACT support for PRPs evolved as experience working together accumulated. Increasing integration of patients into the program (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) combined with the achievement of specific milestones was accompanied by greater attention to the support of PRPs (Table <xref rid="Tab2" ref-type="table">2</xref>). Orientation and training sessions have been cumulative and written into the conference program design. The increasing time demand on PRPs has resulted in the introduction of personalized programs to ensure that each PRP is able to attend the sessions most relevant to their condition. Arriving 1 day before the conference and scheduling ‘down time’ during the meeting are included to prevent overburdening and respect disease management (e.g., time for activities of daily living, resting, and doing exercises). An important innovation in 2008 was the introduction of a ‘buddy system,’ where new patient participants are paired with more experienced PRPs. New participants found this extremely helpful [<xref ref-type="bibr" rid="CR23">23</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Milestones and cumulative patient research partner support activities: 2000–2016</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Year</th><th align="left">Milestone</th><th align="left">PRP support activities</th></tr></thead><tbody><tr><td align="left">2000</td><td align="left">Vote at the final plenary to include the patient perspective at the next OMERACT </td><td align="left">Establishment of Patient Stream Coordinator with allocated funding for patient support</td></tr><tr><td align="left">2002</td><td align="left">First patients participating in the conference</td><td align="left">Participation in two main sessions only with special patient group workshop<break/>Pre-session briefing and post-session debriefing<break/>Experienced clinical researcher available for questions, discussion, and general support<break/>Nominated clinician available for individual assistance</td></tr><tr><td align="left" rowspan="3">2004</td><td align="left" rowspan="3">Establishment of Patient Panel with a chair</td><td align="left">Production (by PRPs) of OMERACT Glossary</td></tr><tr><td align="left">Post-meeting educational day in Bristol for European patients</td></tr><tr><td align="left">Patient newsletter started (by PRPs)</td></tr><tr><td align="left" rowspan="3">2006</td><td align="left" rowspan="3">First policy statement: patient involvement becomes mandatory for module and workshop applications</td><td align="left">Patients provided with their own meeting room</td></tr><tr><td align="left">Brief patient introduction session before start of meeting</td></tr><tr><td align="left">Patient Panel wrap-up meeting included in program</td></tr><tr><td align="left" rowspan="3">2008</td><td align="left">PRPs responsible for supporting each other</td><td align="left" rowspan="3">Substantial patient introduction session before start of meeting<break/>Buddy system introduced<break/>Pre-conference PRP dinner</td></tr><tr><td align="left">OMERACT Glossary in conference information pack for all attendees</td></tr><tr><td align="left">Fatigue included as a recommended outcome in the RA core set</td></tr><tr><td align="left">2010</td><td align="left">Second policy statement: integral involvement of patients in all working groups</td><td align="left">Daily patient update sessions introduced</td></tr><tr><td align="left">2012</td><td align="left">Evaluation of a decade of patient involvement in OMERACT presented</td><td align="left">Pre-conference patient information pack, including lay summaries of all the sessions<break/>Introduction of personalized programs<break/>PRPs fully involved in development of OMERACT Filter 2.0</td></tr><tr><td align="left" rowspan="2">2014</td><td align="left">Consensus on recommendations for the involvement of patient research partners in OMERACT working groups approved</td><td align="left">Daily patient evaluation sessions introduced</td></tr><tr><td align="left">PRP becomes a member of OMERACT Executive</td><td align="left"/></tr><tr><td align="left">2016</td><td align="left">Preparatory internet seminars for patients</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>
<italic>OMERACT</italic> Outcome Measures in Rheumatology, <italic>PRP</italic> patient research partner</p></table-wrap-foot></table-wrap>
</p>
        <p>Facilitating PRP participation in ongoing research between meetings has been a challenge. Working Group leaders have been confronted with practical issues such as providing lay summaries of documents, preventing overburdening, ensuring sufficient lead time for PRPs to read information and provide feedback, and adequate acknowledgment of PRPs’ contributions. In addition, it is not always clear whether (all) PRPs fulfil the criteria for authorship of peer-reviewed publications. The criteria can vary between groups, to some degree influenced by the PRP’s decision to be coauthor or not. These processes are continually evolving.</p>
      </sec>
      <sec id="Sec6">
        <title>Acceptance of the Role of PRPs by OMERACT Members</title>
        <p>In 2014, recommendations for the involvement of PRPs in OMERACT Working Groups were approved by an overwhelming majority at the OMERACT plenary voting session [<xref ref-type="bibr" rid="CR13">13</xref>]. Together with the appointment of a patient delegate to the Executive Committee, this demonstrates the OMERACT commitment to the principles and practice of substantive patient engagement in the research process to ensure the inclusion of that perspective as a mandatory feature of high-quality outcomes research [<xref ref-type="bibr" rid="CR13">13</xref>]. This point was arrived at in a stepwise process, with many OMERACT participants gradually changing their views on PRPs’ contributions, and realizing the value they can add to the research process. These developments [<xref ref-type="bibr" rid="CR29">29</xref>] can be summarized in the observation that increasing experience of working with PRPs has the greatest influence on researchers’ perceptions.</p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Organizing the Attendance of PRPs</title>
      <sec id="Sec8">
        <title>Recruitment, Selection, and Representativeness of PRPs</title>
        <p>Potential OMERACT PRPs are first approached by a member of a Working Group, usually a physician. Minimum requirements include being diagnosed with the condition being studied and the ability to speak English, articulate the lived experience with the disease, and travel abroad and participate in an intense 4-day OMERACT working conference. The patient stream leader, who is one of the members of the Executive Committee, approves nominations and invites PRPs to attend the conference. OMERACT aims at an adequate representation of continents, sexes, conditions, and experiences appropriate to each conference program. Ensuring appropriate representativeness of PRPs has been an ongoing challenge. Detailed characteristics have not been systematically collected, but the majority of OMERACT PRPs have been white, middle-class, middle-aged, and higher educated. Attempts have been made to broaden the diversity of the OMERACT PRPs, such as finding participants from Malaysia when the meeting was held there, but it is difficult to involve patients from countries where participatory research is less recognized and physician–patient relationships are traditionally more paternalistic [<xref ref-type="bibr" rid="CR31">31</xref>]. Nevertheless, the countries of residence of the PRPs (Table <xref rid="Tab1" ref-type="table">1</xref>) are similar to those of the rest of the participants in OMERACT, as is the proportion residing in the USA, Europe, and elsewhere (23, 48, and 29 %, respectively, for PRPs compared with 30, 45, and 25 % for other participants).</p>
        <p>Patients and their treating physician are often both involved in OMERACT research, requiring a separation of roles of patient/doctor in the clinic from that of collaborative partners at OMERACT [<xref ref-type="bibr" rid="CR32">32</xref>]. To facilitate this, each OMERACT meeting has a designated consultant physician available for patients if they have health concerns.</p>
        <p>OMERACT expects PRPs to represent their personal perspective of living with the disease, not that of a particular group of patients. Guidelines have been developed to help PRPs and researchers focus on the personal lived experience rather than personal agendas or organizational advocacy [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
      </sec>
      <sec id="Sec9">
        <title>Resources for Participation</title>
        <p>Patient participation in research, and in particular at conferences, requires financial resources. The cost of each PRP attending OMERACT have been met by OMERACT funds or donations organized by Working Groups. These expenses have been considerable, and accommodating patients with severe disabilities may require special transportation arrangements (e.g., supplemental oxygen on flights, personal assistance, or special travel arrangements). The average cost per patient has been similar for almost all meetings; the total cost for patient attendance for each of the last three meetings has been approximately US$100,000 per meeting (in 2014 values [US$] after correction for US inflation). This is a considerable portion of the central funds available to OMERACT and represents a major fundraising commitment by the OMERACT Executive Committee.</p>
      </sec>
    </sec>
    <sec id="Sec10">
      <title>Challenges and Benefits</title>
      <sec id="Sec11">
        <title>Demonstrating the Impact of PRPs</title>
        <p>There is evidence that engaging patients structurally in outcomes research provides benefits for the overall research process [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Patients’ questions, opinions, and concerns provided face validity to the OMERACT process and widened the research agenda [<xref ref-type="bibr" rid="CR24">24</xref>]. New domains, including fatigue, foot problems, stiffness definition, work productivity, and flares, were identified by patients and prompted new research. The involvement of PRPs enhanced the inclusion of patient-relevant outcomes in core sets. It changed the culture of OMERACT and may influence practice in other disciplines and research contexts. At the individual level, PRPs reported ‘positive pay-back’ in feeling more empowered towards their own disease, they appreciated opportunities to contribute to the greater community, and felt better able to keep abreast of research developments related to their disease [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
        <p>In the 2014 OMERACT survey, Working Group leaders valued the PRPs’ feedback as a reality check of the relevance and quality of their project, and stated that the feedback influenced the choice of appropriate outcomes and instruments. Interestingly, patients were less certain about the added value of their experiential knowledge to the overall research. This confirms earlier findings that patients tend to underestimate their contribution to the research process [<xref ref-type="bibr" rid="CR23">23</xref>].</p>
      </sec>
      <sec id="Sec12">
        <title>Risk of Pseudo-Professionalization</title>
        <p>Almost half of OMERACT PRPs have attended two or more OMERACT conferences and some are highly involved in other ongoing research projects. As these patient participants have become more experienced, some researchers have welcomed their increased familiarity with research processes and vocabulary. However, others have questioned the authenticity of their patient perspective because they felt training and support over a long period of time could result in ‘professional patients’ who are not able to represent the ‘naïve’ or ‘authentic’ patient perspective [<xref ref-type="bibr" rid="CR29">29</xref>] and therefore do not represent ‘ordinary’ patients. Whether this is true is open to debate [<xref ref-type="bibr" rid="CR29">29</xref>], but OMERACT minimizes this risk by ensuring a mixture of new and more experienced PRPs at meetings, and by focusing education on the ability of PRPs to articulate their personal experience in the context of outcome research.</p>
      </sec>
      <sec id="Sec13">
        <title>Extent of Patient Participation Between Meetings</title>
        <p>A 2014 internal OMERACT survey showed that 14 of 18 Working Group leaders reported patient involvement between conferences, usually including at least two PRPs. Involvement included regular electronic communications, teleconferences, and face-to-face meetings where possible. The survey revealed differences between researchers and PRPs in their perception of the role played by PRPs. Most PRPs perceived themselves as “advisors” or “information providers”; four viewed themselves as collaborators and one PRP reported a leadership role. In contrast, Working Group leaders perceived that PRPs had higher levels of involvement: ten Working Group leaders viewed PRPs as “collaborators” in their projects and two Working Group leaders mentioned the role as being “in control”. This disparity might be explained by the varying maturity of Working Groups in regards to their activities and the tendency of PRPs to underestimate the influence of their participation [<xref ref-type="bibr" rid="CR23">23</xref>].</p>
      </sec>
      <sec id="Sec14">
        <title>PRPs in Different Types of Projects</title>
        <p>There remains some debate as to whether the appropriate extent of patient participation may depend on the particular research project. Although OMERACT recommends involvement of patients as PRPs throughout the research process, in reality this is not always feasible. Some patients provide valuable input into one or more research phases, not as a PRP but as a patient advisor. For example, in a study to develop or evaluate a new imaging modality, it may be argued that patients’ perspectives are not as necessary for the assessment of the measurement algorithms or scoring method. However, it would be appropriate for patients to comment on the burden, safety, and feasibility of a test and to understand how the results could be used in guiding their care.</p>
      </sec>
      <sec id="Sec15">
        <title>Examples of PRPs in Working Groups</title>
        <p>A detailed analysis of the consequences of PRP involvement in OMERACT has been published [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Here we showcase two working groups that substantively engaged patients in all their activities. After patients identified fatigue as an often ignored and under-researched disease symptom, the OMERACT Fatigue Working Group initiated a research agenda with studies at different centers to systematically explore the phenomenon of fatigue. The Working Group looked at its severity and evaluated existing measurement instruments and are developing new ones. Patients have been involved on different levels and in different roles [<xref ref-type="bibr" rid="CR35">35</xref>]. In the development of a new patient-reported outcome measure for fatigue, patients played a pivotal role in focus group meetings, individual interviews, surveys, clinical trials, cognitive interviews, as well as in the OMERACT Working Group. The result has been a new instrument, the Bristol Rheumatoid Arthritis Fatigue (BRAF) questionnaire [<xref ref-type="bibr" rid="CR36">36</xref>], which is based on the conceptual framework developed from qualitative studies, ensuring its face validity. New data on the impact and measurement of fatigue have resulted in the recommendation to measure fatigue in clinical trials [<xref ref-type="bibr" rid="CR37">37</xref>] and in clinical care to reconcile disparities between physician and patient assessments of disease activity [<xref ref-type="bibr" rid="CR38">38</xref>].</p>
        <p>The OMERACT RA Flare Working Group involved patients from its initiation through every stage of the project. Since the inception of the project in 2006, the role of PRPs has been intense and diverse [<xref ref-type="bibr" rid="CR35">35</xref>]. Tasks were related to developing the design of the study, co-organizing focus group meetings, and coding and analyzing transcripts. PRPs participated in international, bi-weekly teleconferences to discuss the development of an instrument to measure flares, and a patient committee held additional face-to-face meetings and teleconferences with other group leaders for feedback and discussion of research progress and interim findings [<xref ref-type="bibr" rid="CR39">39</xref>]. This work is ongoing.</p>
      </sec>
    </sec>
    <sec id="Sec16" sec-type="discussion">
      <title>Discussion</title>
      <p>The way patients are involved as research partners in OMERACT has grown from an initial tightly circumscribed and experimental arrangement in 2002 to complete involvement at all levels of activity, supported by an inclusive and supportive code of practice approved by the membership in 2014. During this time, OMERACT has successfully introduced a number of conceptual, structural, and practical processes to ensure the integration of the patient perspective and substantive engagement throughout outcome measure development. These have centered on recognizing PRPs as an essential element of all OMERACT activities and funding and organizing the attendance of PRPs. Initial leadership commitment to providing resources for participation and a structure for the recruitment, selection, and support of PRPs was crucial. The experience of working with PRPs led to a stepwise acceptance and then encouragement of the role by OMERACT members and has resulted in increased PRP engagement in Working Group activities between OMERACT meetings. This approach can be applied by other societies and research groups [<xref ref-type="bibr" rid="CR40">40</xref>], and may result in the development of different structural and procedural changes to ensure that PRPs are supported and productive in that setting.</p>
      <p>PRP inclusion in the OMERACT process is not intended to represent the perspective of all patients as they only represent themselves and their experiences. However, having two patients within a Working Group, whatever their background and experience, is infinitely better than not involving patients at all. Ensuring a more representative view may be achieved through the use of mixed research methods that include qualitative interviews, focus groups, Delphi methods, or surveys to expand the input across a wider spectrum of patients [<xref ref-type="bibr" rid="CR19">19</xref>]. Such methods are increasingly recognized as an essential requisite of outcomes research in identifying and defining the concept of measurement (e.g., what you are seeking to measure) grounded in the patient experience, and to ensure that the ultimate measure is reflective of this concept [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>While many have advocated increased participation in research, developing metrics to demonstrate the added value of such inclusion is challenging. In this report we provide not only experiential evidence from the perspectives of patients and researchers, but real evidence of change in the direction of research endeavors, and more detailed analyses are available [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The recognition of fatigue as an important aspect of living with RA has now been incorporated into recommendations for patient assessments in clinical care, and for clinical trials, though the optimal measure has yet to be defined. There are few publications that have described methods of successful engagement in detail [<xref ref-type="bibr" rid="CR41">41</xref>], and further studies are needed to provide additional evidence of the benefits and impact of patient participation.</p>
      <p>While the work reported here has been limited to rheumatology, the conceptual foundations and the framework developed for patient inclusion are widely applicable across all chronic diseases and beyond outcomes research [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. EULAR now recommends involvement of PRPs throughout the research process, preferably from the beginning [<xref ref-type="bibr" rid="CR12">12</xref>]. PCORI has also recently developed a rubric for patient and stakeholder engagement that provides examples of how patients can be involved at different phases of research [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. The US Food &amp; Drug Administration Critical Path Initiative, the Core Outcome Measures in Effectiveness Trials (COMET) initiative [<xref ref-type="bibr" rid="CR46">46</xref>], and the International Society for Quality of Life research (ISOQOL) [<xref ref-type="bibr" rid="CR47">47</xref>] have also begun to integrate PRPs in their work. The process explained here should be useful in other contexts and to other specialties. Moving such an agenda forward is time consuming and necessitates enthusiasm and perseverance, particularly to support and train patients and health professionals. However, OMERACT researchers value patient participation highly in conferences and this is one of the central reasons for their ongoing participation [<xref ref-type="bibr" rid="CR30">30</xref>]. The dialogue and engagement between researchers and PRPs has greatly improved the quality of core outcome sets, by ensuring that outcomes are relevant to patients [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Patient participation has enriched the research agendas and enhanced mutual understanding of outcomes of importance for both patients and researchers [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
      <p>The experience of OMERACT should help move policy makers, funders, and researchers closer to the view that participatory research is not only a normative imperative for outcome research, but is also effective in producing relevant research and health outcomes [<xref ref-type="bibr" rid="CR41">41</xref>].</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Author contributions</title>
      <p>MdeW, JRK, PT, and LG drew together the main elements of the article. All authors were then involved in drafting the article or revising it critically for important intellectual content and all authors approved the final version to be submitted for publication.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with Ethical Standards</title>
      <sec id="FPar2">
        <title>Conflict of interest</title>
        <p>All authors declare no conflict of interest relevant to the content of this paper. PGC is supported in part by the National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.</p>
      </sec>
      <sec id="FPar3">
        <title>Financial disclosures</title>
        <p>The authors received no specific funding for this paper and have no financial disclosures directly linked with the contents of this paper. OMERACT (Outcome Measures in Rheumatology) is an international research group that is supported by registration fees and has received unrestricted hands-off funding from more than 23 pharmaceutical and clinical research companies over the past 2 years. MdeW, JRK, PT, DB, MB, PB, PGC, MADA, LM, LSS, JAS, VS, COB, and LG are, or were previously, members of the OMERACT Executive Committee; they received no financial remuneration for their participation in this role. COB was supported, in part, through a Patient-Centered Outcomes Research Institute (PCORI) Pilot Project Program Award (1IP2-PI000737-01) and a PCORI Methods Award (SC14-1402-10818). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or Methodology Committee.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Staniszewska</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Haywood</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Brett</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tutton</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Patient and public involvement in patient-reported outcome measures: evolution not revolution</article-title>
          <source>Patient</source>
          <year>2012</year>
          <volume>5</volume>
          <fpage>79</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="doi">10.2165/11597150-000000000-00000</pub-id>
          <?supplied-pmid 22428752?>
          <pub-id pub-id-type="pmid">22428752</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Speight</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barendse</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>FDA guidance on patient reported outcomes</article-title>
          <source>BMJ</source>
          <year>2010</year>
          <volume>340</volume>
          <fpage>c2921</fpage>
          <pub-id pub-id-type="doi">10.1136/bmj.c2921</pub-id>
          <?supplied-pmid 20566597?>
          <pub-id pub-id-type="pmid">20566597</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wright</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Roche</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>von Unger</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Block</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gardner</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>A call for an international collaboration on participatory research for health</article-title>
          <source>Health Promot Int</source>
          <year>2010</year>
          <volume>25</volume>
          <fpage>115</fpage>
          <lpage>122</lpage>
          <pub-id pub-id-type="doi">10.1093/heapro/dap043</pub-id>
          <?supplied-pmid 19854843?>
          <pub-id pub-id-type="pmid">19854843</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slager</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tritter</surname>
              <given-names>JQ</given-names>
            </name>
          </person-group>
          <article-title>Exchanging knowledge on participation by EU health consumers and patients in research, quality and policy [conference report]</article-title>
          <source>Health Expect</source>
          <year>2013</year>
          <volume>16</volume>
          <fpage>128</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="doi">10.1111/hex.12114</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brett</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Staniszewska</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mockford</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Herron-Marx</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tysall</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A systematic review of the impact of patient and public involvement on service users, researchers and communities</article-title>
          <source>Patient</source>
          <year>2014</year>
          <volume>7</volume>
          <fpage>387</fpage>
          <lpage>395</lpage>
          <pub-id pub-id-type="doi">10.1007/s40271-014-0065-0</pub-id>
          <?supplied-pmid 25034612?>
          <pub-id pub-id-type="pmid">25034612</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frank</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Basch</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Selby</surname>
              <given-names>JV</given-names>
            </name>
          </person-group>
          <article-title>The PCORI perspective on patient-centered outcomes research</article-title>
          <source>JAMA</source>
          <year>2014</year>
          <volume>312</volume>
          <fpage>1513</fpage>
          <lpage>1514</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.2014.11100</pub-id>
          <?supplied-pmid 25167382?>
          <pub-id pub-id-type="pmid">25167382</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miller</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Teare</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Marlett</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Shklarov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Support for living a meaningful life with osteoarthritis: a patient-to-patient research study</article-title>
          <source>Patient</source>
          <year>2016</year>
          <volume>9</volume>
          <issue>5</issue>
          <fpage>457</fpage>
          <lpage>464</lpage>
          <pub-id pub-id-type="doi">10.1007/s40271-016-0169-9</pub-id>
          <?supplied-pmid 27085710?>
          <pub-id pub-id-type="pmid">27085710</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="other">EUPATI. European Patients’ Academy on Therapeutic Innovations. 2013. <ext-link ext-link-type="uri" xlink:href="http://www.patientsacademy.eu/">http://www.patientsacademy.eu/</ext-link>. Accessed 25 Aug 2013.</mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelson</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Consumer collaboration, patient-defined outcomes and the preparation of cochrane reviews</article-title>
          <source>Health Expect</source>
          <year>1999</year>
          <volume>2</volume>
          <fpage>129</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1369-6513.1999.00042.x</pub-id>
          <?supplied-pmid 11281886?>
          <pub-id pub-id-type="pmid">11281886</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shea</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Santesso</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Qualman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Heiberg</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Leong</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Judd</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Consumer-driven health care: building partnerships in research</article-title>
          <source>Health Expect</source>
          <year>2005</year>
          <volume>8</volume>
          <fpage>352</fpage>
          <lpage>359</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1369-7625.2005.00347.x</pub-id>
          <?supplied-pmid 16266423?>
          <pub-id pub-id-type="pmid">16266423</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="other">INVOLVE. Website Supporting public involvement in NHS, public health and social care research. 2016. <ext-link ext-link-type="uri" xlink:href="http://www.invo.org.uk/">http://www.invo.org.uk/</ext-link>. Accessed 10 Feb 2016.</mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Wit</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Berlo</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Aanerud</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Aletaha</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bijlsma</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Croucher</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects</article-title>
          <source>Ann Rheum Dis</source>
          <year>2011</year>
          <volume>70</volume>
          <fpage>722</fpage>
          <lpage>726</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2010.135129</pub-id>
          <?supplied-pmid 21257615?>
          <pub-id pub-id-type="pmid">21257615</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="other">Cheung PP, de Wit M, Bingham CO 3rd, Kirwan JR, Leong A, March LM, et al. Recommendations for the involvement of patient research partners (PRP) in OMERACT Working Groups. A report from the OMERACT 2014 Working Group on PRP. J Rheumatol 2016;43:187–93.</mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Wit</surname>
              <given-names>MPT</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Orbai</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Tillett</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>FitzGerald</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Building bridges between researchers and patient research partners: a report from the GRAPPA 2014 annual meeting</article-title>
          <source>J Rheumatol</source>
          <year>2015</year>
          <volume>42</volume>
          <fpage>1021</fpage>
          <lpage>1026</lpage>
          <pub-id pub-id-type="doi">10.3899/jrheum.150123</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kiltz</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>van der Heijde</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mielants</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Feldtkeller</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version</article-title>
          <source>Ann Rheum Dis</source>
          <year>2009</year>
          <volume>68</volume>
          <fpage>1381</fpage>
          <lpage>1386</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2008.096073</pub-id>
          <?supplied-pmid 18930993?>
          <pub-id pub-id-type="pmid">18930993</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kjeken</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ziegler</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Skrolsvik</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bagge</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Smedslund</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tøvik</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Research priorities, attitudes and experiences among individuals with rheumatic diseases in Scandinavia</article-title>
          <source>Ann Rheum Dis</source>
          <year>2009</year>
          <volume>68</volume>
          <fpage>793</fpage>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Wit</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Elberse</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Broerse</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Abma</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Do not forget the professional - the value of the FIRST model for guiding the structural involvement of patients in rheumatology research</article-title>
          <source>Health Expect</source>
          <year>2015</year>
          <volume>18</volume>
          <fpage>489</fpage>
          <lpage>503</lpage>
          <pub-id pub-id-type="doi">10.1111/hex.12048</pub-id>
          <?supplied-pmid 23363240?>
          <pub-id pub-id-type="pmid">23363240</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="other">CAPA. Canadian Arthritis Patient Alliances: patient involvement in research. 2015. <ext-link ext-link-type="uri" xlink:href="http://www.arthritispatient.ca/research">http://www.arthritispatient.ca/research</ext-link>. Accessed 29 June 2015.</mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Wit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kvien</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gossec</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Patient participation as an integral part of patient reported outcomes development guarantees the representativeness of the patient voice—a case-study from the field of rheumatology</article-title>
          <source>RMD Open</source>
          <year>2015</year>
          <volume>1</volume>
          <fpage>e000129</fpage>
          <?supplied-pmid 26509075?>
          <pub-id pub-id-type="pmid">26509075</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forsythe</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Edmundson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sabharwal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rein</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Konopka</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patient and stakeholder engagement in the PCORI pilot projects: description and lessons learned</article-title>
          <source>J Gen Intern Med</source>
          <year>2016</year>
          <volume>31</volume>
          <fpage>13</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1007/s11606-015-3450-z</pub-id>
          <?supplied-pmid 26160480?>
          <pub-id pub-id-type="pmid">26160480</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="other">OMERACT. 2016. <ext-link ext-link-type="uri" xlink:href="http://www.omeract.org/">http://www.omeract.org/</ext-link>. Accessed 10 Feb 2016.</mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirwan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>de Wit</surname>
              <given-names>MPT</given-names>
            </name>
          </person-group>
          <article-title>What have we learned from a decade of patient involvement in OMERACT and its effect on trial outcome assessments?</article-title>
          <source>Trials</source>
          <year>2011</year>
          <volume>12</volume>
          <issue>suppl 1</issue>
          <fpage>A80</fpage>
          <pub-id pub-id-type="doi">10.1186/1745-6215-12-S1-A80</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="other">de Wit MPT, Koelewijn-van Loon MS, Collins S, Abma TA, Kirwan JR. “If I wasn’t this robust”: patients’ expectations and experiences at the Outcome Measures in Rheumatology Conference 2010. Patient. 2013;6:179–87.</mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="other">de Wit M, Abma T, Koelewijn-van Loon M, Collins S, Kirwan J. Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. BMJ Open. 2013;3. doi:10.1136/bmjopen-2012-002241.</mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tugwell</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Felson</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>van Riel</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Kirwan</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Edmonds</surname>
              <given-names>JP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials</article-title>
          <source>J Rheumatol Suppl</source>
          <year>1994</year>
          <volume>41</volume>
          <fpage>86</fpage>
          <lpage>89</lpage>
          <?supplied-pmid 7799394?>
          <pub-id pub-id-type="pmid">7799394</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wells</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Beaton</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bellamy</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Boers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bombardier</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Minimal clinically important difference module: summary, recommendations, and research agenda</article-title>
          <source>J Rheumatol</source>
          <year>2001</year>
          <volume>28</volume>
          <fpage>452</fpage>
          <lpage>454</lpage>
          <?supplied-pmid 11246695?>
          <pub-id pub-id-type="pmid">11246695</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Wit</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Abma</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Koelewijn-van Loon</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kirwan</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>What has been the effect on trial outcome assessments of a decade of patient participation in OMERACT?</article-title>
          <source>J Rheumatol</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>177</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="doi">10.3899/jrheum.130816</pub-id>
          <?supplied-pmid 24128777?>
          <pub-id pub-id-type="pmid">24128777</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hewlett</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Patients and clinicians have different perspectives on outcomes in arthritis</article-title>
          <source>J Rheumatol</source>
          <year>2003</year>
          <volume>30</volume>
          <fpage>877</fpage>
          <lpage>879</lpage>
          <?supplied-pmid 12672220?>
          <pub-id pub-id-type="pmid">12672220</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Wit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abma</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Koelewijn-Van Loon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kirwan</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Facilitating and inhibiting factors for long-term involvement of patients at outcome conferences–lessons learnt from a decade of collaboration in OMERACT: a qualitative study</article-title>
          <source>BMJ Open</source>
          <year>2013</year>
          <volume>3</volume>
          <fpage>e003311</fpage>
          <pub-id pub-id-type="doi">10.1136/bmjopen-2013-003311</pub-id>
          <?supplied-pmid 23975104?>
          <pub-id pub-id-type="pmid">23975104</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="other">Flurey CA, Kirwan JR, Hadridge P, Richards P, Grosskleg S, Tugwell PS. The spirit of OMERACT: Q methodology analysis of conference characteristics valued by delegates. J Rheumatol. 2015. doi:10.3899/jrheum.150113.</mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gossec</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kirwan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>de Wit</surname>
              <given-names>MPT</given-names>
            </name>
          </person-group>
          <article-title>Patient perspective in outcome measures developed by OMERACT</article-title>
          <source>Indian J Rheumatol</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>17</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1016/j.injr.2013.11.004</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hewlett</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>De Wit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Quest</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Heiberg</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patients and professionals as research partners: challenges, practicalities, and benefits</article-title>
          <source>Arthritis Rheum</source>
          <year>2006</year>
          <volume>55</volume>
          <fpage>676</fpage>
          <lpage>680</lpage>
          <pub-id pub-id-type="doi">10.1002/art.22091</pub-id>
          <?supplied-pmid 16874772?>
          <pub-id pub-id-type="pmid">16874772</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mockford</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Staniszewska</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Herron-Marx</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The impact of patient and public involvement on UK NHS health care: a systematic review</article-title>
          <source>Int J Qual Health Care</source>
          <year>2012</year>
          <volume>24</volume>
          <fpage>28</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1093/intqhc/mzr066</pub-id>
          <?supplied-pmid 22109631?>
          <pub-id pub-id-type="pmid">22109631</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lindenmeyer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hearnshaw</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sturt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ormerod</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Aitchison</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Assessment of the benefits of user involvement in health research from the Warwick Diabetes Care Research User Group: a qualitative case study</article-title>
          <source>Health Expect</source>
          <year>2007</year>
          <volume>10</volume>
          <fpage>268</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1369-7625.2007.00451.x</pub-id>
          <?supplied-pmid 17678515?>
          <pub-id pub-id-type="pmid">17678515</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bingham</surname>
              <given-names>CO</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Alten</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>de Wit</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>The importance of patient participation in measuring rheumatoid arthritis flares</article-title>
          <source>Ann Rheum Dis</source>
          <year>2012</year>
          <volume>71</volume>
          <fpage>1107</fpage>
          <lpage>1109</lpage>
          <pub-id pub-id-type="doi">10.1136/annrheumdis-2011-200870</pub-id>
          <?supplied-pmid 22323439?>
          <pub-id pub-id-type="pmid">22323439</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hewlett</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dures</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for Severity, Effect, and Coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS)</article-title>
          <source>Arthritis Care Res</source>
          <year>2011</year>
          <volume>63</volume>
          <issue>Suppl 11</issue>
          <fpage>S263</fpage>
          <lpage>S286</lpage>
          <pub-id pub-id-type="doi">10.1002/acr.20579</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aletaha</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Landewe</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Karonitsch</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bathon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Boers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bombardier</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations</article-title>
          <source>Arthritis Rheum</source>
          <year>2008</year>
          <volume>59</volume>
          <fpage>1371</fpage>
          <lpage>1377</lpage>
          <pub-id pub-id-type="doi">10.1002/art.24123</pub-id>
          <?supplied-pmid 18821648?>
          <pub-id pub-id-type="pmid">18821648</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Spencer</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Abda</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Aggarwal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alten</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ancuta</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Determinants of discordance in patients’ and physicians’ rating of rheumatoid arthritis disease activity</article-title>
          <source>Arthritis Care Res</source>
          <year>2012</year>
          <volume>64</volume>
          <fpage>206</fpage>
          <lpage>214</lpage>
          <pub-id pub-id-type="doi">10.1002/acr.20685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bykerk</surname>
              <given-names>VP</given-names>
            </name>
            <name>
              <surname>Lie</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bartlett</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Alten</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Boonen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop</article-title>
          <source>J Rheumatol</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>799</fpage>
          <lpage>809</lpage>
          <pub-id pub-id-type="doi">10.3899/jrheum.131252</pub-id>
          <?supplied-pmid 24584927?>
          <pub-id pub-id-type="pmid">24584927</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jinks</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Rhodes</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Beech</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dziedzic</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sustaining patient and public involvement in research: a case study of a research centre</article-title>
          <source>J Care Serv Manag</source>
          <year>2013</year>
          <volume>7</volume>
          <fpage>146</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="doi">10.1179/1750168715Y.0000000003</pub-id>
          <?supplied-pmid 26705412?>
          <pub-id pub-id-type="pmid">26705412</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Staniszewska</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brett</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mockford</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Barber</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The GRIPP checklist: strengthening the quality of patient and public involvement reporting in research</article-title>
          <source>Int J Technol Assess Health Care</source>
          <year>2011</year>
          <volume>27</volume>
          <fpage>391</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="doi">10.1017/S0266462311000481</pub-id>
          <?supplied-pmid 22004782?>
          <pub-id pub-id-type="pmid">22004782</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nierse</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Schipper</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>van Zadelhoff</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>van de Griendt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Abma</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Collaboration and co-ownership in research: dynamics and dialogues between patient research partners and professional researchers in a research team</article-title>
          <source>Health Expect</source>
          <year>2012</year>
          <volume>15</volume>
          <fpage>242</fpage>
          <lpage>254</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1369-7625.2011.00661.x</pub-id>
          <?supplied-pmid 21332617?>
          <pub-id pub-id-type="pmid">21332617</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abma</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Nierse</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Widdershoven</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Patients as partners in responsive research: methodological notions for collaborations in mixed research teams</article-title>
          <source>Qual Health Res</source>
          <year>2009</year>
          <volume>19</volume>
          <fpage>401</fpage>
          <lpage>415</lpage>
          <pub-id pub-id-type="doi">10.1177/1049732309331869</pub-id>
          <?supplied-pmid 19224882?>
          <pub-id pub-id-type="pmid">19224882</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <mixed-citation publication-type="other">PCORI. PCORI engagement rubric. 2015. <ext-link ext-link-type="uri" xlink:href="http://www.pcori.org/sites/default/files/PCORI-Engagement-Rubric-with-Table.pdf">http://www.pcori.org/sites/default/files/PCORI-Engagement-Rubric-with-Table.pdf</ext-link>. Accessed 10 Apr 2015.</mixed-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frank</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Forsythe</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schrandt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sheridan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gerson</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Conceptual and practical foundations of patient engagement in research at the patient-centered outcomes research institute</article-title>
          <source>Qual Life Res</source>
          <year>2015</year>
          <volume>24</volume>
          <issue>5</issue>
          <fpage>1033</fpage>
          <lpage>1041</lpage>
          <pub-id pub-id-type="doi">10.1007/s11136-014-0893-3</pub-id>
          <?supplied-pmid 25560774?>
          <pub-id pub-id-type="pmid">25560774</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <mixed-citation publication-type="other">Williamson P, Clarke M. The COMET (Core Outcome Measures in Effectiveness Trials) initiative: its role in improving Cochrane reviews. Cochrane Database Syst Rev. 2012;5:ED000041.</mixed-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haywood</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Brett</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Salek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marlett</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Penman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shklarov</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patient and public engagement in health-related quality of life and patient-reported outcomes research: what is important and why should we care? Findings from the first ISOQOL patient engagement symposium</article-title>
          <source>Qual Life Res</source>
          <year>2015</year>
          <volume>24</volume>
          <issue>5</issue>
          <fpage>1069</fpage>
          <lpage>1076</lpage>
          <pub-id pub-id-type="doi">10.1007/s11136-014-0796-3</pub-id>
          <?supplied-pmid 25194573?>
          <pub-id pub-id-type="pmid">25194573</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <mixed-citation publication-type="other">Kirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, et al. Updating the OMERACT filter: implications for patient-reported outcomes. J Rheumatol. 2014;41:1011–5.</mixed-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirwan</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Fries</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Hewlett</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Osborne</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Newman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ciciriello</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patient perspective workshop: moving towards OMERACT guidelines for choosing or developing instruments to measure patient-reported outcomes</article-title>
          <source>J Rheumatol</source>
          <year>2011</year>
          <volume>38</volume>
          <fpage>1711</fpage>
          <lpage>1715</lpage>
          <pub-id pub-id-type="doi">10.3899/jrheum.110391</pub-id>
          <?supplied-pmid 21807790?>
          <pub-id pub-id-type="pmid">21807790</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362657</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pflugers Arch</journal-id>
      <journal-id journal-id-type="iso-abbrev">Pflugers Arch</journal-id>
      <journal-title-group>
        <journal-title>Pflugers Archiv</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0031-6768</issn>
      <issn pub-type="epub">1432-2013</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362657</article-id>
      <article-id pub-id-type="pmcid">PMC5362657</article-id>
      <article-id pub-id-type="pmc-uid">5362657</article-id>
      <article-id pub-id-type="pmid">28185068</article-id>
      <article-id pub-id-type="publisher-id">1945</article-id>
      <article-id pub-id-type="doi">10.1007/s00424-017-1945-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Invited Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Physiological roles of macrophages</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Gordon</surname>
            <given-names>Siamon</given-names>
          </name>
          <address>
            <email>siamon.gordon@path.ox.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2331-127X</contrib-id>
          <name>
            <surname>Martinez-Pomares</surname>
            <given-names>Luisa</given-names>
          </name>
          <address>
            <email>luisa.m@nottingham.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.145695.a</institution-id><institution>Graduate Institute of Biomedical Sciences, College of Medicine, </institution><institution>Chang Gung University, </institution></institution-wrap>Taoyuan City, 33302 Taiwan </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution>Sir William Dunn School of Pathology, </institution><institution>Oxford University, </institution></institution-wrap>Oxford, UK </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8868</institution-id><institution-id institution-id-type="GRID">grid.4563.4</institution-id><institution>School of Life Sciences, </institution><institution>University of Nottingham, </institution></institution-wrap>Nottingham, UK </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>469</volume>
      <issue>3</issue>
      <fpage>365</fpage>
      <lpage>374</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>1</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>1</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Macrophages are present in mammals from midgestation, contributing to physiologic homeostasis throughout life. Macrophages arise from yolk sac and foetal liver progenitors during embryonic development in the mouse and persist in different organs as heterogeneous, self-renewing tissue-resident populations. Bone marrow-derived blood monocytes are recruited after birth to replenish tissue-resident populations and to meet further demands during inflammation, infection and metabolic perturbations. Macrophages of mixed origin and different locations vary in replication and turnover, but are all active in mRNA and protein synthesis, fulfilling organ-specific and systemic trophic functions, in addition to host defence. In this review, we emphasise selected properties and non-immune functions of tissue macrophages which contribute to physiologic homeostasis.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Macrophages</kwd>
        <kwd>Homeostasis</kwd>
        <kwd>Tissue heterogeneity</kwd>
        <kwd>Physiology</kwd>
        <kwd>Receptors</kwd>
        <kwd>Phagocytosis</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>University of Nottingham</institution>
          </funding-source>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer-Verlag Berlin Heidelberg 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>“The constancy of the internal environment is the condition for full and independent life: the mechanism that makes it possible is that which assured that maintenance, within the internal environment, conditions necessary for the life of these elements” (Claude Bernard).</p>
      <p>The concept of homeostasis as a physiological principle, a term proposed by the neuroscientist Walter Cannon (1871–1945) and based on the work of Claude Bernard (1813–1878), has influenced the thinking of many macrophage investigators. Elie Metchnikoff (1845–1916), a comparative zoologist who initially was intrigued by intracellular digestion in invertebrates, became an experimental immunologist when he appreciated the role of phagocytes in tissue orthobiosis and inflammation [<xref ref-type="bibr" rid="CR67">67</xref>]. Hans Selye (1907–1982) drew attention to the non-specific neuro-endocrine adaptations of the body to biological stress; however, the contributions of the mononuclear phagocyte system to the mechanisms of homeostasis and stress responses have not achieved full recognition. In this review, we consider topics related to the role of macrophages in development, metabolism and tissue-specific functions in different organs, to illustrate their remarkable ability to recognise and respond to the changing needs of the body. A general overview of the main topic covered is provided in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Physiological roles of macrophages and macrophages heterogeneity. Phenotypic heterogeneity of tissue macrophages is triggered by differences in cellular origin (self-replicated cells of embryonic origin vs monocyte-derived), tissue environment and adaptation to the physiological requirements of the organism (shown on the <italic>left</italic>). Macrophage heterogeneity underpins the vast range of physiological roles performed of these cells (shown on the <italic>right</italic>). Phenotypic heterogeneity is consolidated by tissue-specific “chromatin landscapes” in macrophages in response to environmental signals. Macrophages display a wide range of “sensor systems” in the form of <italic>(a)</italic> cell surface and intracellular pattern recognition receptors that detect microbe-associated molecular patterns and damage-associated molecular patterns; <italic>(b)</italic> receptors for apoptotic cells; <italic>(c)</italic> cytokine receptors such as IFN-γ and IL-4Rα that promote M1/M2-like activation, respectively; <italic>(d)</italic> receptors for neurotransmitters as well as <italic>(e)</italic> receptors that regulate macrophage activation in situ such as the inhibitory receptors SIRP1-α and CD200R. Integrins <italic>(f)</italic> mediate interaction with extracellular matrix. Macrophages produce numerous molecules that contribute to tissue remodelling and inflammation and mediate clearance of apoptotic bodies, cell debris and soluble compounds such as collagen and lysosomal hydrolases. High phagocytic and endocytic activities as well as motility are central to the ability of macrophages to support tissue-dependent functions. <italic>RNS</italic> reactive nitrogen species, <italic>ROS</italic> reactive oxygen species</p></caption><graphic xlink:href="424_2017_1945_Fig1_HTML" id="MO1"/></fig>
</p>
      <p>Blood monocytes and tissue macrophages display many properties in common, but they adapt readily upon entering different tissue microenvironments, where they contribute to the general needs as well as specialised functions of individual organs. Reciprocal interactions between neighbouring cells and tissue macrophages are mediated by close contacts as well as secretory products which act at close range or distally via the circulation. Although primarily known as professional phagocytes [<xref ref-type="bibr" rid="CR29">29</xref>], which engulf dying cells during development and subsequently during adult life, it has not been generally appreciated that macrophage activities extend beyond immunology and host defence. They express a broad repertoire of surface and intracellular receptors and produce a large variety of regulated bioactive molecules; together with their ability to enter all tissues, in the steady state and on demand, they constitute a dispersed organ system, able to influence and respond to every other system in the body.</p>
    </sec>
    <sec id="Sec2">
      <title>Cellular characteristics of the macrophage lineage: relevance to physiology</title>
      <p>To set the stage for subsequent discussion, we briefly summarise some general properties of macrophages relevant to their functions in vivo. The cells originate from progenitors in the embryo and postnatally, as discussed further below, and are seeded throughout the body as relatively long lived, terminally differentiated haematopoietic cells. They are motile and display a range of membrane receptors to recognise and respond to a large repertoire of host-derived and foreign ligands [<xref ref-type="bibr" rid="CR29">29</xref>]. These include adhesion molecules, opsonic and non-opsonic receptors to mediate phagocytic clearance of particulates, including micro-organisms and apoptotic cells, and for endocytosis of soluble ligands. In addition, they are able to sense and respond to the presence of microbial constituents, including RNA and DNA, within their cytoplasm, activating intracellular inflammasomes [<xref ref-type="bibr" rid="CR32">32</xref>], caspase processing and release of IL-1β. A plethora of other cytokines, enzymes, growth factors, lipid-derived and low molecular metabolite products can also be secreted by macrophages in response to phagocytic and various stimuli and, in turn, act on macrophage receptors by autocrine mechanisms. Plasma membrane receptors co-operate in formation of a phagocytic synapse, excluding phosphatases such as CD45, and allow receptor kinases to initiate signalling pathways and cytoskeletal assembly, to bring about ingestion of particles [<xref ref-type="bibr" rid="CR21">21</xref>]. A sequence of dynamic interactions with vesicular membranes derived from the endoplasmic reticulum and Golgi apparatus accompanies phagosome maturation, fusion with primary lysosomes, acidification and digestion [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. Macrophages can internalise its entire surface membrane in 20 min, but recycle components equally rapidly to maintain membrane homeostasis [<xref ref-type="bibr" rid="CR51">51</xref>]. Heterophagy refers to uptake of extracellular cargo; autophagy, the sequestration of effete cytoplasm and intracellular organelles, is well developed in macrophages [<xref ref-type="bibr" rid="CR16">16</xref>]; genetic deficiency of lysosomal digestion or components of the autophagy pathway can result in storage diseases [<xref ref-type="bibr" rid="CR59">59</xref>] or chronic granulomatous inflammation [<xref ref-type="bibr" rid="CR68">68</xref>], respectively.</p>
      <p>The uptake and killing of microbes and opsonised cellular targets by oxygen and nitrogen-derived radicals are mediated by assembly and activation of an NADPH oxidase and inducible nitric oxide synthetase, respectively [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. The ingestion of apoptotic targets, a major physiologic function of tissue-resident and inflammatory macrophages, is mediated by a range of redundant receptors, using exposed phosphatidyl serine and other cues as ligands [<xref ref-type="bibr" rid="CR2">2</xref>]. Apoptotic cell uptake inhibits the inflammatory response associated with uptake of necrotic cells or microbes; anti-inflammatory products include TGF-β, IL-10 and PGE2 [<xref ref-type="bibr" rid="CR38">38</xref>]. The importance of phagoptotic killing during phagocytosis has been emphasised by the studies of Guy Brown and colleagues [<xref ref-type="bibr" rid="CR7">7</xref>]. Finally, macrophages can ingest membrane-enveloped nuclei or intracellular vesicles released from living cells or undergo cell fusion, to form multinucleated giant cells [<xref ref-type="bibr" rid="CR35">35</xref>].</p>
    </sec>
    <sec id="Sec3">
      <title>Phenotypic adaptation of macrophages</title>
      <p>Macrophage gene expression has been intensively studied in recent years and modules of genes regulated by a range of cytokines and other stimuli characterised in tissue-resident and inflammatory macrophages. Both pro- and anti-inflammatory pathways can be induced in macrophage populations, mediated by plasma membrane or cytoplasmic receptors. IFN-γ, for example, induces a characteristic profile of genes and proteins, often termed “classical or M1 activation” [<xref ref-type="bibr" rid="CR47">47</xref>]; prototypic markers include upregulation of MHCII antigens, pro-inflammatory cytokines and induction of i-NOS, whereas CD206 expression is selectively downregulated. By contrast, interleukin-4 and interleukin-13, binding to a common IL-4 receptor alpha chain, induce an “alternative, M2” phenotype, characterised by upregulation of CD206, transglutaminase 2, arginase and, in the mouse, chitinase-like molecules such as YM1 [<xref ref-type="bibr" rid="CR48">48</xref>]. An IL-13-specific receptor pathway has also been demonstrated by induction of macrophage homokaryon formation [<xref ref-type="bibr" rid="CR62">62</xref>]. Phenotypic changes in macrophages are underpinned by metabolic reprogramming. M1 macrophages utilise Warburg metabolism and M2 macrophage oxidative metabolism [<xref ref-type="bibr" rid="CR55">55</xref>]. The M1/M2 terminology arose as counterpart to Th1 and Th2 categories of adaptive immune responses, associated with the above and related cytokines. It is thought that instead of bimodal polarisation, a more complex phenotypic spectrum is more likely, especially in vivo [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. In truth, there is overlap with other cytokine-induced stimuli, e.g. after IL-10 stimulation or immune complex activation [<xref ref-type="bibr" rid="CR19">19</xref>]. The stability or reversibility of phenotype in vivo needs a great deal of further study, at population and the single cell level. In addition, further studies on genetic and epigenetic mechanisms will contribute to a more sophisticated understanding of tissue-specific and generic macrophage phenotypic heterogeneity.</p>
    </sec>
    <sec id="Sec4">
      <title>Macrophage heterogeneity under physiological conditions</title>
      <p>The immune system comprises a complex network of cellular and soluble components that collaborate to respond to challenges, both infectious and non-infectious, identified as potential threats to the organism. Accordingly, immune constituents are widely distributed throughout tissues with specialised lymphoid organs, such as splenic white pulp and lymph nodes, mostly providing unique sites for the induction of specific acquired immunity.</p>
      <p>To date, newcomers to the field are still surprised to learn that healthy tissues incorporate immune cells, in particular, macrophages which are cells commonly associated with protection against infection and as mediators of tissue damage. Macrophages, unlike neutrophils, are integral components of tissues; they contribute to organ development and maintenance of homeostasis through mechanisms similar to those exploited during infection to detect pathogens and trigger inflammation. Widespread distribution of macrophages is accompanied by substantial tissue-specific phenotypic and gene expression profile differences related to the specific environmental cues in each organ that foster tissue-specific macrophage function [<xref ref-type="bibr" rid="CR25">25</xref>]. Differences in gene expression are underpinned by the existence of distinct “chromatin landscapes” in each tissue macrophage population which are determined in large extent by the tissue environment [<xref ref-type="bibr" rid="CR44">44</xref>]. Furthermore, fully differentiated macrophages may retain the capacity to change their gene expression profile when exposed to a new tissue environment [<xref ref-type="bibr" rid="CR44">44</xref>], which highlights the potential ability of macrophages to undergo reprogramming even after differentiation. Phenotypically, there are instances of tissue adaptation in macrophages involving fine tuning of cellular activation thresholds. In mucosal tissues such as the respiratory and gastrointestinal tracts, macrophages display a higher threshold of activation as a means to minimise inflammation-mediated organ damage in response to repeated exposure to foreign material, including microbial products. In the case of alveolar macrophages, exposure to IL-10, surfactant proteins A and D and close interaction with respiratory epithelium through the inhibitory receptor CD200R and ανβ-6 tethered TGF-β, act as effective brakes of macrophage activation minimising the risk of unwanted inflammation [<xref ref-type="bibr" rid="CR40">40</xref>]. In the gut, macrophages are hyporesponsive to stimulation [<xref ref-type="bibr" rid="CR65">65</xref>]. Nevertheless, gut macrophages can trigger inflammation with one mechanism involving the detection of tissue damage through activation of the NLRC4 inflammasome which induces processing of pro-IL-1β constitutively expressed by intestinal macrophages [<xref ref-type="bibr" rid="CR20">20</xref>]. This mechanism ensures detection of pathogens that cause tissue damage through the production of virulence factors [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Macrophages in internal organs, less exposed to microbial constituents, present a lower activation threshold and are considered to be responsible for the induction of systemic inflammation in response to blood-borne pathogens, which can have deadly consequences in the case of sepsis [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
    </sec>
    <sec id="Sec5">
      <title>Origin of tissue macrophages</title>
      <p>In addition to tissue-specific environmental cues, tissue-specific characteristics in macrophages can be linked in part to on site differentiation of macrophages from embryonic precursors during development and maintenance of macrophage numbers in tissues through self-renewal [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR63">63</xref>] with imprinting of macrophage transcriptional programmes by tissue factors of particular importance [<xref ref-type="bibr" rid="CR26">26</xref>]. Indeed, the original idea of monocytes as precursors of tissue macrophages that gave rise to the concept of “the mononuclear phagocyte system” proposed by van Furth et al. 1974 has been questioned by recent studies demonstrating that in many anatomical sites, tissue macrophages originate from precursors derived from the yolk sac during early embryogenesis with a second wave of embryonic precursors derived from foetal liver. This embryonic origin contrasts with the bone marrow origin for most immune cells [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Definitive haematopoiesis takes place in the bone marrow after birth. These findings were accompanied by the identification in the mouse of two populations of circulating monocytes: classical Ly6c<sup>hi</sup> monocytes that originate directly from Ly6c + precursors and non-classical Ly6c<sup>low</sup> monocytes that derive from Ly6c<sup>high</sup> monocytes through the action of the transcription factor Nr4a1 [<xref ref-type="bibr" rid="CR18">18</xref>]. Further, monocytes are now perceived to be not just transitional cells on their way to tissues; some authors refer to circulating Ly6C<sup>lo</sup> monocytes as “blood macrophages” involved in the maintenance of the integrity of the endothelial barrier [<xref ref-type="bibr" rid="CR33">33</xref>]. Ly6C<sup>high</sup> monocytes contribute to replenishment of tissue macrophages with the rate of replenishment varying among anatomical sites. In the steady state, monocyte-derived tissue macrophages are almost non-existent in the case of brain as microglia are derived from yolk sac precursors. Similar scenarios have been observed in the case of Langerhans cells in the epidermis, alveolar macrophages in the lung and Kupffer cells in the liver. Monocyte-derived resident macrophages are more prevalent in the heart and pancreas (which display a slow replacement rate) and gut and dermis (which display a higher replacement rate) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p>
      <p>Ly6C<sup>high</sup> monocytes are recruited to tissues under steady state and inflammatory conditions. In the absence of inflammation, Ly6C<sup>high</sup> monocytes sample the tissues and transport material to draining lymph nodes without differentiating into macrophages or dendritic cells [<xref ref-type="bibr" rid="CR18">18</xref>]. Under inflammatory conditions, Ly6C<sup>high</sup> monocytes differentiate into macrophages and can give rise to tissue macrophages with capacity for self-renewal. This process is highly dependent on the tissue-depletion strategy used and the organ under consideration [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
    </sec>
    <sec id="Sec6">
      <title>Role of macrophages in development</title>
      <sec id="Sec7">
        <title>Osteoclasts and bone remodelling</title>
        <p>Bone remodelling occurs throughout life and is influenced by physical activity, diet and hormones. Bone generation, promoted by cells of mesenchymal origin termed osteoblasts, is balanced by the action of cells of haematopoietic origin termed osteoclasts that mediate bone reabsorption. Bone formation and degradation need to be balanced as disequilibrium would lead to osteoporosis (loss of bone mass) or osteopetrosis (excess bone mineralisation). Further, bone remodelling controls Ca<sup>2+</sup> fluxes into and from the extracellular fluid which is required for the maintenance of the levels of calcium in blood [<xref ref-type="bibr" rid="CR4">4</xref>]. Osteoclasts belong to the myeloid lineage, are M-CSF (CSF-1)-dependent and are multinucleated. Osteoclastogenesis is dependent on receptor activator of NFκB ligands (RANKL). Osteoclasts attach to the bone surface and assume a polarised morphology. The area attached to the bone is sealed, bone is degraded by the release of acid and acidic collagenolytic enzymes and released material is secreted at the opposite side of the cell through transcytosis [<xref ref-type="bibr" rid="CR4">4</xref>]. Exchange of signals between osteoblasts and osteoclasts ensures that bone remodelling is regulated [<xref ref-type="bibr" rid="CR64">64</xref>]. For instance, osteoblast apoptosis upon bone damage promotes osteoclast recruitment to the bone surface and osteoblast-derived RANKL is essential for osteoclast differentiation. IL-33 produced by osteoblasts inhibits osteoclast formation. Similarly, osteoclasts influence osteoblast function through the production of cardiotrophin-1 and semaphorin 4D (CD100), which promote and inhibit bone formation, respectively [<xref ref-type="bibr" rid="CR64">64</xref>]. As a consequence of lack of bone resorption, bone marrow haematopoiesis does not occur due to lack of its anatomical niche. Csf1-deficient animals develop osteopetrosis and survive to adulthood because of extramedullary haematopoiesis in the spleen and liver and generation of osteoclasts takes place by compensatory expression of VEGF. Osteoclast generation enables the establishment of bone marrow haematopoiesis by enabling the creation of the haematopoietic niche [<xref ref-type="bibr" rid="CR54">54</xref>].</p>
        <p>Remodelling deficiencies in the absence of macrophages have been observed in mammary glands, kidney and pancreas, which suggest an important role in morphogenesis; this can be due to the contribution of macrophages to extracellular matrix remodelling and a role in maintenance of the viability and function of stem cells [<xref ref-type="bibr" rid="CR73">73</xref>], as observed in mammary glands and liver.</p>
      </sec>
      <sec id="Sec8">
        <title>Macrophages and erythropoiesis</title>
        <p>Definitive erythropoiesis occurs in the bone marrow; in particular, terminal erythropoiesis takes place in erythroblastic islands where tight clusters can be found between erythroid precursors with a central macrophage [<xref ref-type="bibr" rid="CR8">8</xref>]. Molecules implicated in the interaction between erythroid precursors and macrophages include the erythroblast macrophage protein (Emp), the haemoglobin-haptoglobin receptor CD163, VLA-4 on erythroblasts and VCAM-1 on macrophages, and ICAM-4 on erythroblasts and αV integrin on macrophages. Erythroblastic islands have also been found in areas of definitive haematopoiesis such as foetal liver and splenic red pulp. Macrophages have been shown to promote erythropoiesis through the release of ferritin by exocytosis, which is internalised by erythroblasts where iron is released through acidification and proteolysis [<xref ref-type="bibr" rid="CR15">15</xref>]; factors associated with chronic inflammation such as IFN-ɣ, TNF-α, TGF-β and IL-6 inhibit erythropoiesis [<xref ref-type="bibr" rid="CR15">15</xref>]. Erythropoiesis is completely dependent on the phagocytic activity of macrophages. Macrophages phagocytose extruded erythrocyte nuclei which are released during the final phase of erythrocyte differentiation [<xref ref-type="bibr" rid="CR15">15</xref>]. This is possible through the maintenance of adhesion molecules such as Emp and β1 integrin and exposure of phosphatidyl serine at the surface of the membrane-enveloped nuclei [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
      </sec>
      <sec id="Sec9">
        <title>Macrophages and brain development</title>
        <p>Microglia constitute the resident macrophage population in the brain and spinal cord and are yolk sac-derived. In addition to responding to tissue injury, ramified microglia have been shown to contribute to synaptic maturation during brain development [<xref ref-type="bibr" rid="CR58">58</xref>]. This process is termed “synaptic pruning” and involves the clearance of immature or defective neuronal synapses [<xref ref-type="bibr" rid="CR1">1</xref>]; microglia dysfunction is now considered a major cause of neuropsychiatric or neurological disorders as exemplified by the link between mutations in the gene encoding CSF1R to hereditary diffuse leukoencephalopathy with spheroids [<xref ref-type="bibr" rid="CR1">1</xref>]. Loss of function mutations in TREM-2, a receptor expressed by microglia in the CNS, have been associated with increased risk of developing late-onset Alzheimer’s disease [<xref ref-type="bibr" rid="CR75">75</xref>]. Microglia protect against extension of amyloid fibrils by wrapping around amyloid-β plaques [<xref ref-type="bibr" rid="CR11">11</xref>] and TREM-2 deficiency has been shown to disrupt this process [<xref ref-type="bibr" rid="CR75">75</xref>].</p>
      </sec>
      <sec id="Sec10">
        <title>Macrophages and lung homeostasis</title>
        <p>Alveoli are lined by the alveolar epithelium which is mainly composed of type I and type II alveolar epithelial cells. Type I epithelial cells cover 90% of the alveoli surface while type II epithelial cells are less abundant and mediate the synthesis, secretion and recycling of lung surfactant [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Alveolar surfactant is composed of lipids and proteins and keeps alveoli open by reducing surface tension during breathing. Alveolar macrophages reside in the alveoli and establish close interactions with alveolar epithelial cells, some of which involve interactions such as CD200R-CD200 and CD47-SIPRα as inhibitory receptors. Surfactant proteins A and D also contribute to inhibition of cellular activation in alveolar macrophages by engaging SIRPα [<xref ref-type="bibr" rid="CR37">37</xref>]. Alveolar macrophages are derived from embryonically derived foetal monocytes soon after birth through a process highly dependent on GM-CSF [<xref ref-type="bibr" rid="CR18">18</xref>]. They replicate in situ and, thus, are independent from monocyte input in most instances [<xref ref-type="bibr" rid="CR18">18</xref>]. Alveolar macrophages mediate 20–30% of surfactant lipid metabolism which explains the development of pulmonary alveolar proteinosis in GM-CSF-deficient mice and in mice lacking the ABC transporters (ABC-A1, ABCG1 or peroxisome proliferator-activating receptor gamma (PPAR-ɣ) which display inefficient surfactant catabolism in alveolar macrophages. These same genes are involved in cholesterol metabolism and transport by circulating monocytes and their deficiency has been linked to the development of atherosclerosis [<xref ref-type="bibr" rid="CR46">46</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec11">
      <title>Macrophages and metabolism</title>
      <sec id="Sec12">
        <title>Macrophages and metabolic syndrome</title>
        <p>The involvement of macrophages in metabolic homeostasis was highlighted by major changes in macrophage numbers (10–15 to 45–60% of stromal cells) and phenotype (shift from alternative activation to classical activation) in white adipose tissue in obese insulin-resistant animals and humans [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. These changes have also been observed in other metabolic tissues, liver and muscle, which implies a strong functional link between macrophage phenotype and parameters of tissue homeostasis [<xref ref-type="bibr" rid="CR49">49</xref>]. This is in agreement with macrophages contributing actively to maintenance of tissue homeostasis, but also acting as sensors of tissue dysfunction and promoters of inflammation in the absence of infection. In the case of the metabolic syndrome, the central role of macrophages derives in part from the negative impact of inflammation on signalling events downstream of the insulin receptor, making the cells within metabolic tissues resistant to the action of insulin [<xref ref-type="bibr" rid="CR49">49</xref>]. This effect in turn will lead to maladaptation in glucose metabolism, with increased insulin production by islet cells in the pancreas required to compensate for this inflammation-related effect and establishment of a pre-diabetic state [<xref ref-type="bibr" rid="CR49">49</xref>]. In healthy white adipose tissue, insulin sensitivity in adipocytes is maintained through the action of resident macrophages that express the anti-inflammatory cytokine IL-10 acting as insulin sensitiser. These adipose-tissue macrophages have a phenotype consistent with alternative activation resulting from exposure to IL-4 and IL-13. PPAR-ɣ expression by macrophages is essential for control of alternative activation and improves insulin resistance [<xref ref-type="bibr" rid="CR56">56</xref>]; eosinophils have been identified as the source of IL-4 in adipose tissue and lack of eosinophils has been associated with activation of adipose tissue macrophages and a tendency to develop insulin resistance in response to obesity [<xref ref-type="bibr" rid="CR72">72</xref>]. Changes in macrophage phenotype in white adipose tissue after chronic increase in energy uptake occur in response to metabolic stress in the adipocytes; this leads to the recruitment of inflammatory monocytes by CCL2, CCL5 and CCL8 [<xref ref-type="bibr" rid="CR73">73</xref>]. These inflammatory monocytes differentiate into classically activated macrophages, engulf dying adipocytes and further promote cellular activation. Cytokine production by these activated macrophages is considered major contributors to local and systemic insulin resistance. In the case of hepatic insulin resistance, Kupffer cells regulate the oxidation of fatty acids in hepatocytes; hepatic steatosis develops if Kupffer cells are unable to adopt an alternative activation phenotype because of loss of PPAR-δ in myeloid cells [<xref ref-type="bibr" rid="CR73">73</xref>].</p>
      </sec>
      <sec id="Sec13">
        <title>Macrophages and iron recycling</title>
        <p>Resident bone marrow macrophages and red pulp macrophages are essential for the process of erythrophagocytosis to recycle iron. Senescent or damaged erythrocytes are phagocytosed and digested to extract heme [<xref ref-type="bibr" rid="CR22">22</xref>]. Upon uptake, heme is degraded through the action of heme oxygenase (HO; predominantly HO-1) to release iron into the cytoplasm. Cytoplasmic iron is exported by ferroportin located at the plasma membrane [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Iron flux from macrophages exceeds iron adsorption through diet and iron stored in hepatocytes [<xref ref-type="bibr" rid="CR22">22</xref>]. Intriguingly, heme itself has been shown to induce the development of F4/80<sup>hi</sup>, VCAM<sup>hi</sup> iron recycling macrophages in bone marrow and spleen through induction of the transcription factor Spi-c [<xref ref-type="bibr" rid="CR33">33</xref>]. Red pulp macrophages also express Nramp1 and the haptoglobin-haemoglobin receptor (CD163) which further emphasises their important role in systemic iron haemostasis [<xref ref-type="bibr" rid="CR22">22</xref>]. There are several hypotheses regarding the signals recognised on aged erythrocytes by macrophages for their removal. These signals include the exposure of the universal apoptotic marker phosphatidyl serine in senescent erythrocytes, in spite of the fact that erythrocytes lack a cell nucleus and mitochondria and do not undergo canonical apoptotic process [<xref ref-type="bibr" rid="CR15">15</xref>]. Other possibilities include the loss of CD47 expression, i.e. lack of an inhibitory signal, and conformational changes in CD47 that enable an interaction between CD47 and thrombospondin-1 which results in increased uptake by red pulp macrophages [<xref ref-type="bibr" rid="CR15">15</xref>]. Splenic macrophages have also been implicated in the removal of intracellular inclusions in erythrocytes through a process that leaves the erythrocyte intact. These inclusion bodies are thought to be caused by oxidative damage [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec14">
      <title>Macrophages and tissue regeneration</title>
      <p>Self-contained inflammation with preservation of organ function depends on multifaceted interactions between macrophages and recruited immune cells, particularly neutrophils and monocytes that ensure timely resolution through changes in the activation state of macrophages (from a M1 to a M2-like phenotype). These constitute a “lipid mediator class switch” which shifts the production of lipid mediators from pro-inflammatory (for instance the eicosanoids prostaglandin E2, and leukotriene B4 that promote vasodilatation and chemotaxis) to pro-resolving lipids (such as lipoxins, resolvins, protectins and maresins), production of proteins such as annexin A1, gaseous mediators (carbon monoxide), chemokine inactivation and release of acetylcholine by the vagus nerve [<xref ref-type="bibr" rid="CR34">34</xref>]. Resident macrophages dominate the induction of inflammatory responses in response to injury in the presence and absence of infection through activation of receptors by DAMPs and MAMPs. After stimulation, macrophages produce an array of cytokines such as TNF-α, IL-1β and IL-6 and chemokines as well as pro-inflammatory eicosanoids derived from arachidonic acid, an omega-6 fatty acid. Vasodilation and edema are followed by recruitment of neutrophils which are the first cells that enter the inflamed site. Neutrophil recruitment is favoured by the rapid exposure of P-selectin (CD62P) on activated endothelial cells followed by engagement of β2 integrins by the adhesion molecules ICAM-1 and ICAM-2, culminating in the process of diapedesis. Cues for directional cell migration are provided by the formation of chemokine gradients that guide the migrating neutrophil to the site of injury. Resolution of inflammation is now viewed as an active process and its de-regulation can hamper restoration of tissue function with lack of resolution leading to chronic inflammation and scar formation and fibrosis. The collaborative nature of the resolution process is illustrated by the requirement for transcellular metabolic events between leukocytes and epithelial cells and platelets for the synthesis of lipoxins, the first described pro-resolving lipids. Because of their potential for tissue damage, it appears counterintuitive to consider neutrophils’ essential partners for the resolution of inflammation. However, neutrophils promote resolution by enhancing monocyte recruitment by inducing changes in endothelial cells, for instance through shedding of IL-6Rα which complexes with IL-6. The IL-6Rα-IL-6 complex engages gp130 on endothelial cells and induces the production of E-selectin (CD62E) and VCAM1, thus promoting monocyte recruitment. In addition, apoptotic neutrophils change macrophage activation as uptake of apoptotic neutrophils is non-phlogistic, inducing IL-10, TGF-β and lipoxin synthesis by macrophages [<xref ref-type="bibr" rid="CR66">66</xref>]. These changes are associated with the sensing of an “inflammation threshold” established early during the induction phase and highly dependent on the nature and extent of the original insult. Molecular mechanisms underpinning this concept include the fact that prostaglandin E2 induces changes in the lipoxygenase activity of neutrophils from 5-lipoxygenase to 15-lipoxygenase, required for synthesis of lipoxins [<xref ref-type="bibr" rid="CR34">34</xref>]. During cardiac damage, inflammatory neutrophils and monocytes release oncostatin-M that induces the release by cardiomyocytes of Reg3β. Reg3β promotes the recruitment of reparative macrophages which favours the elimination of neutrophils [<xref ref-type="bibr" rid="CR26">26</xref>]. In addition, macrophages control the neutrophil lifespan through the release of TNF-α, Fas ligand (FasL) and TRAIL [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
      <p>The fate of the recruited monocytes and their contribution to repair depends on the organ and extent of damage. In the heart, recruited monocytes give rise to pro-inflammatory macrophages, while resident macrophages mediate tissue repair. In the spinal cord, both the pro-inflammatory and repair macrophages are monocyte-derived. While the pro-inflammatory macrophages derive from monocytes recruited through the CCR2-CCL2 pathway, repair-promoting macrophages derived from monocytes are recruited through a pathway involving VLA-4, VCAM-1 and CD73 [<xref ref-type="bibr" rid="CR26">26</xref>]. In other scenarios, recruited monocytes have been shown to convert from an initial pro-inflammatory (M1) phenotype to a healing, pro-resolving (M2) phenotype [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR60">60</xref>] consistent with plasticity of myeloid cells. This scenario has been observed in kidney [<xref ref-type="bibr" rid="CR45">45</xref>] and muscle [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
      <p>A key aspect during tissue regeneration and repair is the cross-talk between macrophages and stem cells. For instance, in liver, macrophage depletion has been shown to reduce invasiveness of liver progenitor cells into the parenchyma which is required for differentiation into hepatocytes [<xref ref-type="bibr" rid="CR10">10</xref>]. In addition, macrophages can be induced to produce Wnt3a after uptake of hepatic debris. Wnt3a promotes expression of Numb in liver progenitor cells which inhibits Notch and promotes differentiation into hepatocytes instead of biliary cells [<xref ref-type="bibr" rid="CR10">10</xref>]. Macrophages contribute to muscle regeneration with the sequential change from an early M1-like phenotype into a M2-like phenotype, essential for this process. Disruption of these changes in the phenotype of macrophages by blocking early inflammation (treatment with IL-10 or blocking IFN-ɣ) or late resolution (treatment with anti-IL-10) compromises muscle regeneration. Myogenic precursor cells are stimulated to migrate, grow and survive by macrophages with M1 cells stimulating proliferation and inhibiting fusion and M2 macrophages stimulating commitment of myogenic precursors and differentiation to form myotubes [<xref ref-type="bibr" rid="CR10">10</xref>]. In kidney, macrophages have been found to produce Wnt7b which promotes repair of basement membrane [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
      <p>Scar formation during wound healing can compromise organ function after injury and multiple reports have linked Th2 immunity to the regulation of tissue fibrosis, although the molecular processes of this effect are poorly understood [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. Knipper et al. [<xref ref-type="bibr" rid="CR42">42</xref>] recently revealed an important cross-talk between macrophages and fibroblasts during wound healing in mouse injured skin, required to control the formation of collagen fibrils. This effect is dependent on the expression of IL-4-Rα by myeloid cells which, among others, induces the production of Relm-α, a well-characterised marker of macrophage activation in response to IL-4. IL-4Rα signalling during wound healing promotes the expression of Relm-α by macrophages, and Relm-α, in turn, induces the synthesis of the collagen-modifying enzyme lysyl hydroxylase 2 by fibroblasts, leading to fibrosis [<xref ref-type="bibr" rid="CR42">42</xref>]. In line with the major influence of the tissue environment on macrophage biology, in liver and muscle, Th2 immunity promotes tissue regeneration through direct action on parenchymal cells [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]; this suggests that macrophage contribution to wound healing is largely dependent on the intrinsic regenerative capacity of the tissue and, likely, the nature of the insult.</p>
    </sec>
    <sec id="Sec15">
      <title>Macrophages and thermogenesis</title>
      <p>Brown fat, termed brown adipose tissue, generates heat (thermogenesis) and plays an important role in maintaining body temperature. In contrast to white adipocytes, brown adipocytes contain multilocular fat droplets, a large number of mitochondria, and express high levels of UCP1 (uncoupling protein 1). UCP1 is located in the inner membrane of the mitochondria and uncouples electron transport to promote heat instead of ATP in brown adipocytes. In humans, brown adipose tissue was thought to be restricted to neonates but recent data have shown the presence of brown fat in adults [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Adult human brown fat is dispersed in the supraclavicular, para-aortic and suprarenal regions, is cold-inducible and shares many characteristic with the cold-inducible beige fat found in the subcutaneous white adipose tissue of rodents [<xref ref-type="bibr" rid="CR61">61</xref>]. Beige fat refers to the presence of white adipocytes functionally similar to brown adipocytes within white fat and promotion of beige fat formation is considered as a potential therapeutic tool in the fight against obesity [<xref ref-type="bibr" rid="CR41">41</xref>]. Macrophages have been shown to be essential for adaptation to cold exposure that leads to lipolysis in white fat and thermogenesis in brown fat. The effect of macrophages depends on the acquisition of an alternative activated phenotype driven by lL-4/IL-13 and Stat-6 and that leads to secretion of catecholamines by these cells [<xref ref-type="bibr" rid="CR53">53</xref>]. Indeed, IL-4 exposure of macrophages induces production of the three enzymes required for catecholamine production: tyrosine hydroxylase, dopa decarboxylase and dopamine β-hydroxylase [<xref ref-type="bibr" rid="CR53">53</xref>]; the β3-adrenergic agonist CL-316246 was able to rescue the thermogenic defect in animals unable to produce IL-4 and IL-13 [<xref ref-type="bibr" rid="CR53">53</xref>]. In agreement with these findings in mice, oral administration of the β3-adrenergic receptor agonist mirabegron can stimulate human brown fat thermogenesis in humans [<xref ref-type="bibr" rid="CR13">13</xref>]. Macrophages, together with eosinophils and Th2 cytokines, have also been implicated in the remodelling of subcutaneous white fat into beige fat in mice [<xref ref-type="bibr" rid="CR61">61</xref>].</p>
    </sec>
    <sec id="Sec16">
      <title>Conclusion and therapeutic opportunities</title>
      <p>Macrophages are remarkable for their ability to sense their surroundings, produce a wide range of immune mediators alongside growth factors and opsonins, and their endocytic and phagocytic activity. The recognition of macrophages as intrinsic components of organs, adapted to the particular tissue environment and actively involved in homeostatic processes, opens the opportunity for macrophage-centred therapies that can be exploited to steer pathological processes towards outcomes that favour maintenance of organ function. Furthermore, the potential plasticity shown by these cells [<xref ref-type="bibr" rid="CR44">44</xref>] makes it possible to envisage the possibility of using in vitro-differentiated cells to treat disease by adoptive transfer.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>This article is part of the special issue on macrophages in tissue homeostasis in Pflügers Archiv – European Journal of Physiology</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amit</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis</article-title>
          <source>Nat Immunol</source>
          <year>2016</year>
          <volume>17</volume>
          <fpage>18</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.3325</pub-id>
          <?supplied-pmid 26681458?>
          <pub-id pub-id-type="pmid">26681458</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arandjelovic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ravichandran</surname>
              <given-names>KS</given-names>
            </name>
          </person-group>
          <article-title>Phagocytosis of apoptotic cells in homeostasis</article-title>
          <source>Nat Immunol</source>
          <year>2015</year>
          <volume>16</volume>
          <fpage>907</fpage>
          <lpage>917</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.3253</pub-id>
          <?supplied-pmid 26287597?>
          <pub-id pub-id-type="pmid">26287597</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arnold</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Henry</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Poron</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Baba-Amer</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>van Rooijen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Plonquet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gherardi</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Chazaud</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis</article-title>
          <source>J Exp Med</source>
          <year>2007</year>
          <volume>204</volume>
          <fpage>1057</fpage>
          <lpage>1069</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20070075</pub-id>
          <?supplied-pmid 17485518?>
          <pub-id pub-id-type="pmid">17485518</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bar-Shavit</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell</article-title>
          <source>J Cell Biochem</source>
          <year>2007</year>
          <volume>102</volume>
          <fpage>1130</fpage>
          <lpage>1139</lpage>
          <pub-id pub-id-type="doi">10.1002/jcb.21553</pub-id>
          <?supplied-pmid 17955494?>
          <pub-id pub-id-type="pmid">17955494</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhattacharya</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Westphalen</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Macrophage-epithelial interactions in pulmonary alveoli</article-title>
          <source>Semin Immunopathol</source>
          <year>2016</year>
          <volume>38</volume>
          <fpage>461</fpage>
          <lpage>469</lpage>
          <pub-id pub-id-type="doi">10.1007/s00281-016-0569-x</pub-id>
          <?supplied-pmid 27170185?>
          <pub-id pub-id-type="pmid">27170185</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blander</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Sander</surname>
              <given-names>LE</given-names>
            </name>
          </person-group>
          <article-title>Beyond pattern recognition: five immune checkpoints for scaling the microbial threat</article-title>
          <source>Nat Rev Immunol</source>
          <year>2012</year>
          <volume>12</volume>
          <fpage>215</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3167</pub-id>
          <?supplied-pmid 22362354?>
          <pub-id pub-id-type="pmid">22362354</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Vilalta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fricker</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Phagoptosis—cell death by phagocytosis—plays central roles in physiology, host defense and pathology</article-title>
          <source>Curr Mol Med</source>
          <year>2015</year>
          <volume>15</volume>
          <fpage>842</fpage>
          <lpage>851</lpage>
          <pub-id pub-id-type="doi">10.2174/156652401509151105130628</pub-id>
          <?supplied-pmid 26511705?>
          <pub-id pub-id-type="pmid">26511705</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chasis</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Mohandas</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Erythroblastic islands: niches for erythropoiesis</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>112</volume>
          <fpage>470</fpage>
          <lpage>478</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-03-077883</pub-id>
          <?supplied-pmid 18650462?>
          <pub-id pub-id-type="pmid">18650462</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>YP</given-names>
            </name>
          </person-group>
          <article-title>Macrophage-mediated inflammation in metabolic disease</article-title>
          <source>Nat Rev Immunol</source>
          <year>2011</year>
          <volume>11</volume>
          <fpage>738</fpage>
          <lpage>749</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3071</pub-id>
          <?supplied-pmid 21984069?>
          <pub-id pub-id-type="pmid">21984069</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chazaud</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Macrophages: supportive cells for tissue repair and regeneration</article-title>
          <source>Immunobiology</source>
          <year>2014</year>
          <volume>219</volume>
          <fpage>172</fpage>
          <lpage>178</lpage>
          <pub-id pub-id-type="doi">10.1016/j.imbio.2013.09.001</pub-id>
          <?supplied-pmid 24080029?>
          <pub-id pub-id-type="pmid">24080029</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Condello</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schain</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grutzendler</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques</article-title>
          <source>Nat Commun</source>
          <year>2015</year>
          <volume>6</volume>
          <fpage>6176</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms7176</pub-id>
          <?supplied-pmid 25630253?>
          <pub-id pub-id-type="pmid">25630253</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cypess</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Lehman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tal</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Rodman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Goldfine</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Tseng</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Doria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kolodny</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Identification and importance of brown adipose tissue in adult humans</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>360</volume>
          <fpage>1509</fpage>
          <lpage>1517</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0810780</pub-id>
          <?supplied-pmid 19357406?>
          <pub-id pub-id-type="pmid">19357406</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cypess</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Weiner</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Roberts-Toler</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Franquet Elia</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kessler</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>English</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chatman</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Trauger</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Doria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kolodny</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
          <article-title>Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist</article-title>
          <source>Cell Metab</source>
          <year>2015</year>
          <volume>21</volume>
          <fpage>33</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2014.12.009</pub-id>
          <?supplied-pmid 25565203?>
          <pub-id pub-id-type="pmid">25565203</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Das</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sinha</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Datta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Abas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chaffee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sen</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Monocyte and macrophage plasticity in tissue repair and regeneration</article-title>
          <source>Am J Pathol</source>
          <year>2015</year>
          <volume>185</volume>
          <fpage>2596</fpage>
          <lpage>2606</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajpath.2015.06.001</pub-id>
          <?supplied-pmid 26118749?>
          <pub-id pub-id-type="pmid">26118749</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Back</surname>
              <given-names>DZ</given-names>
            </name>
            <name>
              <surname>Kostova</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>van Kraaij</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>van den Berg</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>van Bruggen</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Of macrophages and red blood cells; a complex love story</article-title>
          <source>Front Physiol</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>9</fpage>
          <?supplied-pmid 24523696?>
          <pub-id pub-id-type="pmid">24523696</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deretic</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Autophagy in leukocytes and other cells: mechanisms, subsystem organization, selectivity, and links to innate immunity</article-title>
          <source>J Leukoc Biol</source>
          <year>2016</year>
          <volume>100</volume>
          <fpage>969</fpage>
          <lpage>978</lpage>
          <pub-id pub-id-type="doi">10.1189/jlb.4MR0216-079R</pub-id>
          <?supplied-pmid 27493243?>
          <pub-id pub-id-type="pmid">27493243</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Donath</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Shoelson</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>Type 2 diabetes as an inflammatory disease</article-title>
          <source>Nat Rev Immunol</source>
          <year>2011</year>
          <volume>11</volume>
          <fpage>98</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="doi">10.1038/nri2925</pub-id>
          <?supplied-pmid 21233852?>
          <pub-id pub-id-type="pmid">21233852</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Epelman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lavine</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Origin and functions of tissue macrophages</article-title>
          <source>Immunity</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>21</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.013</pub-id>
          <?supplied-pmid 25035951?>
          <pub-id pub-id-type="pmid">25035951</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fleming</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Mosser</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Regulatory macrophages: setting the threshold for therapy</article-title>
          <source>Eur J Immunol</source>
          <year>2011</year>
          <volume>41</volume>
          <fpage>2498</fpage>
          <lpage>2502</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.201141717</pub-id>
          <?supplied-pmid 21952805?>
          <pub-id pub-id-type="pmid">21952805</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franchi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kamada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Burberry</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kuffa</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YG</given-names>
            </name>
            <name>
              <surname>Nunez</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense</article-title>
          <source>Nat Immunol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>449</fpage>
          <lpage>456</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2263</pub-id>
          <?supplied-pmid 22484733?>
          <pub-id pub-id-type="pmid">22484733</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freeman</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Goyette</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Furuya</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Woods</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Bertozzi</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Bergmeier</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hinz</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>van der Merwe</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Grinstein</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Integrins form an expanding diffusional barrier that coordinates phagocytosis</article-title>
          <source>Cell</source>
          <year>2016</year>
          <volume>164</volume>
          <fpage>128</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2015.11.048</pub-id>
          <?supplied-pmid 26771488?>
          <pub-id pub-id-type="pmid">26771488</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ganz</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Macrophages and systemic iron homeostasis</article-title>
          <source>J Innate Immun</source>
          <year>2012</year>
          <volume>4</volume>
          <fpage>446</fpage>
          <lpage>453</lpage>
          <pub-id pub-id-type="doi">10.1159/000336423</pub-id>
          <?supplied-pmid 22441209?>
          <pub-id pub-id-type="pmid">22441209</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="other">Gaudet RG, Bradfield CJ, and MacMicking JD 2016 Evolution of cell-autonomous effector mechanisms in macrophages versus non-immune cells. Microbiol Spectr 4</mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gause</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Wynn</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths</article-title>
          <source>Nat Rev Immunol</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>607</fpage>
          <lpage>614</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3476</pub-id>
          <?supplied-pmid 23827958?>
          <pub-id pub-id-type="pmid">23827958</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gautier</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Shay</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Greter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jakubzick</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ivanov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Helft</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Elpek</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Gordonov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mazloom</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Ma'ayan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chua</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Turley</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Immunological</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
          <article-title>Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages</article-title>
          <source>Nat Immunol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>1118</fpage>
          <lpage>1128</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2419</pub-id>
          <?supplied-pmid 23023392?>
          <pub-id pub-id-type="pmid">23023392</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Tissue-resident macrophage ontogeny and homeostasis</article-title>
          <source>Immunity</source>
          <year>2016</year>
          <volume>44</volume>
          <fpage>439</fpage>
          <lpage>449</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.024</pub-id>
          <?supplied-pmid 26982352?>
          <pub-id pub-id-type="pmid">26982352</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goh</surname>
              <given-names>YP</given-names>
            </name>
            <name>
              <surname>Henderson</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Heredia</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Red Eagle</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Odegaard</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Lehwald</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mukundan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Locksley</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Eosinophils secrete IL-4 to facilitate liver regeneration</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2013</year>
          <volume>110</volume>
          <fpage>9914</fpage>
          <lpage>9919</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1304046110</pub-id>
          <?supplied-pmid 23716700?>
          <pub-id pub-id-type="pmid">23716700</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Macrophage heterogeneity and tissue lipids</article-title>
          <source>J Clin Invest</source>
          <year>2007</year>
          <volume>117</volume>
          <fpage>89</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI30992</pub-id>
          <?supplied-pmid 17200712?>
          <pub-id pub-id-type="pmid">17200712</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Phagocytosis: the legacy of Metchnikoff</article-title>
          <source>Cell</source>
          <year>2016</year>
          <volume>166</volume>
          <fpage>1065</fpage>
          <lpage>1068</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2016.08.017</pub-id>
          <?supplied-pmid 27565334?>
          <pub-id pub-id-type="pmid">27565334</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gotts</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Matthay</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Sepsis: pathophysiology and clinical management</article-title>
          <source>BMJ</source>
          <year>2016</year>
          <volume>353</volume>
          <fpage>i1585</fpage>
          <pub-id pub-id-type="doi">10.1136/bmj.i1585</pub-id>
          <?supplied-pmid 27217054?>
          <pub-id pub-id-type="pmid">27217054</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Groves</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dart</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Covarelli</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Caron</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanisms of phagocytic uptake in mammalian cells</article-title>
          <source>Cell Mol Life Sci</source>
          <year>2008</year>
          <volume>65</volume>
          <fpage>1957</fpage>
          <lpage>1976</lpage>
          <pub-id pub-id-type="doi">10.1007/s00018-008-7578-4</pub-id>
          <?supplied-pmid 18322649?>
          <pub-id pub-id-type="pmid">18322649</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Callaway</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Ting</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Inflammasomes: mechanism of action, role in disease, and therapeutics</article-title>
          <source>Nat Med</source>
          <year>2015</year>
          <volume>21</volume>
          <fpage>677</fpage>
          <lpage>687</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.3893</pub-id>
          <?supplied-pmid 26121197?>
          <pub-id pub-id-type="pmid">26121197</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haldar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Origin, development, and homeostasis of tissue-resident macrophages</article-title>
          <source>Immunol Rev</source>
          <year>2014</year>
          <volume>262</volume>
          <fpage>25</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1111/imr.12215</pub-id>
          <?supplied-pmid 25319325?>
          <pub-id pub-id-type="pmid">25319325</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Headland</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Norling</surname>
              <given-names>LV</given-names>
            </name>
          </person-group>
          <article-title>The resolution of inflammation: principles and challenges</article-title>
          <source>Semin Immunol</source>
          <year>2015</year>
          <volume>27</volume>
          <fpage>149</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="doi">10.1016/j.smim.2015.03.014</pub-id>
          <?supplied-pmid 25911383?>
          <pub-id pub-id-type="pmid">25911383</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Helming</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The scavenger receptor CD36 plays a role in cytokine-induced macrophage fusion</article-title>
          <source>J Cell Sci</source>
          <year>2009</year>
          <volume>122</volume>
          <fpage>453</fpage>
          <lpage>459</lpage>
          <pub-id pub-id-type="doi">10.1242/jcs.037200</pub-id>
          <?supplied-pmid 19155290?>
          <pub-id pub-id-type="pmid">19155290</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heredia</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Mukundan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Mueller</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Deo</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Locksley</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Rando</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration</article-title>
          <source>Cell</source>
          <year>2013</year>
          <volume>153</volume>
          <fpage>376</fpage>
          <lpage>388</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2013.02.053</pub-id>
          <?supplied-pmid 23582327?>
          <pub-id pub-id-type="pmid">23582327</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hussell</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>TJ</given-names>
            </name>
          </person-group>
          <article-title>Alveolar macrophages: plasticity in a tissue-specific context</article-title>
          <source>Nat Rev Immunol</source>
          <year>2014</year>
          <volume>14</volume>
          <fpage>81</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3600</pub-id>
          <?supplied-pmid 24445666?>
          <pub-id pub-id-type="pmid">24445666</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <mixed-citation publication-type="other">Janssen WJ, Bratton DL, Jakubzick CV, and Henson PM 2016 Myeloid Cell Turnover and Clearance. Microbiol Spectr 4</mixed-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <mixed-citation publication-type="other">Jaumouille V, and Grinstein S 2016 Molecular mechanisms of phagosome formation. Microbiol Spectr 4</mixed-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaur</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Salek-Ardakani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hussell</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Macrophage adaptation in airway inflammatory resolution</article-title>
          <source>Eur Respir Rev</source>
          <year>2015</year>
          <volume>24</volume>
          <fpage>510</fpage>
          <lpage>515</lpage>
          <pub-id pub-id-type="doi">10.1183/16000617.0030-2015</pub-id>
          <?supplied-pmid 26324813?>
          <pub-id pub-id-type="pmid">26324813</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Plutzky</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Brown fat and browning for the treatment of obesity and related metabolic disorders</article-title>
          <source>Diabetes Metab J</source>
          <year>2016</year>
          <volume>40</volume>
          <fpage>12</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.4093/dmj.2016.40.1.12</pub-id>
          <?supplied-pmid 26912151?>
          <pub-id pub-id-type="pmid">26912151</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Knipper</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Willenborg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brinckmann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bloch</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Maass</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wagener</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Krieg</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sutherland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Munitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rothenberg</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Niehoff</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Richardson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hammerschmidt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Eming</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-4 receptor alpha signaling in myeloid cells controls collagen fibril assembly in skin repair</article-title>
          <source>Immunity</source>
          <year>2015</year>
          <volume>43</volume>
          <fpage>803</fpage>
          <lpage>816</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2015.09.005</pub-id>
          <?supplied-pmid 26474656?>
          <pub-id pub-id-type="pmid">26474656</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lambeth</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>NOX enzymes and the biology of reactive oxygen</article-title>
          <source>Nat Rev Immunol</source>
          <year>2004</year>
          <volume>4</volume>
          <fpage>181</fpage>
          <lpage>189</lpage>
          <pub-id pub-id-type="doi">10.1038/nri1312</pub-id>
          <?supplied-pmid 15039755?>
          <pub-id pub-id-type="pmid">15039755</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lavin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Blecher-Gonen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Keren-Shaul</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Amit</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>159</volume>
          <fpage>1312</fpage>
          <lpage>1326</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2014.11.018</pub-id>
          <?supplied-pmid 25480296?>
          <pub-id pub-id-type="pmid">25480296</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Huen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nishio</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nishio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Ruhrberg</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cantley</surname>
              <given-names>LG</given-names>
            </name>
          </person-group>
          <article-title>Distinct macrophage phenotypes contribute to kidney injury and repair</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2011</year>
          <volume>22</volume>
          <fpage>317</fpage>
          <lpage>326</lpage>
          <pub-id pub-id-type="doi">10.1681/ASN.2009060615</pub-id>
          <?supplied-pmid 21289217?>
          <pub-id pub-id-type="pmid">21289217</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <mixed-citation publication-type="other">Lopez-Rodriguez E, Gay-Jordi G, Mucci A, Lachmann N, Serrano-Mollar A 2016 Lung surfactant metabolism: early in life, early in disease and target in cell therapy. Cell Tissue Res</mixed-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martinez</surname>
              <given-names>FO</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The M1 and M2 paradigm of macrophage activation: time for reassessment</article-title>
          <source>F1000Prime Rep</source>
          <year>2014</year>
          <volume>6</volume>
          <fpage>13</fpage>
          <pub-id pub-id-type="doi">10.12703/P6-13</pub-id>
          <?supplied-pmid 24669294?>
          <pub-id pub-id-type="pmid">24669294</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martinez</surname>
              <given-names>FO</given-names>
            </name>
            <name>
              <surname>Helming</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Milde</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Varin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Melgert</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Draijer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fabbri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Crawshaw</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Ten Hacken</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Cobos Jimenez</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kootstra</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Hamann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Greaves</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Locati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences</article-title>
          <source>Blood</source>
          <year>2013</year>
          <volume>121</volume>
          <fpage>e57</fpage>
          <lpage>e69</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2012-06-436212</pub-id>
          <?supplied-pmid 23293084?>
          <pub-id pub-id-type="pmid">23293084</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McNelis</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Olefsky</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Macrophages, immunity, and metabolic disease</article-title>
          <source>Immunity</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>36</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2014.05.010</pub-id>
          <?supplied-pmid 25035952?>
          <pub-id pub-id-type="pmid">25035952</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mosser</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Exploring the full spectrum of macrophage activation</article-title>
          <source>Nat Rev Immunol</source>
          <year>2008</year>
          <volume>8</volume>
          <fpage>958</fpage>
          <lpage>969</lpage>
          <pub-id pub-id-type="doi">10.1038/nri2448</pub-id>
          <?supplied-pmid 19029990?>
          <pub-id pub-id-type="pmid">19029990</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muller</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Steinman</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>ZA</given-names>
            </name>
          </person-group>
          <article-title>Membrane proteins of the vacuolar system. III. Further studies on the composition and recycling of endocytic vacuole membrane in cultured macrophages</article-title>
          <source>J Cell Biol</source>
          <year>1983</year>
          <volume>96</volume>
          <fpage>29</fpage>
          <lpage>36</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.96.1.29</pub-id>
          <?supplied-pmid 6826650?>
          <pub-id pub-id-type="pmid">6826650</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Biswas</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Gilroy</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Goerdt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Ivashkiv</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Locati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>FO</given-names>
            </name>
            <name>
              <surname>Mege</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Mosser</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Natoli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Saeij</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Schultze</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Shirey</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Sica</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Suttles</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Udalova</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>van Ginderachter</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Wynn</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Macrophage activation and polarization: nomenclature and experimental guidelines</article-title>
          <source>Immunity</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>14</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.008</pub-id>
          <?supplied-pmid 25035950?>
          <pub-id pub-id-type="pmid">25035950</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nguyen</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>YP</given-names>
            </name>
            <name>
              <surname>Mwangi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mukundan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Brombacher</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Locksley</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis</article-title>
          <source>Nature</source>
          <year>2011</year>
          <volume>480</volume>
          <fpage>104</fpage>
          <lpage>108</lpage>
          <pub-id pub-id-type="doi">10.1038/nature10653</pub-id>
          <?supplied-pmid 22101429?>
          <pub-id pub-id-type="pmid">22101429</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niida</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kaku</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Amano</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kataoka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nishikawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tanne</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nishikawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kodama</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption</article-title>
          <source>J Exp Med</source>
          <year>1999</year>
          <volume>190</volume>
          <fpage>293</fpage>
          <lpage>298</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.190.2.293</pub-id>
          <?supplied-pmid 10432291?>
          <pub-id pub-id-type="pmid">10432291</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Neill</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>EJ</given-names>
            </name>
          </person-group>
          <article-title>Immunometabolism governs dendritic cell and macrophage function</article-title>
          <source>J Exp Med</source>
          <year>2016</year>
          <volume>213</volume>
          <fpage>15</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20151570</pub-id>
          <?supplied-pmid 26694970?>
          <pub-id pub-id-type="pmid">26694970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Odegaard</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Ricardo-Gonzalez</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Goforth</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Morel</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Subramanian</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Mukundan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Red Eagle</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vats</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brombacher</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ferrante</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance</article-title>
          <source>Nature</source>
          <year>2007</year>
          <volume>447</volume>
          <fpage>1116</fpage>
          <lpage>1120</lpage>
          <pub-id pub-id-type="doi">10.1038/nature05894</pub-id>
          <?supplied-pmid 17515919?>
          <pub-id pub-id-type="pmid">17515919</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olefsky</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Glass</surname>
              <given-names>CK</given-names>
            </name>
          </person-group>
          <article-title>Macrophages, inflammation, and insulin resistance</article-title>
          <source>Annu Rev Physiol</source>
          <year>2010</year>
          <volume>72</volume>
          <fpage>219</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev-physiol-021909-135846</pub-id>
          <?supplied-pmid 20148674?>
          <pub-id pub-id-type="pmid">20148674</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paolicelli</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Bolasco</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pagani</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Maggi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scianni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Panzanelli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Giustetto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Guiducci</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dumas</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ragozzino</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>Synaptic pruning by microglia is necessary for normal brain development</article-title>
          <source>Science</source>
          <year>2011</year>
          <volume>333</volume>
          <fpage>1456</fpage>
          <lpage>1458</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1202529</pub-id>
          <?supplied-pmid 21778362?>
          <pub-id pub-id-type="pmid">21778362</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pastores</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Non-neuronopathic lysosomal storage disorders: disease spectrum and treatments</article-title>
          <source>Best Pract Res Clin Endocrinol Metab</source>
          <year>2015</year>
          <volume>29</volume>
          <fpage>173</fpage>
          <lpage>182</lpage>
          <pub-id pub-id-type="doi">10.1016/j.beem.2014.08.005</pub-id>
          <?supplied-pmid 25987171?>
          <pub-id pub-id-type="pmid">25987171</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Porcheray</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Viaud</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rimaniol</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Leone</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Samah</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dereuddre-Bosquet</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Dormont</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gras</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Macrophage activation switching: an asset for the resolution of inflammation</article-title>
          <source>Clin Exp Immunol</source>
          <year>2005</year>
          <volume>142</volume>
          <fpage>481</fpage>
          <lpage>489</lpage>
          <?supplied-pmid 16297160?>
          <pub-id pub-id-type="pmid">16297160</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qiu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Odegaard</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Locksley</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Palmiter</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>157</volume>
          <fpage>1292</fpage>
          <lpage>1308</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2014.03.066</pub-id>
          <?supplied-pmid 24906148?>
          <pub-id pub-id-type="pmid">24906148</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheikh</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Dickensheets</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pedras-Vasconcelos</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ramalingam</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Helming</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Donnelly</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
          <article-title>The interleukin-13 receptor-alpha1 chain is essential for induction of the alternative macrophage activation pathway by IL-13 but not IL-4</article-title>
          <source>J Innate Immun</source>
          <year>2015</year>
          <volume>7</volume>
          <fpage>494</fpage>
          <lpage>505</lpage>
          <pub-id pub-id-type="doi">10.1159/000376579</pub-id>
          <?supplied-pmid 25766112?>
          <pub-id pub-id-type="pmid">25766112</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sieweke</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Beyond stem cells: self-renewal of differentiated macrophages</article-title>
          <source>Science</source>
          <year>2013</year>
          <volume>342</volume>
          <fpage>1242974</fpage>
          <pub-id pub-id-type="doi">10.1126/science.1242974</pub-id>
          <?supplied-pmid 24264994?>
          <pub-id pub-id-type="pmid">24264994</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sims</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>NC</given-names>
            </name>
          </person-group>
          <article-title>Intercellular cross-talk among bone cells: new factors and pathways</article-title>
          <source>Curr Osteoporos Rep</source>
          <year>2012</year>
          <volume>10</volume>
          <fpage>109</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="doi">10.1007/s11914-012-0096-1</pub-id>
          <?supplied-pmid 22427140?>
          <pub-id pub-id-type="pmid">22427140</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smythies</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Mosteller-Barnum</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Orenstein</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>PD</given-names>
            </name>
          </person-group>
          <article-title>Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity</article-title>
          <source>J Clin Invest</source>
          <year>2005</year>
          <volume>115</volume>
          <fpage>66</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200519229</pub-id>
          <?supplied-pmid 15630445?>
          <pub-id pub-id-type="pmid">15630445</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soehnlein</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Lindbom</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Phagocyte partnership during the onset and resolution of inflammation</article-title>
          <source>Nat Rev Immunol</source>
          <year>2010</year>
          <volume>10</volume>
          <fpage>427</fpage>
          <lpage>439</lpage>
          <pub-id pub-id-type="doi">10.1038/nri2779</pub-id>
          <?supplied-pmid 20498669?>
          <pub-id pub-id-type="pmid">20498669</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <mixed-citation publication-type="other">Teti G, Biondo C, and Beninati C 2016. The phagocyte, Metchnikoff, and the foundation of immunology. Microbiol Spectr 4</mixed-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van de Veerdonk</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Dinarello</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Deficient autophagy unravels the ROS paradox in chronic granulomatous disease</article-title>
          <source>Autophagy</source>
          <year>2014</year>
          <volume>10</volume>
          <fpage>1141</fpage>
          <lpage>1142</lpage>
          <pub-id pub-id-type="doi">10.4161/auto.28638</pub-id>
          <?supplied-pmid 24879159?>
          <pub-id pub-id-type="pmid">24879159</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Marken Lichtenbelt</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Vanhommerig</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Smulders</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Drossaerts</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kemerink</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Bouvy</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Schrauwen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Teule</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Cold-activated brown adipose tissue in healthy men</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>360</volume>
          <fpage>1500</fpage>
          <lpage>1508</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0808718</pub-id>
          <?supplied-pmid 19357405?>
          <pub-id pub-id-type="pmid">19357405</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vance</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Isberg</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Portnoy</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system</article-title>
          <source>Cell Host Microbe</source>
          <year>2009</year>
          <volume>6</volume>
          <fpage>10</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chom.2009.06.007</pub-id>
          <?supplied-pmid 19616762?>
          <pub-id pub-id-type="pmid">19616762</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vieira</surname>
              <given-names>OV</given-names>
            </name>
            <name>
              <surname>Botelho</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Grinstein</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Phagosome maturation: aging gracefully</article-title>
          <source>Biochem J</source>
          <year>2002</year>
          <volume>366</volume>
          <fpage>689</fpage>
          <lpage>704</lpage>
          <pub-id pub-id-type="doi">10.1042/bj20020691</pub-id>
          <?supplied-pmid 12061891?>
          <pub-id pub-id-type="pmid">12061891</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Molofsky</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Ricardo-Gonzalez</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Jouihan</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Bando</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Locksley</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis</article-title>
          <source>Science</source>
          <year>2011</year>
          <volume>332</volume>
          <fpage>243</fpage>
          <lpage>247</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1201475</pub-id>
          <?supplied-pmid 21436399?>
          <pub-id pub-id-type="pmid">21436399</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wynn</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pollard</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Macrophage biology in development, homeostasis and disease</article-title>
          <source>Nature</source>
          <year>2013</year>
          <volume>496</volume>
          <fpage>445</fpage>
          <lpage>455</lpage>
          <pub-id pub-id-type="doi">10.1038/nature12034</pub-id>
          <?supplied-pmid 23619691?>
          <pub-id pub-id-type="pmid">23619691</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wynn</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Ramalingam</surname>
              <given-names>TR</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of fibrosis: therapeutic translation for fibrotic disease</article-title>
          <source>Nat Med</source>
          <year>2012</year>
          <volume>18</volume>
          <fpage>1028</fpage>
          <lpage>1040</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.2807</pub-id>
          <?supplied-pmid 22772564?>
          <pub-id pub-id-type="pmid">22772564</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yuan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Condello</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Keene</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Bird</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Colonna</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Baddeley</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Grutzendler</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy</article-title>
          <source>Neuron</source>
          <year>2016</year>
          <volume>92</volume>
          <fpage>252</fpage>
          <lpage>264</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuron.2016.09.016</pub-id>
          <?supplied-pmid 27710785?>
          <pub-id pub-id-type="pmid">27710785</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362659</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id>
      <journal-title-group>
        <journal-title>Psychopharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0033-3158</issn>
      <issn pub-type="epub">1432-2072</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362659</article-id>
      <article-id pub-id-type="pmcid">PMC5362659</article-id>
      <article-id pub-id-type="pmc-uid">5362659</article-id>
      <article-id pub-id-type="pmid">28214996</article-id>
      <article-id pub-id-type="publisher-id">4564</article-id>
      <article-id pub-id-type="doi">10.1007/s00213-017-4564-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Investigation</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Alcohol-induced retrograde facilitation renders witnesses of crime less suggestible to misinformation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Gawrylowicz</surname>
            <given-names>Julie</given-names>
          </name>
          <address>
            <email>julie.gawrylowicz@gcu.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ridley</surname>
            <given-names>Anne M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Albery</surname>
            <given-names>Ian P.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barnoth</surname>
            <given-names>Edit</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Young</surname>
            <given-names>Jack</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0669 8188</institution-id><institution-id institution-id-type="GRID">grid.5214.2</institution-id><institution>Department of Psychology, School of Health and Life Sciences, </institution><institution>Glasgow Caledonian University, </institution></institution-wrap>Cowcaddens Road, Glasgow, Scotland G4 0BA UK </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2112 2291</institution-id><institution-id institution-id-type="GRID">grid.4756.0</institution-id><institution>Division of Psychology, School of Applied Sciences, </institution><institution>London South Bank University, </institution></institution-wrap>103 Borough Road, London, SE1 0AA UK </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>19</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>234</volume>
      <issue>8</issue>
      <fpage>1267</fpage>
      <lpage>1275</lpage>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>6</day>
          <month>2</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Rationale</title>
          <p>Research has shown that alcohol can have both detrimental and facilitating effects on memory: intoxication can lead to poor memory for information encoded <italic>after</italic> alcohol consumption (anterograde amnesia) and may improve memory for information encoded <italic>before</italic> consumption (retrograde facilitation). This study examined whether alcohol consumed <italic>after</italic> witnessing a crime can render individuals less vulnerable to misleading post-event information (misinformation).</p>
        </sec>
        <sec>
          <title>Method</title>
          <p>Participants watched a simulated crime video. Thereafter, one third of participants expected and received alcohol (alcohol group), one third did not expect but received alcohol (reverse placebo), and one third did not expect nor receive alcohol (control). After alcohol consumption, participants were exposed to misinformation embedded in a written narrative about the crime. The following day, participants completed a cued-recall questionnaire about the event.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Control participants were more likely to report misinformation compared to the alcohol and reverse placebo group.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>The findings suggest that we may oversimplify the effect alcohol has on suggestibility and that sometimes alcohol can have beneficial effects on eyewitness memory by protecting against misleading post-event information.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Eyewitness memory</kwd>
        <kwd>Suggestibility</kwd>
        <kwd>Alcohol</kwd>
        <kwd>Retrograde facilitation</kwd>
        <kwd>Interference</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>Glasgow Caledonian University</institution>
          </funding-source>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer-Verlag Berlin Heidelberg 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>According to the British Crime Survey (data from 2012/13 and 2013/14 combined), 70% of “public space” violent incidents were alcohol-related and 93% of those occurred in pubs, bars, and clubs where alcohol is sold and consumed (Office for National Statistics <xref ref-type="bibr" rid="CR25">2015</xref>). Evans et al. (<xref ref-type="bibr" rid="CR8">2009</xref>) note that many witnesses are intoxicated either at the time of a crime, when interviewed or both. Given these numbers, studies have explored the effects of alcohol on various aspects of eyewitness memory including free recall, cued recall and line-up performance with generally detrimental (Crossland et al. <xref ref-type="bibr" rid="CR5">2016</xref>; Dysart et al. <xref ref-type="bibr" rid="CR7">2002</xref>; Van Oorsouw and Merckelbach <xref ref-type="bibr" rid="CR36">2012</xref>; Yuille and Tollestrup <xref ref-type="bibr" rid="CR43">1990</xref>) or null effects of alcohol consumption on memory (Hagsand et al. <xref ref-type="bibr" rid="CR13">2013</xref>; Harvey et al. <xref ref-type="bibr" rid="CR14">2013</xref>; Schreiber Compo et al. <xref ref-type="bibr" rid="CR33">2012</xref>). It should be noted that some of these studies obtained fairly low levels of intoxication with their participants and probably underestimated the detrimental effect of alcohol on memory performance. Amongst laboratory studies, the highest peak BAC was .20% (Dysart et al. <xref ref-type="bibr" rid="CR7">2002</xref>) and the smallest peak BAC was .09% (Hagsand et al. <xref ref-type="bibr" rid="CR13">2013</xref>). Low peak BACs ranged from .03% to .05% (Crossland et al. <xref ref-type="bibr" rid="CR5">2016</xref>; Harvey et al. <xref ref-type="bibr" rid="CR14">2013</xref>, respectively). In field studies by Van Oorsouw and Merckelbach (<xref ref-type="bibr" rid="CR36">2012</xref>) and Van Oorsouw et al. (<xref ref-type="bibr" rid="CR37">2015</xref>) slightly higher peak BACs of .24% and .26% were obtained. It could be argued that negative effects of alcohol on eyewitness memory performance might be even more pronounced when higher intoxication levels are present, however, due to ethical reasons this is often not achievable in laboratory studies. Recent research, for example by Crossland et al. (<xref ref-type="bibr" rid="CR5">2016</xref>), Hagsand et al. (<xref ref-type="bibr" rid="CR13">2013</xref>), Van Oorsouw and Merckelbach (<xref ref-type="bibr" rid="CR36">2012</xref>) and Van Oorsouw et al. (<xref ref-type="bibr" rid="CR37">2015</xref>) have managed to reach higher BAC levels, which should not be underestimated.</p>
    <p>Only a few studies to date have examined the relationship between alcohol and suggestibility (Santtila et al. <xref ref-type="bibr" rid="CR30">1998</xref>, <xref ref-type="bibr" rid="CR31">1999</xref>; Schreiber Compo et al. <xref ref-type="bibr" rid="CR33">2012</xref>; Van Oorsouw et al. <xref ref-type="bibr" rid="CR37">2015</xref>). Suggestibility in eyewitnesses is the remembering or reporting of erroneous details about an event either in response to incorrectly leading questions (<italic>immediate</italic> suggestibility) or through exposure to incorrect information about the event that is later recalled (<italic>delayed</italic> suggestibility) (Ridley and Gudjonsson <xref ref-type="bibr" rid="CR29">2013</xref>; Schooler and Loftus <xref ref-type="bibr" rid="CR32">1993</xref>). For example, Van Oorsouw et al. (<xref ref-type="bibr" rid="CR37">2015</xref>) approached sober (BACs &lt;.02%; <italic>M</italic>
<sub>BAC</sub> = 0.01%, <italic>SD</italic> = 0.01), moderately intoxicated (BACs between .02% and .11%; <italic>M</italic>
<sub>BAC</sub> = 0.06%, <italic>SD</italic> = 0.02) or severely intoxicated (BACs &gt; .11%; <italic>M</italic>
<sub>BAC</sub> = 0.16%, <italic>SD</italic> = 0.04) participants drinking in a bar and required them to commit a mock crime. In subsequent interviews (which included 15 incorrectly leading questions), those who were severely intoxicated were more suggestible to the leading questions than those who were sober. Conversely, Schreiber Compo et al. (<xref ref-type="bibr" rid="CR33">2012</xref>), using a delayed rather than immediate suggestibility paradigm in a laboratory environment, found no difference between intoxicated (<italic>M</italic>
<sub>BAC</sub> = .07, <italic>SD</italic> = .02), placebo and control participants on the level of suggestibility. Importantly, in both studies, participants were intoxicated <italic>before</italic> witnessing the crime.</p>
    <p>Santtila et al. (<xref ref-type="bibr" rid="CR30">1998</xref>, <xref ref-type="bibr" rid="CR31">1999</xref>) explored the effect of alcohol on immediate suggestibility using the Gudjonsson Suggestibility Scale 2 (GSS2, Gudjonsson <xref ref-type="bibr" rid="CR12">1997</xref>). Participants received a high (1.32 ml of 95% alcohol per kg of body weight), medium (.66 ml of 95% alcohol per kg of body weight) or low dose of alcohol (.132 ml of 95% alcohol per kg of body weight), or a placebo drink. No BAC readings were taken after alcohol administration. Alcohol, when administered <italic>after</italic> the to-be-remembered narrative, appeared to protect participants from the negative effect of incorrectly leading questions. There was no effect when these questions were repeated following negative feedback. Santtila et al. (<xref ref-type="bibr" rid="CR30">1998</xref>, <xref ref-type="bibr" rid="CR31">1999</xref>) argued that individual differences in emotions (e.g., anger and guilt) and personality (e.g., acquiescence and trait-anxiety) might be responsible for decreased suggestibility scores before negative feedback. However, personality and emotions did not moderate the effects of alcohol on suggestibility. These findings may reflect what Wixted (<xref ref-type="bibr" rid="CR41">2004</xref>) called the “curious phenomenon of retrograde facilitation” (p. 254). Retrograde facilitation refers to memories being enhanced if they are formed prior to intoxication. One explanation for this twisted effect is that alcohol protects already formed memories by reducing new memory formation (Wixted <xref ref-type="bibr" rid="CR42">2005</xref>). That alcohol and benzodiazepines, if consumed prior to learning, can induce temporary anterograde amnesia to a point where individuals do not remember anything at all—alcoholic “blackout”—is well known (see Wetherill and Fromme <xref ref-type="bibr" rid="CR40">2016</xref> for a review). However, these drugs may have a positive effect on memories formed prior to consumption by protecting them against any new incoming information, thereby reducing retrograde interference (Wixted <xref ref-type="bibr" rid="CR42">2005</xref>). It could be argued that this protective function may therefore lead to improved memory even in the absence of a direct interference task by reducing nonspecific interference and thereby protecting still fragile recently formed memories.</p>
    <p>Evidence for this approach comes from several psychological experiments. For example, Parker et al. (<xref ref-type="bibr" rid="CR27">1980</xref>) tested participants’ memory for scenic slides and found that having had alcohol (mean peak BAC = .08%) after learning significantly improved participants’ recognition performance. Similarly, Moulton et al. (<xref ref-type="bibr" rid="CR23">2005</xref>) found that although memory for prose learned while participants were intoxicated (mean peak BAC = .08%) was poor compared to sober controls, the opposite was found for prose learned prior to intoxication. The diphasic effect of alcohol on memory performance has been found with emotional (Bruce and Pihl <xref ref-type="bibr" rid="CR3">1997</xref>; <italic>M</italic>
<sub>BAC</sub> = .06%), neutral, and alcohol-related stimuli (Weafer et al. <xref ref-type="bibr" rid="CR38">2016a</xref>, <xref ref-type="bibr" rid="CR39">b</xref>; peak BAC = .08%). Thus, alcohol seems to impair subsequent recall of information encoded when intoxicated but facilitates recall of material encountered prior to intoxication due to minimizing general new memory formation (Wixted <xref ref-type="bibr" rid="CR42">2005</xref>). The diphasic effect of alcohol on memory performance could have important implications for forensic settings. That is, alcohol may not always render witnesses and victims to crime less reliable, but it depends on the timing of the incident and the alcohol consumption. For example, an individual might observe something in a club or pub prior to consuming any alcohol, and not realize that this will later form a crucial detail during a criminal investigation. Oblivious to the fact that he/she will become a witness, the individual might then consume alcohol during the remaining course of the evening. It could be argued that in such a scenario, this witness will be less susceptible to the incorporation of misinformation than an individual who remained sober.</p>
    <p>The present study used a delayed misinformation paradigm to explore the effects of alcohol administered <italic>after</italic> a witnessed event but <italic>prior</italic> to exposure to misleading information. The misinformation paradigm is a popular task to study false memories and suggestibility and findings have important implications for situations such as eyewitness testimony and investigative interviewing. For instance, Loftus et al. (<xref ref-type="bibr" rid="CR19">1978</xref>) found that information presented after an event can influence individuals’ memory for that event. In a series of experiments depicting an auto-pedestrian accident, participants who had initially seen a stop sign, later reported having seen a yield sign after having been exposed to misleading information. Since then, the misinformation effect has been examined with various stimuli and under a variety of conditions and researchers were even able to induce very rich false memories, such as having attended a hospital appointment (Ost et al. <xref ref-type="bibr" rid="CR26">2005</xref>) or committing a crime (Shaw and Porter <xref ref-type="bibr" rid="CR34">2015</xref>) (see Loftus <xref ref-type="bibr" rid="CR18">2005</xref> for a review).</p>
    <p>In the present experiment, alcohol was administered <italic>after</italic> witnessing a crime but <italic>prior</italic> to the presentation of misinformation. Cued recall was used to test suggestibility 24 h later when participants were sober again. To enable us to separate the physiological and psychological expectancy effects of alcohol on suggestibility a <italic>reverse</italic> placebo treatment condition (participants were told they would not receive alcohol when in fact they did) was included. This is fundamental given the significant body of work demonstrating that alcohol-outcome expectancies can influence different behaviors and cognitions (Moss and Albery <xref ref-type="bibr" rid="CR22">2009</xref>), such as impulsivity (Caswell et al. <xref ref-type="bibr" rid="CR4">2013</xref>), sexual risk taking (Maisto et al. <xref ref-type="bibr" rid="CR20">2012</xref>), self-perception (Bègue et al. <xref ref-type="bibr" rid="CR1">2013</xref>), motor performance (Fillmore and Vogel-Sprott <xref ref-type="bibr" rid="CR9">1995</xref>), and speed of processing (Fillmore et al. <xref ref-type="bibr" rid="CR10">1998</xref>), even in the absence of alcohol consumption.</p>
    <sec id="Sec1">
      <title>Method</title>
      <sec id="Sec2">
        <title>Participants and design</title>
        <p>Eighty-three participants (students and staff from London South Bank University) (60 females, 23 males) aged 18 to 58 years (<italic>M</italic> = 27.38, <italic>SD</italic> = 9.45) took part in the study. One participant did not return to the second session. Participants either received course credits or a small monetary reward for their participation. Each individual completed a comprehensive screening process to establish their eligibility to participate. Age, weight, height, previous drinking history, and any medical conditions were established to ensure it was safe for them to consume alcohol. The experiment followed a 3 × 2 mixed design. The between-subjects factor was condition: alcohol, control, and reverse placebo. The within-subjects factor was item type: control vs. misled. That is all participants were exposed to misleading and control items and had to subsequently answer questions relating to these items. The study was approved by the London South Bank University’s Ethics Committee.</p>
      </sec>
      <sec id="Sec3">
        <title>Materials</title>
        <sec id="FPar1">
          <title>Breath alcohol measurement</title>
          <p>Breath alcohol content (BrAC) was measured with a Lion Alcolmeter 500 breathalyzer. This instrument was checked with an alcohol standard at regular intervals, and recalibrated if required. Participants’ BrAC was subsequently converted into BAC (blood alcohol contents) with the Lion Units Converter.</p>
        </sec>
        <sec id="FPar2">
          <title>Crime event</title>
          <p>The event was a video-recorded staged non-violent crime depicting a distractor burglary. The video footage showed two people, a man and a woman, entering a house and conducting a survey with the homeowner in the living room. After a few minutes, the homeowner went into the kitchen to make some tea. In the mean time, the woman went upstairs into a room and stole some jewelry, while the man stole some money and a laptop from the living room. The robbers then swiftly left the property. The homeowner retuned from the kitchen and ran after the thieves after he realized that he has been robbed. The event was 4 min and 25 s long.</p>
        </sec>
        <sec id="FPar3">
          <title>Post-event information (PEI) and memory test</title>
          <p>Pilot testing was conducted to ensure that memory for each critical detail was reasonable and the misleading suggestions were seen as plausible. Twenty-nine participants, comprising of University students and staff (<italic>M</italic>
<sub>age</sub> = 30.06, <italic>SD</italic> = 9.11, 16 females), watched the video clip and then completed a cued recall test immediately. Only items that were remembered more often than 40% and less than 90% of the time were selected as potential critical items. Next, participants were presented with a multiple-choice test including the correct answer to the previously presented cued recall test and three alternative answers. Participants were asked to circle the option that was actually presented in the video clip and to rate the plausibility of each other alternative on a 1 (highly implausible) to 7 (highly plausible) scale. Items with mean plausibility ratings of 2–6 were included as the misleading details. This was done to ensure that misinformation items were not completely implausible and therefore directly rejected by participants. Similarly, it was important to ensure that misinformation items were not too plausible and therefore more likely to be accepted by participants than original items (a similar procedure was used by Horry et al. <xref ref-type="bibr" rid="CR16">2014</xref>). The mean plausibility rating for misleading items was 4.14 (SD = 1.34). After pilot testing, 10 items (out of 30) were selected as critical items.</p>
          <p>The PEI was presented in a 330-word narrative. Two versions of the narrative were created (versions A and B). Each version included five misleading items. The five misleading items for half of the participants served as control items for the other half of participants in order to give an indication of the extent to which PEI is recounted by chance. Most of the control items were not mentioned in the narrative or were mentioned only in a neutral form (as in Horry et al. <xref ref-type="bibr" rid="CR16">2014</xref>). For example, in version A, participants read the misinformation that the victim was wearing a <italic>green</italic> fleece jumper (misleading item), whereas in version B the victim was only described as wearing a fleece jumper (control item), in the original video footage the jumper was <italic>blue</italic>.</p>
          <p>The cued recall memory test consisted of 10 questions—five enquiring about misleading items and five about control items. For example, “What was the colour of the victims jumper?” or “What did the female perpetrator carry?”. Underneath each question was some space for participants to provide their answer. Underneath the space for the answer was a confidence rating scale ranging from 0% (not very confident at all) to 100% (very confident).</p>
        </sec>
      </sec>
      <sec id="Sec4">
        <title>Procedure</title>
        <p>The study consisted of two sessions separated by one day. Participants took part individually. During the first session, participants watched the staged crime video. They were told to pay close attention. Subsequently, participants were randomly assigned to one of three conditions—received alcohol (Beck’s lager) and expected alcohol (alcohol condition, <italic>N</italic> = 28), received alcohol (Beck’s lager) and did not expect alcohol (participants were told they received Beck’s Blue, an alcohol-free lager) (reverse placebo condition, <italic>N</italic> = 28) and received no alcohol (Beck’s Blue) and expected no alcohol (control condition, <italic>N</italic> = 27). Participants’ gender, height, and weight were used to calculate the required dose with the Curtin’s Blood Alcohol Calculator to achieve a peak BAC of approximately 0.06% (Curtin <xref ref-type="bibr" rid="CR6">2000</xref>). All drinks were poured out of sight of the participants. On being handed their beverage, participants were told to consume their drink within 30 min but no faster than 20 min (a similar procedure was used in Santtila et al. <xref ref-type="bibr" rid="CR30">1998</xref>, <xref ref-type="bibr" rid="CR31">1999</xref>). Participants then rinsed their mouth with water to remove residual traces of alcohol and to avoid contamination of subsequent breathalyzer readings. Thereafter, participants completed some filler tasks (word search games) for 15 min to allow their BAC to rise (see Crossland et al. <xref ref-type="bibr" rid="CR5">2016</xref>). Participants were then breathalyzed (but not informed about the reading). If their BAC reading was below the required 0.06% a further reading was taken 15 min later. It is important to note that all participants underwent the same procedure regardless of condition. That is, all participants had to consume the beverage in the above-described time and all participants were subsequently breathalyzed after a 15-min delay at least once.<xref ref-type="fn" rid="Fn1">1</xref>
</p>
        <p>All participants were then presented with one of two versions of the post-event narrative. To ensure that the information was being processed, the narrative was presented on six different cards in a randomly scrambled order. Participants were told that they would engage in a comprehension task and that they had to read the cards carefully and subsequently sort them in chronological order (this procedure was adopted from Horry et al. <xref ref-type="bibr" rid="CR16">2014</xref>). Finally, participants were asked to read out aloud the sorted narrative cards to the experimenter. Following the comprehension task, participants were informed about the actual nature of their drink and released from the first session. Those displaying BACs above .08% (the UK drink-drive limit) were advised to remain in the lab until their BAC reduced to below 08%. Those who did not wish to stay behind had to sign a waiver form, confirming their awareness of being in excess of the UK drink and drive alcohol limit.</p>
        <p>The second session commenced the following day. All participants completed the cued-recall memory test in their own time. They were instructed to think back to the film they watched and for every question to write down what they remember having seen in the film. They were told that the narrative they read during the comprehension task contained some incorrect details. They were instructed to provide a response to every question. If they could not remember, they were asked to guess. After each question, participants were asked to rate the confidence in their answer on a scale ranging from 0% (not confident at all) to 100% (very confident). After having answered all questions, participants were asked to go back through their answers and to indicate for each whether they would be willing to testify to it in a court of law. With this in mind, participants went through their answers and indicated with a “T” next to the answer that they would testify to it or with a “W” next to it that they would withhold the answer (e.g., Horry et al. <xref ref-type="bibr" rid="CR16">2014</xref>). Finally, participants were debriefed, thanked for their participation, and dismissed.</p>
      </sec>
    </sec>
    <sec id="Sec5">
      <title>Results</title>
      <sec id="Sec6">
        <title>Blood alcohol concentrations</title>
        <p>In line with previous research, all BrACs were converted to BACs with the blood: breath ratio of 2300:1. For the two groups who consumed alcohol (i.e., alcohol and reverse placebo group), the average BAC was .065%; BACs ranged from .03% to .11%. All control participants had a BAC of .00%. A one-way ANOVA revealed a significant difference between conditions, <italic>F</italic> (2, 80) = 174.34, <italic>p</italic> &lt; .001, <italic>η</italic>
<sup>2</sup> = 0.82. The control group differed significantly from both the alcohol and reverse placebo group (<italic>p</italic>s &lt; .001). There was no significant difference between the alcohol and the reverse placebo group (<italic>p</italic> &gt; .999) (alcohol group: <italic>M</italic> = .063, <italic>SD</italic> = .02, 95% CI = [.056, .070]; reverse placebo group: <italic>M</italic> = .067, <italic>SD</italic> = .02, 95% CI = [.060, .073]).</p>
      </sec>
      <sec id="Sec7">
        <title>Coding and analysis of memory test data</title>
        <p>Responses were coded as correct, misled (i.e., contained misinformation provided in narrative), or incorrect (i.e., containing other incorrect information). For example, a response was coded as correct when it coincided with what was actually shown in the video footage, i.e., the victim wore a <italic>blue</italic> fleece jumper in the video and the participant reported on the cued recall test that the fleece jumper was <italic>blue</italic>. A response was coded as misled when it coincided with the misinformation presented in the narrative and not with the information provided in the video clip, i.e., the narrative mentioned that the victim wore a <italic>green</italic> fleece jumper, whereas it was <italic>blue</italic> in the video clip, and the participant reported on the cued recall test that it was <italic>green</italic>. A response was coded as incorrect, when it did not coincide with either the information provided in the video footage or the narrative, i.e., the participant reported that the fleece jumper was <italic>red</italic>. To assess inter-coder reliability, 20% of the cued recall memory tests (16 tests) were coded by two independent coders. Significant Pearson correlations between coders were established (correct responses: <italic>r</italic> = .991, <italic>p</italic> &lt; .001; misled responses: <italic>r</italic> = 1, <italic>p</italic> &lt; .001; incorrect responses: <italic>r</italic> = .989, <italic>p</italic> &lt; .001).</p>
      </sec>
      <sec id="Sec8">
        <title>Proportion of misled responses</title>
        <p>A 2 (item: control vs. misled) × 3 (Condition: alcohol vs. control vs. reverse placebo) mixed ANOVA on the proportion of misled responses (out of five) revealed a significant main effect for item, <italic>F</italic> (1, 79) = 35.39, <italic>p</italic> &lt; .001, <italic>η</italic>
<sup>2</sup> = .0.189. Participants were more likely to provide a misled response to misinformation items (<italic>M</italic> = .36, 95%CI [.309, .405]) than to control items (<italic>M</italic> = .17, 95%CI [.133, .209]). The main effect for condition was also significant, <italic>F</italic> (2, 79) = 3.51, <italic>p</italic> = .035, <italic>η</italic>
<sup>2</sup> = .088). Bonferroni post-hoc tests showed that the control group provided significantly more misled responses than the reverse placebo group (<italic>p</italic> = .038). There was no significant difference between the control and alcohol group (<italic>p</italic> = .183) nor between the reverse placebo and alcohol group (<italic>p</italic> &gt; .999) (alcohol: <italic>M</italic> = .25, 95%CI [.196, .300]; control: <italic>M</italic> = .319, 95%CI [.266, .371]; reverse placebo: <italic>M</italic> = .22, 95%CI [.174, .276]). The interaction between item and condition was significant, <italic>F</italic> (2, 79) = 8.55, <italic>p</italic> &lt; .001, <italic>η</italic>
<sup>2</sup> = .178. Bonferroni post-hoc tests revealed that groups did not differ significantly on control items (alcohol vs. control: <italic>p</italic> = .478; alcohol vs. reverse placebo: <italic>p</italic> &gt; .999; reverse placebo vs. control: <italic>p</italic> &gt; .999). However, for the misinformation items a significant difference was present between the alcohol and control group (<italic>p</italic> = .002), and between the reverse placebo and control group (<italic>p</italic> = .001), but not between the alcohol and reverse placebo group (<italic>p</italic> &gt; .999). Thus, the control group was significantly more likely to give a misled response to misleading items compared to the alcohol and reverse placebo group.<xref ref-type="fn" rid="Fn2">2</xref>
</p>
      </sec>
      <sec id="Sec9">
        <title>Proportion correct responses</title>
        <p>A 2 (item: control vs. misled) × 3 (condition: alcohol vs. control vs. reverse placebo) mixed ANOVA on the proportion of correct responses revealed a significant main effect for item, <italic>F</italic> (1, 79) = 8.84, <italic>p</italic> = .004, η<sup>2</sup> = .101. Participants provided significantly more correct responses to control items (<italic>M</italic> = .55, 95%CI [.498, .609]) than to misleading items (<italic>M</italic> = .44, 95%CI [.384, .498]). The main effect for condition, <italic>F</italic> (2, 79) = .05, <italic>p</italic> = .956, η<sup>2</sup> = .001, and the interaction between item and condition were not significant, <italic>F</italic>(2, 79) = 1.34, <italic>p</italic> = .267, <italic>η</italic>
<sup>2</sup> = .033. Proportions correct and misled responses are presented in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Mean (and 95% CI) proportion correct (out of 5) and misled (out of 5) responses for control and misleading items in each condition (alcohol, control and reverse placebo)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">Item</th><th colspan="6">Condition</th></tr><tr><th colspan="2">Alcohol</th><th colspan="2">Control</th><th colspan="2">Reverse Placebo</th></tr><tr><th>Control</th><th>Misleading</th><th>Control</th><th>Misleading</th><th>Control</th><th>Misleading</th></tr></thead><tbody><tr><td>Correct responses</td><td>.52 [.422, .615]<sup>a</sup>
</td><td>.46 [.360, .558]<sup>a</sup>
</td><td>.60 [.503, .697]<sup>b</sup>
</td><td>.40 [.301, .499]<sup>b</sup>
</td><td>.54 [.448, .638]<sup>c</sup>
</td><td>.46 [.367, .561]<sup>c</sup>
</td></tr><tr><td>Misled responses</td><td>.20 [.134, .266]</td><td>.30 [.213, .380]<sup>d</sup>
</td><td>.13 [.067, .199]</td><td>.50 [.420, .587]<sup>de</sup>
</td><td>.17 [.114, .243]</td><td>.27 [.189, .353]<sup>e</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<sup>a b c d e</sup>Cells sharing the same capital differ significantly from each other</p></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec id="Sec10">
        <title>Proportion testified responses</title>
        <p>A 3 (response type: correct, incorrect, misled) × 3 (condition: alcohol vs. control vs. reverse placebo) mixed ANOVA on the proportion of testified responses revealed a significant main effect for response type, <italic>F</italic> (2, 158) = 89.84, <italic>p</italic> &lt; .001, <italic>η</italic>
<sup>2</sup> = .532 (correct: <italic>M</italic> = .50, 95%CI [.456, .539]; incorrect: <italic>M</italic> = .08, 95%CI [.056, .105]; misled: <italic>M</italic> = .36, 95%CI [ .309, .405]). The main effect for condition was also significant, <italic>F</italic> (2, 79) = 6.50, <italic>p</italic> = .002, <italic>η</italic>
<sup><italic>2</italic></sup> = .141 (alcohol: <italic>M</italic> = .30, 95%CI [.271, .322]; control: <italic>M</italic> = .35, 95%CI [.324, .375]; reverse placebo: <italic>M</italic> = .29, 95%CI [.264, .315]). In addition, the interaction between response type and condition was significant <italic>F</italic> (4, 158) = 4.66, <italic>p</italic> = .001, <italic>η</italic>
<sup>2</sup> = .106. Bonferroni post-hoc tests showed that there were no group differences in the proportion of testified responses for correct and incorrect responses (all <italic>p</italic>s &gt; .05). However, the control group was significantly more likely to testify to a misled response compared to the alcohol (<italic>p</italic> = .002) and the reverse placebo group (<italic>p</italic> = .001). There was no significant difference between the alcohol and the reverse placebo group (<italic>p</italic> &gt; .999). See Table <xref rid="Tab2" ref-type="table">2</xref> for mean proportions of testified responses and confidence intervals.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Mean proportion of testified responses (and 95% confidence intervals) for correct (out of 10), incorrect (out of 10) and misled (out of 5) responses for each condition (alcohol, control and reverse placebo)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Proportion testified</th><th colspan="3">Condition</th></tr><tr><th>Alcohol</th><th>Control</th><th>Reverse Placebo</th></tr></thead><tbody><tr><td>Correct responses</td><td>.49 [.416, .561]</td><td>.50 [.427, .573]</td><td>.50 [.432, .575]</td></tr><tr><td>Incorrect responses</td><td>.10 [.061, .146]</td><td>.04 [.002, .087]</td><td>.09 [.051, .135]</td></tr><tr><td>Misled responses</td><td>.30 [.213, .380]<sup>a</sup>
</td><td>.50 [.420, .587]<sup>ab</sup>
</td><td>.27 [.189, .353]<sup>b</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<sup>a b</sup>Cells sharing the same capital differ significantly from each other</p></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec id="Sec11">
        <title>Confidence ratings in correct, incorrect and misled responses</title>
        <p>A 3 (response: correct vs. incorrect vs. misled) × 3 (Condition: alcohol vs. control vs. reverse placebo) mixed ANOVA revealed a significant main effect for Response Type, <italic>F</italic> (2, 132) = 79.39, <italic>p</italic> &lt; .001, <italic>η</italic>
<sup>2</sup> = .546 . Bonferroni post-hoc tests revealed that participants provided significantly lower confidence ratings for errors compared to misled (<italic>p</italic> &lt; .001) and correct responses (<italic>p</italic> &lt; .001). Confidence ratings for misled responses were also significantly lower than for correct responses (<italic>p</italic> = .003). Neither the main effect for Condition, <italic>F</italic> (2, 66) = .58, <italic>p</italic> = .562, <italic>η</italic>
<sup>2</sup> = .017, nor the interaction between Response Type and Condition, <italic>F</italic> (2, 66) = 1.03, <italic>p</italic> = .390, <italic>η</italic>
<sup>2</sup> = .031 was significant. See Table <xref rid="Tab3" ref-type="table">3</xref> for mean confidence ratings and confidence intervals.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Mean (95% confidence intervals) of confidence ratings to correct, incorrect and misled responses for each condition (alcohol, control and reverse placebo)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Confidence %</th><th colspan="3">Condition</th></tr><tr><th>Alcohol</th><th>Control</th><th>Reverse placebo</th></tr></thead><tbody><tr><td>Correct responses</td><td>74.30 [66.61, 81.98]<sup>a</sup>
</td><td>70.64 [62.63, 78.66]<sup>b</sup>
</td><td>73.20 [64.81, 81.58]<sup>c</sup>
</td></tr><tr><td>Incorrect responses</td><td>33.80 [23.43, 44.16]<sup>a</sup>
</td><td>37.25 [26.44, 48.05]<sup>b</sup>
</td><td>39.56 [27.79, 50.41]<sup>c</sup>
</td></tr><tr><td>Misled responses</td><td>57.13 [48.76, 65.51]<sup>a</sup>
</td><td>65.14 [56.41, 73.87]<sup>b</sup>
</td><td>69.29 [60.15, 78.42]<sup>c</sup>
</td></tr><tr><td>Testified responses</td><td>78.41 [72.36, 84.47]<sup>d</sup>
</td><td>79.19 [73.25, 85.13]<sup>e</sup>
</td><td>80.86 [74.93, 86.80]<sup>f</sup>
</td></tr><tr><td>Withheld responses</td><td>35.85 [28.92, 42.78]<sup>d</sup>
</td><td>39.99 [33.19, 46.79]<sup>e</sup>
</td><td>38.07 [31.27, 44.87]<sup>f</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<sup>a b c d e f</sup>Cells sharing the same capital differ significantly from each other</p></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec id="Sec12">
        <title>Confidence ratings in testified and withheld responses</title>
        <p>A 2 (response type: testify vs. withheld) × 3 (condition: alcohol vs. control vs. reverse placebo) mixed ANOVA on the mean confidence ratings for testified and withheld responses revealed a significant main effect for response type, <italic>F</italic> (1, 77) = 308.43, <italic>p</italic> &lt; .001, <italic>η</italic>
<sup>2</sup> = .800. Participants were significantly more confident in testified responses (<italic>M</italic> = 79.50, 95%CI [76.04, 82.94]) than in withheld responses (<italic>M</italic> = 37.99, 95%CI [34.02, 41.92]). No significant main effect for condition was revealed, <italic>F</italic> (2, 77) = .30, <italic>p</italic> = .738, <italic>η</italic>
<sup>2</sup> = .008. The interaction between response type and condition was not significant, <italic>F</italic> (2, 77) = .24, <italic>p</italic> = .785, <italic>η</italic>
<sup>2</sup> = .006. See Table <xref rid="Tab3" ref-type="table">3</xref> for mean confidence ratings and 95% confidence intervals.</p>
      </sec>
    </sec>
    <sec id="Sec13">
      <title>Discussion</title>
      <p>The current study was designed to examine alcohol-induced retrograde facilitation in a delayed misinformation paradigm. We are the first to show that alcohol consumption after having witnessed a criminal event can protect memory from the negative effects of misinformation. Contrary to the general belief and empirical finding that alcohol impairs eyewitness memory, we found that individuals who consumed alcohol (alcohol and reverse placebo group) <italic>after</italic> the observed event but <italic>prior</italic> to encountering misleading information, reported significantly fewer misinformation items on a subsequent memory test compared to the control group (who did not receive any alcohol). A particularly worrying finding is that the sober participants were also more likely to be prepared to testify a misled response in a court of law. No difference in the proportion of correct responses provided was found between groups. Nor did the groups differ with regards to how confident they were in their responses.</p>
      <p>A potential explanation for reduced suggestibility is that alcohol leads to decreased retrograde interference (Mueller et al. <xref ref-type="bibr" rid="CR24">1983</xref>). That is intoxication reduces the formation of new memories thereby protecting already existing memories and making them less vulnerable to interference. Alcohol-induced retrograde facilitation has been demonstrated in previous studies using list of words, sentences, pictures and prose passages (Bruce and Pihl <xref ref-type="bibr" rid="CR3">1997</xref>; Moulton et al. <xref ref-type="bibr" rid="CR23">2005</xref>; Parker et al. <xref ref-type="bibr" rid="CR27">1980</xref>; Weafer et al. <xref ref-type="bibr" rid="CR38">2016a</xref>, <xref ref-type="bibr" rid="CR39">b</xref>). Our findings demonstrate that alcohol-induced facilitation holds true for autobiographical memories in a misinformation eyewitness paradigm.</p>
      <p>Including a reverse placebo group allowed us to shed more light on expectancy and pharmacological effects of alcohol consumption on retrograde facilitation. Both the alcohol and reverse placebo group were less suggestible to misinformation, indicating that the facilitated memory effect is more likely to be due to the pharmacological effects of alcohol rather than due to alcohol-related beliefs. This is in line with the findings reported by Parker et al. (<xref ref-type="bibr" rid="CR28">1981</xref>) who showed that the alcohol-induced facilitation effect is dose-dependent. These are tentative conclusions and further research is needed to disentangle expectancy and pharmacological effects on retrograde memory facilitation. The current study did not measure participants’ subjective beliefs regarding their intoxication level, and we cannot preclude that control participants thought that they were actually drinking alcohol (even if they were told that they received Beck’s Blue).</p>
      <p>Furthermore, our results disconfirm a competing theory for enhanced learning prior to alcohol consumption—improved consolidation of memory traces (Parker et al. <xref ref-type="bibr" rid="CR27">1980</xref>). According to this theory, alcohol increases processing (i.e., consolidation) of previously learned material. Contrary to this view, we did not find group differences in the proportion of correct responses provided. Our findings are more in line with the interference-reduction view (Mueller et al. <xref ref-type="bibr" rid="CR24">1983</xref>). That is, alcohol reduces the amount of new incoming information from entering memory and as a result preserves already existing memories. Intoxicated eyewitnesses were consequently less suggestible to misinformation in our study.</p>
      <p>It is important to note that we are not implying that incoming misinformation impairs memory for the original event in the absence of alcohol. As highlighted and demonstrated by McCloskey and Zaragoza (<xref ref-type="bibr" rid="CR21">1985</xref>) in a series of studies, originally formed memories may still be intact and co-exist together with the misleading information. They used the misinformation paradigm but included a modified test version. Depending on their condition, participants were either presented with misinformation or no misinformation (control group). At test, participants were presented with two forced-choice alternatives, the original item and a new item (the misleading information was not an option). They found no difference in performance between groups at test. That is, misled participants were as likely as control participants to choose the original item, providing no evidence for memory impairment.</p>
      <p>To test whether alcohol indeed hinders new information from entering memory, future research should use a forced-choice recognition test, similar to McCloskey and Zaragoza’s (<xref ref-type="bibr" rid="CR21">1985</xref>) modified test version, rather than a cued recall test. The test alternatives would be the misinformation item and a new item. If alcohol really blocks/reduces interfering information from entering memory, then participants in the alcohol group should be as likely to choose the misinformation as the new item at test (chance performance). Control participants, however, should be more likely to pick the misinformation item compared to the new item. This finding would provide independent evidence for the claim that alcohol blocks/reduces misinformation from entering memory.</p>
      <p>In relation to the confidence ratings given for cued-recall responses, we did not find any differences between groups. However, we did find that mean confidence levels differed across response type. Participants were significantly more confident in correct responses compared to misled and incorrect responses. Intriguingly, participants were also significantly more confident in misled responses than in incorrect ones. The source-monitoring framework (Johnson et al. <xref ref-type="bibr" rid="CR17">1993</xref>) may offer an explanation for this finding. When participants are asked a cued recall question, several response alternatives are generated. The participant has to then decide whether to report one or not. This decision is dependent on whether the participant can retrieve any source memory for the alternative answers (i.e., any spatial, temporal, modal, or social contextual cues). Erroneous responses are usually associated with an inability to specify the source of the information and are therefore reported with low confidence. Individuals might report suggested details with higher confidence because either the misled response might wrongly elicit event-related cues (i.e., source confusion error), or the misled response was retrieved easily (i.e., with high retrieval fluency). In both cases, the misled response would be given with increased confidence (Horry et al. <xref ref-type="bibr" rid="CR16">2014</xref>). It is interesting to note that in the current study although participants were on average more confident in misled responses than in errors, they were most confident in correct responses.</p>
      <p>It remains to be seen whether the alcohol-induced retrograde facilitation effect can be generalized to other types of misinformation. Misinformation can be introduced indirectly, through embedding it in a set of questions (Loftus et al. <xref ref-type="bibr" rid="CR19">1978</xref>), or directly, through a face-to-face encounter (Blank et al. <xref ref-type="bibr" rid="CR2">2013</xref>; Gabbert et al. <xref ref-type="bibr" rid="CR11">2003</xref>). The scrambled sentence task used in this study can be regarded as an indirect way of introducing misinformation. Further research will be necessary to explore the impact of alcohol on suggestibility when the misinformation is presented in a more direct way.</p>
      <p>Future research should also explore whether alcohol-induced retrograde facilitation is present in more realistic forensic settings. Only a few field studies on the impact of alcohol on eyewitness memory performance exist (Van Oorsouw and Merckelbach <xref ref-type="bibr" rid="CR36">2012</xref>; Van Oorsouw et al. <xref ref-type="bibr" rid="CR37">2015</xref>) and none has explored retrograde facilitation. For example, is this phenomenon also present when people are mildly intoxicated when witnessing the event and more severely intoxicated when presented with misinformation? Such a scenario could be regarded as more ecologically valid, as witnesses may be already mildly intoxicated before observing a crime. The average peak BAC of .065% in the current study could be considered fairly low, and future research should test alcohol-induced retrograde facilitation under higher levels of intoxication, which are more likely to be found in the real world. From a practical and theoretical perspective, it would be also valuable to examine how long the protective effect of alcohol against misinformation lasts for. There are often lengthy passages of time between the crime and the recalling of the event by the witness. It could be argued that with longer delays, all individuals might become more suggestible to misinformation regardless of their intoxication level <italic>after</italic> encoding and <italic>prior</italic> to the endorsement of misinformation (e.g., Hertel et al. <xref ref-type="bibr" rid="CR15">1980</xref>; Loftus et al. <xref ref-type="bibr" rid="CR19">1978</xref>). Would the inoculating effect of alcohol against misinformation disappear with longer time delays? Future studies should also examine the effects of alcohol on retrograde facilitation on different limbs (ascending and descending) of the BAC curve. Research has shown that alcohol might have differential effects on memory depending on the task, the memory type, and limb of the BAC curve (Söderlund et al. <xref ref-type="bibr" rid="CR35">2005</xref>).</p>
      <p>In summary, our findings indicate that the timing of alcohol consumption plays an important role in determining how accurate and reliable subsequent memory reports are. The assumption that alcohol inevitably impairs eyewitness memory performance is oversimplified. We suggest that in certain circumstances alcohol intoxication can protect eyewitness memory by making individuals less suggestible to misinformation. Scientists who are conducting research in the field need to take this into account when designing their experiments and interpreting their findings, for example by asking participants about subsequent drinking behavior between testing sessions.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="Fn1">
        <label>1</label>
        <p>Given that some individuals were breathalyzed twice, the delay between watching the crime video and the subsequent presentation of misinformation varied by approximately15 min.</p>
      </fn>
      <fn id="Fn2">
        <label>2</label>
        <p>A 2 × 3 between-participants ANOVA was conducted on the number of misled responses including the Narrative Version (A vs. B) as another independent variable. A significant main effect for Narrative version (<italic>F</italic> (1, 72) = 10.34, <italic>p</italic> = .002) and condition (<italic>F</italic> (2, 76) = 10.03, <italic>p</italic> &lt; .001, <italic>η</italic>
<sup>2</sup> = .209) was revealed. Participants gave more misled responses for narrative A (<italic>M</italic> = 2.14, 95%CI [1.825, 2.460]) compared to narrative B (<italic>M</italic> = 1.40, 95%CI [1.083, 1.734]). Post-hoc tests showed that the control group provided significantly more misled responses than the alcohol (<italic>p</italic> = .001) and the reserve placebo groups (<italic>p</italic> &lt; .001). There was no significant difference for misled responses between the alcohol and reverse placebo group (<italic>p</italic> &gt; .999). Importantly, the interaction between narrative version and condition was not significant (<italic>F</italic> (2, 76) = .83, <italic>p</italic> = .441, η<sup>2</sup> = 0.21). Thus, individuals gave more misled responses when provided with narrative A compared to narrative B. However, this effect did not moderate the effect of Condition.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bègue</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bushman</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Zerhouni</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Subra</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ourabah</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>‘Beauty is in the eye of the beer holder’: people who think they are drunk also think they are attractive</article-title>
          <source>Br J Psychol</source>
          <year>2013</year>
          <volume>104</volume>
          <issue>2</issue>
          <fpage>225</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="doi">10.1111/j.2044-8295.2012.02114.x</pub-id>
          <?supplied-pmid 23560668?>
          <pub-id pub-id-type="pmid">23560668</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blank</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ost</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lambert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Salmon</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Comparing the influence of directly vs. indirectly encountered post-event misinformation on eyewitness remembering</article-title>
          <source>Acta Psychol</source>
          <year>2013</year>
          <volume>144</volume>
          <issue>3</issue>
          <fpage>635</fpage>
          <lpage>641</lpage>
          <pub-id pub-id-type="doi">10.1016/j.actpsy.2013.10.006</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bruce</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Pihl</surname>
              <given-names>RO</given-names>
            </name>
          </person-group>
          <article-title>Forget “drinking to forget”: enhanced consolidation of emotionally charged memory by alcohol</article-title>
          <source>Exp Clin Psychopharmacol</source>
          <year>1997</year>
          <volume>5</volume>
          <issue>3</issue>
          <fpage>242</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="doi">10.1037/1064-1297.5.3.242</pub-id>
          <?supplied-pmid 9260071?>
          <pub-id pub-id-type="pmid">9260071</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caswell</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Duka</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Acute alcohol effects on subtypes of impulsivity and the role of alcohol-outcome expectancies</article-title>
          <source>Psychopharmacology</source>
          <year>2013</year>
          <volume>229</volume>
          <issue>1</issue>
          <fpage>21</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-013-3079-8</pub-id>
          <?supplied-pmid 23579427?>
          <pub-id pub-id-type="pmid">23579427</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crossland</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kneller</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wilcock</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Intoxicated witnesses: testing the validity of the alcohol myopia theory</article-title>
          <source>Appl Cogn Psychol</source>
          <year>2016</year>
          <volume>30</volume>
          <issue>2</issue>
          <fpage>270</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="doi">10.1002/acp.3209</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <mixed-citation publication-type="other">Curtin JJ (2000) [BAL calculator]. Unpublished computer program</mixed-citation>
      </ref>
      <ref id="CR7">
        <mixed-citation publication-type="other">Dysart JE, Lindsay RC, MacDonald TK, Wicke C (2002) The intoxicated witness: effects of alcohol on identification accuracy from showups. Journal of Applied Psychology 87(1):170</mixed-citation>
      </ref>
      <ref id="CR8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Schreiber Compo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Russano</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Intoxicated witnesses and suspects: procedures and prevalence according to law enforcement</article-title>
          <source>Psychol Public Policy Law</source>
          <year>2009</year>
          <volume>15</volume>
          <issue>3</issue>
          <fpage>194</fpage>
          <lpage>221</lpage>
          <pub-id pub-id-type="doi">10.1037/a0016837</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fillmore</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Vogel-Sprott</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Expectancies about alcohol-induced motor impairment predict individual differences in responses to alcohol and placebo</article-title>
          <source>J Stud Alcohol</source>
          <year>1995</year>
          <volume>56</volume>
          <issue>1</issue>
          <fpage>90</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="doi">10.15288/jsa.1995.56.90</pub-id>
          <?supplied-pmid 7752640?>
          <pub-id pub-id-type="pmid">7752640</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fillmore</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Carscadden</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Vogel-Sprott</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Alcohol, cognitive impairment and expectancies</article-title>
          <source>J Stud Alcohol</source>
          <year>1998</year>
          <volume>59</volume>
          <issue>2</issue>
          <fpage>174</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="doi">10.15288/jsa.1998.59.174</pub-id>
          <?supplied-pmid 9500304?>
          <pub-id pub-id-type="pmid">9500304</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gabbert</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Memon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Allan</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Memory conformity: can eyewitnesses influence each other's memories for an event?</article-title>
          <source>Appl Cogn Psychol</source>
          <year>2003</year>
          <volume>17</volume>
          <issue>5</issue>
          <fpage>533</fpage>
          <lpage>543</lpage>
          <pub-id pub-id-type="doi">10.1002/acp.885</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Gudjonsson</surname>
              <given-names>GH</given-names>
            </name>
          </person-group>
          <source>The Gudjonsson suggestibility scales</source>
          <year>1997</year>
          <publisher-loc>Hove</publisher-loc>
          <publisher-name>Psychology Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hagsand</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Roos-af-Hjelmsäter</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Anders Granhag</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fahlke</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Söderpalm-Gordh</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Do sober eyewitnesses outperform alcohol intoxicated eyewitnesses in a lineup?</article-title>
          <source>The European Journal of Psychology Applied to Legal Context</source>
          <year>2013</year>
          <volume>5</volume>
          <issue>1</issue>
          <fpage>23</fpage>
          <lpage>47</lpage>
        </element-citation>
      </ref>
      <ref id="CR14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harvey</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Kneller</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>The effects of alcohol intoxication on attention and memory for visual scenes</article-title>
          <source>Memory</source>
          <year>2013</year>
          <volume>21</volume>
          <issue>8</issue>
          <fpage>969</fpage>
          <lpage>980</lpage>
          <pub-id pub-id-type="doi">10.1080/09658211.2013.770033</pub-id>
          <?supplied-pmid 23431967?>
          <pub-id pub-id-type="pmid">23431967</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hertel</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Cosden</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Passage recall: schema change and cognitive flexibility</article-title>
          <source>J Educ Psychol</source>
          <year>1980</year>
          <volume>72</volume>
          <issue>2</issue>
          <fpage>133</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="doi">10.1037/0022-0663.72.2.133</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horry</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Colton</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Williamson</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Confidence-accuracy resolution in the misinformation paradigm is influenced by availability to source cues</article-title>
          <source>Acta Psychol</source>
          <year>2014</year>
          <volume>151</volume>
          <fpage>164</fpage>
          <lpage>173</lpage>
          <pub-id pub-id-type="doi">10.1016/j.actpsy.2014.06.006</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Hashtroudi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lindsay</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Source monitoring</article-title>
          <source>Psychol Bull</source>
          <year>1993</year>
          <volume>114</volume>
          <issue>1</issue>
          <fpage>3</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.1037/0033-2909.114.1.3</pub-id>
          <?supplied-pmid 8346328?>
          <pub-id pub-id-type="pmid">8346328</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loftus</surname>
              <given-names>EF</given-names>
            </name>
          </person-group>
          <article-title>Planting misinformation in the human mind: a 30-year investigation of the malleability of memory</article-title>
          <source>Learn Mem</source>
          <year>2005</year>
          <volume>12</volume>
          <issue>4</issue>
          <fpage>361</fpage>
          <lpage>366</lpage>
          <pub-id pub-id-type="doi">10.1101/lm.94705</pub-id>
          <?supplied-pmid 16027179?>
          <pub-id pub-id-type="pmid">16027179</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loftus</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Burns</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
          <article-title>Semantic integration of verbal information into a visual memory</article-title>
          <source>J Exp Psychol Hum Learn Mem</source>
          <year>1978</year>
          <volume>4</volume>
          <issue>1</issue>
          <fpage>19</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1037/0278-7393.4.1.19</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maisto</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Palfai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Vanable</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Heath</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Woolf-King</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>The effects of alcohol and sexual arousal on determinants of sexual risk in men who have sex with men</article-title>
          <source>Arch Sex Behav</source>
          <year>2012</year>
          <volume>41</volume>
          <issue>4</issue>
          <fpage>971</fpage>
          <lpage>998</lpage>
          <pub-id pub-id-type="doi">10.1007/s10508-011-9846-x</pub-id>
          <?supplied-pmid 22009480?>
          <pub-id pub-id-type="pmid">22009480</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCloskey</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zaragoza</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Postevent information and memory: reply to Loftus, Schooler, and Wagenaar</article-title>
          <source>J Exp Psychol Gen</source>
          <year>1985</year>
          <volume>114</volume>
          <issue>3</issue>
          <fpage>381</fpage>
          <lpage>387</lpage>
          <pub-id pub-id-type="doi">10.1037/0096-3445.114.3.381</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moss</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Albery</surname>
              <given-names>IP</given-names>
            </name>
          </person-group>
          <article-title>A dual-process model of the alcohol–behavior link for social drinking</article-title>
          <source>Psychol Bull</source>
          <year>2009</year>
          <volume>135</volume>
          <issue>4</issue>
          <fpage>516</fpage>
          <lpage>530</lpage>
          <pub-id pub-id-type="doi">10.1037/a0015991</pub-id>
          <?supplied-pmid 19586160?>
          <pub-id pub-id-type="pmid">19586160</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moulton</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Petros</surname>
              <given-names>TV</given-names>
            </name>
            <name>
              <surname>Apostal</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>RV</given-names>
              <suffix>2nd</suffix>
            </name>
            <name>
              <surname>Ronning</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Penland</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Alcohol induced impairment and enhancement of memory: a test of the interference theory</article-title>
          <source>Physiology and Behvavior</source>
          <year>2005</year>
          <volume>85</volume>
          <fpage>240</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="doi">10.1016/j.physbeh.2005.03.011</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mueller</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Lisman</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Spear</surname>
              <given-names>NE</given-names>
            </name>
          </person-group>
          <article-title>Alcohol enhancement of human memory: tests of consolidation and interference hypotheses</article-title>
          <source>Psychopharmacology</source>
          <year>1983</year>
          <volume>80</volume>
          <issue>3</issue>
          <fpage>226</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00436158</pub-id>
          <?supplied-pmid 6412266?>
          <pub-id pub-id-type="pmid">6412266</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <mixed-citation publication-type="other">Office for National statistics (2015) Chapter 5: violent crime and sexual offences—alcohol-related violence</mixed-citation>
      </ref>
      <ref id="CR26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ost</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Costall</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bull</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>False reports of childhood events in appropriate interviews</article-title>
          <source>Memory</source>
          <year>2005</year>
          <volume>13</volume>
          <issue>7</issue>
          <fpage>700</fpage>
          <lpage>710</lpage>
          <pub-id pub-id-type="doi">10.1080/09658210444000340</pub-id>
          <?supplied-pmid 16191820?>
          <pub-id pub-id-type="pmid">16191820</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parker</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Birnbaum</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Weingartner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hartley</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Stillman</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Wyatt</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Retrograde enhancement of human memory with alcohol</article-title>
          <source>Psychopharmacology</source>
          <year>1980</year>
          <volume>69</volume>
          <issue>2</issue>
          <fpage>219</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00427653</pub-id>
          <?supplied-pmid 6256791?>
          <pub-id pub-id-type="pmid">6256791</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parker</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Morihisa</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Wyatt</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Weingartner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Stillman</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>The alcohol facilitation effect on memory: a dose-response study</article-title>
          <source>Psychopharmacology</source>
          <year>1981</year>
          <volume>74</volume>
          <issue>1</issue>
          <fpage>88</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00431763</pub-id>
          <?supplied-pmid 6791212?>
          <pub-id pub-id-type="pmid">6791212</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Ridley</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Gudjonsson</surname>
              <given-names>GH</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Ridley</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Gabbert</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>La Rooy</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Suggestibility and individual differences: psychosocial and memory measures</article-title>
          <source>Suggestibility in legal contexts: psychological research and forensic implications</source>
          <year>2013</year>
          <publisher-loc>Chichester</publisher-loc>
          <publisher-name>Wiley-Blackwell</publisher-name>
          <fpage>85</fpage>
          <lpage>106</lpage>
        </element-citation>
      </ref>
      <ref id="CR30">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santtila</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ekholm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Niemi</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Factors moderating the effects of alcohol on interrogative suggestibility</article-title>
          <source>Psychol Crime Law</source>
          <year>1998</year>
          <volume>4</volume>
          <issue>2</issue>
          <fpage>139</fpage>
          <lpage>152</lpage>
          <pub-id pub-id-type="doi">10.1080/10683169808401754</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santtila</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ekholm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Niemi</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The effects of alcohol on interrogative suggestibility: the role of state-anxiety and mood states as mediating factors</article-title>
          <source>Leg Criminol Psychol</source>
          <year>1999</year>
          <volume>4</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1348/135532599167707</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Schooler</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Loftus</surname>
              <given-names>EF</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Picket</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Reese</surname>
              <given-names>HW</given-names>
            </name>
          </person-group>
          <article-title>Multiple mechanisms mediate individual differences in eyewitness accuracy and suggestibility</article-title>
          <source>Mechanisms of everyday cognition</source>
          <year>1993</year>
          <publisher-loc>Hillsdale, NJ</publisher-loc>
          <publisher-name>Lawrence Erlbaum Associates Inc.</publisher-name>
          <fpage>177</fpage>
          <lpage>203</lpage>
        </element-citation>
      </ref>
      <ref id="CR33">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schreiber Compo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Carol</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Villalba</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ham</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Intoxicated eyewitnesses: better than their reputation?</article-title>
          <source>Law Hum Behav</source>
          <year>2012</year>
          <volume>36</volume>
          <issue>2</issue>
          <fpage>77</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="doi">10.1037/h0093951</pub-id>
          <pub-id pub-id-type="pmid">22471412</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Porter</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Constructing rich false memories of committing crime</article-title>
          <source>Psychol Sci</source>
          <year>2015</year>
          <volume>26</volume>
          <issue>3</issue>
          <fpage>291</fpage>
          <lpage>301</lpage>
          <pub-id pub-id-type="doi">10.1177/0956797614562862</pub-id>
          <?supplied-pmid 25589599?>
          <pub-id pub-id-type="pmid">25589599</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <mixed-citation publication-type="other">Söderlund H, Parker ES, Schwartz BL, Tulving, E (2005) Memory encoding and retrieval on the ascending and descending limbs of the blood alcohol concentration curve. Psychopharmacology 182(2):305–317</mixed-citation>
      </ref>
      <ref id="CR36">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Oorsouw</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Merckelbach</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>The effects of alcohol on crime-related memories: a field study</article-title>
          <source>Appl Cogn Psychol</source>
          <year>2012</year>
          <volume>26</volume>
          <issue>1</issue>
          <fpage>82</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1002/acp.1799</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Oorsouw</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Merckelbach</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Smeets</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Alcohol intoxication impairs memory and increases suggestibility for a mock crime: a field study</article-title>
          <source>Appl Cogn Psychol</source>
          <year>2015</year>
          <volume>29</volume>
          <issue>4</issue>
          <fpage>493</fpage>
          <lpage>501</lpage>
          <pub-id pub-id-type="doi">10.1002/acp.3129</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weafer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Wit</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Effect of alcohol on encoding and consolidation of memory for alcohol-related images</article-title>
          <source>Alcohol Clin Exp Res</source>
          <year>2016</year>
          <volume>40</volume>
          <issue>7</issue>
          <fpage>1540</fpage>
          <lpage>1547</lpage>
          <pub-id pub-id-type="doi">10.1111/acer.13103</pub-id>
          <?supplied-pmid 27219099?>
          <pub-id pub-id-type="pmid">27219099</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weafer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>De Wit</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Acute effects of alcohol on encoding and consolidation of memory for emotional stimuli</article-title>
          <source>Journal of Studies on Alcohol and Drugs</source>
          <year>2016</year>
          <volume>77</volume>
          <issue>1</issue>
          <fpage>86</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="doi">10.15288/jsad.2016.77.86</pub-id>
          <?supplied-pmid 26751358?>
          <pub-id pub-id-type="pmid">26751358</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wetherill</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Fromme</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Alcohol-induced blackouts: a review of recent clinical research with practical implications and recommendations for future studies</article-title>
          <source>Alcohol Clin Exp Res</source>
          <year>2016</year>
          <volume>40</volume>
          <issue>5</issue>
          <fpage>922</fpage>
          <lpage>935</lpage>
          <pub-id pub-id-type="doi">10.1111/acer.13051</pub-id>
          <?supplied-pmid 27060868?>
          <pub-id pub-id-type="pmid">27060868</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wixted</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>The psychology and neuroscience of forgetting</article-title>
          <source>Annu Rev Psychol</source>
          <year>2004</year>
          <volume>55</volume>
          <fpage>235</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.psych.55.090902.141555</pub-id>
          <?supplied-pmid 14744216?>
          <pub-id pub-id-type="pmid">14744216</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wixted</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>A theory about why we forget what we once knew</article-title>
          <source>Curr Dir Psychol Sci</source>
          <year>2005</year>
          <volume>14</volume>
          <issue>1</issue>
          <fpage>6</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1111/j.0963-7214.2005.00324.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yuille</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Tollestrup</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Some effects of alcohol on eyewitness memory</article-title>
          <source>J Appl Psychol</source>
          <year>1990</year>
          <volume>75</volume>
          <issue>3</issue>
          <fpage>268</fpage>
          <pub-id pub-id-type="doi">10.1037/0021-9010.75.3.268</pub-id>
          <?supplied-pmid 2354983?>
          <pub-id pub-id-type="pmid">2354983</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362660</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Aging Clin Exp Res</journal-id>
      <journal-id journal-id-type="iso-abbrev">Aging Clin Exp Res</journal-id>
      <journal-title-group>
        <journal-title>Aging Clinical and Experimental Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1594-0667</issn>
      <issn pub-type="epub">1720-8319</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362660</article-id>
      <article-id pub-id-type="pmcid">PMC5362660</article-id>
      <article-id pub-id-type="pmc-uid">5362660</article-id>
      <article-id pub-id-type="pmid">27072353</article-id>
      <article-id pub-id-type="publisher-id">562</article-id>
      <article-id pub-id-type="doi">10.1007/s40520-016-0562-1</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Type 2 diabetes and risk of low-energy fractures in postmenopausal women: meta-analysis of observational studies</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Dytfeld</surname>
            <given-names>Joanna</given-names>
          </name>
          <address>
            <phone>0048 61 8691147</phone>
            <email>dytfeld@poczta.onet.pl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Michalak</surname>
            <given-names>Michał</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2205 0971</institution-id><institution-id institution-id-type="GRID">grid.22254.33</institution-id><institution>Department of Family Medicine, </institution><institution>Poznan University of Medical Sciences, </institution></institution-wrap>ul. Przybyszewskiego 49, 60-355 Poznań, Poland </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2205 0971</institution-id><institution-id institution-id-type="GRID">grid.22254.33</institution-id><institution>Department of Computer Science and Statistics, </institution><institution>Poznan University of Medical Sciences, </institution></institution-wrap>ul. Dąbrowskiego 79, 60-529 Poznań, Poland </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>12</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>29</volume>
      <issue>2</issue>
      <fpage>301</fpage>
      <lpage>309</lpage>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>11</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>3</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Observational studies on osteoporotic fractures in patients with type 2 diabetes indicate their increased incidence compared to those without diabetes, but results are inconsistent. Currently, type 2 diabetes is not considered as an independent risk factor for low-energy fractures in elder subjects. The aim of the study was to assess the association between type 2 diabetes and risk for hip and vertebral fractures in postmenopausal women.</p>
        </sec>
        <sec>
          <title>Materials and methods</title>
          <p>We searched Medline, Web of Science and Cochrane databases for articles published before September 2013. Studies assessing fractures in women aged &gt;50 diagnosed with type 2 diabetes, regardless of the diabetes treatment, were deemed eligible. To estimate fracture risk meta-analysis in a random effect model was performed. The results were shown by the odds ratio (OR) and 95 % confidence interval (CI). Heterogeneity was tested using a Q-Cochrane test (significance was analyzed with <italic>p</italic> &lt; 0.10) and <italic>I</italic>
<sup>2</sup> measure.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>A total of 15 observational studies (11 cohort and 4 cross-sectional, 263.006 diabetics and 502.115 controls) were included. Thirteen papers provided information on the incidence of hip fractures, and seven on vertebral ones. The meta-analysis revealed type 2 diabetes was associated with higher risk for hip fracture (OR 1.296, 95 % CI (1.069–1.571), but not vertebral fracture (OR = 1.134, 95 % CI (0.936–1.374). There was significant heterogeneity between hip fracture studies. American origin was identified as a potential source of such heterogeneity.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>The results of our meta-analysis indicate there is an increased risk for hip fracture in postmenopausal women with type 2 diabetes.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Osteoporosis</kwd>
        <kwd>Fracture</kwd>
        <kwd>Type 2 diabetes</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer International Publishing Switzerland 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Diabetes and osteoporosis are two disease entities that significantly contribute to disease burden among elderly population. Prevalence of diabetes is nearly seven times higher in subjects over 60 than in the age group of 20–39 years [<xref ref-type="bibr" rid="CR1">1</xref>]. Diabetes is estimated to affect approximately 10.9 million (ca. 26.9 %) people over 65 years of age in the USA [<xref ref-type="bibr" rid="CR2">2</xref>], and 25–30 % of patients from that age group in Poland [<xref ref-type="bibr" rid="CR3">3</xref>]. Owing to disease duration and associated complications, medical costs of care for diabetic patients are over two times higher as compared to healthy subjects [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
      <p>Osteoporosis is also one of the main diseases characteristic for old age. Based on the WHO criteria, it has been diagnosed in 22 million women and 5.5 million men, aged 50–84 years, in the European Union [<xref ref-type="bibr" rid="CR5">5</xref>]. These numbers will presumably rise considerably due to population aging. Low-energy fractures, the most significant clinical feature of osteoporosis, are often associated with severe disability and increased mortality. Available data say that the risk of death in a woman after hip fracture increases by 10-20 % when compared to her healthy counterpart [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p>Until recently, type 2 diabetes and osteoporosis have not been linked despite their co-occurrence in people over 50 years of age, especially in postmenopausal women, due to several reasons. There is no clear notion that would jointly describe bone pathology in diabetes. In type 1 diabetes absolute insulin deficiency leads to reduced bone mass density (BMD), what partly explains increased susceptibility to fractures. Meanwhile, type 2 diabetes is usually characterized by hyperinsulinemia and this difference appears to determine the quality of bone in the two subtypes of the disease. Recently, it has become apparent that patients with type 2 diabetes have increased bone mineral density [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref>]. However, many [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]—but not all [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]—observations in these patients report, paradoxically, an increased number of vertebral, hip, distal radius, tibia and other fractures. Therefore, the issue of low-energy fracture risk in diabetics is complex—BMD alone appears not to be the key determinant. Obesity, usually accompanying type 2 diabetes, in some ways has a protective effect on bone density, whereas low body weight has been linked to higher fracture risk [<xref ref-type="bibr" rid="CR14">14</xref>]. Thus, determining whether type 2 diabetes contributes to increased bone fragility and should it be incorporated into the fracture risk calculator, seems to be of importance, as it may contribute to a more effective antifracture intervention.</p>
      <p>Owing to the fact that considerable amount of new data on that topic has become available since the last published meta-analysis, we decided to answer the question whether in postmenopausal women coexistence of type 2 diabetes increases the risk of low-energy fractures, vertebral and non-vertebral, particularly of the hip.</p>
    </sec>
    <sec id="Sec2">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Search strategy</title>
        <p>Two reviewers (JD and MM) performed the search on the association between type 2 diabetes and fracture risk independently. We limited the database search to studies carried out in humans, written in English, and published as full text before September 2013. The scope of the search included available papers from the period between 1967 and 2013. The qualified papers were assessed independently by the authors between September and November 2013.</p>
        <p>We included observational clinical studies searched in the following medical databases: Medline (using the PubMed website), Web of Science, and Cochrane Collaboration. Potentially relevant studies were identified using the following keywords: ‘diabetes type 2’, ‘fracture risk’, ‘osteoporosis’.</p>
      </sec>
      <sec id="Sec4">
        <title>Eligibility criteria</title>
        <p>The studies were considered eligible if they evaluated women, aged &gt;50, diagnosed with type 2 diabetes, regardless of the treatment (diet, oral drugs or insulin). We arbitrarily assumed that the time limit of menopause would be 50 years of age. Thus, we decided not to include papers with younger subjects. If a whole study cohort was separated into age groups, we selected the one that included patients &gt;50 years of age. Studies on men only, men and women analyzed jointly, and type 1 and 2 diabetes cases analyzed jointly were not considered for inclusion.</p>
        <p>Diabetes was diagnosed on the basis of medical records, patient self-reports, or the fact of taking hypoglycemic medication or insulin. We wished to exclude patients with type 1 diabetes from the analysis that is why we did not analyze papers where authors incorporated subjects with diabetes from the age of 18. If possible, we analyzed disease duration and excluded papers with disease onset before the age of 18.</p>
        <p>Studies were included only if there was a comparison group so that we could calculate odds ratios and mean differences in the outcomes between the groups. Similarly, if the control group comprised diabetics treated in a different way than the study group, such a study was also not included. When the authors of a given paper separated subgroups of type 2 diabetics into insulin and other treatments, we took into account these groups as total.</p>
        <p>In cases where data repeated in articles published by the same authors in different journals, the work with the largest study group was taken into account.</p>
        <p>The fractures were confirmed by medical records (reports from GPs, trained adjudicators, discharge cards), radiographs and self-reports. Vertebral and hip fractures were analyzed separately. If a study provided history of prevalent fractures and the number of fractures in prospective observation, we included data on incident fractures. Where incidence density was given, we converted it into incidence rate.</p>
      </sec>
      <sec id="Sec5">
        <title>Data extraction</title>
        <p>Two reviewers (JD and MM) independently screened the titles for relevance. Only titles that were mutually deemed ‘irrelevant’ were excluded. Abstracts and full-text articles were then screened for inclusion/exclusion criteria. Disagreements between the reviewers were resolved by means of a discussion. Furthermore, we supplemented the electronic search by hand-searching reference lists of relevant articles and reviews. One author was contacted personally.</p>
        <p>In case of each paper we extracted data on the surname of the first author, year of publication, country, study design, number of exposed and unexposed subjects, mean age of subjects and controls.</p>
      </sec>
      <sec id="Sec6">
        <title>Statistical analysis</title>
        <p>The analysis was performed using the STATA software, version 13.1 (StataCorp LP, USA). Random-effects model described by DerSimonian and Laird was used to aggregate the study data. In case of zero outcome events, continuity correction was performed by adding a correction factor of 0.5. Meta-analysis was conducted in accordance with the guidelines formulated in the Cochrane Handbook for Systematic Reviews of Interventions [<xref ref-type="bibr" rid="CR15">15</xref>]. The authors followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews and meta-analyses. Fracture risk analysis was performed using the odds ratio (OR). Statistical heterogeneity between the studies was evaluated with the Cochrane’s Q statistics and the <italic>I</italic>
<sup>2</sup> statistics, which demonstrated contribution of heterogeneity relative to the whole in case of each study. The significance level was established at <italic>P</italic> &lt; 0.10.</p>
        <p>The random effect model was used due to great <italic>I</italic>
<sup>2</sup> statistics value for the analyzed studies considering both, vertebral and hip fractures. The publication bias was explored by visual inspection of funnel plots and formally—with Egger’s regression asymmetry test [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, sensitivity analysis was performed for parameters showing significant heterogeneity.</p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Results</title>
      <sec id="Sec8">
        <title>Characteristics of the study group</title>
        <p>Figure <xref rid="Fig1" ref-type="fig">1</xref> shows a flow diagram describing the study selection process. In the 15 included studies, a total of 738.121 patients were analyzed: 263.006 subjects with DMT2 and 502.115 controls (numbers without [<xref ref-type="bibr" rid="CR27">27</xref>], as data were repeated in [<xref ref-type="bibr" rid="CR28">28</xref>]). Patient characteristics are shown in Table <xref rid="Tab1" ref-type="table">1</xref>. Out of these 15 studies, 4 studies were cross-sectional and 11 were cohort. Majority of them (except for one [<xref ref-type="bibr" rid="CR20">20</xref>]) used incidence rate ratios as a relative risk measure; we used unadjusted measures. Five studies were conducted in the USA, 1 in Canada, 6 in Europe (Austria, Spain, Sweden, Italy), and 3 in Asia (South Korea, Japan, Taiwan). Thirteen papers provided information on the incidence of hip fractures [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] (in case of Schwartz et al. [<xref ref-type="bibr" rid="CR27">27</xref>] more recent data on the same population [<xref ref-type="bibr" rid="CR28">28</xref>] were taken into account). In seven papers there were data on vertebral ones [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>PRISMA flow diagram for inclusion of relevant studies</p></caption><graphic xlink:href="40520_2016_562_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the analyzed studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Study</th><th align="left" colspan="3">DMT2</th><th align="left" colspan="3">Control</th><th align="left" rowspan="2">Type of study</th><th align="left">DMT2</th><th align="left">Control</th><th align="left"/></tr><tr><th align="left">Hip fracture</th><th align="left">Vertebral fracture</th><th align="left">
<italic>n</italic>
</th><th align="left">Hip fracture</th><th align="left">Vertebral fracture</th><th align="left">
<italic>n</italic>
</th><th align="left" colspan="2">Mean age (years)</th><th align="left">Region</th></tr></thead><tbody><tr><td align="left">Forsen (1999)</td><td align="left">69</td><td align="left">–</td><td align="left">825</td><td align="left">1112</td><td align="left">–</td><td align="left">17516</td><td align="left">Cohort</td><td align="left">&gt;50</td><td align="left">&gt;50</td><td align="left">Europe</td></tr><tr><td align="left">Nicodemus (2001)</td><td char="." align="left">38</td><td align="left">–</td><td char="." align="left">1682</td><td char="." align="left">452</td><td align="left">–</td><td char="." align="left">30377</td><td align="left">Cohort</td><td char="." align="left">62.3</td><td char="." align="left">61.5</td><td align="left">North America</td></tr><tr><td align="left">Schwartz (2001)</td><td char="." align="left">48<sup>b</sup>
</td><td char="." align="left">23</td><td char="." align="left">657</td><td char="." align="left">501<sup>b</sup>
</td><td char="." align="left">365</td><td char="." align="left">8997</td><td align="left">Cohort</td><td char="." align="left">71.6</td><td char="." align="left">71.7</td><td align="left">North America</td></tr><tr><td align="left">Gerdhem (2005)</td><td char="." align="left">3</td><td char="." align="left">2</td><td char="." align="left">74</td><td char="." align="left">48</td><td char="." align="left">46</td><td char="." align="left">1058</td><td align="left">Cross-sectional</td><td char="." align="left">75</td><td char="." align="left">75</td><td align="left">Europe</td></tr><tr><td align="left">de Liefde (2005)</td><td char="." align="left">28</td><td align="left">–</td><td char="." align="left">483</td><td char="." align="left">137</td><td align="left">–</td><td char="." align="left">3481</td><td align="left">Cohort</td><td char="." align="left">73.8<sup>a</sup>
</td><td char="." align="left">68.8<sup>a</sup>
</td><td align="left">Europe</td></tr><tr><td align="left">Bonds (2006)</td><td char="." align="left">128</td><td char="." align="left">99</td><td char="." align="left">5285</td><td char="." align="left">1531</td><td char="." align="left">1336</td><td char="." align="left">88120</td><td align="left">Cohort</td><td char="." align="left">64.9</td><td char="." align="left">63.5</td><td align="left">North America</td></tr><tr><td align="left">Dobnig (2006)</td><td char="." align="left">41</td><td align="left">–</td><td char="." align="left">583</td><td char="." align="left">69</td><td align="left">–</td><td char="." align="left">1081</td><td align="left">Cohort</td><td char="." align="left">84.3</td><td char="." align="left">82.8</td><td align="left">Europe</td></tr><tr><td align="left">Janghorbani (2006)</td><td char="." align="left">125</td><td align="left">–</td><td char="." align="left">8348</td><td char="." align="left">1255</td><td align="left">–</td><td char="." align="left">101343</td><td align="left">Cohort</td><td char="." align="left">61.7</td><td char="." align="left">55.9</td><td align="left">North America</td></tr><tr><td align="left">Lipscombe (2007)</td><td char="." align="left">48</td><td align="left">–</td><td char="." align="left">5271</td><td char="." align="left">80</td><td align="left">–</td><td char="." align="left">10276</td><td align="left">Cohort</td><td char="." align="left">≥66</td><td char="." align="left">≥66</td><td align="left">North America</td></tr><tr><td align="left">Chen (2008)</td><td char="." align="left">8992</td><td align="left">–</td><td char="." align="left">238129</td><td char="." align="left">5110</td><td align="left">–</td><td char="." align="left">238417</td><td align="left">Cohort</td><td char="." align="left">&gt;45</td><td char="." align="left">&gt;45</td><td align="left">Asia</td></tr><tr><td align="left">Sosa (2008)</td><td char="." align="left">1</td><td char="." align="left">5</td><td char="." align="left">111</td><td char="." align="left">0</td><td char="." align="left">5</td><td char="." align="left">91</td><td align="left">Cross-sectional</td><td char="." align="left">71.7</td><td char="." align="left">69.9</td><td align="left">Europe</td></tr><tr><td align="left">Yamamoto (2009)</td><td align="left">–</td><td char="." align="left">43</td><td char="." align="left">137</td><td align="left">–</td><td char="." align="left">155</td><td char="." align="left">622</td><td align="left">Cross-sectional</td><td char="." align="left">65.9</td><td char="." align="left">67.5</td><td align="left">Asia</td></tr><tr><td align="left">Schwartz (2011)</td><td char="." align="left">84</td><td align="left">–</td><td char="." align="left">770</td><td char="." align="left">1117</td><td align="left">–</td><td char="." align="left">8679</td><td align="left">Cohort</td><td char="." align="left">73.6</td><td char="." align="left">73.4</td><td align="left">North America</td></tr><tr><td align="left">Gaudio (2012)</td><td align="left">–</td><td char="." align="left">8</td><td char="." align="left">40</td><td align="left">–</td><td char="." align="left">3</td><td char="." align="left">40</td><td align="left">Cross-sectional</td><td char="." align="left">63.7</td><td char="." align="left">62.1</td><td align="left">Europe</td></tr><tr><td align="left">Jung (2012)</td><td char="." align="left">20</td><td char="." align="left">35</td><td char="." align="left">1268</td><td char="." align="left">12</td><td char="." align="left">31</td><td char="." align="left">1014</td><td align="left">Cohort</td><td char="." align="left">60.6</td><td char="." align="left">61.4</td><td align="left">Asia</td></tr></tbody></table><table-wrap-foot><p>DMT2—type 2 diabetes mellitus</p><p>
<italic>n</italic>—all patients in the given category (diabetes/controls)</p><p>
<sup>a</sup>Mean age is given for the whole study group, both men and women</p><p>
<sup>b</sup>Hip fractures were not taken into meta-analysis since updated data were given in Schwartz 2011</p></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec id="Sec9">
        <title>Vertebral fractures</title>
        <p>Figure <xref rid="Fig3" ref-type="fig">3</xref> presents individual study results and the overall study result for papers on vertebral fracture frequency in females with type 2 diabetes. It shows that the risk of these fractures is not different than in healthy ones OR = 1.134 (95 % CI (confidence interval) (0.936–1.374). Out of the 7 included studies, one [<xref ref-type="bibr" rid="CR7">7</xref>] showed a difference in vertebral fracture incidence in the studied cohort when compared to the healthy females (OR = 1.240, 95 % CI (1.009–1.524). As it comprised the largest study sample, it had the greatest weight. Four studies showed lower OR when compared to controls, although the difference was not statistically significant. The range of individual risks was 0.611-3.083.</p>
        <p>The results of the funnel plot and the Egger’s test (<italic>P</italic> = 0.733) show that the analysis for vertebral fractures has no publication bias (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a). In addition, the studies appear to be homogeneous (<italic>Q</italic> = 6.96, <italic>P</italic> = 0.325, <italic>I</italic>
<sup>2</sup> = 13.7 %) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Funnel <italic>plot</italic> for vertebral (<bold>a</bold>) and hip (<bold>b</bold>) fracture studies</p></caption><graphic xlink:href="40520_2016_562_Fig2_HTML" id="MO2"/></fig>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Meta-analysis for vertebral fractures</p></caption><graphic xlink:href="40520_2016_562_Fig3_HTML" id="MO3"/></fig>
</p>
        <p>The subgroup meta-analysis by study design shows that the summary estimate remains insignificant when it is calculated separately for cohort and cross-sectional studies (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Meta-analysis for hip/vertebral fractures by study design and geographic region</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Subgroup</th><th align="left" rowspan="2">No. of studies</th><th align="left" rowspan="2">Summary OR</th><th align="left" rowspan="2">95 % CI</th><th align="left" colspan="3">Heterogeneity</th></tr><tr><th align="left">
<italic>Q</italic>
</th><th align="left">
<italic>P</italic>
</th><th align="left">
<italic>I</italic>
<sup>2</sup> (%)</th></tr></thead><tbody><tr><td align="left" colspan="7">Hip fracture</td></tr><tr><td align="left" colspan="7"> Geographic area</td></tr><tr><td align="left">  Asia</td><td char="." align="char">2</td><td char="." align="char">1.790</td><td align="left">1.729–1.854</td><td char="." align="char">0.63</td><td char="." align="char">0.428</td><td char="." align="char">0.0</td></tr><tr><td align="left">  Europe</td><td char="." align="char">5</td><td char="." align="char">1.308</td><td align="left">1.084–1.579</td><td char="." align="char">1.68</td><td char="." align="char">0.794</td><td char="." align="char">0.0</td></tr><tr><td align="left">  North America</td><td char="." align="char">5</td><td char="." align="char">1.197</td><td align="left">0.973–1.473</td><td char="." align="char">14.49</td><td char="." align="char">0.006</td><td char="." align="char">72.4</td></tr><tr><td align="left" colspan="7"> Study design</td></tr><tr><td align="left">  Cohort</td><td char="." align="char">10</td><td char="." align="char">1.304</td><td align="left">1.072–1.586</td><td char="." align="char">74.7</td><td char="." align="char">0.000</td><td char="." align="char">87.9</td></tr><tr><td align="left">  Cross-sectional</td><td char="." align="char">2</td><td char="." align="char">1.007</td><td align="left">0.330–3.075</td><td char="." align="char">0.35</td><td char="." align="char">0.556</td><td char="." align="char">0.0</td></tr><tr><td align="left" colspan="7">Vertebral fracture</td></tr><tr><td align="left"> Geographic area</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">  Asia</td><td char="." align="char">2</td><td char="." align="char">1.140</td><td align="left">0.753–1.727</td><td char="." align="char">1.73</td><td char="." align="char">0.189</td><td char="." align="char">42.1</td></tr><tr><td align="left">  Europe</td><td char="." align="char">3</td><td char="." align="char">1.139</td><td align="left">0.439–2.958</td><td char="." align="char">2.92</td><td char="." align="char">0.233</td><td char="." align="char">31.4</td></tr><tr><td align="left">  North America</td><td char="." align="char">2</td><td char="." align="char">1.084</td><td align="left">0.765–1.536</td><td char="." align="char">2.31</td><td char="." align="char">0.128</td><td char="." align="char">56.7</td></tr><tr><td align="left" colspan="7"> Study design</td></tr><tr><td align="left">  Cohort</td><td char="." align="char">3</td><td char="." align="char">1.058</td><td align="left">0.818–1.369</td><td char="." align="char">3.19</td><td char="." align="char">0.202</td><td char="." align="char">37.4</td></tr><tr><td align="left">  Cross-sectional</td><td char="." align="char">4</td><td char="." align="char">1.315</td><td align="left">0.889–1.944</td><td char="." align="char">3.11</td><td char="." align="char">0.376</td><td char="." align="char">3.4</td></tr></tbody></table><table-wrap-foot><p>
<italic>P</italic>—<italic>P</italic> for heterogeneity</p></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec id="Sec10">
        <title>Hip fractures</title>
        <p>Out of the 12 studies on type 2 diabetes and hip fracture, five [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR26">26</xref>] found a statistically significant association and 7 found no link [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The odds ratio among the studies varied from 0.82 to 2.48 (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). When all 12 studies were analyzed, diabetes was demonstrated to increase the risk of hip fractures by 29.6 % (95 % CI (1.069–1.571) (<italic>P</italic> = 0.008).<fig id="Fig4"><label>Fig. 4</label><caption><p>Meta-analysis for hip fractures</p></caption><graphic xlink:href="40520_2016_562_Fig4_HTML" id="MO4"/></fig>
</p>
        <p>However, a significant heterogeneity between the studies (Q = 75.68, df(Q) = 11, <italic>P</italic> = 0.000 <italic>p</italic> &lt; 0.0001, <italic>I</italic>
<sup><italic>2</italic></sup> = 85.5 %) was observed. The sensitivity analysis showed that papers by Schwartz et al. [<xref ref-type="bibr" rid="CR28">28</xref>] and Chen [<xref ref-type="bibr" rid="CR20">20</xref>] contributed to heterogeneity the most. After exclusion of both papers, the association between type 2 diabetes and hip fractures was shown to increase [OR = 1.314, 95 % CI (1.193–1.448)] and the heterogeneity was no longer significant (<italic>P</italic> = 0.904, <italic>I</italic>
<sup><italic>2</italic></sup> = 0,0 %).</p>
        <p>For the hip fracture studies, the funnel plot suggested an existing bias and their importance was checked by the Egger’s test, which appeared to be significant (<italic>P</italic> = 0.009) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b).</p>
        <p>We also conducted subgroup meta-analysis by geographical region and study design (cohort vs cross-sectional) (Table <xref rid="Tab2" ref-type="table">2</xref>). The analysis revealed that the higher risk of hip fracture was attributable to cohort studies only (OR = 1.304, 95 % CI (1.072–1. 586). The cohort studies were shown to be heterogenous (<italic>P</italic> = 0.00; <italic>I</italic>
<sup>2</sup> = 87.9 %). Moreover, the highest risk of hip fracture was shown in studies conducted in Asia [OR = 1.790; 95 %CI (1.729–1.854)]. For European studies the OR was 1.308 [95 % CI (1.084–1.579)].</p>
      </sec>
    </sec>
    <sec id="Sec11">
      <title>Discussion</title>
      <p>The results of our meta-analysis which included 15 observational studies showed that women with type 2 diabetes aged &gt;50 are at a higher (by ca. 30 %) risk of osteoporotic hip fracture (OR = 1.296; 95 % CI (1.069–1.571), when compared to their healthy peers. In case of vertebral fractures, diabetes did not increase the risk (OR = 1.134, 95 % CI (0.936–1.374). However, there was significant heterogeneity in case of hip fracture studies. In the subgroup meta-analysis, American origin was identified as a potential source of such heterogeneity.</p>
      <p>Although 2 published meta-analyses revealed the risk of fracture in diabetics to be elevated by approximately 20 % [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], from the scientific and clinical point of view it seems substantial to separate a particular subgroup of patients in the calculations—namely postmenopausal women. They constitute the group of the highest prevalence of osteoporosis and, owing to clinical consequences of fractures, postmenopausal women should be the actual target of antifracture intervention. At the same time, type 2 diabetes and osteoporosis often coexist in these patients, sharing some of the risk factors (immobility, age). Similarily to our observations, Vestergaard et al., showed that both men and women with type 2 diabetes are at an increased risk of hip and wrist fracture, but not spinal fracture [<xref ref-type="bibr" rid="CR30">30</xref>]. However, the same study showed the risk of any low-energy fracture in people with diabetes of both sexes was not different than in controls. Janghorbani et al., in their meta-analysis provided data on hip fracture risk in females with type 2 diabetes and the risk ratio (RR) was 2.1 (95 % CI 1.6–2.7). RR calculated cumulatively for men and women with type 2 diabetes, regardless of age, was 1.7 (95 % CI 1.3–2.2) for hip fracture, and 1.2 (95 % CI = 1.01–1.5) for any fracture [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
      <p>One of the studies that made heterogeneity significant in hip fracture studies was the paper by Schwartz et al., which took three observational studies into account—Study of Osteoporotic Fractures (SOF), Osteoporotic Fractures in Men (MrOS), and Health, Aging and Body Composition Study (Health ABC) [<xref ref-type="bibr" rid="CR28">28</xref>]. Due to eligibility criteria, we did not include MrOS data. However, risk estimates were lower in this study (OR 0.829, (95 % CI = 0.655–1.049). Lower fracture incidence might have resulted from inclusion of Afro-Americans in the Health ABC study (ca. 50 % females)—there are data on lower fracture rates in Afro-American women when compared to white females [<xref ref-type="bibr" rid="CR32">32</xref>]. This issue is more complex, as recent studies show that relative risk of non-skull fractures in Afro-American subjects with diabetes is actually higher (HR = 1.87) than in Whites with diabetes (HR = 1.22) [<xref ref-type="bibr" rid="CR33">33</xref>]. By contrast, Schwartz et al. in separate analysis of Health ABC data did not observe an effect of type 2 diabetes on the rate of bone loss for black women at the femoral neck or total hip [<xref ref-type="bibr" rid="CR34">34</xref>]. The role of ethnic differences in fracture incidence is open to debate. This also applies to Asian studies, which influenced hip fracture risk estimates in our meta-analysis. Given the paucity of data on low-energy fractures in Asian population, there have been no such subgroup analyses in previously published meta-analyses.</p>
      <p>There are several complex pathways by which type 2 diabetes might influence bone health. One explanation may be the rate of bone loss or bone turnover in diabetes, which remains the topic of much heated debate. Contrary to previously cited Health ABC study, other authors demonstrated slower bone loss at the spine [<xref ref-type="bibr" rid="CR35">35</xref>]. Lower activity of bone formation markers in patients diagnosed with diabetes was also reported [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], although the data are inconsistent.</p>
      <p>Moreover, there are reports showing that in type 2 diabetes trabecular bone structure is intact or enhanced, whereas it is the cortical bone that is preferentially compromised [<xref ref-type="bibr" rid="CR37">37</xref>]. This finding is relevant as the cortical bone builds 80 % of the skeleton and fractures in diabetes most often occur in sites rich in cortical bone [<xref ref-type="bibr" rid="CR38">38</xref>].</p>
      <p>The underlying mechanisms whereby type 2 diabetes leads to increased likelihood of fracture are plentiful. Much attention has been given to advanced glycation end products (AGEs) and their receptors (RAGE), whose interaction causes pathological cross-linking in organic bone matrix, rendering the bone more fragile and brittle [<xref ref-type="bibr" rid="CR39">39</xref>]. Urine calcium loss resulting from hyperglycemia has a detrimental effect on bone density. Negative calcium balance and—contrary to what one might expect—subsequent secondary hypoparathyroidism also play a role in the process [<xref ref-type="bibr" rid="CR40">40</xref>]. At the same time, diabetic nephropathy itself leads to calcium/phosphorus metabolic disturbances. It is also suggested that microangiopathy contributes to impaired blood supply to the bone and that hyperglycemia worsens bone healing [<xref ref-type="bibr" rid="CR41">41</xref>]. Besides these alterations, type 2 diabetes subjects are known to be more prone to vitamin D deficiency than their healthy peers [<xref ref-type="bibr" rid="CR42">42</xref>]. Last but not least, falls (most often preceding fractures) are more frequent in described patients, among other things due to coexisting neuropathy, retinopathy and episodes of hypoglycemia [<xref ref-type="bibr" rid="CR43">43</xref>].</p>
      <p>The idea of incorporating type 2 diabetes into the fracture risk calculator seems appealing, however, according to expert opinions—premature. To evaluate clinical utility of fracture risk calculation in patients with type 2 diabetes, Schwartz et al., estimated the sensitivity of FRAX in fracture prediction in that particular group [<xref ref-type="bibr" rid="CR28">28</xref>]. Analyzing three study cohorts (SOF, MrOs and HealthABC), they showed that the same value of a 10-year risk in women with diabetes corresponds with the <italic>T</italic> score of about 0.5 units higher than <italic>T</italic> score in healthy counterparts. In other words, women with type 2 diabetes tend to fracture at higher <italic>T</italic> score. That is one of the reasons why clinicians intuitively believe that DXA parameters alone do not reflect the complexity of bone pathology in diabetes. Potential mechanisms that impair bone competence and cause alterations in bone microarchitecture might be assessed by means of diverse methods (e.g. cortical thickness, trabecular bone volume, quantitative computed tomography of the bone), although the vast majority of them have not yet entered everyday clinical practice. Recently, reports on the use of bone microindentation testing have been published. Technological advancement has allowed to make this method minimally invasive [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. This technique evaluates the ability of bone to resist crack generation and propagation by measuring indentation distances performed via in vivo testing. Subsequently, bone material strength (BMS) is calculated. Studies showed BMS is affected in hip fracture patients [<xref ref-type="bibr" rid="CR46">46</xref>].</p>
      <p>Although our findings support the hypothesis that type 2 diabetes increases hip fracture risk, it must be considered within the context of strengths and weaknesses. One cannot exclude that patients with type 1 diabetes or LADA were taken as type 2 and vice versa—type 2 diabetes might have been undiagnosed which would, respectively, overestimate and underestimate the risk. In incorporated papers we tried to critically verify the type of diabetes in the included patients. However, the distinction between type 1 and 2 is not as clear as it was 10 or 20 years ago. We also decided to incorporate studies that relied on self-reported diabetes [<xref ref-type="bibr" rid="CR28">28</xref>], or used old diagnostic criteria [<xref ref-type="bibr" rid="CR18">18</xref>], which altogether might be subject to potential disease misclassification bias. Secondly, there was relatively small amount of data on vertebral fractures—which might result from underestimation of that type of fractures in general. Moreover, some papers relied on self-reports for fractures, which for vertebral ones—contrary to other types—were shown to have relatively low (51 %) validity [<xref ref-type="bibr" rid="CR47">47</xref>]. One study [<xref ref-type="bibr" rid="CR29">29</xref>] took all fractures—not only low-energy ones—into account.</p>
    </sec>
    <sec id="Sec12">
      <title>Conclusions</title>
      <p>Our meta-analysis supports the association between type 2 diabetes and increased hip fracture risk in postmenopausal women. The results, however, should be interpreted with caution due to large heterogeneity of studies. Possibly, they does not answer all questions on bone fragility in patients suffering with type 2 diabetes but implies thinking about low-energy fracture probability in a growing number of postmenopausal women with coexisting type 2 diabetes but implies. Further studies are needed to elucidate the complexity of bone pathology in diabetes.</p>
    </sec>
  </body>
  <back>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <sec id="FPar1">
        <title>Conflict of interest</title>
        <p>The authors declare that they had no conflict of interest.</p>
      </sec>
      <sec id="d29e1659">
        <title>Statement of human and animal rights</title>
        <p>This article does not contain any studies with human participants or animals performed by any of the authors.</p>
      </sec>
      <sec id="d29e1664">
        <title>Informed consent</title>
        <p>For this type of study formal consent is not required.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Sicree</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Zimmet</surname>
              <given-names>PZ</given-names>
            </name>
          </person-group>
          <article-title>Global estimates of the prevalence of diabetes for 2010 and 2030</article-title>
          <source>Diabetes Res Clin Pract</source>
          <year>2010</year>
          <volume>7</volume>
          <fpage>4</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1016/j.diabres.2009.10.007</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="other">Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. [Internet]. Atlanta, GA; 2014 [cited]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf">http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf</ext-link>. Accessed 28 Aug 2015</mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="other">International Diabetes Federation. Diabetes Atlas, 2015. [Internet]. Belgium, Brussels. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.diabetesatlas.org/across-the-globe.html">http://www.diabetesatlas.org/across-the-globe.html</ext-link>. Accessed 23 Mar 2016</mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Dall</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Halder</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>American diabetes association. economic costs of diabetes in the U.S. in 2012</article-title>
          <source>Diabetes Care</source>
          <year>2013</year>
          <volume>36</volume>
          <fpage>1033</fpage>
          <lpage>1046</lpage>
          <pub-id pub-id-type="doi">10.2337/dc12-2625</pub-id>
          <pub-id pub-id-type="pmid">23468086</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ström</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Borgström</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kanis</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)</article-title>
          <source>Arch Osteoporos</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>59</fpage>
          <lpage>155</lpage>
          <pub-id pub-id-type="doi">10.1007/s11657-011-0060-1</pub-id>
          <?supplied-pmid 22886101?>
          <pub-id pub-id-type="pmid">22886101</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abrahamsen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>van Staa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ariely</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Excess mortality following hip fracture: a systematic epidemiological review</article-title>
          <source>Osteoporos Int</source>
          <year>2009</year>
          <volume>20</volume>
          <fpage>1633</fpage>
          <lpage>1650</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-009-0920-3</pub-id>
          <?supplied-pmid 19421703?>
          <pub-id pub-id-type="pmid">19421703</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonds</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>AV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2006</year>
          <volume>91</volume>
          <fpage>3404</fpage>
          <lpage>3410</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2006-0614</pub-id>
          <?supplied-pmid 16804043?>
          <pub-id pub-id-type="pmid">16804043</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melton</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Riggs</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Leibson</surname>
              <given-names>CL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A bone structural basis for fracture risk in diabetes</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>93</volume>
          <fpage>4804</fpage>
          <lpage>4809</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2008-0639</pub-id>
          <?supplied-pmid 18796521?>
          <pub-id pub-id-type="pmid">18796521</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kao</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Kammerer</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Type 2 diabetes is associated with increased bone mineral density in Mexican-American women</article-title>
          <source>Arch Med Res</source>
          <year>2003</year>
          <volume>34</volume>
          <fpage>399</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="doi">10.1016/j.arcmed.2002.07.001</pub-id>
          <?supplied-pmid 14602507?>
          <pub-id pub-id-type="pmid">14602507</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jung</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fracture incidence and risk of osteoporosis in female type 2 diabetic patients in Korea</article-title>
          <source>Diabetes Metab J</source>
          <year>2012</year>
          <volume>36</volume>
          <fpage>144</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.4093/dmj.2012.36.2.144</pub-id>
          <?supplied-pmid 22540051?>
          <pub-id pub-id-type="pmid">22540051</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Daele</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Stolk</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Burger</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study</article-title>
          <source>Ann Intern Med</source>
          <year>1995</year>
          <volume>122</volume>
          <fpage>409</fpage>
          <lpage>414</lpage>
          <pub-id pub-id-type="doi">10.7326/0003-4819-122-6-199503150-00002</pub-id>
          <?supplied-pmid 7856988?>
          <pub-id pub-id-type="pmid">7856988</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerdhem</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Isaksson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Akesson</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus</article-title>
          <source>Osteoporos Int</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>1506</fpage>
          <lpage>1512</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-005-1877-5</pub-id>
          <?supplied-pmid 15824889?>
          <pub-id pub-id-type="pmid">15824889</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dobnig</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Piswanger-Sölkner</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2006</year>
          <volume>91</volume>
          <fpage>3355</fpage>
          <lpage>3363</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2006-0460</pub-id>
          <?supplied-pmid 16735485?>
          <pub-id pub-id-type="pmid">16735485</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Laet</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kanis</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Odén</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Body mass index as a predictor of fracture risk: a meta-analysis</article-title>
          <source>Osteoporos Int</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>1330</fpage>
          <lpage>1338</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-005-1863-y</pub-id>
          <?supplied-pmid 15928804?>
          <pub-id pub-id-type="pmid">15928804</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="other">Higgins JPT, Green S. Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. <ext-link ext-link-type="uri" xlink:href="http://www.cochrane.org/training/cochrane-handbook">http://www.cochrane.org/training/cochrane-handbook</ext-link>. Accessed 15 Nov 2014</mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Davey Smith</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>
          <source>BMJ</source>
          <year>1997</year>
          <volume>315</volume>
          <fpage>629</fpage>
          <lpage>634</lpage>
          <pub-id pub-id-type="doi">10.1136/bmj.315.7109.629</pub-id>
          <?supplied-pmid 9310563?>
          <pub-id pub-id-type="pmid">9310563</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sterne</surname>
              <given-names>JAC</given-names>
            </name>
            <name>
              <surname>Egger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>GD</given-names>
            </name>
          </person-group>
          <article-title>Investigating and dealing with publication and other biases in meta-analysis</article-title>
          <source>BMJ</source>
          <year>2001</year>
          <volume>323</volume>
          <fpage>101</fpage>
          <lpage>105</lpage>
          <pub-id pub-id-type="doi">10.1136/bmj.323.7304.101</pub-id>
          <?supplied-pmid 11451790?>
          <pub-id pub-id-type="pmid">11451790</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Liefde</surname>
              <given-names>II</given-names>
            </name>
            <name>
              <surname>van der Klift</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>de Laet</surname>
              <given-names>CEDH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study</article-title>
          <source>Osteoporos Int</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>1713</fpage>
          <lpage>1720</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-005-1909-1</pub-id>
          <?supplied-pmid 15940395?>
          <pub-id pub-id-type="pmid">15940395</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lipscombe</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Jamal</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Booth</surname>
              <given-names>GL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The risk of hip fractures in older individuals with diabetes: a population-based study</article-title>
          <source>Diabetes Care</source>
          <year>2007</year>
          <volume>30</volume>
          <fpage>835</fpage>
          <lpage>841</lpage>
          <pub-id pub-id-type="doi">10.2337/dc06-1851</pub-id>
          <?supplied-pmid 17392544?>
          <pub-id pub-id-type="pmid">17392544</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>CY</given-names>
            </name>
          </person-group>
          <article-title>Increased risks of hip fracture in diabetic patients of Taiwan: a population-based study</article-title>
          <source>Diabetes Care</source>
          <year>2008</year>
          <volume>31</volume>
          <fpage>75</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.2337/dc07-1072</pub-id>
          <?supplied-pmid 17947342?>
          <pub-id pub-id-type="pmid">17947342</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sosa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saavedra</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jódar</surname>
              <given-names>E</given-names>
            </name>
            <collab>GIUMO Study Group</collab>
            <etal/>
          </person-group>
          <article-title>Bone mineral density and risk of fractures in aging, obese post-menopausal women with type 2 diabetes. The GIUMO Study</article-title>
          <source>Aging Clin Exp Res</source>
          <year>2009</year>
          <volume>21</volume>
          <fpage>27</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1007/BF03324895</pub-id>
          <?supplied-pmid 19225266?>
          <pub-id pub-id-type="pmid">19225266</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamauchi</surname>
              <given-names>MM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications</article-title>
          <source>J Bone Miner Res</source>
          <year>2009</year>
          <volume>24</volume>
          <fpage>702</fpage>
          <lpage>709</lpage>
          <pub-id pub-id-type="doi">10.1359/jbmr.081207</pub-id>
          <?supplied-pmid 19049338?>
          <pub-id pub-id-type="pmid">19049338</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaudio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Privitera</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Battaglia</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2012</year>
          <volume>97</volume>
          <fpage>3744</fpage>
          <lpage>3750</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2012-1901</pub-id>
          <?supplied-pmid 22855334?>
          <pub-id pub-id-type="pmid">22855334</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forsén</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Midthjell</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey</article-title>
          <source>Diabetologia</source>
          <year>1999</year>
          <volume>42</volume>
          <fpage>920</fpage>
          <lpage>925</lpage>
          <pub-id pub-id-type="doi">10.1007/s001250051248</pub-id>
          <?supplied-pmid 10491750?>
          <pub-id pub-id-type="pmid">10491750</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicodemus</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Folsom</surname>
              <given-names>AR</given-names>
            </name>
            <collab>Iowa Women’s Health Study</collab>
          </person-group>
          <article-title>Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women</article-title>
          <source>Diabetes Care</source>
          <year>2001</year>
          <volume>24</volume>
          <fpage>1192</fpage>
          <lpage>1197</lpage>
          <pub-id pub-id-type="doi">10.2337/diacare.24.7.1192</pub-id>
          <?supplied-pmid 11423501?>
          <pub-id pub-id-type="pmid">11423501</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janghorbani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>FB</given-names>
            </name>
            <name>
              <surname>Willett</surname>
              <given-names>WC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses’ Health Study</article-title>
          <source>Diabetes Care</source>
          <year>2007</year>
          <volume>30</volume>
          <fpage>1730</fpage>
          <lpage>1735</lpage>
          <pub-id pub-id-type="doi">10.2337/dc06-2363</pub-id>
          <?supplied-pmid 17389335?>
          <pub-id pub-id-type="pmid">17389335</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Sellmeyer</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Ensrud</surname>
              <given-names>KE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Older women with diabetes have an increased risk of fracture: a prospective study</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2001</year>
          <volume>86</volume>
          <fpage>32</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1210/jcem.86.1.7139</pub-id>
          <?supplied-pmid 11231974?>
          <pub-id pub-id-type="pmid">11231974</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Vittinghoff</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bauer</surname>
              <given-names>DC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes</article-title>
          <source>JAMA</source>
          <year>2011</year>
          <volume>305</volume>
          <fpage>2184</fpage>
          <lpage>2192</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.2011.715</pub-id>
          <?supplied-pmid 21632482?>
          <pub-id pub-id-type="pmid">21632482</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pritchard</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Giangregorio</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Ioannidis</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ankle fractures do not predict osteoporotic fractures in women with or without diabetes</article-title>
          <source>Osteoporos Int</source>
          <year>2012</year>
          <volume>23</volume>
          <fpage>957</fpage>
          <lpage>962</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-011-1648-4</pub-id>
          <?supplied-pmid 21562874?>
          <pub-id pub-id-type="pmid">21562874</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vestergaard</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes–a meta-analysis</article-title>
          <source>Osteoporos Int</source>
          <year>2007</year>
          <volume>18</volume>
          <fpage>427</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-006-0253-4</pub-id>
          <?supplied-pmid 17068657?>
          <pub-id pub-id-type="pmid">17068657</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janghorbani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Van Dam</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Willett</surname>
              <given-names>WC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture</article-title>
          <source>Am J Epidemiol</source>
          <year>2007</year>
          <volume>166</volume>
          <fpage>495</fpage>
          <lpage>505</lpage>
          <pub-id pub-id-type="doi">10.1093/aje/kwm106</pub-id>
          <?supplied-pmid 17575306?>
          <pub-id pub-id-type="pmid">17575306</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Litwic</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Geographic differences in fractures among women</article-title>
          <source>Womens Health</source>
          <year>2012</year>
          <volume>8</volume>
          <fpage>673</fpage>
          <lpage>684</lpage>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Looker</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Eberhardt</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Saydah</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Diabetes and fracture risk in older U.S. adults</article-title>
          <source>Bone</source>
          <year>2016</year>
          <volume>82</volume>
          <fpage>9</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bone.2014.12.008</pub-id>
          <?supplied-pmid 25576672?>
          <pub-id pub-id-type="pmid">25576672</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Ewing</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Porzig</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diabetes and change in bone mineral density at the hip, calcaneus, spine, and radius in older women</article-title>
          <source>Front Endocrinol (Lausanne)</source>
          <year>2013</year>
          <volume>4</volume>
          <fpage>62</fpage>
          <pub-id pub-id-type="pmid">23755040</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khalil</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sutton-Tyrrell</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Strotmeyer</surname>
              <given-names>ES</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Menopausal bone changes and incident fractures in diabetic women: a cohort study</article-title>
          <source>Osteoporos Int</source>
          <year>2011</year>
          <volume>22</volume>
          <fpage>1367</fpage>
          <lpage>1376</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-010-1357-4</pub-id>
          <?supplied-pmid 20658126?>
          <pub-id pub-id-type="pmid">20658126</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kanazawa</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tada</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes</article-title>
          <source>Bone</source>
          <year>2011</year>
          <volume>48</volume>
          <fpage>720</fpage>
          <lpage>725</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bone.2010.12.020</pub-id>
          <?supplied-pmid 21185419?>
          <pub-id pub-id-type="pmid">21185419</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burghardt</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Issever</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>AV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2010</year>
          <volume>95</volume>
          <fpage>5045</fpage>
          <lpage>5055</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2010-0226</pub-id>
          <?supplied-pmid 20719835?>
          <pub-id pub-id-type="pmid">20719835</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leslie</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>AV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Type 2 diabetes and bone</article-title>
          <source>J Bone Miner Res</source>
          <year>2012</year>
          <volume>27</volume>
          <fpage>2231</fpage>
          <lpage>2237</lpage>
          <pub-id pub-id-type="doi">10.1002/jbmr.1759</pub-id>
          <?supplied-pmid 23023946?>
          <pub-id pub-id-type="pmid">23023946</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goh</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>The role of advanced glycation end products in progression and complications of diabetes</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>93</volume>
          <fpage>1143</fpage>
          <lpage>1152</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2007-1817</pub-id>
          <?supplied-pmid 18182449?>
          <pub-id pub-id-type="pmid">18182449</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gregorio</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cristallini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Santeusanio</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes?</article-title>
          <source>Diabetes Res Clin Pract</source>
          <year>1994</year>
          <volume>23</volume>
          <fpage>43</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1016/0168-8227(94)90126-0</pub-id>
          <?supplied-pmid 8013262?>
          <pub-id pub-id-type="pmid">8013262</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kawao</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tamura</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasminogen activator inhibitor-1 is involved in impaired bone repair associated with diabetes in female mice</article-title>
          <source>PLoS One</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>e92686</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0092686</pub-id>
          <?supplied-pmid 24651693?>
          <pub-id pub-id-type="pmid">24651693</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pittas</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Dawson-Hughes</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Vitamin D and calcium intake in relation to type 2 diabetes in women</article-title>
          <source>Diabetes Care</source>
          <year>2006</year>
          <volume>29</volume>
          <fpage>650</fpage>
          <lpage>656</lpage>
          <pub-id pub-id-type="doi">10.2337/diacare.29.03.06.dc05-1961</pub-id>
          <?supplied-pmid 16505521?>
          <pub-id pub-id-type="pmid">16505521</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roman de Mettelinge</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cambier</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Calders</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Understanding the relationship between type 2 diabetes mellitus and falls in older adults: a prospective cohort study</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>e67055</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0067055</pub-id>
          <?supplied-pmid 23825617?>
          <pub-id pub-id-type="pmid">23825617</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diez-Perez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Güerri</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nogues</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Microindentation for in vivo measurement of bone tissue mechanical properties in humans</article-title>
          <source>J Bone Miner Res</source>
          <year>2010</year>
          <volume>25</volume>
          <fpage>1877</fpage>
          <lpage>1885</lpage>
          <pub-id pub-id-type="doi">10.1002/jbmr.73</pub-id>
          <?supplied-pmid 20200991?>
          <pub-id pub-id-type="pmid">20200991</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farr</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Drake</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Amin</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>In vivo assessment of bone quality in postmenopausal women with type 2 diabetes</article-title>
          <source>J Bone Miner Res</source>
          <year>2014</year>
          <volume>29</volume>
          <fpage>787</fpage>
          <lpage>795</lpage>
          <pub-id pub-id-type="doi">10.1002/jbmr.2106</pub-id>
          <?supplied-pmid 24123088?>
          <pub-id pub-id-type="pmid">24123088</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Güerri-Fernández</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Nogués</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Quesada Gómez</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls</article-title>
          <source>J Bone Miner Res</source>
          <year>2013</year>
          <volume>28</volume>
          <fpage>162</fpage>
          <lpage>168</lpage>
          <pub-id pub-id-type="doi">10.1002/jbmr.1731</pub-id>
          <?supplied-pmid 22887720?>
          <pub-id pub-id-type="pmid">22887720</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Kooperberg</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pettinger</surname>
              <given-names>MB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women’s Health Initiative observational study and clinical trials</article-title>
          <source>Menopause</source>
          <year>2004</year>
          <volume>11</volume>
          <fpage>264</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.1097/01.GME.0000094210.15096.FD</pub-id>
          <?supplied-pmid 15167305?>
          <pub-id pub-id-type="pmid">15167305</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362661</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Esophagus</journal-id>
      <journal-id journal-id-type="iso-abbrev">Esophagus</journal-id>
      <journal-title-group>
        <journal-title>Esophagus</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1612-9059</issn>
      <issn pub-type="epub">1612-9067</issn>
      <publisher>
        <publisher-name>Springer Japan</publisher-name>
        <publisher-loc>Tokyo</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362661</article-id>
      <article-id pub-id-type="pmcid">PMC5362661</article-id>
      <article-id pub-id-type="pmc-uid">5362661</article-id>
      <article-id pub-id-type="publisher-id">527</article-id>
      <article-id pub-id-type="doi">10.1007/s10388-016-0527-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Special Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology: magnifying endoscopic classification of the Japan Esophageal Society</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Oyama</surname>
            <given-names>Tsuneo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Inoue</surname>
            <given-names>Haruhiro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Arima</surname>
            <given-names>Miwako</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Momma</surname>
            <given-names>Kumiko</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Omori</surname>
            <given-names>Tai</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ishihara</surname>
            <given-names>Ryu</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hirasawa</surname>
            <given-names>Dai</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takeuchi</surname>
            <given-names>Manabu</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tomori</surname>
            <given-names>Akihisa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Goda</surname>
            <given-names>Kenichi</given-names>
          </name>
          <address>
            <phone>+81-3-3433-1111</phone>
            <email>kengoendoscopy@hotmail.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8962 7491</institution-id><institution-id institution-id-type="GRID">grid.416751.0</institution-id><institution>Department of Endoscopy, </institution><institution>Saku Central Hospital Advanced Care Center, </institution></institution-wrap>Nagano, Japan </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8864 3422</institution-id><institution-id institution-id-type="GRID">grid.410714.7</institution-id><institution>Digestive Disease Center, </institution><institution>Showa University Koto Toyosu Hospital, </institution></institution-wrap>Tokyo, Japan </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8855 274X</institution-id><institution-id institution-id-type="GRID">grid.416695.9</institution-id><institution>Department of Gastroenterology, </institution><institution>Saitama Cancer Center, </institution></institution-wrap>Saitama, Japan </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.415479.a</institution-id><institution>Department of Endoscopy, </institution><institution>Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, </institution></institution-wrap>Tokyo, Japan </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9959</institution-id><institution-id institution-id-type="GRID">grid.26091.3c</institution-id><institution>Center for Diagnostic and Therapeutic Endoscopy, </institution><institution>Keio University, </institution></institution-wrap>Tokyo, Japan </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1793 0765</institution-id><institution-id institution-id-type="GRID">grid.416963.f</institution-id><institution>Department of Gastrointestinal Oncology, </institution><institution>Osaka Medical Center for Cancer and Cardiovascular Diseases, </institution></institution-wrap>Osaka, Japan </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.415495.8</institution-id><institution>Department of Gastroenterology, </institution><institution>Sendai City Medical Center, </institution></institution-wrap>Miyagi, Japan </aff>
        <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0639 8670</institution-id><institution-id institution-id-type="GRID">grid.412181.f</institution-id><institution>Department of Gastroenterology, </institution><institution>Niigata University Medical and Dental Hospital, </institution></institution-wrap>Niigata, Japan </aff>
        <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8962 7491</institution-id><institution-id institution-id-type="GRID">grid.416751.0</institution-id><institution>Department of Gastroenterology, </institution><institution>Saku Central Hospital Advanced Care Center, </institution></institution-wrap>Nagano, Japan </aff>
        <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0661 2073</institution-id><institution-id institution-id-type="GRID">grid.411898.d</institution-id><institution>Department of Endoscopy, </institution><institution>The Jikei University School of Medicine, </institution></institution-wrap>3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461 Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>6</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>6</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>14</volume>
      <issue>2</issue>
      <fpage>105</fpage>
      <lpage>112</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>8</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>2</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Predicting invasion depth of superficial esophageal squamous cell carcinoma is crucial in determining the precise indication for endoscopic resection because the rate of lymph node metastasis increases in proportion to the invasion depth of the carcinoma. Previous studies have shown a close relationship between microvascular patterns observed by Narrow Band Imaging magnifying endoscopy and invasion depth of the superficial carcinoma. Thus, the Japan Esophageal Society (JES) developed a simplified magnifying endoscopic classification for estimating invasion depth of superficial esophageal squamous cell carcinomas. We conducted a prospective study to evaluate the diagnostic values of type B vessels in the pretreatment estimation of invasion depth of superficial esophageal squamous cell carcinomas utilizing JES classification, the criteria of which are based on the degree of irregularity in the microvascular morphology. Type A microvessels corresponded to noncancerous lesions and lack severe irregularity; type B, to cancerous lesions, and exhibit severe irregularity. Type B vessels were subclassified into B1, B2, and B3, diagnostic criteria for T1a-EP or T1a-LPM, T1a-MM or T1b-SM1, and T1b-SM2 tumors, respectively. We enrolled 211 patients with superficial esophageal squamous cell carcinoma. The overall accuracy of type B microvessels in estimating tumor invasion depth was 90.5 %. We propose that the newly developed JES magnifying endoscopic classification is useful in estimating the invasion depth of superficial esophageal squamous cell carcinoma.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Magnifying endoscopy</kwd>
        <kwd>Esophageal cancer</kwd>
        <kwd>Squamous cell carcinoma</kwd>
        <kwd>Invasion depth</kwd>
        <kwd>Japan esophageal society classification</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© The Japan Esophageal Society and Springer Japan 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Endoscopic resection (ER) can offer patients a curative and low-invasive treatment for superficial squamous cell carcinomas (SESCCs) [<xref ref-type="bibr" rid="CR1">1</xref>]. Predicting invasion depth of SESCCs is crucial for determining the precise indication for endoscopic resection (ER) because the lymph node metastasis rate increases in proportion to the invasion depth of the SESCC [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>]. According to the Japanese guidelines for diagnosis and treatment of esophageal cancer, T1a-EP or T1a-LPM SCC is considered an absolute indication for ER; T1a-MM or T1b-SM1, a relative indication; and T1b-SM2, an investigative stage (functionally speaking, a contraindication) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Subclassification of invasion depth of SESCC, the rate of lymph node metastasis, and the precise indication of ER are listed in Table <xref rid="Tab1" ref-type="table">1</xref> based on previous studies [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR5">5</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Relationships among subclassification of invasion depth of SESCC, the rate of lymph node metastasis, and the precise indication of ER</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="3">Tumor depth of superficial esophageal squamous cell carcinoma</th><th align="left">Lymph node metastasis rate (%)</th><th align="left">Indication of endoscopic resection</th></tr></thead><tbody><tr><td align="left" rowspan="3">T1a, Tumor invades mucosa (M)</td><td align="left">EP</td><td align="left">Carcinoma in situ (Tis)</td><td align="left" rowspan="2">0–3.3</td><td align="left" rowspan="2">Absolute</td></tr><tr><td align="left">LPM</td><td align="left">Tumor invades lamina propria mucosa (LPM)</td></tr><tr><td align="left">MM</td><td align="left">Tumor invades lamina muscularis mucosa (MM)</td><td align="left">0–12.2</td><td align="left" rowspan="2">Relative</td></tr><tr><td align="left" rowspan="2">T1b, Tumor invades submucosa (SM)</td><td align="left">SM1</td><td align="left">Tumor invades the submucosa to a depth of 200 µm or less from the muscularis mucosa</td><td align="left">8–26.5</td></tr><tr><td align="left">SM2</td><td align="left">Tumor invades the submucosa to a depth more than 200 µm</td><td align="left">22–61 %</td><td align="left">Investigative stage<sup>a</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>A contraindication</p></table-wrap-foot></table-wrap>
</p>
      <p>Endoscopic prediction of the depth of invasion is essential in making decisions regarding the indication for ER in SESCCs. Although predicting the invasion depth of SESCC is possible by conventional endoscopy, magnifying endoscopy provides a more accurate prediction of the tumor depth, in particular for superficial and flat-type SESCCs [<xref ref-type="bibr" rid="CR6">6</xref>]. Inoue et al. [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref>] and Arima et al. [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR12">12</xref>] proposed magnifying endoscopic classifications based upon microvascular morphology and reported their diagnostic utility in predicting the histological invasion depth of SESCC as well as in deciding precise indications for ER. However, there are concerns that the multiplicity of classifications involving complicated criteria might confuse general endoscopists.</p>
      <p>Hence, the committee of the Japan Esophageal Society (JES) developed a simplified classification for the magnifying endoscopic diagnosis (characterization and predicting invasion depth) of SESCC [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] based on the Inoue and Arima classifications [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR12">12</xref>]. Subsequently, we, the committee members, conducted a prospective multicenter study to evaluate the JES classification for predicting the invasion depth of SESCC.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>The JES classification</title>
        <p>Mainly focused on the abnormal microvessels, this magnifying endoscopic classification offers simplified criteria not only for characterization but also for prediction of the invasion depth of SESCC [<xref ref-type="bibr" rid="CR14">14</xref>]. This is essential for developing a treatment strategy for SESCC, in particular the indication for ER. Therefore, in this classification, morphological types of microvessels are classified into two categories of non-cancerous [normal epithelium, inflammation, and low grade intraepithelial neoplasia (LGIN)] and cancerous [high grade intraepithelial neoplasia (HGIN) and invasive SCC] lesions. The cancerous types of microvessels corresponding to histology of HGIN or invasive SCC are subclassified into three groups based upon an indication for ER as follows: an absolute indication type (HGIN, T1a-EP or T1a-LPM), a relative indication type (T1a-MM or T1b-SM1), and a contraindication type (T1b-SM2).</p>
        <p>Diagnostic criteria of the JES classification are based on the degree of microvascular irregularity in the target lesion observed by magnifying endoscopy. Intrapapillary capillary loops (IPCL) are a basic unit of microvasculature in the squamous mucosal surface. The microvascular irregularity is evaluated for the presence or absence of each of the following morphological factors: weaving (i.e., tortuosity), dilatation, irregular caliber, and different shape (i.e., various shapes) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
        <p>Microvessels are classified as type A if they have three or fewer factors and type B if they have all four. Type B is then subclassified into B1, B2, and B3 based on the running pattern or degree of dilatation of severely irregular microvessels. The JES classification criteria are summarized in Table <xref rid="Tab2" ref-type="table">2</xref> and mentioned in detail as follows:<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary and schema of the criteria of the JES magnifying endoscopic classification</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Type of vessels</th><th align="left">Schema</th><th align="left" colspan="2">Definitions</th><th align="left">Invasion depth</th><th align="left">Histology</th></tr></thead><tbody><tr><td align="left">A</td><td align="left">
<inline-graphic xlink:href="10388_2016_527_Figa_HTML.gif" id="d29e594"/>
</td><td align="left" colspan="2">Normal IPCL or abnormal microvessels without severe irregularity<sup>a</sup>
</td><td align="left">No invasion</td><td align="left">Normal epithelium, inflammation, and LGIN</td></tr><tr><td align="left">B1</td><td align="left">
<inline-graphic xlink:href="10388_2016_527_Figb_HTML.gif" id="d29e616"/>
</td><td align="left" rowspan="3">Abnormal microvessels with severe irregularity or highly dilated abnormal vessels</td><td align="left">Type B vessels with a loop-like formation<sup>b</sup>
</td><td align="left">T1a-EP or T1a-LPM</td><td align="left" rowspan="3">HGIN and invasive SCC</td></tr><tr><td align="left">B2</td><td align="left">
<inline-graphic xlink:href="10388_2016_527_Figc_HTML.gif" id="d29e641"/>
</td><td align="left">Type B vessels without a loop-like formation</td><td align="left">T1a-MM or T1b-SM1</td></tr><tr><td align="left">B3</td><td align="left">
<inline-graphic xlink:href="10388_2016_527_Figd_HTML.gif" id="d29e657"/>
</td><td align="left">Highly dilated vessels which calibers appear to be more than three times that of usual B2 vessels<sup>c</sup>
</td><td align="left">T1b-SM2 or deeper</td></tr></tbody></table><table-wrap-foot><p>
<italic>EP</italic> epithelium, <italic>LPM</italic> lamina propria mucosae, <italic>MM</italic> muscularis mucosae, <italic>SM</italic> submucosa, <italic>LGIN</italic> low grade intraepithelial neoplasia, <italic>HGIN</italic> high grade intraepithelial neoplasia, <italic>SCC</italic> squamous cell carcinoma</p><p>
<sup>a</sup>The caliber of type A vessels is about 7–10 μm [<xref ref-type="bibr" rid="CR15">15</xref>]</p><p>
<sup>b</sup>The caliber of B1 vessels is around 20 μm [<xref ref-type="bibr" rid="CR15">15</xref>]</p><p>
<sup>c</sup>The caliber of B3 vessels is often larger than 60 μm [<xref ref-type="bibr" rid="CR15">15</xref>]</p></table-wrap-foot></table-wrap>
</p>
        <p>Type A: Normal IPCL (Fig. <xref rid="Fig1" ref-type="fig">1</xref>a) or abnormal microvessels without severe irregularity (Fig. <xref rid="Fig1" ref-type="fig">1</xref>b).<fig id="Fig1"><label>Fig. 1</label><caption><p>
<bold>a</bold> Type A vessels of normal intrapapillary capillary loops. <bold>b</bold> Type A vessels of abnormal microvessels without severe irregularity</p></caption><graphic xlink:href="10388_2016_527_Fig1_HTML" id="MO1"/></fig>
</p>
        <p>Type B: Abnormal microvessels with severe irregularity or highly dilated abnormal vessels.</p>
        <p>B1 is defined as type B vessels with a loop-like formation (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a, b). The B1 vessels normally appear as dot-like microvessels in a target area (e.g., a brownish area) under NBI endoscopic observation with low or no magnification.<fig id="Fig2"><label>Fig. 2</label><caption><p>
<bold>a, b</bold> Type B1 vessels with a loop-like formation</p></caption><graphic xlink:href="10388_2016_527_Fig2_HTML" id="MO2"/></fig>
</p>
        <p>B2 is defined as type B vessels without a loop-like formation that have a stretched and markedly elongated transformation. The B2 vessels often show a multilayered arrangement or an irregularly branched/running pattern (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a, b).<fig id="Fig3"><label>Fig. 3</label><caption><p>
<bold>a, b</bold> Type B2 vessels without a loop-like formation (<italic>white arrows</italic> and inside a <italic>white circle</italic>)</p></caption><graphic xlink:href="10388_2016_527_Fig3_HTML" id="MO3"/></fig>
</p>
        <p>B3 is defined as highly dilated abnormal vessels whose caliber appears to be more than three times that of the usual B2 vessels and the B3 vessels often appear green in color (Fig. <xref rid="Fig4" ref-type="fig">4</xref>a, b) [<xref ref-type="bibr" rid="CR15">15</xref>].<fig id="Fig4"><label>Fig. 4</label><caption><p>
<bold>a, b</bold> Type B3 of highly dilated abnormal vessels (<italic>white arrows</italic>) whose caliber will be more than three times that of the B2 vessels around the B3 vessels</p></caption><graphic xlink:href="10388_2016_527_Fig4_HTML" id="MO4"/></fig>
</p>
        <p>When target lesions have only type B1 vessels, the histological invasion depth is predicted as T1a-EP or T1a-LPM. When B2 and B3 vessels are seen in target lesions, the histological invasion depth is predicted as T1a-MM or T1b-SM1 and T1b-SM2 or deeper, respectively.</p>
      </sec>
      <sec id="Sec4">
        <title>Auxiliary criteria of the JES classification</title>
        <sec id="Sec5">
          <title>Avascular area (AVA)</title>
          <p>AVA was originally defined as a low or no vascularity area surrounded by stretched irregular vessels such as B2 or B3 vessels [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The definition of AVA does not include the stretched irregular vessels in this classification. Thus, AVA is surrounded by all subtypes of type B microvessels including B1 vessels. [<xref ref-type="bibr" rid="CR14">14</xref>]. Since a diameter of AVA is positively correlated with the histological invasion depth of SESCC, the AVA was categorized into three types as follows: AVA-small (smaller than 0.5 mm in diameter: Fig. <xref rid="Fig5" ref-type="fig">5</xref>), AVA-middle (0.5 mm or between 0.5 and 3 mm; Fig. <xref rid="Fig6" ref-type="fig">6</xref>), and AVA-large (3 mm or larger; Fig. 7) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Any types of AVA (small, middle, and large) surrounded by B1 vessels are suggestive of T1a-EP or T1a-LPM SCC. AVA-middle and AVA-large surrounded by B2 or B3 vessels are suggestive of T1a-MM or T1b-SM1 and T1b-SM2 invasive SCC, respectively [<xref ref-type="bibr" rid="CR14">14</xref>].<fig id="Fig5"><label>Fig. 5</label><caption><p>
<bold>a</bold> Small-sized avascular area (AVA-small). <bold>b</bold> Middle-sized avascular area (AVA-middle). <bold>c</bold> Large-sized avascular area (AVA-large). Typical AVAs are shown by <italic>white dotted lines</italic>
</p></caption><graphic xlink:href="10388_2016_527_Fig5_HTML" id="MO5"/></fig>
<fig id="Fig6"><label>Fig. 6</label><caption><p>Reticular pattern vessels (Type R)</p></caption><graphic xlink:href="10388_2016_527_Fig6_HTML" id="MO6"/></fig>
</p>
        </sec>
        <sec id="Sec6">
          <title>Reticular pattern (Type R)</title>
          <p>Reticular pattern vessels are defined as plexiform microvessels (Fig. <xref rid="Fig6" ref-type="fig">6</xref>) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. This vascular pattern is often found in invasive SCC or non-SCC types of malignant epithelial neoplasms (e.g., basaloid (-squamous) carcinoma, adenosquamous carcinoma, and endocrine cell carcinoma) with an infiltrative growth pattern (i.e., INFc) composed of single cells, small tumor nests, or a trabecular arrangement of tumor cells.</p>
        </sec>
        <sec id="Sec7">
          <title>Intervascular background coloration</title>
          <p>Brownish epithelium between microvessels in a brownish area visualized by NBI-ME was defined as intervascular background coloration [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p>
        </sec>
      </sec>
      <sec id="Sec8">
        <title>A prospective multicenter study on the predictive value of type B vessels for invasion depth of SESCC</title>
        <p>From January to August 2011, we prospectively enrolled 211 consecutive patients with SESCC lesions scheduled for ER in five high-volume centers (Table <xref rid="Tab3" ref-type="table">3</xref>). Prior to enrollment, we used pretreatment imaging (CT and/or MRI) to confirm no findings of lymph node metastasis or distant metastasis of SESCC among any of the 211 patients. The depth of tumor invasion of the all lesions was estimated prior to treatment using a magnifying endoscope (GIF-H260Z or GIF-Q240Z; Olympus Corporation, Tokyo, Japan) combined with NBI. The estimation of tumor invasion depth by magnifying endoscopy was made based upon type B vessels in the JES classification and recorded in case report form. The aim of this study was to evaluate the diagnostic values of type B vessels in the pretreatment estimation of invasion depth of SESCC.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Participating high-volume centers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Participated institutions</th><th align="left">Number of patients</th></tr></thead><tbody><tr><td align="left">Saku Central Hospital Advanced Care Center</td><td char="." align="char">31</td></tr><tr><td align="left">Saitama Cancer Center</td><td char="." align="char">40</td></tr><tr><td align="left">Osaka Medical Center for Cancer and Cardiovascular Diseases</td><td char="." align="char">71</td></tr><tr><td align="left">Niigata University Medical and Dental Hospital</td><td char="." align="char">41</td></tr><tr><td align="left">Sendai City Medical Center</td><td char="." align="char">28</td></tr></tbody></table></table-wrap>
</p>
        <p>Informed consent was obtained from all participants. The informed consent includes information about the possible risks, benefits, and limits of the endoscopic procedure and treatment. We provided all patients with information about the possibility that additional treatments such as surgery or chemoradiotherapy will be required particularly if ER specimens would show SESCC invading the muscularis mucosa or deeper which is associated with increased risks of lymph node metastasis and distant metastasis. Especially for the patients with pretreatment NBI-ME diagnosis of B3 vessels, we provided the patients with sufficient explanation as follows: (1) B3 vessels will be a suggestive finding of tumor invasion of T1b-SM2 or deeper, (2) T1b-SM2 tumor are basically contraindication for ER because of considerably high risk of lymph node metastasis and distant metastasis, (3) additional therapy such as esophagectomy and chemoradiotherapy will be required if histology from ER would show tumor depth of T1b-SM2 or deeper.</p>
        <p>We performed ER on all enrolled patients. The lesions were removed by endoscopic mucosal resection or endoscopic submucosal dissection. Using the resected specimens, the histological tumor invasion depth was established by pathologists in each center with expertise in gastrointestinal cancer, according to the Japanese classification of esophageal cancer [<xref ref-type="bibr" rid="CR4">4</xref>]. None of the pathologists were aware of any endoscopic findings. We evaluated the diagnostic utility of the JES classification in predicting histological depth of invasion by comparing the pretreatment NBI-ME diagnosis with the histology from resected specimens.</p>
      </sec>
    </sec>
    <sec id="Sec9">
      <title>Results</title>
      <p>All of the SESCC tumors enrolled in this study had type B vessels. The numbers of SESCC tumors subclassified as T1a-EP or T1a-LPM, T1a-MM or T1b-SM1, and T1b-SM2 were 163, 28, and 20, respectively.</p>
      <p>The relationships between histology and pretreatment NBI-ME diagnosis of tumor invasion depth are listed in Table <xref rid="Tab4" ref-type="table">4</xref>. One hundred fifty-nine (97.5 %) of the 163 T1a-EP or T1a-LPM tumors were accurately diagnosed by pretreatment NBI-ME, and four (2.5 %) were overestimated as T1a-MM or T1b-SM1. Twenty-one of 28 (75 %) T1a-MM or T1b-SM1 tumors were accurately diagnosed, and seven (25 %) were underestimated as T1a-EP or T1a-LPM. None of the T1a-EP or T1a-LPM/T1a-MM or T1b-SM1 tumors were overestimated as T1b-SM2. Eleven of 20 (55 %) T1b-SM2 tumors were accurately diagnosed. Six (30 %) and three (15 %) were underestimated as T1a-EP or T1a-LPM and T1a-MM or T1b-SM1, respectively. The overall accuracy of NBI-ME based upon the JES classification was 90.5 % (95 % confidence interval, 85.7–94.1 %).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Relationships between histology and pretreatment ME-NBI diagnosis of depth of invasion of superficial squamous cell carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">NBI-ME diagnosis</th><th align="left" colspan="3">Histological invasion depth, <italic>n</italic>
</th></tr><tr><th align="left">T1a-EP or T1a-LPM</th><th align="left">T1a-MM or T1b-SM1</th><th align="left">T1b-SM2</th></tr></thead><tbody><tr><td align="left">B1 (T1a-EP or T1a-LPM)</td><td char="." align="char">159</td><td char="." align="char">7</td><td char="." align="char">6</td></tr><tr><td align="left">B2 (T1a-MM or T1b-SM1)</td><td char="." align="char">4</td><td char="." align="char">21</td><td char="." align="char">3</td></tr><tr><td align="left">B3 (T1b-SM2)</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">11</td></tr></tbody></table><table-wrap-foot><p>
<italic>NBI-ME</italic> Narrow Band Imaging magnifying endoscopy, <italic>EP</italic> epithelium, <italic>LPM</italic> lamina propria mucosae, <italic>MM</italic> muscularis mucosae, <italic>SM</italic> submucosa, <italic>n</italic> Number of lesions</p></table-wrap-foot></table-wrap>
</p>
      <p>Table <xref rid="Tab5" ref-type="table">5</xref> shows the diagnostic values of B1, B2, and B3 vessels for estimating the depth of invasion of T1a-EP or T1a-LPM, T1a-MM or T1b-SM1, and T1b-SM2 tumors, respectively. The sensitivity/specificity/positive predictive value (PPV) and negative predictive value (NPV) of B1, B2, and B3 vessels were 97.5 %/72.9 %/92.4 % and 89.7 %; 75.0 %/96.2 %/75.0 % and 96.2 %; and 55 %/100 %/100 % and 95.5 %, respectively.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Diagnostic values of type B vessels for estimating invasion depth of superficial squamous cell carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">NBI-ME diagnosis</th><th align="left">Sensitivity (95 % CI)</th><th align="left">Specificity (95 % CI)</th><th align="left">PPV (95 % CI)</th><th align="left">NPV (95 % CI)</th><th align="left">Accuracy (95 % CI)</th></tr></thead><tbody><tr><td align="left">B1 (T1a-EP or T1a-LPM)</td><td char="(" align="char">97.5 (93.8–99.3)</td><td char="(" align="char">72.9 (58.2–84.7)</td><td char="(" align="char">92.4 (87.4–95.9)</td><td char="(" align="char">89.7 (75.8–97.1)</td><td char="(" align="char">91.9 (87.4–95.2)</td></tr><tr><td align="left">B2 (T1a-MM or T1b-SM1)</td><td char="(" align="char">75.0 (55.1–89.3)</td><td char="(" align="char">96.2 (92.3–98.4)</td><td char="(" align="char">75.0 (55.1–89.3)</td><td char="(" align="char">96.2 (92.3–98.4)</td><td char="(" align="char">93.4 (89.1–96.3)</td></tr><tr><td align="left">B3 (T1b-SM2)</td><td char="(" align="char">55.0 (31.5–76.9)</td><td char="(" align="char">100 (98.1–100)</td><td char="(" align="char">100 (71.5–100)</td><td char="(" align="char">95.5 (91.6–97.9)</td><td char="(" align="char">95.9 (92.1–98.0)</td></tr></tbody></table><table-wrap-foot><p>
<italic>NBI-ME</italic> Narrow Band Imaging magnifying endoscopy, <italic>EP</italic> epithelium, <italic>LPM</italic> lamina propria mucosae, <italic>MM</italic> muscularis mucosae, <italic>SM</italic> submucosa, <italic>CI</italic> confidence interval, <italic>PPV</italic> positive predictive value, <italic>NPV</italic> negative predictive value</p></table-wrap-foot></table-wrap>
</p>
    </sec>
    <sec id="Sec10">
      <title>Discussion</title>
      <p>Endoscopic estimation of invasion depth is a key factor in deciding the treatment policy of SESCCs. We, the JES committee members, have developed a simplified magnifying endoscopic diagnosis classification (i.e., the JES classification). We conducted a prospective multicenter study focused on evaluating the diagnostic values of type B vessels in the classification for predicting the depth of invasion of SESCC.</p>
      <p>The overall accuracy rate of the type B1, B2, and B3 microvessels was 90.5 %, which is of sufficiently high accuracy for clinical use. No T1a-EP or T1a-LPM or T1a-MM or T1b-SM1 tumor was overestimated as T1b-SM2. Although 45 % (9/20) of SM2 tumors did not have B3 vessels, B3 vessels may be highly suggestive of T1b-SM2 tumors because the PPV of B3 vessels was 100 %.</p>
      <p>The sensitivity and PPV of B1 vessels for T1a-EP or T1a-LPM tumors were 97.5 and 92.4 %, respectively. Thus, B1 vessels will provide optimal decision-making regarding the indication for ER. In contrast, the sensitivity and PPV of B2 vessels for T1a-MM or T1b-SM1 tumors were both a suboptimal 75.0 %, while the diagnostic accuracy of white light endoscopy showed a lower value at 66–74 % [<xref ref-type="bibr" rid="CR18">18</xref>]. Previous studies have indicated that T1a-MM or T1b-SM1 tumors without lymphovascular invasion had a significantly lower risk of lymph node metastasis and a good prognosis [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>]. Therefore, T1a-MM or T1b-SM1 tumors are potential candidates for curative treatment by ER. Esophagectomy involves severe problems related to its high mortality rate and a decrease in quality of life after surgery [<xref ref-type="bibr" rid="CR22">22</xref>]. Further study on the definition of B2 vessels is warranted to reduce the risk of unnecessary surgery for patients with T1a-MM or T1b-SM1 tumors.</p>
      <p>In the JES classification, we partially modified definitions of AVA, which will be useful to predict invasion depth of SESCC as previous studies showed [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Although AVA was not assessed in this study, we intend to investigate the predictive values of AVA and whether evaluation of AVA has a positive effect on the predictive value based upon type B vessels (especially for B2 vessels) in an upcoming study.</p>
      <p>Arima et al. reported that reticular pattern (Type R) vessels were characteristic vascular structure reflecting a histologic infiltrative growth (i.e., INFc) of invasive SCC tumors or non-SCC types of malignant epithelial neoplasms. This study did not included non-SCC types of malignant epithelial neoplasms and the type R vessels were not seen in invasive SCC tumors included in this study. A validation study on type R vessels in predicting the histologic features of SCC and non-SCC tumors is warranted.</p>
      <p>Intervascular background coloration will be useful for predicting histology of HGIN and invasive SCC [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. A recent study indicated that intervascular background coloration might be caused by an extravascular component of hemoglobin that is produced within tumor cells [<xref ref-type="bibr" rid="CR23">23</xref>]. The other study showed that intervascular background coloration might be related to the thinning of the keratinous layer or the epithelium caused by neoplastic cell proliferation [<xref ref-type="bibr" rid="CR17">17</xref>]. In this study, we did not evaluated diagnostic value of intervascular background coloration to predict HGIN and invasive SCC. The diagnostic validity and reliability of intervascular background coloration should be assessed in further multicenter studies.</p>
      <p>This study had several limitations. First, the number of T1a-MM or T1b-SM1 and T1b-SM2 tumors was relatively small and no tumor resected by surgery was included. Further study including greater or adequate numbers of these tumors should be conducted to validate the results of the current study. Second, a central review on both the magnifying endoscopic findings and the histology was not conducted in this study. The endoscopic diagnosis and histology were left to each endoscopist and each pathologist in their respective hospitals. Thus, this study may lack diagnostic standardization in magnifying endoscopy and histology. Third, the endoscopists involved in this study are all experts. Additional study involving non-experts is needed to determine whether the results of this study on diagnostic values are applicable in general. Fourth, the reliability or reproducibility of the JES classification was not assessed in this study. It would be desirable to investigate inter- or intra-observer agreements in future studies.</p>
    </sec>
    <sec id="Sec11">
      <title>Conclusions</title>
      <p>The newly developed JES classification is proposed to be useful in estimating invasion depth of SESCCs. Modification of the definition of B2 vessels will be necessary, and further studies are required to validate these study results as well as to improve the diagnostic utility of the JES classification.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors would like to thank Drs. Misao Yoshida and Hiroyasu Makuuchi for their guidance and Dr. Akiko Takahashi for her contribution as a secretary.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <sec id="FPar1">
        <title>Ethical Statement</title>
        <p>All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.</p>
      </sec>
      <sec id="FPar2">
        <title>Conflict of interest</title>
        <p>Oyama T, Momma K, Inoue H, Arima M, Goda K, Omori T, Ishihara R, Hirasawa D, Takeuchi M, and Tomori A declare that they have no conflicts of interest.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kodama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kakegawa</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Treatment of superficial cancer of the esophagus: a summary of the responses to a questionnaire on superficial cancer of the esophagus in Japan</article-title>
          <source>Surgery.</source>
          <year>1998</year>
          <volume>123</volume>
          <fpage>432</fpage>
          <lpage>439</lpage>
          <pub-id pub-id-type="doi">10.1016/S0039-6060(98)70165-5</pub-id>
          <?supplied-pmid 9551070?>
          <pub-id pub-id-type="pmid">9551070</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Endo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yoshino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kawano</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus</article-title>
          <source>Dis Esophagus</source>
          <year>2000</year>
          <volume>13</volume>
          <fpage>125</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1442-2050.2000.00100.x</pub-id>
          <?supplied-pmid 14601903?>
          <pub-id pub-id-type="pmid">14601903</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Araki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohno</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Egashira</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pathologic features of superficial esophageal squamous cell carcinoma with lymph node and distal metastasis</article-title>
          <source>Cancer</source>
          <year>2002</year>
          <volume>94</volume>
          <fpage>570</fpage>
          <lpage>575</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.10190</pub-id>
          <?supplied-pmid 11900242?>
          <pub-id pub-id-type="pmid">11900242</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="other">Japan Esophageal Society. Japanese classification of esophageal cancer. 10th English edn. Tokyo: Kanehara &amp; Co Ltd; 2008.</mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuwano</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Otsu</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guidelines for diagnosis and treatment of carcinoma of esophagus April 2007 edition: Part I edited by the Japan Esophageal Society</article-title>
          <source>Esophagus.</source>
          <year>2008</year>
          <volume>5</volume>
          <fpage>61</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="doi">10.1007/s10388-008-0151-2</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tajiri</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ikegami</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Magnifying endoscopy with narrow band imaging for predicting the invasion. Depth of superficial esophageal squamous cell carcinoma</article-title>
          <source>Dis Esophagus</source>
          <year>2009</year>
          <volume>22</volume>
          <fpage>453</fpage>
          <lpage>460</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1442-2050.2009.00942.x</pub-id>
          <?supplied-pmid 19222533?>
          <pub-id pub-id-type="pmid">19222533</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inoue</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Honda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ultra-high magnification endoscopy of the normal esophageal mucosa</article-title>
          <source>Dig Endosc.</source>
          <year>1996</year>
          <volume>8</volume>
          <fpage>134</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1443-1661.1996.tb00429.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inoue</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Honda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ultra-high magnification endoscopic observation of carcinoma in situ of the esophagus</article-title>
          <source>Dig Endosc.</source>
          <year>1997</year>
          <volume>9</volume>
          <fpage>16</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1443-1661.1997.tb00453.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inoue</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Magnification endoscopy in the esophagus and stomach</article-title>
          <source>Dig Endosc.</source>
          <year>2001</year>
          <volume>13</volume>
          <fpage>40</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1443-1661.2001.0130s1S40.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arima</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Magnified observation of esophageal mucosa</article-title>
          <source>Gastroenterol Endosc.</source>
          <year>1998</year>
          <volume>40</volume>
          <fpage>1125</fpage>
          <lpage>1137</lpage>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arima</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arima</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of microvascular patterns of superficial esophageal cancers by magnifying endoscopy</article-title>
          <source>Esophagus.</source>
          <year>2005</year>
          <volume>2</volume>
          <fpage>191</fpage>
          <lpage>197</lpage>
          <pub-id pub-id-type="doi">10.1007/s10388-005-0060-6</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arima</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tada</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Diagnosis of the invasion depth of early esophageal carcinoma using magnifying endoscopy with FICE</article-title>
          <source>Stomach Intest.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>1515</fpage>
          <lpage>1525</lpage>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Momma</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>A new classification of magnified endoscopy for superficial esophageal squamous cell carcinoma</article-title>
          <source>Esophagus.</source>
          <year>2011</year>
          <volume>8</volume>
          <fpage>247</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="doi">10.1007/s10388-011-0301-9</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Momma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Makuuchi</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Japan esophageal society classification of superficial esophageal squamous cell carcinoma</article-title>
          <source>Endosc Dig.</source>
          <year>2012</year>
          <volume>24</volume>
          <fpage>466</fpage>
          <lpage>468</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1443-1661.2012.01312.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santi</surname>
              <given-names>EGR</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Microvascular caliber changes in intramucosal and submucosally invasive esophageal cancer</article-title>
          <source>Endoscopy.</source>
          <year>2013</year>
          <volume>45</volume>
          <fpage>585</fpage>
          <lpage>588</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0033-1344228</pub-id>
          <?supplied-pmid 23801316?>
          <pub-id pub-id-type="pmid">23801316</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Usefulness of background coloration in detection of esophago-pharyngeal lesions using NBI magnification</article-title>
          <source>Gastroenterol Res Pract.</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>529782</fpage>
          <pub-id pub-id-type="doi">10.1155/2012/529782</pub-id>
          <?supplied-pmid 22927837?>
          <pub-id pub-id-type="pmid">22927837</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kanzaki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ishihara</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ishiguro</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Histological features responsible for brownish epithelium in squamous neoplasia of the esophagus by narrow band imaging</article-title>
          <source>J Gastroenterol Hepatol</source>
          <year>2013</year>
          <volume>28</volume>
          <fpage>274</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1111/jgh.12059</pub-id>
          <?supplied-pmid 23190157?>
          <pub-id pub-id-type="pmid">23190157</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chino</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Makuuchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shimada</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnosis of the invasion depth of superficial esophageal carcinoma</article-title>
          <source>Gastroenterol Endosc.</source>
          <year>2015</year>
          <volume>57</volume>
          <fpage>1243</fpage>
          <lpage>1253</lpage>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Miyata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shimatani</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lymph nodal metastasis of m3, sm1 esophageal cancer</article-title>
          <source>Stomach Intest.</source>
          <year>2002</year>
          <volume>37</volume>
          <fpage>71</fpage>
          <lpage>74</lpage>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katada</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Muto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Momma</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical outcome after endoscopic mucosal resection for esophageal squamous cell carcinoma invading the muscularis mucosae—a multicenter retrospective cohort study</article-title>
          <source>Endoscopy.</source>
          <year>2007</year>
          <volume>39</volume>
          <fpage>779</fpage>
          <lpage>783</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2007-966761</pub-id>
          <?supplied-pmid 17703385?>
          <pub-id pub-id-type="pmid">17703385</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamashina</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishihara</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma</article-title>
          <source>Am J Gastroenterol</source>
          <year>2013</year>
          <volume>108</volume>
          <fpage>544</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="doi">10.1038/ajg.2013.8</pub-id>
          <?supplied-pmid 23399555?>
          <pub-id pub-id-type="pmid">23399555</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tachibana</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kinugasa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shibakita</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Surgical treatment of superficial esophageal cancer</article-title>
          <source>Langenbecks Arch Surg.</source>
          <year>2006</year>
          <volume>391</volume>
          <fpage>304</fpage>
          <lpage>321</lpage>
          <pub-id pub-id-type="doi">10.1007/s00423-006-0063-3</pub-id>
          <?supplied-pmid 16830151?>
          <pub-id pub-id-type="pmid">16830151</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Isomoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakayama</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Background coloration of squamous epithelium in esophago-pharyngeal squamous cell carcinoma: what causes the color change?</article-title>
          <source>PLoS One</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>e85553</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0085553</pub-id>
          <?supplied-pmid 24489662?>
          <pub-id pub-id-type="pmid">24489662</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362662</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pflugers Arch</journal-id>
      <journal-id journal-id-type="iso-abbrev">Pflugers Arch</journal-id>
      <journal-title-group>
        <journal-title>Pflugers Archiv</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0031-6768</issn>
      <issn pub-type="epub">1432-2013</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362662</article-id>
      <article-id pub-id-type="pmcid">PMC5362662</article-id>
      <article-id pub-id-type="pmc-uid">5362662</article-id>
      <article-id pub-id-type="pmid">28251312</article-id>
      <article-id pub-id-type="publisher-id">1944</article-id>
      <article-id pub-id-type="doi">10.1007/s00424-017-1944-8</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Invited Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>“Pumping iron”—how macrophages handle iron at the systemic, microenvironmental, and cellular levels</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Nairz</surname>
            <given-names>Manfred</given-names>
          </name>
          <address>
            <phone>+43-512</phone>
            <phone>504-23251</phone>
            <email>manfred.nairz@i-med.ac.at</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Theurl</surname>
            <given-names>Igor</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Swirski</surname>
            <given-names>Filip K.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Weiss</surname>
            <given-names>Guenter</given-names>
          </name>
          <address>
            <phone>+43-512</phone>
            <phone>504-23251</phone>
            <email>guenter.weiss@i-med.ac.at</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8853 2677</institution-id><institution-id institution-id-type="GRID">grid.5361.1</institution-id><institution>Department of Internal Medicine VI, Infectious Diseases, Immunology, Rheumatology, Pneumology, </institution><institution>Medical University of Innsbruck, </institution></institution-wrap>Anichstr. 35, 6020 Innsbruck, Austria </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0386 9924</institution-id><institution-id institution-id-type="GRID">grid.32224.35</institution-id><institution>Center for Systems Biology, </institution><institution>Massachusetts General Hospital and Harvard Medical School, </institution></institution-wrap>Boston, MA USA </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution>Department of Radiology, Massachusetts General Hospital, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>1</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>469</volume>
      <issue>3</issue>
      <fpage>397</fpage>
      <lpage>418</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>11</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>25</day>
          <month>1</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>1</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Macrophages reside in virtually every organ. First arising during embryogenesis, macrophages replenish themselves in the adult through a combination of self-renewal and influx of bone marrow-derived monocytes. As large phagocytic cells, macrophages participate in innate immunity while contributing to tissue-specific homeostatic functions. Among the key metabolic tasks are senescent red blood cell recycling, free heme detoxification, and provision of iron for de novo hemoglobin synthesis. While this systemic mechanism involves the shuttling of iron between spleen, liver, and bone marrow through the concerted function of defined macrophage populations, similar circuits appear to exist within the microenvironment of other organs. The high turnover of iron is the prerequisite for continuous erythropoiesis and tissue integrity but challenges macrophages’ ability to maintain cellular iron homeostasis and immune function.</p>
        <p>This review provides a brief overview of systemic, microenvironmental, and cellular aspects of macrophage iron handling with a focus on exciting and unresolved questions in the field.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Macrophage</kwd>
        <kwd>Iron</kwd>
        <kwd>Infection</kwd>
        <kwd>Inflammation</kwd>
        <kwd>Erythrophagocytosis</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>University of Innsbruck and Medical University of Innsbruck</institution>
          </funding-source>
        </award-group>
        <open-access>
          <p>Open access funding provided by University of Innsbruck and Medical University of Innsbruck.</p>
        </open-access>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer-Verlag Berlin Heidelberg 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Systemic aspects of iron recycling</title>
      <p>The mononuclear phagocyte system (MPS) encompasses monocytes and macrophages residing throughout the body [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. A central role of this multifunctional system beyond immunity and tissue repair is to control the body’s metabolic needs for iron. The maintenance of iron homeostasis at the systemic level requires iron recycling (Fig. <xref rid="Fig1" ref-type="fig">1</xref>), much of which is contained in senescent red blood cells (RBC). This is a prerequisite for sufficient de novo synthesis of hemoglobin (Hb) in the bone marrow (BM), a process which consumes as much as 20–25 mg of iron per day [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR179">179</xref>]. The capacity of the small intestine to absorb dietary iron, in comparison to the daily needs of iron, is rather low; in humans under steady-state conditions, 1–2 mg of iron is absorbed from the diet in the duodenum and upper jejunum. Thus, dietary iron absorption only compensates for obligatory losses of the metal, mainly through desquamation of the epidermis and the intestinal epithelium, and menstrual bleeding [<xref ref-type="bibr" rid="CR168">168</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>
<bold>a</bold> In steady state, 20–25 mg/day of iron is needed to generate new red blood cells (RBC) in the bone marrow (depicted as vertebral body). The RBC of an adult human form the body’s largest iron pool (1500–2500 mg contained in hemoglobin [Hb]). After an average lifetime of 120 days, aged RBC (aRBC) are trapped in the spleen, recognized by red pulp macrophages (RPM), and eliminated. Their Hb is recycled, and ferroportin (Fpn)-1 exports iron into sinusoidal capillaries where it is loaded onto transferrin (TF). TF-bound iron is utilized by developing erythroblasts (EB) via TF receptor (Tfr)-1. Erythroid island macrophages assist in iron uptake and differentiation. Plasma iron content is sensed by hepatocytes, presumably via Tfr1 and other iron-sensitive molecules. They affect the transcriptional activation of hepcidin, the major iron hormone, in hepatocytes. Hepcidin acts as negative feedback regulator of iron influx by targeting Fpn1 resulting in degradation of the latter and thus reduction of iron transfer from the diet and macrophages to the plasma. Kupffer cells (KC) inhibit hepcidin expression by hepatocytes and also engage in erythrophagocytosis. <bold>b</bold> The lifespan of RBC can be reduced as a consequence of autoinflammation and subsequent hemolysis, radical formation and toxin activity or based on intrinsic structural or metabolic defects. The rapid accumulation of damaged RBC (dRBC) may overwhelm the spleen’s clearance capacity. In such a scenario, KC engulf dRBC which may result in cell death. As back-up system, monocytes are recruited from the bone marrow and possibly spleen via chemokines CCL2 and CCL3 and their receptor CCR2. These monocytes encounter a niche in the liver and differentiate into KC-like cells that express Fpn1 which is induced by several mechanisms including the growth factor macrophage colony-stimulating factor (M-CSF). Fpn1-mediated iron export sustains increased erythropoiesis in the bone marrow to compensate for losses by RBC damage</p></caption><graphic xlink:href="424_2017_1944_Fig1_HTML" id="MO1"/></fig>
</p>
      <p>Intestinal iron absorption is regulated, to a large extent, at the basolateral membrane of enterocytes [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR248">248</xref>]. It is at this location that ferroportin-1 (Fpn1; AKA solute carrier family 40 member 1) fulfills its function as the sole cellular efflux protein for ionic iron, shuttling apically absorbed iron to the circulation, where it is oxidized and loaded onto transferrin (TF) [<xref ref-type="bibr" rid="CR173">173</xref>]. The presence of Fpn1 in the absorptive epithelium is under negative control of hepcidin, which is mainly secreted by hepatocytes in response to high circulating and tissue amounts of iron or upon stimulation by inflammatory mediators [<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR229">229</xref>]. This negative feedback loop exists because of the Janus-faced nature of iron. Iron forms the central cation of hemoglobin, other heme-containing proteins (such as myoglobin and cytochrome P450 enzymes including the mitochondrial electron transport chain), and iron-sulfur cluster-containing enzymes found in most cells [<xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]. Free labile forms of iron and heme, however, are potentially toxic and threaten tissue integrity due to their pro-oxidative properties which are largely based on the capacity of iron to non-enzymatically boost reactive oxygen species (ROS) production via Fenton chemistry [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR119">119</xref>].</p>
      <p>Given its essential role in metabolism and cellular processes such as mitochondrial respiration, an efficient and tightly controlled pathway for maintaining iron in the body must exist and likely depends on factors controlling the recognition, uptake, and degradation of erythrocytes by macrophages [<xref ref-type="bibr" rid="CR113">113</xref>]. In steady-state conditions, RBC recycling mainly takes place in the spleen [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR213">213</xref>]. In conditions of excessive RBC damage, liver macrophages (Kupffer cells, henceforward abbreviated as KC) dominate RBC clearance (as detailed in “<xref rid="Sec4" ref-type="sec">Liver—the iron regulatory organ</xref>” section) [<xref ref-type="bibr" rid="CR231">231</xref>].</p>
      <p>During massive hemolysis, circulating hemoglobin (Hb) and heme are bound by hemopexin (HPX) and haptoglobin, respectively, to avoid intravasal radical formation via the catalytic action of iron [<xref ref-type="bibr" rid="CR203">203</xref>, <xref ref-type="bibr" rid="CR235">235</xref>, <xref ref-type="bibr" rid="CR244">244</xref>]. However, when the capacity of red pulp macrophages (the iron-recycling macrophage population in the spleen, henceforward abbreviated as RPM) and KC is overwhelmed, the cells die, presumably by a specific form of cell death called ferroptosis that is induced by iron-mediated oxidative stress and lipid peroxidation [<xref ref-type="bibr" rid="CR54">54</xref>]. To compensate, blood-derived monocytes fill the partial niche after KC loss and differentiate into a transient macrophage population that has a unique phenotype including the high expression of the CC-chemokine receptor 2 (CCR2) [<xref ref-type="bibr" rid="CR231">231</xref>]. Indeed, monocyte recruitment from the BM to the liver is mediated by a liver-specific, KC-derived CC-chemokine gradient of CCL2 and CCL3 that attracts CCR2<sup>+</sup> CCR5<sup>+</sup> monocytes to the organ. As a consequence, the BM enhances myelopoiesis and releases additional monocytes to the circulation to meet the increased demand (Fig. <xref rid="Fig1" ref-type="fig">1</xref>b). This chemokine-mediated monocyte recruitment is essential because if disrupted pharmacologically, damaged RBC accumulate in glomerular capillaries resulting in renal failure [<xref ref-type="bibr" rid="CR231">231</xref>]. Comparable phenomena of KC death, although necroptotic by nature, and replacement of KCs from BM-derived monocytes have been reported in <italic>Listeria monocytogenes</italic> infection [<xref ref-type="bibr" rid="CR21">21</xref>] raising the possibility that the mechanism is a general stress response that can be fine tuned according to whether the initial stressor is endogenous (e.g., RBC, heme) or exogenous (e.g., a pathogen).</p>
      <p>In theory, additional mechanisms by which macrophages may influence systemic iron homeostasis (other than its recycling) include control of dietary iron absorption or excretion. It is generally thought that no regulated pathway of iron excretion exists in the mammalian organism. Duodenal iron absorption, however, appears to rely on macrophages, albeit indirectly via modulating hepcidin production by hepatocytes (see “<xref rid="Sec4" ref-type="sec">Liver—the iron regulatory organ</xref>” section). To the best of our knowledge, no data exist on whether lamina propria macrophages in the small intestine affect absorptive enterocyte iron transporter expression or function, although this is possible given that macrophages produce small amounts of hepcidin in response to inflammatory stimuli [<xref ref-type="bibr" rid="CR185">185</xref>, <xref ref-type="bibr" rid="CR227">227</xref>]. However, one might speculate that intestinal infection might alter absorption by shifting intestinal stem cell differentiation towards non-absorptive progeny such as Paneth or Tuft cells and by promoting recruitment of inflammatory macrophages [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Although hypothetical, such a mechanism might be initiated by myeloid cells since lamina propria macrophages and dendritic cells (DCs) will be one of the first cell types to engage in host response to invasive pathogens [<xref ref-type="bibr" rid="CR125">125</xref>].</p>
      <sec id="Sec2">
        <title>Erythrophagocytosis</title>
        <p>The physiologic senescence of RBC is associated with mechanical and biochemical alterations of their membrane such as reduced flexibility, exposure of phosphatidylserine on their surface, and clustering of band 3 followed by binding of antibodies and complement [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR237">237</xref>]. The microanatomy of splenic sinusoidal capillaries prevents the unhindered passage of these senescent RBC. Macrophages, however, recognize cell surface markers of senescence via scavenger receptors such as Tim4, SR-AI, and CD36 [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR202">202</xref>, <xref ref-type="bibr" rid="CR251">251</xref>]. Damaged and aged RBC are engulfed by RPM (flow cytometrically phenotyped as F4/80<sup>low</sup> CD11b<sup>low</sup> Fpn1<sup>+</sup>) and phagocytosed. The molecular machinery of RBC recycling is relatively well described, and its function is essential to tissue integrity given the pro-oxidative capacity of free labile heme. This capacity is potentiated by the extraordinarily high number of about 1.2 × 10<sup>9</sup> heme moieties contained within a single RBC and the fact that RBC are the body’s most abundant cell type comprising approximately 84% of our cells [<xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR208">208</xref>]. It thus appears conceivable that a stand-by mechanism for heme detoxification exists: The molecular switch to turn on the protective pathways within cells is the transcriptional repressor Btb and Cnc homology 1 (Bach1). Bach1 is a basic leucine zipper (bZip) transcriptional factor which has a high affinity for heme, enabling it to act as a sensor of cellular heme levels. Rising heme levels induce Bach1 proteosomal degradation, releasing the brake on two types of down-stream pathways. First, the competitive inhibition of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) binding to antioxidant-response elements (ARE) ceases for genes containing AREs [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR221">221</xref>], such as ferritin h chain (FTH), FPN1, heme-regulated gene-1 (HRG1), and heme oxygenase (Hmox1) [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR190">190</xref>]. Second, the degradation of Bach1 induces expression of the transcription factor (an E26 transformation-specific transcription factor of the Spi subfamily) SpiC independently of Nrf2 [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR211">211</xref>]. SpiC is a transcription factor that is predominately expressed by RPM and erythroid island macrophages (EIM) in the BM [<xref ref-type="bibr" rid="CR88">88</xref>]. It is essential to the development of these cell types as <italic>Spic</italic>
<sup><italic>−/−</italic></sup> mice have drastically reduced numbers of RPM and EIM which lead to reduced proerythroblast numbers in the steady state, supporting the idea that iron recycling is essential to sustain iron-sufficient erythropoiesis [<xref ref-type="bibr" rid="CR58">58</xref>].</p>
        <p>Hypoxia-inducible factors (HIFs) provide an alternative mechanism to adjust heme iron recycling by macrophages to the degree of anemia and the need for de novo Hb synthesis. Anemia inevitably results in low oxygen concentrations in the tissue microenvironment which counteract HIF degradation in the proteasome so that these transcription factors become available to trans-activate genes containing hypoxia-responsive elements (HREs). HIF-HRE interaction in response to hypoxia thus stimulates iron release from macrophages by inducing Hmox1 and Fpn1 as well as one of its associated ferroxidases, ceruloplasmin [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR200">200</xref>]. Although many genes involved in heme iron recycling are thus HIF-inducible, HIF-1α and HIF-2α in macrophages are dispensable for heme iron recycling under hemolytic stress [<xref ref-type="bibr" rid="CR147">147</xref>]. This suggests that HIF isoforms fulfill redundant functions in macrophages or that they are not essential because Bach1-controlled pathways are dominant.</p>
        <p>Bach1 is not the only cellular sensor for heme. Intracellular free heme can also induce signaling via nuclear receptors Rev-Erbα and Rev-Erbß [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR187">187</xref>]. Furthermore, the inflammasome activation via cryopyrin (AKA NLRP3) is sensitive to surplus intracellular heme while extracellular free heme can activate Toll-like receptor 4 (TLR4), supporting the idea that free heme is an endogenous danger signal [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]. Given its inherent potential toxicity, the majority of free intracellular heme is promptly degraded by Hmox. Hmox1, which itself is induced via Nrf2 in response to heme or other oxidative stressors, is widely expressed in the MPS. Hmox2, by contrast, is a constitutive isoform carrying important functions in the nervous and reproductive systems [<xref ref-type="bibr" rid="CR89">89</xref>]. Both Hmox isoenzymes cleave heme’s protoporphyrin ring which yields bilirubin, carbon monoxide, and iron in equimolar amounts. The iron released during this process is either stored within ferritin (FT), incorporated into iron-containing proteins, or shuttled to the extracellular space via Fpn1. Outside the cell, ferrous iron needs to be oxidized to its ferric form by cell membrane-anchored hephaestin or plasmatic ceruloplasmin. Thereafter, ferric iron can be bound to transferrin (TF) and the bulk of it will re-enter the BM and be utilized in RBC production. Therefore, the incorporation of iron into protoporphyrin IX to form a new heme moiety closes the circle of heme iron recycling.</p>
      </sec>
    </sec>
    <sec id="Sec3">
      <title>Local circuits</title>
      <sec id="Sec4">
        <title>Liver—the iron regulatory organ</title>
        <p>The liver acts as central orchestrator of iron metabolism through various mechanisms. First, among many other carrier proteins, hepatocytes synthesize TF to cargo ferric iron in the circulation and keep free ionic iron at minimal levels. Second, even small fluctuations in plasma iron such as those originating from a single dose of an iron supplement are sensed by the liver and counterbalanced by an accordant change in hepcidin expression [<xref ref-type="bibr" rid="CR158">158</xref>]. An increase in plasma iron stimulates hepcidin secretion which dampens macrophage iron egress and to a lesser extent duodenal iron absorption following its interaction with Fpn1. Conversely, KC appear to dampen hepatocytes’ hepcidin expression since KC depletion with clodronate liposomes augments hepcidin and leads to a dramatic drop in plasma iron levels according to one study [<xref ref-type="bibr" rid="CR228">228</xref>]. However, other data suggest that KC are dispensable for the induction of hepcidin in response to iron or inflammation. Studies in <italic>Il-6</italic>
<sup><italic>−/−</italic></sup> mice confirmed that IL-6 is an important mediator to induce hepcidin in response to TLR4 ligation but KC depletion did not alter hepcidin induction in this model [<xref ref-type="bibr" rid="CR137">137</xref>]. While the physiological role of these observations therefore remains controversial [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR157">157</xref>], it is tempting to speculate that KC may fine-tune hepcidin production or that a liver-intrinsic circuit reports on the amount of iron acquired by KC through erythrophagocytosis. A diphtheria toxin-mediated depletion of C-type lectin domain family 4 member F (Clec4F), a marker specific to KC, might help to test this hypothesis [<xref ref-type="bibr" rid="CR207">207</xref>].</p>
        <p>Hepatocytes are also central effectors of the acute phase reaction that is induced during extracellular hemolysis and thereby produce haptoglobin and HPX which are rapidly consumed. Haptoglobin and HPX scavenge free Hb and heme, respectively, and are ligands to CD163 and CD91 which are primarily present on macrophages including KC [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR120">120</xref>]. The destruction of large amounts of RBC in the circulation further activates F4/80<sup>+</sup> CD11b<sup>low</sup> KC to respond with erythrophagocytosis. KCs have a limited tolerance to iron toxicity and die in the setting of massive hemolysis as discussed above [<xref ref-type="bibr" rid="CR231">231</xref>].</p>
        <p>Erythrophagocytosis augments Fpn1 and FT expression by F4/80<sup>+</sup> CD11b<sup>+</sup> liver-infiltrating monocytes that differentiate to macrophages which transiently replace dying KC. In the liver, M-CSF stimulates Fpn1 expression while GM-CSF, which is produced in the spleen, represses Fpn1 [<xref ref-type="bibr" rid="CR231">231</xref>]. Upon differentiation, these F4/80<sup>+</sup> CD11b<sup>+</sup> Fpn1<sup>+</sup> monocytes also express SpiC and bone morphogenetic protein 6 (Bmp6). While SpiC may program them to recycle iron efficiently, the iron-inducible factor, Bmp6, may have paracrine effects on adjacent hepatocytes by instructing them to increase hepcidin expression, thereby lowering circulating iron levels. However, the major production of Bmp6 in the liver is by yet another liver-resident cell type, sinusoidal endothelial cells [<xref ref-type="bibr" rid="CR28">28</xref>]. Since Bmp6 stimulates both hepcidin production by hepatocytes [<xref ref-type="bibr" rid="CR6">6</xref>] and transcriptionally regulates macrophage effector functions [<xref ref-type="bibr" rid="CR123">123</xref>], it may broadly orchestrate the interplay between various liver-resident cell types. Intriguingly, there might be direct transfer of iron from macrophages to hepatocytes after erythrophagocytosis because iron contained in damaged RBC first accumulates in myeloid cells but is distributed to hepatocytes within 1 week. The underlying mechanism remains elusive but may employ Fpn1 as well as alternative routes of iron trafficking via FT secretion and uptake via FT receptors [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR130">130</xref>]. In fact, it has been shown that macrophages are the major source of plasma FT [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
        <p>The importance of Fpn1 for liver cell functions is evident from the clinical manifestations of ferroportin disease (type 4 hemochromatosis) which is caused by various mutations in the <italic>SLC40A1</italic> (encoding FPN1) gene [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR189">189</xref>]. Classical loss-of-function mutations of <italic>SLC40A1</italic> result in reduced iron transport capacity that are attributable to an amino acid exchange in the iron pore or to protein misfolding of FPN1. The mutations mainly manifest in the MPS (i.e., by iron retention in KC) because the high iron turnover of macrophages cannot be met by 50% of functional FPN1 molecules transcribed from the intact <italic>SLC40A1</italic> allele [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR149">149</xref>]. However, non-classical Fpn1 mutations <italic>SLC40A1</italic> are gain-of-function mutations that cause hepcidin resistance of the FPN1 protein. In this case, hepcidin cannot bind to FPN1 and does not cause its internalization and lysosomal degradation. Consequently, a phenotype of functional hepcidin deficiency that is similar to classical type I hemochromatosis with hepatocellular iron overload occurs [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR188">188</xref>, <xref ref-type="bibr" rid="CR246">246</xref>]. In summary, hepatocytes, KC, and endothelial cells cooperate to maintain the body’s iron homeostasis and we are beginning to decipher the signals that coordinate the function of these and other liver-resident cell types.</p>
      </sec>
      <sec id="Sec5">
        <title>Spleen—iron recycler in steady state</title>
        <p>Similar to the liver, several cell populations co-exist in the spleen. RPM ingest erythrocytes in steady state, eliminating more than 2 × 10<sup>6</sup> of these cells per second in a healthy adult (as deduced from the RBC production rate assuming equilibrium). This enormous task has implications for the spleen’s immune function. For instance, CD47 is a “do not eat me” signal expressed by many cell types including RBC [<xref ref-type="bibr" rid="CR178">178</xref>]. CD47 is recognized by signal regulatory protein alpha (SIRPα) on macrophages which then ignore the intact RBC. In contrast, CD47-deficient RBC are rapidly cleared from the circulation. Aging RBC partially lose surface expression of CD47 [<xref ref-type="bibr" rid="CR109">109</xref>]. Given that CD47 specifically and substantially inhibits FcγR-mediated phagocytosis of IgG-carrying RBC, the CD47 reduction with senescence is thought to enable the elimination of aged RBC. RPM are not the only ones that recognize CD47, though. The absence of CD47 on RBC is also sensed by splenic CD4<sup>+</sup> DCs. Lacking the inhibitory input of CD47-SIRPα interaction, they are licensed to augment MHC-II, CD86, and CCR7 and start their migration to the T cell zone to stimulate T cells [<xref ref-type="bibr" rid="CR253">253</xref>]. However, it remains unclear whether or not erythrophagocytosis by RPM and CD4<sup>+</sup> DC activation affect each other.</p>
        <p>In response to increased demand for erythrophagocytosis, the spleen also produces abundant amount of GM-CSF, which inhibits Fpn1 expression in macrophages [<xref ref-type="bibr" rid="CR231">231</xref>]. It has thus been proposed that the emergency mechanism of iron recycling is less efficient under stress conditions in the spleen. This fundamental difference between spleen and liver may be based on the fact that iron alters the binding affinity of antibodies: Both ferrous iron and free heme interact with IgG to enlarge the antibody repertoire. Specifically, heme-IgG complexes have a broader ability to recognize bacterial antigens and kill intact bacteria. In addition, Fe-IgG complexes protect from <italic>E. coli</italic> sepsis suggesting another possible link between erythrophagocytosis and adaptive immunity [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Another aspect underlying reduced erythrophagocytosis in the spleen under stress conditions including infections can be attributed to the fact that iron loading of macrophages dampens their innate anti-microbial effector function directed against invading pathogens [<xref ref-type="bibr" rid="CR212">212</xref>]. While the function of RPM in continuous erythrophagocytosis is clear, we are lacking a comprehensive understanding of how iron recycling in the splenic red pulp and the organ’s immune functions affect each other.</p>
      </sec>
      <sec id="Sec6">
        <title>Muscle—venue for a closed circuit for iron recycling following myolysis?</title>
        <p>A mechanism comparable to hemolysis-induced RBC recycling in the liver has recently been described in the skeletal muscle in the context of rhabdomyolysis. Rhabdomyolysis, the death of the skeletal muscle, poses a fundamental risk for the body’s integrity because myoglobin, the oxygen transfer protein, is a heme-containing protein that can contribute to iron-mediated radical damage. Additionally, myoglobin’s molecular weight of 17 kDa allows it to penetrate the glomerular filtration apparatus of the kidney which operates at a cutoff of 30–50 kDa so that in rhabdomyolysis large quantities of myoglobin end up in the renal tubuli where they can cause acute kidney injury (crush kidney). Therefore, the skeletal muscle is equipped with a machinery that protects from free myoglobin/heme-mediated damage. This includes HPX formation and myeloid cell recruitment. Macrophages infiltrating the injured skeletal muscle induce the expression of Hmox1, CD163, and FT to contain and detoxify heme [<xref ref-type="bibr" rid="CR41">41</xref>]. It has further been suggested that the induction of Hmox1 and Fpn1 by the infiltrating monocytes allows for local heme iron recycling so that the regenerating myoblasts have enough iron for de novo myoglobin synthesis. It will be interesting to see whether myeloid cells also affect iron metabolism of skeletal muscle during more physiological conditions such as growth and whether there are perturbations in myopathies other than rhabdomyolysis.</p>
      </sec>
      <sec id="Sec7">
        <title>Heart—an organ exquisitely sensitive to iron toxicity</title>
        <p>The presence of a local mechanism of iron recycling by monocytes in skeletal muscle raises the question whether similar circuits exist throughout the body. Given that myocardial ischemia induces substantial recruitment of monocytes from blood, BM, and spleen to the site of damage and its vicinity, these cells may also encounter myoglobin molecules. However, the adult myocardium lacks regenerative potential suggesting that iron handling by monocytes infiltrating the injured heart muscle may be different from that of monocytes infiltrating damaged skeletal muscle [<xref ref-type="bibr" rid="CR92">92</xref>]. Alternatively, it is possible that cardiac fibroblasts use iron recycled by monocytes for proliferation and collagen synthesis [<xref ref-type="bibr" rid="CR80">80</xref>].</p>
        <p>Resident cardiac macrophages are one of the major non-parenchymal cells of the heart [<xref ref-type="bibr" rid="CR223">223</xref>]. They have well-established roles in the pathogenesis of ischemic myocardial injury as well as in tissue repair thereafter [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. In addition, their roles in the metabolic activity of the adjacent myocardium and in chronic cardiac diseases such as congestive heart failure are increasingly appreciated [<xref ref-type="bibr" rid="CR199">199</xref>], and macrophages may either tailor the delivery of iron to the myocardium or accumulate and detoxify heme which may mainly arise from tissue injury [<xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR214">214</xref>].</p>
        <p>The susceptibility of the heart to pathological iron loading is well reflected in Friedreich’s ataxia, an autosomal recessive disease with a complex neurological phenotype that inevitably affects the heart; congestive heart failure is the most frequent cause of death in these patients. Frataxin localizes to mitochondria where it fulfills functions in the assembly of iron-sulfur clusters acting as the mitochondrial iron chaperone [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
        <p>Given the extraordinary energy generation by mitochondria in cardiomyocytes, it is likely that the cardiac phenotype of Friedreich’s ataxia is primarily a parenchymal one that occurs as a consequence of mitochondrial heme accumulation due to defective iron utilization [<xref ref-type="bibr" rid="CR98">98</xref>]. However, it is interesting to note that the number of CD68<sup>+</sup> macrophages is increased in the myocardium of Friedreich ataxia patients and that these cells contain higher amounts of FT. It has been proposed that Fpn1-mediated iron export from cardiac macrophages may be impaired in Friedreich’s disease [<xref ref-type="bibr" rid="CR115">115</xref>].</p>
        <p>Since cardiomyocytes are exquisitely sensitive to iron overload and iron overload disorders commonly affect the heart, a better understanding of iron handling by resident or recruited myeloid cells in the cardiac microenvironment may open new therapeutic options. However, cardiac macrophages are already an established diagnostic target of contrast material in magnetic resonance imaging (MRI). Specifically, nanoscale iron-containing compounds (IONs, for iron oxide nanoparticles) have been designed to being selectively taken up by macrophages [<xref ref-type="bibr" rid="CR183">183</xref>]. After exposure to magnetic fields, these compounds cause a signal alteration which is affected by processes such as ischemia or inflammation secondary to macrophage activation.</p>
      </sec>
      <sec id="Sec8">
        <title>Blood vessels—arterial macrophage iron overload as hallmark of atherosclerosis</title>
        <p>Iron accumulation in arterial macrophages has long been suggested to contribute to the pathogenesis of atherosclerosis [<xref ref-type="bibr" rid="CR220">220</xref>]. A comprehensive pathophysiological understanding of this observation is still pending. However, it is well documented that arterial macrophages, typically identified by CD68 histochemistry on histologic sections within atherosclerotic lesions, contain larger amounts of FT than those outside plaques [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR256">256</xref>]. Accordingly, high levels of plasma FT are an independent risk factor for the severity of carotid artery disease [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>], and high circulating iron levels have been linked to impaired endothelial function and intima media thickening, two early predictors of atherosclerosis [<xref ref-type="bibr" rid="CR76">76</xref>]. Published evidence suggests that microhemorrhages occur in the vasa vasora of the arterial wall and that macrophages remove RBC debris by phagocytosis, which increases their iron levels without overt activation [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR201">201</xref>]. In addition, atherosclerosis is a lipid-driven chronic inflammatory disorder closely linked to the metabolic syndrome, and higher plasma hepcidin levels are associated with vascular damage as documented in a small but well-conducted ultrasonographic pilot study [<xref ref-type="bibr" rid="CR238">238</xref>]. That said, hepcidin levels do not predict an increased risk for myocardial infarction or stroke in a population-based study [<xref ref-type="bibr" rid="CR182">182</xref>].</p>
        <p>The specific role of macrophage iron efflux in the progression of atherosclerosis is controversial. While the presence of the hypofunctional <italic>flatiron</italic> mutation of <italic>Slc40a1</italic> in apolipoprotein E-deficient (<italic>Apoe</italic>
<sup><italic>−/−</italic></sup>) mice did not affect atherosclerosis [<xref ref-type="bibr" rid="CR107">107</xref>], systemic administration of the hepcidin-antagonist LDN-193189 (LDN), which inhibits Bmp-induced hepcidin transcription [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR230">230</xref>], blocked the differentiation of macrophages into foam cells. This latter effect was based on enhanced expression of ATB-binding cassette transporters ABCA1 and ABCG1, two major cholesterol efflux proteins, and on increased cholesterol transfer to apolipoprotein A1 (ApoA1) [<xref ref-type="bibr" rid="CR198">198</xref>]. Importantly, LDN treatment also reduced atherosclerotic lesion size, suggesting that modulating systemic iron metabolism affects atherosclerosis progression. A more selective approach that only targets arterial wall macrophages may be warranted as the metabolic syndrome can be associated not only with functional iron deficiency (predicted to be ameliorated by hepcidin antagonism) but also with iron overload (predicted to be aggravated by systemic hepcidin inhibition).</p>
        <p>The dysregulation of iron metabolism in arterial macrophages is not limited to the hepcidin-Fpn1 axis. In humans, expression of the ferroxidases hephaestin and ceruloplasmin was reduced in atherosclerosis [<xref ref-type="bibr" rid="CR105">105</xref>]. Accordingly, there is in vitro evidence that iron-induced ROS contribute to LDL oxidation and that oxidized LDL particles induce FTH and hepcidin transcription in macrophages which may reduce Fpn1 levels and thus retain cellular iron [<xref ref-type="bibr" rid="CR144">144</xref>].</p>
        <p>In conclusion, evidence is accumulating for a cross-talk between the regulators of iron and cholesterol metabolism both systemically and locally in the microenvironment of the atherosclerotic plaque. However, due to a lack of mechanistic insight, we are not able yet to therapeutically target one metabolite or metabolic pathway in the attempt to beneficially affect the other.</p>
      </sec>
      <sec id="Sec9">
        <title>Brain—cerebral iron overload is implicated in neurodegeneration</title>
        <p>In the central nervous system (CNS), macrophages appear as microglia and are in close proximity to neurons, astrocytes, and oligodendrocytes. The microglia depend on the transcription factors PU.1 (encoded by <italic>SPI1</italic>) and “Spalt-like”-1 (Sall1) [<xref ref-type="bibr" rid="CR25">25</xref>] and are important for maintaining CNS homeostasis in physiological conditions and for restoring it after injury [<xref ref-type="bibr" rid="CR84">84</xref>]. This paradigm has also been addressed in the context of iron metabolism. For instance, after experimental intracranial hemorrhage (ICH), microglia clear RBC but may also sustain inflammation and cause secondary damage. It is thus conceivable that the molecular machinery for RBC degradation and heme iron recycling including Hmox1 and Nramp1 [<xref ref-type="bibr" rid="CR213">213</xref>] is essential for microglial function [<xref ref-type="bibr" rid="CR19">19</xref>]. Indeed, long-term induction of Hmox1 promotes the resolution of ICH [<xref ref-type="bibr" rid="CR260">260</xref>]. However, this may not be a feasible therapeutic approach to be readily translated into clinical practice because various cerebral cell types differ in their cytoprotective enzyme repertoire and thus in their sensitivity to iron-induced damage [<xref ref-type="bibr" rid="CR255">255</xref>]. Cell type-specific overexpression of Hmox1 in astrocytes, although neuroprotective in some in vitro models [<xref ref-type="bibr" rid="CR240">240</xref>] and in ICH in young mice, is deleterious in other settings [<xref ref-type="bibr" rid="CR133">133</xref>, <xref ref-type="bibr" rid="CR215">215</xref>, <xref ref-type="bibr" rid="CR216">216</xref>] and results in spontaneous cerebral iron deposition and consecutive movement and psychiatric abnormalities with aging [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR218">218</xref>]. When the iron chelator deferoxamine (DFO), however, is administered early after experimental ICH, microglial activation is blunted and reduced local concentrations of tumor necrosis factor (TNF) and interleukin (IL)-1ß are associated with protection from neuronal death. Therefore, early DFO treatment in experimental ICH translates into improved neurologic outcome [<xref ref-type="bibr" rid="CR222">222</xref>].</p>
        <p>Local iron accumulation in the brain (particularly in neurons and astrocytes) is linked to several neurodegenerative disorders, collectively referred to as neurodegeneration with brain iron accumulation (NBIA) [<xref ref-type="bibr" rid="CR127">127</xref>]. Although iron-mediated generation of ROS and injury to mitochondria are likely mechanisms [<xref ref-type="bibr" rid="CR196">196</xref>, <xref ref-type="bibr" rid="CR204">204</xref>], the interplay between microglia, neurons, and other cell types in cerebral iron homeostasis is incompletely characterized. A paradigmatic yet rare NBIA condition is the neuroferritinopathy that is caused by a mutation in the coding region of the <italic>FTL</italic> gene [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Although FTH carries the ferroxidase activity that is required to oxidize ferrous iron and to contain it within the FT shell, FTL facilitates the mineralization of ferric iron thus supporting FTH activity. The composition of FT is cell type-specific, and central neuronal FT are L chain-rich [<xref ref-type="bibr" rid="CR236">236</xref>]. In addition, mutated FTL proteins may have a dominant negative effect on FT’s stability and resistance to oxidative damage [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. It would appear that neuronal iron efflux is insufficient to remove surplus and potentially harmful iron from the cytoplasm. Whether or not a transfer of iron between neurons and microglial cells exists is unclear. However, it has been proposed that the siderophore-binding peptide lipocalin-2 (NGAL, Lcn2) is secreted by activated microglia and other cell types including neurons to transfer iron across cellular membranes. Notably, Lcn2 also affects a variety of brain functions from cognition to emotional stress [<xref ref-type="bibr" rid="CR104">104</xref>]. Interestingly, the hyperferritinemia-cataract syndrome that is caused by a mutation in a specific non-coding region of the <italic>FTL</italic> gene, the iron-responsive element (IRE), is not associated with iron accumulation in the brain but with the formation of ferritin crystals in the ocular lenses, resulting in cataracts in early adulthood [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR195">195</xref>].</p>
        <p>Several common neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases are also characterized by iron deposition, but they are not considered as classical NBIA. Whether or not the latter is causatively involved in the pathophysiology of the disease or a consequence of neurodegeneration is currently not known, as the influx of iron-rich inflammatory cells and their subsequent death may contribute to neuronal iron overload [<xref ref-type="bibr" rid="CR233">233</xref>]. In addition, an intrinsic defect of neurons in cellular iron handling may exist. For instance, in neuronal cells exposed to amyloid beta peptide fragments, iron chelation with DFO or deferiprone (DFP) reduces ROS generation via the NADPH oxidase [<xref ref-type="bibr" rid="CR181">181</xref>]. Apart from neurons, activated microglia can accumulate iron in Alzheimer’s disease, e.g., in the hippocampus as detected my ultra-high-resolution MR [<xref ref-type="bibr" rid="CR258">258</xref>]. A similar observation has been made in the setting of the <italic>HFE H63D</italic> polymorphism, which is otherwise associated with type I hereditary hemochromatosis and has been linked to neurodegeneration. Mice with the homologous mutation in <italic>Hfe</italic> have increased FTL chain expression in microglia, suggesting iron overload [<xref ref-type="bibr" rid="CR169">169</xref>]. This phenotype is discrepant from the iron-poor one of other Hfe-deficient macrophage populations, but the underlying mechanism remains unknown.</p>
        <p>Similar to cardiac imaging, IONs are selectively taken up by microglia as a function of its activation state. Conceivably, microglial activation due to ischemia or inflammation results in MR signal alterations that can be used for diagnostics. However, microglia are also exquisitely sensitive to the potential toxicity of IONs because they are rapidly degraded within lysosomes and their iron catalyzes ROS generation [<xref ref-type="bibr" rid="CR184">184</xref>]. Although hepcidin production has been observed in the brain, co-culture models suggest that microglia enhance hepcidin expression by neurons via IL-6 in a paracrine fashion [<xref ref-type="bibr" rid="CR191">191</xref>]. These findings thus contrast to what has been shown for co-cultured primary Kupffer cells and hepatocytes inasmuch as culture supernatants from primary Kupffer cells blunted hepcidin production [<xref ref-type="bibr" rid="CR228">228</xref>].</p>
        <p>The published studies provide growing insight into how microglia affect brain function, local iron homeostasis, and iron-mediated neurodegeneration. The human brain is probably the most complex system known, and we need to better understand how its different cell types interact both under physiological conditions and challenges such as cognition or memory, how iron affects the function of the various cerebral cell types, and how we can potentially interfere to prevent iron from contributing to CNS disease.</p>
      </sec>
      <sec id="Sec10">
        <title>Retina—the location in which iron aggravates light damage</title>
        <p>From an evolutionary standpoint, the retina is part of the CNS. It is thus not surprising that it handles iron similarly to the cerebrum. Since photoreceptors are sensitive to iron toxicity, local iron regulatory circuits including the hepcidin-Fpn1 axis operate in the retina [<xref ref-type="bibr" rid="CR261">261</xref>]. Müller glial cells and endothelial cells of the retina both express Fpn1, but only the latter cell type is sensitive to hepcidin regulation. This suggests that endothelial Fpn1 is the gatekeeper for iron transport into the retina [<xref ref-type="bibr" rid="CR232">232</xref>]. In addition, experimental light damage to the retina results in microglial activation, its migration to the outer retina, and in induction of FT H and L chains. These effects along with oxidative stress to photoreceptors can be prevented by the oral iron chelator DFP [<xref ref-type="bibr" rid="CR217">217</xref>]. Therefore, the retina is another organ that is sensitive to iron toxicity but has evidence of endogenous mechanisms to maintain local iron homeostasis in the microenvironment.</p>
      </sec>
      <sec id="Sec11">
        <title>Bone—osteoclasts are iron-dependent</title>
        <p>Osteoclasts are bone-resident cells of the MPS whose primary function is to absorb bone tissue in order to maintain, repair, and remodel the skeleton. Osteoclast generation requires the fusion of macrophages, the presence of the cytokines RANKL and M-CSF, and iron. Osteoclast precursors take up iron via Tfr1 and utilize six-transmembrane epithelial antigen of prostate (Steap4) as ferrireductase [<xref ref-type="bibr" rid="CR262">262</xref>]. In addition, the transcription factor peroxisome proliferator-activated receptor-gamma coactivator 1 beta (PGC-1ß) is essential for osteoclast differentiation [<xref ref-type="bibr" rid="CR101">101</xref>]. Apparently, both Tfr1-mediated iron uptake and PGC-1ß activation ensure mitochondrial respiration in osteoclasts as prerequisite for energy generation and proton secretion. While PGC-1ß transactivates genes of the mitochondrial respiratory chain, iron acquired via Tfr1 is incorporated into heme moieties and iron-sulfur clusters in mitochondria ensuring activity of their enzyme repertoire. Conceivably, iron overload is often associated with skeletal disease. For instance, surplus iron in thalassemic patients may promote osteoclast differentiation and function and thus contribute to bone resorption [<xref ref-type="bibr" rid="CR101">101</xref>].</p>
        <p>Arthropathy of the second and third metacarpophalangeal joints is a typical manifestation of type I hemochromatosis [<xref ref-type="bibr" rid="CR94">94</xref>]. Elevated vascular cell adhesion molecule 1 (VCAM1) levels are an accurate biomarker to diagnose this condition, but whether the adhesion molecule is also involved in its pathogenesis remains unclear [<xref ref-type="bibr" rid="CR170">170</xref>]. Of interest, circulating VCAM1 is shed by the metalloproteinase ADAM metallopeptidase domain 17 (ADAM17, AKA TNF alpha-converting enzyme (TACE)) which is activated by inflammatory stimuli [<xref ref-type="bibr" rid="CR81">81</xref>]. In addition, membrane VCAM1 is expressed on CD169<sup>+</sup> macrophages in the spleen and provides a molecular anchor to retain hematopoietic stem cells in the murine spleen, although it is unclear whether this is also relevant to arthropathy [<xref ref-type="bibr" rid="CR61">61</xref>]. Taken together, despite the essential role of iron for osteoclast development and the clear association of skeletal disease and iron overload, we have little information about underlying mechanisms.</p>
      </sec>
      <sec id="Sec12">
        <title>Bone marrow—are erythroblasts “nursed” with iron?</title>
        <p>Embedded in cavities and the spongiosa of bones lies the BM as organ of hematopoiesis. Erythroid island macrophages (EIM) are a population of BM-resident macrophages that support erythropoiesis as “nurse cells” [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR192">192</xref>]. The smallest erythropoietic unit thus consists of a central EIM surrounded by several erythroblasts (and stromal cells). This microarchitecture is maintained by adhesive interactions because EIM depend on a set of adhesion molecules. For instance, EIM express the αV integrin which binds ICAM4 on erythroid cells, and ICAM4 KO mice have reduced numbers of erythropoietic islands [<xref ref-type="bibr" rid="CR126">126</xref>]. Similarly, macrophage VCAM1 interacts with the integrin-α4ß1 on erythroblasts. It is well characterized that erythroblasts expel their nuclei during differentiation and that these are taken up by EIM after phosphatidylserine exposure via Tim4 and MER proto-oncogene, tyrosine kinase (MerTK) [<xref ref-type="bibr" rid="CR234">234</xref>, <xref ref-type="bibr" rid="CR254">254</xref>].</p>
        <p>The transcription factor SpiC and its down-stream effector Hmox1 are both essential for EIM differentiation, since ablation of either gene reduces EIM number [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. Less clear however remains the role of EIM and Hmox1 in local iron management in the BM and mechanisms by which EIM may assist erythroblasts in iron acquisition. One possibility is that erythroblasts acquire ionic iron via their proximity to Fpn1 on EIM. However, since Fpn1 exports only divalent iron and erythroblasts largely rely on Tfr1 (AKA CD71) to satisfy their iron demand, one can speculate that either abundant amounts of ceruloplasmin and TF (to oxidize divalent iron) are present in erythroid islands or that direct cell-to-cell transfer of iron from EIM to erythroblasts exists. However, the deletion of Fpn1 by Cre recombinase expressed under the <italic>lysozyme M</italic> promoter results in iron accumulation in macrophages, including BM macrophages, and mild anemia. This suggests that EIM utilize Fpn1 to export iron and thus function as iron-rich nurse cells [<xref ref-type="bibr" rid="CR259">259</xref>]. Such a mechanism may be particularly relevant in contexts when erythropoiesis is hyperactive yet inefficient and when local hemolysis occurs in the BM (i.e., in thalassemia syndromes). Another hypothesis is that EIM act as “iron buffers” that continuously releases adequate amounts of iron even when plasma iron levels fluctuate. Yet, another idea is that despite their other essential functions EIM contribute little to the iron acquisition by erythroblasts and that the latter import any TF-bound iron the blood stream delivers. Data in support of this concept has been generated using the CD169-DTR model: The depletion of EIM (and other CD169<sup>+</sup> macrophages) had only little impact on the restoration of erythropoiesis after BM transplantation. Concretely, a moderate decrease of iron supply to erythroblasts as deduced from the reduced Hb content in reticulocytes was observed [<xref ref-type="bibr" rid="CR38">38</xref>]. In conclusion, much needs to be learned about local mechanisms and their regulation of iron shuttling from EIM to erythroblasts at various stages of their differentiation.</p>
      </sec>
    </sec>
    <sec id="Sec13">
      <title>The complexity of macrophage iron handling at the cellular level</title>
      <p>Macrophages express a range of factors mediating iron uptake (summarized in the Table <xref rid="Tab1" ref-type="table">1</xref>) which essentially face only two pathways for iron efflux, Fpn1 for ionic iron and feline leukemia virus subtype C receptor (Flvcr) for heme iron (Fig. <xref rid="Fig2" ref-type="fig">2</xref>), although alternatives routes may exist [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR136">136</xref>]. One such mechanism may involve Lcn2 and one of its receptors, LcnR (AKA SLC22A17). Lcn2 binds distinct types of so-called siderophores, low molecular mass compounds with remarkably high affinity and specificity for ferric iron. These are best characterized in bacteria, but eukaryotes including fungi and mammals produce siderophores, too [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. While some of these compounds such as citrate are ubiquitous substrates, other mammalian siderophores such as catechols are probably synthesized from commensal metabolites or dietary precursors [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR252">252</xref>]. Much needs to be learned about the biology of mammalian siderophores whose important functions may extend beyond mitochondrial iron homeostasis, erythropoiesis, and host defense [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Selected proteins involved in macrophage iron handling</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Protein</th><th>Designation(s)</th><th>Gene name</th><th>Function</th></tr></thead><tbody><tr><td>TFR1</td><td>Transferrin receptor-1; CD71</td><td>
<italic>TFRC</italic>
</td><td>Uptake of TF-bound iron; essential for erythroblasts and lymphocytes [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR141">141</xref>]; genetic defect associated with common immunodeficiency (IMD-46) [<xref ref-type="bibr" rid="CR103">103</xref>]</td></tr><tr><td>HFE</td><td>HFE; HLA-H</td><td>
<italic>HFE</italic>
</td><td>Associates with TFR1; the <italic>C282Y HFE</italic> mutation causes hemochromatosis (type 1) characterized by macrophage iron depletion [<xref ref-type="bibr" rid="CR18">18</xref>]; affects outcome of infections [<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td>DMT1</td><td>Divalent metal transporter-1; Solute Carrier Family 11 member A2</td><td>
<italic>SLC11A2</italic>
</td><td>Uptake of ferrous iron through the cell surface membrane and from TFR1 endosomes; genetic defect associated with iron deficiency anemia and hepatocellular iron accumulation [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]</td></tr><tr><td>DCYTB</td><td>Duodenal cytochrome b; Cytochrome b reductase 1</td><td>
<italic>CYBRD1</italic>
</td><td>Reduction of ferric iron to its ferrous form prior to uptake via DMT1 [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]; induced in iron deficiency [<xref ref-type="bibr" rid="CR264">264</xref>]</td></tr><tr><td>STEAPs</td><td>Six-transmembrane epithelial antigen of prostate</td><td>
<italic>e.g. STEAP4</italic>
</td><td>Reduction of ferric iron prior to uptake via TFR1, e.g. STEAP4 in osteoclast precursors [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR262">262</xref>]</td></tr><tr><td>LCNR</td><td>Lipocalin-2 receptor; 24P3R</td><td>
<italic>SLC22A17</italic>
</td><td>Bi-directional iron transport across the cell membrane requiring LCN2 and a catecholate-type siderophore [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR210">210</xref>]</td></tr><tr><td>LCN2</td><td>Lipocalin-2; Neutrophil gelatinase associated lipocalin</td><td>
<italic>LCN2</italic>
</td><td>Binds iron-laden siderophores of different classes [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]; acts as chemotaxin [<xref ref-type="bibr" rid="CR206">206</xref>]; associated with cancer metastasis</td></tr><tr><td>NRAMP1</td><td>Natural resistance-associated macrophage protein-1</td><td>
<italic>SLC11A1</italic>
</td><td>Iron (and other divalent metal ion) export out of the phagolysosome for iron withholding from pathogens [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR163">163</xref>]; also affects odds of developing autoimmune diseases</td></tr><tr><td>IRP1</td><td>Iron regulatory protein-1; Aconitase 1</td><td>
<italic>ACO1</italic>
</td><td>Interaction with IREs, stabilize TFR1 and DMT1 mRNAs; blocks translation of FPN1 and FT mRNAs; its iron-sulfur cluster disassembles upon cellular iron starvation [<xref ref-type="bibr" rid="CR242">242</xref>]</td></tr><tr><td>IRP2</td><td>Iron regulatory protein-2</td><td>
<italic>IREB2</italic>
</td><td>Similar to IRP1; becomes deactivated via the ubiquitin proteasome pathway when surplus iron is sensed in the cytosol [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR243">243</xref>]</td></tr><tr><td>FTH</td><td>Ferritin heavy chain</td><td>
<italic>FTH</italic>
</td><td>Iron storage; sole carrier of the ferroxidase activity of cytosolic FT [<xref ref-type="bibr" rid="CR197">197</xref>]; anti-apoptotic [<xref ref-type="bibr" rid="CR186">186</xref>, <xref ref-type="bibr" rid="CR236">236</xref>]</td></tr><tr><td>FTL</td><td>Ferritin light chain</td><td>
<italic>FTL</italic>
</td><td>Iron storage; genetic defect causes neuroferritinopathy (coding region) or hyperferritinemia cataract syndrome (non-coding IRE) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td>FPN1</td><td>Ferroportin-1</td><td>
<italic>SLC40A1</italic>
</td><td>Ionic iron exporter [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR263">263</xref>]; receptor for hepcidin [<xref ref-type="bibr" rid="CR173">173</xref>]</td></tr><tr><td>Hepcidin</td><td>Hepcidin antimicrobial peptide</td><td>
<italic>HAMP</italic>
</td><td>Binds to FPN1 to label it for internalization and degradation; induced by IL-6, IL-22 and Bmp6 [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR172">172</xref>]; genetic defect results in juvenile hemochromatosis (type 2B) [<xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR194">194</xref>]</td></tr><tr><td>HEPH</td><td>Hephaestin</td><td>
<italic>HEPH</italic>
</td><td>Oxidizes ferrous iron for loading onto TF [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td>HRG1</td><td>Heme-regulated gene-1</td><td>
<italic>HRG1</italic>
</td><td>Shifts heme from the lysosome to the cytosol [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR250">250</xref>]</td></tr><tr><td>FLVCR</td><td>Feline leukemia virus subgroup C receptor</td><td>
<italic>FLVCR1</italic>
</td><td>Exports heme across the cell membrane; genetic deletion results in RPM iron overload [<xref ref-type="bibr" rid="CR108">108</xref>]</td></tr></tbody></table></table-wrap>
<fig id="Fig2"><label>Fig. 2</label><caption><p>
<bold>a</bold> In homeostatic conditions, iron uptake and release pathways are coordinated ensuring efficient iron recycling from aged red blood cells (aRBC) and iron delivery to sites of erythropoiesis. Apart from erythrophagocytosis, iron uptake mechanisms include (<italic>left to right</italic>) ferritin (FT) receptors such as scavenger receptor class A member (Scara)-5 and T-cell immunoglobulin and mucin domain-containing molecule (Tim)-2, transferrin (TF; depicted as monomer for simplicity) and its receptor Tfr1, the ferric reductase duodenal cytochrome B (DcytB) and divalent metal transporter (Dmt)-1, lactoferrin (LF) and its receptor LfR, lipocalin (Lcn)-2 and its receptor LcnR, haptoglobin-hemoglobin (Hb) complexes and their receptor CD163, and hemopexin (HPX)-heme complexes and their receptor CD91. Endosomal iron transporters Dmt1, natural resistance-associated macrophage protein-1 (Nramp1), and heme-regulated gene-1 (HRG1) shift ferrous iron or heme to the cytoplasm, from where the former can be exported via ferroportin (Fpn)-1 and the latter metabolized by heme oxygenase (Hmox)-1 or exported via feline leukemia virus subgroup C receptor (Flvcr). Macrophage iron homeostasis ensures proper function including the activity of pivotal transcription factors nuclear factor (NF)-IL6, NF-κB, and hypoxia-inducible factor (HIF)-1α, all of which are iron regulated. <bold>b</bold> Macrophage iron overload may result from an increase in circulating or local hepcidin concentrations, an elevated TF saturation, free iron excess, or hemolysis with subsequent accumulation of damaged RBC (dRBC), free Hb, or free heme. If severe, all these mechanisms will overwhelm the macrophage’s capacity to contain, store, and detoxify iron resulting in an increase of free iron, heme, and/or FT in cells. On the one hand, surplus intracellular iron may serve as nutrient for intraphagosomal or cytoplasmatic pathogens (e.g. for Gram-negative rods in the Tfr1-endosome and the cytoplasm). On the other hand, iron overload differentially affects distinct innate immune pathways. Surplus iron blocks the binding of transcription factors NF-IL6 and HIF-1α to their respective target promoter sequences. In parallel, iron facilitates the generation of ROS and thus NF-κB activation. Therefore, iron overload may cause a dysbalance in the transcriptional response to macrophage activation</p></caption><graphic xlink:href="424_2017_1944_Fig2_HTML" id="MO2"/></fig>
</p>
      <p>As discussed above, scavenger receptors for the uptake of senescent or damaged RBC and for the clearance of complexed and free forms of Hb and heme are expressed at high levels in liver and spleen yet may be induced at other locations in response to inflammatory stimuli. These scavenger receptors are coupled to a down-stream machinery of heme detoxification. Its two major functional components are HRG1 which shifts heme from the endosome/lysosome to the cytoplasm and Hmox1 which then metabolizes heme [<xref ref-type="bibr" rid="CR117">117</xref>]. In addition to the phagocyte-specific scavenger receptors, Tfr1 and divalent metal transporter 1 (Dmt1), two ubiquitous iron import proteins, are also expressed by macrophages.</p>
      <sec id="Sec14">
        <title>A broad spectrum of iron uptake pathways</title>
        <p>Macrophages express a range of factors mediating iron uptake, although the relative importance of these factors to different macrophage populations has not been systematically studied. It is well established that RPM and KC express the complete machinery for RBC clearance and heme iron recycling [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR231">231</xref>]. At either of these locations (spleen and liver), CD163 and CD91, two members of the scavenger receptor family, are expressed at high levels. Whereas CD163 binds both free and haptoglobin-bound Hb, CD91 accepts heme-HPX complexes. However, many other molecules participate in the overall process. Among these, heme-regulated gene 1 (HRG1) shifts heme from the endosome/lysosome to the cytoplasm, which is then metabolized by Hmox1 [<xref ref-type="bibr" rid="CR117">117</xref>]. At the cell surface membrane, macrophages possess the heme exporter Flvcr and its genetic deletion results in RPM iron overload [<xref ref-type="bibr" rid="CR108">108</xref>]. Tfr1, which is also known as CD71, is widely expressed by isolated macrophages, and it may form a major route of iron uptake in the absence of RBC (an indirect iron source), though it also appears to be important in adaptive immunity [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. Dmt1 shifts iron from the extracellular space to the cytoplasm and, in its alternately spliced form, from the Tfr1 endosome to the cytoplasm [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR139">139</xref>]. At either location, Dmt1 only accepts ferrous iron along with other divalent cations, such as copper or manganese, and co-localizes with an iron reductase [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR177">177</xref>].</p>
      </sec>
      <sec id="Sec15">
        <title>The control of cytosolic iron levels</title>
        <p>FT is the central mechanism of iron storage in macrophages and other cell types (25, 179, (236). However, LysM-Cre FTH mice have no apparent phenotype suggesting that iron storage and trafficking are well controlled in myeloid cells by other mechanisms [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR239">239</xref>]. One such mechanism to maintain cytosolic iron levels are the iron regulatory proteins (IRPs) 1 and 2 [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR195">195</xref>]. IRPs sense free labile iron and control cellular iron homeostasis at the post-transcriptional level: Due to their ability to interact with iron-responsive elements (IREs) that are present in the non-coding mRNA sequences of Tfr1, Dmt1, Fpn1, FTH, and FTL chains, fluctuations in intracellular iron are promptly counterbalanced [<xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR195">195</xref>]. Interestingly, the functions of IRPs1 and 2 are redundant in macrophages and only targeted deletion of both isoforms via the LysM-Cre system results in increased FT levels and intracellular iron retention [<xref ref-type="bibr" rid="CR193">193</xref>]. The deletion of both IRPs in macrophages does not affect RBC recycling but impairs their nutritional immune functions against intracellular bacteria, such as <italic>Salmonella</italic> Typhimurium [<xref ref-type="bibr" rid="CR166">166</xref>]. This pathogen preferentially infects murine macrophages and has a proliferative advantage in the absence of both IRPs resulting in increased bacterial burden and reduced survival in a systemic infection model. Therefore, macrophage IRPs are required to regulate their effector functions upon infection with an iron-dependent pathogen.</p>
      </sec>
      <sec id="Sec16">
        <title>Interplay of macrophage iron metabolism and immune functions</title>
        <p>Macrophage iron metabolism and immune functions are interconnected [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR247">247</xref>]. Clinical data as well as many studies in infection models show that macrophage iron overload, often resulting from hemolysis or iron supplementation, interferes with their antimicrobial activity (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). Several mechanisms explain this negative effect that surplus iron has on macrophage effector functions and the outcome of infectious diseases. First, a range of intracellular microbes can resist killing by macrophages by gaining access to macrophage iron pools [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR245">245</xref>]. Second, iron alters gene transcription, translation, and mitochondrial respiration in macrophages [<xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR175">175</xref>]. Specifically, macrophage functions driven by IFN-γ are impaired when macrophages are exposed to surplus iron [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR176">176</xref>] largely because iron directly inhibits the binding activities of the transcription factors nuclear factor interleukin-6 (NF-IL6) and hypoxia-inducible factor (HIF)-1α [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR153">153</xref>] [<xref ref-type="bibr" rid="CR176">176</xref>]. Because of its inhibitory effects on NF-IL6 and HIF-1α, iron excess blocks <italic>Nos2</italic> transcription and the high output formation of NO which worsens bacterial killing of iron-laden macrophages [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR164">164</xref>]. In addition, IFN-γ in conjunction with TLR4 ligation results in NF-κB-dependent activation of HIF-1α and increased transcription of TfR1 thus aggravating macrophage iron overload [<xref ref-type="bibr" rid="CR224">224</xref>]. Moreover, hypoxia impairs NO production by Nos2 and thus blunts the antimicrobial activity of macrophages towards <italic>Leishmania major</italic> [<xref ref-type="bibr" rid="CR142">142</xref>]. Another layer of complexity is added by the fact that TLR4 signaling stabilizes HIF-1α activation via induction of FTH and hypoxia stimulates arginase-1 expression in myeloid cells thus undermining <italic>Leishmania</italic> killing [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR209">209</xref>]. Mechanistically, these two modes of HIF activation are distinct. While TLR4 signaling results in depletion of iron as co-substrate which prolyl hydroxylases (PHDs) require to tag HIF for degradation, hypoxia, per definition, impairs PHD activity due to a lack of their substrate oxygen. Nevertheless, both hypoxia (secondary to anemia or impaired microcirculation) and the presence of TLR ligands may be present at sites of infection in close spatial or temporal association. In addition, monocytes may be exposed to fluctuating levels of both stimuli (hypoxia and inflammation) as they travel to sites of injury and infiltrate the tissue to differentiate and become sessile. Therefore, due to its sensitivity to both oxygen and iron, the transcription factor HIF-1α appears to hold a central position in the interplay of macrophage iron homeostasis and immunity.</p>
        <p>In contrast to its inhibitory effect on NO, iron stimulates the non-enzymatic generation of ROS which may promote their antimicrobial activity but contribute to tissue damage and the pathogenesis of many inflammatory disorders. In this context, iron present in heme can stimulate the production of ROS and of pro-inflammatory cytokines such as TNF, IL-1ß, and IL-6 [<xref ref-type="bibr" rid="CR241">241</xref>]. In contrast, arginase-1, which depletes the Nos2 substrate arginine by converting it to ornithine [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR205">205</xref>], is reduced by heme. These effects may contribute to the inflammatory characteristics of sickle cell disease and can be ameliorated by the heme scavenger HPX. Accordingly, free heme, which is predicted to accumulate when Hmox1 is inhibited, activates NF-κB to induce <italic>TNF</italic> and <italic>Nos2</italic> transcription resulting in improved control of <italic>Salmonella</italic> infection [<xref ref-type="bibr" rid="CR154">154</xref>]. Intriguingly, the accumulation of heme during the course of sepsis-induced hemolysis also impairs phagocyte functions due to interference with actin cytoskeleton rearrangements resulting in poor outcome [<xref ref-type="bibr" rid="CR146">146</xref>].</p>
        <p>A phagolysosomal transporter with homology to Dmt1 (Nramp2) is Nramp1 [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. Its cation transport function is directly linked to the antimicrobial activity of macrophages and DCs [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR219">219</xref>]. In addition, the functional form of Nramp1 in myeloid cells shifts the balance in T helper cell activity towards Th1, which may increase resistance to infections while increasing the susceptibility to autoimmune diseases [<xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR226">226</xref>]. However, the directionality of iron transport is still under some debate [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR225">225</xref>, <xref ref-type="bibr" rid="CR249">249</xref>]: Most studies have shown that Nramp1 shifts iron and other divalent cations from the phagolysosome to the cytosol. This pathway is important for iron recycling after erythrophagocytosis [<xref ref-type="bibr" rid="CR213">213</xref>] and serves as a mechanism of nutrient withdrawal that is particularly efficient in host defense against <italic>Mycobacterium</italic>, <italic>Salmonella</italic>, and <italic>Leishmania</italic> species [<xref ref-type="bibr" rid="CR31">31</xref>]. However, some data suggest that Nramp1 in fact pumps iron into the phagolysosome where it may boost ROS generation [<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>].</p>
        <p>As discussed earlier, nanoparticles are increasingly used in clinical routine for imaging studies. Although intended to be otherwise inert, it has recently been uncovered in tumor models that nanoparticles may alter the biology of both tumor cells and tumor-associated macrophages, albeit with favorable results. Two elegant studies have shown that the application of nanoparticles to tumor-bearing mice is sufficient to induce clinical remission. One of these papers implicated a direct tumoricidal effect of iron delivered by ultrasmall polyethylene glycol particles and attributed tumor regression to the induction of ferroptosis in malignant cells [<xref ref-type="bibr" rid="CR112">112</xref>]. The other study suggested that IONs stimulate TNF expression while inhibiting arginase-1 which results in improved killing of tumor cells [<xref ref-type="bibr" rid="CR257">257</xref>]. These novel and exciting data support the general idea that the modulation of macrophage iron homeostasis is a promising way to control their immune functions and alter myeloid-driven disease processes in infection, auto-immunity, atherosclerosis, and possibly also cancer [<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]</p>
      </sec>
    </sec>
    <sec id="Sec17">
      <title>Conclusion</title>
      <p>The MPS comprises a heterogeneous population of tissue-specific leukocytes. It is a cornerstone of innate immunity, regulates the adaptive immune system, and is indispensable for tissue development, homeostasis, and repair. One of macrophages’ central metabolic functions is to eliminate senescent and damaged RBCs and to recycle their heme-bound iron to maintain systemic and cellular iron homeostasis. The role of macrophages in iron handling preserves iron homeostasis and tissue integrity. Under physiologic conditions, macrophages recycle the iron for erythropoiesis, while under hemolytic stress, macrophages detoxify heme to prevent iron toxicity towards parenchymal cells and tissues.</p>
      <p>Only recently, we have begun to appreciate the specific functions of various macrophage populations in the body and to study their potential roles iron metabolism. New technologies are entering the field including systems biology approaches, in situ LASER capture, single cell RNA sequencing, cell type-specific genomic editing with CRISPR/Cas9, and cell type-specific vectors to silence genes of interest [<xref ref-type="bibr" rid="CR43">43</xref>]. Such methods will be important to critically interrogate results obtained by more drastic and unspecific approaches (such as global macrophage depletion or MAC sorting) and to understand the spatiotemporal orchestration of iron metabolism at the single cell level and in the context of the tissue microenvironment characterized by cell-to-cell contact and paracrine signals. Most of all, we face the challenge to translate findings obtained in small animal models to human subjects to improve patient care.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ABCA1, ABCG1</term>
          <def>
            <p>ATP binding cassette transporter A1 or G1, respectively</p>
          </def>
        </def-item>
        <def-item>
          <term>ADAM17</term>
          <def>
            <p>ADAM metallopeptidase domain 17</p>
          </def>
        </def-item>
        <def-item>
          <term>ApoA1, ApoE</term>
          <def>
            <p>Apolipoprotein A1 or E, respectively</p>
          </def>
        </def-item>
        <def-item>
          <term>ARE</term>
          <def>
            <p>Antioxidant response elements</p>
          </def>
        </def-item>
        <def-item>
          <term>Bach1</term>
          <def>
            <p>Btb And and Cnc Homology homology 1</p>
          </def>
        </def-item>
        <def-item>
          <term>BM</term>
          <def>
            <p>Bone marrow</p>
          </def>
        </def-item>
        <def-item>
          <term>Bmp6</term>
          <def>
            <p>Bone morphogenetic protein 6</p>
          </def>
        </def-item>
        <def-item>
          <term>CCL</term>
          <def>
            <p>CC-chemokine ligand</p>
          </def>
        </def-item>
        <def-item>
          <term>CCR</term>
          <def>
            <p>CC-chemokine receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>CD</term>
          <def>
            <p>Cluster of differentiation</p>
          </def>
        </def-item>
        <def-item>
          <term>Clec4F</term>
          <def>
            <p>C-type Type lectin domain family 4 member F</p>
          </def>
        </def-item>
        <def-item>
          <term>Cas9</term>
          <def>
            <p>CRISPR- associated protein 9</p>
          </def>
        </def-item>
        <def-item>
          <term>CNS</term>
          <def>
            <p>Central nervous system</p>
          </def>
        </def-item>
        <def-item>
          <term>CRISPR</term>
          <def>
            <p>Clustered regulatory interspaced short palindromic repeats</p>
          </def>
        </def-item>
        <def-item>
          <term>DC</term>
          <def>
            <p>Dendritic cell</p>
          </def>
        </def-item>
        <def-item>
          <term>DcytB</term>
          <def>
            <p>Duodenal cytochrome B</p>
          </def>
        </def-item>
        <def-item>
          <term>DFO</term>
          <def>
            <p>Deferoxamine</p>
          </def>
        </def-item>
        <def-item>
          <term>Dmt1</term>
          <def>
            <p>Divalent metal transporter 1</p>
          </def>
        </def-item>
        <def-item>
          <term>DFP</term>
          <def>
            <p>Deferiprone</p>
          </def>
        </def-item>
        <def-item>
          <term>EB</term>
          <def>
            <p>Erythroblast</p>
          </def>
        </def-item>
        <def-item>
          <term>EIM</term>
          <def>
            <p>Erythroid island macrophages</p>
          </def>
        </def-item>
        <def-item>
          <term>FcγR</term>
          <def>
            <p>Fragment, crystallizable, gamma receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>Fpn1</term>
          <def>
            <p>Ferroportin 1</p>
          </def>
        </def-item>
        <def-item>
          <term>Flvcr</term>
          <def>
            <p>Feline leukemia virus subtype C receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>FT</term>
          <def>
            <p>Ferritin</p>
          </def>
        </def-item>
        <def-item>
          <term>FTH, FTL</term>
          <def>
            <p>Ferritin heavy chain or light chain, respectively</p>
          </def>
        </def-item>
        <def-item>
          <term>F4/80</term>
          <def>
            <p>(Murine macrophage marker) EGF-like module-containing mucin-like hormone receptor-like 1</p>
          </def>
        </def-item>
        <def-item>
          <term>GM-CSF</term>
          <def>
            <p>Granulocyte-macrophage colony-stimulating factor</p>
          </def>
        </def-item>
        <def-item>
          <term>Hb</term>
          <def>
            <p>Hemoglobin</p>
          </def>
        </def-item>
        <def-item>
          <term>HFE</term>
          <def>
            <p>Type I hemochromatosis gene</p>
          </def>
        </def-item>
        <def-item>
          <term>HIF</term>
          <def>
            <p>Hypoxia-inducible factor</p>
          </def>
        </def-item>
        <def-item>
          <term>Hmox</term>
          <def>
            <p>Heme oxygenase</p>
          </def>
        </def-item>
        <def-item>
          <term>HPX</term>
          <def>
            <p>Hemopexin</p>
          </def>
        </def-item>
        <def-item>
          <term>HRE</term>
          <def>
            <p>Hypoxia- responsive element</p>
          </def>
        </def-item>
        <def-item>
          <term>HRG1</term>
          <def>
            <p>Heme-regulated gene 1</p>
          </def>
        </def-item>
        <def-item>
          <term>ICH</term>
          <def>
            <p>Intracranial hemorrhage</p>
          </def>
        </def-item>
        <def-item>
          <term>IFN</term>
          <def>
            <p>Interferone</p>
          </def>
        </def-item>
        <def-item>
          <term>Ig</term>
          <def>
            <p>Immunoglobulin</p>
          </def>
        </def-item>
        <def-item>
          <term>IL</term>
          <def>
            <p>Interleukin</p>
          </def>
        </def-item>
        <def-item>
          <term>ION</term>
          <def>
            <p>Iron oxide nanoparticle</p>
          </def>
        </def-item>
        <def-item>
          <term>IRE</term>
          <def>
            <p>Iron responsive element</p>
          </def>
        </def-item>
        <def-item>
          <term>IRP</term>
          <def>
            <p>Iron regulatory protein</p>
          </def>
        </def-item>
        <def-item>
          <term>KC</term>
          <def>
            <p>Kupffer cell</p>
          </def>
        </def-item>
        <def-item>
          <term>Lcn2</term>
          <def>
            <p>Lipocalin 2</p>
          </def>
        </def-item>
        <def-item>
          <term>LcnR</term>
          <def>
            <p>Lcn2 receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>LDN</term>
          <def>
            <p>LDN-193189 a BMP inhibitor that decreases hepcidin expression</p>
          </def>
        </def-item>
        <def-item>
          <term>LF</term>
          <def>
            <p>Lactoferrin</p>
          </def>
        </def-item>
        <def-item>
          <term>LfR</term>
          <def>
            <p>Lactoferrin receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>MAC</term>
          <def>
            <p>Magnetic activated cell (sorting)</p>
          </def>
        </def-item>
        <def-item>
          <term>M-CSF</term>
          <def>
            <p>Macrophage colony-stimulating factor</p>
          </def>
        </def-item>
        <def-item>
          <term>MerTK</term>
          <def>
            <p>MER proto-oncogene, tyrosine kinase</p>
          </def>
        </def-item>
        <def-item>
          <term>MHC-II</term>
          <def>
            <p>Major histocompatibiliy complex class II</p>
          </def>
        </def-item>
        <def-item>
          <term>MPS</term>
          <def>
            <p>Mononuclear phagocyte system</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p>Magnetic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>NADPH oxidase</term>
          <def>
            <p>Nicotinamide adenine dinucleotide phosphate-oxidase</p>
          </def>
        </def-item>
        <def-item>
          <term>NBIA</term>
          <def>
            <p>Neurodegeneration with brain iron accumulation</p>
          </def>
        </def-item>
        <def-item>
          <term>Nrf2</term>
          <def>
            <p>Nuclear factor (erythroid-derived 2)-like 2</p>
          </def>
        </def-item>
        <def-item>
          <term>NF-IL6</term>
          <def>
            <p>Nuclear factor interleukin 6</p>
          </def>
        </def-item>
        <def-item>
          <term>NF-κB</term>
          <def>
            <p>Nuclear factor kappa B</p>
          </def>
        </def-item>
        <def-item>
          <term>NLPR3</term>
          <def>
            <p>NACHT, LRR, and PYD domains-containing protein 3 AKA cryopyrin</p>
          </def>
        </def-item>
        <def-item>
          <term>Nramp1</term>
          <def>
            <p>Natural resistance-associated macrophage protein 1</p>
          </def>
        </def-item>
        <def-item>
          <term>PHD</term>
          <def>
            <p>Prolyl hydroxylase domain proteins</p>
          </def>
        </def-item>
        <def-item>
          <term>PGC-1ß</term>
          <def>
            <p>Peroxisome proliferator-activated receptor-gamma coactivator 1 beta</p>
          </def>
        </def-item>
        <def-item>
          <term>PU.1</term>
          <def>
            <p>An E26 transformation-specific transcription factor encoded by the <italic>SPI1</italic> gene</p>
          </def>
        </def-item>
        <def-item>
          <term>RBC</term>
          <def>
            <p>Red blood cell</p>
          </def>
        </def-item>
        <def-item>
          <term>Rev-ErbAα, Rev-ErbBα</term>
          <def>
            <p>(Nuclear receptors) NR1D1 and NR1D2, for nuclear receptor subfamily 1, group D, member 1 or member 2, respectively</p>
          </def>
        </def-item>
        <def-item>
          <term>RPM</term>
          <def>
            <p>Red pulp macrophage</p>
          </def>
        </def-item>
        <def-item>
          <term>ROS</term>
          <def>
            <p>Reactive oxygen species</p>
          </def>
        </def-item>
        <def-item>
          <term>Sall1</term>
          <def>
            <p>“Spalt-like”-1</p>
          </def>
        </def-item>
        <def-item>
          <term>Scara5</term>
          <def>
            <p>Scavenger receptor class A member 5</p>
          </def>
        </def-item>
        <def-item>
          <term>SIRPα</term>
          <def>
            <p>Signal regulatory protein alpha</p>
          </def>
        </def-item>
        <def-item>
          <term>SpiC</term>
          <def>
            <p>An E26 transformation-specific transcription factor of the Spi subfamily</p>
          </def>
        </def-item>
        <def-item>
          <term>SR-A1</term>
          <def>
            <p>Scavenger receptor class A type 1</p>
          </def>
        </def-item>
        <def-item>
          <term>Steap</term>
          <def>
            <p>Six-transmembrane epithelial antigen of prostate</p>
          </def>
        </def-item>
        <def-item>
          <term>TF</term>
          <def>
            <p>Transferrin</p>
          </def>
        </def-item>
        <def-item>
          <term>Tfr1</term>
          <def>
            <p>Transferrin receptor 1</p>
          </def>
        </def-item>
        <def-item>
          <term>Tim</term>
          <def>
            <p>T-cell immunoglobulin- and mucin- domain-containing molecule</p>
          </def>
        </def-item>
        <def-item>
          <term>TLR4</term>
          <def>
            <p>Toll-like receptor 4</p>
          </def>
        </def-item>
        <def-item>
          <term>VCAM1</term>
          <def>
            <p>Vascular cell adhesion molecule 1</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>This article is part of the special issue on macrophages in tissue homeostasis in Pflügers Archiv – European Journal of Physiology</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abboud</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Haile</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>A novel mammalian iron-regulated protein involved in intracellular iron metabolism</article-title>
          <source>J Biol Chem</source>
          <year>2000</year>
          <volume>275</volume>
          <fpage>19906</fpage>
          <lpage>19912</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M000713200</pub-id>
          <?supplied-pmid 10747949?>
          <pub-id pub-id-type="pmid">10747949</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Haemochromatosis</article-title>
          <source>Lancet</source>
          <year>2007</year>
          <volume>370</volume>
          <fpage>1855</fpage>
          <lpage>1860</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61782-6</pub-id>
          <?supplied-pmid 18061062?>
          <pub-id pub-id-type="pmid">18061062</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aguilar-Martinez</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Biron</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Masmejean</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jeanjean</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schved</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>A novel mutation in the iron responsive element of ferritin L-subunit gene as a cause for hereditary hyperferritinemia-cataract syndrome</article-title>
          <source>Blood</source>
          <year>1996</year>
          <volume>88</volume>
          <fpage>1895</fpage>
          <?supplied-pmid 8781450?>
          <pub-id pub-id-type="pmid">8781450</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Frazer</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>McKie</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Vulpe</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
          <article-title>The ceruloplasmin homolog hephaestin and the control of intestinal iron absorption</article-title>
          <source>Blood Cells Mol Dis</source>
          <year>2002</year>
          <volume>29</volume>
          <fpage>367</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="doi">10.1006/bcmd.2002.0576</pub-id>
          <?supplied-pmid 12547227?>
          <pub-id pub-id-type="pmid">12547227</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eisenstein</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Leibold</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Mammalian iron metabolism and its control by iron regulatory proteins</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2012</year>
          <volume>1823</volume>
          <fpage>1468</fpage>
          <lpage>1483</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbamcr.2012.05.010</pub-id>
          <?supplied-pmid 22610083?>
          <pub-id pub-id-type="pmid">22610083</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andriopoulos</surname>
              <given-names>B</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Corradini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Faasse</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grgurevic</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Knutson</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Pietrangelo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vukicevic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Babitt</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism</article-title>
          <source>Nat Genet</source>
          <year>2009</year>
          <volume>41</volume>
          <fpage>482</fpage>
          <lpage>487</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.335</pub-id>
          <?supplied-pmid 19252486?>
          <pub-id pub-id-type="pmid">19252486</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armitage</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Eddowes</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Gileadi</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Cole</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Spottiswoode</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Selvakumar</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Townsend</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Drakesmith</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Hepcidin regulation by innate immune and infectious stimuli</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>4129</fpage>
          <lpage>4139</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-04-351957</pub-id>
          <?supplied-pmid 21873546?>
          <pub-id pub-id-type="pmid">21873546</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Atkinson</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Blackwell</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Nramp1 locus encodes a 65 kDa interferon-gamma-inducible protein in murine macrophages</article-title>
          <source>Biochem J</source>
          <year>1997</year>
          <volume>325</volume>
          <issue>Pt 3</issue>
          <fpage>779</fpage>
          <lpage>786</lpage>
          <pub-id pub-id-type="doi">10.1042/bj3250779</pub-id>
          <?supplied-pmid 9271100?>
          <pub-id pub-id-type="pmid">9271100</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Auffray</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sieweke</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Geissmann</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Blood monocytes: development, heterogeneity, and relationship with dendritic cells</article-title>
          <source>Annu Rev Immunol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>669</fpage>
          <lpage>692</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132557</pub-id>
          <?supplied-pmid 19132917?>
          <pub-id pub-id-type="pmid">19132917</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Babitt</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Wrighting</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sidis</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Samad</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Campagna</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Schneyer</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Woolf</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>HY</given-names>
            </name>
          </person-group>
          <article-title>Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression</article-title>
          <source>Nat Genet</source>
          <year>2006</year>
          <volume>38</volume>
          <fpage>531</fpage>
          <lpage>539</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1777</pub-id>
          <?supplied-pmid 16604073?>
          <pub-id pub-id-type="pmid">16604073</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bao</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Clifton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoette</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>SX</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Viltard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Paragas</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Leete</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kulkarni</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kalandadze</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ratner</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Pizarro</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Schmidt-Ott</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Landry</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Raymond</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Strong</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Barasch</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex</article-title>
          <source>Nat Chem Biol</source>
          <year>2010</year>
          <volume>6</volume>
          <fpage>602</fpage>
          <lpage>609</lpage>
          <pub-id pub-id-type="doi">10.1038/nchembio.402</pub-id>
          <?supplied-pmid 20581821?>
          <pub-id pub-id-type="pmid">20581821</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baraibar</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Barbeito</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Muhoberac</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Vidal</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>A mutant light-chain ferritin that causes neurodegeneration has enhanced propensity toward oxidative damage</article-title>
          <source>Free Radic Biol Med</source>
          <year>2012</year>
          <volume>52</volume>
          <fpage>1692</fpage>
          <lpage>1697</lpage>
          <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.02.015</pub-id>
          <?supplied-pmid 22348978?>
          <pub-id pub-id-type="pmid">22348978</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barton</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Acton</surname>
              <given-names>RT</given-names>
            </name>
          </person-group>
          <article-title>Hemochromatosis and Vibrio vulnificus wound infections</article-title>
          <source>J Clin Gastroenterol</source>
          <year>2009</year>
          <volume>43</volume>
          <fpage>890</fpage>
          <lpage>893</lpage>
          <pub-id pub-id-type="doi">10.1097/MCG.0b013e31819069c1</pub-id>
          <?supplied-pmid 19349902?>
          <pub-id pub-id-type="pmid">19349902</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barton</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Biggs</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Bowen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Atkinson</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>Nramp1: a link between intracellular iron transport and innate resistance to intracellular pathogens</article-title>
          <source>J Leukoc Biol</source>
          <year>1999</year>
          <volume>66</volume>
          <fpage>757</fpage>
          <lpage>762</lpage>
          <?supplied-pmid 10577506?>
          <pub-id pub-id-type="pmid">10577506</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beaumont</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Leneuve</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Devaux</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Scoazec</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Berthier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Loiseau</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Grandchamp</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bonneau</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract</article-title>
          <source>Nat Genet</source>
          <year>1995</year>
          <volume>11</volume>
          <fpage>444</fpage>
          <lpage>446</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1295-444</pub-id>
          <?supplied-pmid 7493028?>
          <pub-id pub-id-type="pmid">7493028</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">Behnsen J, Raffatellu M (2016) Siderophores: more than stealing iron. MBio 7:e01397–16</mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bessis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Breton-Gorius</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>New observations on the erythroblast islet and rhopheocytosis of ferritin</article-title>
          <source>Rev Hematol</source>
          <year>1959</year>
          <volume>14</volume>
          <fpage>165</fpage>
          <lpage>197</lpage>
          <?supplied-pmid 13675587?>
          <pub-id pub-id-type="pmid">13675587</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beutler</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Hemochromatosis: genetics and pathophysiology</article-title>
          <source>Annu Rev Med</source>
          <year>2006</year>
          <volume>57</volume>
          <fpage>331</fpage>
          <lpage>347</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.med.57.121304.131310</pub-id>
          <?supplied-pmid 16409153?>
          <pub-id pub-id-type="pmid">16409153</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Biggs</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Botham</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Dhital</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>VH</given-names>
            </name>
          </person-group>
          <article-title>Nramp1 modulates iron homoeostasis in vivo and in vitro: evidence for a role in cellular iron release involving de-acidification of intracellular vesicles</article-title>
          <source>Eur J Immunol</source>
          <year>2001</year>
          <volume>31</volume>
          <fpage>2060</fpage>
          <lpage>2070</lpage>
          <pub-id pub-id-type="doi">10.1002/1521-4141(200107)31:7&lt;2060::AID-IMMU2060&gt;3.0.CO;2-L</pub-id>
          <?supplied-pmid 11449359?>
          <pub-id pub-id-type="pmid">11449359</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blackwell</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Structure and function of the natural-resistance-associated macrophage protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility</article-title>
          <source>Mol Med Today</source>
          <year>1996</year>
          <volume>2</volume>
          <fpage>205</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="doi">10.1016/1357-4310(96)88773-9</pub-id>
          <?supplied-pmid 8796889?>
          <pub-id pub-id-type="pmid">8796889</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bleriot</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dupuis</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jouvion</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Eberl</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Disson</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Lecuit</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Liver-resident macrophage necroptosis orchestrates type 1 microbicidal inflammation and type-2-mediated tissue repair during bacterial infection</article-title>
          <source>Immunity</source>
          <year>2015</year>
          <volume>42</volume>
          <fpage>145</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2014.12.020</pub-id>
          <?supplied-pmid 25577440?>
          <pub-id pub-id-type="pmid">25577440</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boyle</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Harrington</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Piper</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Elderfield</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Landis</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Haskard</surname>
              <given-names>DO</given-names>
            </name>
          </person-group>
          <article-title>Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype</article-title>
          <source>Am J Pathol</source>
          <year>2009</year>
          <volume>174</volume>
          <fpage>1097</fpage>
          <lpage>1108</lpage>
          <pub-id pub-id-type="doi">10.2353/ajpath.2009.080431</pub-id>
          <?supplied-pmid 19234137?>
          <pub-id pub-id-type="pmid">19234137</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brooks</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Manova-Todorova</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Farmer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lobmayr</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Eagle</surname>
              <given-names>RC</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>St Pierre</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Stambolian</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Ferritin crystal cataracts in hereditary hyperferritinemia cataract syndrome</article-title>
          <source>Invest Ophthalmol Vis Sci</source>
          <year>2002</year>
          <volume>43</volume>
          <fpage>1121</fpage>
          <lpage>1126</lpage>
          <?supplied-pmid 11923255?>
          <pub-id pub-id-type="pmid">11923255</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bulteau</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>O'Neill</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Kennedy</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Ikeda-Saito</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Isaya</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Szweda</surname>
              <given-names>LI</given-names>
            </name>
          </person-group>
          <article-title>Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity</article-title>
          <source>Science</source>
          <year>2004</year>
          <volume>305</volume>
          <fpage>242</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1098991</pub-id>
          <?supplied-pmid 15247478?>
          <pub-id pub-id-type="pmid">15247478</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <mixed-citation publication-type="other">Buttgereit A, Lelios I, Yu X, Vrohlings M, Krakoski NR, Gautier EL, Nishinakamura R, Becher B, Greter M (2016) Sall1 is a transcriptional regulator defining microglia identity and function. Nat Immunol</mixed-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camaschella</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zecchina</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lockitch</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Roetto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Campanella</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arosio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A new mutation (G51C) in the iron-responsive element (IRE) of L-ferritin associated with hyperferritinaemia-cataract syndrome decreases the binding affinity of the mutated IRE for iron-regulatory proteins</article-title>
          <source>Br J Haematol</source>
          <year>2000</year>
          <volume>108</volume>
          <fpage>480</fpage>
          <lpage>482</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2141.2000.01920.x</pub-id>
          <?supplied-pmid 10759702?>
          <pub-id pub-id-type="pmid">10759702</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Canali</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vecchi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Garuti</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Montosi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Babitt</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Pietrangelo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The SMAD pathway is required for hepcidin response during endoplasmic reticulum stress</article-title>
          <source>Endocrinology</source>
          <year>2016</year>
          <volume>157</volume>
          <fpage>3935</fpage>
          <lpage>3945</lpage>
          <pub-id pub-id-type="doi">10.1210/en.2016-1258</pub-id>
          <?supplied-pmid 27483343?>
          <pub-id pub-id-type="pmid">27483343</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <mixed-citation publication-type="other">Canali S, Zumbrennen-Bullough KB, Core AB, Wang CY, Nairz M, Bouley R, Swirski FK, Babitt JL (2016b) Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood 129:405–414</mixed-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carter</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ragsdale</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>High affinity heme binding to a heme regulatory motif on the nuclear receptor rev-erbbeta leads to its degradation and indirectly regulates its interaction with nuclear receptor Corepressor</article-title>
          <source>J Biol Chem</source>
          <year>2016</year>
          <volume>291</volume>
          <fpage>2196</fpage>
          <lpage>2222</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M115.670281</pub-id>
          <?supplied-pmid 26670607?>
          <pub-id pub-id-type="pmid">26670607</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cassat</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Skaar</surname>
              <given-names>EP</given-names>
            </name>
          </person-group>
          <article-title>Iron in infection and immunity</article-title>
          <source>Cell Host Microbe</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>509</fpage>
          <lpage>519</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chom.2013.04.010</pub-id>
          <?supplied-pmid 23684303?>
          <pub-id pub-id-type="pmid">23684303</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cellier</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Nramp: from sequence to structure and mechanism of divalent metal import</article-title>
          <source>Curr Top Membr</source>
          <year>2012</year>
          <volume>69</volume>
          <fpage>249</fpage>
          <lpage>293</lpage>
          <pub-id pub-id-type="doi">10.1016/B978-0-12-394390-3.00010-0</pub-id>
          <?supplied-pmid 23046654?>
          <pub-id pub-id-type="pmid">23046654</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cellier</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Courville</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Campion</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Nramp1 phagocyte intracellular metal withdrawal defense</article-title>
          <source>Microbes Infect</source>
          <year>2007</year>
          <volume>9</volume>
          <fpage>1662</fpage>
          <lpage>1670</lpage>
          <pub-id pub-id-type="doi">10.1016/j.micinf.2007.09.006</pub-id>
          <?supplied-pmid 18024118?>
          <pub-id pub-id-type="pmid">18024118</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Attieh</surname>
              <given-names>ZK</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>McKie</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Vulpe</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
          <article-title>Systemic regulation of Hephaestin and Ireg1 revealed in studies of genetic and nutritional iron deficiency</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <fpage>1893</fpage>
          <lpage>1899</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-02-0347</pub-id>
          <?supplied-pmid 12730111?>
          <pub-id pub-id-type="pmid">12730111</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Cyster</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Brodsky</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Niemi</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Seaman</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Daws</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis</article-title>
          <source>J Exp Med</source>
          <year>2005</year>
          <volume>202</volume>
          <fpage>955</fpage>
          <lpage>965</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20042433</pub-id>
          <?supplied-pmid 16203866?>
          <pub-id pub-id-type="pmid">16203866</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Samuel</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Sinclair</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dailey</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Hamza</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>An intercellular heme-trafficking protein delivers maternal heme to the embryo during development in <italic>C. elegans</italic></article-title>
          <source>Cell</source>
          <year>2011</year>
          <volume>145</volume>
          <fpage>720</fpage>
          <lpage>731</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2011.04.025</pub-id>
          <?supplied-pmid 21620137?>
          <pub-id pub-id-type="pmid">21620137</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen-Roetling</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schipper</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Regan</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Regan</surname>
              <given-names>RF</given-names>
            </name>
          </person-group>
          <article-title>Astrocyte overexpression of heme oxygenase-1 improves outcome after intracerebral hemorrhage</article-title>
          <source>Stroke</source>
          <year>2015</year>
          <volume>46</volume>
          <fpage>1093</fpage>
          <lpage>1098</lpage>
          <pub-id pub-id-type="doi">10.1161/STROKEAHA.115.008686</pub-id>
          <?supplied-pmid 25690543?>
          <pub-id pub-id-type="pmid">25690543</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiabrando</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Fiorito</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Marro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Silengo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Altruda</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tolosano</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Cell-specific regulation of Ferroportin transcription following experimentally-induced acute anemia in mice</article-title>
          <source>Blood Cells Mol Dis</source>
          <year>2012</year>
          <volume>50</volume>
          <fpage>25</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bcmd.2012.08.002</pub-id>
          <?supplied-pmid 22921471?>
          <pub-id pub-id-type="pmid">22921471</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chow</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Huggins</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lucas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kunisaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Pinho</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Leboeuf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Noizat</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>van Rooijen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>ZJ</given-names>
            </name>
            <name>
              <surname>Bergman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Frenette</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>CD169(+) macrophages provide a niche promoting erythropoiesis under homeostasis and stress</article-title>
          <source>Nat Med</source>
          <year>2013</year>
          <volume>19</volume>
          <fpage>429</fpage>
          <lpage>436</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.3057</pub-id>
          <?supplied-pmid 23502962?>
          <pub-id pub-id-type="pmid">23502962</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clevers</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>The intestinal crypt, a prototype stem cell compartment</article-title>
          <source>Cell</source>
          <year>2013</year>
          <volume>154</volume>
          <fpage>274</fpage>
          <lpage>284</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2013.07.004</pub-id>
          <?supplied-pmid 23870119?>
          <pub-id pub-id-type="pmid">23870119</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cohen</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Gutierrez</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Leichtmann-Bardoogo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Crooks</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Sougrat</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Morgenstern</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Galy</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Lazaro</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Rouault</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Meyron-Holtz</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway</article-title>
          <source>Blood</source>
          <year>2010</year>
          <volume>116</volume>
          <fpage>1574</fpage>
          <lpage>1584</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2009-11-253815</pub-id>
          <?supplied-pmid 20472835?>
          <pub-id pub-id-type="pmid">20472835</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Corna</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Caserta</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Monno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Apostoli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Manfredi</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Camaschella</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rovere-Querini</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The repair of skeletal muscle requires iron recycling through macrophage ferroportin</article-title>
          <source>J Immunol</source>
          <year>2016</year>
          <volume>197</volume>
          <fpage>1914</fpage>
          <lpage>1925</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.1501417</pub-id>
          <?supplied-pmid 27465531?>
          <pub-id pub-id-type="pmid">27465531</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Correnti</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Strong</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>Mammalian siderophores, siderophore-binding lipocalins, and the labile iron pool</article-title>
          <source>J Biol Chem</source>
          <year>2012</year>
          <volume>287</volume>
          <fpage>13524</fpage>
          <lpage>13531</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.R111.311829</pub-id>
          <?supplied-pmid 22389496?>
          <pub-id pub-id-type="pmid">22389496</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Courties</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Heidt</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sebas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jeon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Truelove</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tricot</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wojtkiewicz</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dutta</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sager</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Borodovsky</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Novobrantseva</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Klebanov</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fitzgerald</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Swirski</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Weissleder</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nahrendorf</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2013</year>
          <volume>63</volume>
          <fpage>1556</fpage>
          <lpage>1566</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jacc.2013.11.023</pub-id>
          <?supplied-pmid 24361318?>
          <pub-id pub-id-type="pmid">24361318</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cozzi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Santambrogio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Privitera</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Broccoli</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rotundo</surname>
              <given-names>LI</given-names>
            </name>
            <name>
              <surname>Garavaglia</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Benz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Altamura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Goede</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Muckenthaler</surname>
              <given-names>MU</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Human L-ferritin deficiency is characterized by idiopathic generalized seizures and atypical restless leg syndrome</article-title>
          <source>J Exp Med</source>
          <year>2013</year>
          <volume>210</volume>
          <fpage>1779</fpage>
          <lpage>1791</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20130315</pub-id>
          <?supplied-pmid 23940258?>
          <pub-id pub-id-type="pmid">23940258</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curtis</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Fey</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Bindoff</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Ince</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Chinnery</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Coulthard</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>McHale</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Hay</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Markham</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Burn</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease</article-title>
          <source>Nat Genet</source>
          <year>2001</year>
          <volume>28</volume>
          <fpage>350</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="doi">10.1038/ng571</pub-id>
          <?supplied-pmid 11438811?>
          <pub-id pub-id-type="pmid">11438811</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Darshan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vanoaica</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Richman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Beermann</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
          <article-title>Conditional deletion of ferritin H in mice induces loss of iron storage and liver damage</article-title>
          <source>Hepatology</source>
          <year>2009</year>
          <volume>50</volume>
          <fpage>852</fpage>
          <lpage>860</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.23058</pub-id>
          <?supplied-pmid 19492434?>
          <pub-id pub-id-type="pmid">19492434</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davuluri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wald</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sakaguchi</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Devireddy</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Inactivation of 3-hydroxybutyrate dehydrogenase 2 delays zebrafish erythroid maturation by conferring premature mitophagy</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2016</year>
          <volume>113</volume>
          <fpage>E1460</fpage>
          <lpage>E1469</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1600077113</pub-id>
          <?supplied-pmid 26929344?>
          <pub-id pub-id-type="pmid">26929344</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delaby</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pilard</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hetet</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Driss</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Grandchamp</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Beaumont</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Canonne-Hergaux</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>A physiological model to study iron recycling in macrophages</article-title>
          <source>Exp Cell Res</source>
          <year>2005</year>
          <volume>310</volume>
          <fpage>43</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1016/j.yexcr.2005.07.002</pub-id>
          <?supplied-pmid 16095591?>
          <pub-id pub-id-type="pmid">16095591</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Devireddy</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Gazin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake</article-title>
          <source>Cell</source>
          <year>2005</year>
          <volume>123</volume>
          <fpage>1293</fpage>
          <lpage>1305</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2005.10.027</pub-id>
          <?supplied-pmid 16377569?>
          <pub-id pub-id-type="pmid">16377569</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Devireddy</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Goetz</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production</article-title>
          <source>Cell</source>
          <year>2010</year>
          <volume>141</volume>
          <fpage>1006</fpage>
          <lpage>1017</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2010.04.040</pub-id>
          <?supplied-pmid 20550936?>
          <pub-id pub-id-type="pmid">20550936</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhakshinamoorthy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Bloom</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Jaiswal</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants</article-title>
          <source>J Biol Chem</source>
          <year>2005</year>
          <volume>280</volume>
          <fpage>16891</fpage>
          <lpage>16900</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M500166200</pub-id>
          <?supplied-pmid 15734732?>
          <pub-id pub-id-type="pmid">15734732</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dimitrov</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Ivanovska</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Lacroix-Desmazes</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Doltchinkova</surname>
              <given-names>VR</given-names>
            </name>
            <name>
              <surname>Kaveri</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Vassilev</surname>
              <given-names>TL</given-names>
            </name>
          </person-group>
          <article-title>Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G</article-title>
          <source>J Biol Chem</source>
          <year>2006</year>
          <volume>281</volume>
          <fpage>439</fpage>
          <lpage>446</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M509190200</pub-id>
          <?supplied-pmid 16246843?>
          <pub-id pub-id-type="pmid">16246843</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dimitrov</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Roumenina</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Doltchinkova</surname>
              <given-names>VR</given-names>
            </name>
            <name>
              <surname>Mihaylova</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Lacroix-Desmazes</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kaveri</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Vassilev</surname>
              <given-names>TL</given-names>
            </name>
          </person-group>
          <article-title>Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions</article-title>
          <source>J Biol Chem</source>
          <year>2007</year>
          <volume>282</volume>
          <fpage>26696</fpage>
          <lpage>26706</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M702751200</pub-id>
          <?supplied-pmid 17636257?>
          <pub-id pub-id-type="pmid">17636257</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dixon</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Lemberg</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Lamprecht</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Skouta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zaitsev</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Gleason</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>DN</given-names>
            </name>
            <name>
              <surname>Bauer</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Cantley</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>B</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Stockwell</surname>
              <given-names>BR</given-names>
            </name>
          </person-group>
          <article-title>Ferroptosis: an iron-dependent form of nonapoptotic cell death</article-title>
          <source>Cell</source>
          <year>2012</year>
          <volume>149</volume>
          <fpage>1060</fpage>
          <lpage>1072</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id>
          <?supplied-pmid 22632970?>
          <pub-id pub-id-type="pmid">22632970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dlaska</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Central role of transcription factor NF-IL6 for cytokine and iron-mediated regulation of murine inducible nitric oxide synthase expression</article-title>
          <source>J Immunol</source>
          <year>1999</year>
          <volume>162</volume>
          <fpage>6171</fpage>
          <lpage>6177</lpage>
          <?supplied-pmid 10229861?>
          <pub-id pub-id-type="pmid">10229861</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Donovan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brownlie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shepard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pratt</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Moynihan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Paw</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Drejer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Barut</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zapata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Law</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Brugnara</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lux</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Pinkus</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Pinkus</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Kingsley</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Palis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fleming</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Zon</surname>
              <given-names>LI</given-names>
            </name>
          </person-group>
          <article-title>Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter</article-title>
          <source>Nature</source>
          <year>2000</year>
          <volume>403</volume>
          <fpage>776</fpage>
          <lpage>781</lpage>
          <pub-id pub-id-type="doi">10.1038/35001596</pub-id>
          <?supplied-pmid 10693807?>
          <pub-id pub-id-type="pmid">10693807</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drakesmith</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Prentice</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Hepcidin and the iron-infection axis</article-title>
          <source>Science</source>
          <year>2012</year>
          <volume>338</volume>
          <fpage>768</fpage>
          <lpage>772</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1224577</pub-id>
          <?supplied-pmid 23139325?>
          <pub-id pub-id-type="pmid">23139325</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drakesmith</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schimanski</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Ormerod</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Merryweather-Clarke</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Viprakasit</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Sweetland</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bastin</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Cowley</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chinthammitr</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Robson</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Townsend</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>1092</fpage>
          <lpage>1097</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-02-0561</pub-id>
          <?supplied-pmid 15831700?>
          <pub-id pub-id-type="pmid">15831700</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drakesmith</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nemeth</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ganz</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Ironing out ferroportin</article-title>
          <source>Cell Metab</source>
          <year>2015</year>
          <volume>22</volume>
          <fpage>777</fpage>
          <lpage>787</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2015.09.006</pub-id>
          <?supplied-pmid 26437604?>
          <pub-id pub-id-type="pmid">26437604</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dutra</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Golenbock</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Zamboni</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Bozza</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Hemolysis-induced lethality involves inflammasome activation by heme</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2014</year>
          <volume>111</volume>
          <fpage>E4110</fpage>
          <lpage>E4118</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1405023111</pub-id>
          <?supplied-pmid 25225402?>
          <pub-id pub-id-type="pmid">25225402</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dutta</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hoyer</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Grigoryeva</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Sager</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Leuschner</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Courties</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Borodovsky</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Novobrantseva</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ruda</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Fitzgerald</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wojtkiewicz</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Da Silva</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Swirski</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Weissleder</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nahrendorf</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Macrophages retain hematopoietic stem cells in the spleen via VCAM-1</article-title>
          <source>J Exp Med</source>
          <year>2015</year>
          <volume>212</volume>
          <fpage>497</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20141642</pub-id>
          <?supplied-pmid 25800955?>
          <pub-id pub-id-type="pmid">25800955</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El Kasmi</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Qualls</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Pesce</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Henao-Tamayo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Basaraba</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Konig</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schleicher</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Koo</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fitzgerald</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Tuomanen</surname>
              <given-names>EI</given-names>
            </name>
            <name>
              <surname>Orme</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Kanneganti</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Bogdan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wynn</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens</article-title>
          <source>Nat Immunol</source>
          <year>2008</year>
          <volume>9</volume>
          <fpage>1399</fpage>
          <lpage>1406</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.1671</pub-id>
          <?supplied-pmid 18978793?>
          <pub-id pub-id-type="pmid">18978793</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fang</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Murdoch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Coffelt</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Biswas</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Imityaz</surname>
              <given-names>HZ</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Fredlund</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Greten</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Rius</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>114</volume>
          <fpage>844</fpage>
          <lpage>859</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-12-195941</pub-id>
          <?supplied-pmid 19454749?>
          <pub-id pub-id-type="pmid">19454749</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farin</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Karthaus</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Kujala</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rakhshandehroo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schwank</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vries</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Kalkhoven</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nieuwenhuis</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Clevers</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Paneth cell extrusion and release of antimicrobial products is directly controlled by immune cell-derived IFN-gamma</article-title>
          <source>J Exp Med</source>
          <year>2014</year>
          <volume>211</volume>
          <fpage>1393</fpage>
          <lpage>1405</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20130753</pub-id>
          <?supplied-pmid 24980747?>
          <pub-id pub-id-type="pmid">24980747</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Dutra</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Figueiredo</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Mourao-Sa</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Fortes</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Bergstrand</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lonn</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cevallos</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>UG</given-names>
            </name>
            <name>
              <surname>Travassos</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Paiva</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Bozza</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Heme amplifies the innate immune response to microbial molecules through spleen tyrosine kinase (Syk)-dependent reactive oxygen species generation</article-title>
          <source>J Biol Chem</source>
          <year>2010</year>
          <volume>285</volume>
          <fpage>32844</fpage>
          <lpage>32851</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M110.146076</pub-id>
          <?supplied-pmid 20729208?>
          <pub-id pub-id-type="pmid">20729208</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Figueiredo</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Mourao-Sa</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Porto</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Dutra</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Graca-Souza</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Bozza</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Characterization of heme as activator of Toll-like receptor 4</article-title>
          <source>J Biol Chem</source>
          <year>2007</year>
          <volume>282</volume>
          <fpage>20221</fpage>
          <lpage>20229</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M610737200</pub-id>
          <?supplied-pmid 17502383?>
          <pub-id pub-id-type="pmid">17502383</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischbach</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>How pathogenic bacteria evade mammalian sabotage in the battle for iron</article-title>
          <source>Nat Chem Biol</source>
          <year>2006</year>
          <volume>2</volume>
          <fpage>132</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="doi">10.1038/nchembio771</pub-id>
          <?supplied-pmid 16485005?>
          <pub-id pub-id-type="pmid">16485005</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fleming</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Trenor</surname>
              <given-names>CC</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Foernzler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Beier</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Dietrich</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>NC</given-names>
            </name>
          </person-group>
          <article-title>Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene</article-title>
          <source>Nat Genet</source>
          <year>1997</year>
          <volume>16</volume>
          <fpage>383</fpage>
          <lpage>386</lpage>
          <?supplied-pmid 9241278?>
          <pub-id pub-id-type="pmid">9241278</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fleming</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Garrick</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Garrick</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>NC</given-names>
            </name>
          </person-group>
          <article-title>Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1998</year>
          <volume>95</volume>
          <fpage>1148</fpage>
          <lpage>1153</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.95.3.1148</pub-id>
          <?supplied-pmid 9448300?>
          <pub-id pub-id-type="pmid">9448300</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flo</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Strong</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Akira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aderem</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron</article-title>
          <source>Nature</source>
          <year>2004</year>
          <volume>432</volume>
          <fpage>917</fpage>
          <lpage>921</lpage>
          <pub-id pub-id-type="doi">10.1038/nature03104</pub-id>
          <?supplied-pmid 15531878?>
          <pub-id pub-id-type="pmid">15531878</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forbes</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Gros</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Divalent-metal transport by NRAMP proteins at the interface of host-pathogen interactions</article-title>
          <source>Trends Microbiol</source>
          <year>2001</year>
          <volume>9</volume>
          <fpage>397</fpage>
          <lpage>403</lpage>
          <pub-id pub-id-type="doi">10.1016/S0966-842X(01)02098-4</pub-id>
          <?supplied-pmid 11514223?>
          <pub-id pub-id-type="pmid">11514223</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franken</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Spasova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Elsukova</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wiedwald</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Welz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Knolle</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Farle</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Limmer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kurts</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Splenic red pulp macrophages are intrinsically superparamagnetic and contaminate magnetic cell isolates</article-title>
          <source>Sci Rep</source>
          <year>2015</year>
          <volume>5</volume>
          <fpage>12940</fpage>
          <pub-id pub-id-type="doi">10.1038/srep12940</pub-id>
          <?supplied-pmid 26260698?>
          <pub-id pub-id-type="pmid">26260698</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fraser</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Midwinter</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Coupland</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Yeo</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Andrade</surname>
              <given-names>OC</given-names>
            </name>
            <name>
              <surname>Cromer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Suarna</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maghzal</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Parish</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Stocker</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Heme oxygenase-1 deficiency alters erythroblastic island formation, steady-state erythropoiesis and red blood cell lifespan in mice</article-title>
          <source>Haematologica</source>
          <year>2015</year>
          <volume>100</volume>
          <fpage>601</fpage>
          <lpage>610</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2014.116368</pub-id>
          <?supplied-pmid 25682599?>
          <pub-id pub-id-type="pmid">25682599</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fritsche</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dlaska</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Garimorth</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Nramp1 functionality increases inducible nitric oxide synthase transcription via stimulation of IFN regulatory factor 1 expression</article-title>
          <source>J Immunol</source>
          <year>2003</year>
          <volume>171</volume>
          <fpage>1994</fpage>
          <lpage>1998</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.171.4.1994</pub-id>
          <?supplied-pmid 12902503?>
          <pub-id pub-id-type="pmid">12902503</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fritsche</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mair</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bellmann-Weiler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Modulation of macrophage iron transport by Nramp1 (Slc11a1)</article-title>
          <source>Immunobiology</source>
          <year>2007</year>
          <volume>212</volume>
          <fpage>751</fpage>
          <lpage>757</lpage>
          <pub-id pub-id-type="doi">10.1016/j.imbio.2007.09.014</pub-id>
          <?supplied-pmid 18086376?>
          <pub-id pub-id-type="pmid">18086376</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaenzer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Marschang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sturm</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Neumayr</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Patsch</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2002</year>
          <volume>40</volume>
          <fpage>2189</fpage>
          <lpage>2194</lpage>
          <pub-id pub-id-type="doi">10.1016/S0735-1097(02)02611-6</pub-id>
          <?supplied-pmid 12505233?>
          <pub-id pub-id-type="pmid">12505233</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Galy</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ferring-Appel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kaden</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grone</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum</article-title>
          <source>Cell Metab</source>
          <year>2008</year>
          <volume>7</volume>
          <fpage>79</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2007.10.006</pub-id>
          <?supplied-pmid 18177727?>
          <pub-id pub-id-type="pmid">18177727</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ganz</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Macrophages and systemic iron homeostasis</article-title>
          <source>J Innate Immun</source>
          <year>2012</year>
          <volume>4</volume>
          <fpage>446</fpage>
          <lpage>453</lpage>
          <pub-id pub-id-type="doi">10.1159/000336423</pub-id>
          <?supplied-pmid 22441209?>
          <pub-id pub-id-type="pmid">22441209</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ganz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nemeth</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Iron homeostasis in host defence and inflammation</article-title>
          <source>Nat Rev Immunol</source>
          <year>2015</year>
          <volume>15</volume>
          <fpage>500</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3863</pub-id>
          <?supplied-pmid 26160612?>
          <pub-id pub-id-type="pmid">26160612</pub-id>
        </element-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gardi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Arezzini</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fortino</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Comporti</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Effect of free iron on collagen synthesis, cell proliferation and MMP-2 expression in rat hepatic stellate cells</article-title>
          <source>Biochem Pharmacol</source>
          <year>2002</year>
          <volume>64</volume>
          <fpage>1139</fpage>
          <lpage>1145</lpage>
          <pub-id pub-id-type="doi">10.1016/S0006-2952(02)01257-1</pub-id>
          <?supplied-pmid 12234617?>
          <pub-id pub-id-type="pmid">12234617</pub-id>
        </element-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garton</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Gough</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Philalay</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wille</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Blobel</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Whitehead</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Dempsey</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Raines</surname>
              <given-names>EW</given-names>
            </name>
          </person-group>
          <article-title>Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17)</article-title>
          <source>J Biol Chem</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>37459</fpage>
          <lpage>37464</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M305877200</pub-id>
          <?supplied-pmid 12878595?>
          <pub-id pub-id-type="pmid">12878595</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Tissue-resident macrophage ontogeny and homeostasis</article-title>
          <source>Immunity</source>
          <year>2016</year>
          <volume>44</volume>
          <fpage>439</fpage>
          <lpage>449</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.024</pub-id>
          <?supplied-pmid 26982352?>
          <pub-id pub-id-type="pmid">26982352</pub-id>
        </element-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Girelli</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Corrocher</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bisceglia</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Olivieri</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>De Franceschi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zelante</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gasparini</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the “Verona mutation”)</article-title>
          <source>Blood</source>
          <year>1995</year>
          <volume>86</volume>
          <fpage>4050</fpage>
          <lpage>4053</lpage>
          <?supplied-pmid 7492760?>
          <pub-id pub-id-type="pmid">7492760</pub-id>
        </element-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldmann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wieghofer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jordao</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Prutek</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hagemeyer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Frenzel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Amann</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Staszewski</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Kierdorf</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Krueger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Locatelli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hochgerner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zeiser</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Epelman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Geissmann</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Priller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Bechmann</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kerschensteiner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Linnarsson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Prinz</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Origin, fate and dynamics of macrophages at central nervous system interfaces</article-title>
          <source>Nat Immunol</source>
          <year>2016</year>
          <volume>17</volume>
          <fpage>797</fpage>
          <lpage>805</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.3423</pub-id>
          <?supplied-pmid 27135602?>
          <pub-id pub-id-type="pmid">27135602</pub-id>
        </element-citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>Monocyte and macrophage heterogeneity</article-title>
          <source>Nat Rev Immunol</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>953</fpage>
          <lpage>964</lpage>
          <pub-id pub-id-type="doi">10.1038/nri1733</pub-id>
          <?supplied-pmid 16322748?>
          <pub-id pub-id-type="pmid">16322748</pub-id>
        </element-citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haas</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Fungal siderophore metabolism with a focus on Aspergillus fumigatus</article-title>
          <source>Nat Prod Rep</source>
          <year>2014</year>
          <volume>31</volume>
          <fpage>1266</fpage>
          <lpage>1276</lpage>
          <pub-id pub-id-type="doi">10.1039/C4NP00071D</pub-id>
          <?supplied-pmid 25140791?>
          <pub-id pub-id-type="pmid">25140791</pub-id>
        </element-citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Habib</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Polavarapu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Karmali</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Van Dam</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Akahori</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Saeed</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Nakano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pachura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kolodgie</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Virmani</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Finn</surname>
              <given-names>AV</given-names>
            </name>
          </person-group>
          <article-title>Hepcidin-ferroportin axis controls toll-like receptor 4 dependent macrophage inflammatory responses in human atherosclerotic plaques</article-title>
          <source>Atherosclerosis</source>
          <year>2015</year>
          <volume>241</volume>
          <fpage>692</fpage>
          <lpage>700</lpage>
          <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.06.025</pub-id>
          <?supplied-pmid 26125411?>
          <pub-id pub-id-type="pmid">26125411</pub-id>
        </element-citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haldar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kohyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>So</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Kc</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Briseno</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Satpathy</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Kretzer</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Arase</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rajasekaran</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Egawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Igarashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Baltimore</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Heme-mediated SPI-C induction promotes monocyte differentiation into iron-recycling macrophages</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>156</volume>
          <fpage>1223</fpage>
          <lpage>1234</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2014.01.069</pub-id>
          <?supplied-pmid 24630724?>
          <pub-id pub-id-type="pmid">24630724</pub-id>
        </element-citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamza</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dailey</surname>
              <given-names>HA</given-names>
            </name>
          </person-group>
          <article-title>One ring to rule them all: trafficking of heme and heme synthesis intermediates in the metazoans</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2012</year>
          <volume>1823</volume>
          <fpage>1617</fpage>
          <lpage>1632</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbamcr.2012.04.009</pub-id>
          <?supplied-pmid 22575458?>
          <pub-id pub-id-type="pmid">22575458</pub-id>
        </element-citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Seaman</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Di</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Willingham</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>SV</given-names>
            </name>
          </person-group>
          <article-title>Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells</article-title>
          <source>PLoS One</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>e23800</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0023800</pub-id>
          <?supplied-pmid 21886823?>
          <pub-id pub-id-type="pmid">21886823</pub-id>
        </element-citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haschka</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Demetz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wienerroither</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Decker</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Contrasting regulation of macrophage iron homeostasis in response to infection with <italic>Listeria monocytogenes</italic> depending on localization of bacteria</article-title>
          <source>Metallomics</source>
          <year>2015</year>
          <volume>7</volume>
          <fpage>1036</fpage>
          <lpage>1045</lpage>
          <pub-id pub-id-type="doi">10.1039/C4MT00328D</pub-id>
          <?supplied-pmid 25869778?>
          <pub-id pub-id-type="pmid">25869778</pub-id>
        </element-citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haubner</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schweigmann</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Schuetz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dichtl</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Velik-Salchner</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Penninger</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Functional recovery of a human neonatal heart after severe myocardial infarction</article-title>
          <source>Circ Res</source>
          <year>2015</year>
          <volume>118</volume>
          <fpage>216</fpage>
          <lpage>221</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.307017</pub-id>
          <?supplied-pmid 26659640?>
          <pub-id pub-id-type="pmid">26659640</pub-id>
        </element-citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>He</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chousterman</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Fenn</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Anzai</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hilgendorf</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>YX</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tricot</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Weissleder</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Macphee</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nahrendorf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Swirski</surname>
              <given-names>FK</given-names>
            </name>
          </person-group>
          <article-title>Lp-PLA2 antagonizes left ventricular healing after myocardial infarction by impairing the appearance of reparative macrophages</article-title>
          <source>Circ Heart Fail</source>
          <year>2016</year>
          <volume>8</volume>
          <fpage>980</fpage>
          <lpage>987</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.115.002334</pub-id>
        </element-citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heiland</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Aigner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dallos</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sahinbegovic</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Krenn</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Thaler</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Distler</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Datz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schett</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zwerina</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Synovial immunopathology in haemochromatosis arthropathy</article-title>
          <source>Ann Rheum Dis</source>
          <year>2010</year>
          <volume>69</volume>
          <fpage>1214</fpage>
          <lpage>1219</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2009.120204</pub-id>
          <?supplied-pmid 19933745?>
          <pub-id pub-id-type="pmid">19933745</pub-id>
        </element-citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Muckenthaler</surname>
              <given-names>MU</given-names>
            </name>
            <name>
              <surname>Galy</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Camaschella</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Two to tango: regulation of mammalian iron metabolism</article-title>
          <source>Cell</source>
          <year>2010</year>
          <volume>142</volume>
          <fpage>24</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2010.06.028</pub-id>
          <?supplied-pmid 20603012?>
          <pub-id pub-id-type="pmid">20603012</pub-id>
        </element-citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hilgendorf</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gerhardt</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Holderried</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Chousterman</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zirlik</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scherer-Crosbie</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hedrick</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nahrendorf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weissleder</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Swirski</surname>
              <given-names>FK</given-names>
            </name>
          </person-group>
          <article-title>Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium</article-title>
          <source>Circ Res</source>
          <year>2014</year>
          <volume>114</volume>
          <fpage>1611</fpage>
          <lpage>1622</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.303204</pub-id>
          <?supplied-pmid 24625784?>
          <pub-id pub-id-type="pmid">24625784</pub-id>
        </element-citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hornig</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lutz</surname>
              <given-names>HU</given-names>
            </name>
          </person-group>
          <article-title>Band 3 protein clustering on human erythrocytes promotes binding of naturally occurring anti-band 3 and anti-spectrin antibodies</article-title>
          <source>Exp Gerontol</source>
          <year>2000</year>
          <volume>35</volume>
          <fpage>1025</fpage>
          <lpage>1044</lpage>
          <pub-id pub-id-type="doi">10.1016/S0531-5565(00)00126-1</pub-id>
          <?supplied-pmid 11121688?>
          <pub-id pub-id-type="pmid">11121688</pub-id>
        </element-citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Whitnall</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suryo Rahmanto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ponka</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Richardson</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Elucidation of the mechanism of mitochondrial iron loading in Friedreich’s ataxia by analysis of a mouse mutant</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2009</year>
          <volume>106</volume>
          <fpage>16381</fpage>
          <lpage>16386</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0906784106</pub-id>
          <?supplied-pmid 19805308?>
          <pub-id pub-id-type="pmid">19805308</pub-id>
        </element-citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hubert</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>12345</fpage>
          <lpage>12350</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.192423399</pub-id>
          <?supplied-pmid 12209011?>
          <pub-id pub-id-type="pmid">12209011</pub-id>
        </element-citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hvidberg</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Maniecki</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hojrup</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Moller</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Moestrup</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Identification of the receptor scavenging hemopexin-heme complexes</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>2572</fpage>
          <lpage>2579</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-03-1185</pub-id>
          <?supplied-pmid 15947085?>
          <pub-id pub-id-type="pmid">15947085</pub-id>
        </element-citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ishii</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Fumoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Iwai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takeshita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shimohata</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Aburatani</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Taketani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lelliott</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Vidal-Puig</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation</article-title>
          <source>Nat Med</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>259</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.1910</pub-id>
          <?supplied-pmid 19252502?>
          <pub-id pub-id-type="pmid">19252502</pub-id>
        </element-citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iwasaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mackenzie</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Hailemariam</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsuji</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Hemin-mediated regulation of an antioxidant-responsive element of the human ferritin H gene and role of Ref-1 during erythroid differentiation of K562 cells</article-title>
          <source>Mol Cell Biol</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>2845</fpage>
          <lpage>2856</lpage>
          <pub-id pub-id-type="doi">10.1128/MCB.26.7.2845-2856.2006</pub-id>
          <?supplied-pmid 16537925?>
          <pub-id pub-id-type="pmid">16537925</pub-id>
        </element-citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jabara</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Boyden</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ramesh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Massaad</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Benson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bainter</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Fraulino</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rahimov</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sieff</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>ZJ</given-names>
            </name>
            <name>
              <surname>Alshemmari</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Al-Ramadi</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Al-Dhekri</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Arnaout</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Abu-Shukair</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vatsayan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Silver</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ahuja</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Sola-Visner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ohsumi</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Notarangelo</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Fleming</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Al-Herz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kunkel</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Geha</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency</article-title>
          <source>Nat Genet</source>
          <year>2016</year>
          <volume>48</volume>
          <fpage>74</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.3465</pub-id>
          <?supplied-pmid 26642240?>
          <pub-id pub-id-type="pmid">26642240</pub-id>
        </element-citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jha</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Kook</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Suk</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Diverse functional roles of lipocalin-2 in the central nervous system</article-title>
          <source>Neurosci Biobehav Rev</source>
          <year>2014</year>
          <volume>49</volume>
          <fpage>135</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.12.006</pub-id>
          <?supplied-pmid 25511817?>
          <pub-id pub-id-type="pmid">25511817</pub-id>
        </element-citation>
      </ref>
      <ref id="CR105">
        <label>105.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ji</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Qiao</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Low expression of ferroxidases is implicated in the iron retention in human atherosclerotic plaques</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>2015</year>
          <volume>464</volume>
          <fpage>1134</fpage>
          <lpage>1138</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbrc.2015.07.091</pub-id>
          <?supplied-pmid 26208458?>
          <pub-id pub-id-type="pmid">26208458</pub-id>
        </element-citation>
      </ref>
      <ref id="CR106">
        <label>106.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Grady</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Cerami</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Low molecular weight iron-binding factor from mammalian tissue that potentiates bacterial growth</article-title>
          <source>J Exp Med</source>
          <year>1980</year>
          <volume>151</volume>
          <fpage>418</fpage>
          <lpage>428</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.151.2.418</pub-id>
          <?supplied-pmid 6985950?>
          <pub-id pub-id-type="pmid">6985950</pub-id>
        </element-citation>
      </ref>
      <ref id="CR107">
        <label>107.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kautz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gabayan</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Onwuzurike</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Qiao</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lusis</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Ganz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nemeth</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Testing the iron hypothesis in a mouse model of atherosclerosis</article-title>
          <source>Cell Rep</source>
          <year>2013</year>
          <volume>5</volume>
          <fpage>1436</fpage>
          <lpage>1442</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2013.11.009</pub-id>
          <?supplied-pmid 24316081?>
          <pub-id pub-id-type="pmid">24316081</pub-id>
        </element-citation>
      </ref>
      <ref id="CR108">
        <label>108.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keel</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Doty</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Quigley</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Knoblaugh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kingsley</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>De Domenico</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Vaughn</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Palis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Abkowitz</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>A heme export protein is required for red blood cell differentiation and iron homeostasis</article-title>
          <source>Science</source>
          <year>2008</year>
          <volume>319</volume>
          <fpage>825</fpage>
          <lpage>828</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1151133</pub-id>
          <?supplied-pmid 18258918?>
          <pub-id pub-id-type="pmid">18258918</pub-id>
        </element-citation>
      </ref>
      <ref id="CR109">
        <label>109.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khandelwal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>van Rooijen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Saxena</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation</article-title>
          <source>Transfusion</source>
          <year>2007</year>
          <volume>47</volume>
          <fpage>1725</fpage>
          <lpage>1732</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1537-2995.2007.01348.x</pub-id>
          <?supplied-pmid 17725740?>
          <pub-id pub-id-type="pmid">17725740</pub-id>
        </element-citation>
      </ref>
      <ref id="CR110">
        <label>110.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kiechl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aichner</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gerstenbrand</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Egger</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mair</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rungger</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Spogler</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jarosch</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Oberhollenzer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Willeit</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study</article-title>
          <source>Arterioscler Thromb</source>
          <year>1994</year>
          <volume>14</volume>
          <fpage>1625</fpage>
          <lpage>1630</lpage>
          <pub-id pub-id-type="doi">10.1161/01.ATV.14.10.1625</pub-id>
          <?supplied-pmid 7918313?>
          <pub-id pub-id-type="pmid">7918313</pub-id>
        </element-citation>
      </ref>
      <ref id="CR111">
        <label>111.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kiechl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Willeit</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Egger</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Poewe</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Oberhollenzer</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study</article-title>
          <source>Circulation</source>
          <year>1997</year>
          <volume>96</volume>
          <fpage>3300</fpage>
          <lpage>3307</lpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.96.10.3300</pub-id>
          <?supplied-pmid 9396420?>
          <pub-id pub-id-type="pmid">9396420</pub-id>
        </element-citation>
      </ref>
      <ref id="CR112">
        <label>112.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Riegman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ingold</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Conrad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Turker</surname>
              <given-names>MZ</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Monette</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pauliah</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gonen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zanzonico</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wiesner</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Bradbury</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Overholtzer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth</article-title>
          <source>Nat Nanotechnol</source>
          <year>2016</year>
          <volume>11</volume>
          <fpage>977</fpage>
          <lpage>985</lpage>
          <pub-id pub-id-type="doi">10.1038/nnano.2016.164</pub-id>
          <?supplied-pmid 27668796?>
          <pub-id pub-id-type="pmid">27668796</pub-id>
        </element-citation>
      </ref>
      <ref id="CR113">
        <label>113.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Knutson</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Oukka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koss</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Aydemir</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wessling-Resnick</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2005</year>
          <volume>102</volume>
          <fpage>1324</fpage>
          <lpage>1328</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0409409102</pub-id>
          <?supplied-pmid 15665091?>
          <pub-id pub-id-type="pmid">15665091</pub-id>
        </element-citation>
      </ref>
      <ref id="CR114">
        <label>114.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kobayashi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Karisola</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pena-Cruz</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Dorfman</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Jinushi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Umetsu</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Butte</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Nagumo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Chernova</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sharpe</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dranoff</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Casasnovas</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Umetsu</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Dekruyff</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells</article-title>
          <source>Immunity</source>
          <year>2007</year>
          <volume>27</volume>
          <fpage>927</fpage>
          <lpage>940</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2007.11.011</pub-id>
          <?supplied-pmid 18082433?>
          <pub-id pub-id-type="pmid">18082433</pub-id>
        </element-citation>
      </ref>
      <ref id="CR115">
        <label>115.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koeppen</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Bjork</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Santambrogio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Parsons</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Kruger</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>KX</given-names>
            </name>
            <name>
              <surname>Feustel</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Mazurkiewicz</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>The pathogenesis of cardiomyopathy in Friedreich ataxia</article-title>
          <source>PLoS One</source>
          <year>2015</year>
          <volume>10</volume>
          <fpage>e0116396</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0116396</pub-id>
          <?supplied-pmid 25738292?>
          <pub-id pub-id-type="pmid">25738292</pub-id>
        </element-citation>
      </ref>
      <ref id="CR116">
        <label>116.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kohyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ise</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Edelson</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Wilker</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Hildner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mejia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Frazier</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis</article-title>
          <source>Nature</source>
          <year>2009</year>
          <volume>457</volume>
          <fpage>318</fpage>
          <lpage>321</lpage>
          <pub-id pub-id-type="doi">10.1038/nature07472</pub-id>
          <?supplied-pmid 19037245?>
          <pub-id pub-id-type="pmid">19037245</pub-id>
        </element-citation>
      </ref>
      <ref id="CR117">
        <label>117.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Korolnek</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hamza</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Like iron in the blood of the people: the requirement for heme trafficking in iron metabolism</article-title>
          <source>Front Pharmacol</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>126</fpage>
          <pub-id pub-id-type="doi">10.3389/fphar.2014.00126</pub-id>
          <?supplied-pmid 24926267?>
          <pub-id pub-id-type="pmid">24926267</pub-id>
        </element-citation>
      </ref>
      <ref id="CR118">
        <label>118.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Korolnek</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hamza</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Macrophages and iron trafficking at the birth and death of red cells</article-title>
          <source>Blood</source>
          <year>2015</year>
          <volume>125</volume>
          <fpage>2893</fpage>
          <lpage>2897</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2014-12-567776</pub-id>
          <?supplied-pmid 25778532?>
          <pub-id pub-id-type="pmid">25778532</pub-id>
        </element-citation>
      </ref>
      <ref id="CR119">
        <label>119.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koskenkorva-Frank</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Koppenol</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Burckhardt</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress</article-title>
          <source>Free Radic Biol Med</source>
          <year>2013</year>
          <volume>65</volume>
          <fpage>1174</fpage>
          <lpage>1194</lpage>
          <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2013.09.001</pub-id>
          <?supplied-pmid 24036104?>
          <pub-id pub-id-type="pmid">24036104</pub-id>
        </element-citation>
      </ref>
      <ref id="CR120">
        <label>120.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kristiansen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Graversen</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sonne</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Hoffman</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Law</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Moestrup</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Identification of the haemoglobin scavenger receptor</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>409</volume>
          <fpage>198</fpage>
          <lpage>201</lpage>
          <pub-id pub-id-type="doi">10.1038/35051594</pub-id>
          <?supplied-pmid 11196644?>
          <pub-id pub-id-type="pmid">11196644</pub-id>
        </element-citation>
      </ref>
      <ref id="CR121">
        <label>121.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuhn</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Lafuse</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Zwilling</surname>
              <given-names>BS</given-names>
            </name>
          </person-group>
          <article-title>Differential iron transport into phagosomes isolated from the RAW264.7 macrophage cell lines transfected with Nramp1Gly169 or Nramp1Asp169</article-title>
          <source>J Leukoc Biol</source>
          <year>1999</year>
          <volume>66</volume>
          <fpage>113</fpage>
          <lpage>119</lpage>
          <?supplied-pmid 10410998?>
          <pub-id pub-id-type="pmid">10410998</pub-id>
        </element-citation>
      </ref>
      <ref id="CR122">
        <label>122.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuhn</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Lafuse</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Zwilling</surname>
              <given-names>BS</given-names>
            </name>
          </person-group>
          <article-title>Iron transport into mycobacterium avium-containing phagosomes from an Nramp1(Gly169)-transfected RAW264.7 macrophage cell line</article-title>
          <source>J Leukoc Biol</source>
          <year>2001</year>
          <volume>69</volume>
          <fpage>43</fpage>
          <lpage>49</lpage>
          <?supplied-pmid 11200066?>
          <pub-id pub-id-type="pmid">11200066</pub-id>
        </element-citation>
      </ref>
      <ref id="CR123">
        <label>123.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwon</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>IY</given-names>
            </name>
          </person-group>
          <article-title>Bone morphogenetic protein-6 induces the expression of inducible nitric oxide synthase in macrophages</article-title>
          <source>Immunology</source>
          <year>2009</year>
          <volume>128</volume>
          <fpage>e758</fpage>
          <lpage>e765</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2567.2009.03079.x</pub-id>
          <?supplied-pmid 19740337?>
          <pub-id pub-id-type="pmid">19740337</pub-id>
        </element-citation>
      </ref>
      <ref id="CR124">
        <label>124.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lambe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Dawson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bouriez-Jones</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Crockford</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Lepherd</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Latunde-Dada</surname>
              <given-names>GO</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Raja</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Campagna</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Villarreal</surname>
              <given-names>G</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Ellory</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Goodnow</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Fleming</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>McKie</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Cornall</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>113</volume>
          <fpage>1805</fpage>
          <lpage>1808</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2007-11-120402</pub-id>
          <?supplied-pmid 18955558?>
          <pub-id pub-id-type="pmid">18955558</pub-id>
        </element-citation>
      </ref>
      <ref id="CR125">
        <label>125.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lavin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Macrophages: gatekeepers of tissue integrity</article-title>
          <source>Cancer Immunol Res</source>
          <year>2014</year>
          <volume>1</volume>
          <fpage>201</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0117</pub-id>
        </element-citation>
      </ref>
      <ref id="CR126">
        <label>126.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Short</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Mankelow</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Spring</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Parsons</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Yazdanbakhsh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mohandas</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Anstee</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Chasis</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Targeted gene deletion demonstrates that the cell adhesion molecule ICAM-4 is critical for erythroblastic island formation</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>108</volume>
          <fpage>2064</fpage>
          <lpage>2071</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2006-03-006759</pub-id>
          <?supplied-pmid 16690966?>
          <pub-id pub-id-type="pmid">16690966</pub-id>
        </element-citation>
      </ref>
      <ref id="CR127">
        <label>127.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Finazzi</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms</article-title>
          <source>Front Pharmacol</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>99</fpage>
          <pub-id pub-id-type="doi">10.3389/fphar.2014.00099</pub-id>
          <?supplied-pmid 24847269?>
          <pub-id pub-id-type="pmid">24847269</pub-id>
        </element-citation>
      </ref>
      <ref id="CR128">
        <label>128.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>NC</given-names>
            </name>
          </person-group>
          <article-title>Transferrin receptor is necessary for development of erythrocytes and the nervous system</article-title>
          <source>Nat Genet</source>
          <year>1999</year>
          <volume>21</volume>
          <fpage>396</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="doi">10.1038/7727</pub-id>
          <?supplied-pmid 10192390?>
          <pub-id pub-id-type="pmid">10192390</pub-id>
        </element-citation>
      </ref>
      <ref id="CR129">
        <label>129.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Forssell</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>XM</given-names>
            </name>
          </person-group>
          <article-title>Overexpression of transferrin receptor and ferritin related to clinical symptoms and destabilization of human carotid plaques</article-title>
          <source>Exp Biol Med (Maywood)</source>
          <year>2008</year>
          <volume>233</volume>
          <fpage>818</fpage>
          <lpage>826</lpage>
          <pub-id pub-id-type="doi">10.3181/0711-RM-320</pub-id>
          <pub-id pub-id-type="pmid">18445768</pub-id>
        </element-citation>
      </ref>
      <ref id="CR130">
        <label>130.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Paragas</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ned</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Viltard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leete</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Drexler</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Sanna-Cherchi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mohammed</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Schmidt-Ott</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Barasch</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Scara5 is a ferritin receptor mediating non-transferrin iron delivery</article-title>
          <source>Dev Cell</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>35</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1016/j.devcel.2008.12.002</pub-id>
          <?supplied-pmid 19154717?>
          <pub-id pub-id-type="pmid">19154717</pub-id>
        </element-citation>
      </ref>
      <ref id="CR131">
        <label>131.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Heme induces IL-1beta secretion through activating NLRP3 in kidney inflammation</article-title>
          <source>Cell Biochem Biophys</source>
          <year>2014</year>
          <volume>69</volume>
          <fpage>495</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="doi">10.1007/s12013-014-9823-9</pub-id>
          <?supplied-pmid 24464629?>
          <pub-id pub-id-type="pmid">24464629</pub-id>
        </element-citation>
      </ref>
      <ref id="CR132">
        <label>132.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Eheim</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Uschner</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Brandon-Warner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bonkovsky</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Trebicka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schrum</surname>
              <given-names>LW</given-names>
            </name>
          </person-group>
          <article-title>Novel role of nuclear receptor Rev-erbalpha in hepatic stellate cell activation: potential therapeutic target for liver injury</article-title>
          <source>Hepatology</source>
          <year>2014</year>
          <volume>59</volume>
          <fpage>2383</fpage>
          <lpage>2396</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.27049</pub-id>
          <?supplied-pmid 24497272?>
          <pub-id pub-id-type="pmid">24497272</pub-id>
        </element-citation>
      </ref>
      <ref id="CR133">
        <label>133.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Cressatti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zukor</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schipper</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Heme oxygenase-1 modulates microRNA expression in cultured astroglia: implications for chronic brain disorders</article-title>
          <source>Glia</source>
          <year>2015</year>
          <volume>63</volume>
          <fpage>1270</fpage>
          <lpage>1284</lpage>
          <pub-id pub-id-type="doi">10.1002/glia.22823</pub-id>
          <?supplied-pmid 25820186?>
          <pub-id pub-id-type="pmid">25820186</pub-id>
        </element-citation>
      </ref>
      <ref id="CR134">
        <label>134.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Ciocea</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Devireddy</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Endogenous siderophore 2,5-dihydroxybenzoic acid deficiency promotes anemia and splenic iron overload in mice</article-title>
          <source>Mol Cell Biol</source>
          <year>2014</year>
          <volume>34</volume>
          <fpage>2533</fpage>
          <lpage>2546</lpage>
          <pub-id pub-id-type="doi">10.1128/MCB.00231-14</pub-id>
          <?supplied-pmid 24777603?>
          <pub-id pub-id-type="pmid">24777603</pub-id>
        </element-citation>
      </ref>
      <ref id="CR135">
        <label>135.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Reba</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Porwal</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Boom</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Rojas</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Viswanathan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Devireddy</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Regulation of mammalian siderophore 2,5-DHBA in the innate immune response to infection</article-title>
          <source>J Exp Med</source>
          <year>2014</year>
          <volume>211</volume>
          <fpage>1197</fpage>
          <lpage>1213</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20132629</pub-id>
          <?supplied-pmid 24863067?>
          <pub-id pub-id-type="pmid">24863067</pub-id>
        </element-citation>
      </ref>
      <ref id="CR136">
        <label>136.</label>
        <mixed-citation publication-type="other">Lok HC, Sahni S, Jansson PJ, Kovacevic Z, Hawkins CL, Richardson DR (2016) A nitric oxide storage and transport system that protects activated macrophages from endogenous nitric oxide cytotoxicity. J Biol Chem 291:27042–27061</mixed-citation>
      </ref>
      <ref id="CR137">
        <label>137.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lou</surname>
              <given-names>DQ</given-names>
            </name>
            <name>
              <surname>Lesbordes</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Nicolas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Viatte</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bennoun</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Van Rooijen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Renia</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vaulont</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Iron- and inflammation-induced hepcidin gene expression in mice is not mediated by Kupffer cells in vivo</article-title>
          <source>Hepatology</source>
          <year>2005</year>
          <volume>41</volume>
          <fpage>1056</fpage>
          <lpage>1064</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.20663</pub-id>
          <?supplied-pmid 15793843?>
          <pub-id pub-id-type="pmid">15793843</pub-id>
        </element-citation>
      </ref>
      <ref id="CR138">
        <label>138.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ludwiczek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aigner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Cytokine-mediated regulation of iron transport in human monocytic cells</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>101</volume>
          <fpage>4148</fpage>
          <lpage>4154</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2002-08-2459</pub-id>
          <?supplied-pmid 12522003?>
          <pub-id pub-id-type="pmid">12522003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR139">
        <label>139.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ludwiczek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Muckenthaler</surname>
              <given-names>MU</given-names>
            </name>
            <name>
              <surname>Jakab</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mair</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kiss</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Paulmichl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Ritter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1</article-title>
          <source>Nat Med</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>448</fpage>
          <lpage>454</lpage>
          <pub-id pub-id-type="doi">10.1038/nm1542</pub-id>
          <?supplied-pmid 17293870?>
          <pub-id pub-id-type="pmid">17293870</pub-id>
        </element-citation>
      </ref>
      <ref id="CR140">
        <label>140.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luscieti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Santambrogio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Langlois d'Estaintot</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Granier</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cozzi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Poli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gallois</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Finazzi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cattaneo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Arosio</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Mutant ferritin L-chains that cause neurodegeneration act in a dominant-negative manner to reduce ferritin iron incorporation</article-title>
          <source>J Biol Chem</source>
          <year>2010</year>
          <volume>285</volume>
          <fpage>11948</fpage>
          <lpage>11957</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M109.096404</pub-id>
          <?supplied-pmid 20159981?>
          <pub-id pub-id-type="pmid">20159981</pub-id>
        </element-citation>
      </ref>
      <ref id="CR141">
        <label>141.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Macedo</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>de Sousa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ned</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Mascarenhas</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Correia-Neves</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Transferrin is required for early T-cell differentiation</article-title>
          <source>Immunology</source>
          <year>2004</year>
          <volume>112</volume>
          <fpage>543</fpage>
          <lpage>549</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2567.2004.01915.x</pub-id>
          <?supplied-pmid 15270724?>
          <pub-id pub-id-type="pmid">15270724</pub-id>
        </element-citation>
      </ref>
      <ref id="CR142">
        <label>142.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mahnke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Meier</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Schatz</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Castiglione</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schleicher</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Wolfbeis</surname>
              <given-names>OS</given-names>
            </name>
            <name>
              <surname>Bogdan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jantsch</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Hypoxia in Leishmania major skin lesions impairs the NO-dependent leishmanicidal activity of macrophages</article-title>
          <source>J Invest Dermatol</source>
          <year>2014</year>
          <volume>134</volume>
          <fpage>2339</fpage>
          <lpage>2346</lpage>
          <pub-id pub-id-type="doi">10.1038/jid.2014.121</pub-id>
          <?supplied-pmid 24583949?>
          <pub-id pub-id-type="pmid">24583949</pub-id>
        </element-citation>
      </ref>
      <ref id="CR143">
        <label>143.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mair</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bellmann-Weiler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Muehlbacher</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schroll</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Moser</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Talasz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Nifedipine affects the course of Salmonella enterica serovar Typhimurium infection by modulating macrophage iron homeostasis</article-title>
          <source>J Infect Dis</source>
          <year>2011</year>
          <volume>204</volume>
          <fpage>685</fpage>
          <lpage>694</lpage>
          <pub-id pub-id-type="doi">10.1093/infdis/jir395</pub-id>
          <?supplied-pmid 21844295?>
          <pub-id pub-id-type="pmid">21844295</pub-id>
        </element-citation>
      </ref>
      <ref id="CR144">
        <label>144.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marques</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Negre-Salvayre</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Canonne-Hergaux</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Iron gene expression profile in atherogenic Mox macrophages</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2016</year>
          <volume>1862</volume>
          <fpage>1137</fpage>
          <lpage>1146</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbadis.2016.03.004</pub-id>
          <?supplied-pmid 26972048?>
          <pub-id pub-id-type="pmid">26972048</pub-id>
        </element-citation>
      </ref>
      <ref id="CR145">
        <label>145.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chiabrando</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Messana</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Stolte</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Turco</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tolosano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Muckenthaler</surname>
              <given-names>MU</given-names>
            </name>
          </person-group>
          <article-title>Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter</article-title>
          <source>Haematologica</source>
          <year>2010</year>
          <volume>95</volume>
          <fpage>1261</fpage>
          <lpage>1268</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2009.020123</pub-id>
          <?supplied-pmid 20179090?>
          <pub-id pub-id-type="pmid">20179090</pub-id>
        </element-citation>
      </ref>
      <ref id="CR146">
        <label>146.</label>
        <mixed-citation publication-type="other">Martins R, Maier J, Gorki AD, Huber KV, Sharif O, Starkl P, Saluzzo S, Quattrone F, Gawish R, Lakovits K, Aichinger MC, Radic-Sarikas B, Lardeau CH, Hladik A, Korosec A, Brown M, Vaahtomeri K, Duggan M, Kerjaschki D, Esterbauer H, Colinge J, Eisenbarth SC, Decker T, Bennett KL, Kubicek S, Sixt M, Superti-Furga G, Knapp S (2016) Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions. Nat Immunol</mixed-citation>
      </ref>
      <ref id="CR147">
        <label>147.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mathieu</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Heinis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zumerle</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Delga</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Le Bon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peyssonnaux</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Investigating the real role of HIF-1 and HIF-2 in iron recycling by macrophages</article-title>
          <source>Haematologica</source>
          <year>2014</year>
          <volume>99</volume>
          <fpage>e112</fpage>
          <lpage>e114</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2013.102319</pub-id>
          <?supplied-pmid 24727819?>
          <pub-id pub-id-type="pmid">24727819</pub-id>
        </element-citation>
      </ref>
      <ref id="CR148">
        <label>148.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mayr</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Janecke</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Schranz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Pietrangelo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zoller</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Ferroportin disease: a systematic meta-analysis of clinical and molecular findings</article-title>
          <source>J Hepatol</source>
          <year>2010</year>
          <volume>53</volume>
          <fpage>941</fpage>
          <lpage>949</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jhep.2010.05.016</pub-id>
          <?supplied-pmid 20691492?>
          <pub-id pub-id-type="pmid">20691492</pub-id>
        </element-citation>
      </ref>
      <ref id="CR149">
        <label>149.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mayr</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Hermann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McFarlane</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Halsall</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Finkenstedt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Douds</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Janecke</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Zoller</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Identification of mutations in SLC40A1 that affect ferroportin function and phenotype of human ferroportin iron overload</article-title>
          <source>Gastroenterology</source>
          <year>2011</year>
          <volume>140</volume>
          <issue>2056–2063</issue>
          <fpage>e2051</fpage>
        </element-citation>
      </ref>
      <ref id="CR150">
        <label>150.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKie</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Barlow</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1)</article-title>
          <source>Pflugers Arch</source>
          <year>2004</year>
          <volume>447</volume>
          <fpage>801</fpage>
          <lpage>806</lpage>
          <pub-id pub-id-type="doi">10.1007/s00424-003-1102-3</pub-id>
          <?supplied-pmid 12836025?>
          <pub-id pub-id-type="pmid">12836025</pub-id>
        </element-citation>
      </ref>
      <ref id="CR151">
        <label>151.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKie</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Marciani</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rolfs</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brennan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wehr</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Barrow</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Miret</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bomford</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Farzaneh</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hediger</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation</article-title>
          <source>Mol Cell</source>
          <year>2000</year>
          <volume>5</volume>
          <fpage>299</fpage>
          <lpage>309</lpage>
          <pub-id pub-id-type="doi">10.1016/S1097-2765(00)80425-6</pub-id>
          <?supplied-pmid 10882071?>
          <pub-id pub-id-type="pmid">10882071</pub-id>
        </element-citation>
      </ref>
      <ref id="CR152">
        <label>152.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKie</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Barrow</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Latunde-Dada</surname>
              <given-names>GO</given-names>
            </name>
            <name>
              <surname>Rolfs</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sager</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mudaly</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mudaly</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Richardson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Barlow</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bomford</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Raja</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Shirali</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hediger</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Farzaneh</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>An iron-regulated ferric reductase associated with the absorption of dietary iron</article-title>
          <source>Science</source>
          <year>2001</year>
          <volume>291</volume>
          <fpage>1755</fpage>
          <lpage>1759</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1057206</pub-id>
          <?supplied-pmid 11230685?>
          <pub-id pub-id-type="pmid">11230685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR153">
        <label>153.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melillo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Brooks</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Musso</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Varesio</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine</article-title>
          <source>J Biol Chem</source>
          <year>1997</year>
          <volume>272</volume>
          <fpage>12236</fpage>
          <lpage>12243</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.272.18.12236</pub-id>
          <?supplied-pmid 9115299?>
          <pub-id pub-id-type="pmid">9115299</pub-id>
        </element-citation>
      </ref>
      <ref id="CR154">
        <label>154.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mitterstiller</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Haschka</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dichtl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Demetz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Talasz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Einwallner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Esterbauer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Geley</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Heme oxygenase 1 controls early innate immune response of macrophages to Salmonella typhimurium infection</article-title>
          <source>Cell Microbiol</source>
          <year>2016</year>
          <volume>18</volume>
          <fpage>1374</fpage>
          <lpage>1389</lpage>
          <pub-id pub-id-type="doi">10.1111/cmi.12578</pub-id>
          <?supplied-pmid 26866925?>
          <pub-id pub-id-type="pmid">26866925</pub-id>
        </element-citation>
      </ref>
      <ref id="CR155">
        <label>155.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miyanishi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Koike</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uchiyama</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kitamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Identification of Tim4 as a phosphatidylserine receptor</article-title>
          <source>Nature</source>
          <year>2007</year>
          <volume>450</volume>
          <fpage>435</fpage>
          <lpage>439</lpage>
          <pub-id pub-id-type="doi">10.1038/nature06307</pub-id>
          <?supplied-pmid 17960135?>
          <pub-id pub-id-type="pmid">17960135</pub-id>
        </element-citation>
      </ref>
      <ref id="CR156">
        <label>156.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moestrup</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Moller</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
          <article-title>CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response</article-title>
          <source>Ann Med</source>
          <year>2004</year>
          <volume>36</volume>
          <fpage>347</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="doi">10.1080/07853890410033171</pub-id>
          <?supplied-pmid 15478309?>
          <pub-id pub-id-type="pmid">15478309</pub-id>
        </element-citation>
      </ref>
      <ref id="CR157">
        <label>157.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montosi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Corradini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Garuti</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Barelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Recalcati</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cairo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Valli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pignatti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vecchi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ferrara</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pietrangelo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload</article-title>
          <source>Hepatology</source>
          <year>2005</year>
          <volume>41</volume>
          <fpage>545</fpage>
          <lpage>552</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.20620</pub-id>
          <?supplied-pmid 15726660?>
          <pub-id pub-id-type="pmid">15726660</pub-id>
        </element-citation>
      </ref>
      <ref id="CR158">
        <label>158.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moretti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Goede</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Zeder</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jiskra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chatzinakou</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tjalsma</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Melse-Boonstra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brittenham</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Swinkels</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women</article-title>
          <source>Blood</source>
          <year>2015</year>
          <volume>126</volume>
          <fpage>1981</fpage>
          <lpage>1989</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2015-05-642223</pub-id>
          <?supplied-pmid 26289639?>
          <pub-id pub-id-type="pmid">26289639</pub-id>
        </element-citation>
      </ref>
      <ref id="CR159">
        <label>159.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muckenthaler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Custodio</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Minana</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>deGraaf</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Montross</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis</article-title>
          <source>Nat Genet</source>
          <year>2003</year>
          <volume>34</volume>
          <fpage>102</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1152</pub-id>
          <?supplied-pmid 12704390?>
          <pub-id pub-id-type="pmid">12704390</pub-id>
        </element-citation>
      </ref>
      <ref id="CR160">
        <label>160.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muhoberac</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Baraibar</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Vidal</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Iron loading-induced aggregation and reduction of iron incorporation in heteropolymeric ferritin containing a mutant light chain that causes neurodegeneration</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2013</year>
          <volume>1812</volume>
          <fpage>544</fpage>
          <lpage>548</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbadis.2010.10.010</pub-id>
        </element-citation>
      </ref>
      <ref id="CR161">
        <label>161.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nahrendorf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Swirski</surname>
              <given-names>FK</given-names>
            </name>
          </person-group>
          <article-title>Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction?</article-title>
          <source>Eur Heart J</source>
          <year>2016</year>
          <volume>37</volume>
          <fpage>868</fpage>
          <lpage>872</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehv453</pub-id>
          <?supplied-pmid 26351395?>
          <pub-id pub-id-type="pmid">26351395</pub-id>
        </element-citation>
      </ref>
      <ref id="CR162">
        <label>162.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fritsche</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Talasz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hantke</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Interferon-gamma limits the availability of iron for intramacrophage Salmonella typhimurium</article-title>
          <source>Eur J Immunol</source>
          <year>2008</year>
          <volume>38</volume>
          <fpage>1923</fpage>
          <lpage>1936</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.200738056</pub-id>
          <?supplied-pmid 18581323?>
          <pub-id pub-id-type="pmid">18581323</pub-id>
        </element-citation>
      </ref>
      <ref id="CR163">
        <label>163.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fritsche</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Crouch</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Slc11a1 limits intracellular growth of Salmonella enterica sv. Typhimurium by promoting macrophage immune effector functions and impairing bacterial iron acquisition</article-title>
          <source>Cell Microbiol</source>
          <year>2009</year>
          <volume>11</volume>
          <fpage>1365</fpage>
          <lpage>1381</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1462-5822.2009.01337.x</pub-id>
          <?supplied-pmid 19500110?>
          <pub-id pub-id-type="pmid">19500110</pub-id>
        </element-citation>
      </ref>
      <ref id="CR164">
        <label>164.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schleicher</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Schroll</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sonnweber</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ludwiczek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Talasz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Brandacher</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Moser</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Muckenthaler</surname>
              <given-names>MU</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Bogdan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Nitric oxide-mediated regulation of ferroportin-1 controls macrophage iron homeostasis and immune function in Salmonella infection</article-title>
          <source>J Exp Med</source>
          <year>2013</year>
          <volume>210</volume>
          <fpage>855</fpage>
          <lpage>873</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20121946</pub-id>
          <?supplied-pmid 23630227?>
          <pub-id pub-id-type="pmid">23630227</pub-id>
        </element-citation>
      </ref>
      <ref id="CR165">
        <label>165.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Haschka</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Demetz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Iron at the interface of immunity and infection</article-title>
          <source>Front Pharmacol</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>152</fpage>
          <pub-id pub-id-type="doi">10.3389/fphar.2014.00152</pub-id>
          <?supplied-pmid 25076907?>
          <pub-id pub-id-type="pmid">25076907</pub-id>
        </element-citation>
      </ref>
      <ref id="CR166">
        <label>166.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ferring-Appel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Casarrubea</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sonnweber</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Viatte</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schroll</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haschka</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Galy</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Iron regulatory proteins mediate host resistance to salmonella infection</article-title>
          <source>Cell Host Microbe</source>
          <year>2015</year>
          <volume>18</volume>
          <fpage>254</fpage>
          <lpage>261</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chom.2015.06.017</pub-id>
          <?supplied-pmid 26190773?>
          <pub-id pub-id-type="pmid">26190773</pub-id>
        </element-citation>
      </ref>
      <ref id="CR167">
        <label>167.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schroll</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Demetz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tancevski</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>'Ride on the ferrous wheel'—the cycle of iron in macrophages in health and disease</article-title>
          <source>Immunobiology</source>
          <year>2015</year>
          <volume>220</volume>
          <fpage>280</fpage>
          <lpage>294</lpage>
          <pub-id pub-id-type="doi">10.1016/j.imbio.2014.09.010</pub-id>
          <?supplied-pmid 25240631?>
          <pub-id pub-id-type="pmid">25240631</pub-id>
        </element-citation>
      </ref>
      <ref id="CR168">
        <label>168.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Iron deficiency or anemia of inflammation?: differential diagnosis and mechanisms of anemia of inflammation</article-title>
          <source>Wien Med Wochenschr</source>
          <year>2016</year>
          <volume>166</volume>
          <fpage>411</fpage>
          <lpage>423</lpage>
          <pub-id pub-id-type="doi">10.1007/s10354-016-0505-7</pub-id>
          <?supplied-pmid 27557596?>
          <pub-id pub-id-type="pmid">27557596</pub-id>
        </element-citation>
      </ref>
      <ref id="CR169">
        <label>169.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nandar</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Neely</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Unger</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Connor</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>A mutation in the HFE gene is associated with altered brain iron profiles and increased oxidative stress in mice</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2013</year>
          <volume>1832</volume>
          <fpage>729</fpage>
          <lpage>741</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbadis.2013.02.009</pub-id>
          <?supplied-pmid 23429074?>
          <pub-id pub-id-type="pmid">23429074</pub-id>
        </element-citation>
      </ref>
      <ref id="CR170">
        <label>170.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nell-Duxneuner</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Axmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Husar-Memmer</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dallos</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Datz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stadlmayr</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aigner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Englbrecht</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schett</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zwerina</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>VCAM-1 serum levels are associated with arthropathy in hereditary haemochromatosis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2013</year>
          <volume>72</volume>
          <fpage>2006</fpage>
          <lpage>2010</lpage>
          <pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202800</pub-id>
          <?supplied-pmid 23599437?>
          <pub-id pub-id-type="pmid">23599437</pub-id>
        </element-citation>
      </ref>
      <ref id="CR171">
        <label>171.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nemeth</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ganz</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Regulation of iron metabolism by hepcidin</article-title>
          <source>Annu Rev Nutr</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>323</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.nutr.26.061505.111303</pub-id>
          <?supplied-pmid 16848710?>
          <pub-id pub-id-type="pmid">16848710</pub-id>
        </element-citation>
      </ref>
      <ref id="CR172">
        <label>172.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nemeth</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rivera</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gabayan</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Taudorf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pedersen</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Ganz</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin</article-title>
          <source>J Clin Invest</source>
          <year>2004</year>
          <volume>113</volume>
          <fpage>1271</fpage>
          <lpage>1276</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200420945</pub-id>
          <?supplied-pmid 15124018?>
          <pub-id pub-id-type="pmid">15124018</pub-id>
        </element-citation>
      </ref>
      <ref id="CR173">
        <label>173.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nemeth</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tuttle</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Powelson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vaughn</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Donovan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Ganz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization</article-title>
          <source>Science</source>
          <year>2004</year>
          <volume>306</volume>
          <fpage>2090</fpage>
          <lpage>2093</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1104742</pub-id>
          <?supplied-pmid 15514116?>
          <pub-id pub-id-type="pmid">15514116</pub-id>
        </element-citation>
      </ref>
      <ref id="CR174">
        <label>174.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicolas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bennoun</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Devaux</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Beaumont</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grandchamp</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vaulont</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>8780</fpage>
          <lpage>8785</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.151179498</pub-id>
          <?supplied-pmid 11447267?>
          <pub-id pub-id-type="pmid">11447267</pub-id>
        </element-citation>
      </ref>
      <ref id="CR175">
        <label>175.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oexle</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gnaiger</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1999</year>
          <volume>1413</volume>
          <fpage>99</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="doi">10.1016/S0005-2728(99)00088-2</pub-id>
          <?supplied-pmid 10556622?>
          <pub-id pub-id-type="pmid">10556622</pub-id>
        </element-citation>
      </ref>
      <ref id="CR176">
        <label>176.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oexle</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kaser</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Most</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bellmann-Weiler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Werner</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Werner-Felmayer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Pathways for the regulation of interferon-gamma-inducible genes by iron in human monocytic cells</article-title>
          <source>J Leukoc Biol</source>
          <year>2003</year>
          <volume>74</volume>
          <fpage>287</fpage>
          <lpage>294</lpage>
          <pub-id pub-id-type="doi">10.1189/jlb.0802420</pub-id>
          <?supplied-pmid 12885946?>
          <pub-id pub-id-type="pmid">12885946</pub-id>
        </element-citation>
      </ref>
      <ref id="CR177">
        <label>177.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohgami</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Campagna</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Greer</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Antiochos</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sharp</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Fleming</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells</article-title>
          <source>Nat Genet</source>
          <year>2005</year>
          <volume>37</volume>
          <fpage>1264</fpage>
          <lpage>1269</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1658</pub-id>
          <?supplied-pmid 16227996?>
          <pub-id pub-id-type="pmid">16227996</pub-id>
        </element-citation>
      </ref>
      <ref id="CR178">
        <label>178.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olsson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oldenborg</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>CD47 on experimentally senescent murine RBCs inhibits phagocytosis following Fcgamma receptor-mediated but not scavenger receptor-mediated recognition by macrophages</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>112</volume>
          <fpage>4259</fpage>
          <lpage>4267</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-03-143008</pub-id>
          <?supplied-pmid 18779391?>
          <pub-id pub-id-type="pmid">18779391</pub-id>
        </element-citation>
      </ref>
      <ref id="CR179">
        <label>179.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pantopoulos</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Nitric oxide and oxidative stress (H2O2) control mammalian iron metabolism by different pathways</article-title>
          <source>Mol Cell Biol</source>
          <year>1996</year>
          <volume>16</volume>
          <fpage>3781</fpage>
          <lpage>3788</lpage>
          <pub-id pub-id-type="doi">10.1128/MCB.16.7.3781</pub-id>
          <?supplied-pmid 8668195?>
          <pub-id pub-id-type="pmid">8668195</pub-id>
        </element-citation>
      </ref>
      <ref id="CR180">
        <label>180.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pantopoulos</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Porwal</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Tartakoff</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Devireddy</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of mammalian iron homeostasis</article-title>
          <source>Biochemistry</source>
          <year>2012</year>
          <volume>51</volume>
          <fpage>5705</fpage>
          <lpage>5724</lpage>
          <pub-id pub-id-type="doi">10.1021/bi300752r</pub-id>
          <?supplied-pmid 22703180?>
          <pub-id pub-id-type="pmid">22703180</pub-id>
        </element-citation>
      </ref>
      <ref id="CR181">
        <label>181.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Part</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kunnis-Beres</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Poska</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Land</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shimmo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zetterstrom Fernaeus</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Amyloid beta25-35 induced ROS-burst through NADPH oxidase is sensitive to iron chelation in microglial Bv2 cells</article-title>
          <source>Brain Res</source>
          <year>2015</year>
          <volume>1629</volume>
          <fpage>282</fpage>
          <lpage>290</lpage>
          <pub-id pub-id-type="doi">10.1016/j.brainres.2015.09.034</pub-id>
          <?supplied-pmid 26505916?>
          <pub-id pub-id-type="pmid">26505916</pub-id>
        </element-citation>
      </ref>
      <ref id="CR182">
        <label>182.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pechlaner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kiechl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mayr</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Santer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Weger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Haschka</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bansal</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Willeit</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population</article-title>
          <source>Clin Chem Lab Med</source>
          <year>2016</year>
          <volume>54</volume>
          <fpage>151</fpage>
          <lpage>161</lpage>
          <pub-id pub-id-type="doi">10.1515/cclm-2015-0068</pub-id>
          <?supplied-pmid 26124055?>
          <pub-id pub-id-type="pmid">26124055</pub-id>
        </element-citation>
      </ref>
      <ref id="CR183">
        <label>183.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Penno</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Johnsson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ahlstrom</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Macrophage uptake of ultra-small iron oxide particles for magnetic resonance imaging in experimental acute cardiac transplant rejection</article-title>
          <source>Acta Radiol</source>
          <year>2006</year>
          <volume>47</volume>
          <fpage>264</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="doi">10.1080/02841850500539041</pub-id>
          <?supplied-pmid 16613307?>
          <pub-id pub-id-type="pmid">16613307</pub-id>
        </element-citation>
      </ref>
      <ref id="CR184">
        <label>184.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petters</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Thiel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dringen</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Lysosomal iron liberation is responsible for the vulnerability of brain microglial cells to iron oxide nanoparticles: comparison with neurons and astrocytes</article-title>
          <source>Nanotoxicology</source>
          <year>2015</year>
          <volume>10</volume>
          <fpage>332</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="doi">10.3109/17435390.2015.1071445</pub-id>
          <?supplied-pmid 26287375?>
          <pub-id pub-id-type="pmid">26287375</pub-id>
        </element-citation>
      </ref>
      <ref id="CR185">
        <label>185.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peyssonnaux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zinkernagel</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Datta</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lauth</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Nizet</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>107</volume>
          <fpage>3727</fpage>
          <lpage>3732</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-06-2259</pub-id>
          <?supplied-pmid 16391018?>
          <pub-id pub-id-type="pmid">16391018</pub-id>
        </element-citation>
      </ref>
      <ref id="CR186">
        <label>186.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pham</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Bubici</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zazzeroni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Papa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Alvarez</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jayawardena</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>De Smaele</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cong</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Beaumont</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Franzoso</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species</article-title>
          <source>Cell</source>
          <year>2004</year>
          <volume>119</volume>
          <fpage>529</fpage>
          <lpage>542</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2004.10.017</pub-id>
          <?supplied-pmid 15537542?>
          <pub-id pub-id-type="pmid">15537542</pub-id>
        </element-citation>
      </ref>
      <ref id="CR187">
        <label>187.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phelan</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Gampe</surname>
              <given-names>RT</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Lambert</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Parks</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Montana</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bynum</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Broderick</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Nolte</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Lazar</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Structure of Rev-erbalpha bound to N-CoR reveals a unique mechanism of nuclear receptor-co-repressor interaction</article-title>
          <source>Nat Struct Mol Biol</source>
          <year>2010</year>
          <volume>17</volume>
          <fpage>808</fpage>
          <lpage>814</lpage>
          <pub-id pub-id-type="doi">10.1038/nsmb.1860</pub-id>
          <?supplied-pmid 20581824?>
          <pub-id pub-id-type="pmid">20581824</pub-id>
        </element-citation>
      </ref>
      <ref id="CR188">
        <label>188.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pietrangelo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Hemochromatosis: an endocrine liver disease</article-title>
          <source>Hepatology</source>
          <year>2007</year>
          <volume>46</volume>
          <fpage>1291</fpage>
          <lpage>1301</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.21886</pub-id>
          <?supplied-pmid 17886335?>
          <pub-id pub-id-type="pmid">17886335</pub-id>
        </element-citation>
      </ref>
      <ref id="CR189">
        <label>189.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pietrangelo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment</article-title>
          <source>Gastroenterology</source>
          <year>2010</year>
          <volume>139</volume>
          <fpage>393</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="doi">10.1053/j.gastro.2010.06.013</pub-id>
          <?supplied-pmid 20542038?>
          <pub-id pub-id-type="pmid">20542038</pub-id>
        </element-citation>
      </ref>
      <ref id="CR190">
        <label>190.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pietsch</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>SV</given-names>
            </name>
          </person-group>
          <article-title>Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones</article-title>
          <source>J Biol Chem</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>2361</fpage>
          <lpage>2369</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M210664200</pub-id>
          <?supplied-pmid 12435735?>
          <pub-id pub-id-type="pmid">12435735</pub-id>
        </element-citation>
      </ref>
      <ref id="CR191">
        <label>191.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qian</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>LN</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>QQ</given-names>
            </name>
            <name>
              <surname>Yung</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Ke</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Lipopolysaccharides upregulate hepcidin in neuron via microglia and the IL-6/STAT3 signaling pathway</article-title>
          <source>Mol Neurobiol</source>
          <year>2014</year>
          <volume>50</volume>
          <fpage>811</fpage>
          <lpage>820</lpage>
          <pub-id pub-id-type="doi">10.1007/s12035-014-8671-3</pub-id>
          <?supplied-pmid 24659348?>
          <pub-id pub-id-type="pmid">24659348</pub-id>
        </element-citation>
      </ref>
      <ref id="CR192">
        <label>192.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramos</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Casu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gardenghi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Breda</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Crielaard</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Guy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Marongiu</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Abdel-Wahab</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ebert</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Van Rooijen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ghaffari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grady</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Giardina</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Rivella</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Macrophages support pathological erythropoiesis in polycythemia vera and beta-thalassemia</article-title>
          <source>Nat Med</source>
          <year>2013</year>
          <volume>19</volume>
          <fpage>437</fpage>
          <lpage>445</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.3126</pub-id>
          <?supplied-pmid 23502961?>
          <pub-id pub-id-type="pmid">23502961</pub-id>
        </element-citation>
      </ref>
      <ref id="CR193">
        <label>193.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Recalcati</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Alberghini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Campanella</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gianelli</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>De Camilli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Conte</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cairo</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Iron regulatory proteins 1 and 2 in human monocytes, macrophages and duodenum: expression and regulation in hereditary hemochromatosis and iron deficiency</article-title>
          <source>Haematologica</source>
          <year>2006</year>
          <volume>91</volume>
          <fpage>303</fpage>
          <lpage>310</lpage>
          <?supplied-pmid 16503547?>
          <pub-id pub-id-type="pmid">16503547</pub-id>
        </element-citation>
      </ref>
      <ref id="CR194">
        <label>194.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roetto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Papanikolaou</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Politou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alberti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Girelli</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Christakis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Loukopoulos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Camaschella</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis</article-title>
          <source>Nat Genet</source>
          <year>2003</year>
          <volume>33</volume>
          <fpage>21</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1053</pub-id>
          <?supplied-pmid 12469120?>
          <pub-id pub-id-type="pmid">12469120</pub-id>
        </element-citation>
      </ref>
      <ref id="CR195">
        <label>195.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rouault</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>The role of iron regulatory proteins in mammalian iron homeostasis and disease</article-title>
          <source>Nat Chem Biol</source>
          <year>2006</year>
          <volume>2</volume>
          <fpage>406</fpage>
          <lpage>414</lpage>
          <pub-id pub-id-type="doi">10.1038/nchembio807</pub-id>
          <?supplied-pmid 16850017?>
          <pub-id pub-id-type="pmid">16850017</pub-id>
        </element-citation>
      </ref>
      <ref id="CR196">
        <label>196.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rouault</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Iron metabolism in the CNS: implications for neurodegenerative diseases</article-title>
          <source>Nat Rev Neurosci</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>551</fpage>
          <lpage>564</lpage>
          <pub-id pub-id-type="doi">10.1038/nrn3453</pub-id>
          <?supplied-pmid 23820773?>
          <pub-id pub-id-type="pmid">23820773</pub-id>
        </element-citation>
      </ref>
      <ref id="CR197">
        <label>197.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rucker</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>SV</given-names>
            </name>
          </person-group>
          <article-title>Role of H and L subunits in mouse ferritin</article-title>
          <source>J Biol Chem</source>
          <year>1996</year>
          <volume>271</volume>
          <fpage>33352</fpage>
          <lpage>33357</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.271.52.33352</pub-id>
          <?supplied-pmid 8969195?>
          <pub-id pub-id-type="pmid">8969195</pub-id>
        </element-citation>
      </ref>
      <ref id="CR198">
        <label>198.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saeed</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Otsuka</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Polavarapu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Karmali</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rostad</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pachura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Narula</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kolodgie</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Virmani</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Finn</surname>
              <given-names>AV</given-names>
            </name>
          </person-group>
          <article-title>Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <year>2012</year>
          <volume>32</volume>
          <fpage>299</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.111.240101</pub-id>
          <?supplied-pmid 22095982?>
          <pub-id pub-id-type="pmid">22095982</pub-id>
        </element-citation>
      </ref>
      <ref id="CR199">
        <label>199.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sager</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Hulsmans</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lavine</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Heidt</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Courties</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tricot</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>OF</given-names>
            </name>
            <name>
              <surname>Dahlman</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Borodovsky</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fitzgerald</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Weissleder</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Swirski</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Nahrendorf</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure</article-title>
          <source>Circ Res</source>
          <year>2016</year>
          <volume>119</volume>
          <fpage>853</fpage>
          <lpage>864</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309001</pub-id>
          <?supplied-pmid 27444755?>
          <pub-id pub-id-type="pmid">27444755</pub-id>
        </element-citation>
      </ref>
      <ref id="CR200">
        <label>200.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarkar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Seshadri</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tripoulas</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Ketterer</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Role of ceruloplasmin in macrophage iron efflux during hypoxia</article-title>
          <source>J Biol Chem</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>44018</fpage>
          <lpage>44024</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M304926200</pub-id>
          <?supplied-pmid 12952974?>
          <pub-id pub-id-type="pmid">12952974</pub-id>
        </element-citation>
      </ref>
      <ref id="CR201">
        <label>201.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schaer</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Schoedon</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Imhof</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kurrer</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Schaer</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin</article-title>
          <source>Circ Res</source>
          <year>2006</year>
          <volume>99</volume>
          <fpage>943</fpage>
          <lpage>950</lpage>
          <pub-id pub-id-type="doi">10.1161/01.RES.0000247067.34173.1b</pub-id>
          <?supplied-pmid 17008602?>
          <pub-id pub-id-type="pmid">17008602</pub-id>
        </element-citation>
      </ref>
      <ref id="CR202">
        <label>202.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schaer</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Vinchi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ingoglia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tolosano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Buehler</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
          <article-title>Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development</article-title>
          <source>Front Physiol</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>415</fpage>
          <pub-id pub-id-type="doi">10.3389/fphys.2014.00415</pub-id>
          <?supplied-pmid 25389409?>
          <pub-id pub-id-type="pmid">25389409</pub-id>
        </element-citation>
      </ref>
      <ref id="CR203">
        <label>203.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schaer</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Deuel</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Schildknecht</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mahmoudi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Garcia-Rubio</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Owczarek</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schauer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kissner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Banerjee</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Irwin</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Vallelian</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Buehler</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Schaer</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Haptoglobin preserves vascular nitric oxide signaling during hemolysis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2016</year>
          <volume>193</volume>
          <fpage>1111</fpage>
          <lpage>1122</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.201510-2058OC</pub-id>
          <?supplied-pmid 26694989?>
          <pub-id pub-id-type="pmid">26694989</pub-id>
        </element-citation>
      </ref>
      <ref id="CR204">
        <label>204.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schipper</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases</article-title>
          <source>Neurotox Res</source>
          <year>1999</year>
          <volume>1</volume>
          <fpage>57</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1007/BF03033339</pub-id>
          <?supplied-pmid 12835114?>
          <pub-id pub-id-type="pmid">12835114</pub-id>
        </element-citation>
      </ref>
      <ref id="CR205">
        <label>205.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schleicher</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Paduch</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Debus</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Obermeyer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Konig</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kling</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Ribechini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dudziak</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mougiakakos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Ostuni</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Korner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bogdan</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>TNF-mediated restriction of arginase 1 expression in myeloid cells triggers type 2 NO synthase activity at the site of infection</article-title>
          <source>Cell Rep</source>
          <year>2016</year>
          <volume>15</volume>
          <fpage>1062</fpage>
          <lpage>1075</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.001</pub-id>
          <?supplied-pmid 27117406?>
          <pub-id pub-id-type="pmid">27117406</pub-id>
        </element-citation>
      </ref>
      <ref id="CR206">
        <label>206.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schroll</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Eller</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Feistritzer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sonnweber</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Moser</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Rosenkranz</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Lipocalin-2 ameliorates granulocyte functionality</article-title>
          <source>Eur J Immunol</source>
          <year>2012</year>
          <volume>42</volume>
          <fpage>3346</fpage>
          <lpage>3357</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.201142351</pub-id>
          <?supplied-pmid 22965758?>
          <pub-id pub-id-type="pmid">22965758</pub-id>
        </element-citation>
      </ref>
      <ref id="CR207">
        <label>207.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>De Baetselier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martens</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Saeys</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>De Prijck</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lippens</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Abels</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schoonooghe</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Raes</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Devoogdt</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lambrecht</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Beschin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells</article-title>
          <source>Nat Commun</source>
          <year>2016</year>
          <volume>7</volume>
          <fpage>10321</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms10321</pub-id>
          <?supplied-pmid 26813785?>
          <pub-id pub-id-type="pmid">26813785</pub-id>
        </element-citation>
      </ref>
      <ref id="CR208">
        <label>208.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sender</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fuchs</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Milo</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Revised estimates for the number of human and bacteria cells in the body</article-title>
          <source>PLoS Biol</source>
          <year>2016</year>
          <volume>14</volume>
          <fpage>e1002533</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pbio.1002533</pub-id>
          <?supplied-pmid 27541692?>
          <pub-id pub-id-type="pmid">27541692</pub-id>
        </element-citation>
      </ref>
      <ref id="CR209">
        <label>209.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siegert</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Schodel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schatz</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Dettmer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dick</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kalucka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Franke</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ehrenschwender</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schley</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Beneke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sutter</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moll</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hellerbrand</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wielockx</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Katschinski</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Galy</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Koivunen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Oefner</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Bogdan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Willam</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jantsch</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Ferritin-mediated iron sequestration stabilizes hypoxia-inducible factor-1alpha upon LPS activation in the presence of ample oxygen</article-title>
          <source>Cell Rep</source>
          <year>2015</year>
          <volume>13</volume>
          <fpage>2048</fpage>
          <lpage>2055</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2015.11.005</pub-id>
          <?supplied-pmid 26628374?>
          <pub-id pub-id-type="pmid">26628374</pub-id>
        </element-citation>
      </ref>
      <ref id="CR210">
        <label>210.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>KD</given-names>
            </name>
          </person-group>
          <article-title>Iron metabolism at the host pathogen interface: lipocalin 2 and the pathogen-associated iroA gene cluster</article-title>
          <source>Int J Biochem Cell Biol</source>
          <year>2007</year>
          <volume>39</volume>
          <fpage>1776</fpage>
          <lpage>1780</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biocel.2007.07.003</pub-id>
          <?supplied-pmid 17714976?>
          <pub-id pub-id-type="pmid">17714976</pub-id>
        </element-citation>
      </ref>
      <ref id="CR211">
        <label>211.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soares</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Hamza</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Macrophages and iron metabolism</article-title>
          <source>Immunity</source>
          <year>2016</year>
          <volume>44</volume>
          <fpage>492</fpage>
          <lpage>504</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.016</pub-id>
          <?supplied-pmid 26982356?>
          <pub-id pub-id-type="pmid">26982356</pub-id>
        </element-citation>
      </ref>
      <ref id="CR212">
        <label>212.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soares</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The iron age of host-microbe interactions</article-title>
          <source>EMBO Rep</source>
          <year>2015</year>
          <volume>16</volume>
          <fpage>1482</fpage>
          <lpage>1500</lpage>
          <pub-id pub-id-type="doi">10.15252/embr.201540558</pub-id>
          <?supplied-pmid 26474900?>
          <pub-id pub-id-type="pmid">26474900</pub-id>
        </element-citation>
      </ref>
      <ref id="CR213">
        <label>213.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soe-Lin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Apte</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Andriopoulos</surname>
              <given-names>B</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Schranzhofer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kahawita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Garcia-Santos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ponka</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2009</year>
          <volume>106</volume>
          <fpage>5960</fpage>
          <lpage>5965</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0900808106</pub-id>
          <?supplied-pmid 19321419?>
          <pub-id pub-id-type="pmid">19321419</pub-id>
        </element-citation>
      </ref>
      <ref id="CR214">
        <label>214.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sohn</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Ghoti</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Breuer</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Rachmilewitz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Attar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cabantchik</surname>
              <given-names>ZI</given-names>
            </name>
          </person-group>
          <article-title>The role of endocytic pathways in cellular uptake of plasma non-transferrin iron</article-title>
          <source>Haematologica</source>
          <year>2012</year>
          <volume>97</volume>
          <fpage>670</fpage>
          <lpage>678</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2011.054858</pub-id>
          <?supplied-pmid 22180428?>
          <pub-id pub-id-type="pmid">22180428</pub-id>
        </element-citation>
      </ref>
      <ref id="CR215">
        <label>215.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Paudel</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Schipper</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Over-expression of heme oxygenase-1 promotes oxidative mitochondrial damage in rat astroglia</article-title>
          <source>J Cell Physiol</source>
          <year>2006</year>
          <volume>206</volume>
          <fpage>655</fpage>
          <lpage>663</lpage>
          <pub-id pub-id-type="doi">10.1002/jcp.20509</pub-id>
          <?supplied-pmid 16222706?>
          <pub-id pub-id-type="pmid">16222706</pub-id>
        </element-citation>
      </ref>
      <ref id="CR216">
        <label>216.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schipper</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Astroglia overexpressing heme oxygenase-1 predispose co-cultured PC12 cells to oxidative injury</article-title>
          <source>J Neurosci Res</source>
          <year>2007</year>
          <volume>85</volume>
          <fpage>2186</fpage>
          <lpage>2195</lpage>
          <pub-id pub-id-type="doi">10.1002/jnr.21367</pub-id>
          <?supplied-pmid 17526019?>
          <pub-id pub-id-type="pmid">17526019</pub-id>
        </element-citation>
      </ref>
      <ref id="CR217">
        <label>217.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hadziahmetovic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhong</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Dunaief</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina</article-title>
          <source>Free Radic Biol Med</source>
          <year>2012</year>
          <volume>53</volume>
          <fpage>64</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.04.020</pub-id>
          <?supplied-pmid 22579919?>
          <pub-id pub-id-type="pmid">22579919</pub-id>
        </element-citation>
      </ref>
      <ref id="CR218">
        <label>218.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zukor</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Liberman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tavitian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mui</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vali</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fillebeen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pantopoulos</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Guerquin-Kern</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Schipper</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Unregulated brain iron deposition in transgenic mice over-expressing HMOX1 in the astrocytic compartment</article-title>
          <source>J Neurochem</source>
          <year>2012</year>
          <volume>123</volume>
          <fpage>325</fpage>
          <lpage>336</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07914.x</pub-id>
          <?supplied-pmid 22881289?>
          <pub-id pub-id-type="pmid">22881289</pub-id>
        </element-citation>
      </ref>
      <ref id="CR219">
        <label>219.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stober</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Brode</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Popoff</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Blackwell</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Slc11a1, formerly Nramp1, is expressed in dendritic cells and influences major histocompatibility complex class II expression and antigen-presenting cell function</article-title>
          <source>Infect Immun</source>
          <year>2007</year>
          <volume>75</volume>
          <fpage>5059</fpage>
          <lpage>5067</lpage>
          <pub-id pub-id-type="doi">10.1128/IAI.00153-07</pub-id>
          <?supplied-pmid 17620357?>
          <pub-id pub-id-type="pmid">17620357</pub-id>
        </element-citation>
      </ref>
      <ref id="CR220">
        <label>220.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sullivan</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Iron in arterial plaque: modifiable risk factor for atherosclerosis</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2009</year>
          <volume>1790</volume>
          <fpage>718</fpage>
          <lpage>723</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbagen.2008.06.005</pub-id>
          <?supplied-pmid 18619522?>
          <pub-id pub-id-type="pmid">18619522</pub-id>
        </element-citation>
      </ref>
      <ref id="CR221">
        <label>221.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hoshino</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takaku</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Muto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tashiro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shibahara</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Alam</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Taketo</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Igarashi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene</article-title>
          <source>EMBO J</source>
          <year>2002</year>
          <volume>21</volume>
          <fpage>5216</fpage>
          <lpage>5224</lpage>
          <pub-id pub-id-type="doi">10.1093/emboj/cdf516</pub-id>
          <?supplied-pmid 12356737?>
          <pub-id pub-id-type="pmid">12356737</pub-id>
        </element-citation>
      </ref>
      <ref id="CR222">
        <label>222.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>YM</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>MZ</given-names>
            </name>
          </person-group>
          <article-title>The effects of deferoxamine on inhibition for microglia activation and protection of secondary nerve injury after intracerebral hemorrhage in rats</article-title>
          <source>Pak J Pharm Sci</source>
          <year>2016</year>
          <volume>29</volume>
          <fpage>1087</fpage>
          <lpage>1093</lpage>
          <?supplied-pmid 27383488?>
          <pub-id pub-id-type="pmid">27383488</pub-id>
        </element-citation>
      </ref>
      <ref id="CR223">
        <label>223.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swirski</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Nahrendorf</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure</article-title>
          <source>Science</source>
          <year>2013</year>
          <volume>339</volume>
          <fpage>161</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1230719</pub-id>
          <?supplied-pmid 23307733?>
          <pub-id pub-id-type="pmid">23307733</pub-id>
        </element-citation>
      </ref>
      <ref id="CR224">
        <label>224.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tacchini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gammella</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>De Ponti</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Recalcati</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cairo</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Role of HIF-1 and NF-kappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals</article-title>
          <source>J Biol Chem</source>
          <year>2008</year>
          <volume>283</volume>
          <fpage>20674</fpage>
          <lpage>20686</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M800365200</pub-id>
          <?supplied-pmid 18519569?>
          <pub-id pub-id-type="pmid">18519569</pub-id>
        </element-citation>
      </ref>
      <ref id="CR225">
        <label>225.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Techau</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Valdez-Taubas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Popoff</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Seaman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Blackwell</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Evolution of differences in transport function in Slc11a family members</article-title>
          <source>J Biol Chem</source>
          <year>2007</year>
          <volume>282</volume>
          <fpage>35646</fpage>
          <lpage>35656</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M707057200</pub-id>
          <?supplied-pmid 17932044?>
          <pub-id pub-id-type="pmid">17932044</pub-id>
        </element-citation>
      </ref>
      <ref id="CR226">
        <label>226.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fritsche</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ludwiczek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Garimorth</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bellmann-Weiler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The macrophage: a cellular factory at the interphase between iron and immunity for the control of infections</article-title>
          <source>Biometals</source>
          <year>2005</year>
          <volume>18</volume>
          <fpage>359</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="doi">10.1007/s10534-005-3710-1</pub-id>
          <?supplied-pmid 16158228?>
          <pub-id pub-id-type="pmid">16158228</pub-id>
        </element-citation>
      </ref>
      <ref id="CR227">
        <label>227.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mair</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rumpold</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zoller</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bellmann-Weiler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Niederegger</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Talasz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Autocrine formation of hepcidin induces iron retention in human monocytes</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>111</volume>
          <fpage>2392</fpage>
          <lpage>2399</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2007-05-090019</pub-id>
          <?supplied-pmid 18073346?>
          <pub-id pub-id-type="pmid">18073346</pub-id>
        </element-citation>
      </ref>
      <ref id="CR228">
        <label>228.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theurl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hochegger</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Obrist</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Subramaniam</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>van Rooijen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Schuemann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Kupffer cells modulate iron homeostasis in mice via regulation of hepcidin expression</article-title>
          <source>J Mol Med (Berl)</source>
          <year>2008</year>
          <volume>86</volume>
          <fpage>825</fpage>
          <lpage>835</lpage>
          <pub-id pub-id-type="doi">10.1007/s00109-008-0346-y</pub-id>
          <pub-id pub-id-type="pmid">18521557</pub-id>
        </element-citation>
      </ref>
      <ref id="CR229">
        <label>229.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Aigner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schroll</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sonnweber</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Eberwein</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Witcher</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Wroblewski</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Wurz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Datz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>113</volume>
          <fpage>5277</fpage>
          <lpage>5286</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-12-195651</pub-id>
          <?supplied-pmid 19293425?>
          <pub-id pub-id-type="pmid">19293425</pub-id>
        </element-citation>
      </ref>
      <ref id="CR230">
        <label>230.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Schroll</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sonnweber</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Willenbacher</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Eller</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Babitt</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Menhall</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gearing</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>4977</fpage>
          <lpage>4984</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-03-345066</pub-id>
          <?supplied-pmid 21730356?>
          <pub-id pub-id-type="pmid">21730356</pub-id>
        </element-citation>
      </ref>
      <ref id="CR231">
        <label>231.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hilgendorf</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tymoszuk</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Haschka</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Asshoff</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gerhardt</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Holderried</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sopper</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fenn</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Anzai</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rattik</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McAlpine</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wieghofer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Harder</surname>
              <given-names>NK</given-names>
            </name>
            <name>
              <surname>Chousterman</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Arvedson</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>McKee</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lutz</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Rezoagli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Babitt</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Berra</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Prinz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nahrendorf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Weissleder</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Swirski</surname>
              <given-names>FK</given-names>
            </name>
          </person-group>
          <article-title>On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver</article-title>
          <source>Nat Med</source>
          <year>2016</year>
          <volume>22</volume>
          <fpage>945</fpage>
          <lpage>951</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.4146</pub-id>
          <?supplied-pmid 27428900?>
          <pub-id pub-id-type="pmid">27428900</pub-id>
        </element-citation>
      </ref>
      <ref id="CR232">
        <label>232.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theurl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sterling</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Grieco</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Altamura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Galy</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Muckenthaler</surname>
              <given-names>MU</given-names>
            </name>
            <name>
              <surname>Dunaief</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Mice with hepcidin-resistant ferroportin accumulate iron in the retina</article-title>
          <source>FASEB J</source>
          <year>2016</year>
          <volume>30</volume>
          <fpage>813</fpage>
          <lpage>823</lpage>
          <pub-id pub-id-type="doi">10.1096/fj.15-276758</pub-id>
          <?supplied-pmid 26506980?>
          <pub-id pub-id-type="pmid">26506980</pub-id>
        </element-citation>
      </ref>
      <ref id="CR233">
        <label>233.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomsen</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Andersen</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Christoffersen</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Lichota</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moos</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Neurodegeneration with inflammation is accompanied by accumulation of iron and ferritin in microglia and neurons</article-title>
          <source>Neurobiol Dis</source>
          <year>2015</year>
          <volume>81</volume>
          <fpage>108</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="doi">10.1016/j.nbd.2015.03.013</pub-id>
          <?supplied-pmid 25801802?>
          <pub-id pub-id-type="pmid">25801802</pub-id>
        </element-citation>
      </ref>
      <ref id="CR234">
        <label>234.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Segawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>MerTK-mediated engulfment of pyrenocytes by central macrophages in erythroblastic islands</article-title>
          <source>Blood</source>
          <year>2014</year>
          <volume>123</volume>
          <fpage>3963</fpage>
          <lpage>3971</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2014-01-547976</pub-id>
          <?supplied-pmid 24659633?>
          <pub-id pub-id-type="pmid">24659633</pub-id>
        </element-citation>
      </ref>
      <ref id="CR235">
        <label>235.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tolosano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fagoonee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hirsch</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Baumann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Silengo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Altruda</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>100</volume>
          <fpage>4201</fpage>
          <lpage>4208</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2002-04-1270</pub-id>
          <?supplied-pmid 12393471?>
          <pub-id pub-id-type="pmid">12393471</pub-id>
        </element-citation>
      </ref>
      <ref id="CR236">
        <label>236.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torti</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Torti</surname>
              <given-names>SV</given-names>
            </name>
          </person-group>
          <article-title>Regulation of ferritin genes and protein</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>3505</fpage>
          <lpage>3516</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V99.10.3505</pub-id>
          <?supplied-pmid 11986201?>
          <pub-id pub-id-type="pmid">11986201</pub-id>
        </element-citation>
      </ref>
      <ref id="CR237">
        <label>237.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turrini</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mannu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cappadoro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ulliers</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Giribaldi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Arese</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Binding of naturally occurring antibodies to oxidatively and nonoxidatively modified erythrocyte band 3</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1994</year>
          <volume>1190</volume>
          <fpage>297</fpage>
          <lpage>303</lpage>
          <pub-id pub-id-type="doi">10.1016/0005-2736(94)90087-6</pub-id>
          <?supplied-pmid 8142429?>
          <pub-id pub-id-type="pmid">8142429</pub-id>
        </element-citation>
      </ref>
      <ref id="CR238">
        <label>238.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valenti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dongiovanni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Motta</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Swinkels</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Bonara</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rametta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Burdick</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Frugoni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fracanzani</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Fargion</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <year>2010</year>
          <volume>31</volume>
          <fpage>683</fpage>
          <lpage>690</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.110.214858</pub-id>
          <?supplied-pmid 21183736?>
          <pub-id pub-id-type="pmid">21183736</pub-id>
        </element-citation>
      </ref>
      <ref id="CR239">
        <label>239.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vanoaica</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Darshan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Richman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schumann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
          <article-title>Intestinal ferritin H is required for an accurate control of iron absorption</article-title>
          <source>Cell Metab</source>
          <year>2010</year>
          <volume>12</volume>
          <fpage>273</fpage>
          <lpage>282</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2010.08.003</pub-id>
          <?supplied-pmid 20816093?>
          <pub-id pub-id-type="pmid">20816093</pub-id>
        </element-citation>
      </ref>
      <ref id="CR240">
        <label>240.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vargas</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Pehar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cassina</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martinez-Palma</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Beckman</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Barbeito</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival</article-title>
          <source>J Biol Chem</source>
          <year>2005</year>
          <volume>280</volume>
          <fpage>25571</fpage>
          <lpage>25579</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M501920200</pub-id>
          <?supplied-pmid 15870071?>
          <pub-id pub-id-type="pmid">15870071</pub-id>
        </element-citation>
      </ref>
      <ref id="CR241">
        <label>241.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vinchi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Costa da Silva</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ingoglia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Petrillo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brinkman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Zuercher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cerwenka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tolosano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Muckenthaler</surname>
              <given-names>MU</given-names>
            </name>
          </person-group>
          <article-title>Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease</article-title>
          <source>Blood</source>
          <year>2016</year>
          <volume>127</volume>
          <fpage>473</fpage>
          <lpage>486</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2015-08-663245</pub-id>
          <?supplied-pmid 26675351?>
          <pub-id pub-id-type="pmid">26675351</pub-id>
        </element-citation>
      </ref>
      <ref id="CR242">
        <label>242.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pantopoulos</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Regulation of cellular iron metabolism</article-title>
          <source>Biochem J</source>
          <year>2011</year>
          <volume>434</volume>
          <fpage>365</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="doi">10.1042/BJ20101825</pub-id>
          <?supplied-pmid 21348856?>
          <pub-id pub-id-type="pmid">21348856</pub-id>
        </element-citation>
      </ref>
      <ref id="CR243">
        <label>243.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pantopoulos</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Iron-dependent degradation of IRP2 requires its C-terminal region and IRP structural integrity</article-title>
          <source>BMC Mol Biol</source>
          <year>2008</year>
          <volume>9</volume>
          <fpage>15</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2199-9-15</pub-id>
          <?supplied-pmid 18226225?>
          <pub-id pub-id-type="pmid">18226225</pub-id>
        </element-citation>
      </ref>
      <ref id="CR244">
        <label>244.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Marchand</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Van Lente</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Serum haptoglobin concentrations in concurrent hemolysis and acute-phase reaction</article-title>
          <source>Clin Chem</source>
          <year>1987</year>
          <volume>33</volume>
          <fpage>1265</fpage>
          <lpage>1266</lpage>
          <?supplied-pmid 3109782?>
          <pub-id pub-id-type="pmid">3109782</pub-id>
        </element-citation>
      </ref>
      <ref id="CR245">
        <label>245.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinberg</surname>
              <given-names>ED</given-names>
            </name>
          </person-group>
          <article-title>Iron availability and infection</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2009</year>
          <volume>1790</volume>
          <fpage>600</fpage>
          <lpage>605</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbagen.2008.07.002</pub-id>
          <?supplied-pmid 18675317?>
          <pub-id pub-id-type="pmid">18675317</pub-id>
        </element-citation>
      </ref>
      <ref id="CR246">
        <label>246.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Genetic mechanisms and modifying factors in hereditary hemochromatosis</article-title>
          <source>Nat Rev Gastroenterol Hepatol</source>
          <year>2010</year>
          <volume>7</volume>
          <fpage>50</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1038/nrgastro.2009.201</pub-id>
          <?supplied-pmid 19918260?>
          <pub-id pub-id-type="pmid">19918260</pub-id>
        </element-citation>
      </ref>
      <ref id="CR247">
        <label>247.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schaible</surname>
              <given-names>UE</given-names>
            </name>
          </person-group>
          <article-title>Macrophage defense mechanisms against intracellular bacteria</article-title>
          <source>Immunol Rev</source>
          <year>2015</year>
          <volume>264</volume>
          <fpage>182</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="doi">10.1111/imr.12266</pub-id>
          <?supplied-pmid 25703560?>
          <pub-id pub-id-type="pmid">25703560</pub-id>
        </element-citation>
      </ref>
      <ref id="CR248">
        <label>248.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wessling-Resnick</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Iron imports. III. Transfer of iron from the mucosa into circulation</article-title>
          <source>Am J Physiol Gastrointest Liver Physiol</source>
          <year>2006</year>
          <volume>290</volume>
          <fpage>G1</fpage>
          <lpage>G6</lpage>
          <pub-id pub-id-type="doi">10.1152/ajpgi.00415.2005</pub-id>
          <?supplied-pmid 16354771?>
          <pub-id pub-id-type="pmid">16354771</pub-id>
        </element-citation>
      </ref>
      <ref id="CR249">
        <label>249.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wessling-Resnick</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Nramp1 and other transporters involved in metal withholding during infection</article-title>
          <source>J Biol Chem</source>
          <year>2015</year>
          <volume>290</volume>
          <fpage>18984</fpage>
          <lpage>18990</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.R115.643973</pub-id>
          <?supplied-pmid 26055722?>
          <pub-id pub-id-type="pmid">26055722</pub-id>
        </element-citation>
      </ref>
      <ref id="CR250">
        <label>250.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>White</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Bresciani</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Samuel</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Campagna</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bishop</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Calicchio</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Lapierre</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fleming</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Hamza</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>HRG1 is essential for heme transport from the phagolysosome of macrophages during erythrophagocytosis</article-title>
          <source>Cell Metab</source>
          <year>2013</year>
          <volume>17</volume>
          <fpage>261</fpage>
          <lpage>270</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2013.01.005</pub-id>
          <?supplied-pmid 23395172?>
          <pub-id pub-id-type="pmid">23395172</pub-id>
        </element-citation>
      </ref>
      <ref id="CR251">
        <label>251.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willekens</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Werre</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kruijt</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Roerdinkholder-Stoelwinder</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Groenen-Dopp</surname>
              <given-names>YA</given-names>
            </name>
            <name>
              <surname>van den Bos</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Bosman</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>van Berkel</surname>
              <given-names>TJ</given-names>
            </name>
          </person-group>
          <article-title>Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>105</volume>
          <fpage>2141</fpage>
          <lpage>2145</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2004-04-1578</pub-id>
          <?supplied-pmid 15550489?>
          <pub-id pub-id-type="pmid">15550489</pub-id>
        </element-citation>
      </ref>
      <ref id="CR252">
        <label>252.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Yeoh</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Saha</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Patterson</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Vijay-Kumar</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Modulation of urinary siderophores by the diet, gut microbiota and inflammation in mice</article-title>
          <source>J Nutr Biochem</source>
          <year>2016</year>
          <volume>41</volume>
          <fpage>25</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jnutbio.2016.11.014</pub-id>
          <?supplied-pmid 27951517?>
          <pub-id pub-id-type="pmid">27951517</pub-id>
        </element-citation>
      </ref>
      <ref id="CR253">
        <label>253.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>An</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lowell</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Cyster</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Splenic dendritic cells survey red blood cells for missing self-CD47 to trigger adaptive immune responses</article-title>
          <source>Immunity</source>
          <year>2015</year>
          <volume>43</volume>
          <fpage>764</fpage>
          <lpage>775</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2015.08.021</pub-id>
          <?supplied-pmid 26453377?>
          <pub-id pub-id-type="pmid">26453377</pub-id>
        </element-citation>
      </ref>
      <ref id="CR254">
        <label>254.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kawane</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Koike</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Uchiyama</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Phosphatidylserine-dependent engulfment by macrophages of nuclei from erythroid precursor cells</article-title>
          <source>Nature</source>
          <year>2005</year>
          <volume>437</volume>
          <fpage>754</fpage>
          <lpage>758</lpage>
          <pub-id pub-id-type="doi">10.1038/nature03964</pub-id>
          <?supplied-pmid 16193055?>
          <pub-id pub-id-type="pmid">16193055</pub-id>
        </element-citation>
      </ref>
      <ref id="CR255">
        <label>255.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Differences in vulnerability of neurons and astrocytes to heme oxygenase-1 modulation: implications for mitochondrial ferritin</article-title>
          <source>Sci Rep</source>
          <year>2016</year>
          <volume>6</volume>
          <fpage>24200</fpage>
          <pub-id pub-id-type="doi">10.1038/srep24200</pub-id>
          <?supplied-pmid 27097841?>
          <pub-id pub-id-type="pmid">27097841</pub-id>
        </element-citation>
      </ref>
      <ref id="CR256">
        <label>256.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yuan</surname>
              <given-names>XM</given-names>
            </name>
          </person-group>
          <article-title>Apoptotic macrophage-derived foam cells of human atheromas are rich in iron and ferritin, suggesting iron-catalysed reactions to be involved in apoptosis</article-title>
          <source>Free Radic Res</source>
          <year>1999</year>
          <volume>30</volume>
          <fpage>221</fpage>
          <lpage>231</lpage>
          <pub-id pub-id-type="doi">10.1080/10715769900300241</pub-id>
          <?supplied-pmid 10711792?>
          <pub-id pub-id-type="pmid">10711792</pub-id>
        </element-citation>
      </ref>
      <ref id="CR257">
        <label>257.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zanganeh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hutter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Spitler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lenkov</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Mahmoudi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pajarinen</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Nejadnik</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Goodman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moseley</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Coussens</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Daldrup-Link</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
          <article-title>Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues</article-title>
          <source>Nat Nanotechnol</source>
          <year>2016</year>
          <volume>11</volume>
          <fpage>986</fpage>
          <lpage>994</lpage>
          <pub-id pub-id-type="doi">10.1038/nnano.2016.168</pub-id>
          <?supplied-pmid 27668795?>
          <pub-id pub-id-type="pmid">27668795</pub-id>
        </element-citation>
      </ref>
      <ref id="CR258">
        <label>258.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeineh</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kitzler</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Hammond</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rutt</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
          <article-title>Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease</article-title>
          <source>Neurobiol Aging</source>
          <year>2015</year>
          <volume>36</volume>
          <fpage>2483</fpage>
          <lpage>2500</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.05.022</pub-id>
          <?supplied-pmid 26190634?>
          <pub-id pub-id-type="pmid">26190634</pub-id>
        </element-citation>
      </ref>
      <ref id="CR259">
        <label>259.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>An</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ning</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Nie</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Knutson</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>1912</fpage>
          <lpage>1922</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-01-330324</pub-id>
          <?supplied-pmid 21705499?>
          <pub-id pub-id-type="pmid">21705499</pub-id>
        </element-citation>
      </ref>
      <ref id="CR260">
        <label>260.</label>
        <mixed-citation publication-type="other">Zhang Z, Song Y, Li D, Zhu H, Liang R, Gu Y, Pang Y, Qi J, Wu H, Wang J (2017) Distinct role of heme oxygenase-1 in early- and late-stage intracerebral hemorrhage in 12-month-old mice. J Cereb Blood Flow Metab 37:25–38</mixed-citation>
      </ref>
      <ref id="CR261">
        <label>261.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cwanger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dunaief</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>A high serum iron level causes mouse retinal iron accumulation despite an intact blood-retinal barrier</article-title>
          <source>Am J Pathol</source>
          <year>2014</year>
          <volume>184</volume>
          <fpage>2862</fpage>
          <lpage>2867</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajpath.2014.07.008</pub-id>
          <?supplied-pmid 25174877?>
          <pub-id pub-id-type="pmid">25174877</pub-id>
        </element-citation>
      </ref>
      <ref id="CR262">
        <label>262.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Manolagas</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Steap4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron/reactive oxygen species (ROS) levels and cAMP response element-binding protein (CREB) activation</article-title>
          <source>J Biol Chem</source>
          <year>2013</year>
          <volume>288</volume>
          <fpage>30064</fpage>
          <lpage>30074</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M113.478750</pub-id>
          <?supplied-pmid 23990467?>
          <pub-id pub-id-type="pmid">23990467</pub-id>
        </element-citation>
      </ref>
      <ref id="CR263">
        <label>263.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zohn</surname>
              <given-names>IE</given-names>
            </name>
            <name>
              <surname>De Domenico</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Pollock</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Goodman</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Sanchez</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Niswander</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>109</volume>
          <fpage>4174</fpage>
          <lpage>4180</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2007-01-066068</pub-id>
          <?supplied-pmid 17289807?>
          <pub-id pub-id-type="pmid">17289807</pub-id>
        </element-citation>
      </ref>
      <ref id="CR264">
        <label>264.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zoller</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>McKie</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Duodenal cytochrome b and hephaestin expression in patients with iron deficiency and hemochromatosis</article-title>
          <source>Gastroenterology</source>
          <year>2003</year>
          <volume>125</volume>
          <fpage>746</fpage>
          <lpage>754</lpage>
          <pub-id pub-id-type="doi">10.1016/S0016-5085(03)01063-1</pub-id>
          <?supplied-pmid 12949720?>
          <pub-id pub-id-type="pmid">12949720</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362663</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Mater Sci Mater Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Mater Sci Mater Med</journal-id>
      <journal-title-group>
        <journal-title>Journal of Materials Science. Materials in Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0957-4530</issn>
      <issn pub-type="epub">1573-4838</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>New York</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362663</article-id>
      <article-id pub-id-type="pmcid">PMC5362663</article-id>
      <article-id pub-id-type="pmc-uid">5362663</article-id>
      <article-id pub-id-type="pmid">28332156</article-id>
      <article-id pub-id-type="publisher-id">5882</article-id>
      <article-id pub-id-type="doi">10.1007/s10856-017-5882-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Clinical Applications of Biomaterials</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The pathology of failed McKee-Farrar implants: correlation with modern metal-on-metal-implant failure</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Munemoto</surname>
            <given-names>Mitsuru</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Grammatopoulos</surname>
            <given-names>George</given-names>
          </name>
          <address>
            <phone>+441865 227457</phone>
            <email>george.grammatopoulos@ndorms.ox.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tanaka</surname>
            <given-names>Yasuhito</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gibbons</surname>
            <given-names>Max</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Athanasou</surname>
            <given-names>Nicholas A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution>Nuffield Department Orthopaedics Rheumatology &amp; Musculoskeletal Sciences (NDORMS), </institution><institution>University of Oxford, </institution></institution-wrap>Windmill Road, Oxford, UK </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 782X</institution-id><institution-id institution-id-type="GRID">grid.410814.8</institution-id><institution>Dept of Orthopaedic Surgery, </institution><institution>Nara medical University, </institution></institution-wrap>Kashihara-City, 634-8522 Nara Japan </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0224 3960</institution-id><institution-id institution-id-type="GRID">grid.461589.7</institution-id><institution/><institution>Nuffield Orthopaedic Centre, </institution></institution-wrap>Windmill Road, Headington, Oxford, OX3 7LD UK </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>22</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>28</volume>
      <issue>5</issue>
      <elocation-id>66</elocation-id>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>12</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>3</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Abstract</title>
          <p>The McKee-Farrar (MF) prosthesis was the first widely used total hip replacement (THR) to employ a metal-on-metal (MoM) articulation. These implants had a high rate of early aseptic loosening but a number achieved good long-term implant survival, stimulating the reintroduction of second and third generation implants of this type. In this study we analysed archival histopathology of periprosthetic tissues in twenty cases of MF aseptic implant failure to determine if there was evidence of an innate and adaptive immune response similar to that seen in modern MoM implants. The presence of macrophages, the extent of necrosis and the ALVAL response were graded semi-quantitatively. Variable but in most cases extensive tissue necrosis was associated with a heavy macrophage response to Cobalt-Chrome (Co-Cr) wear particles in periprosthetic tissues; most cases also contained evidence of a predominantly lymphocyte response which in eight cases was moderate or heavy (Oxford Grade 2/3). Our findings show that inflammatory and necrotic changes to deposition of Co-Cr wear particles are found in periprosthetic tissues of failed MF implants, indicating that there is an innate and adaptive response similar to that noted in second/third generation MoM implants; they also suggest that the pathobiological response to metal wear particles is likely to have contributed to MF implant failure in these cases.</p>
        </sec>
        <sec>
          <title>Graphical Abstract</title>
          <p>
<inline-graphic xlink:href="10856_2017_5882_Figa_HTML.gif" id="d29e247"/>
</p>
        </sec>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer Science+Business Media New York 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>G.K. McKee and J Watson-Farrar developed a metal on metal (MoM) hip joint prosthesis for total hip replacement (THR) in the 1960s [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR4">4</xref>]. Large numbers of these metal-on-metal (MoM) implants were implanted but they eventually fell out of favour when superior outcomes were reported with the low-friction Charnley metal on polyethylene (MoP) prosthesis. It was noted that McKee-Farrar (MF) hip replacements had a high rate of aseptic loosening in the first 10 years; McKee stopped using the all-metal system in 1972 [<xref ref-type="bibr" rid="CR1">1</xref>]. Failure of MF implants was thought to be due mainly to poor implant design [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The stem of the femoral component was curved with narrow medial and lateral borders and had multiple sharp corners [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. These features resulted in areas of high localised stress within the cement mantle; the broad neck of the MF femoral component was also prone to impingement against the metal rim of the acetabular component. The original surgical technique for implantation did not include reaming and routine deepening of the acetabulum, and, as a result, the components did not have adequate lateral bone cover [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Despite these shortcomings, some MF hip replacements have shown impressive survival outcomes with several lasting more than 20 years [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR10">10</xref>].</p>
      <p>The relative success of some MF and other first-generation MoM implant designs stimulated the drive to develop second- and third-generation MoM hip implants [<xref ref-type="bibr" rid="CR11">11</xref>]. The modern MoM implants are composed of a cobalt-chrome molybdenum alloy similar to that used in the MF implant. Although some second and third-generation MoM designs have performed reasonably, a number have been associated with implant failure [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. This is considered to be due in large measure to the pathobiological response to deposition of cobalt–chrome (Co–Cr) wear particles in periprosthetic tissues in which extensive necrosis an innate and foreign body macrophage response to Co–Cr wear is often seen as well as prominent lymphoid infiltrate which is characteristically perivascular in distribution; this has been termed ALVAL (aseptic lymphocyte-dominated vasculitis-associated lesion) and is believed to reflect the adaptive immune response to Co–Cr wear in periprosthetic tissues [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR21">21</xref>].</p>
      <p>There are relatively few reports on the histopathology of failed MF hip implants; some of these noted pathological changes similar to those reported in second- and third-generation MoM hip implants [<xref ref-type="bibr" rid="CR22">22</xref>–<xref ref-type="bibr" rid="CR27">27</xref>]. With one exception [<xref ref-type="bibr" rid="CR22">22</xref>], these studies examined only a handful of cases. In this study, we have analysed histopathological findings in periprosthetic tissues around twenty failed MF hip implants with regard to the inflammatory and necrotic changes known to be associated with second- and third-generation MoM hip implants. Our aim has been to determine whether Co-Cr particles from MF implants induced a similar pathobiological response in periprosthetic tissues, particularly with regard to the necrotic and inflammatory changes that reflect the innate (non-specific) and adaptive (specific) host immune response to deposition of Co–Cr wear particles.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <p>Periprosthetic tissue histology from twenty cases of failed MF hip implants undergoing revision arthroplasty for aseptic loosening were obtained from the files of the Histopathology Department, Nuffield Orthopaedic Centre, Oxford. The cases studied included 15 females and 5 males; the age range of the patients was 55 to 84 years. The original hip arthroplasty procedure was carried out between 1968 and 1974 and revision surgery was carried out between 1975 and 2008. There was limited clinical information and radiology for most cases was not available. Implant duration was 2 to 41 years. Clinical information provided on the pathology forms noted that the specimens were associated with “failure” of an MF hip implant: eleven of the cases referred to “loosening” of an MF implant. Two cases of sepsis were excluded. Details of patient age and implant duration are shown in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Case details and pathological findings in 20 failed McKee–Farrar hip implants</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4">Case details</th><th colspan="3">Pathological findings</th></tr><tr><th>Case No.</th><th>Sex</th><th>Age at revision</th><th>Implant duration (year)</th><th>Necrosis</th><th>Macrophage</th><th>Oxford ALVAL score</th></tr></thead><tbody><tr><td>1</td><td>F</td><td>73</td><td>3</td><td>3</td><td>3</td><td>3</td></tr><tr><td>2</td><td>F</td><td>71</td><td>3</td><td>3</td><td>3</td><td>3</td></tr><tr><td>3</td><td>M</td><td>39</td><td>3</td><td>3</td><td>3</td><td>0</td></tr><tr><td>4</td><td>F</td><td>44</td><td>4</td><td>3</td><td>3</td><td>3</td></tr><tr><td>5</td><td>F</td><td>63</td><td>4</td><td>3</td><td>3</td><td>0</td></tr><tr><td>6</td><td>F</td><td>84</td><td>4</td><td>2</td><td>2</td><td>1</td></tr><tr><td>7</td><td>F</td><td>68</td><td>5</td><td>3</td><td>2</td><td>1</td></tr><tr><td>8</td><td>F</td><td>72</td><td>5</td><td>3</td><td>3</td><td>3</td></tr><tr><td>9</td><td>F</td><td>83</td><td>5</td><td>3</td><td>2</td><td>1</td></tr><tr><td>10</td><td>F</td><td>85</td><td>7</td><td>2</td><td>3</td><td>2</td></tr><tr><td>11</td><td>M</td><td>62</td><td>7</td><td>3</td><td>3</td><td>1</td></tr><tr><td>12</td><td>F</td><td>70</td><td>9</td><td>3</td><td>3</td><td>2</td></tr><tr><td>13</td><td>M</td><td>73</td><td>9</td><td>3</td><td>3</td><td>3</td></tr><tr><td>14</td><td>M</td><td>55</td><td>14</td><td>3</td><td>1</td><td>0</td></tr><tr><td>15</td><td>F</td><td>84</td><td>25</td><td>3</td><td>3</td><td>1</td></tr><tr><td>16</td><td>F</td><td>61</td><td>27</td><td>3</td><td>3</td><td>1</td></tr><tr><td>17</td><td>F</td><td>78</td><td>28</td><td>3</td><td>3</td><td>1</td></tr><tr><td>18</td><td>M</td><td>68</td><td>30</td><td>3</td><td>3</td><td>1</td></tr><tr><td>19</td><td>F</td><td>57</td><td>33</td><td>3</td><td>3</td><td>1</td></tr><tr><td>20</td><td>F</td><td>74</td><td>41</td><td>3</td><td>3</td><td>2</td></tr></tbody></table></table-wrap>
</p>
      <p>The tissues analysed were the joint capsule in all cases and the femoral and/or acetabular membrane in 10 cases. The tissues were fixed in 10% formalin, embedded in paraffin wax, sectioned and stained with haematoxylin-eosin. Tissue necrosis and the extent of the inflammatory cell infiltrate in MoM periprosthetic tissues was assessed semi-quantitatively by histology as previously described [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The number of macrophages was scored as 0 (absent), 1+ (few), 2+ (many), 3+ (abundant); necrosis was scored as 0 (absent), 1+ (scattered small necrotic areas), 2+ (frequent small or large necrotic areas: up to 25% tissue involvement), 3+ (extensive necrosis: more than 25% tissue involvement). The perivascular lymphoid infiltrate was graded using the Oxford ALVAL scoring system [<xref ref-type="bibr" rid="CR16">16</xref>], this has been shown to correlate well with the Campbell scoring system [<xref ref-type="bibr" rid="CR28">28</xref>]. In the Oxford System, grade 0 = no evidence of perivascular lymphocyte infiltrate; grade 1 = little evidence of a perivascular lymphocytic infiltrate, with lymphocyte cuffing of vessels being fewer than five cells in thickness; grade 2 = several perivascular lymphoid aggregates, with lymphocytic cuffing of vessels being five to ten cells in thickness; and grade 3 = numerous large perivascular lymphoid aggregates, with lymphocyte cuffing around vessels being more than ten cells in thickness.</p>
      <p>Immunohistochemistry was carried out using an indirect immunoperoxidase technique to determine the antigenic phenotype of phagocytic macrophages and lymphoid cells in the inflammatory infiltrate of periprosthetic tissues. The list of monoclonal antibodies used in this study and their antigen specificity is shown in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Antigen specificity of monoclonal antibodies used in this study</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Antibody (clone)</th><th>Antigen specificity</th><th>Source</th></tr></thead><tbody><tr><td>F7.2.38</td><td>CD3: T cells</td><td>Dakopatts</td></tr><tr><td>NCL-L-CD4-368</td><td>CD4: T helper cells</td><td>Novocastra</td></tr><tr><td>CR/144B</td><td>CD8: T suppressor cells</td><td>Dakopatts</td></tr><tr><td>CD14-223</td><td>CD14: monocytes macrophages</td><td>Novocastra</td></tr><tr><td>L26</td><td>CD20: B cells</td><td>Dakopatts</td></tr><tr><td>KP1</td><td>CD68: monocytes macrophages</td><td>Dakopatts</td></tr><tr><td>CR3/43</td><td>HLA-DR</td><td>Dakopatts</td></tr><tr><td>124</td><td>BCL-2 oncoprotein: apoptosis</td><td>Dakopatts</td></tr><tr><td>NCL-CD163</td><td>CD163: macrophages</td><td>Novocastra</td></tr></tbody></table></table-wrap>
</p>
    </sec>
    <sec id="Sec3" sec-type="results">
      <title>Results</title>
      <p>The most notable feature seen in the joint capsule and periprosthetic fibrous tissue membrane of all MF implant failures was a variable but generally extensive degree of surface tissue necrosis associated with an underlying heavy foreign body macrophage infiltrate (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). The tissues had a prominent zone of surface necrosis in which there were viable macrophages and occasional giant cells containing Co-Cr particles; some macrophages showed changes of apoptosis such as nuclear pyknosis (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). Beneath this zone there was a prominent macrophage infiltrate. Viable macrophages had vesicular nuclei and discrete plump cytoplasm which contained granular brown or black particles, indicating Co–Cr wear particle phagocytosis (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). On the surface, there was macrophage necrosis and apoptosis, evident as loss of cytoplasmic outline, nuclear pyknosis and release of wear particles into the degenerate tissue matrix (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). Histological findings regarding the extent of necrosis and macrophage infiltration are summarised in Table <xref rid="Tab1" ref-type="table">1</xref>. A heavy eosinophil polymorph infiltrate was noted in two specimens. A few neutrophil polymorphs (less than 1 per high power field on average) were noted in two specimens.<fig id="Fig1"><label>Fig. 1</label><caption><p>
<bold>a</bold> Histology of periprosthetic fibrous tissue membrane from a failed MF implant showing necrosis on the surface with underlying foreign body macrophage infiltrate. <bold>b</bold> High power view of area of surface necrosis in 1a. showing a viable giant cell and macrophages with vesicular nuclei (some marked by thick <italic>arrows</italic>); phagocytosed aggregates of metal wear particles are evident as a <italic>black</italic> dot in the cytoplasm. There are also apoptotic macrophages with pyknotic nuclei (some marked by thin <italic>arrows</italic>)</p></caption><graphic xlink:href="10856_2017_5882_Fig1_HTML" id="d29e994"/></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Histology of periprosthetic tissue from a failed MF implant showing: <bold>a</bold> viable macrophages with phagocytosed (<italic>brown-black</italic>) Co–Cr wear particles of variable size (some arrowed) <bold>b</bold> necrotic and apoptotic macrophages with released wear particles (some arrowed) (color figure online)</p></caption><graphic xlink:href="10856_2017_5882_Fig2_HTML" id="d29e1013"/></fig>
</p>
      <p>In all but two of the cases, the sampled periprosthetic tissues contained a scattered, focally heavy lymphocyte infiltrate (Table <xref rid="Tab1" ref-type="table">1</xref>); plasma cells were seen in three cases. Eight cases (some of which were associated with relatively short implant duration) had a moderate or heavy lymphocyte infiltrate with Grade 2/3 Oxford ALVAL scores (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). In nine cases the Oxford ALVAL score was Grade 1. There were three cases in which The Oxford ALVAL score was 0; in these cases, specimens of the capsule were composed entirely of necrotic tissue with only a few scattered macrophages and no obvious lymphocyte infiltrate.<fig id="Fig3"><label>Fig. 3</label><caption><p>Histology of periprosthetic tissue membrane from a failed MF implant showing: <bold>a</bold> a zone of surface necrosis beneath which there are several perivascular lymphoid aggregates (some arrowed). <bold>b</bold> High power view of lymphoid aggregates in 3a</p></caption><graphic xlink:href="10856_2017_5882_Fig3_HTML" id="d29e1037"/></fig>
</p>
      <p>Immunohistochemistry showed that the mononuclear phagocytic cells containing metal wear particles strongly expressed the monocyte/macrophage markers CD14, CD68 (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>) and CD163; these cells also strongly expressed HLA-DR. Lymphocytes in the perivascular lymphoid aggregates expressed the T-cell marker CD3 (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). A few cells also expressed the B-cell marker CD20. Most CD3+ T cells also expressed CD4, a marker of T-helper cells, with a minority of cells weakly expressing CD8, which is characteristic of T-cytotoxic/suppressor cells. Weak expression of the apoptosis marker bcl-2 was noted in macrophages and some lymphoid cells.<fig id="Fig4"><label>Fig. 4</label><caption><p>Immunohistochemistry of periprosthetic tissue membrane from a failed MF implant showing <bold>a</bold> staining of foreign body macrophages for CD68 (pan-macrophage marker) and <bold>b</bold> staining of perivascular lymphocytes for CD3 (T cell marker)</p></caption><graphic xlink:href="10856_2017_5882_Fig4_HTML" id="d29e1061"/></fig>
</p>
    </sec>
    <sec id="Sec4" sec-type="discussion">
      <title>Discussion</title>
      <p>Although the MoM MF total hip prosthesis was characterised by a higher rate of early- and intermediate-term aseptic loosening than the MoP Charnley implant, a few studies reported similar rates of long-term implant loosening. Jacobsson et al. [<xref ref-type="bibr" rid="CR9">9</xref>] reported a 20 year implant survival of 77% in 107 consecutive MF arthroplasties; this compared with 73% for a similar population with the Charnley prosthesis. Brown et al. [<xref ref-type="bibr" rid="CR29">29</xref>] reported a 28 year MF implant survivorship of 74% and noted that the reported survival of MoM total hip arthroplasties was 53–89% at 10 to 15 years while that of the Charnley arthroplasty was 75–84% over 20 to 30 years. A review of short-term outcomes of the first 100 cases that received a MF hip implant in Oxford reported good or excellent results in 90% of cases [<xref ref-type="bibr" rid="CR30">30</xref>]. A subsequent review comparing results of the MF and the Charnley total hip prosthesis in over 200 cases reported superior clinical outcomes and fewer complications with the Charnley implant [<xref ref-type="bibr" rid="CR31">31</xref>]. Amstutz and Grigoris reviewed the clinical results of MF and other first- generation MoM hip implants and noted, as in the present study, some impressive outcomes [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
      <p>The main cause of early MF hip implant failure was aseptic loosening. This complication was ascribed mainly to the MF implant being biomechanically at a disadvantage compared with the Charnley implant in design terms [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. A number of reports, however, noted pathological changes in periprosthetic tissues that were proposed as contributory factors to the development of implant loosening. Evans et al. [<xref ref-type="bibr" rid="CR24">24</xref>] reported necrosis of bone and capsular tissue around MoM hip implants and noted a correlation with the severity and extent of obliterative changes in vessels; it was suggested that these changes occurred as a result of a sensitivity reaction to Co-Cr ions derived from metal wear particles. Winter [<xref ref-type="bibr" rid="CR27">27</xref>] described necrosis in tissues around retrieved MoM hip replacements with particles deposited in acellular collagen and in phagocytic cells Jones et al. [<xref ref-type="bibr" rid="CR26">26</xref>] also reported necrosis of bone and capsular tissue from retrieved first-generation MoM prostheses and attributed this to a toxic and hypersensitivity reaction to cobalt which he suggested caused an avascular phenomenon. The study of Brown et al. [<xref ref-type="bibr" rid="CR22">22</xref>] noted significant tissue necrosis and a chronic inflammatory cell infiltrate in soft tissue and bone; metallic debris within cells and a prominent lymphocytic infiltrate with occasional plasma cells were also identified. Doorn et al. [<xref ref-type="bibr" rid="CR23">23</xref>] and Howie et al. [<xref ref-type="bibr" rid="CR25">25</xref>] also noted tissue necrosis and the presence of lymphocytes in retrieved periprosthetic tissues around MF and other first-generation MoM hip implants. Willert et al. [<xref ref-type="bibr" rid="CR32">32</xref>], investigating (non-MF) failed first-generation MoM total hip arthroplasties, also noted a lymphocyte response in peri-implant tissues. Other studies allude to the presence of macrophages and giant cells, but do not mention tissue necrosis or a lymphoid infiltrate [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR35">35</xref>].</p>
      <p>The MF hip implant was composed of a similar Co–Cr alloy to that used in second- and third-generation MoM implants. In this study we show that periprosthetic tissues around MF implants exhibit similar pathological changes to those reported around modern MoM implants. Cell and tissue necrosis, a heavy infiltrate of macrophages in response to Co–Cr wear particles and ALVAL-like lymphoid aggregates, commonly seen in failed modern MoM hip implants [<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], were also noted in failed MF hip implants with approximately 40% of cases exhibiting a Grade 2/3 ALVAL response.</p>
      <p>The MoM articulation tends to produce less volumetric wear than other implant combinations such as MoP; however, the number of wear particles generated is an order of magnitude higher, the particles being much smaller and therefore much more numerous per unit volume [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. The nanometre-size Co–Cr particles induce a profound innate and adaptive immune response. Macrophage phagocytosis of metal wear particles is probably the major factor in causing the extensive necrosis in MoM periprosthetic tissues. Co–Cr particles are subject to corrosion and produce high levels of metal ions which are cytotoxic, causing apoptosis and necrosis of macrophages that release lysosomal enzymes into the tissues. Metal ions can also act as haptens, combining with cell and tissue proteins to induce a specific cell-mediated delayed hypersensitivity immune response. This is evidenced histologically in MoM implants by the presence of a predominantly T lymphocyte infiltrate which is often perivascular in nature [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. T cells predominated in the lymphoid aggregates seen in failed MF cases, suggesting that the adaptive immune response to metal wear is similar.</p>
      <p>The presence of profound necrotic and inflammatory changes in the MF periprosthetic tissues would indicate that Co–Cr wear particle-induced hypersensitivity and cytotoxicity are likely to have contributed, at least in part, to implant failure. A major limitation of our study is that, due to the many years that have elapsed, we do not have full clinical and radiological information on the cases we have analysed. Pseudotumours have been strongly associated with failure of modern MoM hip implants [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] and, though not seen in our cases, there are two reports of probable pseudotumour-like lesions associated with MF implant failure [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>We would like to thank Sarah Turton for typing the manuscript, and Professor G Bentley and Professor J. Kenwright for helpful discussions on the cases included in this study. The authors acknowledge the support of the Rosetrees Trust and NIHR Biomedical Research Unit.</p>
    </ack>
    <notes notes-type="COI-statement">
      <sec id="FPar1">
        <title>Conflict of interest</title>
        <p>N.A.A. has provided expert medicolegal opinion in arthroplasty-related cases. The other authors declare that they have no competing interests.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amstutz</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Grigoris</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Metal on metal bearings in hip arthroplasty</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>1996</year>
          <volume>329 Suppl</volume>
          <fpage>S11</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1097/00003086-199608001-00003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuckler</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>The rationale for metal-on-metal total hip arthroplasty</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>2005</year>
          <volume>441</volume>
          <fpage>132</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1097/01.blo.0000193809.85587.f8</pub-id>
          <pub-id pub-id-type="pmid">16330995</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Knight</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Aujla</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Biswas</surname>
              <given-names>SP</given-names>
            </name>
          </person-group>
          <article-title>Total hip arthroplasty - over 100 years of operative history</article-title>
          <source>Orthop Rev (Pavia)</source>
          <year>2011</year>
          <volume>3-2</volume>
          <fpage>e16</fpage>
          <pub-id pub-id-type="doi">10.4081/or.2011.e16</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKee</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Watson-Farrar</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Replacement of arthritic hips by the McKee-Farrar prosthesis</article-title>
          <source>J Bone Joint Surg Br</source>
          <year>1966</year>
          <volume>48-2</volume>
          <fpage>245</fpage>
          <lpage>59</lpage>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmalzried</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Szuszczewicz</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Akizuki</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Amstutz</surname>
              <given-names>HC</given-names>
            </name>
          </person-group>
          <article-title>Factors correlating with long term survival of McKee-Farrar total hip prostheses</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>1996</year>
          <volume>329 Suppl</volume>
          <fpage>S48</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="doi">10.1097/00003086-199608001-00005</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walker</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Salvati</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hotzler</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>The wear on removed McKee-Farrar total hip prostheses</article-title>
          <source>J Bone Joint Surg Am</source>
          <year>1974</year>
          <volume>56-1</volume>
          <fpage>92</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="doi">10.2106/00004623-197456010-00011</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clarke</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Darrah</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ingham</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nolan</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Long-term clinical, radiological and histopathological follow-up of a well-fixed Mckee-Farrar metal-on-metal total hip arthroplasty</article-title>
          <source>J Arthroplasty</source>
          <year>2005</year>
          <volume>20-4</volume>
          <fpage>542</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/j.arth.2004.09.063</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobsson</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Djerf</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wahlstrom</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>A comparative study between McKee-Farrar and Charnley arthroplasty with long-term follow-up periods</article-title>
          <source>J Arthroplasty</source>
          <year>1990</year>
          <volume>5-1</volume>
          <fpage>9</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1016/S0883-5403(06)80003-3</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobsson</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Djerf</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wahlstrom</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Twenty-year results of McKee-Farrar versus Charnley prosthesis</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>1996</year>
          <volume>329 Suppl</volume>
          <fpage>S60</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1097/00003086-199608001-00006</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jantsch</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schwagerl</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zenz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Semlitsch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fertschak</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Long-term results after implantation of McKee-Farrar total hip prostheses</article-title>
          <source>Arch Orthop Trauma Surg</source>
          <year>1991</year>
          <volume>110-5</volume>
          <fpage>230</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00572878</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amstutz</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McKellop</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schmalzreid</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Gillespie</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Howie</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Medley</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Merritt</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Metal on metal total hip replacement workshop consensus document</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>1996</year>
          <volume>329 Suppl</volume>
          <fpage>S297</fpage>
          <lpage>303</lpage>
          <pub-id pub-id-type="doi">10.1097/00003086-199608001-00027</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Steiger</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Hang</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>LN</given-names>
            </name>
            <name>
              <surname>Graves</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>Five-year results of the ASR XL acetabular system and the ASR hip resurfacing system: an analysis from the Australian orthopaedic association national joint replacement registry</article-title>
          <source>J Bone Joint Surg Am</source>
          <year>2011</year>
          <volume>93-24</volume>
          <fpage>2287</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.2106/JBJS.J.01727</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langton</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Jameson</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Joyce</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Gandhi</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Sidaginamale</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mereddy</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lord</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nargol</surname>
              <given-names>AV</given-names>
            </name>
          </person-group>
          <article-title>Accelerating failure rate of the ASR total hip replacement</article-title>
          <source>J Bone Joint Surg Br</source>
          <year>2011</year>
          <volume>93-8</volume>
          <fpage>1011</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1302/0301-620X.93B8.26040</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langton</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Jameson</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Joyce</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Hallab</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Natu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nargol</surname>
              <given-names>AV</given-names>
            </name>
          </person-group>
          <article-title>Early failure of metal-on-metal bearings in hip resurfacing and large-diameter total hip replacement: a consequence of excess wear</article-title>
          <source>J Bone Joint Surg Br</source>
          <year>2010</year>
          <volume>92-1</volume>
          <fpage>38</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1302/0301-620X.92B1.22770</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="other">Bauer T. What does the histology tell us? In: Jones LC, Greenwold AS, Haggard WO, editors. Metal-on-metal bearing. A clinical practicum. New York, Springer; 2013. P. 153–62.</mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grammatopoulos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pandit</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kamali</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maggiani</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Glyn-Jones</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Athanasou</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>The correlation of wear with histological features after failed hip resurfacing arthroplasty</article-title>
          <source>J Bone Joint Surg Am</source>
          <year>2013</year>
          <volume>95-12</volume>
          <fpage>e81</fpage>
          <pub-id pub-id-type="doi">10.2106/JBJS.L.00775</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mahendra</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pandit</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kliskey</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Athanasou</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Necrotic and inflammatory changes in metal-on-metal resurfacing hip arthroplasties</article-title>
          <source>Acta Orthop</source>
          <year>2009</year>
          <volume>80-6</volume>
          <fpage>653</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.3109/17453670903473016</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Natu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sidaginamale</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Gandhi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Langton</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Nargol</surname>
              <given-names>AV</given-names>
            </name>
          </person-group>
          <article-title>Adverse reactions to metal debris: histopathological features of periprosthetic soft tissue reactions seen in association with failed metal on metal hip arthroplasties</article-title>
          <source>J Clin Pathol</source>
          <year>2012</year>
          <volume>65-5</volume>
          <fpage>409</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="doi">10.1136/jclinpath-2011-200398</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pandit</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Glyn-Jones</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McLardy-Smith</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gundle</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Whitwell</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gibbons</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Ostlere</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Athanasou</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>Pseudotumours associated with metal-on-metal hip resurfacings</article-title>
          <source>J Bone Joint Surg Br</source>
          <year>2008</year>
          <volume>90-7</volume>
          <fpage>847</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1302/0301-620X.90B7.20213</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campbell</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ebramzadeh</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takamura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>De Smet</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Amstutz</surname>
              <given-names>HC</given-names>
            </name>
          </person-group>
          <article-title>Histological features of pseudotumour-like tissues from metal-on-metal hips</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>2010</year>
          <volume>468</volume>
          <fpage>2321</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1007/s11999-010-1372-y</pub-id>
          <pub-id pub-id-type="pmid">20458645</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watters</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Cardona</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Menon</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Vinson</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>Bolognesi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Dodd</surname>
              <given-names>LG</given-names>
            </name>
          </person-group>
          <article-title>Aseptic lymphocyte-dominated vasculitis-associated lesion: a clinicopathologic review of an underrecognized cause of prosthetic failure</article-title>
          <source>Am J Clin Pathol</source>
          <year>2010</year>
          <volume>134-6</volume>
          <fpage>886</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1309/AJCPLTNEUAH8XI4W</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Lockshin</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Salvati</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Bullough</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>Sensitivity to metal as a possible cause of sterile loosening after cobalt-chromium total hip-replacement arthroplasty</article-title>
          <source>J Bone Joint Surg Am</source>
          <year>1977</year>
          <volume>59-2</volume>
          <fpage>164</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.2106/00004623-197759020-00004</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doorn</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Mirra</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Amstutz</surname>
              <given-names>HC</given-names>
            </name>
          </person-group>
          <article-title>Tissue reaction to metal on metal total hip prostheses</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>1996</year>
          <volume>329 Suppl</volume>
          <fpage>S187</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="doi">10.1097/00003086-199608001-00017</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Vernon-Roberts</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Metal sensitivity as a cause of bone necrosis and loosening of the prosthesis in total joint replacement</article-title>
          <source>J Bone Joint Surg Br</source>
          <year>1974</year>
          <volume>56-B-4</volume>
          <fpage>626</fpage>
          <lpage>42</lpage>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Howie</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>Tissue response in relation to type of wear particles around failed hip arthroplasties</article-title>
          <source>J Arthroplasty</source>
          <year>1990</year>
          <volume>5-4</volume>
          <fpage>337</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1016/S0883-5403(08)80093-9</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Lucas</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>O’Driscoll</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Wibberley</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Cobalt toxicity after McKee hip arthroplasty</article-title>
          <source>J Bone Joint Surg Br</source>
          <year>1975</year>
          <volume>57-3</volume>
          <fpage>289</fpage>
          <lpage>96</lpage>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winter</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Tissue recation to metallic wear and corrosion products in human patients</article-title>
          <source>J Biomed Materials Res</source>
          <year>1974</year>
          <volume>8</volume>
          <fpage>11</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1002/jbm.820080304</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phillips</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Cates</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Kurtz</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Steinbeck</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Histological characterization of periprosthetic tissue responses for metal-on-metal hip replacement</article-title>
          <source>J Long Term Eff Med Implants</source>
          <year>2014</year>
          <volume>24</volume>
          <fpage>13</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1615/JLongTermEffMedImplants.2014010275</pub-id>
          <pub-id pub-id-type="pmid">24941402</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>DeHeer</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Swanson</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Long-term survival of McKee-Farrar total hip prostheses</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>2002</year>
          <volume>402</volume>
          <fpage>157</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="doi">10.1097/00003086-200209000-00013</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="other">Somerville EW, Bentley GJ. McKee-Farrar total hip replacement arthroplasty. a review of the first 100 cases at the nuffield orthopaedic centre. Orthopaedics Oxford 1970;3:73–7.</mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bentley</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Duthie</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
          <article-title>A comparative review of the McKee-Farrar and Charnley total hip prostheses</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>1973</year>
          <volume>95</volume>
          <fpage>127</fpage>
          <lpage>42</lpage>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willert</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Buchhorn</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Gobel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Koster</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schaffner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schenk</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Semlitsch</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Wear behavior and histopathology of classic cemented metal on metal hip endoprostheses</article-title>
          <source>Clin Orthop Relat Res</source>
          <year>1996</year>
          <volume>329 Suppl</volume>
          <fpage>S160</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="doi">10.1097/00003086-199608001-00016</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higuchi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Semlitsch</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Metal-on-metal CoCrMo McKee-Farrar total hip arthroplasty: characteristics from a long-term follow-up study</article-title>
          <source>Arch Orthop Trauma Surg</source>
          <year>1997</year>
          <volume>116-3</volume>
          <fpage>121</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00426058</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmalzried</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Bragdon</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Long-duration metal-on-metal total hip arthroplasties with low wear of the articulating surfaces</article-title>
          <source>J Arthroplasty</source>
          <year>1996</year>
          <volume>11-3</volume>
          <fpage>322</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1016/S0883-5403(96)80085-4</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zahiri</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Schmalzried</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Ebramzadeh</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Szuszczewicz</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Salib</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Amstutz</surname>
              <given-names>HC</given-names>
            </name>
          </person-group>
          <article-title>Lessons learned from loosening of the McKee-Farrar metal-on-metal total hip replacement</article-title>
          <source>J Arthroplasty</source>
          <year>1999</year>
          <volume>14-3</volume>
          <fpage>326</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1016/S0883-5403(99)90059-1</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Willert</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Learmonth</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Case</surname>
              <given-names>CP</given-names>
            </name>
          </person-group>
          <article-title>An unusual lymphocytic perivascular infiltration in tissues around contemporary metal-on-metal joint replacements</article-title>
          <source>J Bone Joint Surg Am</source>
          <year>2005</year>
          <volume>87-1</volume>
          <fpage>18</fpage>
          <lpage>27</lpage>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willert</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Buchhorn</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Fayyazi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Flury</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Windler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koster</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lohmann</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Metal-on-metal bearings and hypersensitivity in patients with artificial hip joints. A clinical and histomorphological study</article-title>
          <source>J Bone Joint Surg Am</source>
          <year>2005</year>
          <volume>87-1</volume>
          <fpage>28</fpage>
          <lpage>36</lpage>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hallab</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Biological effects of implant debris</article-title>
          <source>Bull NYU Hospit Jt Dis</source>
          <year>2009</year>
          <volume>67</volume>
          <fpage>182</fpage>
          <lpage>8</lpage>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Athanasou</surname>
              <given-names>NA</given-names>
            </name>
          </person-group>
          <article-title>The pathobiology and pathology of aseptic implant failure</article-title>
          <source>Bone Joint Res</source>
          <year>2016</year>
          <volume>162</volume>
          <fpage>162</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1302/2046-3758.55.BJR-2016-0086</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Madan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jowett</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Goodwin</surname>
              <given-names>MI</given-names>
            </name>
          </person-group>
          <article-title>Recurrent intrapelvic cyst complicating metal-on-metal cemented total hip arthroplasty</article-title>
          <source>Arch Orthop Trauma Surg</source>
          <year>2000</year>
          <volume>120-9</volume>
          <fpage>508</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1007/s004020000171</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362664</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pflugers Arch</journal-id>
      <journal-id journal-id-type="iso-abbrev">Pflugers Arch</journal-id>
      <journal-title-group>
        <journal-title>Pflugers Archiv</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0031-6768</issn>
      <issn pub-type="epub">1432-2013</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362664</article-id>
      <article-id pub-id-type="pmcid">PMC5362664</article-id>
      <article-id pub-id-type="pmc-uid">5362664</article-id>
      <article-id pub-id-type="pmid">28233125</article-id>
      <article-id pub-id-type="publisher-id">1955</article-id>
      <article-id pub-id-type="doi">10.1007/s00424-017-1955-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Invited Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Macrophage function in obesity-induced inflammation and insulin resistance</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lauterbach</surname>
            <given-names>Mario A. R.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9209-3501</contrib-id>
          <name>
            <surname>Wunderlich</surname>
            <given-names>F. Thomas</given-names>
          </name>
          <address>
            <phone>+49-221 4726 678</phone>
            <email>thomas.wunderlich@sf.mpg.de</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2240 3300</institution-id><institution-id institution-id-type="GRID">grid.10388.32</institution-id><institution>Institute of Innate Immunity, University Hospital, </institution><institution>University of Bonn, </institution></institution-wrap>Sigmund Freud Str. 25, 53127 Bonn, Germany </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8580 3777</institution-id><institution-id institution-id-type="GRID">grid.6190.e</institution-id><institution>Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-associated Diseases (CECAD); Center for Endocrinology, Diabetes and Preventive Medicine (CEDP) Cologne, </institution><institution>Max Planck Institute for Metabolism Research Cologne, University of Cologne, </institution></institution-wrap>Gleueler Straße 50, 50931 Cologne, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>23</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>469</volume>
      <issue>3</issue>
      <fpage>385</fpage>
      <lpage>396</lpage>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>1</month>
          <year>2017</year>
        </date>
        <date date-type="rev-recd">
          <day>6</day>
          <month>2</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>2</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>The steadily increasing obesity epidemic affects currently 30% of western populations and is causative for numerous disorders. It has been demonstrated that immune cells such as macrophages reside in or infiltrate metabolic organs under obese conditions and cause the so-called low-grade inflammation or metaflammation that impairs insulin action thus leading to the development of insulin resistance. Here, we report on data that specifically address macrophage biology/physiology in obesity-induced inflammation and insulin resistance.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Macrophage</kwd>
        <kwd>Polarization</kwd>
        <kwd>Metaflammation</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id>
              <institution>Deutsche Forschungsgemeinschaft</institution>
            </institution-wrap>
          </funding-source>
          <award-id>(SFB670, FTW), (TR134, FTW), (KFO286, FTW), (CECAD, FTW)</award-id>
          <award-id>SFB1123</award-id>
          <principal-award-recipient>
            <name>
              <surname>Wunderlich</surname>
              <given-names>F. Thomas</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005972</institution-id>
              <institution>Deutsche Krebshilfe</institution>
            </institution-wrap>
          </funding-source>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer-Verlag Berlin Heidelberg 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>The steadily rising prevalence of obesity incorporates a major health issue because it is attended by fatal obesity-associated disorders including not only the development of type 2 diabetes and fatty liver diseases but also the rising incidence for certain cancer entities [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. In the first instance, obesity alters whole body metabolism that frequently results in insulin resistance [<xref ref-type="bibr" rid="CR5">5</xref>]. Insulin is produced by the pancreatic beta cells in response to rising blood glucose levels, thereby leading to glucose uptake in insulin responsive organs. Excessive glucose is stored in the white adipose tissue (WAT) as lipids and in the liver as glycogen that can be converted back to glucose during fasting or periods of increased energy demands. All these metabolic processes and many more are controlled by insulin [<xref ref-type="bibr" rid="CR93">93</xref>]. The actions of insulin are mediated via binding to the insulin receptor (IR) [<xref ref-type="bibr" rid="CR5">5</xref>]. The IR and the homologous insulin-like growth factor 1 receptor (IGF1R) are receptor tyrosine kinases that use adaptor molecules for their downstream signaling [<xref ref-type="bibr" rid="CR48">48</xref>]. These molecules belong to the insulin receptor substrate (IRS) family of proteins that upon engagement of the IR or IGF1R are tyrosine phosphorylated further leading to phosphatidylinositide 3-kinase (PI3K) and AKT activation. In diabetes patients, insulin action is impaired. While type 1 diabetes patients exhibit beta cell/insulin loss due to autoimmune reactions against the pancreas, type 2 diabetes develops as a consequence of insulin resistance that is frequent in obese patients. In obesity, the compromised glucose uptake into metabolic organs induces hyperglycemia in turn accelerating insulin production in beta cells. The excessive insulin production can partly compensate for decreased insulin sensitivity but progresses to increased beta cell mass and ultimately to beta cell death. How obesity facilitates the development of insulin resistance has been discovered over the last decade. Obesity has been accepted as low-grade inflammatory state that is also known as metaflammation [<xref ref-type="bibr" rid="CR38">38</xref>]. Metaflammation is mainly derived from innate immune cells, e.g., macrophages whose derivation, fate, and functional consequences are discussed in this review.</p>
    </sec>
    <sec id="Sec2">
      <title>Tissue resident macrophages</title>
      <p>Macrophages are cells of the innate immune system that populate every organ. They display great functional plasticity and are required for maintenance of tissue homeostasis, immunity against invading pathogens, and tissue repair. Different organs harbor different specialized tissue resident macrophages, which include red pulp and marginal zone macrophages in the spleen, microglia in the brain, peritoneal macrophages, osteoclasts in the bone, alveolar macrophages in the lung, and the two major metabolic tissue macrophage subsets in the liver and adipose tissue—liver Kupffer cells and adipose tissue macrophages, respectively [<xref ref-type="bibr" rid="CR73">73</xref>]. Certain tissue macrophage subsets populate their organs during embryogenesis, while in adulthood, tissue resident macrophage subsets are replenished by monocytes that are recruited from the bone marrow [<xref ref-type="bibr" rid="CR22">22</xref>]. The two major subsets of monocytes are termed inflammatory and patrolling monocytes. They are distinguished by a defined panel of surface markers and chemokine receptors and have distinct chemotactic properties. Inflammatory monocytes are C-C chemokine receptor type 2 (CCR2) and lymphocyte antigen 6 c (Ly6C) positive, whereas patrolling monocytes are CCR2 and Ly6C negative, but express high levels of CX3 chemokine receptor 1 (CX3CR1). Expression of these different chemokine receptors allows them to follow diverging chemokine gradients. Under steady state, patrolling monocytes crawl along the vasculature where they function as immune sentinels. They can enter tissues through expression of CX3CR1 and differentiate into tissue resident cells with dendritic cell- and macrophage-like features [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. The degree of macrophage turnover under homeostatic conditions varies between organs [<xref ref-type="bibr" rid="CR22">22</xref>]. Inflammatory monocytes are recruited to tissues in response to infection or tissue damage via chemokine (C-C motif) ligand 2 (CCL-2). In the absence of inflammation, they remain in the blood circulation [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
    </sec>
    <sec id="Sec3">
      <title>Macrophage ontogeny</title>
      <p>Precursors of several tissue macrophage subsets emerge during embryogenesis. Hematopoiesis during embryonic development occurs at two sites in two stages—first extra-embryonically in the yolk sac and later on in the fetal liver [<xref ref-type="bibr" rid="CR22">22</xref>]. Hematopoiesis in the yolk sac was termed “primitive” and thought to solely preserve macrophage pools during embryogenesis, while tissue resident macrophages are derived from adult hematopoietic stem cells (HSC). However, fate-mapping studies revealed that numerous tissue resident macrophage populations are of prenatal origin and emerge from the yolk sac or the fetal liver. Microglia for example were shown to originate from the yolk sac, while Langerhans cells are mainly of fetal liver origin [<xref ref-type="bibr" rid="CR23">23</xref>]. The use of (Myb-deficient) mice, which lack the bone marrow hematopoietic stem cell compartment, shed more light on the development of tissue resident macrophages [<xref ref-type="bibr" rid="CR96">96</xref>]. These mice still develop tissue resident macrophage populations including Langerhans cells, Kupffer cells, microglia, lung alveolar, splenic red pulp, and peritoneal macrophages, indicating that yolk sac-derived progenitors give rise to several long-lasting tissue macrophage subsets beyond embryonic development [<xref ref-type="bibr" rid="CR124">124</xref>]. Notably, these macrophage populations are maintained during adulthood under homeostatic conditions owing to their self-renewal potential.</p>
      <p>It is an ongoing debate whether determination to the distinct tissue resident macrophage subsets occurs during embryonic development or is induced by signals from the local environment once macrophage populate their final tissue. On the one hand, some findings support the concept that macrophage precursors could already be committed to give rise to a certain subset by the time they enter the circulation to populate their target organ. Recent studies for example suggested that microglia are derived from a distinct yolk sac precursor, while other tissue resident macrophages derive from embryonic hematopoietic precursors [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Other studies in contrast provided evidence that cues from the local tissue environment are crucial for differentiation into the distinct tissue resident macrophage subsets. By comparing different tissue resident macrophage populations, it has been assessed that tissue-specific factors shape the chromatin and enhancer landscape of macrophages thus enabling the transcription of subset-specific genes [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Retinoic acid for example drives the differentiation of peritoneal macrophages by inducing the expression of the transcription factor GATA-6, which in turn activates a peritoneal macrophage-specific transcriptional program that is crucial for maintenance and functionality of these cells [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. The idea of in situ differentiation is supported by findings that tissue resident macrophages originate from a common erythro-myeloid progenitor (EMP) in the yolk sac, which populates the fetal liver before entering the blood stream to give rise to tissue resident macrophages [<xref ref-type="bibr" rid="CR25">25</xref>]. Using single-cell RNA sequencing, a recent study investigated the chronology of macrophage differentiation during embryogenesis. EMPs give rise to premature macrophages that share a common gene expression signature. Induction of specific expression profiles is initiated during organogenesis when pre-mature macrophages enter the tissue [<xref ref-type="bibr" rid="CR65">65</xref>].</p>
    </sec>
    <sec id="Sec4">
      <title>Polarization states of macrophages</title>
      <p>Tissue resident macrophages express a multitude of pattern recognition receptors (PRRs) that enable them to sense a wide range of microbial molecules and danger signals. Upon pathogen encounter, they induce a cascade that signals the quality of infection or danger, induces an inflammatory state, and recruits other immune cells to the site of infection [<xref ref-type="bibr" rid="CR44">44</xref>]. Together with neutrophils, they produce bactericidal molecules and phagocytose pathogens to terminate the infection. After the infection has been cleared, they resolute inflammation by anti-inflammatory cytokines and lipid mediators and govern tissue repair by phagocytosing debris and promoting regeneration of extracellular matrix [<xref ref-type="bibr" rid="CR73">73</xref>].</p>
      <p>Macrophages exhibit a high degree of functional plasticity, and the nature of an inflammatory trigger as well as the local cytokine milieu will determine the respective macrophage polarization and its functional state. In this regard, early on, the distinction between classically activated and alternatively activated or—in analogy to the Th1/Th2 nomenclature of T cells—M1 and M2 macrophages has been made [<xref ref-type="bibr" rid="CR64">64</xref>]. In vitro, these subsets can be induced by incubation with interferon gamma (IFNγ) and lipopolysaccharide (LPS) or interleukin-4 (IL-4), respectively. The M1/M2 nomenclature was in particular used to classify macrophages into cells with pro-inflammatory or anti-inflammatory properties or certain effector functions. The following studies revealed that distinct pro- or anti-inflammatory stimuli elicit distinct transcriptomic profiles, which led to the proposal of the spectrum model or more recently the multidimensional model [<xref ref-type="bibr" rid="CR24">24</xref>]. However, many important findings were made using the aforementioned stimuli. Also, many classical M1 and M2 markers are still used to assess the functional state of macrophages in vivo. We thus will refer to macrophages with pro-inflammatory properties as M<sub>pro</sub> and macrophages with anti-inflammatory properties as M<sub>anti</sub>.</p>
      <p>Triggers like the Th1 cytokine IFNγ and/or toll-like receptor (TLR) ligands such as LPS initiate a pro-inflammatory response that equips macrophages to fight bacterial infections [<xref ref-type="bibr" rid="CR64">64</xref>]. These stimuli activate signaling cascades that result in a global transcriptional reprogramming. In this context, signal transducer and activator of transcription (STAT) 1 and 2 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) are key transcription factors of IFNγ and TLR signaling, respectively [<xref ref-type="bibr" rid="CR60">60</xref>]. Pro-inflammatory macrophages (M<sub>pro</sub>) generally have inflammatory properties and are crucial for fighting bacterial infections and immunity against tumors. However, excessive activation can also result in tissue damage and autoimmunity. They present antigen and produce bactericidal agents such as reactive oxygen species (ROS) and nitric oxide (NO). The latter is synthesized by inducible nitric oxide synthase (iNOS) from arginine. They furthermore secrete a multitude of inflammatory cytokines including tumor necrosis factor alpha (TNFα), IL1-β, IL-6, IL-12, and IL-18 [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
      <p>Three major pro-inflammatory cytokines are TNFα, Il-1β, and IL-6. TNFα is one of the first cytokines secreted by macrophages during infection and crucially involved in septic shock. It activates the vascular endothelium and initiates the acute phase in the liver. IL-6 also activates the acute phase and induces fever. In addition, it acts on lymphocytes and activates cytotoxic cells or stimulates differentiation of plasma cells. Depending on the signaling pathways that are activated upon receptor binding, IL-6 can also have anti-inflammatory properties [<xref ref-type="bibr" rid="CR68">68</xref>]. IL-1β is a strong pyrogen, but in addition can induce the secretion of prostaglandins in the central nervous system. Notably, IL-1β and TNFα are both potent inducer of IL-6 and thereby amplify the inflammatory cascade [<xref ref-type="bibr" rid="CR17">17</xref>]. IL-12 induces Th1 differentiation and together with IL-18 induces IFNγ production by Th1 and natural killer (NK) cells which in turn acts on macrophages in a feed forward loop [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
      <p>Alternatively activated macrophages (M<sub>anti</sub>) were initially described during helminth infections and exhibit an anti-inflammatory phenotype. In vitro, they can be induced by the Th2 cytokines IL-4 and IL-13. Similarly as described for pro-inflammatory stimuli, binding of IL-4 to its receptor will result in a global transcriptional reprogramming. One of the key transcription factors mediating these changes is STAT6. It acts in concert with peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and peroxisome proliferator-activated receptor gamma and delta (PPARγ and PPARδ) which, as will be discussed below, are particularly involved in reprogramming cellular energy metabolism [<xref ref-type="bibr" rid="CR60">60</xref>]. M<sub>anti</sub> are important players during helminth infection, response to tissue damage, resolution of inflammation, and wound healing, but can also foster fibrosis and tumor growth [<xref ref-type="bibr" rid="CR26">26</xref>]. Their most important effector molecules include arginase, lectins, scavenger receptors and the cytokines IL-10 and the IL-1 receptor antagonist (IL1-RA). Arginase converts arginine to ornithine, which in turn is used during tissue repair for polyamine and collagen synthesis. Scavenger receptors and lectins mediate clearance of debris and apoptotic cells during resolution of inflammation, while IL-10 and IL-1RA are potent suppressors of inflammation [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p>
    </sec>
    <sec id="Sec5">
      <title>Macrophage metabolism</title>
      <p>The differential use of arginine was an early indication that pro- and anti-inflammatory triggers induce diverging metabolic changes in macrophages. Over the last years, a series of discoveries have highlighted a tight linkage between cellular metabolism and macrophage effector functions [<xref ref-type="bibr" rid="CR83">83</xref>]. While distinct metabolic features of many immune cells were described, we are just beginning to understand how nutrient availability can shape immune responses. In the following, we will briefly summarize these findings with a focus on glycolysis, β-oxidation, and amino acid metabolism.</p>
      <p>Glycolysis describes the sequential breakdown of glucose to pyruvate, which is either converted to lactate and secreted or imported into mitochondria. When shuttled into mitochondria, pyruvate is converted to acetyl-coenzyme A (CoA), which enters the tricarboxylic acid (TCA) cycle by condensation with oxaloacetate. The TCA cycle generates NADH and FADH2, which are used to generate ATP via oxidative phosphorylation (OXPHOS). Apart from glycolysis, multiple catabolic pathways converge into the TCA cycle such as β-oxidation and glutaminolysis. β-Oxidation of fatty acids generates acetyl-CoA, while glutamine can enter the TCA by sequential conversion to α-ketoglutarate [<xref ref-type="bibr" rid="CR15">15</xref>]. Apart from its central role in catabolism, the TCA cycle also serves as a metabolic hub that can redirect its intermediates for anabolic reactions when required. Citrate for example can be exported from mitochondria and cleaved to acetyl-CoA and oxaloacetate by ATP-citrate lyase. Acetyl-CoA in turn serves as a precursor for fatty acid or cholesterol biosynthesis and is substrate for acetylation reactions in the cytoplasm and the nucleus. OXPHOS is the most effective way for cells to generate ATP and is used by most quiescent cell types to cover their energetic demands [<xref ref-type="bibr" rid="CR15">15</xref>]. OXPHOS, however, requires oxygen and has rather slow ATP generation kinetics. Thus, under hypoxic conditions or conditions of increased ATP demand, cells switch from OXPHOS to glycolysis to generate ATP. This phenomenon—glycolytic activity under normoxic conditions—is termed Warburg effect after its discoverer Otto Warburg. Initially discovered in cancer cells, proliferating cells or cells with high anabolic demands such as the developing embryo, epithelial cells, or activated immune cells exhibit Warburg metabolism [<xref ref-type="bibr" rid="CR108">108</xref>]. Switching to glycolysis does not only allow for fast ATP generation, but also enables cells to diverge glycolytic intermediates into anabolic pathways such as amino acid, lipid, or nucleotide biosynthesis, instead of oxidizing them via TCA and OXPHOS [<xref ref-type="bibr" rid="CR108">108</xref>].</p>
      <p>Increased glycolysis was described early on in LPS-stimulated macrophages [<xref ref-type="bibr" rid="CR83">83</xref>]. A series of recent studies has underpinned that commitment to Warburg metabolism equips macrophages to fulfill their effector functions such as production of ROS or NO, phagocytosis, and secretion of inflammatory mediators in the context of bacterial infection. Upon activation with pro-inflammatory stimuli like LPS or IFNγ, macrophages undergo metabolic reprogramming and exhibit increased rates of glycolysis and decreased OXPHOS. By diverting ATP generation from OXPHOS to glycolysis, mitochondria are available for ROS production [<xref ref-type="bibr" rid="CR115">115</xref>]. Furthermore, instead of being used for ATP production, citrate is exported from mitochondria and used for fatty acid biosynthesis [<xref ref-type="bibr" rid="CR42">42</xref>]. To compensate for decreased conversion of citrate to α-ketoglutarate, glutamine is funneled into the TCA via anaplerosis to α-ketoglutarate [<xref ref-type="bibr" rid="CR102">102</xref>]. The molecular mechanisms driving these changes are just being uncovered. Some are NF-κB dependent: LPS for example induces PFKFB3, which increases glycolytic flux by generating fructose-2,6-bisphosphate [<xref ref-type="bibr" rid="CR91">91</xref>]. Moreover, the NF-κB responsive gene hypoxia-inducible factor 1 alpha (HIF1α) was identified as another central metabolic regulator in response to LPS [<xref ref-type="bibr" rid="CR12">12</xref>]. HIF1α is an essential mediator of the hypoxic response, partly by promoting a shift from OXPHOS to glycolysis. Under normoxic conditions, it is constantly degraded by the proteasome and only stabilized under hypoxic conditions. Ubiquitination and subsequent degradation of HIF1α are initiated by hydroxylation of proline residues by prolyl hydroxylases (PHDs). In certain cancer cells that exhibit Warburg metabolism, inhibition of PHDs can lead to HIF1α stabilization under normoxic conditions [<xref ref-type="bibr" rid="CR97">97</xref>]. A similar effect was observed in response to LPS stimulation. In this context, ROS, succinate accumulation and iron were shown to contribute to PHD inhibition [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]. While ROS and succinate inhibit PHD activity, PHDs require iron as cofactor for the hydroxylation reaction. Indeed, ferritin decreases iron availability to PHDs after LPS stimulation and thereby downregulates PHD-dependent HIF1α hydroxylation [<xref ref-type="bibr" rid="CR99">99</xref>]. While HIF1α sustains proliferation in cancer cells [<xref ref-type="bibr" rid="CR97">97</xref>], it upregulates glycolysis [<xref ref-type="bibr" rid="CR12">12</xref>], and also specifically boosts IL-1β expression [<xref ref-type="bibr" rid="CR102">102</xref>] in response to LPS stimulation. As described before, arginine metabolism to citrulline and NO is a key effector function of pro-inflammatory macrophages. Indeed, changes in glutamine metabolism upon stimulation supply arginine and boost NO production by iNOS [<xref ref-type="bibr" rid="CR47">47</xref>].</p>
      <p>While LPS-activated macrophages mainly rely on glycolysis, IL-4-activated macrophages exhibit an oxidative phenotype [<xref ref-type="bibr" rid="CR47">47</xref>]. Upon IL-4 stimulation, macrophages increase fatty acid uptake, β-oxidation, and OXPHOS [<xref ref-type="bibr" rid="CR109">109</xref>]. These metabolic rearrangements are initiated by STAT6 and PGC-1β. In concert with PPARγ and PPAR<underline underline-style="double">δ</underline>, they induce mitochondrial biogenesis and expression of genes that are involved in β-oxidation and OXPHOS [<xref ref-type="bibr" rid="CR79">79</xref>]. These studies also highlighted a role for PPARs in the control of metabolic disease and maintaining insulin sensitivity. Furthermore, recent studies have highlighted the tight connection between macrophage metabolism and its effector functions in helminth infection and identified lysosomal lipolysis as alternative pathway to foster β-oxidation. Notably, the authors of this study showed that blockade of lysosomal liposysis during <italic>H. polygyrus</italic> infection results in defective clearance of the pathogen and inhibits commitment to OXPHOS by macrophages [<xref ref-type="bibr" rid="CR41">41</xref>]. IL-4-stimulated macrophages maintain an intact active TCA cycle and generate ATP mainly via OXPHOS. While changes in β-oxidation are the most striking metabolic adaptations in response to IL-4, metabolomic studies also revealed that glycolysis as well as glutaminolysis contribute to TCA activity [<xref ref-type="bibr" rid="CR47">47</xref>]. Notably, glutamine deprivation inhibits M<sub>anti</sub> macrophage induction in vitro [<xref ref-type="bibr" rid="CR47">47</xref>], whereas inhibition of glycolysis only affects a small subset of IL-4 target genes [<xref ref-type="bibr" rid="CR11">11</xref>]. Thus, while macrophages undergo drastic metabolic changes in response to pro- and anti-inflammatory triggers, like LPS and IL-4, respectively, their diverse effector functions and locations differentially affect whole body metabolism underlining their central role in organismal physiology.</p>
    </sec>
    <sec id="Sec6">
      <title>Adipose tissue macrophages and Kupffer cells in homeostasis</title>
      <p>Besides their role in sensing infection and tissue damage, tissue resident macrophages have important homeostatic and trophic functions. Limiting inflammation and maintaining tissue homeostasis are extra crucial functions of the liver resident Kupffer cells (KC) and adipose tissue macrophages (ATM). In obesity, insulin resistance develops as a consequence of metaflammation in which elevated circulating levels of pro-inflammatory cytokines such as TNFα and IL-6 negatively affect the insulin signaling cascade [<xref ref-type="bibr" rid="CR37">37</xref>]. The main source for these inflammatory mediators in obesity is hepatic and WAT macrophages [<xref ref-type="bibr" rid="CR122">122</xref>]. Macrophages adapt in their residing tissue to local circumstances and exert numerous effector functions such as phagocytosis and cytokine production. In the obese state, macrophages in the WAT and the liver are major players in regulating metaflammation. Macrophages sense factors derived from pathogens or from cells belonging to innate and adaptive systems as well as from specialized cells in the affected tissue. We will refer here on the impact of ATM and liver-derived KC in the development of obesity-associated insulin resistance.</p>
    </sec>
    <sec id="Sec7">
      <title>Adipose tissue macrophages</title>
      <p>Adipose tissue is one of the major metabolic organs that stores excess nutrients as triacylglycerides and releases fatty acids in the fasted state, which serve as energy source for peripheral tissues. Under homeostatic conditions, adipose tissue is populated with macrophages that exhibit a M<sub>anti</sub> like phenotype and govern adipocyte lipid metabolism by secreting factors such as IL-10 and catecholamines. IL-10 enhances adipocyte insulin sensitivity and lipogenesis [<xref ref-type="bibr" rid="CR62">62</xref>], whereas catecholamines trigger lipolysis in adipocytes [<xref ref-type="bibr" rid="CR75">75</xref>]. Under conditions of excessive lipolysis, they control release of fatty acids into the circulation by serving as buffer [<xref ref-type="bibr" rid="CR55">55</xref>]. While the ontogeny of other tissue macrophage subsets is well studied, less is known about ATM. Under inflammatory conditions, monocytes enter adipose tissue in a CCR2-dependent manner [<xref ref-type="bibr" rid="CR62">62</xref>]. The origin of ATMs under homeostatic conditions is a matter of debate. Interestingly, WAT contains a pool of c-Kit<sup>+</sup>/Lin<sup>−</sup>/Sca-1<sup>+</sup> cells that share features of hematopoietic stem cells [<xref ref-type="bibr" rid="CR10">10</xref>]. This population fails to populate bone marrow in non-irradiated mice, but is capable of replenishing the innate immune cell pool in adipose tissue [<xref ref-type="bibr" rid="CR85">85</xref>]. ATMs might thus be regenerated in situ independent of the bone marrow.</p>
      <p>A pioneering study from Hotamisligil and Spiegelman identified adipocytes as source of TNFα in the WAT that ultimately impaired insulin signaling in obesity [<xref ref-type="bibr" rid="CR39">39</xref>]. However, findings by Xu et al. demonstrated that mainly the stromal vascular fraction of the obese WAT expresses inflammatory cytokines [<xref ref-type="bibr" rid="CR122">122</xref>]. Currently, the view that the majority of other cells than adipocytes in the obese WAT are macrophages is supported, whereas in lean conditions, these cells represent approximately 10% [<xref ref-type="bibr" rid="CR112">112</xref>]. While in lean WAT, mainly alternative M<sub>anti</sub> like macrophages express anti-inflammatory molecules, in obese, WAT macrophage polarization is shifted towards a pro-inflammatory M<sub>pro</sub> like phenotype. The increased abundance and activation of macrophages in the obese WAT can be accounted by adipose tissue stress that includes elevated amounts of free fatty acids and LPS [<xref ref-type="bibr" rid="CR28">28</xref>]. LPS, which is presumably microbiome derived, is not only abundant in WAT, but also found in the circulation of obese individuals [<xref ref-type="bibr" rid="CR8">8</xref>]. LPS and fatty acids such as palmitate activate TLR4 signaling in ATMs that polarizes them towards M<sub>pro</sub> macrophages [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Subsequently, these stimuli trigger expression of TNFα and IL-6 in ATMs that compromise insulin action not only locally in the WAT, but also systemically since they are released to circulation [<xref ref-type="bibr" rid="CR82">82</xref>]. Thus, it is tempting to speculate that metaflammation is a consequence of local innate immune response in the WAT that spills over via the blood to other organs due to the blood soluble factors involved. Of note, caloric restriction-induced weight loss including improvements in systemic insulin sensitivity and whole body glucose metabolism ameliorated metaflammation in the liver but not in adipose tissue suggesting that long-lived ATMs maintain WAT inflammation [<xref ref-type="bibr" rid="CR95">95</xref>].</p>
      <p>The M<sub>anti</sub> like ATMs in lean WAT express the cell surface marker CD206 and exhibit anti-inflammatory properties such as IL-10 expression. These M<sub>anti</sub> like ATMs synergize with regulatory T cells (Treg) and innate type 2 lymphoid cells (ILC2) to maintain the anti-inflammatory WAT environment [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Tregs, T cells, ILC2 cells, and even adipocytes provide anti-inflammatory IL-4, IL-13, and IL-33 in the lean WAT to keep ATMs in an M<sub>anti</sub> like state [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. In the course of obesity, monocyte recruitment as well as local proliferation gives rise to novel ATMs that polarize towards a pro-inflammatory M<sub>pro</sub> like phenotype that express the surface marker CD11c [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. Abruptly, the WAT environment has changed from anti- to pro-inflammatory conditions indicated by the lack of Treg cells and infiltration of cytotoxic and Th1 T cells as well as NK cells [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]. Besides the already mentioned M<sub>pro</sub> polarizing LPS, T cells and NK cells in the obese WAT provide IFNγ, which sustains polarization towards the M<sub>pro</sub> phenotype [<xref ref-type="bibr" rid="CR114">114</xref>]. ATMs accumulate intracellular lipids not only via phagocytosis of dying adipocytes resulting in crown like structures in the WAT, but also via fatty acid transporter-mediated uptake [<xref ref-type="bibr" rid="CR123">123</xref>]. The metabolism of obese ATMs has changed to glycolysis, which is necessary for the production of nitric oxide by iNos to increase pro-inflammatory macrophage responses [<xref ref-type="bibr" rid="CR20">20</xref>]. M<sub>pro</sub> macrophages take up glucose via glucose transporter 1 that further triggers M<sub>pro</sub> polarization [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
      <p>Therefore, it is not surprising that the polarizing environment in the obese WAT in vivo cannot be completely recapitulated in vitro in bone marrow-derived macrophages (BMDM) [<xref ref-type="bibr" rid="CR123">123</xref>]. For instance, upregulation of CD11c expression is not induced by sole LPS and IFNγ treatment in BMDM, but can be restored by coculture with adipocytes [<xref ref-type="bibr" rid="CR56">56</xref>]. Treatment with high glucose, insulin, and palmitate induces a M<sub>pro</sub> like phenotype in BMDM culture that releases inflammatory cytokines [<xref ref-type="bibr" rid="CR56">56</xref>]. Consistently, insulin receptor inactivation in macrophages prevents M<sub>pro</sub> like polarization [<xref ref-type="bibr" rid="CR66">66</xref>].</p>
      <p>Conversely, M<sub>anti</sub> macrophages in vitro similarly as present in the lean WAT have not been reported, but M<sub>anti</sub> can be differentiated in BMDM cultures by several means. Supplementation of culture media with IL-4 or IL-13 creates different CD206 expressing M<sub>anti</sub> macrophages, than those that require TLR and IL1R agonists [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. Another M<sub>anti</sub> population can be differentiated by IL-10 which shares anti-inflammatory properties with the other two BMDM subtypes [<xref ref-type="bibr" rid="CR72">72</xref>]. Strikingly, reactivity to IL-6 is required to polarize towards all of these M<sub>anti</sub> type macrophages. In particular, arginase 1 and IL-4Rα expression critically depend on IL-6 signaling [<xref ref-type="bibr" rid="CR67">67</xref>]. Taken together, reallocation from M<sub>pro</sub> like towards M<sub>anti</sub> type ATMs might be a promising strategy to resume whole body insulin sensitivity that would prevent fatal diseases associated with obesity such as development of metabolic syndrome and the progression to cancer. In line with this evidence, nematode infection or vaccination with nematode antigens reprograms the obese WAT microenvironment towards anti-inflammatory conditions resulting in improved insulin sensitivity and glucose tolerance [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
    </sec>
    <sec id="Sec8">
      <title>Kupffer cells and liver infiltrating macrophages</title>
      <p>The liver is essential for life due to its metabolic as well as immunoregulatory functions. On the one hand, under high energy conditions and hyperglycemia, hepatocytes in the liver import excessive glucose that is converted to glycogen. During fasting periods, the liver maintains blood glucose levels via hepatic glucose production that includes degradation of glycogen by glycogenolysis and breakdown of proteins and lipids through gluconeogenesis upon prolonged fasting. On the other, the liver is the first line defense against pathogens via the acute phase response and clears infected as well as exhausted cells. In line with its immune function, the blood stream entering the liver through the portal vein runs through the gut as well as the WAT before. In liver sinusoids, specialized liver resident macrophages, the KC, sense and combat invading commensals from the gut to prevent spreading along circulation [<xref ref-type="bibr" rid="CR88">88</xref>]. Gut-derived LPS for example can be detected in portal vein but less in circulation [<xref ref-type="bibr" rid="CR45">45</xref>]. In obesity, impaired storage of excessive lipids in the WAT leads to liver fat accumulation resulting in steatosis and fatty liver diseases [<xref ref-type="bibr" rid="CR107">107</xref>]. The inappropriate fat storage in the liver results in lipotoxicity which in turn leads to liver damage and inflammation [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. Thus, in obesity, lipotoxicity and elevated microbial load from the microbiota result in excessive inflammation mediated by KCs and infiltrating macrophages. Interestingly, depletion of phagocytic cells in the liver via clodronate liposomes prevents steatosis, inflammation, and the development of insulin resistance thereby identifying hepatic macrophages as mediators of obesity-associated pathologies [<xref ref-type="bibr" rid="CR58">58</xref>]. Hepatic macrophages crosstalk to liver non-parenchymal cells and adapt their polarization to states of liver condition. Obesity-induced pro-inflammatory cytokines and LPS polarize KC towards M<sub>pro</sub> that in turn induce a vicious cycle of TNFα, IL-6, and IL-1β that further boosts and deteriorates liver functions [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. The inflammatory boost in obesity does not alter KC numbers but dramatically increases infiltration of CCR2-positive monocytes [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. Furthermore, inflammatory TNFα released by hepatic macrophages limits systemic insulin action, and IL-6 signaling in hepatocytes instructs downregulation of the inflammatory response in hepatic macrophages [<xref ref-type="bibr" rid="CR120">120</xref>]. Collectively, inflammatory signaling in the liver differentially affects hepatic cell types and might result in complicating outcomes in whole body metabolism.</p>
    </sec>
    <sec id="Sec9">
      <title>Obesity-induced low-grade inflammation and insulin resistance</title>
      <p>Obesity contributes to the development of insulin resistance through the so-called obesity-associated low-grade inflammation or metaflammation. Over the course of this process, immune cells infiltrate metabolic organs, mainly WAT and liver, where they secrete pro-inflammatory cytokines that act locally but also systemically after being released into circulation [<xref ref-type="bibr" rid="CR82">82</xref>].</p>
      <p>The cytokine levels in obesity do not reach levels upon infection, but instead are elevated 2–3-fold compared to homeostatic conditions. Moreover, while during infection, pro-inflammatory cytokines increase acutely and stagnate with the elimination of the pathogen, the obesity-associated low-grade inflammation exhibits chronic character suggesting that dynamic modes of action have to be taken into account. The best-studied inflammatory players in obesity are TNFα and IL-6, but also include IL-17, CCL-2, and many others. In this paragraph, we will delineate how TNFα- and IL-6-induced signaling impact on the insulin signaling cascade.</p>
    </sec>
    <sec id="Sec10">
      <title>TNFα</title>
      <p>In a ground breaking report, Hotamisligil and colleagues discovered that the obese WAT contains high levels of the pro-inflammatory cytokine TNFα [<xref ref-type="bibr" rid="CR39">39</xref>]. In a follow-up study, they could show in tissue culture experiments that media supplemented with TNFα impaired insulin action [<xref ref-type="bibr" rid="CR40">40</xref>]. On a molecular level, TNFα compromises activating tyrosine phosphorylations in the insulin signaling cascade mainly of IRS molecules, but also the IR. While at that time, adipocytes were believed to be the source of TNFα in obesity, Xu et al. demonstrated that the stromal vascular fraction of WAT secretes pro-inflammatory cytokines that inhibit insulin signaling [<xref ref-type="bibr" rid="CR122">122</xref>]. Moreover, bone marrow transplantation experiments revealed that mainly macrophages are the source of TNFα in the obese WAT [<xref ref-type="bibr" rid="CR14">14</xref>]. TNFα interferes with insulin recpetor signaling at the level of IRS molecules. IRS molecules are phosphorylated on inhibitory serine residues by TNFα-induced kinases such as IκB kinase (IKK), c-Jun N-terminal kinase (JNK), and atypical protein kinase C (aPKC) thereby preventing further downstream signaling [<xref ref-type="bibr" rid="CR77">77</xref>]. Of note, these kinases have redundant as well as individual functions in IRS phosphorylation and point mutations of IRS1 serine residues to non-phosporylatable counterparts yielded the conflicting result that mutant mice developed insulin resistance [<xref ref-type="bibr" rid="CR9">9</xref>]. Nevertheless, genetic mouse models provided novel insight into how TNFα-induced signaling interferes with insulin signaling in obesity. On the one hand, TNFα knockout mice exhibit normal glucose tolerance when exposed to normal food, but are protected from the development of obesity-induced insulin resistance in the absence of body weight gain alterations on the other [<xref ref-type="bibr" rid="CR106">106</xref>]. While this study demonstrated the critical importance of TNFα in the development of insulin resistance, the dissection of further downstream signaling at the TNFα-induced kinase level has revealed surprising results. TNFα induces a dual kinase system that comprises the IKK complex and the JNK kinases [<xref ref-type="bibr" rid="CR101">101</xref>]. The IKK complex contains the kinases IKK-1 and IKK-2 as well as the NFκB essential modulator NEMO, all of which are essential for mouse viability as revealed by knockout studies. Muscle-specific IKK-2 inactivation showed no effect on diet-induced obesity and alterations in glucose homeostasis [<xref ref-type="bibr" rid="CR89">89</xref>]. However, while hepatic IKK-2 inactivation conferred insulin sensitivity in this organ, but not in muscle and WAT, myeloid IKK-2 inactivation resulted in systemic improvements of insulin sensitivity upon high-fat diet (HFD) challenge mainly due to reduced inflammatory cytokine release [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Otherwise, hepatic NEMO inactivation resulted in global improvements in insulin sensitivity under obese conditions, but in contrast to IKK-2 KO mice, these mice developed liver tumors due to ongoing TNFα-induced cell death and compensatory hyperproliferation [<xref ref-type="bibr" rid="CR119">119</xref>]. Thus, though activated by the same upstream stimulus, kinases may play redundant and non-redundant roles in impairing the actions of insulin.</p>
      <p>In contrast to the IKK complex genes, knockout of one of the three individual JNK kinases (JNK-1, JNK-2, and JNK-3) is well tolerated in mice, whereas double knockout for the most abundant peripheral JNK-1 and JNK-2 is embryonic lethal [<xref ref-type="bibr" rid="CR57">57</xref>]. It has been shown that JNK-1 but not JNK-2 knockout mice are protected against obesity-induced impairments of glucose homeostasis suggesting an essential role for JNK-1 in serine phosphorylation of IRS molecules [<xref ref-type="bibr" rid="CR35">35</xref>]. However, conditional mouse models aimed at unraveling the cell type-specific as well as redundant functions of the JNK genes in the development of obesity-associated insulin resistance. Opposite to what was expected, hepatic inactivation of JNK-1 revealed a modestly impaired glucose tolerance and hepatic lipid accumulation suggesting a function of JNK-1 in the prevention of steatosis and liver fat accumulation [<xref ref-type="bibr" rid="CR110">110</xref>]. Moreover, skeletal muscle-specific JNK-1 deficiency revealed a minor role in glucose metabolism [<xref ref-type="bibr" rid="CR84">84</xref>], whereas WAT-specific JNK-1 deletion decreased obesity-induced IL-6 levels and thus ameliorated diet-induced insulin resistance [<xref ref-type="bibr" rid="CR92">92</xref>]. However, neuronal-specific JNK-1 deficiency most closely resembled the phenotype of complete JNK-1 knockout mice indicating that a redundancy between JNK isoforms in peripheral organs exist [<xref ref-type="bibr" rid="CR3">3</xref>]. In line with these findings, JNK-1/JNK-2 double-deficient macrophages are unable to produce inflammatory cytokines, and thus, mice with macrophage-specific deletion of JNK-1 and 2 are protected against obesity-induced disorders [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Collectively, deciphering organ-specific downstream actions of TNFα in obesity-induced insulin resistance revealed redundant as well as non-redundant kinase functions on inhibitory IRS serine phosphorylation.</p>
    </sec>
    <sec id="Sec11">
      <title>IL-6</title>
      <p>IL-6 is a pleiotropic cytokine that plays crucial roles in metabolic and immune cells. Similar to TNFα, IL-6 is also slightly increased in serum of obese individuals and mice, which is believed to be detrimental for metabolism [<xref ref-type="bibr" rid="CR2">2</xref>]. Here, a bulk of IL-6 is produced by the stromal vascular fraction of visceral fat depots, which is directly delivered to the liver via the portal vein [<xref ref-type="bibr" rid="CR92">92</xref>]. In contrast, IL-6 is increased manifold during intense exercise in muscle (regulated by JNK-1) that provides beneficial effects on metabolism [<xref ref-type="bibr" rid="CR116">116</xref>]. IL-6 exerts its function by binding to the IL-6 receptor α chain (IL-6Rα) and the GP130 signaling chain complex in classical membrane-bound pathway. The IL-6Rα is expressed mainly on hepatocytes and immune cells, but also non-IL-6Rα-expressing cells can be rendered IL-6-responsive by a mechanism called trans-signaling [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. IL-6 trans-signaling is the process where adam proteases cleave/shed the IL-6Rα from the surface of IL-6Rα-expressing cells that when bound to serum IL-6 generates the soluble IL-6Rα (sIL-6Rα). sIL-6Rα in turn binds ubiquitously expressed GP130 on cells not expressing IL-6Rα to activate the same signaling cascade as the classical membrane IL-6Rα signaling [<xref ref-type="bibr" rid="CR94">94</xref>]. Both cascades initiate Janus kinase (JAK)2/STAT-3-dependent transcriptional activation of target genes such as SOCS-3 [<xref ref-type="bibr" rid="CR33">33</xref>]. SOCS-3 is not only a negative regulator of IL-6 signaling but also inhibits insulin signal transduction at the IRS protein level. Here, IL-6-induced SOCS-3 leads to ubiquitination and subsequent proteasomal degradation of IRS1 [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. Consistently, clinical studies link obesity-induced insulin resistance with increased IL-6 levels. Importantly, weight loss reduces circulating IL-6 and improves insulin sensitivity [<xref ref-type="bibr" rid="CR2">2</xref>]. On the other hand, however, IL-6 itself provides beneficial effects on metabolic processes such as regulation of hepatic gluconeogenesis indicating that the molecular mechanism of how IL-6 affects metabolism and insulin sensitivity is not completely understood [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. When IL-6 would exert negative effects on glucose metabolism exclusively, the expectation for IL-6 knockout mice would be the maintenance of insulin sensitivity. However, while Di Gregorio et al. did not observe metabolic alterations in IL-6 knockout mice [<xref ref-type="bibr" rid="CR16">16</xref>], Wallenius and colleagues demonstrated that IL-6 inactivation favors the development of mature onset obesity and diabetes implicating that IL-6 action on metabolism might be even more complex than hitherto assumed [<xref ref-type="bibr" rid="CR111">111</xref>].</p>
      <p>A potential aspect that may explain these differences might be the chronic/constant presence of IL-6 under obesity conditions. We have demonstrated that in diet-induced obesity, the chronically high IL-6 levels lead to the development of hepatic IL-6 resistance [<xref ref-type="bibr" rid="CR29">29</xref>]. IL-6 resistance is caused by basal IL-6-activated STAT3 that chronically increases expression of SOCS-3 [<xref ref-type="bibr" rid="CR121">121</xref>]. SOCS-3 in turn inhibits IL-6 receptor signaling, which can be identified by the inability of liver cells to react with STAT3 phosphorylation upon exogenous IL-6 treatment. Such high hepatic SOCS-3 levels might not only have impact on IL-6 signaling, but also on the insulin receptor signaling cascade by interfering with IRS proteins. Consistently, inactivation of SOCS-3 in hepatocytes improves hepatic insulin action and steatosis in young mice, but at older age, these mice develop obesity and insulin resistance due to the activation of acute phase response and overt inflammation [<xref ref-type="bibr" rid="CR103">103</xref>]. IL-6 signaling in hepatocytes therefore somehow crosstalks with liver resident KCs that are the source for the inflammatory response. In line with this evidence, inactivation of the IL-6 receptor in hepatocytes fulminates in the development of systemic insulin resistance as a consequence of KC-mediated inflammation. Thus, IL-6 signaling in hepatocytes controls whole body insulin sensitivity by limiting KC-mediated inflammation [<xref ref-type="bibr" rid="CR120">120</xref>]. Therefore, considering the differential aspects of IL-6 action under lean and obese conditions will contribute to our molecular knowledge how the low-grade metaflammation impacts on insulin signaling to ultimately result in the development of metabolic disorders. Given that IL-6 not only impacts on metabolism but also on the development of cancer and that obesity increases the incidence of cancer entities with an inflammatory microenvironment, the context-specific dissection of signaling cascades will be necessary for the development of novel therapeutic interventions to combat such fatal obesity-associated diseases [<xref ref-type="bibr" rid="CR68">68</xref>].</p>
    </sec>
    <sec id="Sec12">
      <title>Conclusion/outlook</title>
      <p>Inflammation triggered by macrophages constitutes a turning point in the development of obesity-related insulin resistance. It is not only that mediators secreted by macrophages trigger insulin resistance, at the same time, also beneficial effects exerted by ATM and KCs under homeostasis are compromised. These include maintenance of a local anti-inflammatory milieu, insulin sensitivity, and control of lipolysis and energy expenditure. Research over the last 15 years has uncovered mechanisms that drive changes in macrophage polarization and how molecules secreted by macrophages affect lipid metabolism and insulin receptor signaling in metabolic organs. The use of mouse models pointed out that macrophage polarization in adipose tissue and the liver is critical for development and progression of metabolic disease. Reprogramming from inflammatory M<sub>pro</sub> towards alternative M<sub>anti</sub> macrophages might represent a promising strategy to recover whole body insulin sensitivity that would prevent fatal diseases associated with obesity. Indeed, thiazolidinediones and omega 3 fatty acids are such exemplary drugs or dietary factors that improve metabolic disease partly by dampening macrophage-mediated inflammation [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. In this context, targeting immune cell metabolism might also hold great potential. Systemic insulin resistance is also observed during pregnancy or puberty, but most notably also during infection, in particular sepsis. During sepsis, inflammatory cytokines in particular IL-6 and TNFα induce a state of insulin resistance [<xref ref-type="bibr" rid="CR69">69</xref>]. Moreover, while in type 2 diabetes, lipolysis in adipose tissue and gluconeogenesis in the liver slowly emerge as a result of insulin resistance, inflammatory cytokines actively induce lipolysis in adipose tissue, protein catabolism in the muscle, and gluconeogenesis in the liver and muscle during sepsis. Central mediators include glucagon, epinephrine, and cortisol, which are released as a consequence of the inflammatory cascade [<xref ref-type="bibr" rid="CR32">32</xref>]. From an evolutionary point of view, this metabolic response serves to support the immune system in fighting the infection and limiting its spread throughout the body in the context of sepsis. As outlined above M<sub>pro</sub> macrophages and also other immune cells rely on glycolysis to fuel their inflammatory response to fight infection [<xref ref-type="bibr" rid="CR83">83</xref>]. In the context of type 2 diabetes and obesity, increased glucose availability to immune cells might initiate a feed forward loop that fosters inflammation and further aggravates disease.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>This article is part of the special issue on macrophages in tissue homeostasis in Pflügers Archiv – European Journal of Physiology</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>Open access funding provided by Max Planck Society. This work was supported by funds of the Deutsche Forschungsgemeinschaft (SFB1123, MARL, SFB670, FTW, TR134, FTW, KFO286, FTW, CECAD, FTW) and the Deutsche Krebshilfe (FTW).</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arkan</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Hevener</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Greten</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>ZW</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Wynshaw-Boris</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Poli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Olefsky</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Karin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>IKK-beta links inflammation to obesity-induced insulin resistance</article-title>
          <source>Nat Med</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>191</fpage>
          <lpage>198</lpage>
          <pub-id pub-id-type="doi">10.1038/nm1185</pub-id>
          <?supplied-pmid 15685170?>
          <pub-id pub-id-type="pmid">15685170</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bastard</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Jardel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bruckert</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Blondy</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Capeau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Laville</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vidal</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hainque</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2000</year>
          <volume>85</volume>
          <fpage>3338</fpage>
          <lpage>3342</lpage>
          <?supplied-pmid 10999830?>
          <pub-id pub-id-type="pmid">10999830</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Belgardt</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Mauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>FT</given-names>
            </name>
            <name>
              <surname>Ernst</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Pal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Spohn</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bronneke</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Brodesser</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hampel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schauss</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2010</year>
          <volume>107</volume>
          <fpage>6028</fpage>
          <lpage>6033</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1001796107</pub-id>
          <?supplied-pmid 20231445?>
          <pub-id pub-id-type="pmid">20231445</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berbudi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Surendar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ajendra</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gondorf</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Wardani</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Layland</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Pfeifer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hoerauf</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hubner</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>Filarial infection or antigen administration improves glucose tolerance in diet-induced obese mice</article-title>
          <source>J Innate Immun</source>
          <year>2016</year>
          <volume>8</volume>
          <fpage>601</fpage>
          <lpage>616</lpage>
          <pub-id pub-id-type="doi">10.1159/000448401</pub-id>
          <?supplied-pmid 27544668?>
          <pub-id pub-id-type="pmid">27544668</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="other">Boucher J, Kleinridders A, Kahn CR (2014) Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol 6. doi:10.1101/cshperspect.a009191</mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cai</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Frantz</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Melendez</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shoelson</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB</article-title>
          <source>Nat Med</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>183</fpage>
          <lpage>190</lpage>
          <pub-id pub-id-type="doi">10.1038/nm1166</pub-id>
          <?supplied-pmid 15685173?>
          <pub-id pub-id-type="pmid">15685173</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calle</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Kaaks</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms</article-title>
          <source>Nat Rev Cancer</source>
          <year>2004</year>
          <volume>4</volume>
          <fpage>579</fpage>
          <lpage>591</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc1408</pub-id>
          <?supplied-pmid 15286738?>
          <pub-id pub-id-type="pmid">15286738</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caricilli</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Picardi</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>de Abreu</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Ueno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Prada</surname>
              <given-names>PO</given-names>
            </name>
            <name>
              <surname>Ropelle</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Hirabara</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Castoldi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vieira</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Camara</surname>
              <given-names>NO</given-names>
            </name>
            <name>
              <surname>Curi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Carvalheira</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Saad</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice</article-title>
          <source>PLoS Biol</source>
          <year>2011</year>
          <volume>9</volume>
          <fpage>e1001212</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pbio.1001212</pub-id>
          <?supplied-pmid 22162948?>
          <pub-id pub-id-type="pmid">22162948</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Copps</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Hancer</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Opare-Ado</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Irs1 serine 307 promotes insulin sensitivity in mice</article-title>
          <source>Cell Metab</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>84</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2009.11.003</pub-id>
          <?supplied-pmid 20074531?>
          <pub-id pub-id-type="pmid">20074531</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Corre</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barreau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cousin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chavoin</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Caton</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Fournial</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Penicaud</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Casteilla</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Laharrague</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Human subcutaneous adipose cells support complete differentiation but not self-renewal of hematopoietic progenitors</article-title>
          <source>J Cell Physiol</source>
          <year>2006</year>
          <volume>208</volume>
          <fpage>282</fpage>
          <lpage>288</lpage>
          <pub-id pub-id-type="doi">10.1002/jcp.20655</pub-id>
          <?supplied-pmid 16619234?>
          <pub-id pub-id-type="pmid">16619234</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="other">Covarrubias AJ, Aksoylar HI, Yu J, Snyder NW, Worth AJ, Iyer SS, Wang J, Ben-Sahra I, Byles V, Polynne-Stapornkul T, Espinosa EC, Lamming D, Manning BD, Zhang Y, Blair IA, Horng T (2016) Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. elife 5. doi:10.7554/eLife.11612</mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cramer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamanishi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Clausen</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Forster</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Pawlinski</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mackman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Haase</surname>
              <given-names>VH</given-names>
            </name>
            <name>
              <surname>Jaenisch</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Corr</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nizet</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Firestein</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Gerber</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Ferrara</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>HIF-1alpha is essential for myeloid cell-mediated inflammation</article-title>
          <source>Cell</source>
          <year>2003</year>
          <volume>112</volume>
          <fpage>645</fpage>
          <lpage>657</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(03)00154-5</pub-id>
          <?supplied-pmid 12628185?>
          <pub-id pub-id-type="pmid">12628185</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davis</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Gabler</surname>
              <given-names>NK</given-names>
            </name>
            <name>
              <surname>Walker-Daniels</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Spurlock</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat</article-title>
          <source>Obesity (Silver Spring)</source>
          <year>2008</year>
          <volume>16</volume>
          <fpage>1248</fpage>
          <lpage>1255</lpage>
          <pub-id pub-id-type="doi">10.1038/oby.2008.210</pub-id>
          <pub-id pub-id-type="pmid">18421279</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Taeye</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Novitskaya</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>McGuinness</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Gleaves</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Medda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Covington</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Vaughan</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity</article-title>
          <source>Am J Physiol Endocrinol Metab</source>
          <year>2007</year>
          <volume>293</volume>
          <fpage>E713</fpage>
          <lpage>E725</lpage>
          <pub-id pub-id-type="doi">10.1152/ajpendo.00194.2007</pub-id>
          <?supplied-pmid 17578885?>
          <pub-id pub-id-type="pmid">17578885</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DeBerardinis</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Chandel</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <article-title>Fundamentals of cancer metabolism</article-title>
          <source>Sci Adv</source>
          <year>2016</year>
          <volume>2</volume>
          <fpage>e1600200</fpage>
          <pub-id pub-id-type="doi">10.1126/sciadv.1600200</pub-id>
          <?supplied-pmid 27386546?>
          <pub-id pub-id-type="pmid">27386546</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Gregorio</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Hensley</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ranganathan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kern</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity</article-title>
          <source>Am J Physiol Endocrinol Metab</source>
          <year>2004</year>
          <volume>287</volume>
          <fpage>E182</fpage>
          <lpage>E187</lpage>
          <pub-id pub-id-type="doi">10.1152/ajpendo.00189.2003</pub-id>
          <?supplied-pmid 15191885?>
          <pub-id pub-id-type="pmid">15191885</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dinarello</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Historical insights into cytokines</article-title>
          <source>Eur J Immunol</source>
          <year>2007</year>
          <volume>37</volume>
          <issue>Suppl 1</issue>
          <fpage>S34</fpage>
          <lpage>S45</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.200737772</pub-id>
          <?supplied-pmid 17972343?>
          <pub-id pub-id-type="pmid">17972343</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feuerer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Herrero</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cipolletta</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Naaz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nayer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Goldfine</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Benoist</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shoelson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mathis</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters</article-title>
          <source>Nat Med</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>930</fpage>
          <lpage>939</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.2002</pub-id>
          <?supplied-pmid 19633656?>
          <pub-id pub-id-type="pmid">19633656</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freemerman</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Sacks</surname>
              <given-names>GN</given-names>
            </name>
            <name>
              <surname>Milner</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Kirk</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Troester</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Macintyre</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Goraksha-Hicks</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rathmell</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Makowski</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype</article-title>
          <source>J Biol Chem</source>
          <year>2014</year>
          <volume>289</volume>
          <fpage>7884</fpage>
          <lpage>7896</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M113.522037</pub-id>
          <?supplied-pmid 24492615?>
          <pub-id pub-id-type="pmid">24492615</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Galvan-Pena</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>O’Neill</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Metabolic reprograming in macrophage polarization</article-title>
          <source>Front Immunol</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>420</fpage>
          <?supplied-pmid 25228902?>
          <pub-id pub-id-type="pmid">25228902</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Geissmann</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Littman</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Blood monocytes consist of two principal subsets with distinct migratory properties</article-title>
          <source>Immunity</source>
          <year>2003</year>
          <volume>19</volume>
          <fpage>71</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1016/S1074-7613(03)00174-2</pub-id>
          <?supplied-pmid 12871640?>
          <pub-id pub-id-type="pmid">12871640</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Tissue-resident macrophage ontogeny and homeostasis</article-title>
          <source>Immunity</source>
          <year>2016</year>
          <volume>44</volume>
          <fpage>439</fpage>
          <lpage>449</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.024</pub-id>
          <?supplied-pmid 26982352?>
          <pub-id pub-id-type="pmid">26982352</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Greter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leboeuf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nandi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>See</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gokhan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mehler</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Conway</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Samokhvalov</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Fate mapping analysis reveals that adult microglia derive from primitive macrophages</article-title>
          <source>Science</source>
          <year>2010</year>
          <volume>330</volume>
          <fpage>841</fpage>
          <lpage>845</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1194637</pub-id>
          <?supplied-pmid 20966214?>
          <pub-id pub-id-type="pmid">20966214</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schultze</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Ochando</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Biswas</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>New insights into the multidimensional concept of macrophage ontogeny, activation and function</article-title>
          <source>Nat Immunol</source>
          <year>2016</year>
          <volume>17</volume>
          <fpage>34</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.3324</pub-id>
          <?supplied-pmid 26681460?>
          <pub-id pub-id-type="pmid">26681460</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gomez Perdiguero</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Klapproth</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Busch</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Azzoni</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Crozet</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Garner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Trouillet</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>de Bruijn</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Geissmann</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rodewald</surname>
              <given-names>HR</given-names>
            </name>
          </person-group>
          <article-title>Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors</article-title>
          <source>Nature</source>
          <year>2015</year>
          <volume>518</volume>
          <fpage>547</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="doi">10.1038/nature13989</pub-id>
          <?supplied-pmid 25470051?>
          <pub-id pub-id-type="pmid">25470051</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Alternative activation of macrophages</article-title>
          <source>Nat Rev Immunol</source>
          <year>2003</year>
          <volume>3</volume>
          <fpage>23</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1038/nri978</pub-id>
          <?supplied-pmid 12511873?>
          <pub-id pub-id-type="pmid">12511873</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gosselin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Link</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Romanoski</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Eichenfield</surname>
              <given-names>DZ</given-names>
            </name>
            <name>
              <surname>Spann</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Stender</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Chun</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Garner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Geissmann</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Glass</surname>
              <given-names>CK</given-names>
            </name>
          </person-group>
          <article-title>Environment drives selection and function of enhancers controlling tissue-specific macrophage identities</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>159</volume>
          <fpage>1327</fpage>
          <lpage>1340</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2014.11.023</pub-id>
          <?supplied-pmid 25480297?>
          <pub-id pub-id-type="pmid">25480297</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gregor</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Hotamisligil</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory mechanisms in obesity</article-title>
          <source>Annu Rev Immunol</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>415</fpage>
          <lpage>445</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101322</pub-id>
          <?supplied-pmid 21219177?>
          <pub-id pub-id-type="pmid">21219177</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gruber</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Straub</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Ackermann</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Mauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Seeger</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Buning</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Heukamp</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kashkar</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schirmacher</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>FT</given-names>
            </name>
          </person-group>
          <article-title>Obesity promotes liver carcinogenesis via mcl-1 stabilization independent of IL-6Ralpha signaling</article-title>
          <source>Cell Rep</source>
          <year>2013</year>
          <volume>4</volume>
          <fpage>669</fpage>
          <lpage>680</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2013.07.023</pub-id>
          <?supplied-pmid 23954788?>
          <pub-id pub-id-type="pmid">23954788</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Morel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lakhani</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Flavell</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation</article-title>
          <source>Science</source>
          <year>2013</year>
          <volume>339</volume>
          <fpage>218</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1227568</pub-id>
          <?supplied-pmid 23223452?>
          <pub-id pub-id-type="pmid">23223452</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Brehm</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Inflammation mediated by JNK in myeloid cells promotes the development of hepatitis and hepatocellular carcinoma</article-title>
          <source>Cell Rep</source>
          <year>2016</year>
          <volume>15</volume>
          <fpage>19</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2016.03.008</pub-id>
          <?supplied-pmid 27052181?>
          <pub-id pub-id-type="pmid">27052181</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hartl</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Jauch</surname>
              <given-names>KW</given-names>
            </name>
          </person-group>
          <article-title>Metabolic self-destruction in critically ill patients: origins, mechanisms and therapeutic principles</article-title>
          <source>Nutrition</source>
          <year>2014</year>
          <volume>30</volume>
          <fpage>261</fpage>
          <lpage>267</lpage>
          <pub-id pub-id-type="doi">10.1016/j.nut.2013.07.019</pub-id>
          <?supplied-pmid 24369911?>
          <pub-id pub-id-type="pmid">24369911</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heinrich</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Behrmann</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Muller-Newen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schaper</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Graeve</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway</article-title>
          <source>Biochem J</source>
          <year>1998</year>
          <volume>334</volume>
          <issue>Pt 2</issue>
          <fpage>297</fpage>
          <lpage>314</lpage>
          <pub-id pub-id-type="doi">10.1042/bj3340297</pub-id>
          <?supplied-pmid 9716487?>
          <pub-id pub-id-type="pmid">9716487</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hevener</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Olefsky</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Reichart</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Bandyopadyhay</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Watt</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Benner</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Febbraio</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Folian</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Subramaniam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Glass</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Ricote</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones</article-title>
          <source>J Clin Invest</source>
          <year>2007</year>
          <volume>117</volume>
          <fpage>1658</fpage>
          <lpage>1669</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI31561</pub-id>
          <?supplied-pmid 17525798?>
          <pub-id pub-id-type="pmid">17525798</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirosumi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tuncman</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gorgun</surname>
              <given-names>CZ</given-names>
            </name>
            <name>
              <surname>Uysal</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Karin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hotamisligil</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>A central role for JNK in obesity and insulin resistance</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>420</volume>
          <fpage>333</fpage>
          <lpage>336</lpage>
          <pub-id pub-id-type="doi">10.1038/nature01137</pub-id>
          <?supplied-pmid 12447443?>
          <pub-id pub-id-type="pmid">12447443</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoeffel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lavin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Low</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>See</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Beaudin</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Lum</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Low</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Forsberg</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Poidinger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zolezzi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Larbi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Greter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Becher</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Samokhvalov</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages</article-title>
          <source>Immunity</source>
          <year>2015</year>
          <volume>42</volume>
          <fpage>665</fpage>
          <lpage>678</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2015.03.011</pub-id>
          <?supplied-pmid 25902481?>
          <pub-id pub-id-type="pmid">25902481</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hotamisligil</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory pathways and insulin action</article-title>
          <source>Int J Obes Relat Metab Disord</source>
          <year>2003</year>
          <volume>27</volume>
          <issue>Suppl 3</issue>
          <fpage>S53</fpage>
          <lpage>S55</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.ijo.0802502</pub-id>
          <?supplied-pmid 14704746?>
          <pub-id pub-id-type="pmid">14704746</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hotamisligil</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Inflammation and metabolic disorders</article-title>
          <source>Nature</source>
          <year>2006</year>
          <volume>444</volume>
          <fpage>860</fpage>
          <lpage>867</lpage>
          <pub-id pub-id-type="doi">10.1038/nature05485</pub-id>
          <?supplied-pmid 17167474?>
          <pub-id pub-id-type="pmid">17167474</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hotamisligil</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Shargill</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Spiegelman</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance</article-title>
          <source>Science</source>
          <year>1993</year>
          <volume>259</volume>
          <fpage>87</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="doi">10.1126/science.7678183</pub-id>
          <?supplied-pmid 7678183?>
          <pub-id pub-id-type="pmid">7678183</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hotamisligil</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Choy</surname>
              <given-names>LN</given-names>
            </name>
            <name>
              <surname>Spiegelman</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor alpha inhibits signaling from the insulin receptor</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1994</year>
          <volume>91</volume>
          <fpage>4854</fpage>
          <lpage>4858</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.91.11.4854</pub-id>
          <?supplied-pmid 8197147?>
          <pub-id pub-id-type="pmid">8197147</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Everts</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ivanova</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>O’Sullivan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Beatty</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Love-Gregory</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>O’Neill</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Abumrad</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Urban</surname>
              <given-names>JF</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Artyomov</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>EJ</given-names>
            </name>
          </person-group>
          <article-title>Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages</article-title>
          <source>Nat Immunol</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>846</fpage>
          <lpage>855</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2956</pub-id>
          <?supplied-pmid 25086775?>
          <pub-id pub-id-type="pmid">25086775</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Infantino</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Convertini</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cucci</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Panaro</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Di Noia</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Calvello</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Palmieri</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Iacobazzi</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>The mitochondrial citrate carrier: a new player in inflammation</article-title>
          <source>Biochem J</source>
          <year>2011</year>
          <volume>438</volume>
          <fpage>433</fpage>
          <lpage>436</lpage>
          <pub-id pub-id-type="doi">10.1042/BJ20111275</pub-id>
          <?supplied-pmid 21787310?>
          <pub-id pub-id-type="pmid">21787310</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inoue</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Asakawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nishizawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Teshigawara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsuki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hiramatsu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Notohara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Katayose</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Okamura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Noda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Akira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Inui</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kasuga</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Role of hepatic STAT3 in brain-insulin action on hepatic glucose production</article-title>
          <source>Cell Metab</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>267</fpage>
          <lpage>275</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2006.02.009</pub-id>
          <?supplied-pmid 16581004?>
          <pub-id pub-id-type="pmid">16581004</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iwasaki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Medzhitov</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Control of adaptive immunity by the innate immune system</article-title>
          <source>Nat Immunol</source>
          <year>2015</year>
          <volume>16</volume>
          <fpage>343</fpage>
          <lpage>353</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.3123</pub-id>
          <?supplied-pmid 25789684?>
          <pub-id pub-id-type="pmid">25789684</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacob</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Bloom</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Degenshein</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Kozinn</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Endotoxin and bacteria in portal blood</article-title>
          <source>Gastroenterology</source>
          <year>1977</year>
          <volume>72</volume>
          <fpage>1268</fpage>
          <lpage>1270</lpage>
          <?supplied-pmid 858472?>
          <pub-id pub-id-type="pmid">858472</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jager</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aparicio-Vergara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aouadi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells</article-title>
          <source>J Intern Med</source>
          <year>2016</year>
          <volume>280</volume>
          <fpage>209</fpage>
          <lpage>220</lpage>
          <pub-id pub-id-type="doi">10.1111/joim.12483</pub-id>
          <?supplied-pmid 26864622?>
          <pub-id pub-id-type="pmid">26864622</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jha</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Sergushichev</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lampropoulou</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ivanova</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Loginicheva</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chmielewski</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Ashall</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Everts</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Driggers</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Artyomov</surname>
              <given-names>MN</given-names>
            </name>
          </person-group>
          <article-title>Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization</article-title>
          <source>Immunity</source>
          <year>2015</year>
          <volume>42</volume>
          <fpage>419</fpage>
          <lpage>430</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2015.02.005</pub-id>
          <?supplied-pmid 25786174?>
          <pub-id pub-id-type="pmid">25786174</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kadowaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tobe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Honda-Yamamoto</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tamemoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kaburagi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Momomura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ueki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yamauchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Akanuma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yazaki</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Signal transduction mechanism of insulin and insulin-like growth factor-1</article-title>
          <source>Endocr J</source>
          <year>1996</year>
          <volume>43</volume>
          <issue>Suppl</issue>
          <fpage>S33</fpage>
          <lpage>S41</lpage>
          <pub-id pub-id-type="doi">10.1507/endocrj.43.Suppl_S33</pub-id>
          <?supplied-pmid 9076340?>
          <pub-id pub-id-type="pmid">9076340</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Reilly</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Karabacak</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gangl</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Fitzgerald</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hatano</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity</article-title>
          <source>Cell Metab</source>
          <year>2008</year>
          <volume>7</volume>
          <fpage>485</fpage>
          <lpage>495</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2008.04.002</pub-id>
          <?supplied-pmid 18522830?>
          <pub-id pub-id-type="pmid">18522830</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pham</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Luttrell</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bannerman</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Tupper</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Thaler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hawn</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Raines</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity</article-title>
          <source>Circ Res</source>
          <year>2007</year>
          <volume>100</volume>
          <fpage>1589</fpage>
          <lpage>1596</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.106.142851</pub-id>
          <?supplied-pmid 17478729?>
          <pub-id pub-id-type="pmid">17478729</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kitade</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sawamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nagashimada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Miyamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ginsberg</surname>
              <given-names>HN</given-names>
            </name>
            <name>
              <surname>Mukaida</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kaneko</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ota</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status</article-title>
          <source>Diabetes</source>
          <year>2012</year>
          <volume>61</volume>
          <fpage>1680</fpage>
          <lpage>1690</lpage>
          <pub-id pub-id-type="doi">10.2337/db11-1506</pub-id>
          <?supplied-pmid 22474027?>
          <pub-id pub-id-type="pmid">22474027</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klueh</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Czajkowski</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ludzinska</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Qiao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Frailey</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kreutzer</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Impact of CCL2 and CCR2 chemokine/receptor deficiencies on macrophage recruitment and continuous glucose monitoring in vivo</article-title>
          <source>Biosens Bioelectron</source>
          <year>2016</year>
          <volume>86</volume>
          <fpage>262</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bios.2016.06.026</pub-id>
          <?supplied-pmid 27376197?>
          <pub-id pub-id-type="pmid">27376197</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kolios</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Valatas</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kouroumalis</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Role of Kupffer cells in the pathogenesis of liver disease</article-title>
          <source>World J Gastroenterol</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>7413</fpage>
          <lpage>7420</lpage>
          <pub-id pub-id-type="doi">10.3748/wjg.v12.i46.7413</pub-id>
          <?supplied-pmid 17167827?>
          <pub-id pub-id-type="pmid">17167827</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kopelman</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>Obesity as a medical problem</article-title>
          <source>Nature</source>
          <year>2000</year>
          <volume>404</volume>
          <fpage>635</fpage>
          <lpage>643</lpage>
          <?supplied-pmid 10766250?>
          <pub-id pub-id-type="pmid">10766250</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kosteli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sugaru</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Haemmerle</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Lei</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zechner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ferrante</surname>
              <given-names>AW</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue</article-title>
          <source>J Clin Invest</source>
          <year>2010</year>
          <volume>120</volume>
          <fpage>3466</fpage>
          <lpage>3479</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI42845</pub-id>
          <?supplied-pmid 20877011?>
          <pub-id pub-id-type="pmid">20877011</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kratz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Hisert</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Hagman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mutskov</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Peris</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schoenfelt</surname>
              <given-names>KQ</given-names>
            </name>
            <name>
              <surname>Kuzma</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Billing</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Landerholm</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Crouthamel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gozal</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages</article-title>
          <source>Cell Metab</source>
          <year>2014</year>
          <volume>20</volume>
          <fpage>614</fpage>
          <lpage>625</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2014.08.010</pub-id>
          <?supplied-pmid 25242226?>
          <pub-id pub-id-type="pmid">25242226</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuan</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Samanta Roy</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Rakic</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Flavell</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development</article-title>
          <source>Neuron</source>
          <year>1999</year>
          <volume>22</volume>
          <fpage>667</fpage>
          <lpage>676</lpage>
          <pub-id pub-id-type="doi">10.1016/S0896-6273(00)80727-8</pub-id>
          <?supplied-pmid 10230788?>
          <pub-id pub-id-type="pmid">10230788</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lanthier</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Molendi-Coste</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Horsmans</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>van Rooijen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cani</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Leclercq</surname>
              <given-names>IA</given-names>
            </name>
          </person-group>
          <article-title>Kupffer cell activation is a causal factor for hepatic insulin resistance</article-title>
          <source>Am J Physiol Gastrointest Liver Physiol</source>
          <year>2010</year>
          <volume>298</volume>
          <fpage>G107</fpage>
          <lpage>G116</lpage>
          <pub-id pub-id-type="doi">10.1152/ajpgi.00391.2009</pub-id>
          <?supplied-pmid 19875703?>
          <pub-id pub-id-type="pmid">19875703</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lavin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Blecher-Gonen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Keren-Shaul</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Amit</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>159</volume>
          <fpage>1312</fpage>
          <lpage>1326</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2014.11.018</pub-id>
          <?supplied-pmid 25480296?>
          <pub-id pub-id-type="pmid">25480296</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawrence</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Natoli</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional regulation of macrophage polarization: enabling diversity with identity</article-title>
          <source>Nat Rev Immunol</source>
          <year>2011</year>
          <volume>11</volume>
          <fpage>750</fpage>
          <lpage>761</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3088</pub-id>
          <?supplied-pmid 22025054?>
          <pub-id pub-id-type="pmid">22025054</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Homer</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lanone</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Koteliansky</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Shipley</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Gotwals</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Noble</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Senior</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Elias</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)</article-title>
          <source>J Exp Med</source>
          <year>2001</year>
          <volume>194</volume>
          <fpage>809</fpage>
          <lpage>821</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.194.6.809</pub-id>
          <?supplied-pmid 11560996?>
          <pub-id pub-id-type="pmid">11560996</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lumeng</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Bodzin</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Saltiel</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Obesity induces a phenotypic switch in adipose tissue macrophage polarization</article-title>
          <source>J Clin Invest</source>
          <year>2007</year>
          <volume>117</volume>
          <fpage>175</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI29881</pub-id>
          <?supplied-pmid 17200717?>
          <pub-id pub-id-type="pmid">17200717</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sica</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sozzani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Allavena</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vecchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Locati</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The chemokine system in diverse forms of macrophage activation and polarization</article-title>
          <source>Trends Immunol</source>
          <year>2004</year>
          <volume>25</volume>
          <fpage>677</fpage>
          <lpage>686</lpage>
          <pub-id pub-id-type="doi">10.1016/j.it.2004.09.015</pub-id>
          <?supplied-pmid 15530839?>
          <pub-id pub-id-type="pmid">15530839</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sica</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Locati</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Macrophage polarization comes of age</article-title>
          <source>Immunity</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>344</fpage>
          <lpage>346</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2005.10.001</pub-id>
          <?supplied-pmid 16226499?>
          <pub-id pub-id-type="pmid">16226499</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <mixed-citation publication-type="other">Mass E, Ballesteros I, Farlik M, Halbritter F, Gunther P, Crozet L, Jacome-Galarza CE, Handler K, Klughammer J, Kobayashi Y, Gomez-Perdiguero E, Schultze JL, Beyer M, Bock C, Geissmann F (2016) Specification of tissue-resident macrophages during organogenesis. Science 353. doi:10.1126/science.aaf4238</mixed-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chaurasia</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Plum</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Quast</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hampel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bluher</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kolanus</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance</article-title>
          <source>PLoS Genet</source>
          <year>2010</year>
          <volume>6</volume>
          <fpage>e1000938</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pgen.1000938</pub-id>
          <?supplied-pmid 20463885?>
          <pub-id pub-id-type="pmid">20463885</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chaurasia</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Goldau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vogt</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Ruud</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Theurich</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hausen</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Schmitz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bronneke</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Estevez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Mesaros</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Partridge</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Febbraio</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>FT</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin</article-title>
          <source>Nat Immunol</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>423</fpage>
          <lpage>430</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2865</pub-id>
          <?supplied-pmid 24681566?>
          <pub-id pub-id-type="pmid">24681566</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Denson</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Versatile functions for IL-6 in metabolism and cancer</article-title>
          <source>Trends Immunol</source>
          <year>2015</year>
          <volume>36</volume>
          <fpage>92</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="doi">10.1016/j.it.2014.12.008</pub-id>
          <?supplied-pmid 25616716?>
          <pub-id pub-id-type="pmid">25616716</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mizock</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>Alterations in fuel metabolism in critical illness: hyperglycaemia</article-title>
          <source>Best Pract Res Clin Endocrinol Metab</source>
          <year>2001</year>
          <volume>15</volume>
          <fpage>533</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="doi">10.1053/beem.2001.0168</pub-id>
          <?supplied-pmid 11800522?>
          <pub-id pub-id-type="pmid">11800522</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Molofsky</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Nussbaum</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Van Dyken</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Mohapatra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Locksley</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages</article-title>
          <source>J Exp Med</source>
          <year>2013</year>
          <volume>210</volume>
          <fpage>535</fpage>
          <lpage>549</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20121964</pub-id>
          <?supplied-pmid 23420878?>
          <pub-id pub-id-type="pmid">23420878</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morinaga</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mayoral</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Heinrichsdorff</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Osborn</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Franck</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hah</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Walenta</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bandyopadhyay</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pessentheiner</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bogner-Strauss</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Olefsky</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>DY</given-names>
            </name>
          </person-group>
          <article-title>Characterization of distinct subpopulations of hepatic macrophages in HFD/obese mice</article-title>
          <source>Diabetes</source>
          <year>2015</year>
          <volume>64</volume>
          <fpage>1120</fpage>
          <lpage>1130</lpage>
          <pub-id pub-id-type="doi">10.2337/db14-1238</pub-id>
          <?supplied-pmid 25315009?>
          <pub-id pub-id-type="pmid">25315009</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mosser</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Exploring the full spectrum of macrophage activation</article-title>
          <source>Nat Rev Immunol</source>
          <year>2008</year>
          <volume>8</volume>
          <fpage>958</fpage>
          <lpage>969</lpage>
          <pub-id pub-id-type="doi">10.1038/nri2448</pub-id>
          <?supplied-pmid 19029990?>
          <pub-id pub-id-type="pmid">19029990</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Wynn</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Protective and pathogenic functions of macrophage subsets</article-title>
          <source>Nat Rev Immunol</source>
          <year>2011</year>
          <volume>11</volume>
          <fpage>723</fpage>
          <lpage>737</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3073</pub-id>
          <?supplied-pmid 21997792?>
          <pub-id pub-id-type="pmid">21997792</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neuschwander-Tetri</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites</article-title>
          <source>Hepatology</source>
          <year>2010</year>
          <volume>52</volume>
          <fpage>774</fpage>
          <lpage>788</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.23719</pub-id>
          <?supplied-pmid 20683968?>
          <pub-id pub-id-type="pmid">20683968</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nguyen</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>YP</given-names>
            </name>
            <name>
              <surname>Mwangi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mukundan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Brombacher</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Locksley</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis</article-title>
          <source>Nature</source>
          <year>2011</year>
          <volume>480</volume>
          <fpage>104</fpage>
          <lpage>108</lpage>
          <pub-id pub-id-type="doi">10.1038/nature10653</pub-id>
          <?supplied-pmid 22101429?>
          <pub-id pub-id-type="pmid">22101429</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicholas</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Sumbayev</surname>
              <given-names>VV</given-names>
            </name>
          </person-group>
          <article-title>The role of redox-dependent mechanisms in the downregulation of ligand-induced toll-like receptors 7, 8 and 4-mediated HIF-1 alpha prolyl hydroxylation</article-title>
          <source>Immunol Cell Biol</source>
          <year>2010</year>
          <volume>88</volume>
          <fpage>180</fpage>
          <lpage>186</lpage>
          <pub-id pub-id-type="doi">10.1038/icb.2009.76</pub-id>
          <?supplied-pmid 19841637?>
          <pub-id pub-id-type="pmid">19841637</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nieto-Vazquez</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fernandez-Veledo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Vila-Bedmar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Garcia-Guerra</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lorenzo</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Insulin resistance associated to obesity: the link TNF-alpha</article-title>
          <source>Arch Physiol Biochem</source>
          <year>2008</year>
          <volume>114</volume>
          <fpage>183</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="doi">10.1080/13813450802181047</pub-id>
          <?supplied-pmid 18629684?>
          <pub-id pub-id-type="pmid">18629684</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishimura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Manabe</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Nagasaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamashita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ohsugi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Otsu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ueki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sugiura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yoshimura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kadowaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity</article-title>
          <source>Nat Med</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>914</fpage>
          <lpage>920</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.1964</pub-id>
          <?supplied-pmid 19633658?>
          <pub-id pub-id-type="pmid">19633658</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Odegaard</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Ricardo-Gonzalez</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Goforth</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Morel</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Subramanian</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Mukundan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Red Eagle</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vats</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brombacher</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ferrante</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance</article-title>
          <source>Nature</source>
          <year>2007</year>
          <volume>447</volume>
          <fpage>1116</fpage>
          <lpage>1120</lpage>
          <pub-id pub-id-type="doi">10.1038/nature05894</pub-id>
          <?supplied-pmid 17515919?>
          <pub-id pub-id-type="pmid">17515919</pub-id>
        </element-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oh</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Talukdar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bae</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Morinaga</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Watkins</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Olefsky</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects</article-title>
          <source>Cell</source>
          <year>2010</year>
          <volume>142</volume>
          <fpage>687</fpage>
          <lpage>698</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2010.07.041</pub-id>
          <?supplied-pmid 20813258?>
          <pub-id pub-id-type="pmid">20813258</pub-id>
        </element-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okabe</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Medzhitov</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Tissue-specific signals control reversible program of localization and functional polarization of macrophages</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>157</volume>
          <fpage>832</fpage>
          <lpage>844</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2014.04.016</pub-id>
          <?supplied-pmid 24792964?>
          <pub-id pub-id-type="pmid">24792964</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olefsky</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Glass</surname>
              <given-names>CK</given-names>
            </name>
          </person-group>
          <article-title>Macrophages, inflammation, and insulin resistance</article-title>
          <source>Annu Rev Physiol</source>
          <year>2010</year>
          <volume>72</volume>
          <fpage>219</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev-physiol-021909-135846</pub-id>
          <?supplied-pmid 20148674?>
          <pub-id pub-id-type="pmid">20148674</pub-id>
        </element-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O’Neill</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Kishton</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Rathmell</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A guide to immunometabolism for immunologists</article-title>
          <source>Nat Rev Immunol</source>
          <year>2016</year>
          <volume>16</volume>
          <fpage>553</fpage>
          <lpage>565</lpage>
          <pub-id pub-id-type="doi">10.1038/nri.2016.70</pub-id>
          <?supplied-pmid 27396447?>
          <pub-id pub-id-type="pmid">27396447</pub-id>
        </element-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Spohn</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bronneke</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Schmidt-Supprian</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>FT</given-names>
            </name>
          </person-group>
          <article-title>Alteration of JNK-1 signaling in skeletal muscle fails to affect glucose homeostasis and obesity-associated insulin resistance in mice</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>e54247</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0054247</pub-id>
          <?supplied-pmid 23349837?>
          <pub-id pub-id-type="pmid">23349837</pub-id>
        </element-citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poglio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>De Toni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lewandowski</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Minot</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arnaud</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Barroca</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Laharrague</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Casteilla</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cousin</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>In situ production of innate immune cells in murine white adipose tissue</article-title>
          <source>Blood</source>
          <year>2012</year>
          <volume>120</volume>
          <fpage>4952</fpage>
          <lpage>4962</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2012-01-406959</pub-id>
          <?supplied-pmid 23071275?>
          <pub-id pub-id-type="pmid">23071275</pub-id>
        </element-citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poltorak</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Schraml</surname>
              <given-names>BU</given-names>
            </name>
          </person-group>
          <article-title>Fate mapping of dendritic cells</article-title>
          <source>Front Immunol</source>
          <year>2015</year>
          <volume>6</volume>
          <fpage>199</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2015.00199</pub-id>
          <?supplied-pmid 25999945?>
          <pub-id pub-id-type="pmid">25999945</pub-id>
        </element-citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reilly</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Ahmadian</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zamarron</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Uhm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Poirier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Krause</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Korytnaya</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Neidert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Liddle</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Lumeng</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Oral</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Downes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Saltiel</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis</article-title>
          <source>Nat Commun</source>
          <year>2015</year>
          <volume>6</volume>
          <fpage>6047</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms7047</pub-id>
          <?supplied-pmid 25581158?>
          <pub-id pub-id-type="pmid">25581158</pub-id>
        </element-citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Harmon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>O’Farrelly</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Liver immunology and its role in inflammation and homeostasis</article-title>
          <source>Cell Mol Immunol</source>
          <year>2016</year>
          <volume>13</volume>
          <fpage>267</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="doi">10.1038/cmi.2016.3</pub-id>
          <?supplied-pmid 27063467?>
          <pub-id pub-id-type="pmid">27063467</pub-id>
        </element-citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rohl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pasparakis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Baudler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Baumgartl</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gautam</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Huth</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Lorenzi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Krone</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Rajewsky</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance</article-title>
          <source>J Clin Invest</source>
          <year>2004</year>
          <volume>113</volume>
          <fpage>474</fpage>
          <lpage>481</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200418712</pub-id>
          <?supplied-pmid 14755344?>
          <pub-id pub-id-type="pmid">14755344</pub-id>
        </element-citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Giles</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Kharfan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>O’Donnell</surname>
              <given-names>VB</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal</article-title>
          <source>Science</source>
          <year>2014</year>
          <volume>344</volume>
          <fpage>645</fpage>
          <lpage>648</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1251414</pub-id>
          <?supplied-pmid 24762537?>
          <pub-id pub-id-type="pmid">24762537</pub-id>
        </element-citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruiz-Garcia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Monsalve</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Novellasdemunt</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Navarro-Sabate</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Manzano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rivero</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Castrillo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Casado</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Laborda</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bartrons</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Diaz-Guerra</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Cooperation of adenosine with macrophage toll-4 receptor agonists leads to increased glycolytic flux through the enhanced expression of PFKFB3 gene</article-title>
          <source>J Biol Chem</source>
          <year>2011</year>
          <volume>286</volume>
          <fpage>19247</fpage>
          <lpage>19258</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M110.190298</pub-id>
          <?supplied-pmid 21464136?>
          <pub-id pub-id-type="pmid">21464136</pub-id>
        </element-citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sabio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mora</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Jun</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Ko</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>A stress signaling pathway in adipose tissue regulates hepatic insulin resistance</article-title>
          <source>Science</source>
          <year>2008</year>
          <volume>322</volume>
          <fpage>1539</fpage>
          <lpage>1543</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1160794</pub-id>
          <?supplied-pmid 19056984?>
          <pub-id pub-id-type="pmid">19056984</pub-id>
        </element-citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saltiel</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Insulin signaling in the control of glucose and lipid homeostasis</article-title>
          <source>Handb Exp Pharmacol</source>
          <year>2016</year>
          <volume>233</volume>
          <fpage>51</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="doi">10.1007/164_2015_14</pub-id>
          <?supplied-pmid 26721672?>
          <pub-id pub-id-type="pmid">26721672</pub-id>
        </element-citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scheller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chalaris</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schmidt-Arras</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rose-John</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The pro- and anti-inflammatory properties of the cytokine interleukin-6</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2011</year>
          <volume>1813</volume>
          <fpage>878</fpage>
          <lpage>888</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.01.034</pub-id>
          <?supplied-pmid 21296109?>
          <pub-id pub-id-type="pmid">21296109</pub-id>
        </element-citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmitz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Evers</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Awazawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nicholls</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Bronneke</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Dietrich</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bluher</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Obesogenic memory can confer long-term increases in adipose tissue but not liver inflammation and insulin resistance after weight loss</article-title>
          <source>Mol Metab</source>
          <year>2016</year>
          <volume>5</volume>
          <fpage>328</fpage>
          <lpage>339</lpage>
          <pub-id pub-id-type="doi">10.1016/j.molmet.2015.12.001</pub-id>
          <?supplied-pmid 27110485?>
          <pub-id pub-id-type="pmid">27110485</pub-id>
        </element-citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schulz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gomez Perdiguero</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chorro</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Szabo-Rogers</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cagnard</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kierdorf</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Prinz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Pollard</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Frampton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Geissmann</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>A lineage of myeloid cells independent of Myb and hematopoietic stem cells</article-title>
          <source>Science</source>
          <year>2012</year>
          <volume>336</volume>
          <fpage>86</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1219179</pub-id>
          <?supplied-pmid 22442384?>
          <pub-id pub-id-type="pmid">22442384</pub-id>
        </element-citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selak</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Armour</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>MacKenzie</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Boulahbel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Mansfield</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase</article-title>
          <source>Cancer Cell</source>
          <year>2005</year>
          <volume>7</volume>
          <fpage>77</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccr.2004.11.022</pub-id>
          <?supplied-pmid 15652751?>
          <pub-id pub-id-type="pmid">15652751</pub-id>
        </element-citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ruedl</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Karjalainen</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Most tissue-resident macrophages except microglia are derived from fetal hematopoietic stem cells</article-title>
          <source>Immunity</source>
          <year>2015</year>
          <volume>43</volume>
          <fpage>382</fpage>
          <lpage>393</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2015.07.016</pub-id>
          <?supplied-pmid 26287683?>
          <pub-id pub-id-type="pmid">26287683</pub-id>
        </element-citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siegert</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Schodel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schatz</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Dettmer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dick</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kalucka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Franke</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ehrenschwender</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schley</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Beneke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sutter</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moll</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hellerbrand</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wielockx</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Katschinski</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Galy</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hentze</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Koivunen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Oefner</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Bogdan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Willam</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jantsch</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Ferritin-mediated iron sequestration stabilizes hypoxia-inducible factor-1alpha upon LPS activation in the presence of ample oxygen</article-title>
          <source>Cell Rep</source>
          <year>2015</year>
          <volume>13</volume>
          <fpage>2048</fpage>
          <lpage>2055</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2015.11.005</pub-id>
          <?supplied-pmid 26628374?>
          <pub-id pub-id-type="pmid">26628374</pub-id>
        </element-citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sierra-Filardi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vega</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sanchez-Mateos</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Corbi</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Puig-Kroger</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Heme oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release</article-title>
          <source>Immunobiology</source>
          <year>2010</year>
          <volume>215</volume>
          <fpage>788</fpage>
          <lpage>795</lpage>
          <pub-id pub-id-type="doi">10.1016/j.imbio.2010.05.020</pub-id>
          <?supplied-pmid 20580464?>
          <pub-id pub-id-type="pmid">20580464</pub-id>
        </element-citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Xiang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Rosner</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis</article-title>
          <source>Mol Cell Biol</source>
          <year>2002</year>
          <volume>22</volume>
          <fpage>8571</fpage>
          <lpage>8579</lpage>
          <pub-id pub-id-type="doi">10.1128/MCB.22.24.8571-8579.2002</pub-id>
          <?supplied-pmid 12446776?>
          <pub-id pub-id-type="pmid">12446776</pub-id>
        </element-citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tannahill</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Adamik</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Palsson-McDermott</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>McGettrick</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Goel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Frezza</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bernard</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gardet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tong</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Jany</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Corr</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Haneklaus</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Caffrey</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Pierce</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Walmsley</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Beasley</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Cummins</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nizet</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Whyte</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Masters</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>VP</given-names>
            </name>
            <name>
              <surname>Clish</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Auron</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Xavier</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>O’Neill</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha</article-title>
          <source>Nature</source>
          <year>2013</year>
          <volume>496</volume>
          <fpage>238</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1038/nature11986</pub-id>
          <?supplied-pmid 23535595?>
          <pub-id pub-id-type="pmid">23535595</pub-id>
        </element-citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torisu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yoshiga</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoshioka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Iida</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yoshimura</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The dual function of hepatic SOCS3 in insulin resistance in vivo</article-title>
          <source>Genes Cells</source>
          <year>2007</year>
          <volume>12</volume>
          <fpage>143</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2443.2007.01044.x</pub-id>
          <?supplied-pmid 17295835?>
          <pub-id pub-id-type="pmid">17295835</pub-id>
        </element-citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ueki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kondo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms</article-title>
          <source>Mol Cell Biol</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>5434</fpage>
          <lpage>5446</lpage>
          <pub-id pub-id-type="doi">10.1128/MCB.24.12.5434-5446.2004</pub-id>
          <?supplied-pmid 15169905?>
          <pub-id pub-id-type="pmid">15169905</pub-id>
        </element-citation>
      </ref>
      <ref id="CR105">
        <label>105.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ueki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kondo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tseng</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>10422</fpage>
          <lpage>10427</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0402511101</pub-id>
          <?supplied-pmid 15240880?>
          <pub-id pub-id-type="pmid">15240880</pub-id>
        </element-citation>
      </ref>
      <ref id="CR106">
        <label>106.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uysal</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Wiesbrock</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Marino</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Hotamisligil</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function</article-title>
          <source>Nature</source>
          <year>1997</year>
          <volume>389</volume>
          <fpage>610</fpage>
          <lpage>614</lpage>
          <pub-id pub-id-type="doi">10.1038/39335</pub-id>
          <?supplied-pmid 9335502?>
          <pub-id pub-id-type="pmid">9335502</pub-id>
        </element-citation>
      </ref>
      <ref id="CR107">
        <label>107.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Herpen</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Schrauwen-Hinderling</surname>
              <given-names>VB</given-names>
            </name>
          </person-group>
          <article-title>Lipid accumulation in non-adipose tissue and lipotoxicity</article-title>
          <source>Physiol Behav</source>
          <year>2008</year>
          <volume>94</volume>
          <fpage>231</fpage>
          <lpage>241</lpage>
          <pub-id pub-id-type="doi">10.1016/j.physbeh.2007.11.049</pub-id>
          <?supplied-pmid 18222498?>
          <pub-id pub-id-type="pmid">18222498</pub-id>
        </element-citation>
      </ref>
      <ref id="CR108">
        <label>108.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vander Heiden</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Cantley</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>CB</given-names>
            </name>
          </person-group>
          <article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title>
          <source>Science</source>
          <year>2009</year>
          <volume>324</volume>
          <fpage>1029</fpage>
          <lpage>1033</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1160809</pub-id>
          <?supplied-pmid 19460998?>
          <pub-id pub-id-type="pmid">19460998</pub-id>
        </element-citation>
      </ref>
      <ref id="CR109">
        <label>109.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vats</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mukundan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Odegaard</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Morel</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Greaves</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation</article-title>
          <source>Cell Metab</source>
          <year>2006</year>
          <volume>4</volume>
          <fpage>13</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2006.05.011</pub-id>
          <?supplied-pmid 16814729?>
          <pub-id pub-id-type="pmid">16814729</pub-id>
        </element-citation>
      </ref>
      <ref id="CR110">
        <label>110.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vernia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cavanagh-Kyros</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Garcia-Haro</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sabio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shulha</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Garber</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>The PPARalpha-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway</article-title>
          <source>Cell Metab</source>
          <year>2014</year>
          <volume>20</volume>
          <fpage>512</fpage>
          <lpage>525</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2014.06.010</pub-id>
          <?supplied-pmid 25043817?>
          <pub-id pub-id-type="pmid">25043817</pub-id>
        </element-citation>
      </ref>
      <ref id="CR111">
        <label>111.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallenius</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Wallenius</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ahren</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rudling</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carlsten</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Ohlsson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jansson</surname>
              <given-names>JO</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-6-deficient mice develop mature-onset obesity</article-title>
          <source>Nat Med</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>75</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="doi">10.1038/nm0102-75</pub-id>
          <?supplied-pmid 11786910?>
          <pub-id pub-id-type="pmid">11786910</pub-id>
        </element-citation>
      </ref>
      <ref id="CR112">
        <label>112.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weisberg</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>McCann</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rosenbaum</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leibel</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Ferrante</surname>
              <given-names>AW</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Obesity is associated with macrophage accumulation in adipose tissue</article-title>
          <source>J Clin Invest</source>
          <year>2003</year>
          <volume>112</volume>
          <fpage>1796</fpage>
          <lpage>1808</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200319246</pub-id>
          <?supplied-pmid 14679176?>
          <pub-id pub-id-type="pmid">14679176</pub-id>
        </element-citation>
      </ref>
      <ref id="CR113">
        <label>113.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weisberg</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lemieux</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Slaymaker</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vaddi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Charo</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Leibel</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Ferrante</surname>
              <given-names>AW</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>CCR2 modulates inflammatory and metabolic effects of high-fat feeding</article-title>
          <source>J Clin Invest</source>
          <year>2006</year>
          <volume>116</volume>
          <fpage>115</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI24335</pub-id>
          <?supplied-pmid 16341265?>
          <pub-id pub-id-type="pmid">16341265</pub-id>
        </element-citation>
      </ref>
      <ref id="CR114">
        <label>114.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wensveen</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Jelencic</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Valentic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sestan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wensveen</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Theurich</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Glasner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mendrila</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stimac</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>FT</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Mandelboim</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Polic</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>NK cells link obesity-induced adipose stress to inflammation and insulin resistance</article-title>
          <source>Nat Immunol</source>
          <year>2015</year>
          <volume>16</volume>
          <fpage>376</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.3120</pub-id>
          <?supplied-pmid 25729921?>
          <pub-id pub-id-type="pmid">25729921</pub-id>
        </element-citation>
      </ref>
      <ref id="CR115">
        <label>115.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>West</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Brodsky</surname>
              <given-names>IE</given-names>
            </name>
            <name>
              <surname>Rahner</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Woo</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Erdjument-Bromage</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tempst</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shadel</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>TLR signalling augments macrophage bactericidal activity through mitochondrial ROS</article-title>
          <source>Nature</source>
          <year>2011</year>
          <volume>472</volume>
          <fpage>476</fpage>
          <lpage>480</lpage>
          <pub-id pub-id-type="doi">10.1038/nature09973</pub-id>
          <?supplied-pmid 21525932?>
          <pub-id pub-id-type="pmid">21525932</pub-id>
        </element-citation>
      </ref>
      <ref id="CR116">
        <label>116.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whitham</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Pal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matthews</surname>
              <given-names>VB</given-names>
            </name>
            <name>
              <surname>Prelovsek</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Lunke</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>El-Osta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Broenneke</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Alber</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>FT</given-names>
            </name>
            <name>
              <surname>Lancaster</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Febbraio</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Contraction-induced interleukin-6 gene transcription in skeletal muscle is regulated by c-Jun terminal kinase/activator protein-1</article-title>
          <source>J Biol Chem</source>
          <year>2012</year>
          <volume>287</volume>
          <fpage>10771</fpage>
          <lpage>10779</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M111.310581</pub-id>
          <?supplied-pmid 22351769?>
          <pub-id pub-id-type="pmid">22351769</pub-id>
        </element-citation>
      </ref>
      <ref id="CR117">
        <label>117.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Paltser</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Truong</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tsui</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bahrami</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dorfman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zielenski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mastronardi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Maezawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Drucker</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Engleman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Winer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dosch</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Normalization of obesity-associated insulin resistance through immunotherapy</article-title>
          <source>Nat Med</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>921</fpage>
          <lpage>929</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.2001</pub-id>
          <?supplied-pmid 19633657?>
          <pub-id pub-id-type="pmid">19633657</pub-id>
        </element-citation>
      </ref>
      <ref id="CR118">
        <label>118.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wree</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kahraman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gerken</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Canbay</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Obesity affects the liver - the link between adipocytes and hepatocytes</article-title>
          <source>Digestion</source>
          <year>2011</year>
          <volume>83</volume>
          <fpage>124</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="doi">10.1159/000318741</pub-id>
          <?supplied-pmid 21042023?>
          <pub-id pub-id-type="pmid">21042023</pub-id>
        </element-citation>
      </ref>
      <ref id="CR119">
        <label>119.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wunderlich</surname>
              <given-names>FT</given-names>
            </name>
            <name>
              <surname>Luedde</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schmidt-Supprian</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Baumgartl</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schirmacher</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pasparakis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2008</year>
          <volume>105</volume>
          <fpage>1297</fpage>
          <lpage>1302</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0707849104</pub-id>
          <?supplied-pmid 18216263?>
          <pub-id pub-id-type="pmid">18216263</pub-id>
        </element-citation>
      </ref>
      <ref id="CR120">
        <label>120.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wunderlich</surname>
              <given-names>FT</given-names>
            </name>
            <name>
              <surname>Strohle</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Konner</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Gruber</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tovar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bronneke</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Juntti-Berggren</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>van Rooijen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Libert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Berggren</surname>
              <given-names>PO</given-names>
            </name>
            <name>
              <surname>Bruning</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action</article-title>
          <source>Cell Metab</source>
          <year>2010</year>
          <volume>12</volume>
          <fpage>237</fpage>
          <lpage>249</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2010.06.011</pub-id>
          <?supplied-pmid 20816090?>
          <pub-id pub-id-type="pmid">20816090</pub-id>
        </element-citation>
      </ref>
      <ref id="CR121">
        <label>121.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wunderlich</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Hovelmeyer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>FT</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity</article-title>
          <source>JAKSTAT</source>
          <year>2013</year>
          <volume>2</volume>
          <fpage>e23878</fpage>
          <?supplied-pmid 24058813?>
          <pub-id pub-id-type="pmid">24058813</pub-id>
        </element-citation>
      </ref>
      <ref id="CR122">
        <label>122.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Sole</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Tartaglia</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance</article-title>
          <source>J Clin Invest</source>
          <year>2003</year>
          <volume>112</volume>
          <fpage>1821</fpage>
          <lpage>1830</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200319451</pub-id>
          <?supplied-pmid 14679177?>
          <pub-id pub-id-type="pmid">14679177</pub-id>
        </element-citation>
      </ref>
      <ref id="CR123">
        <label>123.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Grijalva</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Skowronski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>van Eijk</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Serlie</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Ferrante</surname>
              <given-names>AW</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation</article-title>
          <source>Cell Metab</source>
          <year>2013</year>
          <volume>18</volume>
          <fpage>816</fpage>
          <lpage>830</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2013.11.001</pub-id>
          <?supplied-pmid 24315368?>
          <pub-id pub-id-type="pmid">24315368</pub-id>
        </element-citation>
      </ref>
      <ref id="CR124">
        <label>124.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yona</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mildner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Varol</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Breker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Strauss-Ayali</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Viukov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Misharin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hume</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Perlman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Malissen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zelzer</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis</article-title>
          <source>Immunity</source>
          <year>2013</year>
          <volume>38</volume>
          <fpage>79</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2012.12.001</pub-id>
          <?supplied-pmid 23273845?>
          <pub-id pub-id-type="pmid">23273845</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362666</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Int J Comput Assist Radiol Surg</journal-id>
      <journal-id journal-id-type="iso-abbrev">Int J Comput Assist Radiol Surg</journal-id>
      <journal-title-group>
        <journal-title>International Journal of Computer Assisted Radiology and Surgery</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1861-6410</issn>
      <issn pub-type="epub">1861-6429</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362666</article-id>
      <article-id pub-id-type="pmcid">PMC5362666</article-id>
      <article-id pub-id-type="pmc-uid">5362666</article-id>
      <article-id pub-id-type="pmid">28028655</article-id>
      <article-id pub-id-type="publisher-id">1511</article-id>
      <article-id pub-id-type="doi">10.1007/s11548-016-1511-3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3779-5615</contrib-id>
          <name>
            <surname>Chen</surname>
            <given-names>Mitchell</given-names>
          </name>
          <address>
            <email>d.mitch.chen@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Helm</surname>
            <given-names>Emma</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Joshi</surname>
            <given-names>Niranjan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gleeson</surname>
            <given-names>Fergus</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brady</surname>
            <given-names>Michael</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution>Institute of Biomedical Engineering, </institution><institution>University of Oxford, </institution></institution-wrap>Old Road Campus Research Building, Oxford, OX3 7DQ England </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0440 1440</institution-id><institution-id institution-id-type="GRID">grid.410556.3</institution-id><institution>The Churchill Hospital, </institution><institution>Oxford University Hospitals NHS Trust, </institution></institution-wrap>Old Road, Headington, OX3 7LE England </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>27</day>
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>12</volume>
      <issue>4</issue>
      <fpage>529</fpage>
      <lpage>538</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>12</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Objective</title>
          <p>The aim of this study is to assess the performance of a computer-aided semi-automated algorithm we have adapted for the purpose of segmenting malignant pleural mesothelioma (MPM) on CT.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Forty-five CT scans were collected from 15 patients (M:F <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$=$$\end{document}</tex-math><mml:math id="M2"><mml:mo>=</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq1.gif"/></alternatives></inline-formula> 10:5, mean age 62.8 years) in a multi-centre clinical drug trial. A computer-aided random walk-based algorithm was applied to segment the tumour; the results were then compared to radiologist-drawn contours and correlated with measurements made using the MPM-adapted Response Evaluation Criteria in Solid Tumour (modified RECIST).</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>A mean accuracy (Sørensen–Dice index) of 0.825 (95% CI [0.758, 0.892]) was achieved. Compared to a median measurement time of 68.1 min (range [40.2, 102.4]) for manual delineation, the median running time of our algorithm was 23.1 min (range [10.9, 37.0]). A linear correlation (Pearson’s correlation coefficient: 0.6392, <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p &lt; 0.05$$\end{document}</tex-math><mml:math id="M4"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq2.gif"/></alternatives></inline-formula>) was established between the changes in modified RECIST and computed tumour volume.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Volumetric tumour segmentation offers a potential solution to the challenges in quantifying MPM. Computer-assisted methods such as the one presented in this study facilitate this in an accurate and time-efficient manner and provide additional morphological information about the tumour’s evolution over time.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Malignant pleural mesothelioma</kwd>
        <kwd>Quantitative tumour measurement</kwd>
        <kwd>Computed tomography</kwd>
        <kwd>Image processing</kwd>
        <kwd>Therapy response assessment</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>NIHR Biomedical Research Centre</institution>
          </funding-source>
          <award-id>ID0E3VAE1434</award-id>
          <principal-award-recipient>
            <name>
              <surname>Gleeson</surname>
              <given-names>Fergus</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© CARS 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Malignant pleural mesothelioma (MPM) is an aggressive thoracic malignancy that is closely linked to past exposure to asbestos. It is currently responsible for over 47,000 annual deaths worldwide, a number which continues to increase despite legal restrictions limiting the use of asbestos in many countries [<xref ref-type="bibr" rid="CR1">1</xref>]. MPM is currently the greatest single cause of work-related deaths in the UK [<xref ref-type="bibr" rid="CR2">2</xref>]. Although the production of asbestos was gradually phased out in the 1980s, the disease’s long latency period, typically ranging from 30 to 40 years, has caused a continuing rising trend of MPM in the country, which is projected to peak in 2020 [<xref ref-type="bibr" rid="CR3">3</xref>]. Moreover, asbestos is still being harvested and used in the developing world, most notably in China and India, where MPM is rapidly becoming a prominent occupational health concern [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p>MPM usually originates in the parietal pleura of the lung and grows as a ‘rind’ around the pleural surface. It has a tendency to encase the affected lung, severely impairing its ventilatory function. The detection of early-stage MPM on CT is difficult because of the complexity of thoracic anatomy and the challenge in distinguishing the tumour from neighbouring tissues, in terms of both pixel intensity and regional texture. A sample CT axial slice, with the relevant thoracic tissues highlighted, is shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. Intensity distributions of these tissues (in Hounsfield units) are shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. Their overlapping nature, hence the tumour’s low contrast on CT, is evident.<fig id="Fig1"><label>Fig. 1</label><caption><p>Sample CT image slice with key regional tissues <italic>highlighted</italic>. Tumour is shown in <italic>orange</italic>. <bold>a</bold> Original, <bold>b</bold> segmented CT</p></caption><graphic xlink:href="11548_2016_1511_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Probabilistic intensity distributions of the overall image scan and individual tissues in the thorax. <bold>a</bold> Overall scan, <bold>b</bold> individual tissues</p></caption><graphic xlink:href="11548_2016_1511_Fig2_HTML" id="MO2"/></fig>
</p>
      <p>To quantify the progression of a tumour and its response to treatment in clinical trials and patient follow-ups, current clinical practice recommends the use of MPM-adapted Response Evaluation Criteria in Solid Tumour (modified RECIST) [<xref ref-type="bibr" rid="CR6">6</xref>]. This quantifies the tumour based on a one-dimensional measurement of its thickness at two locations on three axial levels of the scan. A major drawback of modified RECIST is that it measures the tumour at just six singular points, irrespective of the tumour’s overall shape and growth pattern. As a result, it is known to be prone to intra-observer and inter-observer variations. In one study [<xref ref-type="bibr" rid="CR7">7</xref>], major and minor disagreements were found in 40% and 10.5% of the cases, respectively. Such discrepancies can largely be attributed to the inconsistent selection of measurable lesions and radiological artefacts such as the partial volume effect, which gives rise to ambiguous tissue boundaries. Additionally, being one dimensional in nature, the system fails to adequately address tumour growth in the axial direction. Overall, considering the low CT contrast between the MPM tumour and surrounding tissues and the tumour’s characteristic ‘rind-pattern’ growth, modified RECIST is limited both in its ease of application, consistency and overall clinical utility.</p>
      <p>Noting the limitations of modified RECIST, previous works on MPM [<xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR16">16</xref>] have supported the use of segmented tumour volumes for evaluating the tumour’s response to treatments.</p>
      <p>Ak et al. [<xref ref-type="bibr" rid="CR8">8</xref>] estimated the tumour volume by counting the number of evenly spaced dots that fall within the tumour boundary, as determined by the clinical observer. Though the results showed good correlation with patient survival and prognostic data, it remains a manual method, which would require tedious and time-consuming radiological supervision.</p>
      <p>Armato et al. [<xref ref-type="bibr" rid="CR9">9</xref>] developed an automated method to compute for modified RECIST. This method works by first segmenting the lungs by thresholding to mark the inner margin of the tumour, followed by taking a thickness measurement perpendicular to the nearby chest wall or mediastinum. The results were presented in terms of ‘clinical acceptance rate’, as determined by trained radiologists, which was found to be as high as 75%. Although this approach offers some guidance for making RECIST measurements, it still makes use of the modified RECIST framework and does not tackle its intrinsic limitations.</p>
      <p>In view of the challenging nature of automated MPM segmentation, Frauenfelder et al. [<xref ref-type="bibr" rid="CR10">10</xref>] applied interpolation to hand-drawn tumour contours found on every 4–5 axial cuts. Inter-observer agreement of the segmented tumour was reported to be significantly higher than that of modified RECIST (<inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\kappa =0.9$$\end{document}</tex-math><mml:math id="M6"><mml:mrow><mml:mi mathvariant="italic">κ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.9</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq3.gif"/></alternatives></inline-formula> vs <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\kappa =0.33$$\end{document}</tex-math><mml:math id="M8"><mml:mrow><mml:mi mathvariant="italic">κ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.33</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq4.gif"/></alternatives></inline-formula>). However, although interpolation helped reduce the workload, the method did not circumvent the need for manual drawing.</p>
      <p>Liu et al. [<xref ref-type="bibr" rid="CR11">11</xref>] presented some preliminary works on a volume-based MPM tumour evaluation, where the authors studied the baseline and follow-up data collected from 30 patients and found patient survival to be linked to baseline tumour volume with a good degree of certainty.</p>
      <p>Chaosaowong et al. [<xref ref-type="bibr" rid="CR14">14</xref>] introduced a method that computes a contour containing the tumour and pleura. Assuming a convex shape for the pleura, concave irregularities are treated as potential sites of pleural thickening, which would undergo thresholding before the final classification. In addition to being prone to thresholding-related issues, this approach made numerous assumptions about the tumour’s pattern of growth, which would limit its applicability in a wider clinical context.</p>
      <p>Sensakovic et al. [<xref ref-type="bibr" rid="CR15">15</xref>] applied a more advanced MPM segmentation method based on a nonlinear diffusion model and a k-class classifier. For each of the 31 MPM scans examined in the study, 5 axial scans were segmented on a 2-D basis and validated by manual delineations made by five independent clinical observers. Mean Jaccard similarity coefficient (J-index) was found to be 0.517 (<inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p &lt; 0.05$$\end{document}</tex-math><mml:math id="M10"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq5.gif"/></alternatives></inline-formula>) between observers and 0.484 (<inline-formula id="IEq6"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&lt; 0.05$$\end{document}</tex-math><mml:math id="M12"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq6.gif"/></alternatives></inline-formula>) between manual and computed segmentations, which is less than ideal for a wider clinical application. It should also be noted that this method was implemented in 2-D, tested only with diagnostic imaging data, and did not allow the clinician to influence the segmentation itself through user interaction. Labby et al. [<xref ref-type="bibr" rid="CR16">16</xref>] added an interpolation component to the 2-D method of Sensakovic et al. and extended its scope to MPM follow-up studies. An inverse relationship was reported between the tumour and aerated lung volumes, which is in line with clinical expectation.</p>
      <p>It should be noted despite the above efforts, a method that is capable of segmenting all tumour cases accurately is yet to be established.</p>
      <p>The segmentation of MPM presents numerous application-specific challenges, one of which is due to the similarity in CT attenuation of an MPM lesion with its neighbouring tissues. This is made worse by the presence of atelectatic lungs and pleural effusion; commonly found in patients with clinically evident MPM. This largely precludes the direct application of simple segmentation methods such as thresholding, region growing, texture filtering, and active contours. The tumour may also grow in finger-like projections along the lung fissures or hilar vessels and can invade the neighbouring structures. This would severely affect the performance of shape and morphology-based methods [<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover, the long thin shape of the tumour, anatomical complexity of the thoracic region, in particular due to secondary chest conditions such as pleural effusion, intrinsic image noise, and partial volume effect, pose considerable challenges which collectively prevent the application of many established segmentation methods.</p>
      <p>In this paper, we present a computer-aided segmentation algorithm that is capable of accurately segmenting the MPM tumour and has the ability to incorporate input from end-users with good robustness.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods and materials</title>
      <sec id="Sec3">
        <title>Study design</title>
        <p>The data used in this study were collected from a Phase II clinical trial of Vinflunine, which was tested as a therapeutic agent for MPM across nine centres in the UK, France, and Germany. Specifics on the trial design and outcome are given in [<xref ref-type="bibr" rid="CR17">17</xref>]. Informed consent was obtained from all individual participants included in the study.</p>
        <p>For our study, data from the UK centres were available, collected from 15 patients, with a total of 48 baseline and follow-up CT scans. Patient characteristics are given in Table <xref rid="Tab1" ref-type="table">1</xref>. All patients had histologically and cytologically confirmed cases of mesothelioma and at least one lesion that satisfied the measurability criteria in modified RECIST (defined as pleural tumour thickness of at least 5 mm at three locations on the CT scan, with a sum &gt;20 mm). Each participant received one baseline scan and between one to three follow-up scans. All scans are valid for assessing tumour responses under modified RECIST (i.e. at least four weeks have lapsed between subsequent scans). Patients were treated until either disease progression or unacceptable chemotherapeutic toxicity.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Value</th></tr></thead><tbody><tr><td align="left">Patient number</td><td align="left">15</td></tr><tr><td align="left">Mean age (range in years)</td><td align="left">62.8 (47.9–79.7)</td></tr><tr><td align="left">Male/female [<italic>n</italic> (%)]</td><td align="left">10:5 (67:33)</td></tr><tr><td align="left">Karnofsky performance status (%)</td><td align="left"/></tr><tr><td align="left">   80</td><td align="left">7 (46.7)</td></tr><tr><td align="left">   90</td><td align="left">7 (46.7)</td></tr><tr><td align="left">   100</td><td align="left">1 (6.7)</td></tr><tr><td align="left">Histologic type [<italic>n</italic> (%)]</td><td align="left"/></tr><tr><td align="left">   Epithelial</td><td align="left">12 (80.0)</td></tr><tr><td align="left">   Mixed</td><td align="left">2 (13.3)</td></tr><tr><td align="left">   Not specified</td><td align="left">1 (6.7)</td></tr><tr><td align="left">Stage at initial diagnosis (IMIG classification) (%)</td><td align="left"/></tr><tr><td align="left">   I</td><td align="left">1 (6.7)</td></tr><tr><td align="left">   II</td><td align="left">3 (20.1)</td></tr><tr><td align="left">   III</td><td align="left">7 (43.3)</td></tr><tr><td align="left">   IV</td><td align="left">4 (29.9)</td></tr></tbody></table></table-wrap>
</p>
        <p>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Key steps in the computer-aided method</p></caption><graphic xlink:href="11548_2016_1511_Fig3_HTML" id="MO3"/></fig>
</p>
      </sec>
      <sec id="Sec4">
        <title>Data collection</title>
        <p>The CT examinations were performed on a LightSpeed Ultra CT scanner (General Electric Medical Systems). Each CT scan consisted of multiple axial slices of <inline-formula id="IEq7"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$512 \times 512$$\end{document}</tex-math><mml:math id="M14"><mml:mrow><mml:mn>512</mml:mn><mml:mo>×</mml:mo><mml:mn>512</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq7.gif"/></alternatives></inline-formula> pixels. An assortment of thick (5 mm), thin (2.5 mm), and quasi-isotropic (0.625 mm) scans was available, with a voxel spacing of 0.68 mm. No contrast enhancing agent was used.</p>
      </sec>
      <sec id="Sec5">
        <title>Random walk-based image segmentation</title>
        <p>We implemented the semi-automatic random walk-based segmentation method by Grady [<xref ref-type="bibr" rid="CR18">18</xref>], where details of the mathematical formulation are presented. The method handles weak tissue boundaries well and is able to segment any arbitrary shapes with appropriately placed seeds.</p>
        <p>The key steps in our segmentation algorithm are outlined in Fig. <xref rid="Fig3" ref-type="fig">3</xref>.</p>
        <p>We have extended Grady’s original method to 3-D based on a nine-connected graph model, aiming to improve the algorithm performance by adopting additional image information from adjacent axial slices for classifying the image voxel in question. Performance-wise, it is superior to simple interpolation applied in the vertical axis because uneven tumour growth and anatomical irregularities are dealt with equally in the planar and inter-planar domains and are therefore better accounted for.</p>
        <p>Compared to its planar counterpart, a volumetric segmentation would not require exhaustive initialisation on all axial slices; specifying initialisation seeds on just a few axial slices is sufficient to produce accurate full volume segmentations.</p>
      </sec>
      <sec id="Sec6">
        <title>User interaction</title>
        <p>User-defined seeds are initialisation points the radiologically trained user places, based on their clinical experience, in regions they known to be of tumour. Using a semi-automated method with user-defined seeds is advantageous because it gives the radiologists more control of the segmentation process by enabling them to influence both the initialisation and post-segmentation revision steps with their clinical knowledge about the patient’s disease.<fig id="Fig4"><label>Fig. 4</label><caption><p>Segmented tumour contours on axial cuts of two arbitrarily selected CT scans, as shown in <italic>white</italic>. Manually delineated tumour contours are shown in <italic>orange</italic>. <bold>a</bold>, <bold>c</bold> Reference truth, <bold>b</bold>, <bold>d</bold> segmented tumour</p></caption><graphic xlink:href="11548_2016_1511_Fig4_HTML" id="MO4"/></fig>
<fig id="Fig5"><label>Fig. 5</label><caption><p>Effect of user input on the method’s performance. <bold>a</bold> Segmentation accuracy in three different seeding attempts, <bold>b</bold> Number of seeds employed in each scenario</p></caption><graphic xlink:href="11548_2016_1511_Fig5_HTML" id="MO5"/></fig>
<fig id="Fig6"><label>Fig. 6</label><caption><p>A breakdown of accuracy performance of the two trials presented in Fig. <xref rid="Fig5" ref-type="fig">5</xref>. <italic>Arrows point</italic> to the slices where initialisation seeds were placed</p></caption><graphic xlink:href="11548_2016_1511_Fig6_HTML" id="MO6"/></fig>
</p>
        <p>However, defining ’seed regions’, contour areas of known tumour instead of points within the tumour, as required by Grady’s random walk-based method, on a large number of image slices is laborious, substantially reducing the clinical practicality of the algorithm. For our study, initialising seeds are placed by a clinical radiology specialist with five years of MPM diagnostic experience, based on expert knowledge about MPM, and added them to between six and ten axial slices for each image scan, that is, one initialised slice for every ten raw image slices. On average, 20–30 seeds were placed per initialisation slice, taking 20–30 s. The initialisation slices were not evenly distributed across the volume scan; they tend to concentrate around regions of difficulty, marked by the presence of weak tumour boundary, fluid and/or collapsed lung. Additionally, to facilitate an effective response evaluation, the same axial locations were selected for initialisation in follow-up scans of the same patient. This is comparable to modified RECIST, where the measurements are taken from the same transverse cuts for different scans of the same patient. Further seeds can be added at a review stage if deemed necessary by the observer, to enhance the segmentation accuracy. This was only required in one out of every three scans. The additional running time for this additional seeding process is minimal, normally a fraction of the overall time spent on the initial segmentation, as will be presented in the Results section of this paper.</p>
        <p>All computation times are based on using a workstation with Pentium-D CPU 3.39 GHz with 2GB of RAM.</p>
      </sec>
      <sec id="Sec7">
        <title>Gold standard</title>
        <p>To validate our findings, a clinical radiologist with five years of experience in MPM evaluation manually delineated the tumour contours on the whole imaging dataset. Though such delineations vary between observers and over time, for simplicity, we refer to them here as the ’reference truth’. We recognise the fact that the reference truth used might not be ideal, but for the purpose of our study and from an explorative research perspective, we use them here as a surrogate gold standard. To reduce observer bias, a blinded experimental design was implemented, where the delineations were made without knowledge of the clinical outcomes of individual patients and the modified RECIST measurements.</p>
      </sec>
      <sec id="Sec8">
        <title>Data analysis and statistical methods</title>
        <p>The accuracy of the segmentation results is evaluated by calculating the Sørensen–Dice index (DICE) according to the following equation, where <italic>X</italic> and <italic>Y</italic> represents the reference truth and the segmentation result, respectively:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \hbox {DICE}=\frac{2\left| {X\cap Y} \right| }{\left| X \right| +\left| Y \right| } \end{aligned}$$\end{document}</tex-math><mml:math id="M16" display="block"><mml:mrow><mml:mtable columnspacing="0.5ex"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mtext>DICE</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mfenced close="|" open="|" separators=""><mml:mrow><mml:mi>X</mml:mi><mml:mo>∩</mml:mo><mml:mi>Y</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mfenced close="|" open="|"><mml:mi>X</mml:mi></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close="|" open="|"><mml:mi>Y</mml:mi></mml:mfenced></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="11548_2016_1511_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>To assess the clinical utility of the computer-assisted method, we computed the correlation of changes in computed tumour volume with those in modified RECIST measurement.</p>
      </sec>
    </sec>
    <sec id="Sec9">
      <title>Results</title>
      <sec id="Sec10">
        <title>Tumour quantification</title>
        <p>Applying our computer-aided algorithm, segmented MPM tumour contours are computed in the axial planes. Sample results from two arbitrarily selected scans are shown in Fig. <xref rid="Fig4" ref-type="fig">4</xref>. Note the close resemblance of the segmented tumour with the reference truth. The calculated planar DICE measures in these cases were 0.89 and 0.91, respectively.</p>
      </sec>
      <sec id="Sec11">
        <title>Results validation</title>
        <p>An assessment of the effect of user input on the method’s performance and its overall robustness is shown in Fig. <xref rid="Fig5" ref-type="fig">5</xref>. Note the accuracy of segmentation is largely independent of the number of ’seeds’ used, once beyond a certain level. Note also the good reproducibility and consistency of the results, where changing the ’seeding’ map did not significantly impact on the overall segmentation accuracy.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Segmented MPM volumes (<inline-formula id="IEq8"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {mm}^{3})$$\end{document}</tex-math><mml:math id="M18"><mml:mrow><mml:msup><mml:mtext>mm</mml:mtext><mml:mn>3</mml:mn></mml:msup><mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq8.gif"/></alternatives></inline-formula>, % change from baseline to the final cycle of treatment and overall accuracy of the segmentation for our complete patient data: mean 0.825 (95% CI [0.758, 0.892])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Patient</th><th align="left" colspan="4">Scan</th><th align="left" rowspan="2">% Change</th><th align="left" rowspan="2">Overall accuracy (DICE)</th></tr><tr><th align="left">Baseline</th><th align="left">2 cycles</th><th align="left">4 cycles</th><th align="left">6 cycles</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">229,031</td><td align="left">274,025</td><td align="left">165,920</td><td align="left">182,376</td><td align="left">
<inline-formula id="IEq9"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M20"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq9.gif"/></alternatives></inline-formula>19.1</td><td align="left">0.820</td></tr><tr><td align="left">2</td><td align="left">333,650</td><td align="left">289,575</td><td align="left">188,461</td><td align="left">232,001</td><td align="left">
<inline-formula id="IEq10"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M22"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq10.gif"/></alternatives></inline-formula>30.5</td><td align="left">0.843</td></tr><tr><td align="left">3</td><td align="left">231,266</td><td align="left">274,968</td><td align="left">285,437</td><td align="left"/><td align="left">23.4</td><td align="left">0.861</td></tr><tr><td align="left">4</td><td align="left">523,928</td><td align="left">338,702</td><td align="left"/><td align="left"/><td align="left">
<inline-formula id="IEq11"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M24"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq11.gif"/></alternatives></inline-formula>35.4</td><td align="left">0.894</td></tr><tr><td align="left">5</td><td align="left">216,690</td><td align="left">165,982</td><td align="left"/><td align="left"/><td align="left">
<inline-formula id="IEq12"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M26"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq12.gif"/></alternatives></inline-formula>23.4</td><td align="left">0.772</td></tr><tr><td align="left">6</td><td align="left">492,666</td><td align="left">180,036</td><td align="left">389,923</td><td align="left"/><td align="left">
<inline-formula id="IEq13"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M28"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq13.gif"/></alternatives></inline-formula>20.9</td><td align="left">0.814</td></tr><tr><td align="left">7</td><td align="left">348,011</td><td align="left">526,396</td><td align="left"/><td align="left"/><td align="left">51.3</td><td align="left">0.782</td></tr><tr><td align="left">8</td><td align="left">315,052</td><td align="left">340,443</td><td align="left">330,652</td><td align="left">291,806</td><td align="left">
<inline-formula id="IEq14"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M30"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq14.gif"/></alternatives></inline-formula>7.4</td><td align="left">0.852</td></tr><tr><td align="left">9</td><td align="left">813,416</td><td align="left">870,872</td><td align="left"/><td align="left"/><td align="left">7.1</td><td align="left">0.802</td></tr><tr><td align="left">10</td><td align="left">10,6348</td><td align="left">132,937</td><td align="left">182,732</td><td align="left"/><td align="left">71.8</td><td align="left">0.791</td></tr><tr><td align="left">11</td><td align="left">523,828</td><td align="left">348,642</td><td align="left">397,824</td><td align="left">333,911</td><td align="left">
<inline-formula id="IEq15"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M32"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq15.gif"/></alternatives></inline-formula>35.3</td><td align="left">0.832</td></tr><tr><td align="left">12</td><td align="left">939,842</td><td align="left">630,513</td><td align="left">87,445</td><td align="left"/><td align="left">
<inline-formula id="IEq16"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M34"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq16.gif"/></alternatives></inline-formula>7.1</td><td align="left">0.840</td></tr><tr><td align="left">13</td><td align="left">211,220</td><td align="left">209,103</td><td align="left">152,571</td><td align="left"/><td align="left">
<inline-formula id="IEq17"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M36"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq17.gif"/></alternatives></inline-formula>27.8</td><td align="left">0.869</td></tr><tr><td align="left">14</td><td align="left">163,116</td><td align="left">208,185</td><td align="left">238,774</td><td align="left"/><td align="left">46.4</td><td align="left">0.821</td></tr><tr><td align="left">15</td><td align="left">476,943</td><td align="left">505,001</td><td align="left">461,913</td><td align="left">634,501</td><td align="left">33.0</td><td align="left">0.784</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Computation time (s) taken for processing each image scan. The median running time is 1385 s (range [653, 2218])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Patient</th><th align="left" colspan="4">Scan</th><th align="left" rowspan="2">Running time (s)</th></tr><tr><th align="left">Baseline</th><th align="left">2 cycles</th><th align="left">4 cycles</th><th align="left">6 cycles</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">814</td><td align="left">655</td><td align="left">684</td><td align="left">458</td><td align="left">653</td></tr><tr><td align="left">2</td><td align="left">935</td><td align="left">1011</td><td align="left">455</td><td align="left">815</td><td align="left">804</td></tr><tr><td align="left">3</td><td align="left">2557</td><td align="left">780</td><td align="left">900</td><td align="left"/><td align="left">1413</td></tr><tr><td align="left">4</td><td align="left">1400</td><td align="left">1346</td><td align="left"/><td align="left"/><td align="left">1373</td></tr><tr><td align="left">5</td><td align="left">1474</td><td align="left">1147</td><td align="left"/><td align="left"/><td align="left">1311</td></tr><tr><td align="left">6</td><td align="left">1609</td><td align="left">1940</td><td align="left">985</td><td align="left"/><td align="left">1511</td></tr><tr><td align="left">7</td><td align="left">1466</td><td align="left">1314</td><td align="left"/><td align="left"/><td align="left">1390</td></tr><tr><td align="left">8</td><td align="left">2067</td><td align="left">1461</td><td align="left">1656</td><td align="left">1832</td><td align="left">1754</td></tr><tr><td align="left">9</td><td align="left">1846</td><td align="left">1754</td><td align="left"/><td align="left"/><td align="left">1800</td></tr><tr><td align="left">10</td><td align="left">1063</td><td align="left">1233</td><td align="left">1543</td><td align="left"/><td align="left">1280</td></tr><tr><td align="left">11</td><td align="left">1288</td><td align="left">823</td><td align="left">579</td><td align="left">930</td><td align="left">905</td></tr><tr><td align="left">12</td><td align="left">2538</td><td align="left">2491</td><td align="left">1624</td><td align="left"/><td align="left">2218</td></tr><tr><td align="left">13</td><td align="left">1471</td><td align="left">1161</td><td align="left">1145</td><td align="left"/><td align="left">1259</td></tr><tr><td align="left">14</td><td align="left">1572</td><td align="left">1301</td><td align="left">1281</td><td align="left"/><td align="left">1385</td></tr><tr><td align="left">15</td><td align="left">1623</td><td align="left">1721</td><td align="left">1476</td><td align="left">1716</td><td align="left">1634</td></tr></tbody></table></table-wrap>
</p>
        <p>An analysis of the accuracy measure for individual slices in these cases is shown in Fig. <xref rid="Fig6" ref-type="fig">6</xref>. As expected, performance of the algorithm generally deteriorates with distance from the initialisation slices. Full segmentation results and computation times of each individual scan are presented in Tables <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>, respectively.</p>
        <p>Good accuracy of the computerised method is clearly demonstrated, with results yielding a mean accuracy of 0.825 (95% CI [0.758, 0.892]).<fig id="Fig7"><label>Fig. 7</label><caption><p>Scatter plots showing the correlation of segmented tumour volumes with their corresponding modified RECIST measures. Pearson’s correlation coefficient 0.6392, <italic>p</italic> value: 0.0001, <inline-formula id="IEq18"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${R}^{2} = 0.4086$$\end{document}</tex-math><mml:math id="M38"><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0.4086</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="11548_2016_1511_Article_IEq18.gif"/></alternatives></inline-formula>
</p></caption><graphic xlink:href="11548_2016_1511_Fig7_HTML" id="MO8"/></fig>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>A comparison of results from various published works on computer-assisted MPM segmentation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Study size</th><th align="left">Segmentation method</th><th align="left">Performance</th></tr></thead><tbody><tr><td align="left">Ak et al. [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td align="left">57 scans from individual patients</td><td align="left">Manual dot counting</td><td align="left">Method accuracy not assessed for MPM</td></tr><tr><td align="left">Chaisaowong et al. [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">14 scans from 3 patients</td><td align="left">Convex shape with thresholding</td><td align="left">Method accuracy not assessed for MPM</td></tr><tr><td align="left">Frauenfelder et al. [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td align="left">30 scans from individual patients</td><td align="left">Interpolation to hand-drawn tumour contours</td><td align="left">Method accuracy not assessed for MPM</td></tr><tr><td align="left">Sensakovic et al. [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left">31 scans from 31 patients</td><td align="left">Nonlinear diffusion model with k-class classifier</td><td align="left">J-index: 0.484 between manual and computed segmentations</td></tr><tr><td align="left">Labby et al. [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">216 scans from 61 patients</td><td align="left">Interpolation component added to [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left">Method accuracy not assessed for MPM</td></tr><tr><td align="left">Our method</td><td align="left">45 scans from 15 patients</td><td align="left">Automated random walk</td><td align="left">DICE: 0.825 (95% CI [0.758, 0.892])</td></tr></tbody></table></table-wrap>
</p>
      </sec>
      <sec id="Sec12">
        <title>Time efficiency of our method</title>
        <p>The median time spent on manually delineating the tumour in a typical CT scan was 68.1 min (range [40.2, 102.4]). In comparison, the median running time of the computer-aided procedure was 23.1 min (range [10.9, 37.0]). The median total time spent on manual user interaction was 2.8 min (range [1.8, 4.2]) per image scan. The computer running time could potentially be reduced further by increasing the workstation processing power or by incorporating the use of graphics processor units (GPUs).</p>
        <p>Although modified RECIST would take less time to measure from start to finish, it remains a manual process, which requires focused work from a clinician; whereas a computer-aided algorithm such as the one presented in this paper requires little supervision and would enable this clinical time to be invested elsewhere.</p>
      </sec>
      <sec id="Sec13">
        <title>Statistical correlation with modified RECIST</title>
        <p>Correlation with the modified RECIST is shown as a scatter plot with linear fit, as shown in Fig. <xref rid="Fig7" ref-type="fig">7</xref>.</p>
        <p>This shows that tumour response found using the segmented volumes is well correlated with that predicted by the change in modified RECIST and supports the use of volumetric segmentation from a clinical perspective.</p>
      </sec>
    </sec>
    <sec id="Sec14">
      <title>Discussion</title>
      <p>Assessing the therapeutic response of MPM is difficult because of the tumour’s poor image contrast and its large variation in shape and growth pattern, which prevent an effective choice of measurement points when employing modified RECIST. These characteristics also happen to make the computer-assisted segmentation of MPM difficult.</p>
      <p>It should be noted that apart from Sensakovic et al. [<xref ref-type="bibr" rid="CR15">15</xref>], most of the existing works on computer-assisted MPM segmentation did not assess the accuracy of their proposed method in a systematic way. Sensakovic et al. [<xref ref-type="bibr" rid="CR15">15</xref>], whilst presenting a more advanced approach to the problem, produced a less than desirable J-index of 0.484, was implemented only in the planar space, was applied to only diagnostic imaging data, and did not allow the clinician to influence the segmentation itself through user interaction.</p>
      <p>Our proposed method, on the other hand, incorporates a three-dimensional framework, flexibly accepts end-user inputs, and produces results that are consistently accurate and with competitive running times.</p>
      <p>The results from our method are generally satisfactory, yielding a mean accuracy (DICE) of 0.825 (95% CI [0.758, 0.892]), taking a median running time of 1385 s (95% CI [653, 2218]), greatly reducing the time requirement of an otherwise tedious process. The method also exhibits good robustness because changing the user seed number and configuration did not significant alter the end result. A strong correlation was found between the changes in tumour volume and those in modified RECIST. These results support the use of our algorithm in segmenting MPM for both diagnostic and treatment monitoring purposes. A comparison with results from various published works on computer-assisted MPM segmentation is given in Table <xref rid="Tab4" ref-type="table">4</xref>.</p>
      <p>To further assess the applicability of our method in a wider clinical context, it is crucial to develop and validate criteria for categorising tumour changes. Oxnard et al. [<xref ref-type="bibr" rid="CR19">19</xref>] used geometric models to suggest equivalents of the RECIST classification criteria in the volume space. We note that given the small size and distribution of our data, we are unable to validate these thresholds based on our study because only 1 out of our 15 patients would be classified as ‘progressive disease’ and the rest ‘stable disease’. In addition, although these geometric model-derived thresholds provide good insight into potential volume response criteria, because they are based on standard geometric shapes, they may not lend well to the uneven shapes and irregular growth patterns of MPM. Currently, the issue of volume response criteria remains a contentious area requiring more work.</p>
      <p>To further our work, larger patient datasets are needed. It would also be helpful to collect more detailed follow-up clinical data from the patients, such as measures of their quality of life and prognostic data, preferably stratified according to age, gender, and disease stage at diagnosis. These additional clinical data would enable us to better validate our method.</p>
      <p>Due to the challenges in assessing the MPM tumour based on CT scans alone, there is a growing interest in employing metabolic imaging in MPM follow-ups [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. To this end, it might be helpful to examine the possibility of bridging the information obtained from segmented tumour volume to metabolic PET data, such as establishing a correlation between changes in the tumour’s metabolic output and a particular trend of morphological change in its shape.</p>
      <p>Currently, modified RECIST remains the standard approach to quantifying MPM in clinical practice, mostly due to its favourable prediction of patient survival and its existing wide acceptance in the radiological community. However, computer-aided volume-based methods, such as the one presented in this paper, are emerging as a new tactic to the clinical problem, for their automated action and better performance consistency.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Funding</title>
      <p>This study was funded by the National Institute of Health Research—Biomedical Research Centres Research Grant.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <sec id="FPar1">
        <title>Conflict of interest</title>
        <p>The authors declare that they have no conflict of interest.</p>
      </sec>
      <sec id="FPar2">
        <title>Ethical approval</title>
        <p>All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p>
      </sec>
      <sec id="FPar3">
        <title>Informed consent</title>
        <p>Informed consent was obtained from all individual participants included in the study.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">World Health Organization (2007) WHO calls for prevention of cancer through healthy workplaces. Secondary WHO calls for prevention of cancer through healthy workplaces. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/news/notes/2007/np19/en/index.html">http://www.who.int/mediacentre/news/notes/2007/np19/en/index.html</ext-link></mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rushton</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hutchings</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>The burden of cancer at work: estimation as the first step to prevention</article-title>
          <source>Occup Environ Med</source>
          <year>2008</year>
          <volume>65</volume>
          <issue>12</issue>
          <fpage>789</fpage>
          <lpage>800</lpage>
          <pub-id pub-id-type="doi">10.1136/oem.2007.037002</pub-id>
          <?supplied-pmid 18079154?>
          <pub-id pub-id-type="pmid">18079154</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vogel</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Special report: asbestos in the world</article-title>
          <source>HESA Newslett</source>
          <year>2005</year>
          <volume>27</volume>
          <fpage>7</fpage>
          <lpage>21</lpage>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Courtice</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>An updated review on asbestos and related diseases in China</article-title>
          <source>Int J Occup Environ Health</source>
          <year>2012</year>
          <volume>18</volume>
          <issue>3</issue>
          <fpage>247</fpage>
          <lpage>253</lpage>
          <pub-id pub-id-type="doi">10.1179/1077352512Z.00000000021</pub-id>
          <?supplied-pmid 23026008?>
          <pub-id pub-id-type="pmid">23026008</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joshi</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Bhuva</surname>
              <given-names>UB</given-names>
            </name>
            <name>
              <surname>Katoch</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Asbestos ban in India: challenges ahead</article-title>
          <source>Ann NY Acad Sci</source>
          <year>2006</year>
          <volume>1076</volume>
          <fpage>292</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="doi">10.1196/annals.1371.072</pub-id>
          <?supplied-pmid 17119210?>
          <pub-id pub-id-type="pmid">17119210</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Byrne</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Nowak</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Modified RECIST criteria for assessment of response in malignant pleural mesothelioma</article-title>
          <source>Ann Oncol</source>
          <year>2004</year>
          <volume>15</volume>
          <issue>2</issue>
          <fpage>257</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdh059</pub-id>
          <?supplied-pmid 14760119?>
          <pub-id pub-id-type="pmid">14760119</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="other">Thiesse P, Ollivier L, Di Stefano-Louineau D, Négrier S, Savary J, Pignard K, Lasset C, Escudier B (1997) Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d’Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 15(12):3507–3514. doi:10.1200/jco.1997.15.12.3507</mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ak</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Metintas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Metintas</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yildirim</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ozkan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ozden</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma</article-title>
          <source>Eur J Radiol</source>
          <year>2010</year>
          <volume>74</volume>
          <issue>1</issue>
          <fpage>130</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejrad.2009.02.002</pub-id>
          <?supplied-pmid 19268516?>
          <pub-id pub-id-type="pmid">19268516</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armato</surname>
              <given-names>SG</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Oxnard</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Kocherginsky</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vogelzang</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Kindler</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>MacMahon</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans</article-title>
          <source>Acad Radiol</source>
          <year>2005</year>
          <volume>12</volume>
          <issue>10</issue>
          <fpage>1301</fpage>
          <lpage>1309</lpage>
          <pub-id pub-id-type="doi">10.1016/j.acra.2005.05.021</pub-id>
          <?supplied-pmid 16179207?>
          <pub-id pub-id-type="pmid">16179207</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frauenfelder</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tutic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weder</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Götti</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Stahel</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Opitz</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?</article-title>
          <source>Eur Respir J</source>
          <year>2011</year>
          <volume>38</volume>
          <issue>1</issue>
          <fpage>162</fpage>
          <lpage>168</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00146110</pub-id>
          <?supplied-pmid 21273389?>
          <pub-id pub-id-type="pmid">21273389</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Krug</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Ishill</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gorski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Moskowitz</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Rusch</surname>
              <given-names>VW</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
          <article-title>Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans</article-title>
          <source>J Thorac Oncol</source>
          <year>2010</year>
          <volume>5</volume>
          <issue>6</issue>
          <fpage>879</fpage>
          <lpage>884</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e3181dd0ef1</pub-id>
          <?supplied-pmid 20421814?>
          <pub-id pub-id-type="pmid">20421814</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Plathow</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schoebinger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fink</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hof</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Debus</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Meinzer</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Kauczor</surname>
              <given-names>HU</given-names>
            </name>
          </person-group>
          <article-title>Quantification of lung tumor volume and rotation at 3D dynamic parallel MR imaging with view sharing: preliminary results</article-title>
          <source>Radiology</source>
          <year>2006</year>
          <volume>240</volume>
          <issue>2</issue>
          <fpage>537</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1148/radiol.2401050727</pub-id>
          <?supplied-pmid 16801367?>
          <pub-id pub-id-type="pmid">16801367</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="other">Labby ZE, Armato SG, Dignam JJ, Straus C, Kindler HL, Nowak AK (2013) Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol 8(4):478–486. doi:10.1097/JTO.0b013e31828354c8</mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chaisaowong</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Aach</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jager</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Knepper</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kraus</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Computer-assisted diagnosis for early stage pleural mesothelioma: towards automated detection and quantitative assessment of pleural thickening from thoracic CT images</article-title>
          <source>Methods Inf Med</source>
          <year>2007</year>
          <volume>46</volume>
          <issue>3</issue>
          <fpage>324</fpage>
          <lpage>331</lpage>
          <?supplied-pmid 17492119?>
          <pub-id pub-id-type="pmid">17492119</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="other">Sensakovic WF, Armato SG 3rd, Straus C, Roberts RY, Caligiuri P, Starkey A, Kindler HL (2011) Computerized segmentation and measurement of malignant pleural mesothelioma. Med Phys 38(1):238–244. doi:10.1118/1.3525836</mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">Labby ZE, Nowak AK, Dignam JJ, Straus C, Kindler HL, Armato SG (2013) Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol 24(4):999–1005. doi:10.1093/annonc/mds535</mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Talbot</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Margery</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dabouis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dark</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Boussemart</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cadic</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pinel</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Rivière</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ollivier</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ruffié</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Phase II study of vinflunine in malignant pleural mesothelioma</article-title>
          <source>J Clin Oncol</source>
          <year>2007</year>
          <volume>25</volume>
          <issue>30</issue>
          <fpage>4751</fpage>
          <lpage>4756</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2007.12.5641</pub-id>
          <?supplied-pmid 17947722?>
          <pub-id pub-id-type="pmid">17947722</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="other">Grady L (2006) Random walks for image segmentation. IEEE Trans Pattern Anal Mach Intell 28(11):1768–1783. doi:10.1109/TPAMI.2006.233</mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="other">Oxnard GR, Armato SG 3rd, Kindler HL (2006) Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 52(2):141–148. doi:10.1016/j.lungcan.2005.12.013</mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Basu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Saboury</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Torigian</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Alavi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment</article-title>
          <source>Mol Imaging Biol (MIB)</source>
          <year>2011</year>
          <volume>13</volume>
          <issue>5</issue>
          <fpage>801</fpage>
          <lpage>811</lpage>
          <pub-id pub-id-type="doi">10.1007/s11307-010-0426-6</pub-id>
          <pub-id pub-id-type="pmid">21136185</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armato</surname>
              <given-names>SG</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Entwisle</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Truong</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Nowak</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Ceresoli</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Misri</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kindler</surname>
              <given-names>HL</given-names>
            </name>
          </person-group>
          <article-title>Current state and future directions of pleural mesothelioma imaging</article-title>
          <source>Lung Cancer</source>
          <year>2008</year>
          <volume>59</volume>
          <issue>3</issue>
          <fpage>411</fpage>
          <lpage>420</lpage>
          <pub-id pub-id-type="doi">10.1016/j.lungcan.2007.09.027</pub-id>
          <?supplied-pmid 18061303?>
          <pub-id pub-id-type="pmid">18061303</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362667</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pflugers Arch</journal-id>
      <journal-id journal-id-type="iso-abbrev">Pflugers Arch</journal-id>
      <journal-title-group>
        <journal-title>Pflugers Archiv</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0031-6768</issn>
      <issn pub-type="epub">1432-2013</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362667</article-id>
      <article-id pub-id-type="pmcid">PMC5362667</article-id>
      <article-id pub-id-type="pmc-uid">5362667</article-id>
      <article-id pub-id-type="pmid">28283748</article-id>
      <article-id pub-id-type="publisher-id">1958</article-id>
      <article-id pub-id-type="doi">10.1007/s00424-017-1958-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Invited Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Macrophages in gastrointestinal homeostasis and inflammation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4052-5923</contrib-id>
          <name>
            <surname>Grainger</surname>
            <given-names>John R.</given-names>
          </name>
          <address>
            <email>john.grainger-2@manchester.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6525-5499</contrib-id>
          <name>
            <surname>Konkel</surname>
            <given-names>Joanne E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3112-1564</contrib-id>
          <name>
            <surname>Zangerle-Murray</surname>
            <given-names>Tamsin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8107-2836</contrib-id>
          <name>
            <surname>Shaw</surname>
            <given-names>Tovah N.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121662407</institution-id><institution-id institution-id-type="GRID">grid.5379.8</institution-id><institution>Manchester Collaborative Centre for Inflammation Research (MCCIR), </institution><institution>University of Manchester, </institution></institution-wrap>Manchester, M13 9NT UK </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121662407</institution-id><institution-id institution-id-type="GRID">grid.5379.8</institution-id><institution>Faculty of Biological, Medical and Human Sciences (FBMH), </institution><institution>University of Manchester, </institution></institution-wrap>Manchester, UK </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>10</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>469</volume>
      <issue>3</issue>
      <fpage>527</fpage>
      <lpage>539</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>1</month>
          <year>2017</year>
        </date>
        <date date-type="rev-recd">
          <day>12</day>
          <month>2</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>2</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Monocyte-derived mononuclear phagocytes, particularly macrophages, are crucial to maintain gastrointestinal homeostasis in the steady state but are also important for protection against certain pathogens. However, when uncontrolled, they can promote immunopathology. Broadly two subsets of macrophages can be considered to perform the vast array of functions to complete these complex tasks: resident macrophages that dominate in the healthy gut and inflammation-elicited (inflammatory) macrophages that derive from circulating monocytes infiltrating inflamed tissue. Here, we discuss the features of resident and inflammatory intestinal macrophages, complexities in identifying and defining these populations and the mechanisms involved in their differentiation. In particular, focus will be placed on describing their unique ontogeny as well as local gastrointestinal signals that instruct specialisation of resident macrophages in healthy tissue. We then explore the very different roles of inflammatory macrophages and describe new data suggesting that they may be educated not only by the gut microenvironment but also by signals they receive during development in the bone marrow. Given the high degree of plasticity of gut macrophages and their multifaceted roles in both healthy and inflamed tissue, understanding the mechanisms controlling their differentiation could inform development of improved therapies for inflammatory diseases such as inflammatory bowel disease (IBD).</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Macrophage</kwd>
        <kwd>Monocyte</kwd>
        <kwd>Mucosal</kwd>
        <kwd>Gastrointestinal</kwd>
        <kwd>Commensal</kwd>
        <kwd>Inflammatory bowel disease</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id>
              <institution>Wellcome Trust</institution>
            </institution-wrap>
          </funding-source>
          <award-id>104195/Z/14/Z</award-id>
          <principal-award-recipient>
            <name>
              <surname>Grainger</surname>
              <given-names>John R.</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id>
              <institution>Biotechnology and Biological Sciences Research Council</institution>
            </institution-wrap>
          </funding-source>
          <award-id>BB/M025977/1</award-id>
          <principal-award-recipient>
            <name>
              <surname>Konkel</surname>
              <given-names>Joanne E.</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer-Verlag Berlin Heidelberg 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>The mammalian intestine is a complex environment for the immune system. On one hand, it must maintain tolerance to a vast array of antigens derived from food and the dense, but largely harmless, commensal microbiota. On the other, it must be ever ready to respond to potentially life-threatening pathogens that aim to colonise via the oral route. Failure to achieve this knife-edge balance between tolerance and responsiveness can lead to mortality or life-limiting morbidity, as occurs in inflammatory bowel disease (IBD).</p>
      <p>For ongoing homeostasis to be achieved in the gut, interrelated highly specialised structural and cellular strategies have, thus, evolved to support this immunologic balancing act. All the time allowing the tissue to perform its primary physiologic function—absorption of nutrients, water and electrolytes. These structures include a mucus layer that creates a physical barrier to keep bacteria away from the epithelium, a single-cell thick epithelial layer and a specialised immune network enriched in the epithelial layer and <italic>lamina propria</italic>.</p>
      <p>Resulting from their phagocytic capacity, functional plasticity and capability to integrate and interpret diverse food-derived, commensal-derived, pathogen-derived and host-derived signals in their environment, gut-<italic>resident</italic> macrophages are well established as a keystone immune population in barrier homeostasis in health. Moreover, following initiation of an inflammatory response, <italic>inflammation-elicited (inflammatory)</italic> macrophages (derived from circulating blood monocytes called into the affected tissue) in tandem with their resident partners play crucial roles in control of infection. Thus, in the face of the myriad challenges that the intestine will face over a lifetime, the dynamic regulation of the intestinal macrophage pool is at the centre of long-term health.</p>
      <p>Macrophage biology is a field that has seen explosive growth in recent years, particularly in the gut. A large number of studies, including our work, have begun to establish how the ontogeny and differentiation of these cells is tailored by, and to, the gut environment. In this article, we will discuss these findings and particularly explore the unique mechanisms governing resident and recruited inflammatory gut macrophage function.</p>
      <sec id="Sec2">
        <title>Location and functions of resident macrophages in the healthy gut</title>
        <p>The largest population of resident macrophages in the body is present in the steady-state intestine [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. They are found along the entire length of the intestine, from the proximal small intestine to the distal large intestine, and are enriched in the <italic>lamina propria</italic> (LP) close to the epithelial layer (see Fig. <xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR42">42</xref>]. There is also a morphologically distinct population present in the smooth muscle layers [<xref ref-type="bibr" rid="CR21">21</xref>]. Along the length of the gut, the number of macrophages varies, with the highest density found in the colon of both humans and rodents [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Development and functions of resident intestinal macrophages. In the healthy gut, Ly6C<sup>hi</sup> monocytes are constantly recruited from the blood into the gut to replenish the resident macrophage pool. Ly6C<sup>hi</sup> monocytes transit through a series of phenotypically defined stages to eventually become mature CX3CR1<sup>hi</sup>MHCII<sup>hi</sup>Ly6C<sup>low</sup> macrophages in the <italic>lamina propria</italic> and muscularis. These macrophages are hyporesponsive to bacterial ligands, constitutively produce IL-10 and have multiple crucial functions in gut homeostasis including Treg expansion, epithelial maintenance, luminal sampling and bacterial killing</p></caption><graphic xlink:href="424_2017_1958_Fig1_HTML" id="MO1"/></fig>
</p>
        <p>As in most tissues, a key role of macrophages in the gut is to perform housekeeping functions such as tissue remodelling and removal of senescent or dying cells [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. In line with this function, they have high expression of scavenger receptors, including CD36, that are able to support apoptotic cell uptake [<xref ref-type="bibr" rid="CR95">95</xref>]. They are also able to produce soluble factors that can help to support epithelial barrier integrity such as the lipid mediator prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) [<xref ref-type="bibr" rid="CR25">25</xref>]. Additionally, macrophages located in the muscularis and serosa are important in interacting with nerves to support peristalsis, ensuring ongoing movement of ingested material along the intestine [<xref ref-type="bibr" rid="CR69">69</xref>].</p>
        <p>However, alongside these homeostatic functions, macrophages in the gut are also important immune sentinels and effector populations. The positioning of LP macrophages in close apposition to the epithelial layer means that they are able to rapidly uptake and respond to any material breaching this barrier [<xref ref-type="bibr" rid="CR42">42</xref>]. These resident macrophages are highly phagocytic and have bactericidal properties [<xref ref-type="bibr" rid="CR96">96</xref>]. They can also produce chemokines to recruit effector cells from the blood into the tissue when required [<xref ref-type="bibr" rid="CR95">95</xref>]. Intriguingly, unlike other studied macrophage populations in the body, although gut macrophages can respond to bacteria, they do not induce classic pro-inflammatory responses [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. This is a critical feature to prevent aberrant inflammation towards the high commensal bacterial load [<xref ref-type="bibr" rid="CR118">118</xref>]. For example, ingestion of bacteria does not lead to enhanced respiratory burst activity [<xref ref-type="bibr" rid="CR80">80</xref>], and ligation of toll-like receptors (TLRs) or nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) does not result in increased TNF-α or IL-6 production [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. Despite this hyporesponsive phenotype towards bacteria, intestinal macrophages are not completely unresponsive in their cytokine-producing capacity, and they constitutively produce the anti-inflammatory cytokine IL-10 and low levels of TNF-α [<xref ref-type="bibr" rid="CR4">4</xref>]. Although this production of TNF-α may at first seem counterintuitive (due to its inflammatory capacity), TNF-α can impact enterocyte growth [<xref ref-type="bibr" rid="CR61">61</xref>] as well as modulating production of matrix metalloproteinases from intestinal mesechymal cells [<xref ref-type="bibr" rid="CR75">75</xref>], actions which are suggested to allow gut macrophages to support the maintenance of barrier homeostasis [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
        <p>An important component of the gut immune system that is critical in establishing tolerance towards the high burden of food and commensal antigens is the forkhead box protein 3 (Foxp3)<sup>+</sup> T regulatory cell (Treg) network [<xref ref-type="bibr" rid="CR65">65</xref>]. Since gut macrophages are able to uptake orally acquired antigens and also express high levels of major histocompatibility complex class II (MHCII) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR65">65</xref>], it is not surprising that they are suggested to play a key role in supporting development of this network. Of note, Hadis et al. demonstrated that following their priming in the lymph node, antigen-specific Foxp3<sup>+</sup> Tregs that had trafficked to the LP were maintained at this site by macrophages [<xref ref-type="bibr" rid="CR32">32</xref>]. A similar role for macrophages in contributing to the tissue-resident Treg pool has also been suggested in the lung [<xref ref-type="bibr" rid="CR98">98</xref>].</p>
        <p>It is possible that gut macrophages may play roles in supporting maintenance of other T cell subsets in the gut. In particular, macrophages can produce IL-1β following TLR stimulation, and this has been suggested to support Th17 cell development in the healthy gut [<xref ref-type="bibr" rid="CR93">93</xref>]. Along these lines, recruited macrophages have also been shown to support generation of commensal-specific Th17 cells [<xref ref-type="bibr" rid="CR74">74</xref>]. Although gastrointestinal-resident Th17 cells are key mediators of barrier defence [<xref ref-type="bibr" rid="CR113">113</xref>], dysregulated Th17 responses are a driver of colitogenic pathology, and in settings of gastrointestinal inflammation, macrophages have been shown to support amplification of Th17 responses [<xref ref-type="bibr" rid="CR58">58</xref>]. Further studies will be required to establish whether macrophage education of gastrointestinal T cell populations requires cognate MHCII-T cell receptor interactions or whether the cytokine milieu established by macrophages is the major factor. Moreover, the influence of macrophages on other gastrointestinal-resident lymphocyte populations during steady state requires further assessment, especially in the light of reports detailing macrophage-innate lymphoid cell (ILC) interactions which are key to support gastrointestinal immune homeostasis and reinforce barrier integrity [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR88">88</xref>].</p>
        <p>Another way in which gut macrophages may be able to support development of the gut T cell network in an indirect manner is by transfer of soluble antigen from the lumen to gut dendritic cells (DCs) [<xref ref-type="bibr" rid="CR65">65</xref>]. These DCs then drain to the mesenteric lymph nodes to prime T cell responses [<xref ref-type="bibr" rid="CR85">85</xref>]. It is still not entirely clear how LP macrophages acquire these luminal antigens, but one possibility is that they can extend transepithelial dendrites across the epithelium [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. However, this idea remains controversial with original reports disagreeing on which parts of the small intestine these transepithelial dendrites were present in and the necessity for TLR signalling, and subsequent studies unable to identify them [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR72">72</xref>].</p>
        <p>An issue that has confounded functional studies of gut macrophages has been the complexities of identifying this population using flow cytometry [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Initially, this problem largely arose due to the assumption that CD11c and MHCII were markers of gut DCs. In the gut, LP macrophages express high levels of CD11c as well as MHCII and thus in many studies were assumed to be DCs [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Unlike macrophages, DC constantly drain from tissue to lymph nodes where their major role is to prime naïve T cells [<xref ref-type="bibr" rid="CR85">85</xref>]. More recently, the fractalkine receptor CX3CR1 has been used to distinguish gut macrophages from gut DC [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. Notably, resident gut macrophages express high levels of CX3CR1; however, some subsets of gut DC also express this marker (albeit at an intermediate level), which may be the basis of more recent contradictory findings regarding DC and macrophage function [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p>
        <p>One problem with using high expression of CX3CR1 as a marker of gut macrophages is that this can currently only be established using CX3CR1-GFP transgenic mice and not by antibody staining [<xref ref-type="bibr" rid="CR46">46</xref>]. A more useful strategy for identifying gut macrophages by multicolour flow cytometry (that can be used in non CX3CR1-GFP expressing animals) came from large-scale genomic datasets alongside more targeted studies [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. Together, these publications have identified that CD64 (FcγRI), F4/80 and MHCII used in combination with Ly6C and lineage exclusion markers (e.g. for lymphocytes and granulocytes) can reliably define these cells. CD11c expression was found to be of particular relevance to distinguish LP macrophages (CD11c<sup>hi</sup>) from those in the serosa and muscularis (CD11c<sup>low</sup>) [<xref ref-type="bibr" rid="CR6">6</xref>]. When isolated by fluorescence-activated cell sorting (FACS), these cells exhibit characteristic macrophage morphology and cannot be found draining to the mesenteric lymph nodes [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Moreover, their development is critically dependent on colony stimulating factor 1 receptor (CSF1R) (also known as macrophage colony-stimulating factor receptor (MCSFR)) [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>] but independent of the DC growth factor FMS-like tyrosine kinase 3 ligand (FLT3L) [<xref ref-type="bibr" rid="CR104">104</xref>]. Altogether, these findings suggest that CD64 and F4/80 are bona fide markers of gut-resident macrophages and will support researchers in specifically determining gut macrophage functions in future studies.</p>
      </sec>
      <sec id="Sec3">
        <title>The unusual ontogeny of resident gut macrophages</title>
        <p>When the mononuclear phagocyte system (MPS) was first described just over 50 years ago, it was proposed that tissue macrophages were the terminal differentiation stage of blood monocytes after recruitment into tissue [<xref ref-type="bibr" rid="CR110">110</xref>]. However, in more recent years, a number of studies have been published that demonstrate that the majority of tissue macrophages are able to exist independently of blood monocyte precursors [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Frequently these derive from foetal liver precursors although some, including the microglia of the central nervous system (CNS), come from the yolk sac [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. These cells seed tissues prenatally and then are maintained by local proliferation. Resident macrophages include those of the lung alveoli [<xref ref-type="bibr" rid="CR116">116</xref>], the Kuppfer cells of the liver [<xref ref-type="bibr" rid="CR87">87</xref>] and epidermal Langerhans cells [<xref ref-type="bibr" rid="CR39">39</xref>].</p>
        <p>The adult intestinal macrophage pool is a major exception to this rule (along with the dermis [<xref ref-type="bibr" rid="CR103">103</xref>] and more controversially the heart [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]) fitting the original MPS model, requiring constant replenishment from blood monocytes (see Fig. <xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. Blood monocytes are a heterogeneous circulating population in both humans and mice that originate in the bone marrow (BM). In mice, there is a subset that expresses high levels of Ly6C and CCR2 termed “classical” monocytes (the equivalent of human CD14<sup>hi</sup> monocytes [<xref ref-type="bibr" rid="CR43">43</xref>]) that are the precursors to the adult intestinal macrophages [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. Although at birth, there are embryonically derived macrophages present in the gut, around the time of weaning these are replaced by cells derived from an influx of CCR2-dependent Ly6C<sup>hi</sup> monocytes [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
        <p>A number of studies investigating macrophage differentiation in the healthy gut have been instrumental in defining the phenotypic and transcriptional profile of classical (Ly6C<sup>hi</sup>) blood monocytes transitioning into mature gut macrophages. Initially using an adoptive transfer approach in healthy gut, it was shown that Ly6C<sup>hi</sup> monocytes were able to enter into the colon and mature into CD64<sup>+</sup>F4/80<sup>hi</sup>CX3CR1<sup>hi</sup>MHCII<sup>+</sup> macrophages [<xref ref-type="bibr" rid="CR4">4</xref>]. This developmental process involves a series of identifiable intermediaries in which Ly6C expression is lost while expression of F4/80, CX3CR1, CD163 and CD206 are gained. Due to the visual appearance of this transition moving from Ly6C<sup>hi</sup> to MHCII<sup>hi</sup> or CX3CR1<sup>hi</sup> on a flow cytometry plot, this has been referred to as the monocyte to macrophage “waterfall” [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. Differentiation takes approximately 5 days and results in a cell that has increased phagocytic capacity and constitutive IL-10 production and is anergic to TLR stimulation. This rapid differentiation is in line with earlier reports of an approximately 3–5-week half-life for gut-resident macrophages [<xref ref-type="bibr" rid="CR45">45</xref>]. Although the precise mechanisms governing differentiation cannot be easily established in humans, resident gut macrophages deriving from blood monocytes is implied by a similar waterfall of CD14<sup>hi</sup> (marker characteristic of classical monocytes [<xref ref-type="bibr" rid="CR43">43</xref>]) to CD14<sup>low</sup>CD209<sup>hi</sup>CD163<sup>hi</sup> cells [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
        <p>The complex commensal flora is a distinguishing feature of the intestine, and there is a current consensus that it is this feature that is important in regulating the continuous replenishment of resident gut macrophages from blood monocytes [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. Of note, there is a first accumulation of colonic macrophages between 2 and 3 weeks of age in mice that is concurrent with increased commensal colonisation [<xref ref-type="bibr" rid="CR2">2</xref>]. Corroborating the importance of the microbiome in this process, at 3 weeks of age, there were fewer mature macrophages in germ-free mice than conventionally housed controls. Moreover, many of these macrophages did not express MHCII further implicating the microbiome in typical differentiation of macrophages as well as recruitment [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR119">119</xref>].</p>
        <p>It is worth noting, however, that this was not the first study to investigate colonic macrophage abundancy in germ-free animals, and these studies have reached opposing conclusions [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. Animals from different sources are now well known to have very different commensal composition [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. One hypothesis for these differences between studies is that there are unique factors in the gut other than the microbiome that can affect macrophage replacement from blood monocytes but that specific bacterial species present in certain mouse colonies can enhance or decrease the turnover rate.</p>
        <p>Taken together, the studies to date strongly suggest that in both mice and humans, and in stark contrast to other tissues, resident gut macrophages are continuously replenished from circulating blood monocytes. Whether this information can be used to design strategies to specifically target gut macrophages remains to be explored but suggests that they may be impacted by systemic drug administration in a way that macrophages maintained locally in tissue would not.</p>
      </sec>
      <sec id="Sec4">
        <title>Instruction of resident gut macrophage function</title>
        <p>The main cues present in the gut environment that are responsible for monocyte to resident macrophage differentiation are still poorly defined. However, it is likely that there are specific signals or combinations of signals in the gut that induce characteristics not observed at other mucosal sites such as the skin and lung [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR109">109</xref>].</p>
        <p>There are a number of important growth factors involved in the establishment of the MPS, notably, FLT3L, CSF1 (MCSF) and CSF2 (granulocyte macrophage colony-stimulating factor). Although FLT3L and CSF2 may have impacts on gut macrophage function [<xref ref-type="bibr" rid="CR68">68</xref>], they appear to be dispensable for their development [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. This is in stark contrast to lung macrophages for which CSF2 signalling is extremely important [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. Two ligands have been identified for CSF1R: CSF1 itself and IL-34 [<xref ref-type="bibr" rid="CR112">112</xref>]. It seems most likely that development and maintenance of macrophages in the gut are CSF1 dependent as there is a marked reduction of macrophages in mice that have a mutation in the gene that encodes CSF1 (<italic>Csf1</italic>
<sup><italic>op/op</italic></sup>) or following administration of anti-CSF1R antibody [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR82">82</xref>].</p>
        <p>One particularly unusual phenotype of resident gut macrophages is their acquisition of high levels of CX3CR1 expression. In the majority of tissues, CX3CR1 is downregulated on macrophages suggesting that there is a factor in the gut responsible for its continued expression. A recent study has suggested that TGF-β, which is established to induce CX3CR1 expression in the brain [<xref ref-type="bibr" rid="CR9">9</xref>], is also a dominant signal for CX3CR1 expression by gut macrophages [<xref ref-type="bibr" rid="CR84">84</xref>]. This is in line with the identification of Runx3 as a characteristic transcription factor of gut macrophages that is regulated by TGF-β in T cells [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. In addition, it is possible that the interaction of CX3CR1 with CX3CL1 (fractalkine) may be important itself in instructing gut macrophage function. For example, it has been suggested that CX3CR1-CX3CL1 interactions are critical for optimal production of IL-10 by macrophages [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
        <p>IL-10 signalling is one pathway that has been shown to be crucial for instructing macrophage function in the gastrointestinal (GI) mucosa [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. Not only do macrophages make IL-10, but IL-10 signals to the macrophage are vital for the appropriate education of intestinal macrophage populations, providing a key cue that safeguards their hyporesponsive phenotype (discussed below). It has long been known that in the absence of IL-10, severe gastrointestinal inflammation results [<xref ref-type="bibr" rid="CR54">54</xref>]; what is now clear is that IL-10 receptor signalling on macrophages, but not the production of IL-10 itself, is key in restraining this inflammation [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. When unable to respond to IL-10, gut macrophages produce increased levels of inflammatory cytokines in response to bacterial stimulation [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR108">108</xref>] and drive development of colitis [<xref ref-type="bibr" rid="CR40">40</xref>]. More recently, specific deletion of IL-10Rα on CX3CR1-expressing gut macrophages was shown to lead to the development of a spontaneous, and severe, ulcerative colitis-like GI inflammation [<xref ref-type="bibr" rid="CR117">117</xref>]. Part of this IL-10 conditioning of macrophage function has been reported to include limiting levels of NOS2, PGE<sub>2</sub>, IL-23 [<xref ref-type="bibr" rid="CR117">117</xref>], inflammasome components and pro-IL-1β [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Thus, IL-10 signals have emerged as a vital restraint against overt macrophage activation. Interestingly, this pathway has also been implicated in early onset IBD, as similar functional alterations to those seen in animal models have been observed in patients with IL-10R mutations [<xref ref-type="bibr" rid="CR94">94</xref>].</p>
        <p>As mentioned, another key feature of gut macrophages is their apparent hyporesponsiveness to TLR-mediated activation. Intriguingly, gut-resident macrophages both in humans and mice express a full repertoire of TLR receptors, so it is thought that it is downstream mediators that are responsible for the hyporesponsiveness [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. Of note, molecules including MyD88, TRAF-6, TRIF and CD14 are downregulated in mature macrophages [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. Additionally, there may be alternative pathways that impair TLR responsiveness, for example, through increased expression of IRAK-M and IκΒNS [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR119">119</xref>].</p>
        <p>An emerging mediator of gut macrophage function is neuroendocrine signals, controlling macrophage survival and phenotype within the highly innervated gastrointestinal mucosa. Neuronal-macrophage interactions are bidirectional with macrophages in the muscularis capable of controlling peristaltic activity. Bone morphogenetic protein 2 (BMP2), produced by macrophages, acts on enteric neurons to control smooth muscle contractions and thus, peristalsis [<xref ref-type="bibr" rid="CR69">69</xref>]. In return, neuroendocrine signals to macrophages support maintenance of macrophage populations within specific gastrointestinal niches. Bogunovic and colleagues demonstrated that enteric neurons ensure maintenance of macrophages specifically within the muscularis layer of the gastrointestinal tract through production of CSF1 [<xref ref-type="bibr" rid="CR69">69</xref>] (as discussed a key growth factor in gut macrophage development). This neuroendocrine control of macrophage survival was downstream of commensal bacteria colonisation as microbial-derived signals promoted enteric neuron expression of CSF1. Additional macrophage niche specialisation by neuroendocrine pathways can also be driven by norepinephrine signals from sympathetic neurons. Muscarlis macrophages express β2 adrenergic receptors that, upon binding of norepinephrine released from local active neurons, promote acquisition of a tissue-protective programme in muscularis-resident macrophages during infection [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
        <p>Intriguingly, and in line with microbial activation of CSF1 production from enteric neurones [<xref ref-type="bibr" rid="CR69">69</xref>], it has also been reported that the microbiota controls glial cell homeostasis in the intestine [<xref ref-type="bibr" rid="CR47">47</xref>]. These supporting cells provide key maintenance and protection for neurons further highlighting the complex integration of microbial, endocrine and immune signals in controlling GI immune homeostasis and inflammation. The very recent focus on neuroendocrine signals in control of immune cell function within the gut [<xref ref-type="bibr" rid="CR64">64</xref>] will likely yield further insights into tissue training of macrophage function by these signals.</p>
        <p>In addition to the signals described, there are many other factors expressed in the gut environment that may play important roles on macrophages but as yet have been poorly explored. These factors include thymic stromal lymphopoietin (TSLP), the mucus layer itself that has been shown to modify DC function [<xref ref-type="bibr" rid="CR92">92</xref>] and retinoic acid. Retinoic acid is particularly intriguing as it is known to have profound effects on DC in the gut and in tandem with TGF-β support induction of Treg [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. The impact of RA on macrophages has yet to be precisely elucidated.</p>
      </sec>
      <sec id="Sec5">
        <title>Inflammatory gut macrophages in experimental settings of classical inflammation</title>
        <p>Infiltration of classical (Ly6C<sup>hi</sup>) monocytes that differentiate rapidly into effector cells is a common feature following intestinal damage and infection of mice [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR119">119</xref>] (see Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Perhaps the best-studied murine models of this are colitis induced by administration of dextran sodium sulphate (DSS) and T cell transfer colitis [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. In both of these settings, there is a characteristic reversal in the composition of the macrophage compartment. In particular, CX3CR1<sup>hi</sup>-resident gut macrophages that dominate in the healthy gut are outcompeted by inflammation-elicited CX3CR1<sup>int</sup> mononuclear phagocytes (MNPs) that are the progeny of rapidly infiltrating Ly6C<sup>hi</sup> monocytes [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. Precise definitions of the functions of this MNP pool are complex, and the cells within this pool are on a differentiation spectrum that likely includes populations with more macrophage-like or DC-like functions [<xref ref-type="bibr" rid="CR119">119</xref>]. For the rest of this review, focus will be placed on the macrophage-like features of these cells that are present in inflammation that for clarity will be referred to as inflammatory macrophages (although the reader should note, and as will be discussed, that their functional and differentiation potential as well as morphology is very different to resident gut macrophages). These cells have a strong pro-inflammatory signature characterised by the production of factors including TNF-α, IL-1β, IL-6 and inducible nitric oxide synthase (iNOS). Of note, despite their presence in this pro-inflammatory milieu, the resident CX3CR1<sup>hi</sup> macrophages continue to maintain the largely anti-inflammatory characteristics they exhibit in health [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. Not surprisingly, given their pro-inflammatory features, there is strong evidence for a pathologic role for the CX3CR1<sup>int</sup> macrophages in these murine models of colitis. For example, in <italic>Ccr2</italic>
<sup>−/−</sup> mice (which have a paucity of monocyte-derived cells in circulation and tissues due to a failure in classical monocyte release from the bone marrow [<xref ref-type="bibr" rid="CR89">89</xref>]), or animals depleted of CCR2-expressing cells [<xref ref-type="bibr" rid="CR119">119</xref>], there is an amelioration of DSS-driven colitic inflammation.<fig id="Fig2"><label>Fig. 2</label><caption><p>Macrophages during gut inflammation. Following epithelial damage or pathogen invasion, classical monocyte-derived effector cells are elicited and enter the now inflamed GI tract. The functions of these populations are poorly defined but likely highly specialised to the precise challenge and may include DC-like activities. Many differentiate into macrophages that are crucial for pathogen control but can also lead to pathology as a result of their potential to produce inflammatory cytokines such as TNF-α. During <italic>T. gondii</italic> infection, these cells also take on the capacity to suppress neutrophil activation via release of PGE<sub>2</sub>. Of note, during <italic>T. gondii</italic> infection, instruction of macrophage function begins in the bone marrow resulting in monocytes entering the tissue in a primed state characterised by their low expression of CX3CR1 and high expression of MHCII. Although monocytes no longer differentiate to resident macrophages (CX3CR1<sup>hi</sup>
<italic>lamina propria</italic> and muscularis macrophages) during inflammation, those present prior to barrier breach remain in the tissue and continue to exhibit anti-inflammatory features</p></caption><graphic xlink:href="424_2017_1958_Fig2_HTML" id="MO2"/></fig>
</p>
        <p>One intriguing feature of the Ly6C<sup>hi</sup> monocyte differentiation pathway to inflammatory macrophages during colitis is the apparent concurrent impairment in Ly6C<sup>hi</sup> monocyte differentiation to resident CX3CR1<sup>hi</sup> macrophages [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. Indeed, it has been proposed that this arrest in the differentiation pathway may underlie the ongoing capacity of inflammatory macrophages to respond to TLR stimulation in DSS colitis. The precise mechanisms that result in such changes are currently unknown but are likely due to signals being altered in the local microenvironment that are critical for educating monocytes to become resident anti-inflammatory macrophages.</p>
        <p>Despite inflammatory macrophages playing immunopathogenic roles during acute colitic-like inflammation, in certain gastrointestinal infections, they are crucial for pathogen protection [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Following oral inoculation with the highly type 1 polarising intracellular protozoan parasite <italic>Toxoplasma gondii</italic>, there is dramatic infiltration of Ly6C<sup>hi</sup> monocytes into the inflamed small intestine [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Once again, the importance of monocytes in this setting can be revealed by the fact that CCR2-deficient mice or those deficient in its ligand CCL2 fail to control the parasite [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], and this can be restored by monocyte transfer [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
        <p>Although, this parasite control was initially attributed to the capacity of recently recruited macrophages to produce pro-inflammatory cytokines such as TNF-α and iNOS, their function has since been revealed to be more complex [<xref ref-type="bibr" rid="CR25">25</xref>]. Our studies demonstrated that in CCR2-deficient animals infected with <italic>T. gondii</italic>, neutrophils became hyperactivated in the <italic>lamina propria</italic> of the gut where they produced dramatically increased levels of tissue damaging factors including TNF-α and reactive oxygen species (ROS) [<xref ref-type="bibr" rid="CR25">25</xref>]. This was associated with increased severity of gastrointestinal pathology that was independent of increases in parasite load. Immunofluorescent imaging revealed that Ly6C<sup>hi</sup> inflammatory macrophages localised closely with neutrophils in the inflamed gut suggesting that one explanation for their enhanced activity might be direct suppressive actions of Ly6C<sup>hi</sup> macrophages. Supporting this idea, we found that treatment of neutrophils with factors released from Ly6C<sup>hi</sup> macrophages isolated from <italic>T. gondii</italic>-infected guts limited the neutrophils’ capacity to produce pro-inflammatory factors in response to TLR ligands and formyl peptides. Further experiments revealed that this effect was entirely dependent on the release of the lipid mediator PGE<sub>2</sub>, which is highly expressed by inflammatory macrophages during <italic>T. gondii</italic> infection [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] (see Fig. <xref rid="Fig2" ref-type="fig">2</xref>). This lipid mediator can have complex and opposing roles over the course of an inflammatory response as it can favour inflammatory cell recruitment [<xref ref-type="bibr" rid="CR48">48</xref>] but is also a potent suppressor of human neutrophil activation [<xref ref-type="bibr" rid="CR115">115</xref>].</p>
        <p>Following its initial invasion of the gut, <italic>T. gondii</italic> infection eventually disseminates systemically and inflammatory macrophages infiltrate lymphoid tissues including the spleen [<xref ref-type="bibr" rid="CR25">25</xref>]. However, the neutrophil-suppressive activity was only evident in macrophages isolated from the gut. Studies using germ-free (GF) mice revealed that this was critically dependent on commensal-derived ligands. The precise bacteria involved in instructing macrophage function during inflammation are likely very different to those resident macrophages are exposed to in health. Notably, in the context of gut infection, there is tremendous outgrowth of potentially pathogenic commensal populations, specifically γ-proteobacteria such as <italic>Escherichia coli</italic> [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Outgrowth of γ-proteobacteria has also been reported in patients with IBD [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Indeed, in vitro treatment of circulating Ly6C<sup>hi</sup> monocytes from the blood of <italic>T. gondii</italic>-infected animals with a lysate from a commensal form of <italic>E. coli</italic> led to rapid PGE<sub>2</sub> production. Of course, in vivo, there may be additional gut-specific signals responsible for initiating PGE<sub>2</sub> release. For example, stimulated epithelial cells can produce and activate IL-1β [<xref ref-type="bibr" rid="CR99">99</xref>], a strong driver of PGE<sub>2</sub> from macrophages [<xref ref-type="bibr" rid="CR76">76</xref>], and commensal-derived dietary ligands such as short chain fatty acids (SCFAs) can also augment PGE<sub>2</sub> production [<xref ref-type="bibr" rid="CR13">13</xref>]. It is interesting to speculate that in certain individuals or at defined time points during infection, alterations in the composition of commensal species may be able to favour acquisition of regulatory features by infiltrating monocytes.</p>
        <p>Another mechanism by which inflammatory macrophages may act to suppress immune cells during inflammation is via actions on T cells. This could be achieved by modifying L-arginine metabolism, as nitric oxide (NO) limits T cell proliferation [<xref ref-type="bibr" rid="CR5">5</xref>]. Inflammatory macrophages in the GI tract during acute infection and inflammation have been shown to be positive for this immune mediator. In the spleen, during <italic>Listeria monocytogenes</italic> infection, iNOS<sup>+</sup> macrophages suppress antigen-specific T cell responses [<xref ref-type="bibr" rid="CR90">90</xref>]. Given the prevalence of iNOS<sup>+</sup> macrophages in the GI tract during inflammation, these data imply that these cells may well be capable of suppressing effector T cell responses in the GI mucosa. In line with this, a CX3CR1<sup>+</sup>CD11c<sup>+</sup>CD11b<sup>+</sup> MNP in the GI tract has been shown to be capable of limiting CD4<sup>+</sup> T cell proliferation [<xref ref-type="bibr" rid="CR50">50</xref>]. This required cell-cell contact highlighting another mechanism that could be employed by macrophages to curtail gastrointestinal T cell responses.</p>
      </sec>
      <sec id="Sec6">
        <title>Macrophages in human gut inflammation</title>
        <p>Mechanistic understanding of macrophages in human gut inflammation is much more limited than in animal models. One thing that is clear is that CD14<sup>hi</sup> MNP accumulate in the inflamed gut in settings such as IBD [<xref ref-type="bibr" rid="CR49">49</xref>], likely in response to elevated levels of the chemokines CCL2 and CCL4 [<xref ref-type="bibr" rid="CR95">95</xref>]. Indeed, by radiolabelling of autologous blood monocytes, it was demonstrated that the CD14<sup>hi</sup> cells arise from these circulating precursors [<xref ref-type="bibr" rid="CR27">27</xref>]. These cells are the human equivalent of the Ly6C<sup>hi</sup> populations in mice that become dominant during induced colitis and oral <italic>T. gondii</italic> infection [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. As with recruited macrophages in the mouse, the CD14<sup>hi</sup> cells in the inflamed human intestine produce high levels of TNF-α, IL-1β and IL-6 [<xref ref-type="bibr" rid="CR81">81</xref>] and have ongoing responsiveness to microbe-derived factors [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR105">105</xref>].</p>
        <p>In addition to cytokine release, it has also been reported that macrophages in the inflamed mucosa have increased expression of CD40 that may support local interactions with pathology-driving effector T cells [<xref ref-type="bibr" rid="CR7">7</xref>], again mirroring data from murine models [<xref ref-type="bibr" rid="CR119">119</xref>]. Given the currently sparse data on human intestinal macrophage function, but their high relevance to disease pathology, this will no doubt be an area for tremendous future scientific study. The already strong similarities between patient samples and murine models suggest that integration of these two investigative strategies may be key to rapidly progressing our knowledge of this area.</p>
      </sec>
      <sec id="Sec7">
        <title>Long-range instruction of inflammatory gut macrophage function during infection</title>
        <p>At steady state, much research focus has been placed on the cues present in the gut environment that locally instruct resident gut macrophage differentiation. Based on this model, during gut inflammation, factors at the affected tissue site to which infection-elicited macrophages are exposed have been of primary interest. However, a number of recent findings, including those from our group, suggest that a more holistic approach to understanding macrophage differentiation during inflammation needs to be employed.</p>
        <p>It is well established that when stressed, tissues such as the gut can send signals to the bone marrow (BM) niche and blood to improve supply of required circulating immune populations [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. We found that during gut infection, these long-range signals can also instruct for altered functional potential. As early as 4 days after oral infection with <italic>T. gondii</italic>, Ly6C<sup>hi</sup> monocytes developing in the BM niche acquired a characteristic CX3CR1<sup>low</sup>MHCII<sup>hi</sup>Sca-1<sup>hi</sup> phenotype, which was also observed in inflammatory gut macrophages [<xref ref-type="bibr" rid="CR1">1</xref>] suggesting that instruction of eventual macrophage differentiation may be beginning in the BM. Most importantly, when highly pure BM Ly6C<sup>hi</sup> monocytes were isolated by FACS from naïve and <italic>T. gondii</italic>-infected animals and exposed to commensal signals they ultimately would experience in the inflamed gut, they already had enhanced capacity to produce PGE<sub>2</sub> prior to BM efflux. As discussed already, we have established PGE<sub>2</sub> as a critical recruited gut macrophage-derived factor regulating neutrophil-mediated immunopathology during oral <italic>T. gondii</italic> infection [<xref ref-type="bibr" rid="CR25">25</xref>]. Thus, during gut infection, functional priming of inflammatory macrophages can begin in the BM.</p>
        <p>Although PGE<sub>2</sub> production was highlighted, the Ly6C<sup>hi</sup> monocytes had profound transcriptional changes and also had enhanced capacity to produce anti-inflammatory IL-10 in response to bacterial ligands. These transcriptional changes were at least initiated in the direct proliferative precursor to monocytes, the common monocyte progenitor (cMoP) [<xref ref-type="bibr" rid="CR36">36</xref>], but earlier progenitors such as the MDP were not investigated due to issues of identification in infection [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
        <p>The precise mechanisms that the gut can use to communicate to the BM niche are not understood. During <italic>T. gondii</italic> infection, we identified a whole organism signalling loop in which a specific subset of gut DC (Batf3<sup>+</sup>) released the cytokine IL-12 in the serum that was detected by a subset of mature natural killer (NK) cells present in the BM. These NK cells produced IFN-γ locally in the BM in response to the IL-12 signal, which was critical in generating the high PGE<sub>2</sub>-producing CX3CR1<sup>low</sup>MHCII<sup>hi</sup>Sca-1<sup>hi</sup> monocytes. Although IFN-γ was a dominant signal, whether additional signals in the BM environment are also altered following <italic>T. gondii</italic> infection and whether these have specific functional effects on developing monocytes and eventually their gut macrophage progeny remain unknown. One possibility is food-derived ligands such as short-chain fatty acids (SCFAs), as these have previously been shown to modify DC function prior to exit from the BM in an asthma model [<xref ref-type="bibr" rid="CR106">106</xref>].</p>
        <p>Intriguingly, during <italic>T. gondii</italic> infection, our data suggested that perturbations to monocyte-macrophage differentiation capacity might be initiated systemically, as there were dramatic increases in circulating Ly6C<sup>hi</sup> monocytes with a concurrent loss of Ly6C<sup>low</sup> patrolling monocytes (which are suggested to derive from the Ly6C<sup>hi</sup> population [<xref ref-type="bibr" rid="CR116">116</xref>]). This bears striking similarity to the proposed block in differentiation of monocytes to resident gut macrophages in colitis [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. The cytokine IFN-γ was implicated in this process [<xref ref-type="bibr" rid="CR1">1</xref>], but further work will be needed to confirm whether this is due to an arrest in normal differentiation pathways (rather than, for example, increased BM output of Ly6C<sup>hi</sup> monocytes) and whether these Ly6C<sup>hi</sup> monocytes are also unable to differentiate into resident macrophages upon entry into the gut.</p>
      </sec>
      <sec id="Sec8">
        <title>Resident and inflammatory macrophages in resolution of inflammation</title>
        <p>Once the infection, or other inflammation-driving factor, has been cleared or becomes tolerated in the gut, there must be a resolution phase to restore homeostasis. If this does not happen, then chronic inflammation may develop.</p>
        <p>As occurs during inflammation, this resolution phase is also associated with striking alterations to gut macrophage subsets. One example of this is that following resolution of DSS colitis in mice, the augmented CX3CR1<sup>int</sup> MNP subset returns to baseline levels [<xref ref-type="bibr" rid="CR119">119</xref>]. Precise reasons for the loss of the CX3CR1<sup>int</sup> subset are not known, but apoptosis and uptake by resident macrophages seem probable [<xref ref-type="bibr" rid="CR22">22</xref>]. An alternative possibility, based on the idea that CX3CR1<sup>int</sup> cells are blocked in their differentiation to resident gut macrophages during inflammation, is that due to alterations in the cytokine milieu, this limitation is removed. As a result, many of the CX3CR1<sup>int</sup> cells would “disappear” from the gut by differentiating into resident gut macrophages.</p>
        <p>Whatever the case, it seems that gut monocytes/macrophages are important in gut repair and resolution of inflammation. In particular, there is a delay in DSS colitis resolution in animals that lack TGF-β signalling on monocytes/macrophages (CD68-dnTGFβRII) [<xref ref-type="bibr" rid="CR78">78</xref>], while deletion of MyD88 signalling in myeloid cells limits gut healing [<xref ref-type="bibr" rid="CR62">62</xref>].</p>
        <p>Although not well studied specifically in the gut, one set of factors that are important in restoration of homeostasis in all tissues are pro-resolving lipid mediators [<xref ref-type="bibr" rid="CR91">91</xref>]. These factors, as well as limiting influx of additional inflammatory cells, can promote the uptake of apoptotic cells by macrophages [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Types of lipid mediators include lipoxins, resolvins and protectins that can be produced by multiple cell types including macrophages [<xref ref-type="bibr" rid="CR91">91</xref>]. One factor that has been demonstrated to favour production of lipoxins is prostaglandins, in particular PGE<sub>2</sub>. For example, in resolving inflammatory exudates, it has been suggested that PGE<sub>2</sub> and PGD<sub>2</sub> can stimulate production of a functional enzyme for lipoxin in neutrophils [<xref ref-type="bibr" rid="CR57">57</xref>]. Based on our studies in <italic>T. gondii</italic> infection, this raises the intriguing possibility that Ly6C<sup>hi</sup> monocytes/macrophages not only limit neutrophil activation but also deviate their function towards a lipoxin-producing pro-resolution state. Relating to this, macrophages may also be able to regulate wound healing directly by interacting with epithelial progenitor cells during colonic wound healing [<xref ref-type="bibr" rid="CR77">77</xref>]. Again, lipid mediators may play a role in this process as COX-2 expression, a critical factor in PGE<sub>2</sub> production, has been linked to protection of progenitor populations at other tissue sites during inflammation [<xref ref-type="bibr" rid="CR60">60</xref>].</p>
        <p>As well as repairing the barrier, another feature of return to homeostasis is the restoration of the adaptive immune compartment, which can become dramatically perturbed during an inflammatory response [<xref ref-type="bibr" rid="CR73">73</xref>]. At this time, it is unclear how the mononuclear phagocytes of the gut may act together to support this return, but given their suggested role in expanding Tregs at steady state, it is likely that gut-resident macrophages are important to this process.</p>
        <p>With the recent advances in technologies for the generation of transgenic murine systems, novel tools for the temporal knockout of specific genes in defined macrophage/monocyte subsets are likely to become increasingly available. This will allow candidate factors identified as being important to resolution to be depleted during this phase of the inflammatory response without impairing initiation of disease. Already, the tamoxifen-inducible Cx3CR1<sup>creER</sup> mouse that knocks out factors in CX3CR1<sup>hi</sup>-resident gut macrophages holds much promise for this purpose [<xref ref-type="bibr" rid="CR116">116</xref>].</p>
      </sec>
      <sec id="Sec9">
        <title>Concluding remarks</title>
        <p>Utilising novel transgenic animals alongside cutting-edge cytometric and genomic approaches, recent years have seen an explosion in our understanding of macrophage biology in general and more specifically in the gut. In particular, the field is beginning to better define the diverse functions that these cells play in tissue homeostasis and how they can be manipulated in disease states.</p>
        <p>With the advent of single-cell RNA sequencing, it will become more straightforward to define functionally distinct macrophage subsets within complex and potentially inflamed tissue environments. One aspect of macrophage biology that has been largely overlooked in recent years is precise localisation within the tissue. For example, in the gastrointestinal tract, there are diverse structural components to the tissue, e.g. muscle, nerves, blood vessels and epithelium. How macrophage function might be tailored to each of these niches is only just beginning to be understood.</p>
        <p>Another area in the functional diversity arena is to further understand the differential roles of resident macrophages versus inflammatory macrophages in disease states. It is clear that resident macrophages are often maintained in the inflammatory environment but are not acquiring classical activation markers. Whether these cells play a role during the active inflammatory event or in restoring homeostasis post challenge is extremely unclear. This is critical to understand as it would help elucidate specific macrophage factors that can be manipulated at defined time points in the inflammation resolution cycle to alter outcome.</p>
        <p>Whatever the future of macrophage research holds, given the importance of intestinal macrophages to the maintenance of homeostasis and disease progression, better understanding the development and functions of this cell type will no doubt yield novel strategies that can inform development of therapies to improve patient outcome in inflammatory diseases such as IBD.</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>This article is part of the special issue on macrophages in tissue homeostasis in Pflügers Archiv – European Journal of Physiology</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>Funding is provided to J.R.G. through a Sir Henry Dale Fellowship jointly supported by The Wellcome Trust and The Royal Society (104195/Z/14/Z) and by a Manchester Collaborative Centre for Inflammation Research grant. J.E.K. is supported by a BBSRC-funded Sir David Phillips Fellowship (BB/M025977/1) and by a Manchester Collaborative Centre for Inflammation Research grant.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <sec id="FPar1">
        <title>Conflict of interest</title>
        <p>The authors declare that they have no conflict of interest.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Askenase</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Byrd</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Morais da Fonseca</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bouladoux</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wilhelm</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Konkel</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Hand</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Lacerda-Queiroz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>XZ</given-names>
            </name>
            <name>
              <surname>Trinchieri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Grainger</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Belkaid</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Bone-marrow-resident NK cells prime monocytes for regulatory function during infection</article-title>
          <source>Immunity</source>
          <year>2015</year>
          <volume>42</volume>
          <fpage>1130</fpage>
          <lpage>1142</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2015.05.011</pub-id>
          <?supplied-pmid 26070484?>
          <pub-id pub-id-type="pmid">26070484</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bain</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Bravo-Blas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Gomez Perdiguero</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Geissmann</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Henri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Malissen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Osborne</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Artis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mowat</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice</article-title>
          <source>Nat Immunol</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>929</fpage>
          <lpage>937</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2967</pub-id>
          <?supplied-pmid 25151491?>
          <pub-id pub-id-type="pmid">25151491</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bain</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Mowat</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Macrophages in intestinal homeostasis and inflammation</article-title>
          <source>Immunol Rev</source>
          <year>2014</year>
          <volume>260</volume>
          <fpage>102</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="doi">10.1111/imr.12192</pub-id>
          <?supplied-pmid 24942685?>
          <pub-id pub-id-type="pmid">24942685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bain</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Uronen-Hansson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gudjonsson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jansson</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Grip</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Malissen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Agace</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Mowat</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors</article-title>
          <source>Mucosal Immunol</source>
          <year>2013</year>
          <volume>6</volume>
          <fpage>498</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="doi">10.1038/mi.2012.89</pub-id>
          <?supplied-pmid 22990622?>
          <pub-id pub-id-type="pmid">22990622</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bogdan</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Nitric oxide and the immune response</article-title>
          <source>Nat Immunol</source>
          <year>2001</year>
          <volume>2</volume>
          <fpage>907</fpage>
          <lpage>916</lpage>
          <pub-id pub-id-type="doi">10.1038/ni1001-907</pub-id>
          <?supplied-pmid 11577346?>
          <pub-id pub-id-type="pmid">11577346</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bogunovic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Helft</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Greter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jakubzick</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ingersoll</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Leboeuf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Nussenzweig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lira</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Origin of the lamina propria dendritic cell network</article-title>
          <source>Immunity</source>
          <year>2009</year>
          <volume>31</volume>
          <fpage>513</fpage>
          <lpage>525</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2009.08.010</pub-id>
          <?supplied-pmid 19733489?>
          <pub-id pub-id-type="pmid">19733489</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlsen</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Yamanaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rugtveit</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brandtzaeg</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria</article-title>
          <source>Inflamm Bowel Dis</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>1013</fpage>
          <lpage>1024</lpage>
          <pub-id pub-id-type="doi">10.1097/01.mib.0000234135.43336.72</pub-id>
          <?supplied-pmid 17075342?>
          <pub-id pub-id-type="pmid">17075342</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cerovic</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bain</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Mowat</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Milling</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Intestinal macrophages and dendritic cells: what’s the difference?</article-title>
          <source>Trends Immunol</source>
          <year>2014</year>
          <volume>35</volume>
          <fpage>270</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="doi">10.1016/j.it.2014.04.003</pub-id>
          <?supplied-pmid 24794393?>
          <pub-id pub-id-type="pmid">24794393</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Streit</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Harrison</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>TGF-beta1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated signaling in rat microglia</article-title>
          <source>J Neuroimmunol</source>
          <year>2002</year>
          <volume>133</volume>
          <fpage>46</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="doi">10.1016/S0165-5728(02)00354-5</pub-id>
          <?supplied-pmid 12446007?>
          <pub-id pub-id-type="pmid">12446007</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chieppa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rescigno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Germain</surname>
              <given-names>RN</given-names>
            </name>
          </person-group>
          <article-title>Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement</article-title>
          <source>J Exp Med</source>
          <year>2006</year>
          <volume>203</volume>
          <fpage>2841</fpage>
          <lpage>2852</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20061884</pub-id>
          <?supplied-pmid 17145958?>
          <pub-id pub-id-type="pmid">17145958</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chudnovskiy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mortha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kana</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kennard</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Remark</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mogno</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gnjatic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Amir</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Solovyov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Greenbaum</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Clemente</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Faith</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Belkaid</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Grigg</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Host-protozoan interactions protect from mucosal infections through activation of the inflammasome</article-title>
          <source>Cell</source>
          <year>2016</year>
          <volume>167</volume>
          <fpage>444</fpage>
          <lpage>456</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2016.08.076</pub-id>
          <?supplied-pmid 27716507?>
          <pub-id pub-id-type="pmid">27716507</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coombes</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Siddiqui</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Arancibia-Carcamo</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Belkaid</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Powrie</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism</article-title>
          <source>J Exp Med</source>
          <year>2007</year>
          <volume>204</volume>
          <fpage>1757</fpage>
          <lpage>1764</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20070590</pub-id>
          <?supplied-pmid 17620361?>
          <pub-id pub-id-type="pmid">17620361</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cox</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stanton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rojas-Triana</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bober</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Laverty</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Monsma</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Vassileva</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Maguire</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gustafson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bayne</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Lundell</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jenh</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines</article-title>
          <source>World J Gastroenterol</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>5549</fpage>
          <lpage>5557</lpage>
          <pub-id pub-id-type="doi">10.3748/wjg.15.5549</pub-id>
          <?supplied-pmid 19938193?>
          <pub-id pub-id-type="pmid">19938193</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cummings</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Barbet</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bongers</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hartmann</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Gettler</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Muniz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Furtado</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lira</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Blander</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Different tissue phagocytes sample apoptotic cells to direct distinct homeostasis programs</article-title>
          <source>Nature</source>
          <year>2016</year>
          <volume>539</volume>
          <fpage>565</fpage>
          <lpage>569</lpage>
          <pub-id pub-id-type="doi">10.1038/nature20138</pub-id>
          <?supplied-pmid 27828940?>
          <pub-id pub-id-type="pmid">27828940</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Darfeuille-Michaud</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Boudeau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bulois</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Neut</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Glasser</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Barnich</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bringer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Swidsinski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Beaugerie</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Colombel</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>High prevalence of adherent-invasive <italic>Escherichia coli</italic> associated with ileal mucosa in Crohn’s disease</article-title>
          <source>Gastroenterology</source>
          <year>2004</year>
          <volume>127</volume>
          <fpage>412</fpage>
          <lpage>421</lpage>
          <pub-id pub-id-type="doi">10.1053/j.gastro.2004.04.061</pub-id>
          <?supplied-pmid 15300573?>
          <pub-id pub-id-type="pmid">15300573</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Denning</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Norris</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Medina-Contreras</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Manicassamy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Geem</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Madan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Karp</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Pulendran</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Functional specializations of intestinal dendritic cell and macrophage subsets that control Th17 and regulatory T cell responses are dependent on the T cell/APC ratio, source of mouse strain, and regional localization</article-title>
          <source>J Immunol</source>
          <year>2011</year>
          <volume>187</volume>
          <fpage>733</fpage>
          <lpage>747</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.1002701</pub-id>
          <?supplied-pmid 21666057?>
          <pub-id pub-id-type="pmid">21666057</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dunay</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Damatta</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Fux</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Presti</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Greco</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Colonna</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sibley</surname>
              <given-names>LD</given-names>
            </name>
          </person-group>
          <article-title>Gr1(+) inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii</article-title>
          <source>Immunity</source>
          <year>2008</year>
          <volume>29</volume>
          <fpage>306</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2008.05.019</pub-id>
          <?supplied-pmid 18691912?>
          <pub-id pub-id-type="pmid">18691912</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Epelman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lavine</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Beaudin</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Sojka</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Carrero</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Calderon</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Brija</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gautier</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Ivanov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Satpathy</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Schilling</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Schwendener</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sergin</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Razani</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Forsberg</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Unanue</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Colonna</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation</article-title>
          <source>Immunity</source>
          <year>2014</year>
          <volume>40</volume>
          <fpage>91</fpage>
          <lpage>104</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2013.11.019</pub-id>
          <?supplied-pmid 24439267?>
          <pub-id pub-id-type="pmid">24439267</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Filardy</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bennink</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yewdell</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kelsall</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
          <article-title>Posttranscriptional control of NLRP3 inflammasome activation in colonic macrophages</article-title>
          <source>Mucosal Immunol</source>
          <year>2016</year>
          <volume>9</volume>
          <fpage>850</fpage>
          <lpage>858</lpage>
          <pub-id pub-id-type="doi">10.1038/mi.2015.109</pub-id>
          <?supplied-pmid 26627461?>
          <pub-id pub-id-type="pmid">26627461</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freire-de-Lima</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>YQ</given-names>
            </name>
            <name>
              <surname>Gardai</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Bratton</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Schiemann</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Henson</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages</article-title>
          <source>J Biol Chem</source>
          <year>2006</year>
          <volume>281</volume>
          <fpage>38376</fpage>
          <lpage>38384</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M605146200</pub-id>
          <?supplied-pmid 17056601?>
          <pub-id pub-id-type="pmid">17056601</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gabanyi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Feighery</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>TY</given-names>
            </name>
            <name>
              <surname>Costa-Pinto</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Mucida</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Neuro-immune interactions drive tissue programming in intestinal macrophages</article-title>
          <source>Cell</source>
          <year>2016</year>
          <volume>164</volume>
          <fpage>378</fpage>
          <lpage>391</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2015.12.023</pub-id>
          <?supplied-pmid 26777404?>
          <pub-id pub-id-type="pmid">26777404</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gautier</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Ivanov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lesnik</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Local apoptosis mediates clearance of macrophages from resolving inflammation in mice</article-title>
          <source>Blood</source>
          <year>2013</year>
          <volume>122</volume>
          <fpage>2714</fpage>
          <lpage>2722</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2013-01-478206</pub-id>
          <?supplied-pmid 23974197?>
          <pub-id pub-id-type="pmid">23974197</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gautier</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Shay</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Greter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jakubzick</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ivanov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Helft</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Elpek</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Gordonov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mazloom</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Ma’ayan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chua</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Turley</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Immunological</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
          <article-title>Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages</article-title>
          <source>Nat Immunol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>1118</fpage>
          <lpage>1128</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2419</pub-id>
          <?supplied-pmid 23023392?>
          <pub-id pub-id-type="pmid">23023392</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Greter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leboeuf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nandi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>See</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gokhan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mehler</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Conway</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Samokhvalov</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Fate mapping analysis reveals that adult microglia derive from primitive macrophages</article-title>
          <source>Science</source>
          <year>2010</year>
          <volume>330</volume>
          <fpage>841</fpage>
          <lpage>845</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1194637</pub-id>
          <?supplied-pmid 20966214?>
          <pub-id pub-id-type="pmid">20966214</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grainger</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Wohlfert</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Fuss</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Bouladoux</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Askenase</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Legrand</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Koo</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Brenchley</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Belkaid</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory monocytes regulate pathologic responses to commensals during acute gastrointestinal infection</article-title>
          <source>Nat Med</source>
          <year>2013</year>
          <volume>19</volume>
          <fpage>713</fpage>
          <lpage>721</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.3189</pub-id>
          <?supplied-pmid 23708291?>
          <pub-id pub-id-type="pmid">23708291</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Helft</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mortha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Agudo-Cantero</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bogunovic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gautier</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Leboeuf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Aloman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Pollard</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Chipuk</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Frenette</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells</article-title>
          <source>Immunity</source>
          <year>2012</year>
          <volume>36</volume>
          <fpage>1031</fpage>
          <lpage>1046</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.027</pub-id>
          <?supplied-pmid 22749353?>
          <pub-id pub-id-type="pmid">22749353</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grimm</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Pullman</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Pavli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Doe</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
          <article-title>Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa</article-title>
          <source>J Gastroenterol Hepatol</source>
          <year>1995</year>
          <volume>10</volume>
          <fpage>387</fpage>
          <lpage>395</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1440-1746.1995.tb01589.x</pub-id>
          <?supplied-pmid 8527703?>
          <pub-id pub-id-type="pmid">8527703</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Griseri</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>McKenzie</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Schiering</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Powrie</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Dysregulated hematopoietic stem and progenitor cell activity promotes interleukin-23-driven chronic intestinal inflammation</article-title>
          <source>Immunity</source>
          <year>2012</year>
          <volume>37</volume>
          <fpage>1116</fpage>
          <lpage>1129</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2012.08.025</pub-id>
          <?supplied-pmid 23200826?>
          <pub-id pub-id-type="pmid">23200826</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gronert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gewirtz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Madara</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Serhan</surname>
              <given-names>CN</given-names>
            </name>
          </person-group>
          <article-title>Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release</article-title>
          <source>J Exp Med</source>
          <year>1998</year>
          <volume>187</volume>
          <fpage>1285</fpage>
          <lpage>1294</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.187.8.1285</pub-id>
          <?supplied-pmid 9547339?>
          <pub-id pub-id-type="pmid">9547339</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Kleer</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Henri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Post</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vanhoutte</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>De Prijck</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Deswarte</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Malissen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hammad</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lambrecht</surname>
              <given-names>BN</given-names>
            </name>
          </person-group>
          <article-title>Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF</article-title>
          <source>J Exp Med</source>
          <year>2013</year>
          <volume>210</volume>
          <fpage>1977</fpage>
          <lpage>1992</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20131199</pub-id>
          <?supplied-pmid 24043763?>
          <pub-id pub-id-type="pmid">24043763</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gurung</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Subbarao Malireddi</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Lamkanfi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Geiger</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Kanneganti</surname>
              <given-names>TD</given-names>
            </name>
          </person-group>
          <article-title>Chronic TLR stimulation controls NLRP3 inflammasome activation through IL-10 mediated regulation of NLRP3 expression and caspase-8 activation</article-title>
          <source>Sci Rep</source>
          <year>2015</year>
          <volume>5</volume>
          <fpage>14488</fpage>
          <pub-id pub-id-type="doi">10.1038/srep14488</pub-id>
          <?supplied-pmid 26412089?>
          <pub-id pub-id-type="pmid">26412089</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hadis</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Wahl</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Hardtke-Wolenski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schippers</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Sparwasser</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Forster</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pabst</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria</article-title>
          <source>Immunity</source>
          <year>2011</year>
          <volume>34</volume>
          <fpage>237</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2011.01.016</pub-id>
          <?supplied-pmid 21333554?>
          <pub-id pub-id-type="pmid">21333554</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hashimoto</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Noizat</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Teo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Beasley</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Leboeuf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>See</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lucas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Greter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mortha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Boyer</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Forsberg</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>van Rooijen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Garcia-Sastre</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Frenette</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes</article-title>
          <source>Immunity</source>
          <year>2013</year>
          <volume>38</volume>
          <fpage>792</fpage>
          <lpage>804</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2013.04.004</pub-id>
          <?supplied-pmid 23601688?>
          <pub-id pub-id-type="pmid">23601688</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hedl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Chronic stimulation of Nod2 mediates tolerance to bacterial products</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2007</year>
          <volume>104</volume>
          <fpage>19440</fpage>
          <lpage>19445</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0706097104</pub-id>
          <?supplied-pmid 18032608?>
          <pub-id pub-id-type="pmid">18032608</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heimesaat</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Bereswill</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fuchs</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Struck</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Niebergall</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jahn</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Dunay</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Moter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gescher</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Schumann</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Gobel</surname>
              <given-names>UB</given-names>
            </name>
            <name>
              <surname>Liesenfeld</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Gram-negative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii</article-title>
          <source>J Immunol</source>
          <year>2006</year>
          <volume>177</volume>
          <fpage>8785</fpage>
          <lpage>8795</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.177.12.8785</pub-id>
          <?supplied-pmid 17142781?>
          <pub-id pub-id-type="pmid">17142781</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hettinger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Hansson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barra</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Joschko</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Krijgsveld</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Feuerer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Origin of monocytes and macrophages in a committed progenitor</article-title>
          <source>Nat Immunol</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>821</fpage>
          <lpage>830</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2638</pub-id>
          <?supplied-pmid 23812096?>
          <pub-id pub-id-type="pmid">23812096</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirotani</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Kuwata</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kawase</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Akira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria</article-title>
          <source>J Immunol</source>
          <year>2005</year>
          <volume>174</volume>
          <fpage>3650</fpage>
          <lpage>3657</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.174.6.3650</pub-id>
          <?supplied-pmid 15749903?>
          <pub-id pub-id-type="pmid">15749903</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoeffel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lavin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Low</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>See</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Beaudin</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Lum</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Low</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Forsberg</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Poidinger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zolezzi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Larbi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Greter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Becher</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Samokhvalov</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages</article-title>
          <source>Immunity</source>
          <year>2015</year>
          <volume>42</volume>
          <fpage>665</fpage>
          <lpage>678</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2015.03.011</pub-id>
          <?supplied-pmid 25902481?>
          <pub-id pub-id-type="pmid">25902481</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoeffel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Greter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>See</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Teo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Malleret</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Leboeuf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Low</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Oller</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Choy</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Grisotto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Renia</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Conway</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Samokhvalov</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages</article-title>
          <source>J Exp Med</source>
          <year>2012</year>
          <volume>209</volume>
          <fpage>1167</fpage>
          <lpage>1181</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20120340</pub-id>
          <?supplied-pmid 22565823?>
          <pub-id pub-id-type="pmid">22565823</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoshi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Schenten</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nish</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Walther</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Gagliani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Flavell</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Reizis</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Iwasaki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Medzhitov</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice</article-title>
          <source>Nat Commun</source>
          <year>2012</year>
          <volume>3</volume>
          <fpage>1120</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms2113</pub-id>
          <?supplied-pmid 23047678?>
          <pub-id pub-id-type="pmid">23047678</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Houston</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Cerovic</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Thomson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brewer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mowat</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Milling</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The lymph nodes draining the small intestine and colon are anatomically separate and immunologically distinct</article-title>
          <source>Mucosal Immunol</source>
          <year>2016</year>
          <volume>9</volume>
          <fpage>468</fpage>
          <lpage>478</lpage>
          <pub-id pub-id-type="doi">10.1038/mi.2015.77</pub-id>
          <?supplied-pmid 26329428?>
          <pub-id pub-id-type="pmid">26329428</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hume</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>VH</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The mononuclear phagocyte system of the mouse defined by immunohistochemical localisation of antigen F4/80: macrophages associated with epithelia</article-title>
          <source>Anat Rec</source>
          <year>1984</year>
          <volume>210</volume>
          <fpage>503</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="doi">10.1002/ar.1092100311</pub-id>
          <?supplied-pmid 6524692?>
          <pub-id pub-id-type="pmid">6524692</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ingersoll</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Spanbroek</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lottaz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gautier</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Frankenberger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Haniffa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Collin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tacke</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Habenicht</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Ziegler-Heitbrock</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Comparison of gene expression profiles between human and mouse monocyte subsets</article-title>
          <source>Blood</source>
          <year>2010</year>
          <volume>115</volume>
          <fpage>e10</fpage>
          <lpage>e19</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2009-07-235028</pub-id>
          <?supplied-pmid 19965649?>
          <pub-id pub-id-type="pmid">19965649</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ivanov</surname>
              <given-names>II</given-names>
            </name>
            <name>
              <surname>Atarashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Manel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Brodie</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Shima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Karaoz</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Goldfarb</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Santee</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Tanoue</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Imaoka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Itoh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Umesaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Honda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Littman</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Induction of intestinal Th17 cells by segmented filamentous bacteria</article-title>
          <source>Cell</source>
          <year>2009</year>
          <volume>139</volume>
          <fpage>485</fpage>
          <lpage>498</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2009.09.033</pub-id>
          <?supplied-pmid 19836068?>
          <pub-id pub-id-type="pmid">19836068</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jaensson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Uronen-Hansson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pabst</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Eksteen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Coombes</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Berg</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Davidsson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Powrie</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Johansson-Lindbom</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Agace</surname>
              <given-names>WW</given-names>
            </name>
          </person-group>
          <article-title>Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans</article-title>
          <source>J Exp Med</source>
          <year>2008</year>
          <volume>205</volume>
          <fpage>2139</fpage>
          <lpage>2149</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20080414</pub-id>
          <?supplied-pmid 18710932?>
          <pub-id pub-id-type="pmid">18710932</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aliberti</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Graemmel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sunshine</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kreutzberg</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Sher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Littman</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion</article-title>
          <source>Mol Cell Biol</source>
          <year>2000</year>
          <volume>20</volume>
          <fpage>4106</fpage>
          <lpage>4114</lpage>
          <pub-id pub-id-type="doi">10.1128/MCB.20.11.4106-4114.2000</pub-id>
          <?supplied-pmid 10805752?>
          <pub-id pub-id-type="pmid">10805752</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kabouridis</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Lasrado</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>McCallum</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chng</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Snippert</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Clevers</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pettersson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pachnis</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Microbiota controls the homeostasis of glial cells in the gut lamina propria</article-title>
          <source>Neuron</source>
          <year>2015</year>
          <volume>85</volume>
          <fpage>289</fpage>
          <lpage>295</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuron.2014.12.037</pub-id>
          <?supplied-pmid 25578362?>
          <pub-id pub-id-type="pmid">25578362</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalinski</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Regulation of immune responses by prostaglandin E2</article-title>
          <source>J Immunol</source>
          <year>2012</year>
          <volume>188</volume>
          <fpage>21</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.1101029</pub-id>
          <?supplied-pmid 22187483?>
          <pub-id pub-id-type="pmid">22187483</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kamada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hisamatsu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chinen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sakuraba</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kitazume</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Sugita</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Koganei</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Akagawa</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Hibi</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis</article-title>
          <source>J Clin Invest</source>
          <year>2008</year>
          <volume>118</volume>
          <fpage>2269</fpage>
          <lpage>2280</lpage>
          <?supplied-pmid 18497880?>
          <pub-id pub-id-type="pmid">18497880</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kayama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ueda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jeon</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kubo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Okazaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yagita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Intestinal CX3C chemokine receptor 1(high) (CX3CR1(high)) myeloid cells prevent T-cell-dependent colitis</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2012</year>
          <volume>109</volume>
          <fpage>5010</fpage>
          <lpage>5015</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1114931109</pub-id>
          <?supplied-pmid 22403066?>
          <pub-id pub-id-type="pmid">22403066</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Vallon-Eberhard</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zigmond</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Farache</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shezen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Shakhar</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ludwig</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lira</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>In vivo structure/function and expression analysis of the CX3C chemokine fractalkine</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>e156</fpage>
          <lpage>e167</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-04-348946</pub-id>
          <?supplied-pmid 21951685?>
          <pub-id pub-id-type="pmid">21951685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klunker</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Mantel</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Palomares</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Bassin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ziegler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ruckert</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Meiler</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Akdis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Littman</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Akdis</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells</article-title>
          <source>J Exp Med</source>
          <year>2009</year>
          <volume>206</volume>
          <fpage>2701</fpage>
          <lpage>2715</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20090596</pub-id>
          <?supplied-pmid 19917773?>
          <pub-id pub-id-type="pmid">19917773</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Konkel</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Carpenter</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zamarron</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Kulkarni</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bosselut</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Control of the development of CD8alphaalpha+ intestinal intraepithelial lymphocytes by TGF-beta</article-title>
          <source>Nat Immunol</source>
          <year>2011</year>
          <volume>12</volume>
          <fpage>312</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.1997</pub-id>
          <?supplied-pmid 21297643?>
          <pub-id pub-id-type="pmid">21297643</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuhn</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lohler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rennick</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rajewsky</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-10-deficient mice develop chronic enterocolitis</article-title>
          <source>Cell</source>
          <year>1993</year>
          <volume>75</volume>
          <fpage>263</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.1016/0092-8674(93)80068-P</pub-id>
          <?supplied-pmid 8402911?>
          <pub-id pub-id-type="pmid">8402911</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lavin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Blecher-Gonen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Keren-Shaul</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Amit</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>159</volume>
          <fpage>1312</fpage>
          <lpage>1326</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2014.11.018</pub-id>
          <?supplied-pmid 25480296?>
          <pub-id pub-id-type="pmid">25480296</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Starkey</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80</article-title>
          <source>J Exp Med</source>
          <year>1985</year>
          <volume>161</volume>
          <fpage>475</fpage>
          <lpage>489</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.161.3.475</pub-id>
          <?supplied-pmid 3973536?>
          <pub-id pub-id-type="pmid">3973536</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Clish</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gronert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Serhan</surname>
              <given-names>CN</given-names>
            </name>
          </person-group>
          <article-title>Lipid mediator class switching during acute inflammation: signals in resolution</article-title>
          <source>Nat Immunol</source>
          <year>2001</year>
          <volume>2</volume>
          <fpage>612</fpage>
          <lpage>619</lpage>
          <pub-id pub-id-type="doi">10.1038/89759</pub-id>
          <?supplied-pmid 11429545?>
          <pub-id pub-id-type="pmid">11429545</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gurung</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Malireddi</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kanneganti</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Geiger</surname>
              <given-names>TL</given-names>
            </name>
          </person-group>
          <article-title>IL-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T-cell-mediated colitis</article-title>
          <source>Nat Commun</source>
          <year>2015</year>
          <volume>6</volume>
          <fpage>6131</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms7131</pub-id>
          <?supplied-pmid 25607885?>
          <pub-id pub-id-type="pmid">25607885</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>van Kruiningen</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Cartun</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Cortot</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Colombel</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Immunocytochemical evidence of Listeria, <italic>Escherichia coli</italic>, and Streptococcus antigens in Crohn’s disease</article-title>
          <source>Gastroenterology</source>
          <year>1995</year>
          <volume>108</volume>
          <fpage>1396</fpage>
          <lpage>1404</lpage>
          <pub-id pub-id-type="doi">10.1016/0016-5085(95)90687-8</pub-id>
          <?supplied-pmid 7729631?>
          <pub-id pub-id-type="pmid">7729631</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ludin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Itkin</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gur-Cohen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mildner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shezen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Golan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kollet</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Kalinkovich</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Porat</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>D’Uva</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schajnovitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Voronov</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Apte</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lapidot</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Monocytes-macrophages that express alpha-smooth muscle actin preserve primitive hematopoietic cells in the bone marrow</article-title>
          <source>Nat Immunol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>1072</fpage>
          <lpage>1082</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2408</pub-id>
          <?supplied-pmid 22983360?>
          <pub-id pub-id-type="pmid">22983360</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>TY</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Hoa</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>Akotia</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pedram</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Boivin</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Said</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation</article-title>
          <source>Am J Physiol Gastrointest Liver Physiol</source>
          <year>2004</year>
          <volume>286</volume>
          <fpage>G367</fpage>
          <lpage>G376</lpage>
          <pub-id pub-id-type="doi">10.1152/ajpgi.00173.2003</pub-id>
          <?supplied-pmid 14766535?>
          <pub-id pub-id-type="pmid">14766535</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malvin</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Seno</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Stappenbeck</surname>
              <given-names>TS</given-names>
            </name>
          </person-group>
          <article-title>Colonic epithelial response to injury requires Myd88 signaling in myeloid cells</article-title>
          <source>Mucosal Immunol</source>
          <year>2012</year>
          <volume>5</volume>
          <fpage>194</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="doi">10.1038/mi.2011.65</pub-id>
          <?supplied-pmid 22258450?>
          <pub-id pub-id-type="pmid">22258450</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manta</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Heupel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Radulovic</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rossini</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Garbi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Riedel</surname>
              <given-names>CU</given-names>
            </name>
            <name>
              <surname>Niess</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>CX(3)CR1(+) macrophages support IL-22 production by innate lymphoid cells during infection with Citrobacter rodentium</article-title>
          <source>Mucosal Immunol</source>
          <year>2013</year>
          <volume>6</volume>
          <fpage>177</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="doi">10.1038/mi.2012.61</pub-id>
          <?supplied-pmid 22854708?>
          <pub-id pub-id-type="pmid">22854708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Margolis</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Gershon</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Bogunovic</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cellular organization of neuroimmune interactions in the gastrointestinal tract</article-title>
          <source>Trends Immunol</source>
          <year>2016</year>
          <volume>37</volume>
          <fpage>487</fpage>
          <lpage>501</lpage>
          <pub-id pub-id-type="doi">10.1016/j.it.2016.05.003</pub-id>
          <?supplied-pmid 27289177?>
          <pub-id pub-id-type="pmid">27289177</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazzini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Massimiliano</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Penna</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rescigno</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1(+) macrophages to CD103(+) dendritic cells</article-title>
          <source>Immunity</source>
          <year>2014</year>
          <volume>40</volume>
          <fpage>248</fpage>
          <lpage>261</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2013.12.012</pub-id>
          <?supplied-pmid 24462723?>
          <pub-id pub-id-type="pmid">24462723</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Molawi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kandalla</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Favret</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hagemeyer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Frenzel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pinto</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Klapproth</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Henri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Malissen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rodewald</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Rosenthal</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Bajenoff</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Prinz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sieweke</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Progressive replacement of embryo-derived cardiac macrophages with age</article-title>
          <source>J Exp Med</source>
          <year>2014</year>
          <volume>211</volume>
          <fpage>2151</fpage>
          <lpage>2158</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20140639</pub-id>
          <?supplied-pmid 25245760?>
          <pub-id pub-id-type="pmid">25245760</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Molloy</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Grainger</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Bouladoux</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hand</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Koo</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Naik</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Quinones</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dzutsev</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Trinchieri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Belkaid</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Intraluminal containment of commensal outgrowth in the gut during infection-induced dysbiosis</article-title>
          <source>Cell Host Microbe</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>318</fpage>
          <lpage>328</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chom.2013.08.003</pub-id>
          <?supplied-pmid 24034617?>
          <pub-id pub-id-type="pmid">24034617</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mortha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chudnovskiy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bogunovic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Spencer</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Belkaid</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis</article-title>
          <source>Science</source>
          <year>2014</year>
          <volume>343</volume>
          <fpage>1249288</fpage>
          <pub-id pub-id-type="doi">10.1126/science.1249288</pub-id>
          <?supplied-pmid 24625929?>
          <pub-id pub-id-type="pmid">24625929</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muller</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Koscso</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rajani</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Stevanovic</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Berres</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mortha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Leboeuf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>XM</given-names>
            </name>
            <name>
              <surname>Mucida</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Dahan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Margolis</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Gershon</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bogunovic</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>158</volume>
          <fpage>300</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2014.04.050</pub-id>
          <?supplied-pmid 25036630?>
          <pub-id pub-id-type="pmid">25036630</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagashima</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Lamina propria macrophages in the human gastrointestinal mucosa: their distribution, immunohistological phenotype, and function</article-title>
          <source>J Histochem Cytochem</source>
          <year>1996</year>
          <volume>44</volume>
          <fpage>721</fpage>
          <lpage>731</lpage>
          <pub-id pub-id-type="doi">10.1177/44.7.8675993</pub-id>
          <?supplied-pmid 8675993?>
          <pub-id pub-id-type="pmid">8675993</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niess</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Adler</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Enteric flora expands gut lamina propria CX3CR1+ dendritic cells supporting inflammatory immune responses under normal and inflammatory conditions</article-title>
          <source>J Immunol</source>
          <year>2010</year>
          <volume>184</volume>
          <fpage>2026</fpage>
          <lpage>2037</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.0901936</pub-id>
          <?supplied-pmid 20089703?>
          <pub-id pub-id-type="pmid">20089703</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niess</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Brand</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Landsman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McCormick</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Vyas</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Boes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ploegh</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Littman</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Reinecker</surname>
              <given-names>HC</given-names>
            </name>
          </person-group>
          <article-title>CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance</article-title>
          <source>Science</source>
          <year>2005</year>
          <volume>307</volume>
          <fpage>254</fpage>
          <lpage>258</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1102901</pub-id>
          <?supplied-pmid 15653504?>
          <pub-id pub-id-type="pmid">15653504</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oldenhove</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bouladoux</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wohlfert</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dos Santos</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>O’Brien</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Blank</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lamb</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Natarajan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kastenmayer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grigg</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Belkaid</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection</article-title>
          <source>Immunity</source>
          <year>2009</year>
          <volume>31</volume>
          <fpage>772</fpage>
          <lpage>786</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2009.10.001</pub-id>
          <?supplied-pmid 19896394?>
          <pub-id pub-id-type="pmid">19896394</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Panea</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Farkas</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Goto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Abdollahi-Roodsaz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Koscso</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gowda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hohl</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Bogunovic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ivanov</surname>
              <given-names>II</given-names>
            </name>
          </person-group>
          <article-title>Intestinal monocyte-derived macrophages control commensal-specific Th17 responses</article-title>
          <source>Cell Rep</source>
          <year>2015</year>
          <volume>12</volume>
          <fpage>1314</fpage>
          <lpage>1324</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2015.07.040</pub-id>
          <?supplied-pmid 26279572?>
          <pub-id pub-id-type="pmid">26279572</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pender</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Sanderson</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>MacDonald</surname>
              <given-names>TT</given-names>
            </name>
          </person-group>
          <article-title>Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells</article-title>
          <source>Am J Physiol Gastrointest Liver Physiol</source>
          <year>2000</year>
          <volume>279</volume>
          <fpage>G918</fpage>
          <lpage>G924</lpage>
          <?supplied-pmid 11052988?>
          <pub-id pub-id-type="pmid">11052988</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pereira</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Boven</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Middel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Verhoef</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nottet</surname>
              <given-names>HS</given-names>
            </name>
          </person-group>
          <article-title>Induction of cyclooxygenase-2 expression during HIV-1-infected monocyte-derived macrophage and human brain microvascular endothelial cell interactions</article-title>
          <source>J Leukoc Biol</source>
          <year>2000</year>
          <volume>68</volume>
          <fpage>423</fpage>
          <lpage>428</lpage>
          <?supplied-pmid 10985260?>
          <pub-id pub-id-type="pmid">10985260</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pull</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Doherty</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mills</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Stappenbeck</surname>
              <given-names>TS</given-names>
            </name>
          </person-group>
          <article-title>Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2005</year>
          <volume>102</volume>
          <fpage>99</fpage>
          <lpage>104</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0405979102</pub-id>
          <?supplied-pmid 15615857?>
          <pub-id pub-id-type="pmid">15615857</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rani</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Smulian</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Greaves</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Hogan</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Herbert</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>TGF-beta limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function</article-title>
          <source>Eur J Immunol</source>
          <year>2011</year>
          <volume>41</volume>
          <fpage>2000</fpage>
          <lpage>2009</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.201041135</pub-id>
          <?supplied-pmid 21469118?>
          <pub-id pub-id-type="pmid">21469118</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rivollier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kole</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Valatas</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kelsall</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
          <article-title>Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon</article-title>
          <source>J Exp Med</source>
          <year>2012</year>
          <volume>209</volume>
          <fpage>139</fpage>
          <lpage>155</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20101387</pub-id>
          <?supplied-pmid 22231304?>
          <pub-id pub-id-type="pmid">22231304</pub-id>
        </element-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rugtveit</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haraldsen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hogasen</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Bakka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brandtzaeg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells</article-title>
          <source>Gut</source>
          <year>1995</year>
          <volume>37</volume>
          <fpage>367</fpage>
          <lpage>373</lpage>
          <pub-id pub-id-type="doi">10.1136/gut.37.3.367</pub-id>
          <?supplied-pmid 7590432?>
          <pub-id pub-id-type="pmid">7590432</pub-id>
        </element-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rugtveit</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nilsen</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Bakka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carlsen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Brandtzaeg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease</article-title>
          <source>Gastroenterology</source>
          <year>1997</year>
          <volume>112</volume>
          <fpage>1493</fpage>
          <lpage>1505</lpage>
          <pub-id pub-id-type="doi">10.1016/S0016-5085(97)70030-1</pub-id>
          <?supplied-pmid 9136827?>
          <pub-id pub-id-type="pmid">9136827</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ryan</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>XM</given-names>
            </name>
            <name>
              <surname>Dominguez</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Tong</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Chuan</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chisholm</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Pollard</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>ER</given-names>
            </name>
          </person-group>
          <article-title>Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse (Csf1(op)/Csf1(op)) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis</article-title>
          <source>Blood</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>74</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V98.1.74</pub-id>
          <?supplied-pmid 11418465?>
          <pub-id pub-id-type="pmid">11418465</pub-id>
        </element-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schlitzer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>McGovern</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Teo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Zelante</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Atarashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Low</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>See</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wasan</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Hoeffel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Malleret</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Heiseke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chew</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jardine</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Purvis</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Hilkens</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Tam</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Poidinger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Krug</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Renia</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sivasankar</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Collin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ricciardi-Castagnoli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Honda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Haniffa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ginhoux</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses</article-title>
          <source>Immunity</source>
          <year>2013</year>
          <volume>38</volume>
          <fpage>970</fpage>
          <lpage>983</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2013.04.011</pub-id>
          <?supplied-pmid 23706669?>
          <pub-id pub-id-type="pmid">23706669</pub-id>
        </element-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <mixed-citation publication-type="other">Schridde A, Bain CC, Mayer JU, Montgomery J, Pollet E, Denecke B, Milling SW, Jenkins SJ, Dalod M, Henri S, Malissen B, Pabst O, and McL Mowat A. Tissue-specific differentiation of colonic macrophages requires TGFbeta receptor-mediated signaling. Mucosal immunology 2017.</mixed-citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schulz</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Jaensson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Persson</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Worbs</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Agace</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Pabst</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions</article-title>
          <source>J Exp Med</source>
          <year>2009</year>
          <volume>206</volume>
          <fpage>3101</fpage>
          <lpage>3114</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20091925</pub-id>
          <?supplied-pmid 20008524?>
          <pub-id pub-id-type="pmid">20008524</pub-id>
        </element-citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Henri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Mononuclear phagocytes of the intestine, the skin, and the lung</article-title>
          <source>Immunol Rev</source>
          <year>2014</year>
          <volume>262</volume>
          <fpage>9</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1111/imr.12220</pub-id>
          <?supplied-pmid 25319324?>
          <pub-id pub-id-type="pmid">25319324</pub-id>
        </element-citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>De Baetselier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martens</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Saeys</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>De Prijck</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lippens</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Abels</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schoonooghe</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Raes</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Devoogdt</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lambrecht</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Beschin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells</article-title>
          <source>Nat Commun</source>
          <year>2016</year>
          <volume>7</volume>
          <fpage>10321</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms10321</pub-id>
          <?supplied-pmid 26813785?>
          <pub-id pub-id-type="pmid">26813785</pub-id>
        </element-citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seo</surname>
              <given-names>SU</given-names>
            </name>
            <name>
              <surname>Kuffa</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kitamoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nagao-Kitamoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rousseau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YG</given-names>
            </name>
            <name>
              <surname>Nunez</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kamada</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Intestinal macrophages arising from CCR2(+) monocytes control pathogen infection by activating innate lymphoid cells</article-title>
          <source>Nat Commun</source>
          <year>2015</year>
          <volume>6</volume>
          <fpage>8010</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms9010</pub-id>
          <?supplied-pmid 26269452?>
          <pub-id pub-id-type="pmid">26269452</pub-id>
        </element-citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Serbina</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Pamer</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2</article-title>
          <source>Nat Immunol</source>
          <year>2006</year>
          <volume>7</volume>
          <fpage>311</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="doi">10.1038/ni1309</pub-id>
          <?supplied-pmid 16462739?>
          <pub-id pub-id-type="pmid">16462739</pub-id>
        </element-citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Serbina</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Salazar-Mather</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Biron</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Kuziel</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Pamer</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection</article-title>
          <source>Immunity</source>
          <year>2003</year>
          <volume>19</volume>
          <fpage>59</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1016/S1074-7613(03)00171-7</pub-id>
          <?supplied-pmid 12871639?>
          <pub-id pub-id-type="pmid">12871639</pub-id>
        </element-citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Serhan</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Chiang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Van Dyke</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators</article-title>
          <source>Nat Rev Immunol</source>
          <year>2008</year>
          <volume>8</volume>
          <fpage>349</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="doi">10.1038/nri2294</pub-id>
          <?supplied-pmid 18437155?>
          <pub-id pub-id-type="pmid">18437155</pub-id>
        </element-citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gentile</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yeiser</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Walland</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Bornstein</surname>
              <given-names>VU</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cassis</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bigas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cols</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Comerma</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Blander</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Berin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Augenlicht</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Velcich</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cerutti</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals</article-title>
          <source>Science</source>
          <year>2013</year>
          <volume>342</volume>
          <fpage>447</fpage>
          <lpage>453</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1237910</pub-id>
          <?supplied-pmid 24072822?>
          <pub-id pub-id-type="pmid">24072822</pub-id>
        </element-citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Kamada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YG</given-names>
            </name>
            <name>
              <surname>Nunez</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Microbiota-induced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine</article-title>
          <source>J Exp Med</source>
          <year>2012</year>
          <volume>209</volume>
          <fpage>251</fpage>
          <lpage>258</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20111703</pub-id>
          <?supplied-pmid 22291094?>
          <pub-id pub-id-type="pmid">22291094</pub-id>
        </element-citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shouval</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Biswas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Goettel</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>McCann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Conaway</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Redhu</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Mascanfroni</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Al Adham</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lavoie</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ibourk</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Samsom</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Escher</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Somech</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Beier</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Conklin</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Ebens</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Sherlock</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bhan</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mora</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Quintana</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Muise</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Snapper</surname>
              <given-names>SB</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function</article-title>
          <source>Immunity</source>
          <year>2014</year>
          <volume>40</volume>
          <fpage>706</fpage>
          <lpage>719</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2014.03.011</pub-id>
          <?supplied-pmid 24792912?>
          <pub-id pub-id-type="pmid">24792912</pub-id>
        </element-citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Smythies</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Greenwell-Wild</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gliozzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wahl</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Intestinal macrophages and response to microbial encroachment</article-title>
          <source>Mucosal Immunol</source>
          <year>2011</year>
          <volume>4</volume>
          <fpage>31</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1038/mi.2010.66</pub-id>
          <?supplied-pmid 20962772?>
          <pub-id pub-id-type="pmid">20962772</pub-id>
        </element-citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smythies</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Mosteller-Barnum</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Orenstein</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>PD</given-names>
            </name>
          </person-group>
          <article-title>Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity</article-title>
          <source>J Clin Invest</source>
          <year>2005</year>
          <volume>115</volume>
          <fpage>66</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200519229</pub-id>
          <?supplied-pmid 15630445?>
          <pub-id pub-id-type="pmid">15630445</pub-id>
        </element-citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smythies</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bimczok</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Novak</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Eckhoff</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Bouchard</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Dandekar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>PD</given-names>
            </name>
          </person-group>
          <article-title>Inflammation anergy in human intestinal macrophages is due to Smad-induced IkappaBalpha expression and NF-kappaB inactivation</article-title>
          <source>J Biol Chem</source>
          <year>2010</year>
          <volume>285</volume>
          <fpage>19593</fpage>
          <lpage>19604</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M109.069955</pub-id>
          <?supplied-pmid 20388715?>
          <pub-id pub-id-type="pmid">20388715</pub-id>
        </element-citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soroosh</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Doherty</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Duan</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>YF</given-names>
            </name>
            <name>
              <surname>Mikulski</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Khorram</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rosenthal</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Broide</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Croft</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Lung-resident tissue macrophages generate Foxp3+ regulatory T cells and promote airway tolerance</article-title>
          <source>J Exp Med</source>
          <year>2013</year>
          <volume>210</volume>
          <fpage>775</fpage>
          <lpage>788</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20121849</pub-id>
          <?supplied-pmid 23547101?>
          <pub-id pub-id-type="pmid">23547101</pub-id>
        </element-citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stadnyk</surname>
              <given-names>AW</given-names>
            </name>
          </person-group>
          <article-title>Cytokine production by epithelial cells</article-title>
          <source>FASEB J</source>
          <year>1994</year>
          <volume>8</volume>
          <fpage>1041</fpage>
          <lpage>1047</lpage>
          <?supplied-pmid 7926369?>
          <pub-id pub-id-type="pmid">7926369</pub-id>
        </element-citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Blank</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Bouladoux</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Oukka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mora</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Belkaid</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid</article-title>
          <source>J Exp Med</source>
          <year>2007</year>
          <volume>204</volume>
          <fpage>1775</fpage>
          <lpage>1785</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20070602</pub-id>
          <?supplied-pmid 17620362?>
          <pub-id pub-id-type="pmid">17620362</pub-id>
        </element-citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suzuki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Arumugam</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sakagami</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lachmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Chalk</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sallese</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Abe</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Trapnell</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Carey</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Moritz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Malik</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lutzko</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Trapnell</surname>
              <given-names>BC</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary macrophage transplantation therapy</article-title>
          <source>Nature</source>
          <year>2014</year>
          <volume>514</volume>
          <fpage>450</fpage>
          <lpage>454</lpage>
          <pub-id pub-id-type="doi">10.1038/nature13807</pub-id>
          <?supplied-pmid 25274301?>
          <pub-id pub-id-type="pmid">25274301</pub-id>
        </element-citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takeda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Clausen</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Kaisho</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsujimura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Terada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Forster</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Akira</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils</article-title>
          <source>Immunity</source>
          <year>1999</year>
          <volume>10</volume>
          <fpage>39</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="doi">10.1016/S1074-7613(00)80005-9</pub-id>
          <?supplied-pmid 10023769?>
          <pub-id pub-id-type="pmid">10023769</pub-id>
        </element-citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tamoutounour</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Montanana Sanchis</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Terhorst</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Malosse</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pollet</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ardouin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Luche</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sanchez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dalod</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Malissen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Henri</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin</article-title>
          <source>Immunity</source>
          <year>2013</year>
          <volume>39</volume>
          <fpage>925</fpage>
          <lpage>938</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2013.10.004</pub-id>
          <?supplied-pmid 24184057?>
          <pub-id pub-id-type="pmid">24184057</pub-id>
        </element-citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tamoutounour</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Henri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lelouard</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>de Bovis</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>de Haar</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>van der Woude</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Woltman</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Reyal</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Bonnet</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sichien</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bain</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Mowat</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Reis e Sousa</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Poulin</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Malissen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis</article-title>
          <source>Eur J Immunol</source>
          <year>2012</year>
          <volume>42</volume>
          <fpage>3150</fpage>
          <lpage>3166</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.201242847</pub-id>
          <?supplied-pmid 22936024?>
          <pub-id pub-id-type="pmid">22936024</pub-id>
        </element-citation>
      </ref>
      <ref id="CR105">
        <label>105.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thiesen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Janciauskiene</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Uronen-Hansson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Agace</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hogerkorp</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Spee</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hakansson</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Grip</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>CD14(hi)HLA-DR(dim) macrophages, with a resemblance to classical blood monocytes, dominate inflamed mucosa in Crohn’s disease</article-title>
          <source>J Leukoc Biol</source>
          <year>2014</year>
          <volume>95</volume>
          <fpage>531</fpage>
          <lpage>541</lpage>
          <pub-id pub-id-type="doi">10.1189/jlb.0113021</pub-id>
          <?supplied-pmid 24212097?>
          <pub-id pub-id-type="pmid">24212097</pub-id>
        </element-citation>
      </ref>
      <ref id="CR106">
        <label>106.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trompette</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gollwitzer</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Yadava</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sichelstiel</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Sprenger</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ngom-Bru</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Blanchard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Junt</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nicod</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Marsland</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis</article-title>
          <source>Nat Med</source>
          <year>2014</year>
          <volume>20</volume>
          <fpage>159</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="doi">10.1038/nm.3444</pub-id>
          <?supplied-pmid 24390308?>
          <pub-id pub-id-type="pmid">24390308</pub-id>
        </element-citation>
      </ref>
      <ref id="CR107">
        <label>107.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ubeda</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lipuma</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gobourne</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Viale</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Leiner</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Equinda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Khanin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pamer</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice</article-title>
          <source>J Exp Med</source>
          <year>2012</year>
          <volume>209</volume>
          <fpage>1445</fpage>
          <lpage>1456</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20120504</pub-id>
          <?supplied-pmid 22826298?>
          <pub-id pub-id-type="pmid">22826298</pub-id>
        </element-citation>
      </ref>
      <ref id="CR108">
        <label>108.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ueda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kayama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jeon</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Kusu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Isaka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Rakugi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Commensal microbiota induce LPS hyporesponsiveness in colonic macrophages via the production of IL-10</article-title>
          <source>Int Immunol</source>
          <year>2010</year>
          <volume>22</volume>
          <fpage>953</fpage>
          <lpage>962</lpage>
          <pub-id pub-id-type="doi">10.1093/intimm/dxq449</pub-id>
          <?supplied-pmid 21051439?>
          <pub-id pub-id-type="pmid">21051439</pub-id>
        </element-citation>
      </ref>
      <ref id="CR109">
        <label>109.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van de Laar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Saelens</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>De Prijck</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Martens</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Van Isterdael</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Beyaert</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Saeys</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lambrecht</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissue-resident macrophages</article-title>
          <source>Immunity</source>
          <year>2016</year>
          <volume>44</volume>
          <fpage>755</fpage>
          <lpage>768</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.017</pub-id>
          <?supplied-pmid 26992565?>
          <pub-id pub-id-type="pmid">26992565</pub-id>
        </element-citation>
      </ref>
      <ref id="CR110">
        <label>110.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Furth</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>ZA</given-names>
            </name>
            <name>
              <surname>Hirsch</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Humphrey</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Spector</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Langevoort</surname>
              <given-names>HL</given-names>
            </name>
          </person-group>
          <article-title>The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells</article-title>
          <source>Bull World Health Organ</source>
          <year>1972</year>
          <volume>46</volume>
          <fpage>845</fpage>
          <lpage>852</lpage>
          <?supplied-pmid 4538544?>
          <pub-id pub-id-type="pmid">4538544</pub-id>
        </element-citation>
      </ref>
      <ref id="CR111">
        <label>111.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Varol</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vallon-Eberhard</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Elinav</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Aychek</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shapira</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Luche</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fehling</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Hardt</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Shakhar</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Intestinal lamina propria dendritic cell subsets have different origin and functions</article-title>
          <source>Immunity</source>
          <year>2009</year>
          <volume>31</volume>
          <fpage>502</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2009.06.025</pub-id>
          <?supplied-pmid 19733097?>
          <pub-id pub-id-type="pmid">19733097</pub-id>
        </element-citation>
      </ref>
      <ref id="CR112">
        <label>112.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Szretter</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Vermi</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gilfillan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rossini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cella</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Barrow</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Diamond</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Colonna</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia</article-title>
          <source>Nat Immunol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>753</fpage>
          <lpage>760</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2360</pub-id>
          <?supplied-pmid 22729249?>
          <pub-id pub-id-type="pmid">22729249</pub-id>
        </element-citation>
      </ref>
      <ref id="CR113">
        <label>113.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weaver</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Elson</surname>
              <given-names>CO</given-names>
            </name>
            <name>
              <surname>Fouser</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Kolls</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin</article-title>
          <source>Annu Rev Pathol</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>477</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev-pathol-011110-130318</pub-id>
          <?supplied-pmid 23157335?>
          <pub-id pub-id-type="pmid">23157335</pub-id>
        </element-citation>
      </ref>
      <ref id="CR114">
        <label>114.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Saurer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schenk</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dickgreber</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mueller</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>CX3CR1 defines functionally distinct intestinal mononuclear phagocyte subsets which maintain their respective functions during homeostatic and inflammatory conditions</article-title>
          <source>Eur J Immunol</source>
          <year>2011</year>
          <volume>41</volume>
          <fpage>773</fpage>
          <lpage>779</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.201040965</pub-id>
          <?supplied-pmid 21341263?>
          <pub-id pub-id-type="pmid">21341263</pub-id>
        </element-citation>
      </ref>
      <ref id="CR115">
        <label>115.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wertheim</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Kunkel</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Standiford</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Burdick</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Wilke</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Strieter</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Regulation of neutrophil-derived IL-8: the role of prostaglandin E2, dexamethasone, and IL-4</article-title>
          <source>J Immunol</source>
          <year>1993</year>
          <volume>151</volume>
          <fpage>2166</fpage>
          <lpage>2175</lpage>
          <?supplied-pmid 8345201?>
          <pub-id pub-id-type="pmid">8345201</pub-id>
        </element-citation>
      </ref>
      <ref id="CR116">
        <label>116.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yona</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mildner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Varol</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Breker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Strauss-Ayali</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Viukov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Guilliams</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Misharin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hume</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Perlman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Malissen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zelzer</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis</article-title>
          <source>Immunity</source>
          <year>2013</year>
          <volume>38</volume>
          <fpage>79</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2012.12.001</pub-id>
          <?supplied-pmid 23273845?>
          <pub-id pub-id-type="pmid">23273845</pub-id>
        </element-citation>
      </ref>
      <ref id="CR117">
        <label>117.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zigmond</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bernshtein</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Friedlander</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Yona</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Krauthgamer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Varol</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis</article-title>
          <source>Immunity</source>
          <year>2014</year>
          <volume>40</volume>
          <fpage>720</fpage>
          <lpage>733</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2014.03.012</pub-id>
          <?supplied-pmid 24792913?>
          <pub-id pub-id-type="pmid">24792913</pub-id>
        </element-citation>
      </ref>
      <ref id="CR118">
        <label>118.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zigmond</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Intestinal macrophages: well educated exceptions from the rule</article-title>
          <source>Trends Immunol</source>
          <year>2013</year>
          <volume>34</volume>
          <fpage>162</fpage>
          <lpage>168</lpage>
          <pub-id pub-id-type="doi">10.1016/j.it.2013.02.001</pub-id>
          <?supplied-pmid 23477922?>
          <pub-id pub-id-type="pmid">23477922</pub-id>
        </element-citation>
      </ref>
      <ref id="CR119">
        <label>119.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zigmond</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Varol</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Farache</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Elmaliah</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Satpathy</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Friedlander</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mack</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shpigel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Boneca</surname>
              <given-names>IG</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Shakhar</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Halpern</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells</article-title>
          <source>Immunity</source>
          <year>2012</year>
          <volume>37</volume>
          <fpage>1076</fpage>
          <lpage>1090</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2012.08.026</pub-id>
          <?supplied-pmid 23219392?>
          <pub-id pub-id-type="pmid">23219392</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362668</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id>
      <journal-title-group>
        <journal-title>Psychopharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0033-3158</issn>
      <issn pub-type="epub">1432-2072</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362668</article-id>
      <article-id pub-id-type="pmcid">PMC5362668</article-id>
      <article-id pub-id-type="pmc-uid">5362668</article-id>
      <article-id pub-id-type="pmid">28280881</article-id>
      <article-id pub-id-type="publisher-id">4561</article-id>
      <article-id pub-id-type="doi">10.1007/s00213-017-4561-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Investigation</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Tryptophan depletion affects compulsive behaviour in rats: strain dependent effects and associated neuromechanisms</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Merchán</surname>
            <given-names>A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Navarro</surname>
            <given-names>S. V.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Klein</surname>
            <given-names>A. B.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aznar</surname>
            <given-names>S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Campa</surname>
            <given-names>L.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suñol</surname>
            <given-names>C.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moreno</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Flores</surname>
            <given-names>P.</given-names>
          </name>
          <address>
            <phone>+34 950 214632</phone>
            <email>pflores@ual.es</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000101969356</institution-id><institution-id institution-id-type="GRID">grid.28020.38</institution-id><institution>Department of Psychology, </institution><institution>University of Almería, </institution></institution-wrap>CeiA3, Carretera de Sacramento s/n, 04120 Almería, Spain </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0674 042X</institution-id><institution-id institution-id-type="GRID">grid.5254.6</institution-id><institution>Department of Drug Design and Pharmacology, </institution><institution>University of Copenhagen, </institution></institution-wrap>2100 Copenhagen, Denmark </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0646 7373</institution-id><institution-id institution-id-type="GRID">grid.4973.9</institution-id><institution>Research Laboratory for Stereology and Neuroscience, Bispebjerg and Frederiksberg Hospitals, </institution><institution>Copenhagen University Hospital, </institution></institution-wrap>2300 Copenhagen, Denmark </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1794 1077</institution-id><institution-id institution-id-type="GRID">grid.420258.9</institution-id><institution/><institution>Institute of Biomedical Research of Barcelona, IIBB-CSIC-IDIBAPS, CIBERESP (CS), CIBERSAM (LC), </institution></institution-wrap>08028 Barcelona, Spain </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>234</volume>
      <issue>8</issue>
      <fpage>1223</fpage>
      <lpage>1236</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>10</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>2</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Rationale</title>
          <p>Compulsive behaviour, present in different psychiatric disorders, such as obsessive-compulsive disorder, schizophrenia and drug abuse, is associated with altered levels of monoamines, particularly serotonin (5-hydroxytryptamine) and its receptor system.</p>
        </sec>
        <sec>
          <title>Objectives</title>
          <p>The present study investigated whether 5-HT manipulation, through a tryptophan (TRP) depletion by diet in Wistar and Lister Hooded rats, modulates compulsive drinking in schedule-induced polydipsia (SIP) and locomotor activity in the open-field test. The levels of dopamine, noradrenaline, serotonin and its metabolite were evaluated, as well as the 5-HT<sub>2A</sub> and 5-HT<sub>1A</sub> receptor binding, in different brain regions.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Wistar rats were selected as high (HD) or low (LD) drinkers according to their SIP behaviour, while Lister hooded rats did not show SIP acquisition. Both strains were fed for 14 days with either a TRP-free diet (T−) or a TRP-supplemented diet (T+)</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>The TRP depletion diet effectively reduced 5-HT levels in the frontal cortex, amygdala and hippocampus in both strains of rats. The TRP-depleted HD Wistar rats were more sensitive to 5-HT manipulation, exhibiting more licks on SIP than did the non-depleted HD Wistar rats, while the LD Wistar and the Lister Hooded rats did not exhibit differences in SIP. In contrast, the TRP-depleted Lister Hooded rats increased locomotor activity compared to the non-depleted rats, while no differences were found in the Wistar rats. Serotonin 2A receptor binding in the striatum was significantly reduced in the TRP-depleted HD Wistar rats.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>These results suggest that alterations of the serotonergic system could be involved in compulsive behaviour in vulnerable populations.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Compulsivity</kwd>
        <kwd>Inhibitory control</kwd>
        <kwd>Chronic tryptophan depletion</kwd>
        <kwd>Schedule-induced polydipsia</kwd>
        <kwd>Monoamines</kwd>
        <kwd>5-HT<sub>2A</sub> binding</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer-Verlag Berlin Heidelberg 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Compulsivity represents the performance of repetitive and functionally impairing overt or covert behaviours without adaptive function, performed in a habitual or stereotyped fashion, either according to rigid rules or as a means of avoiding perceived negative consequences (Fineberg et al. <xref ref-type="bibr" rid="CR36">2014</xref>). Neuropsychiatric disorders characterized by compulsivity are included in the newly created Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) “obsessive-compulsive and related disorders” (OCRDs) cluster, such as obsessive-compulsive disorder (OCD), body dysmorphic disorder, trichotillomania (repetitive hair pulling), hoarding disorder and excoriation (skin-picking) (American Psychiatric Association <xref ref-type="bibr" rid="CR1">2013</xref>). Moreover, this behaviour is also present across different disorders, such as schizophrenia, attention-deficit hyperactivity disorder (ADHD), pathological gambling, eating disorders, depression or substance addiction (Skodol and Oldham <xref ref-type="bibr" rid="CR76">1996</xref>). Dysfunctions in cortico-limbic-striatal circuits, involving areas such as mOFC, caudate-putamen, amygdala and hippocampus, have been associated with the symptomatology in OCD (Gillan and Robbins <xref ref-type="bibr" rid="CR44">2014</xref>; Rǎdulescu and Marra <xref ref-type="bibr" rid="CR73">2016</xref>).</p>
      <p>Evidence from animal and human studies implicates the serotonin 5-hydroxytryptamine (5-HT) system in impulsivity and compulsivity (Eagle and Baunez <xref ref-type="bibr" rid="CR24">2010</xref>; Fineberg et al. <xref ref-type="bibr" rid="CR34">2010</xref>). Mice lacking the gene encoding brain tryptophan hydroxylase 2 (Tph2−/−), the initial and rate-limiting enzyme in 5-HT synthesis, showed intense impulsive and compulsive behaviours to include extreme aggression (Angoa-Pérez et al. <xref ref-type="bibr" rid="CR2">2012</xref>). Moreover, studies on 5-HT depletion by excitotoxic lesions in rats have revealed an increase of perseverative responding in the five-choice serial reaction time task (Winstanley et al. <xref ref-type="bibr" rid="CR87">2004</xref>), impairment of behavioural flexibility measured through the reversal learning task (Bari et al. <xref ref-type="bibr" rid="CR5">2010</xref>; Lapiz-Bluhm et al. <xref ref-type="bibr" rid="CR57">2009</xref>; Wallace et al. <xref ref-type="bibr" rid="CR85">2014</xref>) and an increment of compulsive cocaine seeking under punishment (Pelloux et al. <xref ref-type="bibr" rid="CR70">2012</xref>).</p>
      <p>A non-invasive and more naturalistic method to reduce central 5-HT is through nutritional depletion of the 5-HT precursor tryptophan (TRP). Under normal physiological conditions, the biosynthesis of 5-HT is limited by the availability of the essential amino acid TRP (Fernstrom <xref ref-type="bibr" rid="CR33">1983</xref>; Gessa et al. <xref ref-type="bibr" rid="CR43">1974</xref>). Rats receiving a TRP-free diet reduced the 5-HT synthesis, content (Gessa et al. <xref ref-type="bibr" rid="CR43">1974</xref>) and release (Stancampiano et al. <xref ref-type="bibr" rid="CR79">1997a</xref>, <xref ref-type="bibr" rid="CR80">b</xref>). While acute tryptophan depletion by diet (ATD) produced a moderate serotonergic reduction in adult rats (Brown et al. <xref ref-type="bibr" rid="CR14">1998</xref>; Lieben et al. <xref ref-type="bibr" rid="CR59">2004</xref>), chronic tryptophan depletions (CTD) have shown stronger effects, reducing 5-HT brain levels to 35–40% at 14 days (Fadda et al. <xref ref-type="bibr" rid="CR28">2000</xref>) and to 75% at 5-week exposures (Vergnes and Kempf <xref ref-type="bibr" rid="CR84">1981</xref>). Moreover, long-term TRP-depleting diets lead to changes in serotonergic receptors in animals, increasing serotonin 5-HT<sub>2A</sub> receptor density but having no effect on serotonin 5-HT<sub>1A</sub> receptor (Cahir et al. <xref ref-type="bibr" rid="CR15">2007</xref>; Franklin et al. <xref ref-type="bibr" rid="CR39">1999</xref>). Behavioural studies in rodents have demonstrated that a TRP depletion by diet increased aggressiveness (Vergnes and Kempf <xref ref-type="bibr" rid="CR84">1981</xref>), locomotor activity (Vergnes and Kempf <xref ref-type="bibr" rid="CR84">1981</xref>) and sexual behaviour (Fratta et al. <xref ref-type="bibr" rid="CR41">1977</xref>). The increase of these behaviours may suggest a lack of inhibitory control leading to compulsive behaviour. However, only one study has evaluated the effect of acute TRP depletion on some facets of compulsivity, showing no effects on behavioural flexibility in reversal learning or in an extinction paradigm (Van der Plasse and Feenstra <xref ref-type="bibr" rid="CR82">2008</xref>). Thus, the effects of chronic TRP depletion by diet on compulsivity remain unknown.</p>
      <p>Because of its characteristics of “excessiveness” and “persistence”, schedule-induced polydipsia (SIP) is a useful model to study neuropsychiatric disorders characterized by the presence of compulsive behaviour (Ford <xref ref-type="bibr" rid="CR38">2014</xref>; Gilpin et al. <xref ref-type="bibr" rid="CR45">2008</xref>; Hawken et al. <xref ref-type="bibr" rid="CR46">2011</xref>; Hawken and Beninger <xref ref-type="bibr" rid="CR47">2014</xref>; for review, see Moreno and Flores <xref ref-type="bibr" rid="CR67">2012</xref>). The SIP model is characterized by the development of excessive drinking in food-deprived animals exposed to intermittent food reinforcement schedules (Falk <xref ref-type="bibr" rid="CR29">1961</xref>, <xref ref-type="bibr" rid="CR30">1971</xref>). Important differences between individuals in the amount of fluid intake and licks support the differentiation of two phenotypes of rats, one with high or excessive drinking (HD) and a second group with low or not SIP acquisition (LD) (López-Grancha et al. <xref ref-type="bibr" rid="CR61">2008</xref>). Recent data have shown that HD animals present increased levels of 5-HT and metabolites in the amygdala compared to the LD group (Moreno et al. <xref ref-type="bibr" rid="CR66">2012</xref>). In addiction, the systemic administration of citalopram and the serotonin 5-HT<sub>2A/C</sub> receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) reduced dose-dependent compulsive drinking in HD rats, without affecting the drinking behaviour of LD rats (Navarro et al. <xref ref-type="bibr" rid="CR68">2015</xref>). All those data point out the involvement of 5-HT system in the vulnerability to the development of compulsive drinking between HD and LD rats.</p>
      <p>In our laboratory, Wistar rats are commonly used in SIP, showing individual differences between HD and LD phenotypes. However, no previous studies have tested the strain-dependent differences between Wistar and Lister Hooded rats in SIP acquisition. In fact, behavioural differences in inhibitory control have been observed between these two strains of rats. Wistar rats compared to Lister Hooded rats show more anticipatory responses in a three-choice serial reaction time task and more food hoarding behaviour (Broersen and Uylings <xref ref-type="bibr" rid="CR13">1999</xref>), indicating a poorer inhibitory control of this strain and a higher vulnerability to develop compulsive drinking on SIP.</p>
      <p>We hypothesised that a reduction of 5-HT through a chronic TRP depletion by diet will increase the compulsive behaviour in vulnerable populations such as the HD Wistar rats compared to non-vulnerable populations such as LD Wistar rats and Lister Hooded rats and that could be accompanied by changes in the serotonin 5-HT<sub>2A</sub> receptor, a serotonin receptor subtype proposed as a candidate for mediating compulsive behaviour (Aznar and Hervig <xref ref-type="bibr" rid="CR4">2016</xref>; Aznar and Klein <xref ref-type="bibr" rid="CR3">2013</xref>; Fineberg et al. <xref ref-type="bibr" rid="CR34">2010</xref>, <xref ref-type="bibr" rid="CR35">2011</xref>; Navarro et al. <xref ref-type="bibr" rid="CR68">2015</xref>). To test the previous hypothesis, we screened high and low drinking rates during SIP in both strains. Next, we produced a dysfunction of the 5-HT system in the brain by a chronic TRP depletion by diet and evaluated possible motor disruptions or hyperactivity in an open-field test and the effect on compulsive drinking on SIP. Then, brain monoamine levels and serotonin 5-HT<sub>2A</sub> and 5-HT<sub>1A</sub> receptor densities were measured in different brain regions of the cortico-limbic-striatal circuits associated with compulsivity.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Subjects</title>
        <p>Two strains of rats were used for this experiment: adult male Lister Hooded rats from Charles River (Barcelona, Spain) and adult male Wistar rats from Harlan Iberica (Barcelona, Spain).</p>
        <p>Both strains of rats weighed approximately 300–400 g at the beginning of the experiment. The animals were housed three/cage or two/cage (57 × 35 × 20 cm) at 22 °C with 08:00–20:00-h light-dark cycle, with food and water available ad libitum. Before the SIP training and after 10 days of habituation to the vivarium conditions, the rats were weighed and handled daily. They were gradually reduced to 80–85% of their free-feeding body weight by controlled feeding and then maintained at this level of deprivation throughout the experiment. Food was made available by daily feeding of lab chow approximately 30 min after each experimental session. Water was always available in the home cages.</p>
        <p>Rats were assigned to each experimental group taking into consideration the amount of water consumed in the previous experimental SIP, in order to match all groups. The Wistar rats were split as following: high drinkers receiving a TRP-free diet (<italic>n</italic> = 7), high drinkers receiving a control diet (<italic>n</italic> = 7), low drinkers with a TRP-free diet (<italic>n</italic> = 7) and low drinkers with a control diet (<italic>n</italic> = 7). The Lister Hooded rats, as they did not show differences in SIP (water intake and licks), were divided into two groups depending on the diet: One group (<italic>n</italic> = 8) received a TRP-free diet, while the other group (<italic>n</italic> = 9) received a control diet. Once the animals started the specific diets, they were housed in cages individually (50 × 25 × 18 cm) to control body weight.</p>
        <p>All procedures were conducted in accordance with the Spanish Royal Decree 53/2013 on the protection of experimental animals, with the European Community Council Directives (86/609/EEC) and with the University of Almería Animal Research Committee approval.</p>
      </sec>
      <sec id="Sec4">
        <title>Experimental design</title>
        <p>The experiment was developed in two phases. One previous phase consisted of screening the acquisition of SIP in the Lister Hooded and Wistar rats. Once the rats were identified as high drinkers or low drinkers by their SIP behaviour, they were divided into groups depending on the given diet. After 14 days of TRP depletion by diet, the rats were exposed to different behavioural tasks. The order of presentation was as follows: one session of the open-field test and six sessions of SIP (see Fig. <xref rid="Fig1" ref-type="fig">1</xref> for the entire experimental design).<fig id="Fig1"><label>Fig. 1</label><caption><p>Experimental procedure illustrated in a timetable</p></caption><graphic xlink:href="213_2017_4561_Fig1_HTML" id="MO1"/></fig>
</p>
      </sec>
      <sec id="Sec5">
        <title>Apparatus and behavioural procedures</title>
        <sec id="Sec6">
          <title>Schedule-induced polydipsia</title>
          <p>We conducted the tests in ten standard operant conditioning chambers (MED Associates) that were 32 cm long × 25 cm wide × 34 cm high, with stainless steel grid floors. A detailed description of the apparatus has been provided previously for the SIP (López-Grancha et al. <xref ref-type="bibr" rid="CR61">2008</xref>; Moreno et al. <xref ref-type="bibr" rid="CR66">2012</xref>). The scheduling and recording of experimental events were controlled by a Med PC computer and commercial software (Cibertec SA, Spain).</p>
          <sec id="FPar1">
            <title>Baseline consumption</title>
            <p>All rats were individually housed in plastic cages containing a dish with the same amount of food to be delivered in the experimental sessions and the same water bottle used in the operant chambers. Over two successive days, 60 food pellets were placed together in a dish, and the amount of water consumed by each rat in 60 min was measured.</p>
          </sec>
          <sec id="FPar2">
            <title>Magazine habituation</title>
            <p>The day after the first baseline consumption sessions, rats were habituated to the test chambers for 60 min and were given 30 food pellets placed in the food magazine.</p>
          </sec>
          <sec id="FPar3">
            <title>Schedule-induced polydipsia pre-treatment</title>
            <p>After the magazine habituation, the animals were exposed to a fixed time 60-s (FT-60s) schedule of food pellet presentation during 60-min sessions. Water bottles containing 100 ml of fresh water were provided immediately before each session. After 20 daily sessions, the average water drinking for each animal was calculated based on the last three SIP sessions. Following Moreno et al.’s protocol (<xref ref-type="bibr" rid="CR66">2012</xref>), rats are classified as high drinkers (HD) and low drinkers (LD) if their average water intake was above or below the group median, respectively. The following measures were recorded for each rat (a) total number of licks, (b) total amount of water (ml) removed from the bottle, (c) total number of magazine entries and (d) licking efficiency, which was calculated as the total number of licks/by the total solution consumed. Lick efficiency detects possible fine motor impairments or changes in the stereotypic manner of licking, which indicates with higher score values that the animal needs more total number of licks to obtain the same amount of target solution (Escher and Mittleman <xref ref-type="bibr" rid="CR26">2006</xref>).</p>
          </sec>
          <sec id="FPar4">
            <title>Schedule-induced polydipsia post-treatment</title>
            <p>After 14 days of the TRP depletion diet, the animals were exposed again to a FT-60s schedule of food pellet presentation during 60-min sessions. Water bottles with fresh water were available.</p>
          </sec>
        </sec>
        <sec id="Sec7">
          <title>Spontaneous locomotor activity</title>
          <p>The test was an open-field test, performed in eight Plexiglas activity cages (measuring 39 × 39 × 15 cm) equipped with photocell beams (16 × 16 × 16) interfaced to a microcomputer VersaMax Animal Activity Monitoring System (AccuScan Instruments Inc., USA). Spontaneous locomotor activity was measured as the number of photocell beam breaks due to the movements of the animals. TRP-depleted and TRP-non-depleted rats were tested for their locomotor responses to a novel environment in the activity cages. Rats were not habituated to the activity cages prior to this test. Spontaneous locomotor behaviour was quantified in 5-min blocks over a 60-min period following placement into the test cage. We measured total distance, counted as the number of centimetres travelled by the animal (an indicator of ambulatory activity).</p>
        </sec>
      </sec>
      <sec id="Sec8">
        <title>Tryptophan depletion diet</title>
        <p>The TRP-free diet (TD08126, Harlan Laboratories S.A., Barcelona, Spain) had a standard nutritional value, but with a complete lack of TRP. The control groups were fed a similar diet, containing a standard amount of TRP (1.8 g/kg diet) (TD99366, Harlan Laboratories S.A., Barcelona Spain). A chronic TRP-free diet exposure of 14 days was given before the behavioural tasks as previous studies have established (Bortolato et al. <xref ref-type="bibr" rid="CR11">2008</xref>; Franklin et al. <xref ref-type="bibr" rid="CR40">2012</xref>; Stancampiano et al. <xref ref-type="bibr" rid="CR81">2013</xref>), and the amount of food was controlled in order to maintain the body weight at 80–85% of their free-feeding body weight.</p>
      </sec>
      <sec id="Sec9">
        <title>Brain analyses</title>
        <p>The day after the SIP post-treatment, the rats were rapidly decapitated using a guillotine. Brains were quickly removed, frozen and stored at −80 °C. The cerebral hemispheres were separated, and each half was used either for measuring monoamines or for measuring serotonin receptor binding. The hemispheres were counterbalanced.</p>
        <sec id="Sec10">
          <title>Brain monoamine analyses</title>
          <p>For brain tissue preparation, the samples were thawed sufficiently to enable dissection of the prefrontal cortex, striatum, nucleus accumbens, hippocampus and amygdala (Moreno et al. <xref ref-type="bibr" rid="CR66">2012</xref>). These were weighed and homogenized in 0.4 N perchloric acid with 0.1 metabisulfite, 0.01% EDTA and 1 ng/ml cysteine. The homogenates were centrifuged at 15,000 rpm for 20 min at 4 °C, and supernatants were collected and frozen at −80 °C until biochemical analyses for determining the levels of norepinephrine (NE), dopamine (DA), serotonin (5-HT) and 5-hydroxy-3-indolacetic acid (5-HIAA), which were measured using reverse-phase high-performance liquid chromatography with electrochemical detection (+0.7 V). The mobile phase, containing 100 mM KH<sub>2</sub>PO<sub>4</sub>,0.1 mM Na<sub>2</sub>-EDTA, 2.06 mM PICB8 and 16% methanol, adjusted to pH 2.65 with orthophosphoric acid, was delivered at 1 ml/ min. Monoamines were separated on a 5-mm particle size column at 30 °C (Phenomenex C25 10 × 0.46 cm, Micron Analitica SA, Spain).</p>
        </sec>
        <sec id="Sec11">
          <title>Autoradiography</title>
          <p>To determine 5-HT<sub>1A</sub>R and 5-HT<sub>2A</sub>R binding in the Wistar and Lister Hooded rats, their brains were cut in 10-μm sections, mounted on Super Frost slides and stored at −80 °C. The protocol was modified from Klein et al. (<xref ref-type="bibr" rid="CR52">2014</xref>). The 5-HT<sub>2A</sub> autoradiography protocol was performed using <sup>3</sup>H-MDL100907 [R(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)-ethyl]-4-piperidin-methanol] (specific activity, 2.8 TBq/mmol, Novandi Chemistry, Sweden; and non-specific binding was determined using 10 μM ketanserin tartrate (3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]-ethyl]-2,4[1H,3H] quinazolinedione tartrate) (Tocris Cookson Ltd., Bristol, UK). For 5-HT<sub>1A</sub> autoradiography, we used <sup>3</sup>H-WAY100635 (specific activity, 2.9 TBq/mmol, Novandi Chemistry) and measured non-specific binding with 10 μM 5-HT (Sigma–Aldrich, Copenhagen, Denmark). Briefly, the sections were allowed to thaw for 1 h at room temperature (RT) and then pre-incubated with 50 mM Tris–HCl (Sigma), pH 7.4, containing 0.01% ascorbic acid (Sigma) and 10 μM pargyline hydrochloride (<italic>N</italic>-methyl-<italic>N</italic>-2-propynylbenzylamine hydrochloride) (Research Biochemicals International, MA, USA) for 30 min at RT under constant gentle shaking. Sections were then incubated for 60 min at RT using the same buffer containing 2 nM of <sup>3</sup>H-MDL100907 (1.5 nM of <sup>3</sup>H-WAY100635 for 5-HT<sub>1A</sub> binding). Following incubation, the slides were washed 2 × 2 min in ice-cold 50 mM Tris–HCl, pH 7.4, and 1 × 20 s in ice-cold dH<sub>2</sub>O and dried for 1 h under a gentle stream of air.</p>
          <p>All sections were placed at 4 °C in a fixator containing paraformaldehyde vapour and later placed in an exicator box for 3 h before the slides, and the <sup>3</sup>H-microscales (GE Healthcare, UK) were exposed to a BAS-TR2040 Imaging Plate (Science Imaging Scandinavia AB, Nacka, Sweden) for 3–14 days at 4 °C. Finally, the imaging plate was scanned on a CR-35 scanner (Raytest, Straubenhardt, Germany) and specific and non-specific binding was determined in the frontal cortex, striatum and hippocampus using the AIDA 5.0 software (Raytest) and expressed as femtomole per milligramme tissue equivalents (TE).</p>
        </sec>
      </sec>
      <sec id="Sec12">
        <title>Data analyses</title>
        <p>Data analyses of the different strains were performed separately, due to the complexity of the groups. Analyses of variance (ANOVAs) were performed with two between-subject factors for the Wistar strain data, group (HD and LD) and treatment (T+ and T−) and one between-subject factor for the Lister Hooded strain data (treatment, T+ and T−). The within-subject factors were sessions of SIP, bins on the locomotor activity, body weight, brain monoamine data and receptor binding. Lick efficiency was analysed by repeated measures ANOVA, with treatment as between-subject and sessions as within-subject factors, in HD and LD rats. When appropriate, post hoc comparisons were made using the Newman-Keuls test. The significance level was set at <italic>p</italic>≤ 0.05. All statistics were two-tailed.</p>
      </sec>
    </sec>
    <sec id="Sec13">
      <title>Results</title>
      <sec id="Sec14">
        <title>Body weight measure</title>
        <p>Figure <xref rid="Fig2" ref-type="fig">2</xref> shows body weight during 14 days of TRP depletion by diet and 6 days of SIP post-treatment in Wistar and Lister Hooded rats. No differences in body weight between T+ and T− groups were found neither in Wistar (treatment effect <italic>F</italic>
<sub>1,24</sub> = 0.09; <italic>p =</italic> 0.761) nor in Lister Hooded rats (treatment effect <italic>F</italic>
<sub>1,15</sub> = 0.496; <italic>p =</italic> 0.492).<fig id="Fig2"><label>Fig. 2</label><caption><p>Body weight during 14 days of TRP depletion by diet and six sessions of schedule-induced polydipsia post-treatment for Wistar (<bold>a</bold>) and Lister Hooded rats (<bold>b</bold>). Wistar rats are grouped as TRP non-depleted high drinkers (HD T+), TRP-depleted high drinkers (HD T−), TRP non-depleted low drinkers (LD T+) and TRP-depleted low drinkers (LD T−). Lister Hooded rats are grouped as TRP non-depleted (T+) and TRP-depleted rats (T−). Data are means ± SEM</p></caption><graphic xlink:href="213_2017_4561_Fig2_HTML" id="MO2"/></fig>
</p>
      </sec>
      <sec id="Sec15">
        <title>Schedule-induced polydipsia pre-treatment</title>
        <p>Figure <xref rid="Fig3" ref-type="fig">3</xref> shows the mean total licks, water intake and total magazine entries in high-drinker Wistar rats (WHD), low-drinker Wistar rats (WLD) and Lister Hooded (LH) rats on the SIP pre-treatment FT-60s schedule of food presentation. ANOVA revealed significant differences on SIP acquisition between WHD and WLD in total licks (group effect <italic>F</italic>
<sub>1,26</sub> = 71.5; <italic>p</italic> &lt; 0.001) and water intake (group effect <italic>F</italic>
<sub>1,26</sub> = 44.18; <italic>p</italic> &lt; 0.001). SIP session effects were significant in both measures: total licks (<italic>F</italic>
<sub>19,494</sub> = 23.6; <italic>p</italic> &lt; 0.001) and water intake (<italic>F</italic>
<sub>19,494</sub> = 13.03; <italic>p</italic> &lt; 0.001). Interaction between sessions and group was also significant in total licks (<italic>F</italic>
<sub>19,494</sub> = 15.5; <italic>p</italic> &lt; 0.001) and water intake (<italic>F</italic>
<sub>19,494</sub> = 9.24; <italic>p</italic> &lt; 0.001). Post hoc analysis indicated that the FT-60s schedule of food delivery induced different drinking rates across the 20 test sessions in both groups. Differences in total licks between WHD and WLD animals were evident from session 3 (<italic>p =</italic> 0.031) and from session 3 in water intake (<italic>p =</italic> 0.039). WHD animals significantly increased their consumption of water from session 3 (<italic>p =</italic> 0.002) to the end of training, reaching stable levels from session 10. WLD animals did not show a significant increase in their consumption of water across SIP sessions. No interaction effect was found in magazine entries (<italic>F</italic>
<sub>19,494</sub> = 0.56; <italic>p =</italic> 0.933) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>e).<fig id="Fig3"><label>Fig. 3</label><caption><p>The mean (±SEM) total licks (<bold>a</bold>, <bold>b</bold>), water intake (<bold>c</bold>, <bold>d</bold>) and total magazine entries (<bold>e</bold>, <bold>f</bold>) in FT-60s across 20 sessions of SIP pre-treatment and six sessions of SIP post-treatment for both Wistar and Lister Hooded rats. Rats are grouped in the SIP pre-treatment as high-drinker Wistar rats (WHD), low-drinker Wistar rats (WLD) and Lister Hooded rats (LH). Wistar rats are grouped in the SIP post-treatment as TRP non-depleted high drinkers (WHD T+), TRP-depleted high drinkers (WHD T−), TRP non-depleted low drinkers (WLD T+) and TRP-depleted low drinkers (WLD T−). Lister Hooded rats are grouped in the SIP post-treatment as TRP non-depleted (LH T+) and TRP-depleted rats (LH T−). <italic>Asterisks</italic>: statistical analyses indicate significant differences between HD T+ and HD T−. <italic>Number sign</italic>: statistical analyses indicate significant differences between WHD and WLD from that session onward</p></caption><graphic xlink:href="213_2017_4561_Fig3_HTML" id="MO3"/></fig>
</p>
        <p>No significant differences were found between LH and WLD rats in water intake (strain effect <italic>F</italic>
<sub>1,29</sub> = 1.76; <italic>p =</italic> 0.195), total licks (strain effect <italic>F</italic>
<sub>1,29</sub> = 2.26; <italic>p =</italic> 0.143) and magazine entries (strain effect <italic>F</italic>
<sub>1,29</sub> = 1.56; <italic>p =</italic> 0.696).</p>
      </sec>
      <sec id="Sec16">
        <title>Schedule-induced polydipsia post-treatment</title>
        <p>Figure <xref rid="Fig3" ref-type="fig">3</xref> shows the effects of the chronic TRP depletion by diet on Wistar and LH rats on SIP. The TRP depletion in WHD T− rats increased the total number of licks over the days (see Fig. <xref rid="Fig3" ref-type="fig">3</xref>b; group × treatment × session effect <italic>F</italic>
<sub>5,120</sub> = 2.46; <italic>p =</italic> 0.037) but did not affect water intake on SIP (see Fig. <xref rid="Fig3" ref-type="fig">3</xref>d; group × treatment × session effect <italic>F</italic>
<sub>5,120</sub> = 1.06; <italic>p =</italic> 0.387). Post hoc analysis indicated that the differences on licks between WHD T+ and WHD T− occur from session 3 (<italic>p =</italic> 0.007). WHD T− animals significantly increased their licks rate from session 3 (<italic>p =</italic> 0.021). Differences between WHD and WLD rats remained stable in water intake (group effect <italic>F</italic>
<sub>1,24</sub> = 55.33; <italic>p</italic> &lt; 0.001) and total licks (group effect <italic>F</italic>
<sub>1,24</sub> = 32.44; <italic>p</italic> &lt; 0.001). An increase of total licks was observed in WHD T+ (<italic>p =</italic> 0.020) and WLD T− (<italic>p =</italic> 0.002) on session 6, but these groups remain statistically different from each other (<italic>p =</italic> 0.040). To understand the discrepancy of finding increments in total licks not observed in water intake, we explored licking efficiency in WHD and WLD rats during the six sessions of SIP. Interestingly, we found statistical increases of licking efficiency in WHD T− compared to WHD T+ (treatment × session <italic>F</italic>
<sub>5,60</sub> = 3.283; <italic>p =</italic> 0.011), but no differences were found in WLD T− compared to WLD T+ (treatment × session <italic>F</italic>
<sub>5,60</sub> <italic>=</italic> 0.205<italic>; p =</italic> 0.959) (data not shown). Post hoc analysis revealed increments of licking efficiency in WHD T− compared to WHD T+ from session 2 onwards (<italic>p</italic> &lt; 0.001).</p>
        <p>LH T+ and LH T− did not differ in water intake (Fig. <xref rid="Fig3" ref-type="fig">3</xref>d; treatment × session effect <italic>F</italic>
<sub>5,75</sub> = 0.353; <italic>p =</italic> 0.879), total number of licks (Fig. <xref rid="Fig3" ref-type="fig">3</xref>b; treatment × session effect <italic>F</italic>
<sub>5,75</sub> = 1.013; <italic>p =</italic> 0.416) and licking efficiency (treatment × session <italic>F</italic>
<sub>5,75</sub> = 0.790; <italic>p =</italic> 0.560) (data not shown). TRP depletion by diet did not alter total number of magazine entries neither in the Wistar rats (group × treatment × session: <italic>F</italic>
<sub>5,120</sub> = 1.02; <italic>p =</italic> 0.410) nor in the LH rats (group × treatment × session: <italic>F</italic>
<sub>5,75</sub> = 2.076; <italic>p =</italic> 0.078) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>f).</p>
      </sec>
      <sec id="Sec17">
        <title>Spontaneous locomotor activity</title>
        <p>Figure <xref rid="Fig4" ref-type="fig">4</xref> shows locomotor response measured as total distance (cm) in four blocks of 15 min for Wistar and LH rats. TRP depletion by diet increased locomotor response only in the LH rats (treatment × blocks <italic>F</italic>
<sub>3.45</sub> = 3.08; <italic>p =</italic> 0.037). Post hoc analyses revealed that LH T− showed an increased locomotor activity in the first 15 min (<italic>p =</italic> 0.015) and the second 15 min (<italic>p =</italic> 0.008) of the 60-min session compared to LH T+ (Fig. <xref rid="Fig4" ref-type="fig">4</xref>b). No effects of the TRP depletion by diet were found in locomotor response in the Wistar rats (treatment × blocks <italic>F</italic>
<sub>3,72</sub> = 1.30; <italic>p =</italic> 0.280), not even considering groups of HD and LD rats (see Fig. <xref rid="Fig4" ref-type="fig">4</xref>a; group × treatment × blocks <italic>F</italic>
<sub>3.72</sub> = 0.78; <italic>p =</italic> 0.508). Wistar (<italic>F</italic>
<sub>3,72</sub> = 79.91; <italic>p</italic> &lt; 0.001) and LH rats (<italic>F</italic>
<sub>3,45</sub> = 81.16; <italic>p</italic> &lt; 0.001) decreased the activity over the session significantly.<fig id="Fig4"><label>Fig. 4</label><caption><p>Total distance in four blocks of 15 min for Wistar (<bold>a</bold>) and Lister Hooded rats (<bold>b</bold>). Wistar rats are grouped as TRP non-depleted high drinkers (HD T+), TRP-depleted high drinkers (HD T−), TRP non-depleted low drinkers (LD T+) and TRP-depleted low drinkers (LD T−). Lister Hooded rats are grouped as TRP non-depleted (T+) and TRP-depleted rats (T−). Data are means ± SEM. <italic>Asterisks</italic>: statistical analyses indicate significant differences between T+ and T−</p></caption><graphic xlink:href="213_2017_4561_Fig4_HTML" id="MO4"/></fig>
</p>
      </sec>
      <sec id="Sec18">
        <title>Serotonin receptor binding</title>
        <p>Table <xref rid="Tab1" ref-type="table">1</xref> shows mean ± SEM <sup>3</sup>H-MDL100907 and <sup>3</sup>H-WAY100635 binding for groups of depleted and non-depleted Wistar and LH groups of rats. For the 5-HT<sub>2A</sub> receptor in Wistar rats, there was a group × treatment interaction in the striatum for <sup>3</sup>H-MDL100907 binding (<italic>F</italic>
<sub>1,23</sub> = 8.648; <italic>p =</italic> 0.007) (see Fig. <xref rid="Fig5" ref-type="fig">5</xref>a). Post hoc analyses revealed a reduction of 5-HT<sub>2A</sub> receptor density in WHD T− rats compared to WHD T+ rats (<italic>p =</italic> 0.014). In the frontal cortex, we observed a 10% reduction of 5-HT<sub>2A</sub> binding in the HD T− compared to HD T+ rats; however, the statistical analysis did not detect statistical differences (group × treatment <italic>F</italic>
<sub>1,24</sub> = 0.990; <italic>p =</italic> 0.330). TRP depletion by diet did not alter 5-HT<sub>2A</sub> levels of LH T− compared to LH T+ neither in the frontal cortex (<italic>F</italic>
<sub>1,16</sub> = 0.117; <italic>p =</italic> 0.737) nor in the striatum (<italic>F</italic>
<sub>1,16</sub> = 0.066; <italic>p =</italic> 0.801).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<sup>3</sup>H-MDL100907 and <sup>3</sup>H-WAY100635 binding (fmol/mg TE) in the frontal cortex, striatum and hippocampus in all groups of Wistar and Lister Hooded rats</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" colspan="2"/><th colspan="4">Wistar</th><th colspan="2">Lister Hooded</th></tr><tr><th colspan="2">HD</th><th colspan="2">LD</th><th colspan="2"/></tr><tr><th>T+</th><th>T−</th><th>T+</th><th>T−</th><th>T+</th><th>T−</th></tr></thead><tbody><tr><td rowspan="2">FC</td><td>5-HT<sub>2A</sub>
</td><td>73.16 ± 4.68</td><td>65.44 ± 2.87</td><td>73.90 ± 4.86</td><td>76.39 ± 7.17</td><td>102.70 ± 4.59</td><td>105.7 ± 7.85</td></tr><tr><td>5-HT<sub>1A</sub>
</td><td>27.13 ± 0.95</td><td>29.07 ± 1.84</td><td>26.57 ± 2.07</td><td>26.49 ± 2.90</td><td>45.44 ± 1.57</td><td>
<italic>37.07 ± 1.00</italic>**</td></tr><tr><td rowspan="2">Striat</td><td>5-HT<sub>2A</sub>
</td><td>19.13 ± 0.75</td><td>
<italic>16.41 ± 0.49</italic>*</td><td>16.91 ± 0.73</td><td>18.34 ± 0.80</td><td>25.51 ± 0.80</td><td>25.23 ± 0.70</td></tr><tr><td>5-HT<sub>1A</sub>
</td><td>10.48 ± 0.33</td><td>10.38 ± 0.41</td><td>10.03 ± 0.30</td><td>9.68 ± 0.28</td><td>14.75 ± 0.26</td><td>14.41 ± 0.79</td></tr><tr><td>Hippo</td><td>5-HT<sub>1A</sub>
</td><td>121.23 ± 4.02</td><td>116.6 ± 3.88</td><td>111.43 ± 7.42</td><td>117.54 ± 8.69</td><td>110.73 ± 7.29</td><td>96.36 ± 6.33</td></tr></tbody></table><table-wrap-foot><p>Data are mean ± SEM. Significant differences between T+ and T− (*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01)</p><p>
<italic>FC</italic> frontal cortex, <italic>Striat</italic> striatum, <italic>Hippo</italic> hippocampus</p></table-wrap-foot></table-wrap>
<fig id="Fig5"><label>Fig. 5</label><caption><p>The mean (±SEM) 5-HT<sub>2A</sub> receptor binding of striatum slices in the Wistar rats (<bold>a</bold>) and 5-HT<sub>1A</sub> receptor binding of frontal cortex slices in the Lister Hooded rats (<bold>b</bold>). 5-HT<sub>2A</sub> receptor binding was detected by [<sup>3</sup>H]MDL100907, and 5-HT<sub>1A</sub> binding was detected by [<sup>3</sup>H]WAY100635. Wistar rats are grouped as TRP non-depleted high drinkers (HD T+), TRP-depleted high drinkers (HD T−), TRP non-depleted low drinkers (LD T+), and TRP-depleted low drinkers (LD T−). Lister Hooded rats are grouped as TRP non-depleted (T+) and TRP-depleted rats (T−). <italic>Asterisks</italic>: statistical analyses indicate significant differences between T+ and T− (*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01)</p></caption><graphic xlink:href="213_2017_4561_Fig5_HTML" id="MO5"/></fig>
</p>
        <p>The 5-HT<sub>1A</sub> receptor density in the frontal cortex showed a reduction in LH T− rats compared to LH T+ in terms of <sup>3</sup>H-WAY100635 binding (<italic>F</italic>
<sub>1,16</sub> = 19.091; <italic>p =</italic> 0.001) (see Fig. <xref rid="Fig5" ref-type="fig">5</xref>b), but no differences in density were found in the striatum (<italic>F</italic>
<sub>1,16</sub> <italic>=</italic> 1.80; <italic>p =</italic> 0.677) and the hippocampus (<italic>F</italic>
<sub>1,16</sub> = 2.157; <italic>p =</italic> 0.163). The effect of TRP depletion by diet in the 5-HT<sub>1A</sub> receptor density observed in LH T− did not occur in the depleted Wistar rats (group × treatment <italic>F</italic>
<sub>1,24</sub> = 0.240; <italic>p =</italic> 0.629). Also, 5-HT<sub>1A</sub> density was unaffected in the striatum (group × treatment <italic>F</italic>
<sub>1,23</sub> = 0.138; <italic>p =</italic> 0.714) and hippocampus (group × treatment <italic>F</italic>
<sub>1,25</sub> = 1.672; <italic>p =</italic> 0.209) in the depleted Wistar rats.</p>
      </sec>
      <sec id="Sec19">
        <title>Monoamine concentration levels</title>
        <p>The chronic TRP depletion by diet significantly reduced 5-HT, 5-HIAA and 5-HIAA/5-HT turnover ratio in the prefrontal cortex (PFC), amygdala and hippocampus in both strains of rats. No interaction effects of group and treatment were found in monoamine concentration levels in the different areas for Wistar rats. In the depleted groups of Wistar rats, 5-HT levels were reduced in the PFC (<italic>F</italic>
<sub>1,23</sub> = 20.86; <italic>p</italic> &lt; 0.001) and hippocampus (<italic>F</italic>
<sub>1,24</sub> = 5.89; <italic>p</italic> &lt; 0.023) (see Table <xref rid="Tab2" ref-type="table">2</xref>), and there was a tendency toward significance in the amygdala (<italic>F</italic>
<sub>1,24</sub> = 3.92; <italic>p =</italic> 0.059). 5-HIAA levels were decreased in the PFC (<italic>F</italic>
<sub>1,23</sub> = 29.52; <italic>p</italic> &lt; 0.001), striatum (<italic>F</italic>
<sub>1,22</sub> = 4.79; <italic>p =</italic> 0.040), amygdala (<italic>F</italic>
<sub>1,24</sub> = 29.79; <italic>p</italic> &lt; 0.001) and hippocampus (<italic>F</italic>
<sub>1,24</sub> = 19.837; <italic>p</italic> &lt; 0.001). In addition, a decreased 5-HIAA/5-HT turnover ratio in all areas was found: PFC (<italic>F</italic>
<sub>1,23</sub> = 16.13; <italic>p</italic> &lt; 0.001), striatum (<italic>F</italic>
<sub>1,22</sub> = 51.90; <italic>p</italic> &lt; 0.001), amygdala (<italic>F</italic>
<sub>1,24</sub> = 52.97; <italic>p</italic> &lt; 0.001), nucleus accumbens (<italic>F</italic>
<sub>1,19</sub> = 19.67; <italic>p</italic> &lt; 0.001) and hippocampus (<italic>F</italic>
<sub>1,24</sub> = 64.45; <italic>p</italic> &lt; 0.001). No significant changes in levels of 5-HT and 5-HIAA were observed in the nucleus accumbens. NE and DA were not significantly affected in any brain regions.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Monoamine concentration levels (picomole/milligramme of tissue) in the prefrontal cortex, striatum, amygdala, nucleus accumbens and hippocampus in T+ and T− for Wistar rats (<italic>n</italic> = 11–14)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th>5-HT</th><th>5-HIAA</th><th>5-HIAA/5-HT ratio</th><th>NE</th><th>DA</th></tr></thead><tbody><tr><td rowspan="2">PFC</td><td>T+</td><td>1.67 ± 0.15</td><td>1.16 ± 0.14</td><td>0.70 ± 0.06</td><td>1.86 ± 0.14</td><td>1.68 ± 0.46</td></tr><tr><td>T−</td><td>
<italic>0.86 ± 0.09</italic>**</td><td>
<italic>0.36 ± 0.03</italic>**</td><td>
<italic>0.44 ± 0.03</italic>**</td><td>1.72 ± 0.13</td><td>2.87 ± 0.77</td></tr><tr><td rowspan="2">Striat</td><td>T+</td><td>3.56 ± 0.81</td><td>4.13 ± 0.88</td><td>1.17 ± 0.07</td><td>0.14 ± 0.03</td><td>130.64 ± 27.47</td></tr><tr><td>T−</td><td>3.08 ± 0.47</td><td>
<italic>2.08 ± 0.37</italic>*</td><td>
<italic>0.65 ± 0.03</italic>**</td><td>0.22 ± 0.08</td><td>146.89 ± 23.26</td></tr><tr><td rowspan="2">Amyg</td><td>T+</td><td>2.93 ± 0.32</td><td>2.36 ± 0.22</td><td>0.83 ± 0.04</td><td>1.10 ± 0.21</td><td>18.89 ± 3.57</td></tr><tr><td>T−</td><td>
<italic>2.16 ± 0.21</italic>
<sup>#</sup>
</td><td>
<italic>1.01 ± 0.09</italic>**</td><td>
<italic>0.48 ± 0.02</italic>**</td><td>1.47 ± 0.25</td><td>20.23 ± 2.83</td></tr><tr><td rowspan="2">NAc</td><td>T+</td><td>2.78 ± 0.75</td><td>2.50 ± 0.69</td><td>0.90 ± 0.02</td><td>2.50 ± 0.55</td><td>41.04 ± 13.00</td></tr><tr><td>T−</td><td>2.61 ± 1.22</td><td>1.45 ± 0.59</td><td>
<italic>0.62 ± 0.06</italic>**</td><td>5.73 ± 2.58</td><td>44.67 ± 20.58</td></tr><tr><td rowspan="2">Hippo</td><td>T+</td><td>1.23 ± 0.15</td><td>1.70 ± 0.22</td><td>1.38 ± 0.03</td><td>1.97 ± 0.20</td><td>1.11 ± 0.19</td></tr><tr><td>T−</td><td>
<italic>0.78 ± 0.10</italic>*</td><td>
<italic>0.67</italic> ± <italic>0.05</italic>**</td><td>
<italic>0.91 ± 0.04</italic>**</td><td>1.56 ± 0.11</td><td>1.72 ± 0.25</td></tr></tbody></table><table-wrap-foot><p>Data are mean ± SEM. Significant differences between T+ and T− (*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, <sup>#</sup>
<italic>p =</italic> 0.059)</p><p>
<italic>PFC</italic> prefrontal cortex, <italic>NAc</italic> nucleus accumbens, <italic>Amyg</italic> amygdala, <italic>Striat</italic> striatum, <italic>Hippo</italic> hippocampus</p></table-wrap-foot></table-wrap>
</p>
        <p>In the depleted group of LH rats, 5-HT levels were reduced in the PFC (<italic>F</italic>
<sub>1,15</sub> = 33.43; <italic>p</italic> &lt; 0.001), striatum (<italic>F</italic>
<sub>1,14</sub> = 16.82; <italic>p</italic> &lt; 0.001), amygdala (<italic>F</italic>
<sub>1,14</sub> = 6.63; <italic>p =</italic> 0.022) and hippocampus (<italic>F</italic>
<sub>1,15</sub> = 9.10; <italic>p =</italic> 0.009) (see Table <xref rid="Tab3" ref-type="table">3</xref>). 5-HIAA levels and 5-HIAA/5-HT turnover ratio decreased in the PFC (<italic>F</italic>
<sub>1,13</sub> = 38.89; <italic>p</italic> &lt; 0.001; <italic>F</italic>
<sub>1,13</sub> = 10.25; <italic>p =</italic> 0.007), striatum (<italic>F</italic>
<sub>1,14</sub> = 21.82; <italic>p</italic> &lt; 0.001; <italic>F</italic>
<sub>1,14</sub> = 14.45; <italic>p =</italic> 0.002), amygdala (<italic>F</italic>
<sub>1,14</sub> = 31.85; <italic>p</italic> &lt; 0.001; <italic>F</italic>
<sub>1,14</sub> = 40.83; <italic>p</italic> &lt; 0.001), nucleus accumbens (<italic>F</italic>
<sub>1,11</sub> = 17.65; <italic>p</italic> &lt; 0.001; <italic>F</italic>
<sub>1,11</sub> = 20.56; <italic>p</italic> &lt; 0.001) and hippocampus (<italic>F</italic>
<sub>1,15</sub> = 32.38; <italic>p</italic> &lt; 0.001; <italic>F</italic>
<sub>1,15</sub> = 56.49; <italic>p</italic> &lt; 0.001). Besides, there was a compensatory increase in DA in nucleus accumbens (<italic>F</italic>
<sub>1,11</sub> = 8.28; <italic>p =</italic> 0.015) and a decrease in NE in PFC (<italic>F</italic>
<sub>1,15</sub> = 6.42; <italic>p =</italic> 0.023); DA and NE were not affected in other areas.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Monoamine concentration levels (picomole/milligramme of tissue) in the prefrontal cortex, striatum, amygdala, nucleus accumbens and hippocampus in T+ and T− for Lister Hooded rats (<italic>n</italic> = 4–9)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th>5-HT</th><th>5-HIAA</th><th>5-HIAA/5-HT ratio</th><th>NE</th><th>DA</th></tr></thead><tbody><tr><td rowspan="2">PFC</td><td>T+</td><td>1.77 ± 0.09</td><td>1.02 ± 0.09</td><td>0.56 ± 0.04</td><td>1.62 ± 0.09</td><td>3.89 ± 1.08</td></tr><tr><td>T−</td><td>
<italic>0.99 ± 0.11</italic>**</td><td>
<italic>0.04 ± 0.07</italic>**</td><td>
<italic>0.35 ± 0.07</italic>**</td><td>
<italic>1.31 ± 0.08</italic>*</td><td>2.34 ± 0.72</td></tr><tr><td rowspan="2">Striat</td><td>T+</td><td>2.20 ± 0.27</td><td>1.98 ± 0.31</td><td>0.88 ± 0.04</td><td>0.25 ± 0.07</td><td>79.35 ± 11.61</td></tr><tr><td>T−</td><td>
<italic>0.92 ± 0.15</italic>**</td><td>
<italic>0.52 ± 0.06</italic>**</td><td>
<italic>0.60 ± 0.06</italic>**</td><td>0.22 ± 0.08</td><td>83.19 ± 7.21</td></tr><tr><td rowspan="2">Amyg</td><td>T+</td><td>2.81 ± 0.32</td><td>2.12 ± 0.21</td><td>0.78 ± 0.05</td><td>1.38 ± 0.28</td><td>12.94 ± 2.56</td></tr><tr><td>T−</td><td>
<italic>1.75 ± 0.21</italic>*</td><td>
<italic>0.68 ± 0.09</italic>**</td><td>
<italic>0.39 ± 0.02</italic>**</td><td>1.13 ± 0.34</td><td>20.18 ± 3.28</td></tr><tr><td rowspan="2">NAc</td><td>T+</td><td>2.74 ± 0.31</td><td>2.34 ± 0.19</td><td>0.90 ± 0.06</td><td>8.01 ± 1.98</td><td>23.14 ± 4.36</td></tr><tr><td>T−</td><td>2.09 ± 0.22</td><td>
<italic>1.01 ± 0.15</italic>**</td><td>
<italic>0.48 ± 0.02*</italic>*</td><td>3.40 ± 1.96</td><td>
<italic>48.99 ± 9.52</italic>*</td></tr><tr><td rowspan="2">Hippo</td><td>T+</td><td>1,45 ± 0.19</td><td>2.17 ± 0.24</td><td>1.54 ± 0.07</td><td>2.60 ± 0.23</td><td>4.95 ± 1.71</td></tr><tr><td>T−</td><td>
<italic>0.79 ± 0.07</italic>**</td><td>
<italic>0.64 ± 0.07</italic>**</td><td>
<italic>0.81 ± 0.06</italic>**</td><td>3.05 ± 0.62</td><td>9.45 ± 3.46</td></tr></tbody></table><table-wrap-foot><p>Data are mean ± SEM. Significant differences between T+ and T− (*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01)</p><p>
<italic>PFC</italic> prefrontal cortex, <italic>NAc</italic> nucleus accumbens, <italic>Amyg</italic> amygdala, <italic>Striat</italic> striatum, <italic>Hippo</italic> hippocampus</p></table-wrap-foot></table-wrap>
</p>
      </sec>
    </sec>
    <sec id="Sec20">
      <title>Discussion</title>
      <p>The present study has shown the effects of chronic TRP depletion by diet in two strains of rats: Wistar and LH. Before TRP depletion by diet, we examined between-strain differences in the model of compulsive behaviour, SIP, and we found in the Wistar strain two groups of rats based on their drinking behaviour, HD and LD, while the LH strain did not show acquisition of compulsive drinking. After the chronic TRP depletion by diet, the TRP-depleted HD group of Wistar rats increased their compulsive drinking based on the total number of licks, but no changes in drinking behaviour were observed in either the LD Wistar or LH rats. Conversely, TRP depletion produced an increase in spontaneous locomotor activity only in LH rats, while the Wistar rats were unaffected. A reduction of striatal 5-HT<sub>2A</sub> receptor binding was observed in depleted HD Wistar rats compared to non-depleted HD Wistar rats, while depleted LD Wistar rats were not affected by the TRP manipulation. On the contrary, depleted LH rats showed reduced binding of the 5-HT<sub>1A</sub> receptor in the frontal cortex. Monoamine measures confirmed that 5-HT, 5-HIAA and the 5-HIAA/5-HT ratio were depleted in different brain regions in both Wistar and LH rats. These results will be further discussed in terms of the relationship between serotonin and inhibitory control.</p>
      <sec id="Sec21">
        <title>Acquisition of schedule-induced polydipsia and strain differences</title>
        <p>In the SIP procedure, the exposure of the Wistar strain to an FT-60s schedule of food delivery differentiated two populations based on the amount of drinking: high and low drinkers. The HD Wistar rats showed an increased volume of water intake and number of licks from session 3 compared to the LD Wistar rats. These results confirm previous studies in which consistent individual differences are found (for review, see Moreno and Flores <xref ref-type="bibr" rid="CR67">2012</xref>). However, the LH rats did not show an acquisition of SIP. This study is the first to evaluate strain differences between Wistar and LH rats in SIP acquisition and the development of SIP drinking. Regarding strain differences, LH rats compared to Wistar rats show a higher inhibitory control measured by less anticipatory responses in the 3-CSRT task and less food hoarding behaviour (Broersen and Uylings <xref ref-type="bibr" rid="CR13">1999</xref>). Other strains exhibiting inhibitory control deficits have shown increased SIP behaviour. For instance, spontaneously hypertensive rats, characterized as hyperactive and impulsive in terms of exacerbated sensitivity to delay of reinforcement, displayed increased drinking in SIP compared to Wistar–Kyoto rats (Ibias and Pellón <xref ref-type="bibr" rid="CR50">2011</xref>), as well as two rat lines selectively bred for high ethanol preference compared to their non-preferring counterparts (Gilpin et al. <xref ref-type="bibr" rid="CR45">2008</xref>). Moreover, the selective breeding of Roman high- (RHA) and low-avoidance (RLA) rats for rapid vs. extremely poor acquisition of active avoidance behaviour in a shuttle box resulted in two phenotypes that present differences in SIP acquisition (Moreno et al. <xref ref-type="bibr" rid="CR65">2010</xref>). RHA rats, which show traits such as higher novelty seeking, susceptibility to addictive drugs and impulse behaviours in the delay-discounting task and five-choice serial reaction time (5-CSRT) task (Escorihuela et al. <xref ref-type="bibr" rid="CR27">1999</xref>; Fattore et al. <xref ref-type="bibr" rid="CR31">2009</xref>; Moreno et al. <xref ref-type="bibr" rid="CR65">2010</xref>), also display increased SIP acquisition compared to RLA rats. Thus, SIP seems to be sensitive in distinguishing phenotypes of rats that have shown deficits in inhibitory control responses in different tasks of impulsivity/compulsivity, indicating a lack of inhibitory control as the main characteristic involved in the compulsive drinking in SIP (Moreno and Flores <xref ref-type="bibr" rid="CR67">2012</xref>).</p>
      </sec>
      <sec id="Sec22">
        <title>Effect of chronic tryptophan-deficient diet on schedule-induced polydipsia and possible mechanisms</title>
        <p>Chronic TRP-deficient diet exposure increased the total number of licks in the HD Wistar rats without affecting the amount of water drunk on SIP. We found similar observations in our laboratory of an increase in total licks on SIP after 6 months of an acute chlorpyrifos (CPF) administration (Cardona et al. <xref ref-type="bibr" rid="CR16">2006</xref>, <xref ref-type="bibr" rid="CR17">2011</xref>). There is evidence that long-term CPF intoxication affects the serotonergic system (Chen et al. <xref ref-type="bibr" rid="CR18">2011</xref>; Moreno et al. <xref ref-type="bibr" rid="CR64">2008</xref>), possibly by inducing TRP hydroxylase, the rate-limiting enzyme for 5-HT biosynthesis, and suppressing expression of 5-HT transporter genes (Slotkin and Seidler <xref ref-type="bibr" rid="CR77">2008</xref>). Therefore, a disruption in serotonin levels may be the underlying mechanism for the increased total licks observed on SIP. On the other hand, the increase in licks is task-dependent because groups differ from session 3 onward and not from session 1. The effect of increasing the number of licks without affecting the amount of water intake, also observed by Cardona et al. (<xref ref-type="bibr" rid="CR16">2006</xref>, <xref ref-type="bibr" rid="CR17">2011</xref>), may suggest a change of the drinking behaviour understood as an expression of compulsivity. In this sense, lick efficiency analyses showed differences in HD Wistar rats due to the TRP depletion by diet. This result could be interpreted as an increase in the stereotypic/compulsive manner of drinking by depleted HD rats, and this increase is not due to motor problems since depleted LD Wistar and LH rats did not differ in lick efficiency. The specific effect of the chronic TRP depletion increasing total licks and licking efficiency in HD Wistar rats but not in LD Wistar rats indicates a vulnerability of the HD group to compulsive symptoms and an implication of the serotonergic system mediating this vulnerability.</p>
        <p>Only a few studies have tested the effect of acute TRP depletion in OCD patients, showing not significant increases of obsessions or compulsions according to the scores of the Yale Brown Obsessive Compulsive Scale at rest or following symptom provocation (Barr et al. <xref ref-type="bibr" rid="CR7">1994</xref>; Berney et al. <xref ref-type="bibr" rid="CR9">2006</xref>). However, taking into account studies using neuropsychological tasks instead of questionnaires, patients with psychopathologies from the impulsive-compulsive spectrum seem to aggravate their symptoms when exposed to ATD. For instance, ATD increased omissions in the continuous performance task (Mette et al. <xref ref-type="bibr" rid="CR62">2013</xref>; Zepf et al. <xref ref-type="bibr" rid="CR90">2010</xref>) and aggressive behaviour in ADHD patients (Kötting et al. <xref ref-type="bibr" rid="CR54">2013</xref>; Stadler et al. <xref ref-type="bibr" rid="CR78">2007</xref>; Zepf et al. <xref ref-type="bibr" rid="CR88">2008</xref>, <xref ref-type="bibr" rid="CR89">2009</xref>; Zimmermann et al. <xref ref-type="bibr" rid="CR91">2012</xref>). Interestingly, ATD impaired go/no-go performance (LeMarquand et al. <xref ref-type="bibr" rid="CR56">1999</xref>) and stop signal reaction time (Crean et al. <xref ref-type="bibr" rid="CR20">2002</xref>) in healthy men with family history of alcoholism and also increased commission errors in the go/no-go task in an aggressive subgroup of people with ADHD (LeMarquand et al. <xref ref-type="bibr" rid="CR55">1998</xref>). These findings suggest that ATD may reveal vulnerable 5-HT systems in certain populations at risk of impulse control disorders (Faulkner and Deakin <xref ref-type="bibr" rid="CR32">2014</xref>), though it is still unknown precisely which receptor subtypes may lay behind this vulnerability.</p>
        <p>In our study, we found a reduction of striatal 5-HT<sub>2A</sub> receptor density in TRP-depleted HD Wistar rats compared to non-depleted HD Wistar rats. No differences were obtained in the LD Wistar or LH rats. Alterations of 5-HT<sub>2A</sub> receptor levels in 5-HT depletion studies are controversial. Several studies report upregulation of this receptor subtype in the hippocampus and frontal cortex (Franklin et al. <xref ref-type="bibr" rid="CR40">2012</xref>; Heal et al. <xref ref-type="bibr" rid="CR48">1985</xref>; Seeman et al. <xref ref-type="bibr" rid="CR74">1980</xref>), while other studies do not observe any difference (Blackshear et al. <xref ref-type="bibr" rid="CR10">1981</xref>; Conn and Sanders-Bush <xref ref-type="bibr" rid="CR19">1986</xref>; Fischette et al. <xref ref-type="bibr" rid="CR37">1987</xref>). In support of our findings, Licht et al. (<xref ref-type="bibr" rid="CR58">2009</xref>) found that 5-HT<sub>2A</sub> receptor binding was markedly reduced in striatum and prefrontal cortex regions after 5-HT depletion. Barlow et al. (<xref ref-type="bibr" rid="CR6">2015</xref>) had similar findings regarding the 5-HT<sub>2A</sub> receptor reductions and low levels of 5-HT in the orbitofrontal cortex in perseverative rats in the reversal learning task. They furthermore reported differences in gene expression levels of the MAO-A and MAO-B enzymes. They suggest that decreased MAO activity in the DRN resulted in reduced 5-HT breakdown and consequently increased autoinhibition of 5-HT neurons by somatodendritic 5-HT receptors (Barlow et al. <xref ref-type="bibr" rid="CR6">2015</xref>; Liu et al. <xref ref-type="bibr" rid="CR60">2005</xref>).</p>
        <p>The specific downregulation of the striatal 5HT<sub>2A</sub> receptor in HD but not LD rats by manipulation of the central 5-HT system reveals a specific role of the 5-HT<sub>2A</sub> receptor system in the observed increase in compulsive drinking on SIP. Evidence from animal and human studies underlies a key role of the 5-HT<sub>2A/C</sub> receptors in compulsive symptoms (Fineberg et al. <xref ref-type="bibr" rid="CR34">2010</xref>, <xref ref-type="bibr" rid="CR35">2011</xref>). Activation of prefrontal 5-HT<sub>2A</sub> receptors has been proposed to underpin the anticompulsive effect of SSRIs (Dannon et al. <xref ref-type="bibr" rid="CR21">2000</xref>; for a review, see El Mansari and Blier <xref ref-type="bibr" rid="CR25">2006</xref>; Westenberg et al. <xref ref-type="bibr" rid="CR86">2007</xref>). Second-generation antipsychotics may exacerbate compulsive behaviours in patients with schizophrenia and proposed to be through the potent 5-HT<sub>2A</sub> antagonism (Poyurovsky et al. <xref ref-type="bibr" rid="CR72">2008</xref>). In fact, activation of the 5-HT<sub>2A/C</sub> by DOI reduces compulsive drinking on SIP, and this reduction is blocked by the 5-HT<sub>2A</sub> receptor antagonists ketanserin and M100907, but not by the 5-HT<sub>2C</sub> receptor antagonist SB242084, indicating that the 5-HT<sub>2A</sub> receptor mediates the anticompulsive effect of DOI on SIP (Navarro et al. <xref ref-type="bibr" rid="CR68">2015</xref>). Moreover, systemic administration of M100907 in rats impairs spatial reversal learning, increasing perseverative responses (Boulougouris et al. <xref ref-type="bibr" rid="CR12">2008</xref>). Alterations in 5-HT<sub>2A</sub> receptor levels have also been observed in Roman high-avoidance (RHA) rats (Klein et al. <xref ref-type="bibr" rid="CR52">2014</xref>), an inbred strain characterized by a compulsive drinking profile on SIP, impulsivity on the delay-discounting task and poor inhibitory control in the 5-CSRT task (Moreno et al. <xref ref-type="bibr" rid="CR65">2010</xref>). In humans, neuroimaging studies have also linked differences in 5-HT<sub>2A</sub> receptor levels to the development of compulsive spectrum disorders. Positron emission tomography (PET) studies in drug-naive OCD patients reveal a reduction in frontal cortex serotonin 5-HT<sub>2A</sub> receptor availability (Perani et al. <xref ref-type="bibr" rid="CR71">2008</xref>), with specific correlations between serotonin 5-HT<sub>2A</sub> receptor availability in the orbitofrontal cortex and age of onset of the disorder (Simpson et al. <xref ref-type="bibr" rid="CR75">2011</xref>).</p>
        <p>Little is known regarding the contribution of the striatal serotonin receptor subtypes to cognitive function. In the striatum, 5-HT receptors modulate the activity of DA, GABA and glutamate neurotransmission and output regions of the basal ganglia (Nicholson and Brotchie <xref ref-type="bibr" rid="CR69">2002</xref>), suggesting a role of the 5-HT system in regulating action selection and motor control (Di Matteo et al. <xref ref-type="bibr" rid="CR22">2008</xref>). More studies are needed to evaluate the role of the striatal 5-HT<sub>2A</sub> receptor in the impulsive-compulsive spectrum disorders.</p>
      </sec>
      <sec id="Sec23">
        <title>Effect of chronic tryptophan-deficient diet on spontaneous locomotor activity and possible mechanisms</title>
        <p>The diet-induced chronic TRP depletion resulted in the LH strain in an increase in spontaneous locomotor activity not observed in the Wistar strain. Contrary to our results, previous studies with Wistar rats reported increases in locomotor activity after a 5-week exposure to a TRP-deficient diet (Vergnes and Kempf <xref ref-type="bibr" rid="CR84">1981</xref>). Possibly, the effect of TRP depletion by diet on locomotor activity depends on the severity of 5-HT reductions, based on the observations of greater global reductions of 5-HT and its metabolite in LH but not in Wistar rats in our study. In fact, the increases of locomotor activity in Vergnes and Kempf’s study (<xref ref-type="bibr" rid="CR84">1981</xref>) were found after a period of 5-week exposure to a TRP-free diet, in which 75% of reductions in brain 5-HT levels were observed. However, we have carried out an exposure of 2 weeks that is similar to the chronic TRP treatment in Fadda et al.’s study (<xref ref-type="bibr" rid="CR28">2000</xref>), in which 35–45% of 5-HT reductions were found. Moreover, central 5-HT depletion by administration of 5,7-dihydroxytryptamine, an invasive neurotoxic method that drastically reduces 5-HT levels, reported an increase in locomotor activity in LH rats (Eagle et al. <xref ref-type="bibr" rid="CR23">2008</xref>). On the other hand, our results confirm previous observations of no differences in locomotor activity between the HD and LD Wistar rats (Moreno et al. <xref ref-type="bibr" rid="CR65">2010</xref>).</p>
        <p>Besides this effect, depleted LH rats showed a downregulation of prefrontal 5-HT<sub>1A</sub> receptor that was not observed in the depleted Wistar rats. This is interesting as 5-HT<sub>1A</sub> receptors seem to be less susceptible to changes in serotonergic tonus compared to other 5-HT receptor subtypes, based on several studies of 5,7-DHT lesions (Berendsen et al. <xref ref-type="bibr" rid="CR8">1991</xref>; Frazer and Hensler <xref ref-type="bibr" rid="CR42">1990</xref>; Hensler et al. <xref ref-type="bibr" rid="CR49">1991</xref>; Miquel et al. <xref ref-type="bibr" rid="CR63">1992</xref>; Verge et al. <xref ref-type="bibr" rid="CR83">1986</xref>). However, Kawai et al. (<xref ref-type="bibr" rid="CR51">1994</xref>) proposed a downregulation of 5-HT<sub>1A</sub> receptors in the frontal cortex as a homeostatic adaptive change in response to chronic TRP deprivation.</p>
      </sec>
      <sec id="Sec24">
        <title>Effect of chronic tryptophan-deficient diet on monoaminergic concentration levels</title>
        <p>Chronic TRP depletion was effective in reducing the levels of 5-HIAA/5-HT turnover ratio in prefrontal cortex, striatum, amygdala, nucleus accumbens and hippocampus in both strains of rats. In addition, the serotonin metabolite 5-HIAA was reduced in all cases with the exception of nucleus accumbens of the Wistar rats. More variability was found when exploring significant reductions of 5-HT, which was effectively decreased in all areas but not in the striatum of the Wistar rats and the nucleus accumbens of both strains. Previous studies have reported similar findings regarding significant reductions of serotonin and its metabolite in prefrontal cortex and hippocampus when challenging rats to a TRP depletion by diet (Cahir et al. <xref ref-type="bibr" rid="CR15">2007</xref>; Franklin et al. <xref ref-type="bibr" rid="CR40">2012</xref>; Koot et al. <xref ref-type="bibr" rid="CR53">2012</xref>). However, there were strain differences, as the LH rats showed additional changes in other monoamines such as DA, which was increased in the nucleus accumbens, and NE, which was decreased in the prefrontal cortex, not observed in the Wistar rats. Alterations of DA and NA when depleting chronically TRP by diet were also observed by Koot et al. (<xref ref-type="bibr" rid="CR53">2012</xref>) in Wistar rats, indicating that this non-invasive depleting method of 5-HT may possibly lead to alterations in other brain neurotransmitter systems.</p>
        <p>In conclusion, the primary findings of the present study highlight the contribution of serotonergic mechanisms in the compulsive drinking behaviour of rats on SIP, in which the serotonin depletion by chronic exposure to a TRP-free diet increased compulsive licking in HD Wistar rats compared to LD Wistar and LH rats on SIP. Moreover, the TRP depletion by diet produced a modulation of 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptor subtypes. The depleted HD Wistar rats showed 5-HT<sub>2A</sub> receptor reductions in the striatum, which may underlie the increases in licking on SIP. Changes in the 5-HT<sub>2A</sub> receptor subtype may represent a good potential biomarker for the vulnerability to compulsive spectrum disorders and a new target in the development of new therapeutic strategies.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors thank Luis Ruedas for his invaluable and continuous help and Hans Jørgen Jensen for skilled technical assistance.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <p>All procedures were conducted in accordance with the Spanish Royal Decree 53/2013 on the protection of experimental animals, with the European Community Council Directives (86/609/EEC) and with the University of Almería Animal Research Committee approval.</p>
      <sec id="FPar5">
        <title>Funding</title>
        <p>This study was funded by grants from the Ministerio de Economía y Competitividad, Spanish Government (grants numbers PSI2012-31660 and PSI2015-70037-R).</p>
      </sec>
      <sec id="FPar6">
        <title>Conflicts of interest</title>
        <p>The authors declare that they have no conflict of interest.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>American Psychiatric Association</collab>
          </person-group>
          <source>Diagnostic and Statistical Manual of Mental Disorders</source>
          <year>2013</year>
          <edition>5</edition>
          <publisher-loc>Washington DC</publisher-loc>
          <publisher-name>American Psychiatric Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Angoa-Pérez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kane</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Briggs</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Francescutti</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivity</article-title>
          <source>J Neurochem</source>
          <year>2012</year>
          <volume>121</volume>
          <fpage>974</fpage>
          <lpage>984</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07739.x</pub-id>
          <?supplied-pmid 22443164?>
          <pub-id pub-id-type="pmid">22443164</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aznar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Regulating prefrontal cortex activation: an emerging role for the 5-HT serotonin receptor in the modulation of emotion-based actions?</article-title>
          <source>Mol Neurobiol</source>
          <year>2013</year>
          <volume>48</volume>
          <fpage>841</fpage>
          <lpage>853</lpage>
          <pub-id pub-id-type="doi">10.1007/s12035-013-8472-0</pub-id>
          <?supplied-pmid 23696058?>
          <pub-id pub-id-type="pmid">23696058</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aznar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hervig</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>The 5-HT2A serotonin receptor in executive function: implications for neuropsychiatric and neurodegenerative diseases</article-title>
          <source>Neurosci Biobehav Rev</source>
          <year>2016</year>
          <volume>64</volume>
          <fpage>63</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.02.008</pub-id>
          <?supplied-pmid 26891819?>
          <pub-id pub-id-type="pmid">26891819</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Theobald</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Caprioli</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mar</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Aidoo-Micah</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dalley</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats</article-title>
          <source>Neuropsychopharmacol</source>
          <year>2010</year>
          <volume>35</volume>
          <fpage>1290</fpage>
          <lpage>1301</lpage>
          <pub-id pub-id-type="doi">10.1038/npp.2009.233</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barlow</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Alsiö</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jupp</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rabinovich</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shrestha</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>AC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Markers of serotonergic function in the orbitofrontal cortex and dorsal raphé nucleus predict individual variation in spatial-discrimination serial reversal learning</article-title>
          <source>Neuropsychopharmacol</source>
          <year>2015</year>
          <volume>40</volume>
          <issue>7</issue>
          <fpage>1619</fpage>
          <lpage>1630</lpage>
          <pub-id pub-id-type="doi">10.1038/npp.2014.335</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barr</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Goodman</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>McDougle</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Delgado</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Heninger</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Charney</surname>
              <given-names>DS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors</article-title>
          <source>Arch Gen Psychiatry</source>
          <year>1994</year>
          <volume>51</volume>
          <fpage>309</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="doi">10.1001/archpsyc.1994.03950040053007</pub-id>
          <?supplied-pmid 8161291?>
          <pub-id pub-id-type="pmid">8161291</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berendsen</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Broekkamp</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Van Delft</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Depletion of brain serotonin differently affects behaviour induced by 5-HT1A, 5-HT1C and 5-HT2 receptor activation in rats</article-title>
          <source>Behav Neural Biol</source>
          <year>1991</year>
          <volume>55</volume>
          <fpage>214</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="doi">10.1016/0163-1047(91)80140-A</pub-id>
          <?supplied-pmid 1829353?>
          <pub-id pub-id-type="pmid">1829353</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berney</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sookman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Leyton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Benkelfat</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients</article-title>
          <source>Biol Psychiatry</source>
          <year>2006</year>
          <volume>59</volume>
          <issue>9</issue>
          <fpage>853</fpage>
          <lpage>857</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biopsych.2005.08.023</pub-id>
          <?supplied-pmid 16213470?>
          <pub-id pub-id-type="pmid">16213470</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blackshear</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Steranka</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Sanders-Bush</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Multiple serotonin receptors: regional distribution and effect of raphe lesions</article-title>
          <source>Eur J Pharmacol</source>
          <year>1981</year>
          <volume>76</volume>
          <fpage>325</fpage>
          <lpage>334</lpage>
          <pub-id pub-id-type="doi">10.1016/0014-2999(81)90103-5</pub-id>
          <?supplied-pmid 7327207?>
          <pub-id pub-id-type="pmid">7327207</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bortolato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Frau</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Orrù</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Collu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mereu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Carta</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of tryptophan deficiency on prepulse inhibition of the acoustic startle in rats</article-title>
          <source>Psychopharmacol (Berl)</source>
          <year>2008</year>
          <volume>198</volume>
          <issue>2</issue>
          <fpage>191</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-008-1116-9</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boulougouris</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Glennon</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats</article-title>
          <source>Neuropsychopharmacol</source>
          <year>2008</year>
          <volume>33</volume>
          <fpage>2007</fpage>
          <lpage>2019</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.npp.1301584</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Broersen</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Uylings</surname>
              <given-names>HB</given-names>
            </name>
          </person-group>
          <article-title>Visual attention task performance in Wistar and Lister hooded rats: response inhibition deficits after medial prefrontal cortex lesions</article-title>
          <source>Neuroscience</source>
          <year>1999</year>
          <volume>94</volume>
          <fpage>47</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.1016/S0306-4522(99)00312-7</pub-id>
          <?supplied-pmid 10613496?>
          <pub-id pub-id-type="pmid">10613496</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Coscina</surname>
              <given-names>DV</given-names>
            </name>
          </person-group>
          <article-title>Acute amino acid loads that deplete brain serotonin fail to alter behavior</article-title>
          <source>Pharmacol Biochem Be</source>
          <year>1998</year>
          <volume>59</volume>
          <fpage>115</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="doi">10.1016/S0091-3057(97)00381-X</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cahir</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ardis</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Reynolds</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Acute and chronic tryptophan depletion differentially regulate central 5-HT1A and 5-HT2A receptor binding in the rat</article-title>
          <source>Psychopharmacol</source>
          <year>2007</year>
          <volume>190</volume>
          <fpage>497</fpage>
          <lpage>506</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-006-0635-5</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardona</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>López-Grancha</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>López-Crespo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nieto-Escámez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sánchez-Santed</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Vulnerability of long-term neurotoxicity of chlorpyrifos: effect on schedule-induced polydipsia and a delay discounting task</article-title>
          <source>Psychopharmacol</source>
          <year>2006</year>
          <volume>189</volume>
          <fpage>47</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-006-0547-4</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardona</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>López-Crespo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sánchez-Amate</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sánchez-Santed</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Impulsivity as long-term sequelae after chlorpyrifos intoxication: time course and individual differences</article-title>
          <source>Neurotox Res</source>
          <year>2011</year>
          <volume>19</volume>
          <fpage>128</fpage>
          <lpage>137</lpage>
          <pub-id pub-id-type="doi">10.1007/s12640-009-9149-3</pub-id>
          <?supplied-pmid 20087798?>
          <pub-id pub-id-type="pmid">20087798</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>WQ</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>YF</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>YZ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Repeated exposure to chlorpyrifos alters the performance of adolescent male rats in animal models of depression and anxiety</article-title>
          <source>Neurotoxicology</source>
          <year>2011</year>
          <volume>32</volume>
          <fpage>355</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuro.2011.03.008</pub-id>
          <?supplied-pmid 21453723?>
          <pub-id pub-id-type="pmid">21453723</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conn</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Sanders-Bush</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Regulation of serotonin-stimulated phosphoinositide hydrolysis: regulation to the serotonin 5-HT2 binding site</article-title>
          <source>J Neurosci</source>
          <year>1986</year>
          <volume>6</volume>
          <fpage>3669</fpage>
          <lpage>3675</lpage>
          <?supplied-pmid 3025382?>
          <pub-id pub-id-type="pmid">3025382</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crean</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>de Wit</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Effect of tryptophan depletion on impulsive behavior in men with or without a family history of alcoholism</article-title>
          <source>Behav Brain Res</source>
          <year>2002</year>
          <volume>136</volume>
          <fpage>349</fpage>
          <lpage>357</lpage>
          <pub-id pub-id-type="doi">10.1016/S0166-4328(02)00132-8</pub-id>
          <?supplied-pmid 12429396?>
          <pub-id pub-id-type="pmid">12429396</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dannon</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Sasson</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hirschmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Iancu</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Grunhaus</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Zohar</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial</article-title>
          <source>Eur Neuropsychopharm</source>
          <year>2000</year>
          <volume>3</volume>
          <fpage>165</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="doi">10.1016/S0924-977X(00)00065-1</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Matteo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pierucci</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Esposito</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Crescimanno</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Benigno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Di Giovanni</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders</article-title>
          <source>Prog Brain Res</source>
          <year>2008</year>
          <volume>172</volume>
          <fpage>423</fpage>
          <lpage>463</lpage>
          <pub-id pub-id-type="doi">10.1016/S0079-6123(08)00921-7</pub-id>
          <?supplied-pmid 18772045?>
          <pub-id pub-id-type="pmid">18772045</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eagle</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Baunez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hutcheson</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Lehmann</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>Stop-signal reaction-time task performance: role of prefrontal cortex and subthalamic nucleus</article-title>
          <source>Cereb Cortex</source>
          <year>2008</year>
          <volume>18</volume>
          <fpage>178</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="doi">10.1093/cercor/bhm044</pub-id>
          <?supplied-pmid 17517682?>
          <pub-id pub-id-type="pmid">17517682</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eagle</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Baunez</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition</article-title>
          <source>Neurosci Biobehav R</source>
          <year>2010</year>
          <volume>34</volume>
          <issue>1–3</issue>
          <fpage>50</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neubiorev.2009.07.003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El Mansari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Blier</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder</article-title>
          <source>Prog Neuro-psychoph Biol Psychiatry</source>
          <year>2006</year>
          <volume>30</volume>
          <fpage>362</fpage>
          <lpage>373</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pnpbp.2005.11.005</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Escher</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mittleman</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Preclinical study: schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone</article-title>
          <source>Addict Biol</source>
          <year>2006</year>
          <volume>11</volume>
          <fpage>55</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1369-1600.2006.00004.x</pub-id>
          <?supplied-pmid 16759337?>
          <pub-id pub-id-type="pmid">16759337</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Escorihuela</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Fernández-Teruel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gil</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Aguilar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tobeña</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Driscoll</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Inbred Roman high- and low-avoidance rats: differences in anxiety, novelty-seeking, and shuttlebox behaviors</article-title>
          <source>Physiol Behav</source>
          <year>1999</year>
          <volume>67</volume>
          <fpage>19</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1016/S0031-9384(99)00064-5</pub-id>
          <?supplied-pmid 10463624?>
          <pub-id pub-id-type="pmid">10463624</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fadda</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cocco</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stancampiano</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>A physiological method to selectively decrease brain serotonin release</article-title>
          <source>Brain Res Protocol</source>
          <year>2000</year>
          <volume>5</volume>
          <fpage>219</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="doi">10.1016/S1385-299X(00)00016-7</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Falk</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Production of polydipsia in normal rats by an intermittent food schedule</article-title>
          <source>Science</source>
          <year>1961</year>
          <volume>133</volume>
          <fpage>195</fpage>
          <lpage>196</lpage>
          <pub-id pub-id-type="doi">10.1126/science.133.3447.195</pub-id>
          <?supplied-pmid 13698026?>
          <pub-id pub-id-type="pmid">13698026</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Falk</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>The nature and determinants of adjunctive behavior</article-title>
          <source>Physiol Behav</source>
          <year>1971</year>
          <volume>6</volume>
          <fpage>577</fpage>
          <lpage>588</lpage>
          <pub-id pub-id-type="doi">10.1016/0031-9384(71)90209-5</pub-id>
          <?supplied-pmid 5004684?>
          <pub-id pub-id-type="pmid">5004684</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fattore</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Piras</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Corda</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Giorgi</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>The Roman high- and low-avoidance rat lines differ in the acquisition, maintenance, extinction, and reinstatement of intravenous cocaine self-administration</article-title>
          <source>Neuropsychopharmacol</source>
          <year>2009</year>
          <volume>34</volume>
          <fpage>1091</fpage>
          <lpage>1101</lpage>
          <pub-id pub-id-type="doi">10.1038/npp.2008.43</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faulkner</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Deakin</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>The role of serotonin in reward, punishment and behavioural inhibition in humans: insights from studies with acute tryptophan depletion</article-title>
          <source>Neurosci Biobehav R</source>
          <year>2014</year>
          <volume>46</volume>
          <issue>3</issue>
          <fpage>365</fpage>
          <lpage>378</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.07.024</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernstrom</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Role of precursor availability in control of monoamine biosynthesis in brain</article-title>
          <source>Physiol Rev</source>
          <year>1983</year>
          <volume>63</volume>
          <fpage>484</fpage>
          <lpage>546</lpage>
          <?supplied-pmid 6132421?>
          <pub-id pub-id-type="pmid">6132421</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fineberg</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Potenza</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Chamberlain</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Berlin</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Menzies</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bechara</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review</article-title>
          <source>Neuropsychopharmacol</source>
          <year>2010</year>
          <volume>35</volume>
          <fpage>591</fpage>
          <lpage>604</lpage>
          <pub-id pub-id-type="doi">10.1038/npp.2009.185</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fineberg</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Chamberlain</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Hollander</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Boulougouris</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment</article-title>
          <source>Brit J Pharmacol</source>
          <year>2011</year>
          <volume>4</volume>
          <fpage>1044</fpage>
          <lpage>1061</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01422.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fineberg</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Chamberlain</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Goudriaan</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Vanderschuren</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Gillan</surname>
              <given-names>CM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>New developments in human neurocognition: clinical, genetic, and brain imaging correlates of impulsivity and compulsivity</article-title>
          <source>CNS Spectrums</source>
          <year>2014</year>
          <volume>19</volume>
          <fpage>69</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="doi">10.1017/S1092852913000801</pub-id>
          <?supplied-pmid 24512640?>
          <pub-id pub-id-type="pmid">24512640</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischette</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Nock</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Renner</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Effects of 5,7-DHT on serotonin 1 and serotonin 2 receptors throughout the rat central nervous system using quantitative autoradiography</article-title>
          <source>Brain Res</source>
          <year>1987</year>
          <volume>421</volume>
          <fpage>263</fpage>
          <lpage>279</lpage>
          <pub-id pub-id-type="doi">10.1016/0006-8993(87)91296-0</pub-id>
          <?supplied-pmid 3690273?>
          <pub-id pub-id-type="pmid">3690273</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ford</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Applications of schedule-induced polydipsia in rodents for the study of an excessive ethanol intake phenotype</article-title>
          <source>Alcohol</source>
          <year>2014</year>
          <volume>48</volume>
          <fpage>265</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="doi">10.1016/j.alcohol.2014.01.005</pub-id>
          <?supplied-pmid 24680665?>
          <pub-id pub-id-type="pmid">24680665</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franklin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Craven</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Dowling</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Campling</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Cowen</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Effect of a long-term low tryptophan diet on the prolactin responses to the 5-HT1A and 5-HT2C agonists, 8-OH-DPAT and mCPP in the male rat</article-title>
          <source>J Psychopharmacol</source>
          <year>1999</year>
          <volume>13</volume>
          <fpage>58</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="doi">10.1177/026988119901300107</pub-id>
          <?supplied-pmid 10221360?>
          <pub-id pub-id-type="pmid">10221360</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franklin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bermudez</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Murck</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Singewald</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gaburro</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Sub-chronic dietary tryptophan depletion—an animal model of depression with improved face and good construct validity</article-title>
          <source>J Psychiat Res</source>
          <year>2012</year>
          <volume>46</volume>
          <fpage>239</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpsychires.2011.10.003</pub-id>
          <?supplied-pmid 22074993?>
          <pub-id pub-id-type="pmid">22074993</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fratta</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Biggio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gessa</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
          <article-title>Homosexual mounting behavior induced in male rats and rabbits by a tryptophan-free diet</article-title>
          <source>Life Sci</source>
          <year>1977</year>
          <volume>21</volume>
          <fpage>379</fpage>
          <lpage>384</lpage>
          <pub-id pub-id-type="doi">10.1016/0024-3205(77)90518-5</pub-id>
          <?supplied-pmid 302380?>
          <pub-id pub-id-type="pmid">302380</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frazer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hensler</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>5-HT1A-mediated responses: effects of treatments that modify serotonergic neurotransmission</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>1990</year>
          <volume>600</volume>
          <fpage>460</fpage>
          <lpage>474</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1749-6632.1990.tb16902.x</pub-id>
          <?supplied-pmid 2174665?>
          <pub-id pub-id-type="pmid">2174665</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gessa</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Biggio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fadda</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Corsini</surname>
              <given-names>GU</given-names>
            </name>
            <name>
              <surname>Tagliamonte</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Effect of the oral administration of tryptophan-free amino acid mixtures on serum tryptophan and serotonin metabolism</article-title>
          <source>J Neurochem</source>
          <year>1974</year>
          <volume>22</volume>
          <fpage>869</fpage>
          <lpage>870</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1471-4159.1974.tb04308.x</pub-id>
          <?supplied-pmid 4407107?>
          <pub-id pub-id-type="pmid">4407107</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gillan</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>Goal-directed learning and obsessive-compulsive disorder</article-title>
          <source>Phil Trans R Soc B</source>
          <year>2014</year>
          <volume>369</volume>
          <fpage>1655</fpage>
          <pub-id pub-id-type="doi">10.1098/rstb.2013.0475</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilpin</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Badia-Elder</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Elder</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Schedule-induced polydipsia in lines of rats selectively bred for high and low ethanol preference</article-title>
          <source>Behav Genet</source>
          <year>2008</year>
          <volume>38</volume>
          <fpage>515</fpage>
          <lpage>524</lpage>
          <pub-id pub-id-type="doi">10.1007/s10519-008-9224-1</pub-id>
          <?supplied-pmid 18780177?>
          <pub-id pub-id-type="pmid">18780177</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hawken</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Delva</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Reynolds</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Beninger</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Increased schedule-induced polydipsia in the rat following subchronic treatment with MK-801</article-title>
          <source>Schizophr Res</source>
          <year>2011</year>
          <volume>125</volume>
          <fpage>93</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="doi">10.1016/j.schres.2010.07.022</pub-id>
          <?supplied-pmid 20719474?>
          <pub-id pub-id-type="pmid">20719474</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hawken</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Beninger</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>The amphetamine sensitization model of schizophrenia symptoms and its effects on schedule-induced polydipsia in the rat</article-title>
          <source>Psychopharmacol</source>
          <year>2014</year>
          <volume>231</volume>
          <fpage>2001</fpage>
          <lpage>2008</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-013-3345-9</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heal</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Philpot</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Molyneux</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Metz</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Intracerebroventricular administration of 5,7-DHT to mice increases both head twitch response and the number of cortical 5-HT2 receptors</article-title>
          <source>Neuropharmacology</source>
          <year>1985</year>
          <volume>24</volume>
          <fpage>1201</fpage>
          <lpage>1205</lpage>
          <pub-id pub-id-type="doi">10.1016/0028-3908(85)90155-8</pub-id>
          <?supplied-pmid 4094656?>
          <pub-id pub-id-type="pmid">4094656</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hensler</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Kovachich</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Frazer</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A quantitative autoradiographic study of serotonin1A receptor regulation. Effects of 5,7-dihydroxytryptamine and antidepressant treatments</article-title>
          <source>Neuropsychopharmacol</source>
          <year>1991</year>
          <volume>4</volume>
          <fpage>131</fpage>
          <lpage>144</lpage>
        </element-citation>
      </ref>
      <ref id="CR50">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ibias</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pellón</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Schedule-induced polydipsia in the spontaneously hypertensive rat and its relation to impulsive behaviour</article-title>
          <source>Behav Brain Res</source>
          <year>2011</year>
          <volume>223</volume>
          <fpage>58</fpage>
          <lpage>69</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbr.2011.04.017</pub-id>
          <?supplied-pmid 21540060?>
          <pub-id pub-id-type="pmid">21540060</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yokota</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yamawaki</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Effect of chronic tryptophan depletion on the circadian rhythm of wheel-running activity in rats</article-title>
          <source>Physiol Behav</source>
          <year>1994</year>
          <volume>55</volume>
          <fpage>1005</fpage>
          <lpage>1013</lpage>
          <pub-id pub-id-type="doi">10.1016/0031-9384(94)90381-6</pub-id>
          <?supplied-pmid 7519351?>
          <pub-id pub-id-type="pmid">7519351</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klein</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Ultved</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Adamsen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Santini</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Tobeña</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fernandez-Teruel</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>5-HT2A and mGlu2 receptor binding levels are related to differences in impulsive behavior in the Roman low- (RLA) and high- (RHA) avoidance rat strains</article-title>
          <source>Neuroscience</source>
          <year>2014</year>
          <volume>263</volume>
          <fpage>36</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.12.063</pub-id>
          <?supplied-pmid 24412375?>
          <pub-id pub-id-type="pmid">24412375</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koot</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zoratto</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cassano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Colangeli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Laviola</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>van den Bos</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Adriani</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Compromised decision-making and increased gambling proneness following dietary serotonin depletion in rats</article-title>
          <source>Neuropharmacology</source>
          <year>2012</year>
          <volume>62</volume>
          <fpage>1640</fpage>
          <lpage>1650</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.11.002</pub-id>
          <?supplied-pmid 22118880?>
          <pub-id pub-id-type="pmid">22118880</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kötting</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Bubenzer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Helmbold</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Eisert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gaber</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Zepf</surname>
              <given-names>FD</given-names>
            </name>
          </person-group>
          <article-title>Effects of tryptophan depletion on reactive aggression and aggressive decision-making in young people with ADHD</article-title>
          <source>Acta Psychiat Scand</source>
          <year>2013</year>
          <volume>128</volume>
          <fpage>114</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="doi">10.1111/acps.12001</pub-id>
          <?supplied-pmid 22913430?>
          <pub-id pub-id-type="pmid">22913430</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>LeMarquand</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Pihl</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Tremblay</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Séguin</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Palmour</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Benkelfat</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Tryptophan depletion, executive functions and disinhibition in aggressive, adolescent males</article-title>
          <source>Neuropsychopharmacol</source>
          <year>1998</year>
          <volume>19</volume>
          <issue>4</issue>
          <fpage>333</fpage>
          <lpage>341</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.npp.1395196</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>LeMarquand</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Benkelfat</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pihl</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Palmour</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
          <article-title>Behavioral disinhibition induced by tryptophan depletion in nonalcoholic young men with multigenerational family histories of paternal alcoholism</article-title>
          <source>Am J Psychiat</source>
          <year>1999</year>
          <volume>156</volume>
          <fpage>1771</fpage>
          <lpage>1779</lpage>
          <?supplied-pmid 10553742?>
          <pub-id pub-id-type="pmid">10553742</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lapiz-Bluhm</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Soto-Pina</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Hensler</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Morilak</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Chronic intermittent cold stress and serotonin depletion induce deficits of reversal learning in an attentional set-shifting test in rats</article-title>
          <source>Psychopharmacol</source>
          <year>2009</year>
          <volume>202</volume>
          <fpage>329</fpage>
          <lpage>341</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-008-1224-6</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Licht</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Marcussen</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Wegener</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Overstreet</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Aznar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Knudsen</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
          <article-title>The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration</article-title>
          <source>J Neurochem</source>
          <year>2009</year>
          <volume>109</volume>
          <issue>5</issue>
          <fpage>1363</fpage>
          <lpage>1374</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06050.x</pub-id>
          <?supplied-pmid 19476548?>
          <pub-id pub-id-type="pmid">19476548</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lieben</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Blokland</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Westerink</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Deutz</surname>
              <given-names>NE</given-names>
            </name>
          </person-group>
          <article-title>Acute tryptophan and serotonin depletion using an optimized tryptophan-free protein-carbohydrate mixture in the adult rat</article-title>
          <source>Neurochem Int</source>
          <year>2004</year>
          <volume>44</volume>
          <fpage>9</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1016/S0197-0186(03)00102-5</pub-id>
          <?supplied-pmid 12963083?>
          <pub-id pub-id-type="pmid">12963083</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Lambe</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Aghajanian</surname>
              <given-names>GK</given-names>
            </name>
          </person-group>
          <article-title>Somatodendritic autoreceptor regulation of serotonergic neurons: dependence on L-tryptophan hydroxylase-activating kinases</article-title>
          <source>Eur J Neurosci</source>
          <year>2005</year>
          <volume>21</volume>
          <fpage>945</fpage>
          <lpage>958</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.03930.x</pub-id>
          <?supplied-pmid 15787701?>
          <pub-id pub-id-type="pmid">15787701</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>López-Grancha</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>López-Crespo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sanchez-Amate</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Individual differences in schedule-induced polydipsia and the role of gabaergic and dopaminergic systems</article-title>
          <source>Psychopharmacol</source>
          <year>2008</year>
          <volume>197</volume>
          <fpage>487</fpage>
          <lpage>498</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-007-1059-6</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mette</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grabemann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abdel-Hamid</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uekermann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Biskup</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Wiltfang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zepf</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Kis</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The impact of acute tryptophan depletion on attentional performance in adult patients with ADHD</article-title>
          <source>Acta Psychiatr Scand</source>
          <year>2013</year>
          <volume>128</volume>
          <issue>2</issue>
          <fpage>124</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="doi">10.1111/acps.12090</pub-id>
          <?supplied-pmid 23419004?>
          <pub-id pub-id-type="pmid">23419004</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miquel</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Doucet</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Riad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Adrien</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Verge</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hamon</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Effect of the selective lesion of serotoninergic neurons on the regional distribution of 5-HT1A receptor mRNA in the rat brain</article-title>
          <source>Mol Brain Res</source>
          <year>1992</year>
          <volume>14</volume>
          <fpage>357</fpage>
          <lpage>362</lpage>
          <pub-id pub-id-type="doi">10.1016/0169-328X(92)90104-J</pub-id>
          <?supplied-pmid 1326699?>
          <pub-id pub-id-type="pmid">1326699</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cañadas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cardona</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Suñol</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Campa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sánchez-Amate</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sánchez-Santed</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Long-term monoamine changes in the striatum and nucleus accumbens after acute chlorpyrifos exposure</article-title>
          <source>Toxicol Lett</source>
          <year>2008</year>
          <volume>176</volume>
          <fpage>162</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="doi">10.1016/j.toxlet.2007.11.003</pub-id>
          <?supplied-pmid 18164878?>
          <pub-id pub-id-type="pmid">18164878</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cardona</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gómez</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Sánchez-Santed</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tobeña</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fernández-Teruel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impulsivity characterization in the Roman high- and low-avoidance rat strains: behavioral and neurochemical differences</article-title>
          <source>Neuropsychopharmacol</source>
          <year>2010</year>
          <volume>35</volume>
          <fpage>1198</fpage>
          <lpage>1208</lpage>
          <pub-id pub-id-type="doi">10.1038/npp.2009.224</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gutiérrez-Ferre</surname>
              <given-names>VE</given-names>
            </name>
            <name>
              <surname>Ruedas</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Campa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Suñol</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Poor inhibitory control and neurochemical differences in high compulsive drinker rats selected by schedule-induced polydipsia</article-title>
          <source>Psychopharmacol (Berl)</source>
          <year>2012</year>
          <volume>219</volume>
          <fpage>661</fpage>
          <lpage>672</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-011-2575-y</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Schedule-induced polydipsia as a model of compulsive behavior: neuropharmacological and neuroendocrine bases</article-title>
          <source>Psychopharmacol</source>
          <year>2012</year>
          <volume>219</volume>
          <fpage>647</fpage>
          <lpage>659</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-011-2570-3</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Navarro</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Gutiérrez-Ferre</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Moreno</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Activation of serotonin 5-HT2A receptors inhibits high compulsive drinking on schedule-induced polydipsia</article-title>
          <source>Psychopharmacol (Berl)</source>
          <year>2015</year>
          <volume>232</volume>
          <issue>4</issue>
          <fpage>683</fpage>
          <lpage>697</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-014-3699-7</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicholson</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Brotchie</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>5-hydroxytryptamine (5-HT, serotonin) and Parkinson’s disease—opportunities for novel therapeutics to reduce the problems of levodopa therapy</article-title>
          <source>Eur J Neurol</source>
          <year>2002</year>
          <volume>9</volume>
          <issue>3</issue>
          <fpage>1</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1468-1331.9.s3.1.x</pub-id>
          <?supplied-pmid 12464115?>
          <pub-id pub-id-type="pmid">12464115</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pelloux</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Dilleen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Economidou</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Theobald</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Everitt</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Reduced forebrain serotonin transmission is causally involved in the development of compulsive cocaine seeking in rats</article-title>
          <source>Neuropsychopharmacol</source>
          <year>2012</year>
          <volume>37</volume>
          <fpage>2505</fpage>
          <lpage>2514</lpage>
          <pub-id pub-id-type="doi">10.1038/npp.2012.111</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perani</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Garibotto</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gorini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moresco</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Henin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Panzacchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Matarrese</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carpinelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bellodi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fazio</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder</article-title>
          <source>NeuroImage</source>
          <year>2008</year>
          <volume>42</volume>
          <fpage>306</fpage>
          <lpage>314</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuroimage.2008.04.233</pub-id>
          <?supplied-pmid 18511303?>
          <pub-id pub-id-type="pmid">18511303</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poyurovsky</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Faragian</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shabeta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kosov</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Comparison of clinical characteristics, co-morbidity and pharmacotherapy in adolescent schizophrenia patients with and without obsessive-compulsive disorder</article-title>
          <source>Psychiatry Res</source>
          <year>2008</year>
          <volume>159</volume>
          <fpage>133</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="doi">10.1016/j.psychres.2007.06.010</pub-id>
          <?supplied-pmid 18406469?>
          <pub-id pub-id-type="pmid">18406469</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rǎdulescu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marra</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>A mathematical model of reward and executive circuitry in obsessive compulsive disorder</article-title>
          <source>J Theor Biol</source>
          <year>2016</year>
          <volume>414</volume>
          <fpage>165</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jtbi.2016.11.025</pub-id>
          <?supplied-pmid 27915073?>
          <pub-id pub-id-type="pmid">27915073</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seeman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Westman</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Coscina</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Warsh</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Serotonin receptors in hippocampus and frontal cortex</article-title>
          <source>Eur J Pharmacol</source>
          <year>1980</year>
          <volume>66</volume>
          <fpage>179</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="doi">10.1016/0014-2999(80)90141-7</pub-id>
          <?supplied-pmid 7439270?>
          <pub-id pub-id-type="pmid">7439270</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simpson</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Slifstein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bender</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Hackett</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Maher</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Abi-Dargham</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL100907</article-title>
          <source>Biol Psychiatry</source>
          <year>2011</year>
          <volume>70</volume>
          <fpage>897</fpage>
          <lpage>904</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biopsych.2011.06.023</pub-id>
          <?supplied-pmid 21855857?>
          <pub-id pub-id-type="pmid">21855857</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Skodol</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Oldham</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Oldham</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Hollander</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Skodol</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>
          <article-title>Phenomenology, differential diagnosis, and comorbidity of impulsive-compulsive spectrum of disorders</article-title>
          <source>Impulsivity and compulsivity</source>
          <year>1996</year>
          <publisher-loc>Washington</publisher-loc>
          <publisher-name>American Psychiatric Press, Inc.</publisher-name>
          <fpage>1</fpage>
          <lpage>36</lpage>
        </element-citation>
      </ref>
      <ref id="CR77">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slotkin</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Seidler</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
          <article-title>Developmental neurotoxicants target neurodifferentiation into the serotonin phenotype: chlorpyrifos, diazinon, dieldrin and divalent nickel</article-title>
          <source>Toxicol Appl Pharm</source>
          <year>2008</year>
          <volume>233</volume>
          <fpage>211</fpage>
          <lpage>219</lpage>
          <pub-id pub-id-type="doi">10.1016/j.taap.2008.08.020</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stadler</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zepf</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Demisch</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Landgraf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Poustka</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Influence of rapid tryptophan depletion on laboratory-provoked aggression in children with ADHD</article-title>
          <source>Neuropsychobiology</source>
          <year>2007</year>
          <volume>56</volume>
          <issue>2–3</issue>
          <fpage>104</fpage>
          <lpage>110</lpage>
          <?supplied-pmid 18182830?>
          <pub-id pub-id-type="pmid">18182830</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stancampiano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Melis</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sarais</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cocco</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cugusi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fadda</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Acute administration of a tryptophan-free amino acid mixture decreases 5-HT release in rat hippocampus in vivo</article-title>
          <source>Am J Phys</source>
          <year>1997</year>
          <volume>272</volume>
          <fpage>991</fpage>
          <lpage>994</lpage>
        </element-citation>
      </ref>
      <ref id="CR80">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stancampiano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cocco</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Melis</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cugusi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sarais</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fadda</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>The decrease of serotonin release induced by a tryptophan-free amino acid diet does not affect spatial and passive avoidance learning</article-title>
          <source>Brain Res</source>
          <year>1997</year>
          <volume>762</volume>
          <fpage>269</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.1016/S0006-8993(97)00506-4</pub-id>
          <?supplied-pmid 9262189?>
          <pub-id pub-id-type="pmid">9262189</pub-id>
        </element-citation>
      </ref>
      <ref id="CR81">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stancampiano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Frau</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bini</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Collu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carta</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fadda</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bortolato</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Chronic tryptophan deprivation attenuates gating deficits induced by 5-HT(1A), but not 5-HT<sub>2</sub> receptor activation</article-title>
          <source>Eur Neuropsychopharmacol</source>
          <year>2013</year>
          <volume>23</volume>
          <fpage>1329</fpage>
          <lpage>1335</lpage>
          <pub-id pub-id-type="doi">10.1016/j.euroneuro.2012.10.009</pub-id>
          <?supplied-pmid 23141373?>
          <pub-id pub-id-type="pmid">23141373</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van der Plasse</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Feenstra</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>Serial reversal learning and acute tryptophan depletion</article-title>
          <source>Behav Brain Res</source>
          <year>2008</year>
          <volume>186</volume>
          <fpage>23</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbr.2007.07.017</pub-id>
          <?supplied-pmid 17714800?>
          <pub-id pub-id-type="pmid">17714800</pub-id>
        </element-citation>
      </ref>
      <ref id="CR83">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verge</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Daval</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Marcinkiewiczm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Patey</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mestikawy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gozlan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hamon</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats</article-title>
          <source>J Neurosci</source>
          <year>1986</year>
          <volume>6</volume>
          <fpage>3474</fpage>
          <lpage>3482</lpage>
          <?supplied-pmid 2947981?>
          <pub-id pub-id-type="pmid">2947981</pub-id>
        </element-citation>
      </ref>
      <ref id="CR84">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vergnes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kempf</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Tryptophan deprivation: effects on mouse-killing and reactivity in the rat</article-title>
          <source>Pharmacol Biochem Be</source>
          <year>1981</year>
          <volume>14</volume>
          <issue>1</issue>
          <fpage>19</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1016/S0091-3057(81)80005-6</pub-id>
        </element-citation>
      </ref>
      <ref id="CR85">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallace</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pehrson</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Sánchez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Morilaz</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats</article-title>
          <source>Int J Neuropsychopharmacol</source>
          <year>2014</year>
          <volume>23</volume>
          <fpage>1</fpage>
          <lpage>12</lpage>
        </element-citation>
      </ref>
      <ref id="CR86">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Westenberg</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Fineberg</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Denys</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Neurobiology of obsessive-compulsive disorder: serotonin and beyond</article-title>
          <source>CNS Spectr</source>
          <year>2007</year>
          <volume>12</volume>
          <fpage>14</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="doi">10.1017/S1092852900002479</pub-id>
        </element-citation>
      </ref>
      <ref id="CR87">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winstanley</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Theobald</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Dalley</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Glennon</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion</article-title>
          <source>Psychopharmacol (Berl)</source>
          <year>2004</year>
          <volume>176</volume>
          <fpage>376</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-004-1884-9</pub-id>
        </element-citation>
      </ref>
      <ref id="CR88">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zepf</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Holtmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stadler</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Demisch</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wöckel</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Poustka</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Diminished serotonergic functioning in hostile children with ADHD: tryptophan depletion increases behavioural inhibition</article-title>
          <source>Pharmacopsychiatry</source>
          <year>2008</year>
          <volume>41</volume>
          <fpage>60</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2007-1004593</pub-id>
          <?supplied-pmid 18311686?>
          <pub-id pub-id-type="pmid">18311686</pub-id>
        </element-citation>
      </ref>
      <ref id="CR89">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zepf</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Holtmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stadler</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Magnus</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wöckel</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Poustka</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Diminished central nervous 5-HT neurotransmission and mood self-ratings in children and adolescents with ADHD: no clear effect of rapid tryptophan depletion</article-title>
          <source>Hum Psychopharmacol Clin Exp</source>
          <year>2009</year>
          <volume>24</volume>
          <fpage>87</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="doi">10.1002/hup.1002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR90">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zepf</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gaber</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Baurmann</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bubenzer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Konrad</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Herpetz-Dahlmann</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serotonergic neurotransmission and lapses of attention in children and adolescents with attention deficit hyperactivity disorder: availability of tryptophan influences attentional performance</article-title>
          <source>International Neuropsychopharmacol</source>
          <year>2010</year>
          <volume>13</volume>
          <fpage>933</fpage>
          <lpage>941</lpage>
          <pub-id pub-id-type="doi">10.1017/S146114571000012X</pub-id>
        </element-citation>
      </ref>
      <ref id="CR91">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zimmermann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grabemann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mette</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Abdel-Hamid</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ueckermann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kraemer</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The effects of acute tryptophan depletion on reactive aggression in adults with attention-deficit/hyperactivity disorder (ADHD) and healthy controls</article-title>
          <source>PLoS One</source>
          <year>2012</year>
          <volume>7</volume>
          <issue>3</issue>
          <fpage>e32023</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0032023</pub-id>
          <?supplied-pmid 22431971?>
          <pub-id pub-id-type="pmid">22431971</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362669</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Int J Comput Assist Radiol Surg</journal-id>
      <journal-id journal-id-type="iso-abbrev">Int J Comput Assist Radiol Surg</journal-id>
      <journal-title-group>
        <journal-title>International Journal of Computer Assisted Radiology and Surgery</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1861-6410</issn>
      <issn pub-type="epub">1861-6429</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362669</article-id>
      <article-id pub-id-type="pmcid">PMC5362669</article-id>
      <article-id pub-id-type="pmc-uid">5362669</article-id>
      <article-id pub-id-type="pmid">27718124</article-id>
      <article-id pub-id-type="publisher-id">1490</article-id>
      <article-id pub-id-type="doi">10.1007/s11548-016-1490-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The impact of manual threshold selection in medical additive manufacturing</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9208-283X</contrib-id>
          <name>
            <surname>van Eijnatten</surname>
            <given-names>Maureen</given-names>
          </name>
          <address>
            <phone>+31 6 31240513</phone>
            <email>m.vaneijnatten@vumc.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Koivisto</surname>
            <given-names>Juha</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Karhu</surname>
            <given-names>Kalle</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Forouzanfar</surname>
            <given-names>Tymour</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wolff</surname>
            <given-names>Jan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution>Department of Oral and Maxillofacial Surgery/Oral Pathology, 3D Innovation Lab, </institution><institution>VU University Medical Center, </institution></institution-wrap>De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands </aff>
        <aff id="Aff2"><label>2</label>Research and Technology, Planmeca Ltd, Helsinki, Finland </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>7</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>7</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>12</volume>
      <issue>4</issue>
      <fpage>607</fpage>
      <lpage>615</lpage>
      <history>
        <date date-type="received">
          <day>5</day>
          <month>6</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>9</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Purpose</title>
          <p>Medical additive manufacturing requires standard tessellation language (STL) models. Such models are commonly derived from computed tomography (CT) images using thresholding. Threshold selection can be performed manually or automatically. The aim of this study was to assess the impact of manual and default threshold selection on the reliability and accuracy of skull STL models using different CT technologies.</p>
        </sec>
        <sec>
          <title>Method</title>
          <p>One female and one male human cadaver head were imaged using multi-detector row CT, dual-energy CT, and two cone-beam CT scanners. Four medical engineers manually thresholded the bony structures on all CT images. The lowest and highest selected mean threshold values and the default threshold value were used to generate skull STL models. Geometric variations between all manually thresholded STL models were calculated. Furthermore, in order to calculate the accuracy of the manually and default thresholded STL models, all STL models were superimposed on an optical scan of the dry female and male skulls (“gold standard”).</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>The intra- and inter-observer variability of the manual threshold selection was good (intra-class correlation coefficients &gt;0.9). All engineers selected grey values closer to soft tissue to compensate for bone voids. Geometric variations between the manually thresholded STL models were 0.13 mm (multi-detector row CT), 0.59 mm (dual-energy CT), and 0.55 mm (cone-beam CT). All STL models demonstrated inaccuracies ranging from −0.8 to +1.1 mm (multi-detector row CT), −0.7 to +2.0 mm (dual-energy CT), and −2.3 to +4.8 mm (cone-beam CT).</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>This study demonstrates that manual threshold selection results in better STL models than default thresholding. The use of dual-energy CT and cone-beam CT technology in its present form does not deliver reliable or accurate STL models for medical additive manufacturing. New approaches are required that are based on pattern recognition and machine learning algorithms.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Additive manufacturing</kwd>
        <kwd>Three-dimensional (3D)printing</kwd>
        <kwd>Computed tomography (CT)</kwd>
        <kwd>Medical imaging</kwd>
        <kwd>Segmentation</kwd>
        <kwd>Thresholding</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>VU University Medical Center (VUmc)</institution>
          </funding-source>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© CARS 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Additive manufacturing (AM), also known as three-dimensional (3D) printing, refers to a process where a series of successive layers are laid down to create a 3D construct. AM combined with advanced medical imaging technologies such as computed tomography (CT) and magnetic resonance imaging (MRI) has resulted in a paradigm shift in medicine from traditional serial production to patient-specific constructs. This combination of technologies offers new possibilities for the fabrication of implants, saw guides and drill guides that are designed to meet the specific anatomical needs of patients [<xref ref-type="bibr" rid="CR1">1</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>A schematic diagram of the three steps required to fabricate an AM medical construct</p></caption><graphic xlink:href="11548_2016_1490_Fig1_HTML" id="MO1"/></fig>
</p>
      <p>The three-step medical AM process begins with image acquisition (Fig. <xref rid="Fig1" ref-type="fig">1</xref>, Step 1), which is commonly performed using a multi-detector row computed tomography (MDCT) scanner. However, dual-energy computed tomography (DECT), which offers the possibility of acquiring CT images using two different X-ray spectra, is becoming more common in hospital environments [<xref ref-type="bibr" rid="CR2">2</xref>]. Furthermore, cone-beam computed tomography (CBCT) is being increasingly used in dentistry and maxillofacial surgery due to its low costs and reduced radiation dose when compared with MDCT scanners [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
      <p>Images acquired using CT technologies are commonly saved as Digital Imaging and Communications in Medicine (DICOM) files. These files contain voxels with grey values that are proportional to the attenuation coefficient in the corresponding volume of the patient. In MDCT, these grey values are scaled according to Hounsfield units (HU): air (−1000 HU), water (0 HU), and compact bone (+1000 HU). In CBCT technology, the degree of X-ray attenuation is scaled using grey values, hence voxel values [<xref ref-type="bibr" rid="CR4">4</xref>]. CBCT grey values are often arbitrary and do not correspond to MDCT HU values [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, a large variability in the grey values has been reported between different CBCT scanners [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>At present, medical AM requires the conversion of DICOM images into virtual 3D surface models that are commonly saved as standard tessellation language (STL) files (Fig. <xref rid="Fig1" ref-type="fig">1</xref>, Step 2). STL models are commonly used to design medical constructs using computer-aided design (CAD) software. The DICOM-to-STL conversion process requires the partitioning and hence the segmentation of voxels into different tissue types. The most common segmentation method used to date is thresholding. During the thresholding process, all voxels with a grey value that is equal or greater than a selected threshold value <italic>t</italic> are included in a segmented volume [<xref ref-type="bibr" rid="CR9">9</xref>] using a binary mask <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$M_{x,y}$$\end{document}</tex-math><mml:math id="M2"><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq1.gif"/></alternatives></inline-formula> (Eq. <xref rid="Equ1" ref-type="">1</xref>):<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \hbox {M}_{\mathrm{x,y}} =\left\{ {\begin{array}{lllll} 0&amp;{}\quad \hbox {I}_{\mathrm{x,y}} &amp;{}&lt;&amp;{}t \\ 1&amp;{}\quad \hbox {I}_{\mathrm{x,y}} &amp;{}\ge &amp;{}\hbox {t} \\ \end{array}},\right. \end{aligned}$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:mtable columnspacing="0.5ex"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>M</mml:mtext><mml:mrow><mml:mi mathvariant="normal">x</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">y</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced close="" open="{" separators=""><mml:mrow><mml:mtable columnspacing="0.5ex"><mml:mtr><mml:mtd columnalign="left"><mml:mn>0</mml:mn></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mspace width="1em"/><mml:msub><mml:mtext>I</mml:mtext><mml:mrow><mml:mi mathvariant="normal">x</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">y</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mo>&lt;</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mi>t</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mn>1</mml:mn></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mspace width="1em"/><mml:msub><mml:mtext>I</mml:mtext><mml:mrow><mml:mi mathvariant="normal">x</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">y</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mo>≥</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mtext>t</mml:mtext></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>,</mml:mo></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="11548_2016_1490_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq2"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {I}_{\mathrm{x,y}}$$\end{document}</tex-math><mml:math id="M6"><mml:msub><mml:mtext>I</mml:mtext><mml:mrow><mml:mi mathvariant="normal">x</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">y</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq2.gif"/></alternatives></inline-formula> denotes the grey value at coordinates <italic>x</italic> and <italic>y</italic>.</p>
      <p>The medical image segmentation software packages available offer only a single, default threshold value for compact bone, soft tissue, and cartilage. However, these default values are often not optimized for all types of MDCT, DECT, and CBCT images and do not take into account the variations in grey values between different scanners [<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, in most cases, manual threshold selection is necessary to acquire an optimal STL model. Threshold selection, however, still remains a subjective task [<xref ref-type="bibr" rid="CR11">11</xref>], especially in the head area due to the plethora of complex bony geometries (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Furthermore, minor dislocations in the facial area can have an impact on patient function and aesthetic appearance.<fig id="Fig2"><label>Fig. 2</label><caption><p>The effect of threshold selection on skull STL models</p></caption><graphic xlink:href="11548_2016_1490_Fig2_HTML" id="MO3"/></fig>
</p>
      <p>At present, there is a paucity of the literature on threshold selection in the head area for medical purposes. Therefore, the aim of this study was to assess the impact of manual and default threshold selection on the reliability and accuracy of skull STL models acquired using different MDCT and CBCT technologies.</p>
    </sec>
    <sec id="Sec2">
      <title>Materials and methods</title>
      <p>One female and one male human cadaver head were anonymously provided by the Department of Anatomy, VU University Medical Center Amsterdam, The Netherlands. The two heads were embedded in a novel embalming liquid “Fix for Life” [<xref ref-type="bibr" rid="CR12">12</xref>] that produces near life-like cadavers. Ethical approval for this study was provided by the Medical Ethical Committee of the VU University Medical Center (Ref. 2016.401).<fig id="Fig3"><label>Fig. 3</label><caption><p>Outline of the study</p></caption><graphic xlink:href="11548_2016_1490_Fig3_HTML" id="MO4"/></fig>
</p>
      <p>The two “Fix for Life” cadaver heads were imaged using the following CT technologies: GE Discovery CT750 HD 64-slice MDCT (GE Healthcare, Little Chalfont, Buckinghamshire, UK), NewTom 5G CBCT (NewTom, Verona, Italy), and Vatech PaX Zenith 3D CBCT (Vatech, Fort Lee, USA) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, Step 1). The GE Discovery CT750 MDCT scanner was also operated using a dual-energy imaging mode (DECT). All scanners and image acquisition parameters are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Image acquisition parameters for all CT scans</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">GE discovery CT750 HD 64-slice (MDCT)</th><th align="left" colspan="2">GE discovery CT750 HD 64-slice (DECT)</th><th align="left" colspan="2">NewTom 5G (CBCT)</th><th align="left" colspan="2">Vatech PaX Zenith 3D (CBCT)</th></tr><tr><th align="left"/><th align="left">Female</th><th align="left">Male</th><th align="left">Female</th><th align="left">Male</th><th align="left">Female</th><th align="left">Male</th><th align="left">Female</th><th align="left">Male</th></tr></thead><tbody><tr><td align="left">Tube voltage (kV)</td><td align="left">120</td><td align="left">120</td><td align="left">80,140</td><td align="left">80,140</td><td align="left">110</td><td align="left">110</td><td align="left">115</td><td align="left">115</td></tr><tr><td align="left">Tube current (mA)</td><td align="left">300</td><td align="left">300</td><td align="left">375</td><td align="left">375</td><td align="left">7</td><td align="left">7</td><td align="left">6</td><td align="left">6</td></tr><tr><td align="left">Exposure time (s)</td><td align="left">0.638</td><td align="left">0.912</td><td align="left">0.912</td><td align="left">0.699</td><td align="left">10</td><td align="left">10</td><td align="left">24</td><td align="left">24</td></tr><tr><td align="left">Spacing between slices (mm)</td><td align="left">0.312</td><td align="left">0.312</td><td align="left">0.312</td><td align="left">0.312</td><td align="left">n.a.</td><td align="left">n.a.</td><td align="left">n.a.</td><td align="left">n.a.</td></tr><tr><td align="left">Slices thickness (mm)</td><td align="left">0.625</td><td align="left">0.625</td><td align="left">0.625</td><td align="left">0.625</td><td align="left">0.300</td><td align="left">0.300</td><td align="left">0.300</td><td align="left">0.300</td></tr><tr><td align="left">Number of voxels</td><td align="left">512 <inline-formula id="IEq3"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M8"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq3.gif"/></alternatives></inline-formula> 512 <inline-formula id="IEq4"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M10"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq4.gif"/></alternatives></inline-formula> 767</td><td align="left">512 <inline-formula id="IEq5"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M12"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq5.gif"/></alternatives></inline-formula> 512 <inline-formula id="IEq6"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M14"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq6.gif"/></alternatives></inline-formula> 919</td><td align="left">512 <inline-formula id="IEq7"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M16"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq7.gif"/></alternatives></inline-formula> 512 <inline-formula id="IEq8"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M18"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq8.gif"/></alternatives></inline-formula> 767</td><td align="left">512 <inline-formula id="IEq9"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M20"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq9.gif"/></alternatives></inline-formula> 512 <inline-formula id="IEq10"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M22"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq10.gif"/></alternatives></inline-formula> 919</td><td align="left">610 <inline-formula id="IEq11"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M24"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq11.gif"/></alternatives></inline-formula> 610 <inline-formula id="IEq12"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M26"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq12.gif"/></alternatives></inline-formula> 539</td><td align="left">610 <inline-formula id="IEq13"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M28"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq13.gif"/></alternatives></inline-formula> 610 <inline-formula id="IEq14"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M30"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq14.gif"/></alternatives></inline-formula> 541</td><td align="left">800 <inline-formula id="IEq15"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M32"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq15.gif"/></alternatives></inline-formula> 800 <inline-formula id="IEq16"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M34"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq16.gif"/></alternatives></inline-formula> 632</td><td align="left">800 <inline-formula id="IEq17"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M36"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq17.gif"/></alternatives></inline-formula> 800 <inline-formula id="IEq18"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times $$\end{document}</tex-math><mml:math id="M38"><mml:mo>×</mml:mo></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq18.gif"/></alternatives></inline-formula> 632</td></tr><tr><td align="left">Reconstruction kernel</td><td align="left">Boneplus</td><td align="left">Boneplus</td><td align="left">Soft</td><td align="left">Soft</td><td align="left">Standard</td><td align="left">Standard</td><td align="left">n.a.</td><td align="left">n.a.</td></tr></tbody></table></table-wrap>
</p>
      <p>After CT image acquisition, all DICOM files were imported into Osirix<inline-formula id="IEq19"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{{\circledR }}$$\end{document}</tex-math><mml:math id="M40"><mml:msup><mml:mrow/><mml:mo>®</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq19.gif"/></alternatives></inline-formula> MD software (Osirix Foundation, Geneva, Switzerland). This software is FDA-cleared, CE-labelled for primary diagnostics, and is commonly used in medical AM. Osirix<inline-formula id="IEq20"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{{\circledR }}$$\end{document}</tex-math><mml:math id="M42"><mml:msup><mml:mrow/><mml:mo>®</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq20.gif"/></alternatives></inline-formula> MD software provides options for both manual and default threshold selection.</p>
      <p>Four medical engineers were subsequently requested to manually select the optimal threshold value for bone in order to create an accurate STL model of the female and male skull, hence facial bony structures (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, Step 2). All four engineers were blinded for their own results and those of others. The manual threshold selection procedure was repeated after a six-week interval in order to determine the intra-observer variability and to calculate the mean threshold value. In addition, the inter-observer variability and intra-class correlation coefficients (ICC) were calculated using SPSS<inline-formula id="IEq21"><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{{\circledR }}$$\end{document}</tex-math><mml:math id="M44"><mml:msup><mml:mrow/><mml:mo>®</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq21.gif"/></alternatives></inline-formula> software (SPSS<inline-formula id="IEq22"><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{{\circledR }}$$\end{document}</tex-math><mml:math id="M46"><mml:msup><mml:mrow/><mml:mo>®</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq22.gif"/></alternatives></inline-formula> version 22, Chicago, IL, USA). ICC ranges between 0 and 1, with 0 corresponding to no agreement and 1 corresponding to complete agreement [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
      <p>In order to graphically represent the distribution of grey values in the manually selected and default threshold values, histograms were plotted for each of the four CT scanners using MatLab<inline-formula id="IEq23"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{{\circledR }}$$\end{document}</tex-math><mml:math id="M48"><mml:msup><mml:mrow/><mml:mo>®</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq23.gif"/></alternatives></inline-formula> software (MatLab v.2012, MathWorks, Natick, Massachusetts, USA) (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Only the highest and lowest mean selected threshold values presented on the eight histograms were used to generate STL models (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, Step 3). The generated STL models were subsequently geometrically compared to each other using GOM Inspect<inline-formula id="IEq24"><alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{{\circledR }}$$\end{document}</tex-math><mml:math id="M50"><mml:msup><mml:mrow/><mml:mo>®</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq24.gif"/></alternatives></inline-formula> software (GOM Inspect v8, GOM mbH, Braunschweig, Germany) in order to calculate the variations between the highest and lowest threshold STL models (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, Step 4).<fig id="Fig4"><label>Fig. 4</label><caption><p>
<bold>a–h</bold> The mean threshold values (HU) selected by four medical engineers and the pre-defined default threshold value (500 HU) are presented in histograms <bold>a</bold>–<bold>h</bold>. The y-axis of the histograms (frequencies) is set to a logarithmic scale</p></caption><graphic xlink:href="11548_2016_1490_Fig4_HTML" id="MO5"/></fig>
<fig id="Fig5"><label>Fig. 5</label><caption><p>Geometric variations in mm between the highest and lowest thresholded STL models acquired using four different CT scanners (see also Fig. <xref rid="Fig4" ref-type="fig">4</xref>).</p></caption><graphic xlink:href="11548_2016_1490_Fig5_HTML" id="MO6"/></fig>
</p>
      <p>In a final step, all soft tissues were manually removed from the cadaver heads using standard dissection equipment (i.e., scrapers and scalpels) by a highly experienced technician at the Department of Anatomy. Manual removal was opted for since this procedure ensured minimal dimensional changes in the bony structures of the cadaver skulls [<xref ref-type="bibr" rid="CR14">14</xref>]. The resulting dry female and male skulls were subsequently scanned using a GOM ATOS<inline-formula id="IEq25"><alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\mathrm{TM}}$$\end{document}</tex-math><mml:math id="M52"><mml:msup><mml:mrow/><mml:mi mathvariant="normal">TM</mml:mi></mml:msup></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq25.gif"/></alternatives></inline-formula> III optical 3D scanner (GOM GmbH, Braunschweig, Germany) with an accuracy of &lt;0.05 mm to acquire a “gold standard” STL model of the skulls (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). These “gold standard” STL models were subsequently superimposed on the STL models generated using the highest and lowest manually selected and default threshold values in order to calculate the accuracy of each thresholded STL model (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, Step 5).<fig id="Fig6"><label>Fig. 6</label><caption><p>
<bold>(a–k)</bold> Accuracy of all STL models of the female skull acquired using the lowest (<italic>left</italic>) and highest (<italic>middle</italic>) mean threshold value selected by the four engineers and the default threshold value of 500 HU (<italic>right</italic>). The arrows indicate missing data (<bold>c</bold>, <bold>f</bold>) or excessive noise (<bold>i</bold>) in the default threshold STL models</p></caption><graphic xlink:href="11548_2016_1490_Fig6_HTML" id="MO7"/></fig>
</p>
    </sec>
    <sec id="Sec3">
      <title>Results</title>
      <p>The intra- and inter-observer reliability results of all manually selected threshold values are presented in Table <xref rid="Tab2" ref-type="table">2</xref>. All selected threshold values ranged from 113 to 303 HU for the MDCT and DECT technologies and from 537 to 1281 gv for the CBCT technologies (Fig. <xref rid="Fig4" ref-type="fig">4</xref>a–h). As shown in the histograms, all the selected threshold values differed from the default threshold value provided by Osirix MD<inline-formula id="IEq26"><alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{{\circledR }}$$\end{document}</tex-math><mml:math id="M54"><mml:msup><mml:mrow/><mml:mo>®</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="11548_2016_1490_Article_IEq26.gif"/></alternatives></inline-formula> software (500 HU). Furthermore, the geometric variations between the highest and lowest thresholded STL models were larger in the STL models derived from DECT and CBCT when compared with the MDCT-derived STL models (Fig. <xref rid="Fig5" ref-type="fig">5</xref>).</p>
      <p>When compared to the “gold standard”, all manually and automatically thresholded STL models demonstrated inaccuracies ranging from −0.8 to +1.1 mm, −0.7 to +2.0 mm, and −2.3 to +4.8 mm for all STL models derived from MDCT, DECT, and CBCT, respectively (Fig. <xref rid="Fig6" ref-type="fig">6</xref>a–k). The male skull presented comparable accuracies to those observed on the female skull. The MDCT- and DECT-derived STL models acquired using the default threshold value demonstrated the highest loss of bone HU values (Fig. <xref rid="Fig6" ref-type="fig">6</xref>c, f). The NewTom CBCT-derived STL model acquired using the default threshold value (500 HU) provided by Osirix MD software resulted in an increase in artefacts and noise (Fig. <xref rid="Fig6" ref-type="fig">6</xref>i). The Vatech CBCT DICOM images did not allow the creation of an STL model using the 500-HU default threshold value since the grey values were not scaled to HU values (Fig. <xref rid="Fig4" ref-type="fig">4</xref>d, h).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Intra- and inter-observer variability of manual threshold selection by four medical engineers on CT images of a female and a male cadaver head</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Intra-observer variability</th><th align="left" colspan="4">Inter-observer variability between the engineers</th></tr><tr><th align="left" colspan="2">Intra-class correlation coefficient (ICC)</th><th align="left"/><th align="left">ICC</th><th align="left">ICC</th><th align="left">ICC</th></tr><tr><th align="left"/><th align="left"/><th align="left"/><th align="left">Engineer 2</th><th align="left">Engineer 3</th><th align="left">Engineer 4</th></tr><tr><th align="left">Cadaver head</th><th align="left">Female/male</th><th align="left"/><th align="left">Female/male</th><th align="left">Female/male</th><th align="left">Female/male</th></tr></thead><tbody><tr><td align="center">Engineer 1</td><td align="center">0.999/0.997</td><td align="center">Engineer 1</td><td align="center">0.994/0.988</td><td align="center">0.980/0.987</td><td align="left">0.970/0.954</td></tr><tr><td align="center">Engineer 2</td><td align="center">0.995/0.995</td><td align="center">Engineer 2</td><td align="center"/><td align="center">0.978/0.998</td><td align="left">0.961/0.931</td></tr><tr><td align="center">Engineer 3</td><td align="center">0.992/0.999</td><td align="center">Engineer 3</td><td align="center"/><td align="center"/><td align="left">0.914/0.917</td></tr><tr><td align="center">Engineer 4</td><td align="center">0.969/0.989</td><td align="center">Engineer 4</td><td align="center"/><td align="center"/><td align="left"/></tr></tbody></table></table-wrap>
</p>
    </sec>
    <sec id="Sec4">
      <title>Discussion</title>
      <p>To date, thresholding is the most commonly used segmentation method in medical AM. However, accurate bone segmentation often requires manual threshold selection, which still remains a subjective task. Moreover, recent studies suggest that the majority of inaccuracies that occur during the medical AM process are introduced during the image acquisition and image processing phases, rather than during the manufacturing, i.e., the 3D printing process itself [<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR17">17</xref>]. Such inaccuracies can markedly influence the resulting STL model (see Fig. <xref rid="Fig6" ref-type="fig">6</xref>) and subsequently lead to ill-fitting AM implants [<xref ref-type="bibr" rid="CR18">18</xref>]. Therefore, the aim of the present study was to assess the impact of manual and automatic default threshold selection on the reliability and accuracy of skull STL models.<fig id="Fig7"><label>Fig. 7</label><caption><p>MDCT-derived low-threshold STL model of the female cadaver skull (<italic>grey</italic>) with disjointed “soft-tissue” structures (<italic>red</italic>)</p></caption><graphic xlink:href="11548_2016_1490_Fig7_HTML" id="MO8"/></fig>
</p>
      <p>In the present study, all threshold values selected by the four engineers demonstrated a good intra-observer reliability (ICC &gt; 0.9). Furthermore, the inter-observer reliability was also good (ICC &gt; 0.9), as shown in Table <xref rid="Tab2" ref-type="table">2</xref>. Interestingly, all engineers that were blinded during the experiment selected threshold values for bone that were very close to the grey values of soft tissues (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). This resulted in small disjointed structures in the STL model (marked red in Fig. <xref rid="Fig7" ref-type="fig">7</xref>) that represent the transition from bone into soft tissue grey values. Such disjointed “soft-tissue” structures can be manually removed during STL post-processing [<xref ref-type="bibr" rid="CR19">19</xref>]. All engineers purposely selected the “soft tissue” threshold values during bone segmentation in order to incorporate the maximum number of bone-specific grey values. These grey values are allocated to voxels that represent different tissues during the CT image reconstruction process. However, during this process, voxels on the bone-to-soft tissue boundaries that are partially filled with soft tissue are commonly assigned a lower grey value than bone. This phenomenon is coined the partial volume effect (PVE) [<xref ref-type="bibr" rid="CR20">20</xref>]. As a consequence of the PVE, voxels may be erroneously allocated to “soft tissue” instead of “bone”, resulting in data loss and hence bone voids in the STL model (Fig. <xref rid="Fig6" ref-type="fig">6</xref>). Therefore, engineers should be aware of this phenomenon since data loss can lead to large inaccuracies in individualized printed medical constructs [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p>
      <p>Another major finding in this study was the difference between the MDCT and CBCT DICOM files that were used to construct STL models (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). One explanation for this phenomenon is the inherent difference between these technologies. CBCT technology is typically more heavily affected by image noise and distortions due to the “cone-beam” geometry of the X-ray beam [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In CBCT, the simultaneously irradiated area is typically larger than in MDCT technology. This causes increased scatter levels and results in cupping, reduced contrast, and other scatter-induced artefacts in the reconstructed image. In addition, CBCT images are more subject to cone-beam artefacts due to the large cone-beam angle and the imaging geometry comprising a single focal plane. The cone-beam artefacts result from violating Tuy’s sufficiency condition [<xref ref-type="bibr" rid="CR23">23</xref>] that requires that each plane intersecting a region of interest must intersect the focal trajectory, i.e., the path defining the radiation source position during the imaging. The embodiments of cone-beam artefacts are dependent on the reconstruction algorithm and the imaging geometry. Typical cone-beam artefacts include the elongation of structures in the axial direction and negative undershoots at sharp edges in the transaxial planes [<xref ref-type="bibr" rid="CR24">24</xref>]. In CBCT, the focal trajectory consists of a single planar circle or arc that results in a violation of Tuy’s sufficiency condition in all regions outside the focal plane. The resulting cone-beam artefacts are more pronounced the further away the region of interest is from the focal plane. In MDCT, the volume that satisfies Tuy’s sufficiency condition is notably larger due to the helical nature of the focal trajectory.</p>
      <p>The presence of artefacts makes the segmentation and hence the thresholding of bone-specific grey values in CBCT images more cumbersome [<xref ref-type="bibr" rid="CR25">25</xref>]. This subsequently leads to a larger variation in manually selected threshold values for CBCT images (Fig. <xref rid="Fig4" ref-type="fig">4</xref>) and to the larger geometric variations of up to 0.55 mm in CBCT-derived STL models observed in this study (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). DECT-derived STL models demonstrated geometric variations of up to 0.59 mm (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). As a consequence of these geometric variations in STL models, the use of DECT and CBCT technology in its present form does not deliver reproducible STL models for medical AM. Therefore, the authors of this study suggest that only MDCT technology should be used for AM applications because of the lower variability (0.13 mm, see Fig.  <xref rid="Fig5" ref-type="fig">5</xref>) and higher accuracy (Fig. <xref rid="Fig6" ref-type="fig">6</xref>) of the technology.</p>
      <p>The present study demonstrates that the “human factor”, i.e., the medical engineer, influences the outcome of the segmentation process. Moreover, no single bone threshold value is applicable for all facial bones. The authors of this study therefore recommend the use of individual threshold values for each anatomical buttress. Recently, attempts have been made to develop novel segmentation algorithms using multi-thresholding [<xref ref-type="bibr" rid="CR26">26</xref>], adaptive thresholding [<xref ref-type="bibr" rid="CR11">11</xref>], and semi-automatic region growing [<xref ref-type="bibr" rid="CR27">27</xref>]. However, these algorithms are still in an early stage of development [<xref ref-type="bibr" rid="CR28">28</xref>] and do not take the inherent differences between MDCT and CBCT technologies into account. Future research should therefore focus on developing novel medical image segmentation software that is suitable for different CT imaging modalities. Furthermore, new approaches should be developed using pattern recognition and machine learning algorithms.</p>
    </sec>
    <sec id="Sec5">
      <title>Conclusion</title>
      <p>This study shows that manual threshold selection results in better skull STL models than default thresholding since all the medical engineers in our study selected grey values closer to soft tissue to compensate for bone voids. Our study also showed that MDCT-derived STL models offer the lowest variability and highest accuracy, whilst the use of DECT and CBCT technology in its present form does not deliver reliable STL models for medical AM. New approaches based on pattern recognition and machine learning algorithms are required.</p>
    </sec>
  </body>
  <back>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <sec id="FPar1">
        <title>Conflict of interest</title>
        <p>Juha Koivisto and Kalle Karhu are currently employed by Planmeca Ltd (Finland), a company that specializes in the manufacture of cone-beam computed tomography scanners. The other authors declare that they have no conflict of interest.</p>
      </sec>
      <sec id="FPar2">
        <title>Ethical approval</title>
        <p>This article does not contain any studies with human participants or animals performed by any of the authors. All human cadaveric materials that were used in the present study (one female and one male head) were anonymously acquired through the body donor programme of the Department of Anatomy of the VU University Medical Center Amsterdam, The Netherlands, in full accordance with Article 1 of the Dutch law on funeral services (<ext-link ext-link-type="uri" xlink:href="http://wetten.overheid.nl/BWBR0005009/2015-07-01">http://wetten.overheid.nl/BWBR0005009/2015-07-01</ext-link>) and European legislation. Furthermore, ethical approval for this study was provided by the Medical Ethical Committee (METC) of the VU University Medical Center (Ref. 2016.401).</p>
      </sec>
      <sec id="FPar3">
        <title>Informed consent</title>
        <p>For this type of study, no formal consent was required.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abou-El Fetouh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Barakat</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Abdel-Ghany</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Computer-guided rapid-prototyped templates for segmental mandibular osteotomies: a preliminary report</article-title>
          <source>Int J Med Robot</source>
          <year>2011</year>
          <volume>7</volume>
          <fpage>187</fpage>
          <lpage>192</lpage>
          <pub-id pub-id-type="doi">10.1002/rcs.387</pub-id>
          <pub-id pub-id-type="pmid">21412965</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>TRC</given-names>
            </name>
          </person-group>
          <article-title>Dual-energy CT: general principles</article-title>
          <source>Am J Roentgenol</source>
          <year>2012</year>
          <volume>199</volume>
          <fpage>3</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.2214/AJR.12.9116</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pauwels</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nackaerts</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Bellaiche</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Stamatakis</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tsiklakis</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bosmans</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bogaerts</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Horner</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Variability of dental cone beam CT grey values for density estimations</article-title>
          <source>Br J Radiol</source>
          <year>2013</year>
          <volume>86</volume>
          <fpage>20120135</fpage>
          <pub-id pub-id-type="doi">10.1259/bjr.20120135</pub-id>
          <?supplied-pmid 23255537?>
          <pub-id pub-id-type="pmid">23255537</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Razi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Niknami</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alavi Ghazani</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Relationship between Hounsfield Unit in CT scan and gray scale in CBCT</article-title>
          <source>J Dent Res Dent Clin Dent Prospects</source>
          <year>2014</year>
          <volume>8</volume>
          <fpage>107</fpage>
          <lpage>110</lpage>
          <?supplied-pmid 25093055?>
          <pub-id pub-id-type="pmid">25093055</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katsumata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hirukawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Naitoh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fujishita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ariji</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Langlais</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
          <article-title>Effects of image artifacts on gray-value density in limited-volume cone-beam computerized tomography</article-title>
          <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>
          <year>2007</year>
          <volume>104</volume>
          <fpage>829</fpage>
          <lpage>836</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tripleo.2006.12.005</pub-id>
          <?supplied-pmid 17448704?>
          <pub-id pub-id-type="pmid">17448704</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Silva</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>DQ</given-names>
            </name>
            <name>
              <surname>Ambrosano</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Bóscolo</surname>
              <given-names>FN</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Bone density: comparative evaluation of Hounsfield units in multislice and cone-beam computed tomography</article-title>
          <source>Braz Oral Res</source>
          <year>2012</year>
          <volume>26</volume>
          <fpage>550</fpage>
          <lpage>556</lpage>
          <pub-id pub-id-type="doi">10.1590/S1806-83242012000600011</pub-id>
          <?supplied-pmid 23184166?>
          <pub-id pub-id-type="pmid">23184166</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nackaerts</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Maes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Couto Souza</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pauwels</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Analysis of intensity variability in multislice and cone beam computed tomography</article-title>
          <source>Clin Oral Implants Res</source>
          <year>2011</year>
          <volume>22</volume>
          <fpage>873</fpage>
          <lpage>879</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0501.2010.02076.x</pub-id>
          <?supplied-pmid 21244502?>
          <pub-id pub-id-type="pmid">21244502</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reeves</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mah</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McDavid</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Deriving Hounsfield units using grey levels in cone beam CT: a clinical application</article-title>
          <source>Dentomaxillofacial Radiol</source>
          <year>2012</year>
          <volume>41</volume>
          <fpage>500</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="doi">10.1259/dmfr/31640433</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sahoo</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Soltani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>AKC</given-names>
            </name>
          </person-group>
          <article-title>A survey of thresholding techniques</article-title>
          <source>Comput Vision Graph Image Process</source>
          <year>1988</year>
          <volume>41</volume>
          <fpage>233</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="doi">10.1016/0734-189X(88)90022-9</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Logan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wolfaardt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Boulanger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hodgetts</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Seikaly</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of the accuracy of cone beam computerized tomography (CBCT): medical imaging technology in head and neck reconstruction</article-title>
          <source>J Otolaryngol Head Neck Surg</source>
          <year>2013</year>
          <volume>42</volume>
          <fpage>25</fpage>
          <pub-id pub-id-type="doi">10.1186/1916-0216-42-25</pub-id>
          <?supplied-pmid 23672880?>
          <pub-id pub-id-type="pmid">23672880</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nackaerts</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Depypere</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vandenberghe</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Maes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Segmentation of trabecular jaw bone on cone beam CT datasets</article-title>
          <source>Clin Implant Dent Relat Res</source>
          <year>2015</year>
          <volume>17</volume>
          <fpage>1082</fpage>
          <lpage>1091</lpage>
          <pub-id pub-id-type="doi">10.1111/cid.12217</pub-id>
          <?supplied-pmid 24629139?>
          <pub-id pub-id-type="pmid">24629139</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="other">van Dam A, van, Munsteren C, de, Ruiter M, (2015) Fix for life. The development of a new embalming method to preserve life-like morphology. FASEB J 29(547):10</mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bartko</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>The intraclass correlation coefficient as a measure of reliability</article-title>
          <source>Psychol Rep</source>
          <year>1966</year>
          <volume>19</volume>
          <fpage>3</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.2466/pr0.1966.19.1.3</pub-id>
          <?supplied-pmid 5942109?>
          <pub-id pub-id-type="pmid">5942109</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van den Broeck</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vereecke</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wirix-Speetjens</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Van der Sloten</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Segmentation accuracy of long bones</article-title>
          <source>Med Eng Phys</source>
          <year>2014</year>
          <volume>36</volume>
          <fpage>949</fpage>
          <lpage>953</lpage>
          <pub-id pub-id-type="doi">10.1016/j.medengphy.2014.03.016</pub-id>
          <?supplied-pmid 24768087?>
          <pub-id pub-id-type="pmid">24768087</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huotilainen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Paloheimo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Salmi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Paloheimo</surname>
              <given-names>K-S</given-names>
            </name>
            <name>
              <surname>Björkstrand</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tuomi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Markkola</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mäkitie</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Imaging requirements for medical applications of additive manufacturing</article-title>
          <source>Acta Radiol</source>
          <year>2014</year>
          <volume>55</volume>
          <fpage>78</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="doi">10.1177/0284185113494198</pub-id>
          <?supplied-pmid 23901144?>
          <pub-id pub-id-type="pmid">23901144</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Gibson</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Rosen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stucker</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <source>Additive manufacturing technologies—3D printing, rapid prototyping, and direct digital manufacturing</source>
          <year>2014</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Springer</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Anstey</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Venne</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Using additive manufacturing in accuracy evaluation of reconstructions from computed tomography</article-title>
          <source>Proc Inst Mech Eng H</source>
          <year>2013</year>
          <volume>227</volume>
          <fpage>551</fpage>
          <lpage>559</lpage>
          <pub-id pub-id-type="doi">10.1177/0954411912474612</pub-id>
          <?supplied-pmid 23637265?>
          <pub-id pub-id-type="pmid">23637265</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stoor</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Suomalainen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lindqvist</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mesimaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Danielsson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Westermark</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kontio</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>Rapid prototyped patient specific implants for reconstruction of orbital wall defects</article-title>
          <source>J Craniomaxillofac Surg</source>
          <year>2014</year>
          <volume>42</volume>
          <fpage>1644</fpage>
          <lpage>1649</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcms.2014.05.006</pub-id>
          <?supplied-pmid 25139812?>
          <pub-id pub-id-type="pmid">25139812</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mitsouras</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Liacouras</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Imanzadeh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giannopoulos</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kumamaru</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wake</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Caterson</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Pomahac</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>VB</given-names>
            </name>
            <name>
              <surname>Grant</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Rybicki</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
          <article-title>Medical 3D printing for the radiologist</article-title>
          <source>Radiographics</source>
          <year>2015</year>
          <volume>35</volume>
          <fpage>1965</fpage>
          <lpage>1988</lpage>
          <pub-id pub-id-type="doi">10.1148/rg.2015140320</pub-id>
          <?supplied-pmid 26562233?>
          <pub-id pub-id-type="pmid">26562233</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huotilainen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jaanimets</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Valášek</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marcián</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Salmi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tuomi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mäkitie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Inaccuracies in additive manufactured medical skull models caused by the DICOM to STL conversion process</article-title>
          <source>J Cranio-Maxillofacial Surg</source>
          <year>2014</year>
          <volume>42</volume>
          <fpage>e259</fpage>
          <lpage>e265</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcms.2013.10.001</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feldkamp</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Kress</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Practical cone-beam algorithm</article-title>
          <source>J Opt Soc Am</source>
          <year>1984</year>
          <volume>1</volume>
          <fpage>612</fpage>
          <pub-id pub-id-type="doi">10.1364/JOSAA.1.000612</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Endo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsunoo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nakamori</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Effect of scattered radiation on image noise in cone beam CT</article-title>
          <source>Med Phys</source>
          <year>2001</year>
          <volume>28</volume>
          <fpage>469</fpage>
          <lpage>474</lpage>
          <pub-id pub-id-type="doi">10.1118/1.1357457</pub-id>
          <?supplied-pmid 11339743?>
          <pub-id pub-id-type="pmid">11339743</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tuy</surname>
              <given-names>HK</given-names>
            </name>
          </person-group>
          <article-title>An inversion formula for cone-beam reconstruction</article-title>
          <source>SIAM J Appl Math</source>
          <year>1983</year>
          <volume>43</volume>
          <fpage>546</fpage>
          <lpage>552</lpage>
          <pub-id pub-id-type="doi">10.1137/0143035</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Clack</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Weng</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Christian</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Gullberg</surname>
              <given-names>GT</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Colchester</surname>
              <given-names>ACF</given-names>
            </name>
            <name>
              <surname>Hawkes</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Cone beam single photon emission computed tomography using two orbits</article-title>
          <source>Proceedings of the Information processing in medical imaging: 12th international conference, IPMI ’91 Wye, July 7–12, 1991</source>
          <year>1991</year>
          <publisher-loc>Berlin</publisher-loc>
          <publisher-name>Springer</publisher-name>
          <fpage>45</fpage>
          <lpage>54</lpage>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maret</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Telmon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>OA</given-names>
            </name>
            <name>
              <surname>Lepage</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Treil</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Inglèse</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Peyre</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Sixou</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Effect of voxel size on the accuracy of 3D reconstructions with cone beam CT</article-title>
          <source>Dentomaxillofacial Radiol</source>
          <year>2012</year>
          <volume>41</volume>
          <fpage>649</fpage>
          <lpage>655</lpage>
          <pub-id pub-id-type="doi">10.1259/dmfr/81804525</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rathnayaka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sahama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schuetz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Schmutz</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Effects of CT image segmentation methods on the accuracy of long bone 3D reconstructions</article-title>
          <source>Med Eng Phys</source>
          <year>2011</year>
          <volume>33</volume>
          <fpage>226</fpage>
          <lpage>233</lpage>
          <pub-id pub-id-type="doi">10.1016/j.medengphy.2010.10.002</pub-id>
          <?supplied-pmid 21030288?>
          <pub-id pub-id-type="pmid">21030288</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schreurs</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Heerink</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Bergé</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Maal</surname>
              <given-names>TJJ</given-names>
            </name>
          </person-group>
          <article-title>A novel region-growing based semi-automatic segmentation protocol for three-dimensional condylar reconstruction using cone beam computed tomography (CBCT)</article-title>
          <source>PLoS One</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>e111126</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0111126</pub-id>
          <?supplied-pmid 25401954?>
          <pub-id pub-id-type="pmid">25401954</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pauwels</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Araki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Siewerdsen</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Thongvigitmanee</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>Technical aspects of dental CBCT: state of the art</article-title>
          <source>Dentomaxillofacial Radiol</source>
          <year>2015</year>
          <volume>44</volume>
          <fpage>20140224</fpage>
          <pub-id pub-id-type="doi">10.1259/dmfr.20140224</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362670</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Philos Psychol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rev Philos Psychol</journal-id>
      <journal-title-group>
        <journal-title>Review of Philosophy and Psychology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1878-5158</issn>
      <issn pub-type="epub">1878-5166</issn>
      <publisher>
        <publisher-name>Springer Netherlands</publisher-name>
        <publisher-loc>Dordrecht</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362670</article-id>
      <article-id pub-id-type="pmcid">PMC5362670</article-id>
      <article-id pub-id-type="pmc-uid">5362670</article-id>
      <article-id pub-id-type="publisher-id">313</article-id>
      <article-id pub-id-type="doi">10.1007/s13164-016-0313-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>I Me Mine</italic>: on a Confusion Concerning the Subjective Character of Experience</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Guillot</surname>
            <given-names>Marie</given-names>
          </name>
          <address>
            <phone>00 44 75 23 75 77 11</phone>
            <email>m.guillot@ucl.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution>Department of Philosophy, </institution><institution>University College London, </institution></institution-wrap>Gower Street, London, WC1E 6BT UK </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>5</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>27</day>
        <month>5</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>8</volume>
      <issue>1</issue>
      <fpage>23</fpage>
      <lpage>53</lpage>
      <permissions>
        <copyright-statement>© The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>In recent debates on phenomenal consciousness, a distinction is sometimes made, after Levine (<xref ref-type="bibr" rid="CR44">2001</xref>) and Kriegel (<xref ref-type="bibr" rid="CR43">2009</xref>), between the “qualitative character” of an experience, i.e. the specific way it feels to the subject (e.g. blueish or sweetish or pleasant), and its “subjective character”, i.e. the fact that there is anything at all that it feels like to her. I argue that much discussion of subjective character is affected by a conflation between three different notions. I start by disentangling the three notions in question, under the labels of “for-me-ness”, “me-ness” and “mineness”. Next, I argue that these notions are not equivalent; in particular, there is no conceptual implication from for-me-ness to me-ness or mineness. Empirical considerations based on clinical cases additionally suggest that the three notions may also correspond to different properties (although the claim of conceptual non-equivalence does not depend on this further point). The aim is clarificatory, cautionary but also critical: I examine four existing arguments from subjective character that are fuelled by an undifferentiated use of the three notions, and find them to be flawed for this reason.</p>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/http://dx.doi.org/10.13039/501100003339</institution-id>
              <institution>Consejo Superior de Investigaciones Científicas</institution>
            </institution-wrap>
          </funding-source>
          <award-id>FFI2013-47948-P</award-id>
        </award-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004963</institution-id>
              <institution>Seventh Framework Programme</institution>
            </institution-wrap>
          </funding-source>
          <award-id>622127</award-id>
          <principal-award-recipient>
            <name>
              <surname>Guillot</surname>
              <given-names>Marie</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© Springer Science+Business Media Dordrecht 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <sec id="Sec2">
        <title>The Subjective Character of Experience</title>
        <p>Experiences have intentional properties: they represent the world as being a certain way. Unlike other types of representations, they also have phenomenal properties: there is, as Nagel (<xref ref-type="bibr" rid="CR49">1974</xref>) famously puts it, “something it is like” to have an experience for the subject undergoing it. Take the sentence “honeysuckle has a sweet smell”, and a sensory experience of the sweet smell of honeysuckle. There is an aspect of reality that both representations are <italic>about</italic>; yet they differ in that the existence of the sentence, in itself, doesn’t <italic>affect</italic> anyone in any particular way, while the existence of the experience affects me, the subject in which it occurs, by colouring my state of consciousness in a distinctive way – making it a flowery, fragrant, pleasant state to be in.</p>
        <p>In recent debates on consciousness, a further distinction is sometimes made, following Levine (<xref ref-type="bibr" rid="CR44">2001</xref>) and Kriegel (<xref ref-type="bibr" rid="CR43">2009</xref>),<xref ref-type="fn" rid="Fn1">1</xref> between two dimensions of phenomenality itself. Levine calls them “qualitative character” and “subjectivity”, respectively; Kriegel uses the terms “qualitative character” and “subjective character”, a pair I will prefer for its uniformity. Here is how Levine introduces the two notions:<disp-quote><p>Let’s take my current visual experience as I gaze upon my red diskette case, lying by my side on the computer table. I am having an experience with a complex qualitative character, one component of which is the color I perceive. Let’s dub this aspect of my experience its “reddish” character. There are two important dimensions to my having this reddish experience. First, as mentioned above, there is something it’s like for me to have this experience. […] [B]eing an experience, its being reddish is “for me,” a way it’s like <italic>for me</italic>, in a way that being red is like nothing for—in fact is not in any way “for”—my diskette case. Let’s call this the <italic>subjectivity</italic> of conscious experience. […]</p><p>The second important dimension of experience that requires explanation is qualitative character itself. Subjectivity is the phenomenon of there being something it’s like <italic>for me</italic> to see the red diskette case. Qualitative character concerns the “what” it’s like for me: reddish or greenish, painful or pleasurable, and the like. (Levine <xref ref-type="bibr" rid="CR44">2001</xref>: 7.)</p></disp-quote>
</p>
        <p>To notice the difference between these two dimensions is not to say that they are separable in reality; what is intended, rather, is a conceptual distinction between simultaneously present and interdependent facets of phenomenal consciousness. Within the complete phenomenal character of an experience – what it is like for me to have the experience – we can place the emphasis, and fix our attention, on two different aspects: the qualitative character – <italic>what</italic> it is like for me to have it – and the subjective character – what it is like <italic>for me</italic> to have it.</p>
        <p>In Kriegel’s treatment, this comes out as a difference in levels of generality, or in how fine-grained we make our apprehension of phenomenality. At the most fine-grained end of the spectrum, I can focus on the exquisitely particular way it is like for me when I smell the fur of a wet dog, have pins and needles, or feel a pang of nostalgia. But I can also shift to the opposite end of the spectrum, noticing the general feature, across all of the above experiences, that <italic>there is something or other that it feels like to me</italic>. Whenever I am in a phenomenally conscious state, there is a subjective character to the experience; but depending on what particular experience it is, the subjective character will be specified <italic>as</italic> this or that qualitative character. As Kriegel puts it, subjective character captures what remains <italic>constant</italic> across experiences, while qualitative character captures what <italic>changes</italic>:<disp-quote><p>On the scheme I have adopted, bluish-for-me-ness, reddish-for-me-ness, trumpet-ish-for-me-ness, and so on are all phenomenal characters that are determinates of the determinable something-for-me-ness (or plain for-me-ness for short). One can focus the mind purely on subjective character by considering that which remains invariant among all the different determinates, and on qualitative character by considering that which varies among them. (Kriegel <xref ref-type="bibr" rid="CR43">2009</xref>: 54.)</p></disp-quote>
</p>
        <p>Kriegel thus casts the difference between subjective character and qualitative character as a difference between a <italic>determinable</italic> and its <italic>determinates</italic>.</p>
      </sec>
      <sec id="Sec3">
        <title>Subjective Character by Other Names</title>
        <p>In the literature on phenomenal consciousness, a wide range of alternative terms are used to talk about subjective character. We have already encountered, in the quotes of the previous section, <italic>subjectivity</italic> (Levine <xref ref-type="bibr" rid="CR44">2001</xref>) and <italic>for-me-ness</italic> (Kriegel <xref ref-type="bibr" rid="CR43">2009</xref>); others talk of <italic>me-ishness</italic> (Block <xref ref-type="bibr" rid="CR7">2007</xref>), <italic>me-ness</italic> (Block <xref ref-type="bibr" rid="CR6">1995</xref>), <italic>myness</italic> (Zahavi and Parnas <xref ref-type="bibr" rid="CR77">1998</xref>; Young <xref ref-type="bibr" rid="CR73">2008</xref>), or <italic>mineness</italic> (Zahavi <xref ref-type="bibr" rid="CR74">1999</xref>; Frith <xref ref-type="bibr" rid="CR24">1992</xref>); of a <italic>first-personal character</italic> or <italic>first-personal givenness</italic> of experience (Zahavi and Parnas <xref ref-type="bibr" rid="CR77">1998</xref>); of <italic>non-reflective</italic> or <italic>pre-reflective self-awareness</italic> (Zahavi <xref ref-type="bibr" rid="CR74">1999</xref>, <xref ref-type="bibr" rid="CR75">2005</xref>; Goldman <xref ref-type="bibr" rid="CR29">1970</xref>) or <italic>low-level self-consciousness</italic> (Flanagan <xref ref-type="bibr" rid="CR22">1992</xref>); of <italic>the sense of self</italic> (G. Strawson <xref ref-type="bibr" rid="CR67">1997</xref>; Damasio <xref ref-type="bibr" rid="CR16">1999</xref>) or <italic>sense of ownership</italic> (Zahavi, Gallagher <xref ref-type="bibr" rid="CR26">2004</xref>; Block <xref ref-type="bibr" rid="CR7">2007</xref>) attaching to experiences; and the list goes on. These terms tend to be treated as synonymous. Here is for instance Kriegel (<xref ref-type="bibr" rid="CR42">2006</xref>: 205):<disp-quote><p>Assuming (plausibly) that Block’s notion of <italic>me-ishness</italic> is more or less the same as my notion of <italic>subjective character</italic>, or <italic>for-me-ness</italic> […]. (My emphasis.)</p></disp-quote>
</p>
        <p>And here is the kind of passage from Block that might be taken to support Kriegel’s assumption of synonymy:<disp-quote><p>We may suppose that it is platitudinous that when one has a phenomenally conscious experience, one is in some way aware of having it. […] Sometimes people say Awareness is a matter of having a state whose content is in some sense <italic>‘presented’ to the self</italic> or having a state that is ‘<italic>for me</italic>’ or that comes with <italic>a sense of ownership</italic> or that has ‘<italic>me-ishness</italic>’ […]. (Block <xref ref-type="bibr" rid="CR7">2007</xref>: 484; my emphasis.)</p></disp-quote>
</p>
        <p>In the same spirit, Zahavi and Kriegel (<xref ref-type="bibr" rid="CR76">2015</xref>: 38) write:<disp-quote><p>[…] the point is that each of these objects [of experience], when experienced, is <italic>given to one in a distinctly first-personal way</italic>. […] To deny that such a feature is present in our experiential life, to deny the <italic>for-me-ness</italic> or <italic>mineness</italic> of experience, is to fail to recognize the very <italic>subjectivity</italic> of experience. (My emphasis.)</p></disp-quote>
</p>
        <p>The following characteristic passage from Gallagher and Zahavi (<xref ref-type="bibr" rid="CR27">2005</xref>/2014) uses no less than seven different expressions, treated as broadly equivalent, to capture the subjective character of experience:<disp-quote><p>The notion of <bold>pre-reflective self-awareness</bold> is related to the idea that experiences have a <bold>subjective ‘feel’</bold> to them, a certain (phenomenal) quality of ‘what it is like’ or what it ‘feels’ like to have them. […] [A]s I live through these differences [between various experiences], there is something experiential that is, in some sense, the same, namely, their distinct <bold>first-personal character</bold>. All the experiences are characterized by a quality of <bold><italic>mineness</italic></bold> or <bold><italic>for-me-ness</italic></bold>, the fact that it is <italic>I</italic> who am having these experiences. […]. All of this suggests […] that (phenomenal) consciousness consequently entails <bold>a (minimal) form of self-consciousness</bold>. In short, unless a mental process is <bold>pre-reflectively self-conscious</bold> there will be nothing it is like to undergo the process, and it therefore cannot be a phenomenally conscious process […]. (My bold type; authors’ italics.)</p></disp-quote>
</p>
        <p>However, this terminological luxuriance, I will argue, does not help to delineate the notion at stake precisely. On the contrary, it betrays a certain conceptual blurriness in the discussion. Despite the widespread assumption of a conceptual convergence, the same terms are being used by different authors (and sometimes by the same author in different places) to stand for very different interpretations of the notion of subjective character. Furthermore, this ambiguity amounts to a confusion, which is damaging to a number of current argumentative strategies.</p>
      </sec>
      <sec id="Sec4">
        <title>Goals</title>
        <p>My goal in what follows is threefold: clarificatory, cautionary, and critical. Section <xref rid="Sec5" ref-type="sec">2</xref>, <xref rid="Sec12" ref-type="sec">3</xref> and <xref rid="Sec23" ref-type="sec">4</xref> are devoted to the clarificatory and cautionary parts. I start by showing in Section <xref rid="Sec5" ref-type="sec">2</xref> that ‘subjective character’, and the family of terms widely treated as its synonyms, are used to cover at least three different notions, corresponding to three different ways to think of how the subject features in experience. For convenience, I’ll reserve for each of the three notions one of the expressions currently used indifferently: ‘for-me-ness’, ‘me-ness’, and ‘mineness’.</p>
        <p>In Section <xref rid="Sec12" ref-type="sec">3</xref>, I go on to show that the three notions do not form an equivalence class: they do not stand in relations of mutual <italic>a priori</italic> entailment. In particular, for-me-ness entails neither me-ness nor mineness.</p>
        <p>Section <xref rid="Sec23" ref-type="sec">4</xref> is devoted to an empirically-informed discussion of pathological cases which might be taken to indicate that the corresponding properties do not always occur together. This would suggest that different <italic>properties</italic>, and not just distinct <italic>concepts</italic>, are being conflated in the debate. If this is correct, then my ternary conceptual distinction may open the way for a more accurate description of some pathological forms of experience than coarser-grained frameworks allow. This descriptive gain would provide further support for the threefold distinction.</p>
        <p>Section <xref rid="Sec29" ref-type="sec">5</xref> turns to the critical part. The conflation is problematic not just in principle, but because it makes a difference to existing arguments in the literature. I review four such arguments, and argue that they should be rejected.</p>
      </sec>
    </sec>
    <sec id="Sec5">
      <title>Three Notions</title>
      <sec id="Sec6">
        <title>Subjective Character and the Subject: From For-me-ness to Me-ness and Mineness</title>
        <p>As this section aims to show, actual uses of the expressions listed above – ‘for-me-ness’, ‘me-ishness’, ‘mineness’, ‘first-personal givenness’, etc. – reflect an uncertainty as to what exactly remains constant across experiences.</p>
        <p>One thing seems uncontroversial. The array of terms listed in Section <xref rid="Sec1" ref-type="sec">1</xref> points repeatedly to the subject: “subjective”, “first person”, “self”, “me”, “my”, “mine”, and so on. The suggestion is that the subjective character of experience essentially involves the subject of experience.</p>
        <p>This presumably has to do with the fact that subjective character, as the generic form of phenomenal character, is what characterizes experiences as such (by contrast with other types of representations); and that the existence of experiences in the world is inseparable from the existence of subjects in it. The defining feature of subjects, it is often assumed, is that they are not simply present in the world; the world is <italic>presented to</italic> them. Subjects are <italic>parts</italic> of the world, just like mountains, hurricanes and chairs, but the world also <italic>appears to</italic> them, or is ‘given’ to them, as it does not appear – is not ‘given’ – to mountains or chairs. But to “be appeared to’, for the subject, just is to have experiences, and for those experiences to have a subjective character. The point is often put by saying that a subject’s experiences constitute her ‘point of view’ on the world, and that having such a point of view is what it is to be a subject.</p>
        <p>In short, subjects, experiences, and subjective character, can only be defined in terms of one another. However, this doesn’t tell us what exact form the involvement of the subject should take in the definition of subjective character.</p>
        <p>Clearly, ‘subjective character’ is not merely a label for the <italic>metaphysical fact</italic> that experiences are had by subjects, in the sense that they occur <italic>in</italic> them. It is intended to capture a further, <italic>epistemic fact</italic>, namely that subjects are aware <italic>of</italic> their experiences; and, more demandingly still, a <italic>phenomenological fact</italic>, namely that this awareness is experiential, and registers as a certain “way it feels” to the subject.</p>
        <p>This phenomenological thesis, however, still leaves open a number of ways in which the subject could feature in a description of subjective character. Under the pen of different writers, the subject appears variously:<list list-type="bullet"><list-item><p>as one of the two <italic>relata</italic> in the relation of phenomenal awareness to her experiences, i.e. as the one who is <italic>appeared to</italic>;</p></list-item><list-item><p>as also <italic>appearing</italic> to herself in being aware of the other <italic>relatum</italic> (the experience);</p></list-item><list-item><p>as appearing to herself <italic>as the owner</italic> of the experience.</p></list-item></list>
</p>
        <p>I briefly present the three options below.</p>
      </sec>
      <sec id="Sec7">
        <title>For-me-ness</title>
        <p>To fix ideas, I’ll reserve the expression “for-me-ness” to label the first way in which subjective character is commonly talked about. On this first construal, the object of awareness is the experience itself.</p>
        <sec id="Sec8">
          <title>A Special Awareness of Experiences</title>
          <p>The notion can be introduced by observing that an experience has a manner of being unlike that of other types of things. This is partly because there is someone – a subject – to whom the experience is present in a special way, for whom there is something it is like for that experience to exist at all. And no one else is affected in the same way by the existence of that particular experience. The experience is in this sense <italic>given to</italic> someone; it is <italic>for</italic> that someone, to the exclusion of anyone else. Which amounts to saying that there is someone for whom the experience, by virtue of its mere existence and so long as it exists, is an object of a special sort of awareness:<disp-quote><p>a mental state has subjective character just in case it is for the subject, in the sense that the subject has a certain awareness of <italic>it</italic>. (Kriegel <xref ref-type="bibr" rid="CR43">2009</xref>: 38, my emphasis)</p></disp-quote>
</p>
          <p>If I am feeling hungry or elated, you, too, can be aware of my hunger or elation, but not merely <italic>by virtue</italic> of the experience’s existence. Moreover, my own awareness of my experience is a way the experience <italic>affects</italic> me; it is a <italic>phenomenal</italic> kind of awareness. Not so with your awareness of my experience. You can’t grasp it “from the inside” (although you can of course have a – distinct – experience of the same type).</p>
          <p>The familiar observations above suggest that, on this first interpretation, subjective character is simply another name for phenomenal consciousness, considered generically and under the most neutral description. As Kriegel puts it: “a conscious experience’s qualitative character makes it the conscious experience it is [e.g. a blueish or sweetish experience], while <italic>its subjective character makes it a conscious experience at all</italic>.”<xref ref-type="fn" rid="Fn2">2</xref>
</p>
        </sec>
        <sec id="Sec9">
          <title>The “State-Self-Awareness” View</title>
          <p>In this first reading of subjective character, what is at issue is the <italic>subject</italic>’s special awareness of her experience. However, according to several authors, the most plausible way in which this could obtain is through that <italic>experience</italic>’s awareness <italic>of itself</italic>. Whenever we are aware of something (a wet dog, a bird’s song, a flower’s fragrance), this is because a mental state of ours has that thing as its object. So, the reasoning goes, in the case where what we are aware of is our mental state itself, the same must be true, and the mental state must have <italic>itself</italic> as its object.<xref ref-type="fn" rid="Fn3">3</xref> The fact that a mental state is ‘for-me’ would thus be understood in terms of the state having an “inner awareness”, turned towards itself, in addition to constituting the subject’s awareness of something else, i.e. that which the experience is an experience of (the dog, the song, the fragrance, etc.).</p>
          <p>Let us call the “<italic>state-self-awareness view</italic>” the view that subjective character, construed as the property which experiences have of being “for me”, is constituted by an awareness those experiences have of themselves.<xref ref-type="fn" rid="Fn4">4</xref> This thesis has different variants. The relevant kind of awareness is variously considered as a form of <italic>representation</italic> (Kriegel <xref ref-type="bibr" rid="CR43">2009</xref>); as a form of <italic>acquaintance</italic> (Williford <xref ref-type="bibr" rid="CR71">2015</xref>); or as a more elusive, <italic>sui generis</italic> “<italic>intrinsic glow</italic>”<xref ref-type="fn" rid="Fn5">5</xref> that makes the state aware of itself without the need for it to dissociate itself in an act-object structure (Husserl <xref ref-type="bibr" rid="CR35">1928</xref>/1964, Zahavi <xref ref-type="bibr" rid="CR74">1999</xref>; Drummond <xref ref-type="bibr" rid="CR20">2006</xref>). These differences, however, are immaterial to what follows. I will remain entirely neutral as to whether the state-self-awareness view in general, or in any of its variants, is true. I introduce the view here because it will play a role in the discussion in Section <xref rid="Sec17" ref-type="sec">3.5</xref>. What will matter then is the general claim that a state is “for-me” in so far as it is aware of itself.</p>
          <p>To summarise this sub-section, subjective character construed as ‘for-me-ness’ is the special awareness a subject, and she alone, has of her own experience just by virtue of having it. State-self-awareness theorists believe this is the result of the experience being aware of itself. However this might be, though, what matters is that on the “for-me-ness” interpretation of subjective character, the object-side of the relation of awareness is taken up <italic>by the experience</italic>. The subject, for her part, features only on the “recipient” side of the relation of givenness that gives her access to her experience. Her place is reversed in the second construal, where she (also) features as the object of awareness.</p>
        </sec>
      </sec>
      <sec id="Sec10">
        <title>Me-ness</title>
        <p>A second construal of subjective character places the focus of awareness on the subject herself, rather than (just) her experience. According to a widespread view, what makes an experience special for its subject is the fact that, in living through it, the subject is somehow aware <italic>of herself</italic>. Enjoying phenomenal consciousness is a way to be phenomenally <italic>self</italic>-conscious. I’ll reserve the expression “me-ness” as a label for this second interpretation.</p>
        <p>The more general idea that consciousness involves self-consciousness on the part of the subject has a long history. Descartes, whose term for a conscious mental state is “thought”,<xref ref-type="fn" rid="Fn6">6</xref> argues in the <italic>Second Meditation</italic> that any thought necessarily entails a knowledge of myself. What is more, as he insists in the discussion of the <italic>Seventh Objections</italic> to his <italic>Meditations</italic>, this self-knowledge resides <italic>in</italic> the original conscious state:<disp-quote><p>[T]he initial thought by means of which we become aware of something does not differ from the second thought by means of which we become aware that we were aware of it, any more than this second thought differs from the third thought by means of which we become aware that we were aware that we were aware. (1996, vol. VII, p. 559)</p></disp-quote>
</p>
        <p>Thus, it is at least arguable that for Descartes self-consciousness is a <italic>constitutive</italic> aspect of consciousness. This also may have been the view of Locke, according to whom it is “impossible for anyone to perceive, without perceiving, that <italic>he</italic> does perceive” (<italic>Essay</italic>, 2.27.9; my emphasis).</p>
        <p>The idea of a constitutive link between consciousness and self-consciousness lives on in the works of Kant, Fichte, and Husserl. It is worth noting that neither Kant nor Fichte primarily envisaged a specifically <italic>phenomenal</italic> form of self-consciousness. The chief form of self-consciousness of interest to Kant, what he calls “transcendental apperception”, resides in a formal feature, “the form of the ‘I think’, that structures all experience without being an object of experience. Fichte for his part talks of an “intellectual intuition” of the “I”. Husserl, on the other hand, is a closer forebear to the contemporary notion of subjective character interpreted as “me-ness”. For Husserl, the “transcendental self” is directly given in experience: “I exist for myself and am constantly given to myself, by experiential evidence, as ‘I myself.’ […] [I]t is true, moreover, with respect to any sense of the word ego.” (<xref ref-type="bibr" rid="CR36">1931</xref>/1960, Sec. 33).</p>
        <p>This prefigures<xref ref-type="fn" rid="Fn7">7</xref> the claim, frequently found in the contemporary literature on subjective character, that when phenomenally conscious of anything, the subject is also phenomenally conscious of herself. In Zahavi’s words:<disp-quote><p>[…] phenomenal consciousness must be interpreted precisely as entailing a minimal or thin form of self-awareness. (Zahavi <xref ref-type="bibr" rid="CR75">2005</xref>: 16)</p><p>[…] if a certain organism is in possession of phenomenal consciousness, then it must also be in possession of both a primitive form of self-consciousness and a core self. (<italic>Ibid</italic>., 235–6).</p></disp-quote>
</p>
        <p>Similar claims are found in Frankfurt (<xref ref-type="bibr" rid="CR23">1988</xref>: 162); Flanagan (<xref ref-type="bibr" rid="CR22">1992</xref>), Block (<xref ref-type="bibr" rid="CR6">1995</xref>, <xref ref-type="bibr" rid="CR7">2007</xref>); Chalmers (<xref ref-type="bibr" rid="CR13">1996</xref>); Siewert (<xref ref-type="bibr" rid="CR62">1998</xref>); Burge (<xref ref-type="bibr" rid="CR10">1998</xref>: 248), among many others.</p>
        <p>The need for a distinction between for-me-ness and a second dimension of subjective character has been noted before. Neisser (<xref ref-type="bibr" rid="CR52">2014</xref>), for instance, distinguishes “inner awareness” from “subjectivity”, arguing that “subjectivity is not best understood as inner awareness”.<xref ref-type="fn" rid="Fn8">8</xref> Drummond (<xref ref-type="bibr" rid="CR20">2006</xref>: 199–200) and Sebastian (<xref ref-type="bibr" rid="CR58">2012</xref>) make related distinctions. The binary distinction made in these works (and others) is a valuable one. However, it often consists in separating something like “for-me-ness” from a more “personal” dimension of subjective character which, I believe, still stands in need of further analysis. As I argue below, a finer, ternary distinction is required to pinpoint the confusion pervading the current debate, and to make an accurate description of a range of clinical cases.</p>
      </sec>
      <sec id="Sec11">
        <title>Mineness</title>
        <p>A third common way of glossing subjective character presents it as a phenomenal awareness that my experiences are <italic>mine</italic>. I’ll reserve the term “mineness” for this third interpretation.</p>
        <p>Everyone agrees that subjective character has to do with the fact that the existence of an experience resonates in a particular way with the subject in whom it occurs. While, on the first prominent way of discussing subjective character (as for-me-ness), it corresponds to the fact that the subject is aware <italic>of her experience</italic> (in a special way), on the third interpretation, it corresponds to the subject’s awareness of that very <italic>fact</italic>. As part of the experience being given to a subject, this subject is somehow aware of the experience <italic>being her own</italic>; i.e., of its being an object, for her, of that special sort of awareness we sometimes call “ownership”, or, to use the proprietary term, “for-me-ness”.</p>
        <p>This interpretation of subjective character is more complex than the other two considered so far. It involves, in the subject of experience, (i) an awareness of the experience (as with for-me-ness); (ii) an awareness of herself (as with me-ness); and (iii) an awareness of the <italic>relation</italic> (of ownership, or for-me-ness) between the two.</p>
        <p>The belief that the way an experience is “given” or “presented” to the subject marks, phenomenally, the experience as <italic>hers</italic> goes back at least to William James:<disp-quote><p>[T]houghts […] do not fly about loose, but <italic>seem</italic> each to belong to someone thinker and not to another. Each thought, out of a multitude of other thoughts of which it may think, is able to distinguish those which belong to its own Ego from those which do not. (James <xref ref-type="bibr" rid="CR37">1890</xref>, Chap. 10, 331 sq. My emphasis.)</p></disp-quote>
</p>
        <p>In the recent debate, a similar idea is endorsed by Zahavi<xref ref-type="fn" rid="Fn9">9</xref>:<disp-quote><p>One commonality [between different experiences] is the quality of mineness, the fact that experiences are characterized by first-personal givenness. That is, the experience is given (at least tacitly) as <italic>my</italic> experience, as an experience I am undergoing or living through […]. (Zahavi <xref ref-type="bibr" rid="CR75">2005</xref>: 16. My emphasis.)</p></disp-quote>
</p>
        <p>Block (<xref ref-type="bibr" rid="CR6">1995</xref>, 4.2.1) argues that animals lacking a concept of self, like dogs, still have a “self-orientation”, because their experiences are phenomenally presented as <italic>theirs</italic>:<disp-quote><p>Even if monkeys and dogs have no [conceptualised] self-consciousness, however, no one should deny that they have P[henomenally] conscious pains […]. P[henomenally] conscious states often seem to have a “me-ishness” about them, the phenomenal state often represents the state as “<italic>a state of me</italic>”. (Block <xref ref-type="bibr" rid="CR6">1995</xref>: 235. My emphasis.)</p></disp-quote>
</p>
        <p>To sum up: construed as “for-me-ness”, subjective character is a subject’s characteristic awareness <italic>of her experience</italic>; read as “me-ness”, it is her awareness <italic>of herself,</italic> gained as part of having the experience; understood as “mineness”, it is her awareness of herself <italic>as</italic> having the experience.</p>
      </sec>
    </sec>
    <sec id="Sec12">
      <title>That the Three Concepts are not Equivalent</title>
      <p>There is a clear <italic>prima facie</italic> distinction between the three notions: it is intuitively different to talk of an awareness of an experience, of an awareness of the experiencer, or of an awareness of the experiencer as owner of the experience.</p>
      <sec id="Sec13">
        <title>Formal Differences</title>
        <p>Notice, moreover, the contrast in the form<xref ref-type="fn" rid="Fn10">10</xref> of the three predicates. The common talk of ‘subjective character’ as a “quality” or “feature” our experiences <italic>have</italic> or <italic>come with</italic> suggests a monadic predicate, of the form F(<italic>x</italic>) (where ‘<italic>x</italic>’ ranges over experiences). Understood as for-me-ness, however, subjective character would seem instead to assume the form of a <italic>relation</italic>: a relation R<sub>1</sub> of awareness between a subject <italic>s</italic> and an experience <italic>x</italic> of hers, of the form R<sub>1</sub>(<italic>s,x</italic>). Understood as me-ness, subjective character appears to correspond to a relation R<sub>2</sub> of a different form, R<sub>2</sub>(<italic>s,s</italic>): namely, a reflexive relation of awareness a subject <italic>s</italic> has to herself (while having an experience). Lastly, understood as mineness, subjective character should correspond to a different relation again, R<sub>3</sub>. Here we should expect a relation of higher complexity than the previous two, since it is a relation of awareness between subject <italic>s</italic> and a <italic>fact</italic>, i.e. the fact that she owns the experience she is contemplating. This might be spelled out as R<sub>3</sub>(<italic>s</italic>,[R<sub>1</sub>(<italic>s,x</italic>)]), i.e. as a relation R<sub>3</sub> of awareness between a subject and the fact of ownership (the fact that experience <italic>x</italic> is “for her”). Clearly, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> have very different structures, and this in itself should make us wary of collapsing the three notions into one.</p>
        <p>What I want to argue now is that, in addition, the three notions are not conceptually equivalent, since they do not stand in relations of mutual implication.</p>
      </sec>
      <sec id="Sec14">
        <title>Mineness and its Implications</title>
        <p>It might seem that mineness, at least, should entail both me-ness and for-me-ness, in virtue of its more complex structure. As noted above, to become phenomenally aware of myself as the owner of a given experience, I need the more basic awareness of myself and of the experience. This could be, however, a slightly misleading way to speak, and much depends on what we mean here by “awareness”, i.e. whether or not we give it the narrower sense of a <italic>phenomenally</italic> conscious awareness.</p>
        <p>Take a different kind of complex phenomenal state, like the visual impression of a piano. To achieve the three-dimensional awareness of the piano, I certainly need more basic one-dimensional information about lines, two-dimensional information about surfaces, and “two-and-a-half dimensional” information (Marr <xref ref-type="bibr" rid="CR45">1982</xref>) corresponding to the projection of the volume on the flat surface of the retina. But does this entail that, in being phenomenally aware of the piano as having depth and volume, I am also <italic>phenomenally</italic> aware of it as a two-dimensional, let alone a 2.5-dimensional object? That the one-, two- and 2.5-dimensional information is necessary to construct the phenomenally conscious, visual awareness of the piano occupying space doesn’t mean that this information itself is presented in a phenomenal format, as the final output is. And it is indeed quite unclear whether one can shift the focus of one’s attention, within the total visual impression of the piano, between, say, a 3-D, a 2.5-D and a 2-D appearance, as one can shift attention between the whitish and the blackish components in one’s impression of the keyboard. That we can do the first kind of shift is doubtful, even though we <italic>can</italic> perfectly well, in other contexts, have a 2-D phenomenal awareness of a piano (e.g., by looking at a drawing of the instrument). The complexity of a phenomenal datum does not always entail the <italic>phenomenal</italic> accessibility of each of its components. Thus, even if <italic>some form or other</italic> of awareness of the experience, and of myself, is a necessary condition for the <italic>phenomenal</italic> awareness of myself as owner of the experience (mineness), it doesn’t follow that an <italic>a priori</italic> relation of implication holds from mineness to for-me-ness (a <italic>phenomenal</italic> awareness of the experience) and me-ness (a <italic>phenomenal</italic> awareness of the experiencer).</p>
      </sec>
      <sec id="Sec15">
        <title>Me-ness and its Implications</title>
        <p>It is much more doubtful still, in any case, that any other relations of entailment unite the three notions. Let us consider me-ness. I described it above as the putative phenomenal awareness of myself that I gain in having an experience. Does this not involve, at the very least, an awareness of the experience itself, i.e. for-me-ness?</p>
        <p>A certain kind of transparency argument might make room for questioning this transition. Some<xref ref-type="fn" rid="Fn11">11</xref> writers suggest that when I am asked what it is like, exactly, for me (to smell a wet dog, to hear the song of the swifts), I must attend, in answering, to the same outward objects and properties as I would attend to if I were asked a question about dogs, or birds. This would suggest that what is “given to me” or “for me” in an experience is not the experience itself, but the worldly objects and properties that it represents. Thus Martin (<xref ref-type="bibr" rid="CR46">2002</xref>) on staring at a lavender bush:<disp-quote><p>When my attention is directed out at the world, the lavender bush and its features occupy centre stage. It is also notable that when my attention is turned inwards instead to my experience, the bush is not instead replaced by some other entity belonging to the inner realm of the mind […]. I attend to what it is like for me to inspect the lavender bush through perceptually attending to the bush itself while at the same time reflecting on what I am doing. So it does not seem to me as if there is any object apart from the bush for me to be attending to or reflecting on while doing this. (Martin <xref ref-type="bibr" rid="CR46">2002</xref>: 380–1.)</p></disp-quote>
</p>
        <p>Such a “transparentist” view – considered here merely for the sake of argument –might be compatible with a conception of subjective character as me-ness in which the latter does not entail any direct phenomenal awareness of the experience itself. Take my total experience as I play the piano. I am aware of the piano in front of me, and of the unfolding tune; and, even though this is not the focus of the experience, I am also continually aware of myself (my fingers on the keys, my feet on the pedals, my breathing, the contraction of my muscles). The transparentist could accept that I am thus presented with myself throughout, that there is in this sense a “me-ness” to the experience; she could even entertain the possibility that this might be the case whenever I experience; but she would at the same time deny that there is also a way in which I am presented with the experience itself. This is not conceptually incoherent. Accordingly, it is at least open to question whether the notion of me-ness (simply construed as the phenomenal awareness of myself that I gain through an experience) entails the notion of for-me-ness.</p>
        <p>It is even more doubtful whether me-ness entails mineness. This would require a phenomenal awareness, both of myself and of my experience, and we have just seen that the latter part might not be secured <italic>a priori</italic> by the notion of me-ness. But it would also require something further, namely a phenomenal awareness of the <italic>relation</italic> of ownership between my experience and myself. Even granting that experience provides phenomenal access to both the subject and the experience itself, there is no <italic>a priori</italic> reason why it should also provide phenomenal access to the fact that the latter stands in a special relation to the former. In fact, in some extreme situations, like the pathological phenomenon of “inserted thought” in shizophrenics, there might be reason to think that phenomenal awareness of just such a relation is missing – more about this in Section <xref rid="Sec23" ref-type="sec">4</xref>.</p>
        <p>If it is at least open to question whether either me-ness, or mineness, entail any of the other two notions (insofar as hypotheses under which the entailments don’t hold are not obviously incoherent), then there is in any case no <italic>straightforward</italic> implication to rely on. The transition from me-ness or mineness to the other notions should thus not be made without argument, as it so often is.</p>
      </sec>
      <sec id="Sec16">
        <title>For-me-ness and its Implications</title>
        <p>More decisive than those doubts concerning the implications of mineness and me-ness, however, is the lack of any reason to think that the notion of for-me-ness should entail either me-ness or mineness. (Absent, that is, very substantial theoretical assumptions; more on this in Section <xref rid="Sec17" ref-type="sec">3.5</xref>.)</p>
        <p>For-me-ness is a certain kind of awareness relation, connecting the subject to her experience, and perhaps, more primitively, the experience to itself (if the state-self-awareness thesis is correct). What matters is that in either case, only the <italic>relatum</italic> that isn’t the subject of the awareness figures as the <italic>object</italic> of awareness. The notion of an awareness of an experience will not, as such, yield the notion of an awareness of the self. The experience and the self are distinct particulars.<xref ref-type="fn" rid="Fn12">12</xref> And it is not generally the case that, when we say that something is “for me”, is given to me, we mean that I am aware of that thing <italic>and also</italic> of myself. Take the conscious perception of a table. When we say that this is a way that the table is given to me, we mean to talk about an awareness that has the <italic>table</italic> as its object. Without further assumptions being built into the notion of for-me-ness, i.e. without going beyond the terms in which it is usually introduced – as an awareness of a certain kind <italic>of our experiences</italic> – we shouldn’t accept that what goes for tables doesn’t go for experiences. When a situation is described as one in which things are “for me”, what is asserted is that I’m aware <italic>of those things</italic> (and not, <italic>eo ipso</italic>, of myself). I am <italic>in</italic> an awareness relation to those things; but this is not the same as being aware <italic>of</italic> the relation itself, or of the fact that it obtains. This relation of awareness as such doesn’t make me aware of both <italic>relata</italic>, but only of the <italic>relatum</italic> that isn’t me.</p>
        <p>In the “for-me-ness” construal of subjective character, then, the self, to borrow an evocative expression often used by Zahavi and Drummond, is a mere “dative” of the experience. Only in the “me-ness” and perhaps in the “mineness” readings is it (also) involved in the “accusative” position, as an object of phenomenal awareness. To move from the dative to the accusative is to shift to a different notion. Kenneth Williford makes the point eloquently<xref ref-type="fn" rid="Fn13">13</xref>:<disp-quote><p>If we accept that there is a dative of manifestation, that objects and qualities appear <italic>to</italic> someone or something, we are closer to but not quite up to subjective character just yet. Subjective character, recall, is supposed to be something phenomenologically detectable. And one might raise the following sort of worry. Suppose phenomenally manifest objects and properties are manifest <italic>to</italic> something or someone. It does not follow from this alone that that <italic>to which</italic> they are manifest is itself manifest or even manifestable. Nor does it follow that the <italic>fact that</italic> they are manifest to something is manifest or even manifestable. In other words, there could indeed be a dative of manifestation and yet no direct phenomenological evidence of this at all. Williford (<xref ref-type="bibr" rid="CR71">2015</xref>: 9/27)</p></disp-quote>
</p>
        <p>Now, one might object to the foregoing by insisting that for something to be “given to me” or “for me” isn’t just for me to be enjoying just <italic>any</italic> kind of awareness of it. It’s a matter of being <italic>phenomenally conscious</italic> of that thing; of it being <italic>presented</italic> to me, <italic>manifest</italic> to me – in short, of my <italic>experiencing</italic> it. And one might think that <italic>this</italic> kind of awareness relation, unlike others, does involve being aware of both <italic>relata</italic>.</p>
        <p>To which I would reply that, while this might well be true, it is a substantive claim, and something for which evidence should be produced, rather than an immediate conceptual truth flowing from the notion of for-me-ness, which one could take for granted. The notion of “for-me-ness” that we started with, the pre-theoretical notion that is introduced through the familiar point that a subject is aware of her present experience in a way that others are not, doesn’t by itself yield any suggestion that part of what makes this “way of being aware” special is that it encompasses all of the subject of awareness, the object of her awareness and their relation within its reach. Nor does it follow from the grammar of such expressions as something being “given to <italic>x</italic>” or “for <italic>x</italic>” that <italic>x</italic> should at the same time be given to herself. I also doubt that such implications could be drawn from a mere conceptual analysis of the notion of “experience”, defined as a state there is something it is like to be in for its subject.<xref ref-type="fn" rid="Fn14">14</xref> Unless some non-trivial theoretical preferences are added to the notion of for-me-ness, then, there is no justification for using it interchangeably with the notions of me-ness and mineness, as is too often done without argument.</p>
      </sec>
      <sec id="Sec17">
        <title>For-me-ness and its Implications on (Some) State-Self-Awareness Views</title>
        <p>What kind of further theoretical commitments could conceivably license the transition from for-me-ness to me-ness and mineness?</p>
        <sec id="Sec18">
          <title>Maximalism About For-me-ness</title>
          <p>Perhaps an example could be found in a possible variant of the state-self-awareness view, sketched above in Section <xref rid="Sec7" ref-type="sec">2.2</xref>. According to the state-self-awareness view, the for-me-ness of an experience (that I am aware of it in a special way) is a result of its being, more primitively, aware of itself. This is the view that Kriegel (<xref ref-type="bibr" rid="CR43">2009</xref>), Williford (<xref ref-type="bibr" rid="CR71">2015</xref>) and Zahavi (<xref ref-type="bibr" rid="CR75">2005</xref>) defend under various specifications, as we have seen. One <italic>could</italic> conceivably interpret the claim common to all those variants – that a state that is “for me” is a state that is aware of itself – in a maximalist way, as meaning that such a state is aware of <italic>all</italic> of its properties, including the relational property of being an experience of this or that subject. However, this would not be a particularly attractive theory to defend; phenomenal awareness is not, in general, an awareness of all the properties of its objects, including their relational properties. (The visual awareness of a chair does not include an awareness of its relational property of having been made by a particular carpenter, or of being comfortable for me.) To my knowledge, none of the advocates of the state-self-awareness view endorses this extreme version.<xref ref-type="fn" rid="Fn15">15</xref> In any case, were one to defend such a maximalist version of the state-self-awareness view, this would constitute a substantive step beyond the mere use of the notion of for-me-ness, and it would be very different from assuming a conceptual equivalence between the three notions of subjective character.</p>
        </sec>
        <sec id="Sec19">
          <title>Minimalism About the Self</title>
          <p>Another example of a non-trivial assumption under which for-me-ness might entail at least me-ness is to be found in the “minimalist” approach to the self.<xref ref-type="fn" rid="Fn16">16</xref> A family of writers, including Zahavi (<xref ref-type="bibr" rid="CR75">2005</xref>) and Williford (<xref ref-type="bibr" rid="CR71">2015</xref>), argue that the self, or at least <italic>a</italic> form of selfhood (the “minimal self” or “core self”), is identical either with experience, or with some part or intrinsic property of experience.<xref ref-type="fn" rid="Fn17">17</xref> Williford (<xref ref-type="bibr" rid="CR71">2015</xref>: 2/27) thus proposes that “we identify the subject with the episode or stream of consciousness itself”. Zahavi claims that the subject or self is identical with a <italic>feature</italic> of experience, namely its “givenness”:<disp-quote><p>[…] the self is […] identified with the very first-personal <italic>givenness</italic> of the experiential phenomena. […][T]he most basic form of selfhood is the one constituted by the very self-manifestation of experience […]. Thus, the self referred to is not something standing beyond or opposed to the stream of experiences but is rather a feature or function of its givenness. (Zahavi <xref ref-type="bibr" rid="CR75">2005</xref>: 106)</p></disp-quote>
</p>
          <p>Now, on such views, it could be argued that for-me-ness <italic>does</italic> entail me-ness: if the self <italic>is</italic> the experience (or a part or intrinsic feature thereof), then to be phenomenally aware of the experience (for-me-ness) is to be phenomenally aware of the self (me-ness). Indeed, this is just the way Williford (<xref ref-type="bibr" rid="CR71">2015</xref>) seeks to bridge the gap between for-me-ness and me-ness he so lucidly identifies in the passage quoted above.<xref ref-type="fn" rid="Fn18">18</xref>
<xref ref-type="fn" rid="Fn19">19</xref>
</p>
          <p>However, the entailment between for-me-ness and me-ness, in this context, does not flow from a conceptual equivalence between the two notions, but from the additional support of a substantive extra premise. Namely, that the self is identical with (all or part of) the experience. This is in no way included in the notions of for-me-ness and me-ness, which merely stand for special relations of awareness between the subject and her experience, and between the subject and herself, respectively. No further commitment about the metaphysics of subjects is built into those concepts. And the minimalist thesis about the self is very far from trivial. According to common sense, and in ordinary linguistic practice, I <italic>have</italic> experiences (“I had a really bad experience with her last night”); it can be the case that I <italic>had</italic> an experience an hour or a year ago, now gone (“Visiting Venice was a wonderful experience”). This is incompatible with my <italic>being identical with</italic> the experience. The minimalist view isn’t uncontroversial in the context of philosophical thinking either. It competes, at the very least, with views according to which the self is a mental substance, a substratum <italic>of</italic> experiences (Descartes); an animal with both physical and mental properties (Olson, Snowdon); a spatial part of an animal, typically a brain or part of a brain (Parfit); a causal system that can produce experiences (Dainton, Peacocke); and so on and so forth. Thus, while the minimalist view of the self is a framework in which for-me-ness arguably entails me-ness, the entailment isn’t a matter of conceptual equivalence between those two notions, but depends on substantive extra premises in need of independent argument.</p>
          <p>This last point will have some importance for the critical discussion in Section <xref rid="Sec29" ref-type="sec">5</xref> below. Again, even on a minimalist approach, the implication from for-me-ness to me-ness depends on the minimalist view of the self being independently proved true. To be allowed to draw the implication, we need a separate defence of the thin metaphysics of selfhood. Instead of which, minimalists typically <italic>assume</italic> that the implication from for-me-ness to me-ness holds, because they often use an undifferentiated notion of subjective character to cover both aspects,<xref ref-type="fn" rid="Fn20">20</xref> and then go on to rely on the alleged conceptual connection to defend a thin theory of the self. This is getting it backwards, and the move is unwarranted.<xref ref-type="fn" rid="Fn21">21</xref>
</p>
        </sec>
      </sec>
      <sec id="Sec20">
        <title>A Tentative Diagnosis for the Assumption of a Conceptual Equivalence</title>
        <p>For-me-ness, me-ness and mineness, then, do not form an equivalence class of notions. Whether mineness entails either for-me-ness or me-ness, or whether me-ness entails either for-me-ness or mineness, is at the very least open to question. In any case, it is clear that for-me-ness entails neither me-ness nor mineness, which is enough to defeat the assumption of mutual equivalence.</p>
        <sec id="Sec21">
          <title>The Connotations of “Self-Awareness”</title>
          <p>A number of considerations might help explain why this should be sometimes overlooked. One possible reason could be the ambiguity of the word “self”, which, as a reflexive pronoun, can stand for any reflexive relation, but which, as a noun, stands for a certain kind of particular: a subject. “Self-awareness” can thus mean the awareness that some particular (say an experience) has of itself, or, more specifically, the awareness that a <italic>self</italic> has of herself. But slips might occur between the two notions, encouraging, particularly under the assumption that for-me-ness is a matter of state-self-awareness, an unwarranted transition from for-me-ness to me-ness. The passage from Gallagher and Zahavi (<xref ref-type="bibr" rid="CR27">2005</xref>/2014) already quoted above could well be an illustration of this, or is, more likely, at least guilty of a form of expression that invites the confusion, as it goes in the same breath from a “self-consciousness” understood as a “non-observational access to <italic>myself</italic>”, to a “<italic>mental state</italic>” being “self-conscious”<xref ref-type="fn" rid="Fn22">22</xref>:<disp-quote><p>All the experiences are characterized by a quality of <italic>mineness</italic> or <italic>for-me-ness</italic>, the fact that it is <italic>I</italic> who am having these experiences. All the experiences are given (at least tacitly) as <italic>my</italic> experiences, as experiences <italic>I</italic> am undergoing or living through. All of this suggests that first-person experience presents me with <bold>an immediate and non-observational access to myself</bold>, and that (phenomenal) consciousness consequently entails a (minimal) form of <bold>self-consciousness</bold>. In short, unless <bold>a mental process is pre-reflectively self-conscious</bold> there will be nothing it is like to undergo the process, and it therefore cannot be a phenomenally conscious process […]. (My bold type.)</p></disp-quote>
</p>
        </sec>
        <sec id="Sec22">
          <title>The Connotations of “First-Personal Access”</title>
          <p>Another likely influence is the frequent use in the debate of the notion of a “first-person” access to, or perspective upon, or knowledge of, our own experiences, to capture their for-me-ness. The “first-person” qualifier just means that the subject has the exclusive enjoyment of this type of access, perspective, or knowledge; not that she is their object. By contrast, a “third-person” access, perspective or kind of knowledge are ones that are equally available to all thinkers. The asymmetry between first-person and third-person epistemic relations isn’t defined by what occupies the object side of the relation, but by the constraints on those – just me, or anyone – who can be on the recipient side. And while the self is certainly a salient candidate for being a possible object of first-personal access, not all first-person access is directed to the self; occurrent experience constitutes another such object. Still, the ambiguity in the surface-grammar of the expression “first-person perspective” – a perspective <italic>of</italic> the first person, or <italic>on</italic> the first person? – encourages reading off the notion more than it contains.</p>
          <p>An interesting passage from Kriegel (<xref ref-type="bibr" rid="CR41">2004</xref>) could constitute an illustration of this. Kriegel (<xref ref-type="bibr" rid="CR41">2004</xref>, Section 4) defends the claim that intransitive consciousness depends on intransitive self-consciousness (i.e., on a peripheral consciousness the subject has of herself). In effect, this amounts to the claim that there can be no for-me-ness (the type of awareness of experiences that makes them conscious at all) without me-ness. The first of his two arguments,<xref ref-type="fn" rid="Fn23">23</xref> says Kriegel,<disp-quote><p>[…] can be summarized as follows: conscious states are first-person knowable; first-person knowable mental states must be intransitively self-conscious; therefore, conscious states are intransitively self-conscious. (<xref ref-type="bibr" rid="CR41">2004</xref>: 198)</p></disp-quote>
</p>
          <p>The decisive premise is the second one: that first-person knowable mental states must be states in which the self is intransitively (i.e. peripherally) conscious of herself. And this is just where the connotations of the “first-person” qualifier might be playing a role. Here is the argument Kriegel gives to establish the second premise:<disp-quote><p>Now, it seems that the only experiences and thoughts we can have first-person knowledge of are experiences and thoughts we have self-consciously, that is, experiences and thoughts we are peripherally aware of <italic>having</italic>. For when we have a mental state un-self-consciously – <italic>that is, without any awareness of it whatsoever</italic> – we have to infer its existence on the basis of evidence, which means that our knowledge of it is mediated in a way first-person knowledge is not. (<xref ref-type="bibr" rid="CR41">2004</xref>: 198. My emphasis.)</p></disp-quote>
</p>
          <p>Here is why I think the argument is problematic. The first sentence is a reformulation of the second premise: <italic>one can’t have first-person knowledge of a state without being aware of having it</italic>. In other words: given a mental state of which I know, if I have first-person knowledge of it, then I am aware of the fact that <italic>I</italic> am having it. This is then defended in the second sentence <italic>via</italic> an appeal to the intuitiveness of its contraposition, i.e. the proposition that, given a mental state of which I know, if I don’t have this knowledge in a way that involves self-consciousness on my part, then I don’t have first-person knowledge of it (but only evidence-based, third-person knowledge). But notice the gloss of the antecedent of this contraposition, inserted between the dashes (and italicised by me) in the quote above: not having knowledge of a mental state in a way that involves self-consciousness is suddenly equated to being “without any awareness of it whatsoever”. This is clearly <italic>not</italic> an equivalence that can be taken for granted, as it constitutes precisely what is at issue here, i.e. whether I can be phenomenally aware of my mental state without also being aware of myself. Once we accept the equivalence, the argument goes through, because a state of which I am not phenomenally aware is indeed a state I can only know about third-personally; but we shouldn’t accept it, because it’s question-begging.</p>
          <p>So why is the equivalence put forward? I think it might inherit undue intuitive appeal from the connotations of two of the expressions used in the argument. First, knowing the experience in a way that involves being self-conscious is rephrased in the first sentence of the passage as <italic>being aware of having</italic> it. The surface grammar of the latter form of words might invite an equivocation. The most natural, and correct, way to read the infinitive clause is with an implicit subject or “PRO” argument (Higginbotham <xref ref-type="bibr" rid="CR33">2003</xref>), i.e. as “being aware of <italic>my</italic> having it”, which does express self-consciousness. However, because the subject is elided, the turn of phrase surreptitiously makes available another, weaker reading, namely, “being aware of the state being had”, i.e. being aware of its occurring. That a state I am not aware is being had (or is occurring) is not a state I am (phenomenally) aware of is trivially true; but that a state I am not aware of in a way that involves self-consciousness is a state I am not aware is being had at all is, on the other hand, a substantive claim: precisely the claim that the argument seeks to establish, and precisely the claim, too, that the problematic equivalence between the dashes smuggles in, possibly under the influence of the ambiguity in the expression “being aware of having it”.</p>
          <p>Second, as pointed out above, the expression “first-person knowledge”, while really standing for the kind of knowledge only the subject is in a position to gain, has the potential to mislead, suggesting simultaneously that the subject is what the knowledge is <italic>of</italic>. Under this – unwarranted – suggestion, the claim that a subject who isn’t self-conscious as part of having an experience is unable to know the experience first-personally gains an unearned appearance of intuitiveness.<xref ref-type="fn" rid="Fn24">24</xref>
</p>
        </sec>
      </sec>
    </sec>
    <sec id="Sec23">
      <title>Different Concepts, or Different Properties?</title>
      <p>The upshot of the previous section is that there is no mutual equivalence between the three notions really being conflated in debates on subjective character. At best, mineness might entail both for-me-ness and me-ness, but not as straightforwardly as it might initially seem. For-me-ness and me-ness are likely to be mutually independent, and neither depends on mineness. For-me-ness certainly entails neither me-ness nor mineness.</p>
      <p>This is reason enough to avoid using the three concepts interchangeably. But could it be that they also apply to distinct properties? One way to show this would be to find phenomena in the actual world to which not all three notions are applicable. Some empirical cases might tentatively be taken to suggest that for-me-ness, me-ness and mineness can fail to occur simultaneously in some pathological conditions. In particular, me-ness or mineness may sometimes fail to be instantiated even though for-me-ness is instantiated. If me-ness and mineness can indeed selectively disappear, giving rise to distinct pathologies, then my threefold distinction might prove a useful tool for describing empirical data more accurately.</p>
      <sec id="Sec24">
        <title>For-me-ness Without Me-ness and Mineness?</title>
        <p>In this sub-section, I rely heavily on recent work by Alexandre Billon (Billon <xref ref-type="bibr" rid="CR4">2014</xref>, <xref ref-type="bibr" rid="CR5">forthcoming</xref>), elaborating on it slightly.</p>
        <p>The first type of empirical case of potential relevance is the depersonalisation syndrome (Simeon and Abugel <xref ref-type="bibr" rid="CR63">2006</xref>; Sierra <xref ref-type="bibr" rid="CR60">2009</xref>), as well as its extreme, delusional form, first described by Cotard (<xref ref-type="bibr" rid="CR14">1880</xref>). Patients who experience depersonalisation, typically as a part of severe depression, report an alteration of their experiences. In many cases, it no longer seems as though the experiences are <italic>theirs</italic>. And often, it no longer seems as though <italic>they</italic> (the patients) exist at all.</p>
        <p>Here are two typical reports of the first kind of distortion: some depersonalised patients appear to be phenomenally aware of their experiences, but not of the fact that the experiences are <italic>theirs</italic>:<disp-quote><p>It was as if it was not me walking, it was not me talking, as if it was not me living […] I can look at me, I am somehow bothered by my body, as if it wasn’t me, as if I lived on the side of my body, on the side of myself if you like. I don’t know how to explain. (Janet and Raymond <xref ref-type="bibr" rid="CR39">1898</xref>: 70)<xref ref-type="fn" rid="Fn25">25</xref>
</p><p>When a part of my body hurts, I feel so detached from the pain that it feels as if it were somebody else’s pain. (Sierra and Berrios <xref ref-type="bibr" rid="CR61">2000</xref>: 163)</p></disp-quote>
</p>
        <p>Here are also reports of “feelings of non-existence”, as Billon calls them. Billon interprets those as experiences in which the depersonalised patient lacks a phenomenal awareness of <italic>herself</italic>:<disp-quote><p>I imagine myself seeing life as if it were played like a film in a cinema. But in that case where am I? Who is watching the film? (Simeon and Abugel <xref ref-type="bibr" rid="CR63">2006</xref>: 15)</p><p>It almost feels like I have died, but no one has thought to tell me. So, I’m left living in a shell that I don’t recognize any more. (Sierra <xref ref-type="bibr" rid="CR60">2009</xref>: 27)</p></disp-quote>
</p>
        <p>In a recent series of articles, Billon makes a powerful case for the claim that the experiences of depersonalised and Cotard patients is evidence of the possibility of phenomenal awareness without subjective character. But this claim might strike some as counter-intuitive, insofar as subjective character is supposed to be what makes something an experience at all. While I find the general direction of Billon’s argument very compelling, I think that the three-way distinction I propose in lieu of the misleadingly monolithic notion of subjective character might allow for a more conservative, and perhaps more intuitive, description of the pathology.</p>
        <p>For consider: the first type of report above suggests that the patients lack a phenomenal awareness that the experiences they report are theirs (“I feel so detached from the pain that it feels as if it were somebody else’s pain”). In my terminology, they lack “mineness”. The second type of report suggests that those patients additionally lack a phenomenal awareness of the presence of their own selves (“It almost feels like I have died”; “where am I?”). As Simeon and Abugel (<xref ref-type="bibr" rid="CR63">2006</xref>) put it, in depersonalisation “[there is] no clear feeling of ‘I’ (p. 25)”; “There [is] literally no more experience of a ‘me’ at all (p. 143–4)”. In my terminology, the depersonalised patients lack “me-ness”. On the other hand, <italic>something</italic> of the subjective character of the abnormal experiences does seem to be retained. Those experiences are “for” the subjects undergoing them, given to them in a special way that enables them to report on a phenomenal occurrence (a pain, an impression as of a walking movement, etc.) in the direct manner that no one else could report it. In my terminology, those experiences have “for-me-ness”. I thus propose to describe the depersonalisation syndrome as a condition in which experience lacks both mineness and me-ness, but retains for-me-ness.</p>
        <p>A word on the motivation for locating the manifestation of the disorder at the <italic>phenomenal</italic> level. As Billon stresses, while Cotard patients are delusional, actively denying ownership of their experiences and sometimes claiming to be dead, depersonalised patients refrain from taking the abnormal experiences at face-value. They don’t actually <italic>believe</italic> that they don’t own the experiences, or that they don’t exist, as evidenced by the careful wording of their reports (“it was as if”; “it feels as if”; “it almost feels like”; “I imagine myself seeing”; “somehow”; etc.). As Billon convincingly argues, this makes it plausible that the problem comes specifically from the disturbing lack of an <italic>impression</italic>, of an <italic>experience</italic> that used to be present – rather than, say, from the lack of a <italic>belief</italic> (that the self exists or that the problematic experiences are hers).</p>
      </sec>
      <sec id="Sec25">
        <title>For-me-ness and Me-ness Without Mineness?</title>
        <p>The second type of case of potential interest is the phenomenon of “inserted” or “implanted” or “alien” thoughts in some schizophrenic patients (Jaspers <xref ref-type="bibr" rid="CR40">1963</xref>; Frith <xref ref-type="bibr" rid="CR24">1992</xref>; Gallagher <xref ref-type="bibr" rid="CR26">2004</xref>; Bortolotti <xref ref-type="bibr" rid="CR8">2010</xref>). Inserted thoughts are thoughts that the subject reports as occurring in her stream of consciousness, but which, nonetheless, she refuses to acknowledge <italic>as her own</italic>, typically claiming that someone else produced those thoughts and put them in her mind. Here are some characteristic patients’ reports:<disp-quote><p>[S]he said that sometimes it seemed to be her own thought ‘but I don’t get the feeling that it is’. She said her ‘own thoughts might say the same thing’, ‘but the feeling isn’t the same’, ‘the feeling is that it is somebody else’s.’ […] (Allison-Bolger <xref ref-type="bibr" rid="CR1">1999</xref>, #89)</p><p>I look out of the window and I think the garden looks nice and the grass looks cool, but the thoughts of Eamonn Andrews come into my mind. There are no other thoughts there, only his… He treats my mind like a screen and flashes his thoughts on to it like you flash a picture. (Mellor <xref ref-type="bibr" rid="CR47">1970</xref>: 17)</p><p>One evening one thought was given to me electrically that I should murder Lissi. (Jaspers <xref ref-type="bibr" rid="CR40">1963</xref>: 580)</p></disp-quote>
</p>
        <p>It is a much-debated question how thought insertion is best described and understood. What I will call the ‘simple account’ interprets it as a case where a subject lacks a “sense of ownership” over her thoughts (Metzinger <xref ref-type="bibr" rid="CR48">2003</xref>: 445–6). What is now the standard account treats it, rather, as a case where she <italic>does</italic> have a “sense of ownership”, but no “sense of agency”, over her thoughts, i.e. where she lacks the sense of having actively produced them (Stephens and Graham <xref ref-type="bibr" rid="CR65">1994</xref>; Gallagher <xref ref-type="bibr" rid="CR26">2004</xref>). A third account construes alien thoughts as cases where the subject fails to endorse the content of her thoughts or commit to them (Bortolotti <xref ref-type="bibr" rid="CR8">2010</xref>).<xref ref-type="fn" rid="Fn26">26</xref>
</p>
        <p>A reason which is often given to reject the ‘simple account’ – which construes inserted thoughts as mental states unaccompanied by a feeling of ownership – is that the patient retains <italic>first-personal access</italic> to her inserted thoughts, just as to all of her other, normal thoughts. The “alien” thoughts do occur in her stream of consciousness, as she wouldn’t deny.</p>
        <p>This case for rejecting the ‘simple account’, I suspect, rests in part on a failure to distinguish between different notions of subjective character. As I pointed out at the start, the concept of a “sense of ownership” is generally used in a fashion that doesn’t discriminate between: (i) a special way we are aware of our experiences – <italic>first-personally</italic>, i.e. in a way others can’t be aware of them; (ii) a way we are aware of <italic>ourselves</italic> in having experiences; and (iii) a way we are aware of <italic>owning</italic> those experiences. Once those three sense of “subjective character” are disentangled, more fine-grained conceptual resources become available to describe the predicament of a patient with alien thoughts. In particular, it becomes possible to acknowledge that the abnormal thoughts are given to her in a first-personal way (thus exhibiting <italic>for-me-ness</italic>), while still hypothesising that she might be specifically lacking a sense of <italic>owning</italic> those thoughts (<italic>mineness</italic>). Note that schizophrenics with thought insertion nonetheless seem to retain a phenomenal awareness of <italic>themselves</italic> (<italic>me-ness</italic>) while having the problematic thoughts, as shown by the normal use of first-person terms in their reports.<xref ref-type="fn" rid="Fn27">27</xref>
</p>
        <p>In what amounts to a more sophisticated version of the ‘simple account’,<xref ref-type="fn" rid="Fn28">28</xref> made available by my threefold distinction, I thus propose to describe thought insertion as a condition in which experience lacks mineness, but retains both for-me-ness and me-ness.</p>
      </sec>
      <sec id="Sec26">
        <title>The Descriptive Benefit of the Tripartite Framework</title>
        <p>My three-way distinction has the additional merit of providing us with a principled way to distinguish between the two types of pathologies discussed in the last two sub-sections, i.e. the depersonalisation spectrum and the phenomenon of inserted thoughts.</p>
        <p>It is now customary to describe delusions as broadly rational responses to abnormal experiences (Davies and Coltheart <xref ref-type="bibr" rid="CR17">2000</xref>). <italic>Which</italic> abnormal experience helps us classify the delusions. In particular, the thought-insertion delusion and the depersonalisation syndrome in its delusional form (Cotard syndrome) can both be viewed as rational responses to unusual experiences, whose abnormality specifically has to do with an impaired subjective character.</p>
        <p>But saying only this much leaves us without a way to mark the difference between the two conditions. Further distinguishing, under the blanket expression “subjective character”, the three notions I separate here, permits to characterise the two pathologies in distinct ways. I proposed that the experience of prototypical Cotard patients exhibits for-me-ness, <italic>but neither me-ness nor mineness</italic>. I also suggested that schizophrenic inserted thoughts might exhibit for-me-ness and me-ness, <italic>but not mineness</italic>. Why think that me-ness is lacking in the first type of case, but not the second? First, we should by default accept at face-value the reports of patients, and we have seen that “feelings of non-existence” are a specific complaint of Cotard sufferers. Here is a characteristic report by a patient: “I am not Myself at all. What is missing is myself, it is awful to elude oneself, to live and not to be oneself.<xref ref-type="fn" rid="Fn29">29</xref>” Schizophrenics with thought-insertion do not make such reports of “eluding oneself”.<xref ref-type="fn" rid="Fn30">30</xref> Second, as Billon (<xref ref-type="bibr" rid="CR4">2014</xref>, Sec. 5.1) shows in detail, many Cotard patients are uncomfortable using the word “I”, sometimes preferring “he” or “she” or “it”, proper names or nicknames (“Madam Zero”), or complicated periphrases. This might be taken as a further indication that the underlying “experience of a ‘me’” (Simeon and Abugel <xref ref-type="bibr" rid="CR63">2006</xref>: 143–4) is lacking. Again, this is not matched by the linguistic behaviour of patients with thought-insertion.</p>
        <p>Both the depersonalisation spectrum, and thought-insertion, leave for-me-ness intact while affecting subjective character in some other way. Accepting my tripartite distinction allows us to say what way that might be in each case. The level of detail required to keep separate what are thought to be different nosographic kinds is thus a further motivation for adopting a threefold approach.</p>
        <p>Of course, the psychiatric conditions described in this section are complex and difficult to understand, and a proper defence of the characterisation of depersonalisation and thought-insertion I propose here would require a much more detailed study. The main point of this empirically-informed discussion, however, isn’t so much to argue that the real-life phenomena under consideration <italic>are</italic> indeed best interpreted as I suggest. It is, rather, to show that such an interpretation is <italic>consistent</italic>; and that we can thus conceive of possible cases where for-me-ness, me-ness and mineness fail to be instantiated together, whether or not the real pathologies mentioned above turn out to be just such cases. The three concepts accordingly correspond to different properties, properties which <italic>could</italic> fail to be all satisfied by the same particular. In addition, there is at least some initial appeal to the suggestion that they also fail to be jointly satisfied in some pathological cases in reality.</p>
      </sec>
      <sec id="Sec27">
        <title>For-me-ness, Me-ness and Mineness in Normal Experience</title>
        <p>None of this, it should be emphasised, rules out that all the ordinary experiences of normal subjects exhibit conjointly for-me-ness, me-ness and mineness. In fact, I think there is reason to believe this to be the case.</p>
        <p>Here is an argument from justification. In ordinary circumstances, when I have an experience – say, a tactile experience of the cat’s silky fur – this as such gives me some justification for making a number of judgments. These include at least: (i) the judgment that the cat has silky fur; (ii) the judgment that an experience to this effect is present; (iii) the judgment that I am present; (iv) the judgment that the experience is mine.</p>
        <p>It has been argued<xref ref-type="fn" rid="Fn31">31</xref> that experiences, furthermore, give <italic>immediate</italic> justification for judgments such as (i). Here, I use the notion of ‘immediate justification’ as defined by Soldati (<xref ref-type="bibr" rid="CR64">2012</xref>).<xref ref-type="fn" rid="Fn32">32</xref> To say that the perceptual experience provides the subject with immediate justification to judge (i) is to say that it gives her “a kind of warrant that does not depend on, for instance, any further inferentially acquired justification.” The experience as of the cat’s fur being silky can be used as evidence that the cat’s fur is silky, “without having to rely on any further evidence” to support the experience itself. The experience is a reason to judge the cat’s fur to be silky that is not itself in need of further justification. Note that this notion of immediate justification concerns the type of the epistemic warrant, not the <italic>strength</italic> of this warrant, or the <italic>psychological capacities</italic> involved in arriving at it. Justification that is immediate in this sense does not have to be infallible; in the case of perceptual experience, it is in fact typically defeasible. And to say that the experience <italic>warrants</italic> the corresponding judgment immediately is not to say that the judgment is <italic>arrived at</italic> in a way that is psychologically immediate; it does not, in particular, rule out that conceptual capacities are involved in the process, as they surely are, or that we need to have other beliefs in other to acquire the relevant concepts. The immediacy I have in mind characterises the (normative) <italic>justification</italic> relation between two states (the experience and the judgment), not their (factual) <italic>psychological</italic> relation.</p>
        <p>Now, I think that at least as good a case<xref ref-type="fn" rid="Fn33">33</xref> can be made that experience also immediately justifies judgments (ii), (iii) and (iv). Suppose I am now undergoing some experience or other, e.g. feeling the cat’s smooth fur. The mere presence of this experience, as such, is evidence for judging (ii) that the experience is present, (iii) that I am present, and (iv) that the experience is mine. Having an experience is enough to be licensed to judge it is happening, to self-attribute it, and to judge that I exist. When I reflect on the experience and make those judgments, if asked for my <italic>reason</italic> to do so, it is hard to see what else I could invoke than the experience itself. Again, this does not mean that my <italic>capacity</italic> to make the judgments is unmediated; only that the relevant epistemic <italic>warrant</italic> is provided by the mere having of the experience. It is <italic>something about the experience</italic>, something intrinsic to it, that supports judgments (ii), (iii) and (iv). This I take to be at least a <italic>prima facie</italic> reason to think that we typically have <italic>experiential</italic> access to the experience, to ourselves, and to the fact that the experience is ours; or, in my terminology, that the phenomenal character of a normal experience includes for-me-ness, me-ness, and mineness.</p>
        <p>Further support for this claim is offered by a contrast with blindsight patients.<xref ref-type="fn" rid="Fn34">34</xref> These patients have large blind areas in their visual fields, but are somehow able to respond correctly to visual stimuli located in those areas. No visual phenomenology, however, accompanies those responses. Whether or not it is appropriate to say that blindsight patients <italic>have</italic> visual experiences in those instances, it seems doubtful that they would in any case be <italic>immediately</italic> justified in judging experiences to be present, or in self-attributing those experiences. Their justification would have to proceed through a more circuitous route. Let us imagine a ‘super-blindsight’<xref ref-type="fn" rid="Fn35">35</xref> patient, trained to regularly form beliefs about the objects in her blind field. She could notice that she has the <italic>belief</italic> that a certain object is in her blind area; use her background understanding of her condition, and her knowledge that when she has this sort of belief, it is usually because a form of visual perception she is unaware of is taking place; and infer on this basis that she must be “experiencing” the object in question. This wouldn’t be an <italic>immediate</italic> justification, directly based on the mere <italic>having</italic> of the experience itself and nothing else, as is the case in normal subjects. But note that the only difference between the ‘super-blindsighter’ and a normal subject is that the latter enjoys visual phenomenology, while the former does not. So when a normally-sighted subject has a visual perception, whatever in the experience gives her immediate justification to judge that an experience is occurring, that she herself is present and that the experience is hers must be exclusively based on the <italic>phenomenal</italic> character of the experience. This I take to be a good reason to think that normal experience displays for-me-ness, me-ness and mineness.<xref ref-type="fn" rid="Fn36">36</xref>
</p>
      </sec>
      <sec id="Sec28">
        <title>Taking Stock</title>
        <p>What precedes makes it reasonable, I believe, to hold the following. (i) <italic>For-me-ness</italic> is plausibly present wherever there is phenomenal consciousness. It is extremely hard to imagine a case where this wouldn’t be true; and it might be a conceptual truth, our main handle on the notion of phenomenal awareness consisting in spelling it out in terms of “there being something it is like <italic>for me</italic>” to have an experience. (ii) On the other hand, <italic>mineness</italic> (in the case of inserted thoughts) and even <italic>me-ness</italic> (in the case of depersonalised and Cotard patients) might disappear from phenomenal consciousness in some pathological contexts. At the very least, it is conceivable that they <italic>could</italic> disappear, as attested by the fact that the proposed interpretation of the pathological cases is coherent. This supports the thesis that different properties correspond to the three notions. (iii) Nonetheless, all three properties are likely present in normal experiences.</p>
        <p>Now the fact that the terms standing for subjective character are used in a way that betrays a lack of discrimination between the three different notions is certainly due to the fact that writers take all three concepts to describe adequately phenomenal awareness as they encounter it, i.e. in ordinary cases. And so it probably is, as I have just argued. But that would be a substantial result, and not a conceptual truth. Every time a move is made from for-me-ness to me-ness or mineness, an argument must be produced. But such an argument will very often be found to be lacking, and an equivalence to be presupposed – wrongly, as I hope to have shown; and to damaging effect for existing arguments, as I will argue in what remains of this essay.</p>
      </sec>
    </sec>
    <sec id="Sec29">
      <title>A Confusion Affecting Argumentative Practice: Kriegel and Zahavi</title>
      <p>The aim of my observations is not merely a cautionary one, i.e. to urge for terminological regimentation, lest we fell into equivocations that would invalidate our reasoning on subjective character. It is also critical; the confusion, as I submit in this final section, already has damaging effects on existing arguments.</p>
      <p>Three of the four arguments I review are taken from works by Kriegel or Zahavi. This isn’t to suggest that the conflation I hope to have identified is specific to them. The examples below are representative of a much more widespread tendency in the literature. I concentrate on those two writers because they, with a few others, have greatly contributed to advancing our understanding of subjective character in recent years. Rather than singling them out for criticism, the focus reflects the importance of their work on the issue.</p>
      <p>A first example of an argument undermined by the conceptual shift was already analysed in Section <xref rid="Sec22" ref-type="sec">3.6.2</xref>. An argument offered by Kriegel (<xref ref-type="bibr" rid="CR41">2004</xref>) in support of the claim that a state being conscious at all depends on peripheral self-consciousness on the part of the subject was found to be question-begging, assuming as it does the equivalence between for-me-ness and mineness.</p>
      <p>A second illustration was offered in Section <xref rid="Sec25" ref-type="sec">4.2</xref>, in the discussion of schizophrenic thought-insertion. According to the ‘simple account’ of the phenomenon, this is a case where experiences come without a “sense of ownership”. A widely accepted argument against this interpretation invokes the observation that a patient with alien thoughts still has “first-person access” to them. I suggested that the argument trades on an unwarranted equation between for-me-ness and mineness, and has accordingly little weight.</p>
      <p>A third example is to be found in Zahavi and Kriegel (<xref ref-type="bibr" rid="CR76">2015</xref>). The article introduces subjective character in terms befitting <italic>for-me-ness</italic>: “Compare your experiences of perceiving an apple and remembering a banana. […] the two experiences have something very fundamental in common: in both cases it is <italic>for you</italic> that it is like something to have them.” They go on, however, to use this notion indiscriminately with what is really <italic>me-ness</italic>, talking of a “minimum point of self-awareness” involved on the part of the subject by virtue of the fact that her experiences are given to her “in a distinctly first-personal way”. This shift proves damaging for at least one of the authors’ arguments.</p>
      <p>The authors consider in Section 4 the ease with which we are able to report on our experiences. You are presently absorbed in reading this text; if suddenly “asked what experience [you] are having, [you] can respond immediately and effortlessly.” In addition, there is “never any sense of surprise regarding what the experience is; instead, there is a sense of familiarity.” Zahavi and Kriegel propose that the best explanation for this ease of reportability, and for the feeling of familiarity, is that my awareness of the experience is part of the experience itself. In other words, the experience includes <italic>for-me-ness</italic> as part of its phenomenal character:<disp-quote><p>[…] the best explanation of the sense of familiarity with, and lack of surprise regarding, my concurrent experience is that I was aware of it all along, in that it is built into the very phenomenal character of the experience that it is like something <italic>for me</italic>. (Zahavi and Kriegel <xref ref-type="bibr" rid="CR76">2015</xref>: 46)</p></disp-quote>
</p>
      <p>The phenomenal datum that is for-me-ness grounds another phenomenal datum, namely the feeling of familiarity with our experiences, and also serves as the categorical basis of a disposition, namely our capacity to report the experiences with ease.</p>
      <p>So far, so good. However, the authors go on to rephrase this very convincing point by saying that for-me-ness is a categorical basis for a <italic>distinct</italic> disposition, namely our capacity for first-person thought:<disp-quote><p>Our own explanation is that this ever-present sense of familiarity and lack of surprise is grounded in the ubiquitous for-me-ness of experience, which itself is the categorical basis of one’s capacity for first-person thought in the right kind of creatures. (<italic>Ibid</italic>.: 47)</p></disp-quote>
</p>
      <p>The standard meaning of “first-person thought” identifies it as a thought about the subject entertaining it, typically a self-attribution of the form “I am F”. The suggestion, here, is that for-me-ness grounds the capacity to form thoughts (and reports) in which we self-attribute our experiences, e.g. “<italic>I</italic> am consciously reading”, “<italic>I</italic> am smelling the dog’s fur”, etc. This is quite different from saying that for-me-ness grounds our capacity to report the mere presence of the experience. While I find great intuitive appeal to the weaker, initial claim (that a <italic>phenomenal</italic> awareness of our experiences grounds our capacity to <italic>think</italic> about them), I think that the more substantive one to which the authors transition without warning (that a phenomenal awareness of our <italic>experiences</italic> grounds our capacity to think about <italic>ourselves</italic>) would require much additional support.<xref ref-type="fn" rid="Fn37">37</xref> As I hope to have shown in Section <xref rid="Sec16" ref-type="sec">3.4</xref>, nothing in the notion of for-me-ness, as such, allows us to treat it as an awareness the subject has <italic>of herself</italic>. Even if we accept that for-me-ness is the categorical basis for our capacity to judge a certain experience to be present, it doesn’t follow, without further argument, that this very same property is also the categorical basis of our capacity to judge that <italic>we</italic> are present, and <italic>own</italic> the experience. Distinct phenomenal properties, namely me-ness and mineness, would seem more suited to ground these further dispositions.<xref ref-type="fn" rid="Fn38">38</xref> It is likely that Zahavi and Kriegel’s failure to distinguish between the three different notions, and corresponding properties, is what leads them to present a stronger claim as a mere reformulation of the weaker one they previously argue for.</p>
      <p>A fourth and final example of the effects of the confusion is to be found in an argument from the presence of for-me-ness in phenomenal consciousness, to the conclusion that there exists such a thing as a “core” or “thin” or “minimal” self within the stream of consciousness. This line of thought is familiar from the works of Zahavi (<xref ref-type="bibr" rid="CR75">2005</xref>, Chapter 5), G. Strawson (<xref ref-type="bibr" rid="CR67">1997</xref>, <xref ref-type="bibr" rid="CR68">2009</xref>), Damasio (<xref ref-type="bibr" rid="CR16">1999</xref>), Gallagher (<xref ref-type="bibr" rid="CR25">2000</xref>), and others. The inference is problematic, whether it is taken to yield, by order of increasing strength, an <italic>epistemic</italic> thesis (we have an awareness of the self in having experiences), a <italic>phenomenal</italic> thesis (this access to the self is of the phenomenal kind), or a <italic>metaphysical</italic> thesis (this “self-experience” <italic>is</italic> the self, or at least <italic>a</italic> form of selfhood). Zahavi (<xref ref-type="bibr" rid="CR75">2005</xref>) commits to all three claims, as the characteristic passage below makes clear:<disp-quote><p>[…] the self is claimed to possess experiential reality, is taken to be closely linked to the first-person perspective, and is, in fact, identified with the very first-personal <italic>givenness</italic> of the experiential phenomena. [...] [T]he most basic form of selfhood is the one constituted by the very self-manifestation of experience. To be conscious of one<italic>self</italic>, consequently, is not to capture a pure self that exists in separation from the stream of consciousness, but rather entails just being conscious of an experience in its first-personal mode of givenness; it is a question of having first-personal access to one’s own experiential life. Thus, the self referred to is not something standing beyond or opposed to the stream of experiences but is rather a feature or function of its givenness. In short, the self […] is taken to be an integral part of our conscious life with an immediate experiential reality. (Zahavi <xref ref-type="bibr" rid="CR75">2005</xref>: 106)</p></disp-quote>
</p>
      <p>When undergoing an experience, one is “conscious of oneself” (<italic>epistemic thesis</italic>); nothing more is needed for this awareness of oneself than “being conscious of an experience in its first-personal mode of givenness” (<italic>phenomenal thesis</italic>); furthermore, “the self referred to” just <italic>is</italic> (“is identified with”) “the very first-personal givenness of the experiential phenomena” (<italic>metaphysical thesis</italic>).</p>
      <p>Now, as I argued in Section <xref rid="Sec16" ref-type="sec">3.4</xref> and <xref rid="Sec17" ref-type="sec">3.5</xref>, the “self-manifestation of experience” that Zahavi invokes, i.e. the fact that it manifests itself <italic>to me</italic> (<italic>for-me-ness</italic>), does not entail that I am thereby aware of myself in any way. The uncontroversial observation that experiences are special to their subject, in that they are an object of “first-personal” access to her, cannot be equated with the much more contentious thesis that the experiencing subject is thereby self-aware (<italic>cf</italic>. Section <xref rid="Sec16" ref-type="sec">3.4</xref>). Zahavi’s transition from the subjective character of experience to an awareness of the self in experience is thus a great leap, but one that he considers as relatively innocuous precisely because he fails to distinguish between subjective character as <italic>for-me-ness</italic>, as <italic>me-ness</italic>, and as <italic>mineness</italic>. As the assumption of an equivalence is unwarranted, the argument from the “self-manifestation” of experience (<italic>for-me-ness</italic>) to a phenomenal access to the self (<italic>me-ness)</italic> doesn’t go through. As to the metaphysical thesis that the “me-ish” quality of experience <italic>is</italic> the self, it succumbs to the same objection as the phenomenal thesis in so far as it presupposes it. Both theses might still be true (I gave an argument for the phenomenal thesis in arguing for the presence of me-ness in normal experience in Section <xref rid="Sec27" ref-type="sec">4.4</xref>); but they cannot be established simply on the basis of our noticing that there is something it is like <italic>for us</italic> to experience.</p>
    </sec>
    <sec id="Sec30" sec-type="conclusion">
      <title>Conclusion</title>
      <p>In this essay, I argued that much of the debate on the subjective character of experience is affected by a failure to distinguish between three different dimensions one might identify as the invariant phenomenal core across all experiences: that my experiences appear to me (<italic>for-me-ness</italic>); that I am manifested to myself through them (<italic>me-ness</italic>); and that they are presented as my own (<italic>mineness</italic>).</p>
      <p>I showed that the three corresponding notions do not form a class of mutually equivalent concepts. For-me-ness, at the very least, entails neither me-ness nor mineness. I also gave some reason to doubt whether the complementary relations of entailment hold. The previous point, in any case, suffices to preclude conceptual equivalence between all three notions.</p>
      <p>In addition, I argued that the non-equivalent notions correspond to distinct properties, which <italic>could</italic> fail to be instantiated simultaneously. That this is at least conceivable is showed by presenting an interpretation of some mental pathologies where for-me-ness could be thought to occur without mineness (schizophrenic thought-insertion) and with neither mineness nor me-ness (depersonalisation and Cotard syndrome). Whether or not the interpretation is correct (which would mean that the three properties are not always jointly present in the actual world), it is at least coherent (which means that they are distinct properties).</p>
      <p>That different notions as well as different properties are being conflated in discussions of subjective character invites greater caution in the future, and I recommend the use of distinct terms to keep track of the three dimensions. This essay also amounts to a critique of all arguments trading on the illegitimate assumption of an equivalence between for-me-ness, me-ness and mineness. I analyse in detail four examples of arguments guilty of this, and found them accordingly invalid.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="Fn1">
        <label>1</label>
        <p>See also Zahavi (<xref ref-type="bibr" rid="CR74">1999</xref>) and (<xref ref-type="bibr" rid="CR75">2005</xref>: 123) on subjective character. Other contemporary authors making use of related notions include those cited in Section <xref rid="Sec3" ref-type="sec">1.2</xref>, as well as Shoemaker (<xref ref-type="bibr" rid="CR59">1996</xref>: 157); G. Strawson (<xref ref-type="bibr" rid="CR67">1997</xref>, <xref ref-type="bibr" rid="CR68">2009</xref>); Gallagher (<xref ref-type="bibr" rid="CR25">2000</xref>); Neisser (<xref ref-type="bibr" rid="CR50">2006</xref>, <xref ref-type="bibr" rid="CR51">2008</xref>: 56–8, <xref ref-type="bibr" rid="CR52">2014</xref>, <xref ref-type="bibr" rid="CR53">2015</xref>); Drummond (<xref ref-type="bibr" rid="CR20">2006</xref>: 200); Hohwy (<xref ref-type="bibr" rid="CR34">2007</xref>); Grünbaum (<xref ref-type="bibr" rid="CR31">2012</xref>); Ganeri (<xref ref-type="bibr" rid="CR28">2012</xref>: 151 sq.); Williford (<xref ref-type="bibr" rid="CR71">2015</xref>). This representative list is far from exhaustive.</p>
      </fn>
      <fn id="Fn2">
        <label>2</label>
        <p>Kriegel (<xref ref-type="bibr" rid="CR43">2009</xref>: 101); my emphasis.</p>
      </fn>
      <fn id="Fn3">
        <label>3</label>
        <p>I ignore a complication here: among those who think that the subject’s relevant awareness of a given mental state, <italic>m</italic>, is to be understood as the result of <italic>m</italic> being the object of a mental state <italic>m’</italic>, there is a dispute as to whether <italic>m’</italic> is a <italic>distinct</italic> mental state, or is <italic>identical</italic> to <italic>m</italic>. “Higher-order” theorists (e.g. Rosenthal <xref ref-type="bibr" rid="CR56">1986</xref>) defend the first option, while “same-order” theorists (e.g. Kriegel <xref ref-type="bibr" rid="CR42">2006</xref>) advocate the second option. To simplify, I talk here as if the same-order approach were right; however, nothing in what follows hangs on this. What matters here is just that the <italic>target</italic> of the relevant awareness is the conscious experience, <italic>m</italic>.</p>
      </fn>
      <fn id="Fn4">
        <label>4</label>
        <p>Forebears to the view include Sartre (<xref ref-type="bibr" rid="CR57">1943</xref>: 19–20), Brentano (<xref ref-type="bibr" rid="CR9">1874</xref>/1973: 153–4), and perhaps Aristotle – see Caston (<xref ref-type="bibr" rid="CR12">2002</xref>).</p>
      </fn>
      <fn id="Fn5">
        <label>5</label>
        <p>The expression is Kriegel’s. See his (2009), Chapter 4, in which he gives a perceptive critical account of the view.</p>
      </fn>
      <fn id="Fn6">
        <label>6</label>
        <p>Cf e.g. <italic>Principles of Philosophy</italic>, Part I, §9, in Descartes (<xref ref-type="bibr" rid="CR18">1996</xref>) VIIIA p. 7–8.</p>
      </fn>
      <fn id="Fn7">
        <label>7</label>
        <p>Doing justice to the richness and complexity of the historical roots of the notion of subjective character as me-ness would far exceed the limits of this paper, and would constitute a distinct project. The goal here is simply to highlight an existing use of the notion of subjective character, and to argue that it is conceptually distinct from the other two common uses I identify in sections <xref rid="Sec7" ref-type="sec">2.2</xref> and <xref rid="Sec11" ref-type="sec">2.4</xref>.</p>
      </fn>
      <fn id="Fn8">
        <label>8</label>
        <p>See also Neisser (<xref ref-type="bibr" rid="CR50">2006</xref>) for a similar distinction.</p>
      </fn>
      <fn id="Fn9">
        <label>9</label>
        <p>See also e.g. P. F. Strawson (<xref ref-type="bibr" rid="CR66">1966</xref>: 165).</p>
      </fn>
      <fn id="Fn10">
        <label>10</label>
        <p>I am grateful to Lucy O'Brien for pointing this out to me.</p>
      </fn>
      <fn id="Fn11">
        <label>11</label>
        <p>E.g. Dretske (<xref ref-type="bibr" rid="CR19">1995</xref>), Tye (<xref ref-type="bibr" rid="CR69">1995</xref>), Martin (<xref ref-type="bibr" rid="CR46">2002</xref>).</p>
      </fn>
      <fn id="Fn12">
        <label>12</label>
        <p>But see 3.5 below.</p>
      </fn>
      <fn id="Fn13">
        <label>13</label>
        <p>More on Williford (<xref ref-type="bibr" rid="CR71">2015</xref>) in 3.5 below.</p>
      </fn>
      <fn id="Fn14">
        <label>14</label>
        <p>Dainton (<xref ref-type="bibr" rid="CR15">2008</xref>, Sections 8.1 and 8.2) and Peacocke (<xref ref-type="bibr" rid="CR54">2014</xref>) both make a detailed case that we can conceive a creature endowed with conscious states – states that are ‘for’ the creature – but with no phenomenal awareness of itself whatsoever – no me-ness.</p>
      </fn>
      <fn id="Fn15">
        <label>15</label>
        <p>Kriegel, for instance, appears to restrict the scope of what is covered by the state’s awareness of itself to its <italic>semantic</italic> properties.</p>
      </fn>
      <fn id="Fn16">
        <label>16</label>
        <p>I am grateful to an anonymous reviewer for inviting me to discuss this issue.</p>
      </fn>
      <fn id="Fn17">
        <label>17</label>
        <p>The “pearl view” of the self advocated in G. Strawson (<xref ref-type="bibr" rid="CR67">1997</xref>) bears a resemblance to this type of minimalism, but the close relation it describes between self and experience arguably falls short of <italic>identity</italic>. Minimal notions of selfhood are also to be found in Damasio and Gallagher, among others.</p>
      </fn>
      <fn id="Fn18">
        <label>18</label>
        <p>Williford (<xref ref-type="bibr" rid="CR71">2015</xref>: 9/27), quoted in 3.4 above.</p>
      </fn>
      <fn id="Fn19">
        <label>19</label>
        <p>I am not sure whether it could additionally be argued, on such views, that for-me-ness entails mineness, if only because it is doubtful whether we can still talk of the subject <italic>owning</italic> her experience, if she is <italic>identical</italic> with it (or an aspect of it).</p>
      </fn>
      <fn id="Fn20">
        <label>20</label>
        <p>As I stressed above, this is not the case of Williford.</p>
      </fn>
      <fn id="Fn21">
        <label>21</label>
        <p>More on this in 5.2 below.</p>
      </fn>
      <fn id="Fn22">
        <label>22</label>
        <p>My emphasis.</p>
      </fn>
      <fn id="Fn23">
        <label>23</label>
        <p>The second argument, reprised from Rosenthal, is that one can’t think at all of a <italic>particular</italic> mental state (as opposed to the <italic>kind</italic> of mental state it is an instance of) without thinking of the subject of that state. I don’t see any reason to accept this. Another way to think of a token mental state in an individuating manner is to think of its time and place of occurrence. Yet another way is to think a singular or “<italic>de re</italic>” thought about it, which we can do by being acquainted with it, whether or not we associate any individuating descriptions with it.</p>
      </fn>
      <fn id="Fn24">
        <label>24</label>
        <p>Neisser (<xref ref-type="bibr" rid="CR53">2015</xref>), especially Chapter 3, offers an extended analysis and critique in the same spirit.</p>
      </fn>
      <fn id="Fn25">
        <label>25</label>
        <p>All the reports are quoted by Billon (<xref ref-type="bibr" rid="CR4">2014</xref>); in this first quote, the translation from the French is also his. Billon argues that the depersonalisation syndrome is evidence for the possibility of phenomenal consciousness without “subjective character” (2014). I take him to use the term in a way that encompasses at least me-ness and mineness as defined here, although he doesn’t make those further distinctions. His interpretation of the data he reviews might be compatible with my point here, namely that the absence of subjective character in both those senses doesn’t entail the absence of for-me-ness. (But see Billon <xref ref-type="bibr" rid="CR4">2014</xref>: 21–4 for qualifications.) Putting the claim in this way has the advantage of not equating it to the claim that phenomenal awareness can occur without subjective character <italic>in any sense of the term</italic>. In my interpretation, <italic>some</italic> kind of subjective character (namely for-me-ness), although not all of its three forms, is retained in the experience of depersonalised and Cotard patients.</p>
      </fn>
      <fn id="Fn26">
        <label>26</label>
        <p>For a review of the debate, see Bortolotti (2010), Chapter 5.</p>
      </fn>
      <fn id="Fn27">
        <label>27</label>
        <p>By contrast, as Billon (<xref ref-type="bibr" rid="CR4">2014</xref>, Section 5.1) stresses, some Cotard patients avoid using “I”, “me” and other first-person expressions as much as possible, preferring proper names, third-person expressions and periphrases. This might be taken as further evidence that, in their case, <italic>me-ness</italic> as well as mineness is lacking. More on this below.</p>
      </fn>
      <fn id="Fn28">
        <label>28</label>
        <p>See Billon (<xref ref-type="bibr" rid="CR3">2011</xref>) for a different defence of the simple account.</p>
      </fn>
      <fn id="Fn29">
        <label>29</label>
        <p>Janet (<xref ref-type="bibr" rid="CR38">1928</xref>: 43), quoted and translated by Billon (<xref ref-type="bibr" rid="CR4">2014</xref>).</p>
      </fn>
      <fn id="Fn30">
        <label>30</label>
        <p>Unless they also suffer from depersonalisation, which can happen.</p>
      </fn>
      <fn id="Fn31">
        <label>31</label>
        <p>See e.g. Soldati (<xref ref-type="bibr" rid="CR64">2012</xref>). Pryor (<xref ref-type="bibr" rid="CR55">2005</xref>) and Goldman (<xref ref-type="bibr" rid="CR30">2008</xref>), among others, also argue that there is immediate justification.</p>
      </fn>
      <fn id="Fn32">
        <label>32</label>
        <p>A related notion of immediate justification can be found in Pryor (<xref ref-type="bibr" rid="CR55">2005</xref>).</p>
      </fn>
      <fn id="Fn33">
        <label>33</label>
        <p>As for (i), some might argue that further beliefs about the regular, reliable correlation between experiences and what they represent in the world also need to be in place to warrant perceptual judgements, at least as background assumptions. I will remain neutral on this point. In any case, there is no room for a similar worry when we consider (ii), (iii) or (iv), as no scenario of the kind invoked by Cartesian scepticism seems available that would make us doubt the experience as evidence for its own existence, for my existence, or for the fact that the experience is mine.</p>
      </fn>
      <fn id="Fn34">
        <label>34</label>
        <p>For a detailed presentation of the condition, see e.g. Weiskranz (<xref ref-type="bibr" rid="CR70">1986</xref>/1998).</p>
      </fn>
      <fn id="Fn35">
        <label>35</label>
        <p>
<italic>Cf</italic>. Block (<xref ref-type="bibr" rid="CR6">1995</xref>). Blindsight patients can make correct guesses about the objects in their blind field when prompted, but do not spontaneously form beliefs about those objects.</p>
      </fn>
      <fn id="Fn36">
        <label>36</label>
        <p>I am grateful to Conor McHugh for helping me articulate this argument from justification, and for suggesting the contrast with the blindsight case, which Alexandre Billon helped me sharpen. I am also grateful to an anonymous reviewer for prompting me to spell out the argument more fully. Were the argument to be found unconvincing, please note that this wouldn’t weaken in any way the primary thesis of this essay, i.e. that for-me-ness, me-ness and mineness are not a set of conceptual equivalents (whether or not they normally co-occur).</p>
      </fn>
      <fn id="Fn37">
        <label>37</label>
        <p>As an anonymous reviewer pointed out, the distinction between those two abilities might be related in some way to the distinction between the two uses of the first person identified by Wittgenstein (<xref ref-type="bibr" rid="CR72">1958</xref>), namely the use of “I” ‘as subject’ <italic>vs</italic>. its use ‘as object’. Exploring further this connection, or the specific way in which each ability is grounded in the subjective character of experience, would however take me beyond the limited scope of this essay. Links between the “first-person perspective” built into experience, and the capacity to use the first person to self-refer, have been explored by Shoemaker (<xref ref-type="bibr" rid="CR59">1996</xref>), Evans (<xref ref-type="bibr" rid="CR21">1982</xref>, Chapter 7), Campbell (<xref ref-type="bibr" rid="CR11">1994</xref>), Bermúdez (<xref ref-type="bibr" rid="CR2">1998</xref>), Neisser (<xref ref-type="bibr" rid="CR51">2008</xref>: 56 sq.), Grünbaum (<xref ref-type="bibr" rid="CR31">2012</xref>), among many others.</p>
      </fn>
      <fn id="Fn38">
        <label>38</label>
        <p>This is precisely the theory I defend in Guillot (<xref ref-type="bibr" rid="CR32">2012</xref>).</p>
      </fn>
    </fn-group>
    <ack>
      <p>The research leading to these results has received funding from the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme [FP7/2007–2013] under REA grant agreement [622127]. It was also supported by the DGI, Spanish Government, research project [FFI2013-47948-P]. For fruitful discussions on these issues, I am very grateful to the participants in a reading group on <italic>de se</italic> attitudes at LOGOS (Barcelona) in 2014–2015, and to audiences at LOGOS and at the New College of the Humanities (London). Special thanks are due to Delia Belleri, Manuel García-Carpintero, Francesc Perenya, and Carlota Serrahima. I am also grateful to Brian Ball, Alexandre Billon, Tomis Kapitan, Conor McHugh, Lucy O’Brien and two anonymous reviewers for extremely helpful comments. I thank Brian Ball for suggesting the title of the article, borrowed from the eponymous Beatles song by George Harrison.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <mixed-citation publication-type="other">Allison-Bolger, V.Y. (1999). Collection of case histories. Unpublished typescript. In C. Hoerl, (2001) On thought insertion. <italic>Philosophy, Psychiatry, and Psychology</italic>, 8(2/3), 189–200.</mixed-citation>
      </ref>
      <ref id="CR2">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Bermúdez</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <source>The paradox of self-consciousness</source>
          <year>1998</year>
          <publisher-loc>Cambridge</publisher-loc>
          <publisher-name>MIT Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Billon</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Does consciousness entail subjectivity? The puzzle of thought insertion</article-title>
          <source>Philosophical Psychology</source>
          <year>2011</year>
          <volume>26</volume>
          <issue>2</issue>
          <fpage>291</fpage>
          <lpage>314</lpage>
          <pub-id pub-id-type="doi">10.1080/09515089.2011.625117</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Billon</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Why are we certain that we exist?</article-title>
          <source>Philosophy and Phenomenological Research</source>
          <year>2014</year>
          <volume>91</volume>
          <issue>3</issue>
          <fpage>723</fpage>
          <lpage>759</lpage>
          <pub-id pub-id-type="doi">10.1111/phpr.12113</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <mixed-citation publication-type="other">Billon, A. (forthcoming). Making sense of the Cotard syndrome: Insights from the study of depersonalisation. Forthcoming in <italic>Mind and Language</italic>.</mixed-citation>
      </ref>
      <ref id="CR6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Block</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>On a confusion about a function of consciousness</article-title>
          <source>Behavioral and Brain Sciences</source>
          <year>1995</year>
          <volume>18</volume>
          <issue>2</issue>
          <fpage>227</fpage>
          <lpage>247</lpage>
          <pub-id pub-id-type="doi">10.1017/S0140525X00038188</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Block</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Consciousness, accessibility, and the mesh between psychology and neuroscience</article-title>
          <source>Behavioral and Brain Sciences</source>
          <year>2007</year>
          <volume>30</volume>
          <fpage>481</fpage>
          <lpage>548</lpage>
          <pub-id pub-id-type="pmid">18366828</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Bortolotti</surname>
            </name>
          </person-group>
          <source>Delusions and other irrational beliefs</source>
          <year>2010</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR9">
        <mixed-citation publication-type="other">Brentano, F. (1874 /1973). <italic>Psychology from an empirical standpoint</italic>. London: Routledge.</mixed-citation>
      </ref>
      <ref id="CR10">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Burge</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Wright</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Macdonald</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Reason and the first person</article-title>
          <source>Knowing our own minds</source>
          <year>1998</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR11">
        <mixed-citation publication-type="other">Campbell, J. (1994). <italic>Past, Space, and Self</italic>. MIT Press.</mixed-citation>
      </ref>
      <ref id="CR12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caston</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Aristotle on consciousness</article-title>
          <source>Mind</source>
          <year>2002</year>
          <volume>111</volume>
          <issue>444</issue>
          <fpage>751</fpage>
          <lpage>815</lpage>
          <pub-id pub-id-type="doi">10.1093/mind/111.444.751</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Chalmers</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <source>The conscious mind: In search of a fundamental theory</source>
          <year>1996</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cotard</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Du délire hypocondriaque dans une forme grave de la mélancolie anxieuse</article-title>
          <source>Annales Médico-Psychologiques</source>
          <year>1880</year>
          <volume>38</volume>
          <fpage>168</fpage>
          <lpage>170</lpage>
        </element-citation>
      </ref>
      <ref id="CR15">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Dainton</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <source>The phenomenal self</source>
          <year>2008</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR16">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Damasio</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>The feeling of what happens: Body and emotion in the making of consciousness</source>
          <year>1999</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Harcourt Brace</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR17">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Davis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Coltheart</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <source>Pathologies of belief</source>
          <year>2000</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Blackwell</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR18">
        <mixed-citation publication-type="other">Descartes, R. (1996). <italic>Oeuvres de Descartes</italic>. Edited by Charles Adam and Paul Tannery. 11 vol. Paris: J. Vrin.</mixed-citation>
      </ref>
      <ref id="CR19">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Dretske</surname>
            </name>
          </person-group>
          <source>Naturalizing the mind</source>
          <year>1995</year>
          <publisher-loc>Cambridge</publisher-loc>
          <publisher-name>MIT Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR20">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Drummond</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Kriegel</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Williford</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>The Case(s) of (Self-) Awareness</article-title>
          <source>Self-representational approaches to consciousness</source>
          <year>2006</year>
          <publisher-loc>Cambridge</publisher-loc>
          <publisher-name>MIT Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR21">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <source>The varieties of reference</source>
          <year>1982</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR22">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Flanagan</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <source>Consciousness reconsidered</source>
          <year>1992</year>
          <publisher-loc>Cambridge</publisher-loc>
          <publisher-name>MIT Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR23">
        <mixed-citation publication-type="other">Frankfurt, H. (1988). <italic>The Importance of What We Care About.</italic> Cambridge University Press.</mixed-citation>
      </ref>
      <ref id="CR24">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Frith</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <source>The cognitive neuropsychology of schizophrenia</source>
          <year>1992</year>
          <publisher-loc>Hillsdale</publisher-loc>
          <publisher-name>Lawrence Erlbaum Ass</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gallagher</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Philosophical conceptions of the self: Implications for cognitive science</article-title>
          <source>Trends in Cognitive Sciences</source>
          <year>2000</year>
          <volume>4</volume>
          <issue>1</issue>
          <fpage>14</fpage>
          <pub-id pub-id-type="doi">10.1016/S1364-6613(99)01417-5</pub-id>
          <pub-id pub-id-type="pmid">10637618</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gallagher</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Neurocognitive models of schizophrenia: A neurophenomenological critique</article-title>
          <source>Psychopathology</source>
          <year>2004</year>
          <volume>37</volume>
          <issue>1</issue>
          <fpage>8</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="doi">10.1159/000077014</pub-id>
          <pub-id pub-id-type="pmid">14988645</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <mixed-citation publication-type="other">Gallagher, S. and Zahavi, D. (2005/2014). Phenomenological approaches to self-Consciousness. <italic>The Stanford Encyclopedia of Philosophy</italic>. From <ext-link ext-link-type="uri" xlink:href="http://plato.stanford.edu/entries/self-consciousness-phenomenological/">http://plato.stanford.edu/entries/self-consciousness-phenomenological/</ext-link>.</mixed-citation>
      </ref>
      <ref id="CR28">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Ganeri</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <source>The self</source>
          <year>2012</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR29">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Goldman</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>A theory of action</source>
          <year>1970</year>
          <publisher-loc>Princeton</publisher-loc>
          <publisher-name>Princeton University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR30">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Goldman</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Smith</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>Immediate justification and process reliabilism</article-title>
          <source>Epistemology: New essays</source>
          <year>2008</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
          <fpage>63</fpage>
          <lpage>82</lpage>
        </element-citation>
      </ref>
      <ref id="CR31">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Grünbaum</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Miguens</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Preyer</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>First-person and minimal self-consciousness</article-title>
          <source>Consciousness and subjectivity</source>
          <year>2012</year>
          <publisher-loc>Ontos Verlag</publisher-loc>
          <publisher-name>Heusenstamm</publisher-name>
          <fpage>297</fpage>
          <lpage>320</lpage>
        </element-citation>
      </ref>
      <ref id="CR32">
        <mixed-citation publication-type="other">Guillot, M. (2012). Is the I-concept a Phenomenal Concept? Unpublished manuscript.</mixed-citation>
      </ref>
      <ref id="CR33">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Higginbotham</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Barber</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Remembering, imagining, and the first person</article-title>
          <source>The epistemology of language</source>
          <year>2003</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
          <fpage>496</fpage>
          <lpage>533</lpage>
        </element-citation>
      </ref>
      <ref id="CR34">
        <mixed-citation publication-type="other">Hohwy, J. (2007). The Sense of Self in the Phenomenology of Agency and Perception. <italic>Psyche</italic> 13/2.</mixed-citation>
      </ref>
      <ref id="CR35">
        <mixed-citation publication-type="other">Husserl, E. (1928/1964). <italic>Phenomenology of Internal Time-Consciousness</italic>, ed. M. Heidegger, trans. J. S. Churchill, Bloomington, IN: Indiana University Press.</mixed-citation>
      </ref>
      <ref id="CR36">
        <mixed-citation publication-type="other">Husserl, E. (1931/1960). <italic>Cartesian Meditations: An Introduction to Phenomenology</italic>. Tr. Dorion Cairns. The Hague: Nijhoff.</mixed-citation>
      </ref>
      <ref id="CR37">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>James</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <source>The principles of psychology</source>
          <year>1890</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Henry Hold &amp; company</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR38">
        <mixed-citation publication-type="other">Janet, P. (1928). <italic>De l’angoisse à l’extase</italic>, vol. 2 (<italic>Les sentiments fondamentaux</italic>). Paris, Alcan.</mixed-citation>
      </ref>
      <ref id="CR39">
        <mixed-citation publication-type="other">Janet, P. and Raymond, F. (1898). <italic>Névroses et idées fixes</italic>, vol. 2. Paris: Félix Alcan.</mixed-citation>
      </ref>
      <ref id="CR40">
        <mixed-citation publication-type="other">Jaspers (1963). <italic>General Psychopathology</italic>. Manchester University Press.</mixed-citation>
      </ref>
      <ref id="CR41">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kriegel</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Consciousness and self-consciousness</article-title>
          <source>The Monist</source>
          <year>2004</year>
          <volume>87</volume>
          <issue>2004</issue>
          <fpage>182</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="doi">10.5840/monist20048725</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kriegel</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Thagard</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Consciousness: Phenomenal consciousness, access consciousness, and scientific practice</article-title>
          <source>Handbook of philosophy of psychology and cognitive science</source>
          <year>2006</year>
          <publisher-loc>Amsterdam</publisher-loc>
          <publisher-name>North-Holland</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR43">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kriegel</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <source>Subjective consciousness: A self-representational theory</source>
          <year>2009</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR44">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Levine</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <source>Purple haze: The puzzle of consciousness</source>
          <year>2001</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR45">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Marr</surname>
            </name>
          </person-group>
          <source>Vision: A computational investigation into the human representation and processing of visual information</source>
          <year>1982</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>W. H. Freeman and Company</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR46">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The transparency of experience</article-title>
          <source>Mind and Language</source>
          <year>2002</year>
          <volume>17</volume>
          <issue>4</issue>
          <fpage>376</fpage>
          <lpage>425</lpage>
          <pub-id pub-id-type="doi">10.1111/1468-0017.00205</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mellor</surname>
              <given-names>CS</given-names>
            </name>
          </person-group>
          <article-title>First rank symptoms of schizophrenia</article-title>
          <source>The British Journal of Psychiatry</source>
          <year>1970</year>
          <volume>117</volume>
          <issue>536</issue>
          <fpage>15</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="pmid">5479324</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Metzinger</surname>
            </name>
          </person-group>
          <source>Being no one</source>
          <year>2003</year>
          <publisher-loc>Cambridge</publisher-loc>
          <publisher-name>MIT Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR49">
        <mixed-citation publication-type="other">Nagel, T. (1974). What Is It Like to Be a Bat? <italic>Philosophical Review</italic>, pp. 435–50.</mixed-citation>
      </ref>
      <ref id="CR50">
        <mixed-citation publication-type="other">Neisser, J. (2006). Unconscious Subjectivity. <italic>Psyche</italic> XII: 1–14.</mixed-citation>
      </ref>
      <ref id="CR51">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neisser</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Subjectivity and the limits of narrative</article-title>
          <source>Journal of Consciousness Studies</source>
          <year>2008</year>
          <volume>15</volume>
          <issue>2</issue>
          <fpage>51</fpage>
          <lpage>66</lpage>
        </element-citation>
      </ref>
      <ref id="CR52">
        <mixed-citation publication-type="other">Neisser, J. (2014). What Subjectivity is Not. <italic>Topoi</italic>: 1–13.</mixed-citation>
      </ref>
      <ref id="CR53">
        <mixed-citation publication-type="other">Neisser, J. (2015). <italic>The Science of Subjectivity</italic>. Palgrave Macmillan.</mixed-citation>
      </ref>
      <ref id="CR54">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Peacocke</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <source>The mirror of the world</source>
          <year>2014</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR55">
        <mixed-citation publication-type="other">Pryor, J. (2005). There Is Immediate Justification. In Matthias Steup &amp; Ernest Sosa (eds.), <italic>Contemporary Debates in Epistemology</italic>. Blackwell. 181–202.</mixed-citation>
      </ref>
      <ref id="CR56">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenthal</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Two concepts of consciousness</article-title>
          <source>Philosophical Studies</source>
          <year>1986</year>
          <volume>49</volume>
          <issue>3</issue>
          <fpage>329</fpage>
          <lpage>359</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00355521</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Sartre</surname>
              <given-names>J-P</given-names>
            </name>
          </person-group>
          <source>L’être et le néant</source>
          <year>1943</year>
          <publisher-loc>Paris</publisher-loc>
          <publisher-name>Gallimard</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR58">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sebastian</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Experiential awareness: Do you prefer it to me?</article-title>
          <source>Philosophical Topics</source>
          <year>2012</year>
          <volume>40</volume>
          <issue>2</issue>
          <fpage>155</fpage>
          <lpage>177</lpage>
          <pub-id pub-id-type="doi">10.5840/philtopics201240218</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Shoemaker</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <source>The first-person perspective and other essays</source>
          <year>1996</year>
          <publisher-loc>Cambridge</publisher-loc>
          <publisher-name>Cambridge University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR60">
        <mixed-citation publication-type="other">Sierra, M. (2009). <italic>Depersonalization: A New Look at a Neglected Syndrome</italic>. Cambridge University Press.</mixed-citation>
      </ref>
      <ref id="CR61">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sierra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Berrios</surname>
              <given-names>GE</given-names>
            </name>
          </person-group>
          <article-title>The Cambridge Depersonalization Scale: A new instrument for the measurement of depersonalization</article-title>
          <source>Psychiatry Research</source>
          <year>2000</year>
          <volume>93</volume>
          <issue>2</issue>
          <fpage>153</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1016/S0165-1781(00)00100-1</pub-id>
          <pub-id pub-id-type="pmid">10725532</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Siewert</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <source>The significance of consciousness</source>
          <year>1998</year>
          <publisher-loc>Princeton</publisher-loc>
          <publisher-name>Princeton University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR63">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Simeon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Abugel</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <source>Feeling unreal: Depersonalization disorder and the loss of the self</source>
          <year>2006</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR64">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soldati</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Direct realism and immediate justification</article-title>
          <source>Proceedings of the Aristotelian Society</source>
          <year>2012</year>
          <volume>112</volume>
          <fpage>29</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1467-9264.2012.00324.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stephens</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Self-consciousness, mental agency, and the clinical psychopathology of thought-insertion</article-title>
          <source>Philosophy, Psychiatry, and Psychology</source>
          <year>1994</year>
          <volume>1</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>10</lpage>
        </element-citation>
      </ref>
      <ref id="CR66">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Strawson</surname>
              <given-names>PF</given-names>
            </name>
          </person-group>
          <source>The bounds of sense: An essay on Kant’s Citique of pure reason</source>
          <year>1966</year>
          <publisher-loc>London</publisher-loc>
          <publisher-name>Methuen</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR67">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strawson</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The Self</article-title>
          <source>Journal of Consciousness Studies</source>
          <year>1997</year>
          <volume>4</volume>
          <issue>5/6</issue>
          <fpage>405</fpage>
          <lpage>28</lpage>
        </element-citation>
      </ref>
      <ref id="CR68">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Strawson</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <source>Selves</source>
          <year>2009</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR69">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Tye</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <source>Ten problems of consciousness</source>
          <year>1995</year>
          <publisher-loc>Cambridge</publisher-loc>
          <publisher-name>MIT Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR70">
        <mixed-citation publication-type="other">Weiskranz, L. (1986/1998). <italic>Blindsight: A Case Study and Implications</italic>. Oxford: Oxford University Press.</mixed-citation>
      </ref>
      <ref id="CR71">
        <mixed-citation publication-type="other">Williford, K. (2015). Representationalisms, Subjective Character, and Self-Acquaintance. In T. Metzinger &amp; J. M. Windt (Eds). <italic>Open MIND</italic>: 39(T). Frankfurt am Main: MIND Group.</mixed-citation>
      </ref>
      <ref id="CR72">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Wittgenstein</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <source>The blue and brown books</source>
          <year>1958</year>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Blackwell</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR73">
        <mixed-citation publication-type="other">Young, G. (2008). On how a child’s awareness of thinking informs explanations of thought insertion. <italic>Consciousness and Cognition</italic> 10/2008; 17(3):848–62.</mixed-citation>
      </ref>
      <ref id="CR74">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Zahavi</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <source>Self-awareness and alterity: A phenomenological investigation</source>
          <year>1999</year>
          <publisher-loc>Evanston</publisher-loc>
          <publisher-name>Northwestern University Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR75">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Zahavi</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <source>Subjectivity and selfhood: Investigating the first-person perspective</source>
          <year>2005</year>
          <publisher-loc>Cambridge</publisher-loc>
          <publisher-name>MIT Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR76">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Zahavi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kriegel</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Dahlstrom</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Elpidorou</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hopp</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>For-me-ness: What it is and what it is not</article-title>
          <source>Philosophy of mind and phenomenology: Conceptual and empirical approaches</source>
          <year>2015</year>
          <publisher-loc>London</publisher-loc>
          <publisher-name>Routledge</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR77">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zahavi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Parnas</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Phenomenal consciousness and self-awareness: A phenomenological critique of representational theory</article-title>
          <source>Journal of Consciousness Studies</source>
          <year>1998</year>
          <volume>5</volume>
          <issue>5–6</issue>
          <fpage>687</fpage>
          <lpage>705</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:5362671</identifier><datestamp>2017-04-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arch Osteoporos</journal-id>
      <journal-id journal-id-type="iso-abbrev">Arch Osteoporos</journal-id>
      <journal-title-group>
        <journal-title>Archives of Osteoporosis</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1862-3522</issn>
      <issn pub-type="epub">1862-3514</issn>
      <publisher>
        <publisher-name>Springer London</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5362671</article-id>
      <article-id pub-id-type="pmcid">PMC5362671</article-id>
      <article-id pub-id-type="pmc-uid">5362671</article-id>
      <article-id pub-id-type="pmid">28332125</article-id>
      <article-id pub-id-type="publisher-id">325</article-id>
      <article-id pub-id-type="doi">10.1007/s11657-017-0325-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Osteoarthritis of the hip joint in elderly patients is most commonly atrophic, with low parameters of acetabular dysplasia and possible involvement of osteoporosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Ishidou</surname>
            <given-names>Yasuhiro</given-names>
          </name>
          <address>
            <phone>+81-99-2755381</phone>
            <email>ishidou@m2.kufm.kagoshima-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsuyama</surname>
            <given-names>Kanehiro</given-names>
          </name>
          <address>
            <email>matsukane7795@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sakuma</surname>
            <given-names>Daisuke</given-names>
          </name>
          <address>
            <email>d.saku.from.911@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Setoguchi</surname>
            <given-names>Takao</given-names>
          </name>
          <address>
            <email>setoro@m2.kufm.kagoshima-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nagano</surname>
            <given-names>Satoshi</given-names>
          </name>
          <address>
            <email>naga@m2.kufm.kagoshima-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kawamura</surname>
            <given-names>Ichiro</given-names>
          </name>
          <address>
            <email>k-ichiro@m2.kufm.kagoshima-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maeda</surname>
            <given-names>Shingo</given-names>
          </name>
          <address>
            <email>s-maeda@m3.kufm.kagoshima-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Komiya</surname>
            <given-names>Setsuro</given-names>
          </name>
          <address>
            <email>skomiya@m3.kufm.kagoshima-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1167 1801</institution-id><institution-id institution-id-type="GRID">grid.258333.c</institution-id><institution>Department of Medical Joint Materials, Graduate School of Medical and Dental Sciences, </institution><institution>Kagoshima University, </institution></institution-wrap>8-35-1 Sakuragaoka, Kagoshima, 890-8520 Japan </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1167 1801</institution-id><institution-id institution-id-type="GRID">grid.258333.c</institution-id><institution>The Near-Future Locomotor Organ Medicine Creation Course (Kusunoki Kai), Graduate School of Medical and Dental Sciences, </institution><institution>Kagoshima University, </institution></institution-wrap>Kagoshima, Japan </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1167 1801</institution-id><institution-id institution-id-type="GRID">grid.258333.c</institution-id><institution>Department of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, </institution><institution>Kagoshima University, </institution></institution-wrap>Kagoshima, Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>22</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>12</volume>
      <issue>1</issue>
      <elocation-id>30</elocation-id>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>3</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Abstract</title>
        </sec>
        <sec>
          <title>Summary</title>
          <p>As elderly patients with hip osteoarthritis aged, acetabular dysplasia parameters decreased (Sharp’s angle, acetabular roof obliquity angle, and acetabular head index) and the incidence of the atrophic type increased. Vertebral body fracture was more frequent in the atrophic type, suggesting the involvement of osteoporosis at the onset of hip osteoarthritis.</p>
        </sec>
        <sec>
          <title>Introduction</title>
          <p>Osteoarthritis (OA) is associated with increased bone formation at a local site. However, excessive bone resorption has also been found to occur in the early stages of OA. Osteoporosis may be involved in the onset of OA in elderly patients. We conducted a cross-sectional radiographic study of patients with hip OA and examined the association between age and factors of acetabular dysplasia (Sharp’s angle, acetabular roof obliquity angle, and acetabular head index) as well as the osteoblastic response to determine the potential involvement of osteoporosis.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>This study included 366 patients (58 men, 308 women) who had undergone total hip arthroplasty for the diagnosis of hip OA. We measured the parameters of acetabular dysplasia using preoperative frontal X-ray images and evaluated each patient according to Bombelli classification of OA (hypertrophic, normotrophic, or atrophic type).</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>As the patients aged, the parameters of acetabular dysplasia decreased. The incidence of the atrophic type of OA was significantly higher in older patients. Vertebral body fractures were more frequent in the atrophic type than in the other types. Additionally, the index of acetabular dysplasia was lower in the atrophic type. By contrast, the hypertrophic type was present in relatively younger patients and was associated with an increased index of acetabular dysplasia.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>In elderly patients with hip OA, the parameters of acetabular dysplasia decreased and the incidence of the atrophic type increased as the patients aged. The frequency of vertebral body fracture was high in patients with the atrophic type, suggesting the involvement of osteoporosis in the onset of hip OA.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Osteoarthritis</kwd>
        <kwd>Osteoporosis</kwd>
        <kwd>Acetabular dysplasia</kwd>
        <kwd>Aging</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© International Osteoporosis Foundation and National Osteoporosis Foundation 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Osteoarthritis (OA) is associated with increased bone formation at a local site, whereas osteoporosis involves decreased bone formation with increased bone resorption, resulting in reduced bone mass [<xref ref-type="bibr" rid="CR1">1</xref>]. Therefore, an inverse relationship has been identified between OA and osteoporosis [<xref ref-type="bibr" rid="CR2">2</xref>]. However, excessive bone resorption characteristic of osteoporosis has also been found to occur in the early stages of OA [<xref ref-type="bibr" rid="CR3">3</xref>], drawing attention to the functional unit consisting of articular cartilage and subchondral bone [<xref ref-type="bibr" rid="CR4">4</xref>]. Molecular crosstalk between cartilage and subchondral bone contributes to the pathogenesis of OA [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. Microstructural damage to the subchondral bone and subsequent bone loss by increased remodeling is associated with the pathogenesis of early-stage OA [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Anti-osteoporosis drugs such as bisphosphonates are candidate therapeutic drugs with which to prevent the progression of OA [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. However, the curative effects of these drugs are controversial. The pattern of the biological bone response in OA can be classified as hypertrophic or atrophic based on the presence or absence of osteophytes, respectively [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR15">15</xref>]. As a result of the heterogeneity of OA, differences in radiographic patterns may be useful in elucidating differences in a patient’s reaction to an anti-osteoporosis drug.</p>
      <p>OA is a mechanically induced disease affected by both genetic and acquired factors [<xref ref-type="bibr" rid="CR4">4</xref>]. Acetabular dysplasia is one of the anatomical risk factors for OA [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], and genetic polymorphism associated with the risk of developmental dysplasia of the hip was recently identified [<xref ref-type="bibr" rid="CR18">18</xref>]. OA associated with acetabular dysplasia secondary to genetic factors is predicted to have a relatively early onset. In Japan, developmental acetabular dysplasia of the hip is reportedly among the most common causes of hip OA [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Meanwhile, the incidence of acetabular dysplasia is lower in elderly patients [<xref ref-type="bibr" rid="CR21">21</xref>]. The incidence and prevalence of OA after 50 years of age are higher in women than in men, suggesting that estrogen participates in the development of OA [<xref ref-type="bibr" rid="CR22">22</xref>]. These findings suggest that the etiologic factors of OA in elderly patients may differ from those in young patients and that osteoporosis is involved in the onset of OA in elderly patients. However, few studies have investigated this hypothesis.</p>
      <p>We conducted a cross-sectional radiographic study in patients with hip OA and examined the characteristic of hip OA in the elderly, including the association between parameters of acetabular dysplasia of the hip and age as well as the osteoblastic response, to examine the potential involvement of osteoporosis.</p>
    </sec>
    <sec id="Sec2">
      <title>Patients and methods</title>
      <sec id="Sec3">
        <title>Patients</title>
        <p>A total of 441 consecutive patients who underwent total hip arthroplasty for OA during the 2-year period from January 2013 to December 2014 at Kagoshima University Medical and Dental Hospital and other participating institutions were evaluated. Radiographs and information about the diagnosis were collected from medical records. We excluded cases of posttraumatic OA, OA after infection or osteonecrosis, and previous osteotomy. The study finally included 366 patients (58 men, 308 women; 63 were aged 30–59 years, 90 were aged 60–69 years, 129 were aged 70–79 years, and 84 were aged ≥80 years; there were no significant differences in the sex ratio within each age group).</p>
      </sec>
      <sec id="Sec4">
        <title>Radiographic measurement</title>
        <p>We measured the parameters of acetabular dysplasia using frontal X-ray images of bilateral hip joints taken preoperatively. Sharp’s angle [<xref ref-type="bibr" rid="CR23">23</xref>], the acetabular roof obliquity (ARO) angle [<xref ref-type="bibr" rid="CR24">24</xref>], and the acetabular head index (AHI) [<xref ref-type="bibr" rid="CR25">25</xref>] were used as reproducible radiographic parameters of acetabular dysplasia [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. The center edge (CE) angles showed low reproducibility, as the femoral head center could not be precisely determined due to severe deformities associated with end-stage OA. We also classified the patients according to Bombelli classification of OA (hypertrophic type, normotrophic type, and atrophic type) suggesting a biological osteoblastic response [<xref ref-type="bibr" rid="CR27">27</xref>]. Bombelli classification was carefully evaluated as described by Saito et al. [<xref ref-type="bibr" rid="CR28">28</xref>]. We show typical radiographs of hypertrophic, normotrophic, and atrophic OA in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. The Bombelli classification was independently assessed by three orthopedic surgeons, with required agreement by at least two. When one judgment differed, the determination of the other two was adopted. The kappa score for intra- and interobserver agreement was 0.83 and 0.77–0.93, respectively.<fig id="Fig1"><label>Fig. 1</label><caption><p>Radiographs of OA according to the Bombelli classification. Typical radiographs of hypertrophic (<bold>a</bold>), normotrophic (<bold>b</bold>), and atrophic (<bold>c</bold>) OA</p></caption><graphic xlink:href="11657_2017_325_Fig1_HTML" id="MO1"/></fig>
</p>
        <p>We also evaluated 250 patients (33 men, 217 women; &lt;60 years of age, 43 patients; 60–69 years of age, 50 patients; 70–79 years of age, 93 patients; and ≥80 years of age, 64 patients) for the presence or absence of vertebral compression fracture and compared these findings with the hip joint findings obtained using Bombelli classification. Vertebral compression fractures were assessed by one senior spinal surgeon using a semiquantitative technique described by Genant et al. [<xref ref-type="bibr" rid="CR29">29</xref>].</p>
      </sec>
      <sec id="Sec5">
        <title>Statistical analysis</title>
        <p>Single regression analysis was performed for statistical analysis of the correlation between the parameters of acetabular dysplasia and age. The Steel–Dwass test was used as a nonparametric multiple comparison test in each age group. The Steel–Dwass test was also used as a nonparametric multiple comparison test for the results of Bombelli classification. The significance level was set at <italic>p</italic> &lt; 0.05. Statistical analyses were performed using Statcel3 software (OMS, Saitama, Japan).</p>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Results</title>
      <p>The mean Sharp’s angles were 46.1°, 43.9°, 41.1°, and 41.0° in patients aged &lt;60, 60–69, 70–79, and ≥80 years, respectively. The corresponding ARO angles were 23.0°, 20.6°, 16.3°, and 17.0°, respectively, and the corresponding mean AHIs were 61.8, 64.8, 71.9, and 72.1%, respectively (Table <xref rid="Tab1" ref-type="table">1</xref>). As the patients became older, Sharp’s angle and the ARO angle decreased significantly (<italic>R</italic> = −0.3686, <italic>p</italic> &lt; 0.01 and <italic>R</italic> = −0.2603, <italic>p</italic> &lt; 0.01, respectively) and the AHI increased significantly (<italic>R</italic> = 0.3292, <italic>p</italic> &lt; 0.01) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Namely, as the patients became older, the parameters of acetabular dysplasia decreased. In a comparison according to age group, Sharp’s angle and the ARO angle were significantly smaller in patients aged 70–79 and ≥80 years. The AHI was significantly larger in patients aged 70–79 and ≥80 years (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>The parameters of acetabular dysplasia</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>Age group (years)</th><th>&lt;60</th><th>60–69</th><th>70–79</th><th>≥80</th></tr><tr><th>Number</th><th>63</th><th>90</th><th>129</th><th>84</th></tr></thead><tbody><tr><td rowspan="6">Sharp’s angle</td><td>Average</td><td>46.1</td><td>43.9</td><td>41.1</td><td>41.0<sup>a</sup>
</td></tr><tr><td>SD</td><td>4.66</td><td>5.26</td><td>4.41</td><td>4.84</td></tr><tr><td>SE</td><td>0.587</td><td>0.555</td><td>0.388</td><td>0.528</td></tr><tr><td>Min</td><td>35.0</td><td>30.0</td><td>28.0</td><td>30.0</td></tr><tr><td>Median</td><td>46.0</td><td>44.0</td><td>41.0</td><td>40.0</td></tr><tr><td>Max</td><td>56.0</td><td>58.0</td><td>50.0</td><td>55.8</td></tr><tr><td rowspan="6">ARO angle</td><td>Average</td><td>23.0<sup>a</sup>
</td><td>20.6<sup>a</sup>
</td><td>16.3<sup>a</sup>
</td><td>17.0<sup>a</sup>
</td></tr><tr><td>SD</td><td>9.86</td><td>10.5</td><td>7.47</td><td>8.21</td></tr><tr><td>SE</td><td>1.24</td><td>1.10</td><td>0.658</td><td>0.896</td></tr><tr><td>Min</td><td>5.00</td><td>3.00</td><td>2.00</td><td>5.00</td></tr><tr><td>Median</td><td>23.0</td><td>19.0</td><td>15.0</td><td>13.5</td></tr><tr><td>Max</td><td>59.0</td><td>76.0</td><td>36.0</td><td>42.0</td></tr><tr><td rowspan="6">AHI</td><td>Average</td><td>61.8</td><td>64.8</td><td>71.9</td><td>72.1</td></tr><tr><td>SD</td><td>13.0</td><td>14.9</td><td>12.0</td><td>11.4</td></tr><tr><td>SE</td><td>1.64</td><td>1.57</td><td>1.05</td><td>1.24</td></tr><tr><td>Min</td><td>27.5</td><td>18.9</td><td>43.8</td><td>37.0</td></tr><tr><td>Median</td><td>61.2</td><td>63.0</td><td>72.7</td><td>71.8</td></tr><tr><td>Max</td><td>100.0</td><td>106.6</td><td>100.0</td><td>93.7</td></tr></tbody></table><table-wrap-foot><p>
<italic>SD</italic> standard deviation, <italic>SE</italic> standard error, <italic>Min</italic> minimum, <italic>Max</italic> maximum, <italic>ARO</italic> acetabular roof obliquity, <italic>AHI</italic> acetabular head index</p><p>
<sup>a</sup>Nonnormal distribution</p></table-wrap-foot></table-wrap>
<fig id="Fig2"><label>Fig. 2</label><caption><p>The correlation between the acetabular index and age. Single regression analysis was performed for statistical analysis of the correlation between the parameters of acetabular dysplasia and age. <italic>ARO</italic> acetabular roof obliquity, <italic>AHI</italic> acetabular head index</p></caption><graphic xlink:href="11657_2017_325_Fig2_HTML" id="MO2"/></fig>
<fig id="Fig3"><label>Fig. 3</label><caption><p>The comparison of acetabular index in age groups. The Steel–Dwass test was used as a nonparametric multiple comparison test in each age group. <italic>ARO</italic> acetabular roof obliquity, <italic>AHI</italic> acetabular head index. *<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01</p></caption><graphic xlink:href="11657_2017_325_Fig3_HTML" id="MO3"/></fig>
</p>
      <p>The frequency of the atrophic type of OA according to Bombelli classification was 17.5, 40.0, 53.5, and 53.5% in patients aged &lt;60, 60–69, 70–79, and ≥80 years, respectively, showing an increase with age (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). The frequency of vertebral body fracture was 11.4% in the hypertrophic type, 12.8% in the normotrophic type, and 25.9% in the atrophic type, with the atrophic type showing the highest frequency (Fig. <xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>Bombelli classification in age groups. The Steel–Dwass test was used as a nonparametric multiple comparison test in each age group. <italic>H</italic> hypertrophic type, <italic>N</italic> normotrophic type, <italic>A</italic> atrophic type. *<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01</p></caption><graphic xlink:href="11657_2017_325_Fig4_HTML" id="MO4"/></fig>
<fig id="Fig5"><label>Fig. 5</label><caption><p>The incidence of vertebral body fracture. The Steel–Dwass test was used as a nonparametric multiple comparison test for the results of Bombelli classification. <italic>H</italic> hypertrophic type, <italic>N</italic> normotrophic type, <italic>A</italic> atrophic type. *<italic>p</italic> &lt; 0.05</p></caption><graphic xlink:href="11657_2017_325_Fig5_HTML" id="MO5"/></fig>
</p>
      <p>The atrophic type of OA occurred in patients of a significantly high age. Sharp’s angle and the ARO angle in the atrophic type were smaller than those in the other types. The AHI in atrophic type was larger than that in the other types. Namely, the parameters of acetabular dysplasia decreased in the atrophic type. On the other hand, the hypertrophic type occurred in patients of a relatively low age, in whom the parameters of acetabular dysplasia increased (Fig. <xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6"><label>Fig. 6</label><caption><p>The comparison of acetabular index in Bombelli classification. The Steel–Dwass test was used as a nonparametric multiple comparison test for the results of Bombelli classification. <italic>H</italic> hypertrophic type, <italic>N</italic> normotrophic type, <italic>A</italic> atrophic type, <italic>ARO</italic> acetabular roof obliquity, <italic>AHI</italic> acetabular head index. *<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01</p></caption><graphic xlink:href="11657_2017_325_Fig6_HTML" id="MO6"/></fig>
</p>
    </sec>
    <sec id="Sec7">
      <title>Discussion</title>
      <p>We conducted a radiographic study of patients with hip OA requiring total hip arthroplasty and evaluated the correlation between parameters of acetabular dysplasia and aging. Additionally, we estimated the osteoblastic response in patients with OA according to Bombelli classification. As our patients become older, the parameters of acetabular dysplasia decreased and the incidence of the atrophic type of OA increased.</p>
      <p>Acetabular dysplasia is an anatomical risk factor for hip OA. Reijman et al. [<xref ref-type="bibr" rid="CR16">16</xref>] reported that acetabular dysplasia (center-edge angle of &lt;25°) was associated with a 4.3-fold increased risk for incident radiographic hip OA. Jingushi et al. [<xref ref-type="bibr" rid="CR19">19</xref>] reported that Sharp’s angles of &gt;45° or 50° had significantly increased odds ratios for OA (5- or 65-fold greater, respectively) in comparison to &lt;40°.</p>
      <p>However, a recent epidemiological study of hip OA in Japan demonstrated that the incidence of acetabular dysplasia was lower in elderly patients [<xref ref-type="bibr" rid="CR21">21</xref>]. Lane et al. [<xref ref-type="bibr" rid="CR30">30</xref>] also reported that the association between acetabular dysplasia and OA in white women aged ≥65 years was not determined. In the present study, the indices of acetabular dysplasia in the elderly age groups (70–79 and ≥80 years of age) were significantly lower than those in the younger age groups. Additionally, these acetabular dysplasia parameters were negatively correlated with age.</p>
      <p>Anatomical abnormalities such as acetabular dysplasia produce abnormal or incongruous loading on articular cartilage for long periods, resulting in cartilage degeneration at a comparatively younger age [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Therefore, the incidence of OA secondary to acetabular dysplasia is high in comparatively young individuals, but low in those who are older. OA secondary to acetabular dysplasia has onset in middle age, and induces a brisk osteoblastic response due to the abnormal mechanical load, resulting in hypertrophy.</p>
      <p>Meanwhile, primary OA in hip joints without anatomical abnormalities will maintain essentially normal cartilage under normal conditions of loading at a younger age, but nonmechanical etiological factors such as osteoporosis may cause cartilage failure at a later age. Therefore, primary OA without acetabular dysplasia shows higher incidence in older individuals, and induces a weak osteoblastic response to osteoporosis, resulting in atrophy.</p>
      <p>OA is generally characterized by cartilage degradation, new bone spur formation, and osteosclerotic changes of the subchondral bone. However, there is little osteoblastic activity in the atrophic type of OA, so no osteophytes are observed. The atrophic type of OA is associated with a higher risk of joint destruction [<xref ref-type="bibr" rid="CR32">32</xref>], more rapid disease progression [<xref ref-type="bibr" rid="CR33">33</xref>], lower mineral density, and higher risk of osteoporotic fracture than other types of OA [<xref ref-type="bibr" rid="CR34">34</xref>]. Our data showed that the incidence of atrophic OA was higher as the patients became older. In addition, the incidence of vertebral fracture in the atrophic type was higher than in other types of OA. Schnitzler et al. [<xref ref-type="bibr" rid="CR32">32</xref>] also reported a high prevalence of vertebral fracture in the atrophic type of OA. These views support the concept that osteoporosis is involved in the etiology of the atrophic type of OA.</p>
      <p>However, a limitation of our study was the absence of bone mineral density measurements. Because this osteoporosis study was retrospective, we could not collect sufficient data on bone mineral density. Therefore, we inferred that osteoporosis was potentially related to the etiology of atrophic OA by showing the high incidence of vertebral compression fractures in atrophic OA. A prospective epidemiological study to clarify this concept is necessary.</p>
      <p>Osteoporosis may induce microstructural damage to the subchondral bone by increased remodeling, resulting in the onset of OA [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. A prospective randomized study of alendronate treatment for hip OA showed significant improvement in pain but no significant prevention of structural disease progression [<xref ref-type="bibr" rid="CR36">36</xref>]. More effective curative results may be expected if the patients are limited to the atrophy type strongly influenced by osteoporosis. Microstructural damage to the subchondral bone induces inappropriate crosstalk between osteoblasts and chondrocytes [<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. It is probably important to begin treatment for osteoporosis before such events occur. When planning the optimal OA treatment strategy, it is important that we consider the age of onset and heterogeneity of the etiology.</p>
      <p>Various factors, including genetic predisposition, sex, age, obesity, physical activity, joint injury, joint malalignment, and abnormal joint shape, affect the subchondral bone integrity [<xref ref-type="bibr" rid="CR37">37</xref>]. We statistically demonstrated in this radiographic study that the atrophic type of OA has a predominantly older age at onset and is affected by osteoporosis, whereas the hypertrophic type of OA has a predominantly younger age at onset and is affected by acetabular dysplasia. Because the atrophic type of OA is not accompanied by anatomical abnormalities, it is difficult to predict the onset of atrophic OA before cartilage degradation. No serum biomarkers that are able to demonstrate differences between the atrophic and hypertrophic types of OA have been identified [<xref ref-type="bibr" rid="CR14">14</xref>]. Additionally, the older onset of atrophic OA may be affected not only by osteoporosis but also by mild acetabular dysplasia [<xref ref-type="bibr" rid="CR38">38</xref>]. Some studies have reported that the patterns of osteoblastic reaction in the osteoarthritic hip were not related to the general bone mineral density [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. The uncertain definition of the atrophic type of OA and the lack of appropriate biomarkers are problematic.</p>
      <p>This cross-sectional study showed that atrophic OA increases with aging. Various factors other than anatomical abnormalities affect the pathogenesis of OA. Osteoporosis may be a contributor, but this remains controversial. Pathological classification in individual OA cases may be helpful for selection of drug treatment. Further research is needed to understand the difference in the types of OA and heterogeneity of the etiology.</p>
    </sec>
    <sec id="Sec8">
      <title>Conclusion</title>
      <p>In elderly patients with hip OA, the parameters of acetabular dysplasia decreased and the atrophic type increased as patients become older. The frequency of vertebral body fracture was higher in the atrophic type, suggesting the involvement of osteoporosis in the onset of hip OA.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors thank Mrs. Akemi Godai for her invaluable assistance.</p>
    </ack>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <p>This research protocol was approved by the Institutional Ethics Committee on Clinical Research (No. 27-20). For this type of study, formal consent is not required.</p>
      <sec id="FPar1">
        <title>Funding</title>
        <p>This work was supported by a grant from the Hip Joint Foundation of Japan (to Y.I.).</p>
      </sec>
      <sec id="FPar2">
        <title>Conflicts of interest</title>
        <p>None.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>ZC</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Difference in subchondral cancellous bone between postmenopausal women with hip osteoarthritis and osteoporotic fracture: implication for fatigue microdamage, bone microarchitecture, and biomechanical properties</article-title>
          <source>Arthritis Rheum</source>
          <year>2012</year>
          <volume>64</volume>
          <fpage>3955</fpage>
          <lpage>3962</lpage>
          <pub-id pub-id-type="doi">10.1002/art.34670</pub-id>
          <?supplied-pmid 23124609?>
          <pub-id pub-id-type="pmid">23124609</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dequeker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aerssens</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Luyten</surname>
              <given-names>FP</given-names>
            </name>
          </person-group>
          <article-title>Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship</article-title>
          <source>Aging Clin Exp Res</source>
          <year>2003</year>
          <volume>15</volume>
          <fpage>426</fpage>
          <lpage>439</lpage>
          <pub-id pub-id-type="doi">10.1007/BF03327364</pub-id>
          <?supplied-pmid 14703009?>
          <pub-id pub-id-type="pmid">14703009</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bultink</surname>
              <given-names>IE</given-names>
            </name>
            <name>
              <surname>Lems</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
          <article-title>Osteoarthritis and osteoporosis: what is the overlap?</article-title>
          <source>Curr Rheumatol Rep</source>
          <year>2013</year>
          <volume>15</volume>
          <fpage>328</fpage>
          <pub-id pub-id-type="doi">10.1007/s11926-013-0328-0</pub-id>
          <?supplied-pmid 23508809?>
          <pub-id pub-id-type="pmid">23508809</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lories</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Luyten</surname>
              <given-names>FP</given-names>
            </name>
          </person-group>
          <article-title>The bone-cartilage unit in osteoarthritis</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2011</year>
          <volume>7</volume>
          <fpage>43</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="doi">10.1038/nrrheum.2010.197</pub-id>
          <?supplied-pmid 21135881?>
          <pub-id pub-id-type="pmid">21135881</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldring</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Goldring</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>2010</year>
          <volume>1192</volume>
          <fpage>230</fpage>
          <lpage>237</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.05240.x</pub-id>
          <?supplied-pmid 20392241?>
          <pub-id pub-id-type="pmid">20392241</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Jagga</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Nam</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Interplay between cartilage and subchondral bone contributing to pathogenesis of osteoarthritis</article-title>
          <source>Int J Mol Sci</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>19805</fpage>
          <lpage>19830</lpage>
          <pub-id pub-id-type="doi">10.3390/ijms141019805</pub-id>
          <?supplied-pmid 24084727?>
          <pub-id pub-id-type="pmid">24084727</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Findlay</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Atkins</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Osteoblast-chondrocyte interactions in osteoarthritis</article-title>
          <source>Curr Osteoporos Rep</source>
          <year>2014</year>
          <volume>12</volume>
          <fpage>127</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="doi">10.1007/s11914-014-0192-5</pub-id>
          <?supplied-pmid 24458429?>
          <pub-id pub-id-type="pmid">24458429</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yuan</surname>
              <given-names>XL</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>QY</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>SB</given-names>
            </name>
          </person-group>
          <article-title>Bone-cartilage interface crosstalk in osteoarthritis: potential pathways and future therapeutic strategies</article-title>
          <source>Osteoarthr Cartil</source>
          <year>2014</year>
          <volume>22</volume>
          <fpage>1077</fpage>
          <lpage>1089</lpage>
          <pub-id pub-id-type="doi">10.1016/j.joca.2014.05.023</pub-id>
          <?supplied-pmid 24928319?>
          <pub-id pub-id-type="pmid">24928319</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bellido</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lugo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Roman-Blas</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Castañeda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Caeiro</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Dapia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Calvo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Largo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Herrero-Beaumont</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis</article-title>
          <source>Arthritis Res Ther</source>
          <year>2010</year>
          <volume>12</volume>
          <fpage>R152</fpage>
          <pub-id pub-id-type="doi">10.1186/ar3103</pub-id>
          <?supplied-pmid 20678201?>
          <pub-id pub-id-type="pmid">20678201</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burr</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Gallant</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Bone remodeling in osteoarthritis</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2012</year>
          <volume>8</volume>
          <fpage>665</fpage>
          <lpage>673</lpage>
          <pub-id pub-id-type="doi">10.1038/nrrheum.2012.130</pub-id>
          <?supplied-pmid 22868925?>
          <pub-id pub-id-type="pmid">22868925</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siebelt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Waarsing</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Groen</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Müller</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Koelewijn</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>de Blois</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Verhaar</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weinans</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression</article-title>
          <source>Bone</source>
          <year>2014</year>
          <volume>66</volume>
          <fpage>163</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bone.2014.06.009</pub-id>
          <?supplied-pmid 24933343?>
          <pub-id pub-id-type="pmid">24933343</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Perilli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Parkinson</surname>
              <given-names>IH</given-names>
            </name>
            <name>
              <surname>Humphries</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Fazzalari</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Kuliwaba</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis: effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone/cartilage turnover, and joint discomfort</article-title>
          <source>Osteoarthr Cartil</source>
          <year>2013</year>
          <volume>21</volume>
          <fpage>1595</fpage>
          <lpage>1604</lpage>
          <pub-id pub-id-type="doi">10.1016/j.joca.2013.06.020</pub-id>
          <?supplied-pmid 23827368?>
          <pub-id pub-id-type="pmid">23827368</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Solomon</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Patterns of osteoarthritis of the hip</article-title>
          <source>J Bone Joint Surg Br</source>
          <year>1976</year>
          <volume>58</volume>
          <fpage>176</fpage>
          <lpage>183</lpage>
          <?supplied-pmid 932079?>
          <pub-id pub-id-type="pmid">932079</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conrozier</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Merle-Vincent</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mathieu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Richard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Favret</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Piperno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Caton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vignon</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Epidemiological, clinical, biological and radiological differences between atrophic and hypertrophic patterns of hip osteoarthritis: a case-control study</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2004</year>
          <volume>22</volume>
          <fpage>403</fpage>
          <lpage>408</lpage>
          <?supplied-pmid 15301235?>
          <pub-id pub-id-type="pmid">15301235</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ledingham</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dawson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Preston</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Milligan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Doherty</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Radiographic patterns and associations of osteoarthritis of the hip</article-title>
          <source>Ann Rheum Dis</source>
          <year>1992</year>
          <volume>51</volume>
          <fpage>1111</fpage>
          <lpage>1116</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.51.10.1111</pub-id>
          <?supplied-pmid 1444623?>
          <pub-id pub-id-type="pmid">1444623</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reijman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hazes</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Pols</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Koes</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Bierma-Zeinstra</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Acetabular dysplasia predicts incident osteoarthritis of the hip: the Rotterdam study</article-title>
          <source>Arthritis Rheum</source>
          <year>2005</year>
          <volume>52</volume>
          <fpage>787</fpage>
          <lpage>793</lpage>
          <pub-id pub-id-type="doi">10.1002/art.20886</pub-id>
          <?supplied-pmid 15751071?>
          <pub-id pub-id-type="pmid">15751071</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobsen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sonne-Holm</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Søballe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gebuhr</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Hip dysplasia and osteoarthrosis: a survey of 4151 subjects from the Osteoarthrosis Substudy of the Copenhagen City Heart Study</article-title>
          <source>Acta Orthop</source>
          <year>2005</year>
          <volume>76</volume>
          <fpage>149</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="doi">10.1080/00016470510030517</pub-id>
          <?supplied-pmid 16097538?>
          <pub-id pub-id-type="pmid">16097538</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>CX3CR1 polymorphisms associated with an increased risk of developmental dysplasia of the hip in human</article-title>
          <source>J Orthop Res</source>
          <year>2017</year>
          <volume>35</volume>
          <fpage>377</fpage>
          <lpage>380</lpage>
          <pub-id pub-id-type="doi">10.1002/jor.23294</pub-id>
          <?supplied-pmid 27176135?>
          <pub-id pub-id-type="pmid">27176135</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jingushi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ohfuji</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sofue</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hirota</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Itoman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shindo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takatori</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yasunaga</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Owan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ohashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Miyanishi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iga</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahira</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sugimori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sugiyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Okano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Karita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hamaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirayama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Iwata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakasone</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsuura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mawatari</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Osteoarthritis hip joints in Japan: involvement of acetabular dysplasia</article-title>
          <source>J Orthop Sci</source>
          <year>2011</year>
          <volume>16</volume>
          <fpage>156</fpage>
          <lpage>164</lpage>
          <pub-id pub-id-type="doi">10.1007/s00776-011-0025-7</pub-id>
          <?supplied-pmid 21359510?>
          <pub-id pub-id-type="pmid">21359510</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshimura</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kinoshita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Okayasu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wilman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Coggon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Croft</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Acetabular dysplasia and hip osteoarthritis in Britain and Japan</article-title>
          <source>Br J Rheumatol</source>
          <year>1998</year>
          <volume>37</volume>
          <fpage>1193</fpage>
          <lpage>1197</lpage>
          <pub-id pub-id-type="doi">10.1093/rheumatology/37.11.1193</pub-id>
          <?supplied-pmid 9851268?>
          <pub-id pub-id-type="pmid">9851268</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jingushi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ohfuji</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sofue</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hirota</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Itoman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shindo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takatori</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yasunaga</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Owan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ohashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Miyanishi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iga</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahira</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sugimori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sugiyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Okano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Karita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hamaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirayama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Iwata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakasone</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsuura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mawatari</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Multiinstitutional epidemiological study regarding osteoarthritis of the hip in Japan</article-title>
          <source>J Orthop Sci</source>
          <year>2010</year>
          <volume>15</volume>
          <fpage>626</fpage>
          <lpage>631</lpage>
          <pub-id pub-id-type="doi">10.1007/s00776-010-1507-8</pub-id>
          <?supplied-pmid 20953923?>
          <pub-id pub-id-type="pmid">20953923</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Richette</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Corvol</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bardin</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Estrogens, cartilage, and osteoarthritis</article-title>
          <source>Joint Bone Spine</source>
          <year>2003</year>
          <volume>70</volume>
          <fpage>257</fpage>
          <lpage>262</lpage>
          <pub-id pub-id-type="doi">10.1016/S1297-319X(03)00067-8</pub-id>
          <?supplied-pmid 12951307?>
          <pub-id pub-id-type="pmid">12951307</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="other">Sharp IK (1961) Acetabular dysplasia. The acetabular angle. J Bone Joint Surg Br 43:268–272 </mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Massie</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Howorth</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Congenital dislocation of the hip. Part I. Method of grading results</article-title>
          <source>J Bone Joint Surg Am</source>
          <year>1950</year>
          <volume>32-A</volume>
          <fpage>519</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="doi">10.2106/00004623-195032030-00005</pub-id>
          <?supplied-pmid 15428474?>
          <pub-id pub-id-type="pmid">15428474</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heyman</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Herndon</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Legg-Perthes disease; a method for the measurement of the roentgenographic result</article-title>
          <source>J Bone Joint Surg Am</source>
          <year>1950</year>
          <volume>32-A</volume>
          <fpage>767</fpage>
          <lpage>778</lpage>
          <pub-id pub-id-type="doi">10.2106/00004623-195032040-00004</pub-id>
          <?supplied-pmid 14784485?>
          <pub-id pub-id-type="pmid">14784485</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takatori</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sofue</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hirota</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Itoman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shindo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yasunaga</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Owan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ohashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mawatari</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Iga</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahira</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sugimori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sugiyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Okano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Karita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hamaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirayama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Iwata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsuura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jingushi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Analysis of interobserver reliability for radiographic staging of coxarthrosis and indexes of acetabular dysplasia: a preliminary study</article-title>
          <source>J Orthop Sci</source>
          <year>2010</year>
          <volume>15</volume>
          <fpage>14</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="doi">10.1007/s00776-009-1412-1</pub-id>
          <?supplied-pmid 20151246?>
          <pub-id pub-id-type="pmid">20151246</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Bombelli</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <source>Osteoarthritis of the hip: classification and pathogenesis: the role of osteotomy as a consequent therapy</source>
          <year>1983</year>
          <edition>2</edition>
          <publisher-loc>Berlin</publisher-loc>
          <publisher-name>Springer</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <mixed-citation publication-type="other">Saito M, Saito S, Ohzono K, Ono K (1987) The osteoblastic response to osteoarthritis of the hip. Its influence on the long-term results of arthroplasty. J Bone Joint Surg Br 69:746–751</mixed-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Genant</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>van Kuijk</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nevitt</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Vertebral fracture assessment using a semiquantitative technique</article-title>
          <source>J Bone Miner Res</source>
          <year>1993</year>
          <volume>8</volume>
          <fpage>1137</fpage>
          <lpage>1148</lpage>
          <pub-id pub-id-type="doi">10.1002/jbmr.5650080915</pub-id>
          <?supplied-pmid 8237484?>
          <pub-id pub-id-type="pmid">8237484</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lane</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Nevitt</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pressman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gore</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hochberg</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Acetabular dysplasia and osteoarthritis of the hip in elderly white women</article-title>
          <source>Ann Rheum Dis</source>
          <year>1997</year>
          <volume>56</volume>
          <fpage>627</fpage>
          <lpage>630</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.56.10.627</pub-id>
          <?supplied-pmid 9389226?>
          <pub-id pub-id-type="pmid">9389226</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sandell</surname>
              <given-names>LJ</given-names>
            </name>
          </person-group>
          <article-title>Etiology of osteoarthritis: genetics and synovial joint development</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2012</year>
          <volume>8</volume>
          <fpage>77</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="doi">10.2174/157339712802083795</pub-id>
          <?supplied-pmid 22231237?>
          <pub-id pub-id-type="pmid">22231237</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schnitzler</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Wane</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Bone histomorphometry of the iliac crest, and spinal fracture prevalence in atrophic and hypertrophic osteoarthritis of the hip</article-title>
          <source>Osteoporos Int</source>
          <year>1992</year>
          <volume>2</volume>
          <fpage>186</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="doi">10.1007/BF01623925</pub-id>
          <?supplied-pmid 1611224?>
          <pub-id pub-id-type="pmid">1611224</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bierma-Zeinstra</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Koes</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
          <article-title>Risk factors and prognostic factors of hip and knee osteoarthritis</article-title>
          <source>Nat Clin Pract Rheumatol</source>
          <year>2007</year>
          <volume>3</volume>
          <fpage>78</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="doi">10.1038/ncprheum0423</pub-id>
          <?supplied-pmid 17299445?>
          <pub-id pub-id-type="pmid">17299445</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Castaño-Betancourt</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Rivadeneira</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bierma-Zeinstra</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kerkhof</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Hofman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Uitterlinden</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>van Meurs</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>Bone parameters across different types of hip osteoarthritis and their relationship to osteoporotic fracture risk</article-title>
          <source>Arthritis Rheum</source>
          <year>2013</year>
          <volume>65</volume>
          <fpage>693</fpage>
          <lpage>700</lpage>
          <pub-id pub-id-type="doi">10.1002/art.37792</pub-id>
          <?supplied-pmid 23203458?>
          <pub-id pub-id-type="pmid">23203458</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calvo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Castañeda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Largo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fernández-Valle</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Rodríguez-Salvanés</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Herrero-Beaumont</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits</article-title>
          <source>Osteoarthr Cartil</source>
          <year>2007</year>
          <volume>15</volume>
          <fpage>69</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="doi">10.1016/j.joca.2006.06.006</pub-id>
          <?supplied-pmid 16861013?>
          <pub-id pub-id-type="pmid">16861013</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36</label>
        <mixed-citation publication-type="other">Nishii T, Tamura S, Shiomi T, Yoshikawa H, Sugano N (2013) Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial. Clin Rheumatol 32:1759–1766. doi:10.1007/s10067013-2338-8</mixed-citation>
      </ref>
      <ref id="CR37">
        <label>37</label>
        <mixed-citation publication-type="other">Li G, Yin J, Gao J, Cheng TS, Pavlos NJ, Zhang C, Zheng MH (2013) Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes. Arthritis Res Ther 15:223</mixed-citation>
      </ref>
      <ref id="CR38">
        <label>38</label>
        <mixed-citation publication-type="other">Lane NE, Lin P, Christiansen L, Gore LR, Williams EN, Hochberg MC, Nevitt MC (2000) Association of mild acetabular dysplasia with an increased risk of incident hip osteoarthritis in elderly white women: the study of osteoporotic fractures. Arthritis Rheum 43:400–404</mixed-citation>
      </ref>
      <ref id="CR39">
        <label>39</label>
        <mixed-citation publication-type="other">Okano K, Aoyagi K, Chiba K, Motokawa S, Matsumoto T (2011) Bone mineral density is not related to osteophyte formation in osteoarthritis of the hip. J Rheumatol 38:358–361. doi:10.3899/jrheum.100533</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><resumptionToken>oai%3Apubmedcentral.nih.gov%3A5362672!2017-04-04!2017-04-05!pmc!</resumptionToken></ListRecords></OAI-PMH>